PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ros, S; Floter, J; Kaymak, I; Da Costa, C; Houddane, A; Dubuis, S; Griffiths, B; Mitter, R; Walz, S; Blake, S; Behrens, A; Brindle, KM; Zamboni, N; Rider, MH; Schulze, A				Ros, S.; Floeter, J.; Kaymak, I.; Da Costa, C.; Houddane, A.; Dubuis, S.; Griffiths, B.; Mitter, R.; Walz, S.; Blake, S.; Behrens, A.; Brindle, K. M.; Zamboni, N.; Rider, M. H.; Schulze, A.			6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells	ONCOGENE			English	Article							REGULATES GLUCOSE-METABOLISM; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; TUMOR; GLYCOLYSIS; EXPRESSION; BIOSYNTHESIS; ACTIVATION; SURVIVAL; HYPOXIA	The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4) controls metabolic flux through allosteric regulation of glycolysis. Here we show that p53 regulates the expression of PFKFB4 and that p53-deficient cancer cells are highly dependent on the function of this enzyme. We found that p53 downregulates PFKFB4 expression by binding to its promoter and mediating transcriptional repression via histone deacetylases. Depletion of PFKFB4 from p53-deficient cancer cells increased levels of the allosteric regulator fructose-2,6-bisphosphate, leading to increased glycolytic activity but decreased routing of metabolites through the oxidative arm of the pentose-phosphate pathway. PFKFB4 was also required to support the synthesis and regeneration of nicotinamide adenine dinucleotide phosphate (NADPH) in p53-deficient cancer cells. Moreover, depletion of PFKFB4-attenuated cellular biosynthetic activity and resulted in the accumulation of reactive oxygen species and cell death in the absence of p53. Finally, silencing of PFKFB4-induced apoptosis in p53-deficient cancer cells in vivo and interfered with tumour growth. These results demonstrate that PFKFB4 is essential to support anabolic metabolism in p53-deficient cancer cells and suggest that inhibition of PFKFB4 could be an effective strategy for cancer treatment.	[Ros, S.; Griffiths, B.; Schulze, A.] Canc Res UK London Res Inst, Gene Express Anal Lab, London, England; [Ros, S.; Brindle, K. M.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Floeter, J.; Kaymak, I.; Schulze, A.] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; [Da Costa, C.; Blake, S.; Behrens, A.] Francis Crick Inst, Adult Stem Cell Lab, London, England; [Houddane, A.; Rider, M. H.] Catholic Univ Louvain, de Duve Inst, Prot Phosphorylat Unit, Brussels, Belgium; [Dubuis, S.; Zamboni, N.] ETH, Inst Mol Syst Biol, Zurich, Switzerland; [Mitter, R.] Francis Crick Inst, Bioinformat & Biostat, London, England; [Walz, S.] Comprehens Canc Ctr, Core Unit Bioinformat, Bioctr, Wurzburg, Germany; [Behrens, A.] Kings Coll London, Fac Life Sci & Med, Guys Campus, London, England	Cancer Research UK; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Wurzburg; Francis Crick Institute; Universite Catholique Louvain; Swiss Federal Institutes of Technology Domain; ETH Zurich; Francis Crick Institute; University of Wurzburg; University of London; King's College London	Schulze, A (corresponding author), Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	almut.schulze@uni-wuerzburg.de	Zamboni, Nicola/K-3042-2012; Schulze, Almut/AAX-8257-2020; Ros, Susana/B-6350-2019	Zamboni, Nicola/0000-0003-1271-1021; Schulze, Almut/0000-0002-8199-6422; Behrens, Axel/0000-0002-1557-1143; Da Costa, Clive/0000-0002-0435-6747; Mitter, Richard/0000-0002-1279-3760; Ros, Susana/0000-0002-5451-1880	Cancer Research UK; German Cancer Aid [111917]; German Research Foundation [FOR 2314]; CRUK-EPSRC Imaging Centre in Cambridge and Manchester [16465]; The Francis Crick Institute [10039, 10002] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); German Cancer Aid(Deutsche Krebshilfe); German Research Foundation(German Research Foundation (DFG)); CRUK-EPSRC Imaging Centre in Cambridge and Manchester; The Francis Crick Institute	We thank C. Esnault (LRI) for advice on ChIP and H. Miess for help with Seahorse Analysis, C. Watkins and J. Bee (LRI, BRU) for help with animal experimentation, F. Lassailly, P. Johnson and T. Snoeks (In vivo imaging facility, LRI) for assistance with in vivo imaging and the LRI research services for technical support. We also thank C. Ade and Barbara Bauer (Theodor-Boveri-Institute, Wurzburg) for help with RNAseq analysis and histology, Beatrice Dankworth for help with cell line generation and W. Schmitz for insightful discussions. Cancer Research UK, the German Cancer Aid (grant 111917), the German Research Foundation (FOR 2314), and the CRUK-EPSRC Imaging Centre in Cambridge and Manchester (grant 16465) supported this work.	Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Buescher JM, 2010, ANAL CHEM, V82, P4403, DOI 10.1021/ac100101d; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; Chesney J, 2014, ONCOTARGET, V5, P6670, DOI 10.18632/oncotarget.2213; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Ralser M., 2007, J BIOL, V6, P10, DOI [DOI 10.1186/jbiol61, 10.1186/jbiol61]; Rinn JL, 2011, TRENDS CELL BIOL, V21, P344, DOI 10.1016/j.tcb.2011.04.002; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Ruhl M, 2012, BIOTECHNOL BIOENG, V109, P763, DOI 10.1002/bit.24344; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Strohecker AM, 2015, ONCOGENE, V34, P5662, DOI 10.1038/onc.2015.23; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	45	43	43	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3287	3299		10.1038/onc.2016.477	http://dx.doi.org/10.1038/onc.2016.477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092678	Green Submitted			2022-12-28	WOS:000402869800008
J	Li, J; Xi, Y; Li, W; McCarthy, RL; Stratton, SA; Zou, W; Li, W; Dent, SY; Jain, AK; Barton, MC				Li, J.; Xi, Y.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Zou, W.; Li, W.; Dent, S. Y.; Jain, A. K.; Barton, M. C.			TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; BREAST-CANCER CELLS; IN-VITRO PROPAGATION; EXPRESSION ANALYSIS; COMPLEX PRC2; PROTEIN EED; GENOME; METHYLATION; REPRESSION; BINDING	Histone methyl transferase EZH2 (Enhancer of Zeste Homolog 2) is generally associated with H3K27 methylation and gene silencing, as a member of the polycomb repressor 2 (PRC2) complex. Immunoprecipitation and mass spectrometry of the EZH2-protein interactome in estrogen receptor positive, breast cancer-derived MCF7 cells revealed EZH2 interactions with subunits of chromatin remodeler SWI/SNF complex and TRIM28, which formed a complex with EZH2 distinct from PRC2. Unexpectedly, transcriptome profiling showed that EZH2 primarily activates, rather than represses, transcription in MCF7 cells and with TRIM28 co-regulates a set of genes associated with stem cell maintenance and poor survival of breast cancer patients. TRIM28 depletion repressed EZH2 recruitment to chromatin and expression of this gene set, in parallel with decreased CD44(hi)/CD24(lo) mammosphere formation. Mammosphere formation, inhibited by EZH2 depletion, was rescued by ectopic expression of EZH2 but not by TRIM28 expression or by EZH2 mutated at the region (pre-SET domain) of TRIM28 interaction. These results support PRC2-independent functions of EZH2 and TRIM28 in activation of gene expression that promotes mammary stem cell enrichment and maintenance.	[Li, J.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Univ Texas Grad Sch Biomed Sci Houston, Genes & Dev Grad Program, Houston, TX 77030 USA; [Li, J.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Dent, S. Y.; Jain, A. K.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Li, J.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Dent, S. Y.; Jain, A. K.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA; [Xi, Y.; Zou, W.] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA; [Li, W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; Baylor College of Medicine	Barton, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mbarton@mdanderson.org	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Barton, Michelle/0000-0002-4042-1374; Jain, Abhinav/0000-0003-3268-514X	CPRIT [RP110471]; Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX; Laura and John Arnold Foundation; Odyssey Program fellowship; CPRIT Core Facility Support [RP120348]; National Institutes of Health through MD Anderson's Cancer Center Support [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA190176] Funding Source: NIH RePORTER	CPRIT; Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX; Laura and John Arnold Foundation; Odyssey Program fellowship; CPRIT Core Facility Support; National Institutes of Health through MD Anderson's Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by CPRIT RP110471 to MCB, WL and SYD. JL received support by a Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX. AKJ was supported by The Laura and John Arnold Foundation and Odyssey Program fellowship. We thank Dr M-C Hung for the Myc-EZH2 plasmid, Dr J-I Park for Flag-EZH2 plasmids and Dr PR Potts for HA-TRIM28, GST-TRIM28 full-length and RBCC only plasmids. This study used the Science Park NGS Core, supported by CPRIT Core Facility Support Grant RP120348, and the Flow Cytometry and Cellular Imaging Facility, which is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA016672.	Addison J, 2014, CANCER RES, V75, P344; Akdemir KC, 2014, NUCLEIC ACIDS RES, V42, P205, DOI 10.1093/nar/gkt866; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Cama A, 2013, ACTA NEUROPATHOL, V126, P575, DOI 10.1007/s00401-013-1165-y; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Changchien YC, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-216; Cheung RK, 2011, NAT REV RHEUMATOL, V7, P502, DOI 10.1038/nrrheum.2011.110; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Fienberg HG, 2012, CYTOM PART A, V81A, P467, DOI 10.1002/cyto.a.22067; Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim H, 2009, NUCLEIC ACIDS RES, V37, P2940, DOI 10.1093/nar/gkp149; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rowe HM, 2013, GENOME RES, V23, P452, DOI 10.1101/gr.147678.112; Sarma K, 2014, CELL, V159, P869, DOI 10.1016/j.cell.2014.10.019; Seki Y, 2010, P NATL ACAD SCI USA, V107, P10926, DOI 10.1073/pnas.0907601107; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Wolf D, 2007, CELL, V131, P46, DOI 10.1016/j.cell.2007.07.026; Wu RC, 2014, ELECTRON J QUAL THEO, P1; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	66	34	34	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2991	3001		10.1038/onc.2016.453	http://dx.doi.org/10.1038/onc.2016.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28068325	Green Accepted			2022-12-28	WOS:000402000400007
J	Modi, DA; Tagare, RD; Karthikeyan, S; Russo, A; Dean, M; Davis, DA; Lantvit, DD; Burdette, JE				Modi, D. A.; Tagare, R. D.; Karthikeyan, S.; Russo, A.; Dean, M.; Davis, D. A.; Lantvit, D. D.; Burdette, J. E.			PAX2 function, regulation and targeting in fallopiantube-derived high-grade serous ovarian cancer	ONCOGENE			English	Article							TUBE EPITHELIAL-CELLS; GENE-EXPRESSION; BRCT-DOMAIN; DNA-DAMAGE; STATHMIN 1; TRANSFORMATION; MODEL; PTIP; P53; CARCINOGENESIS	The fallopian tube epithelium (FTE) is one of the progenitor populations for high-grade serous ovarian cancer (HGSC). Loss of PAX2 is the earliest known molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53. Pathological studies report consistent loss of PAX2 in benign lesions as well as serous tumors. In the current study, the combined loss of PAX2 and expression of the R273H p53 mutant protein in murine oviductal epithelial (MOE) cells enhanced proliferation and growth in soft agar in vitro but was insufficient to drive tumorigenesis in vivo. A serially passaged model was generated to investigate the role of aging, but was also insufficient to drive tumorigenesis. These models recapitulate early benign lesions and suggest that a latency period exists between loss of PAX2, p53 mutation and tumor formation. Stathmin and fut8 were identified as downstream targets regulated by loss of PAX2 and mutation of p53 in MOE cells. Re-expression of PAX2 in PAX2-null human HGSC cells reduced cell survival via apoptosis. Phosphatase and tensin homolog (PTEN)(shRNA) negatively regulated PAX2 expression and stable re-expression of PAX2 in MOE: PTENshRNA cells significantly reduced proliferation and peritoneal tumor formation in athymic nude mice. PAX2 was determined to be a direct transcriptional target that was activated by wild-type p53, whereas mutant p53 inhibited PAX2 transcription in MOE cells. A small molecule screen using the proximal PAX2 promoter driving luciferase identified four small molecules that were able to enhance PAX2 mRNA expression in MOE cells. PAX2 re-expression in HGSC cells and PTEN-deficient oviductal tumors may have the potential to induce apoptosis. In summary, mutant p53 and PTEN loss negatively regulated PAX2 and PAX2 re-expression in HGSC cells induced cell death.	[Modi, D. A.; Tagare, R. D.; Karthikeyan, S.; Russo, A.; Dean, M.; Davis, D. A.; Lantvit, D. D.; Burdette, J. E.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Biomol Sci, M-C 870,Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Burdette, JE (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Biomol Sci, M-C 870,Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	joannab@uic.edu		Karthikeyan, Subbulakshmi/0000-0003-0815-164X; Dean, Matthew/0000-0001-5014-9311	American Cancer Society (ACS) [RSG-12-230-01]; NIH [R21 CA208610-01]; Office of the Director, National Institutes of Health (OD); National Center for Complementary & Integrative Health (NCCIH) [T32AT007533]; Tell Every Amazing Lady About Ovarian Cancer; NATIONAL CANCER INSTITUTE [R21CA208610] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT007533] Funding Source: NIH RePORTER	American Cancer Society (ACS)(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Director, National Institutes of Health (OD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health (NCCIH); Tell Every Amazing Lady About Ovarian Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by American Cancer Society (ACS) grant RSG-12-230-01 (J.E.B.), NIH R21 CA208610-01 (J.E.B.), the Office of the Director, National Institutes of Health (OD) & National Center for Complementary & Integrative Health (NCCIH; T32AT007533; M.D.) and Tell Every Amazing Lady About Ovarian Cancer, T.E.A.L. (J.E.B). We thank Dr Barbara Vanderhyden (University of Ottawa) for kindly providing MOE and MOSE cells, Dr Kwong Wong (University of Texas, M.D. Anderson Cancer Center) for the NEO and PAX2 plasmids, Dr Gregory Dressler (University of Michigan) for the PAX2-Luc plasmid, Dr Kiira Ratia (University of Illinois at Chicago, High Throughput Screen Core) for providing compounds for screening.	Al-Hujaily EM, 2015, CANCER PREV RES, V8, P1163, DOI 10.1158/1940-6207.CAPR-15-0121-T; Alli E, 2002, CANCER RES, V62, P6864; Auersperg N, 2011, INT J GYNECOL PATHOL, V30, P12, DOI 10.1097/PGP.0b013e3181f45f3e; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Cai Y, 2002, J BIOL CHEM, V277, P1217, DOI 10.1074/jbc.M109663200; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Chen WL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1988-0; Dressler GR, 1999, INT J DEV BIOL, V43, P463; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hilliard TS, 2013, INT J MOL SCI, V14, P4762, DOI 10.3390/ijms14034762; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Karst AM, 2011, GYNECOL ONCOL, V123, P5, DOI 10.1016/j.ygyno.2011.05.021; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kim JS, 2005, IMMUNOLOGY, V115, P375, DOI 10.1111/j.1365-2567.2005.02156.x; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Monte NM, 2010, CANCER RES, V70, P6225, DOI 10.1158/0008-5472.CAN-10-0149; Ning G, 2014, J PATHOL, V234, P478, DOI 10.1002/path.4417; Novak M, 2015, GYNECOL ONCOL, V139, P104, DOI 10.1016/j.ygyno.2015.07.100; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Patel SR, 2004, DEV BIOL, V267, P505, DOI 10.1016/j.ydbio.2003.11.002; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Quick CM, 2012, MODERN PATHOL, V25, P449, DOI 10.1038/modpathol.2011.175; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Saifudeen Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044869; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song HJ, 2013, INT J MOL SCI, V14, P6090, DOI 10.3390/ijms14036090; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Sukerkar PA, 2011, BIOCONJUGATE CHEM, V22, P2304, DOI 10.1021/bc2003555; Vasudevan D, 2015, CANCER RES, V75, P5299, DOI 10.1158/0008-5472.CAN-15-1582; Wu JX, 2009, J BIOL CHEM, V284, P18078, DOI 10.1074/jbc.M109.002527; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649; Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079	52	11	11	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3015	3024		10.1038/onc.2016.455	http://dx.doi.org/10.1038/onc.2016.455			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991925	Green Accepted			2022-12-28	WOS:000402000400009
J	Chen, Y; Li, C; Xie, H; Fan, Y; Yang, Z; Ma, J; He, D; Li, L				Chen, Y.; Li, C.; Xie, H.; Fan, Y.; Yang, Z.; Ma, J.; He, D.; Li, L.			Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K -> AKT -> GSK3 beta -> AM signaling	ONCOGENE			English	Article							PROSTATE-CANCER; MICROVESSEL DENSITY; THERAPEUTIC TARGET; TUMOR ANGIOGENESIS; ADRENOMEDULLIN; ACTIVATION; EXPRESSION; AXIS	The recruitment of vascular endothelial cells from the tumor microenvironment (TME) to promote angiogenesis plays key roles in the progression of renal cell carcinoma (RCC). The potential impact of immune cells in the TME on RCC angiogenesis, however, remains unclear. Here, we found that recruitment of mast cells resulted in increased RCC angiogenesis in both in vitro cell lines and in vivo mouse models. Mechanistic analyses revealed that RCC recruited mast cells by modulating PI3K -> AKT -> GSK3 beta -> AM signaling. A clinical survey of human RCC samples also showed that higher expression of the PI3K -> AKT -> GSK3 beta -> AM signaling pathway correlated with increased angiogenesis. Interruption of PI3K -> AKT -> GSK3 beta -> AM signaling via specific inhibitors led to decreased recruitment of mast cells, and targeting this infiltrating mast cell-related signaling via an AKT-specific inhibitor suppressed RCC angiogenesis in xenograft mouse models. Together, these results identified a novel role of infiltrating mast cells in RCC angiogenesis and metastasis and suggest a new strategy for treating RCC by targeting this newly identified signaling pathway.	[Chen, Y.; Xie, H.; Fan, Y.; Yang, Z.; Ma, J.; He, D.; Li, L.] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Yanta Wast Rd, Xian 710061, Peoples R China; [Li, C.] Chinese Acad Sci, Inst Biophys, Core Facil Prot Res, Beijing, Peoples R China; [Li, C.] Beijing Jianlan Inst Med, Beijing, Peoples R China	Xi'an Jiaotong University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Li, L (corresponding author), Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Yanta Wast Rd, Xian 710061, Peoples R China.	lilydr@hotmail.com			The National High Technology Research and Development Program of China (863 Program) [SS2014AA020607]; National Natural Science Foundation of China [81072107, 81472679, 81302227, 81130041]; National Key Research and Development Program [2016YFC0902603]	The National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program	This work was supported by The National High Technology Research and Development Program of China (863 Program, NO SS2014AA020607) and National Natural Science Foundation of China grant (No. 81072107, 81472679, 81302227, 81130041), and the National Key Research and Development Program (2016YFC0902603).	Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; Deville JL, 2010, EXPERT OPIN THER TAR, V14, P1059, DOI 10.1517/14728222.2010.522328; Deville JL, 2009, INT J CANCER, V125, P2307, DOI 10.1002/ijc.24568; Eddy AA, 2001, KIDNEY INT, V60, P375, DOI 10.1046/j.1523-1755.2001.00811.x; Forster A, 2015, ALLERGY, V70, P764, DOI 10.1111/all.12612; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Galinsky DST, 2008, CRIT REV ONCOL HEMAT, V68, P115, DOI 10.1016/j.critrevonc.2008.06.001; Guldur ME, 2014, J PAK MED ASSOC, V64, P300; Hollins F, 2008, J IMMUNOL, V181, P2772, DOI 10.4049/jimmunol.181.4.2772; Horstmann M, 2012, ANTICANCER RES, V32, P4339; Juengel E, 2015, J CELL MOL MED, V19, P430, DOI 10.1111/jcmm.12471; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kitamura Y, 2007, P JPN ACAD B-PHYS, V83, P164, DOI 10.2183/pjab.83.164; Kornakiewicz A, 2013, CURR SIGNAL TRANSD T, V8, P210; Li L, 2015, ONCOTARGET, V6, P14179, DOI 10.18632/oncotarget.3651; Liu XD, 2015, CANCER IMMUNOL RES, V3, P1017, DOI 10.1158/2326-6066.CIR-14-0244; Maltby S, 2009, BBA-REV CANCER, V1796, P19, DOI 10.1016/j.bbcan.2009.02.001; Mohseni MG, 2010, INT UROL NEPHROL, V42, P109, DOI 10.1007/s11255-009-9577-2; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ning H, 2012, CHINESE MED J-PEKING, V125, P2120, DOI 10.3760/cma.j.issn.0366-6999.2012.12.008; Park JY, 2007, EXPERT REV ANTICANC, V7, P863, DOI 10.1586/14737140.7.6.863; Patel PH, 2006, BRIT J CANCER, V94, P614, DOI 10.1038/sj.bjc.6602978; PAVONE-MACALUSO M, 1960, Acta Pathol Microbiol Scand, V50, P337; Ribatti D, 2016, EUR J PHARMACOL, V778, P152, DOI 10.1016/j.ejphar.2015.02.056; Ribatti D, 2012, BBA-MOL BASIS DIS, V1822, P2, DOI 10.1016/j.bbadis.2010.11.010; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Safdari Y, 2015, PHARMACOL RES, V93, P1, DOI 10.1016/j.phrs.2014.12.004; Samayawardhena LA, 2008, J BIOL CHEM, V283, P29175, DOI 10.1074/jbc.M804077200; SARUTA T, 1977, Keio Journal of Medicine, V26, P163; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Shi GP, 2013, CURR VASC PHARMACOL, V11, P314, DOI 10.2174/1570161111311030006; Siebenhaar F, 2014, EXP DERMATOL, V23, P159, DOI 10.1111/exd.12328; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Toge H, 2009, INT J UROL, V16, P801, DOI 10.1111/j.1442-2042.2009.02377.x; Trojan L, 2004, ANTICANCER RES, V24, P1651; Tuna B, 2006, EUR UROL, V50, P530, DOI 10.1016/j.eururo.2005.12.040; Watanabe S, 2012, HUM PATHOL, V43, P888, DOI 10.1016/j.humpath.2011.07.019; Wickenden JA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2558; Zhang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019144; Zhang W, 2000, CANCER RES, V60, P6757	43	38	40	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2879	2888		10.1038/onc.2016.442	http://dx.doi.org/10.1038/onc.2016.442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28114284	hybrid, Green Published			2022-12-28	WOS:000401697800010
J	Zou, M; Bhatia, A; Dong, H; Jayaprakash, P; Guo, J; Sahu, D; Hou, Y; Tsen, F; Tong, C; O'Brien, K; Situ, AJ; Schmidt, T; Chen, M; Ying, Q; Ulmer, TS; Woodley, DT; Li, W				Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; Tong, C.; O'Brien, K.; Situ, A. J.; Schmidt, T.; Chen, M.; Ying, Q.; Ulmer, T. S.; Woodley, D. T.; Li, W.			Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression	ONCOGENE			English	Article							CANCER-CELL INVASION; MONOCLONAL-ANTIBODY; MOLECULAR CHAPERONE; HSP90-ALPHA; GROWTH; MIGRATION; MOTILITY; MECHANISM; RECEPTOR	Both intracellular and extracellular heat shock protein-90 (Hsp90) family proteins (alpha and beta) have been shown to support tumour progression. The tumour-supporting activity of the intracellular Hsp90 is attributed to their N-terminal ATPase-driven chaperone function. What molecular entity determines the extracellular function of secreted Hsp90 and the distinction between Hsp90 alpha and Hsp90 beta was unclear. Here we demonstrate that CRISPR/Case9 knocking out Hsp90 alpha nullifies tumour cells' ability to migrate, invade and metastasize without affecting the cell survival and growth. Knocking out Hsp90 beta leads to tumour cell death. Extracellular supplementation with recombinant Hsp90 alpha, but not Hsp90 alpha, protein recovers tumourigenicity of the Hsp90 alpha-knockout cells. Sequential mutagenesis identifies two evolutionarily conserved lysine residues, lys-270 and lys-277, in the Hsp90 alpha subfamily that determine the extracellular Hsp90 alpha function. Hsp90 beta subfamily lacks the dual lysine motif and the extracellular function. Substitutions of gly-262 and thr-269 in Hsp90 beta with lysines convert Hsp90 beta to a Hsp90 alpha-like protein. Newly constructed monoclonal antibody, 1G6-D7, against the dual lysine region of secreted Hsp90 alpha inhibits both de novo tumour formation and expansion of already formed tumours in mice. This study suggests an alternative therapeutic approach to target Hsp90 in cancer, that is, the tumour-secreted Hsp90 alpha, instead of the intracellular Hsp90 alpha and Hsp90 beta.	[Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; O'Brien, K.; Chen, M.; Woodley, D. T.; Li, W.] Dept Dermatol, Los Angeles, CA USA; [Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; O'Brien, K.; Chen, M.; Woodley, D. T.; Li, W.] Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Tong, C.; Ying, Q.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA; [Tong, C.; Ying, Q.] Dept Cell & Neurobiol, Los Angeles, CA USA; [Situ, A. J.; Schmidt, T.; Ulmer, T. S.] Univ Southern Calif, Keck Med Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Situ, A. J.; Schmidt, T.; Ulmer, T. S.] Univ Southern Calif, Keck Med Ctr, Zilkha Neurogenet Inst, Los Angeles, CA USA; [Chen, M.; Woodley, D. T.; Li, W.] Greater Los Angeles Vet Affairs Heath Care Syst, Dept Med Res, Los Angeles, CA USA; [Zou, M.; Dong, H.] Southern Med Univ, Nanfang Hosp, Dept Endocrinol & Metab, Guangzhou 510515, Guangdong, Peoples R China	University of Southern California; University of Southern California; Southern Medical University - China	Li, W (corresponding author), Univ Southern Calif, Dept Dermatol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	wli@usc.edu		Jayaprakash, Priyamvada/0000-0003-3729-2943	NIH [GM066193, GM067100, AR059853, AR33625]; VA Merit Award [I01 BX002028]; National Cancer Institute [P30CA014089]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046538, R01AR059853, R01AR033625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067100, R01GM066193] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002028] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work is supported by NIH grants GM066193, GM067100 and AR059853 (to WL), AR33625 (MC and DTW) and VA Merit Award I01 BX002028 (to DTW). The project described was also supported in part by award number P30CA014089 from the National Cancer Institute (to USC).	ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chen JS, 2010, J BIOL CHEM, V285, P25458, DOI 10.1074/jbc.M110.139345; Cheng CF, 2008, MOL CELL BIOL, V28, P3344, DOI 10.1128/MCB.01287-07; Cheng CF, 2011, J CLIN INVEST, V121, P4348, DOI 10.1172/JCI46475; Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494; Devarakonda CV, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1608-z; Dong HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20605; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; El Hamidieh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042722; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Grad I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015770; Imai T, 2011, P NATL ACAD SCI USA, V108, P16363, DOI 10.1073/pnas.1108372108; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Li W, 2012, BBA-MOL CELL RES, V1823, P730, DOI 10.1016/j.bbamcr.2011.09.009; Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McCready J, 2014, CANCERS, V6, P1031, DOI 10.3390/cancers6021031; McCready J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-294; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Sahu D, 2012, MOL BIOL CELL, V23, P602, DOI 10.1091/mbc.E11-06-0575; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi YK, 2014, CLIN CANCER RES, V20, P6016, DOI 10.1158/1078-0432.CCR-14-0174; Sidera K, 2008, J BIOL CHEM, V283, P2031, DOI 10.1074/jbc.M701803200; Stellas D, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-51; Tsen F, 2013, MOL CELL BIOL, V33, P4947, DOI 10.1128/MCB.00559-13; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Tsutsumi S, 2008, ONCOGENE, V27, P2478, DOI 10.1038/sj.onc.1210897; Tsutsumi S, 2007, CANCER SCI, V98, P1536, DOI 10.1111/j.1349-7006.2007.00561.x; Voss AK, 2000, DEVELOPMENT, V127, P1; Wang XF, 2009, P NATL ACAD SCI USA, V106, P21288, DOI 10.1073/pnas.0908151106; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zagouri F, 2011, IN VIVO, V25, P669	41	41	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2160	2171		10.1038/onc.2016.375	http://dx.doi.org/10.1038/onc.2016.375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721406	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000399782500011
J	Tran, TQ; Lowman, XH; Reid, MA; Mendez-Dorantes, C; Pan, M; Yang, Y; Kong, M				Tran, T. Q.; Lowman, X. H.; Reid, M. A.; Mendez-Dorantes, C.; Pan, M.; Yang, Y.; Kong, M.			Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction	ONCOGENE			English	Article							GAIN-OF-FUNCTION; METABOLIC ADAPTATION; PANCREATIC-CANCER; INHIBITION; DRIVES; MUTATIONS; ARREST; GROWTH; GENES	Cancer cells depend on glutamine to sustain their increased proliferation and manage oxidative stress, yet glutamine is often depleted at tumor sites owing to excessive cellular consumption and poor vascularization. We have previously reported that p53 protein, although a well-known tumor suppressor, can contribute to cancer cell survival and adaptation to low-glutamine conditions. However, the TP53 gene is frequently mutated in tumors, and the role of mutant p53 (mutp53) in response to metabolic stress remains unclear. Here, we demonstrate that tumor-associated mutp53 promotes cancer cell survival upon glutamine deprivation both in vitro and in vivo. Interestingly, cancer cells expressing mutp53 proteins are more resistant to glutamine deprivation than cells with wild-type p53. Depletion of endogenous mutp53 protein in human lymphoma cells leads to cell sensitivity to glutamine withdrawal, whereas expression of mutp53 in p53 null cells results in resistance to glutamine deprivation. Furthermore, we found that mutp53 proteins hyper-transactivate p53-target gene CDKN1A upon glutamine deprivation, thus triggering cell cycle arrest and promoting cell survival. Together, our results reveal an unidentified mechanism by which mutp53 confers oncogenic functions by promoting cancer cell adaptation to metabolic stress.	[Tran, T. Q.; Lowman, X. H.; Reid, M. A.; Mendez-Dorantes, C.; Pan, M.; Yang, Y.; Kong, M.] City Hope Canc Ctr, Dept Canc Biol, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Kong, M (corresponding author), City Hope Canc Ctr, Dept Canc Biol, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA.	mekong@coh.org	Yang, Ying/I-8380-2019	MENDEZ-DORANTES, CARLOS/0000-0002-8190-8568; Reid, Michael/0000-0001-6222-9538	National Institutes of Health (NIH) [R01CA183989]; V Foundation for Cancer Research; NIH/NCI [P30CA33572]; NATIONAL CANCER INSTITUTE [P30CA033572, T32CA186895, R01CA183989] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Kong laboratory for helpful comments on the manuscript. We also thank Dr Zhaohui Feng (Rutgers University, New Jersey) for the mutp53 constructs. This work was supported by National Institutes of Health (NIH)/R01CA183989 to MK and the V Foundation for Cancer Research to MK. MK is the Pew Scholar in Biomedical Sciences and American Cancer Society Research Scholar (RSG-16-085-01-TBE). Research reported here includes work carried out in Core Facilities, supported by the NIH/NCI under grant number P30CA33572.	Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Budanov Andrei V, 2014, Subcell Biochem, V85, P337, DOI 10.1007/978-94-017-9211-0_18; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chakrabarti G, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0137-1; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; HARPER JW, 1993, CELL, V75, P805; Hernandez-Davies JE, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0581-2; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Korangath P, 2015, CLIN CANCER RES, V21, P3263, DOI 10.1158/1078-0432.CCR-14-1200; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lukey MJ, 2013, FUTURE MED CHEM, V5, P1685, DOI 10.4155/fmc.13.130; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Reid MA, 2013, MOL CELL, V50, P200, DOI 10.1016/j.molcel.2013.02.008; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; ROBERTS E, 1949, CANCER RES, V9, P350; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Rosales KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145938; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Thangavelu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep03827; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Young VR, 2001, J NUTR, V131, p2449S, DOI 10.1093/jn/131.9.2449S; Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	44	41	44	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1991	2001		10.1038/onc.2016.360	http://dx.doi.org/10.1038/onc.2016.360			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27721412	Green Accepted, Green Submitted			2022-12-28	WOS:000398898500009
J	Wang, SH; Chang, JS; Hsiao, JR; Yen, YC; Jiang, SS; Liu, SH; Chen, YL; Shen, YY; Chang, JY; Chen, YW				Wang, S-H; Chang, J. S.; Hsiao, J-R; Yen, Y-C; Jiang, S. S.; Liu, S-H; Chen, Y-L; Shen, Y-Y; Chang, J-Y; Chen, Y-W			Tumour cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial endothelial-mesenchymal transition of lymphatic endothelial cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA CELLS; SIGNALING PATHWAY; NODE METASTASIS; BINDING-PROTEIN; BREAST-CANCER; PROLIFERATION; EXPRESSION; PROMOTES; ANGIOGENESIS; VASCULATURE	Metastasis of the cervical lymph nodes frequently leads to poor survival of patients with oral squamous cell carcinoma (OSCC). The underlying mechanisms of lymph node metastasis are unclear. Wingless-type MMTV integration site family, member 5B (WNT5B), one component of the WNT signal pathway, was markedly up-regulated in OSCC sublines with high potential of lymphatic metastasis compared to that in OSCC cells with low nodal metastasis. Increased WNT5B mRNA was demonstrated in human OSCC tissues in comparison with adjacent non-tumorous tissues. Interestingly, the high level of WNT5B protein in serum was associated with lymph node metastasis in OSCC patients. Knockdown of WNT5B expression in OSCC sublines did not affect tumour growth but impaired lymph node metastasis and tumour lymphangiogenesis of orthotopic transplantation. Conditioned medium from WNT5B knockdown cells reduced the tube formation of lymphatic endothelial cells (LECs). In contrast, recombinant WNT5B enhanced the tube formation, permeability and migration of LECs. In LECs stained with phalloidin, the morphology of those treated with recombinant WNT5B changed from flat to spindle-like. Recombinant WNT5B also increased alpha-smooth muscle actin and inhibited the expression of vascular endothelial-cadherin but retained characteristics of endothelial cells. The results suggest that WNT5B functions in the partial endothelial-mesenchymal transition (EndoMT). Furthermore, WNT5B-induced tube formation was impaired in the LECs following the knockdown of EndoMT-related transcription factor, SNAIL or SLUG. The WNT5B-induced expression of Snail or Slug was abolished by IWR-1-endo and Rac1 inhibitors, which are involved in the WNT/beta-catenin and planar cell polarity pathways, respectively. Collectively, the data suggest that WNT5B induces tube formation by regulating the expression of Snail and Slug proteins through activation of canonical and non-canonical WNT signalling pathways.	[Wang, S-H; Yen, Y-C; Jiang, S. S.; Liu, S-H; Chen, Y-L; Chen, Y-W] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan Town 35053, Miaoli County, Taiwan; [Chang, J. S.] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hsiao, J-R] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Otolaryngol, Coll Med, Tainan, Taiwan; [Shen, Y-Y] Natl Hlth Res Inst, Pathol Core Lab, Miaoli, Taiwan; [Chang, J-Y] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Chen, Y-W] China Med Univ, Grad Inst Basic Med Sci, PhD Program Aging, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; China Medical University Taiwan	Chen, YW (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan Town 35053, Miaoli County, Taiwan.	ywc@nhri.org.tw	Chen, Ya-Wen/AAG-7549-2019; Chang, Jeffrey Shu-Ming/AAR-4161-2020; Jiang, Shih Sheng/J-9671-2019	Chen, Ya-Wen/0000-0002-6080-8859; Chang, Jeffrey Shu-Ming/0000-0002-3236-6205; Jiang, Shih Sheng/0000-0003-1909-437X	NSC [NSC 97-3112-B-001-016]; Ministry of Science and Technology [MOST 104-2314-B-400-014, NHRI CA-104-PP-04, MOHW105-TDU-B-212-112015]; National Health Research Institutes; Ministry of Health and Welfare, Taiwan	NSC(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health and Welfare, Taiwan	The authors thank Dr Wen-Chun Hung (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan) for providing technical support and reagents and Pathology Core Laboratory (National Health Research Institutes, Miaoli, Taiwan) for the scoring of immunohistochemistry staining. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). We are also grateful to the Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital for providing clinical samples. This study was supported by grants MOST 104-2314-B-400-014, NHRI CA-104-PP- 04 and MOHW105-TDU-B-212-112015 from Ministry of Science and Technology, National Health Research Institutes and Ministry of Health and Welfare, Taiwan, respectively.	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Andre P, 2012, J BIOL CHEM, V287, P44518, DOI 10.1074/jbc.M112.414441; Buttler K, 2013, DEV BIOL, V381, P365, DOI 10.1016/j.ydbio.2013.06.028; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166; Cooley BC, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006927; Dale TC, 1998, BIOCHEM J, V329, P209; Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750; Deraz EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025438; Dieterich LC, 2016, ADV DRUG DELIVER REV, V99, P148, DOI 10.1016/j.addr.2015.12.011; Festing Michael F W, 2002, ILAR J, V43, P244; Ghiabi P, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0386-3; Goodwin AM, 2007, GROWTH FACTORS, V25, P25, DOI 10.1080/08977190701272933; Green JL, 2008, TRENDS CELL BIOL, V18, P536, DOI 10.1016/j.tcb.2008.08.006; Hong YK, 2003, CELL TISSUE RES, V314, P85, DOI 10.1007/s00441-003-0747-8; Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007; Kato S, 2014, CANCER SCI, V105, P281, DOI 10.1111/cas.12336; Kestler HA, 2008, PHILOS T R SOC B, V363, P1333, DOI 10.1098/rstb.2007.2251; Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282; Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173; Liao CT, 2009, INT J RADIAT ONCOL, V73, P764, DOI 10.1016/j.ijrobp.2008.05.004; Lin F, 2012, IUBMB LIFE, V64, P717, DOI 10.1002/iub.1059; Lin ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043593; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Macheda ML, 2012, J BIOL CHEM, V287, P29312, DOI 10.1074/jbc.M112.362681; Mangioni S, 2005, J CLIN ENDOCR METAB, V90, P5349, DOI 10.1210/jc.2005-0272; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Miyahara M, 2007, CANCER-AM CANCER SOC, V110, P1287, DOI 10.1002/cncr.22900; Nicenboim J, 2015, NATURE, V522, P56, DOI 10.1038/nature14425; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pan MR, 2009, J CELL SCI, V122, P3358, DOI 10.1242/jcs.050005; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sleeman JP, 2009, INT J CANCER, V125, P2747, DOI 10.1002/ijc.24702; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Takeshita A, 2014, INT J ONCOL, V44, P59, DOI 10.3892/ijo.2013.2172; Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653; Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220; Welch-Reardon KM, 2014, J CELL SCI, V127, P2017, DOI 10.1242/jcs.143420; Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944; Yang LX, 2014, BMC CANCER, V14, DOI [10.1186/1471-2407-14-228, 10.1186/1471-2407-14-124]; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yen YC, 2015, ONCOTARGET, V6, P41837, DOI 10.18632/oncotarget.5995; Yen YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-6; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613	47	48	50	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1503	1515		10.1038/onc.2016.317	http://dx.doi.org/10.1038/onc.2016.317			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27593938				2022-12-28	WOS:000397458100005
J	Zhang, L; Wang, P; Qin, Y; Cong, Q; Shao, C; Du, Z; Ni, X; Li, P; Ding, K				Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Shao, C.; Du, Z.; Ni, X.; Li, P.; Ding, K.			RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-2; CLINICOPATHOLOGICAL SIGNIFICANCE; ACTIVATOR PROTEIN-1; FACTOR RECEPTOR; EXPRESSION; TRANSDUCTION; ANGIOGENESIS; METASTASIS; APOPTOSIS; GCS-100	Galectin-3 (Gal-3) has been implicated in pancreatic ductal adenocarcinoma (PDAC), and its candidacy as a therapeutic target has been evaluated. Gal-3 is widely upregulated in tumors, and its expression is associated with the development and malignancy of PDAC. In the present study, we demonstrate that a polysaccharide, RN1, purified from the flower of Panax notoginseng binds to Gal-3 and suppresses its expression. In addition, RN1 markedly inhibits PDAC cells growth in vitro, in vivo and in patient-derived xenografts. Mechanistically, RN1 binds to epidermal growth factor receptor (EGFR) and Gal-3, thereby disrupting the interaction between Gal-3 and EGFR and downregulating extracellular-related kinase (ERK) phosphorylation and the transcription factor of Gal-3, Runx1 expression. Inhibiting the expression of Runx1 by RN1, suppresses Gal-3 expression and inactivates Gal-3-associated signaling pathways, including the EGFR/ERK/Runx1, BMP/smad/Id-3 and integrin/FAK/JNK signaling pathways. In addition, RN1 can also bind to bone morphogenetic protein receptors (BMPR1A and BMPR2) and block the interaction between Gal-3 and the BMPRs. Thus, our results suggest that a novel Gal-3 inhibitor RN1 may be a potential candidate for human PDAC treatment via multiple targets and multiple signaling pathways.	[Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Du, Z.; Ni, X.; Ding, K.] Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; [Zhang, L.; Li, P.] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China; [Shao, C.] Second Mil Med Univ, Changzheng Hosp, Dept Gen Surg, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; China Pharmaceutical University; Naval Medical University	Ding, K (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.; Li, P (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China.	liping2004@126.com; dingkan@simm.ac.cn	Li, Ping/GYV-4914-2022	Cong, Qifei/0000-0002-4446-7222; Ding, Kan/0000-0002-8140-9259	National Natural Science Foundation of China [31230022]; New Drug Creation and Manufacturing Program [2012ZX09301001-003]; National Science Foundation of China [81421005]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010302]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Drug Creation and Manufacturing Program; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from National Natural Science Foundation of China (31230022), New Drug Creation and Manufacturing Program (2012ZX09301001-003), Innovative Research Groups of the National Science Foundation of China (81421005), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010302).	Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Blanchard H, 2014, EXPERT OPIN THER PAT, V24, DOI 10.1517/13543776.2014.947961; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chauhan D, 2005, CANCER RES, V65, P8350, DOI 10.1158/0008-5472.CAN-05-0163; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Di Lella S, 2011, BIOCHEMISTRY-US, V50, P7842, DOI 10.1021/bi201121m; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Iurisci I, 2000, CLIN CANCER RES, V6, P1389; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kobayashi T, 2011, INT J CANCER, V129, P2775, DOI 10.1002/ijc.25946; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Merlin J, 2011, ONCOGENE, V30, P2514, DOI 10.1038/onc.2010.631; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nangia-Makker P, 2002, JNCI-J NATL CANCER I, V94, P1854, DOI 10.1093/jnci/94.24.1854; Ochieng J, 2002, GLYCOCONJUGATE J, V19, P527, DOI 10.1023/B:GLYC.0000014082.99675.2f; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Shimamura T, 2002, CLIN CANCER RES, V8, P2570; Shin S, 2009, MOL CANCER RES, V7, P745, DOI 10.1158/1541-7786.MCR-08-0462; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; Stegmayr J, 2016, J BIOL CHEM, V291, P13318, DOI 10.1074/jbc.M116.721464; Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood-2009-10-251660; Tellez-Sanz R, 2013, CURR MED CHEM, V20, P2979, DOI 10.2174/09298673113209990163; Tobita K, 2003, INT J MOL MED, V11, P305; Uegaki K, 1997, ANTICANCER RES, V17, P3841; Wang PP, 2015, CARBOHYD POLYM, V121, P328, DOI 10.1016/j.carbpol.2014.11.073; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; YAMANAKA Y, 1993, ANTICANCER RES, V13, P565; Zhang HY, 2009, ENDOCRINE, V35, P101, DOI 10.1007/s12020-008-9129-z	44	45	46	5	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1297	1308		10.1038/onc.2016.306	http://dx.doi.org/10.1038/onc.2016.306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27617577				2022-12-28	WOS:000395861300013
J	Zamborszky, J; Szikriszt, B; Gervai, JZ; Pipek, O; Poti, A; Krzystanek, M; Ribli, D; Szalai-Gindl, JM; Csabai, I; Szallasi, Z; Swanton, C; Richardson, AL; Szuts, D				Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Pipek, O.; Poti, A.; Krzystanek, M.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.; Szallasi, Z.; Swanton, C.; Richardson, A. L.; Szuets, D.			Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions	ONCOGENE			English	Article							DNA-REPLICATION; HOMOLOGOUS RECOMBINATION; TRANSLESION SYNTHESIS; H2AX PHOSPHORYLATION; MUTATIONAL PROCESSES; HISTONE H2AX; REPAIR; CANCER; INSTABILITY; DAMAGE	Loss-of-function mutations in the BRCA1 and BRCA2 genes increase the risk of cancer. Owing to their function in homologous recombination repair, much research has focused on the unstable genomic phenotype of BRCA1/2 mutant cells manifest mainly as large-scale rearrangements. We used whole-genome sequencing of multiple isogenic chicken DT40 cell clones to precisely determine the consequences of BRCA1/2 loss on all types of genomic mutagenesis. Spontaneous base substitution mutation rates increased sevenfold upon the disruption of either BRCA1 or BRCA2, and the arising mutation spectra showed strong and specific correlation with a mutation signature associated with BRCA1/2 mutant tumours. To model endogenous alkylating damage, we determined the mutation spectrum caused by methyl methanesulfonate (MMS), and showed that MMS also induces more base substitution mutations in BRCA1/2-deficient cells. Spontaneously arising and MMS-induced insertion/deletion mutations and large rearrangements were also more common in BRCA1/2 mutant cells compared with the wild-type control. A difference in the short deletion phenotypes of BRCA1 and BRCA2 suggested distinct roles for the two proteins in the processing of DNA lesions, as BRCA2 mutants contained more short deletions, with a wider size distribution, which frequently showed microhomology near the breakpoints resembling repair by non-homologous end joining. An increased and prolonged gamma-H2AX signal in MMS-treated BRCA1/2 cells suggested an aberrant processing of stalled replication forks as the cause of increased mutagenesis. The high rate of base substitution mutagenesis demonstrated by our experiments is likely to significantly contribute to the oncogenic effect of the inactivation of BRCA1 or BRCA2.	[Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Poti, A.; Szuets, D.] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary; [Pipek, O.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.] Eotvos Lorand Univ, Dept Phys Complex Syst, Budapest, Hungary; [Krzystanek, M.; Szallasi, Z.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, Lyngby, Denmark; [Szallasi, Z.] Boston Childrens Hosp, CHIP, Boston, MA USA; [Szallasi, Z.] Harvard Med Sch, Boston, MA USA; [Szallasi, Z.] Semmelweis Univ, Dept Pathol 2, Brain Metastasis Res Grp, MTA SE NAP, Budapest, Hungary; [Swanton, C.] UCL Canc Inst, CRUK Lung Canc Ctr Excellence, London, England; [Swanton, C.] Francis Crick Inst, 44 Lincolns Inn Fields, London WCA2 3PX, England; [Richardson, A. L.] Johns Hopkins Med, Sibley Pathol Dept, Dept Pathol, 5255 Loughboro Rd NW, Washington, DC 20016 USA	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Technical University of Denmark; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Semmelweis University; University of London; University College London; Johns Hopkins University; Johns Hopkins Medicine	Szuts, D (corresponding author), Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary.; Swanton, C (corresponding author), Francis Crick Inst, 44 Lincolns Inn Fields, London WCA2 3PX, England.; Richardson, AL (corresponding author), Johns Hopkins Med, Sibley Pathol Dept, Dept Pathol, 5255 Loughboro Rd NW, Washington, DC 20016 USA.	charles.swanton@crick.ac.uk; aricha58@jhmi.edu; szuts.david@ttk.mta.hu	Pipek, Orsolya/J-3124-2018; Szalai-Gindl, Janos M/I-4734-2017; Csabai, Istvan/F-6045-2011; Szuts, David/N-1149-2016	Pipek, Orsolya/0000-0001-8109-0340; Szalai-Gindl, Janos M/0000-0002-0169-0547; Csabai, Istvan/0000-0001-9232-9898; Szuts, David/0000-0001-7985-0136; Swanton, Charles/0000-0002-4299-3018; Szallasi, Zoltan/0000-0001-5395-7509	Momentum of the Hungarian Academy of Sciences [LP2011-015]; Breast Cancer Research Foundation of the National Research, Development and Innovation Office, Hungary [KMR-12-1-2012-0216]; Novo Nordisk Foundation Interdisciplinary Synergy Programme [NNF15OC0016584]; Basser Foundation; Cancer Research UK (TRACERx); CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C); Rosetrees Trust; Prostate Cancer Foundation; Breast Cancer Research Foundation; University College London Hospitals Biomedical Research Centre; Cancer Research UK University College London Experimental Cancer Medicine Centre; Szechenyi Progam, Hungary [KTIA_NAP_13-2014-0021]; Novo Nordisk Foundation [16584]; EU FP7 [259303]; European Research Council (THESEUS); National Institute for Health Research; Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish	Momentum of the Hungarian Academy of Sciences; Breast Cancer Research Foundation of the National Research, Development and Innovation Office, Hungary; Novo Nordisk Foundation Interdisciplinary Synergy Programme; Basser Foundation; Cancer Research UK (TRACERx); CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C); Rosetrees Trust(Rosetrees Trust); Prostate Cancer Foundation; Breast Cancer Research Foundation; University College London Hospitals Biomedical Research Centre(General Electric); Cancer Research UK University College London Experimental Cancer Medicine Centre; Szechenyi Progam, Hungary; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EU FP7(European Commission); European Research Council (THESEUS)(European Research Council (ERC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Janos Molnar for his assistance in data processing. This study was supported by Momentum Grant LP2011-015 of the Hungarian Academy of Sciences (DS), the Breast Cancer Research Foundation (AR, ZS, CS), grant KMR-12-1-2012-0216 of the National Research, Development and Innovation Office, Hungary (IC). and Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant NNF15OC0016584 (ZS and IC). ZS acknowledges support by the Basser Foundation and the Szechenyi Progam, Hungary (KTIA_NAP_13-2014-0021). CS is a senior Cancer Research UK clinical research fellow and is funded by Cancer Research UK (TRACERx), the CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), the Rosetrees Trust, Novo Nordisk Foundation (ID 16584), EU FP7 (projects PREDICT and RESPONSIFY, ID: 259303), the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council (THESEUS) and support was provided to CS by the National Institute for Health Research, the University College London Hospitals Biomedical Research Centre, and the Cancer Research UK University College London Experimental Cancer Medicine Centre.	Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Arakawa H, 2006, PLOS BIOL, V4, P1947, DOI 10.1371/journal.pbio.0040366; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Branzei D, 2011, FEBS LETT, V585, P2810, DOI 10.1016/j.febslet.2011.04.053; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; COSMIC, SIGN MUT PROC HUM CA; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Edmunds CE, 2008, MOL CELL, V30, P519, DOI 10.1016/j.molcel.2008.03.024; Ensminger M, 2014, J CELL BIOL, V206, P29, DOI 10.1083/jcb.201312078; Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054; Faust GG, 2014, BIOINFORMATICS, V30, P2503, DOI 10.1093/bioinformatics/btu314; Feng ZZ, 2012, J PALAEOGEOG-ENGLISH, V1, P1, DOI 10.3724/SP.J.1261.2012.00001; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; JORGENSEN TJ, 1991, RADIAT RES, V127, P107, DOI 10.2307/3578096; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Loeb LA, 2011, NAT REV CANCER, V11, P450, DOI 10.1038/nrc3063; Lundin C, 2005, NUCLEIC ACIDS RES, V33, P3799, DOI 10.1093/nar/gki681; Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290; Mayle R, 2015, SCIENCE, V349, P742, DOI 10.1126/science.aaa8391; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Molnar J, 2014, G3-GENES GENOM GENET, V4, P2231, DOI 10.1534/g3.114.013482; Murugaesu N, 2015, CANCER DISCOV, V5, P821, DOI 10.1158/2159-8290.CD-15-0412; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ottaviani D, 2014, TRENDS GENET, V30, P85, DOI 10.1016/j.tig.2014.01.001; Pathania S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6496; Pathania S, 2011, MOL CELL, V44, P235, DOI 10.1016/j.molcel.2011.09.002; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pfeifer GP, 2006, CURR TOP MICROBIOL, V301, P259; Pipek O, ACCURATE MUTAT UNPUB; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Ribli D, ISOMUT ROBUST METHOD; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; Sale JE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012708; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Su X, 2008, NAT STRUCT MOL BIOL, V15, P1049, DOI 10.1038/nsmb.1490; Szuts D, 2008, NUCLEIC ACIDS RES, V36, P6767, DOI 10.1093/nar/gkn651; Szuts D, 2004, J CELL SCI, V117, P4897, DOI 10.1242/jcs.01374; Szuts D, 2006, MOL CELL BIOL, V26, P8032, DOI 10.1128/MCB.01291-06; Thorslund T, 2007, ONCOGENE, V26, P7720, DOI 10.1038/sj.onc.1210870; Timms KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0475-x; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Varga A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052472; Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/nmeth.1628, 10.1038/NMETH.1628]; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	58	57	57	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					746	755		10.1038/onc.2016.243	http://dx.doi.org/10.1038/onc.2016.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27452521	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000394168200002
J	Cai, G; Wu, D; Wang, Z; Xu, Z; Wong, KB; Ng, CF; Chan, FL; Yu, S				Cai, G.; Wu, D.; Wang, Z.; Xu, Z.; Wong, K-B; Ng, C-F; Chan, F. L.; Yu, S.			Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization	ONCOGENE			English	Article							MOLECULAR CHARACTERIZATION; THERAPEUTIC TARGET; CELL INVASION; EXPRESSION; RECEPTOR; GROWTH; PROGRESSION; UNC-33; FAMILY; DIHYDROPYRIMIDINASE	The cancer cells can acquire migration and invasion capacities during the metastasis process through the developmental regulatory program epithelial-mesenchymal-transition (EMT), and through its reverse process mesenchymal-epithelial transition cancer cells can recolonize at distant metastatic sites. Among the multifaceted effects exerted by this program, reorganization of actin cytoskeleton is the key mechanical drive for the invasive properties gained by cancer cells. Collapsin response mediator protein-1 (CRMP1) is a cytosolic phosphoprotein and originally characterized as the mediator of semaphorin 3A signaling involved in axon differentiation during neural development. Here we report that CRMP1 can act as a suppressor of tumorigenicity and metastasis in prostate cancer cells. We demonstrated that CRMP1 exhibited a decreased expression pattern in high-grade prostate cancer tissues and many prostate cancer cell lines, and its downregulation in cancer cells was attributed to histone deacetylation and direct repression of its gene by the EMT regulator Snail. Functional analyses revealed that CRMP1 suppressed EMT in prostate cancer cells, as its knockdown could trigger EMT and enhance in vitro invasion capacity, whereas its overexpression could inhibit EMT and suppress both in vitro invasion and in vivo metastasis capacities of prostate cancer cells. Moreover, CRMP1 overexpression could significantly confer resistance to EMT induced by Snail or transforming growth factor-beta 1 in prostatic epithelial cells and prostate cancer cells. Finally, we demonstrated that CRMP1 could associate with actin and WAVE1, an activator of actin nucleation complex Arp2/3, and also its knockdown could stabilize F-actin and trigger the formation of stress fibers in prostate cancer cells. Together, our study shows that CRMP1 acts an EMT and metastasis suppressor in prostate cancer cells via its regulation of actin polymerization and also suggests that targeting the CRMP1-actin signaling in actin organization could be a potential strategy for management of prostate cancer metastasis.	[Cai, G.; Wu, D.; Wang, Z.; Xu, Z.; Chan, F. L.; Yu, S.] Chinese Univ Hong Kong, Sch Biomed Sci, Kwee Seong Integrated Biomed Sci Bldg, Shatin, Hong Kong, Peoples R China; [Wong, K-B] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Ng, C-F] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, FL; Yu, S (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Kwee Seong Integrated Biomed Sci Bldg, Shatin, Hong Kong, Peoples R China.	franky-chan@cuhk.edu.hk; yushan771@hotmail.com	Chi-fai, NG/AAV-8270-2021; Wong, Kam-Bo/AAU-9364-2021; Ng, Chi-Fai/E-5134-2011; Wong, Kam-Bo/G-4258-2013; Chan, Franky L./M-1043-2018	Wong, Kam-Bo/0000-0002-6984-5373; Ng, Chi-Fai/0000-0002-1723-9646; Wong, Kam-Bo/0000-0002-6984-5373; Chan, Franky L./0000-0003-0567-2052; Wang, Zhu/0000-0002-5457-3731; Wu, Dinglan/0000-0002-5057-9626	earmarked research grant from the Research Grants Council of Hong Kong [CUHK4411-/06M]; research grant from the National Natural Science Foundation of China	earmarked research grant from the Research Grants Council of Hong Kong; research grant from the National Natural Science Foundation of China	We thank Dr Isaiah Fidler for providing the PC-3M and PC-3M-LN4 cell lines, Dr Andrew ML Chan for the A549 cell line, Dr Cheng-Chung Wu for the pGL3-CRMP1-Luc and Dr Alexander Staruschenko for the pcDNA3.1-His-WASF1. This work was supported by an earmarked research grant from the Research Grants Council of Hong Kong (project no. CUHK4411-/06M) and a research grant from the National Natural Science Foundation of China.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Byk T, 1996, J NEUROSCI, V16, P688; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gao M, 2008, BIOCHEM BIOPH RES CO, V376, P283, DOI 10.1016/j.bbrc.2008.08.144; Gao X, 2010, ONCOGENE, V29, P4555, DOI 10.1038/onc.2010.213; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Hiroshima Y, 2013, ANN SURG ONCOL, V20, pS369, DOI 10.1245/s10434-012-2491-3; Hu Y, 2002, J BIOL CHEM, V277, P44462, DOI 10.1074/jbc.M205784200; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kawano Y, 2005, MOL CELL BIOL, V25, P9920, DOI 10.1128/MCB.25.22.9920-9935.2005; Leung T, 2002, FEBS LETT, V532, P445, DOI 10.1016/S0014-5793(02)03736-5; Lui K, 2006, PROSTATE, V66, P1600, DOI 10.1002/pros.20429; Meyronet D, 2008, AM J SURG PATHOL, V32, P1699, DOI 10.1097/PAS.0b013e31817dc37c; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Oliemuller E, 2013, INT J CANCER, V132, P1986, DOI 10.1002/ijc.27881; Pan SH, 2011, J CLIN INVEST, V121, P3189, DOI 10.1172/JCI42975; Pan SH, 2010, LUNG CANCER, V67, P93, DOI 10.1016/j.lungcan.2009.03.006; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Smith BN, 2012, CELL ADHES MIGR, V6, P433, DOI 10.4161/cam.21687; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wu CC, 2008, MOL CANCER THER, V7, P1365, DOI 10.1158/1535-7163.MCT-08-0091; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Yamashita N, 2012, MOL NEUROBIOL, V45, P234, DOI 10.1007/s12035-012-8242-4; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110	40	32	32	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					546	558		10.1038/onc.2016.227	http://dx.doi.org/10.1038/onc.2016.227			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321179	Green Published, hybrid			2022-12-28	WOS:000394166700011
J	Yao, R; Oyanagi, J; Natsume, Y; Kusama, D; Kato, Y; Nagayama, S; Noda, T				Yao, R.; Oyanagi, J.; Natsume, Y.; Kusama, D.; Kato, Y.; Nagayama, S.; Noda, T.			Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cells	ONCOGENE			English	Article							IN-VIVO; FUNCTION LEADS; CANCER; EXPRESSION; GENE; PROTEIN; TACC3; LRIG1; CRYPT; LGR5	Human colorectal cancer is often initiated by the aberrant activation of Wnt signaling, notably following adenomatous polyposis coli (Apc) inactivation. Recent studies identified adult intestinal stem cells (ISCs) and demonstrated their role as the cells of origin for intestinal tumors. However, the early consequences of aberrant Wnt signaling activation remain to be fully elucidated. Here, using organoid cultures established from conditional knockout mice and in vitro gene ablation, we show that Apc inactivation led to aberrant ISC proliferation and the expansion of the crypt domain. This system was used to evaluate the potential of a cancer-related spindle protein, Tacc3, as a target of cancer therapy, as its disruption led to the suppression of tumor formation in an animal model of intestinal tumors. We found that Tacc3 is required for the proper mitosis of Apc-deficient ISCs, and its disruption significantly attenuated the expansion of the crypt domain. In vivo analysis of corresponding mutant mice demonstrated that Tacc3 disruption led to a significant decrease in tumor number and prolonged survival. These observations demonstrated that Tacc3 is a potential chemotherapeutic target for intestinal tumors by perturbing the aberrant cell proliferation of Apc-deficient ISCs and provides an opportunity for the development of novel cancer prevention and treatment.	[Yao, R.; Oyanagi, J.; Natsume, Y.; Kusama, D.; Kato, Y.; Noda, T.] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan; [Nagayama, S.] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Koto Ku, Tokyo, Japan; [Noda, T.] Japanese Fdn Canc Res, Inst Canc, Koto Ku, Directors Room, Tokyo, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Yao, R (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp			Japan Agency for Medical Research and Development, AMED; Ministry of Education, Culture, Sports, Science and Technology of Japan; Vehicle Racing Commemorative Foundation; Grants-in-Aid for Scientific Research [25640094, 16K14620] Funding Source: KAKEN	Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Vehicle Racing Commemorative Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Tomoyuki Kitagawa for continuous support and Ms Yuki Ota for technical assistance with the microarray analysis. We also thank Dr Toshiro Sato for valuable advice on the mouse intestine organoid culture. This study is partially supported by the research program for the Project for Development of Innovative Research on Cancer Therapeutics, P-Direct from the Japan Agency for Medical Research and Development, AMED (RY), Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (RY), and The Vehicle Racing Commemorative Foundation (RY).	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031; Fatehullah A, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0014; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Holik AZ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004453; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kabiri Z, 2014, DEVELOPMENT, V141, P2206, DOI 10.1242/dev.104976; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Phesse TJ, 2008, MOL CELL BIOL, V28, P6094, DOI 10.1128/MCB.00539-08; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roman AKS, 2014, STEM CELL REP, V2, P127, DOI 10.1016/j.stemcr.2013.12.012; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Snippert HJ, 2009, GASTROENTEROLOGY, V136, P2187, DOI 10.1053/j.gastro.2009.03.002; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Yao R, 2012, ONCOGENE, V31, P135, DOI 10.1038/onc.2011.235; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	46	7	8	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6109	6119		10.1038/onc.2016.148	http://dx.doi.org/10.1038/onc.2016.148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157623				2022-12-28	WOS:000388509800007
J	Zhou, JZ; Riquelme, MA; Gu, S; Kar, R; Gao, X; Sun, L; Jiang, JX				Zhou, J. Z.; Riquelme, M. A.; Gu, S.; Kar, R.; Gao, X.; Sun, L.; Jiang, J. X.			Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis	ONCOGENE			English	Article							GAP-JUNCTION HEMICHANNELS; HUMAN-TUMOR-CELLS; PARATHYROID-HORMONE; IN-VIVO; INTERCELLULAR COMMUNICATION; PHYSICAL-ACTIVITY; ATP RELEASE; FLUID-FLOW; SURVIVAL; MICE	Although the skeleton is one of the predominant sites for breast cancer metastasis, why breast cancer cells often become dormant after homing to bone is not well understood. Here, we reported an intrinsic self-defense mechanism of bone cells against breast cancer cells: a critical role of connexin (Cx) 43 hemichannels in osteocytes in the suppression of breast cancer bone metastasis. Cx43 hemichannels allow passage of small molecules between the intracellular and extracellular environments. The treatment of bisphosphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43 hemichannels in osteocytes. Conditioned media (CM) collected from MLO-Y4 osteocyte cells treated with bisphosphonates inhibited the anchorage-independent growth, migration and invasion of MDA-MB-231 human breast cancer cells and Py8119 mouse mammary carcinoma cells, and this inhibitory effect was attenuated with Cx43(E2), a specific hemichannel-blocking antibody. The opening of osteocytic Cx43 hemichannels by mechanical stimulation had similar inhibitory effects on breast cancer cells and this inhibition was attenuated by Cx43(E2) antibody as well. These inhibitory effects on cancer cells were mediated by ATP released from osteocyte Cx43 hemichannels. Furthermore, both Cx43 osteocyte-specific knockout mice and osteocyte-specific.130-136 transgenic mice with impaired Cx43 gap junctions and hemichannels showed significantly increased tumor growth and attenuated the inhibitory effect of ZOL. However, R76W transgenic mice with functional hemichannels but not gap junctions in osteocytes did not display a significant difference. Together, our studies establish the specific inhibitory role of osteocytic Cx43 hemichannels, and exploiting the activity of this channel could serve as a de novo therapeutic strategy.	[Zhou, J. Z.; Riquelme, M. A.; Gu, S.; Kar, R.; Gao, X.; Jiang, J. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Sun, L.] Dept Cellular & Struct Biol, San Antonio, TX USA; [Sun, L.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu	Riquelme, Manuel/B-1082-2015	Riquelme, Manuel/0000-0002-1915-0434; Jiang, Jean/0000-0002-2185-5716	Welch Foundation [AQ-1507]; NIH [EY012085, ES022057]; NCI Cancer Center grant [2 P30 CA054174-17]; NATIONAL CANCER INSTITUTE [R01CA196214, P30CA054174] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012085, R29EY012085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022057] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Hongyun Cheng for technical assistance, Dr Lesley Ellies at the University of California at San Diego for providing Py8119 cells, Dr Lynda Bonewald at the University of Missouri at Kansas City for MLO-Y4 osteocytic cells, Dr Stephen Harris at UTHSCSA for 10-kb dentin matrix protein 1 (DMP1)-Cre mice and Dr Klaus Willecke at the University of Bonn and Dr Roberto Civitelli for mice with floxed Cx43 gene. The work was supported by Welch Foundation grant AQ-1507 and NIH grant EY012085 to JXJ, ES022057 to LZS and the NCI Cancer Center grant 2 P30 CA054174-17 to Cancer Therapy and Research Center.	AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304; Avanzo JL, 2004, CARCINOGENESIS, V25, P1973, DOI 10.1093/carcin/bgh193; Bennett MVL, 2012, BRAIN RES, V1487, P3, DOI 10.1016/j.brainres.2012.08.042; Bivi N, 2013, J ORTHOP RES, V31, P1075, DOI 10.1002/jor.22341; Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548; Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120; Calder BW, 2015, TISSUE ENG PT A, V21, P1752, DOI [10.1089/ten.tea.2014.0651, 10.1089/ten.TEA.2014.0651]; Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; Cherian PP, 2008, CELL COMMUN ADHES, V15, P43, DOI 10.1080/15419060802310208; Chung DJ, 2006, J CELL SCI, V119, P4187, DOI 10.1242/jcs.03162; Cronier L, 2009, ANTIOXID REDOX SIGN, V11, P323, DOI 10.1089/ars.2008.2153; D'hondt C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00348; Dbouk HA, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-4; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055-9965.EPI-07-0771; Irwin ML, 2011, CANCER PREV RES, V4, P522, DOI 10.1158/1940-6207.CAPR-10-0295; Jiang JX, 2007, FRONT BIOSCI-LANDMRK, V12, P1450, DOI 10.2741/2159; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622; Klein-Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013; Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147-007-0726-2; Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555-012-9378-4; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Loiselle AE, 2013, J ORTHOP RES, V31, P147, DOI 10.1002/jor.22178; Lynch ME, 2013, J BONE MINER RES, V28, P2357, DOI 10.1002/jbmr.1966; Matsuo K, 2009, CURR OPIN NEPHROL HY, V18, P292, DOI 10.1097/MNH.0b013e32832b75f1; Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Milne HM, 2008, BREAST CANCER RES TR, V108, P279, DOI 10.1007/s10549-007-9602-z; Orellana JA, 2012, GLIA, V60, P53, DOI 10.1002/glia.21246; Orellana JA, 2011, J NEUROSCI, V31, P4962, DOI 10.1523/JNEUROSCI.6417-10.2011; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Plante I, 2011, ONCOGENE, V30, P1681, DOI 10.1038/onc.2010.551; Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Plotkin LI, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00131; RAPAPORT E, 1983, CANCER RES, V43, P4402; Riquelme MA, 2013, NEUROPHARMACOLOGY, V75, P525, DOI 10.1016/j.neuropharm.2013.02.021; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022; Saez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365-201X.2003.01196.x; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969; Schwartz AL, 2007, ONCOL NURS FORUM, V34, P627, DOI 10.1188/07.ONF.627-633; Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x; Siller-Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200; Stains JP, 2005, BBA-BIOMEMBRANES, V1719, P69, DOI 10.1016/j.bbamem.2005.10.012; Sterling Julie A, 2011, Curr Osteoporos Rep, V9, P89, DOI 10.1007/s11914-011-0052-5; Stoletov K, 2013, J CELL SCI, V126, P904, DOI 10.1242/jcs.112748; Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526-968X(200101)29:1<1::AID-GENE1000>3.0.CO;2-0; Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Welch D. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P30; White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004; Xu HY, 2014, J BONE MINER RES, V29, pS430; Xu HY, 2015, J BONE MINER RES, V30, P550, DOI 10.1002/jbmr.2374; Yang WC, 2005, J BIOL CHEM, V280, P20680, DOI 10.1074/jbc.M500104200; Zhang W, 2011, BIOCHEM PHARMACOL, V82, P411, DOI 10.1016/j.bcp.2011.05.009; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516; Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113; Zhou JZ, 2014, FEBS LETT, V588, P1186, DOI 10.1016/j.febslet.2014.01.001	74	57	61	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5597	5607		10.1038/onc.2016.101	http://dx.doi.org/10.1038/onc.2016.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27041582	Green Accepted			2022-12-28	WOS:000386998300003
J	Weekes, D; Kashima, TG; Zandueta, C; Perurena, N; Thomas, DP; Sunters, A; Vuillier, C; Bozec, A; El-Emir, E; Miletich, I; Patino-Garcia, A; Lecanda, F; Grigoriadis, AE				Weekes, D.; Kashima, T. G.; Zandueta, C.; Perurena, N.; Thomas, D. P.; Sunters, A.; Vuillier, C.; Bozec, A.; El-Emir, E.; Miletich, I.; Patino-Garcia, A.; Lecanda, F.; Grigoriadis, A. E.			Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1 (vol 35, pg 2852, 2016)	ONCOGENE			English	Correction													Bozec, Aline/M-6942-2015; Patiño-Garcia, Ana/I-4299-2012	Bozec, Aline/0000-0001-8174-2118; Patiño-Garcia, Ana/0000-0002-4066-8203; Weekes, Daniel/0000-0001-8083-7617; Zandueta Pascual, Carolina/0000-0002-7931-8649				Weekes D, 2016, ONCOGENE, V35, P2852, DOI 10.1038/onc.2015.344	1	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2948	2948		10.1038/onc.2015.420	http://dx.doi.org/10.1038/onc.2015.420			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	27251742	Bronze			2022-12-28	WOS:000377473700014
J	Weitsman, G; Mitchell, NJ; Evans, R; Cheung, A; Kalber, TL; Bofinger, R; Fruhwirth, GO; Keppler, M; Wright, ZVF; Barber, PR; Gordon, P; de Koning, T; Wulaningsih, W; Sander, K; Vojnovic, B; Ameer-Beg, S; Lythgoe, M; Arnold, JN; Arstad, E; Festy, F; Hailes, HC; Tabor, AB; Ng, T				Weitsman, G.; Mitchell, N. J.; Evans, R.; Cheung, A.; Kalber, T. L.; Bofinger, R.; Fruhwirth, G. O.; Keppler, M.; Wright, Z. V. F.; Barber, P. R.; Gordon, P.; de Koning, T.; Wulaningsih, W.; Sander, K.; Vojnovic, B.; Ameer-Beg, S.; Lythgoe, M.; Arnold, J. N.; Arstad, E.; Festy, F.; Hailes, H. C.; Tabor, A. B.; Ng, T.			Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NEGATIVE BREAST-CANCER; TUMOR-CELL MIGRATION; PHASE-II TRIAL; COLORECTAL-CANCER; PEPTIDE LIGAND; DELIVERY; MACROPHAGES; PHOSPHORYLATION; QUANTIFICATION	Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of overall survival. Intratumoral heterogeneity is proposed as a major mechanism underlying treatment failure of these moleculetargeted agents. Here we highlight the application of fluorescence lifetime microscopy (FLIM)-based biosensing to demonstrate intratumoral heterogeneity of EGFR activity. For sensing EGFR activity in cells, we used a genetically encoded CrkII-based biosensor which undergoes conformational changes upon tyrosine-221 phosphorylation by EGFR. We transfected this biosensor into EGFR-positive tumour cells using targeted lipopolyplexes bearing EGFR-binding peptides at their surfaces. In a murine model of basal-like breast cancer, we demonstrated a significant degree of intratumoral heterogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ. Furthermore, a significant correlation between high EGFR activity in tumour cells and macrophage-tumour cell proximity was found to in part account for the intratumoral heterogeneity in EGFR activity observed. The same effect of macrophage infiltrate on EGFR activation was also seen in a colorectal cancer xenograft. In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR conformational mutant exhibited macrophage proximity-independent EGFR activity. Our study validates the use of this methodology to monitor therapeutic response in terms of EGFR activity. In addition, we found iNOS gene induction in macrophages that are cultured in tumour cell-conditioned media as well as an iNOS activity-dependent increase in EGFR activity in tumour cells. These findings point towards an immune microenvironment-mediated regulation that gives rise to the observed intratumoral heterogeneity of EGFR signalling activity in tumour cells in vivo.	[Weitsman, G.; Evans, R.; Cheung, A.; Fruhwirth, G. O.; Keppler, M.; Ameer-Beg, S.; Ng, T.] Kings Coll London, Randall Div, Richard Dimbleby Dept Canc Res, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England; [Weitsman, G.; Evans, R.; Cheung, A.; Fruhwirth, G. O.; Keppler, M.; de Koning, T.; Ameer-Beg, S.; Arnold, J. N.; Ng, T.] Kings Coll London, Div Canc Studies, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England; [Mitchell, N. J.; Bofinger, R.; Wright, Z. V. F.; Hailes, H. C.; Tabor, A. B.] UCL, Dept Chem, London WC1H 0AJ, Greater London, England; [Cheung, A.; Gordon, P.; Ng, T.] Kings Coll London, Breast Canc Now Res Unit, London, England; [Kalber, T. L.; Lythgoe, M.] UCL, Div Med, UCL Ctr Adv Biomed Imaging, London, England; [Barber, P. R.; Vojnovic, B.] Canc Res UK, Dept Oncol, Gray Labs, London, England; [Barber, P. R.; Vojnovic, B.] MRC, Oxford Inst Radiat Oncol, Oxford, England; [Wulaningsih, W.] Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England; [Sander, K.; Arstad, E.] UCL, Inst Nucl Med, London, England; [Festy, F.] Kings Coll London, Dent Inst, Tissue Engn & Biophoton, Guys Hosp Campus, London, England; [Ng, T.] UCL, UCL Canc Inst, Paul Ogorman Bldg, London, England; [Fruhwirth, G. O.] Kings Coll London, St Thomas Hosp, Div Imaging Sci & Biomed Engn, Dept Imaging Chem & Biol, London SE1 7EH, England; [Mitchell, N. J.] Univ Nottingham, Sch Chem, Univ Pk, Nottingham NG7 2RD, England	University of London; King's College London; University of London; King's College London; University of London; University College London; University of London; King's College London; University of London; University College London; Cancer Research UK; University of Oxford; University of London; King's College London; University of London; University College London; University of London; King's College London; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Nottingham	Ng, T (corresponding author), Kings Coll London, Randall Div, Richard Dimbleby Dept Canc Res, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England.; Ng, T (corresponding author), Kings Coll London, Div Canc Studies, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England.; Tabor, AB (corresponding author), UCL, Dept Chem, London WC1H 0AJ, Greater London, England.	a.b.tabor@ucl.ac.uk; tony.ng@kcl.ac.uk	Arnold, James/ABE-3900-2021; Mitchell, Nicholas/N-7555-2015; Evans, Rachel/GYU-7083-2022; Vojnovic, Borivoj/AAV-4756-2021; Fruhwirth, Gilbert/AAP-5559-2021	Arnold, James/0000-0002-6949-0613; Mitchell, Nicholas/0000-0002-9041-1852; Vojnovic, Borivoj/0000-0001-9013-3816; Fruhwirth, Gilbert/0000-0002-1438-2674; Kalber, Tammy/0000-0002-3378-3748; Evans, Rachel/0000-0002-3723-2249; Hailes, Helen/0000-0001-5574-4742; Bofinger, Robin/0000-0002-3866-1301; Arstad, Erik/0000-0002-3240-2106; Ng, Tony/0000-0003-3894-5619; Lythgoe, Mark/0000-0002-4945-0171; Ameer-Beg, Simon/0000-0001-5227-575X	Cancer Research-UK [C1519/A6906, C5255/A15935]; King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK EPSRC); EU; EC GRANT [259881]; The European Research Council [335326]; National Institute of Health Research (NIHR) Biomedical Research Centre; St Thomas' NHS Foundation Trust; King's College London; Cancer Research UK [15677, 16463, 21840] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/L006472/1] Funding Source: researchfish; EPSRC [EP/L006472/1] Funding Source: UKRI	Cancer Research-UK(Cancer Research UK); King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EU(European Commission); EC GRANT; The European Research Council(European Research Council (ERC)); National Institute of Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); St Thomas' NHS Foundation Trust; King's College London(General Electric); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by Cancer Research-UK (grants C1519/A6906 and C5255/A15935); the King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK & EPSRC) and in association with the MRC and DoH; by the EU FP7 grants IMAGINT (EC GRANT: 259881); by The European Research Council (335326). National Institute of Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.	Arrowsmith J, 2011, NAT REV DRUG DISCOV, V10, P1, DOI 10.1038/nrd3375; Barber PR, 2009, J R SOC INTERFACE, V6, pS93, DOI 10.1098/rsif.2008.0451.focus; Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Fan YS, 2013, GENET TEST MOL BIOMA, V17, P515, DOI 10.1089/gtmb.2012.0510; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fruhwirth GO, 2014, J NUCL MED, V55, P686, DOI 10.2967/jnumed.113.127480; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Grosse SM, 2010, FASEB J, V24, P2301, DOI 10.1096/fj.09-144220; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Hurley CA, 2004, J ORG CHEM, V69, P980, DOI 10.1021/jo035422g; Hurley CA, 2008, ORG BIOMOL CHEM, V6, P2554, DOI 10.1039/b719702k; Irshad S, 2011, CURR OPIN ONCOL, V23, P566, DOI 10.1097/CCO.0b013e32834bf8ae; Kasic T, 2011, EUR J IMMUNOL, V41, P1843, DOI 10.1002/eji.201040868; Keese M, 2005, J BIOL CHEM, V280, P27826, DOI 10.1074/jbc.M504485200; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kudsiova L, 2011, MOL PHARMACEUT, V8, P1831, DOI 10.1021/mp2001796; Kullberg M, 2013, J CONTROL RELEASE, V172, P730, DOI 10.1016/j.jconrel.2013.08.300; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Li ZH, 2005, FASEB J, V19, P1978, DOI 10.1096/fj.05-4058com; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Medina OP, 2011, J CONTROL RELEASE, V149, P292, DOI 10.1016/j.jconrel.2010.10.024; Mickler FM, 2012, NANO LETT, V12, P3417, DOI 10.1021/nl300395q; Mitchell N, 2013, BIOMATERIALS, V34, P1179, DOI 10.1016/j.biomaterials.2012.09.070; Modi S, 2006, CLIN BREAST CANCER, V7, P270, DOI 10.3816/CBC.2006.n.040; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Mustapa MFM, 2007, BIOCHEMISTRY-US, V46, P12930, DOI 10.1021/bi701014y; Mustapa MFM, 2009, BIOCONJUGATE CHEM, V20, P518, DOI 10.1021/bc800450r; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Nuciforo P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0561-8; Ongarora BG, 2012, J MED CHEM, V55, P3725, DOI 10.1021/jm201544y; Oppenheim DE, 2014, BRIT J CANCER, V110, P1221, DOI 10.1038/bjc.2014.35; Pal A, 2006, MOL IMAGING BIOL, V8, P262, DOI 10.1007/s11307-006-0049-0; Park SY, 2010, INT J PHARMACEUT, V383, P178, DOI 10.1016/j.ijpharm.2009.08.039; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Pietras K, 2002, CANCER RES, V62, P5476; Pietras K, 2001, CANCER RES, V61, P2929; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Song SX, 2009, FASEB J, V23, P1396, DOI 10.1096/fj.08-117002; Switzer CH, 2012, MOL CANCER RES, V10, P1203, DOI 10.1158/1541-7786.MCR-12-0124; Tagawa T, 2002, GENE THER, V9, P564, DOI 10.1038/sj.gt.3301686; de Ilarduya CT, 2010, EUR J PHARM SCI, V40, P159, DOI 10.1016/j.ejps.2010.03.019; Wang AZ, 2008, CHEMMEDCHEM, V3, P1311, DOI 10.1002/cmdc.200800091; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823	56	10	11	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3618	3628		10.1038/onc.2016.522	http://dx.doi.org/10.1038/onc.2016.522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166195	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-28	WOS:000403878600011
J	Ma, X; Huang, J; Tian, Y; Chen, Y; Yang, Y; Zhang, X; Zhang, F; Xue, L				Ma, X.; Huang, J.; Tian, Y.; Chen, Y.; Yang, Y.; Zhang, X.; Zhang, F.; Xue, L.			Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling	ONCOGENE			English	Article							ONCOGENIC RAS; DNA-BINDING; DROSOPHILA; DEATH; EXPRESSION; APOPTOSIS; METASTASIS; ACTIVATION; GROWTH; MAX	Tumor metastasis, but not primary overgrowth, is the leading cause of mortality for cancer patients. During the past decade, Drosophila melanogaster has been well-accepted as an excellent model to address the intrinsic mechanism of different aspects of cancer progression, ranging from tumor initiation to metastasis. In a genetic screen performed in Drosophila, aiming to find novel modulators of tumor invasion, we identified the oncoprotein Myc as a negative regulator. While expression of Myc dramatically blocks tumor invasion and cell migration, loss of Myc promotes cell migration in vivo. The activity of Myc is further enhanced by the co-expression of its transcription partner Max. Mechanistically, we found Myc/Max directly upregulates the transcription of puc, which encodes an inhibitor of JNK signaling crucial for tumor invasion and cell migration. Furthermore, we demonstrated that human cMyc potently suppresses JNK-dependent cell invasion and migration in both Drosophila and lung adenocarcinoma cell lines. These findings provide novel molecular insights into Myc-mediated cancer progression and raise the noteworthy problem in therapeutic strategies as inhibiting Myc might conversely accelerate tumor metastasis.	[Ma, X.; Huang, J.; Chen, Y.; Zhang, X.; Xue, L.] Tongji Univ, Shanghai Peoples Hosp 10, Inst Intervent Vessel, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, Shanghai, Peoples R China; [Tian, Y.; Yang, Y.; Zhang, F.] Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Clin Translat Res Ctr, Shanghai, Peoples R China; [Ma, X.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 333 Cedar St, New Haven, CT 06519 USA	Tongji University; Tongji University; Howard Hughes Medical Institute; Yale University	Zhang, X; Zhang, F; Xue, L (corresponding author), Tongji Univ, Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.	zxpkxy@126.com; fzhang@tongji.edu.cn; lei.xue@tongji.edu.cn		Ma, Xianjue/0000-0003-4360-3947; Zhang, Fan/0000-0003-4068-3726	National Basic Research Program of China (973 Program) [2011CB943903]; National Natural Sciences Foundation of China [31171413, 31371490]; Ministry of Education of China [20120072110023]; Shanghai Committee of Science and Technology [09DZ2260100, 14JC1406000]; Shanghai Pulmonary Hospital and Tongji University [129212]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Shanghai Pulmonary Hospital and Tongji University	We thank Dr Peter Gallant, Bloomington, VDRC and NIG stock centers for fly stocks and reagents. This work was supported by the National Basic Research Program of China (973 Program) (2011CB943903), National Natural Sciences Foundation of China (31171413 and 31371490), the PhD Programs Foundation of Ministry of Education of China (20120072110023), and Shanghai Committee of Science and Technology (09DZ2260100 and 14JC1406000) to LX, and the research start-up funds from Shanghai Pulmonary Hospital and Tongji University (No. 129212) to FZ.	ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen YH, 2008, EXPERT REV ANTICANC, V8, P1689, DOI 10.1586/14737140.8.10.1689; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 1999, MOL CELL BIOL, V19, P1; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.111; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Willoughby LF, 2013, DIS MODEL MECH, V6, P521, DOI 10.1242/dmm.009985; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947	46	30	33	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3159	3167		10.1038/onc.2016.463	http://dx.doi.org/10.1038/onc.2016.463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068320				2022-12-28	WOS:000402617900008
J	Wu, H; Zhang, XY; Hu, Z; Hou, Q; Zhang, H; Li, Y; Li, S; Yue, J; Jiang, Z; Weissman, SM; Pan, X; Ju, BG; Wu, S				Wu, H.; Zhang, X-Y; Hu, Z.; Hou, Q.; Zhang, H.; Li, Y.; Li, S.; Yue, J.; Jiang, Z.; Weissman, S. M.; Pan, X.; Ju, B-G; Wu, S.			Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing	ONCOGENE			English	Article							COLON-CANCER; INTRATUMOR HETEROGENEITY; SOMATIC MUTATIONS; EPITHELIAL-CELLS; PROSTATE-CANCER; BREAST-CANCER; IN-VIVO; TUMOR; IDENTIFICATION; INSTABILITY	Recently single-cell whole-exome sequencing (scWES) has deeply expanded and sharpened our knowledge of cancer evolution and subclonality. Herein, with scWES and matched bulk whole-exome sequencing (bulk WES) on two colorectal cancer (CRC) patients with normal or adenomatous polyps, we found that both the adenoma and cancer were of monoclonal origin, and both shared partial mutations in the same signaling pathways, but each showed a specific spectrum of heterogeneous somatic mutations. In addition, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonrandom somatic mutations specifically in GPCR, PI3K-Akt and FGFR signaling pathways. We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution. In summary, we demonstrated that both colorectal adenoma and CRC are monoclonal in origin, and the CRCs further diversified into different subclones with heterogeneous mutation profiles accumulating in GPCR, PI3K-Akt and FGFR signaling pathways. ScWES provides evidence for the importance of mutations in certain pathways that would not be as apparent from bulk sequencing of tumors, and can potentially establish whether specific mutations are mutually exclusive or occur sequentially in the same subclone of cells.	[Wu, H.; Zhang, X-Y; Hu, Z.; Hou, Q.; Zhang, H.; Li, Y.; Li, S.; Yue, J.; Jiang, Z.; Wu, S.] Hangzhou Canc Hosp, Canc Res Inst, 34 Yanguan St, Hangzhou 310002, Zhejiang, Peoples R China; [Wu, H.; Ju, B-G] Sogang Univ, Dept Life Sci, Seoul, South Korea; [Weissman, S. M.; Pan, X.] Yale Sch Med, Dept Genet, New Haven, CT 06510 USA	Sogang University; Yale University	Wu, S (corresponding author), Hangzhou Canc Hosp, Canc Res Inst, 34 Yanguan St, Hangzhou 310002, Zhejiang, Peoples R China.; Ju, BG (corresponding author), Sogang Univ, Dept Life Sci, Seoul, South Korea.; Pan, X (corresponding author), Yale Sch Med, Dept Genet, New Haven, CT 06510 USA.	xinghua.pan@yale.edu; bgju@sogang.ac.kr; wushixiu@medmail.com.cn	Wu, Hongjin/AAF-6122-2019	Wu, Hongjin/0000-0002-2053-7441; Pan, Xinghua (Victor)/0000-0002-7421-8155	Natural Science Foundation of Zhejiang Province [LZ15H220001, LY14H160005]; Zhejiang Medical and Health Ministry Training Program [2015PYA009]; The Science and Technology of Hangzhou Medical and Health Project [2012ZD001]; National Natural Science Foundation of China (CN) [81402529]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Zhejiang Medical and Health Ministry Training Program; The Science and Technology of Hangzhou Medical and Health Project; National Natural Science Foundation of China (CN)(National Natural Science Foundation of China (NSFC))	We thank Dr Sherman Weissman for his critical comments on the manuscript. We are indebted to all the individuals who consented to participate in this study. ScWES and bulk WES was performed at the Genseeq Company. The sequenced data was analyzed by Yunkang Biotechnology Co. Ltd. This work was supported by Natural Science Foundation of Zhejiang Province (LZ15H220001 and LY14H160005), Zhejiang Medical and Health Ministry Training Program (2015PYA009), The Science and Technology of Hangzhou Medical and Health Project (2012ZD001), National Natural Science Foundation of China (CN; 81402529).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ashktorab H, 2013, EPIGENETICS-US, V8, P807, DOI 10.4161/epi.25497; Ashktorab H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008879; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047; Cebrat M, 2004, CANCER LETT, V206, P107, DOI 10.1016/j.canlet.2003.10.024; Charbonneau B, 2012, AM J HEMATOL, V87, P880, DOI 10.1002/ajh.23273; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Farrell CL, 2008, CANCER BIOL THER, V7, P609, DOI 10.4161/cbt.7.4.5623; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gemoll T., 2015, CANCER RES, V200, P81; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gylfe AE, 2010, INT J CANCER, V127, P2974, DOI 10.1002/ijc.25529; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Huang L, 2015, ANNU REV GENOM HUM G, V16, P79, DOI 10.1146/annurev-genom-090413-025352; Kanojia D, 2015, ONCOTARGET, V6, P42429, DOI 10.18632/oncotarget.6464; Katayama K, 2013, CANCER SCI, V104, P694, DOI 10.1111/cas.12145; Kirley SD, 2005, CANCER BIOL THER, V4, P861, DOI 10.4161/cbt.4.8.1894; Kober P, 2011, MOL CARCINOGEN, V50, P846, DOI 10.1002/mc.20763; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Latini FRM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-11; Lederer A, 2015, HEPATOLOGY, V62, P841, DOI 10.1002/hep.27885; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85; Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892; Lum AM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-40; Mangerich A, 2012, P NATL ACAD SCI USA, V109, pE1820, DOI 10.1073/pnas.1207829109; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Palamaro L, 2014, INT REV IMMUNOL, V33, P83, DOI 10.3109/08830185.2013.870171; Patel Swati G, 2012, Curr Gastroenterol Rep, V14, P428, DOI 10.1007/s11894-012-0280-6; Pericas JM, 2016, NEW ENGL J MED, V375, P387, DOI [10.1056/NEJMra1513581, 10.1056/NEJMc1604867]; Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Ross JB, 2015, NAT CELL BIOL, V17, P651, DOI 10.1038/ncb3148; Rowe J, 2001, J CELL SCI, V114, P3323; Seneviratne D, 2015, GASTROENTEROLOGY, V148, P181, DOI 10.1053/j.gastro.2014.09.019; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Teng G, 2015, CELL, V162, P751, DOI 10.1016/j.cell.2015.07.009; Tsukahara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081139; Vasen HFA, 2000, J CLIN ONCOL, V18, p81S; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Wang ZY, 2012, GYNECOL ONCOL, V127, P403, DOI 10.1016/j.ygyno.2012.08.007; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Yu C, 2014, CELL RES, V24, P701, DOI 10.1038/cr.2014.43; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhang R, 2014, TUMOR BIOL, V35, P4419, DOI 10.1007/s13277-013-1581-6; Zhang XY, 2016, CANCER RES, V76, P1305, DOI 10.1158/0008-5472.CAN-15-1907	52	39	39	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2857	2867		10.1038/onc.2016.438	http://dx.doi.org/10.1038/onc.2016.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941887				2022-12-28	WOS:000401697800008
J	Puccetti, MV; Fischer, MA; Arrate, MP; Boyd, KL; Duszynski, RJ; Betous, R; Cortez, D; Eischen, CM				Puccetti, M. V.; Fischer, M. A.; Arrate, M. P.; Boyd, K. L.; Duszynski, R. J.; Betous, R.; Cortez, D.; Eischen, C. M.			Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; IMMUNO-OSSEOUS DYSPLASIA; HEMATOPOIETIC STEM-CELLS; DNA-DAMAGE RESPONSE; SMARCAL1; APOPTOSIS; EXPRESSION; MUTATIONS; HALLMARK; REPAIR	DNA replication stress promotes genome instability in cancer. However, the contribution of the replication stress response to the development of malignancies remains unresolved. The DNA replication stress response protein SMARCAL1 stabilizes DNA replication forks and prevents replication fork collapse, a cause of DNA breaks and apoptosis. While the fork regression/remodeling functions of SMARCAL1 have been investigated, its in vivo functions in replication stress and cancer are unclear. Using a gamma radiation (IR)-induced replication stress T-cell lymphoma mouse model, we observed a significant inhibition of lymphomagenesis in mice lacking one or both alleles of Smarcal1. Notably, a quarter of the Smarcal1-deficient mice did not develop tumors. Moreover, hematopoietic stem/progenitor cells (HSPCs) and developing thymocytes in Smarcal1-deficient mice showed increased DNA damage and apoptosis during the proliferation burst following IR and an impaired ability to repopulate the thymus after IR. Additionally, mice lacking Smarcal1 showed significant HSPC defects when challenged to respond to other replication stress stimuli. Thus, our data reveal the critical function of the DNA replication stress response and, specifically, Smarcal1 in hematopoietic cell survival and tumor development. Our results also provide important insight into the immunodeficiency observed in individuals with mutations in SMARCAL1 by suggesting that it is an HSPC defect.	[Puccetti, M. V.; Fischer, M. A.; Arrate, M. P.; Boyd, K. L.; Duszynski, R. J.; Eischen, C. M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Puccetti, M. V.; Eischen, C. M.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Betous, R.; Cortez, D.] Vanderbilt Univ, Dept Biochem, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Jefferson University; Vanderbilt University	Eischen, CM (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233S 10th St Bluemle Life Sci Bldg, Philadelphia, PA 19107 USA.	christine.eischen@jefferson.edu	Bétous, Rémy/ABF-4789-2020; Bétous, Rémy/P-2355-2014	Bétous, Rémy/0000-0003-0518-1763; 	Ann Melly Scholarship [F30CA189433, T32GM007347, R01CA160432]; NCI Cancer Center Support Grants [P30CA068485, P30CA056036]; NATIONAL CANCER INSTITUTE [P30CA056036, R01CA160432, F30CA189433, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	Ann Melly Scholarship; NCI Cancer Center Support Grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors would like to thank Dr Cornelius Boerkoel for providing the Smarcal1<SUP>+/triangle</SUP> mice, Carol Bansbach for technical assistance with Figure 1b, Catherine Alford for technical assistance with flow cytometry, the Bioimaging Shared Resource of the Sidney Kimmel Cancer Center, and Dr Sandy Zinkel, Dr Scott Hiebert, and members of the Eischen lab for helpful discussions. This work was supported by F30CA189433 (MVP), T32GM007347 (MVP), Ann Melly Scholarship (MVP), R01CA160432 (CME and DC), and NCI Cancer Center Support Grants P30CA068485 and P30CA056036.	Adams PD, 2015, CELL STEM CELL, V16, P601, DOI 10.1016/j.stem.2015.05.002; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alvarez S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9548; Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Bansbach CE, 2009, GENE DEV, V23, P2405, DOI 10.1101/gad.1839909; Baradaran-Heravi A, 2012, HUM MOL GENET, V21, P2572, DOI 10.1093/hmg/dds083; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Betous R, 2013, CELL REP, V3, P1958, DOI 10.1016/j.celrep.2013.05.002; Betous R, 2012, GENE DEV, V26, P151, DOI 10.1101/gad.178459.111; Boerkoel CF, 2002, NAT GENET, V30, P215, DOI 10.1038/ng821; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SH, 2007, STEM CELLS DEV, V16, P707, DOI 10.1089/scd.2007.0017; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Ciccia A, 2009, GENE DEV, V23, P2415, DOI 10.1101/gad.1832309; Couch FB, 2013, GENE DEV, V27, P1610, DOI 10.1101/gad.214080.113; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Flach J, 2014, NATURE, V512, P198, DOI 10.1038/nature13619; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Keka IS, 2015, NUCLEIC ACIDS RES, V43, P6359, DOI 10.1093/nar/gkv621; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Nam EA, 2011, BIOCHEM J, V436, P527, DOI 10.1042/BJ20102162; Nombela-Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049; Postow L, 2009, J BIOL CHEM, V284, P35951, DOI 10.1074/jbc.M109.048330; Sanyal M, 2015, CLIN IMMUNOL, V161, P355, DOI 10.1016/j.clim.2015.10.005; SPRANGER J, 1991, J PEDIATR-US, V119, P64, DOI 10.1016/S0022-3476(05)81040-6; Walter D, 2015, NATURE, V520, P549, DOI 10.1038/nature14131; Yilmaz OH, 2006, BLOOD, V107, P924, DOI 10.1182/blood-2005-05-2140; Yuan JS, 2009, GENE DEV, V23, P2394, DOI 10.1101/gad.1836409; Yusufzai T, 2008, SCIENCE, V322, P748, DOI 10.1126/science.1161233; Yusufzai T, 2009, GENE DEV, V23, P2400, DOI 10.1101/gad.1831509; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2553	2564		10.1038/onc.2016.408	http://dx.doi.org/10.1038/onc.2016.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27797382	Green Accepted			2022-12-28	WOS:000400597300006
J	van Andel, H; Kocemba, KA; de Haan-Kramer, A; Mellink, CH; Piwowar, M; Broijl, A; van Duin, M; Sonneveld, P; Maurice, MM; Kersten, MJ; Spaargaren, M; Pals, ST				van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Mellink, C. H.; Piwowar, M.; Broijl, A.; van Duin, M.; Sonneveld, P.; Maurice, M. M.; Kersten, M. J.; Spaargaren, M.; Pals, S. T.			Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease	ONCOGENE			English	Article							TUMOR-SUPPRESSOR CYLD; EPIGENETIC DYSREGULATION; PATHWAY; ENZYME; PROLIFERATION; PATHOGENESIS; ACTIVATION; MUTATIONS; RECEPTORS; APOPTOSIS	Deletion or mutation of the gene encoding the deubiquitinating enzyme CYLD is a common genomic aberration in multiple myeloma (MM). However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established. Here, we show that CYLD expression is highly variable in myeloma cell lines and primary MMs and that low CYLD expression is associated with disease progression from monoclonal gammopathy of undetermined significance to MM, and with poor overall and progression free-survival of MM patients. Functional assays revealed that CYLD represses MM cell proliferation and survival. Furthermore, CYLD acts as a negative regulator of NF-kappa B and Wnt/beta-catenin signaling and loss of CYLD sensitizes MM cells to NF-kappa B-stimuli and Wnt ligands. Interestingly, in primary MMs, low CYLD expression strongly correlated with a proliferative and Wnt signaling-gene expression signature, but not with an NF kappa B target gene signature. Altogether, our findings identify CYLD as a negative regulator of NF-kappa B and Wnt/beta-catenin signaling in MM and indicate that loss of CYLD enhances MM aggressiveness through Wnt pathway activation. Thus, targeting the Wnt pathway could be a promising therapeutic strategy in MM with loss of CYLD activity.	[van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Kersten, M. J.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, Amsterdam, Netherlands; [Kocemba, K. A.] Jagiellonian Univ, Dept Med Biochem, Med Coll, Krakow, Poland; [Mellink, C. H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [Piwowar, M.] Jagiellonian Univ, Dept Bioinformat & Telemed, Med Coll, Krakow, Poland; [Broijl, A.; van Duin, M.; Sonneveld, P.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands; [Maurice, M. M.] Univ MC Utrecht, Dept Cell Biol, Utrecht, Netherlands; [Kersten, M. J.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Jagiellonian University; Collegium Medicum Jagiellonian University; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.t.pals@amc.uva.nl	kocemba, kinga/AAE-2305-2019; Spaargaren, Marcel/AAU-1298-2021; Kocemba, Kinga/AAE-6520-2021; Piwowar, Monika Weronika/L-5452-2013	kocemba, kinga/0000-0002-7119-2412; Spaargaren, Marcel/0000-0002-3135-5109; Piwowar, Monika Weronika/0000-0003-4645-8730; Pals, Steven/0000-0002-1419-0939; Maurice, Madelon/0000-0001-6885-5361	Dutch Cancer Society; EU-FP7 OVER-MYR	Dutch Cancer Society(KWF Kankerbestrijding); EU-FP7 OVER-MYR	This study was supported by grants from the Dutch Cancer Society and EU-FP7 OVER-MYR.	An CH, 2010, PATHOLOGY, V42, P583, DOI 10.3109/00313025.2010.508735; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Dutta-Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood-2008-12-194290; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jost E, 2009, CANCER LETT, V281, P24, DOI 10.1016/j.canlet.2009.02.002; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188; Kumar S, 2012, BLOOD, V119, P2100, DOI 10.1182/blood-2011-11-390658; Lawasut P, 2013, SEMIN ONCOL, V40, P537, DOI 10.1053/j.seminoncol.2013.07.010; Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2011, FUTURE ONCOL, V7, P285, DOI 10.2217/FON.10.187; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Rajan N, 2014, ONCOTARGET, V5, P12126, DOI 10.18632/oncotarget.2573; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Smith EM, 2015, ONCOTARGET, V6, P17314, DOI 10.18632/oncotarget.1168; Sonneveld P, 2012, J CLIN ONCOL, V30, P2946, DOI 10.1200/JCO.2011.39.6820; Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Walker BA, 2015, J CLIN ONCOL, V33, P3911, DOI 10.1200/JCO.2014.59.1503; Winterhalter C, 2014, BIOINFORMATICS, V30, P1029, DOI 10.1093/bioinformatics/btt732; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	42	31	32	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2105	2115		10.1038/onc.2016.368	http://dx.doi.org/10.1038/onc.2016.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27775078				2022-12-28	WOS:000399782500007
J	Deng, X; Shao, G; Zhang, HT; Li, C; Zhang, D; Cheng, L; Elzey, BD; Pili, R; Ratliff, TL; Huang, J; Hu, CD				Deng, X.; Shao, G.; Zhang, H-T; Li, C.; Zhang, D.; Cheng, L.; Elzey, B. D.; Pili, R.; Ratliff, T. L.; Huang, J.; Hu, C-D			Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth	ONCOGENE			English	Article							SPLICE VARIANTS; GENE-EXPRESSION; IN-VITRO; PRMT5; TARGET; METHYLATION; TRANSCRIPTION; COMPLEX; RESISTANCE; INITIATION	Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones H4R3, H3R8 and H2AR3. Accumulating evidence suggests that PRMT5 may function as an oncogene to drive cancer cell growth by epigenetic inactivation of several tumor suppressors. Here, we provide evidence that PRMT5 promotes prostate cancer cell growth by epigenetically activating transcription of the androgen receptor (AR) in prostate cancer cells. Knockdown of PRMT5 or inhibition of PRMT5 by a specific inhibitor reduces the expression of AR and suppresses the growth of multiple AR-positive, but not AR-negative, prostate cancer cells. Significantly, knockdown of PRMT5 in AR-positive LNCaP cells completely suppresses the growth of xenograft tumors in mice. Molecular analysis reveals that PRMT5 binds to the proximal promoter region of the AR gene and contributes mainly to the enriched symmetric dimethylation of H4R3 in the same region. Mechanistically, PRMT5 is recruited to the AR promoter by its interaction with Sp1, the major transcription factor responsible for AR transcription, and forms a complex with Brg1, an ATP-dependent chromatin remodeler, on the proximal promoter region of the AR gene. Furthermore, PRMT5 expression in prostate cancer tissues is significantly higher than that in benign prostatic hyperplasia tissues, and PRMT5 expression correlates positively with AR expression at both the protein and mRNA levels. Taken together, our results identify PRMT5 as a novel epigenetic activator of AR in prostate cancer. Given that inhibiting AR transcriptional activity or androgen synthesis remains the major mechanism of action for most existing anti-androgen agents, our findings also raise an interesting possibility that targeting PRMT5 may represent a novel approach for prostate cancer treatment by eliminating AR expression.	[Deng, X.; Shao, G.; Zhang, H-T; Hu, C-D] Purdue Univ, Dept Med Chem & Mol Pharmacol, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA; [Shao, G.] Jiangsu Univ, Sch Med, Dept Bas Med Sci, Zhenjiang, Peoples R China; [Zhang, H-T] Jinan Univ, First Affiliated Hosp, Inst Orthoped Dis, Dept Orthoped, Guangzhou, Peoples R China; [Li, C.] Ohio State Univ, Div Med Chem & Pharmacognosy, Columbus, OH USA; [Zhang, D.] Purdue Univ, Dept Stat, W Lafayette, IN USA; [Cheng, L.] Indiana Univ, Dept Pathol, Indianapolis, IN USA; [Cheng, L.] Indiana Univ, Lab Med, Indianapolis, IN USA; [Elzey, B. D.; Ratliff, T. L.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN USA; [Pili, R.] Indiana Univ, Simon Canc Ctr, Dept Med Oncol, Indianapolis, IN USA; [Ratliff, T. L.; Hu, C-D] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Huang, J.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Jiangsu University; Jinan University; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Los Angeles	Hu, CD (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.	hu1@purdue.edu		Cheng, Liang/0000-0001-6049-5293	U.S. Army Medical Research Acquisition Activity; Prostate Cancer Research Program [PC11190, PC120512, PC150697]; Purdue University Center for Cancer Research Small Grants; NCI CCSG; China Scholarship Council; NATIONAL CANCER INSTITUTE [P30CA023168, R01CA212403] Funding Source: NIH RePORTER	U.S. Army Medical Research Acquisition Activity; Prostate Cancer Research Program; Purdue University Center for Cancer Research Small Grants; NCI CCSG; China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partially supported by grants from U.S. Army Medical Research Acquisition Activity, Prostate Cancer Research Program (PC11190, PC120512, and PC150697) to C-D Hu, and Purdue University Center for Cancer Research Small Grants. DNA sequencing and animal experiments were conducted in Genomic Core facility and the Biological Evaluation Shared Resource facility, respectively, supported by NCI CCSG CA23168 to Purdue University Center for Cancer Research. Genbao Shao and Huan-Tian Zhang were visiting scholars supported by the China Scholarship Council.	Agoulnik IU, 2008, ADV EXP MED BIOL, V617, P245, DOI 10.1007/978-0-387-69080-3_23; Alinari L, 2015, BLOOD, V125, P2530, DOI 10.1182/blood-2014-12-619783; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Cai CM, 2013, TRANSL ANDROL UROL, V2, P148, DOI 10.3978/j.issn.2223-4683.2013.09.02; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chandrasekar T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0457-6; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Dacwag CS, 2007, MOL CELL BIOL, V27, P384, DOI 10.1128/MCB.01528-06; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Deng XH, 2011, AM J CANCER RES, V1, P834; Dutt SS, 2009, FUTURE ONCOL, V5, P1403, DOI 10.2217/FON.09.117; FABER PW, 1993, J BIOL CHEM, V268, P9296; Gao L, 2010, EPIGENETICS-US, V5, P100, DOI 10.4161/epi.5.2.10778; Giacinti S, 2014, ANTICANCER RES, V34, P6265; Gu ZP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044033; Gu ZP, 2012, BIOCHEM J, V446, P235, DOI 10.1042/BJ20120768; Guo ZY, 2011, INT J BIOL SCI, V7, P815, DOI 10.7150/ijbs.7.815; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hay CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139990; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Hedges LV, 1985, STATISCAL METHODS ME; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Hsu CC, 2013, MOL CELL ENDOCRINOL, V372, P12, DOI 10.1016/j.mce.2013.03.004; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Krause CD, 2007, PHARMACOL THERAPEUT, V113, P50, DOI 10.1016/j.pharmthera.2006.06.007; LeBlanc SE, 2012, MOL ENDOCRINOL, V26, P583, DOI 10.1210/me.2011-1162; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Nakazawa M, 2014, HORM CANCER-US, V5, P265, DOI 10.1007/s12672-014-0190-1; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Powers MA, 2011, CANCER RES, V71, P5579, DOI 10.1158/0008-5472.CAN-11-0458; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Seth-Vollenweider T, 2014, J BIOL CHEM, V289, P33958, DOI 10.1074/jbc.M114.583302; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Tee WW, 2010, GENE DEV, V24, P2772, DOI 10.1101/gad.606110; Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008-5472.CAN-06-4206; TILLEY WD, 1990, CANCER RES, V50, P5382; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08; Wei TYW, 2012, CANCER SCI, V103, P1640, DOI 10.1111/j.1349-7006.2012.02367.x; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884; Zhang HT, 2014, BBA-GENE REGUL MECH, V1839, P1330, DOI 10.1016/j.bbagrm.2014.09.015	53	70	73	2	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1223	1231		10.1038/onc.2016.287	http://dx.doi.org/10.1038/onc.2016.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546619	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000395861300006
J	Fang, D; Chen, H; Zhu, JY; Wang, W; Teng, Y; Ding, HF; Jing, Q; Su, SB; Huang, S				Fang, D.; Chen, H.; Zhu, J. Y.; Wang, W.; Teng, Y.; Ding, H-F; Jing, Q.; Su, S-B; Huang, S.			Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways	ONCOGENE			English	Article							NF-KAPPA-B; E-CADHERIN; DOWN-REGULATION; BETA-CATENIN; EMT; METASTASIS; EXPRESSION; CARCINOMA; INFLAMMATION; MIGRATION	Epithelial-mesenchymal transition (EMT) is regarded as a crucial contributing factor to cancer progression. Diverse factors have been identified as potent EMT inducers in ovarian cancer. However, molecular mechanism sustaining EMT of ovarian cancer cells remains elusive. Here we show that the presence of SOS1/EPS8/ABI1 complex is critical for sustained EMT traits of ovarian cancer cells. Consistent with the role of SOS1/EPS8/ABI1 complex as a Rac1-specific guanine nucleotide exchange factor, depleting Rac1 results in the loss of most of mesenchymal traits in mesenchymal-like ovarian cancer cells, whereas expressing constitutively active Rac1 leads to EMT in epithelial-like ovarian cancer cells. With the aid of clinically tested inhibitors targeting various EMT-associated signaling pathways, we show that only combined treatment of mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) and Src inhibitors can abolish constitutively active Rac1-led EMT and mesenchymal traits displayed by mesenchymal-like ovarian cancer cells. Further experiments also reveal that EMT can be induced in epithelial-like ovarian cancer cells by co-expressing constitutively active MEK1 and Src rather than either alone. As the activities of Erk and Src are higher in ovarian cancer cells with constitutively active Rac1, we conclude that Rac1 sustains ovarian cancer cell EMT through simultaneous activation of MEK1/2 and Src signaling pathways. Importantly, we demonstrate that combined use of MEK1/2 and Src inhibitors effectively suppresses development of intraperitoneal xenografts and prolongs the survival of ovarian cancer-bearing mice. This study suggests that cocktail of MEK1/2 and Src inhibitors represents an effective therapeutic strategy against ovarian cancer progression.	[Fang, D.; Wang, W.; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Fang, D.; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Comm, Shanghai, Peoples R China; [Chen, H.] Wuhan Univ, Zhongnan Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China; [Zhu, J. Y.; Huang, S.] Univ Florida, Coll Med, Dept Anat & Cell Biol, 2033 Mowry Rd,POB 103633, Gainesville, FL 32610 USA; [Teng, Y.] Augusta Univ, Dent Coll Georgia, Dept Oral Biol, Augusta, GA USA; [Teng, Y.; Ding, H-F] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA; [Jing, Q.] Changhai Hosp, Dept Cardiol, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai Municipal Education Commission (SHMEC); Shanghai University of Traditional Chinese Medicine; Wuhan University; State University System of Florida; University of Florida; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Naval Medical University	Su, SB (corresponding author), Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China.; Huang, S (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 2033 Mowry Rd,POB 103633, Gainesville, FL 32610 USA.	shibingsu07@163.com; shuanghuang@ufl.edu	Teng, Yong/AAK-4160-2020; Jing, Qing/F-6752-2016	Teng, Yong/0000-0002-1856-7289; Jing, Qing/0000-0001-9834-1214; Ding, Han-Fei/0000-0001-5702-3439	E-Institutes of Shanghai Municipal Education Commission [E03008]; Shanghai University of TCM [085ZY1206]; National Science Foundation of China [31229002]; NIH [CA 187152]; DoD [OC120313, W81XWH-13-1-0122]; NATIONAL CANCER INSTITUTE [R01CA187152] Funding Source: NIH RePORTER	E-Institutes of Shanghai Municipal Education Commission; Shanghai University of TCM; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by E-Institutes of Shanghai Municipal Education Commission (Project E03008), '085' First-Class Discipline Construction Innovation Science and Technology Support Project of Shanghai University of TCM (085ZY1206), National Science Foundation of China (31229002), NIH CA 187152 and DoD OC120313 (W81XWH-13-1-0122).	Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen DY, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-50; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chen HJ, 2010, CANCER RES, V70, P9979, DOI 10.1158/0008-5472.CAN-10-2394; Cheng SM, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0494-1; Cichon MA, 2014, ONCOTARGET, V5, P2827, DOI 10.18632/oncotarget.1940; Condello S, 2013, FASEB J, V27, P3100, DOI 10.1096/fj.12-222620; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Davidson B, 2015, HUM PATHOL, V46, P1, DOI 10.1016/j.humpath.2014.10.004; Gou WF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-477; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Hu Q, 2013, ONCOGENE, V32, P3933, DOI 10.1038/onc.2012.414; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Javle MM, 2007, ANN SURG ONCOL, V14, P3527, DOI 10.1245/s10434-007-9540-3; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Leng RB, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0329-5; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Li Y., 2012, GENES CANC, V2, P880; Li Y, 2014, ONCOTARGET, V5, P2596, DOI 10.18632/oncotarget.1841; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; McGrail DJ, 2014, J CELL SCI, V127, P2621, DOI 10.1242/jcs.144378; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Prasanphanich AE, 2014, FREE RADICAL BIO MED, V76, P1, DOI 10.1016/j.freeradbiomed.2014.07.032; Radisky DC, 2007, NAT CELL BIOL, V9, P361, DOI 10.1038/ncb0407-361; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Seward SM, 2015, CANCER METAST REV, V34, P5, DOI 10.1007/s10555-014-9536-y; Takai M, 2014, J OVARIAN RES, V7, DOI [10.1186/1757-2215-7-38, 10.1186/1757-2215-7-76]; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tian LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12357; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Yamada SD, 2002, CANCER RES, V62, P6717; Yang L, 2015, ONCOTARGET, V6, P20801, DOI 10.18632/oncotarget.4600; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yoshida S, 2009, INT J GYNECOL CANCER, V19, P992, DOI 10.1111/IGC.0b013e3181aaa93a; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	50	63	65	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1546	1558		10.1038/onc.2016.323	http://dx.doi.org/10.1038/onc.2016.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617576	Green Accepted			2022-12-28	WOS:000397458100009
J	Hu, L; Li, X; Liu, Q; Xu, J; Ge, H; Wang, Z; Wang, H; Wang, Z; Shi, C; Xu, X; Huang, J; Lin, Z; Pieper, RO; Weng, C				Hu, L.; Li, X.; Liu, Q.; Xu, J.; Ge, H.; Wang, Z.; Wang, H.; Wang, Z.; Shi, C.; Xu, X.; Huang, J.; Lin, Z.; Pieper, R. O.; Weng, C.			UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy	ONCOGENE			English	Article							STRAND BREAK REPAIR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CONJUGATING ENZYME E2-EPF; UBIQUITIN CARRIER PROTEIN; TUMOR-GROWTH; CELL-CYCLE; LIGASE-IV; CANCER; INHIBITION; PHOSPHORYLATION	Glioblastoma multiforme (GBM) is the most common primary malignant brain cancer in adults. However, the molecular events underlying carcinogenesis and their interplay remain elusive. Here, we report that the stability of Ubiquitin-conjugating enzyme E2S (UBE2S) is regulated by the PTEN/Akt pathway and that its degradation depends on the ubiquitin-proteasome system. Mechanistically, Akt1 physically interacted with and phosphorylated UBE2S at Thr 152, enhancing its stability by inhibiting proteasomal degradation. Additionally, accumulated UBE2S was found to be associated with the components of the nonhomologous end-joining (NHEJ) complex and participated in the NHEJ-mediated DNA repair process. The association of Ku70 with UBE2S was enhanced, and the complex was recruited to double-stranded break (DSB) sites in response to etoposide treatment. Furthermore, knockdown of UBE2S expression inhibited NHEJ-mediated DSB repair and rendered glioblastoma cells more sensitive to chemotherapy. Overall, our findings provide a novel drug target that may serve as the rationale for the development of a new therapeutic approach.	[Hu, L.; Ge, H.; Lin, Z.] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang Pr, Peoples R China; [Hu, L.; Liu, Q.; Weng, C.] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Heilongjiang Pe, Peoples R China; [Li, X.] Shandong Univ, Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Peoples R China; [Xu, J.] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Wang, Z.] Harbin Med Univ, Dept Epidemiol & Biostatist, Harbin, Peoples R China; [Wang, H.] Harbin Med Univ, Affiliated Hosp 1, Dept Pathol, Harbin, Peoples R China; [Wang, Z.] Univ Paris 06, St Antoine Res Ctr, CURIE, Paris, France; [Shi, C.] Univ Texas Dallas, Southwestern Med Ctr, Dept Neurosurg, Dallas, TX 75390 USA; [Xu, X.] Capital Normal Univ, DNA Damage Response & Coll Life Sci, Beijing Key Lab, Beijing, Peoples R China; [Huang, J.] Univ Florida, Dept Neurosurg, Gainesville, FL USA; [Pieper, R. O.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Harbin Medical University; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS; Shandong University; Harbin Medical University; Harbin Medical University; Harbin Medical University; UDICE-French Research Universities; Sorbonne Universite; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Capital Normal University; State University System of Florida; University of Florida; University of California System; University of California San Francisco	Lin, Z (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang Pr, Peoples R China.; Weng, C (corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Heilongjiang Pe, Peoples R China.; Pieper, RO (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	linzhgu@sina.com; rpieper@cc.ucsf.edu; wengchji@163.com	Liu, Qinfang/ABC-9159-2021; weng, changjiang/HHR-8479-2022	Liu, Qinfang/0000-0003-2930-3892	National Natural Science Foundation of China [81372721]; International Science & Technology Cooperation Program of China [2014DFA31630]; Specialized Research Fund for the Doctoral Program of Higher Education [20132307110029]; National Cancer Institute [R01 CA171610T]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Science & Technology Cooperation Program of China; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Vera Gorbunova for providing the pEGFP-Pem1-Ad2 system. We thank Jane Gordon and Qimeng Tao for technical support. We thank Dr Lei Pan, Dr Changbin Shi for their critical review of the article. This work was supported by the National Natural Science Foundation of China (81372721); International Science & Technology Cooperation Program of China (2014DFA31630); Specialized Research Fund for the Doctoral Program of Higher Education (20132307110029) and National Cancer Institute (R01 CA171610T).	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen MF, 2009, J MOL MED-JMM, V87, P307, DOI 10.1007/s00109-008-0430-3; Chen YC, 2008, J MOL MED, V86, P401, DOI 10.1007/s00109-008-0302-x; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Fang LH, 2007, CELL RES, V17, P572, DOI 10.1038/cr.2007.50; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gan WJ, 2015, NUCLEUS-PHILA, V6, P261, DOI 10.1080/19491034.2015.1074365; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Idogawa M, 2007, CANCER RES, V67, P911, DOI 10.1158/0008-5472.CAN-06-2360; Jung CR, 2006, NAT MED, V12, P809, DOI 10.1038/nm1440; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Liang J, 2012, ONCOL REP, V28, P1519, DOI 10.3892/or.2012.1949; Liu PD, 2015, MOL CELL, V57, P648, DOI 10.1016/j.molcel.2015.01.005; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Meerang M, 2011, NAT CELL BIOL, V13, P1376, DOI 10.1038/ncb2367; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Roos FC, 2011, AM J PATHOL, V178, P853, DOI 10.1016/j.ajpath.2010.10.033; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Squatrito M, 2011, CANCER RES, V71, P5945, DOI 10.1158/0008-5472.CAN-11-1245; Tedesco D, 2007, NEOPLASIA, V9, P601, DOI 10.1593/neo.07385; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Williams GJ, 2014, DNA REPAIR, V17, P110, DOI 10.1016/j.dnarep.2014.02.009; Woodbine L, 2014, DNA REPAIR, V16, P84, DOI 10.1016/j.dnarep.2014.02.011; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	47	32	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1145	1156		10.1038/onc.2016.281	http://dx.doi.org/10.1038/onc.2016.281			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593939				2022-12-28	WOS:000395371500012
J	Jeffery, JM; Kalimutho, M; Johansson, P; Cardenas, DG; Kumar, R; Khanna, KK				Jeffery, J. M.; Kalimutho, M.; Johansson, P.; Cardenas, D. G.; Kumar, R.; Khanna, K. K.			FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition	ONCOGENE			English	Article							E3 UBIQUITIN LIGASES; F-BOX; TRANSCRIPTION FACTOR; CELL-CYCLE; MITOTIC PROGRESSION; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; DEGRADATION; PROTEOLYSIS; CDT1	F-box proteins in conjunction with Skp1, Cul1 and Rbx1 generate SCF complexes that are responsible for the ubiquitination of proteins, leading to their activation or degradation. Here we show that the F-box protein FBXO31 is required for normal mitotic progression and genome stability due to its role in regulating FOXM1 levels during the G2/M transition. FBXO31-depleted cells undergo a transient delay in mitosis due to an activated spindle checkpoint concomitant with an increase in lagging chromosomes and anaphase bridges. FBXO31 regulates mitosis in part by controlling the levels of FOXM1, a transcription factor and master regulator of mitosis. FBXO31 specifically interacts with FOXM1 during the G2/M transition, resulting in FOXM1 ubiquitination and degradation. FBXO31 depletion results in increased expression of FOXM1 transcriptional targets and mimics the FOXM1 overexpression. In contrast, co-depletion of FBXO31 and FOXM1 restores the genomic instability phenotype but not the delay in mitosis, indicating that FBXO31 probably has additional mitotic substrates. Thus, FBXO31 is the first described negative regulator of FOXM1 during the G2/M transition.	[Jeffery, J. M.; Kalimutho, M.; Cardenas, D. G.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Dept Cell & Mol Biol, Brisbane, Qld, Australia; [Johansson, P.] Univ Gothenburg, Dept Clin Chem & Transfus Med, Sahlgrenska Acad, Gothenburg, Sweden; [Kumar, R.] Univ Adelaide, Dept Paediat, Sch Med, Adelaide, SA, Australia; [Kumar, R.] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5000, Australia	QIMR Berghofer Medical Research Institute; University of Gothenburg; University of Adelaide; Robinson Research Institute; University of Adelaide	Kumar, R (corresponding author), Univ Adelaide, Robinson Res Inst, Adelaide, SA 5000, Australia.; Kumar, R (corresponding author), Univ Adelaide, Sch Med, Adelaide, SA 5000, Australia.; Khanna, KK (corresponding author), Queensland Inst Med Res, Dept Cell & Mol Biol, 300 Herston Rd, Herston, Qld 4006, Australia.	raman.sharma@adelaide.edu.au; kumkum.khanna@qimrberghofer.edu.au	Kumar, Raman/AHE-0538-2022; Kalimutho, Murugan/AAD-1441-2019	Kumar, Raman/0000-0001-7976-8386; Khanna, Kum Kum/0000-0001-8650-5381; Kalimutho, Murugan/0000-0002-0772-8673	NHMRC; Cancer Council of Queensland; Cancer Council of South Australia; Cancer Council Queensland	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of South Australia(Cancer Council South Australia); Cancer Council Queensland(Cancer Council Queensland)	This work is funded by the NHMRC (Program Grant), the Cancer Council of Queensland and the Cancer Council of South Australia. Murugan Kalimutho is supported by project grant from the Cancer Council Queensland. Pegah Johansson is a Swedish Research Council (Vetenskapsradet) post-doctoral fellow. We thank Professor Michele Pagano for the Skp1, Cul1 and Rbx1 antibodies, and the FLAG-Skp2, FLAG-FBW9, FLAG-HAFBXO10, FLAG-HA-FBXO24 and FLAG-beta-Trcp1 constructs; Dr Sabine Elowe for BUBR1 pS676 antibody; and Stephen Miles for tissue culture assistance.	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Carter SL, 2009, Patent No. [US20090215054 A1, 20090215054]; Chen C, 2006, MOL CANCER RES, V4, P695, DOI 10.1158/1541-7786.MCR-06-0182; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Huang HL, 2010, ONCOL REP, V24, P715, DOI 10.3892/or_00000912; Jeffery JM, 2010, ONCOGENE, V29, P2649, DOI 10.1038/onc.2010.37; Johansson P, 2014, J BIOL CHEM, V289, P18514, DOI 10.1074/jbc.M114.559930; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Kogo R, 2011, INT J ONCOL, V39, P155, DOI 10.3892/ijo.2011.1018; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kumar R, 2005, CANCER RES, V65, P11304, DOI 10.1158/0008-5472.CAN-05-0936; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Lee EK, 2014, ONCOGENE, V33, P2011, DOI 10.1038/onc.2013.144; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Liu J, 2014, J BIOL CHEM, V289, P21508, DOI 10.1074/jbc.M114.560342; Malonia SK, 2015, P NATL ACAD SCI USA, V112, P8632, DOI 10.1073/pnas.1510929112; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Sivan G, 2008, CELL CYCLE, V7, P741, DOI 10.4161/cc.7.6.5596; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45; Vadhvani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057530; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Zhang XC, 2014, ONCOTARGET, V5, P6178, DOI 10.18632/oncotarget.2183; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	39	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					1012	1022		10.1038/onc.2016.268	http://dx.doi.org/10.1038/onc.2016.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27568981				2022-12-28	WOS:000394169100013
J	Eguchi, R; Nakano, T; Wakabayashi, I				Eguchi, R.; Nakano, T.; Wakabayashi, I.			Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; GROWTH-FACTOR; EPITHELIN PRECURSOR; TUMOR ANGIOGENESIS; PROGNOSTIC MARKER; CANCER; CISPLATIN; THERAPY; TUMORIGENESIS; EXPRESSION	Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes and is associated with tumor angiogenesis, which is a prerequisite for tumor progression. Vascular endothelial growth factors (VEGFs) including VEGF-A have a crucial role in tumor angiogenesis. However, bevacizumab, a monoclonal antibody to VEGF-A, has recently been reported not to improve the progression-free survival of patients with malignant mesothelioma. Cell culture supernatant contains extracellular components such as serum, which can mask the existence of unknown cell-derived factors in the supernatant and make it difficult to detect the factors by subsequent protein analysis. We tried using serum-free culture for human mesothelioma cell lines, NCI-H28, NCI-H2452 and NCI-H2052, and only NCI-H2052 cells adapted to serum-free culture. We found that serum-free culture supernatant derived from NCI-H2052 cells induces the formation of capillary-like tube structures (tube formation) in three-dimensional culture, in which endothelial cells sandwiched between two layers of collagen or embedded in collagen are incubated with various angiogenic inducers. However, neither neutralization of VEGF-A nor RNA interference of VEGF receptor 2 (VEGFR2) suppressed the supernatant-induced tube formation. Using mass spectrometry, we identified a total of 399 proteins in the supernatant, among which interleukin-8 (IL-8), growth-regulated a-protein, midkine, IL-18, IL-6, hepatoma-derived growth factor, clusterin and granulin (GRN), also known as progranulin (PGRN), were included as a candidate protein inducing angiogenesis. Neutralizing assays and RNA interference showed that PGRN, but not the above seven candidate proteins, caused the supernatant-induced tube formation. We also found that NCI-H28 and NCI-H2452 cells express PGRN. Furthermore, we demonstrate that not only PGRN but also GRN-like protein have an important role in the supernatant-induced tube formation. Thus, mesothelioma-derived GRNs induce VEGF-independent angiogenesis.	[Eguchi, R.; Wakabayashi, I.] Hyogo Coll Med, Dept Environm & Prevent Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan; [Nakano, T.] Hyogo Coll Med, Dept Internal Med, Div Resp Med, Nishinomiya, Hyogo, Japan	Hyogo College of Medicine; Hyogo College of Medicine	Eguchi, R (corresponding author), Hyogo Coll Med, Dept Environm & Prevent Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	r-eguchi@hyo-med.ac.jp		Eguchi, Ryoji/0000-0002-2417-7578	Hyogo College of Medicine; MEXT-Supported Program for the Strategic Research Foundation at Private Universities; JSPS KAKENHI [16K14626]	Hyogo College of Medicine; MEXT-Supported Program for the Strategic Research Foundation at Private Universities(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Ms Naoko Hamaue and Mr Daiki Haruguchi for their excellent technical assistance. This work was supported by a Grant-in-Aid for Researchers, Hyogo College of Medicine, 2013, the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2012-2015 and JSPS KAKENHI Grant Number 16K14626.	Bao CH, 2014, FUTURE ONCOL, V10, P2675, DOI 10.2217/fon.14.194; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Dowell JE, 2012, LUNG CANCER, V77, P567, DOI 10.1016/j.lungcan.2012.05.111; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Edwards JG, 2001, BRIT J CANCER, V85, P863, DOI 10.1054/bjoc.2001.1997; Eguchi R, 2008, PROTEOMICS, V8, P2897, DOI 10.1002/pmic.200800055; Eguchi R, 2013, CELL SIGNAL, V25, P1731, DOI 10.1016/j.cellsig.2013.05.008; Eguchi R, 2012, CARCINOGENESIS, V33, P969, DOI 10.1093/carcin/bgs109; Eguchi R, 2010, INT J ONCOL, V37, P1289, DOI 10.3892/ijo_00000780; Gijselinck I, 2008, HUM MUTAT, V29, P1373, DOI 10.1002/humu.20785; Goudar Ranjit Kumar, 2005, Curr Oncol Rep, V7, P260, DOI 10.1007/s11912-005-0048-3; Gourlaouen M, 2013, J BIOL CHEM, V288, P7467, DOI 10.1074/jbc.M112.446401; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Ho JC, 2008, HEPATOLOGY, V47, P1524, DOI 10.1002/hep.22191; Kadomatsu K, 2014, BRIT J PHARMACOL, V171, P936, DOI 10.1111/bph.12537; Karch CM, 2013, NEUROBIOL AGING, V34, P2538, DOI 10.1016/j.neurobiolaging.2013.05.004; Keeley EC, 2010, ADV CANCER RES, V106, P91, DOI 10.1016/S0065-230X(10)06003-3; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Koltai T, 2014, ONCOTARGETS THER, V7, P447, DOI 10.2147/OTT.S58622; Kumar-Singh S, 1997, J PATHOL, V182, P211, DOI 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Palma G, 2013, BBA-REV CANCER, V1836, P296, DOI 10.1016/j.bbcan.2013.09.001; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Sun XJ, 2004, AM J RESP CELL MOL, V30, P510, DOI 10.1165/rcmb.2003-0266OC; Toh HS, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075073, 10.1371/journal.pone.0064989]; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Vogelzang NJ, 2008, LANCET, V371, P1640, DOI 10.1016/S0140-6736(08)60703-5; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; Yang D, 2015, AM J CANCER RES, V5, P3085; ZHOU J, 1993, J BIOL CHEM, V268, P10863	38	23	25	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					714	722		10.1038/onc.2016.226	http://dx.doi.org/10.1038/onc.2016.226			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345409				2022-12-28	WOS:000394167700012
J	Yu, J; Liang, Q; Wang, J; Wang, K; Gao, J; Zhang, J; Zeng, Y; Chiu, PWY; Ng, EKW; Sung, JJY				Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Gao, J.; Zhang, J.; Zeng, Y.; Chiu, P. W. Y.; Ng, E. K. W.; Sung, J. J. Y.			REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype	ONCOGENE			English	Article							PROMOTER HYPERMETHYLATION; CELL-PROLIFERATION; DNA METHYLATION; E-CADHERIN; EXPRESSION; CARCINOMA; PATHWAY; GENE; AGGRESSIVENESS; INHIBITION	REC8 meiotic recombination protein (REC8) was found to be preferentially methylated in gastric cancer (GC) using promoter methylation array. We aimed to elucidate the epigenetic alteration and biological function of REC8 in GC. REC8 was downregulated in 100% (3/3) of Epstein Barr virus (EBV)-positive and 80% (8/10) of EBV-negative GC cell lines by promoter methylation, but the expression could be restored through demethylation treatment. Protein expression of REC8 was significantly lower in human primary gastric tumors than in adjacent non-tumor tissues. A negative correlation between methylation and mRNA expression of REC8 was observed in 223 gastric samples of The Cancer Genome Atlas study (r= 0.7018, P < 0.001). The methylation level (%) of the REC8 promoter was significantly higher in EBV-positive gastric tumors than in EBV-negative gastric tumors, as shown by bisulfite genomic sequencing (77.6 (69.3-80.5) vs 51.4 (39.5-62.3), median (interquartile range); P < 0.001); methylation levels in both subtypes of tumors were significantly higher than in normal stomach tissues (14.8 (4.2-24.0)) (both P < 0.001). Multivariate analysis revealed that REC8 methylation was an independent factor for poor survival in GC patients (hazard ratio = 1.68, P < 0.05). REC8 expression significantly suppressed cell viability, clonogenicity and cell cycle progression; it induced apoptosis and inhibited migration of AGS-EBV (EBV-positive) and BGC823 (EBV-negative) GC cells, and it suppressed tumorigenicity in nude mice. In contrast, knockdown of REC8 in gastric epithelial immortalized GES-1 cells significantly increased cell viability, clonogenicity and migration ability. The tumor-suppressive effect of REC8 is mediated at least in part by the downregulation of genes involved in cell growth (G6PD, SLC2A1, NOL3, MCM2, SNAI7 and SNAI2), and the upregulation of apoptosis/migration inhibitors (GADD45G and LDHA) and tumor suppressors (PinX7, IGFBP3 and ETS2). In conclusion, REC8 is a novel tumor suppressor that is commonly downregulated by promoter methylation in GC, especially in the EBV-associated subtype. Promoter methylation of REC8 is an independent risk factor for the shortened survival of GC patients.	[Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Zhang, J.; Zeng, Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Zhang, J.; Zeng, Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Gao, J.] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China; [Chiu, P. W. Y.; Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Chiu, Philip/A-4019-2009; Liang, Qiaoyi Jessie/G-9612-2019; Ng, Enders Kwok Wai/E-8276-2016; Sung, Joseph J. Y./R-3203-2018; Chiu, Philip/ABB-1454-2020; ZHANG, Jingwan/AIC-2560-2022; WANG, JIA/A-2799-2019; Jun, Yu/D-8569-2015	Chiu, Philip/0000-0001-9292-112X; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Sung, Joseph J. Y./0000-0003-3125-5199; Chiu, Philip/0000-0001-9292-112X; ZHANG, Jingwan/0000-0002-0344-3398; Jun, Yu/0000-0001-5008-2153; WANG, JIA/0000-0001-5339-8954	HMRF [11100022]; RGC-GRF Hong Kong [766613]; National Natural Science Foundation of China [81272304]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology R D fund [JCYJ20130401151108652]; Shenzhen Virtual University Park Support Scheme	HMRF; RGC-GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme	This project was supported by research funds of HMRF (11100022), RGC-GRF Hong Kong (766613), National Natural Science Foundation of China (81272304), China 863 Program (2012AA02A504), Shenzhen Municipal Science and Technology R & D fund (JCYJ20130401151108652) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Arseneault R, 2013, CANCER LETT, V338, P255, DOI 10.1016/j.canlet.2013.03.034; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Feng WH, 2007, J VIROL, V81, P10113, DOI 10.1128/JVI.00692-07; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Kabbout M, 2013, CLIN CANCER RES, V19, P3383, DOI 10.1158/1078-0432.CCR-13-0341; Kim MO, 2012, BBA-GEN SUBJECTS, V1820, P1636, DOI 10.1016/j.bbagen.2012.05.008; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Liu DX, 2015, ONCOTARGET, V6, P39211, DOI 10.18632/oncotarget.5391; Liu JY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-148; Medina-Ramirez CM, 2011, CANCER RES, V71, P7705, DOI 10.1158/0008-5472.CAN-11-2192; Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Regel I, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-9; Sudo M, 2004, INT J CANCER, V109, P194, DOI 10.1002/ijc.11701; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wockner LF, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.177; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao J, 2013, INT J DISTRIB SENS N, DOI 10.1155/2013/241913; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724; Zhao JH, 2012, CANCER-AM CANCER SOC, V118, P924, DOI 10.1002/cncr.26184	34	34	37	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					182	193		10.1038/onc.2016.187	http://dx.doi.org/10.1038/onc.2016.187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27212034	Green Published, hybrid			2022-12-28	WOS:000393938100004
J	He, XH; Zhu, W; Yuan, P; Jiang, S; Li, D; Zhang, HW; Liu, MF				He, X-H; Zhu, W.; Yuan, P.; Jiang, S.; Li, D.; Zhang, H-W; Liu, M-F			miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; MICRORNA-155 PROMOTES; CANCER; TUMOR; TARGETS; TRASTUZUMAB; EXPRESSION; GROWTH; HER2; OVEREXPRESSION	ErbB2 is a vital breast cancer gene and its overexpression has a decisive role in breast tumor initiation and malignant progression. However, the molecular mechanisms that underlie ErbB2 dysregulation in breast cancer cells remain incompletely understood. In this study, we found that ErbB2 expression is inversely correlated with the level of miR-155, a well-documented oncogenic miRNA, in ErbB2-positive breast tumors. We further determined that miR-155 potently suppresses ErbB2 in breast cancer cells. Mechanistically, miR-155 acts to downregulate ErbB2 via two distinct mechanisms. First, miR-155 represses ErbB2 transcription by targeting HDAC2, a transcriptional activator of ErbB2. Second, miR-155 directly targets ErbB2 via a regulatory element in its coding region. Intriguingly, miR-155 is upregulated by trastuzumab and in turn leads to a reduction of ErbB2 expression in trastuzumab-treated ErbB2-positive breast cancer cells. Functional studies showed that miR-155 inhibits ErbB2-induced malignant transformation of human breast epithelial cells. Thus, our findings reveal an intriguing miR-155-ErbB2 context in regulating the malignant transformation of breast epithelial cells, and thereby indicate a novel mode of action for miR-155 in ErbB2-positive breast cancer.	[He, X-H; Yuan, P.; Jiang, S.; Liu, M-F] Univ Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Ctr RNA Res, State Key Lab Mol Biol, Shanghai, Peoples R China; [He, X-H; Yuan, P.; Jiang, S.; Liu, M-F] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Key Lab Mol Androl, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Zhu, W.; Zhang, H-W] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Li, D.] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Informat Ctr Life Sci, Shanghai, Peoples R China; [Liu, M-F] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Information Center for Life Sciences; ShanghaiTech University	Liu, MF (corresponding author), Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	mfliu@sibcb.ac.cn		Jiang, Shuai/0000-0002-0572-4660; liu, mo fang/0000-0003-1800-466X	Ministry of Science and Technology of China [2012CB910803, 2014CB943103, 2014CB964802]; National Natural Science Foundation of China [31325008, 91419307, 81502267, 31300656]; Science and Technology Commission of the Shanghai Municipality [13ZR1464300, 16XD1404900]; Chinese Academy of Sciences [KJZD-EW-L01-2, 2013KIP202]; Foundation of Key Laboratory of Gene Engineering of the Ministry of Education	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of the Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Chinese Academy of Sciences(Chinese Academy of Sciences); Foundation of Key Laboratory of Gene Engineering of the Ministry of Education	We thank Dr Gao-Xiang Ge for suggestions and critical comments on the manuscript. This work was supported by grants from the Ministry of Science and Technology of China (2012CB910803, 2014CB943103 and 2014CB964802), the National Natural Science Foundation of China (31325008, 91419307, 81502267, and 31300656), the Science and Technology Commission of the Shanghai Municipality (13ZR1464300 and 16XD1404900), and the Chinese Academy of Sciences (KJZD-EW-L01-2 and 2013KIP202) and Foundation of Key Laboratory of Gene Engineering of the Ministry of Education.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; American Type Culture Collection, 2007, ATCC TECHN B, V8; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Cai ZK, 2015, MOL MED REP, V11, P533, DOI 10.3892/mmr.2014.2744; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dinami R, 2014, CANCER RES, V74, P4145, DOI 10.1158/0008-5472.CAN-13-2038; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Guarnieri DJ, 2008, ANN MED, V40, P197, DOI 10.1080/07853890701771823; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Hicks DG, 2008, ARCH PATHOL LAB MED, V132, P1008, DOI 10.1043/1543-2165(2008)132[1008:TAATFE]2.0.CO;2; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Huang SL, 2010, NUCLEIC ACIDS RES, V38, P7211, DOI 10.1093/nar/gkq564; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Koudelakova V, 2015, J MOL DIAGN, V17, P446, DOI 10.1016/j.jmoldx.2015.03.007; Krauss W C, 2000, Breast Dis, V11, P113; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Melton C, 2010, NATURE, V463, P621, DOI 10.1038/nature08725; Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735; Muller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215; Nofech-Mozes S, 2005, ADV ANAT PATHOL, V12, P256, DOI 10.1097/01.pap.0000184177.65919.5e; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Pinto AC, 2013, BREAST, V22, pS152, DOI 10.1016/j.breast.2013.07.029; Pouliot LM, 2012, CANCER RES, V72, P5945, DOI 10.1158/0008-5472.CAN-12-1400; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023; Sandhu SK, 2012, P NATL ACAD SCI USA, V109, P20047, DOI 10.1073/pnas.1213764109; Scott GK, 2002, MOL CANCER THER, V1, P385; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Wu L, 2008, MOL CELL, V29, P1, DOI 10.1016/j.molcel.2007.12.010; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang XP, 2013, J CLIN ENDOCR METAB, V98, pE1305, DOI 10.1210/jc.2012-3602; Zhang YL, 2012, HEPATOLOGY, V56, P1631, DOI 10.1002/hep.25849; Zhao S, 2013, DEV CELL, V24, P13, DOI 10.1016/j.devcel.2012.12.006	50	28	28	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6015	6025		10.1038/onc.2016.132	http://dx.doi.org/10.1038/onc.2016.132			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27065318				2022-12-28	WOS:000388509400008
J	Hoyos, JM; Ferraro, A; Sacchetti, S; Keller, S; De Martino, I; Borbone, E; Pallante, P; Fedele, M; Montanaro, D; Esposito, F; Cserjesi, P; Chiariotti, L; Troncone, G; Fusco, A				Hoyos, J. M.; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Fedele, M.; Montanaro, D.; Esposito, F.; Cserjesi, P.; Chiariotti, L.; Troncone, G.; Fusco, A.			HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas (vol 28, pg 876, 2009)	ONCOGENE			English	Correction													Pallante, Pierlorenzo/AAX-8758-2020; Chiariotti, Lorenzo/AAC-5262-2022					Hoyos JM, 2009, ONCOGENE, V28, P876, DOI 10.1038/onc.2008.438	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5930	5930		10.1038/onc.2016.137	http://dx.doi.org/10.1038/onc.2016.137			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27345408	Bronze			2022-12-28	WOS:000387560800012
J	Joshi, S; Kumar, S; Ponnusamy, MP; Batra, SK				Joshi, S.; Kumar, S.; Ponnusamy, M. P.; Batra, S. K.			Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival	ONCOGENE			English	Article							EXPRESSION; GROWTH; METASTASIS; ALPHA; DEATH; ADENOCARCINOMA; ANGIOGENESIS; INHIBITION; STABILIZES; REQUIRES	Pancreatic cancer (PC) and associated pre-neoplastic lesions have been reported to be hypoxic, primarily due to hypovascular nature of PC. Though the presence of hypoxia under cancerous condition has been associated with the overexpression of oncogenic proteins (MUC1), multiple emerging reports have also indicated the growth inhibitory effects of hypoxia. In spite of being recognized as the top-most differentially expressed and established oncogenic protein in PC, MUC4 regulation in terms of micro-environmental stress has not been determined. Herein, for the first time, we are reporting that MUC4 protein stability is drastically affected in PC, under hypoxic condition in a hypoxia inducible factor 1 alpha (HIF-1 alpha)-independent manner. Mechanistically, we have demonstrated that hypoxia-mediated induction of reactive oxygen species (ROS) promotes autophagy by inhibiting pAkt/mTORC1 pathway, one of the central regulators of autophagy. Immunohistofluorescence analyses revealed significant negative correlation (P-value = 0.017) between 8-hydroxy guanosine (8-OHG) and MUC4 in primary pancreatic tumors (n=25). Moreover, we found pronounced colocalization between MUC4 and LAMP1/LC3 (microtubule-associated protein 1A/1B-light chain 3) in PC tissues and also observed their negative relationship in their expression pattern, suggesting that areas with high autophagy rate had less MUC4 expression. We also found that hypoxia and ROS have negative impact on overall cell growth and viability, which was partially, though significantly (P<0.05), rescued in the presence of MUC4. Altogether, hypoxia-mediated oxidative stress induces autophagy in PC, leading to the MUC4 degradation to enhance survival, possibly by offering required metabolites to stressed cells.	[Joshi, S.; Kumar, S.; Ponnusamy, M. P.; Batra, S. K.] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Kumar, S; Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	skumar@unmc.edu; sbatra@unmc.edu		Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NIH [UO1 CA111294, P50 CA127297, U54 CA163120, RO1 CA183459]; NATIONAL CANCER INSTITUTE [P50CA127297, R01CA183459, U01CA111294, U54CA163120] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jerred Garrison, Dr Pankaj K Singh and Dr Michael Hollingsworth for providing us hypoxia chamber, HIF-1 alpha Sh RNA constructs and human MUC1 antibody, respectively. We would also like to thank Kavita Mallya, James Talaska, Janice Taylor, Dr Nilesh Wagh and Dr Phillip Hexley for technical support. Finally, we would like to thank RAPID autopsy program and related personnel and UNMC graduate studies fellowship. The work was supported, in parts, by grants from the NIH (UO1 CA111294, P50 CA127297, U54 CA163120 and RO1 CA183459).	Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blanco FF, 2016, ONCOGENE, V35, P2529, DOI 10.1038/onc.2015.325; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chandel NS, 2014, NEW ENGL J MED, V371, P177, DOI 10.1056/NEJMcibr1405701; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Dhillon H, 2014, TOXICOL REP, V1, P309, DOI 10.1016/j.toxrep.2014.05.011; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Endo H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098858; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greco E, 2010, PANCREAS, V39, P662, DOI 10.1097/MPA.0b013e3181c8b48c; Gupta D, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-69; Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011; Hinoda Y, 2003, J GASTROENTEROL, V38, P1162, DOI 10.1007/s00535-003-1224-6; Joshi S, 2015, CANCER METAST REV, V34, P593, DOI 10.1007/s10555-015-9549-1; Joshi S, 2014, ONCOTARGET, V5, P7272, DOI 10.18632/oncotarget.2370; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kim YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098136; Kitamoto S, 2013, ONCOGENE, V32, P4614, DOI 10.1038/onc.2012.478; Kitamoto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044108; Kumar S, 2015, ONCOGENE, V34, P4879, DOI 10.1038/onc.2014.409; Liu C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-622; Liu ZH, 2007, DEV CELL, V12, P484, DOI 10.1016/j.devcel.2007.03.016; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Munafo DB, 2001, J CELL SCI, V114, P3619; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Senapati S, 2011, CLIN CANCER RES, V17, P267, DOI 10.1158/1078-0432.CCR-10-1937; Sendoel A, 2014, PHYSIOLOGY, V29, P168, DOI 10.1152/physiol.00016.2013; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Shao MXG, 2005, J IMMUNOL, V175, P4009, DOI 10.4049/jimmunol.175.6.4009; Siddiqui A, 2007, AM J SURG, V194, P362, DOI 10.1016/j.amjsurg.2007.02.007; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Vasseur Sophie, 2010, Cancers (Basel), V2, P2138, DOI 10.3390/cancers2042138; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang R., 2012, MATH PROBL ENG, V2012, P1, DOI DOI 10.1109/IEVC2012.6183284.URL; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Zhang XW, 2004, CHEMOSPHERE, V55, P1303, DOI 10.1016/j.chemosphere.2003.12.004; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021; Zhou J, 2013, EURASIP J WIREL COMM, DOI 10.1186/1687-1499-2013-218	52	34	35	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5882	5892		10.1038/onc.2016.119	http://dx.doi.org/10.1038/onc.2016.119			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109098	Green Accepted			2022-12-28	WOS:000387560800007
J	Zhou, Z; Wang, M; Li, J; Xiao, M; Chin, YE; Cheng, J; Yeh, ETH; Yang, J; Yi, J				Zhou, Z.; Wang, M.; Li, J.; Xiao, M.; Chin, Y. E.; Cheng, J.; Yeh, E. T. H.; Yang, J.; Yi, J.			SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; CONSTITUTIVE ACTIVATION; CROSS-TALK; TRANSCRIPTION STAT; SIGNAL TRANSDUCERS; LARYNGEAL-CANCER; CIGARETTE-SMOKE; DE-SUMOYLATION	Hyperphosphorylation of signal transducer and activator of transcription 3 (STAT3) has been found in various types of human cancers, including head and neck cancer (HNC). Although smoking is critical in the development and progression of HNC, how tobacco components activate STAT3 is unclear. We demonstrated that exposure of HNC cell lines to a tobacco extract induced a rapid Y705 phosphorylation of STAT3 and a rapid increase in the SUMO protease SENP3 that depended on a simultaneous increase in reactive oxygen species. We identified that SUMOylation at the lysine 451 site facilitated STAT3 binding to the phosphatase TC45 through an SUMO-interacting motif of TC45. SENP3 could thus enhance STAT3 phosphorylation by de-conjugating the SUMO2/3 modification of STAT3. Knocking-down of SENP3 greatly impaired basal and induced STAT3 phosphorylation by tobacco extract or interleukin 6. A correlation between SENP3 protein levels and STAT3 Y705 phosphorylation levels in human laryngeal carcinoma specimens was found, which was more significant in the specimens derived from the smoker patients and with poor clinicopathological parameters. Our data identified SUMOylation as a previously undescribed post-translational modification of STAT3 and SENP3 as a critical positive modulator of tobacco-or cytokine-induced STAT3 activation. These findings provide novel insights into the hyperphosphorylation of STAT3 in development of HNC.	[Zhou, Z.; Wang, M.; Cheng, J.; Yang, J.; Yi, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol,Inst Med Sci, Shanghai Key Lab Tumor Microenviron & Inflammat, Shanghai, Peoples R China; [Zhou, Z.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Otolaryngol, Shanghai, Peoples R China; [Xiao, M.; Chin, Y. E.] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci, Inst Hlth Sci,Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; University of Texas System; UTMD Anderson Cancer Center	Yang, J; Yi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Biochem & Mol Cell Biol, 280 S Chongqing Rd, Shanghai 200025, Peoples R China.	yangjieyj@shsmu.edu.cn; yijing@shsmu.edu.cn			National Ministry of Science and Technology of China [2013CB910900]; National Natural Science Foundation of China [31230037]; Shanghai Municipal Science and Technology Commission [11DZ2260200, 13ZR1425300]	National Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Science and Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by grants from the National Ministry of Science and Technology of China (2013CB910900), the National Natural Science Foundation of China (31230037) and Shanghai Municipal Science and Technology Commission (11DZ2260200, 13ZR1425300). The plasmid Flag-STAT3 and Flag-TC45 were gifts of Dr Guoliang Xu (Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China).	Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bito T, 2010, EXP DERMATOL, V19, P654, DOI 10.1111/j.1600-0625.2010.01084.x; BLOT WJ, 1988, CANCER RES, V48, P3282; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RM, 2011, ABSTR APPL ANAL, DOI 10.1155/2011/589862; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P476, DOI 10.1016/j.jaci.2004.06.042; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Csiszar A, 2009, FRONT BIOSCI-LANDMRK, V14, P3128, DOI 10.2741/3440; Droescher M, 2011, J BIOL CHEM, V286, P18731, DOI 10.1074/jbc.M111.235978; Gao LF, 2006, ACTA PHARMACOL SIN, V27, P347, DOI 10.1111/j.1745-7254.2006.00277.x; Gao LF, 2005, ACTA PHARMACOL SIN, V26, P377, DOI 10.1111/j.1745-7254.2005.00053.x; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Han Y, 2010, J BIOL CHEM, V285, P12906, DOI 10.1074/jbc.M109.071431; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; He QY, 2015, ONCOTARGET, V6, P16422, DOI 10.18632/oncotarget.3847; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hittelman WN, 2001, ANN NY ACAD SCI, V952, P1; Huang C., 2009, 2009 IEEE CIRC SYST, V1, P1, DOI DOI 10.1109/CAS-ICTD.2009.4960873; Huang CT, 2014, BBA-MOL CELL RES, V1843, P483, DOI 10.1016/j.bbamcr.2013.11.015; Huang RY, 2011, ONCOGENE, V30, P106, DOI 10.1038/onc.2010.390; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; IWAMOTO H, 1975, LARYNGOSCOPE, V85, P1162, DOI 10.1288/00005537-197507000-00007; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Khariwala SS, 2011, HEAD NECK-J SCI SPEC, V34, P441; Kim DY, 2009, J GASTROEN HEPATOL, V24, P646, DOI 10.1111/j.1440-1746.2008.05671.x; Kim PM, 1996, CANCER RES, V56, P1526; Le QT, 2003, CLIN CANCER RES, V9, P4287; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lewin F, 1998, CANCER-AM CANCER SOC, V82, P1367, DOI 10.1002/(SICI)1097-0142(19980401)82:7&lt;1367::AID-CNCR21&gt;3.0.CO;2-3; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Liu TY, 2010, EUR J PHARMACOL, V641, P15, DOI 10.1016/j.ejphar.2010.04.062; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Macha MA, 2011, CARCINOGENESIS, V32, P368, DOI 10.1093/carcin/bgq278; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda M, 2002, CANCER RES, V62, P3351; Masuda M, 2010, CURR CANCER DRUG TAR, V10, P117, DOI 10.2174/156800910790980197; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Nagpal JK, 2002, CANCER, V94, P2393, DOI 10.1002/cncr.10499; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Perry E, 2004, ONCOGENE, V23, P8908, DOI 10.1038/sj.onc.1208149; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Pryor WA, 1998, CHEM RES TOXICOL, V11, P441, DOI 10.1021/tx970159y; Qu Y, 2013, CANCER RES, V73, P7090, DOI 10.1158/0008-5472.CAN-13-1560; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; Ren YH, 2014, ONCOTARGET, V5, P7093, DOI 10.18632/oncotarget.2197; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889; Sang J, 2011, BIOCHEM J, V435, P489, DOI 10.1042/BJ20101474; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Sriuranpong V, 2003, CANCER RES, V63, P2948; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Ulane CM, 2003, J VIROL, V77, P6385, DOI 10.1128/JVI.77.11.6385-6393.2003; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yan S, 2010, EMBO J, V29, P3773, DOI 10.1038/emboj.2010.245; Yang J, 2004, FREE RADICAL BIO MED, V37, P2027, DOI 10.1016/j.freeradbiomed.2004.09.016; Yang J., 2010, 2010 2 INT C SIGN PR; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZANG LY, 1995, FREE RADICAL BIO MED, V19, P161, DOI 10.1016/0891-5849(94)00236-D; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	85	40	43	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5826	5838		10.1038/onc.2016.124	http://dx.doi.org/10.1038/onc.2016.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27181202	Green Published, hybrid			2022-12-28	WOS:000387560800002
J	Si, H; Lu, H; Yang, X; Mattox, A; Jang, M; Bian, Y; Sano, E; Viadiu, H; Yan, B; Yau, C; Ng, S; Lee, SK; Romano, RA; Davis, S; Walker, RL; Xiao, W; Sun, H; Wei, L; Sinha, S; Benz, CC; Stuart, JM; Meltzer, PS; Van Waes, C; Chen, Z				Si, H.; Lu, H.; Yang, X.; Mattox, A.; Jang, M.; Bian, Y.; Sano, E.; Viadiu, H.; Yan, B.; Yau, C.; Ng, S.; Lee, S. K.; Romano, R-A; Davis, S.; Walker, R. L.; Xiao, W.; Sun, H.; Wei, L.; Sinha, S.; Benz, C. C.; Stuart, J. M.; Meltzer, P. S.; Van Waes, C.; Chen, Z.			TNF-alpha modulates genome-wide redistribution of Delta Np63 alpha/TAp73 and NF-kappa B cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer	ONCOGENE			English	Article							CELL CARCINOMA; C-JUN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSION; SIGNAL PATHWAYS; GROWTH-FACTOR; NECK-CANCER; P53 HOMOLOG; HUMAN HEAD; P63	The Cancer Genome Atlas (TCGA) network study of 12 cancer types (PanCancer 12) revealed frequent mutation of TP53, and amplification and expression of related TP63 isoform Delta Np63 in squamous cancers. Further, aberrant expression of inflammatory genes and TP53/p63/p73 targets were detected in the PanCancer 12 project, reminiscent of gene programs comodulated by cREL/Delta Np63/TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas (HNSCCs). However, how inflammatory gene signatures and cREL/p63/p73 targets are comodulated genome wide is unclear. Here, we examined how the inflammatory factor tumor necrosis factor-alpha (TNF-alpha) broadly modulates redistribution of cREL with Delta Np63 alpha/TAp73 complexes and signatures genome wide in the HNSCC model UM-SCC46 using chromatin immunoprecipitation sequencing (ChIP-seq). TNF-alpha enhanced genome-wide co-occupancy of cREL with Delta Np63 alpha on TP53/p63 sites, while unexpectedly promoting redistribution of TAp73 from TP53 to activator protein-1 (AP-1) sites. cREL, Delta Np63 alpha and TAp73 binding and oligomerization on NF-kappa B-, TP53- or AP-1-specific sequences were independently validated by ChIP-qPCR (quantitative PCR), oligonucleotide-binding assays and analytical ultracentrifugation. Function of the binding activity was confirmed using TP53-, AP-1- and NF-kappa B-specific REs or p21, SERPINE1 and IL-6 promoter luciferase reporter activities. Concurrently, TNF-alpha regulated a broad gene network with cobinding activities for cREL, Delta Np63 alpha and TAp73 observed upon array profiling and reverse transcription-PCR. Overlapping target gene signatures were observed in squamous cancer subsets and in inflamed skin of transgenic mice overexpressing Delta Np63 alpha. Furthermore, multiple target genes identified in this study were linked to TP63 and TP73 activity and increased gene expression in large squamous cancer samples from PanCancer 12 TCGA by CircleMap. PARADIGM inferred pathway analysis revealed the network connection of TP63 and NF-kappa B complexes through an AP-1 hub, further supporting our findings. Thus, inflammatory cytokine TNF-a mediates genome-wide redistribution of the cREL/p63/p73, and AP-1 interactome, to diminish TAp73 tumor suppressor function and reciprocally activate NF-kappa B and AP-1 gene programs implicated in malignancy.	[Si, H.; Lu, H.; Yang, X.; Mattox, A.; Jang, M.; Bian, Y.; Lee, S. K.; Van Waes, C.; Chen, Z.] NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA; [Lu, H.] Zhujiang Hosp Guangzhou, Orthopaed Ctr, Guangzhou, Guangdong, Peoples R China; [Sano, E.] Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA; [Viadiu, H.] Univ Nacl Autonoma Mexico, Inst Quim, Ciudad Univ, Mexico City, DF, Mexico; [Yan, B.] Univ Hong Kong, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Yan, B.] Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yan, B.] Univ Hong Kong, Ctr Genome Sci, Hong Kong, Hong Kong, Peoples R China; [Yau, C.; Benz, C. C.] Buck Inst Res Aging, Novato, CA USA; [Ng, S.; Stuart, J. M.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Romano, R-A; Sinha, S.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY USA; [Davis, S.; Walker, R. L.] NCI, Canc Genet Branch, Bethesda, MD 20892 USA; [Xiao, W.] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AK USA; [Sun, H.] NIAMSD, Biodata Min & Discovery Sect, Bethesda, MD 20892 USA; [Wei, L.] NEI, Clin Immunol Sect, NIH, Bethesda, MD 20892 USA; [Wei, L.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Southern Medical University - China; University of California System; University of California San Diego; Universidad Nacional Autonoma de Mexico; University of Hong Kong; University of Hong Kong; University of Hong Kong; Buck Institute for Research on Aging; University of California System; University of California Santa Cruz; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Sun Yat Sen University	Van Waes, C (corresponding author), NIDCD, NIH, Bldg 10-CRC,4-2732,10 Ctr Dr, Bethesda, MD 20892 USA.; Chen, Z (corresponding author), NIDCD, Clin Genom Unit, Head & Neck Surg Branch, NIH, Bldg 10-5D55,10 Ctr Dr, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov; chenz@nidcd.nih.gov	Davis, Sean/AAD-1801-2021	Davis, Sean/0000-0002-8991-6458; Walker, Robert/0000-0001-8235-4686; Stuart, Joshua/0000-0002-2171-565X; /0000-0002-2168-3379; Lu, Hai/0000-0002-4212-3282	NIH [R01AR049238]; NCI [R01-CA180778, U24-CA143858]; Stand Up to Cancer; Prostate Cancer Foundation; Movember Foundation;  [ZIA-DC-000073];  [ZIA-DC-000074]; NATIONAL CANCER INSTITUTE [U24CA210990, U24CA143858, R01CA180778, ZIABC011091] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG006097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073, Z01DC000073, ZIADC000016, ZIADC000074] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stand Up to Cancer; Prostate Cancer Foundation; Movember Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Dr Fan Yang (NCI/NIH), Dr Kairong Cui (NHLBI/NIH), Dr Bingmei Zhu (NIDDK/NIH), Jeffery Burnett (NIDCD/NIH), Jamie Coupar (NIDCD/NIH), Guanmei Liang (Thomas Jefferson High School for Science and Technology, Alexandria, VA, USA) and Eric Nicolson (Ithaca High School, Ithaca, New York, NY, USA) for their technical assistance and suggestions. The authors express appreciation to Drs James W Rocco and Leif W Ellisen (Harvard University) for providing Delta Np63 and TAp63 expression vectors, Dr Thomas Gilmore (Boston University) for cRel expression plasmids, Professor Gerry Melino (University of Leicester) for TAp73 alpha expression plasmids, Dr J Silvio Gutkind (NIDCR/NIH) for IL-6 promoter reporter plasmids, Dr Gourisankar Ghosh (UCSD) for the cRel expression plasmid, and Drs Michal Karin (University of California, San Diego), Cheng-Ming Chiang (University of Texas, Southwestern) and Xuan Liu (University of California, Riverside) for critique of and helpful suggestions for the manuscript. HL, HS, XY, AM, MJ, YB, CVW and ZC are supported by intramural projects ZIA-DC-000073, ZIA-DC-000074 and RAR and SS are supported by a grant from NIH (R01AR049238). JMS acknowledges support from NCI (R01-CA180778 and U24-CA143858), Stand Up to Cancer, Prostate Cancer Foundation and the Movember Foundation.	Andreasen PA, 2007, CURR DRUG TARGETS, V8, P1030, DOI 10.2174/138945007781662346; Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Barenco M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.84; Belyi VA, 2009, P NATL ACAD SCI USA, V106, P17609, DOI 10.1073/pnas.0910634106; Bid HK, 2014, CANCER RES, V74, P320, DOI 10.1158/0008-5472.CAN-13-0894; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Chatterjee A, 2010, CANCER RES, V70, P1419, DOI 10.1158/0008-5472.CAN-09-2613; Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Dong G, 2004, ONCOGENE, V23, P6199, DOI 10.1038/sj.onc.1207851; Dong G, 2001, CANCER RES, V61, P5911; Du JH, 2014, J PATHOL, V232, P356, DOI 10.1002/path.4302; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Jiang H, 2010, BIOINFORMATICS, V26, P1781, DOI 10.1093/bioinformatics/btq286; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; King KE, 2008, CANCER RES, V68, P5122, DOI 10.1158/0008-5472.CAN-07-6123; Koeppel M, 2011, NUCLEIC ACIDS RES, V39, P6069, DOI 10.1093/nar/gkr028; Koshiba S, 2008, J PATHOL, V214, P75, DOI 10.1002/path.2266; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leslie M, 2011, SCIENCE, V331, P1551, DOI 10.1126/science.331.6024.1551; Lu H, 2011, CANCER RES, V71, P6867, DOI 10.1158/0008-5472.CAN-11-2460; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Natan E, 2012, J MOL BIOL, V415, P503, DOI 10.1016/j.jmb.2011.11.007; Ng S, 2012, BIOINFORMATICS, V28, pI640, DOI 10.1093/bioinformatics/bts402; Nottingham LK, 2014, ONCOGENE, V33, P1135, DOI 10.1038/onc.2013.49; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2011, INDIAN J EXP BIOL, V49, P721; Romano RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005623; Rosenbluth JM, 2011, P NATL ACAD SCI USA, V108, P2076, DOI 10.1073/pnas.1011936108; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Sethi G, 2012, BIOSCIENCE REP, V32, P1, DOI 10.1042/BSR20100136; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Smeenk L, 2008, NUCLEIC ACIDS RES, V36, P3639, DOI 10.1093/nar/gkn232; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Wong CK, 2013, NUCLEIC ACIDS RES, V41, pW218, DOI 10.1093/nar/gkt473; Yang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011572; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	55	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5781	5794		10.1038/onc.2016.112	http://dx.doi.org/10.1038/onc.2016.112			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27132513	Green Accepted, Green Submitted			2022-12-28	WOS:000386998400009
J	Griveau, A; Devailly, G; Eberst, L; Navaratnam, N; Le Calve, B; Ferrand, M; Faull, P; Augert, A; Dante, R; Vanacker, JM; Vindrieux, D; Bernard, D				Griveau, A.; Devailly, G.; Eberst, L.; Navaratnam, N.; Le Calve, B.; Ferrand, M.; Faull, P.; Augert, A.; Dante, R.; Vanacker, J. M.; Vindrieux, D.; Bernard, D.			The PLA2R1-JAK2 pathway upregulates ERR alpha and its mitochondrial program to exert tumor-suppressive action	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTOR; BREAST-CANCER; CELLS; PGC-1-ALPHA; METABOLISM; PGC-1-BETA; MIGRATION; STRESS; GROWTH; VEGF	Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this study, we observed that PLA2R1 increases the mitochondrial content, judged by increased levels of numerous mitochondrial proteins, of the mitochondrial structural component cardiolipin, of the mitochondrial DNA content, and of the mitochondrial DNA replication and transcription factor TFAM. This effect of PLA2R1 relies on a transcriptional program controlled by the estrogen-related receptor alpha1 (ERR alpha) mitochondrial master regulator. Expression of ERR alpha and of its nucleus-encoded mitochondrial targets is upregulated upon PLA2R1 ectopic expression, and this effect is mediated by JAK2. Conversely, downregulation of PLA2R1 decreases the level of ERR alpha and of its nucleus-encoded mitochondrial targets. Finally, blocking the ERR alpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERR alpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression.	[Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] CNRS, UMR 5286, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Ctr Leon Berard, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Univ Lyon, Lyon, France; [Navaratnam, N.] Imperial Coll, Fac Med, MRC Clin Sci Ctr, Cellular Stress Grp, Hammersmith Campus, London, England; [Faull, P.] Imperial Coll London, MRC Clin Sci Ctr, Biol Mass Spectrometry & Prote Lab, London, England; [Vanacker, J. M.] Univ Lyon 1, CNRS, UMR5242, Inst Genom Fonctionnelle Lyon,Ecole Normale Super, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Imperial College London; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON)	Bernard, D (corresponding author), Ctr Rech Cancerol Lyon, CNRS, INSERM, U1052, F-69373 Lyon 08, France.	david.bernard@lyon.unicancer.fr	Devailly, Guillaume/S-3998-2019; Bernard, David/D-6265-2018	Devailly, Guillaume/0000-0001-8878-9357; Bernard, David/0000-0002-1557-2074; Vindrieux, David/0000-0002-4713-5768; Faull, Peter/0000-0001-8491-8086; GRIVEAU, Audrey/0000-0002-5928-6328	Association for International Cancer Research [AICR-11-0722]; ANR [ANR-14-CE12-0003]; Groupe Pasteur Mutualite; Ligue contre le cancer, comite du Puy de Dome et de la Drome	Association for International Cancer Research; ANR(French National Research Agency (ANR)); Groupe Pasteur Mutualite; Ligue contre le cancer, comite du Puy de Dome et de la Drome	We thank the laboratory members for helpful discussions. This work was carried out with the support of the Association for International Cancer Research (AICR-11-0722) and the ANR (ANR-14-CE12-0003) for DB, the Groupe Pasteur Mutualite for LE and the Ligue contre le cancer, comite du Puy de Dome et de la Drome for JMV.	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Augert A, 2013, FREE RADICAL BIO MED, V65, P969, DOI 10.1016/j.freeradbiomed.2013.08.177; Augert A, 2009, EMBO REP, V10, P271, DOI 10.1038/embor.2008.255; Bernard D, 2014, BBA-REV CANCER, V1846, P40, DOI 10.1016/j.bbcan.2014.03.003; Bianco S, 2012, J STEROID BIOCHEM, V130, P180, DOI 10.1016/j.jsbmb.2011.03.014; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Devailly G, 2015, NUCLEIC ACIDS RES, V43, P5838, DOI 10.1093/nar/gkv508; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; Gallet M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054837; Hong EJ, 2013, P NATL ACAD SCI USA, V110, P17975, DOI 10.1073/pnas.1315319110; Li Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003230; Manna S, 2015, CLIN CANC RES; Menschikowski M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-576; Miwa S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4837; Sailland J, 2014, P NATL ACAD SCI USA, V111, P15108, DOI 10.1073/pnas.1402094111; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Vindrieux D, 2014, ONCOTARGET, V5, P1004, DOI 10.18632/oncotarget.1681; Vindrieux D, 2013, CANCER RES, V73, P6334, DOI 10.1158/0008-5472.CAN-13-0318; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	29	14	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5033	5042		10.1038/onc.2016.43	http://dx.doi.org/10.1038/onc.2016.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041564				2022-12-28	WOS:000383965300007
J	Zhang, P; Feng, S; Liu, G; Wang, H; Fu, A; Zhu, H; Ren, Q; Wang, B; Xu, X; Bai, H; Dong, C				Zhang, P.; Feng, S.; Liu, G.; Wang, H.; Fu, A.; Zhu, H.; Ren, Q.; Wang, B.; Xu, X.; Bai, H.; Dong, C.			CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation	ONCOGENE			English	Article							COLON-CARCINOMA CELLS; BREAST-CANCER CELLS; V600E B-RAF; E-SELECTIN; ENDOTHELIAL-CELLS; VARIANT ISOFORMS; MESSENGER-RNA; BINDING-KINETICS; TUMOR-CELLS; VE-CADHERIN	Melanoma is one of the most lethal forms of skin cancer because of its early metastatic spread. The variant form of CD44 CD44v), a cell surface glycoprotein, is highly expressed on metastatic melanoma. The mechanisms of regulation of CD44 alternative splicing in melanoma and its pathogenic contributions are so far poorly understood. Here, we investigated the expression level of CD44 in a large set of melanocytic lesions at different stages. We found that the expression of CD44v8-10 and a splicing factor, U2AF2, is significantly increased during melanoma progression, whereas CD82/KAI1, a tetraspanin family of tumor suppressor, is reduced in metastatic melanoma. CD44v8-10 and U2AF2 expression levels, which are negatively correlated with CD82 levels, are markedly elevated in primary melanoma compared with dysplastic nevi and further increased in metastatic melanoma. We also showed that patients with higher CD44v8-10 and U2AF2 expression levels tended to have shorter survival. By using both in vivo and in vitro assays, we demonstrated that CD82 inhibits the production of CD44v8-10 on melanoma. Mechanistically, U2AF2 is a downstream target of CD82 and in malignant melanoma facilitates CD44v8-10 alternative splicing. U2AF2-mediated CD44 isoform switch is required for melanoma migration in vitro and lung and liver metastasis in vivo. Notably, overexpression of CD82 suppresses U2AF2 activity by inducing U2AF2 ubiquitination. In addition, our data suggested that enhancement of melanoma migration by U2AF2-dependent CD44v8-10 splicing is mediated by Src/focal adhesion kinase/RhoA activation and formation of stress fibers, as well as CD44-E-selectin binding reinforcement. These findings uncovered a hitherto unappreciated function of CD82 in severing the linkage between U2AF2-mediated CD44 alternative splicing and cancer aggressiveness, with potential prognostic and therapeutic implications in melanoma.	[Zhang, P.; Feng, S.; Fu, A.; Zhu, H.; Ren, Q.; Xu, X.; Bai, H.] Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing 400715, Peoples R China; [Zhang, P.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada; [Liu, G.; Wang, H.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai, Peoples R China; [Wang, B.] Chongqing Univ, Coll Bioengn, Chongqing, Peoples R China; [Dong, C.] Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA	Southwest University - China; University of Alberta; Tongji University; Chongqing University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhang, P (corresponding author), Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing 400715, Peoples R China.	pu1@ualberta.ca			Fundamental Research Funds for the Central Universities [XDJK2014C176, XDJK2012B010, XDJK2015C154, XDJK2015C155]; Start-up Foundation of Southwest University [SWU114017]; National Natural Science Foundation of China (NSFC) [NSFC-81402393, NSFC-81572678, NSFC-81272433, NSFC-81472732, NSFC-81073084]; National Science Foundation [CBET-0729091]; NATIONAL CANCER INSTITUTE [R01CA125707] Funding Source: NIH RePORTER	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Start-up Foundation of Southwest University; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Go J Yoshida (Tokyo Medical and Dental University) for helpful discussion. This study was funded by Fundamental Research Funds for the Central Universities (XDJK2014C176 to PZ, XDJK2012B010 to HFZ, XDJK2015C154 to QR and XDJK2015C155 to FS), the Start-up Foundation of Southwest University (SWU114017 to PZ), National Natural Science Foundation of China (NSFC) (NSFC-81402393 to PZ, NSFC-81572678 to PZ, NSFC-81272433 to GTL, NSFC-81472732 to GTL and NSFC-81073084 to HFZ) and National Science Foundation grants (CBET-0729091 to CD).	Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Fu CL, 2011, J BIOL CHEM, V286, P34777, DOI 10.1074/jbc.M111.281642; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jacobs PP, 2011, FEBS LETT, V585, P3148, DOI 10.1016/j.febslet.2011.07.039; Khanna P, 2014, ONCOGENE, V33, P2898, DOI 10.1038/onc.2013.249; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konstantopoulos K, 2009, ANNU REV BIOMED ENG, V11, P177, DOI 10.1146/annurev-bioeng-061008-124949; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Mackereth CD, 2011, NATURE, V475, P408, DOI 10.1038/nature10171; Marzese DM, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12307; McEver RP, 2010, ANNU REV CELL DEV BI, V26, P363, DOI 10.1146/annurev.cellbio.042308.113238; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2013, J BIOL CHEM, V288, P26323, DOI 10.1074/jbc.M112.439380; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prochazka L, 2014, CELL SIGNAL, V26, P2234, DOI 10.1016/j.cellsig.2014.07.011; Reinke LM, 2012, J BIOL CHEM, V287, P36435, DOI 10.1074/jbc.M112.397125; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shirure VS, 2015, AM J PHYSIOL-CELL PH, V308, pC68, DOI 10.1152/ajpcell.00094.2014; Sridhar SC, 2006, ONCOGENE, V25, P2367, DOI 10.1038/sj.onc.1209269; Stoilov P, 2008, P NATL ACAD SCI USA, V105, P11218, DOI 10.1073/pnas.0801661105; Subbaram S, 2014, J CELL SCI, V127, P1179, DOI 10.1242/jcs.131227; Takahashi K, 1995, ONCOGENE, V11, P2223; Takeo K, 2009, AM J PHYSIOL-CELL PH, V297, pC330, DOI 10.1152/ajpcell.00009.2009; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wei Q, 2014, CIRCULATION, V130, P1493, DOI 10.1161/CIRCULATIONAHA.114.011096; Wei WJ, 2012, NUCLEIC ACIDS RES, V40, P8622, DOI 10.1093/nar/gks579; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Xiong FY, 2012, MOL BIOL REP, V39, P1935, DOI 10.1007/s11033-011-0940-x; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yago T, 2010, BLOOD, V116, P485, DOI 10.1182/blood-2009-12-259556; Zeng Y, 2013, CANCER RES, V73, P4123, DOI 10.1158/0008-5472.CAN-12-1343; Zhang P, 2015, AM J PHYSIOL-HEART C, V308, pH1205, DOI 10.1152/ajpheart.00005.2015; Zhang P, 2014, FEBS LETT, V588, P4573, DOI 10.1016/j.febslet.2014.10.027; Zhang P, 2014, FASEB J, V28, P4591, DOI 10.1096/fj.11-202747; Zhang P, 2011, J IMMUNOL, V186, P242, DOI 10.4049/jimmunol.1000494; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574; Zhu S, 2016, ONCOGENE, V35, P1847, DOI 10.1038/onc.2015.250; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	52	22	23	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5056	5069		10.1038/onc.2016.67	http://dx.doi.org/10.1038/onc.2016.67			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041584	Green Accepted			2022-12-28	WOS:000383965300009
J	Liu, WT; Huang, KY; Lu, MC; Huang, HL; Chen, CY; Cheng, YL; Yu, HC; Liu, SQ; Lai, NS; Huang, HB				Liu, W-T; Huang, K-Y; Lu, M-C; Huang, H-L; Chen, C-Y; Cheng, Y-L; Yu, H-C; Liu, S-Q; Lai, N-S; Huang, H-B			TGF-beta upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability	ONCOGENE			English	Article							CELL SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; P53-MDM2 PATHWAY; DNA-DAMAGE; ACTIVATION; USP7/HAUSP; RESPONSES; SMADS; MDM2	Crosstalk between transforming growth factor beta (TGF-beta) signaling and p53 has a critical role in cancer progression. TGF-beta signals via Smad and non-Smad pathways. Under normal conditions, wild-type p53 forms a complex with Smad2/3 and co-activates transcription of a variety of tumor suppressor genes, resulting in tumor suppressive effects. Thus, p53 stability is essential in progression of tumor suppressive responses mediated by TGF-beta signaling. However, it remains unknown whether p53 stability is regulated by TGF-beta. In the current study, we identify that USP15 binds to and stabilizes p53 through deubiquitination in U2OS and HEK293 cells. TGF-beta promotes the translation of USP15 through activation of mammalian target of rapamycin by the phosphoinositide 3-kinase/AKT pathway. Upregulation of USP15 translation links the crosstalk between TGF-beta signaling and p53 stability, allowing this cytokine to have a critical role in cancer progression.	[Liu, W-T; Huang, K-Y; Chen, C-Y; Cheng, Y-L; Yu, H-C; Huang, H-B] Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan; [Liu, W-T; Huang, K-Y; Chen, C-Y; Cheng, Y-L; Yu, H-C; Huang, H-B] Natl Chung Cheng Univ, Inst Mol Biol, 168 Univ Rd, Chiayi 62102, Taiwan; [Huang, K-Y; Lu, M-C; Yu, H-C; Liu, S-Q; Lai, N-S] DaLin Tzu Chi Buddhist Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan; [Huang, K-Y; Lu, M-C; Lai, N-S] Tzu Chi Univ, Coll Med, Dept Med, Hualien, Taiwan; [Huang, H-L] Fooyin Univ, Dept Nutr & Hlth Sci, Kaohsiung, Taiwan	National Chung Cheng University; National Chung Cheng University; Buddhist Tzu Chi General Hospital; Tzu Chi University; Fooyin University	Huang, HB (corresponding author), Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan.; Huang, HB (corresponding author), Natl Chung Cheng Univ, Inst Mol Biol, 168 Univ Rd, Chiayi 62102, Taiwan.; Lai, NS (corresponding author), DaLin Tzu Chi Buddhist Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan.	Q12015@tzuchi.com.tw; biohbh@ccu.edu.tw			DaLin Tzu-Chi Buddhist Hospital [DTCRD 97-14, DTCRD 102-E-06, DTCRD103(2)-I-10]; National Science Council, ROC [NSC 102-2320-B194-002]	DaLin Tzu-Chi Buddhist Hospital; National Science Council, ROC(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the DaLin Tzu-Chi Buddhist Hospital (DTCRD 97-14, DTCRD 102-E-06 and DTCRD103(2)-I-10) and from the National Science Council, ROC (NSC 102-2320-B194-002).	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016/j.canlet.2004.06.008; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Huang T, 2011, EMBO J, V30, P1263, DOI 10.1038/emboj.2011.54; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Khoronenkova SV, 2012, CELL CYCLE, V11, P2409, DOI 10.4161/cc.20800; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lee H, 2000, INT J CANCER, V88, P454, DOI 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2008, MOL CELL, V29, P149, DOI 10.1016/j.molcel.2008.01.006; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Vos RM, 2009, J VIROL, V83, P8885, DOI 10.1128/JVI.00605-09; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	36	57	60	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2715	2723		10.1038/onc.2016.424	http://dx.doi.org/10.1038/onc.2016.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893708	Green Published, hybrid			2022-12-28	WOS:000401120900009
J	Urbinati, C; Grillo, E; Chiodelli, P; Tobia, C; Caccuri, F; Fiorentini, S; David, G; Rusnati, M				Urbinati, C.; Grillo, E.; Chiodelli, P.; Tobia, C.; Caccuri, F.; Fiorentini, S.; David, G.; Rusnati, M.			Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via alpha(v)beta(3)/pp60src/pp125FAK pathway	ONCOGENE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEPARAN-SULFATE PROTEOGLYCANS; INTEGRIN-MEDIATED ADHESION; ENDOTHELIAL-CELLS; IN-VIVO; SIGNALING PATHWAY; VASCULAR-PERMEABILITY; CYTOPLASMIC DOMAINS; INDUCED CHEMOTAXIS; MULTIPLE-MYELOMA	Syndecan-1 is a heparan sulfate proteoglycan (HSPG) commonly upregulated in AIDS-related B lymphoid malignancies. Tat is the main HIV-1 transactivating factor that has a major role in the pathogenesis of AIDS-related lymphomas (ARL) by engaging heparan sulfate proteoglycans (HSPGs), chemokine receptors and integrins at the lymphoid cell (LC) surface. Here B-lymphoid Namalwa cell clones that do not express or overexpress syndecan-1 (EV-Ncs and SYN-Ncs, respectively) were compared for their responsiveness with Tat: in the absence of syndecan-1, Tat induces a limited EV-Nc migration via C-X-C motif chemokine receptor 4 (CXCR4), G-proteins and Rac. Syndecan-1 overexpression increases SYN-Nc responsiveness to Tat and makes this response independent from CXCR4 and G-protein and dependent instead on pp60src phosphorylation. Tat-induced SYN-Nc migration and pp60src phosphorylation require the engagement of alpha(v)beta(3) integrin and consequent pp125FAK phosphorylation. This complex set of Tat-driven activations is orchestrated by the direct interaction of syndecan-1 with pp60src and its simultaneous coupling with alpha(v)beta(3). The Tat/syndecan-1/alpha(v)beta(3) interplay is retained in vivo and is shared also by other syndecan-1(+) B-LCs, including BJAB cells, whose responsiveness to Tat is inhibited by syndecan-1 knockdown. In conclusion, overexpression of syndecan-1 confers to B-LCs an increased capacity to migrate in response to Tat, owing to a switch from a CXCR4/G-protein/Rac to a syndecan-1/alpha(v)beta(3)/pp60src/pp125FAK signal transduction pathway that depends on the formation of a complex in which syndecan-1 interacts with Tat via its HS-chains, with alpha(v)beta(3) via its core protein ectodomain and with pp60src via its intracellular tail. These findings have implications in ARL progression and may help in identifying new therapeutical targets for the treatment of AIDS-associated neoplasia.	[Urbinati, C.; Grillo, E.; Chiodelli, P.; Tobia, C.; Rusnati, M.] Univ Brescia, Dept Mol & Translat Med, Sect Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy; [Caccuri, F.; Fiorentini, S.] Univ Brescia, Dept Mol & Translat Med, Sect Microbiol, Brescia, Italy; [David, G.] Univ Leuven, Dept Human Genet, Leuven, Belgium; [David, G.] Flanders Inst Biotechnol, Leuven, Belgium	University of Brescia; University of Brescia; KU Leuven; Flanders Institute for Biotechnology (VIB)	Rusnati, M (corresponding author), Univ Brescia, Dept Mol & Translat Med, Sect Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	marco.rusnati@unibs.it	Tobia, Chiara/ABA-5682-2021; Rusnati, Marco/F-1168-2010; Grillo, Elisabetta/AAS-3884-2021; Caccuri, Francesca/AAC-1281-2022	Rusnati, Marco/0000-0001-9968-5908; Caccuri, Francesca/0000-0002-1923-9033; FIORENTINI, SIMONA/0000-0002-1866-314X; Grillo, Elisabetta/0000-0002-8403-0607; Urbinati, Chiara Eva/0000-0002-0138-7871; Tobia, Chiara/0000-0002-0985-7356	MIUR; Fondazione Italiana per la Ricerca sul Cancro Fellowship	MIUR(Ministry of Education, Universities and Research (MIUR)); Fondazione Italiana per la Ricerca sul Cancro Fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Professor Marco Presta (University of Brescia) for helpful discussion. This work was supported by grants from MIUR to MR. PC was supported by Fondazione Italiana per la Ricerca sul Cancro Fellowship.	Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Arai A, 2005, CELL SIGNAL, V17, P497, DOI 10.1016/j.cellsig.2004.09.007; Arai A, 2006, CELL SIGNAL, V18, P2162, DOI 10.1016/j.cellsig.2006.05.001; Arese M, 2001, J IMMUNOL, V166, P1380, DOI 10.4049/jimmunol.166.2.1380; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Bonnet F, 2008, CURR OPIN ONCOL, V20, P534, DOI 10.1097/CCO.0b013e32830a5080; Brule S, 2009, BBA-GEN SUBJECTS, V1790, P1643, DOI 10.1016/j.bbagen.2009.08.001; Calpe E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081221; Carbone A, 1999, INT J BIOL MARKER, V14, P144, DOI 10.1177/172460089901400304; Chirivi RGS, 1999, BLOOD, V94, P1747, DOI 10.1182/blood.V94.5.1747.417a02_1747_1754; Choi Y, 2010, BIOCHEM BIOPH RES CO, V391, P921, DOI 10.1016/j.bbrc.2009.11.165; Colombrino E, 2004, EXP CELL RES, V295, P539, DOI 10.1016/j.yexcr.2004.01.018; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dhawan S, 1997, BLOOD, V90, P1535; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Fadnes B, 2012, GLYCOCONJUGATE J, V29, P513, DOI 10.1007/s10719-012-9427-9; Feistritzer C, 2005, EXP CELL RES, V305, P214, DOI 10.1016/j.yexcr.2005.01.001; Gatignol A, 2000, Adv Pharmacol, V48, P209; Ghezzi S, 2000, BIOCHEM BIOPH RES CO, V270, P992, DOI 10.1006/bbrc.2000.2523; Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Hoffmann C, 2005, BLOOD, V106, P1762, DOI 10.1182/blood-2004-12-4631; Huang LL, 1997, BIOCHEM BIOPH RES CO, V237, P461, DOI 10.1006/bbrc.1997.7162; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jarousse N, 2011, J IMMUNOL, V187, P5540, DOI 10.4049/jimmunol.1003495; Jarousse N, 2008, J VIROL, V82, P12591, DOI 10.1128/JVI.01167-08; Kaneider NC, 2002, J CELL SCI, V115, P227; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lamorte S, 2012, LEUKEMIA, V26, P1081, DOI 10.1038/leu.2011.290; Lebakken CS, 2000, EXP CELL RES, V259, P315, DOI 10.1006/excr.2000.4981; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LEVINE AM, 1992, BLOOD, V80, P8; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martis N, 2012, CURR HEMATOL MALIG R, V7, P228, DOI 10.1007/s11899-012-0125-2; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Montecucco F, 2006, ANN NY ACAD SCI, V1069, P463, DOI 10.1196/annals.1351.045; Mosheimer BA, 2005, J CLIN ENDOCR METAB, V90, P2964, DOI 10.1210/jc.2004-1895; Murphy JW, 2007, J BIOL CHEM, V282, P10018, DOI 10.1074/jbc.M608796200; Noonan D, 2000, Adv Pharmacol, V48, P229; Okabe S, 2002, J HEMATOTH STEM CELL, V11, P923, DOI 10.1089/152581602321080583; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Rabkin CS, 2001, EUR J CANCER, V37, P1316, DOI 10.1016/S0959-8049(01)00104-6; Rapraeger AC, 2013, FEBS J, V280, P2207, DOI 10.1111/febs.12160; Reijmers RM, 2013, FEBS J, V280, P2180, DOI 10.1111/febs.12180; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; SALCEDO R, 1995, CELL IMMUNOL, V160, P165, DOI 10.1016/0008-8749(95)80023-C; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Shah BK, 2010, J CLIN ONCOL, V28, pE459, DOI 10.1200/JCO.2010.28.3077; Toborek M, 2003, J NEUROCHEM, V84, P169, DOI 10.1046/j.1471-4159.2003.01543.x; Toschi E, 2001, MOL BIOL CELL, V12, P2934, DOI 10.1091/mbc.12.10.2934; Urbinati C, 2005, ARTERIOSCL THROM VAS, V25, P2315, DOI 10.1161/01.ATV.0000186182.14908.7b; Urbinati C, 2005, J CELL SCI, V118, P3949, DOI 10.1242/jcs.02518; Urbinati C, 2009, BLOOD, V114, P3335, DOI 10.1182/blood-2009-01-198945; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; van der Voort R, 2000, J EXP MED, V192, P1115, DOI 10.1084/jem.192.8.1115; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wang HY, 2010, J BIOL CHEM, V285, P13569, DOI 10.1074/jbc.M110.102137; WESTERFIELD M, 1995, ZEBRAFISH BOOK; Whiteford JR, 2007, EXP CELL RES, V313, P3902, DOI 10.1016/j.yexcr.2007.08.002; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Yarchoan R, 2005, NAT CLIN PRACT ONCOL, V2, P406, DOI 10.1038/ncponc0253; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	72	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2609	2618		10.1038/onc.2016.420	http://dx.doi.org/10.1038/onc.2016.420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819680				2022-12-28	WOS:000400597300011
J	Xie, X; Kaoud, TS; Edupuganti, R; Zhang, T; Kogawa, T; Zhao, Y; Chauhan, GB; Giannoukos, DN; Qi, Y; Tripathy, D; Wang, J; Gray, NS; Dalby, KN; Bartholomeusz, C; Ueno, NT				Xie, X.; Kaoud, T. S.; Edupuganti, R.; Zhang, T.; Kogawa, T.; Zhao, Y.; Chauhan, G. B.; Giannoukos, D. N.; Qi, Y.; Tripathy, D.; Wang, J.; Gray, N. S.; Dalby, K. N.; Bartholomeusz, C.; Ueno, N. T.			c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun	ONCOGENE			English	Article							NH2-TERMINAL KINASE; JNK; EXPRESSION; APOPTOSIS; SURVIVAL; PROLIFERATION; MODELS; MOUSE	c-Jun N-terminal kinase (JNK) plays a vital role in malignant transformation of different cancers, and JNK is highly activated in basallike triple-negative breast cancer (TNBC). However, the roles of JNK in regulating cancer stem-like cell (CSC) phenotype and tumorigenesis in TNBC are not well defined. JNK is known to mediate many cellular events via activating c-Jun. Here, we found that JNK regulated c-Jun activation in TNBC cells and that JNK activation correlated with c-Jun activation in TNBC tumors. Furthermore, the expression level of c-Jun was significantly higher in TNBC tumors than in non-TNBC tumors, and high c-Jun mRNA level was associated with shorter disease-free survival of patients with TNBC. Thus, we hypothesized that the JNK/c-Jun signaling pathway contributes to TNBC tumorigenesis. We found that knockdown of JNK1 or JNK2 or treatment with JNK-IN-8, an adenosine triphosphate-competitive irreversible pan-JNK inhibitor, significantly reduced cell proliferation, the ALDH1(+) and CD44(+)/CD24 -CSC subpopulations, and mammosphere formation, indicating that JNK promotes CSC self-renewal and maintenance in TNBC. We further demonstrated that both JNK1 and JNK2 regulated Notch1 transcription via activation of c-Jun and that the JNK/c-Jun signaling pathway promoted CSC phenotype through Notch1 signaling in TNBC. In a TNBC xenograft mouse model, JNK-IN-8 significantly suppressed tumor growth in a dose-dependent manner by inhibiting acquisition of the CSC phenotype. Taken together, our data demonstrate that JNK regulates TNBC tumorigenesis by promoting CSC phenotype through Notch1 signaling via activation of c-Jun and indicate that JNK/c-Jun/Notch1 signaling is a potential therapeutic target for TNBC.	[Xie, X.; Kogawa, T.; Chauhan, G. B.; Giannoukos, D. N.; Tripathy, D.; Bartholomeusz, C.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA; [Xie, X.; Kogawa, T.; Chauhan, G. B.; Giannoukos, D. N.; Tripathy, D.; Bartholomeusz, C.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Kaoud, T. S.; Edupuganti, R.; Dalby, K. N.] Univ Texas Austin, Coll Pharm, Div Med Chem, 107 West Dean Keeton,Biomed Engn Bldg, Austin, TX 78712 USA; [Zhang, T.; Gray, N. S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Kogawa, T.] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan; [Zhao, Y.; Qi, Y.; Wang, J.] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Harvard University; Harvard Medical School; National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center	Dalby, KN (corresponding author), Univ Texas Austin, Coll Pharm, Div Med Chem, 107 West Dean Keeton,Biomed Engn Bldg, Austin, TX 78712 USA.; Bartholomeusz, C; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Sect Translat Breast Canc Res, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dalby@austin.utexas.edu; chbartho@mdanderson.org; nueno@mdanderson.org	Kaoud, Tamer S/C-3618-2019; Dalby, Kevin N/A-1905-2013	Kaoud, Tamer S/0000-0003-1298-8725; Dalby, Kevin N/0000-0001-9272-5129	MD Anderson Cancer Center Inflammatory Breast Cancer funds [105655]; Nylene Eckles funds [101478]; MD Anderson Cancer Center [111411]; Cancer Prevention and Research Institute of Texas [RP140648, RP140649]; Susan G Komen for the Cure Postdoctoral Fellowship [KG111170]; National Institutes of Health Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson Cancer Center Inflammatory Breast Cancer funds; Nylene Eckles funds; MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; Susan G Komen for the Cure Postdoctoral Fellowship(Susan G. Komen Breast Cancer Foundation); National Institutes of Health Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The MIGR1 vectors were generous gifts from Dr Khaled A. Hassan (University of Michigan, Ann Arbor, MI). We thank Naoko Matsuda of the Department of Breast Medical Oncology at MD Anderson for assistance with the RPPA data analysis. We acknowledge Stephanie P Deming of the Department of Scientific Publications at MD Anderson for editorial assistance and Wendy Schober, Nalini Patel and Duncan Mak of the Flow Cytometry and Cellular Imaging Facility at MD Anderson for assistance with cell cycle distribution and stem cell subpopulation analyses. This work was supported by MD Anderson Cancer Center Inflammatory Breast Cancer funds (105655) and Nylene Eckles funds (101478) to Naoto T Ueno; startup funds from MD Anderson Cancer Center (111411) to Chandra Bartholomeusz; Cancer Prevention and Research Institute of Texas (RP140648 and RP140649) to Kevin N Dalby; a Susan G Komen for the Cure Postdoctoral Fellowship to Xuemei Xie (KG111170); and National Institutes of Health Cancer Center Support Grant to MD Anderson Cancer Center (CA016672).	Bartholomeusz C, 2012, ONCOLOGIST, V17, P766, DOI 10.1634/theoncologist.2011-0377; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Cantrell MA, 2015, ONCOTARGET, V6, P11863, DOI 10.18632/oncotarget.3787; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chang QS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-64; Chaterjee M, 2011, BONE MARROW RES, DOI 10.1155/2011/362938; Chen F, 2012, CANCER RES, V72, P379, DOI 10.1158/0008-5472.CAN-11-1982; Cheng L, 2010, TOXICOL PATHOL, V38, P62, DOI 10.1177/0192623309354109; Cubero Francisco Javier, 2011, Hepatology, V54, P1470, DOI 10.1002/hep.24532; D'Amato NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045684; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Economopoulou P, 2012, ONCOLOGIST, V17, P1394, DOI 10.1634/theoncologist.2012-0163; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gozdecka M, 2014, CELL REP, V9, P1361, DOI 10.1016/j.celrep.2014.10.043; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Li JY, 2008, J NEURO-ONCOL, V88, P11, DOI 10.1007/s11060-008-9529-1; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Malhotra Gautam K, 2011, J Carcinog, V10, P38, DOI 10.4103/1477-3163.91413; McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; She QB, 2002, CANCER RES, V62, P1343; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Trosko JE, 2009, VET PATHOL, V46, P176, DOI 10.1354/vp.46-2-176; Tsuiki H, 2003, CANCER RES, V63, P250; Wang JL, 2012, ADV EXP MED BIOL, V727, P174, DOI 10.1007/978-1-4614-0899-4_13; Wang JH, 2010, MOL CANCER RES, V8, P266, DOI 10.1158/1541-7786.MCR-09-0221; Wang X, 2010, HUM PATHOL, V41, P401, DOI 10.1016/j.humpath.2009.08.018; Wang Yue J, 2013, Methods Mol Biol, V980, P281, DOI 10.1007/978-1-62703-287-2_15; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; Xia Y, 2013, J BIOL CHEM, V288, P19321, DOI 10.1074/jbc.M113.475442; Yeh YT, 2006, INT J CANCER, V118, P2678, DOI 10.1002/ijc.21707; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010	46	54	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2599	2608		10.1038/onc.2016.417	http://dx.doi.org/10.1038/onc.2016.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941886	Green Accepted			2022-12-28	WOS:000400597300010
J	Wachter, F; Morgan, AM; Godes, M; Mourtada, R; Bird, GH; Walensky, LD				Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.			Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting	ONCOGENE			English	Article							CANCER-THERAPY; IN-VIVO; MDM2; PROTEIN; HELIX; ACTIVATION; MUTATIONS; APOPTOSIS; AFFINITY; BIMSAHB	Hydrocarbon-stapled peptides that display key residues of the p53 transactivation domain have emerged as bona fide clinical candidates for reactivating the tumor suppression function of p53 in cancer by dual targeting of the negative regulators HDM2 and HDMX. A recent study questioned the mechanistic specificity of such stapled peptides based on interrogating their capacity to disrupt p53/HDM2 and p53/HDMX complexes in living cells using a new recombinase enhanced bimolecular luciferase complementation platform (ReBiL). Here, we directly evaluate the cellular uptake, intracellular targeting selectivity and p53-dependent cytotoxicity of the clinical prototype ATSP-7041. We find that under standard serum-containing tissue culture conditions, ATSP-7041 achieves intracellular access without membrane disruption, dose-dependently dissociates both p53/HDM2 and p53/HDMX complexes but not an unrelated protein complex in long-term ReBiL experiments, and is selectively cytotoxic to cancer cells bearing wild-type p53 by inducing a surge in p53 protein level. These studies underscore the importance of a thorough stepwise approach, including consideration of the time-dependence of cellular uptake and intracellular distribution, in evaluating and advancing stapled peptides for clinical translation.	[Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.] Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,LC3216, Boston, MA 02215 USA; [Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02115 USA; [Mourtada, R.] MIT, Harvard MIT Program Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT)	Walensky, LD (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,LC3216, Boston, MA 02215 USA.	Loren_Walensky@dfci.harvard.edu	Wachter, Franziska/AAI-9671-2021	Wachter, Franziska/0000-0001-9185-3612	Alexander von Humboldt Foundation Feodor Lynen Fellowship; NIH training grant [T32GM007753]; Doctoral Foreign Studies Award from the Canadian Institutes of Health Research [DFS-134963]; William Lawrence and Blanche Hughes Foundation; Hyundai Hope on Wheels Quantum Award; Alex's Lemonade Stand Reach Grant; Todd J Schwartz Memorial Fund; Leukemia and Lymphoma SCOR and Scholar Awards; NATIONAL CANCER INSTITUTE [R50CA211399, R35CA197583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008313, T32GM007753] Funding Source: NIH RePORTER	Alexander von Humboldt Foundation Feodor Lynen Fellowship; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doctoral Foreign Studies Award from the Canadian Institutes of Health Research; William Lawrence and Blanche Hughes Foundation; Hyundai Hope on Wheels Quantum Award; Alex's Lemonade Stand Reach Grant; Todd J Schwartz Memorial Fund; Leukemia and Lymphoma SCOR and Scholar Awards; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank E Smith for graphical assistance, Lisa Cameron for assistance with confocal microscopy, and Alexandra Zoraian and Katherine Franklin for technical support. We appreciate the generosity of Drs Y Li and G Wahl for providing the ReBiL cells for this study, hosting FW in their laboratory to conduct confirmatory experiments and for helpful feedback on the manuscript. This work was supported by a Hyundai Hope on Wheels Quantum Award, Alex's Lemonade Stand Reach Grant, the Todd J Schwartz Memorial Fund, and Leukemia and Lymphoma SCOR and Scholar Awards to LDW. FW is supported by an Alexander von Humboldt Foundation Feodor Lynen Fellowship, AMM by NIH training grant T32GM007753, RM by Doctoral Foreign Studies Award DFS-134963 from the Canadian Institutes of Health Research, and AZ and KF by the William Lawrence and Blanche Hughes Foundation and a generous gift from Jim and Lisa LaTorre, respectively.	BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Bird GH, 2014, ACS CHEM BIOL, V9, P831, DOI 10.1021/cb4003305; Bird GH, 2008, METHOD ENZYMOL, V446, P369, DOI 10.1016/S0076-6879(08)01622-4; Bird Gregory H, 2011, Curr Protoc Chem Biol, V3, P99, DOI 10.1002/9780470559277.ch110042; Brown CJ, 2013, ACS CHEM BIOL, V8, P506, DOI 10.1021/cb3005148; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Edwards AL, 2015, ACS CHEM BIOL, V10, P2149, DOI 10.1021/acschembio.5b00214; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LaBelle JL, 2012, J CLIN INVEST, V122, P2018, DOI 10.1172/JCI46231; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li YC, 2014, CELL REP, V9, P1946, DOI 10.1016/j.celrep.2014.10.058; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Okamoto T, 2013, ACS CHEM BIOL, V8, P297, DOI 10.1021/cb3005403; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Tan BX, 2015, SCI REP-UK, V5, DOI 10.1038/srep12116; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675	25	29	29	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2184	2190		10.1038/onc.2016.361	http://dx.doi.org/10.1038/onc.2016.361			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721413	Green Accepted			2022-12-28	WOS:000399782500013
J	Queisser, A; Hagedorn, S; Wang, H; Schaefer, T; Konantz, M; Alavi, S; Deng, M; Vogel, W; Von Mssenhausen, A; Kristiansen, G; Duensing, S; Kirfel, J; Lengerke, C; Perner, S				Queisser, A.; Hagedorn, S.; Wang, H.; Schaefer, T.; Konantz, M.; Alavi, S.; Deng, M.; Vogel, W.; Von Mssenhausen, A.; Kristiansen, G.; Duensing, S.; Kirfel, J.; Lengerke, C.; Perner, S.			Ecotropic viral integration site 1, a novel oncogene in prostate cancer	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; STEM-LIKE CELL; EVI1; EXPRESSION; OVARIAN; ERG; AMPLIFICATION; ONCOPROTEIN; INHIBITOR; ZEBRAFISH	Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men in the western world. Mutations in tumor suppressor genes and in oncogenes are important for PCa progression, whereas the role of stem cell proteins in prostate carcinogenesis is insufficiently examined. This study investigates the role of the transcriptional regulator Ecotropic Viral Integration site 1 (EVI1), known as an essential modulator of hematopoietic and leukemic stem cell biology, in prostate carcinogenesis. We show that in healthy prostatic tissue, EVI1 expression is confined to the prostate stem cell compartment located at the basal layer, as identified by the stem cell marker CD44. Instead, in a PCa progression cohort comprising 219 samples from patients with primary PCa, lymph node and distant metastases, EVI1 protein was heterogeneously distributed within samples and high expression is associated with tumor progression (P<0.001), suggesting EVI1 induction as a driver event. Functionally, short hairpin RNAmediated knockdown of EVI1 inhibited proliferation, cell cycle progression, migratory capacity and anchorage-independent growth of human PCa cells, while enhancing their apoptosis sensitivity. Interestingly, modulation of EVI1 expression also strongly regulated stem cell properties (including expression of the stem cell marker SOX2) and in vivo tumor initiation capacity. Further emphasizing a functional correlation between EVI1 induction and tumor progression, upregulation of EVI1 expression was noted in experimentally derived docetaxel-resistant PCa cells. Importantly, knockdown of EVI1 in these cells restored sensitivity to docetaxel, in part by downregulating anti-apoptotic BCL2. Together, these data indicate EVI1 as a novel molecular regulator of PCa progression and therapy resistance that may control prostate carcinogenesis at the stem cell level.	[Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Perner, S.] Univ Hosp Bonn, Sect Prostate Canc Res, Bonn, Germany; [Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Kristiansen, G.; Kirfel, J.; Perner, S.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Kristiansen, G.; Kirfel, J.; Perner, S.] Univ Hosp Bonn, Ctr Integrated Oncol Cologne Bonn, Bonn, Germany; [Wang, H.; Schaefer, T.; Konantz, M.; Lengerke, C.] Univ Basel Hosp, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland; [Vogel, W.; Perner, S.] Univ Med Ctr Schleswig Holstein, Campus Luebeck & Res Ctr Borstel, Leibniz Ctr Med & Biosci, Borstel, Germany; [Duensing, S.] Heidelberg Univ, Sch Med, Dept Urol, Sect Mol Urooncol, Heidelberg, Germany; Univ Basel Hosp, Dept Biomed, Hebelstrasse 20, CH-4031 Basel, Switzerland	University of Bonn; University of Bonn; University of Bonn; University of Basel; Forschungszentrum Borstel; University of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls University Heidelberg; University of Basel	Lengerke, C (corresponding author), Univ Basel Hosp, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.; Lengerke, C (corresponding author), Pathol Univ Hosp Luebeck, Leibniz Res Ctr Borstel, Inst Pathol, Ratzeburger Allee 160,Bldg 50, D-23538 Lubeck, Germany.	Claudia.Lengerke@unibas.ch; Sven.Perner@uksh.de	alavi, samin/Y-3285-2019; Lengerke, Claudia/AAV-8745-2021; , Anne/ABC-3403-2021	Lengerke, Claudia/0000-0001-5442-2805; , Anne/0000-0002-4727-782X; Schaefer, Thorsten/0000-0003-4867-8374; Konantz, Martina/0000-0002-4319-3119	German Research Foundation (Deutsche Forschungsgemeinschaft) [PE 1179/11-1]; Schweizer Nationalfonds [310030_149735]; Rudolf-Becker-Foundation; Wilhelm-Sander-Foundation [2011.077.2]; German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship)	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Schweizer Nationalfonds; Rudolf-Becker-Foundation; Wilhelm-Sander-Foundation; German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship)	The study was supported by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft (PE 1179/11-1)) to SP, the Schweizer Nationalfonds to CL (310030_149735), the Rudolf-Becker-Foundation and the Wilhelm-Sander-Foundation (2011.077.2) to SP and the German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship) to SH. We also acknowledge the TCGA Research Network for providing their cancer data sets.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bard-Chapeau EA, 2012, P NATL ACAD SCI USA, V109, P2168, DOI 10.1073/pnas.1119229109; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Braun M, 2012, PROSTATE CANCER P D, V15, P165, DOI 10.1038/pcan.2011.67; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen X, 2013, CELL CYCLE, V12, P579, DOI 10.4161/cc.23721; Choi J, 2007, DEV BIOL, V304, P735, DOI 10.1016/j.ydbio.2007.01.023; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Deng XY, 2013, MOL CARCINOGEN, V52, P255, DOI 10.1002/mc.21852; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Fan XL, 2012, UROL ONCOL-SEMIN ORI, V30, P314, DOI 10.1016/j.urolonc.2010.03.019; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goyama S, 2010, INT J HEMATOL, V91, P753, DOI 10.1007/s12185-010-0618-5; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; Han L, 2013, ACTA PHARM SIN B, V3, P65, DOI 10.1016/j.apsb.2013.02.006; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kataoka K, 2012, CANCER SCI, V103, P1371, DOI 10.1111/j.1349-7006.2012.02303.x; Kerr CL, 2014, CURR OPIN ONCOL, V26, P328, DOI 10.1097/CCO.0000000000000080; Konantz M, 2013, LEUKEMIA, V27, P56, DOI 10.1038/leu.2012.211; Konantz M, 2012, ANN NY ACAD SCI, V1266, P124, DOI 10.1111/j.1749-6632.2012.06575.x; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kustikova OS, 2013, LEUKEMIA, V27, P1127, DOI 10.1038/leu.2012.355; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; McGilvray R, 2007, FEBS J, V274, P3960, DOI 10.1111/j.1742-4658.2007.05928.x; Mosquera JM, 2007, J PATHOL, V212, P91, DOI 10.1002/path.2154; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nayak KB, 2013, INT J BIOCHEM CELL B, V45, P1568, DOI 10.1016/j.biocel.2013.04.032; Nwachukwu JC, 2009, CANCER RES, V69, P3140, DOI 10.1158/0008-5472.CAN-08-3738; Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rosa-Ribeiro R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097080; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Schaefer T, 2015, ONCOTARGET, V6, P43540, DOI 10.18632/oncotarget.6183; Scheble VJ, 2010, MODERN PATHOL, V23, P1061, DOI 10.1038/modpathol.2010.87; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Sethi S, 2013, AM J TRANSL RES, V5, P200; Shackelford D, 2006, CANCER RES, V66, P11360, DOI 10.1158/0008-5472.CAN-06-1774; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Tanaka M, 2014, ONCOGENE, V33, P2454, DOI 10.1038/onc.2013.204; Taneja SS, 2004, J BIOL CHEM, V279, P13944, DOI 10.1074/jbc.M306576200; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tu SM, 2012, CLIN GENITOURIN CANC, V10, P69, DOI 10.1016/j.clgc.2012.01.002; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Van Leenders GJLH, 2001, BJU INT, V88, P35, DOI 10.1046/j.1464-410X.2001.00117.x; Volkert S, 2014, CANCER GENET-NY, V207, P103, DOI 10.1016/j.cancergen.2014.02.010; Wang H, 2015, JOVE-J VIS EXP, V95; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Zhang BB, 2014, TUMOR BIOL, V35, P11861, DOI 10.1007/s13277-014-2417-8	68	26	26	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1573	1584		10.1038/onc.2016.325	http://dx.doi.org/10.1038/onc.2016.325			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617580				2022-12-28	WOS:000397458100011
J	Yim, H; Shin, SB; Woo, SU; Lee, PCW; Erikson, RL				Yim, H.; Shin, S-B; Woo, S. U.; Lee, P. C-W; Erikson, R. L.			Plk1-mediated stabilization of 53BP1 through USP7 regulates centrosome positioning to maintain bipolarity	ONCOGENE			English	Article							POLO-LIKE KINASE; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; CENP-F; CHECKPOINT ACTIVATION; SPINDLE-CHECKPOINT; TUMOR-SUPPRESSOR; HISTONE H2AX; P53; MITOSIS	Although 53BP1 has been established well as a mediator in DNA damage response, its function in mitosis is not clearly understood. We found that 53BP1 is a mitotic-binding partner of the kinases Plk1 and AuroraA, and that the binding with Plk1 increases the stability of 53BP1 by accelerating its interaction with the deubiquitinase USP7. Depletion of 53BP1 induces mitotic defects such as chromosomal missegregation, misorientation of spindle poles and the generation of extra centrosomes, which is similar phenotype to USP7-knockdown cells. In addition, 53BP1 depletion reduces the levels of p53 and centromere protein F ( CENPF), interacting proteins of 53BP1. These phenotypes induced by 53BP1 depletion were rescued by expression of wild-type or phosphomimic mutant 53BP1 but not by expression of a dephosphomimic mutant. We propose that phosphorylation of 53BP1 at S380 accelerates complex formation with USP7 and CENPF to regulate their stability, thus having a crucial role in proper centrosome positioning, chromosomal alignment, and centrosome number.	[Yim, H.; Shin, S-B; Woo, S. U.] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea; [Yim, H.; Erikson, R. L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Lee, P. C-W] Univ Ulsan, Coll Med, CDRC, Dept Biomed Sci, Seoul, South Korea	Hanyang University; Harvard University; University of Ulsan	Yim, H (corresponding author), Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea.	hsyim@hanyang.ac.kr	Shin, Sol-bi/N-7443-2019	Shin, Sol-bi/0000-0002-2519-9605	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2012R1A2A2A06044458, NRF-2014R1A2A1 A11049701]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	We thank Dr Phillip B Carpenter (University of Texas Health Sciences Center, TX, USA), Dr Stephen J Elledge (Harvard University, MA, USA), Dr Daniel Durocher (University of Toronto, Canada) and Dr Anindya Dutta (University of Virginia School of Medicine, VA, USA) for generously providing plasmids for HA-53BP1, GFP-53BP1 and USP7, respectively. We thank Dr Jeong-Ho Hong (Korea University, Korea), Dr Mi-Ran Byun, Mi Kyung Sung and Hay Ran Jang (Hanyang University, Korea) for technical assistance. This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A2A2A06044458; NRF-2014R1A2A1 A11049701) to HY.	Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Benada J, 2015, CELL CYCLE, V14, P219, DOI 10.4161/15384101.2014.977067; Bolhy S, 2011, J CELL BIOL, V192, P855, DOI 10.1083/jcb.201007118; Bomont P, 2005, EMBO J, V24, P3927, DOI 10.1038/sj.emboj.7600848; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; Eletr ZM, 2014, BBA-MOL CELL RES, V1843, P114, DOI 10.1016/j.bbamcr.2013.06.027; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Eliezer Y, 2009, J BIOL CHEM, V284, P426, DOI 10.1074/jbc.M807375200; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gurden MDJ, 2010, J CELL SCI, V123, P321, DOI 10.1242/jcs.062075; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Holt SV, 2005, J CELL SCI, V118, P4889, DOI 10.1242/jcs.02614; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Izumi H, 2009, ONCOGENE, V28, P2806, DOI 10.1038/onc.2009.141; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jullien D, 2002, J CELL SCI, V115, P71; Kang YH, 2011, J BIOL CHEM, V286, P19744, DOI 10.1074/jbc.M111.224105; Kishi K, 2009, MOL CELL BIOL, V29, P3134, DOI 10.1128/MCB.01663-08; Kwak HJ, 2005, J CANCER RES CLIN, V131, P789, DOI 10.1007/s00432-005-0035-y; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Li J, 2005, NEOPLASIA, V7, P312, DOI 10.1593/neo.04325; Liu J, 2006, STRUCTURE, V14, P1811, DOI 10.1016/j.str.2006.10.009; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Moynihan KL, 2009, MOL BIOL CELL, V20, P4790, DOI 10.1091/mbc.E09-07-0560; Nakamura T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2752; Nelson G, 2009, CELL CYCLE, V8, P3379, DOI 10.4161/cc.8.20.9857; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Orthwein A, 2014, SCIENCE, V344, P189, DOI 10.1126/science.1248024; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Scully R, 2013, MUTAT RES-FUND MOL M, V750, P5, DOI 10.1016/j.mrfmmm.2013.07.007; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Varis A, 2006, CHROMOSOMA, V115, P288, DOI 10.1007/s00412-005-0046-0; Vergnolle MAS, 2007, CURR BIOL, V17, P1173, DOI 10.1016/j.cub.2007.05.077; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yim H, 2014, MUTAT RES-REV MUTAT, V761, P31, DOI 10.1016/j.mrrev.2014.02.005; Yim HS, 2009, MOL CELL BIOL, V29, P2609, DOI 10.1128/MCB.01277-08; Yoo E, 2005, ONCOGENE, V24, P5423, DOI 10.1038/sj.onc.1208710; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	57	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					966	978		10.1038/onc.2016.263	http://dx.doi.org/10.1038/onc.2016.263			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27477698				2022-12-28	WOS:000394169100009
J	Cui, Y; Sun, Y; Hu, S; Luo, J; Li, L; Li, X; Yeh, S; Jin, J; Chang, C				Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Li, X.; Yeh, S.; Jin, J.; Chang, C.			Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals	ONCOGENE			English	Article							SHOCK-PROTEIN 27; ACQUIRED DOCETAXEL RESISTANCE; MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; P38 MAPK; CELL-SURVIVAL; GROWTH; EXPRESSION; ACTIVATION; KINASE	Prostatic neuroendocrine cells (NE) are an integral part of prostate cancer (PCa) and are associated with PCa progression. As the current androgen deprivation therapy with anti-androgens may promote the neuroendocrine PCa (NEPCa) development, and few therapies can effectively suppress NEPCa, understanding the impact of NEPCa on PCa progression may help us to develop better therapies to battle PCa. Here, we found NEPCa cells could increase the docetaxel resistance of their neighboring PCa cells. Mechanism dissection revealed that through secretion of PTHrP, NEPCa cells could alter the p38/MAPK/Hsp27 signals in their neighboring PCa cells that resulted in increased androgen receptor (AR) activity via promoting AR nuclear translocation. The consequences of increased AR function might then increase docetaxel resistance via increasing p21 expression. In vivo xenograft mice experiments also confirmed that NEPCa could increase the docetaxel resistance of neighboring PCa, and targeting this newly identified PTHrP/p38/Hsp27/AR/p21 signaling pathway with either p38 inhibitor (SB203580) or shPTHrP may result in improving/restoring the docetaxel sensitivity to better suppress PCa.	[Cui, Y.; Hu, S.; Li, X.; Jin, J.] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Peking University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA.; Jin, J (corresponding author), Peking Univ, Hosp 1, Dept Urol, Natl Urol Canc Ctr, Xishiku St 8, Beijing 100034, Peoples R China.	jinjie@vip.163.com; chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]; China 973 Program [2012CB518305]; George Whipple Professorship Endowment; NATIONAL CANCER INSTITUTE [R01CA156700, R01CA155477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial, Research Center of Excellence; China 973 Program(National Basic Research Program of China); George Whipple Professorship Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan) and China 973 Program (2012CB518305). We thank Karen Wolf for help in preparing the manuscript.	Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; BERCHEM GJ, 1995, CANCER RES, V55, P735; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Bhardwaj A, 2014, ONCOTARGET, V5, P11490, DOI 10.18632/oncotarget.2571; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cerasuolo M, 2015, CANCER RES, V75, P2975, DOI 10.1158/0008-5472.CAN-14-3830; Chung LY, 2012, CLIN CANCER RES, V18, P4037, DOI 10.1158/1078-0432.CCR-11-3348; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; DaSilva J, 2009, CANCER RES, V69, P7402, DOI 10.1158/0008-5472.CAN-08-4687; DaSilva JO, 2013, PROSTATE, V73, P801, DOI 10.1002/pros.22624; Dizeyi N, 2004, PROSTATE, V59, P328, DOI 10.1002/pros.10374; Dizeyi N, 2011, UROL ONCOL-SEMIN ORI, V29, P436, DOI 10.1016/j.urolonc.2009.09.013; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Fan WQ, 2007, J BIOL CHEM, V282, P7329, DOI 10.1074/jbc.M610447200; Fizazi K, 2015, LANCET ONCOL, V16, P787, DOI 10.1016/S1470-2045(15)00011-X; Geng H, 2010, CANCER RES, V70, P3239, DOI 10.1158/0008-5472.CAN-09-3186; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Harper ME, 1996, BRIT J CANCER, V74, P910, DOI 10.1038/bjc.1996.456; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hobisch A, 1998, CANCER RES, V58, P4640; Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P1516, DOI 10.1002/cncr.25599; Hu S, 2015, MOL ONCOL, V9, P44, DOI 10.1016/j.molonc.2014.07.013; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim JY, 2008, ENDOCRINOLOGY, V149, P3085, DOI 10.1210/en.2007-1367; Lamoureux F, 2014, EUR UROL, V66, P145, DOI 10.1016/j.eururo.2013.12.019; Leotoing L, 2007, J MOL ENDOCRINOL, V39, P151, DOI 10.1677/JME-07-0021; Levine L, 2003, CANCER RES, V63, P3495; Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602; Lin JQ, 1999, CANCER RES, V59, P2891; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; Ongkeko WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085803; Park SI, 2013, CANCER RES, V73, P6574, DOI 10.1158/0008-5472.CAN-12-4692; Pienta KJ, 2005, CA-CANCER J CLIN, V55, P300, DOI 10.3322/canjclin.55.5.300; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Razandi M, 2010, MOL CELL BIOL, V30, P3249, DOI 10.1128/MCB.01354-09; Salido M, 2004, CELL BIOL INT, V28, P397, DOI 10.1016/j.cellbi.2004.03.008; Shah GV, 2008, ENDOCR-RELAT CANCER, V15, P953, DOI 10.1677/ERC-08-0136; Small GW, 2007, CANCER RES, V67, P4459, DOI 10.1158/0008-5472.CAN-06-2644; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; Thadani-Mulero M, 2014, CANCER RES, V74, P2270, DOI 10.1158/0008-5472.CAN-13-2876; Thadani-Mulero M, 2012, CANCER RES, V72, P4611, DOI 10.1158/0008-5472.CAN-12-0783; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vilches J, 2004, HISTOL HISTOPATHOL, V19, P951, DOI 10.14670/HH-19.951; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yuan J, 2008, J CELL BIOCHEM, V103, P648, DOI 10.1002/jcb.21439; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhao YP, 2006, J SURG RES, V136, P325, DOI 10.1016/j.jss.2006.06.031; Zhu YZ, 2013, MOL CANCER THER, V12, P1829, DOI 10.1158/1535-7163.MCT-13-0208; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	69	15	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6065	6076		10.1038/onc.2016.135	http://dx.doi.org/10.1038/onc.2016.135			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27375022	Green Accepted			2022-12-28	WOS:000388509800003
J	Lin, LY; Du, LM; Cao, K; Huang, Y; Yu, PF; Zhang, LY; Li, FY; Wang, Y; Shi, YF				Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Zhang, L. Y.; Li, F. Y.; Wang, Y.; Shi, Y. F.			Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities	ONCOGENE			English	Article							STEM-CELLS; ANGIOGENESIS; PROGRESSION; BIOGENESIS; MICRORNAS	Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying the conversion of normal MSCs into tumour-associated MSCs are unknown. We report here a critical role of tumour cell-derived exosomes in endowing bone marrow-derived MSCs (BM-MSCs) with a tumour-favourable phenotype. Tumour cell-derived exosomes affected neither the growth factor production nor the immunosuppressive property of MSCs; rather, they endowed MSCs with a strong ability to promote macrophage infiltration into B16-F0 melanoma or EL-4 lymphoma. Ablation of macrophages by clodronate liposome administration reversed the tumour-promoting effect of MSCs educated by tumour cell-derived exosomes (TE-MSCs) on the tumour growth. By comparing the chemokine profile of BM-MSCs with that of TE-MSCs, we found that TE-MSCs produced a large amount of CCR2 ligands, CCL2 and CCL7, which are responsible for macrophage recruitment. CCR2-specific inhibitor was found to block the tumour-promoting effect of TE-MSCs. Thus, our investigations demonstrated that tumour cell-derived exosomes confer BM-MSCs the ability to enhance tumour growth. Therefore, we uncovered a novel mechanism underlying the conversion of normal MSCs to tumour-associated MSCs.	[Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Li, F. Y.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200030, Peoples R China; [Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Li, F. Y.; Wang, Y.; Shi, Y. F.] Shanghai Jiao Tong Univ Med, 320 Yueyang Rd, Shanghai 200030, Peoples R China; [Zhang, L. Y.; Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, 199 Renai Rd, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200030, Peoples R China.; Wang, Y; Shi, YF (corresponding author), Shanghai Jiao Tong Univ Med, 320 Yueyang Rd, Shanghai 200030, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	HUANG, YIN/AAH-6871-2020; Yu, Pengfei/AHC-3497-2022; Du, Liming/M-8227-2019; cao, kai/AAG-6833-2021; Shi, Yufang/AAE-4431-2020	HUANG, YIN/0000-0001-5602-9871; Yu, Pengfei/0000-0002-3894-5697; Shi, Yufang/0000-0001-8964-319X; cao, kai/0000-0002-7939-7279; Du, Liming/0000-0002-0527-3556; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107]; Ministry of Science and Technology of China [2015CB964400]; Programs of National Natural Science of China [81330046, 81273316, 81530043, 81571612]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Rising-Star Program [14QA1404200]	Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Municipal Key Projects of Basic Research; Shanghai Rising-Star Program	This study was supported by grants from the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107), the Ministry of Science and Technology of China (2015CB964400), the Programs of National Natural Science of China (81330046, 81273316, 81530043 and 81571612), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Municipal Key Projects of Basic Research (12JC1409200) and Shanghai Rising-Star Program (14QA1404200).	Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Beckermann BM, 2008, BRIT J CANCER, V99, P622, DOI 10.1038/sj.bjc.6604508; Christianson HC, 2013, P NATL ACAD SCI USA, V110, P17380, DOI 10.1073/pnas.1304266110; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang WH, 2013, ONCOGENE, V32, P4343, DOI 10.1038/onc.2012.458; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Lin R, 2013, STEM CELLS DEV, V22, P2836, DOI 10.1089/scd.2013.0166; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560	27	54	61	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6038	6042		10.1038/onc.2016.131	http://dx.doi.org/10.1038/onc.2016.131			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27132512	Green Published, hybrid			2022-12-28	WOS:000388509400010
J	Liu, PP; Liu, J; Jiang, WQ; Carew, JS; Ogasawara, MA; Pelicano, H; Croce, CM; Estrov, Z; Xu, RH; Keating, MJ; Huang, P				Liu, P-P; Liu, J.; Jiang, W-Q; Carew, J. S.; Ogasawara, M. A.; Pelicano, H.; Croce, C. M.; Estrov, Z.; Xu, R-H; Keating, M. J.; Huang, P.			Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline	ONCOGENE			English	Article							LIPOPROTEIN-LIPASE EXPRESSION; PROGNOSTIC-FACTOR; CLL CELLS; SURVIVAL; METABOLISM; ENERGY; APOPTOSIS; GENES; MITOCHONDRIA; CARDIOLIPIN	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western countries and is currently incurable due, in part, to difficulty in eliminating the leukemia cells protected by stromal microenvironment. Based on previous observations that CLL cells exhibit mitochondrial dysfunction and altered lipid metabolism and that carnitine palmitoyltransferases (CPT) have a major role in transporting fatty acid into mitochondria to support cancer cell metabolism, we tested several clinically relevant inhibitors of lipid metabolism for their ability to eliminate primary CLL cells. We discovered that perhexiline, an antiangina agent that inhibits CPT, was highly effective in killing CLL cells in stromal microenvironment at clinically achievable concentrations. These effective concentrations caused low toxicity to normal lymphocytes and normal stromal cells. Mechanistic study revealed that CLL cells expressed high levels of CPT1 and CPT2. Suppression of fatty acid transport into mitochondria by inhibiting CPT using perhexiline resulted in a depletion of cardiolipin, a key component of mitochondrial membranes, and compromised mitochondrial integrity, leading to rapid depolarization and massive CLL cell death. The therapeutic activity of perhexiline was further demonstrated in vivo using a CLL transgenic mouse model. Perhexiline significantly prolonged the overall animal survival by only four drug injections. Our study suggests that targeting CPT using an antiangina drug is able to effectively eliminate leukemia cells in vivo, and is a novel therapeutic strategy for potential clinical treatment of CLL.	[Liu, P-P; Jiang, W-Q; Xu, R-H; Huang, P.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Liu, P-P; Liu, J.; Ogasawara, M. A.; Pelicano, H.; Huang, P.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd, Houston, TX 77030 USA; [Carew, J. S.] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA; [Croce, C. M.] Ohio State Univ, Med Ctr, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Estrov, Z.; Keating, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Cleveland Clinic Foundation; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd, Houston, TX 77030 USA.	phuang@mdanderson.org	jiang, wen/GYI-9662-2022; Young, Richard A/F-6495-2012; Xu, Rui-Hua/AAW-4766-2021	Young, Richard A/0000-0001-8855-8647; Xu, Rui-Hua/0000-0001-9771-8534; Liu, Jinyun/0000-0002-4763-2684	Natural Science Foundation of China [81430060]; National Institutes of Health [CA085563, CA172724]; CLL Global Research Foundation; NATIONAL CANCER INSTITUTE [R35CA197706, P01CA081534, R01CA085563, R01CA172724] Funding Source: NIH RePORTER	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLL Global Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank BA Hayes and R LaPushin for their assistance in handling CLL samples. This work was supported, in part, by a grant from Natural Science Foundation of China ( No. 81430060), Grants CA085563 and CA172724 from the National Institutes of Health, and a grant for the CLL Global Research Foundation.	Abreu C, 2013, LEUKEMIA LYMPHOMA, V54, P1844, DOI 10.3109/10428194.2013.796057; Bilban M, 2006, LEUKEMIA, V20, P1080, DOI 10.1038/sj.leu.2404220; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Carew JS, 2004, LEUKEMIA, V18, P1934, DOI 10.1038/sj.leu.2403545; Carew JS, 2003, LEUKEMIA, V17, P1437, DOI 10.1038/sj.leu.2403043; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; DeFilippis RA, 2012, CANCER DISCOV, V2, P826, DOI 10.1158/2159-8290.CD-12-0107; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Grdisa M, 2003, LEUKEMIA RES, V27, P951, DOI 10.1016/S0145-2126(03)00028-6; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; Kaderi MA, 2011, HAEMATOL-HEMATOL J, V96, P1153, DOI 10.3324/haematol.2010.039396; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Liu J, 2014, LEUKEMIA, V28, P118, DOI 10.1038/leu.2013.125; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Moreno P, 2013, LEUKEMIA, V27, P721, DOI 10.1038/leu.2012.212; NAKAHARA I, 1992, J NEUROSURG, V76, P244, DOI 10.3171/jns.1992.76.2.0244; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nikitin EA, 2007, LEUKEMIA LYMPHOMA, V48, P912, DOI 10.1080/10428190701245112; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Nuckel H, 2006, LEUKEMIA LYMPHOMA, V47, P1053, DOI 10.1080/10428190500464161; OKAYASU T, 1985, ARCH BIOCHEM BIOPHYS, V236, P638, DOI 10.1016/0003-9861(85)90668-X; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; Oltra AM, 2001, FREE RADICAL BIO MED, V30, P1286, DOI 10.1016/S0891-5849(01)00521-4; Oppezzo P, 2005, BLOOD, V106, P650, DOI 10.1182/blood-2004-08-3344; Pallasch CP, 2008, LEUKEMIA, V22, P585, DOI 10.1038/sj.leu.2405058; Pandey PR, 2012, RECENT PAT ANTI-CANC, V7, P185; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Porpaczy E, 2013, LEUKEMIA RES, V37, P631, DOI 10.1016/j.leukres.2013.02.008; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; SINGLAS E, 1978, EUR J CLIN PHARMACOL, V14, P195, DOI 10.1007/BF02089960; Stamatopoulos B, 2012, HAEMATOL-HEMATOL J, V97, P608, DOI 10.3324/haematol.2011.052779; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; van't Veer MB, 2006, HAEMATOLOGICA, V91, P56; Vasconcelos Y, 2005, LEUKEMIA, V19, P2002, DOI 10.1038/sj.leu.2403865; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Woyach JA, 2012, LEUKEMIA, V26, P1442, DOI 10.1038/leu.2011.375; Zhang W, 2012, NAT CELL BIOL, V14, P276, DOI 10.1038/ncb2432; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	51	42	44	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5663	5673		10.1038/onc.2016.103	http://dx.doi.org/10.1038/onc.2016.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065330	Green Accepted			2022-12-28	WOS:000386998300009
J	Patil, MD; Bhaumik, J; Babykutty, S; Banerjee, UC; Fukumura, D				Patil, M. D.; Bhaumik, J.; Babykutty, S.; Banerjee, U. C.; Fukumura, D.			Arginine dependence of tumor cells: targeting a chink in cancer's armor	ONCOGENE			English	Review							RECOMBINANT HUMAN ARGINASE; ADI-PEG 20; HUMAN HEPATOCELLULAR-CARCINOMA; APOPTOSIS-INDUCING FACTOR; NITRIC-OXIDE SYNTHASE; ARGININOSUCCINATE-SYNTHETASE; DEIMINASE ADI; GROWTH-INHIBITION; AMINO-ACIDS; IN-VITRO	Arginine, one among the 20 most common natural amino acids, has a pivotal role in cellular physiology as it is being involved in numerous cellular metabolic and signaling pathways. Dependence on arginine is diverse for both tumor and normal cells. Because of decreased expression of argininosuccinate synthetase and/or ornithine transcarbamoylase, several types of tumor are auxotrophic for arginine. Deprivation of arginine exploits a significant vulnerability of these tumor cells and leads to their rapid demise. Hence, enzyme-mediated arginine depletion is a potential strategy for the selective destruction of tumor cells. Arginase, arginine deiminase and arginine decarboxylase are potential enzymes that may be used for arginine deprivation therapy. These arginine catabolizing enzymes not only reduce tumor growth but also make them susceptible to concomitantly administered anti-cancer therapeutics. Most of these enzymes are currently under clinical investigations and if successful will potentially be advanced as anti-cancer modalities.	[Patil, M. D.; Bhaumik, J.; Banerjee, U. C.] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Biotechnol, Mohali, Punjab, India; [Babykutty, S.; Fukumura, D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs, 100 Blossom St, Boston, MA 02114 USA; [Babykutty, S.; Fukumura, D.] Harvard Med Sch, 100 Blossom St, Boston, MA 02114 USA	National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fukumura, D (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs, 100 Blossom St, Boston, MA 02114 USA.; Fukumura, D (corresponding author), Harvard Med Sch, 100 Blossom St, Boston, MA 02114 USA.	dai@steele.mgh.harvard.edu	Bhaumik, Jayeeta/AAR-4561-2021; BABYKUTTY, SUBOJ/R-3723-2017; Patil, Mahesh/AAF-8676-2019	Patil, Mahesh/0000-0002-5602-3442; Banerjee, uttam Chand/0000-0002-7363-4042; Babykutty, Suboj/0000-0002-1376-6959	National Institutes of Health [CA080124, CA096915, CA126642, CA197743]; NATIONAL CANCER INSTITUTE [R01CA096915, R01CA126642, P01CA080124, R35CA197743] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health (CA080124, CA096915, CA126642, CA197743).	Agrawal V, 2012, EXPERT OPIN BIOL TH, V12, P53, DOI 10.1517/14712598.2012.636349; Allen MD, 2014, CANCER RES, V74, P896, DOI 10.1158/0008-5472.CAN-13-1702; [Anonymous], [No title captured]; [Anonymous], [No title captured]; Appleton Jeremy, 2002, Altern Med Rev, V7, P512; Ascierto PA, 2005, J CLIN ONCOL, V23, P7660, DOI 10.1200/JCO.2005.02.0933; BACH S J, 1947, Enzymologia, V12, P198; BACH SJ, 1953, BIOCHIM BIOPHYS ACTA, V11, P69, DOI 10.1016/0006-3002(53)90009-2; Beauchamp EM, 2013, ONCOGENE, V32, P3923, DOI 10.1038/onc.2012.567; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Bobak YP, 2010, CELL BIOL INT, V34, P1085, DOI 10.1042/CBI20100451; Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028; Bowles TL, 2008, INT J CANCER, V123, P1950, DOI 10.1002/ijc.23723; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cantelmo AR, 2015, CANCER J, V21, P244, DOI 10.1097/PPO.0000000000000133; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cao ZF, 2013, BBA-REV CANCER, V1836, P273, DOI 10.1016/j.bbcan.2013.08.001; Carreau A, 2011, EXP CELL RES, V317, P29, DOI 10.1016/j.yexcr.2010.08.011; Cetinbas N, 2015, ONCOGENE, V34, P4005, DOI 10.1038/onc.2014.316; Chamorro-Jorganes A, 2016, CIRC RES, V118, P38, DOI 10.1161/CIRCRESAHA.115.307408; Changou CA, 2014, P NATL ACAD SCI USA, V111, P14147, DOI 10.1073/pnas.1404171111; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Cheng PNM, 2007, CANCER RES, V67, P309, DOI 10.1158/0008-5472.CAN-06-1945; Choi YS, 1999, J BIOCHEM MOL BIOL, V32, P173; Chow AKM, 2012, CURR CANCER DRUG TAR, V12, P1233; Cui JZ, 2013, BBA-REV CANCER, V1836, P15, DOI 10.1016/j.bbcan.2013.02.003; CURRIE GA, 1978, NATURE, V273, P758, DOI 10.1038/273758a0; Daylami R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0102-9; Delage B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.83; Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146; Dillon Brian J, 2002, Med Sci Monit, V8, pBR248; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011; Dudkowska M, 2003, BBA-GEN SUBJECTS, V1619, P159, DOI 10.1016/S0304-4165(02)00476-2; DURDEN DL, 1981, INT J CANCER, V27, P59, DOI 10.1002/ijc.2910270110; Eelen G, 2015, CIRC RES, V116, P1231, DOI 10.1161/CIRCRESAHA.116.302855; Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007; Elms S, 2013, AM J PHYSIOL-HEART C, V305, pH651, DOI 10.1152/ajpheart.00755.2012; Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220; Ensor CM, 2002, CANCER RES, V62, P5443; Ferraro E, 2007, ARCH BIOCHEM BIOPHYS, V462, P210, DOI 10.1016/j.abb.2007.02.006; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Feun L, 2008, CURR PHARM DESIGN, V14, P1049, DOI 10.2174/138161208784246199; Feun LG, 2010, J CLIN ONCOL, V28; Feun LG, 2012, BRIT J CANCER, V106, P1481, DOI 10.1038/bjc.2012.106; Feun Lynn, 2006, Expert Opin Investig Drugs, V15, P815, DOI 10.1517/13543784.15.7.815; Feun LG, 2015, CURR OPIN CLIN NUTR, V18, P78, DOI 10.1097/MCO.0000000000000122; Fimia GM, 2013, ONCOGENE, V32, P3311, DOI 10.1038/onc.2012.455; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fraisl P, 2013, EXP CELL RES, V319, P1331, DOI 10.1016/j.yexcr.2013.02.010; Fu YM, 2003, NUTR CANCER, V45, P60, DOI 10.1207/S15327914NC4501_8; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Garcia-Navas R, 2012, AUTOPHAGY, V8, P1557, DOI 10.4161/auto.21315; Gelb T, 2015, ONCOGENE, V34, P2711, DOI 10.1038/onc.2014.231; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GILL P, 1970, CAN J MICROBIOL, V16, P415, DOI 10.1139/m70-071; Glazer ES, 2011, TRANSL ONCOL, V4, P138, DOI 10.1593/tlo.10265; Glazer ES, 2010, SURGERY, V148, P310, DOI 10.1016/j.surg.2010.03.022; Glazer ES, 2010, J CLIN ONCOL, V28, P2220, DOI 10.1200/JCO.2009.26.7765; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gong H, 1999, BIOCHEM BIOPH RES CO, V261, P10, DOI 10.1006/bbrc.1999.1004; Gong H, 2000, LEUKEMIA, V14, P826, DOI 10.1038/sj.leu.2401763; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Graham ML, 2003, ADV DRUG DELIVER REV, V55, P1293, DOI 10.1016/S0169-409X(03)00110-8; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hernandez CP, 2010, BLOOD, V115, P5214, DOI 10.1182/blood-2009-12-258822; Holtsberg FW, 2002, J CONTROL RELEASE, V80, P259, DOI 10.1016/S0168-3659(02)00042-1; Hsueh EC, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-17; Huang CC, 2012, ORAL ONCOL, V48, P1227, DOI 10.1016/j.oraloncology.2012.06.004; Huang HY, 2013, CLIN CANCER RES, V19, P2861, DOI 10.1158/1078-0432.CCR-12-2641; HUANG MH, 1992, LIFE SCI, V51, P1725, DOI 10.1016/0024-3205(92)90301-5; Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001; Izzo F, 2004, J CLIN ONCOL, V22, P1815, DOI 10.1200/JCO.2004.11.120; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Jungbluth A, 2010, MODERN PATHOL, V23, p387A; Jurasz P, 2001, CANCER RES, V61, P376; Kalucka J, 2015, CELL CYCLE, V14, P3379, DOI 10.1080/15384101.2015.1090068; Kashiwagi S, 2005, J CLIN INVEST, V115, P1816, DOI 10.1172/JCI24015; Kashiwagi S, 2008, NAT MED, V14, P255, DOI 10.1038/nm1730; Kelly MP, 2012, BRIT J CANCER, V106, P324, DOI 10.1038/bjc.2011.524; Khoury O, 2015, J NEURO-ONCOL, V122, P75, DOI 10.1007/s11060-014-1698-5; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; Kim JH, 2007, ONCOL REP, V18, P1373; Kim JH, 2003, ELEC SOC S, V2003, P1; Kim RH, 2009, AUTOPHAGY, V5, P567, DOI 10.4161/auto.5.4.8252; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Kobayashi E, 2010, MOL CANCER THER, V9, P535, DOI 10.1158/1535-7163.MCT-09-0774; Kohler ES, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-107; KOJI T, 1984, EXP CELL RES, V155, P359, DOI 10.1016/0014-4827(84)90196-4; Kung HJ, 2015, AUTOPHAGY, V11, P419, DOI 10.1080/15548627.2015.1009789; Lam TL, 2009, CANCER LETT, V277, P91, DOI 10.1016/j.canlet.2008.11.031; Lam TL, 2011, PIGM CELL MELANOMA R, V24, P366, DOI 10.1111/j.1755-148X.2010.00798.x; Lee MY, 2014, P NATL ACAD SCI USA, V111, P12865, DOI 10.1073/pnas.1408472111; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Li LH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/423129; Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046; Lind DS, 2004, J NUTR, V134, p2837S, DOI 10.1093/jn/134.10.2837S; Liu JB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-686; Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014; Long Y, 2013, MOL CANCER THER, V12, P2581, DOI 10.1158/1535-7163.MCT-13-0302; Loreni F, 2014, ONCOGENE, V33, P2145, DOI 10.1038/onc.2013.153; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Luo JQ, 2013, NUTRITION, V29, P284, DOI 10.1016/j.nut.2012.05.008; Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006; Manca A, 2011, ONCOL REP, V25, P1495, DOI 10.3892/or.2011.1220; Mandal S, 2013, P NATL ACAD SCI USA, V110, P2169, DOI 10.1073/pnas.1219002110; Marino T, 2013, INORG CHEM, V52, P655, DOI 10.1021/ic301703t; Mayeur C, 2005, BBA-MOL CELL RES, V1745, P111, DOI 10.1016/j.bbamcr.2004.12.004; McAlpine JA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-621; MIYAZAKI K, 1990, CANCER RES, V50, P4522; Moens S, 2014, CYTOKINE GROWTH F R, V25, P473, DOI 10.1016/j.cytogfr.2014.07.009; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; Molderings GJ, 2012, PHARMACOL THERAPEUT, V133, P351, DOI 10.1016/j.pharmthera.2011.12.005; Morbidelli L, 2004, CANC TREAT, V117, P155; Morris SM, 2007, J NUTR, V137, p1602S, DOI 10.1093/jn/137.6.1602S; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Morrow K, 2013, LEUKEMIA, V27, P569, DOI 10.1038/leu.2012.247; Ni Y, 2008, CANCER LETT, V261, P1, DOI 10.1016/j.canlet.2007.11.038; Nicholson LJ, 2009, INT J CANCER, V125, P1454, DOI 10.1002/ijc.24546; Noh EJ, 2004, INT J CANCER, V112, P502, DOI 10.1002/ijc.20435; Noh EJ, 2002, MOL CELLS, V13, P137; Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163; Ohmura M, 2015, NITRIC OXIDE-BIOL CH, V46, P102, DOI 10.1016/j.niox.2014.11.005; Ott PA, 2013, INVEST NEW DRUG, V31, P425, DOI 10.1007/s10637-012-9862-2; Palii SS, 2009, AMINO ACIDS, V37, P79, DOI 10.1007/s00726-008-0199-2; Park IS, 2003, BRIT J CANCER, V89, P907, DOI 10.1038/sj.bjc.6601181; Peranzoni E, 2007, IMMUNOBIOLOGY, V212, P795, DOI 10.1016/j.imbio.2007.09.008; Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285; Philip R, 2003, BRIT J CANCER, V88, P613, DOI 10.1038/sj.bjc.6600681; Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Popovic PJ, 2007, J NUTR, V137, p1681S, DOI 10.1093/jn/137.6.1681S; Pradelli LA, 2010, CELL MOL LIFE SCI, V67, P1589, DOI 10.1007/s00018-010-0285-y; Proud CG, 2014, AM J CLIN NUTR, V99, p231S, DOI 10.3945/ajcn.113.066753; Qie S, 2012, CELL CYCLE, V11, P3679, DOI 10.4161/cc.21944; Qiu FM, 2015, CANCER LETT, V364, P1, DOI 10.1016/j.canlet.2015.04.020; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; Roberts DD, 2007, CLIN CANCER RES, V13, P795, DOI 10.1158/1078-0432.CCR-06-1758; Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8; Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Savaraj N, 2010, CURR MOL MED, V10, P405, DOI 10.2174/156652410791316995; Savaraj N, 2007, DRUG TARGET INSIGHT, V2, P119; Savaraj N, 2015, ONCOTARGET, V6, P6295, DOI 10.18632/oncotarget.3370; Scott L, 2000, BRIT J CANCER, V83, P800, DOI 10.1054/bjoc.2000.1353; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen LJ, 2006, CANCER LETT, V231, P30, DOI 10.1016/j.canlet.2005.01.007; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Sikalidis AK, 2015, PATHOL ONCOL RES, V21, P9, DOI 10.1007/s12253-014-9860-0; Stapor P, 2014, J CELL SCI, V127, P4331, DOI 10.1242/jcs.153908; Stasyk OV, 2015, CELL BIOL INT, V39, P246, DOI 10.1002/cbin.10383; Stone EM, 2010, ACS CHEM BIOL, V5, P333, DOI 10.1021/cb900267j; SUGIMURA K, 1992, MELANOMA RES, V2, P191, DOI 10.1097/00008390-199209000-00007; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197; Synakiewicz A, 2014, EXPERT OPIN INV DRUG, V23, P1517, DOI 10.1517/13543784.2014.934808; Szlosarek PW, 2006, CLIN CANCER RES, V12, P7126, DOI 10.1158/1078-0432.CCR-06-1101; Szlosarek PW, 2013, J CLIN ONCOL, V31, pE111, DOI 10.1200/JCO.2012.42.1784; TAKAKU H, 1993, JPN J CANCER RES, V84, P1195, DOI 10.1111/j.1349-7006.1993.tb02821.x; Takano N, 2014, MOL CANCER RES, V12, P1398, DOI 10.1158/1541-7786.MCR-14-0184; Tan B, 2010, AMINO ACIDS, V38, P1227, DOI 10.1007/s00726-009-0334-8; Tanios R, 2013, LEUKEMIA RES, V37, P1565, DOI 10.1016/j.leukres.2013.08.007; TERAYAMA H, 1982, BIOCHIM BIOPHYS ACTA, V720, P188, DOI 10.1016/0167-4889(82)90011-8; Thomas JB, 2002, BIOCHEM J, V363, P581, DOI 10.1042/0264-6021:3630581; Tomlinson B, 2013, J CLIN ONCOL, V31; Tomlinson BK, 2015, CLIN CANCER RES, V21, P2480, DOI 10.1158/1078-0432.CCR-14-2610; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Tsai WB, 2009, MOL CANCER THER, V8, P3223, DOI 10.1158/1535-7163.MCT-09-0794; Tsui SM, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-9; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Ulukaya E, 2011, CELL BIOCHEM FUNCT, V29, P468, DOI 10.1002/cbf.1774; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Wang Z, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.503; Wang ZY, 2014, APPL MICROBIOL BIOT, V98, P2485, DOI 10.1007/s00253-013-5118-0; Wangpaichitr M, 2014, ANTICANCER RES, V34, P6991; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weiger TM, 2014, AMINO ACIDS, V46, P681, DOI 10.1007/s00726-013-1536-7; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Wheatley DN, 2004, ANTI-CANCER DRUG, V15, P825, DOI 10.1097/00001813-200410000-00002; Wheatley DN, 2000, CELL PHYSIOL BIOCHEM, V10, P37, DOI 10.1159/000016333; Wheatley DN, 2003, BRIT J CANCER, V89, P573, DOI 10.1038/sj.bjc.6601134; Wheatley DN, 2003, MOL CELL BIOCHEM, V244, P177, DOI 10.1023/A:1022451705701; Wheatley DN, 2005, GENE THER MOL BIOL, V9, P33; Wu GY, 2009, AMINO ACIDS, V37, P153, DOI 10.1007/s00726-008-0210-y; Wu GY, 2013, AMINO ACIDS, V45, P407, DOI 10.1007/s00726-013-1500-6; Wu GY, 2013, AMINO ACIDS, V44, P1107, DOI 10.1007/s00726-012-1444-2; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Yan LJ, 2012, SEMIN CELL DEV BIOL, V23, P621, DOI 10.1016/j.semcdb.2012.02.001; Yang TS, 2010, BRIT J CANCER, V103, P954, DOI 10.1038/sj.bjc.6605856; Yau CC, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13503; Yau T, 2013, INVEST NEW DRUG, V31, P99, DOI 10.1007/s10637-012-9807-9; Yoon JK, 2013, CLIN PHARMACOL-ADV A, V5, P11, DOI 10.2147/CPAA.S37350; You M, 2013, MOL CELL BIOCHEM, V374, P181, DOI 10.1007/s11010-012-1518-1; You M, 2010, BIOCHEM BIOPH RES CO, V394, P760, DOI 10.1016/j.bbrc.2010.03.066; Zecchin A, 2015, CURR OPIN BIOTECH, V34, P73, DOI 10.1016/j.copbio.2014.11.022; Zhang HQ, 2012, SEMIN CELL DEV BIOL, V23, P722, DOI 10.1016/j.semcdb.2012.03.017; Zhang L, 2015, CANCER LETT, V357, P346, DOI 10.1016/j.canlet.2014.11.042; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu MY, 2004, BBA-GEN SUBJECTS, V1670, P156, DOI 10.1016/j.bbagen.2003.11.006	214	143	143	1	51	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4957	4972		10.1038/onc.2016.37	http://dx.doi.org/10.1038/onc.2016.37			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27109103	Green Accepted, Green Submitted			2022-12-28	WOS:000383965300001
J	Lin, C; Liao, W; Jian, Y; Peng, Y; Zhang, X; Ye, L; Cui, Y; Wang, B; Wu, X; Xiong, Z; Wu, S; Li, J; Wang, X; Song, L				Lin, C.; Liao, W.; Jian, Y.; Peng, Y.; Zhang, X.; Ye, L.; Cui, Y.; Wang, B.; Wu, X.; Xiong, Z.; Wu, S.; Li, J.; Wang, X.; Song, L.			CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling	ONCOGENE			English	Article							INFLUENZA-VIRUS POLYMERASE; LYMPH-NODE METASTASIS; C14ORF166 OVEREXPRESSION; MONOCLONAL-ANTIBODY; PRECLINICAL MODELS; TUMOR PROGRESSION; MULTIPLE-MYELOMA; CELLULAR-PROTEIN; BINDING PROTEIN; POOR-PROGNOSIS	Metastatic relapse remains largely incurable and a major challenge of clinical management in breast cancer, but the underlying mechanisms are poorly understood. Herein, we report that CGI-99 is overexpressed in breast cancer tissues from patients with metastatic recurrence within 5 years. High CGI-99 significantly predicts poorer 5-year metastasis-free patient survival. We find that CGI-99 increases breast cancer stem cell properties, and potentiates efficient tumor lung colonization and outgrowth in vivo. Furthermore, we demonstrate that CGI-99 activates the autocrine interleukin-6 (IL-6)/STAT3 signaling by increasing the accumulation and activity of RNA polymerase II and p300 cofactor at the proximal promoter of IL-6. Importantly, delivery of the IL-6receptor humanized monoclonal antibody tocilizumab robustly abrogates CGI-99-induced metastasis in vivo. Finally, we find that high levels of CGI-99 are significantly correlated with STAT3 hyperactivation in breast cancer patients. These findings reveal a potential mechanism for constitutive activation of autocrine IL-6/STAT3 signaling and may suggest a novel target for clinical intervention in breast cancer.	[Lin, C.; Zhang, X.; Ye, L.; Cui, Y.; Wang, B.; Wu, X.; Wu, S.; Song, L.] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Liao, W.; Jian, Y.] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Peng, Y.] Guangdong Country Garden Sch, Guangzhou, Guangdong, Peoples R China; [Xiong, Z.; Wang, X.] Sun Yat Sen Univ, Canc Ctr, Dept Breast Surg, Guangzhou 510060, Guangdong, Peoples R China; [Li, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University	Wang, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Breast Surg, Guangzhou 510060, Guangdong, Peoples R China.; Song, L (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Expt Res, State Key Lab Oncol Southern China, 651 Dongfend Rd, Guangzhou 510060, Guangdong, Peoples R China.	wangxi@sysucc.org.cn; songlb@sysucc.org.cn	Song, LB/AAL-1968-2020; Wang, Bin/AAJ-6007-2020; Lin, Chuyong/AAA-9931-2020; Zhang, Xin/C-2464-2017	Wang, Bin/0000-0002-9093-5381; Lin, Chuyong/0000-0003-4887-5386; Zhang, Xin/0000-0001-6036-2685; Ye, Liping/0000-0002-2263-0631	Ministry of Science and Technology of China [973-2014CB910604]; Natural Science Foundation of China [81472546, 81672854, 81530082, 81272198, 81572687, 81325013, 91529301, 81572688]; Science and Technology of Guangdong Province [2016A030308002, 2014A030313008, 2014A030313220]; Science and Technology Program of Guangzhou [15020077]; Guangdong Esophageal Cancer Institute [M201409]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology of Guangdong Province; Science and Technology Program of Guangzhou; Guangdong Esophageal Cancer Institute	This work was supported by the Ministry of Science and Technology of China grant (no. 973-2014CB910604); Natural Science Foundation of China (no. 81472546, 81672854, 81530082, 81272198, 81572687, 81325013, 91529301 and 81572688), the Science and Technology of Guangdong Province (no. 2016A030308002, 2014A030313008 and 2014A030313220), Science and Technology Program of Guangzhou (no. 15020077) and Guangdong Esophageal Cancer Institute (no. M201409).	Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheang TY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0805-0; Conze D, 2001, CANCER RES, V61, P8851; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Cui YZ, 2009, INT J CANCER, V124, P1614, DOI 10.1002/ijc.24163; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Guo JH, 2009, CANCER SCI, V100, P2292, DOI 10.1111/j.1349-7006.2009.01324.x; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Howng SL, 2004, FEBS LETT, V566, P162, DOI 10.1016/j.febslet.2004.04.024; Huarte M, 2001, J VIROL, V75, P8597, DOI 10.1128/JVI.75.18.8597-8604.2001; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Lee JW, 2011, J PROTEOME RES, V10, P4522, DOI 10.1021/pr200338d; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Perez-Gonzalez A, 2006, J MOL BIOL, V362, P887, DOI 10.1016/j.jmb.2006.07.085; Perez-Gonzalez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090957; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rodriguez-Frandsen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20744; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Voorhees PM, 2009, BRIT J HAEMATOL, V145, P481, DOI 10.1111/j.1365-2141.2009.07647.x; Yang L, 2015, TUMOR BIOL, V36, P7977, DOI 10.1007/s13277-015-3518-8; Yokoe T, 1997, ANTICANCER RES, V17, P695; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang GJ, 1999, ANTICANCER RES, V19, P1427; Zhang WJ, 2016, TUMOR BIOL, V37, P369, DOI 10.1007/s13277-015-3806-3	48	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3695	3705		10.1038/onc.2016.525	http://dx.doi.org/10.1038/onc.2016.525			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28166202				2022-12-28	WOS:000404349700005
J	Franzetti, GA; Laud-Duval, K; van der Ent, W; Brisac, A; Irondelle, M; Aubert, S; Dirksen, U; Bouvier, C; de Pinieux, G; Snaar-Jagalska, E; Chavrier, P; Delattre, O				Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Irondelle, M.; Aubert, S.; Dirksen, U.; Bouvier, C.; de Pinieux, G.; Snaar-Jagalska, E.; Chavrier, P.; Delattre, O.			Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells	ONCOGENE			English	Article							CHROMOSOME-TRANSLOCATION; MOLECULAR PATHOGENESIS; TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; GENOMIC LANDSCAPE; MELANOMA-CELLS; HUMAN TUMORS; IN-VITRO; GROWTH; EXPRESSION	Ewing sarcoma is characterized by the expression of the chimeric EWSR1-FLI1 transcription factor. Proteomic analyses indicate that the decrease of EWSR1-FLI1 expression leads to major changes in effectors of the dynamics of the actin cytoskeleton and the adhesion processes with a shift from cell-to-cell to cell-matrix adhesion. These changes are associated with a dramatic increase of in vivo cell migration and invasion potential. Importantly, EWSR1-FLI1 expression, evaluated by single-cell RT-ddPCR/immunofluorescence analyses, and activity, assessed by expression of EWSR1-FLI1 downstream targets, are heterogeneous in cell lines and in tumours and can fluctuate along time in a fully reversible process between EWSR1-FLI1(high) states, characterized by highly active cell proliferation, and EWSR1-FLI1(low) states where cells have a strong propensity to migrate, invade and metastasize. This new model of phenotypic plasticity proposes that the dynamic fluctuation of the expression level of a dominant oncogene is an intrinsic characteristic of its oncogenic potential.	[Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Irondelle, M.; Chavrier, P.; Delattre, O.] PSL Res Univ, Inst Curie, Paris 05, France; [Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Delattre, O.] Inst Curie, Res Ctr, INSERM U830, Genet & Biol Pediat Tumors Grp, 26 Rue Ulm, F-75005 Paris, Ile De France, France; [van der Ent, W.; Snaar-Jagalska, E.] Leiden Univ, Inst Biol, Leiden, Netherlands; [Irondelle, M.; Chavrier, P.] Inst Curie, Res Ctr, UMR144, Membrane & Cytoskeleton Dynam Grp, Paris, France; [Irondelle, M.] Inst Curie, Res Ctr, UMR144, Cell & Tissue Imaging Facil PICT IBiSA, Paris, France; [Aubert, S.] Univ Hosp, Dept Pathol, Lille, France; [Dirksen, U.] Univ Hosp Muenster, Dept Pediat Hematol & Oncol, Albert Schweitzer Campus 1,A1, Munster, Germany; [Dirksen, U.] Westfalian Wilhelms Univ, Munster, Germany; [Bouvier, C.] La Timone Univ Hosp, Dept Pathol, Marseille, France; [de Pinieux, G.] Univ Hosp Tours, Dept Pathol, Chambray Les Tours, France; [de Pinieux, G.] Univ Tours, Chambray Les Tours, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Leiden University; Leiden University - Excl LUMC; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; University of Munster; University of Munster; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Tours; Universite de Tours	Delattre, O (corresponding author), Inst Curie, Res Ctr, INSERM U830, Genet & Biol Pediat Tumors Grp, 26 Rue Ulm, F-75005 Paris, Ile De France, France.	Olivier.delattre@curie.fr	CHAVRIER, Philippe/B-4707-2010; Dirksen, Uta/AGX-8472-2022; CHAVRIER, Philippe/AAG-2645-2020	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; delattre, olivier/0000-0002-8730-2276; van der Ent, Wietske/0000-0003-2165-9624	INSERM; Ligue Nationale Contre le Cancer (Equipe labellisse); Institut National du Cancer [PLBIO14-237]; European PROVABES [ERA-649, 01KT1310]; ASSET [FP7- HEALTH- 2010-259348]; EEC [HEALTH-F2-2013-602856]; German Cancer Aid [DKH 108128]; Ministere de l'Enseignement Superieur et de la Recherche (France); FRM [FDT20130928190]; Stichting Kinderen Kankervrij [30677]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale Contre le Cancer (Equipe labellisse); Institut National du Cancer(Institut National du Cancer (INCA) France); European PROVABES; ASSET; EEC; German Cancer Aid(Deutsche Krebshilfe); Ministere de l'Enseignement Superieur et de la Recherche (France); FRM(Fondation pour la Recherche Medicale); Stichting Kinderen Kankervrij	This work was supported by grants from the Institut Curie, the INSERM, the Ligue Nationale Contre le Cancer (Equipe labellisse), the Institut National du Cancer (PLBIO14-237), the European PROVABES (ERA-649 NET TRANSCAN JTC- 2011; 01KT1310), ASSET (FP7- HEALTH- 2010-259348), and EEC (HEALTH-F2-2013-602856) projects, the German Cancer Aid (DKH 108128) and the following associations: the Societe Francaise de lutte contre les Cancers et des leucemies de l'enfant et de l'adolescent, the Etoile de Martin, Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon, Enfants et Sante, les Amis de Claire and M la vieavec Lisa. Georges-Alain Franzetti was supported by a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche (France) and from the FRM (FDT20130928190). Wietske van der Ent was supported by Stichting Kinderen Kankervrij (Grant No. 30677). The authors are grateful to Laura Brulle-Soumare (INSERM U1143, CNRS UMR3666, Institut Curie, Paris, France) for her help with mice experiments. The authors would like to acknowledge the Nikon Imaging Center @ Institut Curie-CNRS and the Cell and Tissue Imaging Platform (member of FranceBioimaging) of the Genetics and Developmental Biology Department (UMR3215/U934) of Institut Curie, and also the Cytometry Plateform of Tumor Biology Department of Institut Curie.	Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; Amsellem V, 2005, EXP CELL RES, V304, P443, DOI 10.1016/j.yexcr.2004.10.035; Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Ban J, 2014, CANCER RES, V74, P6578, DOI 10.1158/0008-5472.CAN-14-1736; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; BIEDLER JL, 1973, CANCER RES, V33, P2643; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Chakrabarti Lina, 2012, Front Oncol, V2, P82, DOI 10.3389/fonc.2012.00082; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; DAHLIN DC, 1961, J BONE JOINT SURG AM, V43, P185, DOI 10.2106/00004623-196143020-00004; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deley M-CL, 2014, J CLIN ONCOL, V32, P2440; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Ghotra VPS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031281; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; HaDuong JH, 2015, PEDIATR CLIN N AM, V62, P179, DOI 10.1016/j.pcl.2014.09.012; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; Kovar H, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00054; Krook MA, 2014, MOL CANCER RES, V12, P953, DOI 10.1158/1541-7786.MCR-13-0668; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Montagnac G, 2013, NATURE, V502, P567, DOI 10.1038/nature12571; Noursadeghi M, 2008, J IMMUNOL METHODS, V329, P194, DOI 10.1016/j.jim.2007.10.015; Poomthavorn P, 2009, ENDOCR-RELAT CANCER, V16, P991, DOI 10.1677/ERC-08-0340; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sengupta A, 2013, INT J ONCOL, V43, P803, DOI 10.3892/ijo.2013.2016; Sibarita JB, 2005, ADV BIOCHEM ENG BIOT, V95, P201, DOI 10.1007/b102215; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Stoll G, 2013, NUCLEIC ACIDS RES, V41, P8853, DOI 10.1093/nar/gkt678; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; van der Ent W, 2014, J PATHOL, V233, P415, DOI 10.1002/path.4378; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; Wiles Elizabeth T, 2013, Genes Cancer, V4, P486, DOI 10.1177/1947601913506115	49	93	96	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3505	3514		10.1038/onc.2016.498	http://dx.doi.org/10.1038/onc.2016.498			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28135250	hybrid, Green Published			2022-12-28	WOS:000403878600001
J	Jiang, C; Zhu, Y; Zhou, Z; Gumin, J; Bengtsson, L; Wu, W; Songyang, Z; Lang, FF; Lin, X				Jiang, C.; Zhu, Y.; Zhou, Z.; Gumin, J.; Bengtsson, L.; Wu, W.; Songyang, Z.; Lang, F. F.; Lin, X.			TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-kappa B activation and tumor progression	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; NECROSIS-FACTOR-ALPHA; PATHWAYS; FAMILY; CELLS; PROTEINS; COMPLEX; CARMA3	Epidermal growth factor receptor (EGFR) family members play pivotal roles in cell proliferation, differentiation and survival. Overexpression and mutations of EGFRs, or aberrant EGFR signaling are commonly associated with the development of various cancers, where constitutive NF-kappa B activation is often found to promote the expression of various proteins involved in the proliferation, survival, migration and epithelial-to-mesenchymal transition of cancer cells. However, the mechanism of EGFR-induced NF-kappa B activation is not fully defined. Here, we used a Bimolecular Fluorescence Complementation-based functional genomics method to perform a high throughput screening and identified TMEM43/LUMA as a critical component in EGFR signaling network, mediating EGFR-induced NF-kappa B activation. Our data show that EGFR recruits TMEM43 following EGF stimulation. TMEM43 interacts with the scaffold protein CARMA3 and its associating complex to induce downstream NF-kappa B activation, and plays a critical role in controlling cell survival. TMEM43 deficiency significantly affects colony formation, survival of anoikis-induced cell death, migration and invasion of cancer cells in vitro, as well as tumor progression in vivo. Importantly, higher expression of TMEM43 closely correlates with brain tumor malignancy, and suppression of TMEM43 expression in brain tumor cells inhibited their growth both in vitro and in vivo. Altogether, our studies reveal a crucial link of EGF receptor to NF-kappa B activation and tumor progression.	[Jiang, C.; Zhu, Y.; Zhou, Z.; Wu, W.; Lin, X.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Neurosurg, Houston, TX 77030 USA; [Bengtsson, L.] Max Delbrueck Ctr Mol Med, Berlin, Germany; [Songyang, Z.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Lin, X.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Inst Immunol, Beijing, Peoples R China; [Zhu, Y.] Sun Yet San Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wu, W.] Nankai Univ, Dept Microbiol, Coll Life Sci, Tianjin, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Baylor College of Medicine; Tsinghua University; Sun Yat Sen University; Nankai University	Jiang, C; Lin, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	cjiang@mdanderson.org; linxin307@tsinghua.edu.cn	Jiang, Changying/AAL-3711-2020	Jiang, Changying/0000-0003-3778-4438; Bengtsson, Luiza/0000-0001-6048-3743	National Natural Science Foundation of China [81570211]; Cancer Prevention Research Institute of Texas [RP120316]; National Institutes of Health [R01 AI116722]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Cancer Prevention Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was partially supported by grants from the National Natural Science Foundation of China (81570211), Cancer Prevention Research Institute of Texas (RP120316) and National Institutes of Health (R01 AI116722) to X Lin.	Ando K, 2005, CLIN CANCER RES, V11, P8872, DOI 10.1158/1078-0432.CCR-05-0811; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Bengtsson L, 2008, J CELL SCI, V121, P536, DOI 10.1242/jcs.019281; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Biswas Debajit K, 2005, Sci STKE, V2005, ppe27, DOI 10.1126/stke.2882005pe27; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2003, CANCER RES, V63, P290; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Driskell OJ, 2007, NAT CELL BIOL, V9, P113, DOI 10.1038/ncb1525; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Haywood AFM, 2013, EUR HEART J, V34, P1002, DOI 10.1093/eurheartj/ehs383; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kerppola TK, 2009, CHEM SOC REV, V38, P2876, DOI 10.1039/b909638h; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Le Page C, 2005, PROSTATE, V65, P130, DOI 10.1002/pros.20234; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Marciniak DJ, 2004, MOL CANCER THER, V3, P1615; Merner ND, 2008, AM J HUM GENET, V82, P809, DOI 10.1016/j.ajhg.2008.01.010; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Pan D, 2016, ONCOGENE, V35, P919, DOI 10.1038/onc.2015.146; Pan D, 2016, MOL CANCER RES, V14, P93, DOI 10.1158/1541-7786.MCR-15-0229-T; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Sun JY, 2008, P NATL ACAD SCI USA, V105, P17085, DOI 10.1073/pnas.0802701105; Thornburg NJ, 2003, CANCER RES, V63, P8293; Vanderschuren KLA, 2013, GENET RES INT, V2013, DOI 10.1155/2013/460805; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang ZW, 2006, CANCER RES, V66, P7653, DOI 10.1158/0008-5472.CAN-06-1019	36	24	25	3	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2813	2823		10.1038/onc.2016.430	http://dx.doi.org/10.1038/onc.2016.430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991920				2022-12-28	WOS:000401697800004
J	Steinhauser, K; Kloble, P; Kreis, NN; Ritter, A; Friemel, A; Roth, S; Reichel, JM; Michaelis, J; Rieger, MA; Louwen, F; Oswald, F; Yuan, J				Steinhaeuser, K.; Kloeble, P.; Kreis, N-N; Ritter, A.; Friemel, A.; Roth, S.; Reichel, J. M.; Michaelis, J.; Rieger, M. A.; Louwen, F.; Oswald, F.; Yuan, J.			Deficiency of RITA results in multiple mitotic defects by affecting microtubule dynamics	ONCOGENE			English	Article							CENTROMERE-ASSOCIATED KINESIN; TUMOR-SUPPRESSOR P53; KINASE 1 INHIBITORS; ALPHA-TUBULIN; POSTTRANSLATIONAL MODIFICATIONS; FLUORESCENT-PROBES; CANCER-CELLS; SPINDLE; ACETYLATION; ACETYLTRANSFERASE	Deregulation of mitotic microtubule (MT) dynamics results in defective spindle assembly and chromosome missegregation, leading further to chromosome instability, a hallmark of tumor cells. RBP-J interacting and tubulin-associated protein (RITA) has been identified as a negative regulator of the Notch signaling pathway. Intriguingly, deregulated RITA is involved in primary hepatocellular carcinoma and other malignant entities. We were interested in the potential molecular mechanisms behind its involvement. We show here that RITA binds to tubulin and localizes to various mitotic MT structures. RITA coats MTs and affects their structures in vitro as well as in vivo. Tumor cell lines deficient of RITA display increased acetylated alpha-tubulin, enhanced MT stability and reduced MT dynamics, accompanied by multiple mitotic defects, including chromosome misalignment and segregation errors. Re-expression of wild-type RITA, but not RITA.tub ineffectively binding to tubulin, restores the phenotypes, suggesting that the role of RITA in MT modulation is mediated via its interaction with tubulin. Mechanistically, RITA interacts with tubulin/histone deacetylase 6 (HDAC6) and its suppression decreases the binding of the deacetylase HDAC6 to tubulin/MTs. Furthermore, the mitotic defects and increased MT stability are also observed in RITA(-/-) mouse embryonic fibroblasts. RITA has thus a novel role in modulating MT dynamics and its deregulation results in erroneous chromosome segregation, one of the major reasons for chromosome instability in tumor cells.	[Steinhaeuser, K.; Kreis, N-N; Ritter, A.; Friemel, A.; Roth, S.; Louwen, F.; Yuan, J.] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Kloeble, P.; Oswald, F.] Univ Med Ctr Ulm, Dept Internal Med 1, Ctr Internal Med, Ulm, Germany; [Reichel, J. M.; Michaelis, J.] Ulm Univ, Inst Biophys, Ulm, Germany; [Rieger, M. A.] Goethe Univ Frankfurt, Dept Hematol Oncol, Frankfurt, Germany; [Rieger, M. A.] German Canc Consortium DKTK, Heidelberg, Germany; [Rieger, M. A.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Ulm University; Ulm University; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Oswald, Franz/AAO-9584-2020; Ritter, Andreas/AAX-3938-2020; Rieger, Michael A/L-8324-2017; Ritter, Andreas/ABB-6348-2020; Kreis, Nina-Naomi/AAF-5407-2019	Ritter, Andreas/0000-0002-5955-859X; Rieger, Michael A/0000-0002-4158-5872; Kreis, Nina-Naomi/0000-0003-4304-0160; Michaelis, Jens/0000-0002-2739-4172; Yuan, Juping/0000-0003-0694-0565	Deutsche Forschungsgemeinschaft [SFB1074/A3]; BMBF (research nucleus SyStAR); International Graduate School in Molecular Medicine, Ulm, Germany [GSC270]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (research nucleus SyStAR)(Federal Ministry of Education & Research (BMBF)); International Graduate School in Molecular Medicine, Ulm, Germany	We thank Dr L Wordeman, University of Washington, and Dr A Bird, MPI, Dortmund, Germany, for their critical manuscript reading and valuable comments. The work was supported by the Deutsche Forschungsgemeinschaft (SFB1074/A3 to FO), the BMBF (research nucleus SyStAR to FO). PK was supported by the International Graduate School in Molecular Medicine, Ulm, Germany (GSC270).	Akella JS, 2010, NATURE, V467, P218, DOI 10.1038/nature09324; Akhmanova A, 2010, J CELL SCI, V123, P3415, DOI 10.1242/jcs.062414; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Brouhard GJ, 2014, J CELL BIOL, V207, P323, DOI 10.1083/jcb.201407095; CAMBRAYDEAKIN MA, 1987, CELL MOTIL CYTOSKEL, V8, P284, DOI 10.1002/cm.970080309; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Eckerdt F, 2005, J BIOL CHEM, V280, P36575, DOI 10.1074/jbc.M504548200; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Giustiniani J, 2009, CELL SIGNAL, V21, P529, DOI 10.1016/j.cellsig.2008.12.004; Goshima G, 2010, ANNU REV CELL DEV BI, V26, P21, DOI 10.1146/annurev-cellbio-100109-104006; Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376; Hoogendoorn E, 2014, SCI REP-UK, V4, DOI 10.1038/srep03854; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2015, ONCOTARGET, V6, P6611, DOI 10.18632/oncotarget.2844; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Luders J, 2006, NAT CELL BIOL, V8, P137, DOI 10.1038/ncb1349; Magiera MM, 2013, METHOD CELL BIOL, V115, P247, DOI 10.1016/B978-0-12-407757-7.00016-5; Manning AL, 2008, CURR OPIN CELL BIOL, V20, P101, DOI 10.1016/j.ceb.2007.11.004; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Meunier S, 2011, NAT CELL BIOL, V13, P1406, DOI 10.1038/ncb2372; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Miyake Y, 2016, NAT CHEM BIOL, V12, P748, DOI 10.1038/nchembio.2140; Muschol-Steinmetz C, 2016, CELL CYCLE, V15, P827, DOI 10.1080/15384101.2016.1149273; Muschol-Steinmetz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073337; Nguyen HL, 1999, J CELL SCI, V112, P1813; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Pakala SB, 2012, J BIOL CHEM, V287, P40560, DOI 10.1074/jbc.M112.399576; Penela P, 2014, CURR OPIN CELL BIOL, V27, P10, DOI 10.1016/j.ceb.2013.10.005; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Ritter A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00186; Ritter A, 2015, CELL CYCLE, V14, P3755, DOI 10.1080/15384101.2015.1068481; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Sanhaji M, 2014, ONCOTARGET, V5, P3130, DOI 10.18632/oncotarget.1861; Sanhaji M, 2013, CELL CYCLE, V12, P1340, DOI 10.4161/cc.24573; Sanhaji M, 2012, CELL CYCLE, V11, P543, DOI 10.4161/cc.11.3.19076; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Sharma N, 2011, MOL BIOL CELL, V22, P806, DOI 10.1091/mbc.E10-03-0269; Shida T, 2010, P NATL ACAD SCI USA, V107, P21517, DOI 10.1073/pnas.1013728107; Song YY, 2015, TRENDS CELL BIOL, V25, P125, DOI 10.1016/j.tcb.2014.10.004; Soppina V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048204; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wacker SA, 2011, EMBO J, V30, P43, DOI 10.1038/emboj.2010.289; Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479; Wang HH, 2014, BIOCHEM BIOPH RES CO, V454, P71, DOI 10.1016/j.bbrc.2014.10.023; Wang HH, 2012, ONCOL RES, V20, P437, DOI 10.3727/096504013X13685487925059; WEBSTER DR, 1989, J CELL SCI, V92, P57; Yount AL, 2015, EXP CELL RES, V334, P70, DOI 10.1016/j.yexcr.2014.12.015	56	21	21	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2146	2159		10.1038/onc.2016.372	http://dx.doi.org/10.1038/onc.2016.372			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721410				2022-12-28	WOS:000399782500010
J	Doudican, NA; Orlow, SJ				Doudican, N. A.; Orlow, S. J.			Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib	ONCOGENE			English	Article							BRAF V600E MUTATION; RAF INHIBITION; B-RAF; MELANOMA; PROHIBITIN; CELLS; SURVIVAL; PATHWAY; MEK; ACTIVATION	Activating BRAF mutations promote constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway and are common in a variety of human malignancies, including melanoma and colon cancer. Several small molecule BRAF inhibitors such as vemurafenib have been developed and demonstrate remarkable clinical efficacy. However, resistance typically emerges in most melanoma patients. Studies have demonstrated that reactivation of MAPK signaling via CRAF overexpression and dysregulation is a mechanism for vemurafenib resistance in melanoma. Prohibitins (PHBs) are highly conserved proteins that are thought to control the cell cycle, senescence and tumor suppression. PHB1 is essential for CRAF-mediated ERK1/2 activation through direct binding to CRAF. We developed a CRAF-mediated model of vemurafenib resistance in melanoma cells to assess the importance of the interaction between CRAF and PHB1 in resistance to BRAF-targeting agents. We demonstrate that CRAF overexpression renders melanoma cells resistant to BRAF-targeting agents. Moreover, treatment with the natural compound rocaglamide A disrupts the interaction between PHB and CRAF in melanoma cells, thus reducing MEK1/2 and ERK1/2 signaling, inhibiting melanoma cell growth and inducing apoptosis. The efficacy of these compounds was also demonstrated in a human melanoma xenograft model. Taken together, these data suggest that PHB1 may serve as a novel, druggable target in CRAF-mediated vemurafenib resistance.	[Doudican, N. A.; Orlow, S. J.] NYU, Sch Med, Ronald O Perelman Dept Dermatol, 522 First Ave,Smilow 401, New York, NY 10016 USA; [Orlow, S. J.] NYU, Sch Med, Dept Cell Biol, New York, NY USA	New York University; New York University	Orlow, SJ (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 522 First Ave,Smilow 401, New York, NY 10016 USA.	seth.orlow@nyumc.org		Orlow, Seth/0000-0003-2548-7380	Orbuch & Brand Pilot Grant Program for Cancers of the Skin; Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	Orbuch & Brand Pilot Grant Program for Cancers of the Skin; Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the NYUMC Immunohistochemistry Core for their help with the immunohistochemistry experiments. This study was supported by the Orbuch & Brand Pilot Grant Program for Cancers of the Skin. The NYUMC Immunohistochemistry Core performed the immunohistochemistry experiments outlined in this manuscript. This shared resource is partially supported by the Cancer Center Support Grant, P30CA016087, at the Laura and Isaac Perlmutter Cancer Center.	Al-Obeidi FA, 2000, ONCOGENE, V19, P5690, DOI 10.1038/sj.onc.1203926; ASAMOTO M, 1994, CANCER LETT, V83, P201, DOI 10.1016/0304-3835(94)90320-4; Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Chowdhury Indrajit, 2012, Front Biosci (Elite Ed), V4, P690; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Doudican N, 2008, MOL CANCER RES, V6, P1308, DOI 10.1158/1541-7786.MCR-07-2159; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hossen MN, 2010, J CONTROL RELEASE, V147, P261, DOI 10.1016/j.jconrel.2010.07.100; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johansson CH, 2014, PHARMACOL THERAPEUT, V142, P176, DOI 10.1016/j.pharmthera.2013.11.011; Katona TM, 2007, AM J SURG PATHOL, V31, P1029, DOI 10.1097/PAS.0b013e31802b3488; Li DD, 2015, FRONT BIOSCI-LANDMRK, V20, P1068, DOI 10.2741/4359; Luan Z, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-38; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Martin-Liberal J, 2015, FUTURE ONCOL, V11, P579, DOI 10.2217/fon.14.252; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Osman C, 2009, J CELL BIOL, V184, P583, DOI 10.1083/jcb.200810189; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Peng YT, 2015, APOPTOSIS, V20, P1135, DOI 10.1007/s10495-015-1143-z; Polier G, 2012, CHEM BIOL, V19, P1093, DOI 10.1016/j.chembiol.2012.07.012; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Robert C, 2011, CURR OPIN ONCOL, V23, P177, DOI 10.1097/CCO.0b013e3283436e8c; Ross JA, 2008, J BIOL CHEM, V283, P4699, DOI 10.1074/jbc.M708232200; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Spagnolo F, 2015, ONCOTARGETS THER, V8, P157, DOI 10.2147/OTT.S39096; Sripathi SR, 2011, BIOCHEMISTRY-US, V50, P8342, DOI 10.1021/bi2008933; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Sullivan RJ, 2013, ONCOGENE, V32, P2373, DOI 10.1038/onc.2012.345; Tan YH, 2008, PATHOLOGY, V40, P295, DOI 10.1080/00313020801911512; Tu NN, 2015, J THORAC ONCOL, V10, P1396, DOI 10.1097/JTO.0000000000000644; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Zhou TB, 2013, J RECEPT SIG TRANSD, V33, P28, DOI 10.3109/10799893.2012.752006; Zhu JY, 2007, INT J CANCER, V121, P1839, DOI 10.1002/ijc.22883	45	25	26	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					423	428		10.1038/onc.2016.214	http://dx.doi.org/10.1038/onc.2016.214			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321184				2022-12-28	WOS:000394166000011
J	Saha, SK; Choi, HY; Kim, BW; Dayem, AA; Yang, GM; Kim, KS; Yin, YF; Cho, SG				Saha, S. K.; Choi, H. Y.; Kim, B. W.; Dayem, A. A.; Yang, G-M; Kim, K. S.; Yin, Y. F.; Cho, S-G			KRT19 directly interacts with beta-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties	ONCOGENE			English	Article							KERATIN 19 EXPRESSION; BETA-CATENIN; ESTROGEN-RECEPTOR; PERIPHERAL-BLOOD; GENE SIGNATURE; INTERMEDIATE-FILAMENTS; CELL-PROLIFERATION; DOWN-REGULATION; POOR-PROGNOSIS; TUMOR-CELLS	Studies have reported that interactions between keratins (KRTs) and other proteins initiate signaling cascades that regulate cell migration, invasion, and metastasis. In the current study, we found that expression of KRT19 was specifically high in breast cancers and significantly correlated with their invasiveness. Moreover, knockdown of KRT19 led to increased proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cells via an upregulated NOTCH signaling pathway. This was owing to reduced expression of NUMB, an inhibitory protein of the NOTCH signaling pathway. In addition, we found that KRT19 interacts with beta-catenin/RAC1 complex and enhances the nuclear translocation of beta-catenin. Concordantly, knockdown of KRT19 suppressed the nuclear translocation of beta-catenin as well as beta-catenin-mediated NUMB expression. Furthermore, modulation of KRT19mediated regulation of NUMB and NOTCH1 expression led to the repression of the cancer stem cell properties of breast cancer patient-derived CD133(high)/CXCR4(high)/ALDH1(high) cancer stem-like cells (CSLCs), which showed very low KRT19 and high NOTCH1 expression. Taken together, our study suggests a novel function for KRT19 in the regulation of nuclear import of the beta-catenin/RAC1 complex, thus modulating the NUMB-dependent NOTCH signaling pathway in breast cancers and CSLCs, which might bear potential clinical implications for cancer or CSLC treatment.	[Cho, S-G] Konkuk Univ, Dept Anim Biotechnol Stem Cell & Regenerat Biotec, 120 Neungdong Ro, Seoul 05029, South Korea; [Cho, S-G] Konkuk Univ, Incurable Dis Anim Model & Stem Cell Inst IDASI, 120 Neungdong Ro, Seoul, South Korea	Konkuk University; Konkuk University	Cho, SG (corresponding author), Konkuk Univ, Dept Anim Biotechnol Stem Cell & Regenerat Biotec, 120 Neungdong Ro, Seoul 05029, South Korea.; Cho, SG (corresponding author), Konkuk Univ, Incurable Dis Anim Model & Stem Cell Inst IDASI, 120 Neungdong Ro, Seoul, South Korea.	ssangoo@konkuk.ac.kr	Saha, Subbroto Kumar/L-2627-2018; CHOI, HYEYEON/O-1234-2019; Dayem, Ahmed M Abdal/D-4773-2011	Saha, Subbroto Kumar/0000-0003-1325-3499; Dayem, Ahmed M Abdal/0000-0003-3873-9903; Cho, Ssang-Goo/0000-0002-0968-7932	National Research Foundation (NRF) - Korean government [2013M3A9D3045880, 2015R1A5A1009701]	National Research Foundation (NRF) - Korean government(Korean Government)	This work was supported by grants from the National Research Foundation (NRF) funded by the Korean government (2013M3A9D3045880 and 2015R1A5A1009701).	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bambang IF, 2009, EXP CELL RES, V315, P1964, DOI 10.1016/j.yexcr.2009.02.017; Bernemann C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-174; Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046; Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018-009-8668-7; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Bozionellou V, 2004, CLIN CANCER RES, V10, P8185, DOI 10.1158/1078-0432.CCR-03-0094; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Camps J, 2013, CANCER RES, V73, P2003, DOI 10.1158/0008-5472.CAN-12-3159; Carter S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-221; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Chen TF, 2007, LUNG CANCER, V56, P105, DOI 10.1016/j.lungcan.2006.11.006; Cheng X, 2008, DEVELOPMENT, V135, P3447, DOI 10.1242/dev.025916; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; Dayem AA, 2014, BIOTECHNOL J, V9, P934, DOI 10.1002/biot.201300555; de Silanes IL, 2007, CELL ONCOL, V29, P1; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Esufali S, 2007, FEBS LETT, V581, P4850, DOI 10.1016/j.febslet.2007.09.013; Feldman JP, 2009, J APPL QUANT METHODS, V4, P455, DOI DOI 10.1111/J.2042-3306.2010.TB05629.X; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Gulino A, 2010, EXP CELL RES, V316, P900, DOI 10.1016/j.yexcr.2009.11.017; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hua GJ, 2014, ONCOL REP, V31, P2727, DOI 10.3892/or.2014.3156; Ignatiadis M, 2007, J CLIN ONCOL, V25, P5194, DOI 10.1200/JCO.2007.11.7762; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465; Ju JH, 2015, CELL DEATH DIFFER, V22, P665, DOI 10.1038/cdd.2014.155; Ju JH, 2013, CLIN CANCER RES, V19, P4335, DOI 10.1158/1078-0432.CCR-12-3295; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; Kabir NN, 2014, MOL BIOL REP, V41, P7729, DOI 10.1007/s11033-014-3684-6; Karaczyn A, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-31; Katoh M, 2006, INT J MOL MED, V18, P517; Kawai T, 2015, CLIN CANCER RES, V21, P3081, DOI 10.1158/1078-0432.CCR-14-1936; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313; Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Leung WH, 2013, J EXP MED, V210, P2675, DOI 10.1084/jem.20122292; Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Liu XH, 2013, J BIOL CHEM, V288, P17990, DOI 10.1074/jbc.M113.478487; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Moggs JG, 2004, ENVIRON HEALTH PERSP, V112, P1589, DOI 10.1289/ehp.7345; Moggs JG, 2004, ENVIRON HEALTH PERSP, V112, P1137, DOI 10.1289/ehp.7028; Moon SH, 2013, INT J ONCOL, V42, P921, DOI 10.3892/ijo.2013.1765; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Nishikawa S, 2015, ONCOL LETT, V9, P2361, DOI 10.3892/ol.2015.3063; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Patsialou A, 2015, ONCOGENE, V34, P2721, DOI 10.1038/onc.2014.226; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Pethe VV, 2011, INT J ONCOL, V39, P805, DOI 10.3892/ijo.2011.1066; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pui CH, 2009, CANCER CELL, V15, P85, DOI 10.1016/j.ccr.2009.01.007; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Salmon Patrick, 2007, Curr Protoc Hum Genet, VChapter 12, DOI 10.1002/0471142905.hg1210s54; Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stathopoulos EN, 2005, ANN ONCOL, V16, P240, DOI 10.1093/annonc/mdi043; StoneO MR, 2007, J CELL SCI, V120, P3999, DOI 10.1242/jcs.009241; Strazzabosco M, 2013, J HEPATOL, V58, P181, DOI 10.1016/j.jhep.2012.08.006; Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03-06-0360; Valkenburg Kenneth C, 2011, Cancers (Basel), V3, P2050, DOI 10.3390/cancers3022050; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; Xiao YF, 2016, INT J ONCOL, V48, P437, DOI 10.3892/ijo.2015.3280; Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	95	62	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					332	349		10.1038/onc.2016.221	http://dx.doi.org/10.1038/onc.2016.221			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345400	Green Published, hybrid			2022-12-28	WOS:000394166000004
J	Mendoza-Villanueva, D; Balamurugan, K; Ali, HR; Kim, SR; Sharan, S; Johnson, RC; Merchant, AS; Caldas, C; Landberg, G; Sterneck, E				Mendoza-Villanueva, D.; Balamurugan, K.; Ali, H. R.; Kim, S-R; Sharan, S.; Johnson, R. C.; Merchant, A. S.; Caldas, C.; Landberg, G.; Sterneck, E.			The C/EBP delta protein is stabilized by estrogen receptor alpha activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer	ONCOGENE			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; MAMMARY-GLAND INVOLUTION; GENE-EXPRESSION; TUMOR PROGRESSION; CELL-STATE; CYCLIN D1; SLUG; PATHWAY; BETA; IDENTIFICATION	Hypoxia and inflammatory cytokines like interleukin-6 (IL-6, IL6) are strongly linked to cancer progression, and signal in part through the transcription factor Ccaat/enhancer-binding protein d (C/EBPd, CEBPD), which has been shown to promote mesenchymal features and malignant progression of glioblastoma. Here we report a different role for C/EBPd in breast cancer. We found that the C/EBPd protein is expressed in normal breast epithelial cells and in low-grade cancers. C/EBPd protein (but not mRNA) expression correlates with estrogen receptor (ER+) and progesterone receptor (PGR) expression and longer progression-free survival of breast cancer patients. Specifically in ER+ breast cancers, CEBPD-but not the related CEBPB-mRNA in combination with IL6 correlated with lower risk of progression. Functional studies in cell lines showed that ERa promotes C/EBPd expression at the level of protein stability by inhibition of the FBXW7 pathway. Furthermore, we found that C/EBPd attenuates cell growth, motility and invasiveness by inhibiting expression of the SNAI2 (Slug) transcriptional repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21(CIP1/WAF1)). These findings identify a molecular mechanism by which ERa signaling reduces the aggressiveness of cancer cells, and demonstrate that C/EBPd can have different functions in different types of cancer. Furthermore, our results support a potentially beneficial role for the IL-6 pathway specifically in ER+ breast cancer and call for further evaluation of the role of intra-tumoral IL-6 expression and of which cancers might benefit from current attempts to target the IL-6 pathway as a therapeutic strategy.	[Mendoza-Villanueva, D.; Balamurugan, K.; Kim, S-R; Sharan, S.; Sterneck, E.] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, POB B, Frederick, MD 21702 USA; [Ali, H. R.; Caldas, C.] Univ Cambridge, Cambridge Inst, Dept Oncol, Canc Res UK,Li Ka Shing Ctr, Cambridge, England; [Johnson, R. C.; Merchant, A. S.] Frederick Natl Lab, CCR Collaborat Bioinformat Resource, Adv Biomed Comp Ctr, Leidos Biomed, Frederick, MD USA; [Landberg, G.] Univ Manchester, Breakthrough Breast Canc Unit, Inst Canc Sci, Paterson Inst Canc Res, Manchester, Lancs, England; [Kim, S-R] US FDA, Div Biotechnol Review & Res 4, Off Biotechnol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Landberg, G.] Gothenburg Univ, Dept Pathol, Sahlgrenska Canc Ctr, Medicinaregatan 1F, S-40530 Gothenburg, Sweden	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Paterson Institute for Cancer Research; University of Manchester; US Food & Drug Administration (FDA); University of Gothenburg	Sterneck, E (corresponding author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, POB B, Frederick, MD 21702 USA.	sternecg@mail.nih.gov	Johnson, Randall C/B-1517-2014; Kuppusamy, Balamurugan/AAC-6020-2022; Caldas, Carlos/U-7250-2019	Johnson, Randall C/0000-0001-7754-0847; Caldas, Carlos/0000-0003-3547-1489; Sterneck, Esta/0000-0001-7716-8766	Intramural Research Program of the NIH, National Cancer Institute; Frederick National Laboratory (NIH) [HHSN261200800001E]; National Council on Science and Technology (CONACYT), Mexico; MRC [MR/M008975/1] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL11-Ali] Funding Source: researchfish; Cancer Research UK [16942] Funding Source: researchfish; Medical Research Council [MR/M008975/1] Funding Source: researchfish; National Institute for Health Research [CL-2013-14-006, NF-SI-0611-10154, NF-SI-0515-10090] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [ZIABC010307] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frederick National Laboratory (NIH); National Council on Science and Technology (CONACYT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to the Laboratory Animal Sciences Program (Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research) for excellent support, especially Donna Butcher and Glenn Summers for superb services, and Bao Tran and Jyoti Shetty (Leidos Biomedical Research, Inc.) for mRNA-Seq data. We also thank Elise Nilsson for excellent technical assistance. We thank student interns Katherine L Zhou and Yasmin Y Lachir for their valuable contributions, Linda Miller for preparation of plasmids, and Allen Kane and Joseph Meyer (Leidos Biomedical Research, Inc.) for preparing the figures for publication. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute and in part with Federal Funds from the Frederick National Laboratory (NIH) under contract no. HHSN261200800001E. DM-V was supported in part by a scholarship from the National Council on Science and Technology (CONACYT), Mexico. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Bailey CK, 2012, J BIOL CHEM, V287, P19472, DOI 10.1074/jbc.M112.345728; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Baranda-Avila N, 2013, STEROIDS, V78, P717, DOI 10.1016/j.steroids.2013.03.003; Begay V, 2015, J MOL MED, V93, P39, DOI 10.1007/s00109-014-1215-5; Bermejo-Rodriguez C, 2006, GENOMICS, V87, P113, DOI 10.1016/j.ygeno.2005.09.014; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chaudary Naz, 2006, Breast Dis, V26, P55; Chen JC, 2014, CELL, V159, P402, DOI 10.1016/j.cell.2014.09.021; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hagedorn M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-9; Hefti MM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3462; Hutt JA, 2002, MOL CANCER THER, V1, P601; Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Liao XH, 2014, FEBS J, V281, P927, DOI 10.1111/febs.12658; Liu J, 2015, TUMOR BIOL, V36, P1849, DOI 10.1007/s13277-014-2787-y; Lyng MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054078; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Martinson HA, 2015, INT J CANCER, V136, P1803, DOI 10.1002/ijc.29181; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Naderi A, 2007, ONCOGENE, V26, P1507, DOI 10.1038/sj.onc.1209920; Pawar SA, 2010, P NATL ACAD SCI USA, V107, P9210, DOI 10.1073/pnas.0913813107; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Porter DA, 2001, CANCER RES, V61, P5697; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Reed W, 1999, VIRCHOWS ARCH, V435, P116, DOI 10.1007/s004280050408; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Sanchez-Garcia F, 2014, CELL, V159, P1461, DOI 10.1016/j.cell.2014.10.048; Sanford DC, 2005, PROSTATE, V63, P143, DOI 10.1002/pros.20159; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; van Roosmalen W, 2015, J CLIN INVEST, V125, P1648, DOI 10.1172/JCI74440; Wang Y, 2015, BIOMED RES INT, V2015, P6, DOI DOI 10.1128/MBI0.01280-15; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Wei Guangwei, 2012, J Cancer Sci Ther, V4, P299; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yu XY, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-48; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	58	16	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6166	6176		10.1038/onc.2016.156	http://dx.doi.org/10.1038/onc.2016.156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27181204	Green Accepted			2022-12-28	WOS:000388857700002
J	Yuan, S; Yu, Z; Liu, Q; Zhang, M; Xiang, Y; Wu, N; Wu, L; Hu, Z; Xu, B; Cai, T; Ma, X; Zhang, Y; Liao, C; Wang, L; Yang, P; Bai, L; Li, Y				Yuan, S.; Yu, Z.; Liu, Q.; Zhang, M.; Xiang, Y.; Wu, N.; Wu, L.; Hu, Z.; Xu, B.; Cai, T.; Ma, X.; Zhang, Y.; Liao, C.; Wang, L.; Yang, P.; Bai, L.; Li, Y.			GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/beta-catenin signaling in lung adenocarcinoma	ONCOGENE			English	Article							HEPARAN-SULFATE; CANCER; WNT; GENE; GLYPICAN-5; PATHWAY; EPIDEMIOLOGY; ENDOCYTOSIS; EXPRESSION; TARGET	Glypican-5 (GPC5) is a member of the heparin sulfate proteoglycans. Previous studies of GPC5 in lung tumorigenesis showed conflicting results. In this study, we confirmed that GPC5 was downregulated in lung adenocarcinoma tissues compared with adjacent normal lung tissues. The low expression of GPC5 was significantly associated with poor outcome in lung adenocarcinoma. To understand the biological mechanism of the downregulation, we examined the promoter methylation status of GPC5 gene. We found that GPC5 was significantly hypermethylated in lung cancer tissues and lung cancer cell lines compared with normal lung tissues. The methylation level of GPC5 was negatively correlated with its transcriptional expression. De-methylation experiments further confirmed that the loss of GPC5 expression was regulated by its hypermethylation. Overexpression of GPC5 inhibited proliferation, migration and invasion of lung cancer cells in vitro, and repressed tumor growth in vivo, whereas knockdown of GPC5 was able to reverse the effect. Furthermore, we demonstrated that GPC5 could suppress the Wnt/beta-catenin signaling by binding to Wnt3a at the cell surface, which mediated its function as a tumor suppressor. Overall, these findings demonstrate that GPC5 is a novel epigenetically silenced tumor suppressor, which inhibits tumor growth by suppressing Wnt/beta-catenin signaling in lung adenocarcinoma. Our findings substantially expand our understanding about the role and the molecular mechanism of GPC5 in tumorigenesis of lung cancer.	[Yuan, S.; Liu, Q.; Zhang, M.; Xiang, Y.; Wu, N.; Wu, L.; Hu, Z.; Xu, B.; Cai, T.; Ma, X.; Zhang, Y.; Li, Y.] Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China; [Yu, Z.] Third Mil Med Univ, Xinqiao Hosp, Dept Thorac Surg, Chongqing, Peoples R China; [Liao, C.; Bai, L.] Third Mil Med Univ, Xinqiao Hosp, Dept Resp Dis, Chongqing, Peoples R China; [Wang, L.] Med Coll Wisconsin, Dept Pathol, MCW Canc Ctr, Milwaukee, WI 53226 USA; [Yang, P.] Mayo Clin, Coll Med, Hlth Sci Res, Rochester, MN USA	Army Medical University; Army Medical University; Army Medical University; Medical College of Wisconsin; Mayo Clinic	Li, Y (corresponding author), Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	liyafei2008@hotmail.com	翔宇, 马/ABH-3164-2021; Cai, Tong-Jian/AAX-6338-2021	翔宇, 马/0000-0001-7967-3950; Cai, Tong-Jian/0000-0003-3188-6265; Liu, Qingyun/0000-0002-6315-6796	National Natural Science Foundation of China [81171903, 81472190, 81370139]; Chongqing Natural Science Foundation of China [cstc2015jcyjBX0110]; Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University; Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University [2014YLC13]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Natural Science Foundation of China; Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University; Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University	This work was supported by the National Natural Science Foundation of China (no. 81171903 and no. 81472190 to Y Li; no. 81370139 to L Bai), the Chongqing Natural Science Foundation of China (no. cstc2015jcyjBX0110 to Y Li), the Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University (to L Bai), and Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University (no. 2014YLC13 to L Bai).	Avanesov A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002503; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130; Capurro M, 2014, J CELL SCI, V127, P1565, DOI 10.1242/jcs.140871; Capurro MI, 2008, DEV CELL, V14, P700, DOI 10.1016/j.devcel.2008.03.006; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Christianson HC, 2014, MATRIX BIOL, V35, P51, DOI 10.1016/j.matbio.2013.10.004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Filmus J, 2014, MATRIX BIOL, V35, P248, DOI 10.1016/j.matbio.2013.12.007; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hu XY, 2004, NUCLEIC ACIDS RES, V32, P4609, DOI 10.1093/nar/gkh790; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Knelson EH, 2014, TRENDS BIOCHEM SCI, V39, P277, DOI 10.1016/j.tibs.2014.03.001; Kumar S, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-44; Labidi-Galy SI, 2015, ONCOGENE, V34, P299, DOI 10.1038/onc.2013.562; Li FC, 2011, J CELL BIOL, V192, P691, DOI 10.1083/jcb.201008087; Li YF, 2011, J THORAC ONCOL, V6, P2, DOI 10.1097/JTO.0b013e3181fd6b04; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Li Y, 2013, ONCOL LETT, V6, P1565, DOI 10.3892/ol.2013.1622; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Liu WB, 2012, BIOCHEM BIOPH RES CO, V429, P180, DOI 10.1016/j.bbrc.2012.10.116; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lv J, 2015, J VIRAL HEPATITIS, V22, P201, DOI 10.1111/jvh.12265; Neri S, 2014, ANN SURG, V260, P383, DOI 10.1097/SLA.0000000000000617; Nishimura R, 2013, CANCER SCI, V104, P856, DOI 10.1111/cas.12173; Okolicsanyi RK, 2014, J CELL BIOCHEM, V115, P967, DOI 10.1002/jcb.24746; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song HH, 2002, BBA-GEN SUBJECTS, V1573, P241, DOI 10.1016/S0304-4165(02)00390-2; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Wanders R, 2011, EUR J CANCER, V47, P2691, DOI 10.1016/j.ejca.2011.06.023; Wang HQ, 2012, BIOCHEM BIOPH RES CO, V417, P62, DOI 10.1016/j.bbrc.2011.11.055; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; Xi YM, 2014, CANCER LETT, V353, P8, DOI 10.1016/j.canlet.2014.07.010; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang JJ, 2015, J THORAC ONCOL, V10, P682, DOI 10.1097/JTO.0000000000000456	46	42	42	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6120	6131		10.1038/onc.2016.149	http://dx.doi.org/10.1038/onc.2016.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157618				2022-12-28	WOS:000388509800008
J	Lim, SY; Yuzhalin, AE; Gordon-Weeks, AN; Muschel, RJ				Lim, S. Y.; Yuzhalin, A. E.; Gordon-Weeks, A. N.; Muschel, R. J.			Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells	ONCOGENE			English	Article							CALCIUM-BINDING PROTEINS; MYELOID CELLS; MATRIX METALLOPROTEINASES; OXIDATIVE MODIFICATIONS; ROLES; METASTASIS; DIFFERENTIATION; INFLAMMATION; RECRUITMENT; PROGRESSION	Myeloid cells promote the development of distant metastases, but little is known about the molecular mechanisms underlying this process. Here we have begun to uncover the effects of myeloid cells on cancer cells in a mouse model of liver metastasis. Monocytes/macrophages, but not granulocytes, isolated from experimental liver metastases stimulated migration and invasion of MC38 colon and Lewis lung carcinoma cells. In response to conditioned media from tumor-infiltrating monocytes/macrophages, cancer cells upregulated S100a8 and S100a9 messenger RNA expression through an extracellular signal-related kinase-dependent mechanism. Suppression of S100A8 and S100A9 in cancer cells using short hairpin RNA significantly diminished migration and invasion in culture. Downregulation of S100A8 and S100A9 had no effect on subcutaneous tumor growth. However, colony size was greatly reduced in liver metastases with decreased invasion into adjacent tissue. In tissue culture and in the liver colonies derived from cancer cells with knockdown of S100A8 and S100A9, MMP2 and MMP9 expression was decreased, consistent with the reduction in migration and invasion. Our findings demonstrate that monocytes/macrophages in the metastatic liver microenvironment induce S100A8 and S100A9 in cancer cells, and that these proteins are essential for tumor cell migration and invasion. S100A8 and S100A9, however, are not responsible for stimulation of proliferation. This study implicates S100A8 and S100A9 as important mediators of tumor cell aggressiveness, and highlights the therapeutic potential of S100A8 and S100A9 for interference of metastasis.	[Lim, S. Y.; Yuzhalin, A. E.; Gordon-Weeks, A. N.; Muschel, R. J.] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England	University of Oxford	Muschel, RJ (corresponding author), Univ Oxford, Dept Oncol, Old Rd Campus,Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.	ruth.muschel@oncology.ox.ac.uk	Gordon-Weeks, Alex/L-1831-2019; Yuzhalin, Arseniy E./J-3951-2013	Gordon-Weeks, Alex/0000-0003-2997-4194; Yuzhalin, Arseniy E./0000-0001-7454-6653; Lim, Su Yin/0000-0001-9576-5441; Muschel, Ruth/0000-0002-5656-5970	CRUK; CRUK Oxford Cancer Centre; Cancer Research UK [20407] Funding Source: researchfish	CRUK(Cancer Research UK); CRUK Oxford Cancer Centre; Cancer Research UK(Cancer Research UK)	This study was supported by CRUK funding to the Oxford Institute for Radiation Oncology and Biology and by the CRUK Oxford Cancer Centre.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x; Arai K, 2008, CURR CANCER DRUG TAR, V8, P243, DOI 10.2174/156800908784533445; Bozzuto G, 2010, ANN I SUPER SANITA, V46, P66, DOI 10.4415/ANN_10_01_09; Souto JC, 2011, MED RES REV, V31, P311, DOI 10.1002/med.20185; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x; DeNardo D, 2010, CANCER METAST REV, V29, P309, DOI 10.1007/s10555-010-9223-6; Duan L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062092; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; Hermani A, 2005, CLIN CANCER RES, V11, P5146, DOI 10.1158/1078-0432.CCR-05-0352; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; KOHN EC, 1994, J BIOL CHEM, V269, P21505; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leukert N, 2006, J MOL BIOL, V359, P961, DOI 10.1016/j.jmb.2006.04.009; Lim SY, 2008, J IMMUNOL, V181, P5627, DOI 10.4049/jimmunol.181.8.5627; Lim SY, 2015, HEPATOLOGY, V62, P521, DOI 10.1002/hep.27838; Lim SY, 2011, ANTIOXID REDOX SIGN, V15, P2235, DOI 10.1089/ars.2010.3641; Lim SY, 2010, J BIOL CHEM, V285, P14377, DOI 10.1074/jbc.M109.075242; Lim SY, 2009, J LEUKOCYTE BIOL, V86, P577, DOI 10.1189/jlb.1008608; LOHI J, 1995, J BIOL CHEM, V270, P17602, DOI 10.1074/jbc.270.29.17602; Luschen S, 2005, EXP CELL RES, V310, P33, DOI 10.1016/j.yexcr.2005.07.022; Moon A, 2008, MOL CANCER RES, V6, P1544, DOI 10.1158/1541-7786.MCR-08-0189; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Raymond E, 2014, CANCER CHEMOTH PHARM, V73, P1, DOI 10.1007/s00280-013-2321-8; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Srikrishna G, 2012, J INNATE IMMUN, V4, P31, DOI 10.1159/000330095; Strupat K, 2000, J AM SOC MASS SPECTR, V11, P780, DOI 10.1016/S1044-0305(00)00150-1; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wu CY, 2009, GLIA, V57, P1775, DOI 10.1002/glia.20890; Yong HY, 2007, ARCH PHARM RES, V30, P75, DOI 10.1007/BF02977781; Zhao L, 2013, HEPATOLOGY, V57, P829, DOI 10.1002/hep.26094	44	110	114	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5735	5745		10.1038/onc.2016.107	http://dx.doi.org/10.1038/onc.2016.107			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27086923	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000386998400005
J	Amar, D; Izraeli, S; Shamir, R				Amar, D.; Izraeli, S.; Shamir, R.			Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications	ONCOGENE			English	Article							HEDGEHOG SIGNALING PATHWAY; GENE-EXPRESSION PROFILES; INTEGRATED ANALYSIS; IDENTIFICATION; CYTOSCAPE; ONTOLOGY; BIOLOGY; SMAD4; KRAS	Large cancer projects measure somatic mutations in thousands of samples, gradually assembling a catalog of recurring mutations in cancer. Many methods analyze these data jointly with auxiliary information with the aim of identifying subtype-specific results. Here, we show that somatic gene mutations alone can reliably and specifically predict cancer subtypes. Interpretation of the classifiers provides useful insights for several biomedical applications. We analyze the COSMIC database, which collects somatic mutations from The Cancer Genome Atlas (TCGA) as well as from many smaller scale studies. We use multi-label classification techniques and the Disease Ontology hierarchy in order to identify cancer subtype-specific biomarkers. Cancer subtype classifiers based on TCGA and the smaller studies have comparable performance, and the smaller studies add a substantial value in terms of validation, coverage of additional subtypes, and improved classification. The gene sets of the classifiers are used for threefold contribution. First, we refine the associations of genes to cancer subtypes and identify novel compelling candidate driver genes. Second, using our classifiers we successfully predict the primary site of metastatic samples. Third, we provide novel hypotheses regarding detection of subtype-specific synthetic lethality interactions. From the cancer research community perspective, our results suggest that curation efforts, such as COSMIC, have great added and complementary value even in the era of large international cancer projects.	[Amar, D.; Shamir, R.] Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv Univ Campus, IL-69978 Tel Aviv, Israel; [Izraeli, S.] Sheba Med Ctr, Safra Childrens Hosp, Dept Pediat Hematol Oncol, Ramat Gan, Israel; [Izraeli, S.] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Shamir, R (corresponding author), Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv Univ Campus, IL-69978 Tel Aviv, Israel.	rshamir@tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870	Israel Science Foundation [317/13]; IDEA grant from the Dotan Center in Hemato-Oncology; Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease [41/11]; Azrieli Foundation; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	Israel Science Foundation(Israel Science Foundation); IDEA grant from the Dotan Center in Hemato-Oncology; Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease; Azrieli Foundation; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	This study was supported in part by the Israel Science Foundation (grant 317/13), an IDEA grant from the Dotan Center in Hemato-Oncology, and the Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease, Center No 41/11. DA is grateful to the Azrieli Foundation for the award of an Azrieli Fellowship. DA was also supported in part by fellowships from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. Part of the work was done while DA and RS were visiting the Simons Institute for the Theory of Computing.	Amar D, 2015, NUCLEIC ACIDS RES, V43, P7779, DOI 10.1093/nar/gkv810; Amar D, 2014, NUCLEIC ACIDS RES, V42, P4208, DOI 10.1093/nar/gku102; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Ding JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9554; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Eser S, 2014, BRIT J CANCER, V111, P1; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Furth N, 2015, GENE DEV, V29, P2325, DOI 10.1101/gad.268185.115; Gonzalez-Perez A, 2013, NAT METHODS, V10, P723, DOI 10.1038/nmeth.2562; Guo J, 2016, NUCLEIC ACIDS RES, V44, pD1011, DOI 10.1093/nar/gkv1108; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hofree M, 2013, NAT METHODS, V10, P1108, DOI [10.1038/NMETH.2651, 10.1038/nmeth.2651]; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jerby-Arnon L, 2014, CELL, V158, P1199, DOI 10.1016/j.cell.2014.07.027; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Kelleher FC, 2011, CARCINOGENESIS, V32, P445, DOI 10.1093/carcin/bgq280; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lan A, 2011, NUCLEIC ACIDS RES, V39, pW424, DOI 10.1093/nar/gkr359; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee YS, 2013, BIOINFORMATICS, V29, P3036, DOI 10.1093/bioinformatics/btt529; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep10204; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Onishi H, 2014, WORLD J GASTROENTERO, V20, P2335, DOI 10.3748/wjg.v20.i9.2335; Raphael BJ, 2014, GENOME MED, V6, DOI 10.1186/gm524; Schriml LM, 2012, NUCLEIC ACIDS RES, V40, pD940, DOI 10.1093/nar/gkr972; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Torgo L, 2011, DATA MINING R LEARNI, P289; Truty MJ, 2007, PANCREATOLOGY, V7, P423, DOI 10.1159/000108959; Tsoumakas G, 2011, J MACH LEARN RES, V12, P2411; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Ulitsky I, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-8; Vandin F, 2012, BIOCOMPUT-PAC SYM, P55; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Vlasblom J, 2014, BIOINFORMATICS, P1; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Wright M. N., 2015, RANGER FAST IMPLEMEN; Zhang ML, 2007, PATTERN RECOGN, V40, P2038, DOI 10.1016/j.patcog.2006.12.019; Zhang ML, 2014, IEEE T KNOWL DATA EN, V26, P1819, DOI 10.1109/TKDE.2013.39; Zhao ZM, 2016, P NATL ACAD SCI USA, V113, P2140, DOI 10.1073/pnas.1525677113	51	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3375	3383		10.1038/onc.2016.489	http://dx.doi.org/10.1038/onc.2016.489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092680	Green Published, hybrid			2022-12-28	WOS:000403340700002
J	Zhao, L; Ji, G; Le, X; Luo, Z; Wang, C; Feng, M; Xu, L; Zhang, Y; Lau, WB; Lau, B; Yang, Y; Lei, L; Yang, H; Xuan, Y; Chen, Y; Deng, X; Yi, T; Yao, S; Zhao, X; Wei, Y; Zhou, S				Zhao, L.; Ji, G.; Le, X.; Luo, Z.; Wang, C.; Feng, M.; Xu, L.; Zhang, Y.; Lau, W. B.; Lau, B.; Yang, Y.; Lei, L.; Yang, H.; Xuan, Y.; Chen, Y.; Deng, X.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.			An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; TUMOR MICROENVIRONMENT; EXPRESSION; INVASION; PROMOTES; FIBROBLASTS; GROWTH; MODEL	Epithelial ovarian cancer (EOC) is one of the most common gynecological cancers, with diagnosis often at a late stage. Metastasis is a major cause of death in patients with EOC, but the underlying molecular mechanisms remain obscure. Here, we utilized an integrated approach to find potential key transcription factors involved in ovarian cancer metastasis and identified STAT4 as a critical player in ovarian cancer metastasis. We found that activated STAT4 was overexpressed in epithelial cells of ovarian cancer and STAT4 overexpression was associated with poor outcome of ovarian cancer patients, which promoted metastasis of ovarian cancer in both in vivo and in vitro. Although STAT4 mediated EOC metastasis via inducing epithelial-to-mesenchymal transition (EMT) of ovarian cancer cells in vivo, STAT4 failed to induce EMT directly in vitro, suggesting that STAT4 might mediate EMT process via cancer-stroma interactions. Further functional analysis revealed that STAT4 overexpression induced normal omental fibroblasts and adipose- and bone marrow-derived mesenchymal stem cells to obtain cancer-associated fibroblasts (CAF)-like features via induction of tumor-derived Wnt7a. Reciprocally, increased production of CAF-induced CXCL12, IL6 and VEGFA within tumor microenvironment could enable peritoneal metastasis of ovarian cancer via induction of EMT program. In summary, our study established a model that STAT4 promotes ovarian cancer metastasis via tumor-derived Wnt7a-induced activation of CAFs.	[Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women, Chengdu 610041, Peoples R China; [Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, Children Minist Educ, West China Second Hosp, Chengdu 610041, Peoples R China; [Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr, West China Hosp, Chengdu 610041, Peoples R China; [Luo, Z.; Wang, C.] Sichuan Univ, Coll Biol Sci, Chengdu, Peoples R China; [Feng, M.; Xu, L.] Sichuan Univ, West China Second Hosp, Dept Pathol, Chengdu, Peoples R China; [Lau, W. B.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA; [Lau, B.] Affiliate Stanford Univ, Kaiser Santa Clara Med Ctr, Dept Surg Emergency Med, Santa Clara, CA USA; [Yang, Y.; Lei, L.] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China; [Yang, H.] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China; [Chen, Y.; Deng, X.] Sichuan Univ, West China Hosp, Dept Surg Gastroenterol, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Jefferson University; Sichuan University; Sichuan University; Sichuan University	Zhao, L (corresponding author), Sichuan Univ, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women, Chengdu 610041, Peoples R China.; Zhao, L (corresponding author), Sichuan Univ, Children Minist Educ, West China Second Hosp, Chengdu 610041, Peoples R China.; Zhao, L (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr, West China Hosp, Chengdu 610041, Peoples R China.	taotaovip2005@163.com		Zhang, Yaguang/0000-0002-9216-1834; Lau, Wayne Bond/0000-0002-8064-8290; Zhou, Shengtao/0000-0001-8322-5536	National Natural Science Foundation of China [81402396]; Sichuan Science-Technology Soft Sciences Project [2016ZR0086]; Yi Yao Foundation [14H0563]; West China Second Hospital, Sichuan University [KS021]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Science-Technology Soft Sciences Project; Yi Yao Foundation; West China Second Hospital, Sichuan University	This work was supported by grants from the National Natural Science Foundation of China (grant #81402396), Sichuan Science-Technology Soft Sciences Project (grant #2016ZR0086), Yi Yao Foundation (grant #14H0563) and Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021).	Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Baumann C, 2015, P NATL ACAD SCI USA, V112, P4056, DOI 10.1073/pnas.1418549112; Charlet J, 2016, MOL CELL, V62, P422, DOI 10.1016/j.molcel.2016.03.033; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Cheng JM, 2015, J BIOL REG HOMEOS AG, V29, P85; Cordero AB, 2010, JOVE-J VIS EXP, V42, P2125, DOI DOI 10.3791/2125;42; Gandellini P, 2015, SEMIN CANCER BIOL, V35, P96, DOI 10.1016/j.semcancer.2015.08.008; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kim KW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0197-8; King ML, 2015, ONCOGENE, V34, P3452, DOI 10.1038/onc.2014.277; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Litvinov IV, 2014, CELL CYCLE, V13, P2975, DOI 10.4161/15384101.2014.947759; Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Nick AM, 2015, NAT REV CLIN ONCOL, V12, P239, DOI 10.1038/nrclinonc.2015.26; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, P1; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Roider HG, 2009, BIOINFORMATICS, V25, P435, DOI 10.1093/bioinformatics/btn627; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Shen HJ, 2016, CELL, V165, P331, DOI 10.1016/j.cell.2016.02.064; Tang LJ, 2015, CELL PHYSIOL BIOCHEM, V37, P143, DOI 10.1159/000430340; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wubetu GY, 2014, ANN SURG ONCOL, V21, pS721, DOI 10.1245/s10434-014-3861-9; Xu XF, 2014, MOL CANCER THER, V13, P1729, DOI 10.1158/1535-7163.MCT-13-0982; Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541-7786.MCR-11-0177; Yu KH, 2016, MOL CELL PROTEOMICS, V15, P2525, DOI 10.1074/mcp.O116.059253; Zhou ST, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017988; Zhou XY, 2014, CELL PHYSIOL BIOCHEM, V33, P1003, DOI 10.1159/000358671	35	51	53	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3384	3396		10.1038/onc.2016.487	http://dx.doi.org/10.1038/onc.2016.487			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114283				2022-12-28	WOS:000403340700003
J	Janakiraman, H; House, RP; Talwar, S; Courtney, SM; Hazard, ES; Hardiman, G; Mehrotra, S; Howe, PH; Gangaraju, V; Palanisamy, V				Janakiraman, H.; House, R. P.; Talwar, S.; Courtney, S. M.; Hazard, E. S.; Hardiman, G.; Mehrotra, S.; Howe, P. H.; Gangaraju, V.; Palanisamy, V.			Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma	ONCOGENE			English	Article							COX-2 EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; MEDIATED CLEAVAGE; PROSTATE-CANCER; CYCLO-OXYGENASE-2; OVEREXPRESSION; APOPTOSIS; LESIONS	A well-studied RNA-binding protein Hu Antigen-R (HuR), controls post-transcriptional gene regulation and undergoes stress-activated caspase-3 dependent cleavage in cancer cells. The cleavage products of HuR are known to promote cell death; however, the underlying molecular mechanisms facilitating caspase-3 activation and HuR cleavage remains unknown. Here, we show that HuR cleavage associated with active caspase-3 in oral cancer cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel. We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells. Specific inhibition of COX-2 by celecoxib, promoted apoptosis through activation of caspase-3 and cleavage of HuR in paclitaxel-resistant oral cancer cells, both in vitro and in vivo. In addition, oral cancer cells overexpressing cellular HuR increased the half-life of COX-2 mRNA, promoted COX-2 protein expression and exhibited enhanced tumor growth in vivo in comparison with cells expressing a cleavable form of HuR. Finally, our ribonucleoprotein immunoprecipitation and sequencing (RIP-seq) analyses of HuR in oral cancer cells treated with ionizing radiation (IR), determined that HuR cleavage product-1 (HuR-CP1) bound and promoted the expression of mRNAs encoding proteins involved in apoptosis. Our results indicated that, cellular non-cleavable HuR controls COX-2 mRNA expression and enzymatic activity. In addition, overexpressed COX-2 protein repressed the cleavage of caspase-3 and HuR to promote drug resistance and tumor growth. Altogether, our observations support the use of the COX-2 inhibitor celecoxib, in combination with paclitaxel, for the management of paclitaxel resistant oral cancer cells.	[Janakiraman, H.; House, R. P.; Talwar, S.; Palanisamy, V.] Med Univ South Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA; [Janakiraman, H.; House, R. P.; Talwar, S.; Palanisamy, V.] Med Univ South Carolina, Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC 29425 USA; [Courtney, S. M.; Hazard, E. S.; Hardiman, G.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA; [Courtney, S. M.] Med Univ South Carolina, Dept Pathol, Charleston, SC 29425 USA; [Hazard, E. S.] Med Univ South Carolina, Lib Sci & Informat, Charleston, SC 29425 USA; [Hardiman, G.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Hardiman, G.] Med Univ South Carolina, Dept Publ Hlth, Charleston, SC 29425 USA; [Mehrotra, S.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Howe, P. H.; Gangaraju, V.; Palanisamy, V.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Palanisamy, V (corresponding author), Med Univ South Carolina, Dept Oral Hlth Sci, BSB 230-F, Charleston, SC 29425 USA.	visu@musc.edu		Hardiman, Gary/0000-0003-4558-0400; Janakiraman, Harinarayanan/0000-0002-3043-2352	National Institutes of Health [R01DE022776, R01DE022776S1]; NIH grant [P30 GM103331]; NATIONAL CANCER INSTITUTE [R01CA154663, P30CA138313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103331] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the funding source from the National Institutes of Health R01DE022776 and R01DE022776S1 to VP. We acknowledge the Center for Oral Health Research (L-COHR) which is supported by the NIH grant P30 GM103331.	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Barbisan F, 2009, EUR UROL, V56, P105, DOI 10.1016/j.eururo.2008.04.043; Beauchamp P, 2010, CELL DEATH DIFFER; Bombard Y, 2013, J NATL COMPR CANC NE, V11, P1343, DOI 10.6004/jnccn.2013.0158; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Brody JR, 2011, WIRES RNA, V2, P435, DOI 10.1002/wrna.62; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Costantino CL, 2009, CANCER RES, V69, P4567, DOI 10.1158/0008-5472.CAN-09-0371; Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Do SI, 2008, TUMORI, V94, P347; Ferrandina G, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-182; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Hague A, 2004, J PATHOL, V204, P175, DOI 10.1002/path.1630; Hida T, 1998, CANCER RES, V58, P3761; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Idro R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014001; Itoh S, 2003, ORAL ONCOL, V39, P829, DOI 10.1016/S1368-8375(03)00105-2; KARGMAN SL, 1995, CANCER RES, V55, P2556; Katsanou V, 2009, MOL CELL BIOL, V29, P2762, DOI 10.1128/MCB.01393-08; Kozak I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074712; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Li M, 2014, SCI REP-UK, V4, DOI 10.1038/srep07380; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mazroui R, 2008, J CELL BIOL, V180, P113, DOI 10.1083/jcb.200709030; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Mohammad Shadab, 2011, Natl J Maxillofac Surg, V2, P17, DOI 10.4103/0975-5950.85848; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Niesporek S, 2008, INT J ONCOL, V32, P341; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Paolini P, 2014, PHARMACOGENOMICS, V15, P759, DOI [10.2217/PGS.14.39, 10.2217/pgs.14.39]; Papadaki O, 2009, J IMMUNOL, V182, P6779, DOI 10.4049/jimmunol.0900377; Renkonen J, 2002, VIRCHOWS ARCH, V440, P594, DOI 10.1007/s00428-002-0616-y; Ristimaki A, 1997, CANCER RES, V57, P1276; Sakurai K, 2007, HEAD NECK-J SCI SPEC, V29, P1002, DOI 10.1002/hed.20627; Shirahama T, 2000, CLIN CANCER RES, V6, P2424; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Sudbo J, 2003, ORAL ONCOL, V39, P497, DOI 10.1016/S1368-8375(03)00012-5; Talwar S, 2014, J BIOL CHEM, V289, P3487, DOI 10.1074/jbc.M113.504951; Talwar S, 2011, J BIOL CHEM, V286, P32333, DOI 10.1074/jbc.M111.255927; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; von Roretz C, 2013, CELL DEATH DIFFER, V20, P154, DOI 10.1038/cdd.2012.111; von Roretz C, 2010, J BIOL CHEM, V285, P16806, DOI 10.1074/jbc.M109.087320; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Zimmermann KC, 1999, CANCER RES, V59, P198	51	24	24	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3137	3148		10.1038/onc.2016.451	http://dx.doi.org/10.1038/onc.2016.451			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941877	Green Accepted			2022-12-28	WOS:000402617900006
J	Fu, L; Dong, Q; He, J; Wang, X; Xing, J; Wang, E; Qiu, X; Li, Q				Fu, L.; Dong, Q.; He, J.; Wang, X.; Xing, J.; Wang, E.; Qiu, X.; Li, Q.			SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway	ONCOGENE			English	Article							CELL-PROLIFERATION; INSULIN-SECRETION; FISSION; CANCER; DRP1; PHOSPHORYLATION; MIGRATION; SIRTUINS; DIVISION; FUSION	SIRT4 is well-known for its deacetylase activity in energy metabolism, but little is known about its roles in carcinogenesis. We demonstrated that SIRT4 was decreased in 70 out of 133 non-small cell lung cancer (NSCLC) cases by immunohistochemical staining and localized in the mitochondria using confocal microscopy. Low levels of SIRT4 expression was correlated with tumor node metastasis (TNM) stage, histological type of tumor (adenocarcinoma), lymph nodal status, Ki-67 (proliferation index) and poor overall survival. We also studied the biological role of SIRT4 in lung cancer cell lines transfected with SIRT4 plasmid or SIRT4-siRNA. SIRT4 inhibited lung cancer cell proliferation, blocked the cell cycle and repressed cell invasion and migration. Mitochondrial dynamics has been implicated in malignant properties of cells, particularly metastasis that is the major cause of death in patients diagnosed with cancer including lung cancer. This is the first study to identify an association between SIRT4 expression and decreased mitochondrial fission, which was driven by Drp1. SIRT4 inhibited Drp1 phosphorylation and weakened Drp1 recruitment to the mitochondrial membrane via an interaction with Fis-1. SIRT4 expression was lower in nodal metastatic tumor samples than their corresponding primary tumors, and cases with low expression of SIRT4 tended to have high p-Drp1 labeling. Also, MEK/ERK activity appeared to be hampered by SIRT4 expression, which may have implications for cells' invasive capacities. In conclusion, our findings suggest that SIRT4 functions as an important antitumor protein in NSCLC, and should be investigated further with respect to future anticancer strategies.	[Li, Q.] China Med Univ, Coll Basic Med Sci, Shenyang 11000, Liaoning, Peoples R China; China Med Univ Shenyang, Dept Pathol, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China		Li, Q (corresponding author), China Med Univ, Coll Basic Med Sci, Shenyang 11000, Liaoning, Peoples R China.; Li, Q (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang 11000, Peoples R China.	liqingchangcmu@126.com			National Natural Science Foundation of China [81672964, 81302022]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the National Natural Science Foundation of China (No. 81672964 to Qingchang Li and No. 81302022 to Qianze Dong).	Ahuja N, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705488200; Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Argmann C, 2006, CELL, V126, P837, DOI 10.1016/j.cell.2006.08.031; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Carafa V, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00004; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Fu L, 2015, MOL CARCINOGEN, V54, pE35, DOI 10.1002/mc.22148; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Huang GY, 2015, BIOMED PHARMACOTHER, V72, P135, DOI 10.1016/j.biopha.2015.04.013; Jeong SM, 2014, J BIOL CHEM, V289, P4135, DOI 10.1074/jbc.M113.525949; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Laurent G, 2013, MOL CELL, V50, P686, DOI 10.1016/j.molcel.2013.05.012; Lennon FE, 2014, EXPERT OPIN INV DRUG, V23, P675, DOI 10.1517/13543784.2014.899350; Miyo M, 2015, BRIT J CANCER, V113, P492, DOI 10.1038/bjc.2015.226; Nasrin N, 2010, J BIOL CHEM, V285, P31995, DOI 10.1074/jbc.M110.124164; Pal AD, 2014, CARCINOGENESIS, V35, P1592, DOI 10.1093/carcin/bgu069; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Roberts ER, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/csbj.201303019; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Wang Y, 2013, MOL CARCINOGEN, V52, P890, DOI 10.1002/mc.21935; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	38	80	82	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2724	2736		10.1038/onc.2016.425	http://dx.doi.org/10.1038/onc.2016.425			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27941873				2022-12-28	WOS:000401120900010
J	Omarjee, S; Jacquemetton, J; Poulard, C; Rochel, N; Dejaegere, A; Chebaro, Y; Treilleux, I; Marangoni, E; Corbo, L; Le Romancer, M				Omarjee, S.; Jacquemetton, J.; Poulard, C.; Rochel, N.; Dejaegere, A.; Chebaro, Y.; Treilleux, I.; Marangoni, E.; Corbo, L.; Le Romancer, M.			The molecular mechanisms underlying the ER alpha-36-mediated signaling in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; REGULATED KINASE; ER-ALPHA; VARIANT; PAXILLIN; PROTEIN; CELLS; RECEPTOR-ALPHA-36; PHOSPHORYLATION; PROLIFERATION	Alterations in estrogen-mediated cellular signaling have largely been implicated in the pathogenesis of breast cancer. Here, we investigated the signaling regulation of a splice variant of the estrogen receptor, namely estrogen receptor (ER alpha-36), associated with a poor prognosis in breast cancers. Coupling in vitro and in vivo approaches we determined the precise sequential molecular events of a new estrogen signaling network in an ERa-negative cell line and in an original patient-derived xenograft. After estrogen treatment, ERa-36 rapidly associates with Src at the level of the plasma membrane, initiating downstream cascades, including MEK1/ERK activation and paxillin phosphorylation on S126, which in turn triggers a higher expression of cyclin D1. Of note, the direct binding of ERa-36 to ERK2 prevents its dephosphorylation by MKP3 and enhances the downstream signaling. These findings improve our understanding of the regulation of non-genomic estrogen signaling and open new avenues for personalized therapeutic approaches targeting Src or MEK in ERa-36-positive patients.	[Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] Univ Lyon 1, Lyon, France; [Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] INSERM, Ctr Rech Cancerol Lyon, U1052, Lyon, France; [Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] CNRS, Ctr Rech Cancerol Lyon, UMR5286, Lyon, France; [Poulard, C.] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] CNRS, UMR7104, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] INSERM, U964, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] Univ Strasbourg, Illkirch Graffenstaden, France; [Treilleux, I.] Ctr Leon Berard, Dept Pathol, Lyon, France; [Marangoni, E.] Inst Curie, Translat Res Dept, Paris, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Le Romancer, M (corresponding author), Ctr Leon Berard, CNRS 5286, INSERM 1052, CRCL, 28 Rue Laennec, F-69373 Lyon, France.	muriel.leromancer@lyon.unicancer.fr	Chebaro, Yassmine/M-2174-2019; Marangoni, Elisabetta/GSO-3945-2022; Rochel, Natacha/A-5718-2016	Chebaro, Yassmine/0000-0002-5970-2117; Marangoni, Elisabetta/0000-0002-3337-6448; Rochel, Natacha/0000-0002-3573-5889; Poulard, coralie/0000-0003-4821-908X; Omarjee, Soleilmane/0000-0001-8686-7286	Fondation Arc Cancer [ANR-10-LABX-0030-INRT]	Fondation Arc Cancer	We thank F Nasri, C. Languilaire, A. Colombe, L Odeyer and F Assayag for technical support, Y Mikaelian (CRCL, Lyon) for the Histone-GFP vector, G Castoria for the PI3K plasmid, Dr Wang for the pCDNA3-ER alpha-36 plasmid, P Chambon for the HEGO plasmid, F Lenfant for the ERa-46 plasmid, B. Manship for the proofreading of the manuscript. Ligue Nationale Contre le Cancer (comite de Saone-et-Loire), 'Fondation Arc Cancer', Canceropole CLARA, INCA and DGOS. 'region Rhone-Alpes' and 'Ligue Contre le Cancer' for SO, French Ministry of Research, 'Fondation Arc Cancer' and NIH for CP. 'Fondation Arc Cancer' for JJ, NR, YC and AD: grant ANR-10-LABX-0030-INRT.	Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cai XM, 2006, MOL CELL BIOL, V26, P2857, DOI 10.1128/MCB.26.7.2857-2868.2006; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chaudhri RA, 2012, J BIOL CHEM, V287, P7169, DOI 10.1074/jbc.M111.292946; Coste I, 2010, J CLIN INVEST, V120, P3663, DOI 10.1172/JCI42771; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gu Y, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-16; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kong EH, 2003, BIOCHEM SOC T, V31, P56, DOI 10.1042/BST0310056; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Lee LMJ, 2008, ANTICANCER RES, V28, P479; Levin ER, 2015, ANNU REV MED, V66, P271, DOI 10.1146/annurev-med-050913-021703; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Luo ML, 2015, CELL REP, V11, P111, DOI 10.1016/j.celrep.2015.03.002; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Martin MC, 2008, J BIOL CHEM, V283, P3854, DOI 10.1074/jbc.M705647200; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Poulard C, 2012, EMBO MOL MED, V4, P1200, DOI 10.1002/emmm.201201615; Rao J, 2011, J STEROID BIOCHEM, V127, P231, DOI 10.1016/j.jsbmb.2011.08.004; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Sen A, 2010, J BIOL CHEM, V285, P28787, DOI 10.1074/jbc.M110.134064; Shi L, 2009, J CLIN ONCOL, V27, P3423, DOI 10.1200/JCO.2008.17.2254; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; Wang ZY, 2015, MOL CELL ENDOCRINOL, V418, P193, DOI 10.1016/j.mce.2015.04.017; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Yin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107369; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhang J, 2012, STEROIDS, V77, P666, DOI 10.1016/j.steroids.2012.02.013; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458; Zhang XT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030174	42	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2503	2514		10.1038/onc.2016.415	http://dx.doi.org/10.1038/onc.2016.415			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941878	Green Published, hybrid			2022-12-28	WOS:000400597300002
J	Kim, LC; Cook, RS; Chen, J				Kim, L. C.; Cook, R. S.; Chen, J.			mTORC1 and mTORC2 in cancer and the tumor microenvironment	ONCOGENE			English	Review							ADVANCED SOLID TUMORS; I DOSE-ESCALATION; TRANSFER-RNA SYNTHETASE; P70 S6 KINASE; PHASE-I; MAMMALIAN TARGET; PI3K/MTOR INHIBITOR; TUBEROUS SCLEROSIS; COMPLEX 2; PHOSPHOPROTEOME REVEALS	The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates environmental cues to regulate cell survival, proliferation and metabolism, and is often deregulated in human cancer. mTOR kinase acts in two functionally distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), whose activities and substrate specificities are regulated by complex co-factors. Deregulation of this centralized signaling pathway has been associated with a variety of human diseases including diabetes, neurodegeneration and cancer. Although mTORC1 signaling has been extensively studied in cancer, recent discoveries indicate a subset of human cancers harboring amplifications in mTORC2-specific genes as the only actionable genomic alterations, suggesting a distinct role for mTORC2 in cancer as well. This review will summarize recent advances in dissecting the relative contributions of mTORC1 versus mTORC2 in cancer, their role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors.	[Kim, L. C.; Cook, R. S.; Chen, J.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Cook, R. S.; Chen, J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Chen, J.] Vanderbilt Univ, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; [Chen, J.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Chen, J.] Tennessee Valley Healthcare Syst, Vet Affairs Med Ctr, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, Med Ctr North T3207E, 1161 21st Ave South, Nashville, TN 37232 USA.; Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Cell & Dev Biol, Med Ctr North T3207E, 1161 21st Ave South, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	Department of Veterans Affairs; NIH [R01 CA95004, R01 CA177681, T-32 CA009592]; NATIONAL CANCER INSTITUTE [R01CA114301, R01CA177681, R01CA095004, T32CA009592] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000134] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Deanna Edwards for careful review of the manuscript. This work was supported by the Department of Veterans Affairs through a VA Merit Award and a Research Career Scientist Award (J Chen), NIH grants R01 CA95004 and R01 CA177681 (J Chen) and T-32 CA009592 (L Kim).	Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Aylett CHS, 2016, SCIENCE, V351, P48, DOI 10.1126/science.aaa3870; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Basu B, 2015, CLIN CANCER RES, V21, P3412, DOI 10.1158/1078-0432.CCR-14-2422; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Bendell JC, 2015, CANCER-AM CANCER SOC, V121, P3481, DOI 10.1002/cncr.29422; Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bonfils G, 2012, MOL CELL, V46, P105, DOI 10.1016/j.molcel.2012.02.009; Britten CD, 2014, INVEST NEW DRUG, V32, P510, DOI 10.1007/s10637-013-0062-5; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Cheng HY, 2015, CANCER DISCOV, V5, P1262, DOI 10.1158/2159-8290.CD-14-0971; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Dolly SO, 2016, CLIN CANCER RES, V22, P2874, DOI 10.1158/1078-0432.CCR-15-2225; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farhan MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135245; Fazio N, 2016, ANTICANCER RES, V36, P713; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fokas E, 2012, CANCER RES, V72, P239, DOI 10.1158/0008-5472.CAN-11-2263; Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023; Gaubitz C, 2015, MOL CELL, V58, P977, DOI 10.1016/j.molcel.2015.04.031; Granot Z, 2015, CANCER RES, V75, P4441, DOI 10.1158/0008-5472.CAN-15-1502; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Han JM, 2012, CELL, V149, P410, DOI 10.1016/j.cell.2012.02.044; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janne PA, 2014, J THORAC ONCOL, V9, P316, DOI 10.1097/JTO.0000000000000088; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008-5472.CAN-15-3393; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lane HA, 2009, CLIN CANCER RES, V15, P1612, DOI 10.1158/1078-0432.CCR-08-2057; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lee K, 2013, BLOOD, V122, P2369, DOI 10.1182/blood-2013-01-477505; Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470; Lee K, 2010, IMMUNITY, V32, P743, DOI 10.1016/j.immuni.2010.06.002; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mahadevan D, 2012, EUR J CANCER, V48, P3319, DOI 10.1016/j.ejca.2012.06.027; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; del Campo JM, 2016, GYNECOL ONCOL, V142, P62, DOI 10.1016/j.ygyno.2016.04.019; Markman B, 2012, ANN ONCOL, V23, P2399, DOI 10.1093/annonc/mds011; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Masui K, 2013, CELL METAB, V18, P726, DOI 10.1016/j.cmet.2013.09.013; Mateo J, 2016, BRIT J CANCER, V114, P889, DOI 10.1038/bjc.2016.59; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Morrison MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005291; Munster P, 2016, CLIN CANCER RES, V22, P1932, DOI 10.1158/1078-0432.CCR-15-1665; Naing A, 2012, BRIT J CANCER, V107, P1093, DOI 10.1038/bjc.2012.368; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017; Papadopoulos KP, 2015, LEUKEMIA LYMPHOMA, V56, P1763, DOI 10.3109/10428194.2014.974040; Papadopoulos KP, 2014, CLIN CANCER RES, V20, P2445, DOI 10.1158/1078-0432.CCR-13-2403; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pollizzi KN, 2015, J CLIN INVEST, V125, P2090, DOI 10.1172/JCI77746; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808; Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035; Pusapati RV, 2016, CANCER CELL, V29, P548, DOI 10.1016/j.ccell.2016.02.018; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Ricoult SJH, 2016, ONCOGENE, V35, P1250, DOI 10.1038/onc.2015.179; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Roy D, 2013, CANCER RES, V73, P2235, DOI 10.1158/0008-5472.CAN-12-1851; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Seront E, 2016, BJU INT, V118, P408, DOI 10.1111/bju.13415; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shapiro GI, 2015, CLIN CANCER RES, V21, P1888, DOI 10.1158/1078-0432.CCR-14-1306; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shimobayashi M, 2016, CELL RES, V26, P7, DOI 10.1038/cr.2015.146; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Shor B, 2010, J BIOL CHEM, V285, P15380, DOI 10.1074/jbc.M109.071639; Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342; Stracka D, 2014, J BIOL CHEM, V289, P25010, DOI 10.1074/jbc.M114.574335; Sun SG, 2015, CANCER CELL, V28, P758, DOI 10.1016/j.ccell.2015.10.004; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang S, 2015, MOL CELL BIOL, V35, P1299, DOI 10.1128/MCB.00306-14; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Weiler M, 2014, P NATL ACAD SCI USA, V111, P409, DOI 10.1073/pnas.1314469111; Wen PY, 2015, NEURO-ONCOLOGY, V17, P1275, DOI 10.1093/neuonc/nov083; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wilhelm K, NATURE; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016; Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023; Zhang LJ, 2016, CELL REP, V14, P1206, DOI 10.1016/j.celrep.2015.12.095; Zhuang GL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003572; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014	143	239	249	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2191	2201		10.1038/onc.2016.363	http://dx.doi.org/10.1038/onc.2016.363			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748764	Green Accepted			2022-12-28	WOS:000399782700001
J	Rada, M; Vasileva, E; Lezina, L; Marouco, D; Antonov, AV; Macip, S; Melino, G; Barlev, NA				Rada, M.; Vasileva, E.; Lezina, L.; Marouco, D.; Antonov, A. V.; Macip, S.; Melino, G.; Barlev, N. A.			Human EHMT2/G9a activates p53 through methylation-independent mechanism	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; GENOTOXIC STRESS; TRANSCRIPTIONAL REGULATION; LYSINE METHYLATION; TUMOR SUPPRESSION; DNA-DAMAGE; G9A; SET7/9; GLP; H3	p53 is a critical tumor suppressor in humans. It functions mostly as a transcriptional factor and its activity is regulated by numerous post-translational modifications. Among different covalent modifications found on p53 the most controversial one is lysine methylation. We found that human G9a (hG9a) unlike its mouse orthologue (mG9a) potently stimulated p53 transcriptional activity. Both ectopic and endogenous hG9a augmented p53-dependent transcription of pro-apoptotic genes, including Bax and Puma, resulting in enhanced apoptosis and reduced colony formation. Significantly, shRNA-mediated knockdown of hG9a attenuated p53-dependent activation of Puma. On the molecular level, hG9a interacted with histone acetyltransferase, p300/CBP, resulting in increased histone acetylation at the promoter of Puma. The bioinformatics data substantiated our findings showing that positive correlation between G9a and p53 expression is associated with better survival of lung cancer patients. Collectively, this study demonstrates that depending on the cellular and organismal context, orthologous proteins may exert both overlapping and opposing functions. Furthermore, this finding has important ramifications on the use of G9a inhibitors in combination with genotoxic drugs to treat p53-positive tumors.	[Rada, M.; Lezina, L.; Marouco, D.; Macip, S.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Vasileva, E.; Lezina, L.; Antonov, A. V.; Barlev, N. A.] Inst Cytol, St Petersburg, Russia; [Antonov, A. V.; Melino, G.] MRC Toxicol Unit, Leicester, Leics, England	University of Leicester; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Barlev, NA (corresponding author), Inst Cytol, Gene Express Lab, St Petersburg 194064, Russia.	nick.a.barlev@gmail.com	Barlev, Nikolai A/K-5268-2017; Macip, Salvador/S-6358-2019; Macip, Salvador/P-4233-2019; Lezina, Larissa/AAO-3574-2020	Barlev, Nikolai A/0000-0001-7111-2446; Macip, Salvador/0000-0003-1963-8840; 	RSF [14-15-00816]; Kurdistan Regional Government (Iraq); MCB RAS programme; Medical Research Council; AIRC [IG15653, MCO9979, IG11955]; Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD); Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	RSF(Russian Science Foundation (RSF)); Kurdistan Regional Government (Iraq); MCB RAS programme; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD)(Fondazione Roma); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr O. Binda (Newcastle University, UK), Dr MR. Stallcup (University of Southern California, USA), Dr C-M Chiang (University of Texas Southwestern Medical Center, USA), Dr SB Seo (Chung-Ang University, Korea), Dr P. Muller (MRC Toxicology Unit, UK) for providing various constructs and reagents. We also thank S Cowley lab (University of Leicester, UK) for providing E14 cells. This work was supported by grants from RSF 14-15-00816 to (E.V. and N.B.); M.R. was supported by a Doctoral Studentship from the Kurdistan Regional Government (Iraq); A.V.A. was supported by MCB RAS programme; G. M. acknowledges the grant support from Medical Research Council, AIRC 2014 IG15653, AIRC 5xmille MCO9979, AIRC 2011 IG11955 and Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD).	Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Bittencourt D, 2012, P NATL ACAD SCI USA, V109, P19673, DOI 10.1073/pnas.1211803109; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Brown SE, 2001, MAMM GENOME, V12, P916, DOI 10.1007/s00335-001-3029-3; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560; Chaturvedi CP, 2012, P NATL ACAD SCI USA, V109, P18845, DOI 10.1073/pnas.1213951109; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081; Dong C, 2012, CANCER CELL, V23, P316; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fedorova OA, 2011, BIOCHEM BIOPH RES CO, V416, P258, DOI 10.1016/j.bbrc.2011.10.126; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Henry RA, 2013, BIOCHEMISTRY-US, V52, P5746, DOI 10.1021/bi400684q; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Lezina L, 2014, CELL DEATH DIFFER, V21, P1889, DOI 10.1038/cdd.2014.108; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Lezina L, 2015, ONCOTARGET, V6, P25843, DOI 10.18632/oncotarget.4584; Liu XY, 2011, P NATL ACAD SCI USA, V108, P1925, DOI 10.1073/pnas.1019619108; Marouco D, 2013, ONCOTARGET, V4, P1556, DOI 10.18632/oncotarget.1436; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Moiseeva TN, 2013, ONCOTARGET, V4, P1338, DOI 10.18632/oncotarget.1060; Mulligan P, 2008, MOL CELL, V32, P718, DOI 10.1016/j.molcel.2008.10.025; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oh ST, 2014, FEBS LETT, V588, P685, DOI 10.1016/j.febslet.2014.01.039; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Purcell DJ, 2011, J BIOL CHEM, V286, P41963, DOI 10.1074/jbc.M111.298463; Shankar SR, 2013, EPIGENETICS-US, V8, P16, DOI 10.4161/epi.23331; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Trojer P, 2009, J BIOL CHEM, V284, P8395, DOI 10.1074/jbc.M807818200; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Weiss T, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-7; Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012; Yu YX, 2012, MOL CELL, V46, P7, DOI 10.1016/j.molcel.2012.01.019; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013	54	22	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					922	932		10.1038/onc.2016.258	http://dx.doi.org/10.1038/onc.2016.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452519	Green Submitted			2022-12-28	WOS:000394169100005
J	Chouaib, S; Noman, MZ; Kosmatopoulos, K; Curran, MA				Chouaib, S.; Noman, M. Z.; Kosmatopoulos, K.; Curran, M. A.			Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer	ONCOGENE			English	Review							CYTOTOXIC T-LYMPHOCYTES; REGULATORY T; INDUCIBLE FACTOR-1-ALPHA; TUMOR MICROENVIRONMENT; INDUCED AUTOPHAGY; INTRATUMORAL INFILTRATION; CELL CYTOTOXICITY; SUPPRESSOR-CELLS; EXTRACELLULAR PH; GENE-EXPRESSION	Tumors use several strategies to evade the host immune response, including creation of an immune-suppressive and hostile tumor environment. Tissue hypoxia due to inadequate blood supply is reported to develop very early during tumor establishment. Hypoxic stress has a strong impact on tumor cell biology. In particular, tissue hypoxia contributes to therapeutic resistance, heterogeneity and progression. It also interferes with immune plasticity, promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this regard, manipulating host-tumor interactions in the context of the hypoxic tumor microenvironment may be important in preventing or reverting malignant conversion. We will discuss how tumor microenvironmentdriven transient compositional tumor heterogeneity involves hypoxic stress. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of conventional therapies as well as cancer immunotherapy. Thus, understanding how tumor and stromal cells respond to hypoxia will allow for the design of innovative cancer therapies that can overcome these barriers. A better understanding of hypoxia-dependent mechanisms involved in the regulation of immune tolerance could lead to new strategies to enhance antitumor immunity. Therefore, discovery and validation of therapeutic targets derived from the hypoxic tumor microenvironment is of major importance. In this context, critical hypoxia-associated pathways are attractive targets for immunotherapy of cancer. In this review, we summarize current knowledge regarding the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on therapeutic resistance and immune suppression. We emphasize mechanisms of manipulating hypoxic stress and its associated pathways, which may support the development of more durable and successful cancer immunotherapy approaches in the future.	[Chouaib, S.; Noman, M. Z.] INSERM, UMR1186, Lab Integrat Tumor Immunol & Genet Oncol, Villejuif, France; [Chouaib, S.; Noman, M. Z.] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, INSERM, Villejuif, France; [Kosmatopoulos, K.] Vaxon Biotech, Paris, France; [Curran, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U1186, 39 Camille Desmoulins, F-94805 Villejuif, Ile De France, France.	salem.chouaib@gustaveroussy.fr	NOMAN, Muhammmad Zaeem/AAJ-1466-2021; Noman, Muhammad zaeem/AAF-8483-2020; Chouaib, Salem/F-7939-2016; NOMAN, Muhammmad Zaeem/AAJ-1465-2021	NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; Curran, Michael/0000-0003-4996-7207	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allavena P, 2012, CLIN EXP IMMUNOL, V167, P195, DOI 10.1111/j.1365-2249.2011.04515.x; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6; Bellone M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00231; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Blay J, 1997, CANCER RES, V57, P2602; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Cary, 2014, NEURO-ONCOLOGY, V16, pII3; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Chafe SC, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1048955; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; DROGE W, 1987, CELL IMMUNOL, V108, P405, DOI 10.1016/0008-8749(87)90223-1; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Hamai A, 2010, TISSUE ANTIGENS, V75, P1, DOI 10.1111/j.1399-0039.2009.01401.x; Hasmim M, 2013, J IMMUNOL, V191, P5802, DOI 10.4049/jimmunol.1302140; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Hoskin DW, 2008, INT J ONCOL, V32, P527; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780; Kotsakis A, 2012, ANN ONCOL, V23, P442, DOI 10.1093/annonc/mdr396; Kryczek I, 2011, J IMMUNOL, V186, P4388, DOI 10.4049/jimmunol.1003251; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee JH, 2015, IMMUNITY, V42, P1062, DOI 10.1016/j.immuni.2015.05.016; Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347; Lin SS, 2012, CANCER SCI, V103, P904, DOI 10.1111/j.1349-7006.2012.02259.x; Lugini L, 2006, CANCER RES, V66, P3629, DOI 10.1158/0008-5472.CAN-05-3204; Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Lukashev D, 2006, J IMMUNOL, V177, P4962, DOI 10.4049/jimmunol.177.8.4962; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mellor AL, 2008, NAT REV IMMUNOL, V8, P74, DOI 10.1038/nri2233; Messai Y, 2015, AUTOPHAGY; Messai Y, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985951; Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303; Metelo AM, 2015, ONCOTARGET, V6, P23036, DOI 10.18632/oncotarget.4564; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609; Nakagawa Y, 2015, IMMUNOL LETT, V167, P72, DOI 10.1016/j.imlet.2015.07.003; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Noman MZ, 2016, CANCER LETT, V380, P257, DOI 10.1016/j.canlet.2015.10.026; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Noman MZ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954463; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Noman MZ, 2012, AUTOPHAGY, V8, P704, DOI 10.4161/auto.19572; Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Noman MZ, 2011, B CANCER, V98, pE19, DOI 10.1684/bdc.2010.1295; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Ohta A, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00027; Palazon A, 2012, CANCER DISCOV, V2, P608, DOI 10.1158/2159-8290.CD-11-0314; Payen VL, 2016, CELL MOL LIFE SCI, V73, P1333, DOI 10.1007/s00018-015-2098-5; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; RATNER S, 1990, J NATL CANCER I, V82, P612, DOI 10.1093/jnci/82.7.612; REDEGELD F, 1991, J IMMUNOL, V147, P3638; Robbins JR, 2005, J PHYSIOL-LONDON, V564, P131, DOI 10.1113/jphysiol.2004.081893; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154; Sarkar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064835; Scardino A, 2002, J IMMUNOL, V168, P5900, DOI 10.4049/jimmunol.168.11.5900; Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Semenza GL, 2009, CURR PHARM DESIGN, V15, P3839, DOI 10.2174/138161209789649402; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sitkovsky MV, 2008, BLOOD, V111, P5424, DOI 10.1182/blood-2008-03-143990; Takehara H, 2006, DIGEST DIS SCI, V51, P2188, DOI 10.1007/s10620-006-9436-2; Tan S, 1998, J NEUROPATH EXP NEUR, V57, P544, DOI 10.1097/00005072-199806000-00002; Terry Stephane, 2015, Oncoscience, V2, P841; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thiel M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000853; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924; Widmer DS, 2013, J INVEST DERMATOL, V133, P2436, DOI 10.1038/jid.2013.115; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wolter F, 2015, J HEPATOL, V63, P1334, DOI 10.1016/j.jhep.2015.08.008; Xia Y, 2012, EUR J MED CHEM, V49, P24, DOI 10.1016/j.ejmech.2012.01.033; Yamada N, 2012, INT J ONCOL, V41, P2005, DOI 10.3892/ijo.2012.1630; Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107; Zhang JJ, 2016, J AM SOC NEPHROL, V27, P92, DOI 10.1681/ASN.2014121248	100	200	204	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					439	445		10.1038/onc.2016.225	http://dx.doi.org/10.1038/onc.2016.225			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345407	Green Accepted			2022-12-28	WOS:000394166700001
J	Nezu, Y; Hagiwara, K; Yamamoto, Y; Fujiwara, T; Matsuo, K; Yoshida, A; Kawai, A; Saito, T; Ochiya, T				Nezu, Y.; Hagiwara, K.; Yamamoto, Y.; Fujiwara, T.; Matsuo, K.; Yoshida, A.; Kawai, A.; Saito, T.; Ochiya, T.			miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma	ONCOGENE			English	Article							ROUND-CELL LIPOSARCOMA; MICRORNA SIGNATURES; EXPRESSION ANALYSIS; COLORECTAL-CANCER; FUS/TLS-CHOP; METASTASIS; INVASION; IDENTIFICATION; GENE; THROMBOSPONDIN-2	Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.	[Nezu, Y.; Hagiwara, K.; Yamamoto, Y.; Ochiya, T.] Natl Canc Ctr, Div Mol & Cellular Med, Res Inst, Tokyo, Japan; [Nezu, Y.; Matsuo, K.; Saito, T.] Yokohama City Univ, Grad Sch Med, Dept Orthopaed Surg, Yokohama, Kanagawa, Japan; [Fujiwara, T.] Okayama Univ, Dept Orthopaed Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Yoshida, A.] Natl Canc Ctr, Div Pathol, Tokyo, Japan; [Yoshida, A.] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Kawai, A.] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan	National Cancer Center - Japan; Yokohama City University; Okayama University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Ochiya, T (corresponding author), Natl Canc Ctr, Div Mol & Cellular Med, Res Inst, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019		Ministry of Education, Culture, Sports, Science, and Technology; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio); Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program); Council for Science and Technology Policy; Japanese Ministry of Education, Culture, Sports, Science, and Technology	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation); Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Council for Science and Technology Policy(Council for Science and Technology Policy (CSTP)); Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Masahiko Kuroda for kindly providing MLS cell lines. We also acknowledge Luc Gailhouste for his careful review of the manuscript. This work was supported in part by a grant-in-aid for the third term of a comprehensive 10-year strategy for cancer control, a grant-in-aid for scientific research on priority area cancers from the Ministry of Education, Culture, Sports, Science, and Technology, and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), the Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program) initiated by the Council for Science and Technology Policy, and a grant-in-aid for Scientific Research on Innovative Areas (functional machinery for non-coding RNAs) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borjigin N, 2012, BIOCHEM BIOPH RES CO, V427, P355, DOI 10.1016/j.bbrc.2012.09.063; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910; Chijiwa Tsuyoshi, 2009, Int J Oncol, V34, P5; Chou J, 2013, CELL CYCLE, V12, P3262, DOI 10.4161/cc.26087; De Cecco L, 2014, ONCOTARGET, V5, P5965, DOI 10.18632/oncotarget.2023; Dei Tos AP, 2014, HISTOPATHOLOGY, V64, P38, DOI 10.1111/his.12311; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fiore M, 2007, CANCER-AM CANCER SOC, V109, P2522, DOI 10.1002/cncr.22720; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P229, DOI 10.1309/AJCP90YNOKBAGCDM; Fujiwara T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/592868; Gits CMM, 2014, INT J CANCER, V135, P348, DOI 10.1002/ijc.28694; Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4; Guan ZH, 2015, ONCOTARGETS THER, V8, P125, DOI 10.2147/OTT.S72722; Haniball J, 2011, SARCOMA, V2011, P1; He YQ, 2015, AM J CANCER RES, V5, P1382; Kim HS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-205; KNIGHT JC, 1995, CANCER RES, V55, P24; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee DH, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.10; Li Y, 2015, ONCOTARGET, V6, P2421, DOI 10.18632/oncotarget.2965; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Matos AR, 2013, EXP MOL PATHOL, V94, P438, DOI 10.1016/j.yexmp.2013.02.002; Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284; Moreau LC, 2012, ANN SURG ONCOL, V19, P1081, DOI 10.1245/s10434-011-2127-z; Munding JB, 2012, INT J CANCER, V131, pE86, DOI 10.1002/ijc.26466; Nabeshima A, 2015, BRIT J CANCER, V112, P547, DOI 10.1038/bjc.2014.637; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Nakamura M, 2008, MOL MED REP, V1, P423; Oda Y, 2005, J PATHOL, V207, P410, DOI 10.1002/path.1848; Pei H, 2015, MOL CELL BIOCHEM, V400, P245, DOI 10.1007/s11010-014-2281-2; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Renner M, 2012, GENE CHROMOSOME CANC, V51, P982, DOI 10.1002/gcc.21980; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Sato H, 2010, CANCER SCI, V101, P843, DOI 10.1111/j.1349-7006.2010.01498.x; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Schneider-Stock R, 2003, J PATHOL, V199, P517, DOI 10.1002/path.1315; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004; Smith SM, 2015, J SURG ONCOL, V111, P520, DOI 10.1002/jso.23882; Smith TA, 1996, AM J SURG PATHOL, V20, P171, DOI 10.1097/00000478-199602000-00005; Sun RC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-225; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Tokunaga T, 1999, BRIT J CANCER, V79, P354, DOI 10.1038/sj.bjc.6690056; Tsukamoto O, 2014, GYNECOL ONCOL, V132, P715, DOI 10.1016/j.ygyno.2014.01.029; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Wu CW, 2014, CLIN CANCER RES, V20, P2994, DOI 10.1158/1078-0432.CCR-13-1750; Wu WY, 2014, MOL CELL BIOCHEM, V388, P249, DOI 10.1007/s11010-013-1916-z; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zen K, 2012, MED RES REV, V32, P326, DOI 10.1002/med.20215	58	33	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6177	6188		10.1038/onc.2016.157	http://dx.doi.org/10.1038/onc.2016.157			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157622	Green Published, hybrid			2022-12-28	WOS:000388857700003
J	Das, CM; Taylor, P; Gireud, M; Singh, A; Lee, D; Fuller, G; Ji, L; Fangusaro, J; Rajaram, V; Goldman, S; Eberhart, C; Gopalakrishnan, V				Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Fuller, G.; Ji, L.; Fangusaro, J.; Rajaram, V.; Goldman, S.; Eberhart, C.; Gopalakrishnan, V.			The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation (vol 32, pg 1691, 2012)	ONCOGENE			English	Correction														Fuller, Gregory/0000-0001-9447-2647				DAS CM, 2012, ONCOGENE, V32, P1691	1	2	3	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6153	6154		10.1038/onc.2016.141	http://dx.doi.org/10.1038/onc.2016.141			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27425592	Bronze			2022-12-28	WOS:000388509800011
J	Wakim, J; Arman, E; Becker-Herman, S; Kramer, MP; Bakos, E; Shachar, I; Elson, A				Wakim, J.; Arman, E.; Becker-Herman, S.; Kramer, M. P.; Bakos, E.; Shachar, I.; Elson, A.			The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia	ONCOGENE			English	Article							RECEPTOR-TYPE-O; HEPATOCELLULAR-CARCINOMA; MOLECULAR-CLONING; MOUSE MODEL; EXPRESSION; CLL; GENE; KINASE; TRANSFORMATION; METHYLATION	The tyrosine phosphatase PTPROt is a suggested tumor suppressor (TS) in B-cell chronic lymphocytic leukemia (CLL), and its expression is reduced in this disease. In order to examine how reduced PTPROt expression affects CLL in vivo we induced CLL in PTPROt-targeted mice. Unexpectedly, loss of both Ptprot alleles delayed disease detection and progression and lengthened survival relative to mice carrying two intact alleles, indicating that PTPROt fulfills a novel tumor-promoting role in CLL. Tumor cells from mice lacking PTPROt exhibited reduced B-cell receptor (BCR)-induced signaling, as well as increased apoptosis and autophagy. Inhibition of BCR/Src signaling in CLL cells induced their apoptosis, indicating that these findings are linked causally. These results suggest a cell-autonomous mechanism for the weakened CLL phenotype of PTPROt-deficient mice and uncover non-redundant roles for PTPROt in support of BCR signaling and survival of CLL cells. In contrast, loss of only one Ptprot allele induced earlier detection and progression of CLL and reduced survival, consistent with a tumor-suppressing role for PTPROt. Tumor cells from mice lacking one or both Ptprot allele exhibited increased interleukin-10 (IL-10) expression and signaling, factors known to support CLL; cells lacking one Ptprot alleles exhibited normal BCR signaling and cell death rates. We conclude that loss of one Ptprot allele promotes CLL, most likely by activating IL-10 signaling. Loss of both Ptprot alleles also reduces BCR signaling and increases cell death rates, offsetting the IL-10 effects and reducing the severity of the disease. PTPROt thus functions as an obligate haploinsufficient TS in CLL, where its expression levels determine its role as a promoter or inhibitor of the tumorigenic process in mice. Partial loss of PTPROt generates the strongest disease phenotype, suggesting that its intermediate expression levels in CLL are selected for.	[Wakim, J.; Arman, E.; Elson, A.] Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel; [Becker-Herman, S.; Kramer, M. P.; Bakos, E.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel.	ari.elson@weizmann.ac.il	Kramer, Matthias/L-1782-2016; Kramer, Matthias P/A-6224-2009	Kramer, Matthias/0000-0002-0289-5261; Elson, Ari/0000-0001-9808-9135	German-Israeli Helmholtz Research School in Cancer Biology; Israel Cancer Research Foundation; Minerva Foundation; Federal German Ministry for Education and Research; Kekst Family Center for Medical Genetics	German-Israeli Helmholtz Research School in Cancer Biology; Israel Cancer Research Foundation; Minerva Foundation; Federal German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Kekst Family Center for Medical Genetics	We thank Professor Carlo Croce for the E mu-TCL1 mice, Professor Zvulun Elazar for the anti-LC3 antibodies, Dr Rebecca Haffner-Krausz for help in preparing PTPROt-targeted mice, Ms Ofira Higfa and Mr Neriah Sharabi for expert animal care, Dr Ron Rotkopf for help with statistical analyses, Dr Ayala Sharp and Mr Eitan Ariel for help with FACS analyses, and Dr Gil Hornung for assistance with analysis of IL-10 expression. JW is supported in part by a studentship from the German-Israeli Helmholtz Research School in Cancer Biology. This study was supported by project grants from the Israel Cancer Research Foundation, from the Minerva Foundation with funds from the Federal German Ministry for Education and Research, and from the Kekst Family Center for Medical Genetics, to AE. AE is the incumbent of the Marshall and Renette Ezralow Professorial Chair.	Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Amoui M, 2004, AM J PHYSIOL-CELL PH, V287, pC874, DOI 10.1152/ajpcell.00294.2003; Amoui M, 2003, J BIOL CHEM, V278, P44273, DOI 10.1074/jbc.M303933200; Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Burger JA, 2013, TRENDS IMMUNOL, V34, P592, DOI 10.1016/j.it.2013.07.002; Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821; Chong SY, 2001, GENES IMMUN, V2, P239, DOI 10.1038/sj.gene.6363773; DiLillo DJ, 2013, LEUKEMIA, V27, P170, DOI 10.1038/leu.2012.165; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Fayad L, 2001, BLOOD, V97, P256, DOI 10.1182/blood.V97.1.256; Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388; Gallardo M, 2015, CANCER CELL, V28, P486, DOI 10.1016/j.ccell.2015.09.001; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Hermiston ML, 2009, IMMUNOL REV, V228, P288, DOI 10.1111/j.1600-065X.2008.00752.x; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Hsu SH, 2013, J CELL BIOCHEM, V114, P1810, DOI 10.1002/jcb.24525; Iacovelli S, 2015, BLOOD, V125, P1578, DOI 10.1182/blood-2014-07-587790; Jones JA, 2014, BLOOD, V123, P1455, DOI 10.1182/blood-2013-09-453092; Juszczynski P, 2009, BLOOD, V114, P5315, DOI 10.1182/blood-2009-02-204362; Kara IO, 2007, ADV THER, V24, P29, DOI 10.1007/BF02849990; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lau KHW, 2012, AM J PHYSIOL-CELL PH, V302, pC1676, DOI 10.1152/ajpcell.00042.2012; Lau KHW, 2006, J CELL BIOCHEM, V97, P940, DOI 10.1002/jcb.20667; Levy-Apter E, 2014, J BIOL CHEM, V289, P36048, DOI 10.1074/jbc.M114.603548; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Motiwala T, 2015, LEUKEMIA, V29, P1350, DOI 10.1038/leu.2014.341; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Motiwala T, 2011, BLOOD, V118, P6132, DOI 10.1182/blood-2011-01-323147; Motiwala T, 2010, J CELL BIOCHEM, V110, P846, DOI 10.1002/jcb.22593; Motiwala T, 2009, J BIOL CHEM, V284, P455, DOI 10.1074/jbc.M802840200; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Saulep-Easton D, 2016, LEUKEMIA, V30, P163, DOI 10.1038/leu.2015.174; Saulep-Easton D, 2014, LEUKEMIA, V28, P2005, DOI 10.1038/leu.2014.105; Sheng MHC, 2009, J BIOL CHEM, V284, P11531, DOI 10.1074/jbc.M808324200; Simonetti G, 2014, BLOOD, V124, P1010, DOI 10.1182/blood-2014-05-577122; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Wang ZD, 2000, J IMMUNOL METHODS, V233, P167, DOI 10.1016/S0022-1759(99)00184-2; White HN, 1998, EUR J IMMUNOL, V28, P3268, DOI 10.1002/(SICI)1521-4141(199810)28:10&lt;3268::AID-IMMU3268&gt;3.0.CO;2-F; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wu LW, 1996, BIOCHEM J, V316, P515, DOI 10.1042/bj3160515; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zanesi N, 2012, CURR PHARM DESIGN, V18, P3363, DOI 10.2174/138161212801227104	51	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3686	3694		10.1038/onc.2016.523	http://dx.doi.org/10.1038/onc.2016.523			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28166196				2022-12-28	WOS:000404349700004
J	Prange, KHM; Mandoli, A; Kuznetsova, T; Wang, SY; Sotoca, AM; Marneth, AE; van der Reijden, BA; Stunnenberg, HG; Martens, JHA				Prange, K. H. M.; Mandoli, A.; Kuznetsova, T.; Wang, S-Y; Sotoca, A. M.; Marneth, A. E.; van der Reijden, B. A.; Stunnenberg, H. G.; Martens, J. H. A.			MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia	ONCOGENE			English	Article							MLL FUSION PROTEINS; H3K79 METHYLATION; TRANSCRIPTION FACTORS; HOX GENES; INHIBITION; CHROMATIN; BET; EXPRESSION; COMPLEX; MEIS1	In 11q23 leukemias, the N-terminal part of the mixed lineage leukemia (MLL) gene is fused to 460 different partner genes. In order to define a core set of MLL rearranged targets, we investigated the genome-wide binding of the MLL-AF9 and MLL-AF4 fusion proteins and associated epigenetic signatures in acute myeloid leukemia (AML) cell lines THP-1 and MV4-11. We uncovered both common as well as specific MLL-AF9 and MLL-AF4 target genes, which were all marked by H3K79me2, H3K27ac and H3K4me3. Apart from promoter binding, we also identified MLL-AF9 and MLL-AF4 binding at specific subsets of non-overlapping active distal regulatory elements. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, which represents part of the RUNX1 gene program and constitutes of CD34(+) and monocyte-specific genes. Comparing these data sets identified several zinc finger transcription factors (TFs) as potential MLL-AF9 co-regulators. Together, these results suggest that MLL fusions collaborate with specific subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs. Oncogene (2017)	[Prange, K. H. M.; Mandoli, A.; Kuznetsova, T.; Wang, S-Y; Sotoca, A. M.; Stunnenberg, H. G.; Martens, J. H. A.] Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl 26, NL-6500 HB Nijmegen, Netherlands; [Marneth, A. E.; van der Reijden, B. A.] Radboud Univ Nijmegen, Dept Lab Med, Lab Hematol, Med Ctr, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Martens, JHA (corresponding author), Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl 26, NL-6500 HB Nijmegen, Netherlands.	j.martens@ncmls.ru.nl	Martens, Joost/D-4966-2012; Stunnenberg, Hendrik G./D-6875-2012; van der Reijden, Bert A/A-3543-2014; Marneth, Anna/G-6236-2016	Martens, Joost/0000-0003-2008-6537; Stunnenberg, Hendrik G./0000-0002-0066-1576; Kuznetsova, Tatyana/0000-0001-7533-3334; Prange, Koen/0000-0002-9835-1735; Marneth, Anna/0000-0001-9065-0581; Wang, Shuang-Yin/0000-0001-9683-4103	Dutch Cancer Foundation [KWF KUN 2009-4527, KUN 2011-4937]; Netherlands Organization for Scientific Research (NWO-VIDI)	Dutch Cancer Foundation(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO))	We thank A Singh, A Brinkman, G Georgiou, S van Heeringen and K Francoijs for bioinformatic support. This work was supported by the Dutch Cancer Foundation (KWF KUN 2009-4527 and KUN 2011-4937) and Netherlands Organization for Scientific Research (NWO-VIDI to JHAM).	Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Benito JM, 2015, CELL REP, V13, P2715, DOI 10.1016/j.celrep.2015.12.003; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Bousquet M, 2013, MOL CANCER RES, V11, P912, DOI 10.1158/1541-7786.MCR-13-0002-T; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Erben P, 2010, HAEMATOL-HEMATOL J, V95, P738, DOI 10.3324/haematol.2009.016345; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Geng HM, 2012, CANCER DISCOV, V2, P1004, DOI 10.1158/2159-8290.CD-12-0208; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Kuntimaddi A, 2015, CELL REP, V11, P808, DOI 10.1016/j.celrep.2015.04.004; LANGE B, 1987, BLOOD, V70, P192; Leach BI, 2013, STRUCTURE, V21, P176, DOI 10.1016/j.str.2012.11.011; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Mandoli A, 2014, GENOM DATA, V2, P170, DOI 10.1016/j.gdata.2014.06.014; Mandoli A, 2014, LEUKEMIA, V28, P770, DOI 10.1038/leu.2013.257; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; Merkenschlager M, 2013, CELL, V152, P1285, DOI 10.1016/j.cell.2013.02.029; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Okuda H, 2014, NUCLEIC ACIDS RES, V42, P4241, DOI 10.1093/nar/gkt1394; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Patel B, 2014, LEUKEMIA, V28, P349, DOI 10.1038/leu.2013.158; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Pession A, 2003, ONCOGENE, V22, P8671, DOI 10.1038/sj.onc.1207125; Phillips-Cremins JE, 2013, MOL CELL, V50, P461, DOI 10.1016/j.molcel.2013.04.018; Pospisil V, 2011, EMBO J, V30, P4450, DOI 10.1038/emboj.2011.317; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Quentmeier H, 2004, LEUKEMIA LYMPHOMA, V45, P567, DOI 10.1080/10428190310001609942; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Rousseau M, 2013, NUCLEIC ACIDS RES, V42; Rousseau M, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r60; Sotoca AM, 2016, ONCOGENE, V35, P1965, DOI 10.1038/onc.2015.261; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; van Heeringen SJ, 2011, BIOINFORMATICS, V27, P270, DOI 10.1093/bioinformatics/btq636; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Zhao XiuHai, 2014, Forest Ecosystems, V1, P8, DOI 10.1186/2197-5620-1-8	65	58	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3346	3356		10.1038/onc.2016.488	http://dx.doi.org/10.1038/onc.2016.488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28114278	Green Published, hybrid			2022-12-28	WOS:000402869800013
J	Tsuruta-Kishino, T; Koya, J; Kataoka, K; Narukawa, K; Sumitomo, Y; Kobayashi, H; Sato, T; Kurokawa, M				Tsuruta-Kishino, T.; Koya, J.; Kataoka, K.; Narukawa, K.; Sumitomo, Y.; Kobayashi, H.; Sato, T.; Kurokawa, M.			Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASMS; GENOMIC INSTABILITY; ACTIVATING MUTATION; PROGENITOR CELLS; GENETIC-ANALYSIS; MOUSE MODEL; DNA-DAMAGE	As leukemic transformation of myeloproliferative neoplasms (MPNs) worsens the clinical outcome, reducing the inherent risk of the critical event in MPN cases could be beneficial. Among genetic alterations concerning the transformation, the frequent one is TP53 mutation. Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase. The leukemic mice had severe anemia, hepatosplenomegaly, pulmonary hemorrhage and expansion of dysplastic erythroid progenitors. Primitive leukemia cells (c-kit+ Sca1+ Lin-(KSL) and CD34-CD16/32c- kit+ Sca1-Lin-(megakaryocyte-erythroid progenitor; MEP)) and erythroid progenitors (CD71+) from Jak2 V617F-transduced p53-null leukemic mice had leukemia-initiating capacity, however, myeloid differentiated populations (Mac-1+) could not recapitulate the disease. Interestingly, recipients transplanted with CD71+ cells rapidly developed erythroid leukemia, which was in sharp contrast to leukemic KSL cells to cause lethal leukemia after the polycythemic state. The leukemic CD71+ cells were more sensitive to INCB18424, a potent JAK inhibitor, than KSL cells. p53 restoration could ameliorate Jak2 V617F-transduced p53-null erythroleukemia. Taken together, our results show that p53 loss is sufficient for inducing leukemic transformation in Jak2 V617Fpositive MPN.	[Tsuruta-Kishino, T.; Koya, J.; Kataoka, K.; Narukawa, K.; Sumitomo, Y.; Kobayashi, H.; Sato, T.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan; [Sumitomo, Y.] Kyowa Hakko Kirin Co, Oncol Res Labs, Machida, Tokyo, Japan; [Sato, T.] Univ Tokyo Hosp, Dept Transfus Med, Bunkyo Ku, Tokyo, Japan; [Kurokawa, M.] Univ Tokyo Hosp, Dept Cell Therapy & Transplantat, Bunkyo Ku, Tokyo, Japan	University of Tokyo; Kyowa Kirin Ltd; University of Tokyo; University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Kataoka, Keisuke/AAS-2546-2020	Kataoka, Keisuke/0000-0002-8263-9902; Koya, Junji/0000-0002-0605-1226; Sato, Tomohiko/0000-0002-8244-075X	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Kitamura for Plat-E packaging cells; H Nakauchi and M Onodera for pGCDNsam-IRES-EGFP and Kusabira Orange retroviral vector; S Aizawa for p53 knockout mice (RIKEN BRC, Acc. no. CDB 0001K); A Berns for p53 conditional knockout mice; J Takeda for Mx1-Cre transgenic mice; F Ueki, R Takizawa-Toyama and Y Oikawa for expert for technical assistance. This study was supported by the Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; [Anonymous], 2015, JAKAVI TABLETS 5 MG; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beer PA, 2010, BLOOD, V115, P2891, DOI 10.1182/blood-2009-08-236596; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Chen JC, 2008, EXP HEMATOL, V36, P1236, DOI 10.1016/j.exphem.2008.04.012; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Santos Leonardo Caires dos, 2011, Rev. Bras. Hematol. Hemoter., V33, P417, DOI 10.5581/1516-8484.20110116; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556; Harutyunyan A, 2011, NEW ENGL J MED, V364, P488, DOI 10.1056/NEJMc1012718; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kennedy JA, 2013, BLOOD, V121, P2725, DOI 10.1182/blood-2012-10-464248; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kumar C Chandra, 2011, Genes Cancer, V2, P95, DOI 10.1177/1947601911408076; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lee HJ, 2013, CLIN CANCER RES, V19, P327, DOI 10.1158/1078-0432.CCR-12-2087; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Marino S, 2000, GENE DEV, V14, P994; Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063; Mullally A, 2012, BLOOD, V120, P166, DOI 10.1182/blood-2012-01-402396; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Nakatake M, 2012, ONCOGENE, V31, P1323, DOI 10.1038/onc.2011.313; Nam C, 2010, HISTOL HISTOPATHOL, V25, P485, DOI 10.14670/HH-25.485; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pant V, 2012, BLOOD, V120, P5118, DOI 10.1182/blood-2012-05-356014; Pei SS, 2012, BEST PRACT RES CL HA, V25, P415, DOI 10.1016/j.beha.2012.10.003; Peller S, 2003, HUM MUTAT, V21, P277, DOI 10.1002/humu.10190; Pellicano F, 2014, STEM CELLS, V32, P1373, DOI 10.1002/stem.1678; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Rampal R, 2014, P NATL ACAD SCI USA, V111, pE5401, DOI 10.1073/pnas.1407792111; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Shin DM, 2001, CANCER EPIDEM BIOMAR, V10, P603; Tefferi A, 2012, BLOOD, V119, P2721, DOI 10.1182/blood-2011-11-395228; TeKippe M, 2003, EXP HEMATOL, V31, P521, DOI 10.1016/S0301-472X(03)00072-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Xu HM, 2012, BLOOD, V120, P3089, DOI 10.1182/blood-2012-01-405332; Zhang SJ, 2012, BLOOD, V119, P4480, DOI 10.1182/blood-2011-11-390252; Zhao WK, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-15; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	60	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3300	3311		10.1038/onc.2016.478	http://dx.doi.org/10.1038/onc.2016.478			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068330				2022-12-28	WOS:000402869800009
J	Swidnicka-Siergiejko, AK; Gomez-Chou, SB; Cruz-Monserrate, Z; Deng, D; Liu, Y; Huang, H; Ji, B; Azizian, N; Daniluk, J; Lu, W; Wang, H; Maitra, A; Logsdon, CD				Swidnicka-Siergiejko, A. K.; Gomez-Chou, S. B.; Cruz-Monserrate, Z.; Deng, D.; Liu, Y.; Huang, H.; Ji, B.; Azizian, N.; Daniluk, J.; Lu, W.; Wang, H.; Maitra, A.; Logsdon, C. D.			Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53	ONCOGENE			English	Article							FACTOR-KAPPA-B; ACINAR DIFFERENTIATION; DUCTAL ADENOCARCINOMAS; MICE; OVEREXPRESSION; CELLS; ACTIVATION; EXPRESSION; INDUCTION; NEOPLASMS	Chronic inflammation (CI) is a risk factor for pancreatic cancer (PC) including the most common type, ductal adenocarcinoma (PDAC), but its role and the mechanisms involved are unclear. To investigate the role of CI in PC, we generated genetic mouse models with pancreatic specific CI in the presence or absence of TP53. Mice were engineered to express either cyclooxygenase-2 (COX-2) or I kappa B kinase-2 (IKK2), and TP53(+/+) or TP53(f/f) specifically in adult pancreatic acinar cells by using a full-length pancreatic elastase promoter-driven Cre. Animals were followed for > 80 weeks and pancreatic lesions were evaluated histologically and immunohistochemically. The presence of K-ras mutations was assessed by direct sequencing, locked nuclei acid (LNA)-based PCR, and immunohistochemistry. We observed that sustained COX-2/IKK2 expression caused histological abnormalities of pancreas, including increased immune cell infiltration, proliferation rate and DNA damage. A minority of animals with CI developed pre-neoplastic lesions, but cancer was not observed in any TP53(+/+) animals within 84 weeks. In contrast, all animals with CI-lacking TP53 developed various subtypes of PC, including acinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks. No evidence of K-ras mutations was observed. Variations in the activity of the Hippo, pERK and c-Myc pathways were found in the diverse cancer subtypes. In summary, chronic inflammation is extremely inefficient at inducing PC in the presence of TP53. However, in the absence of TP53, CI leads to the development of several rare K-ras-independent forms of PC, with infrequent PDAC. This may help explain the rarity of PDAC in persons with chronic inflammatory conditions.	[Swidnicka-Siergiejko, A. K.; Gomez-Chou, S. B.; Deng, D.; Liu, Y.; Huang, H.; Ji, B.; Azizian, N.; Daniluk, J.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 1906,1515 Holcombe Blvd, Houston, TX 77030 USA; [Swidnicka-Siergiejko, A. K.; Daniluk, J.] Univ Bialystok, Dept Gastroenterol & Internal Med, Bialystok, Poland; [Cruz-Monserrate, Z.] Ohio State Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Wexner Med Ctr, Columbus, OH 43210 USA; [Huang, H.] Second Mil Med Univ, Shanghai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Ji, B.] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Lu, W.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; [Wang, H.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Bialystok; University System of Ohio; Ohio State University; Naval Medical University; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Logsdon, CD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 1906,1515 Holcombe Blvd, Houston, TX 77030 USA.	clogsdon@mdanderson.org	Daniluk, Jaroslaw/T-3437-2018	Daniluk, Jaroslaw/0000-0002-0787-1461; Cruz-Monserrate, Zobeida/0000-0003-0849-655X; , Agnieszka/0000-0001-6577-5796; azizian, nancy/0000-0002-1158-0608	Lockton Endowment;  [NIH-DK05206];  [AA020822]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020822] Funding Source: NIH RePORTER	Lockton Endowment; ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Bogdan Czerniak, Dr Tadeusz Majewski and Jolanta Bondaruk from Department of Pathology and Todd Moore from Department of Surgery, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA for technical support. Grant support: NIH-DK05206, AA020822 and The Lockton Endowment (to CDL).	Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Cho CH, 2012, ADV DIAGNOSIS THERAP; Colby JK, 2008, NEOPLASIA, V10, P782, DOI 10.1593/neo.08330; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; Feldmann G, 2011, CANCER BIOL THER, V11, P959, DOI 10.4161/cbt.11.11.15534; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hill R, 2010, CANCER RES, V70, P7114, DOI 10.1158/0008-5472.CAN-10-1649; Holmes C, 2007, STEM CELLS, V25, P1339, DOI 10.1634/stemcells.2006-0644; Hu Y, 2009, MUTAT RES-GEN TOX EN, V677, P27, DOI 10.1016/j.mrgentox.2009.05.003; Huang H, 2014, ONCOGENE, V33, P532, DOI 10.1038/onc.2012.619; Huang HJ, 2013, GASTROENTEROLOGY, V144, P202, DOI 10.1053/j.gastro.2012.09.059; Ji BA, 2008, GENESIS, V46, P390, DOI 10.1002/dvg.20411; Jiao YC, 2014, J PATHOL, V232, P428, DOI 10.1002/path.4310; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kamei K, 2006, GENESIS, V44, P177, DOI 10.1002/dvg.20199; Kwon MJ, 2015, PANCREAS, V44, P484, DOI 10.1097/MPA.0000000000000280; La Rosa S, 2016, VIRCHOWS ARCH, V468, P289, DOI 10.1007/s00428-015-1882-9; La Rosa S, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00041; Ling SB, 2014, ONCOL LETT, V7, P1747, DOI 10.3892/ol.2014.2003; Liu B, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0260-7; Marrache F, 2008, GASTROENTEROLOGY, V135, P1277, DOI 10.1053/j.gastro.2008.06.078; Morton JP, 2008, AM J PATHOL, V172, P1081, DOI 10.2353/ajpath.2008.070778; Morvaridi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16759; Murata M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/623019; Myant K, 2015, CELL REP, V12, P1019, DOI 10.1016/j.celrep.2015.07.003; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Philip B, 2013, GASTROENTEROLOGY, V145, P1449, DOI 10.1053/j.gastro.2013.08.018; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Rowley M, 2011, GASTROENTEROLOGY, V140, P1303, DOI 10.1053/j.gastro.2010.12.039; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; URBAN T, 1993, J NATL CANCER I, V85, P2008, DOI 10.1093/jnci/85.24.2008; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wood LD, 2014, SEMIN DIAGN PATHOL, V31, P491, DOI 10.1053/j.semdp.2014.08.003	38	30	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3149	3158		10.1038/onc.2016.461	http://dx.doi.org/10.1038/onc.2016.461			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27991926	hybrid, Green Published			2022-12-28	WOS:000402617900007
J	Wilson, C; Qiu, L; Hong, Y; Karnik, T; Tadros, G; Mau, B; Ma, T; Mu, Y; New, J; Louie, RJ; Gunewardena, S; Godwin, AK; Tawfik, OW; Chien, J; Roby, KF; Krieg, AJ				Wilson, C.; Qiu, L.; Hong, Y.; Karnik, T.; Tadros, G.; Mau, B.; Ma, T.; Mu, Y.; New, J.; Louie, R. J.; Gunewardena, S.; Godwin, A. K.; Tawfik, O. W.; Chien, J.; Roby, K. F.; Krieg, A. J.			The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer	ONCOGENE			English	Article							LYSINE DEMETHYLASE; GENE-EXPRESSION; GROWTH-FACTOR; COPY GAIN; HYPOXIA; METASTASIS; TARGET; JMJD2B; CELLS; METHYLATION	Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence because of widespread dissemination of peritoneal metastases at diagnosis. Multiple pathways contribute to the aggressiveness of ovarian cancer, including hypoxic signaling mechanisms. In this study, we have determined that the hypoxia-inducible histone demethylase KDM4B is expressed in similar to 60% of EOC tumors assayed, including primary and matched metastatic tumors. Expression of KDM4B in tumors is positively correlated with expression of the tumor hypoxia marker CA-IX, and is robustly induced in EOC cell lines exposed to hypoxia. KDM4B regulates expression of metastatic genes and pathways, and loss of KDM4B increases H3K9 trimethylation at the promoters of target genes like LOXL2, LCN2 and PDGFB. Suppressing KDM4B inhibits ovarian cancer cell invasion, migration and spheroid formation in vitro. KDM4B also regulates seeding and growth of peritoneal tumors in vivo, where its expression corresponds to hypoxic regions. This is the first demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients.	[Wilson, C.; Qiu, L.; Hong, Y.; Mu, Y.; Krieg, A. J.] Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Kansas City, KS 66103 USA; [Wilson, C.; Qiu, L.; Karnik, T.; Tadros, G.; Mau, B.; Ma, T.; Godwin, A. K.; Tawfik, O. W.; Krieg, A. J.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [New, J.] Univ Kansas, Med Ctr, Med Scholars Program, Kansas City, KS 66103 USA; [Louie, R. J.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA; [Chien, J.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Roby, K. F.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Krieg, A. J.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California San Francisco; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Oregon Health & Science University	Krieg, AJ (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Div Reprod & Dev Sci, Oregon Natl Primate Res Ctr, 505 NW 185th Ave,Mail Stop L584, Beaverton, OR 97006 USA.	kriega@ohsu.edu	Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374; New, Jacob/0000-0003-0707-9324; Krieg, Adam/0000-0002-3069-0378	Institutional Development Award (IDeA) [P20GM104936]; American Cancer Society Institutional Research Grant [ACS IRG-09-062-04]; KUMC Department of OB/GYN start-up funds; KU Cancer Center's Cancer Center Support Grant [P30 CA168524]; NATIONAL CANCER INSTITUTE [P30CA168524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104936] Funding Source: NIH RePORTER	Institutional Development Award (IDeA); American Cancer Society Institutional Research Grant(American Cancer Society); KUMC Department of OB/GYN start-up funds; KU Cancer Center's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research was supported by an Institutional Development Award (IDeA) P20GM104936 (to AJK and SG), an American Cancer Society Institutional Research Grant ACS IRG-09-062-04 (to AJK) and KUMC Department of OB/GYN start-up funds (to AJK). We thank the staff of the University of Kansas Cancer Center's Biospecimen Repository Core Facility staff for specimen collection (Colleen Reilly and Zaid Naima) and for excellent histological assistance in the creation of the TMAs (Dr Rashna Madan and Tara Meyer). We acknowledge the KU Cancer Center's Cancer Center Support Grant (P30 CA168524 to AJK, AKG, JC, KFR). Special appreciation is given to Dr Denise A Chan (UCSF), whose untimely passing in 2014 prevents inclusion as a co-author.	ACS, 2015, AM CANC SOC CANC FAC; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Apte SM, 2004, GYNECOL ONCOL, V93, P78, DOI 10.1016/j.ygyno.2003.12.041; Barker HE, 2011, FUTURE ONCOL, V7, P707, DOI [10.2217/fon.11.46, 10.2217/FON.11.46]; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Birner P, 2001, CLIN CANCER RES, V7, P1661; Black JC, 2015, GENE DEV, V29, P1018, DOI 10.1101/gad.259796.115; Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Goode EL, 2011, CANCER EPIDEM BIOMAR, V20, P1638, DOI 10.1158/1055-9965.EPI-11-0455; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Iwamori N, 2011, BIOL REPROD, V84, P1225, DOI 10.1095/biolreprod.110.088955; Joberty G, 2016, ACS CHEM BIOL, V11, P2002, DOI 10.1021/acschembio.6b00080; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lu CH, 2010, CANCER BIOL THER, V9, P176, DOI 10.4161/cbt.9.3.10635; Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36; Maes T, 2015, CURR OPIN PHARMACOL, V23, P52, DOI 10.1016/j.coph.2015.05.009; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pack LR, 2016, J BIOL CHEM, V291, P6060, DOI 10.1074/jbc.M115.696864; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Rai G., 2010, PROBE REPORTS NIH MO; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Sanchez-Fernandez EM, 2013, BIOCHEM J, V449, P491, DOI 10.1042/BJ20121155; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Swenson-Fields KI, 2013, KIDNEY INT, V83, P855, DOI 10.1038/ki.2012.446; Thalhammer A, 2011, ORG BIOMOL CHEM, V9, P127, DOI 10.1039/c0ob00592d; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	52	35	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2565	2576		10.1038/onc.2016.412	http://dx.doi.org/10.1038/onc.2016.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27869162	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000400597300007
J	Ai, J; Pascal, LE; Wei, L; Zang, Y; Zhou, Y; Yu, X; Gong, Y; Nakajima, S; Nelson, JB; Levine, AS; Lan, L; Wang, Z				Ai, J.; Pascal, L. E.; Wei, L.; Zang, Y.; Zhou, Y.; Yu, X.; Gong, Y.; Nakajima, S.; Nelson, J. B.; Levine, A. S.; Lan, L.; Wang, Z.			EAF2 regulates DNA repair through Ku70/Ku80 in the prostate	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; DAMAGE RESPONSE; ANDROGEN RECEPTOR; CANCER; PROTEIN; RADIATION; SUPPRESSION; POLYMERASE; EXPRESSION; PATHWAYS	Androgens are known to protect prostate cancer cells from DNA damage. Recent studies showed regulation of DNA repair genes by androgen receptor signaling in prostate cancers. ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor and its intracellular localization can be modulated by ultraviolet light, suggesting a potential role for EAF2 in androgen regulation of DNA repair in prostate cancer cells. Here we show that knockdown of EAF2 or its homolog EAF1 sensitized prostate cancer cells to DNA damage and the sensitization did not require p53. EAF2 knockout mouse prostate was also sensitized to gamma-irradiation. Furthermore, EAF2 knockdown blocked androgen repression of LNCaP or C4-2 cells from doxorubicin induction of gamma H2ax, a DNA damage marker. In human prostate cancer specimens, EAF2 expression was inversely correlated with the level of gamma H2ax. Further analysis showed that EAF2 and EAF1 are required for the recruitment and retention of Ku70/Ku80 to DNA damage sites and play a functional role in nonhomologous end-joining DNA repair. These findings provide evidence for EAF2 as a key factor mediating androgen protection of DNA damage via Ku70/Ku80 in prostate cancer cells.	[Ai, J.; Pascal, L. E.; Zang, Y.; Zhou, Y.; Yu, X.; Gong, Y.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA; [Wei, L.; Nakajima, S.; Levine, A. S.; Lan, L.; Wang, Z.] Univ Pittsburgh, Sch Med, Canc Inst, Pittsburgh, PA USA; [Wei, L.; Levine, A. S.; Lan, L.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Zang, Y.; Zhou, Y.] Soochow Univ, Affiliated Hosp 2, Dept Urol, Suzhou, Peoples R China; [Yu, X.] Southern Med Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Gong, Y.] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China; [Gong, Y.] Peking Univ, Inst Urol, Beijing, Peoples R China; [Nakajima, S.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Soochow University - China; Southern Medical University - China; Peking University; Peking University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Pascal, Laura E./AAH-5743-2019; Zang, Yachen/GNW-5928-2022	Pascal, Laura E./0000-0003-3840-1662; 	National Institutes of Health [R01CA186780, 1 P50 CA180995, 1R50CA211242, T32 DK007774]; Tippens Foundation; Flow Cytometry and Tissue and Research Pathology Services (TARPS) [P30CA047904]; NATIONAL CANCER INSTITUTE [P50CA180995, P30CA047904, R50CA211242, R01CA186780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM118833] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tippens Foundation; Flow Cytometry and Tissue and Research Pathology Services (TARPS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This investigation was supported in part by the National Institutes of Health Grants R01CA186780, 1 P50 CA180995, 1R50CA211242 and T32 DK007774 and a scholarship from the Tippens Foundation (to LEP). This project used the UPCI Animal Facility, Flow Cytometry and Tissue and Research Pathology Services (TARPS), and was supported in part by award P30CA047904. We thank Dr Leland WK Chung for providing C4-2 cells and Drs Javid Dar, Amy Deng, Tomoko Koya and Xinhui Wang for assistance in generating the EAF1 antibody. We thank Marie Acquafondata, Jon Duboy, Anthony Green, Bratislav Janjic, Marianne Notaro, Aiyuan Zhang and Katie Leschak for technical assistance. We thank Dr Michael Epperly for assistance in designing and performing irradiation experiments. We thank Dr Anil V Parwani for reviewing human prostate specimens and Dr Lora H Rigatti for reviewing mouse prostate specimens. We also thank Drs Weijun Liu, Susanne M Gollin and Dale W Lewis and all members of the Wang laboratory for insightful discussion during this project and critical reading of the manuscript.	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Ai J, 2014, ONCOGENE, V33, P2286, DOI 10.1038/onc.2013.190; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Bowen C, 2015, CANCER RES, V75, P2686, DOI 10.1158/0008-5472.CAN-14-3387; Chatrchyan S, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.182001; Chen Z, 2014, MOL CELL BIOL, V34, P1085, DOI 10.1128/MCB.00718-13; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dobbs TA, 2010, DNA REPAIR, V9, P1307, DOI 10.1016/j.dnarep.2010.09.019; Erbaykent-Tepedelen B, 2014, J STEROID BIOCHEM, V141, P26, DOI 10.1016/j.jsbmb.2014.01.001; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kong SE, 2005, P NATL ACAD SCI USA, V102, P10094, DOI 10.1073/pnas.0503017102; Koontz Bridget F., 2011, Archivos Espanoles de Urologia, V64, P858; Kuo LJ, 2008, IN VIVO, V22, P305; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lawrence MD, 2013, RADIAT RES, V180, P376, DOI 10.1667/RR3381.2; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Liu Jing, 2013, J Toxicol, V2013, P967029, DOI 10.1155/2013/967029; Liu YG, 2001, CARCINOGENESIS, V22, P851, DOI 10.1093/carcin/22.6.851; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Pascal LE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079542; Pascal LE, 2011, ANGIOGENESIS, V14, P331, DOI 10.1007/s10456-011-9217-1; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saporita AJ, 2007, PROSTATE, V67, P509, DOI 10.1002/pros.20541; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Su F, 2010, ONCOGENE, V29, P421, DOI 10.1038/onc.2009.326; Ta HQ, 2014, ENDOCR-RELAT CANCER, V21, pR395, DOI 10.1530/ERC-14-0217; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; Valenzuela MT, 1995, ANTI-CANCER DRUG, V6, P749, DOI 10.1097/00001813-199512000-00006; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Xiao F, 2012, INT J OPHTHALMOL-CHI, V5, P570, DOI 10.3980/j.issn.2222-3959.2012.05.05; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2003, CANCER RES, V63, P4698; Xiao WH, 2009, CANCER RES, V69, P2599, DOI 10.1158/0008-5472.CAN-08-2595; Zhang H, 2015, APPL NMR SPECTROSC, V1, P3; Zhang ZW, 2011, CELL CYCLE, V10, P3545, DOI 10.4161/cc.10.20.17841; Zhuang FF, 2008, DNA CELL BIOL, V27, P649, DOI 10.1089/dna.2008.0733	52	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2054	2065		10.1038/onc.2016.373	http://dx.doi.org/10.1038/onc.2016.373			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721405	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000399782500002
J	Jung, LA; Gebhardt, A; Koelmel, W; Ade, CP; Walz, S; Kuper, J; von Eyss, B; Letschert, S; Redel, C; d'Artista, L; Biankin, A; Zender, L; Sauer, M; Wolf, E; Evan, G; Kisker, C; Eilers, M				Jung, L. A.; Gebhardt, A.; Koelmel, W.; Ade, C. P.; Walz, S.; Kuper, J.; von Eyss, B.; Letschert, S.; Redel, C.; d'Artista, L.; Biankin, A.; Zender, L.; Sauer, M.; Wolf, E.; Evan, G.; Kisker, C.; Eilers, M.			OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors	ONCOGENE			English	Article							ANTI-APOPTOTIC FACTOR; DOMAIN-CONTAINING 3A; C-MYC; COLORECTAL TUMORIGENESIS; MITOCHONDRIAL DYNAMICS; UBIQUITIN RECEPTOR; BREAST-CANCER; DNA-BINDING; GENOME; CELLS	MYC genes have both essential roles during normal development and exert oncogenic functions during tumorigenesis. Expression of a dominant-negative allele of MYC, termed OmoMYC, can induce rapid tumor regression in mouse models with little toxicity for normal tissues. How OmoMYC discriminates between physiological and oncogenic functions of MYC is unclear. We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC/MAX heterodimer. OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites. OmoMYC causes the largest decreases in promoter occupancy and changes in expression on genes that are invaded by oncogenic MYC levels. A signature of OmoMYC-regulated genes defines subgroups with high MYC levels in multiple tumor entities and identifies novel targets for the eradication of MYC-driven tumors.	[Jung, L. A.; Gebhardt, A.; Ade, C. P.; von Eyss, B.; Redel, C.; Wolf, E.; Eilers, M.] Univ Wurzburg, Bioctr, Theodor Boveri Inst, D-97074 Wurzburg, Germany; [Jung, L. A.; Koelmel, W.; Kuper, J.; Kisker, C.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Walz, S.] Bioctr, Core Unit Bioinformat, Comprehens Canc Ctr, Wurzburg, Germany; [Letschert, S.; Sauer, M.] Univ Wurzburg, Bioctr, Dept Biotechnol & Biophys, Wurzburg, Germany; [d'Artista, L.; Zender, L.] Univ Tubingen, Dept Internal Med 1, Div Translat Gastrointestinal Oncol, Tubingen, Germany; [Biankin, A.] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Garscube Estate,Switchback Rd, Glasgow, Lanark, Scotland; [Biankin, A.] Glasgow Royal Infirm, West Scotland Pancreat Unit, Glasgow, Lanark, Scotland; [Biankin, A.] Univ NSW, South Western Sydney Clin Sch, Fac Med, Liverpool, NSW, Australia; [Evan, G.] Univ Cambridge, Dept Biochem, Cambridge, England	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Eberhard Karls University of Tubingen; University of Glasgow; University of Glasgow; University of Cambridge	Eilers, M (corresponding author), Univ Wurzburg, Bioctr, Theodor Boveri Inst, D-97074 Wurzburg, Germany.; Kisker, C (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany.	caroline.kisker@virchow.uni-wuerzburg.de; martin.eilers@biozentrum.uni-wuerzburg.de	von Eyss, Bjoern/P-1077-2019; Wolf, Elmar/AAY-8493-2021; Kisker, Caroline/T-1724-2019; Sauer, Markus/C-4378-2017	von Eyss, Bjoern/0000-0002-4731-6841; Wolf, Elmar/0000-0002-5299-6335; Sauer, Markus/0000-0002-1692-3219; Redel, Cornelia/0000-0002-3632-3317; Evan, Gerard/0000-0003-0412-1216; Kisker, Caroline/0000-0002-0216-6026; Jung, Lisa Anna/0000-0003-4149-1662; Biankin, Andrew/0000-0002-0362-5597	Worldwide Cancer Research; German Research Foundation [2341]; German National Academic Foundation; Cancer Research UK [12077, 19013, 22585, 17263, 22533] Funding Source: researchfish; Pancreatic Cancer UK [FLF2015_04_Glasgow] Funding Source: researchfish	Worldwide Cancer Research; German Research Foundation(German Research Foundation (DFG)); German National Academic Foundation; Cancer Research UK(Cancer Research UK); Pancreatic Cancer UK	We thank Laura Soucek for sharing results before publication, Agnes Elias and Werner Schmitz for help with protein purification, Hermann Schindelin for help with determining the structures of OmoMYC, Christopher Bombeck for help with generating the targeted shRNA library and Jens Siveke (Technical University of Munich) for kindly providing KPCs. The expert technical assistance of Barbara Bauer, Andre Kutschke, Angela Grun and Renate Metz is gratefully acknowledged. This work was supported by grants from Worldwide Cancer Research and the German Research Foundation via Research Group 2341 to ME, GE, LZ and CK, and a pre-doctoral fellowship from the German National Academic Foundation to LAJ. High-throughput-sequencing data are available at the Gene Expression Omnibus under the accession number GEO: GSE77328. We thank the European Synchrotron Radiation Facility for beamtime and the staff of ID23-1 for technical support. We thank the Helmholtz Zentrum Berlin for the allocation of beamtime and the staff of BL14.1 for technical support. Atomic coordinates have been deposited in the Protein Data Bank under accession codes 5I4Z (apo structure) and 5I50 (DNA-bound structure).	ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Anchoori RK, 2013, CANCER CELL, V24, P791, DOI 10.1016/j.ccr.2013.11.001; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chiang SF, 2012, INT J MOL MED, V29, P365, DOI 10.3892/ijmm.2011.849; Chung KY, 2011, HEPATOLOGY, V54, P307, DOI 10.1002/hep.24372; Cunningham JT, 2014, CELL, V157, P1088, DOI 10.1016/j.cell.2014.03.052; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Fang HY, 2010, J CELL SCI, V123, P1171, DOI 10.1242/jcs.062034; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Gilquin B, 2010, MOL CELL BIOL, V30, P1984, DOI 10.1128/MCB.00007-10; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guo JN, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0482-3; Hoffmann M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007644; Hong SL, 2000, GENE DEV, V14, P17; Huang KH, 2011, INT J MOL MED, V28, P9, DOI 10.3892/ijmm.2011.670; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; Jaenicke LA, 2016, MOL CELL, V61, P54, DOI 10.1016/j.molcel.2015.11.007; Killian A, 2006, GENE CHROMOSOME CANC, V45, P874, DOI 10.1002/gcc.20351; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rohrmoser M, 2007, MOL CELL BIOL, V27, P3682, DOI 10.1128/MCB.00172-07; Ruggero D, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012336; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Scognamiglio R, 2016, CELL, V164, P668, DOI 10.1016/j.cell.2015.12.033; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Truitt ML, 2015, CELL, V162, P59, DOI 10.1016/j.cell.2015.05.049; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006	51	51	51	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1911	1924		10.1038/onc.2016.354	http://dx.doi.org/10.1038/onc.2016.354			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27748763	Green Accepted, Green Submitted			2022-12-28	WOS:000398898500003
J	Daly, CS; Shaw, P; Ordonez, LD; Williams, GT; Quist, J; Grigoriadis, A; Van Es, JH; Clevers, H; Clarke, AR; Reed, KR				Daly, C. S.; Shaw, P.; Ordonez, L. D.; Williams, G. T.; Quist, J.; Grigoriadis, A.; Van Es, J. H.; Clevers, H.; Clarke, A. R.; Reed, K. R.			Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium	ONCOGENE			English	Article							ADENOMATOUS-POLYPOSIS-COLI; PRIMARY BREAST CANCERS; BETA-CATENIN; TUMOR-SUPPRESSOR; E-CADHERIN; C-MYC; CYTOPLASMIC LOCALIZATION; MESENCHYMAL TRANSITION; GENE PROMOTER; FREQUENT LOSS	Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue remains poorly understood and the consequences of immediate or long-term dysregulation remain elusive. The exact contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathogenesis of human breast cancer are ill-defined, but our analysis of publically available array data sets indicates that tumors with concomitant low expression of both proteins occurs more frequently in the 'triple negative' phenotype, which is a subtype of breast cancer with particularly poor prognosis. We have used mouse transgenics to delete Apc and/or Apc2 from mouse mammary epithelium to elucidate the significance of these proteins in mammary homeostasis and delineate their influences on Wnt signaling and tumorigenesis. Loss of either protein alone failed to affect Wnt signaling levels or tissue homeostasis. Strikingly, concomitant loss led to local disruption of beta-catenin status, disruption in epithelial integrity, cohesion and polarity, increased cell division and a distinctive form of ductal hyperplasia with 'squamoid' ghost cell nodules in young animals. Upon aging, the development of Wnt activated mammary carcinomas with squamous differentiation was accompanied by a significantly reduced survival. This novel Wnt-driven mammary tumor model highlights the importance of functional redundancies existing between the Apc proteins both in normal homeostasis and in tumorigenesis.	[Daly, C. S.; Shaw, P.; Ordonez, L. D.; Clarke, A. R.; Reed, K. R.] Cardiff Univ, Sch Biosci, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Williams, G. T.] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff, S Glam, Wales; [Quist, J.; Grigoriadis, A.] Kings Coll London, Guys Hosp London, Breast Canc Now Unit, London, England; [Quist, J.; Grigoriadis, A.] Kings Coll London, Guys Hosp London, Canc Bioinformat, London, England; [Van Es, J. H.; Clevers, H.] Netherlands Inst Dev Biol, Hubrecht Lab, Utrecht, Netherlands	Cardiff University; Cardiff University; University of London; King's College London; University of London; King's College London; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Reed, KR (corresponding author), Cardiff Univ, Sch Biosci, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.	ReedKR@Cardiff.ac.uk	van+Es, Johan/ABD-5411-2021; Reed, Karen/B-8813-2011	Reed, Karen/0000-0002-7467-1718; Grigoriadis, Anita/0000-0003-3434-201X	Biotechnology and Biomedical Sciences Research Council; Cancer Research UK [C1295/A15937]; Wales Gene Park; NIHR Biomedical Research Centre at Guy's and St Thomas; Breast Cancer NOW; Cancer Research UK [15937] Funding Source: researchfish	Biotechnology and Biomedical Sciences Research Council; Cancer Research UK(Cancer Research UK); Wales Gene Park; NIHR Biomedical Research Centre at Guy's and St Thomas; Breast Cancer NOW; Cancer Research UK(Cancer Research UK)	This project was funded by Biotechnology and Biomedical Sciences Research Council and Cancer Research UK (ARC Program grant C1295/A15937). GTW is supported by the Wales Gene Park. Jelmar Quist is funded by a PhD studentship from the NIHR Biomedical Research Centre at Guy's and St Thomas. Anita Grigoriadis is supported by Breast Cancer NOW (former Breakthrough Breast Cancer Research). We thank Luke Bradshaw, Oro Asby, Bridget Allen and Elaine Taylor for assistance with mouse husbandry. We would also like to thank Mark Bishop and Matthew Zverev for technical support and genotyping and Derek Scarborough and Marc Isaacs for their assistance in histology.	Ahmed Y, 2002, DEVELOPMENT, V129, P1751; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Bray K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3487; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hassanein AM, 2003, AM J CLIN PATHOL, V120, P732, DOI 10.1309/EALEG7LD6W7167PX; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Ho KYK, 1999, HISTOPATHOLOGY, V35, P249; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Irshad S, 2011, CURR OPIN ONCOL, V23, P566, DOI 10.1097/CCO.0b013e32834bf8ae; Jarrett CR, 2001, CANCER RES, V61, P7978; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Khalil S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033421; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lesko AC, 2014, CURR DRUG TARGETS, V15, P90, DOI 10.2174/1389450114666131108155418; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mohinta S, 2007, FRONT BIOSCI-LANDMRK, V12, P4020, DOI 10.2741/2368; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Nelson S, 2013, J CELL SCI, V126, P873, DOI 10.1242/jcs.100479; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Roberts DM, 2012, MOL BIOL CELL, V23, P2041, DOI 10.1091/mbc.E11-11-0965; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Schlosshauer PW, 2000, MODERN PATHOL, V13, P1066, DOI 10.1038/modpathol.3880196; Schneikert J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068072; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Tanaka A, 2007, J ORAL PATHOL MED, V36, P400, DOI 10.1111/j.1600-0714.2007.00550.x; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705; van der Meer M, 2001, TRANSGENIC RES, V10, P399, DOI 10.1023/A:1012244404020; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Williams TM, 2006, AM J PATHOL, V169, P1784, DOI 10.2353/ajpath.2006.060590; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zardawi SJ, 2009, HISTOL HISTOPATHOL, V24, P385, DOI 10.14670/HH-24.385	63	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1793	1803		10.1038/onc.2016.342	http://dx.doi.org/10.1038/onc.2016.342			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27694902	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000398128900005
J	Liu, T; Xiong, J; Yi, S; Zhang, H; Zhou, S; Gu, L; Zhou, M				Liu, T.; Xiong, J.; Yi, S.; Zhang, H.; Zhou, S.; Gu, L.; Zhou, M.			FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2	ONCOGENE			English	Article							UBIQUITIN-PROTEIN LIGASE; P53 TUMOR-SUPPRESSOR; FK506-BINDING PROTEINS; PROLYL ISOMERASE; DEGRADATION; PROMOTES; TRANSACTIVATION; STABILIZATION; IMMUNOPHILIN; EXPRESSION	The FK506-binding protein 12 (FKBP12) is a cytoplasmic protein and has been reported to possess multiple functions in signaling transduction based on its interaction with different cellular targets. Here, we report that FKBP12 interacts with oncoprotein MDM2 and induces MDM2 degradation. We demonstrate that FKBP12 degrades MDM2 through binding to MDM2 protein, disrupting MDM2/MDM4 interaction and inducing MDM2 self-ubiquitination. The FKBP12-mediated MDM2 degradation was significantly enhanced when the transfected MDM2 was localized in the cytoplasm. The endogenous MDM2, when it was induced by p53 subjecting to DNA-damaging stimuli such as treatment with doxorubicin, was also significantly inhibited by FKBP12. This is due to translocation of p53-induced MDM2 from the nucleus to the cytoplasm, which facilitates interaction with cytoplasmic FKBP12. Furthermore, the enhanced level of MDM2 following p53 activation in nutlin-3 treated cells was also inhibited by FKBP12. The FKBP12-mediated downregulation of MDM2 in response to doxorubicin or nutlin-3 results in continuing and constitutive activation of p53, inhibition of XIAP and sensitization of cancer cells to apoptosis. These results identify a novel function for FKBP12 in downregulating MDM2, which directly enhances sensitivity of cancer cells to chemotherapy and nutlin-3 treatment.	[Liu, T.; Yi, S.; Zhang, H.; Gu, L.; Zhou, M.] Emory Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Aflac Canc Ctr & Blood Disorder, 1760 Haygood Dr, Atlanta, GA 30322 USA; [Xiong, J.; Zhou, S.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Pathol, Wuhan, Peoples R China	Emory University; Huazhong University of Science & Technology	Gu, L; Zhou, M (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Aflac Canc Ctr & Blood Disorder, 1760 Haygood Dr, Atlanta, GA 30322 USA.	lbgu@emory.edu; mzhou@emory.edu			R01 grants [CA180519, CA123490, CA143107]; Hyundai Hope on Wheels [79387GA]; CURE; National Natural Science Foundation of China [81472488]; NATIONAL CANCER INSTITUTE [R01CA123490, R01CA143107, R01CA180519] Funding Source: NIH RePORTER	R01 grants; Hyundai Hope on Wheels; CURE; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 grants (CA180519, CA123490 and CA143107) to MZ; the Scholar award (79387GA) from Hyundai Hope on Wheels to MZ; research grants from CURE to MZ and LG; and a National Natural Science Foundation of China grant (No. 81472488) to SZ.	BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Cheng QA, 2011, CELL CYCLE, V10, P1162, DOI 10.4161/cc.10.7.15249; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Gudavicius G, 2014, RNA, V20, P1014, DOI 10.1261/rna.042648.113; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; JUVEN T, 1993, ONCOGENE, V8, P3411; Kang CB, 2008, NEUROSIGNALS, V16, P318, DOI 10.1159/000123041; Linares LK, 2003, FEBS LETT, V554, P73, DOI 10.1016/S0014-5793(03)01108-6; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu T, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0334-0; Mathea S, 2011, BIOCHEMISTRY-US, V50, P10844, DOI 10.1021/bi2013855; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Ochocka AM, 2009, FEBS LETT, V583, P621, DOI 10.1016/j.febslet.2009.01.009; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schreiber KH, 2015, AGING CELL, V14, P265, DOI 10.1111/acel.12313; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Somarelli JA, 2008, PROTEINS, V72, P197, DOI 10.1002/prot.21908; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wawrzynow B, 2007, J BIOL CHEM, V282, P32603, DOI 10.1074/jbc.M702767200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	36	18	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1678	1686		10.1038/onc.2016.331	http://dx.doi.org/10.1038/onc.2016.331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27617579	Green Published, hybrid			2022-12-28	WOS:000397460600007
J	Chen, H; Lorton, B; Gupta, V; Shechter, D				Chen, H.; Lorton, B.; Gupta, V.; Shechter, D.			A TGF beta-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression	ONCOGENE			English	Article							SYMMETRIC DIMETHYLATION; LUNG ADENOCARCINOMA; DNA METHYLATION; PRMT5; METHYLTRANSFERASE; PROTEIN; EXPRESSION; EMT; PROGRESSION; VALIDATION	Protein arginine methyltransferase 5 (PRMT5) complexed with MEP50/WDR77 catalyzes arginine methylation on histones and other proteins. PRMT5-MEP50 activity is elevated in cancer cells and its expression is highly correlated with poor prognosis in many human tumors. We demonstrate that PRMT5-MEP50 is essential for transcriptional regulation promoting cancer cell invasive phenotypes in lung adenocarcinoma, lung squamous cell carcinoma and breast carcinoma cancer cells. RNA-Seq transcriptome analysis demonstrated that PRMT5 and MEP50 are required to maintain expression of metastasis and Epithelial-to-mesenchymal transition (EMT) markers and to potentiate an epigenetic mechanism of the TGF beta response. We show that PRMT5-MEP50 activity both positively and negatively regulates expression of a wide range of genes. Exogenous TGF beta promotes EMT in a unique pathway of PRMT5-MEP50 catalyzed histone mono-and dimethylation of chromatin at key metastasis suppressor and EMT genes, defining a new mechanism regulating cancer invasivity. PRMT5 methylation of histone H3R2me1 induced transcriptional activation by recruitment of WDR5 and concomitant H3K4 methylation at targeted genes. In parallel, PRMT5 methylation of histone H4R3me2s suppressed transcription at distinct genomic loci. Our decoding of histone methylarginine at key genes supports a critical role for complementary PRMT5-MEP50 transcriptional activation and repression in cancer invasion pathways and in response to TGF beta stimulation and therefore orients future chemotherapeutic opportunities.	[Chen, H.; Lorton, B.; Shechter, D.] Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA; [Gupta, V.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Chen, H; Shechter, D (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	hongshan.chen@einstein.yu.edu; david.shechter@einstein.yu.edu	Shechter, David/B-4660-2008	Shechter, David/0000-0001-9388-6004	Albert Einstein College of Medicine; Alexandrine and Alexander Sinsheimer Fund; American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant [124891-RSG-13-396-01-DMC]; NIH [R01GM108646-01A1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108646] Funding Source: NIH RePORTER	Albert Einstein College of Medicine; Alexandrine and Alexander Sinsheimer Fund; American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to C. Arrowsmith, GlaxoSmithKline and the Structural Genomics Consortium for the gift of GSK591, C. Wilczek, R. Mazur and P. Bailey for preliminary knockdown experiments, E. Burgos for recombinant PRMT5-MEP50, S. Maqbool, R. Dubin, and B. Ye at the Einstein Center for Epigenomics for assistance with RNASeq and initial analysis, and members of the Shechter lab for comments. This work was supported by startup funds from the Albert Einstein College of Medicine, The Alexandrine and Alexander Sinsheimer Fund, The American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant (124891-RSG-13-396-01-DMC) and NIH R01GM108646-01A1 (all to D.S.).	Alinari L, 2015, BLOOD, V125, P2530, DOI 10.1182/blood-2014-12-619783; Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Burgos ES, 2015, J BIOL CHEM, V290, P9674, DOI 10.1074/jbc.M115.636894; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chen HS, 2015, MOL CELL, V59, P719, DOI 10.1016/j.molcel.2015.07.011; Chen HS, 2014, NAT STRUCT MOL BIOL, V21, P981, DOI 10.1038/nsmb.2903; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chung J, J BIOL CHEM, V288, P35534; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Dacwag CS, 2009, MOL CELL BIOL, V29, P1909, DOI 10.1128/MCB.00742-08; Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112; Dhar S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01311; Di Lorenzo A, 2011, FEBS LETT, V585, P2024, DOI 10.1016/j.febslet.2010.11.010; Diez-Villanueva A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0014-8; Duncan KW, 2015, ACS MED CHEM LETT; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Girardot M, 2014, NUCLEIC ACIDS RES, V42, P235, DOI 10.1093/nar/gkt884; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/nchembio.1859, 10.1038/NCHEMBIO.1859]; Greenblatt SM, 2016, EXP HEMATOL, V44, P435, DOI 10.1016/j.exphem.2016.03.009; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Ho MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057008; Ibrahim R, 2014, HUM PATHOL, V45, P1397, DOI 10.1016/j.humpath.2014.02.013; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Kallio MA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-507; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Koh C.M., 2015, CURR MOL BIOL REP, V1, P19, DOI [10.1007/s40610-015-0003-5, DOI 10.1007/S40610-015-0003-5]; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Liu J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.37; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Nicklay JJ, 2009, J BIOL CHEM, V284, P1075, DOI 10.1074/jbc.M807274200; Otani J, 2009, EMBO REP, V10, P1235, DOI 10.1038/embor.2009.218; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sarkar S, 2013, INT J MOL SCI, V14, P21087, DOI 10.3390/ijms141021087; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Smil D, 2015, ACS MED CHEM LETT, V6, P408, DOI 10.1021/ml500467h; Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016; Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Wang M, 2014, BIOCHEMISTRY-US, V53, P7884, DOI 10.1021/bi501279g; Wang M, 2013, BIOCHEMISTRY-US, V52, P5430, DOI 10.1021/bi4005123; Wilczek C, 2011, J BIOL CHEM, V286, P42221, DOI 10.1074/jbc.M111.303677; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884; Yan JC, 2013, HISTOL HISTOPATHOL, V28, P285, DOI 10.14670/HH-28.285; Yang HP, 2015, ONCOL REP, V34, P87, DOI 10.3892/or.2015.3961; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yuan CC, 2012, CELL REPORTS, V1, P83, DOI 10.1016/j.celrep.2011.12.008; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	61	101	108	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					373	386		10.1038/onc.2016.205	http://dx.doi.org/10.1038/onc.2016.205			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270440	Green Accepted			2022-12-28	WOS:000394166000007
J	Li, J; Gu, D; Lee, SSY; Song, B; Bandyopadhyay, S; Chen, S; Konieczny, SF; Ratliff, TL; Liu, X; Xie, J; Cheng, JX				Li, J.; Gu, D.; Lee, S. S-Y; Song, B.; Bandyopadhyay, S.; Chen, S.; Konieczny, S. F.; Ratliff, T. L.; Liu, X.; Xie, J.; Cheng, J-X			Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer	ONCOGENE			English	Article							ACYL-COENZYME; TUMOR PROGRESSION; INHIBITION; CAVEOLIN-1; MIGRATION; PATHWAY; CELLS; ACYLTRANSFERASE; ACCUMULATION; METABOLISM	Cancer cells are known to execute reprogramed metabolism of glucose, amino acids and lipids. Here, we report a significant role of cholesterol metabolism in cancer metastasis. By using label-free Raman spectromicroscopy, we found an aberrant accumulation of cholesteryl ester in human pancreatic cancer specimens and cell lines, mediated by acyl-CoA cholesterol acyltransferase-1 (ACAT-1) enzyme. Expression of ACAT-1 showed a correlation with poor patient survival. Abrogation of cholesterol esterification, either by an ACAT-1 inhibitor or by shRNA knockdown, significantly suppressed tumor growth and metastasis in an orthotopic mouse model of pancreatic cancer. Mechanically, ACAT-1 inhibition increased intracellular free cholesterol level, which was associated with elevated endoplasmic reticulum stress and caused apoptosis. Collectively, our results demonstrate a new strategy for treating metastatic pancreatic cancer by inhibiting cholesterol esterification.	[Li, J.; Lee, S. S-Y; Song, B.; Cheng, J-X] Purdue Univ, Weldon Sch Biomed Engn, 206 S Martin Jischke Dr, W Lafayette, IN 47907 USA; [Gu, D.; Xie, J.] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, IU Simon Canc Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA; [Bandyopadhyay, S.; Konieczny, S. F.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Chen, S.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Konieczny, S. F.; Ratliff, T. L.; Liu, X.; Cheng, J-X] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Ratliff, T. L.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Liu, X.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cheng, JX (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, 206 S Martin Jischke Dr, W Lafayette, IN 47907 USA.; Xie, J (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, IU Simon Canc Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	jinxie@iupui.edu; jcheng@purdue.edu	Xie, J/AAR-7259-2020; Li, Junjie/B-1424-2017; Liu, Bingya/GMW-5655-2022	Li, Junjie/0000-0003-4542-300X; Bandyopadhyay, Shovik/0000-0003-3919-3914	Indiana State CTSI grant [106564]; NIH [CA182608, CA124586, CA155086, P30CA023168]; NCI [R25CA128770]; NATIONAL CANCER INSTITUTE [P30CA023168, R21CA182608, R01CA124586, R01CA155086, R25CA128770, R01CA196835] Funding Source: NIH RePORTER	Indiana State CTSI grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We greatly appreciate the help from Dr Tian Shao, Dr Zhiguo Li for their technical support. This work was supported by Indiana State CTSI grant 106564 to JX and JXC, NIH CA182608 to JXC, NCI R25CA128770 CPIP fellowship to JL, NIH CA124586 to SFK, and CA155086 to JX, and NIH grant P30CA023168 to Purdue University Center for Cancer Research for publications.	Antalis CJ, 2010, BREAST CANCER RES TR, V122, P661, DOI 10.1007/s10549-009-0594-8; Bemlih S, 2010, CANCER BIOL THER, V9, P1025, DOI 10.4161/cbt.9.12.11875; Bonovas S, 2008, AM J GASTROENTEROL, V103, P2646, DOI 10.1111/j.1572-0241.2008.02051.x; Campbell L, 2008, BRIT J CANCER, V98, P931, DOI 10.1038/sj.bjc.6604243; Cao S, 2005, J BIOL CHEM, V280, P1901, DOI 10.1074/jbc.M407941200; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Gu DS, 2013, MOL CANCER THER, V12, P1038, DOI 10.1158/1535-7163.MCT-12-1030; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Jakobisiak M, 2003, INT J ONCOL, V23, P1055; KRITCHEVSKY SB, 1992, ANNU REV NUTR, V12, P391, DOI 10.1146/annurev.nu.12.070192.002135; Lee SSY, 2015, ACS NANO, V9, P2420, DOI 10.1021/nn504025a; Li JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06807; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Liu L., 2014, INT J PHOTOENERGY, V2014, P1, DOI DOI 10.1371/J0URNAL.P0NE.0094160; Llaverias G, 2003, CARDIOVASC DRUG REV, V21, P33; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; Movasaghi Z, 2007, APPL SPECTROSC REV, V42, P493, DOI 10.1080/05704920701551530; Mulas MF, 2011, CELL PROLIFERAT, V44, P360, DOI 10.1111/j.1365-2184.2011.00758.x; Murai Toshiyuki, 2012, Int J Cell Biol, V2012, P763283, DOI 10.1155/2012/763283; Murai T, 2011, J BIOL CHEM, V286, P1999, DOI 10.1074/jbc.M110.184010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Ramprasad OG, 2007, CELL MOTIL CYTOSKEL, V64, P199, DOI 10.1002/cm.20176; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tanase CP, 2009, J MOL HISTOL, V40, P23, DOI 10.1007/s10735-008-9209-7; Thysell E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014175; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	43	137	145	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6378	6388		10.1038/onc.2016.168	http://dx.doi.org/10.1038/onc.2016.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27132508	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000390247600003
J	Shah, MY; Martinez-Garcia, E; Phillip, JM; Chambliss, AB; Popovic, R; Ezponda, T; Small, EC; Will, C; Phillip, MP; Neri, P; Bahlis, NJ; Wirtz, D; Licht, JD				Shah, M. Y.; Martinez-Garcia, E.; Phillip, J. M.; Chambliss, A. B.; Popovic, R.; Ezponda, T.; Small, E. C.; Will, C.; Phillip, M. P.; Neri, P.; Bahlis, N. J.; Wirtz, D.; Licht, J. D.			MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; T(4/14) MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; HISTONE H3; HOMOLOGOUS RECOMBINATION; ALU ELEMENTS; LYSINE 36; CHROMATIN; MMSET; METHYLATION	MMSET/WHSC1 is a histone methyltransferase (HMT) overexpressed in t(4;14)+ multiple myeloma (MM) patients, believed to be the driving factor in the pathogenesis of this MM subtype. MMSET overexpression in MM leads to an increase in histone 3 lysine 36 dimethylation (H3K36me2), and a decrease in histone 3 lysine 27 trimethylation (H3K27me3), as well as changes in proliferation, gene expression and chromatin accessibility. Prior work linked methylation of histones to the ability of cells to undergo DNA damage repair. In addition, t(4;14)+ patients frequently relapse after regimens that include DNA damage-inducing agents, suggesting that MMSET may play a role in DNA damage repair and response. In U2OS cells, we found that MMSET is required for efficient non-homologous end joining as well as homologous recombination. Loss of MMSET led to loss of expression of several DNA repair proteins, as well as decreased recruitment of DNA repair proteins to sites of DNA double-strand breaks (DSBs). By using genetically matched MM cell lines that had either high (pathological) or low (physiological) expression of MMSET, we found that MMSET-high cells had increased damage at baseline. Upon addition of a DNA-damaging agent, MMSET-high cells repaired DNA damage at an enhanced rate and continued to proliferate, whereas MMSET-low cells accumulated DNA damage and entered cell cycle arrest. In a murine xenograft model using t(4;14)+ KMS11 MM cells harboring an inducible MMSET shRNA, depletion of MMSET enhanced the efficacy of chemotherapy, inhibiting tumor growth and extending survival. These findings help explain the poorer prognosis of t(4;14) MM and further validate MMSET as a potential therapeutic target in MM and other cancers.	[Shah, M. Y.; Martinez-Garcia, E.; Popovic, R.; Ezponda, T.; Small, E. C.; Will, C.; Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, 303 E Super St,Lurie 5-123, Chicago, IL 60611 USA; [Phillip, J. M.; Chambliss, A. B.; Phillip, M. P.; Wirtz, D.] Johns Hopkins Univ, Inst Nanobiotechnol, Dept Chem & Biomol Engn, Baltimore, MD USA; [Neri, P.; Bahlis, N. J.] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Neri, P.; Bahlis, N. J.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Neri, P.; Bahlis, N. J.] Tom Baker Canc Clin, Calgary, AB, Canada; [Wirtz, D.] Johns Hopkins Univ, Sch Med, Dept Oncol & Pathol, Baltimore, MD USA	Northwestern University; Feinberg School of Medicine; Johns Hopkins University; University of Calgary; University of Calgary; Tom Baker Cancer Clinic; University of Calgary; Johns Hopkins University	Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, 303 E Super St,Lurie 5-123, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Ezponda, Teresa/AAA-5040-2020; Licht, Jonathan/AAL-9184-2020; Phillip, Jude/AAR-6240-2020	Ezponda, Teresa/0000-0003-3682-7125; Licht, Jonathan/0000-0002-3942-1369; Chambliss, Allison/0000-0002-0461-8137	NIH [R01CA123204, R01CA174388, U54CA143868]; Leukemia & Lymphoma Society Specialized Center for Research Award; Physical Sciences Oncology Center [U54CA143869]; Celgene; Samuel Waxman Cancer Research Foundation; Canadian Institute of Health and Research operating grant [287300]; NATIONAL CANCER INSTITUTE [R01CA195732, U54CA143869, U54CA210173, R01CA123204, R01CA174388, U54CA143868] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Society Specialized Center for Research Award; Physical Sciences Oncology Center; Celgene(Bristol-Myers SquibbCelgene Corporation); Samuel Waxman Cancer Research Foundation; Canadian Institute of Health and Research operating grant(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant R01CA123204, Leukemia & Lymphoma Society Specialized Center for Research Award, Physical Sciences Oncology Center U54CA143869, Celgene and the Samuel Waxman Cancer Research Foundation (to JDL); NIH grants R01CA174388 and U54CA143868 (to DW); and Canadian Institute of Health and Research operating grant (287300; to NJB). We thank Dr Gaelle Legube for the AsiSI-U2OS cells and members of the Licht lab for their helpful comments.	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Banath JP, 2009, EXP CELL RES, V315, P1505, DOI 10.1016/j.yexcr.2008.12.007; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Chambliss AB, 2013, FASEB J, V27, P2667, DOI 10.1096/fj.12-227108; Chen WC, 2013, INTEGR BIOL-UK, V5, P523, DOI 10.1039/c2ib20246h; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Cook G, 2014, LANCET ONCOL, V15, P874, DOI 10.1016/S1470-2045(14)70245-1; Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236; Efroni S, 2008, CELL STEM CELL, V2, P437, DOI 10.1016/j.stem.2008.03.021; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Englander EW, 1997, MUTAT RES-DNA REPAIR, V385, P31, DOI 10.1016/S0921-8777(97)00036-0; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Guo QY, 2013, BIOMATERIALS, V34, P9365, DOI 10.1016/j.biomaterials.2013.08.061; Hajdu I, 2011, P NATL ACAD SCI USA, V108, P13130, DOI 10.1073/pnas.1110081108; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hudlebusch HR, 2011, CANCER RES, V71, P4226, DOI 10.1158/0008-5472.CAN-10-3810; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Jaksic W, 2005, J CLIN ONCOL, V23, P7069, DOI 10.1200/JCO.2005.17.129; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Li L, 2011, DNA REPAIR HUMAN HLT; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016; Lupi M, 2006, CANCER CHEMOTH PHARM, V57, P443, DOI 10.1007/s00280-005-0044-1; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Min DJ, 2013, LEUKEMIA, V27, P686, DOI 10.1038/leu.2012.269; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Pai CC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5091; Palumbo A, 2014, NEW ENGL J MED, V371, P895, DOI 10.1056/NEJMoa1402888; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pei HD, 2013, J IMMUNOL, V190, P756, DOI 10.4049/jimmunol.1201811; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; Ransom M, 2010, CELL, V140, P183, DOI 10.1016/j.cell.2010.01.004; Roussel M, 2010, BLOOD, V115, P32, DOI 10.1182/blood-2009-06-229658; Silber JR, 2002, CLIN CANCER RES, V8, P3008; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Sousa MML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055493; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Tuzon CT, 2014, CELL REP, V8, P429, DOI 10.1016/j.celrep.2014.06.013; Wang Q, 2016, CANC RES; Zheng YP, 2012, P NATL ACAD SCI USA, V109, P13549, DOI 10.1073/pnas.1205707109	62	56	59	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5905	5915		10.1038/onc.2016.116	http://dx.doi.org/10.1038/onc.2016.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109101	Green Accepted			2022-12-28	WOS:000387560800009
J	Lee, SC; Min, HY; Jung, HJ; Park, KH; Hyun, SY; Cho, J; Woo, JK; Kwon, SJ; Lee, HJ; Johnson, FM; Lee, HY				Lee, S. C.; Min, H-Y; Jung, H. J.; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Kwon, S. J.; Lee, H-J; Johnson, F. M.; Lee, H-Y			Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; FACTOR RECEPTOR; VORINOSTAT; ACTIVATION; STAT3; IGF2; METHYLATION; PROMOTERS; CANCER; TRIAL	Histone deacetylase (HDAC) inhibitors (HDIs) are promising anticancer therapies and have been clinically used for the treatment of hematological malignancy. However, their efficacy in solid tumors is marginal and drug resistance hampers their further clinical utility. To develop novel strategies for the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study, we investigated the mechanisms underlying resistance to HDI treatment in NSCLC cells. We show the STAT3-mediated IGF2/IGF-1R signaling cascade as a key modulator for both acquired and primary HDI resistance. The treatment with HDI upregulated IGF2 transcription in NSCLC cells carrying intrinsic or acquired drug resistance via direct binding of STAT3 in IGF2 P3 and P4 promoters. Acetylated STAT3 emerged upon HDAC inhibition was protected from the proteasome-mediated degradation of STAT3 and functioned as a direct transcription factor for IGF2 expression. Genomic or pharmacological strategies targeting STAT3 diminished the HDI-induced IGF2 mRNA expression and overcame the resistance to HDI treatment in HDI-resistant NSCLC-or patient-derived tumor xenograft models. These findings provide new insights into the role of acetylated STAT3-mediated activation of IGF2 transcription in HDI resistance, suggesting IGF2 or STAT3 as novel targets to overcome HDI resistance in NSCLC.	[Lee, S. C.; Min, H-Y; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Lee, H-Y] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea; [Lee, S. C.; Min, H-Y; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Lee, H-Y] Seoul Natl Univ, Pharmaceut Sci Res Inst, 1 Gwanak Ro, Seoul 08826, South Korea; [Jung, H. J.; Lee, H-Y] Seoul Natl Univ, Interdisciplinary Program Genet Engn, Seoul, South Korea; [Kwon, S. J.; Lee, H-J] Inje Univ, Coll Pharm, Gimhae, South Korea; [Johnson, F. M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Inje University; University of Texas System; UTMD Anderson Cancer Center	Lee, HY (corresponding author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea.; Lee, HY (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, 1 Gwanak Ro, Seoul 08826, South Korea.	hylee135@snu.ac.kr		Lee, Ho-Young/0000-0001-7556-9312; Lee, Hyo-Jong/0000-0003-4826-7954	National Research Foundation of Korea (NRF); Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea [NRF-2011-0017639, NRF-2011-0030001]; Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea (National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea) [1520250]; National Institutes of Health [R01 CA100816]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100816] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea; Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea (National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tomas Ekstrom (Karolinska Hospital, Sweden) to kindly provide the information on the structure and sequence of IGF2 promoters. This work was supported by grants from the National Research Foundation of Korea (NRF), the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea ((Nos. NRF-2011-0017639 and NRF-2011-0030001), the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1520250)) and the National Institutes of Health (R01 CA100816).	Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Desbois-Mouthon C, 2006, INT J CANCER, V119, P2557, DOI 10.1002/ijc.22221; Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Eckstein N, 2009, CANCER RES, V69, P2996, DOI 10.1158/0008-5472.CAN-08-3153; Fantin VR, 2008, CANCER RES, V68, P3785, DOI 10.1158/0008-5472.CAN-07-6091; Fantin VR, 2007, CLIN CANCER RES, V13, P7237, DOI 10.1158/1078-0432.CCR-07-2114; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Huang GS, 2010, CLIN CANCER RES, V16, P2999, DOI 10.1158/1078-0432.CCR-09-3233; Jin QR, 2014, CARCINOGENESIS, V35, P2232, DOI 10.1093/carcin/bgu129; Kim JS, 2015, CANCER LETT, V361, P197, DOI 10.1016/j.canlet.2015.02.038; Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016; Kohda M, 2001, MOL CARCINOGEN, V31, P184, DOI 10.1002/mc.1053; Lawson EA, 2009, J CLIN ENDOCR METAB, V94, P2226, DOI 10.1210/jc.2009-0153; Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109; Lee JG, 2015, BIG DATA RES, V2, P74, DOI 10.1016/j.bdr.2015.01.003; Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1; Licciardi PV, 2013, CURR MOL MED, V13, P640; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lui JC, 2013, P NATL ACAD SCI USA, V110, P6181, DOI 10.1073/pnas.1219079110; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McCue J, 2005, CURR PROTOC TOXICOL; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nordin M, 2014, CELL PROLIFERAT, V47, P189, DOI 10.1111/cpr.12106; O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shin DH, 2013, JNCI-J NATL CANCER I, V105, P1558, DOI 10.1093/jnci/djt263; Shin DH, 2011, MOL CANCER THER, V10, P2437, DOI 10.1158/1535-7163.MCT-11-0235; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang KP, 2008, J BIOL CHEM, V283, P34029, DOI 10.1074/jbc.M803012200; Wang XC, 2012, INT J ONCOL, V41, P1181, DOI 10.3892/ijo.2012.1568; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang XD, 2008, NAT METHODS, V5, P163, DOI [10.1038/nmeth1170, 10.1038/NMETH1170]	50	19	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5515	5526		10.1038/onc.2016.92	http://dx.doi.org/10.1038/onc.2016.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27086926	Green Accepted			2022-12-28	WOS:000386998200006
J	Wen, J; Lee, J; Malhotra, A; Nahta, R; Arnold, AR; Buss, MC; Brown, BD; Maier, C; Kenney, AM; Remke, M; Ramaswamy, V; Taylor, MD; Castellino, RC				Wen, J.; Lee, J.; Malhotra, A.; Nahta, R.; Arnold, A. R.; Buss, M. C.; Brown, B. D.; Maier, C.; Kenney, A. M.; Remke, M.; Ramaswamy, V.; Taylor, M. D.; Castellino, R. C.			WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma	ONCOGENE			English	Article							PHOSPHATASE; PATHWAY; PPM1D; SUPPRESSOR; CHILDREN; TUMORS; GROWTH; MODEL; MDM2; MICE	High-level amplification of the protein phosphatase PPM1D (WIP1) is present in a subset of medulloblastomas (MBs) that have an expression profile consistent with active Sonic Hedgehog (SHH) signaling. We found that WIP1 overexpression increased expression of Shh target genes and cell proliferation in response to Shh stimulation in NIH3T3 and cerebellar granule neuron precursor cells in a p53-independent manner. Thus, we developed a mouse in which WIP1 is expressed in the developing brain under control of the Neurod2 promoter (ND2:WIP1). The external granule layer (EGL) in early postnatal ND2:WIP1 mice exhibited increased proliferation and expression of Shh downstream targets. MB incidence increased and survival decreased when ND2:WIP1 mice were crossed with an Shh-activated MB mouse model. Conversely, Wip1 knockout significantly suppressed MB formation in two independent mouse models of Shh-activated MB. Furthermore, Wip1 knockdown or treatment with a WIP1 inhibitor suppressed the effects of Shh stimulation and potentiated the growth inhibitory effects of SHH pathway-inhibiting drugs in Shh-activated MB cells in vitro. This suggests an important cross-talk between SHH and WIP1 pathways that accelerates tumorigenesis and supports WIP1 inhibition as a potential treatment strategy for MB.	[Wen, J.; Lee, J.; Malhotra, A.; Arnold, A. R.; Buss, M. C.; Brown, B. D.; Maier, C.; Kenney, A. M.; Castellino, R. C.] Aflac Canc & Blood Disorders Ctr, Dept Pediat, Atlanta, GA USA; [Nahta, R.; Kenney, A. M.; Castellino, R. C.] Winship Canc Ctr, Atlanta, GA USA; [Nahta, R.; Kenney, A. M.; Castellino, R. C.] Emory Univ, Sch Med, Atlanta, GA USA; [Nahta, R.] Dept Pharmacol, Atlanta, GA USA; [Remke, M.; Taylor, M. D.] Arthur & Sonia Labatt Brain Tumour Res Ctr, Div Neurosurg, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Program Dev & Stem Cell Biol, Toronto, ON, Canada; [Ramaswamy, V.] Univ Toronto, Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Castellino, R. C.] Childrens Healthcare Atlanta, Atlanta, GA USA	Emory University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's Healthcare of Atlanta (CHOA)	Castellino, RC (corresponding author), 1760 Haygood Dr,NE,Room E394, Atlanta, GA 30322 USA.	rccaste@emory.edu	Arnold, Amanda/AAH-6678-2020; Castellino, Robert/GRF-7847-2022	Ramaswamy, Vijay/0000-0002-6557-895X; Taylor, Michael/0000-0001-7009-3466; Malhotra, Anshu/0000-0002-0255-2680; Roe, Caroline/0000-0003-4680-9553; Remke, Marc/0000-0002-9404-9993	NIH [1R01CA172392, CA159859]; St Baldrick's Foundation; CURE Childhood Cancer Foundation; Dr Mildred-Scheel Foundation; NATIONAL CANCER INSTITUTE [R01CA148699, R01CA159859, R01CA172392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; CURE Childhood Cancer Foundation; Dr Mildred-Scheel Foundation(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We acknowledge Drs James Olson and Xiongbin Lu for providing mice and expression constructs, and Dr Oskar Laur in the Emory University CCCF for plasmid construction. This work was supported by the NIH (1R01CA172392, RCC; CA159859, MDT), St Baldrick's Foundation (RCC), CURE Childhood Cancer Foundation (RCC) and the Dr Mildred-Scheel Foundation (MR).	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; Buss MC, 2015, ONCOGENE, V34, P1126, DOI 10.1038/onc.2014.37; Buss MC, 2012, NEURO-ONCOLOGY, V14, P440, DOI 10.1093/neuonc/nos001; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Castellino RC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-127; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Doucette TA, 2012, NEUROSURGERY, V70, P1003, DOI 10.1227/NEU.0b013e31823e5332; Ellison D, 2002, NEUROPATH APPL NEURO, V28, P257, DOI 10.1046/j.1365-2990.2002.00419.x; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Emelyanov A, 2015, ONCOGENE, V34, P4429, DOI 10.1038/onc.2014.375; Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/nchembio.1427, 10.1038/NCHEMBIO.1427]; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Lu XB, 2008, CELL CYCLE, V7, P164, DOI 10.4161/cc.7.2.5299; Marino S, 2000, GENE DEV, V14, P994; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Samkari A, 2015, EXPERT REV NEUROTHER, V15, P763, DOI 10.1586/14737175.2015.1052796; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yoda A, 2008, J BIOL CHEM, V283, P18969, DOI 10.1074/jbc.M800560200	46	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5552	5564		10.1038/onc.2016.96	http://dx.doi.org/10.1038/onc.2016.96			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27086929	Green Accepted			2022-12-28	WOS:000386998200009
J	Vaidyanathan, S; Cato, K; Tang, L; Pavey, S; Haass, NK; Gabrielli, BG; Duijf, PHG				Vaidyanathan, S.; Cato, K.; Tang, L.; Pavey, S.; Haass, N. K.; Gabrielli, B. G.; Duijf, P. H. G.			In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-CYCLE; CANCER; ANEUPLOIDY; COMPLEX/CYCLOSOME; P53; PROGRESSION; INHIBITOR; ORIGIN; LEADS	Cell cycle genes are often aberrantly expressed in cancer, but how their misexpression drives tumorigenesis mostly remains unclear. From S phase to early mitosis, EMI1 (also known as FBXO5) inhibits the anaphase-promoting complex/ cyclosome, which controls cell cycle progression through the sequential degradation of various substrates. By analyzing 7403 human tumor samples, we find that EMI1 overexpression is widespread in solid tumors but not in blood cancers. In solid cancers, EMI1 overexpression is a strong prognostic marker for poor patient outcome. To investigate causality, we generated a transgenic mouse model in which we overexpressed Emi1. Emi1-overexpressing animals develop a wide variety of solid tumors, in particular adenomas and carcinomas with inflammation and lymphocyte infiltration, but not blood cancers. These tumors are significantly larger and more penetrant, abundant, proliferative and metastatic than control tumors. In addition, they are highly aneuploid with tumor cells frequently being in early mitosis and showing mitotic abnormalities, including lagging and incorrectly segregating chromosomes. We further demonstrate in vitro that even though EMI1 overexpression may cause mitotic arrest and cell death, it also promotes chromosome instability (CIN) following delayed chromosome alignment and anaphase onset. In human solid tumors, EMI1 is co-expressed with many markers for CIN and EMI1 overexpression is a stronger marker for CIN than most well-established ones. The fact that Emi1 overexpression promotes CIN and the formation of solid cancers in vivo indicates that Emi1 overexpression actively drives solid tumorigenesis. These novel mechanistic insights have important clinical implications.	[Vaidyanathan, S.; Cato, K.; Tang, L.; Pavey, S.; Haass, N. K.; Gabrielli, B. G.; Duijf, P. H. G.] Univ Queensland, Translat Res Inst, Diamantina Inst, 37 Kent St, Brisbane, Qld 4102, Australia; [Tang, L.] Fudan Univ, Sch Basic Med Sci, Shanghai, Peoples R China	University of Queensland; Fudan University	Duijf, PHG (corresponding author), Univ Queensland, Translat Res Inst, Diamantina Inst, 37 Kent St, Brisbane, Qld 4102, Australia.	p.duijf@uq.edu.au	Haass, Nikolas K/M-8507-2015; Gabrielli, Brian/B-3655-2011; Duijf, Pascal/E-7110-2012	Haass, Nikolas K/0000-0002-3928-5360; Gabrielli, Brian/0000-0003-3933-1651; vaidyanathan, srividya/0000-0003-3931-5942; Duijf, Pascal/0000-0001-8646-9843	IPRS; University of Queensland (UQ) Centennial Scholarships; UQ Diamantina Institute; UQ; National Breast Cancer Foundation; National Breast Cancer Foundation [ECF-14-008] Funding Source: researchfish	IPRS; University of Queensland (UQ) Centennial Scholarships; UQ Diamantina Institute; UQ; National Breast Cancer Foundation; National Breast Cancer Foundation	We thank Robert Benezra for support, Kym French for animal husbandry, Andrew Brooks for plasmids, Sandrine Roy, Ali Ju, Loredana Spoerri, Yvette Chin and Nicole Chee for technical assistance, Kim-Anh Le Cao for statistical advice, Marianna Datseris for general support and Pulari Thangavelu and Mehlika Hazar-Rethinam for critically reading the manuscript. This work was supported by IPRS and University of Queensland (UQ) Centennial Scholarships (to SV), grants from UQ Diamantina Institute and UQ and a Career Development Fellowship from the National Breast Cancer Foundation (to PHGD).	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Dexter TJ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-127; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Duijf PHG, 2013, INT J CANCER, V132, P2316, DOI 10.1002/ijc.27924; Foijer F, 2008, BBA-REV CANCER, V1786, P73, DOI 10.1016/j.bbcan.2008.07.004; Frye JJ, 2013, NAT STRUCT MOL BIOL, V20, P827, DOI 10.1038/nsmb.2593; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee H, 2006, MOL CELL BIOL, V26, P5373, DOI 10.1128/MCB.00043-06; Lehman NL, 2007, AM J PATHOL, V170, P1793, DOI 10.2353/ajpath.2007.060767; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Malumbres M, 2011, CANCER CELL, V19, P691, DOI 10.1016/j.ccr.2011.05.023; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manning AL, 2014, ONCOGENE, V33, P2487, DOI 10.1038/onc.2013.201; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neelsen KJ, 2013, GENE DEV, V27, P2537, DOI 10.1101/gad.226373.113; Network TCGAR, 2014, NATURE, V511, P1; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ricke RM, 2013, J CELL BIOL, V201, P11, DOI 10.1083/jcb.201301061; Robu ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047658; RUSSELL PJ, 1986, CANCER RES, V46, P2035; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Verschuren EW, 2007, MOL CELL BIOL, V27, P7955, DOI 10.1128/MCB.00908-07; Wang WP, 2013, NAT CELL BIOL, V15, P797, DOI 10.1038/ncb2755; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266	48	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5446	5455		10.1038/onc.2016.94	http://dx.doi.org/10.1038/onc.2016.94			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065322				2022-12-28	WOS:000386677800010
J	Bernaudo, S; Salem, M; Qi, X; Zhou, W; Zhang, C; Yang, W; Rosman, D; Deng, Z; Ye, G; Yang, BB; Vanderhyden, B; Wu, Z; Peng, C				Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Deng, Z.; Ye, G.; Yang, B. B.; Vanderhyden, B.; Wu, Z.; Peng, C.			Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/beta-catenin signalling (vol 35, pg 4816, 2016)	ONCOGENE			English	Correction																		Bernaudo S, 2016, ONCOGENE, V35, P4816, DOI 10.1038/onc.2016.15	1	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4828	4828		10.1038/onc.2016.65	http://dx.doi.org/10.1038/onc.2016.65			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	27477697	hybrid, Green Published			2022-12-28	WOS:000383324700015
J	Luo, S; Li, Y; Ma, R; Liu, J; Xu, P; Zhang, H; Tang, K; Ma, J; Liu, N; Zhang, Y; Sun, Y; Ji, T; Liang, X; Yin, X; Liu, Y; Tong, W; Niu, Y; Wang, N; Wang, X; Huang, B				Luo, S.; Li, Y.; Ma, R.; Liu, J.; Xu, P.; Zhang, H.; Tang, K.; Ma, J.; Liu, N.; Zhang, Y.; Sun, Y.; Ji, T.; Liang, X.; Yin, X.; Liu, Y.; Tong, W.; Niu, Y.; Wang, N.; Wang, X.; Huang, B.			Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; ATP-CITRATE LYASE; CANCER; GROWTH; INHIBITION; ADAPTATION; EXPRESSION; SUCCINATE; FUMARATE; FH	For cancer cells to proliferate, a balance must be built between biomass-forming, glucose-metabolized intermediates and ATP production. How intrinsic glucose carbon flow regulates this balance remains unclear. Here we show that mitochondrial phosphoenolpyruvate carboxykinase (PCK2), the hub molecule linking tricarboxylic acid (TCA) cycle, glycolysis and gluconeogenesis by conversion of mitochondrial oxaloacetate (OAA) to phosphoenolpyruvate, regulates glucose carbon flow direction in stem-like cells that repopulate tumors (tumor-repopulating cells (TRCs)). PCK2 downregulation accelerated biosynthesis and transportation of citrate from mitochondria to the cytosol, leading to cytosolic glucose carbon flow via OAA-malate-pyruvate and acetyl-CoA-fatty acid pathways in TRCs. On the other hand, downregulating PCK2 hindered fumarate carbon flows in TCA cycle, leading to attenuated oxidative phosphorylation. In pathological terms, PCK2 overexpression slowed TRC growth in vitro and impeded tumorigenesis in vivo. Overall, our work unveiled unexpected glucose carbon flows of TRCs in melanoma that have implications for targeting metabolic aspects of melanoma.	[Luo, S.; Li, Y.; Ma, R.; Liu, J.; Xu, P.; Tang, K.; Ma, J.; Liu, N.; Zhang, Y.; Sun, Y.; Ji, T.; Huang, B.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Wang, X.; Huang, B.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Huang, B.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Dong Dan San Tiao 5, Beijing 100005, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Tong, W.; Niu, Y.; Wang, X.; Huang, B.] Peking Union Med Coll, Dong Dan San Tiao 5, Beijing 100005, Peoples R China; [Tong, W.; Niu, Y.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, Beijing, Peoples R China; [Wang, N.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Lab Cell Biomech & Regenerat Med, Wuhan, Peoples R China; [Wang, N.] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL USA	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Huazhong University of Science & Technology; University of Illinois System; University of Illinois Urbana-Champaign	Huang, B (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Dong Dan San Tiao 5, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Peking Union Med Coll, Dong Dan San Tiao 5, Beijing 100005, Peoples R China.	tjhuangbo@hotmail.com	Ma, Ruihua/K-2183-2019	Li, Yong/0000-0001-8265-577X; Liu, Na/0000-0001-9903-1314; luo, shunqun/0000-0002-5728-2112	National Basic Research Program of China [2014CB542100]; National Natural Science Foundation of China [81472653, 81530080, 81661128007]; CAMS Initiative for Innovative Medicine [2016-I2M-1-007]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Basic Research Program of China (2014CB542100), National Natural Science Foundation of China (81472653, 81530080, 81661128007) and CAMS Initiative for Innovative Medicine (2016-I2M-1-007).	Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Cairns RA, 2006, NAT REV CANCER, V11, P85; Chowdhury F, 2010, NAT MATER, V9, P82, DOI [10.1038/NMAT2563, 10.1038/nmat2563]; Costello LC, 2005, MOL CELL BIOCHEM, V280, P1, DOI 10.1007/s11010-005-8841-8; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Kolukula VK, 2014, ONCOTARGET, V5, P1212, DOI 10.18632/oncotarget.1831; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Mendez-Lucas A, 2014, J BIOL CHEM, V289, P22090, DOI 10.1074/jbc.M114.566927; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zelle RM, 2008, APPL ENVIRON MICROB, V74, P2766, DOI 10.1128/AEM.02591-07	27	34	37	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3609	3617		10.1038/onc.2016.520	http://dx.doi.org/10.1038/onc.2016.520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166201				2022-12-28	WOS:000403878600010
J	Tse, BWC; Volpert, M; Ratther, E; Stylianou, N; Nouri, M; McGowan, K; Lehman, ML; McPherson, SJ; Roshan-Moniri, M; Butler, MS; Caradec, J; Gregory-Evans, CY; McGovern, J; Das, R; Takhar, M; Erho, N; Alshalafa, M; Davicioni, E; Schaeffer, EM; Jenkins, RB; Ross, AE; Karnes, RJ; Den, RB; Fazli, L; Gregory, PA; Gleave, ME; Williams, ED; Rennie, PS; Buttyan, R; Gunter, JH; Selth, LA; Russell, PJ; Nelson, CC; Hollier, BG				Tse, B. W. C.; Volpert, M.; Ratther, E.; Stylianou, N.; Nouri, M.; McGowan, K.; Lehman, M. L.; McPherson, S. J.; Roshan-Moniri, M.; Butler, M. S.; Caradec, J.; Gregory-Evans, C. Y.; McGovern, J.; Das, R.; Takhar, M.; Erho, N.; Alshalafa, M.; Davicioni, E.; Schaeffer, E. M.; Jenkins, R. B.; Ross, A. E.; Karnes, R. J.; Den, R. B.; Fazli, L.; Gregory, P. A.; Gleave, M. E.; Williams, E. D.; Rennie, P. S.; Buttyan, R.; Gunter, J. H.; Selth, L. A.; Russell, P. J.; Nelson, C. C.; Hollier, B. G.			Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR SPLICE VARIANTS; CANCER-CELLS; DEPRIVATION THERAPY; BREAST-CANCER; CASTRATION; EXPRESSION; GROWTH; MECHANISMS; BINDING	Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.	[Tse, B. W. C.; Volpert, M.; Ratther, E.; Stylianou, N.; McGowan, K.; Lehman, M. L.; McPherson, S. J.; Williams, E. D.; Gunter, J. H.; Russell, P. J.; Nelson, C. C.; Hollier, B. G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Princess Alexandra Hosp,Translatio, 37 Kent St, Brisbane, Qld 4102, Australia; [Nouri, M.; Roshan-Moniri, M.; Butler, M. S.; Caradec, J.; Fazli, L.; Gleave, M. E.; Rennie, P. S.; Buttyan, R.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Gregory-Evans, C. Y.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada; [McGovern, J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Das, R.; Selth, L. A.] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Das, R.; Selth, L. A.] Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Discipline Med, Adelaide, SA, Australia; [Takhar, M.; Erho, N.; Alshalafa, M.; Davicioni, E.] GenomeDX Biosci, Vancouver, BC, Canada; [Schaeffer, E. M.] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA; [Jenkins, R. B.] Mayo Clin, Dept Pathol, Rochester, MN USA; [Den, R. B.] Mayo Clin, Lab Med, Rochester, MN USA; [Ross, A. E.] Johns Hopkins Univ, Dept Urol, Brady Urol Inst, Baltimore, MD USA; [Karnes, R. J.] Mayo Clin, Dept Urol, Rochester, MN USA; [Den, R. B.] Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Gregory, P. A.] SA Pathol & Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia	Queensland University of Technology (QUT); University of British Columbia; University of British Columbia; Queensland University of Technology (QUT); University of Adelaide; University of Adelaide; GenomeDx Biosciences; Northwestern University; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Mayo Clinic; Jefferson University; Centre for Cancer Biology; SA Pathology; University of South Australia	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Princess Alexandra Hosp,Translatio, 37 Kent St, Brisbane, Qld 4102, Australia.	b.hollier@qut.edu.au	Gregory-Evans, Cheryl Y/G-9550-2011; Gregory, Philip/F-4089-2013; Gunter, Jennifer H/B-8960-2016; Selth, Luke/AAH-4823-2021; Williams, Elizabeth D/B-1538-2008; Russell, Pamela/O-8504-2019; Stylianou, Nataly/GOP-1782-2022; Tse, Brian/X-8909-2019	Gregory, Philip/0000-0002-0999-0632; Gunter, Jennifer H/0000-0003-2447-5732; Selth, Luke/0000-0002-4686-1418; Williams, Elizabeth D/0000-0002-3364-6655; Tse, Brian/0000-0002-5982-8369; Nouri, Mannan/0000-0002-7442-9251; Gleave, Martin/0000-0003-4235-0167; Stylianou, Nataly/0000-0002-8006-5730; Volpert, Marianna/0000-0002-6537-0729; Butler, Miriam/0000-0002-1582-8383; Den, Robert/0000-0002-8653-1763	Cure Cancer Australia Foundation; Cancer Australia PdCCRS grant [108878]; Australian Government Department of Health; Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; Prostate Cancer Foundation of Australia	Cure Cancer Australia Foundation; Cancer Australia PdCCRS grant; Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; Prostate Cancer Foundation of Australia	We thank Dr Leland Chung and Dr Simon Hayward for kindly providing the C4-2B and BPH-1 cell lines, respectively, used in this study. This research was supported by Cure Cancer Australia Foundation, Prostate Cancer Foundation of Australia and Cancer Australia PdCCRS grant 108878 and the Australian Government Department of Health, Queensland Government National and International Research Alliance Program funding to the Australian-Canadian Prostate Cancer Research Alliance, as well as by the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award.	Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen MQ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-89; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glinka Y, 2011, CARCINOGENESIS, V32, P613, DOI 10.1093/carcin/bgq281; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; McShane LM, 2005, EUR J CANCER, V41, P1690, DOI 10.1016/j.ejca.2005.03.032; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Patel P, 2010, MATRIX BIOL, V29, P97, DOI 10.1016/j.matbio.2009.10.004; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Peng Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094422; Pepe MS, 2008, J NATL CANCER I, V100, P1432, DOI 10.1093/jnci/djn326; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ross AE, 2015, EUR UROL; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Sprenger CCT, 2014, HORM CANCER-US, V5, P207, DOI 10.1007/s12672-014-0177-y; Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-9	53	47	48	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3417	3427		10.1038/onc.2016.482	http://dx.doi.org/10.1038/onc.2016.482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092670	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000403340700006
J	Amit, M; Na'ara, S; Leider-Trejo, L; Binenbaum, Y; Kulish, N; Fridman, E; Shabtai-Orbach, A; Wong, RJ; Gil, Z				Amit, M.; Na'ara, S.; Leider-Trejo, L.; Binenbaum, Y.; Kulish, N.; Fridman, E.; Shabtai-Orbach, A.; Wong, R. J.; Gil, Z.			Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CANCER CELL INVASION; NEUROTROPHIC FACTOR; NEURAL INVASION; NEURONAL PLASTICITY; LIGAND COMPLEXES; NEUROPATHIC PAIN; TYROSINE KINASE; CARCINOMA CELLS; BREAST-CANCER	Tumor spread along nerves, a phenomenon known as perineurial invasion, is common in various cancers including pancreatic ductal adenocarcinoma PDAC). Neural invasion is associated with poor outcome, yet its mechanism remains unclear. Using the transgenic Pdx1- Cre/KrasG12D/p53R172H (KPC) mouse model, we investigated the mechanism of neural invasion in PDAC. To detect tissue-specific factors that influence neural invasion by cancer cells, we characterized the perineurial microenvironment using a series of bone marrow transplantation (BMT) experiments in transgenic mice expressing single mutations in the Cx3cr1, GDNF and CCR2 genes. Immunolabeling of tumors in KPC mice of different ages and analysis of human cancer specimens revealed that RET expression is upregulated during PDAC tumorigenesis. BMT experiments revealed that BM-derived macrophages expressing the RET ligand GDNF are highly abundant around nerves invaded by cancer. Inhibition of perineurial macrophage recruitment, using the CSF-1R antagonist GW2580 or BMT from CCR2-deficient donors, reduced perineurial invasion. Deletion of GDNF expression by perineurial macrophages, or inhibition of RET with shRNA or a small-molecule inhibitor, reduced perineurial invasion in KPC mice with PDAC. Taken together, our findings show that RET is upregulated during pancreas tumorigenesis and its activation induces cancer perineurial invasion. Trafficking of BM-derived macrophages to the perineurial microenvironment and secretion of GDNF are essential for pancreatic cancer neural spread.	[Amit, M.] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg Dept, Houston, TX 77030 USA; [Amit, M.; Na'ara, S.; Binenbaum, Y.; Kulish, N.; Fridman, E.; Shabtai-Orbach, A.; Gil, Z.] Technion Israel Inst Technol, Rappaport Inst Med & Res, Clin Res Inst Rambam, Lab Appl Canc Res, Haifa, Israel; [Amit, M.; Na'ara, S.; Fridman, E.; Gil, Z.] Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg,Head & Neck Ctr, Rappaport Inst Med & Res,Rambam Med Ctr, Rambam Healthcare Campus,Clin Res Inst Rambam, 8 HaAliya St,POB 9602, IL-31096 Haifa, Israel; [Leider-Trejo, L.] Tel Aviv Med Ctr & Sch Med, Dept Pathol, Tel Aviv, Israel; [Wong, R. J.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg,Head & Neck Ctr, Rappaport Inst Med & Res,Rambam Med Ctr, Rambam Healthcare Campus,Clin Res Inst Rambam, 8 HaAliya St,POB 9602, IL-31096 Haifa, Israel.	ziv@baseofskull.org			Israeli Science Foundation; Binational US-Israel Science Foundation; Barbara S Goodman ICRF grant; Israel Cancer Association; Rappaport Research Institute; Clinical Research Institute	Israeli Science Foundation(Israel Science Foundation); Binational US-Israel Science Foundation(US-Israel Binational Science Foundation); Barbara S Goodman ICRF grant; Israel Cancer Association; Rappaport Research Institute; Clinical Research Institute	We thank Cindy Cohen for her editorial assistance. We also thank Dr Inna Narodezky for her assistance in reviewing pathological specimens. This study was supported by grants from the Israeli Science Foundation, Binational US-Israel Science Foundation, Barbara S Goodman ICRF grant, Israel Cancer Association, the Rappaport Research Institute and the Clinical Research Institute at Rambam.	Amit M, 2016, NAT REV CANCER, V16, P399, DOI 10.1038/nrc.2016.38; Amit M, 2013, CANCER MED-US, V2, P155, DOI 10.1002/cam4.45; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2010, ANN SURG, V251, P923, DOI 10.1097/SLA.0b013e3181d974d4; Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Cullen-McEwen LA, 2001, KIDNEY INT, V60, P31, DOI 10.1046/j.1523-1755.2001.00767.x; Demir IE, 2010, NEUROGASTROENT MOTIL, V22, P480, DOI 10.1111/j.1365-2982.2009.01428.x; Demir IE, 2016, GUT, V65, P1001, DOI 10.1136/gutjnl-2015-309784; Demir IE, 2015, NAT REV GASTRO HEPAT, V12, P649, DOI 10.1038/nrgastro.2015.166; Demir IE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060529; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Edstrom E, 2000, INT J MOL MED, V6, P469; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Frisk T, 2000, EUR J ENDOCRINOL, V142, P643, DOI 10.1530/eje.0.1420643; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gil Z, 2009, ARCH OTOLARYNGOL, V135, P173, DOI 10.1001/archoto.2008.525; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; He SZ, 2015, MOL CANCER RES, V13, P380, DOI 10.1158/1541-7786.MCR-14-0303; Jamieson NB, 2012, ANN SURG ONCOL, V19, P3581, DOI 10.1245/s10434-012-2370-y; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; Kelly DJ, 2005, J AM SOC NEPHROL, V16, P1654, DOI 10.1681/ASN.2004070578; Kelly K, 2008, FASEB J, V22, P1839, DOI 10.1096/fj.07-097808; Kieseier BC, 2006, CURR OPIN NEUROL, V19, P437, DOI 10.1097/01.wco.0000245365.51823.72; Kim-Fuchs C, 2014, BRAIN BEHAV IMMUN, V40, P40, DOI 10.1016/j.bbi.2014.02.019; Liebl F, 2014, ANN SURG, V260, P900, DOI 10.1097/SLA.0000000000000968; Liebl F, 2013, CLIN CANCER RES, V19, P50, DOI 10.1158/1078-0432.CCR-12-2392; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Qiao S, 2009, CLIN NEUROPATHOL, V28, P105; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Veit C, 2004, CANCER RES, V64, P5291, DOI 10.1158/0008-5472.CAN-04-1112; Wang K, 2014, CARCINOGENESIS, V35, P103, DOI 10.1093/carcin/bgt312; Yamaguchi R, 2002, BRIT J SURG, V89, P1130, DOI 10.1046/j.1365-2168.2002.02184.x; Yoshikawa K, 2012, CANCER SCI, V103, P2012, DOI 10.1111/j.1349-7006.2012.02411.x; Zeng LJ, 2014, J CANCER, V5, P754, DOI 10.7150/jca.10238; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044	53	34	43	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3232	3239		10.1038/onc.2016.483	http://dx.doi.org/10.1038/onc.2016.483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092668				2022-12-28	WOS:000402869800003
J	Jia, H; Song, L; Cong, Q; Wang, J; Xu, H; Chu, Y; Li, Q; Zhang, Y; Zou, X; Zhang, C; Chin, YE; Zhang, X; Li, Z; Zhu, K; Wang, B; Peng, H; Hou, Z				Jia, H.; Song, L.; Cong, Q.; Wang, J.; Xu, H.; Chu, Y.; Li, Q.; Zhang, Y.; Zou, X.; Zhang, C.; Chin, Y. E.; Zhang, X.; Li, Z.; Zhu, K.; Wang, B.; Peng, H.; Hou, Z.			The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; EXPRESSION; RECEPTOR; PATHWAY; FAMILY; GAMMA; SOCS; LOCALIZATION; MIGRATION; ACTIVATOR	The LIM protein AJUBA is a scaffold protein participating in the regulation of cell adhesion, mitosis, DNA damage, cell differentiation, proliferation, migration and gene transcription. However, its roles in tumorigenesis and progression are poorly defined. Here, we report that AJUBA is highly expressed in colorectal cancer (CRC) and promotes CRC cell growth in culture and in xenografted mice via an inhibition of apoptosis. AJUBA represses the expression of IFIT2 gene, an interferon-stimulated gene and a known apoptosis inducer and tumour suppressor to mediate its resistance to apoptosis. Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFN gamma recepter, resulting in an inhibition of STAT1 phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC specimens is negatively correlated with the levels of IFIT2 and pSTAT1. Collectively, these studies demonstrate that AJUBA can promote CRC growth via inhibiting apoptosis and serve as a target for the therapeutics and a marker for diagnosis of CRC.	[Jia, H.; Song, L.; Wang, J.; Xu, H.; Li, Q.; Zhang, Y.; Zou, X.; Peng, H.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Hongqiao Inst Med,Shanghai Tongren Hosp, Shanghai, Peoples R China; [Jia, H.; Chu, Y.; Peng, H.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Digest Endoscopy Ctr, 1111 Xianxia Rd, Shanghai 200336, Peoples R China; [Jia, H.; Wang, J.; Xu, H.; Li, Q.; Zhang, Y.; Zou, X.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cellular Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai, Peoples R China; [Song, L.; Wang, B.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Gen Surg, Shanghai 200011, Peoples R China; [Cong, Q.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai, Peoples R China; [Zhang, C.; Chin, Y. E.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Zhang, X.; Li, Z.] Dalian Med Univ, Canc Ctr, Inst Canc Stem Cells, Dalian, Liaoning, Peoples R China; [Zhu, K.] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Dalian Medical University; Fudan University; Shanghai Jiao Tong University	Peng, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Digest Endoscopy Ctr, 1111 Xianxia Rd, Shanghai 200336, Peoples R China.; Wang, B (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Gen Surg, Shanghai 200011, Peoples R China.; Hou, Z (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Sch Med, 280 South Chongqing Rd,Bldg 7,Room 110, Shanghai 200025, Peoples R China.	wangbin1766@163.com; haixiapeng@163.com; houzy@sjtu.edu.cn	Cong, Qian/AAZ-4404-2021	Jia, Hao/0000-0003-1856-6013; Cong, Qian/0000-0002-9493-5784	Ministry of Sciences & Technology of China [2013CB 910900]; National Science Foundation of China [81372309, 81402376, 31671415, 31601114, 81402177]; Shanghai Committee of Science and Technology [13JC1401302, 15410724200]; Shanghai Municipal Commission of Health and Family Planning [201440426]; Science and Technology Commission of Changning District of Shanghai [CNKW2014F01]; China Postdoctoral Science Foundation [2015M570369]	Ministry of Sciences & Technology of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Shanghai Municipal Commission of Health and Family Planning; Science and Technology Commission of Changning District of Shanghai; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Dr Frank J Rauscher III for his critical reading and insightful suggestions, and Xinyu Hou for her technical support. This work was supported by the Ministry of Sciences & Technology of China (2013CB 910900); the National Science Foundation of China (grant Nos. 81372309, 81402376, 31671415, 31601114, 81402177); Shanghai Committee of Science and Technology (13JC1401302, 15410724200); Shanghai Municipal Commission of Health and Family Planning (No. 201440426); and Science and Technology Commission of Changning District of Shanghai No. CNKW2014F01); and the China Postdoctoral Science Foundation (No. 2015M570369).	Ayyanathan K, 2007, CANCER RES, V67, P9097, DOI 10.1158/0008-5472.CAN-07-2987; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Blouin CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00267; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Burglin TR, 2016, CHROMOSOMA, V125, P497, DOI 10.1007/s00412-015-0543-8; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Du LY, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-51; Gongora C, 1999, B CANCER, V86, P911; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Jia H, 2015, ONCOGENE, V34, P3568, DOI 10.1038/onc.2014.287; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Krebs DL, 2000, J CELL SCI, V113, P2813; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Li Q, 2016, CELL DEATH DIFFER, V23, P158, DOI 10.1038/cdd.2015.83; Mertens C, 2007, CELL, V131, DOI 10.1016/j.cell.2007.10.033; O'Connell D, 2015, AM J PHYSIOL-LUNG C, V309, pL348, DOI 10.1152/ajplung.00099.2015; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109; Quispel WT, 2014, J CLIN IMMUNOL, V34, P84, DOI 10.1007/s10875-013-9959-1; Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080; Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159; Schimizzi GV, 2015, CURR BIOL, V25, pR445, DOI 10.1016/j.cub.2015.02.034; Srichai MB, 2004, J BIOL CHEM, V279, P14398, DOI 10.1074/jbc.M314155200; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Stawowczyk M, 2011, J BIOL CHEM, V286, P7257, DOI 10.1074/jbc.M110.207068; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Tiwari M, 2015, APOPTOSIS, V20, P1019, DOI 10.1007/s10495-015-1136-y; Vlotides G, 2004, BIOCHEM BIOPH RES CO, V320, P1007, DOI 10.1016/j.bbrc.2004.06.051; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhou X, 2013, INT J BIOL SCI, V9, P200, DOI 10.7150/ijbs.5613	34	43	44	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2655	2666		10.1038/onc.2016.418	http://dx.doi.org/10.1038/onc.2016.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893714				2022-12-28	WOS:000401120900004
J	Cacace, A; Sboarina, M; Vazeille, T; Sonveaux, P				Cacace, A.; Sboarina, M.; Vazeille, T.; Sonveaux, P.			Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism	ONCOGENE			English	Article							PENTOSE-PHOSPHATE PATHWAY; TUMOR-CELLS; SERINE PHOSPHORYLATION; SIGNALING PATHWAYS; TRANSPORTER MCT4; GROWTH; LACTATE; HYPOXIA; RESISTANCE; INHIBITION	Cancer cells can use a variety of metabolic substrates to fulfill the bioenergetic and biosynthetic needs of their oncogenic program. Besides bioenergetics, cancer cell metabolism also directly influences genetic, epigenetic and signaling events associated with tumor progression. Many cancer cells are addicted to glutamine, and this addiction is observed in oxidative as well as in glycolytic cells. Although both oxidative and bioreductive glutamine metabolism can contribute to cancer progression and glutamine can further serve to generate peptides (including glutathione) and proteins, we report that glutamine promotes the proliferation of cancer cells independently of its use as a metabolic fuel or as a precursor of glutathione. Extracellular glutamine activates transcription factor signal transducer and activator of transcription 3 (STAT3), which is necessary and sufficient to mediate the proliferative effects of glutamine on glycolytic and oxidative cancer cells. Glutamine also activates transcription factors hypoxia-inducible factor-1, mammalian target of rapamycin and c-Myc, but these factors do not mediate the effects of glutamine on cancer cell proliferation. Our findings shed a new light on the anticancer effects of L-asparaginase that possesses glutaminase activity and converts glutamine into glutamate extracellularly. Conversely, cancer resistance to treatments that block glutamine metabolism could arise from glutamine-independent STAT3 reactivation.	[Cacace, A.; Sboarina, M.; Vazeille, T.; Sonveaux, P.] Catholic Univ Louvain, IREC, Pole Pharmacol, Ave Emmanuel Mounier 52 Box B1-53-09, B-1200 Brussels, Belgium	Universite Catholique Louvain	Sonveaux, P (corresponding author), Catholic Univ Louvain, IREC, Pole Pharmacol, Ave Emmanuel Mounier 52 Box B1-53-09, B-1200 Brussels, Belgium.	pierre.sonveaux@uclouvain.be			Starting Grant from the European Research Council (ERC) [243188 TUMETABO]; Interuniversity Attraction Pole (IAP) from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique [UP7-03, ARC 14/19-058]; Belgian Fonds National de la Recherche Scientifique (FRS-FNRS); Televie and the Belgian Fondation contre le Cancer [2012-186]	Starting Grant from the European Research Council (ERC); Interuniversity Attraction Pole (IAP) from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique; Belgian Fonds National de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Televie and the Belgian Fondation contre le Cancer	This work was supported by a Starting Grant from the European Research Council (ERC no. 243188 TUMETABO), Interuniversity Attraction Pole (IAP) grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058), the Belgian Fonds National de la Recherche Scientifique (FRS-FNRS), the Televie and the Belgian Fondation contre le Cancer (2012-186). PS is a FRS-FNRS Research Associate. AC is a Postdoctoral Fellow and MS a Research Fellow of the Televie. We thank Marylene Focant from Promega (Leiden, The Netherlands) for having provided glutamine/glutamate-Glo Assay kits.	Avramis VI, 2006, INT J NANOMED, V1, P241; Banda M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081126; Bellance N, 2009, FRONT BIOSCI-LANDMRK, V14, P4015, DOI 10.2741/3509; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chandra V, 2015, ARCH PHARM RES, V38, P321, DOI 10.1007/s12272-015-0561-3; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; De Preter G, 2016, ONCOTARGET, V7, P2910, DOI 10.18632/oncotarget.6272; De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Groner Bernd, 2012, JAKSTAT, V1, P211, DOI 10.4161/jkst.21469; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; HAKIMI J, 1979, RES COMMUN CHEM PATH, V26, P581; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Hou PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113865; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Kumarevel T, 2008, NUCLEIC ACIDS RES, V36, P4808, DOI 10.1093/nar/gkn456; Li F, 2013, J GENET GENOMICS, V40, P367, DOI 10.1016/j.jgg.2013.05.002; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Mates JM, 2013, CURR MOL MED, V13, P514; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Munoz J, 2014, ONCOLOGIST, V19, P536, DOI 10.1634/theoncologist.2013-0407; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Parmentier JH, 2015, LEUKEMIA RES, V39, P757, DOI 10.1016/j.leukres.2015.04.008; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115; Payen VL, 2015, CANCER J, V21, P75, DOI 10.1097/PPO.0000000000000098; Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Prickett TD, 2012, CLIN CANCER RES, V18, P4240, DOI 10.1158/1078-0432.CCR-11-1217; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Thorne JL, 2015, INT J CANCER, V137, P1519, DOI 10.1002/ijc.29012; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Van Hee VF, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00228; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yaguchi T, 2010, CELL PHYSIOL BIOCHEM, V26, P125, DOI 10.1159/000320518; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zaganas IV, 2014, NEUROCHEM RES, V39, P471, DOI 10.1007/s11064-014-1251-0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	64	43	44	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2074	2084		10.1038/onc.2016.364	http://dx.doi.org/10.1038/onc.2016.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27748760	Green Accepted			2022-12-28	WOS:000399782500004
J	Xue, Y; Raharja, A; Sim, W; Wong, ESM; Rahmat, SAB; Lane, DP				Xue, Y.; Raharja, A.; Sim, W.; Wong, E. S. M.; Rahmat, S. A. B.; Lane, D. P.			The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage	ONCOGENE			English	Article							LIGHT-MICROSCOPIC CHARACTERIZATION; GERM-CELL TUMORS; STEM-CELLS; PROLIFERATING CELLS; CERVICAL-CARCINOMA; SERTOLI-CELLS; IN-VITRO; P53; MOUSE; EXPRESSION	Overexpression of mutant p53 is a common finding in most cancers but testicular tumours accumulate wild-type p53 (wtp53). In contrast to the accepted concept that p53 homozygous mutant mice do not accumulate mutant p53 in normal cells, our study on a mutant p53 mouse model of Li-Fraumeni syndrome harbouring the hot-spot p53R172H mutation described an elevated level of mutant p53 in non-cancerous mouse tissues. Here we use detailed immunohistochemical analysis to document the expression of p53R172H in mouse testis. In developing and adult testes, p53R172H was expressed in gonocytes, type A, Int, B spermatogonia as well as in pre-Sertoli cells and Leydig cells but was undetectable in spermatocytes and spermatids. A similar staining pattern was demonstrated for wtp53. However, the intensity of wtp53 staining was generally weaker than that of p53R172H, which indicates that the expression of p53R172H can be a surrogate marker of p53 gene transcription. Comparing the responses of wtp53 and p53R172H to irradiation, we found persistent DNA double-strand breaks in p53R172H testes and the formation of giant spermatogonia (GSG) following persistent DNA damage in p53R172H and p53-null mice. Strikingly, we found that p53R172H promotes spontaneous formation of GSG in non-stressed p53R172H ageing mice. Two types of GSG: Viable and Degenerative GSG were defined. We elucidate the factors involved in the formation of GSG: the loss of p53 function is a requirement for the formation of GSG whereas DNA damage acts as a promoting trigger. The formation of GSG does not translate to higher efficacy of testicular tumorigenesis arising from mutant p53 cells, which might be due to the presence of delayed-onset of p53-independent apoptosis.	[Xue, Y.; Sim, W.; Rahmat, S. A. B.; Lane, D. P.] ASTAR, Lab p53, Singapore, Singapore; [Raharja, A.] Barts & London Queen Marys Sch Med & Dent, London, England; [Wong, E. S. M.] ASTAR, Inst Med Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); University of London; Queen Mary University London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Lane, DP (corresponding author), 8A Biomed Grove,Neuros Immunos 06-04-05, Singapore 138648, Singapore.	dplane@p53Lab.a-star.edu.sg	Raharja, Antony/AAR-6885-2020	Raharja, Antony/0000-0001-6163-7927; Lane, David/0000-0003-0551-3545	Agency for Science, Technology and Research (A*STAR) of Singapore	Agency for Science, Technology and Research (A*STAR) of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Farid John Ghadessy for critical reading of the manuscript. We thank Ms Sarah Binte Zulkifli for microscope technical assistance. This work was funded by the Agency for Science, Technology and Research (A*STAR) of Singapore.	Ahmed EA, 2009, BIOL REPROD, V80, P1084, DOI 10.1095/biolreprod.108.071662; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; Ariizumi T, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-44; Barker Nick, 2010, Curr Protoc Stem Cell Biol, VChapter 5, DOI 10.1002/9780470151808.sc05a04s13; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1170, DOI 10.1095/biolreprod65.4.1170; Chiarini-Garcia Helio, 2008, V450, P95, DOI 10.1007/978-1-60327-214-8_6; Chung P, 2016, BMJ CLIN EVID, V2016; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; DEROOIJ DG, 1988, J CELL SCI, P181; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ERICKSON BH, 1983, MUTAT RES, V108, P317, DOI 10.1016/0027-5107(83)90129-X; GINSBERG SS, 1992, CANCER-AM CANCER SOC, V70, P606, DOI 10.1002/1097-0142(19920801)70:3<606::AID-CNCR2820700311>3.0.CO;2-L; Goh AM, 2015, ONCOTARGET, V6, P17968, DOI 10.18632/oncotarget.4956; Guillou L, 1996, AM J PATHOL, V149, P1221; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Manecksha RP, 2009, BJU INT, V104, P1329, DOI 10.1111/j.1464-410X.2009.08854.x; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Oatley JM, 2012, PHYSIOL REV, V92, P577, DOI 10.1152/physrev.00025.2011; Okwun OE, 1996, J REPROD FERTIL, V107, P137, DOI 10.1530/jrf.0.1070137; PENG HQ, 1993, CANCER RES, V53, P3574; Rajpert-De Meyts E, 2016, LANCET, V387, P1762, DOI 10.1016/S0140-6736(15)00991-5; Raverot G, 2005, DEV BIOL, V283, P215, DOI 10.1016/j.ydbio.2005.04.013; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; VONHOCHSTETTER AR, 1985, VIRCHOWS ARCH A, V407, P309; Xue Y, 2015, ONCOTARGET, V6, P34979, DOI 10.18632/oncotarget.5512; Xue YZ, 2010, CANCER RES, V70, P5316, DOI 10.1158/0008-5472.CAN-09-3789; Yin YZ, 2002, J ANDROL, V23, P64, DOI 10.1002/jand.2002.23.1.64	35	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2002	2013		10.1038/onc.2016.374	http://dx.doi.org/10.1038/onc.2016.374			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869164	Green Published, hybrid			2022-12-28	WOS:000398898500010
J	Palacio, L; Krishnan, V; Le, NLO; Sharpless, NE; Beausejour, CM				Palacio, L.; Krishnan, V.; Le, N. L. O.; Sharpless, N. E.; Beausejour, C. M.			Sustained p16(INK4a) expression is required to prevent IR-induced tumorigenesis in mice	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; SENESCENT CELLS; CELLULAR SENESCENCE; TUMOR SUPPRESSION; DNA-DAMAGE; LIFE-SPAN; IN-VIVO; P53; FIBROBLASTS; PROGRESSION	Exposure of murine and human tissues to ionizing radiation (IR) induces the expression of p16(INK4a), a tumor suppressor gene and senescence/aging biomarker. Increased p16(INK4a) expression is often delayed several weeks post exposure to IR. In this context, it remains unclear if it occurs to suppress aberrant cellular growth of potentially transformed cells or is simply a result of IR-induced loss of tissue homeostasis. To address this question, we used a conditional p16(INK4a) null mouse model and determined the impact of p16(INK4a) inactivation long-term post exposure to IR. We found that, in vitro, bone marrow stromal cells exposed to IR enter DNA replication following p16(INK4a) inactivation. However, these cells did not resume growth; instead, they mostly underwent cell cycle arrest in G2. Similarly, delayed inactivation of p16(INK4a) in mice several weeks post exposure to IR resulted in increased BrdU incorporation and cancer incidence. In fact, we found that the onset of tumorigenesis was similar whether p16(INK4a) was inactivated before or after exposure to IR. Overall, our results suggest that IR-induced p16(INK4a) dependent growth arrest is reversible in mice and that sustained p16(INK4a) expression is necessary to protect against tumorigenesis.	[Palacio, L.; Krishnan, V.; Le, N. L. O.; Beausejour, C. M.] Ctr Hosp Univ Ste Justine, Ctr Rech, Montreal, PQ, Canada; [Palacio, L.; Krishnan, V.; Beausejour, C. M.] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada; [Sharpless, N. E.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; [Sharpless, N. E.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA	Universite de Montreal; Universite de Montreal; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Beausejour, CM (corresponding author), Ctr Hosp Univ Ste Justine, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	christian.beausejour@recherche-ste-justine.qc.ca	Krishnan, Vimal/AAP-1616-2020		Canadian Institute of Health Research [MOP-341566]; Fondation des Etoiles; Fonds de recherche du Quebec - Sante; NATIONAL INSTITUTE ON AGING [R01AG024379] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Fondation des Etoiles; Fonds de recherche du Quebec - Sante(Fonds de la Recherche en Sante du Quebec); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to the members of Dr Elie Haddad's laboratory, flow cytometry and animal facility for providing technical support. We also would like to thank Dr Francis Rodier and Mohamad El-Ariss for the critical reading of the manuscript. This work was supported by a grant from the Canadian Institute of Health Research #MOP-341566 to CMB LP has been supported by a student fellowship from the Fondation des Etoiles. CMB is supported by a scientist award from the Fonds de recherche du Quebec - Sante.	Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood-2011-06-361626; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Johmura Y, 2014, MOL CELL, V55, P73, DOI 10.1016/j.molcel.2014.05.003; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Le ONL, 2010, AGING CELL, V9, P398, DOI 10.1111/j.1474-9726.2010.00567.x; Marcoux S, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-252; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Sanoff HK, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju057; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sorrentino JA, 2014, J CLIN INVEST, V124, P169, DOI 10.1172/JCI70960; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; Stein GH, 1999, MOL CELL BIOL, V19, P2109; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Wang Y, 2006, BLOOD, V107, P358, DOI 10.1182/blood-2005-04-1418; Yamakoshi K, 2009, J CELL BIOL, V186, P393, DOI 10.1083/jcb.200904105; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1309	1314		10.1038/onc.2016.298	http://dx.doi.org/10.1038/onc.2016.298			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27568978	Green Accepted, Green Submitted			2022-12-28	WOS:000395861300014
J	Chen, R; Duan, J; Li, L; Ma, Q; Sun, Q; Ma, J; Li, C; Zhou, X; Chen, H; Jing, Y; Zhao, S; Wu, X; Zhang, H				Chen, R.; Duan, J.; Li, L.; Ma, Q.; Sun, Q.; Ma, J.; Li, C.; Zhou, X.; Chen, H.; Jing, Y.; Zhao, S.; Wu, X.; Zhang, H.			mTOR promotes pituitary tumor development through activation of PTTG1	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; TRANSFORMING GENE PTTG; PROLACTIN-SECRETING CELLS; RECEPTOR-DEFICIENT MICE; LACTOTROPH HYPERPLASIA; MAMMALIAN TARGET; SUPPRESSOR GENE; TRANSGENIC MICE; MOUSE MODEL; ADENOMAS	As one of the most common intracranial tumors, pituitary tumor is associated with high morbidity. Effective therapy is currently not available for some pituitary tumors due to the largely undefined pathological processes of pituitary tumorigenesis. In this study, hyperactivation of mammalian/mechanistic target of rapamycin (mTOR) signaling was observed in estrogen-induced rat pituitary tumor and mTOR inhibitor rapamycin blocked the tumor development. Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment. Mechanistically, the expression of pituitary tumor transforming gene 1 (PTTG1) was upregulated in an mTOR complex 1-dependent manner. Overexpressed PTTG1 was crucial in hyperactive mTOR-mediated tumorigenesis. mTOR-PTTG1 signaling axis may be targeted for the treatment of tumors with mTOR hyperactivation.	[Chen, R.; Duan, J.; Li, L.; Ma, Q.; Sun, Q.; Ma, J.; Li, C.; Zhou, X.; Chen, H.; Jing, Y.; Zhao, S.; Zhang, H.] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch,State Key Lab Med Mol Biol, Sch Basic Med,Inst Basic Med Sci,Dept Physiol, Beijing, Peoples R China; [Wu, X.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Internal Med, Div Endocrinol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhang, H (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Physiol & Pathophysiol, Room 445,Old Res Bldg,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	hbzhang@ibms.pumc.edu.cn			National Basic Research Program of China (973 Program) [2015CB553802]; National Natural Science Foundation of China [81372861, 30788004]; Ministry of Education of China (111 project) [B08007]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China (111 project)	We thank the staff of Animal Center, and Department of Pathology, Peking Union Medical College (Beijing, China) for help with in vivo studies and instructions on pathological analysis. This work was supported by the National Basic Research Program of China (973 Program) (2015CB553802), the National Natural Science Foundation of China (81372861, 30788004), and the Ministry of Education of China (111 project: B08007).	Abbud RA, 2005, MOL ENDOCRINOL, V19, P1383, DOI 10.1210/me.2004-0403; Asa SL, 1999, ENDOCRINOLOGY, V140, P5348, DOI 10.1210/en.140.11.5348; Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Cano DA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00203; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carson RP, 2012, NEUROBIOL DIS, V45, P369, DOI 10.1016/j.nbd.2011.08.024; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Cruz-Soto ME, 2002, ENDOCRINOLOGY, V143, P4429, DOI 10.1210/en.2002-220173; Donangelo I, 2006, ENDOCRINOLOGY, V147, P4781, DOI 10.1210/en.2006-0544; Dworakowska D, 2009, ENDOCR-RELAT CANCER, V16, P1329, DOI 10.1677/ERC-09-0101; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Feng ZZ, 2012, MED ONCOL, V29, P304, DOI 10.1007/s12032-010-9775-x; Fukuoka H, 2011, J CLIN INVEST, V121, P4712, DOI 10.1172/JCI60417; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hikake T, 2009, J ENDOCRINOL, V203, P231, DOI 10.1677/JOE-09-0232; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee M, 2015, CLIN CANCER RES, V21, P3204, DOI 10.1158/1078-0432.CCR-15-0288; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liang M, 2015, TUMOR BIOL, V36, P7085, DOI 10.1007/s13277-015-3420-4; Lin SJ, 2015, ONCOTARGET, V6, P39329, DOI 10.18632/oncotarget.5744; Lin YH, 2015, TUMOUR BIOL; Lin Y, 2009, ENDOCR-RELAT CANCER, V16, P301, DOI 10.1677/ERC-08-0167; Lines KE, 2016, MOL CELL ENDOCRINOL, V421, P68, DOI 10.1016/j.mce.2015.08.024; Lu CX, 2008, ENDOCRINOLOGY, V149, P3339, DOI 10.1210/en.2007-1696; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Malhowski AJ, 2011, HUM MOL GENET, V20, P1290, DOI 10.1093/hmg/ddq570; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marko NF, 2012, NAT REV ENDOCRINOL, V8, P572, DOI 10.1038/nrendo.2012.143; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40; Monsalves E, 2014, ENDOCR-RELAT CANCER, V21, pR331, DOI 10.1530/ERC-14-0188; Musat M, 2005, ENDOCR-RELAT CANCER, V12, P423, DOI 10.1677/erc.1.00949; Palumbo T, 2013, ONCOGENE, V32, P1651, DOI 10.1038/onc.2012.190; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pelletier G, 2003, NEUROENDOCRINOLOGY, V77, P324, DOI 10.1159/000070898; Peng H, 2013, ONCOGENE, V32, P4702, DOI 10.1038/onc.2012.481; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rubinfeld H, 2012, ENDOCRINE, V42, P285, DOI 10.1007/s12020-012-9682-3; Schuff KG, 2002, J CLIN INVEST, V110, P973, DOI 10.1172/JCI200215912; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Stefaneanu L, 1999, ENDOCRINOLOGY, V140, P3881, DOI 10.1210/en.140.9.3881; Thompson AD, 2005, FEBS LETT, V579, P3195, DOI 10.1016/j.febslet.2005.05.008; Vlotides G, 2006, MOL ENDOCRINOL, V20, P3321, DOI 10.1210/me.2006-0280; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Xie R, 2015, J NEURO-ONCOL, V125, P79, DOI 10.1007/s11060-015-1895-x; Yin Z, 2008, GENESIS, V46, P37, DOI 10.1002/dvg.20362; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Yu J, 2006, CANCER RES, V66, P9461, DOI 10.1158/0008-5472.CAN-06-1895; Yu R, 2010, PROG BRAIN RES, V182, P207, DOI 10.1016/S0079-6123(10)82009-6; Zha XJ, 2011, CANCER RES, V71, P13, DOI 10.1158/0008-5472.CAN-10-1668; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	62	25	26	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					979	988		10.1038/onc.2016.264	http://dx.doi.org/10.1038/onc.2016.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27524416				2022-12-28	WOS:000394169100010
J	Li, G; Li, M; Hu, J; Lei, R; Xiong, H; Ji, H; Yin, H; Wei, Q; Hu, G				Li, G.; Li, M.; Hu, J.; Lei, R.; Xiong, H.; Ji, H.; Yin, H.; Wei, Q.; Hu, G.			The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis	ONCOGENE			English	Article							TARGETING HEXOKINASE 2; AEROBIC GLYCOLYSIS; GLUCOSE-METABOLISM; MIR-182 EXPRESSION; UP-REGULATION; FATTY-ACID; CANCER; CELL; KINASE; MICRORNA	Reprogrammed metabolism is one of the hallmarks of cancer. The dysregulation of glycolysis in cancer has been heavily studied. However, it remains largely unclear how other metabolic processes are regulated in cancer cells. Here we show that microRNA-182 (miR-182) suppresses pyruvate dehydrogenase (PDH) kinase 4 (PDK4) and promotes lung tumorigenesis. miR-182 is dysregulated and inversely correlated with PDK4 in human lung adenocarcinomas. The miR-182-PDK4 axis regulates lung cancer cell growth by modulating the activity of PDH, the gatekeeping enzyme of pyruvate flux into acetyl-CoA, and subsequently de novo lipogenesis of cancer cells. Suppression of lipogenesis by silencing ATP citrate lyase (ACLY) and fatty acid synthase (FASN) or by chemical inhibitors diminishes the effects of miR-182-PDK4 in tumor growth. Alteration of de novo lipogenesis also affects reactive oxygen species (ROS) production and the downstream JNK signaling pathway. Hence, our work suggests that the miR-182-PDK4 axis is a crucial regulator of cancer cell metabolism and a potential target for antitumor therapy.	[Li, G.; Hu, J.; Lei, R.; Hu, G.] Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, G.; Hu, J.; Lei, R.; Hu, G.] Shanghai Jiao Tong Univ, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, G.; Hu, J.; Lei, R.; Hu, G.] Univ Chinese Acad Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, M.; Yin, H.] Chinese Acad Sci, Key Lab Food Safety Res, Inst Nutr Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Xiong, H.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China; [Ji, H.] Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Wei, Q.] Tongji Univ, Sch Med, Dept Pathol, Shanghai Peoples Hosp 10, 301 Yanchang Rd, Shanghai 200072, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Huazhong University of Science & Technology; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Tongji University	Hu, G (corresponding author), Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, G (corresponding author), Univ Chinese Acad Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Wei, Q (corresponding author), Tongji Univ, Sch Med, Dept Pathol, Shanghai Peoples Hosp 10, 301 Yanchang Rd, Shanghai 200072, Peoples R China.	weiqing1971@aliyun.com; ghhu@sibs.ac.cn		Hu, Guohong/0000-0002-2980-5166; Li, Gang/0000-0001-9761-1323; yin, hui yong/0000-0001-7049-1560	Ministry of Science and Technology of China [2011CB510105, 2012ZX09506-001-005, 2013CB910904]; National Natural Science Foundation of China [81430070, 81222032, 31371409]; Chinese Academy of Sciences [XDA01040402]; Science and Technology Commission of Shanghai Municipality [14431900800]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	We thank Dr Weihong Sun at the Tissue Bank of the Institute of Health Sciences for technical support. The study was funded by grants from the Ministry of Science and Technology of China (2011CB510105, 2012ZX09506-001-005 and 2013CB910904), National Natural Science Foundation of China (81430070, 81222032 and 31371409), Chinese Academy of Sciences (XDA01040402) and Science and Technology Commission of Shanghai Municipality (14431900800).	Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen B, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-228; Chiang CH, 2013, BBA-GEN SUBJECTS, V1830, P3067, DOI 10.1016/j.bbagen.2013.01.009; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Fang ZY, 2012, CELL RES, V22, P565, DOI 10.1038/cr.2011.149; Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Horie T, 2009, BIOCHEM BIOPH RES CO, V389, P315, DOI 10.1016/j.bbrc.2009.08.136; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; LABER B, 1987, BIOCHEM J, V248, P351, DOI 10.1042/bj2480351; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liu AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086872; Liu H, 2013, INT J COLORECTAL DIS, V28, P697, DOI 10.1007/s00384-013-1674-0; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; OOKHTENS M, 1984, AM J PHYSIOL, V247, pR146, DOI 10.1152/ajpregu.1984.247.1.R146; Park YY, 2013, HEPATOLOGY, V58, P182, DOI 10.1002/hep.26310; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Qin J, 2014, GENE, V538, P342, DOI 10.1016/j.gene.2013.12.043; Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040; SABINE JR, 1967, CANCER RES, V27, P793; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Singh Pankaj K, 2011, Mol Cell Pharmacol, V3, P125; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sun JB, 2015, INT J CLIN EXP PATHO, V8, P4755; Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Wang J, 2015, ONCOTARGET, V6, P19456, DOI 10.18632/oncotarget.3318; Wang PY, 2013, ONCOL LETT, V6, P1681, DOI 10.3892/ol.2013.1593; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei Q, 2015, THORAC CANCER, V6, P2, DOI 10.1111/1759-7714.12164; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang WB, 2014, ONCOTARGET, V5, P740, DOI 10.18632/oncotarget.1608; Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10; Zhu HL, 2014, BIOCHEM BIOPH RES CO, V450, P857, DOI 10.1016/j.bbrc.2014.06.073	57	47	48	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					989	998		10.1038/onc.2016.265	http://dx.doi.org/10.1038/onc.2016.265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27641336				2022-12-28	WOS:000394169100011
J	Bianchi-Smiraglia, A; Bagati, A; Fink, EE; Moparthy, S; Wawrzyniak, JA; Marvin, EK; Battaglia, S; Jowdy, P; Kolesnikova, M; Foley, CE; Berman, AE; Kozlova, NI; Lipchick, BC; Paul-Rosner, LM; Bshara, W; Ackroyd, JJ; Shewach, DS; Nikiforov, MA				Bianchi-Smiraglia, A.; Bagati, A.; Fink, E. E.; Moparthy, S.; Wawrzyniak, J. A.; Marvin, E. K.; Battaglia, S.; Jowdy, P.; Kolesnikova, M.; Foley, C. E.; Berman, A. E.; Kozlova, N. I.; Lipchick, B. C.; Paul-Rosner, L. M.; Bshara, W.; Ackroyd, J. J.; Shewach, D. S.; Nikiforov, M. A.			Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools	ONCOGENE			English	Article							MELANOMA-CELL INVASION; MATRIX-METALLOPROTEINASE; LINEAGE SURVIVAL; RHO-GTPASES; MITF; EXPRESSION; PROLIFERATION; METASTASIS; RESISTANCE; DEPLETION	Melanoma progression is associated with increased invasion and, often, decreased levels of microphthalmia-associated transcription factor (MITF). Accordingly, downregulation of MITF induces invasion in melanoma cells; however, little is known about the underlying mechanisms. Here, we report for the first time that depletion of MITF results in elevation of intracellular GTP levels and increased amounts of active (GTP-bound) RAC1, RHO-A and RHO-C. Concomitantly, MITF-depleted cells display larger number of invadopodia and increased invasion. We further demonstrate that the gene for guanosine monophosphate reductase (GMPR) is a direct MITF target, and that the partial repression of GMPR accounts mostly for the above phenotypes in MITF-depleted cells. Reciprocally, transactivation of GMPR is required for MITF-dependent suppression of melanoma cell invasion, tumorigenicity and lung colonization. Moreover, loss of GMPR accompanies downregulation of MITF in vemurafenib-resistant BRAF(V600E)-melanoma cells and underlies the increased invasion in these cells. Our data uncover novel mechanisms linking MITF-dependent inhibition of invasion to suppression of guanylate metabolism.	[Bianchi-Smiraglia, A.; Bagati, A.; Fink, E. E.; Moparthy, S.; Wawrzyniak, J. A.; Marvin, E. K.; Jowdy, P.; Kolesnikova, M.; Foley, C. E.; Lipchick, B. C.; Paul-Rosner, L. M.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317, Buffalo, NY 14263 USA; [Battaglia, S.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Berman, A. E.; Kozlova, N. I.] Orekhovich Inst Biomed Chem, Moscow, Russia; [Bshara, W.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Ackroyd, J. J.; Shewach, D. S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Wawrzyniak, J. A.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Wawrzyniak, J. A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Roswell Park Cancer Institute; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317, Buffalo, NY 14263 USA.	mikhail.nikiforov@roswellpark.org	EBerman, Albert/F-5042-2017; Kozlova, Nadezda/ABD-7878-2020	Kolesnikova, Masha/0000-0001-7803-9632; Bianchi-Smiraglia, Anna/0000-0002-5963-103X; Ackroyd, Jeffrey/0000-0003-3796-4447; Fink, Emily/0000-0003-2738-5732	NIH [CA120244, CA190533, CA083081]; Ruth L Kirschstein National Research Service Award [F32CA189622]; American Cancer Society [RSG-10-121-01]; Jennifer Linscott Tietgen Foundation; NCI Cancer Center [CA016056]; NATIONAL CANCER INSTITUTE [R01CA083081, R01CA120244, F32CA189622, R01CA190533, P30CA016056] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Jennifer Linscott Tietgen Foundation; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Dominic Smiraglia (Roswell Park Cancer Institute) for critical reading of the manuscript and to the Pathology Resource Network and the Clinical Data Network at Roswell Park Cancer Institute for providing human specimens. This work has been supported by NIH grants CA120244 and CA190533 (MAN), CA083081 (DSS), Ruth L Kirschstein National Research Service Award F32CA189622 (AB-S); American Cancer Society grant RSG-10-121-01 (MAN) and Jennifer Linscott Tietgen Foundation (MAN). This work was also supported in part by NCI Cancer Center Support Grant CA016056 to the Roswell Park Cancer Institute.	Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bauer NN, 2007, EXP CELL RES, V313, P3832, DOI 10.1016/j.yexcr.2007.08.017; Bianchi-Smiraglia A, 2015, CELL DEATH DIFFER, V22, P1858, DOI 10.1038/cdd.2015.47; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Fink EE, 2016, LEUKEMIA, V30, P104, DOI 10.1038/leu.2015.190; FRANKLIN TJ, 1977, EUR J BIOCHEM, V77, P113, DOI 10.1111/j.1432-1033.1977.tb11648.x; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Golan T, 2015, MOL CELL, V59, P664, DOI 10.1016/j.molcel.2015.06.028; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hallett MA, 2003, AM J PHYSIOL-CELL PH, V285, pC129, DOI 10.1152/ajpcell.00007.2003; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Imamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kollareddy M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8389; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mondin M, 2007, BIOCHEM PHARMACOL, V73, P1491, DOI 10.1016/j.bcp.2006.12.025; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Salti GI, 2000, CANCER RES, V60, P5012; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vachtenheim J, 2015, EXP DERMATOL, V24, P481, DOI 10.1111/exd.12724; van Horssen R, 2009, J BIOL CHEM, V284, P1620, DOI 10.1074/jbc.M806974200; Wang JH, 2015, J INVEST DERMATOL, V135, P532, DOI 10.1038/jid.2014.418; Wawrzyniak JA, 2013, CELL REP, V5, P493, DOI 10.1016/j.celrep.2013.09.015; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Zubrilov I, 2015, CANCER LETT, V361, P86, DOI 10.1016/j.canlet.2015.02.041	50	20	21	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					84	96		10.1038/onc.2016.178	http://dx.doi.org/10.1038/onc.2016.178			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27181209	Green Accepted			2022-12-28	WOS:000394069100008
J	Su, R; Dong, L; Zou, D; Zhao, H; Ren, Y; Li, F; Yi, P; Li, L; Zhu, Y; Ma, Y; Wang, J; Wang, F; Yu, J				Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Yi, P.; Li, L.; Zhu, Y.; Ma, Y.; Wang, J.; Wang, F.; Yu, J.			microRNA-23a,-27a and-24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DIFFERENTIATION; ERYTHROLEUKEMIA; PATHWAY; GATA-1; CELLS; ERYTHROPOIESIS; PROLIFERATION; RUXOLITINIB	Acute erythroid leukemia (AEL) is characterized by lower incidence, poorer prognosis and worse survival than other types of leukemia and results from collaboration of malignant proliferation and erythroid differentiation blockage. The expression, function and therapeutic significance of noncoding RNAs in AEL have not been well studied. Here, we show that one miRNA cluster, including miR-23a,-27a and -24, is dramatically downregulated in AEL patients. Restoration of miR-23a,-27a and -24 expression induces apoptosis and erythropoiesis, inhibits adverse growth and partly relieves the leukemic symptoms of AEL patients. At the whole-genome scale, we identify that miR-23a,-27a and -24 synergistically target multiple members of the oncogenic gp130-JAK1-Stat3 pathway, and thus reinforce their inhibition on the cascade to regulate cell proliferation and apoptosis. Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes induced by miR-23a,-27a and -24 inhibitors. Furthermore, miR-23a cluster-mediated-inactivation of the JAK1-Stat3 pathway promotes the expression and activity of GATA1 via inhibiting PU. 1, thereby improving erythroid differentiation. Collectively, we reveal an important regulatory circuit comprising GATA1, the miR-23a cluster and gp130-JAK1-Stat3 pathway, that synergistically facilitates apoptosis and erythropoiesis and restrains adverse proliferation, indicating the therapeutic significance of miR-23a,-27a and -24 for AEL treatment.	[Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Zhu, Y.; Ma, Y.; Wang, F.; Yu, J.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Dept Biochem, Beijing, Peoples R China; [Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Zhu, Y.; Ma, Y.; Wang, J.; Wang, F.; Yu, J.] Peking Union Med Coll, Beijing, Peoples R China; [Su, R.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45219 USA; [Zou, D.] Chongqing Canc Inst, Dept Gynecol Oncol, Chongqing, Peoples R China; [Yi, P.; Li, L.] Third Millitary Med Univ, Dept Obstet & Gynecol, Daping Hosp, Inst Surg Res, Chongqing, Peoples R China; [Wang, J.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathophysiol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University System of Ohio; University of Cincinnati; Army Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS	Su, R (corresponding author), Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45219 USA.; Wang, F; Yu, J (corresponding author), Peking Union Med Coll, Inst Basic Med Sci, New Res Bldg,Room 608,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	suri@ucmail.uc.edu; wo_wfang@hotmail.com; j-yu@ibms.pumc.edu.cn	Su, Rui/Y-8157-2018; Dong, Lei/AAA-9495-2020	Dong, Lei/0000-0001-9574-0148; Yu, Jia/0000-0003-3499-5133; Su, Rui/0000-0002-4807-6229	National Key Basic Research Program of China [2011CBA01100]; National Natural Science Foundation of China [81530007, 31040021, 31171311, 31471227, 30970616]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank for Dr Jianjun Chen for his assistance and constructive suggestions. This work was supported by the National Key Basic Research Program of China (2011CBA01100 to JY); National Natural Science Foundation of China (81530007 to JY, 31040021 to JY, 31171311 to FW, 31471227 to FW and 30970616 to FW).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Blum S, 2012, BLOOD, V120, P1974, DOI 10.1182/blood-2011-11-390047; Cui JW, 2007, BLOOD, V110, P2631, DOI 10.1182/blood-2006-10-053850; de Thonel A, 2010, BLOOD, V116, P85, DOI 10.1182/blood-2009-09-241778; Eaves CJ, 2010, NEW ENGL J MED, V362, P2326, DOI 10.1056/NEJMcibr1003522; Fan CQ, 2011, LEUKEMIA LYMPHOMA, V52, P502, DOI 10.3109/10428194.2010.543712; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Gallipoli P, 2014, BLOOD, V124, P1492, DOI 10.1182/blood-2013-12-545640; Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010; Goldberg SL, 1998, AM J CLIN ONCOL-CANC, V21, P42, DOI 10.1097/00000421-199802000-00010; Grossmann V, 2013, LEUKEMIA, V27, P1940, DOI 10.1038/leu.2013.144; Hasserjian RP, 2010, BLOOD, V115, P1985, DOI 10.1182/blood-2009-09-243964; Hegde S, 2009, ONCOGENE, V28, P3349, DOI 10.1038/onc.2009.202; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kadri Z, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000123; Kayali S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046799; Lo MC, 2013, LEUKEMIA, V27, P2272, DOI 10.1038/leu.2013.197; Lunghi P, 2005, LEUKEMIA, V19, P234, DOI 10.1038/sj.leu.2403585; Ma YN, 2015, EMBO J, V34, P361, DOI 10.15252/embj.201489957; Ma YN, 2013, MOL CELL BIOL, V33, P3994, DOI 10.1128/MCB.00623-13; Mancini E, 2012, EMBO J, V31, P351, DOI 10.1038/emboj.2011.390; Mascarenhas J, 2012, CLIN CANCER RES, V18, P3008, DOI 10.1158/1078-0432.CCR-11-3145; Maude SL, 2015, BLOOD, V125, P1759, DOI 10.1182/blood-2014-06-580480; McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184; Monaghan KA, 2011, LEUKEMIA, V25, P1891, DOI 10.1038/leu.2011.175; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Neri LM, 2014, LEUKEMIA, V28, P739, DOI 10.1038/leu.2013.226; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Ren JG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012520; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Santos FPS, 2009, LEUKEMIA, V23, P2275, DOI 10.1038/leu.2009.181; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Su R, 2015, ONCOGENE, V34, P3226, DOI 10.1038/onc.2014.274; Suzuki M, 2013, GENES CELLS, V18, P921, DOI 10.1111/gtc.12086; Teramo A, 2013, BLOOD, V121, P3843, DOI 10.1182/blood-2012-07-441378; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Wang F, 2014, NUCLEIC ACIDS RES, V42, P442, DOI 10.1093/nar/gkt848; Wells AW, 2001, J CLIN PATHOL, V54, P608, DOI 10.1136/jcp.54.8.608; Zhang P, 2000, BLOOD, V96, P2641; Zhou T, 2014, LEUKEMIA, V28, P471, DOI 10.1038/leu.2013.299; Zhu Y, 2013, NUCLEIC ACIDS RES, V41, P4129, DOI 10.1093/nar/gkt093	44	25	25	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6001	6014		10.1038/onc.2016.127	http://dx.doi.org/10.1038/onc.2016.127			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27086927				2022-12-28	WOS:000388509400007
J	Fremin, C; Guegan, JP; Plutoni, C; Mahaffey, J; Philips, MR; Emery, G; Meloche, S				Fremin, C.; Guegan, J-P; Plutoni, C.; Mahaffey, J.; Philips, M. R.; Emery, G.; Meloche, S.			ERK1/2-induced phosphorylation of R-Ras GTPases stimulates their oncogenic potential	ONCOGENE			English	Article							P21(RAS) S-NITROSYLATION; GENE-EXPRESSION; BCL-XL; K-RAS; TC21; PROTEIN; PHOSPHOPROTEOMICS; OVEREXPRESSION; TRANSFORMATION; M-RAS/R-RAS3	The Ras-related (R-Ras) isoforms TC21, R-Ras and M-Ras are members of the Ras superfamily of small GTPases. R-Ras family proteins are frequently overexpressed in human cancers, and expression of activated mutants of these GTPases is sufficient to induce cell transformation. Unlike Ras, few activating mutations of R-Ras proteins have been reported in human cancer, and very little is known about the regulation of their activity. In this study, we report that TC21 and R-Ras are phosphorylated on a conserved serine, Ser186 and Ser201, respectively, in intact cells. This residue is located in the C-terminal hypervariable region of the proteins and is not conserved in M-Ras. We show that the MAP kinases ERK1/2 phosphorylate TC21 and R-Ras on this C-terminal serine residue both in vitro and in vivo. Phosphorylation of R-Ras proteins does not affect their subcellular localization or stability but rather stimulates their activation. Phosphorylation-defective mutants of R-Ras and TC21 are compromised in their ability to promote cancer cell adhesion and migration/invasion, respectively. Importantly, we show that phosphorylation of TC21 and R-Ras potentiates their tumorigenic activity in immunodeficient mice. Our results identify a novel regulatory mechanism of the small GTPases TC21 and R-Ras that controls their oncogenic potential.	[Fremin, C.; Guegan, J-P; Plutoni, C.; Emery, G.; Meloche, S.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Mahaffey, J.; Philips, M. R.] NYU, Dept Med, Perlmutter Canc Inst, 550 1St Ave, New York, NY 10016 USA; [Mahaffey, J.; Philips, M. R.] NYU, Dept Cell Biol & Pharmacol, Perlmutter Canc Inst, 550 1St Ave, New York, NY 10016 USA; [Emery, G.; Meloche, S.] Univ Montreal, Program Mol Biol, Montreal, PQ, Canada; [Emery, G.] Univ Montreal, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Meloche, S.] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada	Universite de Montreal; New York University; New York University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Res Immunol & Canc, 2950 Chemin Polytech, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca		Mark, Philips/0000-0002-1179-8156; Guegan, Jean-Philippe/0000-0002-3993-0956; Emery, Gregory/0000-0002-6874-6875	Cole Foundation; Association pour la Recherche centre le Cancer (ARC); Fonds de la recherche en sante du Quebec (FRSQ); Fondation pour la Recherche Medicale (FRM); Canadian Institutes of Health Research; NATIONAL CANCER INSTITUTE [R01CA116034] Funding Source: NIH RePORTER	Cole Foundation; Association pour la Recherche centre le Cancer (ARC); Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B Alarcon (CBMSO, Madrid) for pGex-4T3-TC21 and pEGFP-TC21 plasmids. CF is a recipient of fellowships from the Cole Foundation, the Association pour la Recherche centre le Cancer (ARC) and the Fonds de la recherche en sante du Quebec (FRSQ). JPG is a recipient of fellowships from the Fondation pour la Recherche Medicale (FRM), the Cole Foundation and the Fonds de la recherche en sante du Quebec (FRSQ). SM and GE hold the Canada Research Chairs in Cellular Signaling and Vesicle Transport and Cell Signaling, respectively. This work was supported by grants from the Canadian Institutes of Health Research to SM and GE.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Castro AF, 2012, J CELL BIOCHEM, V113, P1253, DOI 10.1002/jcb.23458; Clark GJ, 1996, ONCOGENE, V12, P169; Courcelles M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.25; COX AD, 1994, ONCOGENE, V9, P3281; Delgado P, 2009, NAT IMMUNOL, V10, P880, DOI 10.1038/ni.1749; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fremin C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-8; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grosstessner-Hain K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008540; Guo X, 2006, ONCOGENE, V25, P4241, DOI 10.1038/sj.onc.1209452; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Kim JY, 2013, P NATL ACAD SCI USA, V110, P12414, DOI 10.1073/pnas.1220674110; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Lee JH, 2011, INT J DERMATOL, V50, P956, DOI 10.1111/j.1365-4632.2010.04846.x; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Luo HR, 2010, INT J ONCOL, V37, P853, DOI 10.3892/ijo_00000736; Macha MA, 2010, J ORAL PATHOL MED, V39, P477, DOI 10.1111/j.1600-0714.2009.00854.x; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Sandri C, 2012, CELL RES, V22, P1479, DOI 10.1038/cr.2012.110; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Sawada J, 2012, CANCER CELL, V22, P235, DOI 10.1016/j.ccr.2012.06.013; Sung PJ, 2013, P NATL ACAD SCI USA, V110, P20593, DOI 10.1073/pnas.1306431110; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109	35	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5692	5698		10.1038/onc.2016.122	http://dx.doi.org/10.1038/onc.2016.122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27086924				2022-12-28	WOS:000386998300012
J	Joly, AL; Deepti, A; Seignez, A; Goloudina, A; Hebrard, S; Schmitt, E; Richaud, S; Fourmaux, E; Hammann, A; Collura, A; Svrcek, M; Jego, G; Robinet, E; Solary, E; Demidov, O; Kohli, E; Garrido, C				Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Collura, A.; Svrcek, M.; Jego, G.; Robinet, E.; Solary, E.; Demidov, O.; Kohli, E.; Garrido, C.			The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development (vol 35, pg 2842, 2016)	ONCOGENE			English	Correction									[Joly, A-L] INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, Dijon, France; [Joly, A-L] Lab Excellence LipSTIC, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Joly, AL (corresponding author), INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, Dijon, France.; Joly, AL (corresponding author), Lab Excellence LipSTIC, Dijon, France.		Garrido, Carolina/GWM-5557-2022; Demidov, Oleg/AAC-4462-2021; Demidov, Oleg/U-2050-2017; Garrido, carmen/G-1633-2018	Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				Joly AL, 2016, ONCOGENE, V35, P2842, DOI 10.1038/onc.2015.242	1	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2948	2948		10.1038/onc.2016.63	http://dx.doi.org/10.1038/onc.2016.63			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	27251741	Bronze			2022-12-28	WOS:000377473700015
J	Riverso, M; Montagnani, V; Stecca, B				Riverso, M.; Montagnani, V.; Stecca, B.			KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; TUMOR-SUPPRESSOR; SELF-RENEWAL; STEM-CELL; MUTATIONS; CANCER; INDUCTION; GENE; BRAF; PHOSPHORYLATION	Melanoma is the most lethal form of skin cancer and treatment of metastatic melanoma remains challenging. BRAF/MEK inhibitors show only temporary benefit due the occurrence of resistance and immunotherapy is effective only in a subset of patients. To improve patient survival, there is a need to better understand molecular mechanisms that drive melanoma growth and operate downstream of the mitogen activated protein kinase (MAPK) signaling. The Kruppel-like factor 4 (KLF4) is a zinc-finger transcription factor that plays a critical role in embryonic development, stemness and cancer, where it can act either as oncogene or tumor suppressor. KLF4 is highly expressed in post-mitotic epidermal cells, but its role in melanoma remains unknown. Here, we address the function of KLF4 in melanoma and its interaction with the MAPK signaling pathway. We find that KLF4 is highly expressed in a subset of human melanomas. Ectopic expression of KLF4 enhances melanoma cell growth by decreasing apoptosis. Conversely, knock-down of KLF4 reduces melanoma cell proliferation and induces cell death. In addition, depletion of KLF4 reduces melanoma xenograft growth in vivo. We find that the RAS/RAF/MEK/ERK signaling positively modulates KLF4 expression through the transcription factor E2F1, which directly binds to KLF4 promoter. Overall, our data demonstrate the pro-tumorigenic role of KLF4 in melanoma and uncover a novel ERK1/2-E2F1-KLF4 axis. These findings identify KLF4 as a possible new molecular target for designing novel therapeutic treatments to control melanoma growth.	[Riverso, M.; Montagnani, V.; Stecca, B.] Ist Toscano Tumori, Core Res Lab, Viale Pieraccini 6, I-50139 Florence, Italy; [Stecca, B.] Careggi Univ Hosp, Dept Oncol, Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Azienda Ospedaliero Universitaria Careggi	Stecca, B (corresponding author), Ist Toscano Tumori, Core Res Lab, Viale Pieraccini 6, I-50139 Florence, Italy.	barbara.stecca@ittumori.it		Stecca, Barbara/0000-0003-1197-1622	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG-14184]	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro)	We thank Lorenzo Borgognoni, Gianni Gerlini (S. Maria Annunziata Hospital, Florence, Italy), Nicola Pimpinelli (Department of Dermatology, University of Florence, Florence, Italy) and Riccardo Gattai (Department of Medical-Surgical Critical Area, General and Oncological Surgery, University of Florence, Florence, Italy) for providing melanoma samples, Laura Poliseno (Istituto Toscano Tumori, Pisa, Italy) for providing SK-Mel-2, SK-Mel-5, SK-Mel-28 melanoma cell lines and pCDNA3.1-BRAF wt and pCDNA3.1-BRAF-V600E plasmids, Rosario Notaro (Istituto Toscano Tumori, Florence, Italy) for providing K562 cells, and Silvia Pietrobono for assistance with FACS analysis. This work was supported by a grant from AIRC (Associazione Italiana per la Ricerca sul Cancro IG-14184) to BS.	Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Brose MS, 2002, CANCER RES, V62, P6997; Camacho-Vanegas O, 2013, FASEB J, V27, P432, DOI 10.1096/fj.12-220319; Cercek A, 2015, INVEST NEW DRUG, V33, P1086, DOI 10.1007/s10637-015-0273-z; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delaney AM, 2002, MOL CELL BIOL, V22, P7593, DOI 10.1128/MCB.22.21.7593-7602.2002; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; El-Karim EA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-89; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Farrugia MK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.65; FILMUS J, 1994, ONCOGENE, V9, P3627; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Huang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.433; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Kharas MG, 2007, BLOOD, V109, P747, DOI 10.1182/blood-2006-03-011106; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Korotayev K, 2008, CELL SIGNAL, V20, P1221, DOI 10.1016/j.cellsig.2008.02.012; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Li H, 2013, CARCINOGENESIS, V34, P2262, DOI 10.1093/carcin/bgt189; Li J, 2012, CARCINOGENESIS, V33, P1239, DOI 10.1093/carcin/bgs143; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Montagnani V, 2016, ONCOTARGET, V7, P30365, DOI 10.18632/oncotarget.8758; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Muthusamy V, 2013, J INVEST DERMATOL, V133, P1827, DOI 10.1038/jid.2013.48; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Pandolfi S, 2015, CELL DEATH DIFFER, V22, P2006, DOI 10.1038/cdd.2015.56; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Putzer BM, 2010, EXPERT REV ANTICANC, V10, P1707, DOI 10.1586/ERA.10.153; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rubin SM, 2013, TRENDS BIOCHEM SCI, V38, P12, DOI 10.1016/j.tibs.2012.10.007; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Wei DY, 2010, GASTROENTEROLOGY, V139, P2135, DOI 10.1053/j.gastro.2010.08.022; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yang YZ, 2016, CANCER BIOL THER, V17, P422, DOI 10.1080/15384047.2016.1156260; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Yu T, 2016, CELL DEATH DIFFER, V23, P207, DOI 10.1038/cdd.2015.85; Zhang L, 2016, ONCOTARGET, V7, P30990, DOI 10.18632/oncotarget.8824	60	57	59	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3322	3333		10.1038/onc.2016.481	http://dx.doi.org/10.1038/onc.2016.481			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068326	Green Published, hybrid			2022-12-28	WOS:000402869800011
J	Shahriari, K; Shen, F; Worrede-Mahdi, A; Liu, Q; Gong, Y; Garcia, FU; Fatatis, A				Shahriari, K.; Shen, F.; Worrede-Mahdi, A.; Liu, Q.; Gong, Y.; Garcia, F. U.; Fatatis, A.			Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche	ONCOGENE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; NEUROENDOCRINE DIFFERENTIATION; BREAST-CANCER; TUMOR-GROWTH; PROGRESSION; FIBROBLASTS; EXPRESSION; MICE; ADENOCARCINOMA; IDENTIFICATION	The growth of disseminated tumor cells into metastatic lesions depends on the establishment of a favorable microenvironment in the stroma of the target organs. Here we show that mice treated with anakinra, an antagonist of the interleukin (IL)-1 beta receptor (IL-1R), or harboring a targeted deletion of IL-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation with human prostate cancer (PCa) cells expressing IL-1 beta. Interestingly, human mesenchymal stem cells exposed in vitro to medium conditioned by IL-1 beta-expressing cancer cells responded by upregulating S100A4, a marker of cancer-associated fibroblasts (CAFs), and this effect was blocked by anakinra. Analogously, the stroma adjacent to skeletal metastases generated in mice by IL-1 beta-expressing cancer cells showed a dramatic increase in S100A4, COX-2 and the alteration of 30 tumor-related genes as measured by Nanostring analysis. These effects were not observed in the stroma associated with the rare and much smaller metastases generated by the same cells in IL-1R knockout animals, confirming that tumor-secreted IL-1 beta generates skeletal CAFs and conditions the surrounding bone microenvironment. In skeletal lesions from patients with metastatic PCa, histological and molecular analyses revealed that IL-1 beta is highly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR-), whereas this cytokine is uniformly absent in the AR-positive (AR+) metastatic cells. The stroma conditioned by IL-1 beta-expressing cancer cells served as a supportive niche also for coexisting IL-1 beta-lacking cancer cells, which are otherwise unable to generate tumors after independently seeding the skeleton of mice. This niche is established very early following tumor seeding and hints to a role of IL-1 beta in promoting early colonization of PCa at the skeletal level.	[Shahriari, K.; Shen, F.; Worrede-Mahdi, A.; Liu, Q.; Fatatis, A.] Drexel Univ, Coll Med, Dept Pharmacol & Physiol, 245N 15th St,NCB 8211, Philadelphia, PA 19102 USA; [Gong, Y.; Garcia, F. U.; Fatatis, A.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Garcia, F. U.] Eastern Reg Med Ctr, Canc Treatment Ctr Amer, Philadelphia, PA USA; [Fatatis, A.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Prostate Canc, Philadelphia, PA 19107 USA; [Liu, Q.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Drexel University; Drexel University; Jefferson University; University of Texas System; UTMD Anderson Cancer Center	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Pharmacol & Physiol, 245N 15th St,NCB 8211, Philadelphia, PA 19102 USA.	afatatis@drexelmed.edu		Worrede, Asurayya/0000-0003-2013-0112	NIH [F30CA192896-01]; Department of Defense [PC080987]; NATIONAL CANCER INSTITUTE [F30CA192896] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Olimpia Meucci (Department of Pharmacology and Physiology at Drexel University College of Medicine) for invaluable advice, Dr Kevin Kelly (Medical Oncology) and all the other members of the Greater Philadelphia Prostate Cancer Working Group at the Sidney Kimmel Cancer Center, Thomas Jefferson University for insightful discussions, Dr Ruth Birbe (Pathology) at Thomas Jefferson University for providing the human specimens of skeletal metastases and Danielle Jernigan (Fatatis laboratory) for critical reading of the manuscript. This work was supported by NIH F30CA192896-01 grant to KS and in part by Department of Defense PC080987 Idea Award to AF.	Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bersani F, 2014, CANCER RES, V74, P7229, DOI 10.1158/0008-5472.CAN-14-1809; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Childs RW, 2015, NAT REV DRUG DISCOV, V14, P487, DOI 10.1038/nrd4506; Cindolo L, 2007, EUR UROL, V52, P1365, DOI 10.1016/j.eururo.2006.11.030; Cohen SB, 2004, RHEUM DIS CLIN N AM, V30, P365, DOI 10.1016/j.rdc.2004.01.005; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Drake JM, 2010, CANCER BIOL THER, V9, P607, DOI 10.4161/cbt.9.8.11112; Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372; FENTON MJ, 1992, INT J IMMUNOPHARMACO, V14, P401, DOI 10.1016/0192-0561(92)90170-P; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Goel HL, 2008, ENDOCR-RELAT CANCER, V15, P657, DOI 10.1677/ERC-08-0019; Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Jiborn T, 1998, UROLOGY, V51, P585, DOI 10.1016/S0090-4295(97)00684-5; Kalos M, 2004, PROSTATE, V60, P246, DOI 10.1002/pros.20043; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kim S, 2000, P NATL ACAD SCI USA, V97, P2731, DOI 10.1073/pnas.050588297; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Komiya A, 2009, INT J UROL, V16, P37, DOI 10.1111/j.1442-2042.2008.02175.x; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Liu QX, 2013, CANCER RES, V73, P3297, DOI 10.1158/0008-5472.CAN-12-3970; Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004; MICKEY DD, 1977, CANCER RES, V37, P4049; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pio R, 2014, ADV EXP MED BIOL, V772, P229, DOI 10.1007/978-1-4614-5915-6_11; Russell MR, 2009, ONCOGENE, V28, P412, DOI 10.1038/onc.2008.390; Shariff AH, 2006, UROLOGY, V68, P2, DOI 10.1016/j.urology.2006.02.002; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Sun Y, 2009, AM J TRANSL RES, V1, P148; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Valdivia-Silva JE, 2009, CANCER LETT, V283, P176, DOI 10.1016/j.canlet.2009.03.040; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Weckermann D, 2001, J UROLOGY, V166, P699, DOI 10.1016/S0022-5347(05)66046-6; Wurth R, 2015, TRANSL ONCOL, V8, P358, DOI 10.1016/j.tranon.2015.07.002; Xu JC, 2001, CANCER RES, V61, P1563; Yu DD, 2015, ONCOTARGET, V6, P42687, DOI 10.18632/oncotarget.5883; Zhao Y, 2014, INT J BIOL SCI, V10, P614, DOI 10.7150/ijbs.8389	47	28	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2846	2856		10.1038/onc.2016.436	http://dx.doi.org/10.1038/onc.2016.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991924	Green Accepted			2022-12-28	WOS:000401697800007
J	Harrod, A; Fulton, J; Nguyen, VTM; Periyasamy, M; Ramos-Garcia, L; Lai, CF; Metodieva, G; de Giorgio, A; Williams, RL; Santos, DB; Gomez, PJ; Lin, ML; Metodiev, MV; Stebbing, J; Castellano, L; Magnani, L; Coombes, RC; Buluwela, L; Ali, S				Harrod, A.; Fulton, J.; Nguyen, V. T. M.; Periyasamy, M.; Ramos-Garcia, L.; Lai, C-F; Metodieva, G.; de Giorgio, A.; Williams, R. L.; Santos, D. B.; Gomez, P. J.; Lin, M-L; Metodiev, M. V.; Stebbing, J.; Castellano, L.; Magnani, L.; Coombes, R. C.; Buluwela, L.; Ali, S.			Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; LIGAND-BINDING DOMAIN; ER-ALPHA; ENDOCRINE RESISTANCE; POSTMENOPAUSAL WOMEN; GENE-EXPRESSION; RETINOIC ACID; TYROSINE 537; PHOSPHORYLATION; TRANSCRIPTION	Drugs that inhibit estrogen receptor-a (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical problem. Recent genetic studies have shown that mutations in the ER gene are found in > 20% of tumours that progress on endocrine therapies. Remarkably, the great majority of these mutations localize to just a few amino acids within or near the critical helix 12 region of the ER hormone binding domain, where they are likely to be single allele mutations. Understanding how these mutations impact on ER function is a prerequisite for identifying methods to treat breast cancer patients featuring such mutations. Towards this end, we used CRISPR-Cas9 genome editing to make a single allele knock-in of the most commonly mutated amino acid residue, tyrosine 537, in the estrogen-responsive MCF7 breast cancer cell line. Genomic analyses using RNA-seq and ER ChIP-seq demonstrated that the Y537S mutation promotes constitutive ER activity globally, resulting in estrogen-independent growth. MCF7-Y537S cells were resistant to the antiestrogen tamoxifen and fulvestrant. Further, we show that the basal transcription factor TFIIH is constitutively recruited by ER-Y537S, resulting in ligand-independent phosphorylation of Serine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7. The CDK7 inhibitor, THZ1 prevented Ser118 phosphorylation and inhibited growth of MCF7-Y537S cells. These studies confirm the functional importance of ER mutations in endocrine resistance, demonstrate the utility of knock-in mutational models for investigating alternative therapeutic approaches and highlight CDK7 inhibition as a potential therapy for endocrine-resistant breast cancer mediated by ER mutations.	[Harrod, A.; Fulton, J.; Nguyen, V. T. M.; Periyasamy, M.; Ramos-Garcia, L.; Lai, C-F; de Giorgio, A.; Williams, R. L.; Santos, D. B.; Gomez, P. J.; Lin, M-L; Stebbing, J.; Castellano, L.; Magnani, L.; Coombes, R. C.; Buluwela, L.; Ali, S.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England; [Metodieva, G.; Metodiev, M. V.] Univ Essex, Sch Biol Sci, Wivenhoe Pk, Colchester, Essex, England	Imperial College London; University of Essex	Buluwela, L; Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	l.buluwela@imperial.ac.uk; simak.ali@imperial.ac.uk	periyasamy, manikandan/AAB-7924-2020; Castellano, Leandro/AAE-1366-2021; Periyasamy, Manikandan/AAL-6211-2020; Ali, Simak/M-6912-2018; magnani, luca/N-1094-2015	Ali, Simak/0000-0002-1320-0816; magnani, luca/0000-0002-7534-0785; Nguyen, Thuy Mai Van/0000-0002-5898-0043; Castellano, Leandro/0000-0002-3059-4829; Coombes, Raoul Charles/0000-0002-4811-1100; Harrod, Alison/0000-0002-3977-2791; Periyasamy, Manikandan/0000-0001-7626-2531; Stebbing, Justin/0000-0002-1117-6947	Breast Cancer Now [2014MayPR234]; Cancer Research UK [C37/A18784]; Cancer Research UK Imperial Centre; Cancer Research UK [12011, 14549, 18784] Funding Source: researchfish	Breast Cancer Now; Cancer Research UK(Cancer Research UK); Cancer Research UK Imperial Centre; Cancer Research UK(Cancer Research UK)	This work was funded by grants from Breast Cancer Now (2014MayPR234) and Cancer Research UK (C37/A18784). AH is supported by a PhD studentship from the Cancer Research UK Imperial Centre. We thank M Jones and L Game, MRC CSC Genomics Facility, Imperial College London. This study is dedicated to the memory of Professor Susan Malcolm.	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Anghel SI, 2000, J BIOL CHEM, V275, P20867, DOI 10.1074/jbc.M002098200; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garner F, 2015, ANTI-CANCER DRUG, V26, P948, DOI 10.1097/CAD.0000000000000271; Guttery DS, 2015, CLIN CHEM, V61, P974, DOI 10.1373/clinchem.2015.238717; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lai A, 2015, J MED CHEM, V58, P4888, DOI 10.1021/acs.jmedchem.5b00054; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu YW, 2014, BIOINFORMATICS, V30, P301, DOI 10.1093/bioinformatics/btt688; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mali P, 2013, NAT METHODS, V10, P957, DOI [10.1038/NMETH.2649, 10.1038/nmeth.2649]; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McCormack P, 2008, CLIN BREAST CANCER, V8, P347, DOI 10.3816/CBC.2008.n.040; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Periyasamy M, 2015, CELL REP, V13, P108, DOI 10.1016/j.celrep.2015.08.066; Piccart M., 2013, ANN ONCOL, V24, P25; Pritchard KI, 2010, BREAST CANCER RES TR, V123, P453, DOI 10.1007/s10549-010-1022-9; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Schiavon G, 2015, SCI TRANSL MED; Segal CV, 2014, CLIN CANCER RES, V20, P1724, DOI 10.1158/1078-0432.CCR-14-0067; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030; Tharun IM, 2015, ACS CHEM BIOL, V10, P475, DOI 10.1021/cb5007097; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Wang PL, 2016, CLIN CANCER RES, V22, P1130, DOI 10.1158/1078-0432.CCR-15-1534; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wittmann BM, 2007, CANCER RES, V67, P9549, DOI 10.1158/0008-5472.CAN-07-1590; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zhang QX, 1997, CANCER RES, V57, P1244; Zhao CQ, 2003, J BIOL CHEM, V278, P27278, DOI 10.1074/jbc.M303840200	64	94	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2286	2296		10.1038/onc.2016.382	http://dx.doi.org/10.1038/onc.2016.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748765	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000399782700009
J	Pandita, TK				Pandita, T. K.			Critical role of the POT1 OB domain in maintaining genomic stability	ONCOGENE			English	Editorial Material							DNA-DAMAGE RESPONSE; TELOMERE DYSFUNCTION; DYSKERATOSIS-CONGENITA; BINDING PROTEIN; ATM; MUTATIONS; PREDISPOSE; PROTECTION; COMPONENT; VARIANTS	Oligonucleotide/oligosaccharide-binding (OB) domain-containing proteins have been identified as critical for telomere maintenance, DNA repair, transcription and other DNA metabolism processes. Protection of telomere 1 (POT1), a telomere binding protein, has an OB domain like single-strand binding protein (SSB1). In this issue of Oncogene, Gu et al. present evidence that POT1, like SSB1, is required to maintain genomic stability. This work, in conjunction with results from previous investigators, highlights the importance of POT1 in telomere metabolism. Inactivation of POT1 telomere protective functions in mouse models lacking p53 expression in the breast epithelium unleashes a torrent of DNA damage responses (DDRs) at the telomeres, culminating in karyotypic alterations with massive arrays of telomere fusions. Therefore, POT1 is not only required to promote telomere homeostasis, but also plays an essential role in maintaining a stable genome.	[Pandita, T. K.] Houston Methodist Hosp, Weill Cornell Med Coll, Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX USA	Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston	Pandita, TK (corresponding author), Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA.	tpandita@houstonmethodist.org	Pandita, Tej K/AAM-9188-2020		National Institute of Health [CA129537, GM109768]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The research in the author's laboratory is funded by the National Institute of Health Grants CA129537 and GM109768.	Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Attwooll CL, 2009, MOL CELL BIOL, V29, P5540, DOI 10.1128/MCB.00479-09; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Calvete O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9383; Chan SS, 2010, FEBS LETT, V584, P3773, DOI 10.1016/j.febslet.2010.06.016; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Flynn RL, 2011, NATURE, V471, P532, DOI 10.1038/nature09772; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hills M, 2009, ANN NY ACAD SCI, V1176, P178, DOI 10.1111/j.1749-6632.2009.04565.x; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Maser RS, 2004, DNA REPAIR, V3, P979, DOI 10.1016/j.dnarep.2004.05.009; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pandita RK, 2015, CANCER RES, V75, P858, DOI 10.1158/0008-5472.CAN-14-2289; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Rai R, 2010, EMBO J, V29, P2598, DOI 10.1038/emboj.2010.142; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; Scott SP, 2006, J CELL BIOCHEM, V99, P1463, DOI 10.1002/jcb.21067; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shakirov EV, 2005, MOL CELL BIOL, V25, P7725, DOI 10.1128/MCB.25.17.7725-7733.2005; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Veldman T, 2004, CURR BIOL, V14, P2264, DOI 10.1016/j.cub.2004.12.031; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Walne AJ, 2008, BLOOD, V112, P3594, DOI 10.1182/blood-2008-05-153445; Wang Y, 2011, BLOOD, V118, P6068, DOI 10.1182/blood-2011-06-361527; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005	48	3	3	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1908	1910		10.1038/onc.2016.365	http://dx.doi.org/10.1038/onc.2016.365			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869169				2022-12-28	WOS:000398898500002
J	Romero, OA; Verdura, S; Torres-Diz, M; Gomez, A; Moran, S; Condom, E; Esteller, M; Villanueva, A; Sanchez-Cespedes, M				Romero, O. A.; Verdura, S.; Torres-Diz, M.; Gomez, A.; Moran, S.; Condom, E.; Esteller, M.; Villanueva, A.; Sanchez-Cespedes, M.			Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEXES; C-MYC; SWI/SNF COMPLEX; CELL-LINES; NUCLEOSOME DISRUPTION; ACID RECEPTOR; BRG1 COMPLEX; DIFFERENTIATION; EXPRESSION; GENE	Components of the SWI/SNF chromatin remodeling complex, including BRG1 (also SMARCA4), are inactivated in cancer. Among other functions, SWI/SNF orchestrates the response to retinoid acid (RA) and glucocorticoids (GC) involving downregulation of MYC. The epigenetic drugs SAHA and azacytidine, as well as RA and GC, are currently being used to treat some malignancies but their therapeutic potential in lung cancer is not well established. Here we aimed to determine the possible therapeutic effects of azacytidine and SAHA (A/S) alone or in combination with GC plus RA (GC/RA) in lung cancers with either BRG1 inactivation or MYC amplification. In vitro, responses to GC/RA treatment were more effective in MYC-amplified cells. These effects were mediated by BRG1 and involved a reprogramming towards prodifferentiation gene expression signatures and downregulation of MYC. In MYC-amplified cells, administration of GC/RA enhanced the cell growth inhibitory effects of A/S which, in turn, accentuated the prodifferentiation features promoted by GC/RA. Finally, these treatments improved overall survival of mice orthotopically implanted with MYC-amplified, but not BRG1-mutant, cells and reduced tumor cell viability and proliferation. We propose that the combination of epigenetic treatments with retinoids and corticoids of MYC-driven lung tumors constitute a strategy for therapeutic intervention in this otherwise incurable disease.	[Romero, O. A.; Verdura, S.; Torres-Diz, M.; Sanchez-Cespedes, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Genes & Canc Grp, Barcelona, Spain; [Gomez, A.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Can Epigenet Grp, Barcelona, Spain; [Condom, E.] Bellvitge Hosp, Dept Pathol, Barcelona, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol, Translat Res Lab, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Sanchez-Cespedes, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Genes & Canc Grp, Av Gran Via Hosp 199-203, Barcelona 08908, Spain.	mscespedes@idibell.cat	Romero, Octavio A./AAA-8078-2020; verdura, Sara/AAC-3696-2022; Sanchez-Cespedes, Montse/H-8485-2012; Esteller, Manel/L-5956-2014; torres-diz, manuel/ABG-1024-2021; Moran, Sebastian/G-5293-2013	Romero, Octavio A./0000-0003-0229-6530; verdura, Sara/0000-0001-8980-0423; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Esteller, Manel/0000-0003-4490-6093; torres-diz, manuel/0000-0002-5487-8113; condom, enric/0000-0003-0142-3729; Moran, Sebastian/0000-0003-4192-8983	Spanish MINECO [SAF2011-22897]; Institute of Health Carlos III (ISCIII) [PIE13/ 00022]; RTICC [RD12/0036/0045, RD12/0036/0039]; Fundacion Cientifica Asociacion Espanola Contra el Cancer [GCB14-2170]; Spanish MINECO; European Union Seventh Framework Programme (FP7/2007-13) [HEALTH-F2-2010-258677-CURELUNG]	Spanish MINECO(Spanish Government); Institute of Health Carlos III (ISCIII); RTICC(Instituto de Salud Carlos III); Fundacion Cientifica Asociacion Espanola Contra el Cancer; Spanish MINECO(Spanish Government); European Union Seventh Framework Programme (FP7/2007-13)	We thank Patricia Cabral (Genes and Cancer Group) at IDIBELL for technical assistance. This work was supported by the grants from the Spanish MINECO SAF2011-22897, Institute of Health Carlos III (ISCIII)-PIE13/ 00022 ( ONCOPROFILE) and RTICC (RD12/0036/0045 to MS-C and RD12/0036/ 0039 to ME) and a grant from the Fundacion Cientifica Asociacion Espanola Contra el Cancer-GCB14-2170. MT-D is supported by a fellowship from the Spanish MINECO. Funding was also provided by the European Union Seventh Framework Programme (FP7/2007-13), under grant agreement HEALTH-F2-2010-258677-CURELUNG.	Angulo B, 2008, J PATHOL, V214, P347, DOI 10.1002/path.2267; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; BOGUE CW, 1994, AM J PHYSIOL, V266, pL448, DOI 10.1152/ajplung.1994.266.4.L448; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Collins SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Hahn CK, 2008, P NATL ACAD SCI USA, V105, P9751, DOI 10.1073/pnas.0710413105; Hopfinger G, 2014, ANN HEMATOL, V93, P459, DOI 10.1007/s00277-014-2009-0; Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Liu SV, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00135; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Malpel S, 2000, DEVELOPMENT, V127, P3057; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Romero OA, 2014, ONCOGENE, V33, P2681, DOI 10.1038/onc.2013.227; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schenk T, 2014, BRIT J CANCER, V111, P2039, DOI 10.1038/bjc.2014.412; Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shi Wei, 2009, Proc Am Thorac Soc, V6, P558, DOI 10.1513/pats.200905-031RM; Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31; Sionov RV, 2008, ADV CANCER RES, V101, P127, DOI 10.1016/S0065-230X(08)00406-5; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; THULASI R, 1993, J BIOL CHEM, V268, P18306; Vendetti FP, 2013, EXPERT OPIN BIOL TH, V13, P1273, DOI 10.1517/14712598.2013.819337; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	50	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1287	1296		10.1038/onc.2016.296	http://dx.doi.org/10.1038/onc.2016.296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27593925	Green Accepted			2022-12-28	WOS:000395861300012
J	Song, X; Hao, J; Wang, J; Guo, C; Wang, Y; He, Q; Tang, H; Qin, X; Li, Y; Zhang, Y; Yin, Y				Song, X.; Hao, J.; Wang, J.; Guo, C.; Wang, Y.; He, Q.; Tang, H.; Qin, X.; Li, Y.; Zhang, Y.; Yin, Y.			The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; IN-VIVO; MOLECULAR TARGETS; UBIQUITIN LIGASE; MELANOMA-CELLS; BREAST-CANCER; EXPRESSION; ACTIVATION; MOTILITY; DEGRADATION	The biological function of MAGEC2, a cancer/testis antigen highly expressed in various cancers, remains largely unknown. Here we demonstrate that expression of MAGEC2 induces rounded morphology and amoeboid-like movement of tumor cells in vitro and promotes tumor metastasis in vivo. The pro-metastasis effect of MAGEC2 was mediated by signal transducer and activator of transcription 3 (STAT3) activation. Mechanistically, MAGEC2 interacts with STAT3 and inhibits the polyubiquitination and proteasomal degradation of STAT3 in the nucleus of tumor cells, resulting in accumulation of phosphorylated STAT3 and enhanced transcriptional activity. Notably, expression levels of MAGEC2 and phosphorylated STAT3 are positively correlated and both are associated with incidence of metastasis in human hepatocellular carcinoma. This study not only reveals a previously unappreciated role of MAGEC2 in promoting tumor metastasis, but also identifies a new molecular mechanism by which MAGEC2 sustains hyperactivation of STAT3 in the nucleus of tumor cells. Thus, MAGEC2 may represent a new antitumor metastasis target for treatment of cancer.	[Song, X.; Hao, J.; Wang, J.; Guo, C.; Wang, Y.; Tang, H.; Qin, X.; Li, Y.; Zhang, Y.; Yin, Y.] Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [He, Q.] Peking Univ, Hlth Sci Ctr, Ctr Med & Hlth Anal, Beijing, Peoples R China	Peking University; Peking University	Zhang, Y; Yin, Y (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	zhangyu007@bjmu.edu.cn; yinyanhui@bjmu.edu.cn	Hao, Jiaqing/F-1266-2017	Hao, Jiaqing/0000-0002-2834-7255; Xiao, Song/0000-0002-3171-4300	National Natural Science Foundation of China [81472645]; Beijing Natural Science Foundation [7142087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	We thank Drs Xinmin Cao (National University of Singapore), Zhijie Chang (Tsinghua University) and Ning Guo (Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences) for providing vectors. This work was supported by grants from National Natural Science Foundation of China (no. 81472645) and Beijing Natural Science Foundation (7142087).	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Ayyoub M, 2014, J IMMUNOTHER, V37, P73, DOI 10.1097/CJI.0000000000000013; Bhatia N, 2013, J INVEST DERMATOL, V133, P759, DOI 10.1038/jid.2012.355; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chomez P, 2001, CANCER RES, V61, P5544; Christoph DC, 2012, BRIT J CANCER, V107, P823, DOI 10.1038/bjc.2012.324; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Curioni-Fontecedro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021418; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hao JQ, 2015, ONCOTARGET, V6, P42028, DOI 10.18632/oncotarget.5973; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Li B, 2003, LAB INVEST, V83, P1185, DOI 10.1097/01.LAB.0000080605.73839.96; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Marcar L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127713; Pabst C, 2010, EXP MOL PATHOL, V89, P175, DOI 10.1016/j.yexmp.2010.06.011; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Pinner S, 2008, J MICROSC-OXFORD, V231, P441, DOI 10.1111/j.1365-2818.2008.02056.x; Riener MO, 2009, INT J CANCER, V124, P352, DOI 10.1002/ijc.23966; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Su SF, 2013, J BIOL CHEM, V288, P24809, DOI 10.1074/jbc.M113.468579; Tanaka T, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001637; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; von Boehmer L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021366; Wang YM, 2014, MOL CELL, V53, P752, DOI 10.1016/j.molcel.2014.01.020; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Weon JL, 2015, CURR OPIN CELL BIOL, V37, P1, DOI 10.1016/j.ceb.2015.08.002; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Yang F, 2014, BREAST CANCER RES TR, V145, P23, DOI 10.1007/s10549-014-2915-9; Yin B, 2014, INT J CLIN EXP PATHO, V7, P2934; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhuang Ran, 2006, Cancer Immun, V6, P7	56	18	18	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1476	1486		10.1038/onc.2016.314	http://dx.doi.org/10.1038/onc.2016.314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27775077				2022-12-28	WOS:000397458100003
J	Wendler, F; Favicchio, R; Simon, T; Alifrangis, C; Stebbing, J; Giamas, G				Wendler, F.; Favicchio, R.; Simon, T.; Alifrangis, C.; Stebbing, J.; Giamas, G.			Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention	ONCOGENE			English	Review							CELL-DERIVED EXOSOMES; BREAST-CANCER; ENDOTHELIAL-CELLS; LEUKEMIA-CELLS; LUNG-CANCER; PANCREATIC-CANCER; STEM-CELLS; IN-VITRO; MICROVESICLES; ANGIOGENESIS	Intercellular communication sets the pace for transformed cells to survive and to thrive. Extracellular vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are involved in this process shuttling reciprocal signals and other molecules between transformed and stromal cells, including fibroblasts, endothelial and immune cells. As a result, these cells are adapted or recruited to a constantly evolving cancer microenvironment. Moreover, EVs take part in the response to anticancer therapeutics not least by promoting drug resistance throughout the targeted tumor. Finally, circulating EVs can also transport important molecules to remote destinations in order to prime metastatic niches in an otherwise healthy tissue. Although the understanding of EV biology remains a major challenge in the field, their characteristics create new opportunities for advances in cancer diagnostics and therapeutics.	[Wendler, F.; Simon, T.; Giamas, G.] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Favicchio, R.; Stebbing, J.] Imperial Coll London, Dept Surg & Canc, Div Canc, London, England; [Alifrangis, C.] Hammersmith Hosp, NHS Trust, Imperial Coll London, Dept Med Oncol, London, England	University of Sussex; Imperial College London; Imperial College London	Wendler, F; Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	F.Wendler@sussex.ac.uk; G.Giamas@sussex.ac.uk	Giamas, Georgios/AAP-3487-2021	Simon, Thomas/0000-0002-3280-2716; Stebbing, Justin/0000-0002-1117-6947; Giamas, Georgios/0000-0002-4417-2707	Action Against Cancer; NIHR grant [NIHR-RP-011-053]; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Worldwide Cancer Research [10-0510] Funding Source: researchfish	Action Against Cancer; NIHR grant; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Worldwide Cancer Research	This work was supported by Action Against Cancer and NIHR grant #NIHR-RP-011-053.	Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571-016-0366-z; Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66; Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Amorim M, 2014, PROTEOMICS, V14, P1472, DOI 10.1002/pmic.201300485; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Belmont PJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005516; Bovy N, 2015, ONCOTARGET, V6, P10253, DOI 10.18632/oncotarget.3520; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466; Cazzoli R, 2013, J THORAC ONCOL, V8, P1156, DOI 10.1097/JTO.0b013e318299ac32; Chen WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095240; Chen Y, 2015, ONCOL LETT, V10, P3742, DOI 10.3892/ol.2015.3806; Cho JA, 2012, INT J ONCOL, V40, P130, DOI 10.3892/ijo.2011.1193; Chowdhury R, 2015, ONCOTARGET, V6, P715, DOI 10.18632/oncotarget.2711; Clark DJ, 2016, J PROTEOMICS, V133, P161, DOI 10.1016/j.jprot.2015.12.023; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Fan GC, 2014, BLOOD, V124, P3669, DOI 10.1182/blood-2014-10-607846; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Franzen CA, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.21; Frydrychowicz M, 2015, SCAND J IMMUNOL, V81, P2, DOI 10.1111/sji.12247; Gopal SK, 2016, ONCOTARGET, DOI 10.18632/ONCOTARGET.7573; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hood JL, 2009, LAB INVEST, V89, P1317, DOI 10.1038/labinvest.2009.94; Huber V, 2005, GASTROENTEROLOGY, V128, P1796, DOI 10.1053/j.gastro.2005.03.045; Hurley JH, 2015, EMBO J, V34, P2398, DOI 10.15252/embj.201592484; Ji H, 2008, ELECTROPHORESIS, V29, P2660, DOI 10.1002/elps.200800015; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kerr EM, 2016, NATURE, V531, P110, DOI 10.1038/nature16967; Khan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046737; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kosaka N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020022; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588; Ma X, 2014, P NATL ACAD SCI USA, V111, P6389, DOI 10.1073/pnas.1400272111; Mazzeo C, 2016, CELL DEATH DIFFER, V23, P99, DOI 10.1038/cdd.2015.72; Meckes DG, 2013, P NATL ACAD SCI USA, V110, pE2925, DOI 10.1073/pnas.1303906110; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Millimaggi D, 2007, NEOPLASIA, V9, P349, DOI 10.1593/neo.07133; Minciacchi VR, 2015, ONCOTARGET, V6, P11327, DOI 10.18632/oncotarget.3598; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152; Plebanek MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15724; Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Ragusa Marco, 2014, Oncoscience, V1, P132; Raimondo S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/821613; Ronquist KG, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.29877; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Sun L, 2014, ACTA PHARMACOL SIN, V35, P381, DOI 10.1038/aps.2013.166; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Taverna S, 2012, INT J CANCER, V130, P2033, DOI 10.1002/ijc.26217; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhao H., 2016, ELIFE, V5; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	86	93	95	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					877	884		10.1038/onc.2016.253	http://dx.doi.org/10.1038/onc.2016.253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27546617	Green Accepted			2022-12-28	WOS:000394169100001
J	Zhong, H; Fazenbaker, C; Chen, C; Breen, S; Huang, J; Yao, X; Ren, P; Yao, Y; Herbst, R; Hollingsworth, RE				Zhong, H.; Fazenbaker, C.; Chen, C.; Breen, S.; Huang, J.; Yao, X.; Ren, P.; Yao, Y.; Herbst, R.; Hollingsworth, R. E.			Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies	ONCOGENE			English	Article							GROWTH-FACTOR-I; FACTOR RECEPTOR; ANTITUMOR-ACTIVITY; FACTOR (IGF)-I; INSULIN; GENE; EXPRESSION; INHIBITOR; RISK; MECHANISMS	Colorectal cancer (CRC) is a heterogeneous disease with a broad spectrum of genetic and epigenetic changes. A comprehensive molecular characterization of CRC by The Cancer Genome Atlas Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a subset of CRC tumors. In this study, we investigated the oncogenic potential of IGF-2 in IGF2-overexpressing CRC models and the efficacy of MEDI-573, an IGF-1/2-neutralizing antibody. We found that a subset of CRC cell lines express high IGF-2 levels owing to an increased DNA copy number and hypermethylation in the H19 promoter of the IGF2 gene. MEDI-573 efficiently neutralized IGF-2 and induced apoptosis, which resulted in significant tumor growth inhibition in CRC mouse models that express high levels of IGF-2. These effects were specific to CRCs overexpressing IGF-2, as MEDI-573 did not affect the growth CRC cell lines with normal levels. Moreover, blockade of IGF-2 by MEDI-573 modulated other signaling pathways, suggesting combination therapies with inhibitors of these pathways. Indeed, in vivo efficacy was significantly enhanced when MEDI-573 was used in combination with trastuzumab, AZD2014 (dual mTORC1/2i), AZD5363 (AKTi) and selumetinib (AZD6244/ARRY-142886, MEK1/2i) or cetuximab. These results demonstrate that overexpressed IGF-2 is the major tumorigenic driver in a subset of CRCs and encourage testing of MEDI-573, alone and in combinations, in IGF2-overexpressing CRC patients.	[Zhong, H.; Fazenbaker, C.; Chen, C.; Breen, S.; Herbst, R.; Hollingsworth, R. E.] MedImmune, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA; [Huang, J.; Yao, X.; Yao, Y.] MedImmune, Translat Sci, Gaithersburg, MD USA; [Ren, P.] MedImmune, Biostat, Gaithersburg, MD USA	AstraZeneca; Medimmune; AstraZeneca; Medimmune; AstraZeneca; Medimmune	Hollingsworth, RE (corresponding author), MedImmune, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA.	hollingsworthr@medimmune.com			MedImmune	MedImmune(AstraZenecaMedimmune)	We thank Mohammed Dar, Parthiv Mahadevia, Dirk Mendel, Robert Sikorski, Teresa Klinowska, Sabina Cosulich, Barry Davies and Stephen Green for scientific input and manuscript review. This work was supported by MedImmune.	Abraham J, 2011, MOL CANCER THER, V10, P697, DOI 10.1158/1535-7163.MCT-10-0695; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Cheng YW, 2010, INT J CANCER, V127, P568, DOI 10.1002/ijc.25086; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fidler MJ, 2012, THER ADV MED ONCOL, V4, P51, DOI 10.1177/1758834011427576; Gao J, 2011, CANCER RES, V71, P1029, DOI 10.1158/0008-5472.CAN-10-2274; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Gualberto A, 2009, CURR DRUG TARGETS, V10, P923, DOI 10.2174/138945009789577945; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Haluska P, 2014, CLIN CANCER RES, V20, P4747, DOI 10.1158/1078-0432.CCR-14-0114; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Mazzoletti M, 2011, CANCER RES, V71, P4573, DOI 10.1158/0008-5472.CAN-10-4322; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Ou DL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-2; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; REMACLEBONNET M, 1992, INT J CANCER, V52, P910, DOI 10.1002/ijc.2910520614; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shin DH, 2011, MOL CANCER THER, V10, P2437, DOI 10.1158/1535-7163.MCT-11-0235; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Tran TN, 2014, J CLIN PATHOL, V67, P985, DOI 10.1136/jclinpath-2014-202347; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhao RH, 2008, CURR COLORECT CANC R, V4, P65, DOI 10.1007/s11888-008-0012-3; Zhong HH, 2014, MOL CANCER THER, V13, P2662, DOI 10.1158/1535-7163.MCT-14-0144	47	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					797	806		10.1038/onc.2016.248	http://dx.doi.org/10.1038/onc.2016.248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399333				2022-12-28	WOS:000394168200007
J	Liu, T; Zhao, M; Liu, J; He, Z; Zhang, Y; You, H; Huang, J; Lin, X; Feng, XH				Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; You, H.; Huang, J.; Lin, X.; Feng, X-H			Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-beta responses	ONCOGENE			English	Article							NASOPHARYNGEAL CARCINOMA-CELLS; BRD7 EXPRESSION; TRANSCRIPTIONAL REGULATION; GENE; COACTIVATOR; ACTIVATION; INTERACTS; PATHWAYS; SUBUNIT; BINDS	Smad proteins are central mediators in the canonical transforming growth factor-beta (TGF-beta) signaling pathway in mammalian cells. We report here that bromodomain-ontaining protein 7 (BRD7) functions as a novel transcription coactivator for Smads in TGF-beta signaling. BRD7 forms a TGF-beta inducible complex with Smad3/ 4 through its N-terminal Smad-binding domain. BRD7 simultaneously binds to acetylated histones to promote Smad-chromatin association, and associates with histone acetyltransferase p300 to enhance Smad transcriptional activity. Ectopic expression of BRD7, but not its mutants defective in Smad binding, enhances TGF-beta transcriptional, tumor-suppressing and epithelial-mesenchymal transition responses. Conversely, depletion of BRD7 inhibits TGF-beta responses. Thus, our study provides compelling evidence for a new function of BRD7 in fine-tuning TGF-beta physiological responses.	[Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; Huang, J.; Feng, X-H] Zhejiang Univ, Life Sci Inst, Hangzhou, Zhejiang, Peoples R China; [Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; Huang, J.; Feng, X-H] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China; [Liu, T.] Zhejiang Univ, Sch Med, Dept Cell Biol, Hangzhou, Zhejiang, Peoples R China; [Liu, T.] Zhejiang Univ, Sch Med, Program Mol Cell Biol, Hangzhou, Zhejiang, Peoples R China; [You, H.] Coll Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [You, H.] Coll Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Lin, X.; Feng, X-H] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Lin, X.; Feng, X-H] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Baylor College of Medicine; Baylor College of Medicine	Liu, T; Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	liuting518@zju.edu.cn; xfeng@bcm.edu		Liu, Jinquan/0000-0002-5180-5613	NSFC [91540205, 31571447, 31171347]; MOST [2012CB966600, 2015CB553800, 2013CB945303]; NIH [R01GM63773, R01AR053591, R01CA108454, R01DK073932]; Project 111; PhD Programs Foundation of Ministry of Education of China [20110101120152]; Fundamental Research Funds for the Central Universities; NATIONAL CANCER INSTITUTE [R21CA112939, R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NSFC(National Natural Science Foundation of China (NSFC)); MOST; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Project 111(Ministry of Education, China - 111 Project); PhD Programs Foundation of Ministry of Education of China(Ministry of Education, China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Luskutoff for p800 (PAI-1)-luc, Bert Vogelstein for WWP1 (p21)-luc and SBE-luc. We are grateful to the laboratory members for helpful discussion and technical assistance. This research was partly supported by grants from NSFC (91540205, 31571447, 31171347) and MOST (2012CB966600, 2015CB553800, 2013CB945303), NIH (R01GM63773, R01AR053591, R01CA108454, and R01DK073932), Project 111, PhD Programs Foundation of Ministry of Education of China (20110101120152), and the Fundamental Research Funds for the Central Universities.	Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Balasubramanian Anandh, 2015, Asian Pac J Cancer Prev, V16, P1615; Burrows AE, 2010, P NATL ACAD SCI USA, V107, P14280, DOI 10.1073/pnas.1009559107; Chan HM, 2001, J CELL SCI, V114, P2363; Chiu YH, 2014, MOL CELL, V54, P193, DOI 10.1016/j.molcel.2014.02.016; Dai FY, 2009, DEV CELL, V16, P345, DOI 10.1016/j.devcel.2009.01.022; Derynck R, 2007, TGF BETA FAMILY CELL; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Kim ES, 2004, INT J ONCOL, V25, P1375; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu HY, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-111; Liu HY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-253; Mantovani F, 2010, CELL CYCLE, V9, P2777; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Park YA, 2014, CLIN CANCER RES, V20, P565, DOI 10.1158/1078-0432.CCR-13-1271; Park YA, 2012, GYNECOL ONCOL, V124, P125, DOI 10.1016/j.ygyno.2011.09.026; Peng C, 2006, J CELL BIOCHEM, V97, P882, DOI 10.1002/jcb.20645; Peng C, 2007, MOL CELL BIOCHEM, V303, P141, DOI 10.1007/s11010-007-9466-x; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang DG, 2008, CANCER RES, V68, P783, DOI 10.1158/0008-5472.CAN-07-0008; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Wu WJ, 2013, EUR J CLIN INVEST, V43, P131, DOI 10.1111/eci.12024; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Y, 2015, BEHAV BRAIN RES, V286, P1, DOI 10.1016/j.bbr.2015.02.031; Zhou J, 2004, J CELL PHYSIOL, V200, P89, DOI 10.1002/jcp.20013	39	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					362	372		10.1038/onc.2016.204	http://dx.doi.org/10.1038/onc.2016.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270427	Green Accepted			2022-12-28	WOS:000394166000006
J	Linke, F; Zaunig, S; Nietert, MM; von Bonin, F; Lutz, S; Dullin, C; Janovska, P; Beissbarth, T; Alves, F; Klapper, W; Bryja, V; Pukrop, T; Trumper, L; Wilting, J; Kube, D				Linke, F.; Zaunig, S.; Nietert, M. M.; von Bonin, F.; Lutz, S.; Dullin, C.; Janovska, P.; Beissbarth, T.; Alves, F.; Klapper, W.; Bryja, V.; Pukrop, T.; Truemper, L.; Wilting, J.; Kube, D.			WNT5A: a motility-promoting factor in Hodgkin lymphoma	ONCOGENE			English	Article							PLANAR CELL POLARITY; REED-STERNBERG CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; GENE-EXPRESSION; BREAST-CANCER; PROLIFERATION; MIGRATION; PATHOGENESIS	Classical Hodgkin lymphoma (cHL) has a typical clinical manifestation, with dissemination involving functionally neighboring lymph nodes. The factors involved in the spread of lymphoma cells are poorly understood. Here we show that cHL cell lines migrate with higher rates compared with non -Hodgkin lymphoma cell lines. cHL cell migration, invasion and adhesion depend on autocrine WNT signaling as revealed by the inhibition of WNT secretion with the porcupine inhibitors Wnt-059/IWP-2, but did not affect cell proliferation. While application of recombinant WNT5A or WNT5A overexpression stimulates cHL cell migration, neither WNT10A, WNT1OB nor WNT16 did so. Time-lapse studies revealed an amoeboid type of cell migration modulated by WNT5A. Reduced migration distances and velocity of cHL cells, as well as altered movement patterns, were observed using porcupine inhibitor or WNT5A antagonist. Knockdown of Frizzled5 and Dishevelled3 disrupted the WNT5A-mediated RHOA activation and cell migration. Overexpression of DVL3-K435M or inhibition of ROCK (Rho-associated protein kinase) by Y-27632/H1152P disrupted cHL cell migration. In addition to these mechanistic insights into the role of WNT5A in vitro, global gene expression data revealed an increased WNT5A expression in primary HL cells in comparison with normal B-cell subsets and other lymphomas. Furthermore, the activity of both porcupine and WNT5A in cHL cells had an impact on lymphoma development in the chick chorionallantoic membrane assay. Massive bleeding of these lymphomas was significantly reduced after inhibition of WNT secretion by Wnt-059. Therefore, a model is proposed where WNT signaling has an important role in regulating tumor-promoting processes.	[Linke, F.; Zaunig, S.; von Bonin, F.; Alves, F.; Pukrop, T.; Truemper, L.; Kube, D.] Georg August Univ Gottingen, Univ Med Ctr, Clin Hematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Nietert, M. M.; Beissbarth, T.] Georg August Univ Gottingen, Univ Med Ctr, Dept Med Stat, Gottingen, Germany; [Lutz, S.] Georg August Univ Gottingen, Univ Med Ctr, Inst Pharmacol, Gottingen, Germany; [Dullin, C.; Alves, F.] Georg August Univ Gottingen, Univ Med Ctr, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Janovska, P.; Bryja, V.] Masaryk Univ, Inst Expt Biol, Fac Sci, Brno, Czech Republic; [Alves, F.] Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, Gottingen, Germany; [Klapper, W.] UKSH Campus Kiel, Hematopathol Sect, Kiel, Germany; [Bryja, V.] Acad Sci Czech Republ, Inst Biophys, Dept Cytokinet, Brno, Czech Republic; [Wilting, J.] Georg August Univ Gottingen, Dept Anat & Cell Biol, Univ Med Ctr, Gottingen, Germany; [Pukrop, T.] Univ Hosp Regensburg, Dept Internal Med Hematol & Internal Oncol 3, Regensburg, Germany	University of Gottingen; University of Gottingen; University of Gottingen; University of Gottingen; Masaryk University Brno; Max Planck Society; University of Kiel; Schleswig Holstein University Hospital; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; University of Gottingen; University of Regensburg	Kube, D (corresponding author), Georg August Univ Gottingen, Univ Med Ctr, Clin Hematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.	dkube@med.uni-goettingen.de	Janovska, Pavlina/AAM-2683-2020; Linke, Franziska/AAD-7600-2022; Bryja, Vítězslav/P-4217-2019; Klapper, Wolfram/S-6314-2016	Linke, Franziska/0000-0002-7005-9687; Bryja, Vítězslav/0000-0002-9136-5085; Dullin, Christian/0000-0003-4297-8077; Nietert, Manuel/0000-0001-5443-7943	Deutsche Forschungsgemeinschaft within the Forschergruppe [Ku 954/12-1, FOR942]	Deutsche Forschungsgemeinschaft within the Forschergruppe(German Research Foundation (DFG))	We thank Moritz Harenberg for evaluating the vascularization of the CAM tumors in a blinded manner. We are very thankful to Mrs S Schwoch, Mrs C Zelent and Mrs S Hellbach for their technical assistance in the histological analysis of the CAM tumors. We kindly acknowledge Dr Aldo Ferrari from the ETH Zurich to provide the sketch on the amoeboid migration type (integrated into Figure 3a). This work was supported by grants of the Deutsche Forschungsgemeinschaft Ku 954/12-1 within the Forschergruppe FOR942.	Aldinucci D, 2008, INT J CANCER, V122, P769, DOI 10.1002/ijc.23119; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bernatik O, 2014, J BIOL CHEM, V289, P23520, DOI 10.1074/jbc.M114.590638; Boll B, 2013, J CLIN ONCOL, V31, P4431, DOI 10.1200/JCO.2013.49.8246; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Bryja V, 2007, J CELL SCI, V120, P586, DOI 10.1242/jcs.03368; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood-2006-04-015958; Corrigan PM, 2009, STEM CELLS DEV, V18, P759, DOI 10.1089/scd.2008.0270; Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Fhu CW, 2014, BLOOD, V124, P2973, DOI 10.1182/blood-2014-05-576140; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Gentzel M, 2015, MOL BIOL CELL, V26, P966, DOI 10.1091/mbc.E14-06-1089; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guermazi A, 2001, RADIOGRAPHICS, V21, P161, DOI 10.1148/radiographics.21.1.g01ja02161; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; Introcaso CE, 2008, J AM ACAD DERMATOL, V58, P295, DOI 10.1016/j.jaad.2005.11.1055; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Jenei V, 2009, P NATL ACAD SCI USA, V106, P19473, DOI 10.1073/pnas.0909409106; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kafka A, 2014, INT J MOL SCI, V15, P10635, DOI 10.3390/ijms150610635; Kaucka M, 2013, CANCER RES, V73, P1491, DOI 10.1158/0008-5472.CAN-12-1752; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Klingenberg M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-339; Kluk MJ, 2013, LAB INVEST, V93, P462, DOI 10.1038/labinvest.2013.7; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kuppers R, 2012, J CLIN INVEST, V122, P3439, DOI [10.1172/JCI6124.5, 10.1172/JCI61245]; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Long A, 2015, CARCINOGENESIS, V36, P598, DOI 10.1093/carcin/bgv025; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; MacDonald BT, 2014, J BIOL CHEM, V289, P18122, DOI 10.1074/jbc.M114.575027; MacMillan CD, 2014, SCI REP-UK, V4, DOI 10.1038/srep06315; Malhotra S, 2008, J IMMUNOL, V181, P3955, DOI 10.4049/jimmunol.181.6.3955; Mayor R, 2014, BIOCHEM J, V457, P19, DOI 10.1042/BJ20131182; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; PALS ST, 1989, IMMUNOL REV, V108, P111, DOI 10.1111/j.1600-065X.1989.tb00015.x; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Qin L, 2015, ONCOTARGET, V6, P10239, DOI 10.18632/oncotarget.3518; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Samarzija I, 2009, BIOCHEM BIOPH RES CO, V386, P449, DOI 10.1016/j.bbrc.2009.06.033; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Sohlbach K, 2012, LEUKEMIA LYMPHOMA, V53, P996, DOI 10.3109/10428194.2011.634046; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Tiacci E, 2012, BLOOD, V120, P4609, DOI 10.1182/blood-2012-05-428896; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Vockerodt M, 2001, GENES IMMUN, V2, P433, DOI 10.1038/sj.gene.6363803; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250; Xargay-Torrent S, 2013, CLIN CANCER RES, V19, P586, DOI 10.1158/1078-0432.CCR-12-1935; Yao LL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832562; Zepeda-Moreno A, 2014, CELL ADHES MIGR, V5, P215; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823	63	25	25	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					13	23		10.1038/onc.2016.183	http://dx.doi.org/10.1038/onc.2016.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270428				2022-12-28	WOS:000394069100002
J	Chakravarthi, BVSK; Goswami, MT; Pathi, SS; Robinson, AD; Cieslik, M; Chandrashekar, DS; Agarwal, S; Siddiqui, J; Daignault, S; Carskadon, SL; Jing, X; Chinnaiyan, AM; Kunju, LP; Palanisamy, N; Varambally, S				Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Robinson, A. D.; Cieslik, M.; Chandrashekar, D. S.; Agarwal, S.; Siddiqui, J.; Daignault, S.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.			MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer	ONCOGENE			English	Article							POSITIVE COACTIVATOR 4; RNA-POLYMERASE-II; POLO-LIKE KINASES; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; CELL-PROLIFERATION; GASTRIC-CANCER; PC4; ACTIVATION; DNA	MicroRNA-101, a tumor suppressor microRNA (miR), is often downregulated in cancer and is known to target multiple oncogenes. Some of the genes that are negatively regulated by miR-101 expression include histone methyltransferase EZH2 (enhancer of zeste homolog 2), COX2 (cyclooxygenase-2), POMP (proteasome maturation protein), CERS6, STMN1, MCL-1 and ROCK2, among others. In the present study, we show that miR-101 targets transcriptional coactivator SUB1 homolog (Saccharomyces cerevisiae)/PC4 (positive cofactor 4) and regulates its expression. SUB1 is known to have diverse role in vital cell processes such as DNA replication, repair and heterochromatinization. SUB1 is known to modulate transcription and acts as a mediator between the upstream activators and general transcription machinery. Expression profiling in several cancers revealed SUB1 overexpression, suggesting a potential role in tumorigenesis. However, detailed regulation and function of SUB1 has not been elucidated. In this study, we show elevated expression of SUB1 in aggressive prostate cancer. Knockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo. Gene expression analyses coupled with chromatin immunoprecipitation revealed that SUB1 binds to the promoter regions of several oncogenes such as PLK1 (Polo-like kinase 1), C-MYC, serine-threonine kinase BUB1B and regulates their expression. Additionally, we observed SUB1 downregulated CDKN1B expression. PLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells. Thus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis. This study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.	[Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Cieslik, M.; Siddiqui, J.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Cieslik, M.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Chakravarthi, B. V. S. K.; Robinson, A. D.; Chandrashekar, D. S.; Agarwal, S.; Varambally, S.] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol, Birmingham, AL 35294 USA; [Daignault, S.] Univ Michigan, Dept Biostat, Ctr Canc Biostat, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.; Palanisamy, N.; Varambally, S.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Varambally, S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Pathi, S. S.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Carskadon, S. L.; Palanisamy, N.] Henry Ford Hlth Syst, Vattikuti Urol Inst, Dept Urol, Detroit, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Henry Ford Health System; Henry Ford Hospital	Varambally, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, Ctr Comprehens Canc, Mol & Cellular Pathol, Birmingham, AL 35233 USA.	soorya@uab.edu	AGARWAL, SUMIT/I-9349-2019; Palanisamy, Nallasivam/ABC-8844-2020; Daignault-Newton, Stephanie/GYD-6133-2022	AGARWAL, SUMIT/0000-0003-4051-7146; Palanisamy, Nallasivam/0000-0002-0633-9772; Robinson, Alyncia/0000-0002-9369-7665; Varambally, Sooryanarayana/0000-0002-2277-1127	National Institutes of Health [R01CA157845]; University of Michigan Prostate Cancer SPORE Career Development award;  [R01CA154980]; NATIONAL CANCER INSTITUTE [R01CA154980, R01CA157845] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan Prostate Cancer SPORE Career Development award; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Twani Dhar, Sherin John, Sivakumar Nallasivam, Samuel Lee and Sai Akshaya Hodigere Balasubramanya for their assistance. We also thank the University of Michigan Vector Core for generating lentivirus. This work is supported, in part, by National Institutes of Health R01CA157845. SV is also supported by R01CA154980 and the University of Michigan Prostate Cancer SPORE Career Development award (to SV). Gene expression data has been deposited in the GEO database under accession number GSE74895.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bargiela-Iparraguirre J, 2014, CELL CYCLE, V13, P3590, DOI 10.4161/15384101.2014.962952; Batta K, 2007, MOL CELL BIOL, V27, P7603, DOI 10.1128/MCB.01064-07; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Chain B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-344; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chen L, 2014, J NEUROL SCI, V346, P293, DOI 10.1016/j.jns.2014.09.014; Conesa C, 2010, RNA BIOL, V7, P287, DOI 10.4161/rna.7.3.11491; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Das C, 2010, J MOL BIOL, V397, P1, DOI 10.1016/j.jmb.2009.12.058; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Ferreira PG, 2014, GENOME RES, V24, P212, DOI 10.1101/gr.152132.112; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; Goswami MT, 2015, ONCOTARGET, V6, P23445, DOI 10.18632/oncotarget.4352; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Holloway AF, 2000, J BIOL CHEM, V275, P21668, DOI 10.1074/jbc.M909058199; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Kleivi K, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-2; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lada AG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005217; Lee JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122628; Lin CC, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3725; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Luo L, 2012, MED ONCOL, V29, P1681, DOI 10.1007/s12032-011-0085-8; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; Peng Y, 2012, CANCER GENE THER, V19, P690, DOI 10.1038/cgt.2012.52; Pezuk JA, 2013, CANCER GENE THER, V20, P499, DOI 10.1038/cgt.2013.46; Qian D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.416; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Shi CM, 2008, EXP HEMATOL, V36, pS82; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sikorski TW, 2011, MOL CELL, V44, P397, DOI 10.1016/j.molcel.2011.09.013; Smith M, 2012, AACR 103 ANN M S, V72; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suzuki M, 2016, J CLIN INVEST, V126, P254, DOI 10.1172/JCI79775; Tao SL, 2015, AM J CANCER RES, V5, P1878; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wang L, 2015, CANCER CELL, V28, P240, DOI 10.1016/j.ccell.2015.07.005; Wang L, 2014, HEPATOLOGY, V59, P1850, DOI 10.1002/hep.26720; Wang R., 2012, MATH PROBL ENG, V2012, P1, DOI DOI 10.1109/IEVC2012.6183284.URL; Wang R, 2012, NEOPLASIA, V14, P905, DOI 10.1593/neo.121192; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wissing MD, 2013, FASEB J, V27, P4279, DOI 10.1096/fj.12-222893; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Yan F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.380; Yang J, 2015, BIOCHEM BIOPH RES CO, V463, P900, DOI 10.1016/j.bbrc.2015.06.032; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zhang X, 2015, MOL CELL, V59, P243, DOI 10.1016/j.molcel.2015.05.036; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhong L, 2003, GENE, V320, P155, DOI 10.1016/S0378-1119(03)00823-0; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	75	47	49	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6330	6340		10.1038/onc.2016.164	http://dx.doi.org/10.1038/onc.2016.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270442	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000390247000006
J	Lee-Sherick, AB; Eisenman, KM; Sather, S; McGranahan, A; Armistead, PM; McGary, CS; Hunsucker, SA; Schlegel, J; Martinson, H; Cannon, C; Keating, AK; Earp, HS; Liang, X; DeRyckere, D; Graham, DK				Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.			Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia (vol 32, pg 5359, 2013)	ONCOGENE			English	Correction														Martinson, Holly/0000-0003-2745-2755				Lee-Sherick AB, 2013, ONCOGENE, V32, P5359, DOI 10.1038/onc.2013.40	1	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6270	6270		10.1038/onc.2016.295	http://dx.doi.org/10.1038/onc.2016.295			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27593932	hybrid, Green Published			2022-12-28	WOS:000388857700011
J	Tang, W; Wang, H; Ha, HL; Tassi, I; Bhardwaj, R; Claudio, E; Siebenlist, U				Tang, W.; Wang, H.; Ha, H. L.; Tassi, I.; Bhardwaj, R.; Claudio, E.; Siebenlist, U.			The B-cell tumor promoter Bcl-3 suppresses inflammation associated colon tumorigenesis in epithelial cells	ONCOGENE			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; MICE DEFICIENT; COLITIS; ONCOPROTEIN; EXPRESSION; SURVIVAL; SODIUM; STAT3	Bcl-3 is an atypical member of the inhibitor of kappa light polypeptide gene enhancer in B-cells (I.B) family. It associates with p50/nuclear factor-kappa B1 (NF-kappa B1) and p52/NF-kappa B2 homodimers in nuclei where it modulates transcription in a context-dependent manner. A subset of B-cell tumors exhibits recurrent translocations of Bcl-3, resulting in overexpression. Elevated expression without translocations is also observed in various B-cell lymphomas and even some solid tumors. Here we investigated the role of Bcl-3 in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors, a mouse model for colitis-associated colorectal cancers in humans. Contrary to expectations, Bcl-3 suppressed colorectal tumor formation: Bcl-3-deficient mice were relatively protected from DSS-induced epithelial damage and developed more polyps after AOM/DSS treatment, although polyp size was unaffected. DSSchallenged mutant mice exhibited increased recruitment of myeloid-derived suppressor cells, consistent with protection of the epithelium. Loss of Bcl-3 in intestinal epithelial cells was sufficient to increase tumorigenesis. The added tumor burden in mutant mice was dependent on tumor necrosis factor-a (TNF alpha), a tumorigenic, NF-kappa B-mediated signaling pathway that was dampened by Bcl-3. These findings reveal a tumor-suppressive role for Bcl-3 in this inflammation-associated cancer model. Bcl-3 thus functions as a tumor promoter or suppressor, depending on the cellular and environmental context.	[Tang, W.; Wang, H.; Ha, H. L.; Tassi, I.; Bhardwaj, R.; Claudio, E.; Siebenlist, U.] NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Siebenlist, U (corresponding author), NIH, Bldg 10,Room 11N210, Bethesda, MD 20892 USA.	usiebenlist@niaid.nih.gov		tassi, ilaria/0000-0002-5803-9499	Intramural Research Program of NIAID, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000722] Funding Source: NIH RePORTER	Intramural Research Program of NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We greatly appreciate the constructive inputs provided by all members of the Siebenlist laboratory. This research was supported by the Intramural Research Program of NIAID, NIH.	Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Burkitt MD, 2015, J PATHOL, V236, P326, DOI 10.1002/path.4527; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Diaz-Montero CM, 2014, SEMIN ONCOL, V41, P174, DOI 10.1053/j.seminoncol.2014.02.003; Eigenbrod T, 2013, J IMMUNOL, V190, P6533, DOI 10.4049/jimmunol.1300324; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hinz M, 2012, IMMUNOL REV, V246, P59, DOI 10.1111/j.1600-065X.2012.01102.x; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Liu ZJ, 2013, J MOL CELL BIOL, V5, P280, DOI 10.1093/jmcb/mjt020; Maldonado V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-152; Manjili MH, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00303; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Naito Y, 2003, J GASTROEN HEPATOL, V18, P560, DOI 10.1046/j.1440-1746.2003.03034.x; Nielsen OH, 2014, FRONT MED-LAUSANNE, V1, DOI 10.3389/fmed.2014.00003; Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008; Palmer S, 2008, IMMUNOL RES, V42, P210, DOI 10.1007/s12026-008-8075-4; Pasparakis M, 2012, IMMUNOL REV, V246, P346, DOI 10.1111/j.1600-065X.2012.01109.x; Pene F, 2011, J IMMUNOL, V186, P2412, DOI 10.4049/jimmunol.1001331; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schuster M, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-23; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Tang WH, 2014, IMMUNITY, V41, P555, DOI 10.1016/j.immuni.2014.09.017; Tassi I, 2015, EUR J IMMUNOL, V45, P1059, DOI 10.1002/eji.201444994; Tassi I, 2014, J IMMUNOL, V193, P4303, DOI 10.4049/jimmunol.1401505; Wakefield A, 2013, CANCER RES, V73, P745, DOI 10.1158/0008-5472.CAN-12-1321; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003	34	6	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6203	6211		10.1038/onc.2016.152	http://dx.doi.org/10.1038/onc.2016.152			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27132515	Green Accepted			2022-12-28	WOS:000388857700005
J	Montenegro, MF; Sanchez-del-Campo, L; Gonzalez-Guerrero, R; Martinez-Barba, E; Pinero-Madrona, A; Cabezas-Herrera, J; Rodriguez-Lopez, JN				Montenegro, M. F.; Sanchez-del-Campo, L.; Gonzalez-Guerrero, R.; Martinez-Barba, E.; Pinero-Madrona, A.; Cabezas-Herrera, J.; Rodriguez-Lopez, J. N.			Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LYSINE METHYLATION; ESTROGEN-RECEPTOR; DNA METHYLATION; E2F1; METHYLTRANSFERASE; EXPRESSION; LSD1; REPRESSION	During the course of cancer progression, neoplastic cells undergo dynamic and reversible transitions between multiple phenotypic states, and this plasticity is enabled by underlying shifts in epigenetic regulation. Our results identified a negative feedback loop in which SET9 controls DNA methyltransferase-1 protein stability, which represses the transcriptional activity of the SET9 promoter in coordination with Snail. The modulation of SET9 expression in breast cancer cells revealed a connection with E2F1 and the silencing of SET9 was sufficient to complete an epigenetic program that favored epithelial-mesenchymal transition and the generation of cancer stem cells, indicating that SET9 plays a role in modulating breast cancer metastasis. SET9 expression levels were significantly higher in samples from patients with pathological complete remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a tumor suppressor in breast cancer and that its expression may serve as a prognostic marker for malignancy.	[Montenegro, M. F.; Gonzalez-Guerrero, R.; Rodriguez-Lopez, J. N.] Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain; [Sanchez-del-Campo, L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England; [Martinez-Barba, E.] Univ Hosp Virgen Arrixaca, IMIB, Dept Pathol, Murcia, Spain; [Pinero-Madrona, A.] Univ Hosp Virgen Arrixaca, IMIB, Dept Surg, Murcia, Spain; [Cabezas-Herrera, J.] Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain	University of Murcia; Ludwig Institute for Cancer Research; University of Oxford; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca	Rodriguez-Lopez, JN (corresponding author), Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain.; Cabezas-Herrera, J (corresponding author), Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain.	juan.cabezas@carm.es; neptuno@um.es	del Campo, Luis Sanchez/R-1308-2018; CABEZAS-HERRERA, JUAN/J-9434-2015; Piñero-Madrona, Antonio/AAB-5138-2022; Montenegro, Maria Fernanda/AAF-2695-2021	CABEZAS-HERRERA, JUAN/0000-0001-9053-5380; Sanchez del Campo, Luis/0000-0002-9537-7761; Montenegro, Maria Fernanda/0000-0002-0064-0484; Gonzalez Guerrero, Rebeca/0000-0003-1006-7658; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173	Ministerio de Economia y Competitividad (MINECO); Fondos (FEDER) [SAF2013-48375-C2-1-R]; Fundacion Seneca, Region de Murcia (FS-RM) [15230/PI/10, 19304/PI/14]; Ludwig Institute for Cancer Research; FAECC	Ministerio de Economia y Competitividad (MINECO); Fondos (FEDER); Fundacion Seneca, Region de Murcia (FS-RM)(Fundacion Seneca); Ludwig Institute for Cancer Research; FAECC	This work was supported by grants from Ministerio de Economia y Competitividad (MINECO; Co-financing with Fondos FEDER) (SAF2013-48375-C2-1-R) to JNR-L and Fundacion Seneca, Region de Murcia (FS-RM) (15230/PI/10 and 19304/PI/14) to JNR-L, JC-H, and AP-M. JC-H is contracted by the FFIS. MFM is contracted by Fundacion de la Asociacion Espanola contra el Cancer (FAECC). LS-d-C is supported by the Ludwig Institute for Cancer Research and FAECC.	Alla V, 2010, JNCI-J NATL CANCER I, V102, P127, DOI 10.1093/jnci/djp458; Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang HW, 2014, MOLECULES, V19, P3149, DOI 10.3390/molecules19033149; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Engelmann D, 2010, CELL MOL LIFE SCI, V67, P931, DOI 10.1007/s00018-009-0222-0; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Geng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054959; Gupta A, 2003, CANCER, V97, P2341, DOI 10.1002/cncr.11332; Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Laine A, 2014, CLIN CANCER RES, V20, P3644, DOI 10.1158/1078-0432.CCR-13-1942; Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281; Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605; Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006; Nakshatri H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2559; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Pyle AD, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-235; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tao DY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0412-y; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914; Yui S, 2005, CANCER SCI, V96, P560, DOI 10.1111/j.1349-7006.2005.00097.x	55	22	23	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6143	6152		10.1038/onc.2016.154	http://dx.doi.org/10.1038/onc.2016.154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132511				2022-12-28	WOS:000388509800010
J	An, HT; Yoo, S; Ko, J				An, H-T; Yoo, S.; Ko, J.			alpha-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and beta-catenin stabilization in cervical cancer	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; WNT SIGNALING PATHWAY; TRANSCRIPTION FACTOR; N-CADHERIN; DOWN-REGULATION; CELL-MIGRATION; OVARIAN-CANCER; KAPPA-B; INVASION; ACTININ-4	alpha-Actinin-4 (ACTN4) is frequently amplified and overexpressed in various cancers. Although ACTN4 functions in cancer cell migration and invasion, the roles of ACTN4 during the epithelial-to-mesenchymal transition (EMT) and cervical cancer tumorigenesis are unknown. In this study, we investigated the function of ACTN4 in the progression of cervical cancer and the mechanisms of EMT and tumorigenesis induced by ACTN4. We found that ACTN4 induced EMT by upregulating Snail, which was dependent on the Akt signaling pathway in cervical cancer. ACTN4 induced cell migration and invasion through Snail-mediated matrix metalloproteinase-9 expression. ACTN4 expression level was correlated with stabilization of beta-catenin. Accumulatioin of beta-catenin owing to ACTN4 induced tumorigenesis via upregulation of genes involved in cell proliferation, including cyclin D1 and c-myc. ACTN4 knockdown reduced cervical cancer cell proliferation and tumor formation in vivo. The expression level of ACTN4 is highly elevated in human cervical tumors, compared with that in normal cervical tissues. ACTN4-overexpressing MDCK cells induced tumor formation and metastatic nodules in nude mice. Our findings indicate that ACTN4 promotes EMT and tumorigenesis by regulating Snail expression and the Akt pathway in cervical cancer. We propose a novel mechanism for EMT and tumorigenesis in cervical cancer.	[An, H-T; Yoo, S.; Ko, J.] Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea	Korea University	Ko, J (corresponding author), Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr		An, Hyoung-Tae/0000-0002-0732-2083	Basic Science Research Program [NRF-2014R1A2A2 A01002826]; Tunneling Nanotube Research Center through the National Research Foundation of Korea (NRF) - Korea government (MSIP) [NRF-2015R1A5A1009024]; Korea University Grant	Basic Science Research Program; Tunneling Nanotube Research Center through the National Research Foundation of Korea (NRF) - Korea government (MSIP); Korea University Grant	This work was supported by Basic Science Research Program (NRF-2014R1A2A2 A01002826) and Tunneling Nanotube Research Center (NRF-2015R1A5A1009024) through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) and the Korea University Grant.	Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; An HT, 2014, J BIOL CHEM, V289, P4969, DOI 10.1074/jbc.M113.515395; Babakov VN, 2008, EXP CELL RES, V314, P1030, DOI 10.1016/j.yexcr.2007.12.001; Barker N, 2000, BIOESSAYS, V22, P961; Bertelsen BI, 2006, INT J CANCER, V118, P1877, DOI 10.1002/ijc.21461; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bolshakova A, 2007, CELL BIOL INT, V31, P360, DOI 10.1016/j.cellbi.2007.01.021; Brognard J, 2001, CANCER RES, V61, P3986; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Di Croce L, 2003, EUR J CANCER, V39, P413, DOI 10.1016/S0959-8049(02)00815-8; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Eastham AM, 2007, CANCER RES, V67, P11254, DOI 10.1158/0008-5472.CAN-07-2253; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Ilyas M, 1997, J PATHOL, V182, P128; Jawhari A, 1997, GASTROENTEROLOGY, V112, P46, DOI 10.1016/S0016-5085(97)70218-X; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kang H, 2011, J BIOL CHEM, V286, P42072, DOI 10.1074/jbc.M111.272302; Kumeta M, 2010, J CELL SCI, V123, P1020, DOI 10.1242/jcs.059568; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Nakayama H, 2001, CANCER, V92, P3037, DOI 10.1002/1097-0142(20011215)92:12<3037::AID-CNCR10171>3.0.CO;2-#; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Polakis P, 2000, GENE DEV, V14, P1837; Prasad SB, 2014, J CANCER, V5, P655, DOI 10.7150/jca.6554; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Schmidt-Ott KM, 2007, DEVELOPMENT, V134, P3177, DOI 10.1242/dev.006544; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Shao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013921; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Xu DM, 2010, CANCER RES, V70, P6988, DOI 10.1158/0008-5472.CAN-10-0242; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	47	46	48	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5893	5904		10.1038/onc.2016.117	http://dx.doi.org/10.1038/onc.2016.117			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27065319				2022-12-28	WOS:000387560800008
J	Suzuki, E; Umezawa, K; Bonavida, B				Suzuki, E.; Umezawa, K.; Bonavida, B.			RETRACTION: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (Retraction of vol 26, pg 6184, 2016)	ONCOGENE			English	Retraction																		SUZUKI E, 2016, ONCOGENE, V26, P6184, DOI DOI 10.1038/SJ.0NC.1210448	1	2	2	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5576	5576		10.1038/onc.2016.207	http://dx.doi.org/10.1038/onc.2016.207			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27345401	Bronze			2022-12-28	WOS:000386998200012
J	Ozes, AR; Miller, DF; Ozes, ON; Fang, F; Liu, Y; Matei, D; Huang, T; Nephew, KP				Ozes, A. R.; Miller, D. F.; Ozes, O. N.; Fang, F.; Liu, Y.; Matei, D.; Huang, T.; Nephew, K. P.			NF-kappa B-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer	ONCOGENE			English	Article							NONCODING RNA HOTAIR; EPITHELIAL-MESENCHYMAL TRANSITION; ONCOGENE-INDUCED SENESCENCE; GENE-EXPRESSION; CISPLATIN RESISTANCE; SECRETORY PHENOTYPE; IN-VIVO; CELLS; METASTASIS; ACTIVATION	The transcription factor nuclear factor kappa B (NF-kappa B) and the long non-coding RNA (lncRNA) HOTAIR (HOX transcript antisense RNA) have diverse functional roles in cancer. In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors. To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment. We demonstrate that ectopic expression of HOTAIR induces NF-kappa B activation during DDR and interleukin-6 and interleukin-6 expression, both key NF-kappa B target genes. We show that HOTAIR regulates activation of NF-kappa B by decreasing I kappa-B alpha (NF-kappa B inhibitor) and establish that by inducing prolonged NF-kappa B activation and expression of NF-kappa B target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity. Our findings suggest that an NF-.B- HOTAIR axis drives a positive-feedback loop cascade during DDR and contributes to cellular senescence and chemotherapy resistance in ovarian and other cancers.	[Ozes, A. R.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN USA; [Miller, D. F.; Fang, F.; Nephew, K. P.] Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA; [Ozes, O. N.] Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey; [Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Liu, Y.] Ctr Computat Biol & Bioinformat, Indianapolis, IN USA; [Liu, Y.; Matei, D.; Nephew, K. P.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA; [Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Matei, D.; Nephew, K. P.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Huang, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78229 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Akdeniz University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, Med Sci Program, Dept Cellular & Integrat Physiol, Jordan Hall 302,1001 East Third St, Bloomington, IN 47405 USA.	knephew@indiana.edu		Matei, Daniela/0000-0003-2169-5035	National Cancer Institute [CA13001, CA182832]; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN); NATIONAL CANCER INSTITUTE [R01CA182832, U54CA113001] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001108] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Aaron Buechlein (Indiana University) for help with bioinformatic analysis of TCGA data, Dr Craig Pikaard (Indian University) for the pAV-spinach vector, Dr Howard Chang (Stanford University) for LZRS-HOTAIR vector, and Dr Heather O'Hagan for carefully reading this manuscript and helpful suggestions. This work was made possible by funding from the National Cancer Institute (Awards CA13001 and CA182832), Walther Cancer Foundation (Indianapolis, IN), and the Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN).	Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003; Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Guil S, 2012, NAT STRUCT MOL BIOL, V19, P664, DOI 10.1038/nsmb.2315; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Heubach J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0371-8; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jing L, 2014, TUMOR BIOL, V36, P3611; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Liu ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077293; Malek E, 2014, ONCOTARGET, V5, P8027, DOI 10.18632/oncotarget.2469; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Miller DFB, 2013, METHODS, V63, P126, DOI 10.1016/j.ymeth.2013.03.023; Miller DF, 2015, CURR PROTOC HUM GENE; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Ozes ON, 1999, NATURE, V401, P82; Paige JS, 2011, SCIENCE, V333, P642, DOI 10.1126/science.1207339; Qiu JJ, 2014, GYNECOL ONCOL, V134, P121, DOI 10.1016/j.ygyno.2014.03.556; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Tian C, 2014, TUMOR BIOL, V35, P3003, DOI 10.1007/s13277-013-1387-6; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wan GH, 2013, EMBO J, V32, P2833, DOI 10.1038/emboj.2013.221; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022; Wang Y, 2010, CANCER LETT, V295, P110, DOI 10.1016/j.canlet.2010.02.019; Wu ZH, 2014, ONCOL REP, V32, P395, DOI 10.3892/or.2014.3186; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yang G, 2011, CLIN CANCER RES, V17, P2181, DOI 10.1158/1078-0432.CCR-10-3265; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhang XP, 2012, BIOPHYS J, V102, P2251, DOI 10.1016/j.bpj.2012.04.002	57	188	199	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5350	5361		10.1038/onc.2016.75	http://dx.doi.org/10.1038/onc.2016.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041570	Green Submitted, Green Accepted			2022-12-28	WOS:000386677800002
J	Zhu, L; Cheng, X; Shi, J; Lin, J; Chen, G; Jin, H; Liu, AB; Pyo, H; Ye, J; Zhu, Y; Wang, H; Chen, H; Fang, J; Cai, L; Wang, TC; Yang, CS; Tu, SP				Zhu, L.; Cheng, X.; Shi, J.; Lin, J.; Chen, G.; Jin, H.; Liu, A. B.; Pyo, H.; Ye, J.; Zhu, Y.; Wang, H.; Chen, H.; Fang, J.; Cai, L.; Wang, T. C.; Yang, C. S.; Tu, S. P.			Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; TUMOR-GROWTH; EXPRESSION; MICROENVIRONMENT; FIBROBLASTS; INITIATION; NICHE; STAT3; MICE; IL-6	Bone marrow-derived cells have important roles in cancer development and progression. Our previous studies demonstrated that murine bone marrow-derived myofibroblasts (BMFs) enhanced tumor growth. In this study, we investigated the mechanisms of BMF actions. We found that co-injection of BMFs with gastric cancer cells markedly promoted tumorigenesis. Co-cultured BMFs or BMF-conditioned medium (BMF-CM) induced the formation of spheres, which expressed stem cell signatures and exhibited features of self-renewal, epithelial-to-mesenchymal transition and tumor initiation. Furthermore, CD44(+) fractions in spheres were able to initiate tumorigenesis and re-establish tumors in serially passaged xenografts. In co-culture systems, BMFs secreted high levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF), whereas cancer cells produced high level of transformation growth factor-beta 1 (TGF-beta 1). BMF-CM and IL-6 activated BMFs to produce mHGF, which activated signal transducer and activator of transcription 3 (STAT3) and upregulated TGF-beta 1 in human cancer cells. In return, cancer cell-CM stimulated BMFs to produce IL-6, which was inhibited by anti-TGF-beta 1 neutralizing antibody. Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-beta 1 signaling by specific inhibitors inhibited BMF-induced sphere formation. STAT3 knockdown in cancer cells also inhibited BMF-induced sphere formation and tumorigenesis. Moreover, TGF-beta 1 overexpression in cancer cells was co-related with IL-6 and HGF overexpression in stromal cells in human gastric cancer tissues. Our results show that BMF-derived IL-6/HGF and cancer cell-derived TGF-beta 1 mediate the interactions between BMFs and gastric cancer cells, which regulate cancer stemness and promote tumorigenesis. Targeting inhibition of the interactions between BMFs and cancer cells may be a new strategy for cancer therapy.	[Zhu, L.; Cheng, X.; Lin, J.; Chen, G.; Tu, S. P.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China; [Zhu, L.; Shi, J.; Chen, G.; Jin, H.; Liu, A. B.; Pyo, H.; Wang, H.; Yang, C. S.; Tu, S. P.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA; [Ye, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Emergency Med, Shanghai, Peoples R China; [Zhu, Y.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai, Peoples R China; [Chen, H.; Fang, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Cai, L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA; [Wang, T. C.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA	Shanghai Jiao Tong University; Rutgers State University New Brunswick; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Columbia University	Tu, SP (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China.; Yang, CS; Tu, SP (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA.	csyang@pharmacy.rutgers.edu; tushuiping@yahoo.com	LIN, JIACHENG/ABG-9209-2021	Cai, Li/0000-0003-3344-337X; LIN, JIACHENG/0000-0002-6132-9163; Wang, Timothy/0000-0001-5730-3019	NIH [R21CA149865, RO1 CA133021]; NSFC [81172159, 81272403, 81472727, 91029718, 91429307]; Shanghai Education Committee Key Discipline and Specialty Foundation [J50208]; Science and Technology Commission of Shanghai Municipality [15JC1403100]; NATIONAL CANCER INSTITUTE [R21CA149865, R01CA133021] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Education Committee Key Discipline and Specialty Foundation; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The project was supported by NIH R21CA149865, NSFC 81172159, NSFC 81272403, NSFC 81472727, NSFC 91029718, NSFC 91429307 and NIH RO1 CA133021; Shanghai Education Committee Key Discipline and Specialty Foundation (J50208), Science and Technology Commission of Shanghai Municipality (15JC1403100). National Laboratory of Oncogene and Cancer-related Genes foundation (90-15-05).	Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Birkenkamp-Demtroder K, 2011, BRIT J CANCER, V105, P552, DOI 10.1038/bjc.2011.268; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Castano Z, 2012, SEMIN CANCER BIOL, V22, P462, DOI 10.1016/j.semcancer.2012.04.006; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Giraud AS, 2012, EXPERT OPIN THER TAR, V16, P889, DOI 10.1517/14728222.2012.709238; Gomes I, 2005, J ALLERGY CLIN IMMUN, V116, P796, DOI 10.1016/j.jaci.2005.06.031; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; Hawinkels LJ, 2012, ONCOGENE, V33, P97, DOI [DOI 10.1038/ONC.2012.536, DOI 10.1038/onc.2012.536]; Hayward SW, 2001, CANCER RES, V61, P8135; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Lecomte J, 2012, NEOPLASIA, V14, P943, DOI 10.1593/neo.121092; Lee BS, 2009, CELL SIGNAL, V21, P419, DOI 10.1016/j.cellsig.2008.11.010; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tu SP, 2003, CANCER RES, V63, P7724; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	33	23	24	5	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5388	5399		10.1038/onc.2016.76	http://dx.doi.org/10.1038/onc.2016.76			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27109105	Green Accepted			2022-12-28	WOS:000386677800005
J	Nodomi, S; Umeda, K; Saida, S; Kinehara, T; Hamabata, T; Daifu, T; Kato, I; Hiramatsu, H; Watanabe, KI; Kuwahara, Y; Iehara, T; Adachi, S; Konishi, E; Nakahata, T; Hosoi, H; Heike, T				Nodomi, S.; Umeda, K.; Saida, S.; Kinehara, T.; Hamabata, T.; Daifu, T.; Kato, I.; Hiramatsu, H.; Watanabe, K-I; Kuwahara, Y.; Iehara, T.; Adachi, S.; Konishi, E.; Nakahata, T.; Hosoi, H.; Heike, T.			CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor	ONCOGENE			English	Article							CANCER STEM-CELLS; ATYPICAL TERATOID/RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; NATIONAL-WILMS-TUMOR; INITIATING CELLS; HUMAN-MELANOMA; BREAST-CANCER; LINE; IDENTIFICATION; EXPRESSION	Malignant rhabdoid tumor (MRT) is a rare, highly aggressive pediatric malignancy that primarily develops during infancy and early childhood. Despite the existing standard of intensive multimodal therapy, the prognosis of patients with MRT is dismal; therefore, a greater understanding of the biology of this disease is required to establish novel therapies. In this study, we identified a highly tumorigenic sub-population in MRT, based on the expression of CD146 (also known as melanoma cell adhesion molecule), a cell adhesion molecule expressed by neural crest cells and various derivatives. CD146(+) cells isolated from four MRT cell lines by cell sorting exhibited enhanced self-renewal and invasive potential in vitro. In a xenograft model using immunodeficient NOD/Shi-scid IL-2R gamma-null mice, purified CD146+ cells obtained from MRT cell lines or a primary tumor exhibited the exclusive ability to form tumors in vivo. Blocking of CD146-related mechanisms, either by short hairpin RNA knockdown or treatment with a polyclonal antibody against CD146, effectively suppressed tumor growth of MRT cells both in vitro and in vivo via induction of apoptosis by inactivating Akt. Furthermore, CD146 positivity in immunohistological analysis of 11 MRT patient samples was associated with poor patient outcomes. These results suggest that CD146 defines a distinct sub-population in MRT with high tumorigenic capacity and that this marker represents a promising therapeutic target.	[Nodomi, S.; Umeda, K.; Saida, S.; Kinehara, T.; Hamabata, T.; Daifu, T.; Kato, I.; Hiramatsu, H.; Watanabe, K-I; Heike, T.] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Kuwahara, Y.; Iehara, T.; Hosoi, H.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan; [Adachi, S.] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Japan; [Konishi, E.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg Pathol, Kyoto, Japan; [Nakahata, T.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan	Kyoto University; Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine; Kyoto University	Umeda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto, Kyoto 6068507, Japan.	umeume@kuhp.kyoto-u.ac.jp		Kuwahara, Yasumichi/0000-0002-0139-8503; Konishi, Eiichi/0000-0002-7122-2271	Takeda Science Foundation;  [24591407];  [25461602]	Takeda Science Foundation(Takeda Science Foundation (TSF)); ; 	We thank all staff for help with histological analysis. We also thank Dr Y Yui and Dr R Nishikomori for providing a critical reading of the manuscript. We are grateful to Dr R Yamada for helpful discussions about statistical analysis of microarray data. This study was supported by grants from the Grant-in-Aid for Scientific Research (C) (24591407 and 25461602) and the Takeda Science Foundation.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Biegel JA, 1999, CANCER RES, V59, P74; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chen DH, 2013, CANCER RES, V73, P5821, DOI 10.1158/0008-5472.CAN-13-1080; Chiou SH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002090; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Gadd S, 2010, LAB INVEST, V90, P724, DOI 10.1038/labinvest.2010.66; Ginn KF, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00114; Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073; Ho DMT, 2000, ACTA NEUROPATHOL, V99, P482, DOI 10.1007/s004010051149; Ito A, 2009, J IMMUNOL, V183, P4782, DOI 10.4049/jimmunol.0900699; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108; Jiang XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-116; Jouve N, 2013, J BIOL CHEM, V288, P2571, DOI 10.1074/jbc.M112.418848; Katsumi Y, 2008, CLIN CANCER RES, V14, P1192, DOI 10.1158/1078-0432.CCR-07-1661; Kuroda H, 2005, CANCER GENET CYTOGEN, V158, P172, DOI 10.1016/j.cancergencyto.2004.08.032; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; McGary EC, 2003, CLIN CANCER RES, V9, P6560; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Mills L, 2002, CANCER RES, V62, P5106; Misawa A, 2004, J HUM GENET, V49, P586, DOI 10.1007/s10038-004-0191-y; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Okuno K, 2010, ONCOL REP, V23, P485, DOI 10.3892/or_00000659; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Pujades C, 2002, INT J DEV BIOL, V46, P263; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shiokawa M, 2010, BIOCHEM BIOPH RES CO, V399, P733, DOI 10.1016/j.bbrc.2010.07.145; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Sugimoto T, 1999, INT J CANCER, V82, P678, DOI 10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K; Sultan I, 2010, PEDIATR BLOOD CANCER, V54, P35, DOI 10.1002/pbc.22285; Tekautz TM, 2005, J CLIN ONCOL, V23, P1491, DOI 10.1200/JCO.2005.05.187; Tomlinson GE, 2005, J CLIN ONCOL, V23, P7641, DOI 10.1200/JCO.2004.00.8110; Tu T, 2015, CELL RES, V25, P275, DOI 10.1038/cr.2015.15; van den Heuvel-Eibrink MM, 2011, PEDIAT BLOOD CANC, V56, P733; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; WEEKS DA, 1989, AM J SURG PATHOL, V13, P439, DOI 10.1097/00000478-198906000-00001; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Yanagisawa S, 2009, CLIN CANCER RES, V15, P3014, DOI 10.1158/1078-0432.CCR-08-2237; Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636; Zhang Y, 2008, HYBRIDOMA, V27, P345, DOI 10.1089/hyb.2008.0034; Zhong Y, 2010, CANCER LETT, V299, P150, DOI 10.1016/j.canlet.2010.08.013; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	52	15	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5317	5327		10.1038/onc.2016.72	http://dx.doi.org/10.1038/onc.2016.72			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041577	hybrid, Green Published			2022-12-28	WOS:000386053000010
J	Cannistraci, A; Federici, G; Addario, A; Di Pace, AL; Grassi, L; Muto, G; Collura, D; Signore, M; De Salvo, L; Sentinelli, S; Simone, G; Costantini, M; Nanni, S; Farsetti, A; Coppola, V; De Maria, R; Bonci, D				Cannistraci, A.; Federici, G.; Addario, A.; Di Pace, A. L.; Grassi, L.; Muto, G.; Collura, D.; Signore, M.; De Salvo, L.; Sentinelli, S.; Simone, G.; Costantini, M.; Nanni, S.; Farsetti, A.; Coppola, V.; De Maria, R.; Bonci, D.			C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition	ONCOGENE			English	Article							ANDROGEN-RECEPTOR GENE; PROSTATE-CANCER; MICRORNA SIGNATURES; INCREASED SURVIVAL; C-MET; METASTASIS; EXPRESSION; GROWTH; PHOSPHORYLATION; PROGRESSION	Although a significant subset of prostate tumors remain indolent during the entire life, the advanced forms are still one of the leading cause of cancer-related death. There are not reliable markers distinguishing indolent from aggressive forms. Here we highlighted a new molecular circuitry involving microRNA and coding genes promoting cancer progression and castration resistance. Our preclinical and clinical data demonstrated that c-Met activation increases miR-130b levels, inhibits androgen receptor expression, promotes cancer spreading and resistance to hormone ablation therapy. The relevance of these findings was confirmed on patients' samples and by in silico analysis on an independent patient cohort from Taylor's platform. Data suggest c-Met/miR-130b axis as a new prognostic marker for patients' risk assessment and as an indicator of therapy resistance. Our results propose new biomarkers for therapy decision-making in all phases of the pathology. Data may help identify high-risk patients to be treated with adjuvant therapy together with alternative cure for castration-resistant forms while facilitating the identification of possible patients candidates for anti-Met therapy. In addition, we demonstrated that it is possible to evaluate Met/miR-130b axis expression in exosomes isolated from peripheral blood of surgery candidates and advanced patients offering a new non-invasive tool for active surveillance and therapy monitoring.	[Cannistraci, A.; Federici, G.; Addario, A.; Di Pace, A. L.; Grassi, L.; Signore, M.; Coppola, V.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Federici, G.; Grassi, L.; De Salvo, L.; Sentinelli, S.; Simone, G.; Costantini, M.; Bonci, D.] Regina Elena Inst Canc Res, Rome, Italy; [Di Pace, A. L.] Sapienza Univ Rome, Histol & Med Embryol Sect, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy; [Muto, G.; Collura, D.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Muto, G.] Campus Biomed Univ, Dept Urol, Rome, Italy; [Nanni, S.] Univ Cattolica, Inst Med Pathol, Rome, Italy; [Farsetti, A.] CNR, Inst Cell Biol & Neurobiol, Rome, Italy; [De Maria, R.] Univ Cattolica, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy; [De Maria, R.] Policlin Gemelli, Largo Francesco Vito 1, I-00168 Rome, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; University Campus Bio-Medico - Rome Italy; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bonci, D (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.; De Maria, R (corresponding author), Univ Cattolica, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy.; De Maria, R (corresponding author), Policlin Gemelli, Largo Francesco Vito 1, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; desiree.bonci@iss.it	Addario, Antonio/AAC-4707-2022; Signore, Michele/J-8563-2016; Farsetti, Antonella/I-8710-2018; Federici, Giulia/AAC-8820-2019; Di Pace, Anna Laura/K-6494-2016; Bonci, Desiree/K-6488-2016; De Maria, Ruggero/S-6385-2019; simone, giuseppe/K-9607-2016; Coppola, Valeria/K-5120-2016	Addario, Antonio/0000-0001-8527-8738; Signore, Michele/0000-0002-0262-842X; Farsetti, Antonella/0000-0002-8603-7925; Federici, Giulia/0000-0002-4684-0270; Di Pace, Anna Laura/0000-0002-1712-9033; Bonci, Desiree/0000-0002-2472-5140; De Maria, Ruggero/0000-0003-2255-0583; simone, giuseppe/0000-0002-4868-9025; Coppola, Valeria/0000-0002-5745-2572; collura, devis/0000-0002-8964-5248; Muto, Giovanni/0000-0003-3593-6450	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer (AIRC); Fondazione Roma	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank Giuseppe Loreto and Tania Merlino for their technical support. We thank Alessandra Boe for cytofluorimetric analysis. This manuscript was supported by National Ministry of Health, Under-forty researcher (2012) and Italy-USA microRNA program to DB and the Italian Association for Cancer (AIRC) and Fondazione Roma funding to RDM.	Adolfsson J, 2008, BJU INT, V102, P10, DOI 10.1111/j.1464-410X.2008.07585.x; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; BRAWN PN, 1989, BRIT J CANCER, V59, P85, DOI 10.1038/bjc.1989.16; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; D'Amico Anthony V, 2004, J Urol, V172, pS42, DOI 10.1097/01.ju.0000141845.99899.12; D'Amico AV, 2004, NEW ENGL J MED, V351, P125, DOI 10.1056/NEJMoa032975; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Dean M, 1987, Haematol Blood Transfus, V31, P464; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Haas GP, 2008, CAN J UROL, V15, P3866; Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219; ISAACS JT, 1981, CANCER RES, V41, P5070; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li BL, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0484-0; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Liu AM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000825; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Maeda A, 2006, BIOCHEM BIOPH RES CO, V347, P1158, DOI 10.1016/j.bbrc.2006.07.040; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mueller C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023780; Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Pierobon M, 2015, ONCOGENE, V34, P805, DOI 10.1038/onc.2014.16; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TILLEY WD, 1990, CANCER RES, V50, P5382; Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verhoef EI, 2016, ONCOTARGET, V7, P31029, DOI 10.18632/oncotarget.8829; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Zhao G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073803	58	28	28	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3718	3728		10.1038/onc.2016.505	http://dx.doi.org/10.1038/onc.2016.505			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192399				2022-12-28	WOS:000404349700007
J	He, Y; Northey, JJ; Pelletier, A; Kos, Z; Meunier, L; Haibe-Kains, B; Mes-Masson, AM; Cote, JF; Siegel, PM; Lamarche-Vane, N				He, Y.; Northey, J. J.; Pelletier, A.; Kos, Z.; Meunier, L.; Haibe-Kains, B.; Mes-Masson, A-M; Cote, J-F; Siegel, P. M.; Lamarche-Vane, N.			The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer	ONCOGENE			English	Article							SMAD-INTERACTING PROTEIN-1; GTPASE-ACTIVATING PROTEIN; ADAMS-OLIVER SYNDROME; OF-FUNCTION MUTATIONS; PHOSPHORYLATES CDGAP; CELL MOTILITY; EXPRESSION; GENE; ARHGAP31; RECEPTOR	The loss of E-cadherin causes dysfunction of the cell-cell junction machinery, which is an initial step in epithelial-to-mesenchymal transition (EMT), facilitating cancer cell invasion and the formation of metastases. A set of transcriptional repressors of E-cadherin (CDH1) gene expression, including Snail1, Snail2 and Zeb2 mediate E-cadherin downregulation in breast cancer. However, the molecular mechanisms underlying the control of E-cadherin expression in breast cancer progression remain largely unknown. Here, by using global gene expression approaches, we uncover a novel function for Cdc42 GTPase-activating protein (CdGAP) in the regulation of expression of genes involved in EMT. We found that CdGAP used its proline-rich domain to form a functional complex with Zeb2 to mediate the repression of E-cadherin expression in ErbB2-transformed breast cancer cells. Conversely, knockdown of CdGAP expression led to a decrease of the transcriptional repressors Snail1 and Zeb2, and this correlated with an increase in E-cadherin levels, restoration of cell-cell junctions, and epithelial-like morphological changes. In vivo, loss of CdGAP in ErbB2-transformed breast cancer cells impaired tumor growth and suppressed metastasis to lungs. Finally, CdGAP was highly expressed in basal-type breast cancer cells, and its strong expression correlated with poor prognosis in breast cancer patients. Together, these data support a previously unknown nuclear function for CdGAP where it cooperates in a GAP-independent manner with transcriptional repressors to function as a critical modulator of breast cancer through repression of E-cadherin transcription. Targeting Zeb2-CdGAP interactions may represent novel therapeutic opportunities for breast cancer treatment.	[He, Y.; Lamarche-Vane, N.] McGill Univ, Dept Anat & Cell Biol, McGill Univ Hlth Ctr, Canc Res Program,Res Inst, Montreal, PQ, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pelletier, A.; Cote, J-F] Inst Rech Clin Montreal, Montreal, PQ, Canada; [Kos, Z.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Meunier, L.; Mes-Masson, A-M] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada; [Haibe-Kains, B.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Haibe-Kains, B.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Haibe-Kains, B.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Northey, J. J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of California System; University of California San Francisco	Lamarche-Vane, N (corresponding author), McGill Univ, Anat & Cell Biol, RI MUHC, 1001 Boul Decarie,Room E02-6230, Montreal, PQ H4A 3J1, Canada.	Nathalie.lamarche@mcgill.ca	Northey, Jason/AAX-6365-2021; Haibe-Kains, Benjamin/D-3702-2011	Northey, Jason/0000-0003-3115-2560; Mes-Masson, Anne-Marie/0000-0002-6498-266X; Haibe-Kains, Benjamin/0000-0002-7684-0079	FRSQ chercheur-national; William Dawson scholar; Canadian Institute for Health Research (CIHR) [MOP-119544, MOP-144425]; FRQS senior scholarship	FRSQ chercheur-national(Fonds de la Recherche en Sante du Quebec); William Dawson scholar; Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); FRQS senior scholarship	We thank Dr Patricia Tonin for helpful discussions and Dr John J Bergeron for critically reading this manuscript. We are grateful to Dr Morag Park (McGill University) for providing the Zeb2 and E-cadherin-luc constructs. We thank Dr Torsten Nielsen for providing the human breast cancer TMA and the CdGAP IHC staining through the Genetic Pathology Evaluation Center (GPEC), ZF Dong for IHC staining of primary tumors, Dr Min Fu for assistance with confocal microscopy at the imaging platform of the RI-MUHC, Martin Primeau and Vilayphone Luangrath for affinity purification of the CdGAP antibodies. NL-V was a recipient of a FRSQ chercheur-national and a William Dawson scholar. Canadian Institute for Health Research (CIHR) MOP-119544 to NL-V and MOP-144425 to JFC. JFC is a recipient of a FRQS senior scholarship.	Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Barras D, 2014, CANCER METAST REV, V33, P87, DOI 10.1007/s10555-013-9458-0; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Caron C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27485; Danek EI, 2007, J BIOL CHEM, V282, P3624, DOI 10.1074/jbc.M610073200; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hajra KM, 2002, CANCER RES, V62, P1613; Hassed SJ, 2012, AM J HUM GENET, V91, P391, DOI 10.1016/j.ajhg.2012.07.005; He Y, 2011, ONCOGENE, V30, P1032, DOI 10.1038/onc.2010.477; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hu QP, 2016, INT J CANCER, V138, P2804, DOI 10.1002/ijc.29982; Isrie M, 2014, AM J MED GENET A, V164, P1576, DOI 10.1002/ajmg.a.36486; Karimzadeh F, 2012, J BIOL CHEM, V287, P19610, DOI 10.1074/jbc.M112.344606; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; Meester JAN, 2015, AM J HUM GENET, V97, P475, DOI 10.1016/j.ajhg.2015.07.015; Metzger O, 2013, J CLIN ONCOL, V31, P3083, DOI 10.1200/JCO.2012.46.1574; Naji L, 2011, BIOCHEM BIOPH RES CO, V409, P96, DOI 10.1016/j.bbrc.2011.04.116; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shaheen R, 2013, AM J HUM GENET, V92, P598, DOI 10.1016/j.ajhg.2013.02.012; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Southgate L, 2015, CIRC-CARDIOVASC GENE, V8, P572, DOI 10.1161/CIRCGENETICS.115.001086; Southgate L, 2011, AM J HUM GENET, V88, P574, DOI 10.1016/j.ajhg.2011.04.013; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang CA, 2014, CANCER RES, V74, P7357, DOI 10.1158/0008-5472.CAN-14-0666; Wang JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5735; Wong TS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/921564; Wu ZQ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4998	46	26	28	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3490	3503		10.1038/onc.2016.492	http://dx.doi.org/10.1038/onc.2016.492			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28135249	Green Accepted			2022-12-28	WOS:000403340700012
J	Kim, HS; Jung, M; Kang, HN; Kim, H; Park, CW; Kim, SM; Shin, SJ; Kim, SH; Kim, SG; Kim, EK; Yun, MR; Zheng, Z; Chung, KY; Greenbowe, J; Ali, SM; Kim, TM; Cho, BC				Kim, H. S.; Jung, M.; Kang, H. N.; Kim, H.; Park, C-W; Kim, S-M; Shin, S. J.; Kim, S. H.; Kim, S. G.; Kim, E. K.; Yun, M. R.; Zheng, Z.; Chung, K. Y.; Greenbowe, J.; Ali, S. M.; Kim, T-M; Cho, B. C.			Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition	ONCOGENE			English	Article							SEQUENCING DATA; IMPROVED SURVIVAL; TARGETED THERAPY; MUTATED MELANOMA; MUTANT MELANOMA; MEK INHIBITION; RAF INHIBITORS; GENE FUSIONS; CANCER; MUTATIONS	Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational landscape of primary mucosal melanomas (PMM) remains unclear. Forty-six PMMs underwent targeted exome sequencing of 111 cancer-associated genes. Seventy-six somatic nonsynonymous mutations in 42 genes were observed, and recurrent mutations were noted on eight genes, including TP53 (13%), NRAS (13%), SNX31 (9%), NF1 (9%), KIT (7%) and APC (7%). Mitogen-activated protein kinase (MAPK; 37%), cell cycle (20%) and phosphatidylinositol 3-kinase (PI3K)-mTOR (15%) pathways were frequently mutated. We biologically characterized a novel ZNF767-BRAF fusion found in a vemurafenib-refractory respiratory tract PMM, from which cell line harboring ZNF767-BRAF fusion were established for further molecular analyses. In an independent data set, NFIC-BRAF fusion was identified in an oral PMM case and TMEM178B-BRAF fusion and DGKI-BRAF fusion were identified in two malignant melanomas with a low mutational burden (number of mutation per megabase, 0.8 and 4, respectively). Subsequent analyses revealed that the ZNF767-BRAF fusion protein promotes RAF dimerization and activation of the MAPK pathway. We next tested the in vitro and in vivo efficacy of vemurafenib, trametinib, BKM120 or LEE011 alone and in combination. Trametinib effectively inhibited tumor cell growth in vitro, but the combination of trametinib and BKM120 or LEE011 yielded more than additive anti-tumor effects both in vitro and in vivo in a melanoma cells harboring the BRAF fusion. In conclusion, BRAF fusions define a new molecular subset of PMM that can be targeted therapeutically by the combination of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/ 6 inhibitors.	[Kim, H. S.; Jung, M.; Shin, S. J.; Cho, B. C.] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med,Yonsei Canc Ctr, 50 Yonsei Ro, Seoul 120752, South Korea; [Kim, H. S.] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Dept Pharmacol, Seoul, South Korea; [Kang, H. N.; Kim, H.; Park, C-W; Kim, S-M; Kim, S. G.; Yun, M. R.] JEUK Co Ltd, JEUK Inst Canc Res, Gumi, Kyungbuk, South Korea; [Kim, S. H.; Kim, E. K.] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Kim, S. H.] Seegene Med Fdn, Anat Pathol Reference Lab, Seoul, South Korea; [Zheng, Z.] Yanbian Univ Hosp, Dept Dermatol, Yanji, Peoples R China; [Chung, K. Y.] Yonsei Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Greenbowe, J.; Ali, S. M.] Fdn Med Inc, Cambridge, MA 02141 USA; [Kim, T-M] Catholic Univ Korea, Dept Med Informat, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yanbian University; Yonsei University; Yonsei University Health System; Foundation Medicine; Catholic University of Korea	Cho, BC (corresponding author), Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med,Yonsei Canc Ctr, 50 Yonsei Ro, Seoul 120752, South Korea.; Ali, SM (corresponding author), Fdn Med Inc, Cambridge, MA 02141 USA.; Kim, TM (corresponding author), Catholic Univ Korea, Seoul 137701, South Korea.	sali@foundationmedicine.com; tmkim@catholic.ac.kr; cbc1971@yuhs.ac	Kim, Han Sang/R-3768-2019; Ali, Siraj/AAE-2958-2019; Kim, Eun-Kyung/E-5211-2017	Kim, Han Sang/0000-0002-6504-9927; Jung, Minkyu/0000-0001-8281-3387; Kim, Eun-Kyung/0000-0002-3368-5013; Shin, Sang Joon/0000-0001-5350-7241; Cho, Byoung Chul/0000-0002-5562-270X; Chung, Kee Yang/0000-0003-3257-0297	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2014R1A1A1004823]; NRF by the Korean government (MEST) [2012R1A2A2A01046927]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; NRF by the Korean government (MEST)	This study was supported in part by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (2014R1A1A1004823 to M Jung), and the NRF by the Korean government (MEST; 2012R1A2A2A01046927 to B Cho). The results of the analysis of mutation frequencies in cutaneous melanomas compared with corresponding frequencies in PMM were based on TCGA Research Network generated data (http://cancergenome.nih.gov/).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Deuker MM, 2015, CANCER DISCOV, V5, P143, DOI 10.1158/2159-8290.CD-14-0856; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Ge HY, 2011, BIOINFORMATICS, V27, P1922, DOI 10.1093/bioinformatics/btr310; Ghai R, 2011, P NATL ACAD SCI USA, V108, P7763, DOI 10.1073/pnas.1017110108; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Iyer MK, 2011, BIOINFORMATICS, V27, P2903, DOI 10.1093/bioinformatics/btr467; Jeuken JWM, 2010, J PATHOL, V222, P324, DOI 10.1002/path.2780; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; McVey M, 2008, TRENDS GENET, V24, P529, DOI 10.1016/j.tig.2008.08.007; Mihajlovic M, 2012, INT J CLIN EXP PATHO, V5, P739; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Seetharamu N, 2010, ONCOLOGIST, V15, P772, DOI 10.1634/theoncologist.2010-0067; Stark MS, 2012, NAT GENET, V44, P165, DOI 10.1038/ng.1041; Sullivan RJ, 2013, ONCOGENE, V32, P2373, DOI 10.1038/onc.2012.345; The National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	52	57	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3334	3345		10.1038/onc.2016.486	http://dx.doi.org/10.1038/onc.2016.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092667				2022-12-28	WOS:000402869800012
J	Goreczny, GJ; Ouderkirk-Pecone, JL; Olson, EC; Krendel, M; Turner, CE				Goreczny, G. J.; Ouderkirk-Pecone, J. L.; Olson, E. C.; Krendel, M.; Turner, C. E.			Hic-5 remodeling of the stromal matrix promotes breast tumor progression	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; TGF-BETA; MESENCHYMAL TRANSITION; COLLECTIVE INVASION; GENE-EXPRESSION; CELL-MIGRATION; MYOFIBROBLAST; PAXILLIN	The remodeling of the stromal extracellular matrix (ECM) has a crucial, but incompletely understood role during tumor progression and metastasis. Hic-5, a focal adhesion scaffold protein, has previously been implicated in tumor cell invasion, proliferation and metastasis. To investigate the role of Hic-5 in breast tumor progression in vivo, Hic-(5-/-) mice were generated and crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T-Antigen mouse. Tumors from the Hic-5(-/-) ;PyMT mice exhibited increased latency and reduced growth, with fewer lung metastases, as compared with Hic-5(+/-); PyMT mice. Immunohistochemical analysis showed that Hic-5 is primarily expressed in the cancer-associated fibroblasts (CAFs). Further analysis revealed that the Hic-5(-/-); PyMT tumor stroma contains fewer CAFs and exhibits reduced ECM deposition. The remodeling of the stromal matrix by CAFs has been shown to increase tumor rigidity to indirectly regulate FAK Y397 phosphorylation in tumor cells to promote their growth and invasion. Accordingly, the Hic-5(-/-) ;PyMT tumor cells exhibited a reduction in FAK Y397 phosphorylation. Isolated Hic-5(-/-); PyMT CAFs were defective in stress fiber organization and exhibited reduced contractility. These cells also failed to efficiently deposit and organize the ECM in two and three dimensions. This, in turn, impacted three-dimensional MDA-MB-231 tumor cell migration behavior. Thus, using a new knockout mouse model, we have identified Hic-5 expression in CAFs as a key requirement for deposition and remodeling of the stromal ECM to promote non-cell autonomous breast tumor progression.	[Goreczny, G. J.; Ouderkirk-Pecone, J. L.; Krendel, M.; Turner, C. E.] SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 East Adams St, Syracuse, NY 13210 USA; [Olson, E. C.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 East Adams St, Syracuse, NY 13210 USA.	turnerce@upstate.edu			National Institutes of Health [R01 CA163296, R01 GM047607, R01 NS066071, R01 DK083345]; Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE [R01CA163296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS066071] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank members of the Turner lab for critical reading of this manuscript and for insightful discussions. We are grateful to Ian Forsythe for the mouse genotyping and additional technical assistance. We also thank Nicholas Deakin for his assistance in isolating CTCs. This work was supported by the National Institutes of Health Grant R01 CA163296 and R01 GM047607 to CET R01 NS066071 to ECO and CET, R01 DK083345 to MK and the Carol M Baldwin Breast Cancer Research Fund of CNY awards to CET and MK.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boyd NF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2942; Burridge K, 2016, EXP CELL RES, V343, P14, DOI 10.1016/j.yexcr.2015.10.029; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cirri P, 2011, AM J CANCER RES, V1, P482; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kuo JC, 2013, J CELL MOL MED, V17, P704, DOI 10.1111/jcmm.12054; Kutys ML, 2013, EXP CELL RES, V319, P2434, DOI 10.1016/j.yexcr.2013.05.030; Lei XF, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000747; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nguyen-Ngoc KV, 2015, METHODS MOL BIOL, V1189, P135, DOI 10.1007/978-1-4939-1164-6_10; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ouderkirk-Pecone JL, 2016, ONCOTARGET, DOI 10.18632/oncotarget.10139; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Plante Isabelle, 2011, J Vis Exp, DOI 10.3791/2828; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Rezakhaniha R, 2012, BIOMECH MODEL MECHAN, V11, P461, DOI 10.1007/s10237-011-0325-z; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shola DTN, 2012, ONCOGENE, V31, P2480, DOI 10.1038/onc.2011.422; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Thomas SM, 1999, J CELL SCI, V112, P181; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Varney SD, 2016, J CELL SCI, V129, P774, DOI 10.1242/jcs.170589; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	52	31	32	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2693	2703		10.1038/onc.2016.422	http://dx.doi.org/10.1038/onc.2016.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893716	Green Accepted			2022-12-28	WOS:000401120900007
J	Kang, J; Kim, W; Lee, S; Kwon, D; Chun, J; Son, B; Kim, E; Lee, JM; Youn, H; Youn, B				Kang, J.; Kim, W.; Lee, S.; Kwon, D.; Chun, J.; Son, B.; Kim, E.; Lee, J-M; Youn, H.; Youn, B.			TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183-and miR-33a-mediated cell cycle regulation	ONCOGENE			English	Article							AP-2-GAMMA TRANSCRIPTION FACTOR; CANCER CELLS; BREAST-CANCER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; AP-2 FAMILY; PROTEIN; RADIORESISTANCE; INHIBITION; GROWTH	Non-small cell lung cancer (NSCLC) remains one of the leading causes of death worldwide, and thus new molecular targets need to be identified to improve treatment efficacy. Although epidermal growth factor receptor (EGFR)/KRAS mutation-driven lung tumorigenesis is well understood, the mechanism of EGFR/KRAS-independent signal activation remains elusive. Enhanced TFAP2C (transcription factor activating enhancer-binding protein 2C) expression is associated with poor prognosis in some types of cancer patients, but little is known of its relation with the pathogenesis of lung cancer. In the present study, we found that TFAP2C overexpression was associated with cell cycle activation and NSCLC cell tumorigenesis. Interestingly, TFAP2C blocked AKAP12mediated cyclin D1 inhibition by inducing the overexpression of oncogenic microRNA (miRNA)-183 and simultaneously activated cyclin-dependent kinase 6-mediated cell cycle progression by downregulating tumor-suppressive miRNA-33a. In a mouse xenograft model, TFAP2C promoted lung tumorigenesis and disease aggressiveness via the miR-183 and miR-33a pathways. The study provides a mechanism of mitogenic and oncogenic signaling via two functionally opposed miRNAs and suggests that TFAP2Cinduced cell cycle hyperactivation contributes to lung tumorigenesis.	[Kang, J.; Lee, S.; Kwon, D.; Chun, J.; Son, B.; Kim, E.; Youn, B.] Pusan Natl Univ, Dept Integrated Biol Sci, Busan, South Korea; [Kim, W.; Youn, B.] Pusan Natl Univ, Dept Biol Sci, 303 Biol Bldg, Busan 46241, South Korea; [Kim, W.] Pusan Natl Univ, Integrat Grad Program, Ship & Offshore Plant Technol Ocean Energy Resour, Busan, South Korea; [Lee, J-M] Pusan Natl Univ, Dept Naval Architecture & Ocean Engn, Busan, South Korea; [Youn, H.] Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong ro, Seoul 05006, South Korea	Pusan National University; Pusan National University; Pusan National University; Pusan National University; Sejong University	Youn, B (corresponding author), Pusan Natl Univ, Dept Biol Sci, 303 Biol Bldg, Busan 46241, South Korea.; Youn, H (corresponding author), Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong ro, Seoul 05006, South Korea.	hsyoun@sejong.ac.kr; bhyoun72@pusan.ac.kr	Kim, EunGi/AAZ-6121-2021		National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [2014R1A1A1A05002112, 2013M2A2A7042502]; Ministry of Education [2013R1A1A2059832, 2014R1A1A2004061]; Ministry of Science, ICT & Future Planning through GCRC-SOP [2011-0030013]	National Research Foundation of Korea - Ministry of Science, ICT & Future Planning; Ministry of Education; Ministry of Science, ICT & Future Planning through GCRC-SOP	This work was supported by the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1A05002112 and 2013M2A2A7042502), the Ministry of Education (2013R1A1A2059832 to W Kim and 2014R1A1A2004061 to H Youn) and the Ministry of Science, ICT & Future Planning through GCRC-SOP (2011-0030013).	Akakura S, 2008, CANCER RES, V68, P5096, DOI 10.1158/0008-5472.CAN-07-5619; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bogachek MV, 2014, CANCER CELL, V25, P748, DOI 10.1016/j.ccr.2014.04.008; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-1; Cirera-Salinas D, 2012, CELL CYCLE, V11, P922, DOI 10.4161/cc.11.5.19421; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Grossel MJ, 2006, CELL CYCLE, V5, P266, DOI 10.4161/cc.5.3.2385; Guin S, 2015, ACTA PHARMACOL SIN, V36, P291, DOI 10.1038/aps.2014.129; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang MH, 2013, MOL ONCOL, V7, P112, DOI 10.1016/j.molonc.2012.09.002; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Imielinski M, 2014, J CLIN INVEST, V124, P1582, DOI 10.1172/JCI72763; Janku F, 2010, NAT REV CLIN ONCOL, V7, P401, DOI 10.1038/nrclinonc.2010.64; Kim E, 2014, CANCER RES, V74, P5520, DOI 10.1158/0008-5472.CAN-14-0735; Kim W, 2015, EXP DERMATOL, V24, P611, DOI 10.1111/exd.12735; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kwon T, 2016, ONCOTARGET, V7, P7193, DOI 10.18632/oncotarget.6887; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lazar V, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-53; Leung WKC, 2015, CANCER LETT, V362, P97, DOI 10.1016/j.canlet.2015.03.023; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin H, 2013, EXP MOL PATHOL, V94, P73, DOI 10.1016/j.yexmp.2012.08.004; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Mansi L, 2011, B CANCER, V98, P1019, DOI 10.1684/bdc.2011.1380; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Odegaard E, 2006, GYNECOL ONCOL, V100, P462, DOI 10.1016/j.ygyno.2005.09.022; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Perkins SM, 2015, BREAST CANCER RES TR, V152, P519, DOI 10.1007/s10549-015-3492-2; Shai A, 2015, CANCER RES, V75, P3167, DOI 10.1158/0008-5472.CAN-14-3701; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Wong PP, 2012, MOL CELL BIOL, V32, P1633, DOI 10.1128/MCB.06373-11; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Yamagata N, 2003, CLIN CANCER RES, V9, P4695; Yang HJ, 2013, J BIOL CHEM, V288, P2965, DOI 10.1074/jbc.M112.385989; Yang HJ, 2011, BIOCHEM PHARMACOL, V82, P524, DOI 10.1016/j.bcp.2011.05.027; Yoon DK, 2007, CANCER LETT, V254, P111, DOI 10.1016/j.canlet.2007.02.017; Zhang LQ, 2015, TUMOR BIOL, V36, P8121, DOI 10.1007/s13277-015-3550-8; Zhou JD, 2015, CANCER BIOL THER, V16, P846, DOI 10.1080/15384047.2015.1030545	56	43	43	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1585	1596		10.1038/onc.2016.328	http://dx.doi.org/10.1038/onc.2016.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27593936				2022-12-28	WOS:000397458100012
J	Molinuevo, R; Freije, A; de Pedro, I; Stoll, SW; Elder, JT; Gandarillas, A				Molinuevo, R.; Freije, A.; de Pedro, I.; Stoll, S. W.; Elder, J. T.; Gandarillas, A.			FOXM1 allows human keratinocytes to bypass the oncogene-induced differentiation checkpoint in response to gain of MYC or loss of p53	ONCOGENE			English	Article							BASAL-CELL CARCINOMAS; EPIDERMAL STEM-CELLS; HUMAN SKIN; C-MYC; TRANSCRIPTION FACTOR; REPLICATION STRESS; INDUCED APOPTOSIS; CANCER; EXPRESSION; PROGRESSION	Tumour suppressor p53 or proto-oncogene MYC is frequently altered in squamous carcinomas, but this is insufficient to drive carcinogenesis. We have shown that overactivation of MYC or loss of p53 via DNA damage triggers an anti-oncogenic differentiation-mitosis checkpoint in human epidermal keratinocytes, resulting in impaired cell division and squamous differentiation. Forkhead box M1 (FOXM1) is a transcription factor recently proposed to govern the expression of a set of mitotic genes. Deregulation of FOXM1 occurs in a wide variety of epithelial malignancies. We have ectopically expressed FOXM1 in keratinocytes of the skin after overexpression of MYC or inactivation of endogenous p53. Ectopic FOXM1 rescues the proliferative capacity of MYC- or p53-mutant cells in spite of higher genetic damage and a larger cell size typical of differentiation. As a consequence, differentiation induced by loss of p53 or MYC is converted into increased proliferation and keratinocytes displaying genomic instability are maintained within the proliferative compartment. The results demonstrate that keratinocyte oncogene-induced differentiation is caused by mitosis control and provide new insight into the mechanisms driving malignant progression in squamous cancer.	[Molinuevo, R.; Freije, A.; de Pedro, I.; Gandarillas, A.] Inst Res Marques Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain; [Stoll, S. W.; Elder, J. T.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Elder, J. T.] Dept Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI USA; [Gandarillas, A.] INSERM, Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Gandarillas, A (corresponding author), Inst Res Marques Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain.	agandarillas@idival.org			Instituto de Salud Carlos III ISCIII FIS/FEDER Grants [PI11/02070, PI14/00900]; National Institutes of Health, NIH [R03 AR049420, R01 AR052889]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052889, R03AR049420] Funding Source: NIH RePORTER	Instituto de Salud Carlos III ISCIII FIS/FEDER Grants; National Institutes of Health, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was funded by Instituto de Salud Carlos III ISCIII FIS/FEDER Grants PI11/02070 and PI14/00900 (to AG) and National Institutes of Health, NIH Awards R03 AR049420 (to SWS) and R01 AR052889 (to JTE).	Alonso-Lecue P, BYPASS MITOTIC UNPUB; Borowiec AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077507; Brash DE, 2006, BRIT J DERMATOL, V154, P8, DOI 10.1111/j.1365-2133.2006.07230.x; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duarte B, 2014, MOL THER, V22, P1878, DOI 10.1038/mt.2014.187; Freije A, 2012, ONCOGENE, V31, P5180, DOI 10.1038/onc.2012.22; Freije A, 2014, CELL REP, V9, P1349, DOI 10.1016/j.celrep.2014.10.012; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Gandarillas A, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.997127; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; le Pelletier F, 2001, J INVEST DERMATOL, V117, P1324; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Macias E, 2008, CANCER RES, V68, P162, DOI 10.1158/0008-5472.CAN-07-2461; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Orr-Weaver TL, 2015, TRENDS GENET, V31, P307, DOI 10.1016/j.tig.2015.03.011; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Ren ZP, 1997, AM J PATHOL, V150, P1791; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Rios AC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11400; Ritchie A, 2009, CELL DEATH DIFFER, V16, P838, DOI 10.1038/cdd.2009.13; Rodriguez R, 2011, STEM CELLS, V29, P179, DOI 10.1002/stem.571; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosa-Garrido M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039371; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; SHEA CR, 1992, AM J PATHOL, V141, P25; Stoll SW, 2016, ONCOGENE, V35, P2075, DOI 10.1038/onc.2015.269; Teh MT, 2002, CANCER RES, V62, P4773; Teh MT, 2013, INT J CANCER, V132, P2095, DOI 10.1002/ijc.27886; Toll A, 2008, CELL CYCLE, V7, P2674, DOI 10.4161/cc.7.17.6523; van Deursen JM, 2007, CANCER CELL, V11, P1, DOI 10.1016/j.ccr.2006.12.006; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Xue YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-200; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701	51	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					956	965		10.1038/onc.2016.262	http://dx.doi.org/10.1038/onc.2016.262			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452522	Green Published, hybrid			2022-12-28	WOS:000394169100008
J	Thurlings, I; Martinez-Lopez, LM; Westendorp, B; Zijp, M; Kuiper, R; Tooten, P; Kent, LN; Leone, G; Vos, HJ; Burgering, B; de Bruin, A				Thurlings, I.; Martinez-Lopez, L. M.; Westendorp, B.; Zijp, M.; Kuiper, R.; Tooten, P.; Kent, L. N.; Leone, G.; Vos, H. J.; Burgering, B.; de Bruin, A.			Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer	ONCOGENE			English	Article							FAMILY-MEMBER; CELL-PROLIFERATION; ATYPICAL E2FS; DNA-REPAIR; TARGET; P53; DIFFERENTIATION; TRANSCRIPTION; ORGANIZATION; EXPRESSION	E2F transcription factors are important regulators of the cell cycle, and unrestrained activation of E2F-dependent transcription is considered to be an important driver of tumor formation and progression. Although highly expressed in normal skin and skin cancer, the role of the atypical E2Fs, E2F7 and E2F8, in keratinocyte homeostasis, regeneration and tumorigenesis is unknown. Surprisingly, keratinocyte-specific deletion of E2F7 and E2F8 in mice did not interfere with skin development and wound healing. However, the rate for successful isolation and establishment of E2f7/8-deficient primary keratinocyte cultures was much higher than for wild-type keratinocytes. Moreover, E2f7/8-deficient primary keratinocytes proliferate more efficiently under stress conditions, such as low/high confluence or DNA damage. Application of in vivo stress using the DMBA/TPA skin carcinogenesis protocol revealed that combined inactivation of E2f7/8 enhanced tumorigenesis and accelerated malignant progression. Loss of atypical E2Fs resulted in increased expression of E2F target genes, including E2f1. Additional loss of E2f1 did not rescue, but worsened skin tumorigenesis. We show that loss of E2F7/8 triggers apoptosis via induction of E2F1 in response to stress, indicating that the tumor-promoting effect of E2F7/8 inactivation can be partially compensated via E2F1-dependent apoptosis. Importantly, E2F7/8 repressed a large set of E2F target genes that are highly expressed in human patients with skin cancer. Together, our studies demonstrate that atypical E2Fs act as tumor suppressors, most likely via transcriptional repression of cell cycle genes in response to stress.	[Thurlings, I.; Martinez-Lopez, L. M.; Westendorp, B.; Zijp, M.; Kuiper, R.; Tooten, P.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dept Pathol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands; [Kent, L. N.; Leone, G.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol Med Genet, Columbus, OH 43210 USA; [Vos, H. J.; Burgering, B.] Univ Med Ctr Utrecht, Mol Canc Res, Utrecht, Netherlands; [de Bruin, A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands; [Kuiper, R.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, S-17177 Stockholm, Sweden	Utrecht University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Utrecht University; Utrecht University Medical Center; University of Groningen; Karolinska Institutet; Karolinska University Hospital	de Bruin, A (corresponding author), Univ Utrecht, Fac Vet Med, Dept Pathol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.	a.debruin@uu.nl	de Bruin, Alain/AAL-9195-2020	Vos, Harmjan/0000-0002-4696-6068; Westendorp, Bart/0000-0003-1043-3638; Kuiper, Raoul/0000-0001-5645-2389; Kent, Lindsey N./0000-0003-4990-8477	Dutch Cancer Society [UU2013-5777]; Netherlands Organization of Scientific Research [NWO-ALW:843.11.002]; NATIONAL CANCER INSTITUTE [R01CA121275] Funding Source: NIH RePORTER	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization of Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was financially supported by a Dutch Cancer Society grant (KWF: UU2013-5777) to BW and AdB, and the Netherlands Organization of Scientific Research (NWO-ALW:843.11.002). We like to thank M Greenberg (Duke University Medical Center, USA) for kindly providing the E2f1 conventional knockout mice, and R Caldelari (University of Berne, Switzerland) for technical assistance and advice with the keratinocyte isolations. We are also thankful for the technical support by Elsbeth van Liere and Ronald Molenbeek (Utrecht University, The Netherlands).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Biswas AK, 2014, CANCER RES, V74, P3369, DOI 10.1158/0008-5472.CAN-13-3216; Boekhout M, 2016, EMBO REP, V17, P414, DOI 10.15252/embr.201540984; Caldelari R, 2010, METHODS MOL BIOL, V633, P125, DOI 10.1007/978-1-59745-019-5_10; Carnevale J, 2012, MOL CELL BIOL, V32, P900, DOI 10.1128/MCB.06286-11; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen HZ, 2012, NAT CELL BIOL, V14, P1192, DOI 10.1038/ncb2595; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Cohen M, 2013, CELL CYCLE, V12, P2992, DOI 10.4161/cc.26030; Costa C, 2013, ONCOGENE, V32, P2937, DOI 10.1038/onc.2012.316; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Deng Q, 2010, CANCER RES, V70, P782, DOI 10.1158/0008-5472.CAN-09-3082; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Endo-Munoz L, 2009, CANCER RES, V69, P1800, DOI 10.1158/0008-5472.CAN-08-2725; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hazar-Rethinam M, 2015, CLIN CANCER RES, V21, P417, DOI 10.1158/1078-0432.CCR-14-1962; Hazar-Rethinam M, 2011, J INVEST DERMATOL, V131, P1077, DOI 10.1038/jid.2010.430; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Johnson DG, 2006, CURR MOL MED, V6, P731; Kim C, 2014, EMBO MOL MED, V6, P970, DOI 10.15252/emmm.201303541; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Ouseph MM, 2012, DEV CELL, V22, P849, DOI 10.1016/j.devcel.2012.01.013; Pandit SK, 2012, NAT CELL BIOL, V14, P1181, DOI 10.1038/ncb2585; Park S-A, 2015, JNCI-J NATL CANCER I, V107, P1; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Salvatori B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.151; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; Zalmas LP, 2013, CELL CYCLE, V12, P3037, DOI 10.4161/cc.26078	49	31	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					829	839		10.1038/onc.2016.251	http://dx.doi.org/10.1038/onc.2016.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27452520	Green Published, hybrid			2022-12-28	WOS:000394168200010
J	Gugnoni, M; Sancisi, V; Gandolfi, G; Manzotti, G; Ragazzi, M; Giordano, D; Tamagnini, I; Tigano, M; Frasoldati, A; Piana, S; Ciarrocchi, A				Gugnoni, M.; Sancisi, V.; Gandolfi, G.; Manzotti, G.; Ragazzi, M.; Giordano, D.; Tamagnini, I.; Tigano, M.; Frasoldati, A.; Piana, S.; Ciarrocchi, A.			Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; PROTEIN GABARAP; CELL-MIGRATION; EXPRESSION; TRANSFORMATION; TRANSITIONS; INHIBITION; INDUCTION; MARKER; BNIP3	The transdifferentiation of epithelial cells toward a mesenchymal condition (EMT) is a complex process that allows tumor cells to migrate to ectopic sites. Cadherins are not just structural proteins, but they act as sensors of the surrounding microenvironment and as signaling centers for cellular pathways. However, the molecular mechanisms underlying these signaling functions remain poorly characterized. Cadherin-6 (CDH6) is a type 2 cadherin, which drives EMT during embryonic development and it is aberrantly re-activated in cancer. We recently showed that CDH6 is a TGF beta target and an EMT marker in thyroid cancer, suggesting a role for this protein in the progression of this type of tumor. Papillary thyroid carcinomas (PTCs) are usually indolent lesions. However, metastatic spreading occurs in about 5% of the cases. The identification of molecular markers that could early predict the metastatic potential of these lesions would be strategic to design more tailored approaches and reduce patients overtreatment. In this work, we assessed the role of CDH6 in the metastatic progression of thyroid cancer. We showed that loss of CDH6 expression profoundly changes cellular architecture, alters the inter-cellular interaction modalities and attenuates EMT features in thyroid cancer cells. Using a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism. Analysis of the LIR domains suggests that the interaction with the autophagic machinery may be a common feature of many cadherin family members. Finally, the analysis of CDH6 expression in a unique cohort of human PTCs showed that CDH6 expression marks specifically EMT cells. and it is strongly associated with metastatic behavior and worse outcome of PTCs.	[Gugnoni, M.; Sancisi, V.; Gandolfi, G.; Manzotti, G.; Tigano, M.; Ciarrocchi, A.] Arcispedale S Maria Nuova IRCCS, Dept Sci Direct, Lab Translat Res, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy; [Ragazzi, M.; Tamagnini, I.; Piana, S.] Arcispedale S Maria Nuova IRCCS, Deptartment Oncol & Adv Technol, Pathol Unit, Reggio Emilia, Italy; [Giordano, D.] Arcispedale S Maria Nuova IRCCS, Otolaryngol Unit, Dept Gen Surg, Reggio Emilia, Italy; [Giordano, D.; Frasoldati, A.] Arcispedale S Maria Nuova IRCCS, Specialist Unit, Reggio Emilia, Italy; [Frasoldati, A.] Arcispedale S Maria Nuova IRCCS, Dept Gen Surg, Endocrinol Unit, Reggio Emilia, Italy	IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova	Ciarrocchi, A (corresponding author), Arcispedale S Maria Nuova IRCCS, Dept Sci Direct, Lab Translat Res, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy.	Alessia.Ciarrocchi@asmn.re.it	Sancisi, Valentina/H-6701-2018; PIANA, SIMONETTA/AAC-9158-2019; Giordano, Davide/AAC-3553-2020; Manzotti, Gloria/J-7235-2016; Ciarrocchi, Alessia/AAA-1130-2019; Ragazzi, Moira/J-5737-2018; Frasoldati, Andrea/AAB-3338-2021; Gugnoni, Mila/H-6952-2018	Sancisi, Valentina/0000-0003-4357-1228; PIANA, SIMONETTA/0000-0003-4875-6977; Manzotti, Gloria/0000-0002-0639-3605; Ciarrocchi, Alessia/0000-0002-5541-2075; Ragazzi, Moira/0000-0002-8761-9265; Frasoldati, Andrea/0000-0001-9002-9293; Gugnoni, Mila/0000-0003-4630-3958; Gandolfi, Greta/0000-0001-7498-424X; Tigano, Marco/0000-0002-4353-9220	Italian Association for Cancer Research (AIRC) [MFAG10745]; Italian Ministry of Health [GR-2011-02350937]; fellowship of the Umberto Veronesi Foundation	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); fellowship of the Umberto Veronesi Foundation(Fondazione Umberto Veronesi)	Additional Materials and Methods are supplied in the Supplementary Information. This work was supported by the Italian Association for Cancer Research (AIRC, MFAG10745) and by the Italian Ministry of Health (GR-2011-02350937). GG is supported by a fellowship of the Umberto Veronesi Foundation.	Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Boutet A, 2006, EMBO J, V25, P5603, DOI 10.1038/sj.emboj.7601421; BRABANT G, 1993, CANCER RES, V53, P4987; Cai DF, 2014, CELL, V157, P1146, DOI 10.1016/j.cell.2014.03.045; Call G, 2012, ENDOCRINOLOGY, V153, P522, DOI 10.1210/en.2011-1572; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cho EA, 1998, DEVELOPMENT, V125, P803; Choi PW, 2016, ONCOTARGET, V7, P4110, DOI 10.18632/oncotarget.6588; Ciarrocchi A, 2011, EUR J CANCER, V47, P934, DOI 10.1016/j.ejca.2010.11.009; Clay MR, 2014, DEVELOPMENT, V141, P2506, DOI 10.1242/dev.105551; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Davies L, 2010, ARCH OTOLARYNGOL, V136, P440, DOI 10.1001/archoto.2010.55; Desai SP, 2013, BIOPHYS J, V104, P2077, DOI 10.1016/j.bpj.2013.03.025; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gandolfi G, 2015, INT J CANCER, V137, P1001, DOI 10.1002/ijc.28976; Gomes LC, 2013, BBA-MOL CELL RES, V1833, P205, DOI 10.1016/j.bbamcr.2012.02.012; Gray RS, 2010, CURR OPIN CELL BIOL, V22, P640, DOI 10.1016/j.ceb.2010.08.019; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Inoue YU, 2008, MOL CELL NEUROSCI, V39, P95, DOI 10.1016/j.mcn.2008.05.020; Jia LW, 2011, MOL BIOL CELL, V22, P2031, DOI 10.1091/mbc.E11-01-0038; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kashef J, 2009, GENE DEV, V23, P1393, DOI 10.1101/gad.519409; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, DOI 10.1155/2013/965212; Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Sancisi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075489; Sancisi V, 2012, J CLIN ENDOCR METAB, V97, pE2006, DOI 10.1210/jc.2012-1903; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shimazui T, 1998, CLIN CANCER RES, V4, P2419; Slobodkin MR, 2013, ESSAYS BIOCHEM, V55, P51, DOI [10.1042/bse0550051, 10.1042/BSE0550051]; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Zaidel-Bar R, 2013, J CELL SCI, V126, P373, DOI 10.1242/jcs.111559; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	54	127	133	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					667	677		10.1038/onc.2016.237	http://dx.doi.org/10.1038/onc.2016.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375021				2022-12-28	WOS:000394167700008
J	Zhang, Q; Liu, S; Parajuli, KR; Zhang, W; Zhang, K; Mo, Z; Liu, J; Chen, Z; Yang, S; Wang, A; Myers, L; You, Z				Zhang, Q.; Liu, S.; Parajuli, K. R.; Zhang, W.; Zhang, K.; Mo, Z.; Liu, J.; Chen, Z.; Yang, S.; Wang, A. R.; Myers, L.; You, Z.			Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition	ONCOGENE			English	Article							VASCULAR ENDOTHELIAL-CELLS; TUMOR-GROWTH; INTESTINAL TUMORIGENESIS; MATRIX-METALLOPROTEINASE; E-CADHERIN; IL-17; INFLAMMATION; MATRILYSIN; EXPRESSION; MICE	Chronic inflammation has been associated with a variety of human cancers including prostate cancer. Interleukin-17 (IL-17) is a critical pro-inflammatory cytokine, which has been demonstrated to promote development of prostate cancer, colon cancer, skin cancer, breast cancer, lung cancer and pancreas cancer. IL-17 promotes prostate adenocarcinoma with a concurrent increase of matrix metalloproteinase 7 (MMP7) expression in mouse prostate. Whether MMP7 mediates IL-17's action and the underlying mechanisms remain unknown. We generated Mmp7 and Pten double knockout (KO) (Mmp7 (-/-)) mouse model and demonstrated that MMP7 promotes prostate adenocarcinoma through induction of epithelial-to-mesenchymal transition (EMT) in Pten-null mice. MMP7 disrupted E-cadherin/beta-catenin complex to upregulate EMT transcription factors in mouse prostate tumors. IL-17 receptor C and Pten double KO mice rcapitulated the weak EMT characteristics observed in Mmp7 (-/-) mice. IL-17 induced MMP7 and EMT in human prostate cancer LNCaP, C4-2B and PC-3 cell lines, while small interfering RNA knockdown of MMP7 inhibited IL-17-induced EMT. Compound III, a selective MMP7 inhibitor, decreased development of invasive prostate cancer in Pten single KO mice. In human normal prostates and prostate tumors, IL-17 mRNA levels were positively correlated with MMP7 mRNA levels. These findings demonstrate that MMP7 mediates IL-17's function in promoting prostate carcinogenesis through induction of EMT, indicating IL-17-MMP7-EMT axis as a potential target for developing new strategies in the prevention and treatment of prostate cancer.	[Zhang, Q.; Liu, S.; Parajuli, K. R.; Mo, Z.; Liu, J.; Chen, Z.; Yang, S.; You, Z.] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA; [Zhang, W.; Zhang, K.] Xavier Univ Louisiana, Dept Comp Sci, New Orleans, LA USA; [Zhang, W.; Zhang, K.] Xavier Univ Louisiana, Biostat Facil, RCMI Canc Res Ctr, New Orleans, LA USA; [Mo, Z.; Liu, J.] Shijiazhuang Maternal & Child Hlth Care Hosp, Dept Obstet & Gynecol, Shijiazhuang, Peoples R China; [Chen, Z.] North China Univ Sci & Technol, Dept Thorac Surg, Affiliated Hosp, Tangshan, Peoples R China; [Yang, S.] Hebei Med Univ, Dept Urol, Hosp 3, Shijiazhuang, Peoples R China; [Wang, A. R.] Tulane Univ, Dept Pathol & Lab Med, New Orleans, LA 70118 USA; [Myers, L.] Tulane Univ, Dept Biostat & Bioinformat, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Dept Orthopaed Surg, New Orleans, LA USA; [You, Z.] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Louisiana Canc Res Consortium, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Tulane Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Tulane Ctr Aging, New Orleans, LA 70118 USA	Tulane University; Xavier University of Louisiana; Xavier University of Louisiana; North China University of Science & Technology; Hebei Medical University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	You, Z (corresponding author), Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA.	zyou@tulane.edu			National Institutes of Health [R01CA174714, P20GM103518]; Department of Defense [W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458, W81XWH-15-1-0444]; Developmental Fund of Tulane Cancer Center (TCC); Louisiana Cancer Research Consortium (LCRC) Fund; Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM); National Institute on Minority Health and Health Disparities [5G12MD007595]; NATIONAL CANCER INSTITUTE [R01CA174714] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103518] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Developmental Fund of Tulane Cancer Center (TCC); Louisiana Cancer Research Consortium (LCRC) Fund; Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	ZY was partially supported by the National Institutes of Health (R01CA174714 and P20GM103518), Department of Defense (W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458 (PI: Feng Chen; Co-I: ZY), and W81XWH-15-1-0444), the Developmental Fund of Tulane Cancer Center (TCC), Louisiana Cancer Research Consortium (LCRC) Fund and Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM). WZ and KZ were partially supported by the National Institute on Minority Health and Health Disparities (5G12MD007595, PIs: Gene D'Amour and Guangdi Wang).	Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Chae WJ, 2011, BIOCHEM BIOPH RES CO, V414, P31, DOI 10.1016/j.bbrc.2011.09.016; Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107; Chang SH, 2014, P NATL ACAD SCI USA, V111, P5664, DOI 10.1073/pnas.1319051111; Chen C, 2015, PROSTATE, V75, P883, DOI 10.1002/pros.22971; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cunningham David, 2015, J Biol Methods, V2; Davies G, 2001, CLIN CANCER RES, V7, P3289; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109868; Easwaran V, 2003, CANCER RES, V63, P3145; Edman K, 2011, CHEMMEDCHEM, V6, P769, DOI 10.1002/cmdc.201000550; Gerstenbluth RE, 2002, J UROLOGY, V167, P2267, DOI 10.1016/S0022-5347(05)65140-3; GILLES C, 1994, INT J CANCER, V59, P661, DOI 10.1002/ijc.2910590514; Gu K, 2015, AM J CANCER RES, V5, P1169; Hirahara N, 2001, ONCOLOGY-BASEL, V61, P79, DOI 10.1159/000055357; Huo N, 2002, CANCER LETT, V177, P95, DOI 10.1016/S0304-3835(01)00772-8; Hyun YS, 2012, CARCINOGENESIS, V33, P931, DOI 10.1093/carcin/bgs106; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Knox JD, 1996, MOL CARCINOGEN, V15, P57; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692; Li QL, 2013, DRUG DES DEV THER, V7, P635, DOI 10.2147/DDDT.S49197; Liu CN, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000382; Liu S, 2016, ONCOTARGET, V7, P13651, DOI 10.18632/oncotarget.7296; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; Nishizuka I, 2001, CANCER LETT, V173, P175, DOI 10.1016/S0304-3835(01)00634-6; Noe V, 2001, J CELL SCI, V114, P111; Novitskiy SV, 2011, CANCER DISCOV, V1, P430, DOI 10.1158/2159-8290.CD-11-0100; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Schatteman PHF, 2000, EUR UROL, V37, P404, DOI 10.1159/000020161; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Sutcliffe S, 2007, UROL ONCOL-SEMIN ORI, V25, P242, DOI 10.1016/j.urolonc.2006.09.014; Tartour E, 1999, CANCER RES, V59, P3698; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang LX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108060; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Wu SG, 1998, P NATL ACAD SCI USA, V95, P14979, DOI 10.1073/pnas.95.25.14979; Wu SG, 2003, GASTROENTEROLOGY, V124, P392, DOI 10.1053/gast.2003.50047; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Xu BB, 2014, AM J PHYSIOL-LUNG C, V307, pL497, DOI 10.1152/ajplung.00125.2014; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang QY, 2014, PROSTATE, V74, P869, DOI 10.1002/pros.22805; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	62	97	102	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					687	699		10.1038/onc.2016.240	http://dx.doi.org/10.1038/onc.2016.240			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375020	Green Accepted			2022-12-28	WOS:000394167700010
J	Chowdhury, AR; Long, A; Fuchs, SY; Rustgi, A; Avadhani, NG				Chowdhury, A. Roy; Long, A.; Fuchs, S. Y.; Rustgi, A.; Avadhani, N. G.			Mitochondrial stress-induced p53 attenuates HIF-1 alpha activity by physical association and enhanced ubiquitination	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR; COLON-CANCER CELLS; TUMOR-SUPPRESSOR P53; FACTOR 1-ALPHA; FACTOR-I; PROLYL HYDROXYLATION; GENE-TRANSCRIPTION; MESSENGER-RNA; ACTIVATION; APOPTOSIS	Retrograde signaling is a mechanism by which mitochondrial dysfunction is communicated to the nucleus for inducing a metabolic shift essential for cell survival. Previously, we showed that partial mitochondrial DNA (mtDNA) depletion in different cell types induced mitochondrial retrograde signaling pathway (MtRS) involving Ca+2-sensitive Calcineurin (Cn) activation as an immediate upstream event of stress response. In multiple cell types, this stress signaling was shown to induce tumorigenic phenotypes in immortalized cells. In this study we show that MtRS also induces p53 expression, which was abrogated by Ca2+ chelators and short hairpin RNA-mediated knockdown of CnA beta mRNA. Mitochondrial dysfunction induced by mitochondrial ionophore, carbonyl cyanide m-chlorophenyl hydrazone and other respiratory inhibitors, which perturb the transmembrane potential, were equally efficient in inducing the expression of p53 and downregulation of MDM2. Stress-induced p53 physically interacted with hypoxiainducible factor-1 alpha (HIF-1 alpha) and attenuated the latter's binding to promoter DNA motifs. In addition, p53 promoted ubiquitination and degradation of HIF-1 alpha in partial mtDNA-depleted cells. The mtDNA depleted cells, with inhibited HIF-1 alpha, showed upregulation of glycolytic pathway genes, glucose transporter 1-4 (Glut1-4), phosphoglycerate kinase 1 and Glucokinase but not of prolyl hydroxylase isoforms. For the first time we show that p53 is induced as part of MtRS and it renders HIF-1 alpha inactive by physical interaction. In this respect, our results show that MtRS induces tumor growth independent of the HIF-1 alpha pathway.	[Chowdhury, A. Roy; Fuchs, S. Y.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Biomed Sci, 189E Old Vet Bldg, Philadelphia, PA 19104 USA; [Chowdhury, A. Roy; Fuchs, S. Y.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, 189E Old Vet Bldg, Philadelphia, PA 19104 USA; [Long, A.; Rustgi, A.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Div Gastroenterol,Dept Med & Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Biomed Sci, 189E Old Vet Bldg, Philadelphia, PA 19104 USA.; Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, 189E Old Vet Bldg, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NIH grant [CA-22762, AR-067066]; Harriet Ellison Woodward trust (NGA); NIH MSTP training grant AL; NATIONAL CANCER INSTITUTE [R01CA092900, R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA022986] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harriet Ellison Woodward trust (NGA); NIH MSTP training grant AL; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Drs Craig Thompson, Gregg Semenza and Bert Vogelstein for generously providing the promoter constructs and cell lines used in this study. This work was supported by NIH grant CA-22762, AR-067066 and an endowment from the Harriet Ellison Woodward trust (NGA) and NIH MSTP training grant AL. We also acknowledge the help of the Imaging Core facility at the School of Veterinary Medicine and the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30DK050306) and its Cell collection core.	Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Barliya T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022849; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Berglind H, 2008, CANCER BIOL THER, V7, P699, DOI 10.4161/cbt.7.5.5712; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Brar SS, 2012, AM J PHYSIOL-LUNG C, V303, pL413, DOI 10.1152/ajplung.00343.2011; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Camenisch Gieri, 2002, Methods Mol Biol, V196, P117; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Chae S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003266; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Dhanasekaran A, 2005, FREE RADICAL BIO MED, V39, P567, DOI 10.1016/j.freeradbiomed.2005.04.016; Formentini L, 2012, MOL CELL, V45, P731, DOI 10.1016/j.molcel.2012.01.008; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2013, MITOCHONDRION, V13, P577, DOI 10.1016/j.mito.2013.08.007; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Haynes CM, 2010, MOL CELL, V37, P529, DOI 10.1016/j.molcel.2010.01.015; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iommarini L, 2014, HUM MOL GENET, V23, P1453, DOI 10.1093/hmg/ddt533; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kojima K, 2011, BLOOD, V118, P4431, DOI 10.1182/blood-2011-02-334136; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Menendez D, 2007, MOL CELL BIOL, V27, P2590, DOI 10.1128/MCB.01742-06; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Obacz J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-93; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Ravi R, 2000, GENE DEV, V14, P34; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Tang WG, 2012, CARCINOGENESIS, V33, P1762, DOI 10.1093/carcin/bgs190; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang G L, 1996, Curr Opin Hematol, V3, P156; Wanka C, 2012, ONCOGENE, V31, P3764, DOI 10.1038/onc.2011.530; Xu HB, 2006, BIOCHEM BIOPH RES CO, V341, P938, DOI 10.1016/j.bbrc.2005.12.227	64	17	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					397	409		10.1038/onc.2016.211	http://dx.doi.org/10.1038/onc.2016.211			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345397	Green Accepted			2022-12-28	WOS:000394166000009
J	Qu, X; Sandmann, T; Frierson, H; Fu, L; Fuentes, E; Walter, K; Okrah, K; Rumpel, C; Moskaluk, C; Lu, S; Wang, Y; Bourgon, R; Penuel, E; Pirzkall, A; Amler, L; Lackner, MR; Tabernero, J; Hampton, GM; Kabbarah, O				Qu, X.; Sandmann, T.; Frierson, H., Jr.; Fu, L.; Fuentes, E.; Walter, K.; Okrah, K.; Rumpel, C.; Moskaluk, C.; Lu, S.; Wang, Y.; Bourgon, R.; Penuel, E.; Pirzkall, A.; Amler, L.; Lackner, M. R.; Tabernero, J.; Hampton, G. M.; Kabbarah, O.			Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter	ONCOGENE			English	Article							DNA METHYLATION; MUTATION STATUS; CETUXIMAB; EPIREGULIN; EXPRESSION; GROWTH; AMPHIREGULIN; KRAS; FLUOROURACIL; BEVACIZUMAB	Key molecular drivers that underlie transformation of colonic epithelium into colorectal adenocarcinoma (CRC) are well described. However, the mechanisms through which clinically targeted pathways are activated during CRC progression have yet to be elucidated. Here, we used an integrative genomics approach to examine CRC progression. We used laser capture microdissection to isolate colonic crypt cells, differentiated surface epithelium, adenomas, carcinomas and metastases, and used gene expression profiling to identify pathways that were differentially expressed between the different cell types. We identified a number of potentially important transcriptional changes in developmental and oncogenic pathways, and noted a marked upregulation of EREG in primary and metastatic cancer cells. We confirmed this pattern of gene expression by in situ hybridization and observed staining consistent with autocrine expression in the tumor cells. Upregulation of EREG during the adenoma-carcinoma transition was associated with demethylation of two key sites within its promoter, and this was accompanied by an increase in the levels of epidermal growth factor receptor (EGFR) phosphorylation, as assessed by reverse-phase protein analysis. In CRC cell lines, we demonstrated that EREG demethylation led to its transcriptional upregulation, higher levels of EGFR phosphorylation, and sensitization to EGFR inhibitors. Low levels of EREG methylation in patients who received cetuximab as part of a phase II study were associated with high expression of the ligand and a favorable response to therapy. Conversely, high levels of promoter methylation and low levels of EREG expression were observed in tumors that progressed after treatment. We also noted an inverse correlation between EREG methylation and expression levels in several other cancers, including those of the head and neck, lung and bladder. Therefore, we propose that upregulation of EREG expression through promoter demethylation might be an important means of activating the EGFR pathway during the genesis of CRC and potentially other cancers.	[Qu, X.; Fu, L.; Walter, K.; Lu, S.; Wang, Y.; Penuel, E.; Amler, L.; Lackner, M. R.; Hampton, G. M.; Kabbarah, O.] Genentech Inc, Oncol Biomarker Dev, 1 DNA Way, San Francisco, CA 94080 USA; [Sandmann, T.; Bourgon, R.] Genentech Inc, Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Frierson, H., Jr.; Rumpel, C.; Moskaluk, C.] Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA USA; [Fuentes, E.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Okrah, K.] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA; [Pirzkall, A.] Genentech Inc, Dept Clin Sci, San Francisco, CA 94080 USA; [Tabernero, J.] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain	Roche Holding; Genentech; Roche Holding; Genentech; University of Virginia; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Hampton, GM; Kabbarah, O (corresponding author), Genentech Inc, Oncol Biomarker Dev, 1 DNA Way, San Francisco, CA 94080 USA.	garreth@gene.com; kabbarao@gene.com	Tabernero, Josep/AAG-5026-2019; Miquel, Josep Maria/AAG-3508-2019	Tabernero, Josep/0000-0002-2495-8139; Sandmann, Thomas/0000-0002-6601-8890; Bourgon, Richard/0000-0002-5890-4374; Wang, Yulei/0000-0002-9057-9786				Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Auf G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-597; Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; Bourgon R, 2014, CLIN CANCER RES, V20, P2080, DOI 10.1158/1078-0432.CCR-13-3114; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; DeAngelo DJ, 2014, LEUKEMIA RES, V38, P430, DOI 10.1016/j.leukres.2013.10.026; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Hansen AR, 2013, J CLIN ONCOL, V31, P1381, DOI 10.1200/JCO.2012.47.9220; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Jonker DJ, 2014, BRIT J CANCER, V110, P648, DOI 10.1038/bjc.2013.753; Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kohsaka S, 2014, NEURO-ONCOLOGY, V16, P960, DOI 10.1093/neuonc/not315; Komurasaki T, 2002, GROWTH FACTORS, V20, P61, DOI 10.1080/08977190290024192; Lainey E, 2013, ONCOGENE, V32, P4331, DOI 10.1038/onc.2012.469; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039; Makky K, 2007, DEV BIOL, V303, P501, DOI 10.1016/j.ydbio.2006.11.030; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Orre LM, 2013, ONCOGENE, V32, P5531, DOI 10.1038/onc.2013.213; Oshima G, 2012, J CANCER RES CLIN, V138, P491, DOI 10.1007/s00432-011-1127-5; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Pasparakis M, 2012, IMMUNOL REV, V246, P346, DOI 10.1111/j.1600-065X.2012.01109.x; Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492; Pentheroudakis G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-49; Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Seniski GG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-80; Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011; Skeen VR, 2012, CURR PHARM DESIGN, V18, P3874; Sun JZ, 2012, HEMATOL ONCOL, V30, P89, DOI 10.1002/hon.1002; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van Es JH, 2005, TRENDS MOL MED, V11, P496, DOI 10.1016/j.molmed.2005.09.008; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walter K, 2012, CLIN CANCER RES, V18, P2360, DOI 10.1158/1078-0432.CCR-11-2635-T; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Watt FM, 2004, TRENDS MOL MED, V10, P577, DOI 10.1016/j.molmed.2004.10.008; Weng WH, 2016, ONCOL REP, V35, P107, DOI 10.3892/or.2015.4336; Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278	56	44	44	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6403	6415		10.1038/onc.2016.170	http://dx.doi.org/10.1038/onc.2016.170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27270421	Green Published, hybrid			2022-12-28	WOS:000390247600005
J	Rajendran, D; Zhang, Y; Berry, DM; McGlade, CJ				Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.			Regulation of Numb isoform expression by activated ERK signaling	ONCOGENE			English	Article							TRACT-BINDING-PROTEIN; PROMOTES NEURONAL DIFFERENTIATION; CELL LUNG-CANCER; MAMMALIAN NUMB; BREAST-CANCER; MULTIPLE ROLES; MOUSE NUMB; NOTCH; KINASE; GROWTH	The endocytic adaptor protein Numb has a major role in development as an intrinsic regulator of cell fate determination and inhibitor of the Notch signaling pathway. In vertebrates, four protein isoforms of Numb are produced through alternative splicing (AS) of two cassette exons (exons 3 and 9). AS of coding exon 9 (E9) produces E9-included (p72/p71) and -excluded (p66/p65) protein products. Expression of Numb isoforms is developmentally regulated and E9-included products are expressed in progenitors, whereas E9-excluded isoforms are dominantly expressed in differentiated cells. Analyses of AS events in multiple cancers previously identified a switch in Numb transcript and protein expression from the E9-excluded to the E9-included isoform, suggesting that misregulation of the mechanisms that control E9 inclusion may have a role in tumorigenesis. Here we identify splicing factors ASF/SF2 and PTBP1 as regulators of E9 splicing and show that activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway promotes E9 inclusion in cancer cells. Our evidence supports a mechanism by which Numb AS is regulated in response to oncogenic signaling pathways, and contributes to activation of downstream pathways to promote tumorigenesis.	[Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Program Cell Biol, Room 17-9706, Toronto, ON M5G 0A4, Canada; [Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Arthur & Sonia Labatt Brain Tumour Res Ctr, Room 17-9706, Toronto, ON M5G 0A4, Canada; [Rajendran, D.; Zhang, Y.; McGlade, C. J.] Univ Toronto, Dept Med Biophys, Room 17-9706, Toronto, ON M5G 0A4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Program Cell Biol, Room 17-9706, Toronto, ON M5G 0A4, Canada.; McGlade, CJ (corresponding author), Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Arthur & Sonia Labatt Brain Tumour Res Ctr, Room 17-9706, Toronto, ON M5G 0A4, Canada.; McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, Room 17-9706, Toronto, ON M5G 0A4, Canada.	jmcglade@sickkids.ca		Zhang, Yangjing/0000-0003-3762-0767	Canadian Institutes of Health Research [MOP-106507]; RESTRACOMP studentship from Garron Family Cancer Centre and Sickkids Research Institute	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); RESTRACOMP studentship from Garron Family Cancer Centre and Sickkids Research Institute	We thank J Woodgett (University of Toronto) for activated MEK and MEKK, V Stambolic (University of Toronto) for Akt constructs, G Zadeh (University of Toronto) for activated RAS, M Moran (University of Toronto) for A549 cells, A Huang (University of Toronto) for YBX1 plasmid, B Blencowe (University of Toronto) for ExonTrap pet01 plasmid, SPARC BioCentre (Hospital for Sick Children, Toronto) for cDNAs and S Dho for comments on the manuscript. This work was supported by an operating grant to CJM from the Canadian Institutes of Health Research (MOP-106507). YZ is supported by a RESTRACOMP studentship from the Garron Family Cancer Centre and Sickkids Research Institute.	Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Bani-Yaghoub M, 2007, DEV DYNAM, V236, P696, DOI 10.1002/dvdy.21072; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Blissenbach M, 2010, J VIROL, V84, P6598, DOI 10.1128/JVI.02264-09; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brognard J, 2001, CANCER RES, V61, P3986; Cheung HC, 2006, MODERN PATHOL, V19, P1034, DOI 10.1038/modpathol.3800635; Cheung HC, 2009, BRAIN, V132, P2277, DOI 10.1093/brain/awp153; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001; Dho SE, 2006, MOL BIOL CELL, V17, P4142, DOI 10.1091/mbc.E06-02-0097; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176; French MB, 2002, J IMMUNOL, V168, P3173, DOI 10.4049/jimmunol.168.7.3173; Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062729; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Izaguirre DI, 2012, MOL CARCINOGEN, V51, P895, DOI 10.1002/mc.20859; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Karaczyn A, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-31; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim KK, 2013, J CELL BIOL, V200, P443, DOI 10.1083/jcb.201206146; Langer W, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-676; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; McCutcheon IE, 2004, NEURO-ONCOLOGY, V6, P9, DOI 10.1215/S1152851703000279; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Nieber F, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471-213X-13-36; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Ohori M, 2005, BIOCHEM BIOPH RES CO, V336, P357, DOI 10.1016/j.bbrc.2005.08.082; Paz I, 2010, NUCLEIC ACIDS RES, V38, pW281, DOI 10.1093/nar/gkq444; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Rasin MR, 2007, NAT NEUROSCI, V10, P819, DOI 10.1038/nn1924; Reugels AM, 2006, DEV DYNAM, V235, P934, DOI 10.1002/dvdy.20699; Revil T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-399; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Sato K, 2011, MOL BIOL CELL, V22, P3103, DOI 10.1091/mbc.E11-03-0274; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Teplova M, 2008, NAT STRUCT MOL BIOL, V15, P1343, DOI 10.1038/nsmb.1519; Toriya M, 2006, DEV NEUROSCI-BASEL, V28, P142, DOI 10.1159/000090760; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yoshida T, 2003, DIFFERENTIATION, V71, P486, DOI 10.1046/j.1432-0436.2003.7108006.x; Zhang CL, 2010, SCIENCE, V329, P439, DOI 10.1126/science.1191150; Zhang SF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091466; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960-9822(01)00149-X; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	60	15	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5202	5213		10.1038/onc.2016.69	http://dx.doi.org/10.1038/onc.2016.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27041567				2022-12-28	WOS:000384433000011
J	Dumartin, L; Alrawashdeh, W; Trabulo, SM; Radon, TP; Steiger, K; Feakins, RM; di Magliano, MP; Heeschen, C; Esposito, I; Lemoine, NR; Crnogorac-Jurcevic, T				Dumartin, L.; Alrawashdeh, W.; Trabulo, S. M.; Radon, T. P.; Steiger, K.; Feakins, R. M.; di Magliano, M. P.; Heeschen, C.; Esposito, I.; Lemoine, N. R.; Crnogorac-Jurcevic, T.			ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; ANTERIOR GRADIENT 2; ONCOGENIC KRAS; CELLS; PROMOTES; INFLAMMATION; EXPRESSION; INDUCTION; OBESITY	The mechanisms of initiation of pancreatic ductal adenocarcinoma (PDAC) are still largely unknown. In the present study, we analysed the role of anterior gradient-2 (AGR2) in the earliest stages of pancreatic neoplasia. Immunohistochemical analysis of chronic pancreatitis (CP) and peritumoral areas in PDAC tissues showed that AGR2 was present in tubular complexes (TC) and early pancreatic intraepithelial neoplasia (PanINs). Moreover, AGR2 was also found in discrete subpopulations of non-transformed cells neighbouring these pre-neoplastic lesions. In primary cells derived from human patient-derived xenograft (PDX) model, flowcytometry revealed that AGR2 was overexpressed in pancreatic cancer stem cells (CSC) compared with non-stem cancer cells. In LSL-Kras(G12D); Pdx1-Cre (KC) mouse model Agr2 induction preceded the formation of pre-neoplastic lesions and their development was largely inhibited by Agr2 deletion in engineered LSL-Kras(G12D); Pdx1-Cre; Agr2(-/-)mice. In vitro, AGR2 expression was stimulated by tunicamycin-induced endoplasmic reticulum (ER) stress in both KRAS wild-type normal pancreas cells, as well as in KRAS mutated pancreatic cancer cells and was essential for ER homoeostasis. The unfolded protein response proteins GRP78, ATF6 and XBP1s were found expressed in CP and PDAC peritumoral tissues, but in contrast to AGR2, their expression was switched off during TC and PanIN formation. Real-time PCR and ELISA analyses showed that ER stress induced a pro-inflammatory phenotype in pancreatic normal, cancer and stellate cells. Moreover, AGR2 expression was inducible by paracrine transfer of ER stress and pro-inflammation between different pancreatic cell types. Our findings demonstrate that AGR2 induced in ER-stressed and inflammatory preneoplastic pancreas is a potential marker of cancer progenitor cells with an important functional role in PDAC initiation.	[Dumartin, L.; Alrawashdeh, W.; Radon, T. P.; Lemoine, N. R.; Crnogorac-Jurcevic, T.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Trabulo, S. M.; Heeschen, C.] Queen Mary Univ London, Barts Canc Inst, Ctr Stem Cells Canc & Ageing, London, England; [Steiger, K.] Tech Univ Munich, Inst Pathol, Munich, Germany; [Feakins, R. M.] Royal London Hosp, Dept Histopathol, London, England; [di Magliano, M. P.] Univ Michigan, Dept Surg Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Esposito, I.] Heinrich Heine Univ Dusseldorf, Inst Pathol, Dusseldorf, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; Technical University of Munich; Barts Health NHS Trust; Royal London Hospital; University of Michigan System; University of Michigan; Heinrich Heine University Dusseldorf	Crnogorac-Jurcevic, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England.; Crnogorac-Jurcevic, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	t.c.jurcevic@qmul.ac.uk	Feakins, Roger/J-6782-2019; Guba, Markus/M-4309-2019; Feakins, Roger/AAO-5570-2020	Lemoine, Nick/0000-0001-8675-058X; Pasca di Magliano, Marina/0000-0001-9632-9035	CR-UK [A12008]; Cancer Research UK [12008] Funding Source: researchfish	CR-UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We would like to thank Profs David Tuveson and David Erle for providing us with KC and germline Agr2<SUP>-/-</SUP> transgenic mice, respectively and Prof Hemant Kocher for PS1 pancreatic stellate cells. We would also like to thank Julie Andow, Hagen Schmid and George Elia for their expert technical assistance. Grant Support: The work was supported by a grant A12008 from CR-UK (L. Dumartin, N.R. Lemoine and T. Crnogorac-Jurcevic).	Aichler M, 2012, J PATHOL, V226, P723, DOI 10.1002/path.3017; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Celli J, 2015, NAT REV MICROBIOL, V13, P71, DOI 10.1038/nrmicro3393; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Collins MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049707; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta A, 2013, J BIOL CHEM, V288, P4321, DOI 10.1074/jbc.M112.433086; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Hess DA, 2011, GASTROENTEROLOGY, V141, P1463, DOI 10.1053/j.gastro.2011.06.045; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kawasaki N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00799; Kong B, 2018, GUT, V67, P146, DOI 10.1136/gutjnl-2015-310913; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Lugea A, 2011, GASTROENTEROLOGY, V140, P987, DOI 10.1053/j.gastro.2010.11.038; Ma SR, 2015, ONCOTARGET, V6, P8807, DOI 10.18632/oncotarget.3556; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Morris JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095486; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pandol SJ, 2010, DIGEST DIS, V28, P776, DOI 10.1159/000327212; Pandol SJ, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00008; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114; Ryu J, 2013, BIOCHEM BIOPH RES CO, V430, P610, DOI 10.1016/j.bbrc.2012.11.105; Sah RP, 2014, J BIOL CHEM, V289, P27551, DOI 10.1074/jbc.M113.528174; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545	46	51	55	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3094	3103		10.1038/onc.2016.459	http://dx.doi.org/10.1038/onc.2016.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941872	Green Published, hybrid			2022-12-28	WOS:000402617900003
J	Sarkar, M; Khare, V; Ghosh, MK				Sarkar, M.; Khare, V.; Ghosh, M. K.			The DEAD box protein p68: a novel coactivator of Stat3 in mediating oncogenesis	ONCOGENE			English	Article							COLORECTAL-CANCER; BETA-CATENIN; RNA HELICASE; EXPRESSION; ACTIVATION; APOPTOSIS; TARGET; CELLS; TRANSFORMATION; PATHWAY	DEAD box RNA helicase p68 acts as a transcriptional coactivator of several oncogenic transcription factors apart from being a vital player of RNA metabolism. Signal transducer and activator of transcription 3 (Stat3) is a major oncogenic contributor of diverse cancers, including that of colon. Deciphering the mechanistic insights of coactivation of Stat3 transcriptional activity may aid in improved therapeutic strategies. Here we report for the first time a novel mechanism of alliance between p68 and Stat3 in stimulating transcriptional activity of Stat3. Interestingly, we observed that the expression of p68 and Stat3 bears strong positive correlation and significant colocalization in normal and colon carcinoma patient samples. We demonstrated that p68 directly interacts with Stat3 in HEK293 cells as well as multiple colon cancer cell lines. Additionally, p68 positively modulated both mRNA and protein expression levels of Stat3 target genes; promoter activity of Stat3 target gene Mcl-1 in multiple colon cancer cell lines. Also, p68 occupied the promoters of multiple Stat3 target genes in enhancing Stat3-dependent transcription. Moreover, the strong positive correlation between the abundance of p68 and Stat3 target genes in the same set of colon carcinoma samples further supported our observations. Enhanced expression levels of Stat3 target genes observed in primary tumors and metastatic lung nodules, generated in mice colorectal allograft model using syngeneic cells stably expressing p68, further reinforced our in vitro findings. Hence, this study unravels novel modes of p68-mediated oncogenesis through coactivation of Stat3 and enhancing Stat3 signaling.	[Sarkar, M.; Khare, V.; Ghosh, M. K.] IICB, CSIR, Canc Biol & Inflammatory Disorder Div, Signal Transduct Canc & Stem Cells Lab, Kolkata, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), IICB, CSIR, Canc Biol & Inflammatory Disorder, Signal Transduct Canc & Stem Cells Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com		Sarkar, Dr Moumita/0000-0002-7437-5353	CSIR, India [EMPOWER-OLP-002, MEDCHEM-BSC0108]; DST Nano Mission programme [SR/NM/NS-1058/2015]; CSIR-MAYO Clinic programme [MLP-0017]	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India); DST Nano Mission programme; CSIR-MAYO Clinic programme	We thank Dr Frances V Fuller-Pace and Dr Kenneth M Yamada for gifting the pGS5-p68 construct and pGZ21dx vector, respectively. We also thank Dr Uttara Chatterjee (Park Clinic, India) for providing human normal colon and colon carcinoma samples, related pathological reports and helping in the data analysis. This work is supported by grants from CSIR, India (EMPOWER-OLP-002, MEDCHEM-BSC0108 and CSIR-MAYO Clinic programme: MLP-0017) and DST Nano Mission programme (SR/NM/NS-1058/2015) to Dr Mrinal K Ghosh.	Ahmed SF, 2015, MOL THER, V23, P255, DOI 10.1038/mt.2014.202; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Bendardaf R, 2008, ANTICANCER RES, V28, P3865; Bhattacharya S, 2015, CELL ONCOL, V38, P265, DOI 10.1007/s13402-015-0228-6; Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.63; Dai TY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0064-y; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Ghosh MK, 2005, ONCOGENE, V24, P7290, DOI 10.1038/sj.onc.1208894; Gordziel C, 2013, BRIT J CANCER, V109, P138, DOI 10.1038/bjc.2013.274; Guturi KKN, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0496-5; Henderson-Jackson EB, 2010, INT J CLIN EXP PATHO, V3, P768; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Langers AMJ, 2012, BRIT J CANCER, V106, P1495, DOI 10.1038/bjc.2012.80; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; Lee WS, 2015, AM J CANCER RES, V5, P101; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Sagawa M, 2008, CANCER SCI, V99, P1820, DOI 10.1111/j.1349-7006.2008.00872.x; Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Sarkar M, 2016, FRONT BIOSCI-LANDMRK, V21, P225, DOI 10.2741/4386; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Siddiquee KAZ, 2008, CELL RES, V18, P254, DOI 10.1038/cr.2008.18; Song YH, 2008, MOL IMMUNOL, V45, P137, DOI 10.1016/j.molimm.2007.04.031; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thakur R, 2013, J CELL MOL MED, V17, P449, DOI 10.1111/jcmm.12033; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 ; Zhang YL, 2008, WORLD J GASTROENTERO, V14, P3069, DOI 10.3748/wjg.14.3069	43	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3080	3093		10.1038/onc.2016.449	http://dx.doi.org/10.1038/onc.2016.449			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941883				2022-12-28	WOS:000402617900002
J	Xiao, T; Zhu, JJ; Huang, S; Peng, C; He, S; Du, J; Hong, R; Chen, X; Bode, AM; Jiang, W; Dong, Z; Zheng, D				Xiao, T.; Zhu, J. J.; Huang, S.; Peng, C.; He, S.; Du, J.; Hong, R.; Chen, X.; Bode, A. M.; Jiang, W.; Dong, Z.; Zheng, D.			Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NFAT1; CYCLIN-DEPENDENT KINASES; NUCLEAR FACTOR; CYCLOOXYGENASE-2 INDUCTION; BEAS-2B CELLS; CL41 CELLS; DIFFERENTIATION; ACTIVATION; EXPRESSION; PATHWAY	The nuclear factor of activated T cells (NFAT) family proteins are transcription factors that regulate the expression of pro-inflammatory cytokines and other genes during the immune response. Although the NFAT proteins have been extensively investigated in the immune system, their role in cancer progression remains controversial. Here, we report that NFAT3 is highly expressed in various skin cancer cell lines and tumor tissues. Knockdown of endogenous NFAT3 expression by short hairpin RNA (shRNA) significantly inhibited tumor cell proliferation, colony formation and anchorage-independent cell growth. Furthermore, results of the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted with NFAT3 and phosphorylated NFAT3 at serine 259 (Ser259), which enhanced the transactivation and transcriptional activity of NFAT3. The phosphorylation site of NFAT3 was critical for epidermal growth factor (EGF)-stimulated cell transformation of the HaCaT immortalized skin cell line and mutation of NFAT3 at Ser259 led to a reduction of colony formation in soft agar. We also found that overexpressing wildtype NFAT3, but not mutant NFAT3-S259A, promoted A431 xenograft tumor growth. Importantly, we showed that CDK3, NFAT3 and phosphorylated NFAT3-Ser259 were highly expressed in skin cancer compared with normal skin tissues. These results provided evidence supporting the oncogenic potential of NFAT3 and suggested that CDK3-mediated phosphorylation of NFAT3 has an important role in skin tumorigenesis.	[Xiao, T.; Zhu, J. J.; Huang, S.; He, S.; Du, J.; Hong, R.; Chen, X.; Jiang, W.; Zheng, D.] Shenzhen Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Shenzhen Key Lab Translat Med Tumor, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China; [Peng, C.] Cent S Univ, Dept Dermatol, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave Northeast, Austin, MN 55912 USA	Shenzhen University; Central South University; University of Minnesota System	Zheng, D (corresponding author), Shenzhen Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Shenzhen Key Lab Translat Med Tumor, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China.; Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave Northeast, Austin, MN 55912 USA.	zgdong@hi.umn.edu; dzheng@szu.edu.cn		Zhu, Joe/0000-0003-4416-7040	National Natural Science Foundation of China [81071655, 81372149, 81401894, 81402289]; National Science Foundation Projects of Guangdong Province [2014A030313547]; High level Talents Project of Guangdong Province; Shenzhen Municipal Government of China [KQCX20140519104925300, JCYJ20140418193546118, JCYJ20140418091413510, ZDSY20130329101130496]; Natural Science Foundation of SZU [201406]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation Projects of Guangdong Province; High level Talents Project of Guangdong Province; Shenzhen Municipal Government of China; Natural Science Foundation of SZU	This study was supported by grants from the National Natural Science Foundation of China (81071655, 81372149, 81401894, 81402289), the National Science Foundation Projects of Guangdong Province (2014A030313547), the High level Talents Project of Guangdong Province (2013), the Shenzhen Municipal Government of China (KQCX20140519104925300, JCYJ20140418193546118, JCYJ20140418091413510, ZDSY20130329101130496) and Natural Science Foundation of SZU (201406). We thank Dr Barrett J. Rollins for the pRcCMV-cdk3 (pCMV-cdk3); Dr Yong-Yeon Cho for the pACT-TFs and Dr Ke Yao for pGal4-NFAT3 and p3xFlag-NFAT3.	Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Braun K, 1998, ONCOGENE, V17, P2259, DOI 10.1038/sj.onc.1202145; Cho YY, 2007, J BIOL CHEM, V282, P8380, DOI 10.1074/jbc.M611322200; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; Ding J, 2006, J BIOL CHEM, V281, P24405, DOI 10.1074/jbc.M600751200; Fougere M, 2010, ONCOGENE, V29, P2292, DOI 10.1038/onc.2009.499; Friday BB, 2001, J CELL SCI, V114, P303; GLASBEY CA, 1993, CVGIP-GRAPH MODEL IM, V55, P532, DOI 10.1006/cgip.1993.1040; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Keezer SM, 2002, J CELL BIOCHEM, V85, P545, DOI 10.1002/jcb.10162; Li JX, 2006, J CELL BIOCHEM, V99, P1010, DOI 10.1002/jcb.20834; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Mizuno H, 2006, MOL CARCINOGEN, V45, P1, DOI 10.1002/mc.20160; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Ouyang W, 2007, CARCINOGENESIS, V28, P2218, DOI 10.1093/carcin/bgm115; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Salazar C, 2005, FEBS LETT, V579, P621, DOI 10.1016/j.febslet.2004.12.029; Tang H, 2007, ARCH BIOCHEM BIOPHYS, V468, P92, DOI 10.1016/j.abb.2007.09.016; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yamochi T, 2001, EUR J BIOCHEM, V268, P6076, DOI 10.1046/j.0014-2956.2001.02555.x; Yan Y, 2006, J CELL SCI, V119, P2985, DOI 10.1242/jcs.03014; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yao K, 2007, CANCER RES, V67, P8725, DOI 10.1158/0008-5472.CAN-06-4788; Zhang H, 2005, J BIOL CHEM, V280, P43188, DOI 10.1074/jbc.M506598200; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137	31	19	19	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2835	2845		10.1038/onc.2016.434	http://dx.doi.org/10.1038/onc.2016.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893713	Green Published, hybrid			2022-12-28	WOS:000401697800006
J	Leung, E; Xue, A; Wang, Y; Rougerie, P; Sharma, VP; Eddy, R; Cox, D; Condeelis, J				Leung, E.; Xue, A.; Wang, Y.; Rougerie, P.; Sharma, V. P.; Eddy, R.; Cox, D.; Condeelis, J.			Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; CANCER METASTASIS; TYROSINE KINASE; MAMMARY-TUMORS; IN-VIVO; PROGNOSTIC MARKER; CARCINOMA CELLS; TRANSENDOTHELIAL MIGRATION; HEMATOGENOUS DISSEMINATION	During metastasis to distant sites, tumor cells migrate to blood vessels. In vivo, breast tumor cells utilize a specialized mode of migration known as streaming, where a linear assembly of tumor cells migrate directionally towards blood vessels on fibronectin-collagen I-containing extracellular matrix (ECM) fibers in response to chemotactic signals. We have successfully reconstructed tumor cell streaming in vitro by co-plating tumors cells, macrophages and endothelial cells on 2.5 mu m thick ECM-coated micro-patterned substrates. We found that tumor cells and macrophages, when plated together on the micro-patterned substrates, do not demonstrate sustained directional migration in only one direction (sustained directionality) but show random bi-directional walking. Sustained directionality of tumor cells as seen in vivo was established in vitro when beads coated with human umbilical vein endothelial cells were placed at one end of the micro-patterned 'ECM fibers' within the assay. We demonstrated that these endothelial cells supply the hepatocyte growth factor (HGF) required for the chemotactic gradient responsible for sustained directionality. Using this in vitro reconstituted streaming system, we found that directional streaming is dependent on, and most effectively blocked, by inhibiting the HGF/C-Met signaling pathway between endothelial cells and tumor cells. Key observations made with the in vitro reconstituted system implicating C-Met signaling were confirmed in vivo in mammary tumors using the in vivo invasion assay and intravital multiphoton imaging of tumor cell streaming. These results establish HGF/ C-Met as a central organizing signal in blood vessel-directed tumor cell migration in vivo and highlight a promising role for C-Met inhibitors in blocking tumor cell streaming and metastasis in vivo, and for use in human trials.	[Leung, E.; Xue, A.; Wang, Y.; Rougerie, P.; Sharma, V. P.; Eddy, R.; Cox, D.; Condeelis, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave,Price 208, Bronx, NY 10461 USA; [Wang, Y.; Condeelis, J.] Albert Einstein Coll Med, Integrated Imaging Program, Bronx, NY 10467 USA; [Sharma, V. P.; Cox, D.; Condeelis, J.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Condeelis, J (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave,Price 208, Bronx, NY 10461 USA.	john.condeelis@einstein.yu.edu	; rougerie, pablo/I-9006-2017	Cox, Dianne/0000-0002-0591-9767; rougerie, pablo/0000-0001-5290-3939	NCI [CA100324, CA150344]; Integrated Imaging Program; Gruss Lipper Biophotonics Center; NATIONAL CANCER INSTITUTE [P01CA100324, P30CA013330, R01CA150344] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Integrated Imaging Program; Gruss Lipper Biophotonics Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank P Guo (Analytical Imaging Facility, Albert Einstein College of Medicine) for technical assistance. They also thank B Smith and D Flynn (Deciphera) for providing Rebastinib, DCC-3014 and Altiratinib. This work was supported by the NCI CA100324, CA150344, the Integrated Imaging Program and the Gruss Lipper Biophotonics Center.	Agarwal S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3318; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; Araki H, 2004, BLOOD, V103, P2973, DOI 10.1182/blood-2003-08-2742; Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Brooks JP, 2005, INT J RADIAT ONCOL, V62, P785, DOI 10.1016/j.ijrobp.2004.12.001; Cabioglu N, 2004, J CLIN ONCOL, V22, p841S; Casbas-Hernandez P, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3476; Cassatella MC, 2012, FUTURE ONCOL, V8, P1253, DOI [10.2217/FON.12.119, 10.2217/fon.12.119]; Chan WW, 2011, CANCER CELL, V19, P556, DOI 10.1016/j.ccr.2011.03.003; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Eichler W, 2004, EXP CELL RES, V299, P68, DOI 10.1016/j.yexcr.2004.05.020; Entenberg D, 2011, NAT PROTOC, V6, P1500, DOI 10.1038/nprot.2011.376; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Flynn DL, 2014, AACR SPEC C CELL HET; Flynn DL, 2013, ACS NAT M 8 APR NEW; Forse CL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1468-6; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giuliani N, 2003, BLOOD, V102, P638, DOI 10.1182/blood-2002-10-3257; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Gupton SL, 2012, J CELL BIOL, V198, P657, DOI 10.1083/jcb.201202079; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hellen E H, 1991, J Fluoresc, V1, P113, DOI 10.1007/BF00865207; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Hernandez L, 2009, CANCER RES, V69, P3221, DOI 10.1158/0008-5472.CAN-08-2871; Hesselgesser J, 1998, J IMMUNOL, V160, P877; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Hughes SK, 2015, MOL BIOL CELL, V26, P3867, DOI 10.1091/mbc.E15-06-0442; Kang JY, 2003, CANCER RES, V63, P1101; Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269; Knutsdottir H, 2016, INTEGR BIOL-UK, V8, P104, DOI 10.1039/c5ib00201j; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Locker J, 2011, AM J PATHOL, V178, P966, DOI 10.1016/j.ajpath.2010.12.013; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Magbanua MJM, 2015, ONCOTARGET, V6, P30715, DOI 10.18632/oncotarget.5568; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Martins D, 2014, CYTOPATHOLOGY, V25, P225, DOI 10.1111/cyt.12158; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Minami T, 2009, J CLIN INVEST, V119, P2257, DOI 10.1172/JCI35738; Mouneimne G, 2006, CURR BIOL, V16, P2193, DOI 10.1016/j.cub.2006.09.016; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Oktay MH, 2012, J HISTOCHEM CYTOCHEM, V60, P168, DOI 10.1369/0022155411435153; Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10; Patsialou A, 2015, ONCOGENE, V34, P2721, DOI 10.1038/onc.2014.226; Patsialou Antonia, 2013, Intravital, V2, pe25294; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pignatelli J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005329; Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Rohan TE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju136; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Roussos ET, 2011, CLIN EXP METASTAS, V28, P515, DOI 10.1007/s10585-011-9388-6; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Sharma VP, 2014, METHODS MOL BIOL, V1172, P115, DOI 10.1007/978-1-4939-0928-5_10; Sharma Ved P, 2012, Intravital, V1, P77; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; Sidani M, 2006, J MAMMARY GLAND BIOL, V11, P151, DOI 10.1007/s10911-006-9021-5; Smith BD, 2013, CANC RES S24, V73; Smith BD, 2013, P AACR SPEC C TUM IN; Smith BD, 2015, MOL CANCER THER, V14, P2023, DOI 10.1158/1535-7163.MCT-14-1105; Smith BD, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.CHTME14-A53; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Timofeevski SL, 2009, BIOCHEMISTRY-US, V48, P5339, DOI 10.1021/bi900438w; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams JK, 2015, INTRAVITAL IN PRESS; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff Jeffrey, 2011, Cold Spring Harb Protoc, V2011, P1232, DOI 10.1101/pdb.prot065912; Wyckoff Jeffrey, 2011, Cold Spring Harb Protoc, V2011, P1167, DOI 10.1101/pdb.top065904; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; Zhao Z, 2016, CANCER RES, V76, P2094, DOI 10.1158/0008-5472.CAN-15-2662	91	56	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2680	2692		10.1038/onc.2016.421	http://dx.doi.org/10.1038/onc.2016.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893712	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000401120900006
J	Goyama, S; Shrestha, M; Schibler, J; Rosenfeldt, L; Miller, W; O'Brien, E; Mizukawa, B; Kitamura, T; Palumbo, JS; Mulloy, JC				Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Kitamura, T.; Palumbo, J. S.; Mulloy, J. C.			Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia	ONCOGENE			English	Article							THROMBIN RECEPTOR; SELF-RENEWAL; PROGENITOR CELLS; CANCER GENOMICS; UP-REGULATION; IN-VIVO; PROMOTES; EXPRESSION; ADHESION; AML1-ETO	Eradication of leukemia stem cells (LSCs) is the ultimate goal of treating acute myeloid leukemia (AML). We recently showed that the combined loss of Runx1/Cbfb inhibited the development of MLL-AF9-induced AML. However, c-Kit(+)/Gr-1(-)cells remained viable in Runx1/Cbfb-deleted cells, indicating that suppressing RUNX activity may not eradicate the most immature LSCs. In this study, we found upregulation of several hemostasis-related genes, including the thrombin-activatable receptor PAR- 1 (protease-activated receptor-1), in Runx1/Cbfb-deleted MLL-AF9 cells. Similar to the effect of Runx1/Cbfb deletion, PAR- 1 overexpression induced CDKN1A/p21 expression and attenuated proliferation in MLL-AF9 cells. To our surprise, PAR- 1 deficiency also prevented leukemia development induced by a small number of MLL-AF9 leukemia stem cells (LSCs) in vivo. PAR- 1 deficiency also reduced leukemogenicity of AML1-ETO-induced leukemia. Re-expression of PAR- 1 in PAR-1-deficient cells combined with a limiting-dilution transplantation assay demonstrated the cell-dose-dependent role of PAR- 1 in MLL-AF9 leukemia: PAR- 1 inhibited rapid leukemic proliferation when there were a large number of LSCs, while a small number of LSCs required PAR- 1 for their efficient growth. Mechanistically, PAR- 1 increased the adherence properties of MLL-AF9 cells and promoted their engraftment to bone marrow. Taken together, these data revealed a multifaceted role for PAR- 1 in leukemogenesis, and highlight this receptor as a potential target to eradicate primitive LSCs in AML.	[Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Palumbo, J. S.; Mulloy, J. C.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Palumbo, J. S.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Goyama, S.; Kitamura, T.] Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Tokyo	Palumbo, JS; Mulloy, JC (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA.	Joe.Palumbo@cchmc.org; james.mulloy@cchmc.org	Kitamura, Toshio/AAA-2071-2021		Institutional Clinical and Translational Science Award; NIH/NCRR Grant [1UL1RR026314-01]; Translational Trials Development and Support Laboratory award (USPHS Grant) [MO1 RR 08084]; Center of Excellence in Molecular Hematology P30 award [DK090971];  [CA176907]; NATIONAL CANCER INSTITUTE [R01CA204058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER	Institutional Clinical and Translational Science Award; NIH/NCRR Grant; Translational Trials Development and Support Laboratory award (USPHS Grant); Center of Excellence in Molecular Hematology P30 award; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr J Trejo and Dr M Onodera for plasmids. We also thank the Flow Cytometry Core and the Mouse Core at Cincinnati Children's Hospital Medical Center for their help. This work was supported by an Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 1UL1RR026314-01, Translational Trials Development and Support Laboratory award (USPHS Grant Number MO1 RR 08084), CA176907 (JCM) and a Center of Excellence in Molecular Hematology P30 award (DK090971). JCM is a Leukemia and Lymphoma Society Scholar.	Aronovich A, 2013, BLOOD, V122, P2562, DOI 10.1182/blood-2012-08-447458; Austin KM, 2013, BLOOD, V121, P431, DOI 10.1182/blood-2012-09-355958; Auvergne R, 2016, ONCOGENE, V35, P3817, DOI 10.1038/onc.2015.452; Baumer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094993; BOWER M, 1994, BLOOD, V84, P3776, DOI 10.1182/blood.V84.11.3776.bloodjournal84113776; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chou FS, 2012, BLOOD, V120, P709, DOI 10.1182/blood-2012-01-403212; COHEN SG, 2015, NAT MED, V21, P1307; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Degen JL, 2012, THROMB RES, V129, pS1, DOI 10.1016/S0049-3848(12)70143-3; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goyama S, 2016, LEUKEMIA, V30, P728, DOI 10.1038/leu.2015.275; Goyama S, 2015, BLOOD, V125, P2630, DOI 10.1182/blood-2014-11-570218; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Heider I, 2004, ONCOL RES, V14, P475, DOI 10.3727/0965040042380496; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Kanemaru M, 2012, HEPATO-GASTROENTEROL, V59, P1614, DOI 10.5754/hge10036; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mulloy JC, 2008, CELL CYCLE, V7, P3314, DOI 10.4161/cc.7.21.6951; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nakahara F, 2014, BLOOD, V123, P3932, DOI 10.1182/blood-2013-01-476747; NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976; Pagel CN, 2009, BONE, V44, P813, DOI 10.1016/j.bone.2008.12.031; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Song SJ, 2005, AM J PATHOL, V166, P857, DOI 10.1016/S0002-9440(10)62306-1; Tanaka Y, 2012, DEV BIOL, V366, P404, DOI 10.1016/j.ydbio.2012.03.024; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Veiga CDB, 2011, BLOOD CELL MOL DIS, V46, P230, DOI 10.1016/j.bcmd.2010.12.005; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Wunderlich Mark, 2009, V538, P263, DOI 10.1007/978-1-59745-418-6_13; Yang E, 2016, ONCOGENE, V35, P1529, DOI 10.1038/onc.2015.217; Ye M, 2015, CELL STEM CELL, V17, P611, DOI 10.1016/j.stem.2015.08.011; Yue R, 2012, DEV CELL, V22, P1092, DOI 10.1016/j.devcel.2012.01.025; Zhong JF, 2005, P NATL ACAD SCI USA, V102, P2448, DOI 10.1073/pnas.0409459102	46	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2589	2598		10.1038/onc.2016.416	http://dx.doi.org/10.1038/onc.2016.416			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819671	Green Accepted			2022-12-28	WOS:000400597300009
J	Yigit, MV; Ghosh, SK; Kumar, M; Petkova, V; Kavishwar, A; Moore, A; Medarova, Z				Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Petkova, V.; Kavishwar, A.; Moore, A.; Medarova, Z.			Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis (vol 32, pg 1530, 2012)	ONCOGENE			English	Correction																		YIGIT MV, 2012, ONCOGENE, V32, P1530, DOI DOI 10.1038/0NC.2016.413	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2628	2628		10.1038/onc.2016.413	http://dx.doi.org/10.1038/onc.2016.413			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27841862	Bronze			2022-12-28	WOS:000400597300013
J	Guo, JY; Hsu, HS; Tyan, SW; Li, FY; Shew, JY; Lee, WH; Chen, JY				Guo, J-Y; Hsu, H-S; Tyan, S-W; Li, F-Y; Shew, J-Y; Lee, W-H; Chen, J-Y			Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CD44; FIBROBLASTS; EXPRESSION; OVEREXPRESSION; ACTIVATION; ADHESION; PROTEOGLYCAN	Tumor microenvironment (TME) plays an active role in promoting tumor progression. To further understand the communication between TME and tumor cells, this study aimed at investigating the involvement of CD44, a type I cell surface receptor, in the crosstalk between tumor cells and TME. We have previously shown that chondroitin sulfate proteoglycan serglycin (SRGN), a CD44-interacting factor, was preferentially secreted by cancer-associated fibroblasts (CAFs) for promoting tumor growth in breast cancer patients. In this study, we show that SRGN is overexpressed in primary non-small cell lung cancers (NSCLCs), by both carcinoma and stromal cells. Using gain-of-function and loss-of-function approaches, we show that SRGN promotes NSCLC cell migration and invasion as well as colonization in the lung and liver in a CD44-dependent manner. SRGN induces lung cancer cell stemness, as demonstrated by its ability to enhance NSCLC cell sphere formation via Nanog induction, accompanied with increased chemoresistance and anoikis-resistance. SRGN promotes epithelial-mesenchymal transition by enhancing vimentin expression via CD44/NF-kappa B/claudin-1(CLDN1) axis. In support, CLDN1 and SRGN expression are tightly linked together in primary NSCLC. Most importantly, increased expression of SRGN and/or CLDN1 predicts poor prognosis in primary lung adenocarcinomas. In summary, we demonstrate that SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44, suggesting that a combined therapy targeting both CD44 and its ligands in the TME may be an attractive approach for cancer therapy.	[Guo, J-Y; Chen, J-Y] Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan; [Hsu, H-S] Taipei Vet Gen Hosp, Dept Thorac Surg, Taipei, Taiwan; [Tyan, S-W] Chia Nan Univ Pharm & Sci, Dept Biotechnol, Tainan, Taiwan; [Li, F-Y] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Lee, W-H] China Med Univ, Inst Clin Med, Taichung, Taiwan; [Chen, J-Y] Natl Yang Ming Univ, Dept Life Sci, Taipei, Taiwan; [Chen, J-Y] Natl Yang Ming Univ, Inst Genome Sci, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Veterans General Hospital; Chia Nan University of Pharmacy & Science; Taipei Veterans General Hospital; Academia Sinica - Taiwan; China Medical University Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	bmchen@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018		Academia Sinica and Ministry of Science and Technology [MOST 104-0210-01-09-02, MOST-104-2320-B-001-010]; Academia Sinica, Taiwan	Academia Sinica and Ministry of Science and Technology; Academia Sinica, Taiwan(Academia Sinica - Taiwan)	This research was supported by Academia Sinica and Ministry of Science and Technology (MOST 104-0210-01-09-02 and MOST-104-2320-B-001-010 to JYC), and a post-doctoral fellowship to JYG from Academia Sinica, Taiwan.	Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen Hong-Chen, 2004, V294, P15; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; dos Reis PP, 2008, CANCER-AM CANCER SOC, V113, P3169, DOI 10.1002/cncr.23934; Edlund K, 2012, INT J CANCER, V131, P2264, DOI 10.1002/ijc.27518; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hassona Y, 2013, CARCINOGENESIS, V34, P1286, DOI 10.1093/carcin/bgt035; He J, 2014, WORLD J GASTROENTERO, V20, P3025, DOI 10.3748/wjg.v20.i11.3025; He L, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0707-4; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Korpetinou A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078157; Lee JC, 2008, NCM 2008: 4TH INTERNATIONAL CONFERENCE ON NETWORKED COMPUTING AND ADVANCED INFORMATION MANAGEMENT, VOL 2, PROCEEDINGS, P28, DOI 10.1109/NCM.2008.203; Lee J, 2007, IEEE ASIAN SOLID STA, P67, DOI 10.1109/ASSCC.2007.4425733; Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155; Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li XJ, 2011, CANCER RES, V71, P3162, DOI 10.1158/0008-5472.CAN-10-3557; LIN H, 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0060516; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Liu Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036949, 10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1186/1746-1596-7-49]; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00154; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Purushothaman A, 2014, J BIOL CHEM, V289, P5499, DOI 10.1074/jbc.M113.532143; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Shiozaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038049; Singh A. K., 2012, J ENV SCI TOXICOL FO, V1, P1, DOI DOI 10.1016/J.BMC.2011.09.022; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Skliris A, 2013, FEBS J, V280, P2342, DOI 10.1111/febs.12179; Sudhir PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep09633; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Tyan SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035128; Tyan SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015313; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Volz Y, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150093	53	72	75	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2457	2471		10.1038/onc.2016.404	http://dx.doi.org/10.1038/onc.2016.404			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819672	Green Published, hybrid			2022-12-28	WOS:000400268900011
J	Zhang, H; Ye, YL; Li, MX; Ye, SB; Huang, WR; Cai, TT; He, J; Peng, JY; Duan, TH; Cui, J; Zhang, XS; Zhou, FJ; Wang, RF; Li, J				Zhang, H.; Ye, Y-L; Li, M-X; Ye, S-B; Huang, W-R; Cai, T-T; He, J.; Peng, J-Y; Duan, T-H; Cui, J.; Zhang, X-S; Zhou, F-J; Wang, R-F; Li, J.			CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer	ONCOGENE			English	Article							NEUTROPHIL RECRUITMENT; TUMOR MICROENVIRONMENT; ACCUMULATION; ACTIVATION; EXPANSION; INFLAMMATION; METASTASIS; MECHANISM; RESPONSES; BLOCKADE	The accumulation of myeloid-derived suppressor cells (MDSCs) has been observed in solid tumors and is correlated with tumor progression; however, the underlying mechanism is still poorly understood. In this study, we identified a mechanism by which tumor cells induce MDSC accumulation and expansion in the bladder cancer (BC) microenvironment via CXCL2/MIF-CXCR2 signaling. Elevated expression of CXCL2 and MIF and an increased number of CD33(+) MDSCs were detected in BC tissues, and these increases were significantly associated with advanced disease stage and poor patient prognosis (P < 0.01). A positive association was observed between CXCL2 or MIF expression and the number of tumor-infiltrating CD33(+) MDSCs (P < 0.01). Subsequently, we demonstrated that CD45(+) CD33(+) CD11b(+) HLA-DR-MDSCs from fresh BC tissues displayed high levels of suppressive molecules, including Arg1, iNOS, ROS, PDL-1 and P-STAT3, and stronger suppression of T-cell proliferation. Interestingly, these CD45(+) CD33+ CD11b(+) HLA-DR -MDSCs exhibited increased CXCR2 expression compared with that in peripheral blood from BC patients or healthy controls (P < 0.05). Chemotaxis assay revealed that bladder cancer cell line J82 induced MDSC migration via CXCL2/MIF-CXCR2 signaling in vitro. Mechanistic studies demonstrated that J82-induced MDSC trafficking and CXCR2 expression were associated with increased phosphorylation of p38, ERK and p65. Conversely, inhibition of the phosphorylation of p38, ERK or p65 decreased J82-induced MDSC trafficking and CXCR2 expression. CXCL2/MIF-stimulated activation of the mitogen-activated protein kinase and nuclear factor kappa B pathways in MDSCs was MyD88 dependent. Overall, our results identify the CXCL2/MIF-CXCR2 axis as an important mediator in MDSC recruitment and as predictors and potential therapeutic targets in BC patients.	[Zhang, H.; Ye, Y-L; Ye, S-B; Cai, T-T; Zhang, X-S; Zhou, F-J; Li, J.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, H.; Ye, Y-L; Ye, S-B; Cai, T-T; Zhang, X-S; Zhou, F-J; Li, J.] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Zhang, H.; Ye, S-B; Cai, T-T; He, J.; Peng, J-Y; Zhang, X-S; Li, J.] Dept Biotherapy, Guangzhou, Guangdong, Peoples R China; [Ye, Y-L; Zhou, F-J] Sun Yat Sen Univ, Dept Urol, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Li, M-X; Huang, W-R] Shenzhen Univ, Shenzhen Peoples Hosp 2, Key Lab Med Reprogramming Technol, Affiliated Hosp 1, Shenzhen, Peoples R China; [Duan, T-H; Cui, J.] Sun Yat Sen Univ, Coll Life Sci, Key Lab Gene Engn, Minist Educ,State Key Lab Biocontrol, Guangzhou, Guangdong, Peoples R China; [Wang, R-F] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX USA; [Wang, R-F] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA	State Key Lab Oncology South China; Sun Yat Sen University; Shenzhen University; Sun Yat Sen University; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University	Wang, RF (corresponding author), Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA.; Li, J (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	rwang3@houstonmethodist.org; lijiang2@mail.sysu.edu.cn	ye, shubiao/GZM-4506-2022	li, jiang/0000-0001-5596-9159	National Key Basic Research Program of China of the National Natural Science Foundation of China [2014CB745200]; Shenzheng City Science Foundation [81572982, 81372442, 81172164, 2014041470821172]	National Key Basic Research Program of China of the National Natural Science Foundation of China; Shenzheng City Science Foundation	This work was supported by grants from the National Key Basic Research Program of China (2014CB745200) of the National Natural Science Foundation of China and the General Program (Grant Nos. 81572982, 81372442 and 81172164, to LJ) and the Sci-Tech Key Program of the Shenzheng City Science Foundation (Grant No. 2014041470821172, to LJ).	Becht E, 2014, CANCER IMMUNOL IMMUN, V63, P991, DOI 10.1007/s00262-014-1590-3; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; De Veirman K, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00349; Dubeykovskaya Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10517; Dubois Raymond N, 2014, Trans Am Clin Climatol Assoc, V125, P358; Errico A, 2015, NAT REV CLIN ONCOL, V12, P63, DOI [10.1038/nrclinonc.2013.247, 10.1038/nrclinonc.2014.221]; Eruslanov E, 2012, INT J CANCER, V130, P1109, DOI 10.1002/ijc.26123; Fang LY, 2013, CANCER RES, V73, P5633, DOI 10.1158/0008-5472.CAN-12-3228; Gabrilovich D, 2015, CANCER CELL, V28, P147, DOI 10.1016/j.ccell.2015.07.007; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hong EH, 2013, INT J CANCER, V132, P2839, DOI 10.1002/ijc.27974; Huang B, 2007, CANCER LETT, V252, P86, DOI 10.1016/j.canlet.2006.12.012; Huang JR, 2014, J IMMUNOL, V192, P1972, DOI 10.4049/jimmunol.1302623; Huang L, 2015, AM J TRANSL RES, V7, P2141; Jablonska J, 2014, INT J CANCER, V134, P1346, DOI 10.1002/ijc.28551; Jiang JW, 2014, HUM IMMUNOL, V75, P1128, DOI 10.1016/j.humimm.2014.09.025; Kaplan AL, 2014, NAT REV UROL, V11, P59, DOI 10.1038/nrurol.2013.180; Kotsakis A, 2012, J IMMUNOL METHODS, V381, P14, DOI 10.1016/j.jim.2012.04.004; Li ZL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1044712; Liakou Chrysoula I, 2007, Cancer Immun, V7, P10; Lin M, 2015, ANAL CELL PATHOL, V2015, DOI 10.1155/2015/313145; Mao YM, 2013, CANCER RES, V73, P3877, DOI 10.1158/0008-5472.CAN-12-4115; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; Mitchell D, 2010, MOL IMMUNOL, V47, P2065, DOI 10.1016/j.molimm.2010.04.004; Mitchell RA, 2014, CELL SIGNAL, V26, P2969, DOI 10.1016/j.cellsig.2014.09.012; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Raval RR, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-14; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Santegoetst SJAM, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0031-3; Scortegagna M, 2008, BLOOD, V111, P3343, DOI 10.1182/blood-2007-10-115758; Shang K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051848; Talmadge JE, 2007, CLIN CANCER RES, V13, P5243, DOI 10.1158/1078-0432.CCR-07-0182; Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006; Vashistha V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-966; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Weiss JM, 2014, J IMMUNOL, V192, P5821, DOI 10.4049/jimmunol.1400404; Winner M, 2007, CANCER RES, V67, P186, DOI 10.1158/0008-5472.CAN-06-3292; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Yamamoto M, 2008, CANCER RES, V68, P9754, DOI 10.1158/0008-5472.CAN-08-1748; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang H, 2015, CANCER IMMUNOL IMMUN, V64, P1587, DOI 10.1007/s00262-015-1765-6; Zhang ZL, 2014, CHIN J CANCER, V33, P165, DOI 10.5732/cjc.012.10312	48	136	140	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2095	2104		10.1038/onc.2016.367	http://dx.doi.org/10.1038/onc.2016.367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721403				2022-12-28	WOS:000399782500006
J	Kang, MH; Jeong, KJ; Kim, WY; Lee, HJ; Gong, G; Suh, N; Gyorffy, B; Kim, S; Jeong, SY; Mills, GB; Park, YY				Kang, M-H; Jeong, K. J.; Kim, W. Y.; Lee, H. J.; Gong, G.; Suh, N.; Gyorffy, B.; Kim, S.; Jeong, S-Y; Mills, G. B.; Park, Y-Y			Musashi RNA- binding protein 2 regulates estrogen receptor 1 function in breast cancer	ONCOGENE			English	Article							HUR; ALPHA; EXPRESSION; STABILITY; SUBSETS; REVEALS	Musashi RNA-binding protein 2 (MSI2) has important roles in human cancer. However, the regulatory mechanisms by which MSI2 alters breast cancer pathophysiology have not been clearly identified. Here we demonstrate that MSI2 directly regulates estrogen receptor 1 (ESR1), which is a well-known therapeutic target and has been shown to reflect clinical outcomes in breast cancer. Based on gene expression data analysis, we found that MSI2 expression was highly enriched in estrogen receptor (ER)-positive breast cancer and that MSI2 expression was significantly correlated with ESR1 expression, including expression of ESR1 downstream target genes. In addition, MSI2 levels were associated with clinical outcomes. MSI2 influenced breast cancer cell growth by altering ESR1 function. MSI2 alters ESR1 by binding specific sites in ESR1 RNA and by increasing ESR1 protein stability. Taken together, our findings identified a novel regulatory mechanism of MSI2 as an upstream regulator of ESR1 and revealed the clinical relevance of the RNA-binding protein MSI2 in breast cancer.	[Kang, M-H; Park, Y-Y] Ulsan Coll Med, Dep Convergence Med, Seoul, South Korea; [Jeong, K. J.; Mills, G. B.] MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77001 USA; [Kim, W. Y.] Korea Univ, Dept Surg, Seoul, South Korea; [Lee, H. J.; Gong, G.] ASAN Med Ctr, Dept Pathol, Seoul, South Korea; [Suh, N.] Chun Hyang Univ, Coll Med Sci, Dept Med Engn, Asan, South Korea; [Gyorffy, B.] Semmelweis Univ, 2 Dept Pediat, MTA TTK lendulet Canc biomarker Res Group, Budapest, Hungary; [Kim, S.] Anging Res Inst, Korea Res Inst Biosci & Biotechnol, Dacjeon, Hungary; [Jeong, S-Y; Park, Y-Y] ASAN Inst Life Sci, ASAN Med Ctr, Seoul, South Korea; [Park, Y-Y] Univ Ulsan Coll Med, Dept Convergence Med, 88 Olympic, Seoul 05505, South Korea	University of Ulsan; University of Texas System; UTMD Anderson Cancer Center; Korea University; University of Ulsan; Asan Medical Center; Semmelweis University; University of Ulsan	Park, YY (corresponding author), Ulsan Coll Med, Dep Convergence Med, Seoul, South Korea.	yypark@amc.seoul.kr	Jeong, Kangjin/HGT-9268-2022; Gyorffy, Balazs/AAA-9135-2021	Gyorffy, Balazs/0000-0002-5772-3766; Mills, Gordon/0000-0002-0144-9614	Ministry of Education [NRF-2014R1A1A2053529, NRF-2013R1A1A2064367]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI15C0972]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Ministry of Education; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Ministry of Education (NRF-2014R1A1A2053529 to Y-YP; NRF-2013R1A1A2064367 to M-HK) and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI15C0972 to Y-YP).	Anji A, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010004; Bennett CG, 2016, NUCLEIC ACIDS RES, V44, P3788, DOI 10.1093/nar/gkw207; Calaluce R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-126; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Lee HJ, 2014, ANN SURG ONCOL, V21, P1561, DOI 10.1245/s10434-013-3456-x; Licata LA, 2010, BREAST CANCER RES TR, V122, P55, DOI 10.1007/s10549-009-0517-8; Morrow PKH, 2009, ANNU REV MED, V60, P153, DOI 10.1146/annurev.med.60.061107.145152; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Okano H, 2002, J CELL SCI, V115, P1355; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Wang MH, 2015, AM J CANCER RES, V5, P1089; Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Woo HH, 2009, ONCOGENE, V28, P1176, DOI 10.1038/onc.2008.469; Wurth L, 2015, BBA-GENE REGUL MECH, V1849, P881, DOI 10.1016/j.bbagrm.2014.10.001; Zhao ZB, 2015, CHEM BIOL, V22, P1608, DOI 10.1016/j.chembiol.2015.10.011	24	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1745	1752		10.1038/onc.2016.327	http://dx.doi.org/10.1038/onc.2016.327			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27593929				2022-12-28	WOS:000397460600013
J	Cao, C; Zhang, T; Zhang, D; Xie, L; Zou, X; Lei, L; Wu, D; Liu, L				Cao, C.; Zhang, T.; Zhang, D.; Xie, L.; Zou, X.; Lei, L.; Wu, D.; Liu, L.			The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma	ONCOGENE			English	Article							METASTASIS; CELLS; TAK1; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; SPONGES; GROWTH	The expression of long non-coding RNAs (lncRNAs) is dysregulated in hepatocellular carcinoma (HCC). However, the functions and contributions of lncRNAs remain largely unknown. Here, we identified a critical role of SNHG6-003 in HCC. We found that five SNHG6 transcripts were differentially expressed in HCC tissues while only the SNHG6-003 had an oncogenic function. Ectopic expression of SNHG6-003 in HCC cells promoted cell proliferation and induced drug resistance, whereas SNHG6-003 knockdown promoted apoptosis. Moreover, SNHG6-003 functioned as a competitive endogenous RNA (ceRNA), effectively becoming sponge for miR-26a/b and thereby modulating the expression of transforming growth factor-beta-activated kinase 1 (TAK1). Importantly, expression analysis revealed that both SNHG6-003 and TAK1 were upregulated in human cancers, exhibiting a co-expression pattern. In HCC patients, high expression of SNHG6-003 closely correlated with tumor progression and shorter survival. Thus, targeting the ceRNA network involving SNHG6-003 may be used as a treatment strategy against HCC.	[Cao, C.; Zhang, D.; Lei, L.; Wu, D.] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, T.; Zou, X.; Liu, L.] Guangdong Prov Key Lab Viral Hepatitis Res, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, T.; Liu, L.] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China; [Xie, L.] Univ Georgia, Ctr Mol Med, Athens, GA USA	Southern Medical University - China; Southern Medical University - China; University System of Georgia; University of Georgia	Wu, D (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.; Liu, L (corresponding author), Guangdong Prov Key Lab Viral Hepatitis Res, Guangzhou 510515, Guangdong, Peoples R China.	wudehua.gd@gmail.com; liuli.fimmu@gmail.com		Wu, De-Hua/0000-0003-0560-0016; Liu, Li/0000-0002-5265-4159; Zou, Xuejing/0000-0001-6360-204X	National Nature Science Foundation of China [81172586, 81401180, 81372283, 91540111]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Schem; Natural Science Funding of Guangdong Province [2014A030311013]; postdoctoral fellowship from American Heart Association [16POST26400005]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Schem; Natural Science Funding of Guangdong Province; postdoctoral fellowship from American Heart Association	This work was supported by the National Nature Science Foundation of China (Grant Nos. 81172586, 81401180, 81372283 and 91540111), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), Natural Science Funding of Guangdong Province (Grant No. 2014A030311013) and postdoctoral fellowship from American Heart Association 16POST26400005 (to XL). LX thanks Dr Hang Yin (University of Georgia) for support of the studies proposed in this manuscript.	Bak RO, 2014, WIRES RNA, V5, P317, DOI 10.1002/wrna.1213; Bodzin AS, 2015, WORLD J HEPATOL, V7, P1157, DOI 10.4254/wjh.v7.i9.1157; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen FC, 2014, EVOL BIOINFORM, V10, P219, DOI 10.4137/EBO.S20772; Chen IT, 2015, SCI REP-UK, V5, DOI 10.1038/srep12300; Fan YH, 2013, APOPTOSIS, V18, P1224, DOI 10.1007/s10495-013-0864-0; Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363; Ghosal S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00249; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Jalali S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053823; Joo JH, 2014, MOL VIS, V20, P1629; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Li L, 2014, SCI REP-UK, V4, DOI 10.1038/srep05406; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu M, 2012, HEPATOLOGY, V55, P1754, DOI 10.1002/hep.25584; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Pilyugin M, 2014, INT J BIOCHEM CELL B, V54, P356, DOI 10.1016/j.biocel.2014.06.018; Tang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.518; Tay FC, 2015, ADV DRUG DELIVER REV, V81, P117, DOI 10.1016/j.addr.2014.05.010; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wang P, 2015, NUCLEIC ACIDS RES, V43, P3478, DOI 10.1093/nar/gkv233; Wu XF, 2014, P NATL ACAD SCI USA, V111, P13870, DOI 10.1073/pnas.1414358111; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang YC, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0512-1; Zheng LF, 2015, BREAST CANCER RES TR, V150, P105, DOI 10.1007/s10549-015-3298-2; Zhou X, 2014, GYNECOL ONCOL, V133, P333, DOI 10.1016/j.ygyno.2014.02.033	34	136	138	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1112	1122		10.1038/onc.2016.278	http://dx.doi.org/10.1038/onc.2016.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27530352				2022-12-28	WOS:000395371500009
J	Milewski, D; Pradhan, A; Wang, X; Cai, Y; Le, T; Turpin, B; Kalinichenko, VV; Kalin, TV				Milewski, D.; Pradhan, A.; Wang, X.; Cai, Y.; Le, T.; Turpin, B.; Kalinichenko, V. V.; Kalin, T. V.			FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor	ONCOGENE			English	Article							FORKHEAD BOX F1; TO-MESENCHYMAL TRANSITION; MICE HETEROZYGOUS NULL; CHILDHOOD RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; DIFFERENTIAL EXPRESSION; LUNG-CANCER; GENE; FUSION; CELLS	The role of Forkhead Box F1 (FoxF1) transcription factor in carcinogenesis is not well characterized. Depending on tissue and histological type of cancer, FoxF1 has been shown to be either an oncogene or a tumor suppressor. Alveolar rhabdomyosarcoma ( RMS) is the most aggressive pediatric soft-tissue sarcoma. Although FoxF1 is highly expressed in alveolar RMS, the functional role of FoxF1 in RMS is unknown. The present study demonstrates that expression of FoxF1 and its closely related transcription factor FoxF2 are essential for RMS tumor growth. Depletion of FoxF1 or FoxF2 in RMS cells decreased tumor growth in orthotopic mouse models of RMS. The decreased tumorigenesis was associated with reduced tumor cell proliferation. Cell cycle regulatory proteins Cdk2, Cdk4/6, Cyclin D1 and Cyclin E2 were decreased in FoxF1-and FoxF2-deficient RMS tumors. Depletion of either FoxF1 or FoxF2 delayed G1-S cell cycle progression, decreased levels of phosphorylated retinoblastoma protein (Rb) and increased protein levels of the CDK inhibitors, p21(Cip1) and p27(Kip1). Depletion of both FoxF1 and FoxF2 in tumor cells completely abrogated RMS tumor growth in mice. Overexpression of either FoxF1 or FoxF2 in tumor cells was sufficient to increase tumor growth in orthotopic RMS mouse model. FoxF1 and FoxF2 directly bound to and repressed transcriptional activity of p21Cip1 promoter through - 556/ - 545 bp region, but did not affect p27Kip1 transcription. Knockdown of p21Cip1 restored cell cycle progression in the FoxF1-or FoxF2-deficient tumor cells. Altogether, FoxF1 and FoxF2 promoted RMS tumorigenesis by inducing tumor cell proliferation via transcriptional repression of p21Cip1 gene promoter. Because of the robust oncogenic activity in RMS tumors, FoxF1 and FoxF2 may represent promising targets for anti-tumor therapy.	[Milewski, D.; Pradhan, A.; Wang, X.; Cai, Y.; Le, T.; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, Cincinnati, OH USA; [Wang, X.] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH USA; [Turpin, B.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Tatiana.kalin@cchmc.org	Milewski, David/GPF-5870-2022	Milewski, David/0000-0002-9778-8548	American Cancer Society [125011-RSG-13-325-01-CSM]; NIH [R01 CA142724, R01 HL84151]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151, R01HL132849, R01HL123490] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Research Grant from the American Cancer Society 125011-RSG-13-325-01-CSM (to TVK), NIH grants R01 CA142724 (to TVK) and R01 HL84151 (to VVK).	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Aitola M, 2000, DEV DYNAM, V218, P136, DOI 10.1002/(SICI)1097-0177(200005)218:1<136::AID-DVDY12>3.0.CO;2-U; Armeanu-Ebinger S, 2011, INT J ONCOL, V38, P993, DOI 10.3892/ijo.2011.921; Balli D, 2012, ONCOGENE, V31, P3875, DOI 10.1038/onc.2011.549; Balli D, 2013, EMBO J, V32, P231, DOI 10.1038/emboj.2012.336; Balli D, 2011, CANCER RES, V71, P40, DOI 10.1158/0008-5472.CAN-10-2004; Bolte C, 2015, J BIOL CHEM, V290, P7563, DOI 10.1074/jbc.M114.609487; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cheng XH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004656; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; DAVIS RJ, 1994, CANCER RES, V54, P2869; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gialmanidis IP, 2013, LUNG, V191, P511, DOI 10.1007/s00408-013-9490-4; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; HOSOI H, 1992, INT J CANCER, V50, P977, DOI 10.1002/ijc.2910500626; Kalin TV, 2008, AM J RESP CELL MOL, V39, P390, DOI 10.1165/rcmb.2008-0044OC; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2003, GENE EXPR PATTERNS, V3, P153, DOI 10.1016/S1567-133X(03)00010-3; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kong PZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061591; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lo PK, 2012, CELL SIGNAL, V24, P316, DOI 10.1016/j.cellsig.2011.09.017; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; McDowell HP, 2003, ARCH DIS CHILD, V88, P354, DOI 10.1136/adc.88.4.354; Mclin VA, 2010, INT J DEV BIOL, V54, P919, DOI 10.1387/ijdb.092916vm; Mclin VA, 2009, GASTROENTEROLOGY, V136, P2074, DOI 10.1053/j.gastro.2009.03.001; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nik AM, 2013, GASTROENTEROLOGY, V144, P1001, DOI 10.1053/j.gastro.2013.01.045; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Ormestad M, 2004, DEV DYNAM, V229, P328, DOI 10.1002/dvdy.10426; Pappo I, 2004, ANN SURG ONCOL, V11, P52, DOI 10.1007/BF02524346; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Qualman Stephen J, 2002, Curr Oncol Rep, V4, P123, DOI 10.1007/s11912-002-0073-4; Ren XM, 2014, CIRC RES, V115, P709, DOI 10.1161/CIRCRESAHA.115.304382; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Tamura M, 2014, ONCOGENE, V33, P4837, DOI 10.1038/onc.2013.427; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wei HJ, 2014, ONCOTARGET, V5, P9514, DOI 10.18632/oncotarget.2413; Weigel BJ, 2003, CLIN CANCER RES, V9, P3105; Wendling DS, 2008, INT J MOL MED, V22, P787, DOI 10.3892/ijmm_00000086; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	54	40	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					850	862		10.1038/onc.2016.254	http://dx.doi.org/10.1038/onc.2016.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27425595	Green Accepted			2022-12-28	WOS:000394168200012
J	Li, XD; Zhang, JX; Jiang, LJ; Wang, FW; Liu, LL; Liao, YJ; Jin, XH; Chen, WH; Chen, X; Guo, SJ; Zhou, FJ; Zeng, YX; Guan, XY; Liu, ZW; Xie, D				Li, X-D; Zhang, J-X; Jiang, L-J; Wang, F-W; Liu, L-L; Liao, Y-J; Jin, X-H; Chen, W-H; Chen, X.; Guo, S-J; Zhou, F-J; Zeng, Y-X; Guan, X-Y; Liu, Z-W; Xie, D.			Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; COLORECTAL-CARCINOMA; GASTRIC-CANCER; CO-REPRESSOR; METASTASIS; EXPRESSION; DNA; COMPLEX; HETEROZYGOSITY	We have recently identified and characterized a novel oncogene, maelstrom (MAEL) from 1q24, in the pathogenesis of hepatocellular carcinoma. In this study, MAEL was investigated for its oncogenic role in urothelial carcinoma of the bladder (UCB) tumorigenesis/aggressiveness and underlying molecular mechanisms. Here, we report that overexpression of MAEL in UCB is important in the acquisition of an aggressive and/or poor prognostic phenotype. In UCB cell lines, knockdown of MAEL by short hairpin RNA is sufficient to inhibit cell growth, invasiveness/metastasis and suppressed epithelial-mesenchymal transition (EMT), whereas ectopic overexpression of MAEL promoted cell growth, invasive and/or metastatic capacity and enhanced EMT both in vitro and in vivo. We further demonstrate that MAEL could induce UCB cell EMT by downregulating a critical downstream target, the metastasis suppressor 1 (MTSS1) gene, ultimately leading to an increased invasiveness of cancer cells. Notably, overexpression of MAEL in UCB cells substantially enhanced the enrichment of DNA methyltrans-ferase (DNMT) 3B and histone deacetylase (HDAC) 1/2 on the promoter of the MTSS1, and thereby epigenetically suppressing the MTSS1 transcription. Downregulation of MTSS1 by MAEL in UCB cells is partially dependent on DNMT3B. Furthermore, we identify that beside the gene amplification of MAEL, miR-186 is a key negative regulator of MAEL and downregulation of miR-186 is another important mechanism for MAEL overexpression in UCBs. These data suggest that overexpression of MAEL, caused by gene amplification and/or decreased miR-186, has a critical oncogenic role in UCB pathogenesis by downregulation of MTSS1, and MAEL could be used as a novel prognostic marker and/or effective therapeutic target for human UCB.	[Li, X-D; Zhang, J-X; Jiang, L-J; Wang, F-W; Liu, L-L; Liao, Y-J; Jin, X-H; Chen, W-H; Chen, X.; Guo, S-J; Zhou, F-J; Zeng, Y-X; Guan, X-Y; Liu, Z-W; Xie, D.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Li, X-D; Jiang, L-J; Chen, X.; Guo, S-J; Zhou, F-J; Liu, Z-W] Sun Yat Sen Univ, Ctr Canc, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Zhang, J-X] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Liu, ZW; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	liuzhw@sysucc.org.cn; xiedan@sysucc.org.cn	LIAO, YIJI/Z-4902-2019; /A-3639-2009	LIAO, YIJI/0000-0002-0849-4573; /0000-0003-1874-9805	Nature Science Foundation of China [81225018, 81472385]; Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan) [14ykpy39]; Natural Science Foundation of Guangdong Province, China [2015A030313009]; Science and Technology Foundation of the Guangdong Province, China [2013B021800173]	Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Science and Technology Foundation of the Guangdong Province, China	This work was supported by grants from the Nature Science Foundation of China (no. 81225018 and no. 81472385), the Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan) (no. 14ykpy39), Natural Science Foundation of Guangdong Province (no. 2015A030313009), China and Science and Technology Foundation of the Guangdong Province, China (grant no. 2013B021800173).	Aravin AA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000764; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004; Clegg NJ, 1997, DEVELOPMENT, V124, P4661; Du P, 2011, ANTICANCER RES, V31, P3205; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Kayser G, 2015, BRIT J CANCER, V112, P866, DOI 10.1038/bjc.2015.2; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Lim SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099687; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; Loberg RD, 2005, INT J ONCOL, V26, P1699; Lopez V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-182; Ma J, 2006, J PATHOL, V210, P205, DOI 10.1002/path.2050; Ma NF, 2008, HEPATOLOGY, V47, P503, DOI 10.1002/hep.22072; Malkowicz SB, 2007, UROLOGY, V69, P3, DOI 10.1016/j.urology.2006.10.040; Maru DM, 2009, CANCER, V115, P1576, DOI 10.1002/cncr.24122; Matsumoto N, 2015, CELL REP, V11, P366, DOI 10.1016/j.celrep.2015.03.030; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Mesquita B, 2013, BREAST CANCER RES TR, V138, P37, DOI 10.1007/s10549-013-2408-2; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; PODDIGHE PJ, 1992, CANCER RES, V52, P4929; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; Sternberg CN, 2013, EUR UROL, V63, P58, DOI 10.1016/j.eururo.2012.08.010; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Xiao L, 2010, MOL BIOL REP, V37, P2355, DOI 10.1007/s11033-009-9741-x; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Yao K, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0372-3; Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhou CZ, 2008, WORLD J GASTROENTERO, V14, P1582, DOI 10.3748/wjg.14.1582	38	33	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6281	6292		10.1038/onc.2016.165	http://dx.doi.org/10.1038/onc.2016.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181205				2022-12-28	WOS:000390247000002
J	Cross, AM; Wilson, AL; Guerrero, MS; Thomas, KS; Bachir, AI; Kubow, KE; Horwitz, AR; Bouton, AH				Cross, A. M.; Wilson, A. L.; Guerrero, M. S.; Thomas, K. S.; Bachir, A. I.; Kubow, K. E.; Horwitz, A. R.; Bouton, A. H.			Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells	ONCOGENE			English	Article							MIGRATION; INTEGRIN; BCAR3; CAS; AND-34/BCAR3; ACTIVATION; EXPRESSION; FAMILY; ASSOCIATION; INDUCTION	Adhesion turnover is critical for cell motility and invasion. We previously demonstrated that the adaptor molecule breast cancer antiestrogen resistance 3 (BCAR3) promotes adhesion disassembly and breast tumor cell invasion. One of two established binding partners of BCAR3 is the adaptor molecule, p130(Cas). In this study, we sought to determine whether signaling through the BCAR3-Cas complex was responsible for the cellular functions of BCAR3. We show that the entire pool of BCAR3 is in complex with Cas in invasive breast tumor cells and that these proteins colocalize in dynamic cellular adhesions. Although accumulation of BCAR3 in adhesions did not require Cas binding, a direct interaction between BCAR3 and Cas was necessary for efficient dissociation of BCAR3 from adhesions. The dissociation rates of Cas and two other adhesion molecules, a-actinin and talin, were also significantly slower in the presence of a Cas-binding mutant of BCAR3, suggesting that turnover of the entire adhesion complex was delayed under these conditions. As was the case for adhesion turnover, BCAR3-Cas interactions were found to be important for BCAR3-mediated breast tumor cell chemotaxis toward serum and invasion in Matrigel. Previous work demonstrated that BCAR3 is a potent activator of Rac1, which in turn is an important regulator of adhesion dynamics and invasion. However, in contrast to wild-type BCAR3, ectopic expression of the Cas-binding mutant of BCAR3 failed to induce Rac1 activity in breast cancer cells. Together, these data show that the ability of BCAR3 to promote adhesion disassembly, tumor cell migration and invasion, and Rac1 activity is dependent on its ability to bind to Cas. The activity of BCAR3-Cas complexes as a functional unit in breast cancer is further supported by the co-expression of these molecules in multiple subtypes of human breast tumors.	[Cross, A. M.; Wilson, A. L.; Thomas, K. S.; Bouton, A. H.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Box 800734, Charlottesville, VA 22908 USA; [Guerrero, M. S.] Fujifilm Diosynth Biotechnol USA Inc, Cary, NC USA; [Bachir, A. I.; Horwitz, A. R.] Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; [Kubow, K. E.] James Madison Univ, Dept Biol, Harrisonburg, VA 22807 USA	University of Virginia; Fujifilm Corporation; University of Virginia; James Madison University	Bouton, AH (corresponding author), Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Box 800734, Charlottesville, VA 22908 USA.	ahb8y@virginia.edu		Kubow, Kristopher/0000-0003-0259-882X	NIH [5 T32 CA009109, 1 R01 CA096846, 1 F31 CA165703, 1 F31 CA130168, GM023244]; Department of Defense Breast Cancer Research Program [BC141713]; American Cancer Society [PF-12-136-01-CSM]; Women's Oncology Research Fund; NCI Cancer Center Support Grant from the UVA Cancer Center [P30 CA44579]; NATIONAL CANCER INSTITUTE [T32CA009109, R01CA096846, F31CA130168, F31CA165703, P30CA044579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023244, R01GM023244] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); American Cancer Society(American Cancer Society); Women's Oncology Research Fund; NCI Cancer Center Support Grant from the UVA Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Jessica Zareno for technical assistance with TIRF microscopy and Dr Kristen Atkins for identification and pathological assessment of human breast tumor samples. This work was supported by grants from the NIH (5 T32 CA009109 (ALW, AMC), 1 R01 CA096846 (AHB), 1 F31 CA165703 (ALW), 1 F31 CA130168 (MSG) and GM023244 (ARH)); the Department of Defense Breast Cancer Research Program (BC141713 to AHB); the American Cancer Society (PF-12-136-01-CSM to KEK); and the Women's Oncology Research Fund and NCI Cancer Center Support Grant P30 CA44579 from the UVA Cancer Center. Breast tumor samples were obtained from the UVA tumor bank and stained by the Biorepository and Tissue Research Facility (BTRF).	Akakura S, 2005, J CELL PHYSIOL, V204, P344, DOI 10.1002/jcp.20288; Borre PV, 2011, CELL SIGNAL, V23, P1030, DOI 10.1016/j.cellsig.2011.01.018; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cai DP, 1999, J IMMUNOL, V163, P2104; Harunaga JS, 2011, MATRIX BIOL, V30, P363, DOI 10.1016/j.matbio.2011.06.001; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Mace PD, 2011, NAT STRUCT MOL BIOL, V18, P1381, DOI 10.1038/nsmb.2152; Near RI, 2007, J CELL PHYSIOL, V212, P655, DOI 10.1002/jcp.21059; Near RI, 2009, MOL VIS, V15, P685; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Petrie RJ, 2012, J CELL SCI, V125, P5917, DOI 10.1242/jcs.093732; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Schrecengost RS, 2007, CANCER RES, V67, P6174, DOI 10.1158/0008-5472.CAN-06-3455; Schuh NR, 2010, J BIOL CHEM, V285, P2309, DOI 10.1074/jbc.M109.046631; Sun GB, 2012, MOL CELL BIOL, V32, P3776, DOI 10.1128/MCB.00214-12; Vervoort VS, 2007, GENE, V391, P161, DOI 10.1016/j.gene.2006.12.016; Wallez Y, 2014, J BIOL CHEM, V289, P10431, DOI 10.1074/jbc.M113.541839; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilson AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065678; Yamazaki D, 2009, ONCOGENE, V28, P1570, DOI 10.1038/onc.2009.2	24	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5850	5859		10.1038/onc.2016.123	http://dx.doi.org/10.1038/onc.2016.123			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109104	Green Accepted			2022-12-28	WOS:000387560800004
J	Zhao, L; Guo, H; Zhou, B; Feng, J; Li, Y; Han, T; Liu, L; Li, L; Zhang, S; Liu, Y; Shi, J; Zheng, D				Zhao, L.; Guo, H.; Zhou, B.; Feng, J.; Li, Y.; Han, T.; Liu, L.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.			Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol	ONCOGENE			English	Article							SNORNA U50; EXPRESSION; PROTEIN; GAS5; PROLIFERATION; CARCINOMA; APOPTOSIS; GROWTH; GENES	Recently, intriguing new roles for some small nucleolar RNA host genes (SNHGs) in cancer have emerged. In the present study, a panel of SNHGs was profiled to detect aberrantly expressed SNHGs in gastric cancer (GC). The expression of SNHG5 was significantly downregulated in GC and was significantly associated with the formation of a tumor embolus and with the tumor, node and metastasis stage. SNHG5 was a long non-coding RNA, which was a class of non-coding RNA transcripts longer than 200 nucleotides. SNHG5 suppressed GC cell proliferation and metastasis in vitro and in vivo. Furthermore, SNHG5 exerted its function through interacting with MTA2, preventing the translocation of MTA2 from the cytoplasm into the nucleus. SNHG5 overexpression led to significant increases in the acetylation levels of histone H3 and p53, indicating that SNHG5 might affect acetylation by trapping MTA2 in the cytosol, thereby interfering with the formation of the nucleosome remodeling and histone deacetylation complex. This study is the first to demonstrate that SNHG5 is a critical and powerful regulator that is involved in GC progression through trapping MTA2 in the cytosol. These results imply that SNHG5 may be a novel therapeutic target for the treatment of GC.	[Zhao, L.; Guo, H.; Li, Y.; Han, T.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Zhao, L.; Guo, H.; Li, Y.; Han, T.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.] Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Zhao, L.; Liu, L.] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang, Peoples R China; [Zhou, B.] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China; [Feng, J.] Chinese PLA, Bethune Int Peace Hosp, Dept Gastroenterol, Shijiazhuang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Hebei Medical University; Harbin Medical University	Shi, J; Zheng, D (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Shi, J; Zheng, D (corresponding author), Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	shijuantt@163.com; zhengdx@pumc.edu.cn		Guo, Hui/0000-0003-3901-6336	State Key Basic Research Program of China [2013CB530805]; Natural Science Foundation of China [81372200, 81572755]; PUMC Youth Fund; Fundamental Research Funds for Central Universities [3332013055, 3332014007]	State Key Basic Research Program of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); PUMC Youth Fund; Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities)	This work was partially supported by the State Key Basic Research Program of China (Grant No. 2013CB530805, to J Shi and D Zheng), the Natural Science Foundation of China (Grant No. 81372200, 81572755, to J Shi), the PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (Grant No. 3332013055 and 3332014007, to J Shi).	Askarian-Amiri ME, 2011, RNA, V17, P878, DOI 10.1261/rna.2528811; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chaudhry MA, 2013, INT J MOL SCI, V14, P9099, DOI 10.3390/ijms14059099; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gee HE, 2011, BRIT J CANCER, V104, P1168, DOI 10.1038/sj.bjc.6606076; Hudson WH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6395; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Lee H, 2009, J GASTROEN HEPATOL, V24, P1445, DOI 10.1111/j.1440-1746.2009.05965.x; Li JM, 2014, PROTEIN CELL, V5, P457, DOI 10.1007/s13238-014-0055-y; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mizrahi I, 2015, J CANCER, V6, P105, DOI 10.7150/jca.10568; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200; Scarpino S, 2013, THYROID, V23, P1127, DOI 10.1089/thy.2011.0421; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x; Williams GT, 2006, GENE THER MOL BIOL, V10B, P255; Wu M, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-1; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Zhou CF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-102	29	95	102	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5770	5780		10.1038/onc.2016.110	http://dx.doi.org/10.1038/onc.2016.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065326				2022-12-28	WOS:000386998400008
J	Kanu, N; Zhang, T; Burrell, RA; Chakraborty, A; Cronshaw, J; DaCosta, C; Gronroos, E; Pemberton, HN; Anderton, E; Gonzalez, L; Sabbioneda, S; Ulrich, HD; Swanton, C; Behrens, A				Kanu, N.; Zhang, T.; Burrell, R. A.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Gronroos, E.; Pemberton, H. N.; Anderton, E.; Gonzalez, L.; Sabbioneda, S.; Ulrich, H. D.; Swanton, C.; Behrens, A.			RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress (vol 35, pg 4009, 2016)	ONCOGENE			English	Correction													Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Ulrich, Helle D./0000-0003-0431-2223; Behrens, Axel/0000-0002-1557-1143; Gronroos, Eva/0000-0001-8303-5409	Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish; The Francis Crick Institute [10169] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); The Francis Crick Institute		Kanu N, 2016, ONCOGENE, V35, P4009, DOI 10.1038/onc.2015.427	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4020	4020		10.1038/onc.2015.500	http://dx.doi.org/10.1038/onc.2015.500			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	27345393	Bronze			2022-12-28	WOS:000381013100013
J	Crosas-Molist, E; Bertran, E; Rodriguez-Hernandez, I; Herraiz, C; Cantelli, G; Fabra, A; Sanz-Moreno, V; Fabregat, I				Crosas-Molist, E.; Bertran, E.; Rodriguez-Hernandez, I.; Herraiz, C.; Cantelli, G.; Fabra, A.; Sanz-Moreno, V.; Fabregat, I.			The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination	ONCOGENE			English	Article							TGF-BETA; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; CELL INVASION; MIGRATION; ACTIVATION; EXPRESSION; METASTASIS; PLASTICITY; ADHESION	Epithelial to mesenchymal transition is a common event during tumour dissemination. However, direct epithelial to amoeboid transition has not been characterized to date. Here we provide evidence that cells from hepatocellular carcinoma (HCC), a highly metastatic cancer, undergo epithelial to amoeboid transition in physiological environments, such as organoids or three-dimensional complex matrices. Furthermore, the NADPH oxidase NOX4 inhibits this transition and therefore suppresses efficient amoeboid bleb-based invasion. Moreover, NOX4 expression is associated with E-cadherin levels and inversely correlated with invasive features. NOX4 is necessary to maintain parenchymal structures, increase cell-cell and cell-to-matrix adhesion, and impair actomyosin contractility and amoeboid invasion. Importantly, NOX4 gene deletions are frequent in HCC patients, correlating with higher tumour grade. Contrary to that observed in mesenchymal cell types, here NOX4 suppresses Rho and Cdc42 GTPase expression and downstream actomyosin contractility. In HCC patients, NOX4 expression inversely correlates with RhoC and Cdc42 levels. Moreover, low expression of NOX4 combined with high expression of either RhoC or Cdc42 is associated with worse prognosis. Therefore, loss of NOX4 increases actomyosin levels and favours an epithelial to amoeboid transition contributing to tumour aggressiveness.	[Crosas-Molist, E.; Bertran, E.; Fabra, A.; Fabregat, I.] Bellvitge Biomed Res Inst IDIBELL, Mol Oncol, Gran Via Hosp 199, Barcelona 08908, Spain; [Crosas-Molist, E.; Rodriguez-Hernandez, I.; Herraiz, C.; Cantelli, G.; Sanz-Moreno, V.] Kings Coll London, Tumour Plast Lab, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England; [Fabregat, I.] Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona, Spain; [Herraiz, C.] Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Murcia, Spain; [Herraiz, C.] IMIB Arrixaca, Murcia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of London; King's College London; University of Barcelona; University of Murcia; Hospital Clinico Universitario Virgen de la Arrixaca	Fabregat, I (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Mol Oncol, Gran Via Hosp 199, Barcelona 08908, Spain.; Sanz-Moreno, V (corresponding author), Kings Coll London, Tumour Plast Lab, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	victoria.sanz_moreno@kcl.ac.uk; ifabregat@idibell.cat	Serrano, Cecilia Herraiz/H-2550-2015; Bertran, Esther/GZK-5458-2022; Fabregat, Isabel/H-7038-2015	Serrano, Cecilia Herraiz/0000-0001-6912-0738; Fabregat, Isabel/0000-0003-0136-8440; Sanz-Moreno, Victoria/0000-0002-5096-9456; Bertran Rodriguez, Esther/0000-0001-9356-7409; Cantelli, Gaia/0000-0003-2650-6280; Rodriguez-Hernandez, Irene/0000-0002-6487-452X	MINECO (FEDER funds), Spain [BFU2012-35538, SAF 2015-64149-R, PIE13/00022, ISCIII-RTICC RD12-0036-0029]; MINECO (European Regional Development Fund), Spain [BFU2012-35538, SAF 2015-64149-R, PIE13/00022, ISCIII-RTICC RD12-0036-0029]; AGAUR, Generalitat de Catalunya [2014SGR0334]; CRUK [c33043/A12065]; Royal Society [RG110591]; Fundacion Alfonso Martin Escudero; FEBS fellowship; MRC [C97993H]; European Cooperation in Science and Technology (COST Action) [BM1203/EU-ROS]; Cancer Research UK [24478, 12065] Funding Source: researchfish	MINECO (FEDER funds), Spain; MINECO (European Regional Development Fund), Spain; AGAUR, Generalitat de Catalunya(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); CRUK(Cancer Research UK); Royal Society(Royal Society of London); Fundacion Alfonso Martin Escudero; FEBS fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Cooperation in Science and Technology (COST Action)(European Cooperation in Science and Technology (COST)); Cancer Research UK(Cancer Research UK)	We acknowledge Pahini Pandya for critical reading of the manuscript. Grants to IF from MINECO (co-funded by FEDER funds and the European Regional Development Fund: a way to build Europe), Spain (Grant numbers: BFU2012-35538, SAF 2015-64149-R, PIE13/00022 and ISCIII-RTICC RD12-0036-0029) and the AGAUR, Generalitat de Catalunya (2014SGR0334). Grants to VS-M and EC-M from CRUK (c33043/A12065) and to VS-M from Royal Society (RG110591). EC-M. was founded by the FPU program (MECD, Spain), IR-H was supported by Fundacion Alfonso Martin Escudero, CH by a FEBS fellowship and GC from MRC (C97993H). IF group is also supported by the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS).	Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Aoyama T, 2012, HEPATOLOGY, V56, P2316, DOI 10.1002/hep.25938; Bergert M, 2015, NAT CELL BIOL, V17, P524, DOI 10.1038/ncb3134; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Blaser H, 2006, DEV CELL, V11, P613, DOI 10.1016/j.devcel.2006.09.023; Boudreau HE, 2014, BRIT J CANCER, V110, P2569, DOI 10.1038/bjc.2014.165; Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046; Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Calvo F, 2011, NAT CELL BIOL, V13, P819, DOI 10.1038/ncb2271; Cantelli G, 2015, CURR BIOL, V25, P2899, DOI 10.1016/j.cub.2015.09.054; Carmona-Cuenca I, 2008, J HEPATOL, V49, P965, DOI 10.1016/j.jhep.2008.07.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Crosas-Molist E, 2015, REDOX BIOL, V6, P106, DOI 10.1016/j.redox.2015.07.005; Crosas-Molist E, 2014, FREE RADICAL BIO MED, V69, P338, DOI 10.1016/j.freeradbiomed.2014.01.040; de Rezende FF, 2012, FREE RADICAL BIO MED, V53, P521, DOI 10.1016/j.freeradbiomed.2012.05.032; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Fernandez I, 2015, ARTERIOSCL THROM VAS, V35, P1198, DOI 10.1161/ATVBAHA.114.305185; Fernando J, 2015, INT J CANCER, V136, pE161, DOI 10.1002/ijc.29097; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gadea G, 2008, CURR BIOL, V18, P1456, DOI 10.1016/j.cub.2008.08.053; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gregg JL, 2014, CANCER RES, V74, P3501, DOI 10.1158/0008-5472.CAN-13-2979; Ha SY, 2016, GUT LIVER, V10, P826, DOI 10.5009/gnl15543; Herraiz C, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv289; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Jacobelli J, 2010, NAT IMMUNOL, V11, P953, DOI 10.1038/ni.1936; Kim HJ, 2015, ONCOTARGET, V6, P16287, DOI 10.18632/oncotarget.3843; Lai KKY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002147; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Li J, 2015, ONCOTARGET, V6, P1031, DOI 10.18632/oncotarget.2671; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Lorentzen A, 2011, J CELL SCI, V124, P1256, DOI 10.1242/jcs.074849; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Montenegro MF, 2015, FREE RADICAL BIO MED, V85, P288, DOI 10.1016/j.freeradbiomed.2015.05.011; Murray TVA, 2015, FREE RADICAL BIO MED, V89, P918, DOI 10.1016/j.freeradbiomed.2015.09.015; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Reichl P, 2012, CURR PHARM DESIGN, V18, P4135, DOI 10.2174/138161212802430477; Ruiz-Ontanon P, 2013, STEM CELLS, V31, P1075, DOI 10.1002/stem.1349; Ruprecht V, 2015, CELL, V160, P673, DOI 10.1016/j.cell.2015.01.008; Sadok Amine, 2014, Small GTPases, V5, pe29710, DOI 10.4161/sgtp.29710; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2012, CURR BIOL, V22, pR449, DOI 10.1016/j.cub.2012.04.024; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Serrander L, 2007, BIOCHEM J, V406, P105, DOI 10.1042/BJ20061903; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; Stanley A, 2014, ANTIOXID REDOX SIGN, V20, P2026, DOI 10.1089/ars.2013.5713; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tozluoglu M, 2013, NAT CELL BIOL, V15, P751, DOI 10.1038/ncb2775; Valdivia A, 2015, CURR PHARM DESIGN, V21, P6009, DOI 10.2174/1381612821666151029112624; Yu JH, 2012, HEPATOLOGY, V56, P2375, DOI 10.1002/hep.25900; Zavattari P, 2015, HEPATOLOGY, V62, P851, DOI 10.1002/hep.27790	61	40	42	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3002	3014		10.1038/onc.2016.454	http://dx.doi.org/10.1038/onc.2016.454			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941881	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000402000400008
J	Berthenet, K; Bokhari, A; Lagrange, A; Marcion, G; Boudesco, C; Causse, S; De Thonel, A; Svrcek, M; Goloudina, AR; Dumont, S; Hammann, A; Biard, DS; Demidov, ON; Seigneuric, R; Duval, A; Collura, A; Jego, G; Garrido, C				Berthenet, K.; Bokhari, A'dem; Lagrange, A.; Marcion, G.; Boudesco, C.; Causse, S.; De Thonel, A.; Svrcek, M.; Goloudina, A. R.; Dumont, S.; Hammann, A.; Biard, D. S.; Demidov, O. N.; Seigneuric, R.; Duval, A.; Collura, A.; Jego, G.; Garrido, C.			HSP110 promotes colorectal cancer growth through STAT3 activation	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; EXPRESSION; HSP70; GENE; PROTEINS; SURVIVAL; CELLS; CD1D; RNA	Heat shock protein 110 (HSP110) is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps cells survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently shown that colorectal cancer patients with microsatellite instability (MSI) had an improved response to chemotherapy because they harbor an HSP110-inactivating mutation (HSP110DE9). In this work, we used patient biopsies, human colorectal cancer cells grown in vitro and in vivo (xenografts), and intestinal crypts to demonstrate that HSP110 is also involved in colon cancer growth. We showed that HSP110 induces colon cancer cell proliferation and that this effect is associated with STAT3 activation, specifically an increase in STAT3 phosphorylation, nuclear translocation and transcription factor activity. STAT3 inhibition blocks the proliferative effect of HSP110. From a molecular standpoint, we demonstrated that HSP110 directly binds to STAT3, thereby facilitating its phosphorylation by JAK2. Finally, we showed a correlation between HSP110 expression and STAT3 phosphorylation in colon cancer patient samples. Thus, the expression of HSP110 in colon cancer contributes to STAT3-dependent tumor growth and the frequent inactivating mutation of this chaperone is probably an important event underlying the improved prognosis in colon cancer displaying MSI.	[Berthenet, K.; Marcion, G.; Boudesco, C.; Causse, S.; Goloudina, A. R.; Hammann, A.; Demidov, O. N.; Seigneuric, R.; Jego, G.; Garrido, C.] Univ Bourgogne Franche Comte, INSERM, UMR866, Fac Sci Sante, 7 Blvd Jeanne dArc, F-21079 Dijon, France; [Berthenet, K.; Marcion, G.; Boudesco, C.; Causse, S.; Goloudina, A. R.; Hammann, A.; Demidov, O. N.; Seigneuric, R.; Jego, G.; Garrido, C.] Equipe Labellisee Ligue Natl Canc, INSERM, LNC UMR866, Dijon, France; [Bokhari, A'dem; Lagrange, A.; Svrcek, M.; Duval, A.; Collura, A.] Equipe Labellisee Ligue Natl Canc, INSERM, UMR 938, Dijon, France; [Bokhari, A'dem; Lagrange, A.; Svrcek, M.; Duval, A.; Collura, A.] Univ Pierre & Marie Curie Paris 6, Paris, France; [De Thonel, A.] CNRS, Epigenet & Cell Fate UMR7216, Paris, France; [Dumont, S.] Hop St Antoine, AP HP, Serv Anat Pathol, Paris, France; [Biard, D. S.] Ctr Etude Atom, Paris, France; [Garrido, C.] CGFL, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Jego, G; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, INSERM, UMR866, Fac Sci Sante, 7 Blvd Jeanne dArc, F-21079 Dijon, France.	gaetan.jego@u-bourgogne.fr; cgarrido@u-bourgogne.fr	Goloudina, Anastasia/T-4989-2019; jego, gaetan/N-7226-2018; Causse, Sebastien Zwe/AAZ-7365-2021; Demidov, Oleg/AAC-4462-2021; Demidov, Oleg/U-2050-2017; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018	jego, gaetan/0000-0003-0376-9299; Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; Garrido, carmen/0000-0003-1368-1493; Berthenet, Kevin/0000-0001-7345-4837; Causse, Sebastien/0000-0003-3246-3491; Marcion, Guillaume/0000-0002-3634-6316; BIARD, Denis Serge Francois/0000-0001-9697-4392; de Thonel, Aurelie/0000-0003-0405-0745	Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer (ARC); Conseil Regional de Bourgogne; program 'Investissements d'Avenir' [ANR-11-LABX-0021-01-LipSTIC LabEx]; FEDER; La Ligue Nationale Contre le Cancer; La Foundation pour la Recherche Medicale	Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); program 'Investissements d'Avenir'(French National Research Agency (ANR)); FEDER(European Commission); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); La Foundation pour la Recherche Medicale	This work was supported by grants from the Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer ('Labeled teams' to CG and AD), the Association pour la Recherche sur le Cancer (ARC), the Conseil Regional de Bourgogne, the program 'Investissements d'Avenir' ANR-11-LABX-0021-01-LipSTIC LabEx. We thank the FEDER for their support. KB and SC have a doctoral fellowship from La Ligue Nationale Contre le Cancer and KB from La Foundation pour la Recherche Medicale. We thank Prof. Dr Ibrahim M. Adham, Institut fur Humangenetik, University of Gottingen for kindly providing the HSP110 KO mice and P Bastable (CHU, Dijon) for the English correction of the manuscript.	Berthenet K, ONCOIMMUNOL IN PRESS; Biard DSF, 2005, MOL CANCER RES, V3, P519, DOI 10.1158/1541-7786.MCR-05-0044; Boissiere-Michot F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29256; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Colgan SP, 2003, J CLIN INVEST, V112, P745, DOI 10.1172/JC1200317241; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Duval A, 2011, ONCOTARGET, V2, P826, DOI 10.18632/oncotarget.353; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Jego G, 2014, LEUKEMIA, V28, P1676, DOI 10.1038/leu.2014.63; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Lanneau D, 2008, J CELL MOL MED, V12, P743, DOI 10.1111/j.1582-4934.2008.00273.x; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Olszak T, 2014, NATURE, V509, P497, DOI 10.1038/nature13150; Prinsloo E, 2012, IUBMB LIFE, V64, P266, DOI 10.1002/iub.607; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Sato N, 2003, BIOCHEM BIOPH RES CO, V300, P847, DOI 10.1016/S0006-291X(02)02941-8; Shaner L, 2007, CELL STRESS CHAPERON, V12, P1, DOI 10.1379/CSC-245R.1; Slaby O, 2009, ONCOL REP, V21, P1235, DOI 10.3892/or_00000346; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Yamagishi N, 2009, FEBS J, V276, P5870, DOI 10.1111/j.1742-4658.2009.07311.x; Yu N, 2015, MOL CELL BIOL, V35, P1390, DOI 10.1128/MCB.01307-14; Zappasodi R, 2015, BLOOD, V125, P1768, DOI 10.1182/blood-2014-07-590034; Zappasodi R, 2011, BLOOD, V118, P4421, DOI 10.1182/blood-2011-06-364570	25	44	45	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2328	2336		10.1038/onc.2016.403	http://dx.doi.org/10.1038/onc.2016.403			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819670				2022-12-28	WOS:000399782700013
J	Demir, O; Ieong, PU; Amaro, RE				Demir, Oe; Ieong, P. U.; Amaro, R. E.			Full-length p53 tetramer bound to DNA and its quaternary dynamics	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; MOLECULAR-DYNAMICS; MUTANT P53; BINDING DOMAIN; ELECTRON-MICROSCOPY; PROTEIN; REACTIVATION; RESTORATION; ELEMENTS	P53 is a major tumor suppressor that is mutated and inactivated in similar to 50% of all human cancers. Thus, reactivation of mutant p53 using small molecules has been a long sought-after anticancer therapeutic strategy. Full structural characterization of the full-length oligomeric p53 is challenging because of its complex architecture and multiple highly flexible regions. To explore p53 structural dynamics, here we developed a series of atomistic integrative models with available crystal structures of the full-length p53 (fl-p53) tetramer bound to three different DNA sequences: a p21 response element, a puma response element and a nonspecific DNA sequence. Explicitly solvated, all-atom molecular dynamics simulations of the three complexes (totaling nearly 1 mu s of aggregate simulation time) yield final structures consistent with electron microscopy maps and, for the first time, show the direct interactions of the p53 C-terminal with DNA. Through a collective principal component analysis, we identify sequence-dependent differential quaternary binding modes of the p53 tetramer interfacing with DNA. Additionally, L1 loop dynamics of fl-p53 in the presence of DNA is revealed, and druggable pockets of p53 are identified via solvent mapping to aid future drug discovery studies.	[Demir, Oe; Ieong, P. U.; Amaro, R. E.] Univ Calif San Diego, Dept Chem & Biochem, 3234 Urey Hall,9500 Gilman Dr,MC 0332, La Jolla, CA 92103 USA; [Ieong, P. U.; Amaro, R. E.] Univ Calif San Diego, Natl Biomed Computat Resource, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Amaro, RE (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 3234 Urey Hall,9500 Gilman Dr,MC 0332, La Jolla, CA 92103 USA.	ramaro@ucsd.edu		Demir, Ozlem/0000-0002-3317-4731	University of California Cancer Research Coordinating Committee award and NIH Innovator award [DP2-007237]; National Biomedical Computation Resource [NIH P41, GM103426]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103426] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD007237] Funding Source: NIH RePORTER	University of California Cancer Research Coordinating Committee award and NIH Innovator award; National Biomedical Computation Resource; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Mikel Valle for kindly providing the three-dimensional cryo-EM maps in 2011 Melero et al. article, and Steffen Lindert, Rob Swift, Clarisse Ricci, Lane Votapka, Jacob Durrant and Elizabeth Villa for helpful discussions. This work was supported by the University of California Cancer Research Coordinating Committee award and NIH Innovator award DP2-007237. Computing time on Stampede and Comet supercomputers was provided through the NSF XSEDE supercomputer resources grant RAC CHE060073N (to REA). Additional support from the National Biomedical Computation Resource NIH P41 GM103426 is acknowledged.	Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Altintas I, 2004, 16TH INTERNATIONAL CONFERENCE ON SCIENTIFIC AND STATISTICAL DATABASE MANAGEMENT, PROCEEDINGS, P423; [Anonymous], 2015, MAESTR VERS 10 4; Arlt C, 2015, PROTEOMICS, V15, P2746, DOI 10.1002/pmic.201400549; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Case D., 2015, AMBER, V14; D'Abramo M, 2016, ONCOGENE, V35, P3272, DOI 10.1038/onc.2015.388; Darden T, 1999, STRUCT FOLD DES, V7, pR55, DOI 10.1016/S0969-2126(99)80033-1; Durrant JD, 2014, J CHEM THEORY COMPUT, V10, P5047, DOI 10.1021/ct500381c; Emamzadah S, 2014, J MOL BIOL, V426, P936, DOI 10.1016/j.jmb.2013.12.020; Emamzadah S, 2011, MOL CANCER RES, V9, P1493, DOI 10.1158/1541-7786.MCR-11-0351; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Janert P.K., 2010, GNUPLOT ACTION UNDER; Joerger AC, 2015, STRUCTURE, V23, P2246, DOI 10.1016/j.str.2015.10.016; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Lavery R, 2009, NUCLEIC ACIDS RES, V37, P5917, DOI 10.1093/nar/gkp608; Leith JS, 2012, P NATL ACAD SCI USA, V109, P16552, DOI 10.1073/pnas.1120452109; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lim KW, 2009, J AM CHEM SOC, V131, P4301, DOI 10.1021/ja807503g; Liu XR, 2013, NUCLEIC ACIDS RES, V41, P6034, DOI 10.1093/nar/gkt305; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Lukman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080221; Ma BY, 2007, NUCLEIC ACIDS RES, V35, P2986, DOI 10.1093/nar/gkm192; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Melero R, 2011, P NATL ACAD SCI USA, V108, P557, DOI [10.1073/pnas.1015520107, 10.1073/pnas.101S520107]; Molecular Operating Environment (MOE), 2016, H3A 2R7; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Natan E, 2011, J MOL BIOL, V409, P358, DOI 10.1016/j.jmb.2011.03.047; Ngan CH, 2012, NUCLEIC ACIDS RES, V40, pW271, DOI 10.1093/nar/gks441; Pang YP, 1999, J MOL MODEL, V5, P196, DOI 10.1007/s008940050119; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Petty TJ, 2011, EMBO J, V30, P2167, DOI 10.1038/emboj.2011.127; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; R-Core-Team, 2015, LANG ENV STAT COMP; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Tafvizi A, 2011, P NATL ACAD SCI USA, V108, P563, DOI 10.1073/pnas.1016020107; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Trabuco LG, 2008, STRUCTURE, V16, P673, DOI 10.1016/j.str.2008.03.005; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Votapka LW, 2013, COMMUN COMPUT PHYS, V13, P256, DOI 10.4208/cicp.170711.111111s; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wiman KG, 2007, ADV CANCER RES, V97, P321, DOI 10.1016/S0065-230X(06)97014-6; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042	63	21	23	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1451	1460		10.1038/onc.2016.321	http://dx.doi.org/10.1038/onc.2016.321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641333	Green Accepted			2022-12-28	WOS:000395862500013
J	Jiang, YX; Yang, SW; Li, PA; Luo, X; Li, ZY; Hao, YX; Yu, PW				Jiang, Y-X; Yang, S-W; Li, P-A; Luo, X.; Li, Z-Y; Hao, Y-X; Yu, P-W			The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; T-CELLS; ASSOCIATION; EXPRESSION; STAT3; CD26; HETEROGENEITY; INFLAMMATION; PREVENTION	Postoperative recurrence and metastasis have crucial roles in the poor prognosis of gastric cancer patients. Previous studies have indicated that gastric cancer originates from cancer stem cells (CSCs), and some investigators have found that a particular subset of CSCs possesses higher metastatic capacity. However, the specific mechanism remains uncertain. In the present study, we aimed to explore the biological functions of the inflammatory cytokine interleukin-17 (IL-17) in gastric cancer metastasis and the distinct IL-17-induced transformation of quiescent gastric CSCs. Our results showed that invasive gastric CSCs were CD26+ and CXCR4+ and were closely associated with increased metastatic ability. The quiescent gastric CSCs, which were CD26- and CXCR4-, were exposed to appropriate concentrations of IL-17; this resulted in the decreased expression of E-cadherin and the increased expression of vimentin and N-cadherin. In addition, the upregulation of IL-17 both in vitro and in vivo resulted in a significant induction of invasion, migration and tumor formation ability in gastric CSCs compared with the control group, which was not treated with IL-17. Further experiments indicated that the activation of the downstream phosphorylated signal transducer and activator of transcription 3 (STAT3) transcription factor pathway was facilitated by IL-17. On the contrary, the downregulation of STAT3 by the specific inhibitor Stattic significantly reversed the IL-17-induced epithelial-mesenchymal transition (EMT)-associated properties of quiescent gastric CSCs. Moreover, tumorigenesis and metastasis were suppressed. Taken together, we suggest that IL-17 is positively correlated with the transformation of quiescent gastric CSCs into invasive gastric CSCs and that targeting IL-17 may emerge as a possible novel therapeutic strategy for gastric cancer.	[Jiang, Y-X; Yang, S-W; Li, P-A; Luo, X.; Li, Z-Y; Hao, Y-X; Yu, P-W] Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Dept Gen Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China	Army Medical University	Hao, YX; Yu, PW (corresponding author), Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Dept Gen Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	haoyingxue@hotmail.com; yupeiwu01@sina.com			National Natural Science Foundation of China [81372559]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by grants from the National Natural Science Foundation of China (81372559).	Bleau AM, 2014, HISTOL HISTOPATHOL, V29, P1499, DOI 10.14670/HH-29.1499; Botelho FM, 2013, J IMMUNOL, V191, P1453, DOI 10.4049/jimmunol.1203318; Das UN, 2011, CANCER METAST REV, V30, P311, DOI 10.1007/s10555-011-9316-x; Davies S, 2015, BIOMED PHARMACOTHER, V71, P135, DOI 10.1016/j.biopha.2015.02.031; Fagoonee S, 2014, PANMINERVA MED, V56, P289; Guo D, 2012, ONCOL REP, V28, P241, DOI 10.3892/or.2012.1781; Guo HQ, 2003, WORLD J GASTROENTERO, V9, P432, DOI 10.3748/wjg.v9.i3.432; Hamada S, 2016, DIGEST DIS SCI, V61, P1561, DOI 10.1007/s10620-015-4001-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Herrero R, 2014, JAMA-J AM MED ASSOC, V312, P1197, DOI 10.1001/jama.2014.10498; Huang XC, 2015, ONCOTARGETS THER, V8, P2989, DOI 10.2147/OTT.S91511; Iacopino F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105166; Jinushi M, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28862; Jung A, 2007, ERNST SCHERING FOUND, V5, P109, DOI 10.1007/2789_2007_047; Lam CSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098582; Liao WT, 2014, AM J STEM CELLS, V3, P46; Lin L, 2012, INT J CANCER, V130, P1459, DOI 10.1002/ijc.26152; Liu S, 2016, ONCOTARGET, V7, P13651, DOI 10.18632/oncotarget.7296; Liu XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106834; Long ZW, 2015, WORLD J GASTROENTERO, V21, P5707, DOI 10.3748/wjg.v21.i18.5707; Lu Z, 2013, J RES MED SCI, V18, P647; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mannello F, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-169; Oliveras-Ferraros C, 2014, CELL CYCLE, V13, P1132, DOI 10.4161/cc.27982; Paganessi LA, 2011, EXP HEMATOL, V39, P384, DOI 10.1016/j.exphem.2010.12.003; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Prabhash K, 2010, ANN ONCOL, V21, P582, DOI 10.1093/annonc/mdp342; Qiao B, 2012, BIOL CELL, V104, P476, DOI 10.1111/boc.201100077; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wu X, 2015, TUMOR BIOL, V37, P5493; Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003; Zhang X, 2016, ONCOTARGET, V7, P9851; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhu YT, 2014, STEM CELL RES, V13, P111, DOI 10.1016/j.scr.2014.04.006; Zhuang Y, 2012, GASTROENTEROLOGY, V143, P951, DOI 10.1053/j.gastro.2012.06.010	40	69	73	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1256	1264		10.1038/onc.2016.291	http://dx.doi.org/10.1038/onc.2016.291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524415	Green Published, hybrid			2022-12-28	WOS:000395861300009
J	Kesarwani, AK; Ramirez, O; Gupta, AK; Yang, X; Murthy, T; Minella, AC; Pillai, MM				Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Murthy, T.; Minella, A. C.; Pillai, M. M.			Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3 ' splice sites within RNA secondary structures	ONCOGENE			English	Article							EXPRESSION ANALYSIS; MUTATIONS; SELECTION; GENES; MYELODYSPLASIA; MITOFERRIN; UPSTREAM; BINDING; STEP	Recurrent mutations in core splicing factors have been reported in several clonal disorders, including cancers. Mutations in SF3B1, a component of the U2 splicing complex, are the most common. SF3B1 mutations are associated with aberrant pre-mRNA splicing using cryptic 3' splice sites (3' SSs), but the mechanism of their selection is not clear. To understand how cryptic 3' SSs are selected, we performed comprehensive analysis of transcriptome-wide changes to splicing and gene expression associated with SF3B1 mutations in patient samples as well as an experimental model of inducible expression. Hundreds of cryptic 3' SS were detectable across the genome in cells expressing mutant SF3B1. These 3' SS are typically sequestered within RNA secondary structures and poorly accessible compared with their corresponding canonical 3' SS. We hypothesized that these cryptic 3' SS are inaccessible during normal splicing catalysis and that this constraint is overcome in spliceosomes containing mutant SF3B1. This model of secondary structure-dependent selection of cryptic 3' SS was found across multiple clonal processes associated with SF3B1 mutations (myelodysplastic syndrome and chronic lymphocytic leukemia). We validated our model predictions in mini-gene splicing assays. Additionally, we found deregulated expression of proteins with relevant functions in splicing factor-related diseases both in association with aberrant splicing and without corresponding splicing changes. Our results show that SF3B1 mutations are associated with a distinct splicing program shared across multiple clonal processes and define a biochemical mechanism for altered 3' SS choice.	[Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Pillai, M. M.] Yale Canc Ctr, Sect Hematol, 300 George St, New Haven, CT 06511 USA; [Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Pillai, M. M.] Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA; [Murthy, T.] Northwestern Univ, Feinberg Sch Med, Driskill Grad Program, Chicago, IL USA; [Minella, A. C.] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI USA	Yale University; Yale University; Northwestern University; Feinberg School of Medicine; Versiti Blood Center of Wisconsin	Pillai, MM (corresponding author), Yale Canc Ctr, Sect Hematol, 300 George St, New Haven, CT 06511 USA.; Pillai, MM (corresponding author), Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA.	Manoj.Pillai@Yale.edu	Gupta, Anjali/HCH-5986-2022	Minella, Alex/0000-0001-6693-3362	National Institutes of Health [R01 HL104070, R01 HL098608]; NATIONAL CANCER INSTITUTE [P30CA016359] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104070, R01HL098608] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Work was funded in part by the National Institutes of Health (R01 HL104070 to MMP and R01 HL098608 to ACM). We thank Barry Paw (Boston Children's Hospital, Boston, MA, USA) for anti-Mitoferrin antibody, Thomas A Cooper (Baylor College of Medicine, Houston, TX, USA) for the RG6 plasmid and Karla Neugebauer (Yale University) for helpful suggestions. We also thank The Yale Center for Genome Analysis (YCGA) for high-throughput sequencing and the Yale University Biomedical High Performance Computing Center for use of compute clusters to run bioinformatics analysis.	Adiconis X, 2013, NAT METHODS, V10, P623, DOI 10.1038/nmeth.2483; Alsafadi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10615; Balakrishnan I, 2014, STEM CELLS, V32, P662, DOI 10.1002/stem.1531; Bejar R, 2014, BLOOD, V124, P2793, DOI 10.1182/blood-2014-04-522136; Bevilacqua PC, 2008, ANNU REV PHYS CHEM, V59, P79, DOI 10.1146/annurev.physchem.59.032607.093743; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Cameron JM, 2011, AM J HUM GENET, V89, P486, DOI 10.1016/j.ajhg.2011.08.011; Chua K, 2001, MOL CELL BIOL, V21, P1509, DOI 10.1128/MCB.21.5.1509-1514.2001; Cordin O, 2013, RNA BIOL, V10, P83, DOI 10.4161/rna.22547; Corvelo A, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001016; Darman RB, 2015, CELL REP, V13, P1033, DOI 10.1016/j.celrep.2015.09.053; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dolatshad H, 2015, LEUKEMIA, V29, P1092, DOI [10.1038/leu.2014.331, 10.1038/leu.2015.178]; Floor SN, 2016, ELIFE, V5, DOI 10.7554/eLife.10921; Gerstein MB, 2014, NATURE, V512, P445, DOI 10.1038/nature13424; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Horowitz DS, 2012, WIRES RNA, V3, P331, DOI 10.1002/wrna.112; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195; Kfir N, 2015, CELL REP, V11, P618, DOI 10.1016/j.celrep.2015.03.048; Kim E, 2015, CANCER CELL, V27, P617, DOI 10.1016/j.ccell.2015.04.006; Kontos CK, 2012, GENE, V505, P153, DOI 10.1016/j.gene.2012.04.084; Lai Y, 2006, HUM GENE THER, V17, P1036, DOI 10.1089/hum.2006.17.1036; Mahen EM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000307; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Mercer TR, 2015, GENOME RES, V25, P290, DOI 10.1101/gr.182899.114; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Meyer M, 2011, MOL CELL, V43, P1033, DOI 10.1016/j.molcel.2011.07.030; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Mupo A, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.140.140; Obeng EA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.828.828; Okeyo-Owuor T, 2015, LEUKEMIA, V29, P909, DOI 10.1038/leu.2014.303; Orengo JP, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl967; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Paradkar PN, 2009, MOL CELL BIOL, V29, P1007, DOI 10.1128/MCB.01685-08; Plass M, 2014, METHODS MOL BIOL, V1126, P341, DOI 10.1007/978-1-62703-980-2_25; Plass M, 2012, RNA, V18, P1103, DOI 10.1261/rna.030767.111; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Polprasert C, 2015, CANCER CELL, V27, P658, DOI 10.1016/j.ccell.2015.03.017; Popp MWL, 2014, MOL CELLS, V37, P1, DOI 10.14348/molcells.2014.2193; Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832; Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Visconte V, 2012, BLOOD, V120, P3173, DOI 10.1182/blood-2012-05-430876; Vorechovsky I, 2006, NUCLEIC ACIDS RES, V34, P4630, DOI 10.1093/nar/gkl535; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Warf MB, 2010, TRENDS BIOCHEM SCI, V35, P169, DOI 10.1016/j.tibs.2009.10.004; Yoshida K, 2014, WIRES RNA, V5, P445, DOI 10.1002/wrna.1222; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	58	44	45	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1123	1133		10.1038/onc.2016.279	http://dx.doi.org/10.1038/onc.2016.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524419	Green Accepted			2022-12-28	WOS:000395371500010
J	Xu, Y; Qin, L; Sun, T; Wu, H; He, T; Yang, Z; Mo, Q; Liao, L; Xu, J				Xu, Y.; Qin, L.; Sun, T.; Wu, H.; He, T.; Yang, Z.; Mo, Q.; Liao, L.; Xu, J.			Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; TUMOR-METASTASIS; LUMINAL SUBTYPE; ER-ALPHA; GENE; CELLS; TARGET; MICE; MORPHOGENESIS	The heterogeneous breast cancers can be classified into different subtypes according to their histopathological characteristics and molecular signatures. Foxa1 expression is linked with luminal breast cancer (LBC) with good prognosis, whereas Twist1 expression is associated with basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial-to-mesenchymal transition (EMT), invasiveness and metastasis. However, the regulatory and functional relationships between Twist1 and Foxa1 in breast cancer progression are unknown. In this study, we demonstrate that in the estrogen receptor (ERa)-positive LBC cells Twist1 silences Foxa1 expression, which has an essential role in relieving Foxa1-arrested migration, invasion and metastasis of breast cancer cells. Mechanistically, Twist1 binds to Foxa1 proximal promoter and recruits the NuRD transcriptional repressor complex to de-acetylate H3K9 and repress RNA polymerase II recruitment. Twist1 also silences Foxa1 promoter by inhibiting AP-1 recruitment. Twist1 expression in MCF7 cells silenced Foxa1 expression, which was concurrent with the induction of EMT, migration, invasion and metastasis of these cells. Importantly, restored Foxa1 expression in these cells largely inhibited Twist1-promoted migration, invasion and metastasis. Restored Foxa1 expression did not change the Twist1-induced mesenchymal cellular morphology and the expression of Twist1-regulated E-cadherin, beta-catenin, vimentin and Slug, but it partially rescued Twist1-silenced ERa and cytokeratin 8 expression and reduced Twist1-induced integrin alpha 5, integrin beta 1 and MMP9 expression. In a xenografted mouse model, restored Foxa1 also increased Twist1-repressed LBC markers and decreased Twist1-induced BLBC markers. Furthermore, Twist1 expression is negatively correlated with Foxa1 in the human breast tumors. The tumors with high Twist1 and low Foxa1 expressions are associated with poor distant metastasis-free survival. These results demonstrate that Twist1's silencing effect on Foxa1 expression is largely responsible for Twist1-induced migration, invasion and metastasis, but less responsible for Twist1-induced mesenchymal morphogenesis and expression of certain EMT markers.	[Xu, Y.; Qin, L.; Sun, T.; Wu, H.; Liao, L.; Xu, J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA; [Xu, Y.; He, T.; Yang, Z.; Xu, J.] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [He, T.; Yang, Z.; Xu, J.] Southwest Med Univ, Inst Canc Med, Luzhou, Peoples R China; [Mo, Q.] Southwest Med Univ, Coll Basic Med Sci, Luzhou, Peoples R China; Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med Hematol Oncol, Houston, TX USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Southwest Medical University; Southwest Medical University; Baylor College of Medicine	Xu, J (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA.	jxu@bcm.edu	xu, yixiang/J-4297-2017	xu, yixiang/0000-0001-5793-7783; Qin, Li/0000-0003-0099-4992	National Institutes of Health (NIH) at Baylor College of Medicine [P30CA125123]; NIH [CA112403, CA193455]; Cancer Prevention and Research Institute of Texas [RP120732-P5, RP150197]; National Natural Science Foundation of China [81572619]; Sichuan Education Department research [15TD0020]; NATIONAL CANCER INSTITUTE [R01CA193455, P30CA125123, R01CA112403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER	National Institutes of Health (NIH) at Baylor College of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Education Department research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Yuqing Xiong for assisting with manuscript preparation and the Genetically Engineered Mouse Core (GEMC) partially supported by the National Institutes of Health (NIH) grant P30CA125123 at Baylor College of Medicine for assisting with mouse models. This study is supported by NIH grants CA112403 and CA193455 and Cancer Prevention and Research Institute of Texas grants RP120732-P5 and RP150197. This study is also partially supported by National Natural Science Foundation of China grants 81572619 and Sichuan Education Department research grant 15TD0020.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; Banerjee S, 2006, J CLIN PATHOL, V59, P729, DOI 10.1136/jcp.2005.033043; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chen HF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5697; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fu JJ, 2012, INT J BIOL SCI, V8, P522, DOI 10.7150/ijbs.4164; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gupta SK, 2013, ONCOGENE, V32, P141, DOI 10.1038/onc.2012.41; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hsu RYC, 2011, CANCER RES, V71, P1989, DOI 10.1158/0008-5472.CAN-10-2833; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lee DK, 2014, INT J BIOL SCI, V10, P1007, DOI 10.7150/ijbs.9997; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCune K, 2010, ONCOL REP, V24, P1233, DOI 10.3892/or_00000977; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Naderi A, 2012, NEOPLASIA, V14, P283, DOI 10.1593/neo.12294; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585-012-9561-6; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Tien JCY, 2014, INT J BIOL SCI, V10, P1116, DOI 10.7150/ijbs.10236; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xu Y, 2013, AM J PATHOL, V183, P1281, DOI 10.1016/j.ajpath.2013.06.021; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	55	95	100	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1157	1166		10.1038/onc.2016.286	http://dx.doi.org/10.1038/onc.2016.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524420	Green Accepted			2022-12-28	WOS:000395371500013
J	Berens, EB; Sharif, GM; Schmidt, MO; Yan, G; Shuptrine, CW; Weiner, LM; Glasgow, E; Riegel, AT; Wellstein, A				Berens, E. B.; Sharif, G. M.; Schmidt, M. O.; Yan, G.; Shuptrine, C. W.; Weiner, L. M.; Glasgow, E.; Riegel, A. T.; Wellstein, A.			Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion	ONCOGENE			English	Article							INTERMEDIATE-FILAMENTS; EXPRESSION; MICROENVIRONMENT; DISSEMINATION; PROGRESSION; METASTASIS; MOTILITY; ADHESION	Cancer cell vascular invasion is a crucial step in the malignant progression toward metastasis. Here we used a genome-wide RNA interference screen with E0771 mammary cancer cells to uncover drivers of endothelial monolayer invasion. We identified keratin-associated protein 5-5 (Krtap5-5) as a candidate. Krtap5-5 belongs to a large protein family that is implicated in crosslinking keratin intermediate filaments during hair formation, yet these Krtaps have no reported role in cancer. Depletion of Krtap5-5 from cancer cells led to cell blebbing and a loss of keratins 14 and 18, in addition to the upregulation of vimentin intermediate filaments. This intermediate filament subtype switching induced dysregulation of the actin cytoskeleton and reduced the expression of hemidesmosomal a6/beta 4-integrins. We further demonstrate that knockdown of keratin 18 phenocopies the loss of Krtap5-5, suggesting that Krtap5-5 crosstalks with keratin 18 in E0771 cells. Disruption of the keratin cytoskeleton by perturbing Krtap5-5 function broadly altered the expression of cytoskeleton regulators and the localization of cell surface markers. Krtap5-5 depletion did not impact cell viability but reduced cell motility and extracellular matrix invasion, as well as extravasation of cancer cells into tissues in zebrafish and mice. We conclude that Krtap5-5 is a previously unknown regulator of cytoskeletal function in cancer cells that modulates motility and vascular invasion. Thus, in addition to its physiologic function, a Krtap can serve as a switch toward malignant progression.	[Berens, E. B.; Sharif, G. M.; Schmidt, M. O.; Yan, G.; Shuptrine, C. W.; Weiner, L. M.; Glasgow, E.; Riegel, A. T.; Wellstein, A.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20007 USA.	wellstea@georgetown.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766; Sharif, Ghada/0000-0001-5344-3575; Glasgow, Eric/0000-0001-7729-3954	NIH/NCI [CA71508, CA51008, CA177466, CA113477]; NATIONAL CANCER INSTITUTE [R01CA050633, P30CA051008, R01CA071508, R01CA113477, R33CA177466, T32CA009686] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peter Johnson of the Georgetown University Microscopy Core for assistance with immunofluorescence, Dr Karen Creswell and Alex Joseph of the Georgetown University Flow Cytometry Core for running our FACS samples, and Idalia Cruz for assistance with the tail vein injections. We extend our gratitude to Dr Rudolf Leube and Dr Nicole Schwarz for generously providing the KRT18 expression vector used in this study, as well as to Dr Anne Cress for the HYD1 hemidesmosomal integrin blocker. Finally, we thank Dr Ian Gallicano for critical evaluation of the manuscript and for providing constructive feedback. This study was supported by NIH/NCI grants CA71508, CA51008, CA177466 (AW) and CA113477 (ATR).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Berens EB, 2015, JOVE-J VIS EXP, DOI 10.3791/53409; Bornschlogl T, 2016, P NATL ACAD SCI USA, V113, P5940, DOI 10.1073/pnas.1520302113; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Cobb JP, 1996, BRIT J ANAESTH, V77, P3, DOI 10.1093/bja/77.1.3; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Cummings MC, 2014, J PATHOL, V232, P23, DOI 10.1002/path.4288; de Pereda JM, 2009, CELL ADHES MIGR, V3, P361, DOI 10.4161/cam.3.4.9525; Deb-Choudhury S, 2015, PROTEINS, V83, P224, DOI 10.1002/prot.24727; DeRoock IB, 2001, CANCER RES, V61, P3308; Dong Y, 2013, NAT BIOTECHNOL, V31, P135, DOI 10.1038/nbt.2478; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fujikawa H, 2013, J INVEST DERMATOL, V133, P2780, DOI 10.1038/jid.2013.233; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Khan I, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-779; Kolsch A, 2010, J CELL SCI, V123, P2266, DOI 10.1242/jcs.068080; Lefkowitz GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027603; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Moller B., 2016, J OPEN RES STW, V4, P6, DOI [10.5334/jors.103, DOI 10.5334/JORS.103]; Ramms L, 2013, P NATL ACAD SCI USA, V110, P18513, DOI 10.1073/pnas.1313491110; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Rogers MA, 2006, INT REV CYTOL, V251, P209, DOI 10.1016/S0074-7696(06)51006-X; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Seltmann K, 2015, J INVEST DERMATOL, V135, P1609, DOI 10.1038/jid.2015.46; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Sharif GM, 2015, ONCOGENE, V34, P5879, DOI 10.1038/onc.2015.44; Shimomura Y, 2015, J INVEST DERMATOL, V10, P230; Sroka TC, 2006, CARCINOGENESIS, V27, P1748, DOI 10.1093/carcin/bgl005; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; Wu DD, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-241; Yahagi S, 2004, BIOCHEM BIOPH RES CO, V318, P655, DOI 10.1016/j.bbrc.2004.04.074; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	45	17	17	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					593	605		10.1038/onc.2016.234	http://dx.doi.org/10.1038/onc.2016.234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375028	Green Accepted			2022-12-28	WOS:000394167700002
J	Di Virgilio, F; Adinolfi, E				Di Virgilio, F.; Adinolfi, E.			Extracellular purines, purinergic receptors and tumor growth	ONCOGENE			English	Review							A(3) ADENOSINE RECEPTORS; P2X7 RECEPTOR; P2X(7) RECEPTOR; CARCINOMA-CELLS; HEPATOCELLULAR-CARCINOMA; NEUROBLASTOMA-CELLS; P2Y2 RECEPTOR; P-2X RECEPTOR; PORE DILATION; ATP RELEASE	Virtually, all tumor cells as well as all immune cells express plasma membrane receptors for extracellular nucleosides (adenosine) and nucleotides (ATP, ADP, UTP, UDP and sugar UDP). The tumor microenvironment is characterized by an unusually high concentration of ATP and adenosine. Adenosine is a major determinant of the immunosuppressive tumor milieu. Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium. Extracellular ATP and adenosine mold both host and tumor responses. Depending on the specific receptor activated, extracellular purines mediate immunosuppression or immunostimulation on the host side, and growth stimulation or cytotoxicity on the tumor side. Recent progress in this field is providing the key to decode this complex scenario and to lay the basis to harness the potential benefits for therapy. Preclinical data show that targeting the adenosine-generating pathway (that is, CD73) or adenosinergic receptors (that is, A2A) relieves immunosuppresion and potently inhibits tumor growth. On the other hand, growth of experimental tumors is strongly inhibited by targeting the P2X7 ATP-selective receptor of cancer and immune cells. This review summarizes the recent data on the role played by extracellular purines (purinergic signaling) in host-tumor interaction and highlights novel therapeutic options stemming from recent advances in this field.	[Di Virgilio, F.; Adinolfi, E.] Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Borsari 46, I-44121 Ferrara, Italy	University of Ferrara	Di Virgilio, F (corresponding author), Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Borsari 46, I-44121 Ferrara, Italy.	fdv@unife.it	Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019; Adinolfi, Elena/F-9169-2010	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929	AIRC [IG 13025, IG16812]; Telethon [GGP 11014]; ERA-NET Neuron 'Nanostroke'; EU COST Program [BM1406]; Ministry of Health of Italy [RF-2011-02348435]; Italian Ministry of Education, University and Research [RBAP11FXBC_001]; University of Ferrara; 7th Framework Program [HEALTH-F2-2007-202231]; Region Emilia Romagna (Bando Alessandro Liberati)	AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); ERA-NET Neuron 'Nanostroke'; EU COST Program; Ministry of Health of Italy(Ministry of Health, Italy); Italian Ministry of Education, University and Research; University of Ferrara; 7th Framework Program(European Commission); Region Emilia Romagna (Bando Alessandro Liberati)	FDV is supported by grants from AIRC (no. IG 13025), Telethon (no. GGP 11014), ERA-NET Neuron 'Nanostroke', EU COST Program no. BM1406, the Ministry of Health of Italy (no. RF-2011-02348435), the Italian Ministry of Education, University and Research (no. RBAP11FXBC_001) and funds from the University of Ferrara. FDV was also supported by the 7th Framework Program HEALTH-F2-2007-202231 'ATPBone'. EA is supported by AIRC (IG16812), a Young investigator grant of the Region Emilia Romagna (Bando Alessandro Liberati) and Institutional funds from the University of Ferrara.	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Aliagas E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/509027; Allard B, 2013, CLIN CANCER RES, V19, P5626, DOI 10.1158/1078-0432.CCR-13-0545; Allsopp RC, 2015, J BIOL CHEM, V290, P14556, DOI 10.1074/jbc.M115.642033; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Barbera-Cremades M, 2012, FASEB J, V26, P2951, DOI 10.1096/fj.12-205765; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Bastid J, 2013, ONCOGENE, V32, P1743, DOI 10.1038/onc.2012.269; Beigi R., 1999, AM J PHYSIOL, V276, P267; Bergamin LS, 2015, J CELL BIOCHEM, V116, P721, DOI 10.1002/jcb.25018; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; Bianco F, 2006, J NEUROCHEM, V99, P745, DOI 10.1111/j.1471-4159.2006.04101.x; Blay J, 1997, CANCER RES, V57, P2602; Borea PA, 2015, PHARMACOL REV, V67, P74, DOI 10.1124/pr.113.008540; Bours Martijn Jan Leo, 2011, Front Biosci (Schol Ed), V3, P1443; Bowser JL, 2016, J CLIN INVEST, V126, P220, DOI 10.1172/JCI79380; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Burnstock G, 2014, EXP PHYSIOL, V99, P16, DOI 10.1113/expphysiol.2013.071951; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Cappellari AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047468; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cekic C, 2014, CANCER RES, V74, P7250, DOI 10.1158/0008-5472.CAN-13-3583; Cekic C, 2012, J IMMUNOL, V188, P198, DOI 10.4049/jimmunol.1101845; Chadet S, 2014, CARCINOGENESIS, V35, P1238, DOI 10.1093/carcin/bgt493; Chong JH, 2010, BIOCHEM BIOPH RES CO, V391, P498, DOI 10.1016/j.bbrc.2009.11.087; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; Coddou C, 2011, PHARMACOL REV, V63, P641, DOI 10.1124/pr.110.003129; Compan V, 2012, J NEUROSCI, V32, P4284, DOI 10.1523/JNEUROSCI.6332-11.2012; Corriden R, 2007, AM J PHYSIOL-CELL PH, V293, pC1420, DOI 10.1152/ajpcell.00271.2007; Corriden R, 2014, FASEB J, V28, P4211, DOI 10.1096/fj.13-247270; Coutinho-Silva R, 2005, AM J PHYSIOL-GASTR L, V288, pG1024, DOI 10.1152/ajpgi.00211.2004; De Marchi E, 2016, ADV PROTEIN CHEM STR, V104, P39, DOI 10.1016/bs.apcsb.2015.11.004; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F., 1994, CELL TISSUE CULTURE; Di Virgilio F, 2015, CURR MED CHEM, V22, P866; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Etique N, 2009, ONCOL REP, V21, P977, DOI 10.3892/or_00000311; Falzoni S, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0101; Fang JQ, 2015, CANCER BIOL THER, V16, P498, DOI 10.1080/15384047.2015.1016663; Ferrari D, 2004, J IMMUNOL, V173, P4652, DOI 10.4049/jimmunol.173.7.4652; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gessi S, 2010, BIOCHEM PHARMACOL, V79, P1483, DOI 10.1016/j.bcp.2010.01.009; Ghalali A, 2014, CARCINOGENESIS, V35, P1547, DOI 10.1093/carcin/bgu019; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Giannuzzo A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0472-4; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gomez-Villafuertes R, 2015, SCI REP-UK, V5, DOI 10.1038/srep18417; Greig AVH, 2003, J INVEST DERMATOL, V121, P315, DOI 10.1046/j.1523-1747.2003.12379.x; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Hayashi S, 2004, SCI STKE, V2004, pl14; Hill LM, 2010, J IMMUNOL, V185, P3028, DOI 10.4049/jimmunol.1001298; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Hoskin DW, 2002, INT J CANCER, V99, P386, DOI 10.1002/ijc.10325; Iannone R, 2013, NEOPLASIA, V15, P1400, DOI 10.1593/neo.131748; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; Jackson SW, 2007, AM J PATHOL, V171, P1395, DOI 10.2353/ajpath.2007.070190; Jacobson KA, 2016, NEUROPHARMACOLOGY, V104, P31, DOI 10.1016/j.neuropharm.2015.12.001; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Jajoo S, 2009, NEOPLASIA, V11, P1132, DOI 10.1593/neo.09744; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Jiang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC1295, DOI 10.1152/ajpcell.00253.2005; Jin XW, 1997, J CLIN INVEST, V100, P2849, DOI 10.1172/JCI119833; Joo YN, 2014, ONCOTARGET, V5, P9322; Kasama H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1577-2; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kotnis S, 2010, MOL PHARMACOL, V77, P953, DOI 10.1124/mol.110.063636; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Kunzli BM, 2011, PURINERG SIGNAL, V7, P231, DOI 10.1007/s11302-011-9228-9; Kumar V, 2013, PURINERG SIGNAL, V9, P145, DOI 10.1007/s11302-012-9349-9; Kwon Ji Hyun, 2014, Korean J Pathol, V48, P30, DOI 10.4132/KoreanJPathol.2014.48.1.30; Lazarowski ER, 2015, MOL PHARMACOL, V88, P151, DOI 10.1124/mol.115.098756; Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302-012-9304-9; Le KT, 1997, FEBS LETT, V418, P195, DOI 10.1016/S0014-5793(97)01380-X; Leclerc BG, 2016, CLIN CANCER RES, V22, P158, DOI 10.1158/1078-0432.CCR-15-1181; Li MF, 2015, NAT NEUROSCI, V18, P1577, DOI 10.1038/nn.4120; Li W, 2015, INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND ENVIRONMENTAL ENGINEERING (CSEE 2015), P1; Li WH, 2013, BRIT J CANCER, V109, P1666, DOI 10.1038/bjc.2013.484; Lin Z, 2010, ONCOGENE, V29, P1114, DOI 10.1038/onc.2009.409; Linden J, 2012, ARTERIOSCL THROM VAS, V32, P2097, DOI 10.1161/ATVBAHA.111.226837; Llaudet E, 2005, ANAL CHEM, V77, P3267, DOI 10.1021/ac048106q; Lohmann K, 1929, NATURWISSENSCHAFTEN, V17, P624; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Longhi MS, 2013, J MOL MED, V91, P165, DOI 10.1007/s00109-012-0991-z; Loo JM, 2015, CELL, V160, P393, DOI 10.1016/j.cell.2014.12.018; MACKENZIE WM, 1994, CANCER RES, V54, P3521; Madi L, 2004, CLIN CANCER RES, V10, P4472, DOI 10.1158/1078-0432.CCR-03-0651; Mandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Maynard JP, 2015, ONCOTARGET, V6, P41162, DOI 10.18632/oncotarget.6240; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mirza A, 2005, CANCER BIOL THER, V4, P1355, DOI 10.4161/cbt.4.12.2196; Mittal D, 2014, CANCER RES, V74, P3652, DOI 10.1158/0008-5472.CAN-14-0957; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Mousavi S, 2015, PROSTATE, V75, P735, DOI 10.1002/pros.22955; Munn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009; Norde WJ, 2009, BLOOD, V113, P2312, DOI 10.1182/blood-2008-04-153825; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Overes IM, 2008, BRIT J HAEMATOL, V141, P799, DOI 10.1111/j.1365-2141.2008.07125.x; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Qiu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114371; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Rigato C, 2012, J NEUROSCI, V32, P11559, DOI 10.1523/JNEUROSCI.1042-12.2012; Rijke BC, 2005, J CLIN INVEST, V115, P3506, DOI 10.1172/JCI24832; Roger S, 2014, BIOCHIM BIOPHYS ACTA, V1848, P2584; Rossi L, 2007, BLOOD, V109, P533, DOI 10.1182/blood-2006-01-035634; Rossi L, 2012, BLOOD, V120, P2365, DOI 10.1182/blood-2012-04-422378; Ryzhov S, 2011, J IMMUNOL, V187, P6120, DOI 10.4049/jimmunol.1101225; Ryzhov SV, 2014, J IMMUNOL, V193, P3155, DOI 10.4049/jimmunol.1400578; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Shabbir M, 2008, BJU INT, V102, P108, DOI 10.1111/j.1464-410X.2008.07578.x; Sitkovsky MV, 2009, TRENDS IMMUNOL, V30, P102, DOI 10.1016/j.it.2008.12.002; Solini A, 2015, ONCOTARGET, V6, P28743, DOI 10.18632/oncotarget.4926; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Stegner D, 2014, THROMB RES, V133, pS149, DOI 10.1016/S0049-3848(14)50025-4; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; Stemmer SM, 2013, ONCOLOGIST, V18, P25, DOI 10.1634/theoncologist.2012-0211; Sun SH, 2010, MOL NEUROBIOL, V41, P351, DOI 10.1007/s12035-010-8120-x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101; Takai E, 2014, PURINERG SIGNAL, V10, P487, DOI 10.1007/s11302-014-9411-x; Thompson BAN, 2012, CELL SIGNAL, V24, P770, DOI 10.1016/j.cellsig.2011.11.012; Tung HC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124654; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vazquez-Cuevas FG, 2014, J CELL BIOCHEM, V115, P1955, DOI 10.1002/jcb.24867; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489; WILEY JS, 1994, BRIT J PHARMACOL, V112, P946, DOI 10.1111/j.1476-5381.1994.tb13172.x; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005; Xia JY, 2015, ONCOL REP, V34, P103, DOI 10.3892/or.2015.3979; Xie R, 2014, J BIOL CHEM, V289, P19137, DOI 10.1074/jbc.M113.540047; Yang G, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-53; Yegutkin GG, 2014, CRIT REV BIOCHEM MOL, V49, P473, DOI 10.3109/10409238.2014.953627; Young A, 2014, CANCER DISCOV, V4, P879, DOI 10.1158/2159-8290.CD-14-0341; Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	169	295	304	12	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					293	303		10.1038/onc.2016.206	http://dx.doi.org/10.1038/onc.2016.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321181	Green Published, hybrid			2022-12-28	WOS:000394166000001
J	Bernasconi-Elias, P; Hu, T; Jenkins, D; Firestone, B; Gans, S; Kurth, E; Capodieci, P; Deplazes-Lauber, J; Petropoulos, K; Thiel, P; Ponsel, D; Choi, SH; LeMotte, P; London, A; Goetcshkes, M; Nolin, E; Jones, MD; Slocum, K; Kluk, MJ; Weinstock, DM; Christodoulou, A; Weinberg, O; Jaehrling, J; Ettenberg, SA; Buckler, A; Blacklow, SC; Aster, JC; Fryer, CJ				Bernasconi-Elias, P.; Hu, T.; Jenkins, D.; Firestone, B.; Gans, S.; Kurth, E.; Capodieci, P.; Deplazes-Lauber, J.; Petropoulos, K.; Thiel, P.; Ponsel, D.; Choi, S. Hee; LeMotte, P.; London, A.; Goetcshkes, M.; Nolin, E.; Jones, M. D.; Slocum, K.; Kluk, M. J.; Weinstock, D. M.; Christodoulou, A.; Weinberg, O.; Jaehrling, J.; Ettenberg, S. A.; Buckler, A.; Blacklow, S. C.; Aster, J. C.; Fryer, C. J.			Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; REGULATORY REGION; INSIGHTS; MICE; MATURATION	Notch receptors have been implicated as oncogenic drivers in several cancers, the most notable example being NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL). To characterize the role of activated NOTCH3 in cancer, we generated an antibody that detects the neo-epitope created upon gamma-secretase cleavage of NOTCH3 to release its intracellular domain (ICD3), and sequenced the negative regulatory region (NRR) and PEST (proline, glutamate, serine, threonine) domain coding regions of NOTCH3 in a panel of cell lines. We also characterize NOTCH3 tumor-associated mutations that result in activation of signaling and report new inhibitory antibodies. We determined the structural basis for receptor inhibition by obtaining the first co-crystal structure of a NOTCH3 antibody with the NRR protein and defined two distinct epitopes for NRR antibodies. The antibodies exhibit potent anti-leukemic activity in cell lines and tumor xenografts harboring NOTCH3 activating mutations. Screening of primary T-ALL samples reveals that 2 of 40 tumors examined show active NOTCH3 signaling. We also identified evidence of NOTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, 2 of which exhibit activation of NOTCH3 without activation of NOTCH1. Our studies provide additional insights into NOTCH3 activation and offer a path forward for identification of cancers that are likely to respond to therapy with NOTCH3 selective inhibitory antibodies.	[Bernasconi-Elias, P.; Gans, S.; Capodieci, P.; Goetcshkes, M.; Nolin, E.; Buckler, A.; Fryer, C. J.] Novartis Inst Biomed Res, Dev & Mol Pathways, 250 Massachusetts Ave,Bldg 600-5B263, Cambridge, MA 02139 USA; [Hu, T.] Novartis Inst Biomed Res, Ctr Prote Chem, Cambridge, MA USA; [Jenkins, D.; Firestone, B.; Kurth, E.; Jones, M. D.; Slocum, K.; Ettenberg, S. A.] Novartis Inst Biomed Res, Dept Oncol, Cambridge, MA USA; [Deplazes-Lauber, J.; Petropoulos, K.; Thiel, P.; Ponsel, D.; Jaehrling, J.] MorphoSys AG, Discovery Alliances & Technol, Martinsried, Germany; [Choi, S. Hee; Weinstock, D. M.; Christodoulou, A.; Blacklow, S. C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Choi, S. Hee; Blacklow, S. C.; Aster, J. C.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [LeMotte, P.; London, A.] Novartis Inst Biomed Res, Dept Biol, Cambridge, MA USA; [Kluk, M. J.; Blacklow, S. C.; Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Weinberg, O.] Children Hosp Boston, Pathol, Boston, MA USA; [Jenkins, D.] Tesaro, Waltham, MA USA; [Thiel, P.] IstQ Deutschland GmbH & Co KG, Mannheim, Germany; [Ponsel, D.] Roche AG, Penzberg, Germany; [Goetcshkes, M.; Buckler, A.] Biogen, Cambridge, MA USA; [Kluk, M. J.] Cornell Weill Med Coll, New York, NY USA; [Ettenberg, S. A.] Unum Therapeut, Cambridge, MA USA	Novartis; Novartis; Novartis; MorphoSys; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Biogen; Cornell University	Fryer, CJ (corresponding author), Novartis Inst Biomed Res, Dev & Mol Pathways, 250 Massachusetts Ave,Bldg 600-5B263, Cambridge, MA 02139 USA.	christy.fryer@novartis.com		Jones, Michael/0000-0001-7541-7634	Industrial Macromolecular Crystallography Association; Hauptman-Woodward Medical Research Institute; US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; Dana Farber-Novartis DDP; National Institutes of Health [P01 CA119070]; Leukemia and Lymphoma Society [7003-13]; NATIONAL CANCER INSTITUTE [R01CA092433, P01CA119070] Funding Source: NIH RePORTER	Industrial Macromolecular Crystallography Association; Hauptman-Woodward Medical Research Institute; US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Dana Farber-Novartis DDP; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The JAGGED1 and DLL1 expressing cell lines were kindly provide by Dr Gerry Weinmaster (UCLA). HPB-ALL cells were kindly provided by Andreas Stasser (Walter and Eliza Hall Institute for Medical Research, Australia). We thank the Novartis Biologics Center including Thomas Pietzonka, Janine Shulok, Nadine Charara, Bill Tschantz and Tony Fleming. We also thank many senior Novartis leaders for supporting this project, including Jeff Porter and William Sellers. We thank Rajiv Chopra and Kirk Clark of Novartis Institutes for BioMedical Research for the instructive discussion on crystallography experiments. Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. This work was financially supported in part by the Dana Farber-Novartis DDP, and grants from the National Institutes of Health (P01 CA119070) and the Leukemia and Lymphoma Society (7003-13).	Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Aste-Amezaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094; Aster JC, 2012, J CLIN ONCOL, V30, P2418, DOI 10.1200/JCO.2012.42.0992; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gordon WR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006613; Gordon WR, 2009, BLOOD, V113, P4381, DOI 10.1182/blood-2008-08-174748; Guruharsha KG, 2012, NAT REV GENET, V13, P654, DOI 10.1038/nrg3272; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Kluk MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067306; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; McCright B, 2001, DEVELOPMENT, V128, P491; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Prassler J, 2011, J MOL BIOL, V413, P261, DOI 10.1016/j.jmb.2011.08.012; Prassler J, 2009, IMMUNOTHERAPY-UK, V1, P571, DOI [10.2217/imt.09.23, 10.2217/IMT.09.23]; Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rauchenberger R, 2003, J BIOL CHEM, V278, P38194, DOI 10.1074/jbc.M303164200; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Stoeck A, 2014, CANCER DISCOV, V4, P1154, DOI 10.1158/2159-8290.CD-13-0830; Tewhey R, 2009, NAT BIOTECHNOL, V27, P1025, DOI 10.1038/nbt.1583; Tiyanont K, 2013, J MOL BIOL, V425, P3192, DOI 10.1016/j.jmb.2013.05.025; Vooijs M, 2011, GASTROENTEROLOGY, V141, P448, DOI 10.1053/j.gastro.2011.06.003; Wang K, 2015, CLIN CANCER RES, V21, P1487, DOI 10.1158/1078-0432.CCR-14-1348; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xu X, 2015, STRUCTURE, V23, P1227, DOI 10.1016/j.str.2015.05.001; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597	45	57	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6077	6086		10.1038/onc.2016.133	http://dx.doi.org/10.1038/onc.2016.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157619	Green Submitted, Green Accepted			2022-12-28	WOS:000388509800004
J	Ma, Y; Yu, C; Mohamed, EM; Shao, H; Wang, L; Sundaresan, G; Zweit, J; Idowu, M; Fang, X				Ma, Y.; Yu, C.; Mohamed, E. M.; Shao, H.; Wang, L.; Sundaresan, G.; Zweit, J.; Idowu, M.; Fang, X.			A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; EML4-ALK FUSION GENE; GLUCOSE CATABOLISM; RESPONSE ELEMENTS; EXPRESSION; METABOLISM; TARGET; IDENTIFICATION	A high rate of aerobic glycolysis is a hallmark of malignant transformation. Accumulating evidence suggests that diverse regulatory mechanisms mediate this cancer-associated metabolic change seen in a wide spectrum of cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is found in approximately 3-7% of non-small cell lung carcinomas (NSCLC). Molecular evidence and therapeutic effectiveness of FDA-approved ALK inhibitors indicated that EML4-ALK is a driving factor of lung tumorigenesis. A recent clinical study showed that NSCLC harboring EML4-ALK rearrangements displayed higher glucose metabolism compared with EML4-ALK-negative NSCLC. In the current work, we presented evidence that EML4-ALK is coupled to overexpression of hexokinase II (HK2), one of the rate-limiting enzymes of the glycolytic pathway. The link from EML4-ALK to HK2 upregulation is essential for a high rate of glycolysis and proliferation of EML4-ALK-rearranged NSCLC cells. We identified hypoxia-inducible factor 1a (HIF1a) as a key transcription factor to drive HK2 gene expression in normoxia in these cells. EML4-ALK induced hypoxia-independent but glucose-dependent accumulation of HIF1a protein via both transcriptional activation of HIF1a mRNA and the phosphatidylinositol 3 kinase-AKT pathway to enhance HIF1a protein synthesis. The EML4ALK- mediated upregulation of HIF1a, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells. Our data reveal a novel EML4-ALK-HIF1a-HK2 cascade to enhance glucose metabolism in EML4-ALK-positive NSCLC.	[Ma, Y.; Mohamed, E. M.; Shao, H.; Fang, X.] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Sanger Hall 2-016,1101 East Marshall St, Richmond, VA 23298 USA; [Yu, C.] Wuhan Univ, Coll Life Sci, Wuhan, Hunan, Peoples R China; [Wang, L.; Sundaresan, G.; Zweit, J.] Virginia Commonwealth Univ, Sch Med, Dept Radiol, Richmond, VA USA; [Idowu, M.] Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA	Virginia Commonwealth University; Wuhan University; Virginia Commonwealth University; Virginia Commonwealth University	Fang, X (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Sanger Hall 2-016,1101 East Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Ma, Yibao/H-3849-2016	Ma, Yibao/0000-0002-3270-8893	Astar Biotech research award; Jeffress Memorial Fund award; NIH [P30 CA16059]; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	Astar Biotech research award; Jeffress Memorial Fund award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported in part by Astar Biotech research award (XF), the Jeffress Memorial Fund award (XF) and the NIH grant P30 CA16059 to Massey Cancer Center of VCU School of Medicine.	Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Choi H, 2013, LUNG CANCER, V79, P242, DOI 10.1016/j.lungcan.2012.11.021; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Ferreira JV, 2013, AUTOPHAGY, V9, P1349, DOI 10.4161/auto.25190; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Ganapathy-Kanniappan S, 2010, CURR PHARM BIOTECHNO, V11, P510, DOI 10.2174/138920110791591427; Gershon TR, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-2; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Horn L, 2009, J CLIN ONCOL, V27, P4232, DOI 10.1200/JCO.2009.23.6661; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Kuo AH, 2007, ONCOGENE, V26, P859, DOI 10.1038/sj.onc.1209840; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Mano H, 2015, P JPN ACAD B-PHYS, V91, P193, DOI 10.2183/pjab.91.193; Martinengo C, 2014, CANCER RES, V74, P6094, DOI 10.1158/0008-5472.CAN-14-0268; Marzec M, 2011, ONCOGENE, V30, P1372, DOI 10.1038/onc.2010.505; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mukherjee A, 2015, NEOPLASIA, V17, P723, DOI 10.1016/j.neo.2015.09.003; Nishino M, 2012, MODERN PATHOL, V25, P1462, DOI 10.1038/modpathol.2012.109; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Rempel A, 1996, CANCER RES, V56, P2468; Ren H, 2012, CANCER RES, V72, P3312, DOI 10.1158/0008-5472.CAN-11-3931; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sasaki T, 2010, EUR J CANCER, V46, P1773, DOI 10.1016/j.ejca.2010.04.002; SATO S, 1969, CANCER RES, V29, P1437; Schonherr C, 2011, TRANSL ONCOL, V4, P248, DOI 10.1593/tlo.11139; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2012, CLIN CANCER RES, V18, P5682, DOI 10.1158/1078-0432.CCR-11-2947; Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu J, 2013, ONCOGENE, V32, P3198, DOI 10.1038/onc.2012.325; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; Younes M, 1997, CANCER-AM CANCER SOC, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7	59	30	30	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6132	6142		10.1038/onc.2016.150	http://dx.doi.org/10.1038/onc.2016.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132509	Green Accepted			2022-12-28	WOS:000388509800009
J	Lu, C; Thoeni, C; Connor, A; Kawabe, H; Gallinger, S; Rotin, D				Lu, C.; Thoeni, C.; Connor, A.; Kawabe, H.; Gallinger, S.; Rotin, D.			Intestinal knockout of Nedd4 enhances growth of Apc(min) tumors	ONCOGENE			English	Article							UBIQUITIN LIGASE NEDD4-1; COLORECTAL-CANCER; BETA-CATENIN; STEM-CELLS; C2 DOMAIN; EXPRESSION; PROTEIN; MOTIF; PHOSPHORYLATION; DEGRADATION	Nedd4 (Nedd4-1) is an E3 ubiquitin ligase that belongs to the HECT family and comprises a C2-WW(n)-HECT domain architecture. Although it has been reported to regulate growth factor receptors and cellular signaling, its role in cancer development has been controversial, with some studies proposing that it promotes cancer while others suggest it inhibits tumor growth. Here, we tested the effect of Nedd4 on intestinal tumor formation and growth using Nedd4-knockout mice (Nedd4 floxed (fl) mice crossed to villin-Cre mice). Although we find that knockout of Nedd4 on its own does not cause tumor growth, its knockout in the context of Apc(+/min)-derived colorectal tumors leads to augmentation of tumor growth, suggesting that Nedd4 normally suppresses intestinal WNT signaling and growth of colonic tumors. WNT signaling microarray, immunoblotting and immunohistochemistry analyses of tumors derived from the Villin-Cre; Nedd4(fl/fl); Apc(+/min) colons demonstrated elevated expression of the WNT upstream effectors LEF1 (full length) and YY1 in these tumors relative to control (Apc(+/min) alone) tumors. Together, these results suggest that Nedd4 suppresses colonic WNT signaling and tumor growth, at least in part, by suppressing the transcription factors LEF1 and YY1.	[Lu, C.; Thoeni, C.; Rotin, D.] Hosp Sick Children, Cell Biol Program, PGCRL 19-9715,686 Bay St, Toronto, ON M5G 0A4, Canada; [Lu, C.; Thoeni, C.; Rotin, D.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Connor, A.; Gallinger, S.] Univ Toronto, Univ Hlth Network, Mt Sinai Hosp, Toronto, ON, Canada; [Kawabe, H.] Max Planck Inst Expt Med, Dept Mol Neurobiol, Gottingen, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; Max Planck Society	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, PGCRL 19-9715,686 Bay St, Toronto, ON M5G 0A4, Canada.	drotin@sickkids.ca	Gallinger, Steven/E-4575-2013; Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696; Connor, Ashton/0000-0002-7596-3771	Canadian Institute of Health Research [MOP-130422]; German Research Foundation [SPP1365/KA3423/1-1]; Fritz Thyssen Foundation; Canada Research Chair form the Canadian Foundation for Innovation (CFI)	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); German Research Foundation(German Research Foundation (DFG)); Fritz Thyssen Foundation; Canada Research Chair form the Canadian Foundation for Innovation (CFI)	We would like to thank Kazuko Hay for technical support and Dr Sylvie Robine for the Vil-Cre<SUP>ERT2</SUP> mice. This grant was supported by the Canadian Institute of Health Research (MOP-130422, to DR), the German Research Foundation SPP1365/KA3423/1-1 (to HK) and the Fritz Thyssen Foundation (to HK). DR is a recipient of a Canada Research Chair form the Canadian Foundation for Innovation (CFI).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adegboyega PA, 2004, CLIN CANCER RES, V10, P5870, DOI 10.1158/1078-0432.CCR-0431-03; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Buller NVJA, 2015, GASTROENTEROLOGY, V148, P170, DOI 10.1053/j.gastro.2014.10.006; Cadigan KM, 2012, COLD SPRING HARB PER, V4, P6; Chinnappan D, 2009, INT J ONCOL, V34, P1417, DOI 10.3892/ijo_00000270; Eide PW, 2013, CELL SIGNAL, V25, P12, DOI 10.1016/j.cellsig.2012.08.012; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fouladkou F, 2010, J BIOL CHEM, V285, P6770, DOI 10.1074/jbc.M109.082347; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsia HE, 2014, P NATL ACAD SCI USA, V111, P13205, DOI 10.1073/pnas.1400737111; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Ing B, 2007, MOL CELL BIOL, V27, P481, DOI 10.1128/MCB.00463-06; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kawabe H, 2010, NEURON, V65, P358, DOI 10.1016/j.neuron.2010.01.007; Kim SS, 2008, APMIS, V116, P779, DOI 10.1111/j.1600-0463.2008.00999.x; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Liu Y, 2009, DEV BIOL, V330, P153, DOI 10.1016/j.ydbio.2009.03.023; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Martin ES, 2007, CANCER RES, V67, P10736, DOI 10.1158/0008-5472.CAN-07-2742; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Owens BMJ, 2013, MUCOSAL IMMUNOL, V6, P224, DOI 10.1038/mi.2012.125; Pali-Scholl I, 2008, EXP TOXICOL PATHOL, V60, P337, DOI 10.1016/j.etp.2008.03.004; Persaud A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005290; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Persaud A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.85; Pinchuk I V, 2010, Curr Gastroenterol Rep, V12, P310, DOI 10.1007/s11894-010-0135-y; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Tanksley JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081514; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang J, 2010, J BIOL CHEM, V285, P12279, DOI 10.1074/jbc.M109.086405; Wang WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076596; Wend P, 2010, SEMIN CELL DEV BIOL, V21, P855, DOI 10.1016/j.semcdb.2010.09.004; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Yang BL, 2008, NAT IMMUNOL, V9, P1356, DOI 10.1038/ni.1670; Yokoyama NN, 2010, NUCLEIC ACIDS RES, V38, P6375, DOI 10.1093/nar/gkq492; Zaravinos A, 2010, CELL CYCLE, V9, P512, DOI 10.4161/cc.9.3.10588; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988	55	16	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5839	5849		10.1038/onc.2016.125	http://dx.doi.org/10.1038/onc.2016.125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27086928				2022-12-28	WOS:000387560800003
J	Bhatt, S; Stender, JD; Joshi, S; Wu, G; Katzenellenbogen, BS				Bhatt, S.; Stender, J. D.; Joshi, S.; Wu, G.; Katzenellenbogen, B. S.			OCT-4: a novel estrogen receptor-alpha collaborator that promotes tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; STEM-CELLS; PROSTATE CARCINOGENESIS; MOLECULAR DETERMINANTS; ENDOCRINE RESISTANCE; ER-ALPHA; PHOSPHORYLATION; TRANSCRIPTION; THERAPY	Tamoxifen has shown great success in the treatment of breast cancer; however, long-term treatment can lead to acquired tamoxifen (TOT) resistance and relapse. TOT classically antagonizes estradiol (E2) -dependent breast cancer cell growth, but exerts partial agonist/antagonist behavior on gene expression. Although both E2 and TOT treatment of breast cancer cells results in recruitment of the estrogen receptor (ER) to common and distinct genomic sites, the mechanisms and proteins underlying TOT preferential recruitment of the ER remains poorly defined. To this end, we performed in silico motif-enrichment analyses within the ER-binding peaks in response to E2 or TOT, to identify factors that would specifically recruit ER to genomic binding sites in the presence of TOT as compared to E2. Intriguingly, we found Nkx3-1 and Oct-transcription factor homodimer motifs to be enriched in TOT preferential binding sites and confirmed the critical role of Oct-3/4 (aka Oct-4) in directing ER recruitment to TOT preferential genomic binding sites, by chromatin immunoprecipitation (ChIP) analyses. Further investigation revealed Oct-4 expression to be basally repressed by Nkx3-1 in MCF-7 cells and TOT treatment appeared to elevate Nkx3-1 degradation through a p38MAPK-dependent phosphorylation of the E3 ligase, Skp2 at serine-64 residue, as observed by quantitative mass-spectrometry analyses. Consistently, Oct-4 upon induction by phospho-Ser64-Skp2-mediated proteasomal degradation of Nkx3-1, participated in ER transcriptional complexes along with p38MAPK and Skp2 in a tamoxifen-dependent manner leading to TOT-dependent gene activation and cell proliferation of the TOT-resistant MCF-7-tam(r) breast cancer cells. Notably, Oct-4 levels were highly elevated in MCF-7-tam(r) cells, and appeared critical for their TOT sensitivity in cell proliferation assays. Furthermore, overexpression of Oct-4 enhanced tumor growth in the presence of tamoxifen in mice in vivo. Collectively, our work presents a novel mechanism for tamoxifen-specific gene activation by ER, secondary to its TOT preferential recruitment to genomic sites by specific activation of Oct-4, a phenomenon that appears to underlie tamoxifen resistance in breast cancer cells and in xenograft tumor models, and could be useful in designing therapeutic interventions to improve treatment outcome.	[Bhatt, S.; Stender, J. D.] Univ Illinois, Dept Biochem, Urbana, IL USA; [Joshi, S.] Agilent Technol, Cedar Creek, TX USA; [Wu, G.] Harvard Med Sch, Joslin Diabet Ctr, Res Div, Boston, MA USA; [Katzenellenbogen, B. S.] Univ Illinois, Mol & Integrat Physiol, Urbana, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; Agilent Technologies; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 South Goodwin Ave, Urbana, IL 61801 USA.	katzenel@illinois.edu			NIH [5RO1 CA18119]; Breast Cancer Research Foundation; Juvenile Diabetes Research Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation)	We thank Dr Peter Yau, Biotechnology Core, UIUC, for contributions to the mass-spectrometry analyses. This work was supported by grants from the NIH 5RO1 CA18119 (BSK), The Breast Cancer Research Foundation (BSK) and Juvenile Diabetes Research Foundation (GW). SB conceived of, designed and executed the study, performed experiments, data analyses and interpretation and wrote the manuscript. JDS conceived the study, performed computational analysis and contributed to experimental data. GW and SJ contributed to experimental data. BSK conceived and designed the study, performed data analyses and interpretation and wrote the manuscript.	Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beelen K, 2012, NAT REV CLIN ONCOL, V9, P529, DOI 10.1038/nrclinonc.2012.121; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bianco S, 2012, TRANSCR-AUSTIN, V3, P165, DOI 10.4161/trns.20496; Bowen C, 2000, CANCER RES, V60, P6111; Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004-0015; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Connor CE, 2001, CANCER RES, V61, P2917; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; de Leeuw R, 2013, ONCOGENE, V32, P3543, DOI 10.1038/onc.2012.361; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Herman ME, 1996, J STEROID BIOCHEM, V59, P121, DOI 10.1016/S0960-0760(96)00114-8; Holmes KA, 2008, CANCER RES, V68, P7380, DOI 10.1158/0008-5472.CAN-08-0133; Hoskins JM, 2009, NAT REV CANCER, V9, P576, DOI 10.1038/nrc2683; Huber-Keener KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041333; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim MJ, 2002, CANCER RES, V62, P2999; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ramos-Mejia V, 2005, DEV DYNAM, V232, P180, DOI 10.1002/dvdy.20211; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88	51	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5722	5734		10.1038/onc.2016.105	http://dx.doi.org/10.1038/onc.2016.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065334				2022-12-28	WOS:000386998400004
J	Khan, IA; Yoo, BH; Masson, O; Baron, S; Corkery, D; Dellaire, G; Attardi, LD; Rosen, KV				Khan, I. A.; Yoo, B. H.; Masson, O.; Baron, S.; Corkery, D.; Dellaire, G.; Attardi, L. D.; Rosen, K. V.			ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells	ONCOGENE			English	Article							BCL-X-L; RAS-INDUCED TRANSFORMATION; ERBB SIGNALING NETWORK; P53/P63 TARGET PERP; IN-VIVO; ANOIKIS RESISTANCE; EXTRACELLULAR-MATRIX; PANCREATIC ADENOCARCINOMA; CONFERS RESISTANCE; BASEMENT-MEMBRANE	The ability of breast cancer cells to resist anoikis, apoptosis caused by detachment of the non-malignant epithelial cells from the extracellular matrix (ECM), is thought to be critical for breast tumor growth, invasion and metastasis. ErbB2, an oncoprotein that is often overproduced in breast tumors, can block breast cancer cell anoikis via mechanisms that are understood only in part. In an effort to understand them better we found that detachment of the non-malignant human breast epithelial cells from the ECM upregulates a protein Perp in these cells. Perp is a component of the desmosomes, multiprotein complexes involved in cell-to-cell adhesion. Perp can cause apoptosis via unknown mechanisms. We demonstrated that Perp upregulation by cell detachment is driven by detachment-induced loss of epidermal growth factor receptor (EGFR). We also found that Perp knockdown by RNA interference (RNAi) rescues detached cells from death which indicates that Perp contributes to their anoikis. We observed that ErbB2, when overexpressed in detached breast epithelial cells, causes Perp downregulation. Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2positive human breast and ovarian carcinoma cells. We established that ErbB2 downregulates Perp by activating an ErbB2 effector protein kinase Mek that blocks detachment-induced EGFR loss in a manner that requires the presence of a signaling protein Sprouty-2. Finally, we observed that restoration of the wild-type Perp levels in ErbB2-overproducing breast epithelial cells increases their anoikis susceptibility and blocks their clonogenicity in the absence of adhesion to the ECM. In summary, we have identified a novel mechanism of ErbB2-mediated mechanism of anoikis resistance of ErbB2-overproducing breast epithelial cells. This mechanism allows such cells to grow without adhesion to the ECM and is driven by ErbB2-induced activation of Mek, subsequent EGFR upregulation and further EGFR-dependent Perp loss.	[Khan, I. A.; Yoo, B. H.; Masson, O.; Rosen, K. V.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Khan, I. A.; Yoo, B. H.; Masson, O.; Corkery, D.; Dellaire, G.; Rosen, K. V.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Baron, S.; Attardi, L. D.] Stanford Univ, Sch Med, Dept Radiat & Canc Biol, Stanford, CA 94305 USA; [Corkery, D.; Dellaire, G.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Stanford University; Dalhousie University	Rosen, KV (corresponding author), Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, CRC, Rm C-304,5849 Univ Ave,POB 15000, Halifax, NS B3H 4R2, Canada.	kirill.rosen@dal.ca	Dellaire, Graham/L-9948-2014	Dellaire, Graham/0000-0002-3466-6316; Rosen, Kirill/0000-0002-4317-9907; Corkery, Dale/0000-0001-7930-0134	Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant [R13 F14]; CBCF Atlantic Region operating grant [R14 F09]; IWK Health Centre Research Associateship; CIBC Graduate Scholarship in Medical Research from Beatrice Hunter Cancer Research Institute	Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant; CBCF Atlantic Region operating grant; IWK Health Centre Research Associateship; CIBC Graduate Scholarship in Medical Research from Beatrice Hunter Cancer Research Institute	This study was supported by the Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant (R13 F14) awarded to KR. Contribution of GD was supported by the CBCF Atlantic Region operating grant (R14 F09). BY was a recipient of the IWK Health Centre Research Associateship. DC was a recipient of a CIBC Graduate Scholarship in Medical Research from the Beatrice Hunter Cancer Research Institute. We are grateful to Drs P Lee and A Stadnyk for the materials provided for this study.	ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attardi LD, 2000, GENE DEV, V14, P704; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Beaudry VG, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001168; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Dusek RL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3171; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Frankel A, 2001, CANCER RES, V61, P4837; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Goc A, 2015, BBA-MOL CELL RES, V1853, P1626, DOI 10.1016/j.bbamcr.2015.03.016; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Gudjonsson T, 2002, J CELL SCI, V115, P39; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Ihrie RA, 2005, CELL CYCLE, V4, P873, DOI 10.4161/cc.4.7.1836; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Kong CS, 2013, OR SURG OR MED OR PA, V115, P95, DOI 10.1016/j.oooo.2012.10.017; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; LJUBIMOV AV, 1992, INT J CANCER, V50, P562, DOI 10.1002/ijc.2910500412; McDonald J.H., 2014, HDB BIOL STAT; Muschler J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003202; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Recondo G, 2014, WORLD J CLIN ONCOL, V5, P440, DOI 10.5306/wjco.v5.i3.440; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOULE HD, 1990, CANCER RES, V50, P6075; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wilken JA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-7; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692	64	19	20	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5759	5769		10.1038/onc.2016.109	http://dx.doi.org/10.1038/onc.2016.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27109096				2022-12-28	WOS:000386998400007
J	Shi, X; Wang, Q; Gu, J; Xuan, Z; Wu, JI				Shi, X.; Wang, Q.; Gu, J.; Xuan, Z.; Wu, J. I.			SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; TUMOR-SUPPRESSOR; CEREBELLAR DEVELOPMENT; NEURAL DEVELOPMENT; CELL-PROLIFERATION; HEDGEHOG PATHWAY; CANCER; TRANSCRIPTION; BRG1; ACTIVATION	Recent large-scale genomic studies have classified medulloblastoma into four subtypes: Wnt, Shh, Group 3 and Group 4. Each is characterized by specific mutations and distinct epigenetic states. Previously, we showed that a chromatin regulator SMARCA4/Brg1 is required for Gli-mediated transcription activation in Sonic hedgehog (Shh) signaling. We report here that Brg1 controls a transcriptional program that specifically regulates Shh-type medulloblastoma growth. Using a mouse model of Shh-type medulloblastoma, we deleted Brg1 in precancerous progenitors and primary or transplanted tumors. Brg1 deletion significantly inhibited tumor formation and progression. Genome-wide expression analyses and binding experiments indicate that Brg1 specifically coordinates with key transcription factors including Gli1, Atoh1 and REST to regulate the expression of both oncogenes and tumor suppressors that are required for medulloblastoma identity and proliferation. Shh-type medulloblastoma displays distinct H3K27me3 properties. We demonstrate that Brg1 modulates activities of H3K27me3 modifiers to regulate the expression of medulloblastoma genes. Brg1-regulated pathways are conserved in human Shh-type medulloblastoma, and Brg1 is important for the growth of a human medulloblastoma cell line. Thus, Brg1 coordinates a genetic and epigenetic network that regulates the transcriptional program underlying the Shh-type medulloblastoma development.	[Shi, X.; Wang, Q.; Wu, J. I.] Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Gu, J.; Xuan, Z.] Univ Texas Dallas, Ctr Syst Biol, Dept Biol Sci, Richardson, TX 75083 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas	Wu, JI (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jiang9.wu@utsouthwestern.edu			March of Dimes Foundation; American Cancer Society; NIMH; Department of Defense Visionary postdoc fellowship	March of Dimes Foundation(March of Dimes); American Cancer Society(American Cancer Society); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Department of Defense Visionary postdoc fellowship	We thank Drs Brent Orr (St. Jude Hospital), Wenzhe Niu and Zilai Zhang, and Mou Cao for technical support and Dr Chao Xing and the University of Texas Southwestern Sequencing Facility for performing the next-generation sequencing and RNA-seq analyses. We thank Drs Lin Gan and Jane Johnson for providing the Atoh1-Cre mice and Dr Ching-Ping Chang for providing human Brg1 shRNA constructs. This work was supported by grants from March of Dimes Foundation (JW), American Cancer Society (JW), NIMH (JW) and Department of Defense Visionary postdoc fellowship (XS).	Anne SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081769; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Dietrich N, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002494; Dubuc AM, 2013, ACTA NEUROPATHOL, V125, P373, DOI 10.1007/s00401-012-1070-9; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hu GQ, 2011, GENOME RES, V21, P1650, DOI 10.1101/gr.121145.111; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson R, 2008, PLOS BIOL, V6, P2205, DOI 10.1371/journal.pbio.0060256; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klisch TJ, 2011, P NATL ACAD SCI USA, V108, P3288, DOI 10.1073/pnas.1100230108; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li QT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004524; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Markant SL, 2013, CANCER RES, V73, P6310, DOI 10.1158/0008-5472.CAN-12-4258; Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028; Moreno N, 2014, J NEUROSCI, V34, P13486, DOI 10.1523/JNEUROSCI.2560-14.2014; Natarajan S, 2013, CANCER RES, V73, P5381, DOI 10.1158/0008-5472.CAN-13-0033; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Ooi L, 2006, J BIOL CHEM, V281, P38974, DOI 10.1074/jbc.M605370200; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Rutkowski S, 2010, J CLIN ONCOL, V28, P4961, DOI 10.1200/JCO.2010.30.2299; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Sengupta R, 2012, CANCER RES, V72, P122, DOI 10.1158/0008-5472.CAN-11-1701; Sengupta S, 2014, ACTA NEUROPATHOL, V127, P593, DOI 10.1007/s00401-013-1205-7; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Shi XM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6425; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Stankunas K, 2008, DEV CELL, V14, P298, DOI 10.1016/j.devcel.2007.11.018; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Triscott J, 2013, CANCER RES, V73, P6734, DOI 10.1158/0008-5472.CAN-12-4331; Uziel T, 2006, CELL CYCLE, V5, P363, DOI 10.4161/cc.5.4.2475; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wetmore C, 2001, CANCER RES, V61, P513; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099; Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009; Yang H, 2010, GENESIS, V48, P407, DOI 10.1002/dvg.20633; Yu Y, 2013, CELL, V152, P248, DOI 10.1016/j.cell.2012.12.006; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhan XM, 2011, P NATL ACAD SCI USA, V108, P12758, DOI 10.1073/pnas.1018510108	76	28	28	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5746	5758		10.1038/onc.2016.108	http://dx.doi.org/10.1038/onc.2016.108			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065321				2022-12-28	WOS:000386998400006
J	Li, J; Wu, H; Li, W; Yin, L; Guo, S; Xu, X; Ouyang, Y; Zhao, Z; Liu, S; Tian, Y; Tian, Z; Ju, J; Ni, B; Wang, H				Li, J.; Wu, H.; Li, W.; Yin, L.; Guo, S.; Xu, X.; Ouyang, Y.; Zhao, Z.; Liu, S.; Tian, Y.; Tian, Z.; Ju, J.; Ni, B.; Wang, H.			Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappa B signaling	ONCOGENE			English	Article							SPHINGOSINE KINASE 1; MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; CISPLATIN RESISTANCE; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; NETWORK; SURVIVAL; GROWTH; PROLIFERATION	The aberrant expression of microRNAs (miRNAs) has emerged as an important hallmark of cancer. However, the molecular mechanisms underlying the changes in miRNA expression remain unclear. In this study, we discovered a novel epigenetic mechanism of miR-506 regulation and investigated its functional significance in pancreatic cancer. Sequencing analysis revealed that the miR-506 promoter is highly methylated in pancreatic cancer tissues compared with non-cancerous tissues. Reduced miR-506 expression was significantly associated with clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic cancer patients. miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells. Furthermore, we identified sphingosine kinase 1 (SPHK1) as a novel target of miR-506, the expression of which inhibited the SPHK1/Akt/NF-kappa B signaling pathway, which is activated in pancreatic cancer. High SPHK1 expression was significantly associated with poor survival in a large cohort of pancreatic cancer specimens. Our data suggest that miR-506 acts as a tumor suppressor miRNA and is epigenetically silenced in pancreatic cancer. The newly identified miR-506/SPHK1 axis represents a novel therapeutic strategy for future pancreatic cancer treatment.	[Li, J.; Yin, L.; Guo, S.; Xu, X.; Ouyang, Y.; Zhao, Z.; Liu, S.; Wang, H.] Third Mil Med Univ, Southwest Hosp, Inst Hepatopancreatobiliary Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China; [Wu, H.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pancreat Surg, Wuhan, Peoples R China; [Li, W.] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China; [Li, W.] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China; [Tian, Y.; Tian, Z.; Ni, B.] Third Mil Med Univ, Inst Immunol PLA, Chongqing, Peoples R China; [Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY USA; [Ni, B.] Third Mil Med Univ, Dept Pathophysiol & High Altitude Pathol, Chongqing, Peoples R China	Army Medical University; Huazhong University of Science & Technology; Army Medical University; Army Medical University; Army Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Army Medical University	Ju, J; Ni, B; Wang, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Inst Hepatopancreatobiliary Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	jingfang.ju@stonybrookmedicine.edu; nibingxi@126.com; whuaizhi@gmail.com	Yin, Liangyu/AAE-4982-2021	Yin, Liangyu/0000-0001-8876-2680; Ni, Bing/0000-0002-4297-5346	National Natural Science Foundation of China [81372242]; National High Technology Research and Development Program of China (Program 863) [2012AA021105]; Research Special Fund for Public Welfare Industry of Health [201202007]; NATIONAL CANCER INSTITUTE [R01CA197098] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (Program 863)(National High Technology Research and Development Program of China); Research Special Fund for Public Welfare Industry of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Renyi Qin from the Department of Biliary-Pancreatic Surgery (Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan) and Professor Yijun Zhao from the Department of Hepatobiliary Surgery (the First Affiliated Hospital of Anhui Medical University, Hefei) for providing human pancreatic cancer samples. This work was supported by the following grants: the National Natural Science Foundation of China (No. 81372242); the National High Technology Research and Development Program of China (Program 863; No. 2012AA021105); and the Research Special Fund for Public Welfare Industry of Health (No. 201202007).	Arora H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064273; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Bracken CP, 2015, CANCER RES, V75, P2594, DOI 10.1158/0008-5472.CAN-15-0287; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Drayton RM, 2014, CLIN CANCER RES, V20, P1990, DOI 10.1158/1078-0432.CCR-13-2805; Frampton AE, 2015, EUR J CANCER, V51, P1389, DOI 10.1016/j.ejca.2015.04.006; Frampton AE, 2014, GASTROENTEROLOGY, V146, P268, DOI 10.1053/j.gastro.2013.10.010; Gao W, 2015, ONCOGENE, V34, P1629, DOI 10.1038/onc.2014.101; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guillermet-Guibert J, 2009, MOL CANCER THER, V8, P809, DOI 10.1158/1535-7163.MCT-08-1096; Guo SX, 2014, CANCER LETT, V344, P40, DOI 10.1016/j.canlet.2013.10.009; Jamieson NB, 2012, CLIN CANCER RES, V18, P534, DOI 10.1158/1078-0432.CCR-11-0679; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Lai NS, 2015, BRIT J CANCER, V112, P1241, DOI 10.1038/bjc.2015.91; Lennox KA, 2011, GENE THER, V18, P1111, DOI 10.1038/gt.2011.100; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; Liu G, 2014, J PATHOL, V233, P308, DOI 10.1002/path.4348; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Sakimura S, 2015, ANN SURG ONCOL, V22, pS1436, DOI 10.1245/s10434-015-4418-2; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Su JA, 2010, INT J BIOCHEM CELL B, V42, P2047, DOI 10.1016/j.biocel.2010.09.009; Sun Y, 2015, J PATHOL, V235, P25, DOI 10.1002/path.4443; Tang YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091551; Tong JL, 2011, FEBS LETT, V585, P3560, DOI 10.1016/j.febslet.2011.10.021; Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598; Wen SY, 2014, ONCOGENE, V34, P717, DOI DOI 10.1038/0NC.2014.9; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yin M, 2015, ONCOGENE, V34, P691, DOI 10.1038/onc.2013.597; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105	47	100	107	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5501	5514		10.1038/onc.2016.90	http://dx.doi.org/10.1038/onc.2016.90			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27065335	Green Published, hybrid			2022-12-28	WOS:000386998200005
J	Lin, KT; Shann, YJ; Chau, GY; Hsu, CN; Huang, CYF				Lin, K-T; Shann, Y-J; Chau, G-Y; Hsu, C-N; Huang, C-Y F.			Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing (vol 33, pg 4786, 2014)	ONCOGENE			English	Correction																		Lin KT, 2014, ONCOGENE, V33, P4786, DOI 10.1038/onc.2013.424	1	1	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5078	5078		10.1038/onc.2016.62	http://dx.doi.org/10.1038/onc.2016.62			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27477694	Bronze			2022-12-28	WOS:000383965300012
J	Gueguinou, M; Crottes, D; Chantome, A; Rapetti-Mauss, R; Potier-Cartereau, M; Clarysse, L; Girault, A; Fourbon, Y; Jezequel, P; Guerin-Charbonnel, C; Fromont, G; Martin, P; Pellissier, B; Schiappa, R; Chamorey, E; Mignen, O; Uguen, A; Borgese, F; Vandier, C; Soriani, O				Gueguinou, M.; Crottes, D.; Chantome, A.; Rapetti-Mauss, R.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Jezequel, P.; Guerin-Charbonnel, C.; Fromont, G.; Martin, P.; Pellissier, B.; Schiappa, R.; Chamorey, E.; Mignen, O.; Uguen, A.; Borgese, F.; Vandier, C.; Soriani, O.			The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis	ONCOGENE			English	Article							ELECTRICAL-ACTIVITY; RECEPTOR; CHANNEL; PLASTICITY; ROLES; INHIBITION; MECHANISM; RESPONSES; MEMBRANE; COMPLEX	The remodeling of calcium homeostasis contributes to the cancer hallmarks and the molecular mechanisms involved in calcium channel regulation in tumors remain to be characterized. Here, we report that SigmaR1, a stress-activated chaperone, is required to increase calcium influx by triggering the coupling between SK3, a Ca2+-activated K+ channel (KCNN3) and the voltage- independent calcium channel Orai1. We show that SigmaR1 physically binds SK3 in BC cells. Inhibition of SigmaR1 activity, either by molecular silencing or by the use of sigma ligand (igmesine), decreased SK3 current and Ca2+ entry in breast cancer (BC) and colorectal cancer (CRC) cells. Interestingly, SigmaR1 inhibition diminished SK3 and/or Orai1 levels in lipid nanodomains isolated from BC cells. Analyses of tissue microarray from CRC patients showed higher SigmaR1 expression levels in cancer samples and a correlation with tumor grade. Moreover, the exploration of a cohort of 4937 BC patients indicated that high expression of SigmaR1 and Orai1 channels was significantly correlated to a lower overall survival. As the SK3/Orai1 tandem drives invasive process in CRC and bone metastasis progression in BC, our results may inaugurate innovative therapeutic approaches targeting SigmaR1 to control the remodeling of Ca2+ homeostasis in epithelial cancers.	[Gueguinou, M.; Chantome, A.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Fromont, G.; Vandier, C.] Univ Tours, INSERM, U1069, Nutr Croissance & Canc, Tours, France; [Crottes, D.; Rapetti-Mauss, R.; Martin, P.; Pellissier, B.; Borgese, F.; Soriani, O.] Univ Cote Azur, INSERM, CNRS, iBV, Nice, France; [Jezequel, P.; Guerin-Charbonnel, C.] INSERM, UMR 892, Ctr Rech Cancerol, Unit Bioinfom,Inst Cancerol Ouest Rene Gauducheau, St Herblain, France; [Fromont, G.] CHRU Tours, Hop Bretonneau, Serv Anat Pathol, Tours, France; [Schiappa, R.; Chamorey, E.] Ctr Antoine Lacassagne, UEB, Nice, France; [Mignen, O.; Uguen, A.] Brest Univ Hosp, INSERM, U1078, Dept Pathol, Brest, France; [Gueguinou, M.; Chantome, A.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Fromont, G.; Mignen, O.; Vandier, C.] Ion Channels & Canc Canceropole Grand Ouest IC CG, Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); CHU Tours; UNICANCER; Centre Antoine Lacassagne; CHU Brest; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Vandier, C; Soriani, O (corresponding author), Univ Nice Sophia Antipolis, Inst Biol Valrose, UFR Sci, iBV, Batiment Sci Nat,Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	christophe.vandier@univ-tours.fr; soriani@unice.fr	MIGNEN, Olivier/M-3258-2019; Rapetti-Mauss, Raphael/P-3437-2016; Chamorey, Emmanuel/AGO-9982-2022; Girault, Alban/AAB-3323-2020; Girault, Alban/AAF-7808-2019; Crottès, David/AAC-2180-2022; Uguen, Arnaud/ABF-7583-2020; fromont, gaelle/N-8708-2016; Vandier, Christophe/AAC-1900-2022; SCHIAPPA, Renaud/K-8192-2019; Potier-Cartereau, marie/AAC-4510-2022	MIGNEN, Olivier/0000-0001-7913-6119; Girault, Alban/0000-0001-5478-9340; Crottès, David/0000-0002-4038-6345; Vandier, Christophe/0000-0003-2559-0660; Potier-Cartereau, marie/0000-0002-1361-3397; soriani, olivier/0000-0001-9485-3992; BORGESE, Franck/0000-0001-7718-2111; RAPETTI-MAUSS, Raphael/0000-0002-3518-4845; Gueguinou, Maxime/0000-0002-5793-2082	Universite Cote d'Azur; CNRS; La Ligue contre le Cancer; Region Centre; INSERM; Canceropole Grand Ouest; association 'CANCEN' and Tours' Hospital oncology association 'ACORT'; Association TiToine Normandie	Universite Cote d'Azur; CNRS(Centre National de la Recherche Scientifique (CNRS)); La Ligue contre le Cancer(Ligue nationale contre le cancer); Region Centre(Region Centre-Val de Loire); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Canceropole Grand Ouest; association 'CANCEN' and Tours' Hospital oncology association 'ACORT'; Association TiToine Normandie	The study was supported by Universite Cote d'Azur, CNRS, La Ligue contre le Cancer, Region Centre (LIPIDS project of ARD2020-Biomedicaments), INSERM, Canceropole Grand Ouest, the association 'CANCEN' and Tours' Hospital oncology association 'ACORT', Association TiToine Normandie. DC is a doctoral fellow with CNRS, Region PACA and Fondation ARC. RR-M is a post-doctoral fellow of La Ligue contre le Cancer and Fondation de France. The microscopy was carried out in the Prism facility, 'Plateforme Universite Cote d'Azur, CNRS, Inserm, iBV, France. MG and LC are respectively doctoral fellows of Region Centre and Region Centre/INSERM. Local tumor tissue biobank BB-0033-00037 ('CRB Sante/Tumorotheque de Brest').	Abou-lovergne A, 2011, CELL CALCIUM, V50, P62, DOI 10.1016/j.ceca.2011.05.008; Balasuriya D, 2014, J BIOL CHEM, V289, P32353, DOI 10.1074/jbc.M114.603506; Balasuriya D, 2012, J BIOL CHEM, V287, P37021, DOI 10.1074/jbc.M112.382077; Calaghan S, 2008, J MOL CELL CARDIOL, V45, P88, DOI 10.1016/j.yjmcc.2008.04.004; Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572; Chantome A, 2009, EXP CELL RES, V315, P3620, DOI 10.1016/j.yexcr.2009.07.021; Chu UB, 2016, MOL PHARMACOL, V89, P142, DOI 10.1124/mol.115.101170; Clarysse L, 2014, PFLUG ARCH EUR J PHY, V466, P1921, DOI 10.1007/s00424-013-1435-5; Crottes D, 2016, CANCER RES, V76, P607, DOI 10.1158/0008-5472.CAN-15-1465; Crottes D, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00175; Crottes D, 2011, J BIOL CHEM, V286, P27947, DOI 10.1074/jbc.M111.226738; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Girault A, 2011, CURR CANCER DRUG TAR, V11, P1111, DOI 10.2174/156800911798073069; Gueguinou M, 2016, ONCOTARGET, V7, P36168, DOI 10.18632/oncotarget.8786; Gueguinou M, 2014, BBA-MOL CELL RES, V1843, P2322, DOI 10.1016/j.bbamcr.2014.02.019; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi T, 2004, P NATL ACAD SCI USA, V101, P14949, DOI 10.1073/pnas.0402890101; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hayashi T, 2015, J PHARMACOL SCI, V127, P2, DOI 10.1016/j.jphs.2014.07.001; Hayashi T, 2010, SUBCELL BIOCHEM, V51, P381, DOI 10.1007/978-90-481-8622-8_13; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Kondratska K, 2014, BBA-MOL CELL RES, V1843, P2263, DOI 10.1016/j.bbamcr.2014.02.012; Kourrich S, 2013, CELL, V152, P236, DOI 10.1016/j.cell.2012.12.004; Kourrich S, 2012, TRENDS NEUROSCI, V35, P762, DOI 10.1016/j.tins.2012.09.007; Martina M, 2007, J PHYSIOL-LONDON, V578, P143, DOI 10.1113/jphysiol.2006.116178; Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Pal A, 2007, MOL PHARMACOL, V72, P921, DOI 10.1124/mol.107.038307; Prause J, 2013, HUM MOL GENET, V22, P1581, DOI 10.1093/hmg/ddt008; Prevarskaya N, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0097; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Raphael M, 2014, P NATL ACAD SCI USA, V111, pE3870, DOI 10.1073/pnas.1413409111; Renaudo A, 2007, J BIOL CHEM, V282, P2259, DOI 10.1074/jbc.M607915200; ROMAN FJ, 1990, J PHARM PHARMACOL, V42, P439, DOI 10.1111/j.2042-7158.1990.tb06588.x; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; Soriani O, 1998, J PHARMACOL EXP THER, V286, P163; Srivats S, 2016, J CELL BIOL, V213, P65, DOI 10.1083/jcb.201506022; Su TP, 2016, TRENDS PHARMACOL SCI, V37, P262, DOI 10.1016/j.tips.2016.01.003; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; van Waarde A., 2014, BIOCHIM BIOPHYS ACTA, V1848, P2703; Vollrath JT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.243; Wu ZP, 2008, J BIOL CHEM, V283, P28198, DOI 10.1074/jbc.M802099200	43	63	63	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3640	3647		10.1038/onc.2016.501	http://dx.doi.org/10.1038/onc.2016.501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28114279				2022-12-28	WOS:000403878600013
J	Lin, Y; Yang, X; Liu, W; Li, B; Yin, W; Shi, Y; He, R				Lin, Y.; Yang, X.; Liu, W.; Li, B.; Yin, W.; Shi, Y.; He, R.			Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; NF-KAPPA-B; SUPPRESSOR-CELLS; ENDOTHELIAL-CELLS; CANCER-CELLS; TUMOR MICROENVIRONMENT; DENDRITIC CELLS; RECEPTOR CCRL2; POOR-PROGNOSIS; T-CELLS	Hepatocellular carcinoma (HCC) is linked to inflammation and immunosuppression. Chemerin is highly expressed in the liver and implicated in the regulation of inflammation. However, the role of chemerin in HCC remains unclear. In this study, we aimed to investigate whether chemerin is able to influence HCC progression by regulating tumor-associated inflammation. Here we demonstrated that chemerin significantly decreased in blood and tumor tissues of HCC patients, and tumor chemerin levels were inversely associated with the prognosis. In an orthotopic mouse model of HCC, Rarres2(-/-)mice exhibited aggressive tumor growth and lung metastasis, whereas chemerin overexpression greatly inhibited tumor growth. The tumor-inhibitory effect of chemerin was accompanied by a shift in tumor-infiltrating immune cells from myeloid-derived suppressive cells (MDSCs) to interferon-gamma'T cells and decreased tumor angiogenesis. Furthermore, we demonstrated that the tumor-inhibitory effect of chemerin was partly dependent on T cells, as chemerin overexpression could inhibit tumor growth, albeit to a lesser extent, in Rag1(-/-) mice when compared with wild-type controls. Mechanistically, chemerin inhibited nuclear factor-.B activation and the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-6) by tumor cells and tumor-associated endothelial cell, respectively, via its receptors, and consequently, MDSC induction was impaired, leading to restoration of antitumor T-cell response and decreased tumor angiogenesis. Clinically, systemic and tumor levels of chemerin were found to inversely correlate with circulating concentrations of GM-CSF or IL-6 and tumor-infiltrating myeloid cells, respectively, in HCC patients. Moreover, neutralization of GM-CSF and IL-6 abrogated HCC progression and MDSC accumulation in Rarres2(-/-) mice. In conclusion, our study reveals the tumor-inhibitory effect of chemerin by suppressing inflammatory tumor microenvironment with therapeutic implications for inflammation-associated cancer-like HCC.	[Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Educ, Dept Immunol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Educ, Key Lab Med Mol Virol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Hlth, Dept Immunol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Hlth, Key Lab Med Mol Virol, Sch Basic Med Sci, Shanghai, Peoples R China; [Liu, W.; Shi, Y.] Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 180 FengLin Rd, Shanghai 200032, Peoples R China; [He, R.] Fudan Univ, Biotherapy Res Ctr, Dept Immunol, Shanghai, Peoples R China	Fudan University; Fudan University	Shi, Y (corresponding author), Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 180 FengLin Rd, Shanghai 200032, Peoples R China.; He, R (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	shi.yinghong@zs-hospital.sh.cn; ruihe@fudan.edu.cn	He, Rui/P-7302-2019; Lin, Yuli/GNP-4999-2022; Yang, Xuguang/GNP-2847-2022	He, Rui/0000-0001-5288-9786; Lin, Yuli/0000-0002-8779-2471; Yang, Xuguang/0000-0002-6198-6008	National Natural Science Foundation of China [813220437, 81471555, 31600715, 81272389, 81472674]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Yongjun Dang (Department of Biochemistry and Molecular Biology, Fudan University) for the assistance with pulldown assay. This work is supported by National Natural Science Foundation of China grant 813220437, 81471555 (to RH), 31600715 (to YL) and 81272389, 81472674 (to YS).	Albanesi C, 2009, J EXP MED, V206, P249, DOI 10.1084/jem.20080129; Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Bondue B, 2011, CYTOKINE GROWTH F R, V22, P331, DOI 10.1016/j.cytogfr.2011.11.004; Bondue B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002358; Chen MF, 2014, ONCOTARGET, V5, P8716, DOI 10.18632/oncotarget.2368; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Dolcetti L, 2010, EUR J IMMUNOL, V40, P22, DOI 10.1002/eji.200939903; Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Imai K, 2014, INT J MOL SCI, V15, P11294, DOI 10.3390/ijms150711294; Kaur J, 2010, BIOCHEM BIOPH RES CO, V391, P1762, DOI 10.1016/j.bbrc.2009.12.150; Lin W, 2011, CLIN LAB, V57, P879; Lin YL, 2014, CELL MOL IMMUNOL, V11, P355, DOI 10.1038/cmi.2014.15; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Monnier J, 2012, J IMMUNOL, V189, P956, DOI 10.4049/jimmunol.1102871; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Parolini S, 2007, BLOOD, V109, P3625, DOI 10.1182/blood-2006-08-038844; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015; Tian ZG, 2013, HEPATOLOGY, V57, P1654, DOI 10.1002/hep.26115; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Wanninger J, 2012, MOL CELL ENDOCRINOL, V349, P248, DOI 10.1016/j.mce.2011.10.032; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Yang S, 2014, IMMUNITY, V41, P973, DOI 10.1016/j.immuni.2014.11.013; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhao L, 2014, ALLERGY, V69, P763, DOI 10.1111/all.12408; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30; Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521	42	83	86	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3599	3608		10.1038/onc.2016.516	http://dx.doi.org/10.1038/onc.2016.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166197				2022-12-28	WOS:000403878600009
J	Pemov, A; Li, H; Patidar, R; Hansen, NF; Sindiri, S; Hartley, SW; Wei, JS; Elkahloun, A; Chandrasekharappa, SC; Boland, JF; Bass, S; Mullikin, JC; Khan, J; Widemann, BC; Wallace, MR; Stewart, DR				Pemov, A.; Li, H.; Patidar, R.; Hansen, N. F.; Sindiri, S.; Hartley, S. W.; Wei, J. S.; Elkahloun, A.; Chandrasekharappa, S. C.; Boland, J. F.; Bass, S.; Mullikin, J. C.; Khan, J.; Widemann, B. C.; Wallace, M. R.; Stewart, D. R.		NISC Comparative Sequencing; NCI DCEG Canc Genomics Res Lab	The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas	ONCOGENE			English	Article							NERVE SHEATH TUMORS; SCHWANN-CELLS; EXPRESSION; CANCER; GENES; MUTATIONS; CHILDREN; BENIGN; PIRFENIDONE; FRAMEWORK	Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor that arises from bi-allelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma. To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed whole-exome sequencing, RNASeq profiling and genome-wide copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material with matching germline DNA. All resected tumors were derived from routine debulking surgeries. None of the tumors were considered at risk for malignant transformation at the time; for example, there was no pain or rapid growth. Deep (similar to 500X) NF1 exon sequencing was also conducted on tumor DNA. Non-NF1 somatic mutation verification was performed using the Ampliseq/IonTorrent platform. We identified 100% of the germline NF1 mutations and found somatic NF1 inactivation in 74% of the PN. One individual with three PNs had different NF1 somatic mutations in each tumor. The median number of somatic mutations per sample, including NF1, was one (range 0-8). NF1 was the only gene that was recurrently somatically inactivated in multiple tumors. Gene Set Enrichment Analysis of transcriptome-wide tumor RNA sequencing identified five significant (FDR < 0.01) and seven trending (0.01 <= FDR < 0.02) gene sets related to DNA replication, telomere maintenance and elongation, cell cycle progression, signal transduction and cell proliferation. We found no recurrent non-NF1 locus copy-number variation in PN. This is the first multi-sample whole-exome and whole-transcriptome sequencing study of NF1-associated PN. Taken together with concurrent copy-number data, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of PN tumorigenesis.	[Pemov, A.; Stewart, D. R.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Li, H.; Wallace, M. R.] Univ Florida, UF Hlth Canc Ctr, UF Genet Inst, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Patidar, R.; Sindiri, S.; Wei, J. S.; Khan, J.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Hansen, N. F.; Elkahloun, A.; Chandrasekharappa, S. C.; Mullikin, J. C.] NHGRI, Canc Genet & Comparat Genom Branch, Rockville, MD USA; [Hartley, S. W.] NCI, Human Genet Program, Div Canc Epidemiol & Genet, Rockville, MD USA; [Mullikin, J. C.; NISC Comparative Sequencing] NHGRI, NIH, Intramural Sequencing Ctr, Rockville, MD USA; [Boland, J. F.; Bass, S.; NCI DCEG Canc Genomics Res Lab] NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, Rockville, MD USA; [Widemann, B. C.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, DR (corresponding author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Rm 6E450, Bethesda, MD 20892 USA.	drstewart@mail.nih.gov	Khan, Javed/P-9157-2014; Patidar, Rajesh/G-9389-2019; Patidar, Rajesh/M-5520-2019	Patidar, Rajesh/0000-0003-3578-8208; Patidar, Rajesh/0000-0003-3578-8208; sindiri, sivasish/0000-0003-2516-969X	National Human Genome Research Institute; Center for Cancer Research of the National Cancer Institute; Division of Cancer Epidemiology and Genetics of the National Cancer Institute; Department of Defense [DAMD17-98-1-8609, DAMD17-00-1-0549]; National Institutes of Health [R29 NS31550]; Children's Tumor Foundation; NATIONAL CANCER INSTITUTE [ZIACP010144, ZIABC010801] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000029, ZIAHG200330, ZICHG200365, ZICHG200346, ZIBHG000196] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Center for Cancer Research of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Division of Cancer Epidemiology and Genetics of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Funding provided by the Intramural Research Programs of the National Human Genome Research Institute, the Center for Cancer Research of the National Cancer Institute and the Division of Cancer Epidemiology and Genetics of the National Cancer Institute. We thank the members of the NISC Comparative Sequencing Program: Betty Barnabas, PhD, Robert Blakesley, PhD, Gerry Bouffard, PhD, Shelise Brooks, BS, Holly Coleman, MSc, Mila Dekhtyar, MSc, Michael Gregory, MSc, Xiaobin Guan, PhD, Jyoti Gupta, MSc, Joel Han, BS, Shi-ling Ho, BS, Richelle Legaspi, MSc, Quino Maduro, BS, Cathy Masiello, MSc, Baishali Maskeri, PhD, Jenny McDowell, PhD, Casandra Montemayor, MSc, Morgan Park, PhD, Nancy Riebow, BS, Karen Schandler, MSc, Brian Schmidt, BS, Christina Sison, BS, Mal Stantripop, BS, James Thomas, PhD, Pam Thomas, PhD, Meg Vemulapalli, MSc, Alice Young, BA. We also thank the members of the NCI DCEG Cancer Genomics Research Laboratory: Michael Beerman, Aaron J Bouk, Seth Brodie, Laurie Burdett, Salma Chowdhury, Charles Chung, Nathan Cole, Michael Cullen, Casey Dagnall, Danielle Debacker, Sadie Frary, Chris Hautman, Belynda Hicks, Herb Higson, Keisha Hines-Harris, Amy Hutchinson, Kristie Jones, Eric Karlins, Sally Larson, Kerrie Lashley, Hyo Jung Lee, Shengchao Li, Tong Li, Wen Luo, Mike Malasky, Michelle Manning, Charles McCoy, Jason Mitchell, Adri O'Neil, Padma Ramya Packirisamy, Timothy Pelc, David Roberson, Aaron Rodriguez, Marianne Siler, Shalabh Suman, Kedest Teshome, Julio Tun, Sue Turner, Bill Utermahlen, Aurelie Vogt, Sarah Wagner, Mingyi Wang, Zhaoming Wang, Kathleen Wyatt, Qi Yang, Meredith Yeager, Sherry Yu, Xijun Zhang, Weiyin Zhou, Bin Zhu. MRW acknowledges funding from the Department of Defense (DAMD17-98-1-8609, DAMD17-00-1-0549), the National Institutes of Health (R29 NS31550), and the Children's Tumor Foundation supporting the development of the PN cultures over a 17-year span. Finally, we thank the patients who enlisted the help of their physicians to contribute tissues to research.	[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Babovic-Vuksanovic D, 2007, PEDIATR NEUROL, V36, P293, DOI 10.1016/j.pediatrneurol.2007.01.009; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Buchstaller J, 2012, NEUROFIBROMATOSIS TY; Castle B, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e109; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dewan R, 2014, NEURO-ONCOLOGY, V17, P566; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Emi M, 1998, JPN J CANCER RES, V89, P12, DOI 10.1111/j.1349-7006.1998.tb00472.x; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hirbe AC, 2015, CLIN CANCER RES, V21, P4201, DOI 10.1158/1078-0432.CCR-14-3049; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Jett K, 2010, GENET MED, V12, P1, DOI 10.1097/GIM.0b013e3181bf15e3; Kannan K, 2012, ONCOTARGET, V3, P1194; Kim A, 2009, NEUROLOGY, V73, P1273, DOI 10.1212/WNL.0b013e3181bd1326; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Levy P, 2007, CLIN CANCER RES, V13, P398, DOI 10.1158/1078-0432.CCR-06-0182; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; Maertens O, 2006, HUM MUTAT, V27, P1030, DOI 10.1002/humu.20389; Mautner VF, 2008, NEURO-ONCOLOGY, V10, P593, DOI 10.1215/15228517-2008-011; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasmant E, 2011, J NATL CANCER I, V103, P1713, DOI 10.1093/jnci/djr416; Pasmant E, 2010, J NEUROPATH EXP NEUR, V69, P60, DOI 10.1097/NEN.0b013e3181c79bff; PELTONEN J, 1988, LAB INVEST, V59, P760; Pemov A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004575; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sabbagh A, 2009, HUM MOL GENET, V18, P2768, DOI 10.1093/hmg/ddp212; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Smithson LJ, 2016, SEMIN CELL DEV BIOL, V58, P118, DOI 10.1016/j.semcdb.2016.06.002; StemmerRachamimov A, 2012, NEUROFIBROMATOSIS TY, P429; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teer JK, 2012, BIOINFORMATICS, V28, P599, DOI 10.1093/bioinformatics/btr711; Teer JK, 2010, GENOME RES, V20, P1420, DOI 10.1101/gr.106716.110; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Upadhyaya M, 2008, HUM MUTAT, V29, P74, DOI [10.1002/humu.20601, 10.1002/humu.20793]; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Uusitalo E, 2016, J CLIN ONCOL, V34, P1978, DOI 10.1200/JCO.2015.65.3576; Van Loo P, 2012, METHODS MOL BIOL, V802, P57, DOI 10.1007/978-1-61779-400-1_4; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weiss B, 2014, PEDIATR BLOOD CANCER, V61, P982, DOI 10.1002/pbc.24873; Widemann BC, 2014, PEDIATR BLOOD CANCER, V61, P1598, DOI 10.1002/pbc.25041; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Youn A, 2011, BIOINFORMATICS, V27, P175, DOI 10.1093/bioinformatics/btq630; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116	57	54	55	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3168	3177		10.1038/onc.2016.464	http://dx.doi.org/10.1038/onc.2016.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068329	Green Accepted			2022-12-28	WOS:000402617900009
J	Ugale, A; Sawen, P; Dudenhoffer-Pfeifer, M; Wahlestedt, M; Norddahl, GL; Bryder, D				Ugale, A.; Sawen, P.; Dudenhoffer-Pfeifer, M.; Wahlestedt, M.; Norddahl, G. L.; Bryder, D.			MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment	ONCOGENE			English	Article							STEM-CELLS; B-CELL; RAS; PROGENITORS; MUTATIONS; TRANSDIFFERENTIATION; TRANSLOCATIONS; TRANSFORMATION; HEMATOPOIESIS; SPECIFICATION	Translocations involving the mixed lineage leukemia-1 are recurrent events in acute leukemia and associate with lymphoid (ALL), myeloid (AML) or mixed lineage (MLL) subtypes. Despite an association with ALL in humans, murine MLL fusion models are persistently restricted to AML. We here explored this issue using an inducible mixed lineage leukemia-eleven nineteen leukemia (MLL-ENL) mouse model. Although multiple progenitor cell types with myeloid potential are potent AML leukemia-initiating cells, also the earliest lymphoid progenitors were capable of initiating AML. This ability to evoke a latent myeloid potential in the earliest lymphoid progenitors was lost upon further lymphoid commitment. At the same time, more downstream/committed lymphoid precursors also failed to initiate lymphoid leukemia. Co-expression of MLL-ENL with a constitutively active RAS allele, the most common co-mutation in MLL fusion leukemias, could influence on both disease latency and lineage assignment of developing leukemia in what appears to be a mutation-order-dependent manner. Finally, CEBPB-mediated transdifferentation of committed and otherwise leukemia-incompetent B-cell progenitors imbued these cells with leukemic competence for AML. Therefore, apart from providing detailed insight into the differential responsiveness of candidate target cells to a first-hit MLL fusion event, our data warrants caution to therapeutic approaches based on the concept of transdifferentiation.	[Ugale, A.; Sawen, P.; Dudenhoffer-Pfeifer, M.; Wahlestedt, M.; Norddahl, G. L.; Bryder, D.] Lund Univ, Inst Lab Med, Mol Hematol, Klinikgatan 26, S-22184 Lund, Sweden	Lund University	Bryder, D (corresponding author), Lund Univ, Inst Lab Med, Mol Hematol, Klinikgatan 26, S-22184 Lund, Sweden.	David.Bryder@med.lu.se	Bryder, David/Q-6292-2019	Bryder, David/0000-0002-8761-4237	Knut and Alice Wallenberg Foundation; Gunnar Nilsson Cancer Foundation; Swedish Research Council; Swedish Cancer Society; Swedish Pediatric Leukemia Foundation; ERC Consolidator [615068]	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Gunnar Nilsson Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Pediatric Leukemia Foundation; ERC Consolidator	We thank Gerd Sten and Eva Erlandsson for expert technical support. This work was supported by a joint project grant from Knut and Alice Wallenberg Foundation and grants from the Gunnar Nilsson Cancer Foundation, the Swedish Research Council, the Swedish Cancer Society, the Swedish Pediatric Leukemia Foundation and an ERC Consolidator grant 615068 to D.B.	Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Bell JJ, 2008, NATURE, V452, P764, DOI 10.1038/nature06840; Cano F, 2008, ONCOGENE, V27, P1945, DOI 10.1038/sj.onc.1210818; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Driessen EMC, 2013, HAEMATOLOGICA, V98, P937, DOI 10.3324/haematol.2012.067983; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Grossmann V, 2013, LEUKEMIA, V27, P1933, DOI 10.1038/leu.2013.90; Inlay MA, 2009, GENE DEV, V23, P2376, DOI 10.1101/gad.1836009; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; King PD, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003669; Krivtsov AV, 2013, LEUKEMIA, V27, P852, DOI 10.1038/leu.2012.363; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lobry C, 2013, J EXP MED, V210, P301, DOI 10.1084/jem.20121484; Luc S, 2012, NAT IMMUNOL, V13, P412, DOI 10.1038/ni.2255; Mansson R, 2008, BLOOD, V112, P1048, DOI 10.1182/blood-2007-11-125385; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Rapino F, 2013, CELL REP, V3, P1153, DOI 10.1016/j.celrep.2013.03.003; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sawen P, 2016, CELL REP, V14, P2809, DOI 10.1016/j.celrep.2016.02.073; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; Ugale A, 2014, CELL REP, V9, P1246, DOI 10.1016/j.celrep.2014.10.036; van Oevelen C, 2015, STEM CELL REP, V5, P232, DOI 10.1016/j.stemcr.2015.06.007; Velasco-Hernandez T, 2016, STEM CELL REP, V7, P21, DOI 10.1016/j.stemcr.2016.06.002; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	27	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3207	3212		10.1038/onc.2016.470	http://dx.doi.org/10.1038/onc.2016.470			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068328				2022-12-28	WOS:000402617900012
J	Dimitrova, N; Nagaraj, AB; Razi, A; Singh, S; Kamalakaran, S; Banerjee, N; Joseph, P; Mankovich, A; Mittal, P; DiFeo, A; Varadan, V				Dimitrova, N.; Nagaraj, A. B.; Razi, A.; Singh, S.; Kamalakaran, S.; Banerjee, N.; Joseph, P.; Mankovich, A.; Mittal, P.; Difeo, A.; Varadan, V.			InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer	ONCOGENE			English	Article							REVEALS; PHOSPHORYLATION; SENSITIVITY; PATHWAYS; BINDING; TARGET; ALPHA; FOXM1	Characterizing the complex interplay of cellular processes in cancer would enable the discovery of key mechanisms underlying its development and progression. Published approaches to decipher driver mechanisms do not explicitly model tissue-specific changes in pathway networks and the regulatory disruptions related to genomic aberrations in cancers. We therefore developed InFlo, a novel systems biology approach for characterizing complex biological processes using a unique multidimensional framework integrating transcriptomic, genomic and/or epigenomic profiles for any given cancer sample. We show that InFlo robustly characterizes tissue-specific differences in activities of signalling networks on a genome scale using unique probabilistic models of molecular interactions on a per-sample basis. Using large-scale multi-omics cancer datasets, we show that InFlo exhibits higher sensitivity and specificity in detecting pathway networks associated with specific disease states when compared to published pathway network modelling approaches. Furthermore, InFlo's ability to infer the activity of unmeasured signalling network components was also validated using orthogonal gene expression signatures. We then evaluated multi-omics profiles of primary high-grade serous ovarian cancer tumours (N = 357) to delineate mechanisms underlying resistance to frontline platinumbased chemotherapy. InFlo was the only algorithm to identify hyperactivation of the cAMP-CREB1 axis as a key mechanism associated with resistance to platinum-based therapy, a finding that we subsequently experimentally validated. We confirmed that inhibition of CREB1 phosphorylation potently sensitized resistant cells to platinum therapy and was effective in killing ovarian cancer stem cells that contribute to both platinum-resistance and tumour recurrence. Thus, we propose InFlo to be a scalable and widely applicable and robust integrative network modelling framework for the discovery of evidence-based biomarkers and therapeutic targets.	[Dimitrova, N.; Kamalakaran, S.; Banerjee, N.; Mankovich, A.] Philips Res North Amer, Dept Clin Informat Solut & Serv, Briarcliff Manor, NY USA; [Nagaraj, A. B.; Razi, A.; Singh, S.; Joseph, P.; Difeo, A.; Varadan, V.] Case Western Reserve Univ, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3125, Cleveland, OH 44106 USA; [Mittal, P.] Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	Philips; Philips Research; Case Western Reserve University; Princeton University	DiFeo, A; Varadan, V (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3125, Cleveland, OH 44106 USA.	analisa.difeo@case.edu; vinay.varadan@case.edu	Varadan, Vinay/AAC-2520-2020; Nagaraj, Anil Belur/V-7779-2019; Singh, Salendra/AAG-8574-2019	Singh, Salendra/0000-0002-4903-9868; DiFeo, Analisa/0000-0001-8319-6763	PHS award: Career Development Program of Case GI SPORE [P50 CA150964]; PHS award: Career Development Program in Computational Genomic Epidemiology of Cancer [R25T CA094186]; Philips Healthcare; Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals; Ohio Cancer Research award; VelaSano Bike for Cure Funds; Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo); NATIONAL CANCER INSTITUTE [P50CA150964, R25CA094186] Funding Source: NIH RePORTER	PHS award: Career Development Program of Case GI SPORE; PHS award: Career Development Program in Computational Genomic Epidemiology of Cancer; Philips Healthcare; Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals; Ohio Cancer Research award; VelaSano Bike for Cure Funds; Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported, in part, by PHS awards: Career Development Program of Case GI SPORE (P50 CA150964) award to Vinay Varadan; Career Development Program in Computational Genomic Epidemiology of Cancer (R25T CA094186) award to Vinay Varadan In addition, this research was supported, in part, by research funding from Philips Healthcare to Vinay Varadan: the Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals to Vinay Varadan: Ohio Cancer Research award to Vinay Varadan: VelaSano Bike for Cure Funds award to Analisa DiFeo and Vinay Varadan: and the Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo).	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benedetti V, 2008, MOL CANCER THER, V7, P679, DOI 10.1158/1535-7163.MCT-07-0450; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Efroni S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000425; Figueroa JD, 2010, BREAST CANCER RES TR, V121, P727, DOI 10.1007/s10549-009-0590-z; Greenblum SI, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-133; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kuroda T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065158; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu J.S., 2001, MONTE CARLO STRATEGI; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mutation C, 2015, NAT METHODS, V12, P615, DOI DOI 10.1038/NMETH.3440; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Varadan V, 2012, IEEE SIGNAL PROC MAG, V29, P35, DOI 10.1109/MSP.2011.943037; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429; Xie Y, 2014, MOL MED REP, V10, P2346, DOI 10.3892/mmr.2014.2490; Yang S, 2009, ANESTH ANALG, V108, P964, DOI 10.1213/ane.0b013e318192442c; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	27	14	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2472	2482		10.1038/onc.2016.398	http://dx.doi.org/10.1038/onc.2016.398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819677	Green Published, hybrid			2022-12-28	WOS:000400268900012
J	Ambrogio, C; Barbacid, M; Santamaria, D				Ambrogio, C.; Barbacid, M.; Santamaria, D.			In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; K-RAS ONCOGENE; CANCER; MUTANT; INHIBITORS; INDUCTION; CARCINOMA; FEATURES; CELLS; GENE	Activating mutations in KRAS and EGFR, the two most frequent oncogenes in human lung adenocarcinoma, are mutually exclusive, a phenotype attributed to functional redundancy implying lack of positive selection. Employing a mouse model expressing EGFR(L858R) in advanced Kras(G12V)-driven tumors we show that their mutual exclusivity can be explained by detrimental effects of their co-expression in lung adenocarcinoma. In vivo, expression of EGFR(L858R) in Kras(G12V)-driven tumors triggers replicative stress and apoptosis, while the surviving cells enter a transient cytostatic state incompatible with tumor development that is fully reversible upon discontinued EGFR(L858R) expression. Eventually, sustained expression of both mutants induces attenuation of oncogenic signaling to levels compatible with proliferation and tumor growth resulting in high sensitivity to Mek inhibition. Our results indicate that the mutual exclusivity of KRAS and EGFR mutations occurs as a combination of cellular toxicity and signal adjustment resulting in lack of selective advantage for cells expressing both oncogenes.	[Ambrogio, C.; Barbacid, M.; Santamaria, D.] CNIO, Expt Oncol, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain; [Ambrogio, C.] Dana Farber Canc Inst, Med Oncol, 360 Longwood Ave,LC-4112, Boston, MA 02215 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Harvard University; Dana-Farber Cancer Institute	Ambrogio, C; Santamaria, D (corresponding author), CNIO, Expt Oncol, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	chiara_ambrogio@dfci.harvard.edu; dsantamaria@cnio.es	Santamaria, David/D-3930-2011	Santamaria, David/0000-0002-4711-3569	European Research Council [ERC-AG/250297-RAS AEAD]; EU [HEALTH-F2-2010-259770/LUNGTARGET, HEALTH-2010-260791/EUROCANPLATFORM]; Spanish Ministry of Economy and Competitiveness [SAF2011-30173]; Autonomous Community of Madrid [S2011/BDM-2470/ONCO-CYCLE]; Spanish Association Against Cancer (AECC)	European Research Council(European Research Council (ERC)European Commission); EU(European Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid; Spanish Association Against Cancer (AECC)	We thank J. Haigh for providing Rosa26-LSLrtTA mice. This work was supported by the European Research Council (ERC-AG/250297-RAS AEAD), EU-Framework Programme (HEALTH-F2-2010-259770/LUNGTARGET and HEALTH-2010-260791/EUROCANPLATFORM), Spanish Ministry of Economy and Competitiveness (SAF2011-30173) and Autonomous Community of Madrid (S2011/BDM-2470/ONCO-CYCLE) to MB. CA is the recipient of a postdoctoral fellowship from the Spanish Association Against Cancer (AECC). We thank A. Ventura, O. Segatto and T. Cash for critical reading of the manuscript and S. Anton for constructive discussion.	Ambrogio C, 2015, BIOPROTOCOL, V5, pe1692; Ambrogio C, 2014, CANCER RES, V74, P5978, DOI 10.1158/0008-5472.CAN-14-1606; Anastasi S, 2016, SEMIN CELL DEV BIOL, V50, P115, DOI 10.1016/j.semcdb.2015.10.001; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Choughule A, 2014, BRIT J CANCER, V111, P2203, DOI 10.1038/bjc.2014.401; Cisowski J, 2015, ONCOGENE, V35, P1; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guha U, 2008, P NATL ACAD SCI USA, V105, P14112, DOI 10.1073/pnas.0806158105; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Li S, 2014, BRIT J CANCER, V110, P2812, DOI 10.1038/bjc.2014.210; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pikor LA, 2013, LUNG CANCER, V82, P179, DOI 10.1016/j.lungcan.2013.07.025; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Segatto O, 2011, J CELL SCI, V124, P1785, DOI 10.1242/jcs.083303; Sharifnia T, 2014, P NATL ACAD SCI USA, V111, P18661, DOI 10.1073/pnas.1412228112; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163	28	18	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2309	2318		10.1038/onc.2016.385	http://dx.doi.org/10.1038/onc.2016.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27775074				2022-12-28	WOS:000399782700011
J	Wang, L; Ren, J; Li, G; Moorman, JP; Yao, ZQ; Ning, S				Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.			LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; MEMBRANE-PROTEIN 1; MULTIPLE-MYELOMA; CELL-SURVIVAL; REGULATORY FACTOR-4; FAMILY-MEMBER; TARGET GENES	Interferon (IFN) regulatory factors (IRFs) have crucial roles in immune regulation and oncogenesis. We have recently shown that IRF4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells. However, the intracellular signaling pathway triggering Src activation of IRF4 remains unknown. In this study, we provide evidence that Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) promotes IRF4 phosphorylation and markedly stimulates IRF4 transcriptional activity, and that Src mediates LMP1 activation of IRF4. As to more precise mechanism, we show that LMP1 physically interacts with c-Src, and the phosphatidylinositol 3 kinase (PI3K) subunit P85 mediates their interaction. Depletion of P85 by P85-specific short hairpin RNAs disrupts their interaction and diminishes IRF4 phosphorylation in EBV-transformed cells. Furthermore, we show that Src is upstream of PI3K for activation of both IRF4 and Akt. In turn, inhibition of PI3K kinase activity by the PI3K-speicfic inhibitor LY294002 impairs Src activity. Our results show that LMP1 signaling is responsible for IRF4 activation, and further characterize the IRF4 regulatory network that is a promising therapeutic target for specific hematological malignancies.	[Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.] East Tennessee State Univ, Div Infect Dis, Dept Internal Med, Quillen Coll Med, Johnson City, TN 37614 USA; [Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.] East Tennessee State Univ, Ctr Excellence Inflammat Infect Dis & Immun, Quillen Coll Med, Johnson City, TN 37614 USA; [Moorman, J. P.; Yao, Z. Q.] James H Quillen VA Med Ctr, Hepatitis HCV HIV Program, Johnson City, TN USA	East Tennessee State University; East Tennessee State University	Ning, S (corresponding author), East Tennessee State Univ, Div Infect Inflammatory & Immunol Dis, Dept Internal Med, Quillen Coll Med, Johnson City, TN 37614 USA.	nings1@etsu.edu	Ning, Shunbin/AAC-6895-2021; Ning, Shunbin/I-3961-2019	Ning, Shunbin/0000-0001-5484-5779	NIH NIDDK grant [R01DK093526]; NIH NIAID grant [R01AI114748]; American Society of Hematology Scholar Award; NIH grant [C06RR0306551]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093526] Funding Source: NIH RePORTER	NIH NIDDK grant; NIH NIAID grant(CGIAR); American Society of Hematology Scholar Award; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by an NIH NIDDK grant to ZQY/JPM (R01DK093526), an NIH NIAID grant to ZQY/JPM (R01AI114748), the American Society of Hematology Scholar Award to SN, and in part by the NIH grant C06RR0306551. We thank Dr Bill Sugden for providing pSV2-LMP1 and its deletion mutant pSV2-LMP1.(12-20). This publication is the result of work supported with resources and the use of facilities at the James H Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.	Alvarez RH, 2006, CANCER-AM CANCER SOC, V107, P1918, DOI 10.1002/cncr.22215; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Banerjee S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003314; Biswas PS, 2010, IMMUNOL REV, V233, P79, DOI 10.1111/j.0105-2896.2009.00864.x; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Carbone A, 2008, ONCOLOGIST, V13, P577, DOI 10.1634/theoncologist.2008-0036; Chang CC, 2002, BLOOD, V100, P4671, DOI 10.1182/blood-2002-01-0104; Davies CC, 2005, MOL CELL BIOL, V25, P9806, DOI 10.1128/MCB.25.22.9806-9819.2005; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Feldman AL, 2009, LEUKEMIA, V23, P574, DOI 10.1038/leu.2008.320; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Gu TL, 2010, LEUKEMIA, V24, P861, DOI 10.1038/leu.2009.293; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Havelange V, 2011, BLOOD, V118, P2827, DOI 10.1182/blood-2011-04-350579; Huye LE, 2007, MOL CELL BIOL, V27, P2910, DOI 10.1128/MCB.02256-06; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Kieser A., 2007, SIGNAL TRANSDUCTION, V7, P20, DOI [10.1002/sita.200600116, DOI 10.1002/SITA.200600116]; Kieser A, 2015, CURR TOP MICROBIOL, V391, P119, DOI 10.1007/978-3-319-22834-1_4; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Martin HJ, 2007, J VIROL, V81, P9748, DOI 10.1128/JVI.01122-07; Middeldorp JM, 2008, SEMIN CANCER BIOL, V18, P388, DOI 10.1016/j.semcancer.2008.10.004; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Ning S, 2013, J ONCOBIOMARKERS, V1, P6; Ning SB, 2008, MOL CELL BIOL, V28, P6536, DOI 10.1128/MCB.00785-08; Pagano JS, 2004, SEMIN CANCER BIOL, V14, P453, DOI 10.1016/j.semcancer.2004.06.009; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Ramos JC, 2007, BLOOD, V109, P3060, DOI 10.1182/blood-2006-07-036368; Rui LX, 2011, NAT IMMUNOL, V12, P933, DOI 10.1038/ni.2094; Saddawi-Konefka R, 2010, J NEUROIMMUNE PHARM, V5, P387, DOI 10.1007/s11481-010-9204-0; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; So T, 2011, J IMMUNOL, V186, P3547, DOI 10.4049/jimmunol.1003156; Soni V, 2007, ADV EXP MED BIOL, V597, P173; Spender LC, 2006, J GEN VIROL, V87, P2859, DOI 10.1099/vir.0.82128-0; St-Germain JR, 2009, P NATL ACAD SCI USA, V106, P20127, DOI 10.1073/pnas.0910957106; Stunz LL, 2014, CRIT REV IMMUNOL, V34, P177, DOI 10.1615/CritRevImmunol.2014010041; Sundram U, 2003, MODERN PATHOL, V16, P802, DOI 10.1097/01.MP.0000081726.49886.CF; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106788; Wang L, 2013, J VIROL, V87, P9672, DOI 10.1128/JVI.01435-13; Wang L, 2011, J VIROL, V85, P8328, DOI 10.1128/JVI.00570-11; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xu DS, 2008, J VIROL, V82, P6251, DOI 10.1128/JVI.00163-08; Zhang BC, 2012, CELL, V148, P739, DOI 10.1016/j.cell.2011.12.031; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004	55	11	11	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2265	2274		10.1038/onc.2016.380	http://dx.doi.org/10.1038/onc.2016.380			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819673	Green Submitted, Green Accepted			2022-12-28	WOS:000399782700007
J	Gu, P; Wang, Y; Bisht, KK; Wu, L; Kukova, L; Smith, EM; Xiao, Y; Bailey, SM; Lei, M; Nandakumar, J; Chang, S				Gu, P.; Wang, Y.; Bisht, K. K.; Wu, L.; Kukova, L.; Smith, E. M.; Xiao, Y.; Bailey, S. M.; Lei, M.; Nandakumar, J.; Chang, S.			Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis	ONCOGENE			English	Article							DNA-DAMAGE; CHECKPOINT ACTIVATION; PROTEIN; CANCER; REPAIR; PROTECTION; TPP1; CHROMOTHRIPSIS; CHROMOSOMES; BINDING	Chromosomal aberrations are a hallmark of human cancers, with complex cytogenetic rearrangements leading to genetic changes permissive for cancer initiation and progression. Protection of Telomere 1 (POT1) is an essential component of the shelterin complex and functions to maintain chromosome stability by repressing the activation of aberrant DNA damage and repair responses at telomeres. Sporadic and familial mutations in the oligosaccharide-oligonucleotide (OB) folds of POT1 have been identified in many human cancers, but the mechanism underlying how hPOT1 mutations initiate tumorigenesis has remained unclear. Here we show that the human POT1's OB-folds are essential for the protection of newly replicated telomeres. Oncogenic mutations in hPOT1 OB-fold fail to bind to single-stranded telomeric DNA, eliciting a DNA damage response at telomeres that promote inappropriate chromosome fusions via the mutagenic alternative non-homologous end joining (A-NHEJ) pathway. hPOT1 mutations also result in telomere elongation and the formation of transplantable hematopoietic malignancies. Strikingly, conditional deletion of both mPot1a and p53 in mouse mammary epithelium resulted in development of highly invasive breast carcinomas and the formation of whole chromosomes containing massive arrays of telomeric fusions indicative of multiple breakage-fusion-bridge cycles. Our results reveal that hPOT1 OB-folds are required to protect and prevent newly replicated telomeres from engaging in A-NHEJ mediated fusions that would otherwise promote genome instability to fuel tumorigenesis.	[Gu, P.; Wang, Y.; Kukova, L.; Chang, S.] Yale Univ, Sch Med, Dept Lab Med, BML 462,333 Cedar St, New Haven, CT 06520 USA; [Bisht, K. K.; Smith, E. M.; Nandakumar, J.] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; [Bisht, K. K.; Smith, E. M.; Nandakumar, J.] Univ Michigan, Program Chem Biol, Ann Arbor, MI 48109 USA; [Wu, L.] UT MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX USA; [Xiao, Y.] Baylor Coll Med, Dept Med & Mol & Cellular Biol, Sect Hematol Oncol, Houston, TX 77030 USA; [Bailey, S. M.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; [Lei, M.] Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Natl Ctr Prot Sci Shanghai,Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Chang, S.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Chang, S.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Yale University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Colorado State University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Yale University; Yale University	Chang, S (corresponding author), Yale Univ, Sch Med, Dept Lab Med, BML 462,333 Cedar St, New Haven, CT 06520 USA.	s.chang@yale.edu		Smith, Eric/0000-0002-5385-4558; Nandakumar, Jayakrishnan/0000-0001-9146-2785	NCI [RO1 CA129037, R01 CA202816, R21 CA200506, R21 CA182280]; CT Department of Public Health [15-002167]; NIH [NIH R00-CA-167644-03, NIH R01-AG050509]; NATIONAL CANCER INSTITUTE [R21CA182280, R01CA129037, R21CA200506, R00CA167644, R01CA202816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114, R01AG050509] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CT Department of Public Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Asha Multani (MDACC, Houston, TX) for SKY analyses and Dr James You (MDACC, Houston, TX) for histological analyses and Dr Christos Hatzis (Yale university School of Medicine) for POT1 mutation analyses. We thank the Chang lab for helpful suggestions. This work was supported by the NCI (RO1 CA129037, R01 CA202816, R21 CA200506 and R21 CA182280) and the CT Department of Public Health (15-002167) to Sandy Chang. Support for Jayakrishnan Nandakumar is from the NIH (NIH R00-CA-167644-03, NIH R01-AG050509 (Jayakrishnan Nandakumar, co-investigator).	Abreu E, 2011, METHODS MOL BIOL, V735, P125, DOI 10.1007/978-1-61779-092-8_12; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Badie S, 2015, EMBO J, V34, P828, DOI 10.15252/embj.201570610; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Calvete O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9383; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chang S, 2013, NAT GENET, V45, P473, DOI 10.1038/ng.2617; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Fan JS, 2010, BLOOD, V116, P5298, DOI 10.1182/blood-2010-03-272591; Flynn RL, 2011, NATURE, V471, P532, DOI 10.1038/nature09772; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gu P, 2013, CELL RES, V23, P705, DOI 10.1038/cr.2013.31; Guirouilh-Barbat J, 2007, P NATL ACAD SCI USA, V104, P20902, DOI 10.1073/pnas.0708541104; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hockemeyer D, 2007, NAT STRUCT MOL BIOL, V14, P754, DOI 10.1038/nsmb1270; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Jones MJK, 2012, DEV CELL, V23, P908, DOI 10.1016/j.devcel.2012.10.010; Lam YC, 2010, EMBO J, V29, P2230, DOI 10.1038/emboj.2010.58; Latrick CM, 2010, EMBO J, V29, P924, DOI 10.1038/emboj.2009.409; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200; Li YL, 2014, NATURE, V508, P98, DOI 10.1038/nature13115; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Maciejowski J, 2015, CELL, V163, P1641, DOI 10.1016/j.cell.2015.11.054; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; McClintock B, 1941, GENETICS, V26, P234; Multani AS, 2011, METHODS MOL BIOL, V735, P139, DOI 10.1007/978-1-61779-092-8_13; Nandakumar J, 2012, NATURE, V492, P285, DOI 10.1038/nature11648; Nandakumar J, 2010, P NATL ACAD SCI USA, V107, P651, DOI 10.1073/pnas.0911099107; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; Palm W, 2009, MOL CELL BIOL, V29, P471, DOI 10.1128/MCB.01352-08; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rai R, 2011, NAT STRUCT MOL BIOL, V18, P1400, DOI 10.1038/nsmb.2172; Rai R, 2010, EMBO J, V29, P2598, DOI 10.1038/emboj.2010.142; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Symington LS, 2011, ANNU REV GENET, V45, P247, DOI 10.1146/annurev-genet-110410-132435; Thanasoula M, 2012, EMBO J, V31, P3398, DOI 10.1038/emboj.2012.191; Tobin LA, 2012, MOL CANCER RES, V10, P96, DOI 10.1158/1541-7786.MCR-11-0255; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Wang Y, 2013, J CLIN INVEST, V123, P4489, DOI 10.1172/JCI69574; Wang Y, 2011, BLOOD, V118, P6068, DOI 10.1182/blood-2011-06-361527; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493; Zhong FL, 2012, CELL, V150, P481, DOI 10.1016/j.cell.2012.07.012	64	35	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1939	1951		10.1038/onc.2016.405	http://dx.doi.org/10.1038/onc.2016.405			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869160	Green Accepted			2022-12-28	WOS:000398898500005
J	Li, Z; Bridges, B; Olson, J; Weinman, SA				Li, Z.; Bridges, B.; Olson, J.; Weinman, S. A.			The interaction between acetylation and serine-574 phosphorylation regulates the apoptotic function of FOXO3	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXO3A; BREAST-CANCER; SIRT1; PROTEIN; DEACETYLATION; DEGRADATION; PROMOTES; STRESS; TUMORIGENESIS; METABOLISM	The multispecific transcription factor and tumor suppressor FOXO3 is an important mediator of apoptosis, but the mechanisms that control its proapoptotic function are poorly understood. There has long been evidence that acetylation promotes FOXO3driven apoptosis and recently a specific JNK (c-Jun N-terminal kinase)-dependent S574 phosphorylated form (p-FOXO3) has been shown to be specifically apoptotic. This study examined whether acetylation and S574 phosphorylation act independently or in concert to regulate the apoptotic function of FOXO3. We observed that both sirtuins 1 and 7 (SIRT1 and SIRT7) are able to deacetylate FOXO3 in vitro and in vivo, and that lipopolysaccharide (LPS) treatment of THP-1 monocytes induced a rapid increase of FOXO3 acetylation, partly by suppression of SIRT1 and SIRT7. Acetylation was required for S574 phosphorylation and cellular apoptosis. Deacetylation of FOXO3 by SIRT activation or SIRT1 or SIRT7 overexpression prevented its S574 phosphorylation and blocked apoptosis in response to LPS. We also found that acetylated FOXO3 preferentially bound JNK1, and a mutant FOXO3 lacking four known acetylation sites (K242, 259, 290 and 569R) abolished JNK1 binding and failed to induce apoptosis. This interplay of acetylation and phosphorylation also regulated cell death in primary human peripheral blood monocytes (PBMs). PBMs isolated from alcoholic hepatitis patients had high expression of SIRT1 and SIRT7 and failed to induce p-FOXO3 and apoptosis in response to LPS. PBMs from healthy controls had lower SIRT1 and SIRT7 and readily formed p-FOXO3 and underwent apoptosis when similarly treated. These results reveal that acetylation is permissive for generation of the apoptotic form of FOXO3 and the activity of SIRT1 and particularly SIRT7 regulate this process in vivo, allowing control of monocyte apoptosis in response to LPS.	[Li, Z.; Olson, J.; Weinman, S. A.] Univ Kansas, Med Ctr, Dept Internal Med, 3901 Rainbow Blvd,Mailstop 1018, Kansas City, KS 66160 USA; [Bridges, B.; Weinman, S. A.] Univ Kansas, Med Ctr, Ctr Liver, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Weinman, SA (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, 3901 Rainbow Blvd,Mailstop 1018, Kansas City, KS 66160 USA.	sweinman@kumc.edu	Li, Zhuan/C-3196-2014	LI, ZHUAN/0000-0002-1310-4584	National Institute on Alcoholism and Alcohol Abuse [AA012863]; Biomedical Research Training Program of the University of Kansas Medical Center; Hubert and Richard Hanlon Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	National Institute on Alcoholism and Alcohol Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Biomedical Research Training Program of the University of Kansas Medical Center; Hubert and Richard Hanlon Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This study was supported by grant AA012863 from the National Institute on Alcoholism and Alcohol Abuse, a fellowship grant from the Biomedical Research Training Program of the University of Kansas Medical Center (to ZL) and by a grant from the Hubert and Richard Hanlon Trust. The human monocytes used in this study were provided by the University of Kansas Liver Center Tissue Bank. We thank Drs Charles Rice and Robert A Davey for providing reagents for these studies.	Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chung YW, 2011, J BIOL CHEM, V286, P29681, DOI 10.1074/jbc.M111.264945; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Elmali N, 2007, INFLAMMATION, V30, P1, DOI 10.1007/s10753-006-9012-0; Flick F, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00029; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Lee SM, 2011, DIABETOLOGIA, V54, P1136, DOI 10.1007/s00125-011-2064-1; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lucey MR, 2009, NEW ENGL J MED, V360, P2758, DOI 10.1056/NEJMra0805786; MCKEEVER UM, 1983, LANCET, V2, P1492; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Nasrin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008414; Ni HM, 2013, AM J PATHOL, V183, P1815, DOI 10.1016/j.ajpath.2013.08.011; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ponugoti B, 2010, J BIOL CHEM, V285, P33959, DOI 10.1074/jbc.M110.122978; Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783; Roychowdhury S, 2009, HEPATOLOGY, V49, P1326, DOI 10.1002/hep.22776; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang YF, 2015, CELL STRESS CHAPERON, V20, P805, DOI 10.1007/s12192-015-0599-7; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872; Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085	41	28	30	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1887	1898		10.1038/onc.2016.359	http://dx.doi.org/10.1038/onc.2016.359			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27669435	Green Accepted			2022-12-28	WOS:000398128900013
J	Mimoto, R; Imawari, Y; Hirooka, S; Takeyama, H; Yoshida, K				Mimoto, R.; Imawari, Y.; Hirooka, S.; Takeyama, H.; Yoshida, K.			Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; DOWN-REGULATION; DNA-DAMAGE; CELLS; PHOSPHORYLATION; PROGRESSION; P53; DIFFERENTIATION; PROLIFERATION; CHEMOTHERAPY	Whereas accumulating studies have supported the cancer stem cell theory, a specific therapy targeting a cancer stem cell subpopulation has not been established. Here, we show that dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) is a novel negative regulator for formation of breast cancer stem cells. Downregulation of DYRK2 promotes cancer stem-like traits in vitro, tumourigenesis in vivo and the proportion of the cancer stem cell population in human breast cancer tissues. We found that Krupple-like factor 4 (KLF4) serves as a key mediator of DYRK2's control over the cancer stem phenotype. Reduced DYRK2 expression increases KLF4 expression, which induces cancer stem-like properties. We identified androgen receptor (AR) as a transcription factor binding to the KLF4 promoter region; this process is dependent on DYRK2 kinase activity. Our findings delineate a mechanism of cancer stem cell regulation by the DYRK2-AR-KLF4 axis in breast cancer. Targeting of this pathway may be a promising strategy against breast cancer stem cells.	[Mimoto, R.; Imawari, Y.; Yoshida, K.] Jikei Univ, Sch Med, Dept Biochem, Tokyo, Japan; [Mimoto, R.; Imawari, Y.; Takeyama, H.] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan; [Hirooka, S.] Jikei Univ, Sch Med, Dept Pathol, Tokyo, Japan	Jikei University; Jikei University; Jikei University	Yoshida, K (corresponding author), Jikei Univ, Sch Med, Dept Biochem, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	kyoshida@jikei.ac.jp		Kudo, Rei/0000-0003-0702-5828	JSPS KAKENHI [26290041, 26861056]; Takeda Science Foundation; Vehicle Racing Commemorative Foundation; Research Grant of the Princess Takamatsu Cancer Research Fund	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Vehicle Racing Commemorative Foundation; Research Grant of the Princess Takamatsu Cancer Research Fund	The authors appreciate all patients who provided the clinical samples for the study. We thank Naoe T Nihira for microarray analysis, Mamiko Owada for immunohistochemistry, Minori Kamada for FACS analysis and Noriko Yamaguchi for xenograft experiments. This work was supported by grants from JSPS KAKENHI Grant Number 26290041 and 26861056, Takeda Science Foundation, the Vehicle Racing Commemorative Foundation and Research Grant of the Princess Takamatsu Cancer Research Fund.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aranda S, 2011, FASEB J, V25, P449, DOI 10.1096/fj.10-165837; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Choi BJ, 2006, PATHOL RES PRACT, V202, P585, DOI 10.1016/j.prp.2006.05.001; Enomoto Y, 2014, TUMOR BIOL, V35, P11021, DOI 10.1007/s13277-014-2413-z; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Hiyama E, 2007, BRIT J CANCER, V96, P1020, DOI 10.1038/sj.bjc.6603671; Jung HY, 2013, J BIOL CHEM, V288, P7252, DOI 10.1074/jbc.M112.416792; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinescu VD, 2005, NUCLEIC ACIDS RES, V33, pD91, DOI 10.1093/nar/gki103; Mimoto R, 2014, BREAST CANCER RES TR, V147, P317, DOI 10.1007/s10549-014-3111-7; Mimoto R, 2013, CANCER LETT, V339, P214, DOI 10.1016/j.canlet.2013.06.005; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nomura S, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0040-7; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Taira N, 2014, P NATL ACAD SCI USA, V111, P717, DOI 10.1073/pnas.1313675111; Taira N, 2012, J CLIN INVEST, V122, P859, DOI 10.1172/JCI60818; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Wang YC, 2015, INT J BIOL MACROMOL, V81, P809, DOI 10.1016/j.ijbiomac.2015.08.067; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yamaguchi N, 2015, TUMOR BIOL, V36, P5913, DOI 10.1007/s13277-015-3264-y; Yamashita SI, 2009, ANTICANCER RES, V29, P2753; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	33	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1862	1872		10.1038/onc.2016.349	http://dx.doi.org/10.1038/onc.2016.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721402				2022-12-28	WOS:000398128900011
J	Takiar, V; Ip, CKM; Gao, M; Mills, GB; Cheung, LWT				Takiar, V.; Ip, C. K. M.; Gao, M.; Mills, G. B.; Cheung, L. W. T.			Neomorphic mutations create therapeutic challenges in cancer	ONCOGENE			English	Review							YIN-YANG 1; TRANSCRIPTION FACTOR YIN-YANG-1; PROTEIN PHOSPHATASE-ACTIVITY; ISOCITRATE-DEHYDROGENASE 1; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; MUTANT P53; GENE-EXPRESSION; ONCOMETABOLITE 2-HYDROXYGLUTARATE; PIK3CA MUTATIONS	Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.	[Takiar, V.] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Dept Radiat Oncol, Cincinnati, OH 45221 USA; [Takiar, V.] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Dept Canc Biol, Cincinnati, OH 45221 USA; [Ip, C. K. M.; Gao, M.; Mills, G. B.; Cheung, L. W. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, G. B.; Cheung, L. W. T.] Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center; University of Hong Kong	Mills, GB; Cheung, LWT (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	gmills@mdanderson.org; lydiacwt@hku.hk		Mills, Gordon/0000-0002-0144-9614; Ip, Carman K.M./0000-0002-6672-5982; Takiar, Vinita/0000-0002-2499-3516; Cheung, Lydia Wai Ting/0000-0003-1137-3200	Adelson Medical Research Foundation; HKU Seed Funding Programme for Basic Research [201606159001];  [U54HG008100];  [U01CA168394];  [P50 CA098258];  [P50CA083639]; NATIONAL CANCER INSTITUTE [P50CA098258, U01CA217842] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG008100] Funding Source: NIH RePORTER	Adelson Medical Research Foundation; HKU Seed Funding Programme for Basic Research; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We apologize to colleagues whose work was not cited owing to space constraints or our oversight. This work was supported by U54HG008100, U01CA168394, P50 CA098258, P50CA083639, the Adelson Medical Research Foundation and HKU Seed Funding Programme for Basic Research (201606159001).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Alagesan B, 2015, CLIN CANCER RES, V21, P396, DOI 10.1158/1078-0432.CCR-14-1591; Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Andronesi OC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002693; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Baritaki S, 2007, INT J ONCOL, V31, P69; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Boulahbel H, 2009, BIOCHEM SOC T, V37, P291, DOI 10.1042/BST0370291; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Britten CD, 2013, CANCER CHEMOTH PHARM, V71, P1395, DOI 10.1007/s00280-013-2121-1; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3810; Castellano G, 2010, CELL CYCLE, V9, P557, DOI 10.4161/cc.9.3.10554; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Cheung LWT, 2015, ELIFE, V4, DOI 10.7554/eLife.06866; Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Clark O, 2016, CLIN CANCER RES, V22, P1837, DOI 10.1158/1078-0432.CCR-13-1333; Costa HA, 2015, P NATL ACAD SCI USA, V112, P13976, DOI 10.1073/pnas.1422504112; Creixell P, 2015, CELL, V163, P187, DOI 10.1016/j.cell.2015.08.057; Creixell P, 2015, CELL, V163, P202, DOI 10.1016/j.cell.2015.08.056; Cromer MK, 2015, P NATL ACAD SCI USA, V112, P4062, DOI 10.1073/pnas.1503696112; Crunkhorn S, 2015, NAT REV DRUG DISCOV, V14, P15, DOI 10.1038/nrd4523; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DALZIEL K, 1980, FEBS LETT, V117, pK45, DOI 10.1016/0014-5793(80)80569-2; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; de Nigris F, 2006, EUR J CANCER, V42, P2420, DOI 10.1016/j.ejca.2006.06.008; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dogruluk T, 2015, CANCER RES, V75, P5341, DOI 10.1158/0008-5472.CAN-15-1654; Eiriksdottir G, 1998, ONCOGENE, V16, P21, DOI 10.1038/sj.onc.1201509; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frum Rebecca A, 2014, Subcell Biochem, V85, P187, DOI 10.1007/978-94-017-9211-0_10; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gong LL, 2015, CELL CYCLE, V14, P2323, DOI 10.1080/15384101.2015.1044174; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Grubach L, 2008, EUR J HAEMATOL, V81, P112, DOI 10.1111/j.1600-0609.2008.01083.x; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hao YJ, 2013, CANCER CELL, V23, P583, DOI 10.1016/j.ccr.2013.03.021; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Janku F, 2014, CELL REP, V6, P377, DOI 10.1016/j.celrep.2013.12.035; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kalinina J, 2012, J MOL MED, V90, P1161, DOI 10.1007/s00109-012-0888-x; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Kramer OH, 2014, TRENDS PHARMACOL SCI, V35, P501, DOI 10.1016/j.tips.2014.08.001; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Ligresti G, 2009, CELL CYCLE, V8, P1352, DOI 10.4161/cc.8.9.8255; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu JL, 2011, MODERN PATHOL, V24, P1327, DOI 10.1038/modpathol.2011.98; Lokshin M, 2007, NUCLEIC ACIDS RES, V35, P340, DOI 10.1093/nar/gkl1047; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Lv S, 2011, ANTICANCER RES, V31, P4457; Ma K, 2008, CELL SIGNAL, V20, P684, DOI 10.1016/j.cellsig.2007.12.004; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsumura N, 2009, MOL CANCER RES, V7, P210, DOI 10.1158/1541-7786.MCR-08-0255; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Moll UM, 2004, MOL CANCER RES, V2, P371; MULLER H. J., 1932, Proceedings. 6th Int. Congr. Genet., V1, P213; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Perez RE, 2010, J CELL PHYSIOL, V225, P394, DOI 10.1002/jcp.22285; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Pitts TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113037; Pope WB, 2012, J NEURO-ONCOL, V107, P197, DOI 10.1007/s11060-011-0737-8; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Quayle SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049466; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Seligson D, 2005, INT J ONCOL, V27, P131; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang W, 2015, J BIOMOL SCREEN, V20, P821, DOI 10.1177/1087057115579637; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Williams SC, 2011, ACTA NEUROPATHOL, V121, P279, DOI 10.1007/s00401-010-0790-y; Wu HY, 2009, P NATL ACAD SCI USA, V106, P20258, DOI 10.1073/pnas.0902369106; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Yi YW, 2013, ONCOTARGET, V4, P984, DOI 10.18632/oncotarget.1070; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	178	17	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1607	1618		10.1038/onc.2016.312	http://dx.doi.org/10.1038/onc.2016.312			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27841866	Green Accepted			2022-12-28	WOS:000397460600001
J	Wang, Y; Ou, Z; Sun, Y; Yeh, S; Wang, X; Long, J; Chang, C				Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Wang, X.; Long, J.; Chang, C.			Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals	ONCOGENE			English	Article							PROSTATE-CANCER; TRANSCRIPTION FACTOR; BLADDER-CANCER; CELL-MIGRATION; MITF; PROGRESSION; RESISTANCE; THERAPY; SURVIVAL; BEHAVIOR	Early studies demonstrated that male melanoma patients have worse survival than female patients, yet the detailed mechanisms for this gender difference remain unclear. We analyzed around 100 cases of human melanoma and found that androgen receptor (AR) positive melanoma patients have worse survival outcomes compared with AR-negative melanoma patients. Here we report that AR can have positive roles to increase melanoma cell invasion in multiple cell lines in vitro and a mouse model in vivo. Mechanism dissection suggest that AR increases melanoma cell invasion via modulating the MITF-AXL signals via altering the miRNA-539-3p/USP13 signaling to increase MITF protein degradation through a reduction of de-ubiquitination. Restoring MITF can reverse AR-enhanced melanoma cell invasion. Together, our results demonstrate that AR can promote melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signal and targeting this newly identified signal with AR degradation enhancer ASC-J9 may help us to better suppress the melanoma metastasis.	[Wang, Y.; Ou, Z.; Wang, X.; Long, J.] Cent South Univ, Xiangya Hosp, Dept Plast Surg, Changsha, Hunan, Peoples R China; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY USA; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY USA; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Central South University; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Long, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol,Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Long, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol,Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	jianhonglong@126.com; chang@urmc.rochester.edu			NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan). We thank Karen Wolf for help with preparing the manuscript. ASC-J9 was patented by the University of Rochester, the University of North Carolina, and AndroScience Corp., and then licensed to AndroScience Corp. Both the University of Rochester and C. Chang own royalties and equity in AndroScience Corp.	Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1969, CANCER RES, V29, P705; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Eccles MR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00229; Fernandez-Barral A, 2014, NEOPLASIA, V16, P529, DOI 10.1016/j.neo.2014.06.001; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hsu JW, 2013, AM J PATHOL, V182, P1811, DOI 10.1016/j.ajpath.2013.01.018; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Ji SR, 2015, CELL RES, V25, P561, DOI 10.1038/cr.2015.30; Joosse A, 2012, J CLIN ONCOL, V30, P2240, DOI 10.1200/JCO.2011.38.0584; Law MH, 2015, NAT GENET, V47, P987, DOI 10.1038/ng.3373; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li WQ, 2013, J CLIN ONCOL, V31, P4394, DOI 10.1200/JCO.2013.51.1915; Lin TH, 2013, J BIOL CHEM, V288, P19359, DOI 10.1074/jbc.M113.477216; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Ma WL, 2012, HEPATOLOGY, V56, P176, DOI 10.1002/hep.25644; Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Scoggins CR, 2006, ANN SURG, V243, P693, DOI 10.1097/01.sla.0000216771.81362.6b; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Tas F, 2012, J ONCOL, V2012, DOI 10.1155/2012/647684; Thomsen FB, 2016, INT J CANCER, V138, P2154, DOI 10.1002/ijc.29961; WHITE LP, 1959, NEW ENGL J MED, V260, P789, DOI 10.1056/NEJM195904162601601; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Yajima I, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/730170; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; Zhu G., 2014, UROLOGY, V83, pe19, DOI DOI 10.1016/J.UR0L0GY.2013.10.022	48	24	25	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1644	1654		10.1038/onc.2016.330	http://dx.doi.org/10.1038/onc.2016.330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27869170				2022-12-28	WOS:000397460600004
J	Sauer, M; Schuldner, M; Hoffmann, N; Cetintas, A; Reiners, KS; Shatnyeva, O; Hallek, M; Hansen, HP; Gasser, S; von Strandmann, EP				Sauer, M.; Schuldner, M.; Hoffmann, N.; Cetintas, A.; Reiners, K. S.; Shatnyeva, O.; Hallek, M.; Hansen, H. P.; Gasser, S.; von Strandmann, E. P.			CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells	ONCOGENE			English	Article							B-ASSOCIATED TRANSCRIPT-3; DNA-DAMAGE RESPONSE; UP-REGULATION; NK CELLS; LEUKEMIA-CELLS; NF-KB; RECEPTOR; ACTIVATION; MUTATIONS; INDUCTION	Tumor surveillance of natural killer (NK) cells is mediated by the cytotoxicity receptor natural-killer group 2 member D (NKG2D). Ligands for NKG2D are generally not expressed on healthy cells, but induced on the surface of malignant cells. To date, NKG2D ligand (NKG2D-L) induction was mainly described to depend on the activation of the DNA damage response, although the molecular mechanisms that regulate NKG2D-L expression remain largely unknown. Here, we show that the acetyltransferases CBP (CREB-binding protein) and p300 play a crucial role in the regulation of NKG2D-L on tumor cells. Loss of CBP/p300 decreased the basal cell surface expression of human ligands and reduced the upregulation of MICA/B and ULBP2 in response to histone deacetylase inhibitors or DNA damage. Furthermore, CBP/P300 deficiency abrogated the sensitivity of stressed cells to NK cell-mediated killing. CBP/p300 were also identified as major regulators of mouse NKG2D ligand RAE-1 in vitro and in vivo using the E mu-Myc lymphoma model. Mechanistically, we observed an enhanced activation of the CBP/p300 binding transcription factor CREB (cAMP response element-binding protein) correlating to the NKG2D-L upregulation. Moreover, increased binding of CREB and CBP/p300 to NKG2D-L promoters and elevated histone acetylation were detectable. This study provides strong evidence for a major role of CBP and p300 in orchestrating NKG2D-L induction and consequently immunosurveillance of tumors in mice and humans. These findings might help to develop novel immunotherapeutic approaches against cancer.	[Sauer, M.; Schuldner, M.; Hoffmann, N.; Cetintas, A.; Reiners, K. S.; Shatnyeva, O.; Hallek, M.; Hansen, H. P.; von Strandmann, E. P.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Hallek, M.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Gasser, S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Immunol Programme, Singapore 117548, Singapore; [von Strandmann, E. P.] Philipps Univ, Ctr Tumor Biol & Immunol, Expt Tumor Res, Clin Hematol Oncol & Immunol, Marburg, Germany	University of Cologne; University of Cologne; National University of Singapore; Philipps University Marburg	von Strandmann, EP (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.	elke.pogge@uk-koeln.de	Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455; Reiners, Katrin/0000-0002-5908-8823	Deutsche Forschungsgemeinschaft [KFO286]; Jose Carreras-Leukamie Stiftung [DJCLS R 14/08]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Jose Carreras-Leukamie Stiftung	This study was supported by the Deutsche Forschungsgemeinschaft (KFO286, RP4; to EPvS) and the Jose Carreras-Leukamie Stiftung (DJCLS R 14/08; to EPvS). This study contains parts of the PhD thesis from MS.	Andresen L, 2007, J IMMUNOL, V179, P8235, DOI 10.4049/jimmunol.179.12.8235; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Arrighetti Noemi, 2015, Critical Reviews in Oncogenesis, V20, P83; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Behera J, 2015, MINI-REV MED CHEM, V15, P731, DOI 10.2174/1389557515666150521162237; Belting L, 2015, EUR J IMMUNOL, V45, P2593, DOI 10.1002/eji.201445375; Besse B, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1071008; Boll B, 2009, CLIN CANCER RES, V15, P5108, DOI 10.1158/1078-0432.CCR-09-0213; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Champsaur M, 2010, IMMUNOL REV, V235, P267, DOI 10.1111/j.0105-2896.2010.00893.x; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Deng WW, 2015, SCIENCE, V348, P136, DOI 10.1126/science.1258867; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Heinemann A, 2012, CANCER RES, V72, P460, DOI 10.1158/0008-5472.CAN-11-1977; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Klein JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079502; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kung AL, 2000, GENE DEV, V14, P272; Lam AR, 2014, CANCER RES, V74, P2193, DOI 10.1158/0008-5472.CAN-13-1703; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Lee Jong-Soo, 2007, Cancer Res Treat, V39, P125, DOI 10.4143/crt.2007.39.3.125; Li H, 2011, CELL CYCLE, V10, P3346, DOI 10.4161/cc.10.19.17630; Lin D, 2012, J BIOL CHEM, V287, P4299, DOI 10.1074/jbc.M111.282152; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Reiners KS, 2013, BLOOD, V121, P3658, DOI 10.1182/blood-2013-01-476606; Routes JM, 2005, J EXP MED, V202, P1477, DOI 10.1084/jem.20050240; Sato T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059702; Sauer M, 2013, BIOL CHEM, V394, P1325, DOI 10.1515/hsz-2013-0161; Schoetterl Sonja, 2015, Critical Reviews in Oncogenesis, V20, P139; Simhadri VR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003377; Soriani A, 2014, J IMMUNOL, V193, P950, DOI 10.4049/jimmunol.1400271; Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263	46	17	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					933	941		10.1038/onc.2016.259	http://dx.doi.org/10.1038/onc.2016.259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27477692	Green Published, hybrid			2022-12-28	WOS:000394169100006
J	Wang, D; Shi, W; Tang, Y; Liu, Y; He, K; Hu, Y; Li, J; Yang, Y; Song, J				Wang, D.; Shi, W.; Tang, Y.; Liu, Y.; He, K.; Hu, Y.; Li, J.; Yang, Y.; Song, J.			Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; CELL-PROLIFERATION; CHAPERONE; PROTEIN; GROWTH; IDENTIFICATION; INHIBITION; TRANSCRIPTION; METASTASIS; COMPLEX	Prefoldin (PFDN) is a co-chaperone protein that is primarily known for its classic cytoplasmic functions in the folding of actin and tubulin monomers during cytoskeletal assembly. Here, we report a marked increase in prefoldin subunit 1 (PFDN1) levels during the transforming growth factor (TGF)-beta 1-mediated epithelial-mesenchymal transition (EMT) and in human lung tumor tissues. Interestingly, the nuclear localization of PFDN1 was also detected. These observations suggest that PFDN1 may be essential for important novel functions. Overexpression of PFDN1 induced EMT and cell invasion. In sharp contrast, knockdown of PFDN1 generated the opposite effects. Overexpression of PFDN1 was also found to induce lung tumor growth and metastasis. Further experiments showed that PFDN1 overexpression inhibits the expression of cyclin A. PFDN1 suppressed cyclin A expression by directly interacting with the cyclin A promoter at the transcriptional start site. Strikingly, cyclin A overexpression abolished the above PFDN1-mediated effects on the behavior of lung cancer cells, whereas cyclin A knockdown alone induced EMT and increased cell migration and invasion ability. This study reveals that the TGF-beta 1/ PFDN1/ cyclin A axis is essential for EMT induction and metastasis of lung cancer cells.	[Wang, D.; Shi, W.; Tang, Y.; Liu, Y.; He, K.; Hu, Y.; Li, J.; Yang, Y.; Song, J.] Chinese Acad Sci, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci,State Key Lab Cell Biol, 320 YueYang Rd, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Song, J (corresponding author), Chinese Acad Sci, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci,State Key Lab Cell Biol, 320 YueYang Rd, Shanghai 200031, Peoples R China.	jgsong@sibcb.ac.cn			Natural Science Foundation of China [81472603]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Natural Science Foundation of China (81472603). We thank Xinwang Yuan, Xiaojie Guo and Guoqing Cai for helpful discussion and technical assistance. We are especially grateful to Dr Lingling Chen for generous support to this work.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Alldinger I, 2005, PANCREATOLOGY, V5, P370, DOI 10.1159/000086537; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Arsic N, 2012, J CELL BIOL, V196, P147, DOI 10.1083/jcb.201102085; Asperger A, 2011, CANCER INVEST, V29, P272, DOI 10.3109/07357907.2010.550666; Barcellos KSA, 2013, J BIOL CHEM, V288, P2179, DOI 10.1074/jbc.M112.432716; Bendris N, 2014, CELL MOL LIFE SCI, V71, P4881, DOI 10.1007/s00018-014-1654-8; Cao S, 2008, J IMMUNOL, V181, P476, DOI 10.4049/jimmunol.181.1.476; Cheung CT, 2015, CARCINOGENESIS, V36, P914, DOI 10.1093/carcin/bgv069; Farooq M, 2013, ASIAN PAC J CANCER P, V14, P915, DOI 10.7314/APJCP.2013.14.2.915; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hu Y, 2013, CARCINOGENESIS, V34, P1764, DOI 10.1093/carcin/bgt132; Iijima M, 1996, ACTA MED OKAYAMA, V50, P73; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kim HRC, 1999, CANCER RES, V59, P4148; Kim SY, 2008, BMB REP, V41, P158, DOI 10.5483/BMBRep.2008.41.2.158; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lopez V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-182; Lundin VF, 2008, DEV BIOL, V313, P320, DOI 10.1016/j.ydbio.2007.10.022; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma XJ, 2015, CANCER RES, V75, P2822, DOI 10.1158/0008-5472.CAN-15-0125; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Millan-Zambrano G, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140085; Millan-Zambrano G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003776; Miyoshi N, 2010, ANN SURG ONCOL, V17, P3030, DOI 10.1245/s10434-010-1138-5; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Narita R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041891; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Ostrov DA, 2007, TISSUE ANTIGENS, V69, P181, DOI 10.1111/j.1399-0039.2006.00730.x; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Shi J, 2009, CANCER RES, V69, P7180, DOI 10.1158/0008-5472.CAN-08-4470; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Tang YN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9230; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tsuchiya H, 1996, CANCER RES, V56, P2881; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang D, 2014, INT J ONCOL, V44, P161, DOI 10.3892/ijo.2013.2170; Wang DM, 2010, BIOL CELL, V102, P1, DOI 10.1042/BC20090070; Whipple RA, 2010, CANCER RES, V70, P8127, DOI 10.1158/0008-5472.CAN-09-4613; Yang Y, 2006, ONCOGENE, V25, P7235, DOI 10.1038/sj.onc.1209712; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin XF, 2013, CLIN CANCER RES, V19, P5686, DOI 10.1158/1078-0432.CCR-13-0405; Yuan XW, 2013, J BIOL CHEM, V288, P31206, DOI 10.1074/jbc.M113.480285; Zhang LA, 2010, FEBS LETT, V584, P4646, DOI 10.1016/j.febslet.2010.10.038; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027	52	36	37	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					885	898		10.1038/onc.2016.257	http://dx.doi.org/10.1038/onc.2016.257			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27694898	Green Published, hybrid			2022-12-28	WOS:000394169100002
J	Martin, PL; Yin, JJ; Seng, V; Casey, O; Corey, E; Morrissey, C; Simpson, RM; Kelly, K				Martin, P. L.; Yin, J-J; Seng, V.; Casey, O.; Corey, E.; Morrissey, C.; Simpson, R. M.; Kelly, K.			Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer	ONCOGENE			English	Article							MITOCHONDRIAL HEXOKINASES; MASS-SPECTROMETRY; PTEN; APOPTOSIS; GROWTH; AKT; MECHANISMS; RESISTANCE; TRANSITION; DELETION	Prostate cancer is characterized by a dependence upon androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) is the accepted treatment for progressive prostate cancer. Although ADT is usually initially effective, acquired resistance termed castrate-resistant prostate cancer (CRPC) develops. PTEN and TP53 are two of the most commonly deleted or mutated genes in prostate cancer, the compound loss of which is enriched in CRPC. To interrogate the metabolic alterations associated with survival following ADT, we used an orthotopic model of Pten/Tp53 null prostate cancer. Metabolite profiles and associated regulators were compared in tumors from androgen-intact mice and in tumors surviving castration. AR inhibition led to changes in the levels of glycolysis and tricarboxylic acid (TCA) cycle pathway intermediates. As anticipated for inhibitory reciprocal feedback between AR and PI3K/AKT signaling pathways, pAKT levels were increased in androgen-deprived tumors. Elevated mitochondrial hexokinase 2 (HK2) levels and enzyme activities also were observed in androgen-deprived tumors, consistent with pAKT-dependent HK2 protein induction and mitochondrial association. Competitive inhibition of HK2-mitochondrial binding in prostate cancer cells led to decreased viability. These data argue for AKT-associated HK2-mediated metabolic reprogramming and mitochondrial association in PI3K-driven prostate cancer as one survival mechanism downstream of AR inhibition.	[Martin, P. L.; Yin, J-J; Seng, V.; Casey, O.; Kelly, K.] NCI, Lab Genitourinary Canc Pathogenesis, Ctr Canc Res, NIH, Bldg 37,Room 1068 A, Bethesda, MD 20892 USA; [Corey, E.; Morrissey, C.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Simpson, R. M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Martin, P. L.] Medimmune, Gaithersburg, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); AstraZeneca; Medimmune	Kelly, K (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, Ctr Canc Res, NIH, Bldg 37,Room 1068 A, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov			Intramural Research Program; Center for Cancer Research; NCI; Pacific Northwest Prostate Cancer SPORE [P50CA97186]; PO1 NIH [PO1CA085859]; Richard M. LUCAS Foundation; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA085859, ZIGBC010931] Funding Source: NIH RePORTER	Intramural Research Program; Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PO1 NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Richard M. LUCAS Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciated the patients and their families who participated in the Prostate Cancer Donor Program. We thank the investigators Drs Robert Vessella, Celestia Higano, Bruce Montgomery, Evan Yu, Peter Nelson, Paul Lange, Martine Roudier and Lawrence True for their contributions to the University of Washington Medical Center Prostate Cancer Donor Rapid Autopsy Program. This research was supported by the Intramural Research Program, Center for Cancer Research, NCI and by the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the PO1 NIH grant (PO1CA085859) and the Richard M. LUCAS Foundation.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abou-Kheir W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026112; Agarwal S., 2015, CELL REP; American Cancer Society, 2015, CANC FACTS FIG 2015; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Arzoine L, 2009, J BIOL CHEM, V284, P3946, DOI 10.1074/jbc.M803614200; Bonizzi G, 2012, TRENDS MOL MED, V18, P6, DOI 10.1016/j.molmed.2011.08.002; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chaux A, 2012, MODERN PATHOL, V25, P1543, DOI 10.1038/modpathol.2012.104; Chiara F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001852; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Craft N, 1999, CANCER RES, V59, P5030; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Gao H, 2006, CANCER RES, V66, P7929, DOI 10.1158/0008-5472.CAN-06-1637; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605; Jadvar H, 2013, J NUCL MED, V54, P1685, DOI 10.2967/jnumed.113.126094; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kami K, 2013, METABOLOMICS, V9, P444, DOI 10.1007/s11306-012-0452-2; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lotan TL, 2011, CLIN CANCER RES, V17, P6563, DOI 10.1158/1078-0432.CCR-11-1244; Lunardi A, 2013, NAT GENET, V45, P747, DOI 10.1038/ng.2650; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; McCall P, 2008, BRIT J CANCER, V99, P1296, DOI 10.1038/sj.bjc.6604680; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Roberts DJ, 2015, CELL DEATH DIFFER, V22, P364, DOI 10.1038/cdd.2014.208; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; Stenman K, 2011, BIOMARK INSIGHTS, V6, P39, DOI 10.4137/BMI.S6794; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Swanson MG, 2003, MAGN RESON MED, V50, P944, DOI 10.1002/mrm.10614; Terry S, 2006, PROSTATE, V66, P1100, DOI 10.1002/pros.20446; Toivanen R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005688; Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wu RX, 2012, EMBO MOL MED, V4, P633, DOI 10.1002/emmm.201200240; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zong Y, 2013, NAT REV UROL, V10, P90, DOI [10.1038/nruro1.2012.237, 10.1038/nrurol.2012.237]	52	31	32	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					525	533		10.1038/onc.2016.223	http://dx.doi.org/10.1038/onc.2016.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375016	Green Accepted			2022-12-28	WOS:000394166700009
J	Ratnikov, BI; Scott, DA; Osterman, AL; Smith, JW; Ronai, ZA				Ratnikov, B. I.; Scott, D. A.; Osterman, A. L.; Smith, J. W.; Ronai, Z. A.			Metabolic rewiring in melanoma	ONCOGENE			English	Review							ENDOTHELIAL GROWTH-FACTOR; PYRUVATE-KINASE; GLUTAMINE-METABOLISM; MITOCHONDRIAL METABOLISM; ONCOMETABOLITE 2-HYDROXYGLUTARATE; OXIDATIVE-PHOSPHORYLATION; CELLULAR ADAPTATION; METASTATIC MELANOMA; MALIGNANT-MELANOMA; GLUCOSE-METABOLISM	Oncogene-driven metabolic rewiring is an adaptation to low nutrient and oxygen conditions in the tumor microenvironment that enables cancer cells of diverse origin to hyperproliferate. Aerobic glycolysis and enhanced reliance on glutamine utilization are prime examples of such rewiring. However, tissue of origin as well as specific genetic and epigenetic changes determines gene expression profiles underlying these metabolic alterations in specific cancers. In melanoma, activation of the mitogen-activated protein kinase (MAPK) pathway driven by mutant BRAF or NRAS is a primary cause of malignant transformation. Activity of the MAPK pathway, as well as other factors, such as HIF1 alpha, Myc and MITF, are among those that control the balance between non oxidative and oxidative branches of central carbon metabolism. Here, we discuss the nature of metabolic alterations that underlie melanoma development and affect its response to therapy.	[Ratnikov, B. I.; Scott, D. A.; Osterman, A. L.; Smith, J. W.; Ronai, Z. A.] Sanford Burnham Prebys Med Discovery Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ratnikov, BI; Ronai, ZA (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	bratnikov@SBPDiscovery.org; zeev@ronailab.net		Scott, David/0000-0002-8668-2449	NATIONAL CANCER INSTITUTE [R35CA197465, P30CA030199, R01CA188372] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA030199, R01 CA188372, R35 CA197465, P01 CA128814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Baenke F, 2016, MOL ONCOL, V10, P73, DOI 10.1016/j.molonc.2015.08.003; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Cassago A, 2012, P NATL ACAD SCI USA, V109, P1092, DOI 10.1073/pnas.1112495109; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045190; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P732, DOI 10.1111/pcmr.12000; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Godic A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/860479; Goodman M, 2011, FREE RADICAL BIO MED, V51, P1068, DOI 10.1016/j.freeradbiomed.2011.05.018; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gupta V, 2014, CURR PHARM DESIGN, V20, P2595, DOI 10.2174/13816128113199990484; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Haq R, 2011, J CLIN ONCOL, V29, P3474, DOI 10.1200/JCO.2010.32.6223; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; HARRIS M, 1980, SOMAT CELL GENET, V6, P699, DOI 10.1007/BF01538969; Hernandez-Davies JE, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0581-2; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Hobbs GA, 2015, FREE RADICAL BIO MED, V79, P237, DOI 10.1016/j.freeradbiomed.2014.09.027; Hobbs G Aaron, 2014, Small GTPases, V5, pe28579, DOI 10.4161/sgtp.28579; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Janzer A, 2014, P NATL ACAD SCI USA, V111, P10574, DOI 10.1073/pnas.1409844111; Jiang BH, 1997, CANCER RES, V57, P5328; Kang HB, 2015, MOL CELL, V59, P345, DOI 10.1016/j.molcel.2015.05.037; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kaufman HL, 2013, NAT REV CLIN ONCOL, V10, P588, DOI 10.1038/nrclinonc.2013.153; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Koch A, 2015, ONCOTARGET, V6, P32748, DOI 10.18632/oncotarget.4977; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuphal S, 2010, EUR J CANCER, V46, P1159, DOI 10.1016/j.ejca.2010.01.031; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Leo MA, 1997, J NATL CANCER I, V89, P1722, DOI 10.1093/jnci/89.22.1722; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Mazure NM, 1996, CANCER RES, V56, P3436; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; McPherson PAC, 2012, J PHYSIOL BIOCHEM, V68, P141, DOI 10.1007/s13105-011-0112-4; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Mitchell L, 2013, ANTIOXID REDOX SIGN, V18, P250, DOI 10.1089/ars.2012.4687; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Olenchock BA, 2013, CELL, V153, P1429, DOI 10.1016/j.cell.2013.06.001; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Shtivelman E, 2014, ONCOTARGET, V5, P1701, DOI 10.18632/oncotarget.1892; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vacanti NM, 2014, MOL CELL, V56, P425, DOI 10.1016/j.molcel.2014.09.024; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Van Vranken JG, 2015, CELL, V162, P471, DOI 10.1016/j.cell.2015.07.027; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; WARBURG O, 1956, SCIENCE, V124, P269; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wawrzyniak JA, 2013, CELL REP, V5, P493, DOI 10.1016/j.celrep.2013.09.015; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Westerlund A, 2011, ANN ONCOL, V22, P967, DOI 10.1093/annonc/mdq456; Willcox JK, 2004, CRIT REV FOOD SCI, V44, P275, DOI 10.1080/10408690490468489; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	134	100	103	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					147	157		10.1038/onc.2016.198	http://dx.doi.org/10.1038/onc.2016.198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270434	Green Accepted			2022-12-28	WOS:000393938100001
J	Ellert-Miklaszewska, A; Wisniewski, P; Kijewska, M; Gajdanowicz, P; Pszczolkowska, D; Przanowski, P; Dabrowski, M; Maleszewska, M; Kaminska, B				Ellert-Miklaszewska, A.; Wisniewski, P.; Kijewska, M.; Gajdanowicz, P.; Pszczolkowska, D.; Przanowski, P.; Dabrowski, M.; Maleszewska, M.; Kaminska, B.			Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression	ONCOGENE			English	Article							INFILTRATING MICROGLIA/MACROPHAGES; CELLS; MACROPHAGES; EXPRESSION; INVASION; STEM; ALPHA(9)BETA(1); METASTASIS; INHIBITION; PHENOTYPE	Tumour tissue is infiltrated by myeloid cells that are reprogrammed into alternatively activated/regenerative (M2) macrophages. The contribution of major signalling pathways and their modulators/targets involved in the macrophage reprogramming is poorly known. Glioblastoma (malignant brain tumour) attracts and reprograms brain-resident microglia and peripheral macrophages into cells that increase invasion, angiogenesis and suppress antitumour immunity. Using a 'function-first' approach and glioma secretome proteomics we identified osteopontin and lactadherin as proteins that cooperatively activate amoeboid transformation, phagocytosis and motility of primary microglia cultures via integrins and FAK-Akt (focal adhesion kinase-Akt) signalling. A synthetic peptide interfering with integrin ligands blocks glioma-microglia communication, functional activation and M2 gene expression. We found that osteopontin/secreted phosphoprotein 1 (Spp1) produced by non-transformed cells acts as a proinflammatory factor inducing inflammatory signalling and M1 genes, and counteracts the action of lactadherin. Using constructs encoding functional mutants of osteopontin, we demonstrated sequential processing of Spp1 by thrombin and matrix metalloproteinase-3 and/or -7 (MMP-3 and/or -7) in glioma cells, which generates a microglia-activating form devoid of the inflammatory activity, while retaining the M2 reprogramming potential. A similar form of osteopontin is secreted by human glioma cells but not normal human astrocytes. Knockdown of osteopontin or lactadherin in glioma cells reduces intracranial glioma growth, blocks amoeboid transformation of myeloid cells and affects M2 reprogramming of microglia/macrophages. Our findings demonstrate how glioma cells misuse macrophage-activating signals and redesign primarily proinflammatory signals towards their advantage to induce M2 reprogramming of tumour-infiltrating brain macrophages.	[Ellert-Miklaszewska, A.; Wisniewski, P.; Kijewska, M.; Gajdanowicz, P.; Pszczolkowska, D.; Przanowski, P.; Dabrowski, M.; Maleszewska, M.; Kaminska, B.] Nencki Inst Expt Biol, Neurobiol Ctr, Mol Neurobiol Lab, Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaminska, B (corresponding author), Nencki Inst Expt Biol, Mol Neurobiol Lab, 3 Pasteur St, PL-02093 Warsaw, Poland.	bozenakk@nencki.gov.pl	Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014; Ellert-Miklaszewska, Aleksandra/AAX-8715-2020; Ellert-Miklaszewska, Aleksandra/H-4423-2011; Dąbrowski, Michał/K-4384-2012	Kaminska, Bozena/0000-0002-2642-4616; Ellert-Miklaszewska, Aleksandra/0000-0002-7947-5660; Ellert-Miklaszewska, Aleksandra/0000-0002-7947-5660; Gajdanowicz, Pawel/0000-0003-3075-5992; Dabrowski, Michal/0000-0002-5335-158X; Maleszewska, Marta/0000-0001-8695-374X	National Science Center (Poland) [2012/04/A/NZ3/00630]; Ministry of Science and Higher Education [264173 Bio-Imagine, IP2011013171]	National Science Center (Poland)(National Science Centre, Poland); Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We thank Beata Kaza and Marcin Sliwa for technical assistance. This work was supported by the Grant 2012/04/A/NZ3/00630 (to BK) from the National Science Center (Poland). PG was supported by GA no. 264173 Bio-Imagine and IP2011013171 from the Ministry of Science and Higher Education.	Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Anborgh PH, 2010, J CELL MOL MED, V14, P2037, DOI 10.1111/j.1582-4934.2010.01115.x; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Grassinger J, 2009, BLOOD, V114, P49, DOI 10.1182/blood-2009-01-197988; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Hussain SF, 2005, EXPERT REV ANTICANC, V5, P777, DOI 10.1586/14737140.5.5.777; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Ku MC, 2013, ACTA NEUROPATHOL, V125, P609, DOI 10.1007/s00401-013-1079-8; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Murray P.J., 2014, OSTEOARTHR CARTILAGE, V41, P14; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Shao ZF, 2014, J BIOL CHEM, V289, P27146, DOI 10.1074/jbc.M114.572172; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	41	57	57	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6366	6377		10.1038/onc.2016.55	http://dx.doi.org/10.1038/onc.2016.55			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27041573				2022-12-28	WOS:000390247600002
J	Hernandez, C; Huebener, P; Schwabe, RF				Hernandez, C.; Huebener, P.; Schwabe, R. F.			Damage-associated molecular patterns in cancer: a double-edged sword	ONCOGENE			English	Review							MOBILITY GROUP BOX-1; REGULATORY T-CELLS; URIC-ACID PROMOTES; FIND-ME SIGNAL; IMMUNE-SYSTEM; TUMOR-GROWTH; ANTICANCER CHEMOTHERAPY; CALRETICULIN EXPOSURE; DIFFERENTIAL EXPRESSION; INFLAMMATORY RESPONSE	Damage-associated molecular patterns (DAMPs) are released in response to cell death and stress, and are potent triggers of sterile inflammation. Recent evidence suggests that DAMPs may also have a key role in the development of cancer, as well as in the host response to cytotoxic anti-tumor therapy. As such, DAMPs may exert protective functions by alerting the immune system to the presence of dying tumor cells, thereby triggering immunogenic tumor cell death. On the other hand, cell death and release of DAMPs may also trigger chronic inflammation and, thereby promote the development or progression of tumors. Here, we will review the contribution of candidate DAMPs and their receptors, and discuss the evidence for DAMPs as tumor-promoting and anti-tumor effectors, as well as unsolved questions such as DAMP release from non-tumor cells as well as the existence of tumorspecific DAMPs.	[Hernandez, C.; Huebener, P.; Schwabe, R. F.] Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavil,Room 415,1150 St Nicholas Ave, New York, NY 10032 USA; [Huebener, P.] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 1, Hamburg, Germany; [Schwabe, R. F.] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Columbia University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavil,Room 415,1150 St Nicholas Ave, New York, NY 10032 USA.	rfs2102@cumc.columbia.edu	Huebener, Peter/AAF-2593-2020; Schwabe, Robert/AAY-6506-2021	Huebener, Peter/0000-0001-7558-7625	NATIONAL CANCER INSTITUTE [R01CA190844, R01CA200597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA021912] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA200597, R01 CA190844] Funding Source: Medline; NIAAA NIH HHS [U01 AA021912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Beavis PA, 2013, P NATL ACAD SCI USA, V110, P14711, DOI 10.1073/pnas.1308209110; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bettum IJ, 2014, CANCER LETT, V344, P28, DOI 10.1016/j.canlet.2013.10.036; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje; Chaiswing L, 2010, ANTIOXID REDOX SIGN, V13, P449, DOI 10.1089/ars.2009.3020; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Cheng BQ, 2008, DIGEST LIVER DIS, V40, P446, DOI 10.1016/j.dld.2007.11.024; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376; Choi YR, 2003, CANCER RES, V63, P2188; Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38; Ciampricotti M, 2012, NAT MED, V18, P344, DOI 10.1038/nm.2652; Daniele S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.487; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Draganov D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16222; Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Fettelschoss A, 2011, P NATL ACAD SCI USA, V108, P18055, DOI 10.1073/pnas.1109176108; Fini MA, 2012, CLIN TRANSL MED, V1, DOI 10.1186/2001-1326-1-16; Fini MA, 2008, J CELL BIOCHEM, V105, P1008, DOI 10.1002/jcb.21901; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Garg AD, 2015, ONCOTARGET, V6, P26841, DOI 10.18632/oncotarget.4754; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo ZS, 2005, CANCER RES, V65, P9991, DOI 10.1158/0008-5472.CAN-05-1630; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; He Y, 2013, CANCER RES, V73, P629, DOI 10.1158/0008-5472.CAN-12-2704; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hockel A, 2005, CANCER RES, V65, P2997; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Hong C, 2010, J IMMUNOL, V185, P4561, DOI 10.4049/jimmunol.1000536; Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jovanovic IP, 2014, INT J CANCER, V134, P1669, DOI 10.1002/ijc.28481; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kono H, 2010, J CLIN INVEST, V120, P1939, DOI 10.1172/JCI40124; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Ladoire S, 2015, AUTOPHAGY, V11, P1878, DOI 10.1080/15548627.2015.1082022; Policastro LL, 2013, ANTIOXID REDOX SIGN, V19, P854, DOI 10.1089/ars.2011.4367; Liu XJ, 2014, BIOCHEM BIOPH RES CO, V453, P486, DOI 10.1016/j.bbrc.2014.09.106; Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Maywald RL, 2015, P NATL ACAD SCI USA, V112, pE2487, DOI 10.1073/pnas.1422445112; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Meyer A, 2008, LEUKEMIA LYMPHOMA, V49, P1184, DOI 10.1080/10428190802064909; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ohta A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00190; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Pawaria S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1524; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Pusterla T, 2013, HEPATOLOGY, V58, P363, DOI 10.1002/hep.26395; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ran S, 2015, CANCER RES, V75, P2405, DOI 10.1158/0008-5472.CAN-14-3525; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; Rider P, 2013, SEMIN IMMUNOL, V25, P430, DOI 10.1016/j.smim.2013.10.005; Romio M, 2011, AM J PHYSIOL-CELL PH, V301, pC530, DOI 10.1152/ajpcell.00385.2010; Ryzhov S, 2011, J IMMUNOL, V187, P6120, DOI 10.4049/jimmunol.1101225; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779; Vanlangenakker N, 2012, CELL DEATH DIFFER, V19, P75, DOI 10.1038/cdd.2011.164; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Vernon PJ, 2013, J IMMUNOL, V190, P1372, DOI 10.4049/jimmunol.1201151; Villarreal DO, 2014, CURR OPIN IMMUNOL, V28, P102, DOI 10.1016/j.coi.2014.03.004; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Wild CA, 2012, ORAL ONCOL, V48, P409, DOI 10.1016/j.oraloncology.2011.12.009; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xu J, 2014, CELL DEATH DIFFER, V21, P1229, DOI 10.1038/cdd.2014.40; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zhou JM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15085; Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014	130	223	234	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5931	5941		10.1038/onc.2016.104	http://dx.doi.org/10.1038/onc.2016.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27086930	Green Accepted			2022-12-28	WOS:000388509400001
J	Shou, P; Chen, Q; Jiang, J; Xu, C; Zhang, J; Zheng, C; Jiang, M; Velletri, T; Cao, W; Huang, Y; Yang, Q; Han, X; Zhang, L; Wei, L; Rabson, AB; Chin, YE; Wang, Y; Shi, Y				Shou, P.; Chen, Q.; Jiang, J.; Xu, C.; Zhang, J.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Zhang, L.; Wei, L.; Rabson, A. B.; Chin, Y. E.; Wang, Y.; Shi, Y.			Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells	ONCOGENE			English	Article							NF-KAPPA-B; DOUBLE-EDGED-SWORD; STEM-CELLS; NITRIC-OXIDE; IFN-GAMMA; IMMUNE-RESPONSES; INOS GENE; ALPHA; PHOSPHORYLATION; ACETYLATION	Mesenchymal stromal cells (MSCs) are strongly immunosuppressive via producing nitric oxide (NO) and known to migrate into tumor sites to promote tumor growth, but the underlying mechanisms remain largely elusive. Here, we found that interferon alpha (IFN alpha)-secreting MSCs showed more dramatic inhibition effect on tumor progression than that of IFN alpha alone. Interestingly, IFN alpha primed MSCs could also effectively suppress tumor growth. Mechanistically, we demonstrated that both IFN alpha and IFN beta (type I IFNs) reversed the immunosuppressive effect of MSCs on splenocyte proliferation. This effect of type I IFNs was exerted through inhibiting inducible NO synthase (iNOS) expression in IFN. and TNFa-stimulated MSCs. Notably, only NO production was inhibited by IFN alpha; production of other cytokines or chemokines tested was not suppressed. Furthermore, IFN alpha promoted the switch from signal transducer and activator of transcription 1 (Stat1) homodimers to Stat1-Stat2 heterodimers. Studies using the luciferase reporter system and chromatin immunoprecipitation assay revealed that IFN alpha suppressed iNOS transcription through inhibiting the binding of Stat1 to iNOS promoter. Therefore, the synergistic anti-tumor effects of type I IFNs and MSCs were achieved by inhibiting NO production. This study provides essential information for understanding the mechanisms of MSC-mediated immunosuppression and for the development of better clinical strategies using IFNs and MSCs for cancer immunotherapy.	[Shou, P.; Chen, Q.; Xu, C.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Chin, Y. E.; Wang, Y.; Shi, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Shou, P.; Chen, Q.; Xu, C.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Chin, Y. E.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China; [Chen, Q.; Zhang, L.; Shi, Y.] Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China; [Jiang, J.] Soochow Univ, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China; [Zhang, J.; Zhang, L.; Rabson, A. B.; Shi, Y.] Rutgers State Univ, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Wei, L.] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China; [Shou, P.] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Soochow University - China; Soochow University - China; Rutgers State University New Brunswick; Rutgers State University Medical Center; Naval Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Shi, Y (corresponding author), Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.; Wang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	Xu, Chunliang/R-7065-2018; HUANG, YIN/AAH-6871-2020; Shi, Yufang/AAE-4431-2020; Shou, Peishun/J-7985-2014	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; Shou, Peishun/0000-0001-7685-7471; Wei, Lixin/0000-0002-9526-5348; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367	Ministry of Science and Technology of China [2015CB964400, 2012CBA01303]; Scientific Innovation Project of the Chinese Academy of Science [XDA01040110, XDA01040107]; External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences [GJHZ201307]; Programs of National Natural Science of China [81330046, 81171653, 31570877, 31570908]; National Institutes of Health of the United States of America [GM866889]; Robert Wood Johnson Foundation [67038]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM866889] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Scientific Innovation Project of the Chinese Academy of Science; External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health of the United States of America(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ms Fengying Li and Ms Jingjing Li for technical assistances in breeding the mice; Ms Yanyan Han, Mr Jianchang Cao, Mr Shijia Wang, Ms Qing Li and Ms Chenxi Zhang for technical assistances and helpful discussion. This work was supported by grants from the Ministry of Science and Technology of China (2015CB964400, 2012CBA01303), Scientific Innovation Project of the Chinese Academy of Science (XDA01040110, XDA01040107), the External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences (GJHZ201307), the Programs of National Natural Science of China (81330046, 81171653, 31570877, 31570908), grants from the National Institutes of Health of the United States of America (GM866889) and a grant to the Child Health Institute from the Robert Wood Johnson Foundation (67038).	Beckermann BM, 2008, BRIT J CANCER, V99, P622, DOI 10.1038/sj.bjc.6604508; Begitt A, 2014, NAT IMMUNOL, V15, P168, DOI 10.1038/ni.2794; Burke SJ, 2013, MOL ENDOCRINOL, V27, P1724, DOI 10.1210/me.2013-1159; Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168; Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567; De Stefano D, 2006, J MOL MED, V84, P65, DOI 10.1007/s00109-005-0713-x; Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; Du JC, 2012, INT J BIOCHEM CELL B, V44, P1305, DOI 10.1016/j.biocel.2012.04.015; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600-0625.2006.00479.x; Frasca L, 2011, THESCIENTIFICWORLDJO, V11, P2071, DOI 10.1100/2011/873895; Galderisi Umberto, 2010, World J Stem Cells, V2, P5, DOI 10.4252/wjsc.v2.i1.5; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Ghislain JJ, 2001, J INTERF CYTOK RES, V21, P379, DOI 10.1089/107999001750277853; Guo L, 2007, SURGERY, V142, P156, DOI 10.1016/j.surg.2007.02.016; Han X, 2014, CELL DEATH DIFFER, V21, P1758, DOI 10.1038/cdd.2014.85; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kim MO, 2004, J NEUROCHEM, V90, P297, DOI 10.1111/j.1471-4159.2004.02487.x; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lee ST, 2002, BRIT J HAEMATOL, V118, P1128, DOI 10.1046/j.1365-2141.2002.03767.x; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Li YZ, 2005, J BIOL CHEM, V280, P10001, DOI 10.1074/jbc.M410972200; Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Ohkouchi S, 2012, MOL THER, V20, P417, DOI 10.1038/mt.2011.259; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032; Qiao L, 2008, CELL RES, V18, P500, DOI 10.1038/cr.2008.40; Rayamajhi M, 2010, J EXP MED, V207, P327, DOI 10.1084/jem.20091746; Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Salam MT, 2012, J ALLERGY CLIN IMMUN, V129, P232, DOI 10.1016/j.jaci.2011.09.037; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Torrone DZ, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-3; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Uddin S, 2000, J BIOL CHEM, V275, P27634; Wang KW, 2011, BBA-MOL CELL RES, V1813, P1395, DOI 10.1016/j.bbamcr.2011.04.004; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wieczorek M, 2012, CYTOKINE GROWTH F R, V23, P293, DOI 10.1016/j.cytogfr.2012.06.005; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu C, 2014, ONCOGENE, V33, P5047, DOI 10.1038/onc.2013.458; Xu CL, 2014, J IMMUNOL, V192, P103, DOI 10.4049/jimmunol.1302164; Yu ZY, 2006, AM J PHYSIOL-RENAL, V290, pF496, DOI 10.1152/ajprenal.00316.2005; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216	55	20	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5953	5962		10.1038/onc.2016.128	http://dx.doi.org/10.1038/onc.2016.128			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27109100	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000388509400003
J	Darido, C; Georgy, SR; Jane, SM				Darido, C.; Georgy, S. R.; Jane, S. M.			The role of barrier genes in epidermal malignancy	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; REGULATES KERATINOCYTE PROLIFERATION; EPITHELIAL STEM-CELLS; NF-KAPPA-B; PERMEABILITY BARRIER; STRATUM-CORNEUM; ALPHA-CATENIN; MICE LACKING; TERMINAL DIFFERENTIATION; ABCA12 MUTATIONS	The outermost layer of the mammalian skin, the epidermis, forms a protective barrier against pathogenic microbes and tissue dehydration. This barrier is formed and maintained by complex genetic networks that connect cellular differentiation processes, enzymatic activities and cellular junctions. Disruption in these networks affects the balance between keratinocyte proliferation and differentiation resulting in barrier function impairment, epidermal hyperproliferation and in some cases, squamous cell carcinoma (SCC). Recent studies in wound-induced inflammation-mediated cancers in mice have identified dysregulation of core barrier components as tumor drivers. We therefore propose a hypothesis in which loss of key barrier genes, induce barrier dysfunction, and promote inflammation-driven epidermal hyperplasia and carcinogenesis over time. This emerging vision suggests that under specific genetic circumstances, localized barrier impairment could be considered as a hallmark of initiating lesions in epidermal SCC.	[Darido, C.; Georgy, S. R.; Jane, S. M.] Alfred Hosp, Dept Med, Epidermal Dev Lab, Prahran, Vic, Australia; [Darido, C.; Georgy, S. R.; Jane, S. M.] Monash Univ, Cent Clin Sch, Prahran, Vic, Australia; [Darido, C.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Jane, S. M.] Alfred Hosp, Dept Hematol, Prahran, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Peter Maccallum Cancer Center; University of Melbourne; Florey Institute of Neuroscience & Mental Health	Darido, C (corresponding author), Monash Univ, Cent Clin Sch, Dept Med, Level 1,Walkway Via Alfred Ctr 99 Commercial Rd, Melbourne, Vic 3004, Australia.	charbel.darido@petermac.org	Darido, Charbel/H-2800-2016	Darido, Charbel/0000-0002-6541-324X; Jane, Stephen Marsden/0000-0002-1045-0481; Georgy, Smitha Rose/0000-0003-4716-8559	Australian National Health and Medical Research Council; Association for International Cancer Research; Victorian Cancer Agency Clare Oliver Memorial Fellowship	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Association for International Cancer Research; Victorian Cancer Agency Clare Oliver Memorial Fellowship	We thank Dr Stephen Goldie and Dr Sebastian Dworkin for their critical reading of the review. The authors are supported by grants from the Australian National Health and Medical Research Council, the Association for International Cancer Research (to SMJ and CD) and the Victorian Cancer Agency Clare Oliver Memorial Fellowship (to CD).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Akiyama M, 2010, HUM MUTAT, V31, P1090, DOI 10.1002/humu.21326; Ambler CA, 2010, DEVELOPMENT, V137, P3569, DOI 10.1242/dev.050310; Arabzadeh A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-196; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Bhandari A, 2013, ONCOGENE, V32, P1497, DOI 10.1038/onc.2012.168; Biniek K, 2012, P NATL ACAD SCI USA, V109, P17111, DOI 10.1073/pnas.1206851109; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Boglev Y, 2011, DEV BIOL, V349, P512, DOI 10.1016/j.ydbio.2010.11.011; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Cangkrama M, 2016, J INVEST DERMATOL, V136, P1438, DOI 10.1016/j.jid.2016.02.806; Cangkrama M, 2013, INT J MOL SCI, V14, P13670, DOI 10.3390/ijms140713670; Cavallaro U, 2011, NAT REV MOL CELL BIO, V12, P189, DOI 10.1038/nrm3068; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Darido C, 2013, ADV WOUND CARE, V2, P87, DOI 10.1089/wound.2011.0352; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Darido Charbel, 2010, Small GTPases, V1, P104, DOI 10.4161/sgtp.1.2.13620; de la Garza G, 2013, J INVEST DERMATOL, V133, P68, DOI 10.1038/jid.2012.269; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2012, CANCER CELL, V22, P494, DOI 10.1016/j.ccr.2012.08.017; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Descargues P, 2008, EMBO J, V27, P2639, DOI 10.1038/emboj.2008.196; Di Piazza M, 2012, CANCER CELL, V22, P479, DOI 10.1016/j.ccr.2012.08.016; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Dworkin S, 2011, ORGANOGENESIS, V7, P202, DOI 10.4161/org.7.3.18431; Fadloun A, 2007, DEVELOPMENT, V134, P2947, DOI 10.1242/dev.005041; Fehrenschild D, 2012, J INVEST DERMATOL, V132, P337, DOI 10.1038/jid.2011.301; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gareus R, 2007, NAT CELL BIOL, V9, P461, DOI 10.1038/ncb1560; Georgy SR, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv152; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Girardi M, 2006, J INVEST DERMATOL, V126, P808, DOI 10.1038/sj.jid.5700120; Gordon WM, 2014, J CLIN INVEST, V124, P5205, DOI 10.1172/JCI77138; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927; Herron BJ, 2005, NAT GENET, V37, P1210, DOI 10.1038/ng1652; Hitomi K, 2005, EUR J DERMATOL, V15, P313; Hobbs RM, 2003, J BIOL CHEM, V278, P19798, DOI 10.1074/jbc.M300513200; Hoste E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6932; Huebner AJ, 2012, DEV CELL, V23, P1238, DOI 10.1016/j.devcel.2012.11.002; Ingraham CR, 2006, NAT GENET, V38, P1335, DOI 10.1038/ng1903; Jensen JM, 2000, J INVEST DERMATOL, V115, P708, DOI 10.1046/j.1523-1747.2000.00103.x; Jiang YJ, 2010, J INVEST DERMATOL, V130, P511, DOI 10.1038/jid.2009.245; Jonca N, 2011, EUR J DERMATOL, V21, P35, DOI 10.1684/ejd.2011.1264; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Koehler K, 2011, EUR J CELL BIOL, V90, P565, DOI 10.1016/j.ejcb.2010.10.017; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Leonard MK, 2011, CELL DEATH DIFFER, V18, P1924, DOI 10.1038/cdd.2011.73; Li J, 2012, CARCINOGENESIS, V33, P1239, DOI 10.1093/carcin/bgs143; Li QT, 2011, CARCINOGENESIS, V32, P1782, DOI 10.1093/carcin/bgr207; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; Lopez-Pajares V, 2013, TRENDS GENET, V29, P31, DOI 10.1016/j.tig.2012.10.005; Man MQ, 2008, J INVEST DERMATOL, V128, P370, DOI 10.1038/sj.jid.5701026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Meyer M, 2011, J INVEST DERM SYMP P, V15, P48, DOI 10.1038/jidsymp.2011.1; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mlacki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089247; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Natsuga K, 2007, J INVEST DERMATOL, V127, P2669, DOI 10.1038/sj.jid.5700885; Nishi K, 2009, J CELL BIOCHEM, V106, P63, DOI 10.1002/jcb.21978; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Perez-Moreno M, 2008, P NATL ACAD SCI USA, V105, P15399, DOI 10.1073/pnas.0807301105; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Plikus MV, 2012, SEMIN CELL DEV BIOL, V23, P946, DOI 10.1016/j.semcdb.2012.10.001; Restivo G, 2011, EMBO J, V30, P4571, DOI 10.1038/emboj.2011.325; Richardson RJ, 2006, NAT GENET, V38, P1329, DOI 10.1038/ng1894; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; She QB, 2002, CANCER RES, V62, P1343; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Tinkle CL, 2008, P NATL ACAD SCI USA, V105, P15405, DOI 10.1073/pnas.0807374105; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; Wang X, 2008, J CELL BIOL, V183, P37, DOI 10.1083/jcb.200804030; Wikramanayake TC, 2014, ADV WOUND CARE, V3, P272, DOI 10.1089/wound.2013.0503; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Yang JX, 2010, J CELL BIOL, V188, P935, DOI 10.1083/jcb.200910126; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Zhong R, 2015, CANCER RES, V75, P3958, DOI 10.1158/0008-5472.CAN-15-0199; Zhu F, 2009, HISTOL HISTOPATHOL, V24, P265, DOI 10.14670/HH-24.265; Zuo Y, 2008, J BIOL CHEM, V283, P36624, DOI 10.1074/jbc.M807377200	101	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5705	5712		10.1038/onc.2016.84	http://dx.doi.org/10.1038/onc.2016.84			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27041586				2022-12-28	WOS:000386998400002
J	Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A				Le Pera, I.; Iuliano, R.; Florio, T.; Susini, C.; Trapasso, F.; Santoro, M.; Chiariotti, L.; Schettini, G.; Viglietto, G.; Fusco, A.			The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (vol 25, pg 3187, 2016)	ONCOGENE			English	Correction													Chiariotti, Lorenzo/AAC-5262-2022; Viglietto, Giuseppe/AAC-2852-2019	Viglietto, Giuseppe/0000-0003-2327-7515				Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5456	5456		10.1038/onc.2016.138	http://dx.doi.org/10.1038/onc.2016.138			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27425594	Bronze			2022-12-28	WOS:000386677800011
J	Wang, G; Yu, Y; Sun, C; Liu, T; Liang, T; Zhan, L; Lin, X; Feng, XH				Wang, G.; Yu, Y.; Sun, C.; Liu, T.; Liang, T.; Zhan, L.; Lin, X.; Feng, X-H			STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling (vol 35, pg 4388, 2016)	ONCOGENE			English	Correction																		Wang G, 2016, ONCOGENE, V35, P4388, DOI 10.1038/onc.2015.446	1	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4422	4422		10.1038/onc.2016.145	http://dx.doi.org/10.1038/onc.2016.145			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	27345395	Bronze			2022-12-28	WOS:000382152100014
J	Chen, CH; Fong, LWR; Yu, E; Wu, R; Trott, JF; Weiss, RH				Chen, C-H; Fong, L. W. R.; Yu, E.; Wu, R.; Trott, J. F.; Weiss, R. H.			Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; C-KINASE SUBSTRATE; PATHWAY; PHOSPHORYLATION; RESISTANCE; BIOMARKER; GROWTH; REGORAFENIB; INHIBITORS; PROTEOMICS	Targeted therapeutics, such as those abrogating hypoxia inducible factor (HIF)/vascular endothelial growth factor signaling, are initially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance frequently occurs via subsequent activation of alternative pathways. Through genome-scale integrated analysis of the HIF-alpha network, we identified the major protein kinase C substrate MARCKS (myristoylated alanine-rich C kinase substrate) as a potential target molecule for kidney cancer. In a screen of nephrectomy samples from 56 patients with RCC, we found that MARCKS expression and its phosphorylation are increased and positively correlate with tumor grade. Genetic and pharmacologic suppression of MARCKS in high-grade RCC cell lines in vitro led to a decrease in cell proliferation and migration. We further demonstrated that higher MARCKS expression promotes growth and angiogenesis in vivo in an RCC xenograft tumor. MARCKS acted upstream of the AKT/mTOR pathway, activating HIF-target genes, notably vascular endothelial growth factor-A. Following knockdown of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced. Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR. Our data suggest a major contribution of MARCKS to kidney cancer growth and provide an alternative therapeutic strategy of improving the efficacy of multikinase inhibitors.	[Chen, C-H; Yu, E.; Trott, J. F.; Weiss, R. H.] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA; [Chen, C-H; Weiss, R. H.] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA 95616 USA; [Fong, L. W. R.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Yu, E.; Wu, R.] Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; [Yu, E.; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Dept Internal Med, Davis, CA 95616 USA; [Weiss, R. H.] Northern Calif Hlth Care Syst, Dept Vet Affairs, Med Serv, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis; University of California System; University of California Davis	Chen, CH; Weiss, RH (corresponding author), Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.	jchchen@ucdavis.edu; rhweiss@ucdavis.edu		Fong, Lon Wolf/0000-0001-6633-3164	NIH [1R01CA135401-01A1, 1R03CA181837-01, 1R01DK082690-01A1]; Medical Service of the US Department of Veterans' Affairs; Dialysis Clinic, Inc.(DCI) [C-3917]; NATIONAL CANCER INSTITUTE [P30CA093373] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Service of the US Department of Veterans' Affairs; Dialysis Clinic, Inc.(DCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Mr Muhammad S Arif (Department of Public Health Sciences, University of California at Davis, Davis, CA, USA) for assistance with the experiments; Dr Yu-Ching Lin (UNIMED Healthcare Inc., Taiwan) and Ms Wen-Hsin Chang (Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan) for technological support in ForteBio system; Dr Guan-Chin Tseng (Department of Pathology, China Medical University Hospital, Taiwan) for useful advice; and the UC Davis Comprehensive Cancer Center Biorepository (University of California at Davis, Davis, CA, USA) for pathology support. This work was supported by NIH grants 1R01CA135401-01A1, 1R03CA181837-01 and 1R01DK082690-01A1, the Medical Service of the US Department of Veterans' Affairs (all to RHW), and a research grant from Dialysis Clinic, Inc. (DCI# C-3917 to C-HC).	ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; Bickeboller M, 2015, ONCOGENE, V34, P1150, DOI 10.1038/onc.2014.40; Brandi J, 2016, J PROTEOMICS, V136, P1, DOI 10.1016/j.jprot.2016.01.017; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Browne BC, 2013, FEBS J, V280, P5237, DOI 10.1111/febs.12441; Chen CH, 2014, ONCOGENE, V33, P3696, DOI 10.1038/onc.2013.336; Chen CH, 2015, ONCOTARGET, V6, P15194, DOI 10.18632/oncotarget.3827; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chen CH, 2014, AM J RESP CRIT CARE, V189, P1002, DOI 10.1164/rccm.201401-0053LE; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Choueiri TK, 2013, CLIN CANCER RES, V19, P5218, DOI 10.1158/1078-0432.CCR-13-0491; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Domblides C, 2013, EXPERT OPIN EMERG DR, V18, P495, DOI 10.1517/14728214.2013.858697; Dorff TB, 2014, EXPERT REV CLIN PHAR, V7, P67, DOI 10.1586/17512433.2014.862496; Eisen T, 2012, LANCET ONCOL, V13, P1055, DOI 10.1016/S1470-2045(12)70364-9; Ferraro D, 2014, THER ADV MED ONCOL, V6, P222, DOI 10.1177/1758834014544892; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Gross-Goupil M, 2012, CURR UROL REP, V13, P16, DOI 10.1007/s11934-011-0232-y; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Han KS, 2015, NEOPLASIA, V17, P805, DOI 10.1016/j.neo.2015.11.001; Hanada S, 2013, CANCER BIOMARK, V13, P289, DOI 10.3233/CBM-130354; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Josic D, 2008, CURR OPIN MOL THER, V10, P116; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Kalwa H, 2011, J BIOL CHEM, V286, P2320, DOI 10.1074/jbc.M110.196022; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Maroto P, 2014, CLIN CANCER RES, V20, P2060, DOI 10.1158/1078-0432.CCR-13-1351; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Naboulsi W, 2016, J PROTEOME RES, V15, P38, DOI 10.1021/acs.jproteome.5b00420; Parekh H, 2015, EXPERT REV ANTICANC, V15, P1305, DOI 10.1586/14737140.2015.1090315; Posadas EM, 2013, EXPERT OPIN PHARMACO, V14, P2221, DOI 10.1517/14656566.2013.832202; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Rohrbach TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140870; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; Sajithlal GB, 2013, MOL PHARMACOL, V84, P562, DOI 10.1124/mol.113.088005; Santoni M, 2014, BBA-REV CANCER, V1845, P221, DOI 10.1016/j.bbcan.2014.01.007; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Su D, 2014, CURR OPIN ONCOL, V26, P321, DOI 10.1097/CCO.0000000000000069; von Roemeling CA, 2014, CANCER RES, V74, P4796, DOI 10.1158/0008-5472.CAN-14-0210; Wettersten HI, 2015, CANCER RES, V75, P2541, DOI 10.1158/0008-5472.CAN-14-1703; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Yang Y, 2014, LEUKEMIA, V29, P715; Zaki K, 2013, CURR ONCOL REP, V15, P91, DOI 10.1007/s11912-013-0292-x; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; Ziemba BP, 2016, BIOPHYS J, V110, P1811, DOI 10.1016/j.bpj.2016.03.001	52	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3588	3598		10.1038/onc.2016.510	http://dx.doi.org/10.1038/onc.2016.510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166200	Green Published, Green Accepted			2022-12-28	WOS:000403878600008
J	Pixberg, CF; Raba, K; Muller, F; Behrens, B; Honisch, E; Niederacher, D; Neubauer, H; Fehm, T; Goering, W; Schulz, WA; Flohr, P; Boysen, G; Lambros, M; De Bono, JS; Knoefel, WT; Sproll, C; Stoecklein, NH; Neves, RPL				Pixberg, C. F.; Raba, K.; Muller, F.; Behrens, B.; Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.; Goering, W.; Schulz, W. A.; Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.; Knoefel, W. T.; Sproll, C.; Stoecklein, N. H.; Neves, R. P. L.			Analysis of DNA methylation in single circulating tumor cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; BREAST-CANCER; MIR-200 FAMILY; PROMOTER METHYLATION; ADHESION MOLECULE; REPRESSORS ZEB1; CPG ISLAND; GENE; BISULFITE	Direct analysis of circulating tumor cells (CTCs) can inform on molecular mechanisms underlying systemic spread. Here we investigated promoter methylation of three genes regulating epithelial-to-mesenchymal transition (EMT), a key mechanism enabling epithelial tumor cells to disseminate and metastasize. For this, we developed a single-cell protocol based on agaroseembedded bisulfite treatment, which allows investigating DNA methylation of multiple loci via a multiplex PCR (multiplexedscAEBS). We established our assay for the simultaneous analysis of three EMT-associated genes miR-200c/141, miR-200b/a/429 and CDH1 in single cells. The assay was validated in solitary cells of GM14667, MDA-MB-231 and MCF-7 cell lines, achieving a DNA amplification efficiency of 70% with methylation patterns identical to the respective bulk DNA. Then we applied multiplexedscAEBS to 159 single CTCs from 11 patients with metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellSearch (EpCAM(pos)/CKpos/CD45(neg)/DAPI(pos)) and subsequent FACS sorting. In contrast to CD45(pos) white blood cells isolated and processed by the identical approach, we observed in the isolated CTCs methylation patterns resembling more those of epithelial-like cells. Methylation at the promoter of microRNA-200 family was significantly higher in prostate CTCs. Data from our single-cell analysis revealed an epigenetic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-associated genes during blood-borne dissemination.	[Pixberg, C. F.; Muller, F.; Behrens, B.; Knoefel, W. T.; Stoecklein, N. H.; Neves, R. P. L.] Univ Hosp, Dept Gen Visceral & Paediat Surg, Dusseldorf, Germany; [Pixberg, C. F.; Raba, K.; Muller, F.; Behrens, B.; Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.; Goering, W.; Schulz, W. A.; Knoefel, W. T.; Sproll, C.; Stoecklein, N. H.; Neves, R. P. L.] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Raba, K.] Univ Hosp, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany; [Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.] Univ Hosp, Dept Obstet & Gynecol, Dusseldorf, Germany; [Goering, W.; Schulz, W. A.] Univ Hosp, Dept Urol, Dusseldorf, Germany; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Canc Therapeut, London, England; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Clin Studies, London, England; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England; [Sproll, C.] Univ Hosp, Dept Oral Maxillo & Plast Facial Surg, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Stoecklein, NH (corresponding author), Heinrich Heine Univ Dusseldorf, Univ Hosp, Dept Gen Visceral & Paediat Surg, Moorenstr 5, D-40225 Dusseldorf, Germany.	nikolas.stoecklein@uni-duesseldorf.de	Schulz, Wolfgang/N-3402-2019; Neves, Rui/AAF-9626-2021; Raba, Katharina/B-8697-2017; Neubauer, Hans/C-4467-2016; Boysen, Gunnar/U-3272-2019	Schulz, Wolfgang/0000-0002-2196-463X; Neves, Rui/0000-0002-4515-739X; Raba, Katharina/0000-0001-8818-4219; Neubauer, Hans/0000-0002-3467-4105; Boysen, Gunnar/0000-0001-8364-9881; de Bono, Johann S/0000-0002-2034-595X; Muller, Fabienne/0000-0002-5845-6305; Fehm, Tanja/0000-0002-4926-0108	Dusseldorf School of Oncology (Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe); EU grant reference EU FP7 project CTCTrap [305341]; Deutsche Krebshilfe [109600]; Innovative Medicines Initiative Joint Undertaking (IMI JU); CANCER-ID [115749]; Dusseldorf School of Oncology (Medical Faculty HHU Dusseldorf); Deutsche Krebshilfe (NHS); Medical Research Council [G0601308] Funding Source: researchfish; MRC [G0601308] Funding Source: UKRI	Dusseldorf School of Oncology (Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe); EU grant reference EU FP7 project CTCTrap; Deutsche Krebshilfe(Deutsche Krebshilfe); Innovative Medicines Initiative Joint Undertaking (IMI JU); CANCER-ID; Dusseldorf School of Oncology (Medical Faculty HHU Dusseldorf); Deutsche Krebshilfe (NHS); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	KR, BB, EH, DN, HN, TF, WTK, CS, NHS and RPLN are members of the Disseminated Cancer Cell Network (DCC Net) Dusseldorf. This work was supported by the Dusseldorf School of Oncology (funded by the Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe and the Medical Faculty HHU Dusseldorf) (to CFP), by an EU grant reference EU FP7 project CTCTrap (Grant #305341 to JSDB), the Deutsche Krebshilfe (Grant #109600 to CS and NHS) and the Innovative Medicines Initiative Joint Undertaking (IMI JU) in conjunction with CANCER-ID (Grant Agreement #115749 to NHS).	Alberter B, 2016, EXPERT REV MOL DIAGN, V16, P25, DOI 10.1586/14737159.2016.1121099; Allard WJ, 2015, CLIN CANCER RES, V21, P2883, DOI 10.1158/1078-0432.CCR-14-2559; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brambert PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117310; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Carmona FJ, 2014, CANCER RES, V74, P5608, DOI 10.1158/0008-5472.CAN-13-3659; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107; Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Genereux DP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn691; Geuns E, 2003, HUM MOL GENET, V12, P2873, DOI 10.1093/hmg/ddg315; Geuns E, 2007, EUR J HUM GENET, V15, P352, DOI 10.1038/sj.ejhg.5201759; Geuns E, 2007, J MED GENET, V44, P144, DOI 10.1136/jmg.2006.044149; Gires O, 2014, CELL MOL LIFE SCI, V71, P4393, DOI 10.1007/s00018-014-1693-1; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; HAYATSU H, 1970, BIOCHEMISTRY-US, V9, P2858, DOI 10.1021/bi00816a016; Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Larson CJ, 2004, CYTOM PART A, V62A, P46, DOI 10.1002/cyto.a.20073; Lianidou ES, 2016, MOL ONCOL, V10, P431, DOI 10.1016/j.molonc.2016.01.011; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Magbanua MJM, 2014, CANCER METAST REV, V33, P757, DOI 10.1007/s10555-014-9503-7; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Neves RPL, 2014, CLIN CHEM, V60, P1290, DOI 10.1373/clinchem.2014.222331; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Pal SK, 2015, CLIN GENITOURIN CANC, V13, P130, DOI 10.1016/j.clgc.2014.08.014; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pixberg CF, 2015, GENES-BASEL, V6, P1053, DOI 10.3390/genes6041053; Polioudaki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1386-7; Polzer B, 2014, EMBO MOL MED, V6, P1371, DOI 10.15252/emmm.201404033; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Rao CG, 2005, INT J ONCOL, V27, P49; Rossi E, 2010, CLIN CANCER RES, V16, P5233, DOI 10.1158/1078-0432.CCR-10-1449; Schwartzman O, 2015, NAT REV GENET, V16, P716, DOI 10.1038/nrg3980; SHAPIRO R, 1973, J BIOL CHEM, V248, P4060; Sieuwerts AM, 2009, J NATL CANCER I, V101, P61, DOI 10.1093/jnci/djn419; Spiliotaki M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0485-8; Steinert G, 2014, CANCER RES, V74, P1694, DOI 10.1158/0008-5472.CAN-13-1885; Stoecklein NH, 2016, EXPERT REV MOL DIAGN, V16, P147, DOI 10.1586/14737159.2016.1123095; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; TIERLING S, BISULFITE SEQUENCING; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	76	50	51	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3223	3231		10.1038/onc.2016.480	http://dx.doi.org/10.1038/onc.2016.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068321				2022-12-28	WOS:000402869800002
J	Jiang, T; Pan, CQ; Low, BC				Jiang, T.; Pan, C. Q.; Low, B. C.			BPGAP1 spatially integrates JNK/ERK signaling crosstalk in oncogenesis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCAFFOLD PROTEINS; RHO-GTPASES; FUNCTIONAL PLASTICITY; CELL-PROLIFERATION; JNK ACTIVATION; CANCER CELLS; PATHWAYS; TARGETS; BINDING	Simultaneous hyperactivation of stress-activated protein kinase/c-Jun N-terminal protein kinase (SAPK/JNK) and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling cascades has been reported in carcinogenesis. However, how they are integrated to promote oncogenesis remains unknown. By analyzing breast invasive carcinoma database (The Cancer Genome Altas), we found that the mRNA expression levels of both JNK1 and ERK2 are positively correlated with the mRNA level of EEA1, an endosome associated protein, indicating the potential JNK/ERK crosstalk at endosome. Unbiased screen of different endosome-associated Rab GTPases reveals that late endosome serves as a unique platform to integrate JNK/ERK signaling. Furthermore, we identify that BPGAP1 (a BCH domain-containing, Cdc42GAP-like Rho GTPase-activating protein) promotes MEK partner 1 (MP1)-induced ERK activation on late endosome through scaffolding MP1/MEK1 complex. This regulatory function requires phosphorylation of BPGAP1 by JNK at its C terminal tail (Ser424) to unlock its autoinhibitory conformation. Consequently, phosphorylated BPGAP1 facilitates endosomal ERK signaling transduction to the nucleus, driving cell proliferation and transformation via the ERK-Myc-CyclinA axis. BPGAP1 therefore provides a crucial spatiotemporal checkpoint where JNK and MP1/MEK1 work in concert to regulate endosomal and nuclear ERK signaling in cell proliferation control.	[Jiang, T.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Pan, C. Q.; Low, B. C.] Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr 1, Singapore 117411, Singapore; [Low, B. C.] Natl Univ Singapore, Univ Scholars Programme, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Pan, CQ; Low, BC (corresponding author), Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr 1, Singapore 117411, Singapore.	mbipqc@nus.edu; dbslowbc@nus.edu.sg	Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X	NUS Research Scholarship, a Ministry of Education Tier 2 [R154-000-236-112]; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education Singapore; National Medical Research Council; CBRG New Investigator Grant (CBRG-NIG) [R-714-000-115-511]	NUS Research Scholarship, a Ministry of Education Tier 2; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education Singapore(Ministry of Education, Singapore); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CBRG New Investigator Grant (CBRG-NIG)	This work was supported by an NUS Research Scholarship (to TJ), a Ministry of Education Tier 2 grant (R154-000-236-112 to BCL) and the Mechanobiology Institute of Singapore (to BCL), funded through the National Research Foundation and the Ministry of Education Singapore. This work was also supported by National Medical Research Council, CBRG New Investigator Grant (CBRG-NIG) (R-714-000-115-511 to CQP). We thank Proteins and Proteomics Center (National University of Singapore) for mass spectrometric analysis. We thank Nisha Mohd Rafiq (National University of Singapore) for the technical support. We also thank Professor Andrew Catling (LSU Health Sciences Center), Professor Kanga Sabapathy (National Cancer Center, Singapore), and Professor Yih-Cherng Liou (National University of Singapore) for providing MP1, phospho-JNK1, CyclinA and CyclinE antibodies, respectively.	Adler V, 2005, BIOCHEMISTRY-US, V44, P10784, DOI 10.1021/bi050619j; Alsayed Y, 2005, BLOOD, V106, p150A; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Brown MD, 2009, CELL SIGNAL, V21, P462, DOI 10.1016/j.cellsig.2008.11.013; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Araujo ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053768; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Engstrom W, 2010, CELL PROLIFERAT, V43, P56, DOI 10.1111/j.1365-2184.2009.00654.x; Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118; Good MC, 2011, SCIENCE, V332, P680, DOI 10.1126/science.1198701; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Hornberg JJ, 2006, BIOSYSTEMS, V83, P81, DOI 10.1016/j.biosystems.2005.05.014; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Johnstone CN, 2004, GENE, V336, P59, DOI 10.1016/j.gene.2004.01.025; Jun S, 2013, CELL REP, V5, P314, DOI 10.1016/j.celrep.2013.09.026; Kang JS, 2008, J CELL BIOL, V182, P497, DOI 10.1083/jcb.200801119; Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lua BL, 2005, J CELL SCI, V118, P2707, DOI 10.1242/jcs.02383; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Miaczynska M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009035; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Palfy M, 2012, TRENDS CELL BIOL, V22, P447, DOI 10.1016/j.tcb.2012.06.004; Pan CQ, 2012, CELL SIGNAL, V24, P2143, DOI 10.1016/j.cellsig.2012.06.002; Pan CQ, 2012, FEBS LETT, V586, P2674, DOI 10.1016/j.febslet.2012.04.023; Pan CQ, 2010, J CELL SCI, V123, P903, DOI 10.1242/jcs.064162; Parameswaran N, 2013, J IMMUNOL, V190, P2017, DOI 10.4049/jimmunol.1201292; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Ramirez A, 2014, ONCOTARGET, V5, P3590, DOI 10.18632/oncotarget.1962; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Sharma C, 2005, J CELL BIOCHEM, V94, P708, DOI 10.1002/jcb.20344; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sirokmany G, 2006, J BIOL CHEM, V281, P6096, DOI 10.1074/jbc.M510619200; Skarpen E, 2008, FASEB J, V22, P466, DOI 10.1096/fj.07-8650com; Song JY, 2008, INT J GYNECOL CANCER, V18, P1051, DOI 10.1111/j.1525-1438.2007.01164.x; Song P, 2015, BIOMED PHARMACOTHER, V69, P70, DOI 10.1016/j.biopha.2014.11.008; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Taub N, 2007, MOL BIOL CELL, V18, P4698, DOI 10.1091/mbc.E07-02-0098; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Teis D, 2006, J CELL BIOL, V175, P861, DOI 10.1083/jcb.200607025; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; West RJH, 2015, J CELL BIOL, V208, P931, DOI 10.1083/jcb.201404066; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Wu P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041354; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	59	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3178	3192		10.1038/onc.2016.466	http://dx.doi.org/10.1038/onc.2016.466			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28092672				2022-12-28	WOS:000402617900010
J	Yu, L; Liang, Y; Cao, X; Wang, X; Gao, H; Lin, SY; Schiff, R; Wang, XS; Li, K				Yu, L.; Liang, Y.; Cao, X.; Wang, X.; Gao, H.; Lin, S-Y; Schiff, R.; Wang, X-S; Li, K.			Identification of MYST3 as a novel epigenetic activator of ER alpha frequently amplified in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ACUTE MYELOID-LEUKEMIA; HOX GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; ENDOCRINE RESISTANCE; THERAPEUTIC TARGET; 8P11-P12 AMPLICON; CELL-LINES; STEM-CELLS; MOZ	Estrogen receptor a (ERa) is a master driver of a vast majority of breast cancers. Breast cancer cells often develop resistance to endocrine therapy via restoration of the ERa activity through survival pathways. Thus identifying the epigenetic activator of ERa that can be targeted to block ERa gene expression is a critical topic of endocrine therapy. Here, integrative genomic analysis identified MYST3 as a potential oncogene target that is frequently amplified in breast cancer. MYST3 is involved in histone acetylation via its histone acetyltransferase domain (HAT) and, as a result, activates gene expression by altering chromatin structure. We found that MYST3 was amplified in 11% and/or overexpressed in 15% of breast tumors, and overexpression of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast cancers. Interestingly, MYST3 depletion drastically inhibited proliferation in MYST3-high, ER+ breast cancer cells, but not in benign breast epithelial cells or in MYST3-low breast cancer cells. Importantly, we discovered that knocking down MYST3 resulted in profound reduction of ERa expression, while ectopic expression of MYST3 had the reversed effect. Chromatin immunoprecipitation revealed that MYST3 binds to the proximal promoter region of ERa gene, and inactivating mutations in its HAT domain abolished its ability to regulate ERa, suggesting MYST3 functioning as a histone acetyltransferase that activates ERa promoter. Furthermore, MYST3 inhibition with inducible MYST3 shRNAs potently attenuated breast tumor growth in mice. Together, this study identifies the first histone acetyltransferase that activates ERa expression which may be potentially targeted to block ERa at transcriptional level.	[Yu, L.; Liang, Y.; Gao, H.; Li, K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Liang, Y.; Cao, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Wang, X-S] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wang, X.; Wang, X-S] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Wang, X.; Wang, X-S] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Lin, S-Y] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center	Wang, XS (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil,5117 Ctr Ave,Room G5a, Pittsburgh, PA 15213 USA.; Li, K (corresponding author), Baylor Coll Med, ABBR, Dept Surg, One Baylor Plaza, Houston, TX 77030 USA.	wangx13@pitt.edu; kli@bcm.edu			National Institutes of Health [CA161513, CA155151, CA181368, CA183976]; Dan L. Duncan Cancer Center at Baylor College of Medicine; Susan G. Komen foundation [PDF15333523, CDMRP W81XWH-13-1-0201]; Susan G. Komen for the cure grants Promise grant [PG12221410]; NIH SPORE Grants [P50 CA058183, CA186784-01]; NIH Cancer Center Grant [P30CA125123]; Breast Cancer Research Foundation; Cancer Prevention Research Institute of Texas [CPRIT RP140102, CRPIT RP130310]; Cancer Research UK; British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA181368, P30CA125123, P50CA186784, R01CA183976, R01CA155151, R21CA161513] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan L. Duncan Cancer Center at Baylor College of Medicine; Susan G. Komen foundation(Susan G. Komen Breast Cancer Foundation); Susan G. Komen for the cure grants Promise grant; NIH SPORE Grants; NIH Cancer Center Grant; Breast Cancer Research Foundation; Cancer Prevention Research Institute of Texas; Cancer Research UK(Cancer Research UK); British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (KL, CA161513, CA155151; X-SW, CA181368 & CA183976), a Pilot Project Grant from the Dan L. Duncan Cancer Center at Baylor College of Medicine (KL), Susan G. Komen foundation PDF15333523 (XW), CDMRP W81XWH-13-1-0201(X-XC). This study was partly supported by the Susan G. Komen for the cure grants Promise grant PG12221410 (RS), NIH SPORE Grants P50 CA058183 (RS) and CA186784-01 (RS), and Cancer Center Grant P30CA125123 (RS), Breast Cancer Research Foundation (RS), Cancer Prevention Research Institute of Texas (RS, CPRIT RP140102) and SYL, CRPIT RP130310. We also thank Dr. Ana Rodriguez from the Research Core Team at Michael E. DeBakey Department of Surgery, Baylor College of Medicine for editing of this manuscript. The results published here are in part based upon data generated by TCGA (dbGaP accession: phs000178.v6.p6). This study also makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium (funding for that project was provided by Cancer Research UK and the British Columbia Cancer Agency Branch).	Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Carlson S, 2014, J CELL PHYSIOL, V229, P1571, DOI 10.1002/jcp.24617; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwek SS, 2009, ONCOGENE, V28, P1892, DOI 10.1038/onc.2009.34; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Paggetti J, 2010, ONCOGENE, V29, P5019, DOI 10.1038/onc.2010.254; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sheikh BN, 2015, ONCOGENE, V34, P5807, DOI 10.1038/onc.2015.33; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Turner-Ivey B, 2014, NEOPLASIA, V16, P644, DOI 10.1016/j.neo.2014.07.007; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang XS, 2009, NAT BIOTECHNOL, V27, P1005, DOI 10.1038/nbt.1584; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077	40	31	32	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2910	2918		10.1038/onc.2016.433	http://dx.doi.org/10.1038/onc.2016.433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893709	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000401697800013
J	Roy, P; Mukherjee, T; Chatterjee, B; Vijayaragavan, B; Banoth, B; Basak, S				Roy, P.; Mukherjee, T.; Chatterjee, B.; Vijayaragavan, B.; Banoth, B.; Basak, S.			Non-canonical NF kappa B mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB: p50 NF kappa B pathway	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; ACTIVATION; ALPHA; CELLS; TARGET; ABNORMALITIES; INFLAMMATION; THALIDOMIDE	Environmental drug resistance constitutes a serious impediment for therapeutic intervention in multiple myeloma. Tumorpromoting cytokines, such as tumor necrosis factor (TNF), induce nuclear factor-kappa B (NF kappa B)-driven expression of pro-survival factors, which confer resistance in myeloma cells to apoptotic insults from TNF-related apoptosis-inducing ligand (TRAIL) and other chemotherapeutic drugs. It is thought that RelA: p50 dimer, activated from I.Ba-inhibited complex in response to TNF-induced canonical NF kappa B signal, mediates the pro-survival NF kappa B function in cancerous cells. Myeloma cells additionally acquire gain-offunction mutations in the non-canonical N kappa B module, which induces partial proteolysis of p100 into p52 to promote RelB: p52/NF kappa B activation from p100-inhibited complex during immune cell differentiation. However, role of non-canonical NF kappa B signaling in the drug resistance in multiple myeloma remains unclear. Here we report that myeloma-associated non-canonical aberrations reinforce pro-survival TNF signaling in producing a protracted TRAIL-refractory state. These mutations did not act through a typical p52 NF kappa B complex, but completely degraded p100 to reposition RelB under I kappa Ba control, whose degradation during TNF signaling induced an early RelB: p50 containing NF kappa B activity. More so, autoregulatory RelB synthesis prolonged this TNF-induced RelB: p50 activity in myeloma cells harboring non-canonical mutations. Intriguingly, TNF-activated RelB: p50 dimer was both necessary and sufficient, and RelA was not required, for NF kappa B-dependent pro-survival gene expressions and suppression of apoptosis. Indeed, high RelB mRNA expressions in myeloma patients correlated with the augmented level of pro-survival factors and resistance to therapeutic intervention. In sum, we provide evidence that cancer-associated mutations perpetuate TNF-induced pro-survival NF kappa B activity through autoregulatory RelB control and thereby exacerbate environmental drug resistance in multiple myeloma.	[Roy, P.; Mukherjee, T.; Chatterjee, B.; Vijayaragavan, B.; Banoth, B.; Basak, S.] Natl Inst Immunol, Syst Immunol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India; [Chatterjee, B.] IIT Delhi, Kusuma Sch Biol Sci, Hauz Khas, New Delhi, India; [Vijayaragavan, B.] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Weizmann Institute of Science	Basak, S (corresponding author), Natl Inst Immunol, Syst Immunol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	sobasak@nii.ac.in	Banoth, Balaji/ABF-7350-2020	Banoth, Balaji/0000-0002-7467-2198; MUKHERJEE, TAPAS/0000-0002-9433-3716; Chatterjee, Budhaditya/0000-0003-2260-8642; Basak, Soumen/0000-0002-3586-1279	SERB; Department of Science and Technology, Govt. of India [EMR/2015/000658]; Wellcome Trust DBT India Alliance [500094/Z/09/Z]; CSIR; UGC	SERB(Department of Science & Technology (India)Science Engineering Research Board (SERB), India); Department of Science and Technology, Govt. of India(Department of Science & Technology (India)); Wellcome Trust DBT India Alliance(Wellcome TrustWellcome Trust DBT India Alliance); CSIR(Council of Scientific & Industrial Research (CSIR) - India); UGC(University Grants Commission, India)	We sincerely thank Ranjan Sen, NIH, and Anna George, NII, for critical reading and constructive suggestions. We also thank Michael Kuehl, NCI, for providing us HMCLs and Dr Shao Cong Sun, University of Texas for p100<INF>S866A, S870A</INF> construct. We thank V Kumar, MVR Prasad, J Sanghani and S Goel for technical assistance. Multiple myeloma-related research was funded by SERB, Department of Science and Technology, Govt. of India (EMR/2015/000658). Research in PI's laboratory is funded by an intermediate fellowship (500094/Z/09/Z) to SB from Wellcome Trust DBT India Alliance and NII-Core. PR and BB thank CSIR, and BC and TM thank UGC for research fellowships.	Almaden JV, 2014, CELL REP, V9, P2098, DOI 10.1016/j.celrep.2014.11.024; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Annunziata CM, 2010, CANCER-AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190; Authier H, 2014, P NATL ACAD SCI USA, V111, P14794, DOI 10.1073/pnas.1410124111; Banoth B, 2015, ELIFE, V4, DOI 10.7554/eLife.05648; Basak S, 2008, CYTOKINE GROWTH F R, V19, P187, DOI 10.1016/j.cytogfr.2008.04.005; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Cormier F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059127; Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037; Demchenko YN, 2014, ONCOTARGET, V5, P4554, DOI 10.18632/oncotarget.2128; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164; Geng CY, 2014, AM J HEMATOL, V89, P1037, DOI 10.1002/ajh.23822; Hengeveld PJ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.3; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Jurisic V, 2002, MED ONCOL, V19, P133, DOI 10.1385/MO:19:3:133; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Koslowski M, 2011, ONCOGENE, V30, P876, DOI 10.1038/onc.2010.481; Latif T, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-27; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Perez LE, 2008, J IMMUNOL, V180, P1545, DOI 10.4049/jimmunol.180.3.1545; Rauert H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.78; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shih VFS, 2012, NAT IMMUNOL, V13, P1162, DOI 10.1038/ni.2446; Siggers T, 2012, NAT IMMUNOL, V13, P95, DOI 10.1038/ni.2151; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002; Vallabhapurapu SD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9428; Wang XS, 2015, LEUKEMIA LYMPHOMA, V56, P1335, DOI 10.3109/10428194.2014.956313; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	52	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1417	1429		10.1038/onc.2016.309	http://dx.doi.org/10.1038/onc.2016.309			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641334	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000395862500010
J	Wang, L; Zhang, P; Molkentine, DP; Chen, C; Molkentine, JM; Piao, H; Raju, U; Zhang, J; Valdecanas, DR; Tailor, RC; Thames, HD; Buchholz, TA; Chen, J; Ma, L; Mason, KA; Ang, KK; Meyn, RE; Skinner, HD				Wang, L.; Zhang, P.; Molkentine, D. P.; Chen, C.; Molkentine, J. M.; Piao, H.; Raju, U.; Zhang, J.; Valdecanas, D. R.; Tailor, R. C.; Thames, H. D.; Buchholz, T. A.; Chen, J.; Ma, L.; Mason, K. A.; Ang, K-K; Meyn, R. E.; Skinner, H. D.			TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; DOUBLE-STRAND BREAKS; DNA-DAMAGE-RESPONSE; P16 GENE; CANCER GENOMICS; POSITIVE HEAD; NUCLEAR FOCI; 53BP1; EXPRESSION; REPAIR	Patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC, but the mechanisms underlying this phenomenon are unknown. p16 is used as a surrogate marker for HPV infection. Our goal was to examine the role of p16 in HPV-related favorable treatment outcomes and to investigate the mechanisms by which p16 may regulate radiosensitivity. HNSCC cells and xenografts (HPV/p16-positive and -negative) were used. p16-overexpressing and small hairpin RNA-knockdown cells were generated, and the effect of p16 on radiosensitivity was determined by clonogenic cell survival and tumor growth delay assays. DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction; and data from The Cancer Genome Atlas HNSCC project were analyzed. p16 overexpression led to downregulation of TRIP12, which in turn led to increased RNF168 levels, repressed DNA damage repair (DDR), increased 53BP1 foci and enhanced radioresponsiveness. Inhibition of TRIP12 expression further led to radiosensitization, and overexpression of TRIP12 was associated with poor survival in patients with HPV-positive HNSCC. These findings reveal that p16 participates in radiosensitization through influencing DDR and support the rationale of blocking TRIP12 to improve radiotherapy outcomes.	[Wang, L.; Zhang, P.; Molkentine, D. P.; Chen, C.; Molkentine, J. M.; Piao, H.; Raju, U.; Zhang, J.; Valdecanas, D. R.; Thames, H. D.; Chen, J.; Ma, L.; Mason, K. A.; Ang, K-K; Meyn, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Z7-3014,1515 Holcombe Blvd,Unit 1052, Houston, TX 77030 USA; [Piao, H.] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, Dalian, Peoples R China; [Tailor, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA; [Buchholz, T. A.; Ang, K-K; Skinner, H. D.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Z7-3014,1515 Holcombe Blvd,Unit 1052, Houston, TX 77030 USA.	Lwang6@mdanderson.org	Ma, Li/GQR-1313-2022; Skinner, Heath/A-1669-2012	Ma, Li/0000-0001-9965-989X; Buchholz, Thomas/0000-0002-7859-5572; Zhang, Peijing/0000-0003-1586-8710; Skinner, Heath/0000-0003-1836-151X; Molkentine, Jessica/0000-0002-3757-7167	National Cancer Institute [R01CA168485, R01CA181029]; Cancer Prevention Research Institute of Texas [RP150293, P30 NCI CA016672]; MD Anderson Cancer Head and Cancer SPORE Career Development Award; Center for Radiation Oncology Research Development Award; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA181029, R01CA168485] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research Institute of Texas; MD Anderson Cancer Head and Cancer SPORE Career Development Award; Center for Radiation Oncology Research Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jeffery Myers and Dr Peter J F Snijders for kindly sharing their cell lines. This work was supported by grants R01CA168485 and R01CA181029 from the National Cancer Institute (REM and KKA) and (LM), respectively, the Gilbert H Fletcher Chair (KKA), Cancer Center Support Grant (P30 NCI CA016672), Individual Investigator Research Award RP150293 from the Cancer Prevention Research Institute of Texas (HDS), an MD Anderson Cancer Head and Cancer SPORE Career Development Award (HDS) and a Center for Radiation Oncology Research Development Award (HDS). The content is solely the responsibility of the authors and does not represent the official views of any grant-awarding agency.	Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2012, SEMIN RADIAT ONCOL, V22, P128, DOI 10.1016/j.semradonc.2011.12.004; Bauer E, 1998, MUTAT RES-FUND MOL M, V398, P101, DOI 10.1016/S0027-5107(97)00246-7; Bihl MP, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-173; Bohgaki M, 2013, P NATL ACAD SCI USA, V110, P20982, DOI 10.1073/pnas.1320302111; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Chou TF, 2011, J BIOL CHEM, V286, P16546, DOI 10.1074/jbc.M110.215319; Collado M, 2010, CANCER CELL, V17, P317, DOI 10.1016/j.ccr.2010.03.015; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Dok R, 2014, CANCER RES, V74, P1739, DOI 10.1158/0008-5472.CAN-13-2479; Duan S., 2012, ABSTRACT APPL ANAL, V2012, P1, DOI DOI 10.1109/SPC0M.2012.6290252; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; HALL M, 1995, ONCOGENE, V11, P1581; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Lee AWC, 2003, MOL CANCER THER, V2, P961; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Li CY, 2013, CELL CYCLE, V12, P923, DOI 10.4161/cc.23882; Li W, 2004, HEAD NECK-J SCI SPEC, V26, P1, DOI 10.1002/hed.10335; Lou-Qian Zhang, 2013, PLoS One, V8, pe54970, DOI 10.1371/journal.pone.0054970; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Matsuda K, 2011, HISTOPATHOLOGY, V59, P441, DOI 10.1111/j.1365-2559.2011.03963.x; Matsumura Y, 1997, CANCER LETT, V115, P91, DOI 10.1016/S0304-3835(97)04714-9; McLaughlin-Drubin ME, 2013, P NATL ACAD SCI USA, V110, P16175, DOI 10.1073/pnas.1310432110; Mirzayans R, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/951574; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Peuscher MH, 2011, NAT CELL BIOL, V13, P1139, DOI 10.1038/ncb2326; Pinato S, 2011, MOL CELL BIOL, V31, P118, DOI 10.1128/MCB.00818-10; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rieckmann T, 2013, RADIOTHER ONCOL, V107, P242, DOI 10.1016/j.radonc.2013.03.013; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang L, 2012, MOL MED REP, V6, P904, DOI 10.3892/mmr.2012.1001; Wang L, 2011, ANTICANCER RES, V31, P2141; Westra WH, 2011, HEAD NECK-J SCI SPEC, V34, P459; Xu RB, 2013, CANCER BIOMARK, V13, P215, DOI 10.3233/CBM-130355; Yang ZH, 2014, ASIAN PAC J CANCER P, V15, P3817, DOI 10.7314/APJCP.2014.15.8.3817	50	27	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					820	828		10.1038/onc.2016.250	http://dx.doi.org/10.1038/onc.2016.250			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27425591	Green Accepted			2022-12-28	WOS:000394168200009
J	Deng, Z; Rong, Y; Teng, Y; Zhuang, X; Samykutty, A; Mu, J; Zhang, L; Cao, P; Yan, J; Miller, D; Zhang, HG				Deng, Z.; Rong, Y.; Teng, Y.; Zhuang, X.; Samykutty, A.; Mu, J.; Zhang, L.; Cao, P.; Yan, J.; Miller, D.; Zhang, H-G			Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis	ONCOGENE			English	Article							SUPPRESSOR-CELLS; BREAST-CANCER; THERAPEUTIC AGENTS; DRUG-RESISTANCE; CHEMOTHERAPY; EXPRESSION; MICRORNA-126-5P; INTERLEUKIN-33; BIOGENESIS; CORRELATE	Acquired resistance to chemotherapy remains a major stumbling block in cancer treatment. Chronic inflammation has a crucial role in induction of chemoresistance and results, in part, from the induction and expansion of inflammatory cells that include myeloidderived suppressor cells (MDSCs) and IL-13(+) Th2 cells. The mechanisms that lead to induction of activated MDSCs and IL-13(+) Th2 cells have not yet been identified. Here we demonstrated that doxorubicin (DOX) treatment of 4T1 breast tumor-bearing mice led to the induction of IL-13R(+) miR-126a(+) MDSCs (DOX-MDSC). DOX-MDSC promote breast tumor lung metastasis through MDSC miR-126a(+) exosomal-mediated induction of IL-13(+) Th2 cells and tumor angiogenesis. The induction of DOX-MDSC is regulated in a paracrine manner. DOX treatment not only increases interleukin (IL)-33 released from breast tumor cells, which is crucial for the induction of IL-13(+) Th2 cells, but it also participates in the induction of IL-13 receptors and miR-126a expressed on/in the MDSCs. IL-13 released from IL-13(+) Th2 cells then promotes the production of DOX-MDSC and MDSC miR-126a(+) exosomes via MDSC IL-13R. MDSC miR-126a+ exosomes further induce IL13(+) Th2 cells in a positive feed-back loop manner. We also showed that MDSC miR-126a rescues DOX-induced MDSC death in a S100A8/A9-dependent manner and promotes tumor angiogenesis. Our findings provide insight into the MDSC exosomal-mediated chemoresistance mechanism, which will be useful for the design of inhibitors targeting the blocking of induction of miR-126a(+) MDSCs.	[Deng, Z.; Rong, Y.; Teng, Y.; Zhuang, X.; Samykutty, A.; Mu, J.; Zhang, L.; Cao, P.; Yan, J.; Miller, D.; Zhang, H-G] Univ Louisville, Dept Microbiol & Immunol, James Graham Brown Canc Ctr, CTRB 309,505 Hancock St, Louisville, KY 40292 USA; [Zhang, H-G] Robley Rex VA Med Ctr, Louisville, KY USA	University of Louisville	Deng, Z; Zhang, HG (corresponding author), Univ Louisville, Dept Microbiol & Immunol, James Graham Brown Canc Ctr, CTRB 309,505 Hancock St, Louisville, KY 40292 USA.	z0deng01@louisville.edu; H0Zhan17@louisville.edu	Yan, Jun/A-8988-2008; samykutty, Abhilash/J-6575-2019	samykutty, Abhilash/0000-0003-3551-045X	National Institutes of Health (NIH) [R01AT008617, UH3TR000875]; Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants; Research Career Scientist (RCS) Award; US Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000875, UH2TR000875] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT008617] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants; Research Career Scientist (RCS) Award; US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the National Institutes of Health (NIH) (R01AT008617, UH3TR000875) and the Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants (to H-G Zhang). H-G Zhang is supported by a Research Career Scientist (RCS) Award, funded by the US Department of Veterans Affairs. We thank Dr Jerald Ainsworth for editorial assistance.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Agudo J, 2014, NAT IMMUNOL, V15, P54, DOI 10.1038/ni.2767; Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Burke MC, 2014, J PROTEOME RES, V13, P5965, DOI 10.1021/pr500854x; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; de Leeuw DC, 2014, CANCER RES, V74, P2094, DOI 10.1158/0008-5472.CAN-13-1733; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Garlanda C, 2009, TRENDS IMMUNOL, V30, P439, DOI 10.1016/j.it.2009.06.001; Ghiringhelli F, 2014, EXPERT REV CLIN IMMU, V10, P19, DOI 10.1586/1744666X.2014.865520; Goerke SM, 2015, BIOL CHEM, V396, P245, DOI 10.1515/hsz-2014-0259; Guabiraba R, 2014, MUCOSAL IMMUNOL, V7, P1079, DOI 10.1038/mi.2013.124; Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357; Joshi BH, 2009, IMMUNOTHERAPY-UK, V1, P321, DOI 10.2217/IMT.09.8; Koch R, 2016, CLIN CANCER RES, V22, P395, DOI 10.1158/1078-0432.CCR-15-0577; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lieberman J, 2013, CELL, V153, P9, DOI 10.1016/j.cell.2013.03.019; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Ohshima K, 2014, PROTEOMICS, V14, P2297, DOI 10.1002/pmic.201300477; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Ozkok A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/967826; Payne KK, 2013, BREAST CANCER RES TR, V142, P45, DOI 10.1007/s10549-013-2733-5; Ran S, 2015, CANCER RES, V75, P2405, DOI 10.1158/0008-5472.CAN-14-3525; Reichenbach DK, 2015, BLOOD, V125, P3183, DOI 10.1182/blood-2014-10-606830; Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009; Schmieder A, 2012, CYTOKINE, V60, P514, DOI 10.1016/j.cyto.2012.06.286; Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487; Seidelin JB, 2011, MUCOSAL IMMUNOL, V4, P496, DOI 10.1038/mi.2011.22; Shen J, 2015, CANCER RES, V75, P783, DOI 10.1158/0008-5472.CAN-14-2568; Shibayama Y, 2015, ONCOL REP, V33, P2176, DOI 10.3892/or.2015.3839; Suzuki A, 2015, CYTOKINE, V75, P79, DOI 10.1016/j.cyto.2015.05.026; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Umansky V, 2012, CANCER IMMUNOL IMMUN, V61, P275, DOI 10.1007/s00262-011-1164-6; Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood-2014-03-562439; Wang QL, 2015, CANCER RES, V75, P2520, DOI 10.1158/0008-5472.CAN-14-3095; Wang QL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2886; Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245; Xiang Y, 2014, ONCOGENE, V33, P378, DOI 10.1038/onc.2012.575; Yang Z, 2015, INT J CLIN EXP PATHO, V8, P8869; Yin Y, 2013, CANCER IMMUNOL RES, V1, P256, DOI 10.1158/2326-6066.CIR-13-0073	54	122	129	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					639	651		10.1038/onc.2016.229	http://dx.doi.org/10.1038/onc.2016.229			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345402	Green Accepted			2022-12-28	WOS:000394167700006
J	Garcia-Rendueles, AR; Rodrigues, JS; Garcia-Rendueles, MER; Suarez-Farina, M; Perez-Romero, S; Barreiro, F; Bernabeu, I; Rodriguez-Garcia, J; Fugazzola, L; Sakai, T; Liu, F; Cameselle-Teijeiro, J; Bravo, SB; Alvarez, CV				Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Barreiro, F.; Bernabeu, I.; Rodriguez-Garcia, J.; Fugazzola, L.; Sakai, T.; Liu, F.; Cameselle-Teijeiro, J.; Bravo, S. B.; Alvarez, C. V.			Rewiring of the apoptotic TGF-beta-SMAD/NF kappa B pathway through an oncogenic function of p27 in human papillary thyroid cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; MESSENGER-RNA; CDK INHIBITOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT KINASES; TUMOR-SUPPRESSOR	Papillary thyroid carcinoma (PTC), the most frequent thyroid cancer, is characterized by low proliferation but no apoptosis, presenting frequent lymph-node metastasis. Papillary thyroid carcinoma overexpress transforming growth factor-beta (TGF-beta). In human cells, TGF-beta has two opposing actions: antitumoral through pro-apoptotic and cytostatic activities, and pro-tumoral promoting growth and metastasis. The switch converting TGF-beta from a tumor-suppressor to tumor-promoter has not been identified. In the current study, we have quantified a parallel upregulation of TGF-beta and nuclear p27, a CDK2 inhibitor, in samples from PTC. We established primary cultures from follicular epithelium in human homeostatic conditions (h7H medium). TGF-beta-dependent cytostasis occurred in normal and cancer cells through p15/CDKN2B induction. However, TGF-beta induced apoptosis in normal and benign but not in carcinoma cultures. In normal thyroid cells, TGF-beta/SMAD repressed the p27/CDKN1B gene, activating CDK2-dependent SMAD3 phosphorylation to induce p50 NF kappa B-dependent BAX upregulation and apoptosis. In thyroid cancer cells, oncogene activation prevented TGF-beta/SMAD-dependent p27 repression, and CDK2/SMAD3 phosphorylation, leading to p65 NF kappa B upregulation which repressed BAX, induced cyclin D1 and promoted TGF-beta-dependent growth. In PTC samples from patients, upregulation of TGF-beta, p27, p65 and cyclin D1 mRNA were significantly correlated, while the expression of the isoform BAX-beta, exclusively transcribed in apoptotic cells, was negatively correlated. Additionally, combined ERK and p65 NF kappa B inhibitors reduced p27 expression and potentiated apoptosis in thyroid cancer cells while not affecting survival in normal thyroid cells. Our results therefore suggest that the oncoprotein p27 reorganizes the effects of TGF-beta in thyroid cancer, explaining the slow proliferation but lack of apoptosis and metastatic behavior of PTC.	[Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Alvarez, C. V.] USC, Ctr Invest Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain; [Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Alvarez, C. V.] USC, Inst Invest Sanitarias IDIS, Grp Endocrine Neoplasia & Differentiat, Santiago De Compostela, Spain; [Barreiro, F.] Univ Hosp Santiago de Compostela CHUS, Dept Surg, Santiago De Compostela, Spain; [Barreiro, F.; Bernabeu, I.; Rodriguez-Garcia, J.; Cameselle-Teijeiro, J.] USC, Santiago De Compostela, Spain; [Bernabeu, I.] Univ Hosp Santiago de Compostela CHUS, Dept Endocrinol, Santiago De Compostela, Spain; [Rodriguez-Garcia, J.] Univ Hosp Santiago de Compostela CHUS, Dept Clin Biochem, Santiago De Compostela, Spain; [Fugazzola, L.] Fdn IRCCS Ca Granda Policlin, Endocrine Unit, Milan, Italy; [Fugazzola, L.] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Sakai, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan; [Liu, F.] Rutgers State Univ, Rutgers Canc Inst New Jersey, Susan Lehman Cullman Lab Canc Res, Ctr Adv Biotechnol & Med,Ernest Mario Sch Pham, Piscataway, NJ USA; [Cameselle-Teijeiro, J.] Univ Hosp Santiago de Compostela CHUS, Dept Pathol, Santiago De Compostela, Spain; [Bravo, S. B.] Univ Hosp Santiago de Compostela CHUS, Dept Prote, Santiago De Compostela, Spain; [Garcia-Rendueles, M. E. R.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Kyoto Prefectural University of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Memorial Sloan Kettering Cancer Center	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Ctr Invest Mol Med & Chron Dis CIMUS, Endocrine Neoplasia & Differentiat Grp P0L5, Santiago De Compostela 15782, A Coruna, Spain.; Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Inst Biomed Res IDIS, Santiago De Compostela 15782, A Coruna, Spain.	clara.alvarez@usc.es	Bernabeu, Ignacio/P-2049-2014; bernabeu, ignacio/GRJ-0401-2022; Alvarez, Clara V/AAN-4173-2020; Fugazzola, laura/AAH-7803-2021; Lopez, Susana Belén Bravo/F-8487-2016; Rodriguez Garcia-Rendueles, Maria/B-6939-2019	Bernabeu, Ignacio/0000-0001-8421-7394; bernabeu, ignacio/0000-0001-8421-7394; Lopez, Susana Belén Bravo/0000-0001-7615-3079; Rodriguez Garcia, Javier/0000-0002-5631-2981; Perez, Sihara/0000-0003-1744-0208; Alvarez, Clara V/0000-0003-1500-4058; R. Garcia-Rendueles, Angela/0000-0002-8675-377X; Suarez, Maria del Carmen/0000-0002-8739-3550	MINECO-FEDER [BFU2013-46109-R]; Xunta de Galicia [R2014/050, 09CSA020208PR]; ISCIII-FEDER [PI12/00749]	MINECO-FEDER; Xunta de Galicia(Xunta de GaliciaEuropean Commission); ISCIII-FEDER	We thank Ana Senra (CIMUS; Spain); Jun Ninomiya-Tsuji, Kuni Matsumoto (Japan), Donald Kufe (Boston), Pura Munoz-Canoves (Barcelona), Celia Pombo and Juan Zalvide (Spain) for technical help, plasmids or materials, and Carlos Dieguez for helpful discussions. The manuscript was edited for English language by Pamela Lear (Oxford University). This project has been supported by grants from the MINECO-FEDER BFU2013-46109-R and Xunta de Galicia R2014/050 to CVA and 09CSA020208PR to SBB; and ISCIII-FEDER PI12/00749 to JC-T.	Adjei A, 2015, EXPLORING PATHWAY IN; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Al-Maghrabi Jaudah, 2012, J Gastrointest Cancer, V43, P279, DOI 10.1007/s12029-011-9292-y; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Bravo SB, 2013, J CLIN ENDOCR METAB, V98, P2431, DOI 10.1210/jc.2012-3812; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chassot AA, 2007, ONCOGENE, V26, P5772, DOI 10.1038/sj.onc.1210386; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng YB, 2015, ONCOTARGET, V6, P4180, DOI 10.18632/oncotarget.2907; Cianfrocca R, 2008, CELL DEATH DIFFER, V15, P354, DOI 10.1038/sj.cdd.4402264; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Coleman J, 2001, BMC Mol Biol, V2, P12, DOI 10.1186/1471-2199-2-12; DARZYNKIEWICZ Z, 1980, P NATL ACAD SCI-BIOL, V77, P6696, DOI 10.1073/pnas.77.11.6696; Darzynkiewicz Z, 2015, ONCOTARGET, V6, P11735, DOI 10.18632/oncotarget.4149; De Lellis R.A., 2004, WHO CLASSIFICATION T, V3rd; De Marco C, 2015, ONCOTARGET, V6, P39634, DOI 10.18632/oncotarget.4022; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Fu NY, 2009, MOL CELL, V33, P15, DOI 10.1016/j.molcel.2008.11.025; GERDES J, 1984, J IMMUNOL, V133, P1710; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Grimm T, 2005, BLOOD, V105, P3263, DOI 10.1182/blood-2004-07-2752; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Landa I, 2010, ENDOCR-RELAT CANCER, V17, P317, DOI 10.1677/ERC-09-0016; Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lloyd RV, 1997, ENDOCR PATHOL, V8, P293, DOI 10.1007/BF02739931; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Maddika S, 2009, MOL CELL BIOL, V29, P1235, DOI 10.1128/MCB.00668-08; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; MIYASHITA T, 1995, CELL, V80, P293; Motti ML, 2007, CELL CYCLE, V6, P2817, DOI 10.4161/cc.6.22.4883; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Palona I, 2006, ENDOCRINOLOGY, V147, P5699, DOI 10.1210/en.2006-0400; Park DS, 1997, J NEUROSCI, V17, P8975; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Qin HX, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-73; Ramesh S, 2008, EMBO REP, V9, P990, DOI 10.1038/embor.2008.158; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Seoane J, 2004, CANCER BIOL THER, V3, P226, DOI 10.4161/cbt.3.2.717; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang GN, 2005, BIOCHEM J, V386, P29, DOI 10.1042/BJ20041820; Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473	84	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					652	666		10.1038/onc.2016.233	http://dx.doi.org/10.1038/onc.2016.233			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27452523				2022-12-28	WOS:000394167700007
J	Fife, CM; Sagnella, SM; Teo, WS; Po'uha, ST; Byrne, FL; Yeap, YYC; Ng, DCH; Davis, TP; McCarroll, JA; Kavallaris, M				Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; Byrne, F. L.; Yeap, Y. Y. C.; Ng, D. C. H.; Davis, T. P.; McCarroll, J. A.; Kavallaris, M.			Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration	ONCOGENE			English	Article							CELL LUNG-CANCER; DEPENDENT PROTEIN-KINASE; POTENTIAL TARGET; RHOA ACTIVATION; POOR-PROGNOSIS; LIVING CELLS; IN-VITRO; EXPRESSION; PHOSPHOPROTEIN; PHOSPHORYLATION	Neuroblastoma, the most common solid tumor of young children, frequently presents with aggressive metastatic disease and for these children the 5-year survival rates are dismal. Metastasis, the movement of cancer cells from one site to another, involves remodeling of the cytoskeleton including altered microtubule dynamics. The microtubule-destabilizing protein, stathmin, has recently been shown to mediate neuroblastoma metastasis although precise functions remain poorly defined. In this study we investigated stathmin's contribution to the metastatic process and potential mechanism(s) by which it exerts these effects. Stathmin suppression significantly reduced neuroblastoma cell invasion of 3D tumor spheroids into an extracellular matrix. Moreover, inhibiting stathmin expression significantly reduced transendothelial migration in two different neuroblastoma cell lines in vitro. Inhibition of ROCK, a key regulator of cell migration, in neuroblastoma cells highlighted that stathmin regulates transendothelial migration through ROCK signaling. Reduced stathmin expression in neuroblastoma cells significantly increased the activation of the RhoA small GTPase. Notably, re-expression of either wild type or a phospho-mimetic stathmin mutant (4E) made defective in tubulin binding returned cell migration and transendothelial migration back to control levels, indicating that stathmin may influence these processes in neuroblastoma cells independent of tubulin binding. Finally, stathmin suppression in neuroblastoma cells significantly reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse model. In conclusion, stathmin suppression interferes with the metastatic process via RhoA/ROCK signaling in neuroblastoma cells. These findings highlight the importance of stathmin to the metastatic process and its potential as a therapeutic target for the treatment of neuroblastoma.	[Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, Childrens Canc Inst, Lowy Canc Res Ctr, Tumour Biol & Targeting Program, Sydney, NSW, Australia; [Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, ARC Ctr Excellence Convergent Bionano Sci & Techn, Sydney, NSW, Australia; [Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, Australian Ctr NanoMed, Sydney, NSW, Australia; [Byrne, F. L.] UNSW Australia, Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Yeap, Y. Y. C.; Ng, D. C. H.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Yeap, Y. Y. C.; Ng, D. C. H.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Davis, T. P.] Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Convergent Bionanosci & Technol, Melbourne, Vic, Australia; [Davis, T. P.] Univ Warwick, Dept Chem, Coventry, W Midlands, England	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of Melbourne; University of Queensland; Monash University; University of Warwick	McCarroll, JA; Kavallaris, M (corresponding author), UNSW Australia, Lowy Canc Res Ctr, Childrens Canc Inst, Tumour Biol & Targeting Program, POB 81, Randwick, NSW 2031, Australia.	jmccarroll@ccia.unsw.edu.au; m.kavallaris@ccia.unsw.edu.au	McCarroll, Joshua/E-8481-2010; Byrne, Frances/AAW-7748-2020; Davis, Thomas/B-6395-2008; Ng, Dominic/C-7291-2015	McCarroll, Joshua/0000-0001-8807-3623; Byrne, Frances/0000-0002-8897-8438; Davis, Thomas/0000-0003-2581-4986; Ng, Dominic/0000-0003-4657-159X	Cancer Council New South Wales; Kids Cancer Project; ARC Future Fellowship [FT120100193]; Hope Funds for Cancer Research Fellowship [HFCR-14-06-04]; Cancer Institute NSW Career Development Fellowship [15/CDF/1-02]; NHMRC Senior Research Fellowships [APP1058299]; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology [CE140100036]; Cancer Institute of New South Wales	Cancer Council New South Wales(Cancer Council New South Wales); Kids Cancer Project; ARC Future Fellowship(Australian Research Council); Hope Funds for Cancer Research Fellowship; Cancer Institute NSW Career Development Fellowship; NHMRC Senior Research Fellowships(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology(Australian Research Council); Cancer Institute of New South Wales	We thank the Children's Cancer Institute, which is affiliated with the University of New South Wales (UNSW Australia), and Sydney Children's Hospital Network and by grants from the Cancer Council New South Wales (to MK), Kids Cancer Project (to MK), ARC Future Fellowship (to DCHN; FT120100193), Hope Funds for Cancer Research Fellowship (to FLB; HFCR-14-06-04), Cancer Institute NSW Career Development Fellowship (15/CDF/1-02) and NHMRC Senior Research Fellowships (to MK; APP1058299). MK and TPD are funded by the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (project number CE140100036). This research was supported by a Cancer Institute of New South Wales infrastructure award.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belletti B, 2005, CURR MED CHEM, V12, P1589, DOI 10.2174/0929867054367149; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; Belletti B, 2010, MOL CELL BIOL, V30, P2229, DOI 10.1128/MCB.00723-09; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Daniel C, 2004, LAB INVEST, V84, P588, DOI 10.1038/labinvest.3700078; Delaloy C, 2010, CELL STEM CELL, V6, P323, DOI 10.1016/j.stem.2010.02.015; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Giampietro C, 2005, ENDOCRINOLOGY, V146, P1825, DOI 10.1210/en.2004-0972; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Gutierrez JC, 2007, PEDIATR SURG INT, V23, P637, DOI 10.1007/s00383-007-1933-7; HAILAT N, 1990, ONCOGENE, V5, P1615; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Maris JM, N ENGL J MED, V362, P2202; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; McCarroll JA, 2010, CANCER RES, V70, P4995, DOI 10.1158/0008-5472.CAN-09-4487; Mistry SJ, 2007, MOL CANCER RES, V5, P773, DOI 10.1158/1541-7786.MCR-06-0290; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sadow PM, 2008, ENDOCR PATHOL, V19, P97, DOI 10.1007/s12022-008-9028-0; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; SOBEL A, 1989, J BIOL CHEM, V264, P3765; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steinmetz MO, 2007, J STRUCT BIOL, V158, P137, DOI 10.1016/j.jsb.2006.07.018; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412; Van Sluis GL, 2009, BLOOD, V114, P1968, DOI 10.1182/blood-2009-04-217679; Verma NK, 2009, J BIOL CHEM, V284, P12349, DOI 10.1074/jbc.M807761200; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29	56	23	24	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					501	511		10.1038/onc.2016.220	http://dx.doi.org/10.1038/onc.2016.220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321182				2022-12-28	WOS:000394166700007
J	Khan, S; Sikander, M; Ebeling, MC; Ganju, A; Kumari, S; Yallapu, MM; Hafeez, BB; Ise, T; Nagata, S; Zafar, N; Behrman, SW; Wan, JY; Ghimire, HM; Sahay, P; Pradhan, P; Chauhan, SC; Jaggi, M				Khan, S.; Sikander, M.; Ebeling, M. C.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Ise, T.; Nagata, S.; Zafar, N.; Behrman, S. W.; Wan, J. Y.; Ghimire, H. M.; Sahay, P.; Pradhan, P.; Chauhan, S. C.; Jaggi, M.			MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression	ONCOGENE			English	Article							FOCAL ADHESION KINASE; CELL-MIGRATION; PROTEIN-KINASE; OVARIAN-CANCER; SURVIVAL; MUCINS; EXPRESSION; MOTILITY; GROWTH; ROLES	Although MUC13, a transmembrane mucin, is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and generally correlates with increased expression of HER2, the underlying mechanism remains poorly understood. Herein, we found that MUC13 co-localizes and interacts with HER2 in PDAC cells (reciprocal co-immunoprecipitation, immunofluorescence, proximity ligation, co-capping assays) and tissues (immunohistofluorescence). The results from this study demonstrate that MUC13 functionally interacts and activates HER2 at p1248 in PDAC cells, leading to stimulation of HER2 signaling cascade, including ERK1/2, FAK, AKT and PAK1 as well as regulation of the growth, cytoskeleton remodeling and motility, invasion of PDAC cells-all collectively contributing to PDAC progression. Interestingly, all of these phenotypic effects of MUC13-HER2 co-localization could be effectively compromised by depleting MUC13 and mediated by the first and second EGF-like domains of MUC13. Further, MUC13-HER2 co-localization also holds true in PDAC tissues with a strong functional correlation with events contributing to increased degree of disorder and cancer aggressiveness. In brief, findings presented here provide compelling evidence of a functional ramification of MUC13-HER2: this interaction could be potentially exploited for targeted therapeutics in a subset of patients harboring an aggressive form of PDAC.	[Khan, S.; Sikander, M.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Chauhan, S. C.; Jaggi, M.] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Canc Res Bldg,19 South Manassas,Ave Suite 226, Memphis, TN 38163 USA; [Khan, S.; Sikander, M.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Chauhan, S. C.; Jaggi, M.] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA; [Ebeling, M. C.] Sanford Res, Canc Biol Res Ctr, Sioux Falls, SD USA; [Ise, T.; Nagata, S.] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Drug Design Res, Ibaraki, Osaka, Japan; [Zafar, N.] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; [Behrman, S. W.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Wan, J. Y.] Univ Tennessee, Ctr Hlth Sci, Dept Biostat & Epidemiol, Memphis, TN 38163 USA; [Ghimire, H. M.; Sahay, P.; Pradhan, P.] Univ Memphis, Dept Phys, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Sanford Health; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	Chauhan, SC; Jaggi, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Canc Res Bldg,19 South Manassas,Ave Suite 226, Memphis, TN 38163 USA.	schauha1@uthsc.edu; mjaggi@uthsc.edu	Ganju, Aditya/AAM-3757-2021; Ganju, Aditya/AAK-4870-2021; Nagata, Satoshi/B-5781-2008	Ganju, Aditya/0000-0003-1258-0105; Nagata, Satoshi/0000-0001-9156-5215	National Institutes of Health [R01 CA142736, U01 CA162106A, R01 EB003682, K22CA174841]; Department of Defense [PC130870]; College of Pharmacy Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center; Grants of the University of Memphis; Herb Kosten Foundation [UT 14-0558]; NATIONAL CANCER INSTITUTE [R01CA142736, U01CA162106, K22CA174841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003682] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); College of Pharmacy Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center; Grants of the University of Memphis; Herb Kosten Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was partially supported by grants from the National Institutes of Health (R01 CA142736 to SCC, U01 CA162106A to SCC and MJ; R01 EB003682 to PP; K22CA174841 to MMY), the Department of Defense (PC130870 to SCC and MJ), the College of Pharmacy 2014 and 2015 Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center (to SCC, MJ and MMY) and Grants of the University of Memphis (to PP). We acknowledge the Herb Kosten Foundation for pancreatic cancer research support (UT 14-0558 to SCC). We are also thankful to Cathy Christopherson for editorial assistance.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-21; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Damania D, 2010, BIOPHYS J, V99, P989, DOI 10.1016/j.bpj.2010.05.023; Grothey A, 2000, ONCOGENE, V19, P4864, DOI 10.1038/sj.onc.1203838; Guddo F, 1998, J CLIN PATHOL, V51, P667, DOI 10.1136/jcp.51.9.667; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Jaggi M, 2005, CANCER RES, V65, P483; Jonckheere Nicolas, 2008, Critical Reviews in Oncogenesis, V14, P177; Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Khan S, 2012, MOL CARCINOGEN, V51, P679, DOI 10.1002/mc.20821; Koos B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8294; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maher DM, 2011, MOL CANCER RES, V9, P531, DOI 10.1158/1541-7786.MCR-10-0443; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Paszek MJ, 2014, NATURE, V511, P319, DOI 10.1038/nature13535; Pradhan P, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/2/026012; Pradhan P, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3524523; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Settleman J, 2015, ONCOTARGET, V6, P588, DOI 10.18632/oncotarget.3036; Subramanian H, 2009, CANCER RES, V69, P5357, DOI 10.1158/0008-5472.CAN-08-3895; Subramanian H, 2008, P NATL ACAD SCI USA, V105, P20118, DOI 10.1073/pnas.0804723105; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200	29	21	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					491	500		10.1038/onc.2016.218	http://dx.doi.org/10.1038/onc.2016.218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321183	Green Accepted			2022-12-28	WOS:000394166700006
J	Qin, H; Malek, S; Cowell, JK; Ren, M				Qin, H.; Malek, S.; Cowell, J. K.; Ren, M.			Transformation of human CD34+hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; EXPRESSION; DEK; T(6/9)(P23,Q34); PROTEIN; GENES; FGFR1	Acute myeloid leukemia (AML) is a heterogeneous disease comprising a large number of subtypes defined by specific chromosome abnormalities. One such subtype carries the t(6; 9)(p22;q34) chromosome rearrangement, which leads to expression of the DEK-NUP214 chimeric gene, and has a particularly poor outcome. To provide a better understanding of the molecular etiology of these relatively rare individual AML variants, it is necessary to generate in vivo models, which can also serve as a means to evaluate targeted therapies based on their specific genetic abnormalities. Here, we describe the development of a human cell AML, generated in CD34+ human hematopoietic progenitor cells xenografted into immunocompromised mice that express human myeloid cell growth factors. Within 6 months, these mice develop a human cell AML with phenotypic characteristics of the primary t(6; 9) disease and a CD45+CD13+CD34+CD38+ immunophenotype. Gene expression studies show that members of the HOX family of genes (HOXA9, 10, B3, B4 and PBX3) are highly upregulated in the AML from this mouse model as well as from primary human t(6; 9) AML. Gene expression analysis also identified several other significantly disregulated pathways involving KRAS, BRCA1 and ALK, for example. This is the first report of a humanized model of the DEK-NUP214 disease and provides a means to study the development and treatment of this particular subtype of AML.	[Qin, H.; Cowell, J. K.; Ren, M.] Georgia Regents Univ, Ctr Canc, CN2133,1120 15th St GRU, Augusta, GA 30912 USA; [Malek, S.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University System of Georgia; Augusta University; University of Michigan System; University of Michigan	Ren, M (corresponding author), Georgia Regents Univ, Ctr Canc, CN2133,1120 15th St GRU, Augusta, GA 30912 USA.	mren@gru.edu			NATIONAL CANCER INSTITUTE [R01CA076167] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA076167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovich C, 2005, CURR OPIN HEMATOL, V12, P210, DOI 10.1097/01.moh.0000160737.52349.aa; Ageberg M, 2006, HAEMATOL-HEMATOL J, V91, P268; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; Balgobind BV, 2011, HAEMATOL-HEMATOL J, V96, P221, DOI 10.3324/haematol.2010.029660; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; Hamaguchi H, 1998, BRIT J HAEMATOL, V102, P1249, DOI 10.1046/j.1365-2141.1998.00900.x; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203; Oancea C, 2010, LEUKEMIA, V24, P1910, DOI 10.1038/leu.2010.180; Oyarzo MP, 2004, AM J CLIN PATHOL, V122, P348, DOI 10.1309/5DGB59KQA527PD47; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; Ren M, 2013, LEUKEMIA, V27, P32, DOI 10.1038/leu.2012.188; Ren MQ, 2013, BLOOD, V122, P1007, DOI 10.1182/blood-2013-03-489823; Ren MQ, 2011, BLOOD, V117, P6837, DOI 10.1182/blood-2010-07-295725; Riveiro-Falkenbach E, 2010, CLIN CANCER RES, V16, P2932, DOI 10.1158/1078-0432.CCR-09-2330; Saito Y, 2011, LEUKEMIA, V25, P921, DOI 10.1038/leu.2011.36; Sanden C, 2015, LEUKEMIA, V29, P1632, DOI 10.1038/leu.2015.72; Sanden C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-440; Slovak ML, 2006, LEUKEMIA, V20, P1295, DOI 10.1038/sj.leu.2404233; SOEKARMAN D, 1992, BLOOD, V79, P2990; Spencer DH, 2015, LEUKEMIA, V29, P1279, DOI 10.1038/leu.2015.6; Vinnedge LMP, 2013, CELL CYCLE, V12, P51, DOI 10.4161/cc.23121; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Yamauchi K, 2002, CANCER-AM CANCER SOC, V94, P1739, DOI 10.1002/cncr.10399	27	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5686	5691		10.1038/onc.2016.118	http://dx.doi.org/10.1038/onc.2016.118			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065320	Green Accepted			2022-12-28	WOS:000386998300011
J	Yang, M; Lewinska, M; Fan, X; Zhu, J; Yuan, ZM				Yang, M.; Lewinska, M.; Fan, X.; Zhu, J.; Yuan, Z-M			PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis	ONCOGENE			English	Article							PROTEIN-KINASE B/AKT; TERMINAL SH3 DOMAIN; PROLINE-RICH MOTIFS; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; CRYSTAL-STRUCTURE; RAS; GRB2; SUBUNIT; SRC	Chromosomal focal amplifications often cause an increase in gene copy number, contributing to the pathogenesis of cancer. PRR14 overexpression is associated with recurrent locus amplification in lung cancer, and it correlates with a poor prognosis. We show that increased PRR14 expression promoted and reduced PRR14 expression impeded lung cancer cell proliferation. Interestingly, PRR14 cells were markedly enlarged in size and exhibited an elevated activity of the PI3-kinase/Akt/mTOR pathway, which was associated with a heightened sensitivity to the inhibitors of PI3K and mammalian target of rapamycin (mTOR). Biochemical analysis revealed that PRR14, as a proline-rich protein, binds to the Src homology 3 (SH3) domains of GRB2 resulting in PI3K activation. Significantly, two cancer patient-derived PRR14 mutants displayed considerably augmented GRB2-binding and an enhanced ability of promoting cell proliferation. Together with the in vivo data demonstrating a strong tumor-promoting activity of PRR14 and the mutants, our work uncovered this proline-rich protein as a novel activator of the PI3K pathway that promoted tumorigenesis in lung cancer.	[Yang, M.; Lewinska, M.; Fan, X.; Zhu, J.; Yuan, Z-M] Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Sch Publ Hlth, Dept Genet & Complex Dis, 655 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Lewinska, Monika/N-9919-2017	Lewinska, Monika/0000-0002-5275-992X; yang, mei/0000-0001-9574-2282	Morningside Foundation; Zhu Fund; National Cancer Institute at the National Institutes of Health [R01CA085679, RO1CA167814, RO1CA125144]; NATIONAL CANCER INSTITUTE [R01CA085679, R01CA125144, R01CA167814, R01CA183074] Funding Source: NIH RePORTER	Morningside Foundation; Zhu Fund; National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to current and former members of the Yuan laboratory for support, advice and helpful discussions. We thank Dr Brendan Manning for reagents. This work was supported in part by the Morningside Foundation, the Zhu Fund and grants from the National Cancer Institute at the National Institutes of Health (R01CA085679, RO1CA167814 and RO1CA125144).	Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brognard J, 2001, CANCER RES, V61, P3986; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Castellano E, 2010, CURR TOP MICROBIOL, V346, P143, DOI 10.1007/82_2010_56; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng HY, 2014, LUNG CANCER MANAG, V3, P67, DOI 10.2217/LMT.13.72; DALY RJ, 1994, ONCOGENE, V9, P2723; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GURUPRASAD L, 1995, J MOL BIOL, V248, P856, DOI 10.1006/jmbi.1995.0266; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Job B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015145; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin XB, 2001, LANGENBECK ARCH SURG, V386, P293, DOI 10.1007/s004230100203; Liu AX, 1998, CANCER RES, V58, P2973; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; Massion PP, 2004, AM J RESP CRIT CARE, V170, P1088, DOI 10.1164/rccm.200404-487OC; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Poleshko A, 2013, CELL REP, V5, P292, DOI 10.1016/j.celrep.2013.09.024; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Shen XC, 2010, J BIOL CHEM, V285, P29416, DOI 10.1074/jbc.M110.155325; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Wissmueller S, 2011, PROTEINS, V79, P2365, DOI 10.1002/prot.23068; Yang XL, 2011, CELL RES, V21, P715, DOI 10.1038/cr.2011.63; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	13	15	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5527	5538		10.1038/onc.2016.93	http://dx.doi.org/10.1038/onc.2016.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041574	Green Accepted			2022-12-28	WOS:000386998200007
J	Tang, X; Ding, CK; Wu, J; Sjol, J; Wardell, S; Spasojevic, I; George, D; McDonnell, DP; Hsu, DS; Chang, JT; Chi, JT				Tang, X.; Ding, C-K; Wu, J.; Sjol, J.; Wardell, S.; Spasojevic, I.; George, D.; McDonnell, D. P.; Hsu, D. S.; Chang, J. T.; Chi, J-T			Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RENAL-CELL CARCINOMA; MALIGNANT-CELLS; TUMOR-CELLS; DEPRIVATION; GLUTAMINE; INHIBITION; PHENOTYPE; APOPTOSIS; PATHWAYS	Despite the advances in the diagnosis and treatment of breast cancer, breast cancers still cause significant mortality. For some patients, especially those with triple-negative breast cancer, current treatments continue to be limited and ineffective. Therefore, there remains an unmet need for a novel therapeutic approach. One potential strategy is to target the altered metabolic state that is rewired by oncogenic transformation. Specifically, this rewiring may render certain outside nutrients indispensable. To identify such a nutrient, we performed a nutrigenetic screen by removing individual amino acids to identify possible addictions across a panel of breast cancer cells. This screen revealed that cystine deprivation triggered rapid programmed necrosis, but not apoptosis, in the basal-type breast cancer cells mostly seen in TNBC tumors. In contrast, luminal-type breast cancer cells are cystine-independent and exhibit little death during cystine deprivation. The cystine addiction phenotype is associated with a higher level of cystine-deprivation signatures noted in the basal type breast cancer cells and tumors. We found that the cystine-addicted breast cancer cells and tumors have strong activation of TNF alpha and MEKK4-p38-Noxa pathways that render them susceptible to cystine deprivation-induced necrosis. Consistent with this model, silencing of TNFa and MEKK4 dramatically reduces cystine-deprived death. In addition, the cystine addiction phenotype can be abrogated in the cystine-addictive cells by miR-200c, which converts the mesenchymal-like cells to adopt epithelial features. Conversely, the introduction of inducers of epithelial-mesenchymal transition (EMT) in cystine-independent breast cancer cells conferred the cystine-addiction phenotype by modulating the signaling components of cystine addiction. Together, our data reveal that cystine-addiction is associated with EMT in breast cancer during tumor progression. These findings provide the genetic and mechanistic basis to explain how cystine deprivation triggers necrosis by activating pre-existing oncogenic pathways in cystine-addicted TNBC with prominent mesenchymal features.	[Tang, X.; Ding, C-K; Wu, J.; Chi, J-T] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Tang, X.; Ding, C-K; Wu, J.; Hsu, D. S.; Chi, J-T] Duke Univ, Ctr Genom & Computat Biol, Durham, NC USA; [Tang, X.] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; [Sjol, J.; Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Wardell, S.; McDonnell, D. P.; Hsu, D. S.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Spasojevic, I.; George, D.] Duke Univ, Dept Med, Durham, NC USA	Duke University; Duke University; Michigan Technological University; University of Texas System; University of Texas Health Science Center Houston; Duke University; Duke University	Chi, JT (corresponding author), Duke Univ, Ctr Genom & Computat Biol, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	jentsan.chi@duke.edu		Chi, Jen-Tsan/0000-0003-3433-903X; Ding, Chien-Kuang/0000-0001-9047-0222	NIH [CA125618, CA106520]; Department of Defense [W81XWH-12-1-0148, W81XWH-14-1-0309, W81XWH-15-1-0486]; NATIONAL CANCER INSTITUTE [R01CA106520, R01CA125618] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to acknowledge the financial support from the NIH (CA125618 and CA106520 to JTC) and Department of Defense (W81XWH-12-1-0148, W81XWH-14-1-0309, W81XWH-15-1-0486 to JTC). We appreciate the technical assistance of Ivan Spasojevic and the DCI's Pharmacokinetics and Investigational Chemotherapy share facility. We are also grateful to members of Chi lab for critical discussions and editing of the manuscript.	Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Chen JLY, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001093; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gatza ML, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2899; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Harten SK, 2009, MOL BIOL CELL, V20, P1089, DOI 10.1091/mbc.E08-06-0566; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Keenan MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005599; Keenan MM, 2015, CANCER J, V21, P49, DOI 10.1097/PPO.0000000000000104; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KREIS W, 1980, CANCER RES, V40, P634; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Lucas JE, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000920; Moore T, 2013, J CHROMATOGR B, V929, P51, DOI 10.1016/j.jchromb.2013.04.004; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Murphy JM, 2014, EMBO REP, V15, P155, DOI 10.1002/embr.201337970; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ohtawa K, 1998, LEUKEMIA, V12, P1651, DOI 10.1038/sj.leu.2401139; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Scott L, 2000, BRIT J CANCER, V83, P800, DOI 10.1054/bjoc.2000.1353; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tang XH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005158; Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yoshikawa M, 2013, CANCER RES, V73, P1855, DOI 10.1158/0008-5472.CAN-12-3609-T; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	48	28	28	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4235	4242		10.1038/onc.2016.394	http://dx.doi.org/10.1038/onc.2016.394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	27869167	Green Accepted			2022-12-28	WOS:000406360600001
J	Dozier, C; Mazzolini, L; Cenac, C; Froment, C; Burlet-Schiltz, O; Besson, A; Manenti, S				Dozier, C.; Mazzolini, L.; Cenac, C.; Froment, C.; Burlet-Schiltz, O.; Besson, A.; Manenti, S.			CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability	ONCOGENE			English	Article							CELL-CYCLE ARREST; BETA-TRCP; DEPENDENT KINASES; MAMMARY TUMORIGENESIS; G(1)/S TRANSITION; PHOSPHATASES; ACTIVATION; DEGRADATION; EXPRESSION; TARGETS	The phosphatase CDC25A is a key regulator of cell cycle progression by dephosphorylating and activating cyclin-CDK complexes. CDC25A is an unstable protein expressed from G1 until mitosis. CDC25A overexpression, which can be caused by stabilization of the protein, accelerates the G1/S and G2/M transitions, leading to genomic instability and promoting tumorigenesis. Thus, controlling CDC25A protein levels by regulating its stability is a critical mechanism for timing cell cycle progression and to maintain genomic integrity. Herein, we show that CDC25A is phosphorylated on Ser40 throughout the cell cycle and that this phosphorylation is established during the progression from G1 to S phase. We demonstrate that CyclinD-CDK4/CDK6 complexes mediate the phosphorylation of CDC25A on Ser40 during G1 and that these complexes directly phosphorylate this residue in vitro. Importantly, we also find that CyclinD1-CDK4 decreases CDC25A stability in a beta TrCP-dependent manner and that Ser40 and Ser88 phosphorylations contribute to this regulation. Thus our results identify cyclinD-CDK4/6 complexes as novel regulators of CDC25A stability during G1 phase, generating a negative feedback loop allowing control of the G1/S transition.	[Dozier, C.; Mazzolini, L.; Cenac, C.; Besson, A.; Manenti, S.] Univ Toulouse III Paul Sabatier, INSERM UMR1037, Canc Res Ctr Toulouse, Toulouse, France; [Dozier, C.; Mazzolini, L.; Manenti, S.] CNRS ERL5294, Equipe Labellisee Ligue Canc, Toulouse, France; [Froment, C.; Burlet-Schiltz, O.] Univ Toulouse, CNRS UMR5089, Inst Pharmacol & Biol Struct, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Dozier, C (corresponding author), Univ Toulouse III Paul Sabatier, INSERM UMR1037, Canc Res Ctr Toulouse, CNRS ERL5294, Toulouse, France.	christine.dozier@inserm.fr	Besson, Arnaud/J-6254-2014; manenti, stephane/P-1518-2014	Besson, Arnaud/0000-0002-9599-3943; manenti, stephane/0000-0002-4793-3196; CENAC, Claire/0000-0001-6641-7851; Schiltz, Odile/0000-0002-3606-2356	Region Midi-Pyrenees; Toulouse Metropole; European funds FEDER (Fonds Europeens de Developpement Regional)	Region Midi-Pyrenees(Region OccitanieRegion Provence-Alpes-Cote d'Azur); Toulouse Metropole; European funds FEDER (Fonds Europeens de Developpement Regional)	We thank H. Piwnica-Worms for providing phospho-Ser76, 82 and 88 CDC25A antibodies, V. Dulic for providing BJ-hTert cells and M. Gotanegre for technical assistance. This work was supported in part by grants to OBS from the Region Midi-Pyrenees, Toulouse Metropole and European funds FEDER (Fonds Europeens de Developpement Regional) for mass spectrometry.	Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chang KH, 2012, J CELL SCI, V125, P5124, DOI 10.1242/jcs.108183; Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863; Clucas C, 2002, EMBO J, V21, P665, DOI 10.1093/emboj/21.4.665; Ducruet AP, 2003, J BIOL CHEM, V278, P31838, DOI 10.1074/jbc.M303604200; Fernandez-Vidal A, 2006, CANCER RES, V66, P7128, DOI 10.1158/0008-5472.CAN-05-2552; Fernandez-Vidal A, 2008, ANTI-CANCER AGENT ME, V8, P825, DOI 10.2174/187152008786847684; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gubanova E, 2013, CELL CYCLE, V12, P3770, DOI 10.4161/cc.26660; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Honaker Y, 2010, ONCOGENE, V29, P3324, DOI 10.1038/onc.2010.96; Hutchins JRA, 2004, CELL CYCLE, V3, P41; Isoda M, 2009, MOL BIOL CELL, V20, P2186, DOI 10.1091/mbc.E09-01-0008; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karagoz ID, 2010, TUMOR BIOL, V31, P597, DOI 10.1007/s13277-010-0075-z; Khaled AR, 2005, J CELL BIOL, V169, P755, DOI 10.1083/jcb.200409099; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kittipatarin C, 2006, CELL CYCLE, V5, P907, DOI 10.4161/cc.5.9.2693; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Ray D, 2007, CANCER RES, V67, P6605, DOI 10.1158/0008-5472.CAN-06-4815; Ray D, 2007, CANCER RES, V67, P984, DOI 10.1158/0008-5472.CAN-06-3927; Shen T, 2012, ANTI-CANCER AGENT ME, V12, P631, DOI 10.2174/187152012800617678; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Yin M, 2011, CELL DIV, V6, P4	37	29	32	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3781	3788		10.1038/onc.2016.506	http://dx.doi.org/10.1038/onc.2016.506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192398				2022-12-28	WOS:000404349700013
J	Worrall, C; Suleymanova, N; Crudden, C; Drakensjo, IT; Candrea, E; Nedelcu, D; Takahashi, SI; Girnita, L; Girnita, A				Worrall, C.; Suleymanova, N.; Crudden, C.; Drakensjo, I. Trocoli; Candrea, E.; Nedelcu, D.; Takahashi, S-I; Girnita, L.; Girnita, A.			Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma	ONCOGENE			English	Article							GROWTH-FACTOR-I; SMALL-MOLECULE ANTAGONISTS; BETA-ARRESTIN; ULTRAVIOLET-RADIATION; PICROPODOPHYLLIN PPP; MONOCLONAL-ANTIBODY; RECEPTOR IGF-1R; UVEAL MELANOMA; TUMOR INVASION; PHASE-I	Melanoma tumors usually retain wild-type p53; however, its tumor-suppressor activity is functionally disabled, most commonly through an inactivating interaction with mouse double-minute 2 homolog (Mdm2), indicating p53 release from this complex as a potential therapeutic approach. P53 and the tumor-promoter insulin-like growth factor type 1 receptor (IGF-1R) compete as substrates for the E3 ubiquitin ligase Mdm2, making their relative abundance intricately linked. Hence we investigated the effects of pharmacological Mdm2 release from the Mdm2/p53 complex on the expression and function of the IGF-1R. Nutlin-3 treatment increased IGF-1R/Mdm2 association with enhanced IGF-1R ubiquitination and a dual functional outcome: receptor downregulation and selective downstream signaling activation confined to the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. This Nutlin-3 functional selectivity translated into IGF-1-mediated bioactivities with biphasic effects on the proliferative and metastatic phenotype: an early increase and late decrease in the number of proliferative and migratory cells, while the invasiveness was completely inhibited following Nutlin-3 treatment through an impaired IGF-1-mediated matrix metalloproteinases type 2 activation mechanism. Taken together, these experiments reveal the biased agonistic properties of Nutlin-3 for the mitogen-activated protein kinase pathway, mediated by Mdm2 through IGF-1R ubiquitination and provide fundamental insights into destabilizing p53/Mdm2/IGF-1R circuitry that could be developed for therapeutic gain.	[Worrall, C.; Suleymanova, N.; Crudden, C.; Drakensjo, I. Trocoli; Candrea, E.; Nedelcu, D.; Girnita, L.; Girnita, A.] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol & Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Drakensjo, I. Trocoli; Girnita, A.] Karolinska Univ Hosp, Dermatol Dept, Stockholm, Sweden; [Candrea, E.] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Dept Dermatol, Cluj Napoca, Romania; [Takahashi, S-I] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Tokyo, Japan; [Takahashi, S-I] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Iuliu Hatieganu University of Medicine & Pharmacy; University of Tokyo; University of Tokyo	Girnita, L; Girnita, A (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, CCK R8 04, S-17196 Stockholm, Sweden.	Leonard.Girnita@ki.se; Ada.Girnita@ki.se	Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008; Crudden, Caitrin/Q-5172-2018	Girnita, Leonard/0000-0003-0280-9500; Crudden, Caitrin/0000-0002-7786-112X; Takahashi, Shin-Ichiro/0000-0002-2323-2010	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society; Stockholm County; JSPS [25221204]; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society; Stockholm County(Stockholm County Council); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Karolinska Institute(Karolinska Institutet)	We thank Professor Rolf Kiessling (CCK, KI) for the BE and DFB cell lines 62, to Juan Castro (CCK, KI) for FACS analysis and to Dr Cath Drummond and Dr Sonia Lain for helpful discussions. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Stockholm Cancer Society, Stockholm County and Karolinska Institute. This work was also supported by Grant-in-Aid of Scientific Research (S) no. 25221204, Core-to-core program from JSPS to S-IT group.	Albino AP, 1993, MELANOMA RES, V55, P562; Box NF, 2008, PIGM CELL MELANOMA R, V21, P525, DOI 10.1111/j.1755-148X.2008.00495.x; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Davenport RJ, 2003, SCI SAGE KE, V10, P1126; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Economou MA, 2005, INVEST OPHTH VIS SCI, V46, P4372, DOI 10.1167/iovs.05-0322; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gasbarri A, 2003, MELANOMA RES, V13, P325, DOI 10.1097/00008390-200308000-00001; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita A, 2012, ONCOGENE, V31, P352, DOI 10.1038/onc.2011.239; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Gombos A, 2012, INVEST NEW DRUG, V30, P2433, DOI 10.1007/s10637-012-9811-0; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hongo A, 1996, ONCOGENE, V12, P1231; Houben R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022096; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Ji ZY, 2012, J INVEST DERMATOL, V132, P356, DOI 10.1038/jid.2011.313; Kanavy HE, 2011, SEMIN CUTAN MED SURG, V30, P222, DOI 10.1016/j.sder.2011.08.003; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Karasic TB, 2010, EXP CELL RES, V316, P1994, DOI 10.1016/j.yexcr.2010.04.014; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macaulay VM, 2013, ANN ONCOL, V24, P784, DOI 10.1093/annonc/mds511; Mahadevan D, 2014, CANCER CHEMOTH PHARM, V73, P467, DOI 10.1007/s00280-013-2372-x; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Neudauer CL, 2003, EXP CELL RES, V286, P128, DOI 10.1016/S0014-4827(03)00049-1; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; SalazarOnfray F, 1997, CANCER RES, V57, P4348; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Soussi T, 2011, ADV CANCER RES, V110, P107, DOI 10.1016/B978-0-12-386469-7.00005-0; van Leeuwen IMM, 2011, CELL CYCLE, V10, P1590, DOI 10.4161/cc.10.10.15519; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Webster NJG, 1996, CANCER RES, V56, P2781; Werner H, 2000, MOL GENET METAB, V71, P315, DOI 10.1006/mgme.2000.3044; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2014, GROWTH HORM IGF RES, V24, P112, DOI 10.1016/j.ghir.2014.03.006; Yeh AH, 2006, ONCOGENE, V25, P6574, DOI 10.1038/sj.onc.1209674; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhang D, 2003, HORM METAB RES, V35, P802; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P20620, DOI 10.1073/pnas.1216348110; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P7055, DOI 10.1073/pnas.1118359109; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	68	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3274	3286		10.1038/onc.2016.472	http://dx.doi.org/10.1038/onc.2016.472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092675	Green Published, hybrid			2022-12-28	WOS:000402869800007
J	Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Vinals, F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Cajal, SRY; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA				Mateo, F.; Arenas, E. J.; Aguilar, H.; Serra-Musach, J.; de Garibay, G. Ruiz; Boni, J.; Maicas, M.; Du, S.; Iorio, F.; Herranz-Ors, C.; Islam, A.; Prado, X.; Llorente, A.; Petit, A.; Vidal, A.; Catala, I.; Soler, T.; Venturas, G.; Rojo-Sebastian, A.; Serra, H.; Cuadras, D.; Blanco, I.; Lozano, J.; Canals, F.; Sieuwerts, A. M.; de Weerd, V.; Look, M. P.; Puertas, S.; Garcia, N.; Perkins, A. S.; Bonifaci, N.; Skowron, M.; Gomez-Baldo, L.; Hernandez, V.; Martinez-Aranda, A.; Martinez-Iniesta, M.; Serrat, X.; Ceron, J.; Brunet, J.; Barretina, M. P.; Gil, M.; Falo, C.; Fernandez, A.; Morilla, I.; Pernas, S.; Pla, M. J.; Andreu, X.; Segui, M. A.; Ballester, R.; Castella, E.; Nellist, M.; Morales, S.; Valls, J.; Velasco, A.; Matias-Guiu, X.; Figueras, A.; Sanchez-Mut, J. V.; Sanchez-Cespedes, M.; Cordero, A.; Gomez-Miragaya, J.; Palomero, L.; Gomez, A.; Gajewski, T. F.; Cohen, E. E. W.; Jesiotr, M.; Bodnar, L.; Quintela-Fandino, M.; Lopez-Bigas, N.; Valdes-Mas, R.; Puente, X. S.; Vinals, F.; Casanovas, O.; Graupera, M.; Hernandez-Losa, J.; Ramon y Cajal, S.; Garcia-Alonso, L.; Saez-Rodriguez, J.; Esteller, M.; Sierra, A.; Martin-Martin, N.; Matheu, A.; Carracedo, A.; Gonzalez-Suarez, E.; Nanjundan, M.; Cortes, J.; Lazaro, C.; Odero, M. D.; Martens, J. W. M.; Moreno-Bueno, G.; Barcellos-Hoff, M. H.; Villanueva, A.; Gomis, R. R.; Pujana, M. A.			Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition	ONCOGENE			English	Article							BREAST-CANCER; MAMMARY STEM; MESENCHYMAL TRANSITION; EMBRYONIC STEM; SELF-RENEWAL; EXPRESSION; GENES; PATHWAY; TARGET; MOUSE	Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.	[Mateo, F.; Aguilar, H.; Serra-Musach, J.; de Garibay, G. Ruiz; Boni, J.; Herranz-Ors, C.; Prado, X.; Llorente, A.; Garcia, N.; Bonifaci, N.; Skowron, M.; Gomez-Baldo, L.; Palomero, L.; Pujana, M. A.] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol ICO, Breast Canc & Syst Biol Lab, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain; [Arenas, E. J.; Gomis, R. R.] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Oncol Program, Baldiri Reixac 10, Barcelona 08028, Spain; [Maicas, M.; Odero, M. D.] Univ Navarra, Ctr Appl Med Res CIMA, Pamplona, Spain; [Maicas, M.; Odero, M. D.] Univ Navarra, Dept Biochem & Genet, Pamplona, Spain; [Du, S.; Barcellos-Hoff, M. H.] NYU, Sch Med, Dept Radiat Oncol, New York, NY 10003 USA; [Iorio, F.; Garcia-Alonso, L.; Saez-Rodriguez, J.] European Bioinformat Inst, European Mol Biol Lab, Wellcome Trust Genome Campus, Cambridge, England; [Iorio, F.] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England; [Islam, A.] Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh; [Petit, A.; Vidal, A.; Catala, I.; Soler, T.; Venturas, G.] Univ Hosp Bellvitge, IDIBELL, Dept Pathol, Barcelona, Spain; [Rojo-Sebastian, A.] MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain; [Serra, H.; Figueras, A.; Vinals, F.] ICO, Angiogenesis Res Grp, ProCURE, IDIBELL, Barcelona, Spain; [Cuadras, D.] IDIBELL, Stat Unit, Barcelona, Spain; [Blanco, I.; Lazaro, C.] IDIBELL, ICO, Hereditary Canc Programme, Barcelona, Spain; [Lozano, J.] Univ Malaga, Dept Mol Biol & Biochem, Malaga, Spain; [Lozano, J.] Univ Hosp Virgen de la Victoria, Mediterranean Inst Adv Biotechnol & Hlth Res IBIM, Mol Oncol Lab, Malaga, Spain; [Canals, F.] Vall Hebron Univ, Vall Hebron Inst Oncol, ProteoRed Inst Salud Carlos 3, Prote Lab, Barcelona, Spain; [Sieuwerts, A. M.; de Weerd, V.; Look, M. P.; Martens, J. W. M.] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Canc Genom Ctr,Dept Med Oncol, Rotterdam, Netherlands; [Puertas, S.; Martinez-Iniesta, M.; Villanueva, A.] IDIBELL, ICO, Chemoresistance & Predict Factors Lab, ProCURE, Barcelona, Spain; [Perkins, A. S.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY USA; [Hernandez, V.; Martinez-Aranda, A.] IDIBELL, Biol Clues Invas & Metastat Phenotype Lab, Barcelona, Spain; [Serrat, X.; Ceron, J.] IDIBELL, Canc & Human Mol Genet, Barcelona, Spain; [Brunet, J.] Girona Biomed Res Inst IDIBGI, ICO, Hereditary Canc Programme, Girona, Spain; [Barretina, M. P.] IDIBGI, ICO, Dept Med Oncol, Girona, Spain; [Gil, M.; Falo, C.; Fernandez, A.; Morilla, I.; Pernas, S.] IDIBELL, ICO, Dept Med Oncol, Barcelona, Spain; [Pla, M. J.] Univ Hosp Bellvitge, IDIBELL, Dept Gynecol, Barcelona, Spain; [Andreu, X.] Parc Tauli Hosp Consortium, Dept Pathol, Barcelona, Spain; [Segui, M. A.] Parc Tauli Hosp Consortium, Med Oncol Serv, Barcelona, Spain; [Ballester, R.] Univ Hosp Germans Trias & Pujol, Germans Trias & Pujol Res Inst IGTP, ICO, Dept Radiat Oncol, Barcelona, Spain; [Castella, E.] Univ Hosp Germans Trias & Pujol, IGTP, ICO, Dept Pathol, Barcelona, Spain; [Nellist, M.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Valls, J.; Velasco, A.; Matias-Guiu, X.] Univ Lleida, Hosp Arnau de Vilanova, Biomed Res Inst Lleida IRB Lleida, Lleida, Spain; [Sanchez-Mut, J. V.; Sanchez-Cespedes, M.; Cordero, A.; Gomez-Miragaya, J.] IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Gajewski, T. F.] Univ Chicago, Dept Pathol, Chicago, IL 60611 USA; [Gajewski, T. F.] Univ Chicago, Dept Med, Chicago, IL USA; [Cohen, E. E. W.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA; [Jesiotr, M.] Mil Inst Med, Dept Pathol, Warsaw, Poland; [Bodnar, L.] Mil Inst Med, Dept Oncol, Warsaw, Poland; [Quintela-Fandino, M.] Spanish Natl Canc Res Ctr CNIO, Breast Canc Clin Res Unit, Madrid, Spain; [Lopez-Bigas, N.] Pompeu Fabra Univ UPF, Dept Expt & Hlth Sci, Barcelona Biomed Res Pk, Barcelona, Spain; [Lopez-Bigas, N.; Esteller, M.; Gomis, R. R.] ICREA, Barcelona, Spain; [Valdes-Mas, R.; Puente, X. S.] Univ Oviedo, Univ Inst Oncol Asturias, Dept Biochem & Mol Biol, Oviedo, Spain; [Hernandez-Losa, J.; Ramon y Cajal, S.] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Sierra, A.] Cent Univ Catalonia, Univ Vic, Fac Sci & Tech,Mol & Translat Oncol Lab, Biomed Res Inst August Pi & Sunyer IDIBAPS,Biomed, Barcelona, Spain; [Sierra, A.] Cent Univ Catalonia, Univ Vic, Fac Sci & Tech, Syst Biol Dept, Barcelona, Spain; [Martin-Martin, N.; Carracedo, A.] Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain; [Matheu, A.] Biodonostia Res Inst, Oncol Dept, Oncol Sect, San Sebastian, Spain; [Matheu, A.; Carracedo, A.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Carracedo, A.] Univ Basque Country UPV EHU, Dept Biochem & Mol Biol, Bilbao, Spain; [Nanjundan, M.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL USA; [Cortes, J.] Vall Hebron Univ Hosp, VHIO, Dept Med Oncol, Barcelona, Spain; [Moreno-Bueno, G.] Autonomous Univ Madrid UAM, Hosp La Paz Inst Hlth Res IdiPAZ, Dept Biochem, Biomed Res Inst Alberto Sols Spanish Natl Res Cou, Madrid, Spain; [Moreno-Bueno, G.] MD Anderson Int Fdn, Madrid, Spain	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Navarra; University of Navarra; New York University; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; Wellcome Trust Sanger Institute; University of Dhaka; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Texas System; UTMD Anderson Cancer Center; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Universidad de Malaga; Vall d'Hebron Institut d'Oncologia (VHIO); Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Rochester; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Erasmus University Rotterdam; Erasmus MC; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Chicago; University of Chicago; University of California System; University of California San Diego; Military Institute of Aviation Medicine; Military Institute of Aviation Medicine; Centro Nacional de Investigaciones Oncologicas (CNIO); Pompeu Fabra University; ICREA; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Hospital Universitari Vall d'Hebron; University of Barcelona; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); CIC bioGUNE; Basque Foundation for Science; University of Basque Country; State University System of Florida; University of South Florida; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center	Gomis, RR (corresponding author), Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Oncol Program, Baldiri Reixac 10, Barcelona 08028, Spain.; Gomis, RR (corresponding author), Hosp Duran & Reynals, Catalan Inst Oncol, IDIBELL, ProCURE, Gran via 199, E-08028 Barcelona, Spain.	roger.gomis@irbbarcelona.org; mapujana@iconcologia.net	Graupera, Mariona/J-1122-2017; Vinals, Francesc/P-6278-2019; Iorio, Francesco/H-3284-2019; Valdés-Mas, Rafael/AAC-2879-2021; Mateo, Francesca/K-7746-2015; Rojo, Alejandro/Y-9674-2019; Boni, Jacopo/I-9587-2016; Vidal, August/N-4662-2016; Viñals, Francesc/F-5928-2016; matias-guiu, xavier/C-3039-2009; GARCIA, CONXI LAZARO/Q-2410-2016; Sanchez-Mut, Jose V./A-8651-2019; Pujana, Miquel Angel/N-3127-2014; VELASCO, ANA/AGH-3671-2022; Gonzalez-Suarez, Eva/L-6298-2014; Blanco, Ignacio/D-2565-2013; Sanchez-Cespedes, Montse/H-8485-2012; Odero/ABG-9860-2020; Lopez-Bigas, Nuria/F-6193-2011; bonifaci, nuria/B-8104-2019; Petit, Anna/GYU-5229-2022; Esteller, Manel/L-5956-2014; MORALES, SERAFIN/L-7216-2019; Moreno-Bueno, Gema/K-9354-2016; Castellà, Eva/K-4140-2017; Ramon y Cajal, Santiago/H-4955-2016; Puente, Xosé S./ADB-0672-2022; Lozano, José/C-2760-2014; Javier, Hernandez Losa/C-1173-2008; Skowron, Margaretha/N-6141-2018; Saez-Rodriguez, Julio/H-7114-2019; Blanco, Ignacio/AAN-5426-2021; Casanovas, Alex Cordero/AAA-8157-2020; Valls, Joan/GXM-6532-2022; Gomis, Roger R/E-9788-2016; de Garibay, Gorka Ruiz/AAB-6579-2020; Morilla, Idoia/P-6155-2019; Carracedo, Arkaitz/F-7029-2011; ceron, julian/AAA-8008-2019; Maicas, Miren/A-9836-2017; Brunet, Joan/C-5292-2018; Palomero, Luis/K-1058-2017; Casanovas, Oriol/L-5210-2014; Herranz, Carmen/K-1043-2017	Graupera, Mariona/0000-0003-4608-4185; Iorio, Francesco/0000-0001-7063-8913; Valdés-Mas, Rafael/0000-0002-0737-5425; Mateo, Francesca/0000-0002-2342-7010; Rojo, Alejandro/0000-0001-6439-3518; Vidal, August/0000-0001-5727-2099; Viñals, Francesc/0000-0002-9918-6751; matias-guiu, xavier/0000-0002-7201-6605; GARCIA, CONXI LAZARO/0000-0002-7198-5906; Sanchez-Mut, Jose V./0000-0002-9292-8521; Pujana, Miquel Angel/0000-0003-3222-4044; VELASCO, ANA/0000-0003-3142-145X; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Blanco, Ignacio/0000-0002-7414-7481; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Odero/0000-0002-8858-2054; Lopez-Bigas, Nuria/0000-0003-4925-8988; bonifaci, nuria/0000-0002-8193-6825; Esteller, Manel/0000-0003-4490-6093; MORALES, SERAFIN/0000-0001-7445-4193; Moreno-Bueno, Gema/0000-0002-5030-6687; Ramon y Cajal, Santiago/0000-0002-3867-1390; Puente, Xosé S./0000-0001-9525-1483; Lozano, José/0000-0002-8187-2833; Javier, Hernandez Losa/0000-0003-1526-3201; Skowron, Margaretha/0000-0003-2152-384X; Saez-Rodriguez, Julio/0000-0002-8552-8976; Blanco, Ignacio/0000-0002-7414-7481; Gomis, Roger R/0000-0001-6473-2858; de Garibay, Gorka Ruiz/0000-0001-9936-8419; Morilla, Idoia/0000-0001-8237-5073; Carracedo, Arkaitz/0000-0001-5957-1260; Maicas, Miren/0000-0003-1404-5552; Gomez-Miragaya, Jorge/0000-0003-1801-4681; ARENAS LAHUERTA, ENRIQUE JAVIER/0000-0001-7076-2666; Serrat Farran, Xenia/0000-0001-7611-5400; SEGUI PALMER, MIQUEL ANGEL/0000-0002-5103-6746; Ceron, Julian/0000-0003-4739-2243; Islam, Abul/0000-0002-7274-0855; Garcia-Alonso, Luz/0000-0002-7863-9619; Brunet, Joan/0000-0003-1945-3512; Palomero, Luis/0000-0002-9144-1017; Martinez-Iniesta, Maria/0000-0001-6252-6671; Boni, Jacopo/0000-0003-2626-9393; Cuadras, Daniel/0000-0001-8780-1764; Casanovas, Oriol/0000-0002-4298-3995; quintela-fandino, miguel/0000-0003-1648-1964; Valls, Joan/0000-0002-4806-7568; Herranz, Carmen/0000-0002-2866-0321; Sierra, Angels/0000-0003-1023-3492; Llorente, Alicia/0000-0002-6056-0566	Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); BBVA Foundation; Eugenio Rodriguez Pascual Foundation; Generalitat de Catalunya AGAUR SGR [283, 290, 312, 364, 530, 535]; Spanish Ministry of Health ISCIII FIS [PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, PI14/00336]; ISCIII RTICC [RD06/0020/1051, RD12/0036/0007, RD12/0036/0008, RD12/0036/0063]; Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO [SAF2010-20203, SAF2013-46196]; Telemaraton 'Todos Somos Raros, Todos Somos Unicos' [P35]; 'la Caixa' PhD fellowship program; EMBL-EBI; Wellcome Trust Sanger Institute Postdoctoral (ESPOD); NL-B; ME; RRG; ICREA; ICREA Funding Source: Custom	Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); BBVA Foundation(BBVA Foundation); Eugenio Rodriguez Pascual Foundation; Generalitat de Catalunya AGAUR SGR; Spanish Ministry of Health ISCIII FIS(Spanish Government); ISCIII RTICC(Instituto de Salud Carlos III); Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO; Telemaraton 'Todos Somos Raros, Todos Somos Unicos'; 'la Caixa' PhD fellowship program; EMBL-EBI; Wellcome Trust Sanger Institute Postdoctoral (ESPOD); NL-B; ME; RRG; ICREA(ICREA); ICREA(ICREA)	We thank Ander Urruticoechea, Gabriel Capella and George Thomas for helpful discussion; Ana Isabel Extremera, Antoni Xaubet and Julio Ancochea for administrative support; and Sebastien Tosi from the Advanced Digital Microscopy Facility at IRB Barcelona for image analysis. We also thank Xiyun Deng, Yanna Cao, Tien C Ko, Yi Zhang (The University of Texas Health Science Centre at Houston) and Adrian W Moore (RIKEN Brain Science Institute) for their support in evaluating antibodies against EVI1. This study was supported by the following bodies and grants: the Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodriguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO grants SAF2010-20203 and SAF2013-46196; and the Telemaraton 2014 'Todos Somos Raros, Todos Somos Unicos' grant P35. EJA was supported by 'la Caixa' PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, either in the submission form or the text of the manuscript.	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bard-Chapeau EA, 2013, P NATL ACAD SCI USA, V110, pE2885, DOI 10.1073/pnas.1309310110; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhola NE, 2016, CANCER RES, V76, P440, DOI 10.1158/0008-5472.CAN-15-1640-T; Campone M, 2013, EUR J CANCER, V49, P2621, DOI 10.1016/j.ejca.2013.04.011; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hagerstrand D, 2013, CANCER DISCOV, V3, P1044, DOI 10.1158/2159-8290.CD-12-0592; Holder AM, 2015, ONCOTARGET, V6, P19500, DOI 10.18632/oncotarget.3669; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang RX, 2015, MOL CELL BIOCHEM, V404, P251, DOI 10.1007/s11010-015-2384-4; Issa A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3379; Janssen EAM, 2003, J PATHOL, V201, P555, DOI 10.1002/path.1475; Kataoka K, 2011, J EXP MED, V208, P2402, DOI 10.1084/jem.20110447; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Malhotra GK, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861-014-0047-4; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Markman B, 2010, ONCOTARGET, V1, P530, DOI 10.18632/oncotarget.188; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Morales M, 2014, EMBO MOL MED, V6, P865, DOI 10.15252/emmm.201303675; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Pool SE, 2013, CANCER RES, V73, P12, DOI 10.1158/0008-5472.CAN-11-2089; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963; de Garibay GR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132546; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Stavropoulou V, 2016, CANCER CELL, V30, P43, DOI 10.1016/j.ccell.2016.05.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Witten IH, 1999, P ICONIP ANZIIS ANNE, V99, P192; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yang ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028405; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	59	27	27	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2737	2749		10.1038/onc.2016.427	http://dx.doi.org/10.1038/onc.2016.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991928	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000401120900011
J	Chiche, A; Moumen, M; Romagnoli, M; Petit, V; Lasla, H; Jezequel, P; de la Grange, P; Jonkers, J; Deugnier, MA; Glukhova, MA; Faraldo, MM				Chiche, A.; Moumen, M.; Romagnoli, M.; Petit, V.; Lasla, H.; Jezequel, P.; de la Grange, P.; Jonkers, J.; Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.			p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; SELF-RENEWAL; WNT/BETA-CATENIN; BASAL; MET; EXPRESSION; GLAND; TUMORIGENESIS; DISTINCT; PROGENITORS	Triple-negative breast cancer is a heterogeneous disease characterized by the expression of basal cell markers, no estrogen or progesterone receptor expression and a lack of HER2 overexpression. Triple-negative tumors often display activated Wnt/beta-catenin signaling and most have impaired p53 function. We studied the interplay between p53 loss and Wnt/beta-catenin signaling in stem cell function and tumorigenesis, by deleting p53 from the mammary epithelium of K5 Delta N beta cat mice displaying a constitutive activation of Wnt/beta-catenin signaling in basal cells. K5 Delta N beta cat transgenic mice present amplification of the basal stem cell pool and develop triple-negative mammary carcinomas. The loss of p53 in K5 Delta N beta cat mice led to an early expansion of mammary stem/progenitor cells and accelerated the formation of triple-negative tumors. In particular, p53-deficient tumors expressed high levels of integrins and extracellular matrix components and were enriched in cancer stem cells. They also overexpressed the tyrosine kinase receptor Met, a feature characteristic of human triple-negative breast tumors. The inhibition of Met kinase activity impaired tumorsphere formation, demonstrating the requirement of Met signaling for cancer stem cell growth in this model. Human basal-like breast cancers with predicted mutated p53 status had higher levels of MET expression than tumors with wild-type p53. These results connect p53 loss and beta-catenin activation to stem cell regulation and tumorigenesis in triple-negative cancer and highlight the role of Met signaling in maintaining cancer stem cell properties, revealing new cues for targeted therapies.	[Chiche, A.; Moumen, M.; Romagnoli, M.; Petit, V.; Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.] PSL Res Univ, CNRS, UMR144, Inst Curie, 26 Rue Ulm, F-75005 Paris, France; [Lasla, H.; Jezequel, P.] Inst Cancerol Ouest, St Herblain, France; [de la Grange, P.] Hop La Pitie Salpetriere, IPEPS ICM, GenoSplice Technol, Paris, France; [Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Jonkers, J.] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Amsterdam, Netherlands; [Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.] Inst Natl Sante & Rech Med, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Netherlands Cancer Institute; Netherlands Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Faraldo, MM (corresponding author), PSL Res Univ, CNRS, UMR144, Inst Curie, 26 Rue Ulm, F-75005 Paris, France.	maria-luisa.martin-faraldo@curie.fr	Deugnier, Marie-Ange/AAF-5877-2021; Jonkers, Jos/AAG-3246-2019; Martin-Faraldo, Maria-Luisa/M-5811-2018; Deugnier, Marie-Ange/M-7556-2018	Deugnier, Marie-Ange/0000-0002-2199-1099; Jonkers, Jos/0000-0002-9264-9792; Faraldo, Marisa/0000-0001-9497-1171; PETIT, Valerie/0000-0003-1645-9396	La Ligue Nationale Contre le Cancer; Canceropole lle de France [2014-1-SEIN-01-ICR-1]; La Ligue Nationale Contre le Cancer Comites d'Ile de France; Association pour la Recherche sur le Cancer; Institut Curie and Servier Laboratories	La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Canceropole lle de France; La Ligue Nationale Contre le Cancer Comites d'Ile de France; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut Curie and Servier Laboratories	We are particularly grateful to A Di Cicco, D Gentien, A Rapinat and B Albaud for expert technical assistance, to Dr I Grandjean, S Jannet and the personnel of the animal facilities at Institut Curie for taking care of the mice and to Z Maciorowski, A Viguier and S Grondin for excellent assistance with flow cytometry. We also thank Dr JL Jorcano for providing mouse strains and Dr D Medina for valuable discussions. The work was supported by grants from La Ligue Nationale Contre le Cancer (Equipe Labelisee 2013), Canceropole lle de France (2014-1-SEIN-01-ICR-1) to MAG. and a grant from La Ligue Nationale Contre le Cancer Comites d'Ile de France to MMF. MM and AC received funding from Association pour la Recherche sur le Cancer; AC, from Institut Curie and Servier Laboratories; MAG. is Directeur de Recherche, MMF, MAD and AG are Charge de Recherche at the Institut National de la Sante et de la Recherche Medicale (INSERM).	Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Arcand SL, 2015, BMC MED GENET, V16, DOI 10.1186/s12881-015-0169-y; Ballard MS, 2015, CELL REP, V13, P290, DOI 10.1016/j.celrep.2015.09.006; Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bonizzi G, 2012, TRENDS MOL MED, V18, P6, DOI 10.1016/j.molmed.2011.08.002; Cagnet S, 2014, ONCOGENE, V33, P4286, DOI 10.1038/onc.2013.391; Chang C, 2015, GENE DEV, V29, P1, DOI 10.1101/gad.253682.114; Chiche A, 2013, STEM CELLS, V31, P1857, DOI 10.1002/stem.1429; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; Di-Cicco A, 2015, ELIFE, V4, DOI 10.7554/eLife.06104; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dumay A, 2013, INT J CANCER, V132, P1227, DOI 10.1002/ijc.27767; Faraldo MM, 2015, METHODS MOL BIOL, V1293, P161, DOI 10.1007/978-1-4939-2519-3_9; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P373, DOI 10.1002/mc.20395; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Holland JD, 2013, CELL REP, V5, P1214, DOI 10.1016/j.celrep.2013.11.001; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kataoka H, 2010, FEBS J, V277, P2230, DOI 10.1111/j.1742-4658.2010.07640.x; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Liao JM, 2014, J MOL CELL BIOL, V6, P206, DOI 10.1093/jmcb/mju018; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lu X, 2013, ONCOGENE, V32, P2900, DOI 10.1038/onc.2012.299; Maroun CR, 2014, PHARMACOL THERAPEUT, V142, P316, DOI 10.1016/j.pharmthera.2013.12.014; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Meniel V, 2005, CANCER RES, V65, P410; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Moumen M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-132; Moumen M, 2012, STEM CELLS, V30, P1246, DOI 10.1002/stem.1090; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Ridgeway AG, 2006, ONCOGENE, V25, P3518, DOI 10.1038/sj.onc.1209391; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shi L, 2013, CIRC RES, V113, P1320, DOI 10.1161/CIRCRESAHA.113.301824; Skibinski A, 2015, ONCOGENE, V34, P5309, DOI 10.1038/onc.2014.475; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Teissedre B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004537; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Miltenburg MHAM, 2014, BRIT J CANCER, V110, P2747, DOI 10.1038/bjc.2014.219; Vieira AF, 2012, STEM CELLS, V30, P854, DOI 10.1002/stem.1075; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zoratti GL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7776	72	15	16	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2355	2365		10.1038/onc.2016.396	http://dx.doi.org/10.1038/onc.2016.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775073				2022-12-28	WOS:000400268900003
J	Zhou, Q; Wang, X; Yu, Z; Wu, X; Chen, X; Li, J; Zhu, Z; Liu, B; Su, L				Zhou, Q.; Wang, X.; Yu, Z.; Wu, X.; Chen, X.; Li, J.; Zhu, Z.; Liu, B.; Su, L.			Transducin (beta)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COREPRESSOR COMPLEX; FREQUENT GAIN; ACTIVATION; TBL1XR1; TRANSCRIPTION; GENES; TBLR1; IDENTIFICATION; METASTASIS	Gastric cancer (GC) is one of the most common types of cancer worldwide, and it involves extensive local tumour invasion, metastasis and poor prognosis. Understanding the mechanisms regulating the progression of GC is necessary for the development of effective therapeutic strategies. Transducin (beta)-like 1 X-linked receptor 1 (TBL1XR1) is an important regulator controlling gene activation and repression, which has been thought to be involved in tumorigenesis. However, the role of TBL1XR1 in human GC remains largely unknown. Here, we find that TBL1XR1 is aberrantly expressed in human GC tissues, and TBL1XR1 levels are highly correlated with local tumour invasion, late tumor, lymph node, metastasis (TNM) stage and poor prognosis. Knockdown of TBL1XR1 by shRNA inhibits GC cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT) in vitro, as well as tumorigenesis and peritoneal metastasis in vivo, whereas overexpression of TBL1XR1 produces the opposite effects. These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1. Moreover, TBL1XR1 mediated ERK1/2 activation is dependent on the beta-catenin/MMP7/EGFR signalling pathway. In conclusion, TBL1XR1 contributes to GC tumorigenesis and progression through the activation of the beta-catenin/MMP7/EGFR/ERK signalling pathway and may act as a new therapeutic target for GC.	[Zhou, Q.; Wang, X.; Yu, Z.; Wu, X.; Chen, X.; Li, J.; Zhu, Z.; Liu, B.; Su, L.] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Inst Digest Surg,Dept Surg,Shanghai Key, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University	Liu, B; Su, L (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Inst Digest Surg,Dept Surg,Shanghai Key, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.	liubingya@sjtu.edu.cn; suliping@shsmu.edu.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762	National Natural Science Foundation of China [81572798, 81272749, 91229106, 91529302]; Key Projects in the National Science & Technology Pillar Program of China [2014BAI09B03]; Shanghai Municipal Education Commission [20152505]; Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine [BXJ201318]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Projects in the National Science & Technology Pillar Program of China; Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. Support: This study was supported by grants from National Natural Science Foundation of China (No. 81572798, No. 81272749, No. 91229106 and No. 91529302), Key Projects in the National Science & Technology Pillar Program of China (No. 2014BAI09B03), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152505), and Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine (BXJ201318).	Andersson S, 2006, BRIT J CANCER, V95, P331, DOI 10.1038/sj.bjc.6603253; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; Chen SP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-195; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Choi HK, 2011, MOL CELL, V43, P203, DOI 10.1016/j.molcel.2011.05.027; Daniels G, 2014, ENDOCR-RELAT CANCER, V21, P127, DOI 10.1530/ERC-13-0293; den Hoed Caroline M, 2016, Curr Gastroenterol Rep, V18, P34, DOI 10.1007/s11894-016-0506-0; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072; Goretsky T, 2016, J BIOL CHEM, V291, P4166, DOI 10.1074/jbc.M115.669416; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Ichikawa K, 2015, MOL CELL, V58, P35, DOI 10.1016/j.molcel.2015.01.023; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kadota M, 2009, CANCER RES, V69, P7357, DOI 10.1158/0008-5472.CAN-09-0064; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Komatsu N, 2015, ONCOGENE, V34, P5607, DOI 10.1038/onc.2015.16; Kuang XJ, 2016, DIGEST DIS SCI, V61, P489, DOI 10.1007/s10620-015-3879-2; Li JY, 2015, AM J CLIN EXP UROL, V3, P13; Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684; Li T, 2015, ONCOL REP, V34, P1469, DOI 10.3892/or.2015.4109; Li XL, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/870597; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu Y, 2007, LUNG CANCER, V56, P307, DOI 10.1016/j.lungcan.2007.01.016; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; Oganesian A, 2011, P NATL ACAD SCI USA, V108, P19796, DOI 10.1073/pnas.1116271108; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 2008, MOL CELL, V29, P755, DOI 10.1016/j.molcel.2008.01.020; Pons L, 2015, AM J MED GENET A, V167, P164, DOI 10.1002/ajmg.a.36759; Qu Y, 2014, J GASTROENTEROL, V49, P408, DOI 10.1007/s00535-013-0809-y; Saitsu H, 2014, J HUM GENET, V59, P581, DOI 10.1038/jhg.2014.71; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Tabet AC, 2014, AM J MED GENET A, V164, P2335, DOI 10.1002/ajmg.a.36619; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Tomita A, 2003, J BIOL CHEM, V278, P30788, DOI 10.1074/jbc.M303309200; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang J, 2014, BRIT J CANCER, V111, P112, DOI 10.1038/bjc.2014.278; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang YC, 2001, CANCER GENET CYTOGEN, V131, P48, DOI 10.1016/S0165-4608(01)00510-6; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang T, 2009, BLOOD, V114, P4081, DOI 10.1182/blood-2009-05-219881; Zhang XM, 2000, EXP HEMATOL, V28, P1286, DOI 10.1016/S0301-472X(00)00539-7	44	27	27	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1873	1886		10.1038/onc.2016.352	http://dx.doi.org/10.1038/onc.2016.352			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27694893	Green Published, hybrid			2022-12-28	WOS:000398128900012
J	Liu, S; Tackmann, NR; Yang, J; Zhang, Y				Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.			Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis	ONCOGENE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; MYC-INDUCED LYMPHOMAGENESIS; B-CELL LINE; C-MYC; RIBOSOME BIOGENESIS; IN-VIVO; P53; CANCER; IDENTIFICATION; GENES	Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is frequently found in colorectal cancer. Loss of APC function results in deregulation of the Wnt/beta-catenin signaling pathway causing overexpression of the c-MYC oncogene. In lymphoma, both p19ARF and ribosomal proteins RPL11 and RPL5 respond to c-MYC activation to induce p53. Their role in c-MYCdriven colorectal carcinogenesis is unclear, as p19ARF deletion does not accelerate APC loss-triggered intestinal tumorigenesis. To determine the contribution of the ribosomal protein (RP)-murine double minute 2 (MDM2)-p53 pathway to APC loss-induced tumorigenesis, we crossed mice bearing MDM2(C305F) mutation, which disrupts RPL11-and RPL5-MDM2 binding, with Apc(min/+) mice, which are prone to intestinal tumor formation. Interestingly, loss of RP-MDM2 binding significantly accelerated colorectal tumor formation while having no discernable effect on small intestinal tumor formation. Mechanistically, APC loss leads to overexpression of c-MYC, RPL11 and RPL5 in mouse colonic tumor cells irrespective of MDM2(C305F) mutation. However, notable p53 stabilization and activation were observed only in Apc(min/+); Mdm2(+/+) but not Apc(min/+); Mdm2(C305F/C305F) colon tumors. These data establish that the RP-MDM2-p53 pathway, in contrast to the p19ARF-MDM2-p53 pathway, is a critical mediator of colorectal tumorigenesis following APC loss.	[Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27514 USA; [Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27514 USA; [Tackmann, N. R.; Zhang, Y.] Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC USA; [Yang, J.; Zhang, Y.] Xuzhou Med Coll, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xuzhou Medical University	Zhang, Y (corresponding author), Univ N Carolina, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27514 USA.; Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu			National Institutes of Health [CA127770, CA 100302, CA167637]; Natural Science Foundation of China (NSFC); National Institute of General Medical Sciences [5T32 GM007092]; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA167637, R01CA155235, R01CA127770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants from the National Institutes of Health (CA127770, CA 100302 and CA167637) and Natural Science Foundation of China (NSFC) to YZ, and the National Institute of General Medical Sciences (5T32 GM007092) to NRT.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Feng Y, 2013, AM J PATHOL, V183, P493, DOI 10.1016/j.ajpath.2013.04.013; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gibson SL, 2005, CANCER BIOL THER, V4, P1389, DOI 10.4161/cbt.4.12.2303; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kim TH, 2014, ONCOTARGET, V5, P860, DOI 10.18632/oncotarget.1784; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Littlewood TD, 2012, CELL, V151, P11, DOI 10.1016/j.cell.2012.09.006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Meng X, 2015, ONCOGENE, V34, P5709, DOI 10.1038/onc.2015.39; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oliner JD, 1993, ONCOPROTEIN MDM2 CON, P53; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Toshiyuki M, 1995, CELL, V80, P293, DOI DOI 10.1016/0092-8674(95)90412-3; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	52	22	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1374	1383		10.1038/onc.2016.301	http://dx.doi.org/10.1038/onc.2016.301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27617574	Green Submitted, Green Accepted			2022-12-28	WOS:000395862500006
J	Jang, JW; Kim, MK; Lee, YS; Lee, JW; Kim, DM; Song, SH; Lee, JY; Choi, BY; Min, B; Chi, XZ; Bae, SC				Jang, J-W; Kim, M-K; Lee, Y-S; Lee, J-W; Kim, D-M; Song, S-H; Lee, J-Y; Choi, B-Y; Min, B.; Chi, X-Z; Bae, S-C			RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PATHWAY; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; TEAD/TEF FAMILY; DROSOPHILA EYE; PROTEIN-KINASE; GROWTH-CONTROL; TISSUE-GROWTH; SIZE-CONTROL; CANCER	The tumor-suppressor RUNX3 has a critical role in a lineage determination, cell cycle arrest and apoptosis. Lozenge (Lz), a Drosophila homolog of mammalian RUNX family members, has integral roles in these processes and specifically in eye cell fate determination. To elucidate the genetic modifiers of Lz/RUNX3, we performed a large-scale functional screen in a fly mutant library. The screen revealed genetic interactions between the Lz, Rac and Hippo pathways. Analysis of interactions among these genes revealed that the defective phenotype resulting from activation of Yki, an end point effector of the Hippo pathway, was suppressed by Lz and enhanced by Rac-Trio. Molecular biological analysis using mammalian homologs reveled that LATS1/2-mediated YAP phosphorylation-facilitated dissociation of the YAP-TEAD4 complex and association of the YAP-RUNX3 complex. When cells were stimulated to proliferate, activated RAC-TRIO signaling inhibited LATS1/2-mediated YAP phosphorylation; consequently, YAP dissociated from RUNX3 and associated with TEAD, thereby replacing the YAP-RUNX3 complex with YAP-TEAD. RUNX3 contributed to both association and dissociation of YAP-TEAD complex, most likely through the formation of the YAP-TEAD-RUNX3 ternary complex. Ectopic expression of RUNX3 in MKN28 gastric cancer cells reduced tumorigenicity, and the tumor-suppressive activity of RUNX3 was associated with its ability to interact with YAP. These results identify a novel regulatory mechanism, mediated by the Hippo and RAC-TRIO pathways, that changes the binding partner of YAP.	[Jang, J-W; Kim, M-K; Lee, Y-S; Lee, J-W; Kim, D-M; Song, S-H; Lee, J-Y; Choi, B-Y; Min, B.; Chi, X-Z; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Coll Med, Cheongju, South Korea	Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 28644, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju 28644, South Korea.	scbae@chungbuk.ac.kr		Bae, Sang-Cheol/0000-0003-4658-1093	National Research Foundation (NRF) of Korea [2014R1A3A2030690]; Chungbuk National University; Basic Science Research Program through the NRF - Ministry of Education of Korea [2014R1A1A2009492]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Chungbuk National University; Basic Science Research Program through the NRF - Ministry of Education of Korea	S-CB is supported by a Creative Research Grant (2014R1A3A2030690) through the National Research Foundation (NRF) of Korea and a Research Grant of Chungbuk National University in 2012. J-WJ is supported by Basic Science Research Program (2014R1A1A2009492) through the NRF funded by the Ministry of Education of Korea.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Bouquier N, 2009, CHEM BIOL, V16, P657, DOI 10.1016/j.chembiol.2009.04.012; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Flores GV, 1998, DEVELOPMENT, V125, P3681; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lee YS, 2016, ONCOGENE, V35, P827, DOI 10.1038/onc.2015.153; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Levy D, 2008, J BIOL CHEM, V283, P27462, DOI 10.1074/jbc.M803941200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Poon CLC, 2011, DEV CELL, V21, P896, DOI 10.1016/j.devcel.2011.09.012; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Ren FF, 2010, DEV BIOL, V337, P303, DOI 10.1016/j.ydbio.2009.10.046; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Wildonger J, 2005, DEVELOPMENT, V132, P2263, DOI 10.1242/dev.01824; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; XU TA, 1995, DEVELOPMENT, V121, P1053; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	38	24	25	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					999	1011		10.1038/onc.2016.266	http://dx.doi.org/10.1038/onc.2016.266			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27425596				2022-12-28	WOS:000394169100012
J	Metheetrairut, C; Adams, BD; Nallur, S; Weidhaas, JB; Slack, FJ				Metheetrairut, C.; Adams, B. D.; Nallur, S.; Weidhaas, J. B.; Slack, F. J.			cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; DNA-DAMAGE RESPONSE; LOCOREGIONAL RECURRENCE; ELEGANS MICRORNAS; MESSENGER-RNAS; C. ELEGANS; EXPRESSION; TARGETS; MIR-125B; MIRNAS	Elucidating the mechanisms involved in sensitizing radioresistant tumors to ionizing radiation (IR) treatments while minimizing injury to surrounding normal tissue is an important clinical goal. Due to their sequence-derived specificity and properties as gene regulators in IR-affected pathways, microRNAs (miRNAs) could serve as adjuvant therapeutic agents that alter cellular sensitivity to radiation treatment. To identify radiosensitizing miRNAs, we initially utilized the Caenorhabditis elegans vulval cell model, an in vivo system developed to study IR-dependent radiosensitivity as a measure of clonogenic cell death. We tested several candidate miRNA-deletion mutants post gamma-irradiation and identified cel-mir-237 as a miRNA which when deleted caused animals to be more resistant to IR, whereas cel-mir-237 overexpressing strains were IR sensitive. In addition, wild-type animals downregulated cel-mir-237 levels post IR in a time-dependent manner. We identified jun-1 (JUN transcription factor homolog) as a novel target of cel-mir-237. Specifically, jun-1 transcript levels increased in wild-type animals post gamma-irradiation, and loss of cel-mir-237 also resulted in higher jun-1 expression. As expected, loss of jun-1 resulted in IR sensitivity, similar to the phenotype of cel-mir-237 overexpressors. As miR-237 is the homolog of human miR-125, we validated our findings in MCF-7 and MDA-MB-231 breast cancer cell lines, which harbor lower hsa-miR-125b levels than normal human mammary epithelial cells (HMECs). Forced expression of hsa-miR-125b in these cells resulted in radiosensitivity, as seen by reduced clonogenic survival, enhanced apoptotic activity and enhanced senescence post IR. Finally, re-expression of c-JUN in MDA-MB-231 cells promoted radioresistance and abrogated miR-125-mediated radiosensitization. Our findings suggest that overexpression of cel-mir-237 and its homolog, hsa-miR-125b, functions as sensitizers to gamma-irradiation in both a nematode in vivo model and breast cancer cells, and could potentially be utilized as an adjuvant therapeutic to enhance radiation sensitivity.	[Metheetrairut, C.; Adams, B. D.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Adams, B. D.; Slack, F. J.] Harvard Med Sch, BIDMC Canc Ctr, Dept Pathol, Inst RNA Med, 3 Blackfan Circle, Boston, MA 02115 USA; [Nallur, S.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA; [Metheetrairut, C.] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Biochem, Bangkok 10700, Thailand; [Weidhaas, J. B.] UCLA, Sch Med, Div Mol & Cellular Oncol, Los Angeles, CA 90095 USA	Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yale University; Mahidol University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Slack, FJ (corresponding author), Harvard Med Sch, BIDMC Canc Ctr, Dept Pathol, Inst RNA Med, 3 Blackfan Circle, Boston, MA 02115 USA.	fslack@bidmc.harvard.edu	Adams, Brian D./D-9476-2017	Adams, Brian D./0000-0001-8372-2970; Metheetrairut, Chanatip/0000-0002-4394-5085	National Institutes of Health National Center; NIH [R01 CA157749, R01 CA131301];  [5T32 HG003198-10]; NATIONAL CANCER INSTITUTE [R01CA131301, R01CA157749] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG003198] Funding Source: NIH RePORTER	National Institutes of Health National Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Geoffrey Lyon, Yale Cell Sorter Core Facility, for assistance with fluorescence- activated cell sorting and analysis, the Yale Cesium Irradiator Shared Resource for use of gamma-irradiator, Valerie Horsley for use of imaging equipment, and to Shirin Bahmanyar for providing space and making equipment available for these studies. We thank Alan Jiao and Catherine O. Adams for critical reading of this manuscript. Nematode strains used in this work were provided by the C. elegans Genetics Center, which is funded by the National Institutes of Health National Center for Research Resources. This work was supported by grants to FJS and JBW from the NIH (R01 CA157749 and R01 CA131301). BDA was supported by a training grant (5T32 HG003198-10).	Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321; Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BRENNER S, 1974, GENETICS, V77, P71; Brown JM, CANC BIOL THER, V2, P477; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emmrich S, 2014, GENE DEV, V28, P858, DOI 10.1101/gad.233791.113; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2005, DEV DYNAM, V234, P868, DOI 10.1002/dvdy.20572; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247; Feng HY, 2012, METHODS MOL BIOL, V786, P21, DOI 10.1007/978-1-61779-292-2_2; Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; Girard LR, 2007, NUCLEIC ACIDS RES, V35, pD472, DOI 10.1093/nar/gkl894; Hammell M, 2008, NAT METHODS, V5, P813, DOI 10.1038/NMETH.1247; Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Isik Meltem, 2013, Methods Mol Biol, V940, P77, DOI 10.1007/978-1-62703-110-3_7; Jan CH, 2011, NATURE, V469, P97, DOI 10.1038/nature09616; Kai ZS, 2010, NAT STRUCT MOL BIOL, V17, P5, DOI 10.1038/nsmb.1762; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin KY, 2016, ONCOGENE, V35, P3376, DOI 10.1038/onc.2015.396; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowery AJ, 2012, BREAST CANCER RES TR, V133, P831, DOI 10.1007/s10549-011-1891-6; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Misso G, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47; Nyholm AM, 2014, BMC DERMATOL, V14, DOI 10.1186/1471-5945-14-8; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Peter ME, 2010, ONCOGENE, V29, P2161, DOI 10.1038/onc.2010.59; Praitis V, 2001, GENETICS, V157, P1217; Puissegur MP, 2012, LEUKEMIA, V26, P2224, DOI 10.1038/leu.2012.95; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Shiiba M, 2013, BRIT J CANCER, V108, P1817, DOI 10.1038/bjc.2013.175; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Song R, 2014, NATURE, V510, P115, DOI 10.1038/nature13413; Stiernagle T., 2006, MAINTENANCE C ELEGAN; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Surdziel E, 2011, BLOOD, V117, P4338, DOI 10.1182/blood-2010-06-289058; Tan GY, 2012, J BIOL CHEM, V287, P33036, DOI 10.1074/jbc.M112.383273; Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414; The C, 2006, WORMBOOK, DOI 10.1895/wormbook.1.54.1; van Haaften G, 2006, CURR BIOL, V16, P1344, DOI 10.1016/j.cub.2006.05.047; Weidhaas JB, 2006, P NATL ACAD SCI USA, V103, P9946, DOI 10.1073/pnas.0603791103; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Welker NC, 2007, RNA, V13, P1090, DOI 10.1261/rna.542107; Wu DY, 2013, ONCOL LETT, V5, P829, DOI 10.3892/ol.2013.1123; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Zaky SS, 2011, ANN SURG ONCOL, V18, P2858, DOI 10.1245/s10434-011-1669-4; Zhang C, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1116-2; Zhang L, 2014, GENE DEV, V28, P2532, DOI 10.1101/gad.248377.114; Zhang LA, 2011, CELL STEM CELL, V8, P294, DOI 10.1016/j.stem.2011.01.014; Zhang Y, 2011, CANCER RES, V71, P1; Zhao ZY, 2010, GENETICS, V184, P853, DOI 10.1534/genetics.109.110270	79	14	16	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					512	524		10.1038/onc.2016.222	http://dx.doi.org/10.1038/onc.2016.222			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321180	Green Submitted, Green Accepted			2022-12-28	WOS:000394166700008
J	Parang, B; Bradley, AM; Mittal, MK; Short, SP; Thompson, JJ; Barrett, CW; Naik, RD; Bilotta, AJ; Washington, MK; Revetta, FL; Smith, JJ; Chen, X; Wilson, KT; Hiebert, SW; Williams, CS				Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Naik, R. D.; Bilotta, A. J.; Washington, M. K.; Revetta, F. L.; Smith, J. J.; Chen, X.; Wilson, K. T.; Hiebert, S. W.; Williams, C. S.			Myeloid translocation genes differentially regulate colorectal cancer programs	ONCOGENE			English	Article							INTESTINAL TUMORIGENESIS; COLON-CANCER; CELL-PROLIFERATION; APC(MIN/+) MICE; NOTCH; COLITIS; APC; ACTIVATION; NEOPLASIA; CARCINOMA	Myeloid translocation genes (MTGs), originally identified as chromosomal translocations in acute myelogenous leukemia, are transcriptional corepressors that regulate hematopoietic stem cell programs. Analysis of The Cancer Genome Atlas (TCGA) database revealed that MTGs were mutated in epithelial malignancy and suggested that loss of function might promote tumorigenesis. Genetic deletion of MTGR1 and MTG16 in the mouse has revealed unexpected and unique roles within the intestinal epithelium. Mtgr1(-/-) mice have progressive depletion of all intestinal secretory cells, and Mtg16(-/-) mice have a decrease in goblet cells. Furthermore, both Mtgr1(-/-) and Mtg16(-/-) mice have increased intestinal epithelial cell proliferation. We thus hypothesized that loss of MTGR1 or MTG16 would modify Apc(1638/+)-dependent intestinal tumorigenesis. Mtgr1(-/-) mice, but not Mtg16(-/-) mice, had a 10-fold increase in tumor multiplicity. This was associated with more advanced dysplasia, including progression to invasive adenocarcinoma, and augmented intratumoral proliferation. Analysis of chromatin immunoprecipitation sequencing data sets for MTGR1 and MTG16 targets indicated that MTGR1 can regulate Wnt and Notch signaling. In support of this, immunohistochemistry and gene expression analysis revealed that both Wnt and Notch signaling pathways were hyperactive in Mtgr1(-/-) tumors. Furthermore, in human colorectal cancer (CRC) samples MTGR1 was downregulated at both the transcript and protein level. Overall our data indicates that MTGR1 has a contextdependent effect on intestinal tumorigenesis.	[Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Naik, R. D.; Bilotta, A. J.; Wilson, K. T.; Williams, C. S.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA; [Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Wilson, K. T.; Williams, C. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA; [Washington, M. K.; Revetta, F. L.] Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Smith, J. J.] Div Surg Oncol, Dept Surg, Nashville, TN USA; [Chen, X.] Dept Biostat, Nashville, TN USA; [Wilson, K. T.; Hiebert, S. W.; Williams, C. S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Wilson, K. T.; Williams, C. S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN USA; [Hiebert, S. W.] Dept Biochem, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Williams, CS (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA.	christopher.williams@vanderbilt.edu	Williams, Christopher/W-3524-2019; Smith, Jesse Joshua/AAN-5440-2020	Williams, Christopher/0000-0002-1541-579X; Smith, Jesse Joshua/0000-0003-2538-5456; Short, Sarah/0000-0001-9606-7370	National Institutes of Health [K08DK080221, R01DK099204, P50CA095103, 1F30DK096718, 1F31 CA167920, T32 GM07347]; Office of Medical Research, Department of Veterans Affairs [1I01BX001426]; ACS-RSG [116552]; NIH [UL1TR000445];  [R01AT004821];  [P30DK058404]; NATIONAL CANCER INSTITUTE [F31CA167920, P50CA095103, R01CA190612, P01CA116087, R01CA178030] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099204, F30DK096718, P30DK058404, K08DK080221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453, I01BX001426] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); ACS-RSG(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We thank the members of the Williams lab, and Karie Ballard for help in revising and proofreading the manuscript. We also thank Dr R Daniel Beauchamp, David Bader and Barbara Fingleton for their advice and counsel in preparing the manuscript. This work was supported by the National Institutes of Health Grants K08DK080221, R01DK099204 (to CSW), P50CA095103 (to MKW), 1F30DK096718 (to BP), 1F31 CA167920 (to CWB), T32 GM07347 (NIH/NIGMS) (to BP), Merit Review Grant from the Office of Medical Research, Department of Veterans Affairs 1I01BX001426 (to CSW), ACS-RSG 116552 (to CSW), R01AT004821 (to KTW), P30DK058404 (Vanderbilt Digestive Disease Research Center), NIH Grant UL1TR000445 (Vanderbilt CTSA). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	American Cancer Society, 2010, CANC FACTS FIG 2010; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chyla BJ, 2008, MOL CELL BIOL, V28, P6234, DOI 10.1128/MCB.00404-08; Dahl JA, 2007, FRONT BIOSCI-LANDMRK, V12, P4925, DOI 10.2741/2438; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Garg P, 2010, CANCER RES, V70, P792, DOI 10.1158/0008-5472.CAN-09-3166; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Katoh M, 2007, INT J ONCOL, V30, P247; Kazanjian A, 2010, GASTROENTEROLOGY, V139, P918, DOI 10.1053/j.gastro.2010.05.081; Kochetkova M, 2002, CANCER RES, V62, P4599; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Li Y, 2014, ONCOGENE, V33, P369, DOI 10.1038/onc.2012.581; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Moore AC, 2008, MOL CELL BIOL, V28, P977, DOI 10.1128/MCB.01242-07; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Parang B, 2015, FASEB J, V29, P786, DOI 10.1096/fj.14-254284; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Poindexter SV, 2015, AM J PHYSIOL-GASTR L, V308, pG562, DOI 10.1152/ajpgi.00253.2014; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Silverman KA, 2002, GENOME RES, V12, P88, DOI 10.1101/gr.206002; Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Soler E, 2010, GENE DEV, V24, P277, DOI 10.1101/gad.551810; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Weyden L, 2008, ONCOGENE, V27, P4503; Williams CS, 2013, GUT, V62, P1446, DOI 10.1136/gutjnl-2011-301439; Williams CS, 2011, J CLIN INVEST, V121, P4056, DOI 10.1172/JCI44228; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705	48	8	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6341	6349		10.1038/onc.2016.167	http://dx.doi.org/10.1038/onc.2016.167			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270437	Green Accepted			2022-12-28	WOS:000390247000007
J	Shen, J; Tsoi, H; Liang, Q; Chu, ESH; Liu, D; Yu, ACS; Chan, TF; Li, X; Sung, JJY; Wong, VWS; Yu, J				Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Yu, A. C-S; Chan, T. F.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.			Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma	ONCOGENE			English	Article							CARBOXYL ESTER LIPASE; FATTY LIVER-DISEASE; CELL-PROLIFERATION; CHOLESTERYL ESTERS; SEQUENCING DATA; DOWN-REGULATION; INHIBITORY ROLE; BILIARY-TRACT; IN-VITRO; CANCER	Epidemiological studies showed that obesity and its related non-alcoholic fatty liver disease (NAFLD) promote hepatocellular carcinoma (HCC) development. We aimed to uncover the genetic alterations of NAFLD-HCC using whole-exome sequencing. We compared HCC development in genetically obese mice and dietary obese mice with wild-type lean mice fed a normal chow after treatment with diethylnitrosamine. HCC tumor and adjacent normal samples from obese and lean mice were then subjected to whole-exome sequencing. Functional and mechanistic importance of the identified mutations in Carboxyl ester lipase (Cel) gene and Harvey rat sarcoma virus oncogene 1 (Hras) was further elucidated. We demonstrated significantly higher incidences of HCC in both genetic and dietary obese mice with NAFLD development as compared with lean mice without NAFLD. The mutational signatures of NAFLD-HCC and lean HCC were distinct, with o3% overlapped. Eight metabolic or oncogenic pathways were found to be significantly enriched by mutated genes in NAFLD-HCC, but only two of these pathways were dysregulated by mutations in lean HCC. In particular, Cel was mutated significantly more frequently in NAFLD-HCC than in lean HCC. The multiple-site mutations in Cel are loss-of-function mutations, with effects similar to Cel knock-down. Mutant Cel caused accumulation of cholesteryl ester in liver cells, which led to induction of endoplasmic reticulum stress and consequently activated the IRE1a/c-Jun N-terminal kinase (JNK)/cJun/ activating protein-1 (AP-1) signaling cascade to promote liver cell growth. In addition, single-site mutations in Hras at codon 61 were found in NAFLD-HCC but none in lean HCC. The gain-of-function mutations in Hras (Q61R and Q61K) significantly promoted liver cell growth through activating the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase-1 (PDK1)/Akt pathways. In conclusion, we have identified mutation signature and pathways in NAFLD-associated HCC. Mutations in Cel and Hras have important roles in NAFLD-associated hepatocellular carcinogenesis.	[Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, A. C-S; Chan, T. F.] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, A. C-S; Chan, T. F.] Chinese Univ Hong Kong, State Key Lab Agrobiotechnol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wong, VWS; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	wongv@cuhk.edu.hk; junyu@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Chan, TingFung/A-6161-2013; Li, Xiao-xing/B-9114-2008; Wong, Vincent WS/K-3864-2014; Liu, Dabin/GNH-2648-2022; Liang, Qiaoyi Jessie/G-9612-2019; Wong, Grace LH/L-8586-2014; Jun, Yu/D-8569-2015	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, TingFung/0000-0002-0489-3884; Li, Xiao-xing/0000-0001-8791-7505; Wong, Vincent WS/0000-0003-2215-9410; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Wong, Grace LH/0000-0002-2863-9389; Yu, Allen Chi-Shing/0000-0002-9568-8316; Jun, Yu/0000-0001-5008-2153; Liu, Dabin/0000-0002-3811-8317; tsoi, ho/0000-0003-2037-9575	RGC-GRF Hong Kong [14106415]; RGC-CRF Hong Kong [CUHK3/CRF/12R, HKU3/CRF11R]; National Basic Research Program of China (973 Program) [2013CB531401]; RGC-Theme-based Research Scheme Hong Kong [T12-403-11]; Shenzhen Virtual University Park Support Scheme	RGC-GRF Hong Kong(Hong Kong Research Grants Council); RGC-CRF Hong Kong; National Basic Research Program of China (973 Program)(National Basic Research Program of China); RGC-Theme-based Research Scheme Hong Kong; Shenzhen Virtual University Park Support Scheme	The project was supported by the RGC-GRF Hong Kong (14106415); RGC-CRF Hong Kong (CUHK3/CRF/12R; HKU3/CRF11R); National Basic Research Program of China (973 Program, 2013CB531401); RGC-Theme-based Research Scheme Hong Kong (T12-403-11); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Borena W, 2012, INT J CANCER, V131, P193, DOI 10.1002/ijc.26338; Camarota LM, 2004, J BIOL CHEM, V279, P27599, DOI 10.1074/jbc.M402946200; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Castellano E, 2010, CURR TOP MICROBIOL, V346, P143, DOI 10.1007/82_2010_56; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Chang WC, 2006, ACTA PHARMACOL SIN, V27, P813, DOI 10.1111/j.1745-7254.2006.00395.x; Chanson M, 2005, BBA-BIOMEMBRANES, V1711, P197, DOI 10.1016/j.bbamem.2004.10.005; Chen HF, 2010, HEPATOLOGY, V52, P155, DOI 10.1002/hep.23641; Cianciola NL, 2013, MOL BIOL CELL, V24, P3309, DOI 10.1091/mbc.E12-10-0760; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; Larsson SC, 2007, BRIT J CANCER, V97, P1005, DOI 10.1038/sj.bjc.6603932; Leithe Edward, 2006, Critical Reviews in Oncogenesis, V12, P225; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Limonta P, 2012, ENDOCR REV, V33, P784, DOI 10.1210/er.2012-1014; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mohit E, 2012, IMMUNOTHERAPY-UK, V4, P807, DOI [10.2217/IMT.12.72, 10.2217/imt.12.72]; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143; Otoda T, 2013, DIABETES, V62, P811, DOI 10.2337/db11-1652; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Raeder H, 2006, NAT GENET, V38, P54, DOI 10.1038/ng1708; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Schlesinger S, 2013, INT J CANCER, V132, P645, DOI 10.1002/ijc.27645; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Swami M, 2010, NAT REV CANCER, V10, P738, DOI 10.1038/nrc2956; Turati F, 2013, BRIT J CANCER, V108, P222, DOI 10.1038/bjc.2012.492; VOGEL MJ, 1971, IBM J RES DEV, V15, P52, DOI 10.1147/rd.151.0052; Wang J, 2013, J PATHOL, V230, P441, DOI 10.1002/path.4206; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001; Wong VWS, 2013, J GASTROEN HEPATOL, V28, P18, DOI 10.1111/jgh.12011; Ximing DU, 2011, [Frontiers in Biology, 生物学前沿], V6, P190; Yu J, 2010, HEPATOLOGY, V51, P2008, DOI 10.1002/hep.23550; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	43	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6271	6280		10.1038/onc.2016.162	http://dx.doi.org/10.1038/onc.2016.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27132506	Green Published, hybrid			2022-12-28	WOS:000390247000001
J	Venturutti, L; Russo, RIC; Rivas, MA; Mercogliano, MF; Izzo, F; Oakley, RH; Pereyra, MG; De Martino, M; Proietti, CJ; Yankilevich, P; Roa, JC; Guzman, P; Cortese, E; Allemand, DH; Huang, TH; Charreau, EH; Cidlowski, JA; Schillaci, R; Elizalde, PV				Venturutti, L.; Russo, R. I. Cordo; Rivas, M. A.; Mercogliano, M. F.; Izzo, F.; Oakley, R. H.; Pereyra, M. G.; De Martino, M.; Proietti, C. J.; Yankilevich, P.; Roa, J. C.; Guzman, P.; Cortese, E.; Allemand, D. H.; Huang, T. H.; Charreau, E. H.; Cidlowski, J. A.; Schillaci, R.; Elizalde, P. V.			MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN-1; GROWTH-HORMONE RECEPTOR; NF-KAPPA-B; CELL-PROLIFERATION; UP-REGULATION; RESISTANCE; EXPRESSION; MYC; MICRORNA; AMPLIFICATION	ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ-and lapatinib-resistant ErbB-2-positive BC and GC.	[Venturutti, L.; Russo, R. I. Cordo; Mercogliano, M. F.; Izzo, F.; Pereyra, M. G.; De Martino, M.; Proietti, C. J.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Mol Mech Carcinogenesis, Buenos Aires, DF, Argentina; [Rivas, M. A.] Weill Cornell Med, Dept Med, New York, NY USA; [Oakley, R. H.; Cidlowski, J. A.] NIEHS, US Dept HHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Pereyra, M. G.] Hosp Gen Agudos Juan A Fernandez, Serv Anat Patol, Buenos Aires, DF, Argentina; [Yankilevich, P.] Max Planck Gesell, Inst Invest Biomed Buenos Aires, CONICET, Partner Inst, Buenos Aires, DF, Argentina; [Roa, J. C.; Guzman, P.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Escuela Med, Dept Anat Patol, Santiago, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile; [Cortese, E.] Hosp Aeronaut Cent, Serv Ginecol, Buenos Aires, DF, Argentina; [Allemand, D. H.] Hosp Gen Agudos Juan A Fernandez, Unidad Patol Mamaria, Buenos Aires, DF, Argentina; [Huang, T. H.] Univ Texas San Antonio, Dept Mol Med, Inst Biotechnol Canc Therapy & Res Expt IBYME, San Antonio, TX USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; University of Buenos Aires; University of Texas System; University of Texas at San Antonio (UTSA)	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Cidlowski, John A/G-2548-2019; Russo, Rosalia Cordo/O-9149-2017; Roa, Juan C./K-4749-2014	Cidlowski, John A/0000-0003-1420-0516; Russo, Rosalia Cordo/0000-0002-5984-9717; Roa, Juan C./0000-0001-8313-8774; De Martino, Mara/0000-0002-3049-6495; Schillaci, Roxana/0000-0002-7776-3378; Elizalde, Patricia V./0000-0002-5923-9898; Yankilevich, Patricio/0000-0002-9606-1072; Mercogliano, Maria Florencia/0000-0003-1094-9247; Rivas, Martin/0000-0002-9603-6897	Susan G Komen for the Cure [KG090250]; National Institute of Cancer (INC, Argentina); National Agency of Scientific Promotion of Argentina (ANPCyT) [IDB/PICT 2012-668, PID 2012-066]; ANPCyT [IDB/PICT 2012-382, IDB/PICT 2008-189, 2012-1017]; Henry Moore Institute of Argentina [Oncomed-Reno CONICET 1819/03]; CONICET [PIP 59]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090057, ZICES102445, ZIAES090079] Funding Source: NIH RePORTER	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); National Institute of Cancer (INC, Argentina); National Agency of Scientific Promotion of Argentina (ANPCyT)(ANPCyT); ANPCyT(ANPCyT); Henry Moore Institute of Argentina; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank AA Molinolo (UCSD, San Diego, CA, USA) for his constant help. This work was supported by KG090250 investigator-initiated research grant from Susan G Komen for the Cure, Financial Assistance for National Research Projects from the National Institute of Cancer (INC, Argentina), IDB/PICT 2012-668 and PID 2012-066 from National Agency of Scientific Promotion of Argentina (ANPCyT), awarded to PVE; IDB/PICT 2012-382 from ANPCyT, awarded to RS; Oncomed-Reno CONICET 1819/03, from Henry Moore Institute of Argentina, awarded to PVE and RS; IDB/PICT 2008-189 and 2012-1017 from ANPCyT, PIP 59 from CONICET, awarded to CJP.	AGRA A, 2012, PLOS ONE, V0007; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bae CD, 2001, EXP MOL MED, V33, P15, DOI 10.1038/emm.2001.3; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bhat-Nakshatri P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02530; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Chamorro-Jorganes A, 2011, ARTERIOSCL THROM VAS, V31, P2595, DOI 10.1161/ATVBAHA.111.236521; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen L, 2013, FEBS LETT, V587, P1366, DOI 10.1016/j.febslet.2013.03.007; Chen L, 2015, CANCER RES, V75, P3832, DOI 10.1158/0008-5472.CAN-14-3690; Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192; Collins DC, 2015, ONCOGENE, V34, P525, DOI 10.1038/onc.2013.586; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Dai LX, 2012, CELL BIOL INT, V36, P765, DOI 10.1042/CBI20110404; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Elzein S, 2014, MOL ENDOCRINOL, V28, P1448, DOI 10.1210/me.2014-1183; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gayle SS, 2013, CURR MED CHEM, V20, P2486, DOI 10.2174/0929867311320190008; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Ichikawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031422; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Jiang QQ, 2013, ASIAN PAC J CANCER P, V14, P4127, DOI 10.7314/APJCP.2013.14.7.4127; Jiao LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032068; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kao SC, 2015, AM J RESP CRIT CARE, V191, P1467, DOI 10.1164/rccm.201503-0461LE; Kapeli K, 2011, J BIOL CHEM, V286, P38498, DOI 10.1074/jbc.M111.276675; Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3; Kim J, 2014, ANTICANCER RES, V34, P3807; Kim SY, 2008, INT J ONCOL, V32, P89; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Le XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041170; Lee YY, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.115; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Mei ZJ, 2015, RADIAT RES, V183, P196, DOI 10.1667/RR13784.1; Motoyama AB, 2002, CANCER RES, V62, P3151; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rivas MA, 2010, BREAST CANCER RES TR, V122, P111, DOI 10.1007/s10549-009-0546-3; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schneeweiss A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3690; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Stajduhar E, 2014, TUMOR BIOL, V35, P6425, DOI 10.1007/s13277-014-1827-y; Tagawa T, 2012, BIOCHEM J, V447, P449, DOI 10.1042/BJ20120434; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Venturutti L, 2015, ONCOGENE; von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261; Wang Shizhen Emily, 2013, Microrna, V2, P137; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Yang TQ, 2014, CANCER SCI, V105, P265, DOI 10.1111/cas.12351; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814; Yu XF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-29; Zhang FC, 2013, ONKOLOGIE, V36, P650, DOI 10.1159/000355659; Zhang J., 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1109/ICNP.2013.6733609; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	76	59	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6189	6202		10.1038/onc.2016.151	http://dx.doi.org/10.1038/onc.2016.151			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157613	Green Accepted, Green Published			2022-12-28	WOS:000388857700004
J	Teo, WW; Merino, VF; Cho, S; Korangath, P; Liang, X; Wu, RC; Neumann, NM; Ewald, AJ; Sukumar, S				Teo, W. W.; Merino, V. F.; Cho, S.; Korangath, P.; Liang, X.; Wu, R-C; Neumann, N. M.; Ewald, A. J.; Sukumar, S.			HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RETINOIC ACID RECEPTOR; STEM-CELLS; GENE-EXPRESSION; MAMMARY-GLAND; DIFFERENTIATION; ACTIVATION; INHIBITION; ALPHA; MORPHOGENESIS	Loss of HOXA5 expression occurs frequently in breast cancer and correlates with higher pathological grade and poorer disease outcome. However, how HOX proteins drive differentiation in mammalian cells is poorly understood. In this paper, we investigated cellular and molecular consequences of loss of HOXA5 in breast cancer, and the role played by retinoic acid in HOXA5 function. Analysis of global gene expression data from HOXA5-depleted MCF10A breast epithelial cells, followed by validation, pointed to a role for HOXA5 in maintaining several molecular traits typical of the epithelial lineage such as cell-cell adhesion, tight junctions and markers of differentiation. Depleting HOXA5 in immortalized MCF10A or transformed MCF10A-Kras cells reduced their CD24(+)/CD44(lo) population, enhanced self-renewal capacity and reduced expression of E-cadherin (CDH1) and CD24. In the case of MCF10A-Kras, HOXA5 loss increased branching and protrusive morphology in Matrigel, all features suggestive of epithelial to basal transition. Further, orthotopically implanted xenografts of MCF10A-Kras-scr grew as well-differentiated pseudo-luminal carcinomas, while MCF10A-Kras-shHOXA5 cells formed aggressive, poorly differentiated carcinomas. Conversely, ectopic expression of HOXA5 in aggressive SUM149 or SUM159 breast cancer cells reversed the cellular and molecular alterations observed in the HOXA5-depleted cells. Retinoic acid is a known upstream regulator of HOXA5 expression. HOXA5 depletion in MCF10A cells engineered to express doxycycline-induced shHOXA5 slowed transition of cells from a less differentiated CD24(-)/CD44(+) to the more differentiated CD24(+)/CD44(+) state. This transition was promoted by retinal treatment, which upregulated endogenous HOXA5 expression and caused re-expression of occludin and claudin-7 (CLDN7). Expression of CDH1 and CD24 was transcriptionally upregulated by direct binding of HOXA5 to their promoter sequences as demonstrated by luciferase and ChIP analyses. Thus, loss of HOXA5 in mammary cells leads to loss of epithelial traits, an increase in stemness and cell plasticity, and the acquisition of more aggressive phenotypes.	[Teo, W. W.; Merino, V. F.; Cho, S.; Korangath, P.; Liang, X.; Sukumar, S.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast Canc Program, Dept Oncol,Sch Med, 1650 Orleans St,CRB1,143, Baltimore, MD 21231 USA; [Teo, W. W.; Wu, R-C; Sukumar, S.] Johns Hopkins Univ, Sch Med, Grad Program Pathobiol, Baltimore, MD USA; [Neumann, N. M.; Ewald, A. J.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD USA; [Liang, X.] Wuhan Univ, Sch Publ Hlth, Wuhan, Peoples R China; [Wu, R-C] Chang Gung Mem Hosp, Dept Anat Pathol, Taoyuan, Taiwan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Wuhan University; Chang Gung Memorial Hospital	Sukumar, S (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast Canc Program, Dept Oncol,Sch Med, 1650 Orleans St,CRB1,143, Baltimore, MD 21231 USA.	saras@jhmi.edu		Neumann, Neil/0000-0001-9779-7754; Teo, Wei Wen/0000-0002-3647-0253; Korangath, Preethi/0000-0002-6623-493X; Cho, Soonweng/0000-0002-1637-2875; Wu, Ren-Chin/0000-0003-1439-0874	Susan G. Komen Foundation Leadership Grant [SAC110050]; Department of Defense Center of Excellence [W81XWH-04-1-0595]; SKCCC Core Grant [P30 CA006973]; AVON Research Foundation Center of Excellence Grant; American Cancer Society [RSG-12-141-01-CSM]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	Susan G. Komen Foundation Leadership Grant; Department of Defense Center of Excellence(United States Department of Defense); SKCCC Core Grant; AVON Research Foundation Center of Excellence Grant; American Cancer Society(American Cancer Society); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Akhilesh Pandey and Edward Gabrielson for guidance; Alan Rein for critically reviewing the manuscript; and help from members of the Sukumar lab. This work was supported by the Susan G. Komen Foundation Leadership Grant # SAC110050, the Department of Defense Center of Excellence-W81XWH-04-1-0595 and the SKCCC Core Grant P30 CA006973 to SS and The AVON Research Foundation Center of Excellence Grant to SS/WWT. AJE is supported by awards from the American Cancer Society (RSG-12-141-01-CSM) and from the Breast Cancer Research Foundation.	Alexander T, 2009, ANNU REV CELL DEV BI, V25, P431, DOI 10.1146/annurev.cellbio.042308.113423; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Arab HH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011007; Aubin J, 1997, DEV BIOL, V192, P432, DOI 10.1006/dbio.1997.8746; Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Ghiaur G, 2013, P NATL ACAD SCI USA, V110, P16121, DOI 10.1073/pnas.1305937110; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Henderson KD, 2000, DEV BIOL, V217, P362, DOI 10.1006/dbio.1999.9560; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jin K, 2015, CANCER DISCOV, V5, P944, DOI 10.1158/2159-8290.CD-15-0090; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; KAY R, 1991, J IMMUNOL, V147, P1412; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Laursen KB, 2013, NUCLEIC ACIDS RES, V41, P6430, DOI 10.1093/nar/gkt367; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; Martin TA, 2010, INT J MOL MED, V26, P721, DOI 10.3892/ijmm_00000519; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Petkova N, 2013, PROSTATE, V73, P1576, DOI 10.1002/pros.22708; PRATT MAC, 1993, DIFFERENTIATION, V53, P105, DOI 10.1111/j.1432-0436.1993.tb00650.x; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Ribeiro AS, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00371; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 2015, BIOMATERIALS, V37, P405, DOI 10.1016/j.biomaterials.2014.10.018; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Thiaville MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036054; Thomas S, 2012, CANCER RES, V72, P5600, DOI 10.1158/0008-5472.CAN-11-3666; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Wang HY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-680; Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570; Yan WX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-62; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	56	47	51	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5539	5551		10.1038/onc.2016.95	http://dx.doi.org/10.1038/onc.2016.95			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27157614	Green Accepted			2022-12-28	WOS:000386998200008
J	Barbelanne, M; Chiu, A; Qian, J; Tsang, WY				Barbelanne, M.; Chiu, A.; Qian, J.; Tsang, W. Y.			Opposing post-translational modifications regulate Cep76 function to suppress centriole amplification	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; CENTROSOME DUPLICATION; CELL-CYCLE; CHROMOSOMAL INSTABILITY; LYSINE ACETYLATION; MAMMALIAN-CELLS; PROTEIN; CDK2; REDUPLICATION; LOCALIZATION	Centrioles are critical for many cellular processes including cell division and cilia assembly. The number of centrioles within a cell is under strict control, and deregulation of centriole copy number is a hallmark of cancer. The molecular mechanisms that halt centriole amplification have not been fully elucidated. Here, we found that centrosomal protein of 76 kDa (Cep76), previously shown to restrain centriole amplification, interacts with cyclin-dependent kinase 2 (CDK2) and is a bona fide substrate of this kinase. Cep76 is preferentially phosphorylated by cyclin A/CDK2 at a single site S83, and this event is crucial to suppress centriole amplification in S phase. A novel Cep76 mutation S83C identified in a cancer patient fails to prevent centriole amplification. Mechanistically, Cep76 phosphorylation inhibits activation of polo-like kinase 1 (Plk1), thereby blocking premature centriole disengagement and subsequent amplification. Cep76 can also be acetylated, and enforced acetylation at K279 dampens the protein's ability to inhibit amplification and precludes S83 phosphorylation. Acetylation of Cep76 normally occurs in G2 phase and correlates with loss of protein function. Our data suggest that temporal changes in post-translational modifications of Cep76 during the cell cycle regulate its capacity to suppress centriole amplification, and its deregulation may contribute to malignancy.	[Barbelanne, M.; Chiu, A.; Qian, J.; Tsang, W. Y.] Inst Rech Clin Montreal, Cell Div & Centrosome Biol Res Unit, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada; [Barbelanne, M.; Tsang, W. Y.] Univ Montreal, Dept Pathol, Fac Med, Montreal, PQ, Canada; [Tsang, W. Y.] McGill Univ, Div Expt Med, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Tsang, WY (corresponding author), Inst Rech Clin Montreal, Cell Div & Centrosome Biol Res Unit, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	william.tsang@ircm.qc.ca		Tsang, William/0000-0002-1584-616X	Canadian Institutes of Health Research [MOP-115033]; Natural Sciences and Engineering Research Council of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	We thank all members of the Tsang laboratory for constructive advice, E Gomes and J Song for assistance with cloning, and Ross Tomaino and Denis Faubert for assistance with mass spectrometry. WYT is a Canadian Institutes of Health Research New Investigator and a Fonds de recherche Sante Junior 1 Research Scholar. This work was supported by the Canadian Institutes of Health Research (MOP-115033 to WYT) and the Natural Sciences and Engineering Research Council of Canada.	Adams PD, 1996, MOL CELL BIOL, V16, P6623; Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Barbelanne M, 2015, HUM MOL GENET, V24, P2185, DOI 10.1093/hmg/ddu738; Barbelanne M, 2013, HUM MOL GENET, V22, P2482, DOI 10.1093/hmg/ddt100; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bornens M, 2012, SCIENCE, V335, P422, DOI 10.1126/science.1209037; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; De Boer L, 2008, ONCOGENE, V27, P4261, DOI 10.1038/onc.2008.74; Douthwright S, 2014, J CELL PHYSIOL, V229, P1427, DOI 10.1002/jcp.24579; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Errico A, 2010, ADV ENZYME REGUL, V50, P375, DOI 10.1016/j.advenzreg.2009.12.001; Ferguson RL, 2008, J CELL SCI, V121, P3224, DOI 10.1242/jcs.034702; Ferguson RL, 2010, J CELL SCI, V123, P2743, DOI 10.1242/jcs.073098; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Hemerly AS, 2009, SCIENCE, V323, P789, DOI 10.1126/science.1166745; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Korzeniewski N, 2009, CANCER RES, V69, P6668, DOI 10.1158/0008-5472.CAN-09-1284; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loncarek J, 2010, CURR BIOL, V20, P1277, DOI 10.1016/j.cub.2010.05.050; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merrick KA, 2011, MOL CELL, V42, P624, DOI 10.1016/j.molcel.2011.03.031; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg E A, 1991, Semin Cell Biol, V2, P261; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Nishimura T, 2005, GENES CELLS, V10, P75, DOI 10.1111/j.1365-2443.2005.00816.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ovejero S, 2012, MOL BIOL CELL, V23, P4515, DOI 10.1091/mbc.E12-04-0260; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pascreau G, 2010, P NATL ACAD SCI USA, V107, P2932, DOI 10.1073/pnas.0914874107; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shiratsuchi G, 2015, EMBO J, V34, P97, DOI 10.15252/embj.201488979; TSAI LH, 1993, ONCOGENE, V8, P1593; Tsang WY, 2008, CELL CYCLE, V7, P702, DOI 10.4161/cc.7.6.5611; Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wu J, 2008, J CELL BIOL, V181, P475, DOI 10.1083/jcb.200710127; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002; Zhang TF, 2012, CELL METAB, V15, P75, DOI 10.1016/j.cmet.2011.12.005; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	63	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5377	5387		10.1038/onc.2016.74	http://dx.doi.org/10.1038/onc.2016.74			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065328	Green Accepted			2022-12-28	WOS:000386677800004
J	Visone, R; Pallante, P; Vecchione, A; Cirombella, R; Ferracin, M; Ferraro, A; Volinia, S; Coluzzi, S; Leone, V; Borbone, E; Liu, CG; Petrocca, F; Troncone, G; Calin, GA; Scarpa, A; Colato, C; Tallini, G; Santoro, M; Croce, CM; Fusco, A				Visone, R.; Pallante, P.; Vecchione, A.; Cirombella, R.; Ferracin, M.; Ferraro, A.; Volinia, S.; Coluzzi, S.; Leone, V.; Borbone, E.; Liu, C-G; Petrocca, F.; Troncone, G.; Calin, G. A.; Scarpa, A.; Colato, C.; Tallini, G.; Santoro, M.; Croce, C. M.; Fusco, A.			Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (vol 26, pg 7590, 2007)	ONCOGENE			English	Correction													Pallante, Pierlorenzo/AAX-8758-2020; Volinia, Stefano/A-3029-2010; Tallini, Giovanni/F-7850-2013; Ferracin, Manuela/K-2097-2016; scarpa, aldo/K-6832-2016; Volinia, Stefano/AAA-9264-2019	Volinia, Stefano/0000-0003-0910-3893; Tallini, Giovanni/0000-0003-0113-6682; Ferracin, Manuela/0000-0002-1595-6887; scarpa, aldo/0000-0003-1678-739X; Volinia, Stefano/0000-0003-0910-3893; Coluzzi, Sabrina/0000-0003-4483-6232				Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564	1	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5214	5214		10.1038/onc.2016.139	http://dx.doi.org/10.1038/onc.2016.139			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27345412	Bronze			2022-12-28	WOS:000384433000012
J	Zhou, X; Zhang, CZ; Lu, SX; Chen, GG; Li, LZ; Liu, LL; Yi, C; Fu, J; Hu, W; Wen, JM; Yun, JP				Zhou, X.; Zhang, C. Z.; Lu, S-X; Chen, G. G.; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Wen, J-M; Yun, J-P			miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma (vol 34, pg 965, 2015)	ONCOGENE			English	Correction																		Zhou X, 2015, ONCOGENE, V34, P965, DOI 10.1038/onc.2014.35	1	8	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5078	5078		10.1038/onc.2016.61	http://dx.doi.org/10.1038/onc.2016.61			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27499093	Bronze			2022-12-28	WOS:000383965300011
J	Escoll, M; Gargini, R; Cuadrado, A; Anton, IM; Wandosell, F				Escoll, M.; Gargini, R.; Cuadrado, A.; Anton, I. M.; Wandosell, F.			Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ	ONCOGENE			English	Article							WASP-INTERACTING PROTEIN; HIPPO PATHWAY; T-CELL; ACTIN ORGANIZATION; TISSUE-GROWTH; ORGAN GROWTH; F-ACTIN; TAZ; YAP; INVASION	Wild-type p53 (wtp53) is described as a tumour suppressor gene; mutations in this gene occur in many human cancers and promote oncogenic capacity. Here, we establish that the oncogenic activity of mutant p53 (mtp53) is driven by the WASP-interacting protein (WIP). WIP knockdown from mtp53-expressing glioblastoma and breast cancer cells (BCC) greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers (CD133, CD44 or YAP/TAZ). mtp53 overexpression in human astrocytes enhanced their proliferative capacity in suspension culture and increased expression of CSC markers and WIP. WIP knockdown compromised tumour glioblastoma and BCC growth capacity in vivo. We show that WIP is phosphorylated by AKT2 and is regulated by mtp53/p63 through enhancement of PI3K/AKT2-mediated integrin/receptor recycling pathways. WIP regulates this oncogenic pathway by controlling YAP/TAZ stability. We thus establish a new CSC signalling pathway downstream of mtp53 in which AKT2 regulates WIP and controls YAP/TAZ stability.	[Escoll, M.; Wandosell, F.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain; [Escoll, M.; Cuadrado, A.; Anton, I. M.; Wandosell, F.] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Valderrebollo 5, Madrid, Spain; [Gargini, R.; Anton, I. M.] Ctr Nacl Biotecnol CNB CSIC, Dept Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain; [Cuadrado, A.] Inst Invest Biomed Alberto Sols CSIC UAM, Inst Invest Sanitaria La Paz IdiPaz, Madrid, Spain; [Cuadrado, A.] Univ Autonoma Madrid, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); CIBERNED; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Wandosell, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain.; Anton, IM (corresponding author), Ctr Nacl Biotecnol CNB CSIC, Dept Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain.	ianton@cnb.csic.es; fwandosell@cbm.csic.es	Wandosell, Francisco/AAV-6391-2020; Gargini, Ricardo/AAA-3542-2020; Anton, Ines M/G-6090-2015; Wandosell, Francisco/G-6105-2015	Anton, Ines M/0000-0002-2935-5919; Wandosell, Francisco/0000-0001-6537-2321; Cuadrado, Antonio/0000-0002-4039-7140; Escoll, Maribel/0000-0003-0043-6878	MICINN; Plan Nacional of the Direccio General de Ciencia y Tecnologia [SAF2012-39148-C03-01, SAF2013-45937-R, SAF2015-70368-R, SAF2013-43271-R]; European Union [EU-FP7-2009-CT222887]; Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED)	MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Plan Nacional of the Direccio General de Ciencia y Tecnologia; European Union(European Commission); Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED)	We thank Catherine Mark for editorial assistance. The proteomic analysis was performed in the proteomics facility of Centro Nacional de Biotecnolog~a that belongs to ProteoRed, PRB2-ISCIII; we particularly acknowledge the exceptional work of Rosana Navajas. This work was supported by grants from the MICINN, the Plan Nacional of the Direccio General de Ciencia y Tecnologia (SAF2012-39148-C03-01 to FW, SAF2013-45937-R to IMA and SAF2015-70368-R to both and SAF2013-43271-R to AC), the European Union (EU-FP7-2009-CT222887 to FW) and the Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; Anton IM, 2007, TRENDS CELL BIOL, V17, P555, DOI 10.1016/j.tcb.2007.08.005; Aspenstrom P, 2005, FEBS LETT, V579, P5253, DOI 10.1016/j.febslet.2005.08.053; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Banon-Rodriguez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070364; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Franco A, 2012, CEREB CORTEX, V22, P1191, DOI 10.1093/cercor/bhr199; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Garcia E, 2014, EUR J CELL BIOL, V93, P413, DOI 10.1016/j.ejcb.2014.07.008; Garcia E, 2012, EUR J CELL BIOL, V91, P869, DOI 10.1016/j.ejcb.2012.06.002; Gargini R, 2016, CELL REP, V17, P1962, DOI 10.1016/j.celrep.2016.10.064; Gargini R, 2015, STEM CELLS, V33, P646, DOI 10.1002/stem.1904; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Imajo M, 2015, NAT CELL BIOL, V17, P7, DOI 10.1038/ncb3084; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Klein C, 2011, ANNU REV IMMUNOL, V29, P399, DOI 10.1146/annurev-immunol-030409-101259; Lanzardo S, 2007, INT J BIOCHEM CELL B, V39, P262, DOI 10.1016/j.biocel.2006.08.011; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Le Bras S, 2009, P NATL ACAD SCI USA, V106, P7519, DOI 10.1073/pnas.0806410106; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Lucas EP, 2013, J CELL BIOL, V201, P875, DOI 10.1083/jcb.201210073; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nagpal J, 2006, ANTICANCER RES, V26, P4633; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Piccolo S, 2013, CLIN CANCER RES, V19, P4925, DOI 10.1158/1078-0432.CCR-12-3172; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shiraishi S, 2002, CANCER-AM CANCER SOC, V95, P249, DOI 10.1002/cncr.10677; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Staub E, 2009, J MOL MED, V87, P633, DOI 10.1007/s00109-009-0467-y; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Thanabalu T, 2007, FEBS J, V274, P4103, DOI 10.1111/j.1742-4658.2007.05936.x; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	65	52	53	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3515	3527		10.1038/onc.2016.518	http://dx.doi.org/10.1038/onc.2016.518			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166194				2022-12-28	WOS:000403878600002
J	Yi, H; Geng, L; Black, A; Talmon, G; Berim, L; Wang, J				Yi, H.; Geng, L.; Black, A.; Talmon, G.; Berim, L.; Wang, J.			The miR-487b-3p/GRM3/TGF beta signaling axis is an important regulator of colon cancer tumorigenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; METABOTROPIC GLUTAMATE RECEPTORS; CONFERS DRUG-RESISTANCE; COLORECTAL-CANCER; PHARMACOLOGICAL BLOCKADE; CARCINOMA; EXPRESSION; CELLS; METASTASIS; PROLIFERATION	Molecular targeting is an import strategy to treat advanced colon cancer. The current study demonstrates that expression of GRM3, a metabotropic glutamate receptor mainly expressed in mammalian central nervous system, is significantly upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in vivo. Mechanistically, GRM3 antagonizes TGF beta-mediated activation of protein kinase A and inhibition of Protein kinase B (AKT). In addition, TGF beta signaling increases GRM3 protein stability and knockdown of GRM3 enhances TGF beta-mediated tumor suppressor function. Further studies indicate that miR-487b-3p directly targets GRM3. Overexpression of miR-487b-3p mimics the effects of GRM3 knockdown and suppresses the tumorigenicity of colon cancer cells in vivo. Expression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expression. Taken together, these studies indicate that upregulation of GRM3 expression is a functionally important molecular event in colon cancer, and that GRM3 is a promising molecular target for colon cancer treatment. This is particularly interesting and important from a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are available, many of which have been found unsuitable for treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood brain barriers. As GRM3 is upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific molecular target for colon cancer treatment.	[Yi, H.; Wang, J.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA; [Geng, L.; Black, A.; Wang, J.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Talmon, G.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Berim, L.] Univ Nebraska Med Ctr, Dept Internal Med Oncol Hematol, Omaha, NE USA; [Wang, J.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wang, J (corresponding author), Univ Nebraska Med Ctr, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	jjwang@unmc.edu			Chinese Scholar Council;  [NIH/NCI R01CA140988-01]	Chinese Scholar Council; 	This work was supported by NIH/NCI R01CA140988-01 to JW. HY was partially supported by Chinese Scholar Council.	ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961; Bacman D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-156; Banerjee A, 2011, BIOMED PHARMACOTHER, V65, P293, DOI 10.1016/j.biopha.2011.03.009; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BOYD DD, 1988, CANCER RES, V48, P2469; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Chang HJ, 2005, CLIN CANCER RES, V11, P3288, DOI 10.1158/1078-0432.CCR-04-1912; Chowdhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019335; Chowdhury SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068818; Ciceroni C, 2008, NEUROPHARMACOLOGY, V55, P568, DOI 10.1016/j.neuropharm.2008.06.064; CURTIS DR, 1959, NATURE, V183, P611, DOI 10.1038/183611a0; D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471-4159.2003.01633.x; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Geng L, 2014, ONCOGENE, V33, P5332, DOI 10.1038/onc.2013.478; Geng LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059918; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gulubova M, 2010, INT J COLORECTAL DIS, V25, P591, DOI 10.1007/s00384-010-0906-9; Hamamoto T, 2002, CANCER RES, V62, P5955; HAYASHI TAKASHI, 1952, JAPANESE JOUR PHYSIOL, V3, P46; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Kim MS, 2008, ONCOGENE, V27, P2045, DOI 10.1038/sj.onc.1210842; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Martino JJ, 2013, ONCOGENE, V32, P4366, DOI 10.1038/onc.2012.471; Minoshima T, 1999, J BIOCHEM-TOKYO, V126, P889, DOI 10.1093/oxfordjournals.jbchem.a022531; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Neto FL, 2000, MOL BRAIN RES, V81, P140; Neto FL, 2001, J NEUROSCI RES, V63, P356, DOI 10.1002/1097-4547(20010215)63:4<356::AID-JNR1030>3.0.CO;2-3; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Simms NAK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-221; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Sodir NM, 2006, CANCER RES, V66, P8430, DOI 10.1158/0008-5472.CAN-06-1437; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tong QC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1324, DOI 10.1152/ajpendo.00460.2001; Veenendaal LM, 2008, CELL ONCOL, V30, P1; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Ye SC, 1999, CANCER RES, V59, P4725; Zeng QH, 2009, CANCER RES, V69, P678, DOI 10.1158/0008-5472.CAN-08-3980; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200; Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252; Zhou K, 2014, CELL BIOL INT, V38, P426, DOI 10.1002/cbin.10207	57	26	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3477	3489		10.1038/onc.2016.499	http://dx.doi.org/10.1038/onc.2016.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114282	Green Accepted			2022-12-28	WOS:000403340700011
J	Wang, T; Xu, X; Xu, Q; Ren, J; Shen, S; Fan, C; Hou, Y				Wang, T.; Xu, X.; Xu, Q.; Ren, J.; Shen, S.; Fan, C.; Hou, Y.			miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-kappa B feedback loops	ONCOGENE			English	Article							NF-KAPPA-B; MOUSE MODEL; TNF-ALPHA; LINEAR POLYUBIQUITIN; DOWN-REGULATION; BREAST-CANCER; COLON-CANCER; A20; ACTIVATION; INHIBITION	Chronic inflammation is believed to have a crucial role in colon cancer development. MicroRNA (miRNA) deregulation is common in human colorectal cancers, but little is known regarding whether miRNA drives tumor progression by regulating inflammation. Here, we showed that miR-19a can promote colitis and colitis-associated colon cancer (CAC) development using a CAC mouse model and an acute colitis mouse model. Tumor necrosis factor-a (TNF-a) stimulation can increase miR-19a expression, and upregulated miR-19a can in turn activate nuclear factor (NF)-kappa B signaling and TNF-a production by targeting TNF alpha-induced protein 3 (TNFAIP3). miR-19a inhibition can also alleviate CAC in vivo. Moreover, the regulatory effects of miR-19a on TNFAIP3 and NF-kappa B signaling were confirmed using tumor samples from patients with colon cancer. These new findings demonstrate that miR-19a has a direct role in upregulating NF-kappa B signaling and that miR-19a has roles in inflammation and CAC.	[Wang, T.; Xu, Q.; Ren, J.; Shen, S.; Hou, Y.] Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Div Immunol, Nanjing 210093, Jiangsu, Peoples R China; [Wang, T.; Shen, S.; Hou, Y.] Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China; [Wang, T.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Xu, X.; Fan, C.] Nanjing Univ, Sch Med, Jinling Hosp, Gen Surg, Nanjing 210093, Jiangsu, Peoples R China	Nanjing University; University of Texas System; UTMD Anderson Cancer Center; Nanjing University	Shen, S; Hou, Y (corresponding author), Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Div Immunol, Nanjing 210093, Jiangsu, Peoples R China.; Fan, C (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Gen Surg, Nanjing 210093, Jiangsu, Peoples R China.	shensn@nju.edu.cn; fancg2002@hotmail.com; yayihou@nju.edu.cn			National Natural Science Foundation of China [81572354, 81571800, 81371680]; Natural Science Foundation of Jiangsu Province [BK20161400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This work was partially supported by grants from the National Natural Science Foundation of China (81572354, 81571800, and 81371680) and Natural Science Foundation of Jiangsu Province (BK20161400).	Ahmed FE, 2014, EXPERT REV ANTICANC, V14, P463, DOI 10.1586/14737140.2014.869479; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bi LK, 2010, J BIOL CHEM, V285, P25969, DOI 10.1074/jbc.M110.131300; Burisch J, 2015, SCAND J GASTROENTERO, V50, P942, DOI 10.3109/00365521.2015.1014407; Cellura D, 2015, MOL CANCER RES, V13, P1095, DOI 10.1158/1541-7786.MCR-14-0466; Chen B, 2013, SCAND J GASTROENTERO, V48, P815, DOI 10.3109/00365521.2013.800991; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Fluckiger A, 2016, ONCOGENE, V35, P4611, DOI 10.1038/onc.2015.523; Gantier MP, 2012, NUCLEIC ACIDS RES, V40, P8048, DOI 10.1093/nar/gks521; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guina T, 2015, ANN NY ACAD SCI, V1340, P95, DOI 10.1111/nyas.12734; Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730; HAYASHITA Y, 2005, CANCER RES, V65, P9628, DOI [DOI 10.1158/0008-5472.CAN-05-2352, 10.1158/0008-5472.CAN-05-2352]; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huang LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13350; Ishikawa TO, 2010, CARCINOGENESIS, V31, P729, DOI 10.1093/carcin/bgq002; Ito Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1315-9; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849; Jin LJ, 2014, BREAST CANCER RES TR, V146, P41, DOI 10.1007/s10549-014-2978-7; Jung SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3562; Kanaan Z, 2012, HUM MUTAT, V33, P551, DOI 10.1002/humu.22021; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Kim SW, 2012, P NATL ACAD SCI USA, V109, P7865, DOI 10.1073/pnas.1200081109; Knudsen KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140503; Landers CJ, 2002, GASTROENTEROLOGY, V123, P689, DOI 10.1053/gast.2002.35379; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liu KJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/867537; Liu M, 2011, INT J ONCOL, V38, P1013, DOI 10.3892/ijo.2011.924; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Ma HB, 2016, CANCER LETT, V376, P293, DOI 10.1016/j.canlet.2016.04.011; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Nakshatri H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.569; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Shao L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062223; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Simpson LJ, 2014, NAT IMMUNOL, V15, P1162, DOI 10.1038/ni.3026; Skaug B, 2011, MOL CELL, V44, P559, DOI 10.1016/j.molcel.2011.09.015; Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Verhelst K, 2012, EMBO J, V31, P3845, DOI 10.1038/emboj.2012.240; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043268; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Zhang J, 2012, BRIT J CANCER, V107, P352, DOI 10.1038/bjc.2012.251; Zhu HQ, 2015, CARCINOGENESIS, V36, P1213, DOI 10.1093/carcin/bgv112	51	36	38	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3240	3251		10.1038/onc.2016.468	http://dx.doi.org/10.1038/onc.2016.468			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991929				2022-12-28	WOS:000402869800004
J	Brown, K; Yang, P; Salvador, D; Kulikauskas, R; Ruohola-Baker, H; Robitaille, AM; Chien, AJ; Moon, RT; Sherwood, V				Brown, K.; Yang, P.; Salvador, D.; Kulikauskas, R.; Ruohola-Baker, H.; Robitaille, A. M.; Chien, A. J.; Moon, R. T.; Sherwood, V.			WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner	ONCOGENE			English	Article							BETA-CATENIN; BRAF MUTATIONS; CLINICOPATHOLOGICAL FEATURES; DISEASE PROGRESSION; SECRETED PROTEINS; EXPRESSION; CANCER; TUMORS; PARKIN; DEGRADATION	Aberrant regulation of WNT/beta-catenin signaling has a crucial role in the onset and progression of cancers, where the effects are not always predictable depending on tumor context. In melanoma, for example, models of the disease predict differing effects of the WNT/beta-catenin pathway on metastatic progression. Understanding the processes that underpin the highly context-dependent nature of WNT/beta-catenin signaling in tumors is essential to achieve maximal therapeutic benefit from WNT inhibitory compounds. In this study, we have found that expression of the tumor suppressor, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), alters the invasive potential of melanoma cells in response to WNT/beta-catenin signaling, correlating with differing metabolic profiles. This alters the bioenergetic potential and mitochondrial activity of melanoma cells, triggered through regulation of prosurvival autophagy. Thus, WNT/beta-catenin signaling is a regulator of catabolic processes in cancer cells, which varies depending on the metabolic requirements of tumors.	[Brown, K.; Sherwood, V.] Univ East Anglia, Sch Pharm, Norwich Res Pk, Norwich, Norfolk, England; [Yang, P.; Kulikauskas, R.; Robitaille, A. M.; Chien, A. J.; Moon, R. T.] Inst Stem Cell & Regenerat Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA USA; [Salvador, D.; Sherwood, V.] Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Jacqui Wood Canc Ctr, Dundee DD1 9SY, Angus, Scotland; [Ruohola-Baker, H.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Chien, A. J.] Univ Washington, Div Dermatol, Seattle, WA 98195 USA; [Brown, K.] NCI, Thorac & GI Oncol Branch, NIH, Bethesda, MD 20892 USA	University of East Anglia; Howard Hughes Medical Institute; University of Dundee; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sherwood, V (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Jacqui Wood Canc Ctr, Dundee DD1 9SY, Angus, Scotland.	v.sherwood@dundee.ac.uk		Robitaille, Aaron Mark/0000-0003-2774-2066	Royal Society, London; British Skin Foundation; CRUK program; Howard Hughes Medical Institute; University of Washington's Proteomics Resource [UWPR95794]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097372] Funding Source: NIH RePORTER	Royal Society, London(Royal Society of London); British Skin Foundation; CRUK program; Howard Hughes Medical Institute(Howard Hughes Medical Institute); University of Washington's Proteomics Resource; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the CRUK Skin Tumor Laboratory (CRUK-STL), University of Dundee, for useful discussions throughout this work and in particular Kenneth Fernandes for technical support. We also thank Brian Johnson (Histology and Imaging core, School of Medicine, University of Washington) for help with IHC. This work was supported by start-up funding awarded to VS and grants from the Royal Society, London, and the British Skin Foundation (also awarded to VS). VS is supported by a CRUK program grant awarded to the CRUK-STL, School of Medicine, University of Dundee. RTM is an investigator of the Howard Hughes Medical Institute, which partially funded this work. This work was supported in part by the University of Washington's Proteomics Resource (UWPR95794).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; de Moura MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040690; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Godoy JA, 2014, J BIOL CHEM, V289, P36179, DOI 10.1074/jbc.M114.557009; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599; James RG, 2013, J BIOL CHEM, V288, P34658, DOI 10.1074/jbc.M113.500314; Jemal A, 2011, J AM ACAD DERMATOL, V65, pS17, DOI 10.1016/j.jaad.2011.04.032; Jenei V, 2009, P NATL ACAD SCI USA, V106, P19473, DOI 10.1073/pnas.0909409106; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Larue L, 2009, PATHOL BIOL, V57, P543, DOI 10.1016/j.patbio.2008.11.003; Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014; Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mikhail M, 2005, CLIN CANCER RES, V11, P5153, DOI 10.1158/1078-0432.CCR-05-0397; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Osborne JE, 2002, BRIT J DERMATOL, V146, P1104, DOI 10.1046/j.1365-2133.2002.47322.x; Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Purdue MP, 2008, J INVEST DERMATOL, V128, P2905, DOI 10.1038/jid.2008.159; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Serrat R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067773; Sherwood V, 2015, MOL CELL BIOL, V35, P2, DOI 10.1128/MCB.00992-14; Sherwood V, 2014, CARCINOGENESIS, V35, P784, DOI 10.1093/carcin/bgt390; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779; Ulivieri A, 2008, J PATHOL, V215, P87, DOI 10.1002/path.2331; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yoon JC, 2010, GENE DEV, V24, P1507, DOI 10.1101/gad.1924910; Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103	103	43	49	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3119	3136		10.1038/onc.2016.450	http://dx.doi.org/10.1038/onc.2016.450			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28092677	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000402617900005
J	Kim, YJ; Jung, K; Baek, DS; Hong, SS; Kim, YS				Kim, Y-J; Jung, K.; Baek, D-S; Hong, S-S; Kim, Y-S			Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin beta 1-drivenSrc-Akt bypass signaling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; TUMOR-GROWTH; BISPECIFIC ANTIBODY; MONOCLONAL-ANTIBODY; ACTIVATION; ANGIOGENESIS; PENETRATION; FIBRONECTIN; METASTASIS	Pancreatic ductal adenocarcinoma (PDAC) cells usually overexpress the epidermal growth factor receptor (EGFR); however, most are resistant to the anti-EGFR monoclonal antibody, cetuximab. In this study, we report that the molecular mechanism of resistance to cetuximab in PDAC cells is mediated by the overexpression of active integrin beta 1 with downstream Src-Akt activation; this triggers an EGFR ligand-independent proliferation signaling, bypassing EGFR-blocking effect. Knockdown of integrin beta 1 or inhibition of Src or Akt sensitized cetuximab-resistant (Ctx(R)) PDAC cells to cetuximab. We found that neuropilin-1 (NRP1) physically interacts with active integrin beta 1, but not inactive one, on the cell surface. To inhibit active integrin beta 1-driven signaling by targeting NRP1, while suppressing EGFR signaling, we generated an EGFR and NRP1 dual targeting antibody, Ctx-TPP11, by genetic fusion of the NRP1-targeting peptide, TPP11, to the C terminus of the cetuximab heavy chain (Ctx-TPP11). We demonstrate that Ctx-TPP11 efficiently inhibited the growth of CtxR PDAC cells, in vitro and in vivo. The sensitization mechanism involved downregulating active integrin beta 1 levels through NRP1-coupled internalization mediated by the TPP11 moiety, leading to the inhibition of active integrin beta 1-driven bypass signaling. Our findings identify aberrant active integrin beta 1-driven Src-Akt hyperactivation as a primary resistance mechanism to cetuximab in PDAC cells and offer an effective therapeutic strategy to overcome this resistance using an EGFR and NRP1 dual targeting antibody.	[Kim, Y-J; Jung, K.; Baek, D-S; Kim, Y-S] Ajou Univ, Dept Mol Sci & Technol, 206 Worldcup Ro, Suwon 16499, South Korea; [Hong, S-S] Inha Univ, Dept Biomed Sci, Coll Med, Incheon, South Korea	Ajou University; Inha University	Kim, YS (corresponding author), Ajou Univ, Dept Mol Sci & Technol, 206 Worldcup Ro, Suwon 16499, South Korea.	kimys@ajou.ac.kr		Kim, Yong-Sung/0000-0003-2673-1509; Baek, Du-San/0000-0002-5356-6716; Jung, Keunok/0000-0003-2967-8432	Mid-career Researcher Program from the National Research Foundation - Korean government [2016R1A2A2A05005108]; Pioneer Research Center Program from the National Research Foundation - the Korean government [2014M3C1A3051470]	Mid-career Researcher Program from the National Research Foundation - Korean government; Pioneer Research Center Program from the National Research Foundation - the Korean government	This work was supported by grants from the Mid-career Researcher Program (2016R1A2A2A05005108) and the Pioneer Research Center Program (2014M3C1A3051470) from the National Research Foundation funded by the Korean government.	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Arnoletti JP, 2004, J GASTROINTEST SURG, V8, P960, DOI 10.1016/j.gassur.2004.09.021; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Choi DK, 2014, MABS-AUSTIN, V6, P1402, DOI 10.4161/mabs.36389; Choi HJ, 2013, MOL CANCER THER, V12, P2748, DOI 10.1158/1535-7163.MCT-13-0628; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653; Fotopoulou C, 2010, ANTICANCER RES, V30, P4619; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Fukasawa M, 2007, CANCER BIOL THER, V6, P1173; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327; Hou S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18430; Iida M, 2013, ONCOGENE, V32, P759, DOI 10.1038/onc.2012.90; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Kanda R, 2013, CANCER RES, V73, P6243, DOI 10.1158/0008-5472.CAN-12-4502; Kim YJ, 2015, J CONTROL RELEASE, V216, P56, DOI 10.1016/j.jconrel.2015.08.016; Larbouret C, 2012, NEOPLASIA, V14, P121, DOI 10.1593/neo.111602; Li BH, 2013, CANCER RES, V73, P6471, DOI 10.1158/0008-5472.CAN-13-0657; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Matsushita A, 2007, CANCER RES, V67, P10309, DOI 10.1158/0008-5472.CAN-07-3256; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Okon IS, 2014, J CLIN INVEST, V124, P4590, DOI 10.1172/JCI75371; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550; Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shin TH, 2014, MOL CANCER THER, V13, P651, DOI 10.1158/1535-7163.MCT-13-0748; Sugahara KN, 2015, MOL CANCER THER, V14, P120, DOI 10.1158/1535-7163.MCT-14-0366; Sung ES, 2009, MOL CANCER THER, V8, P2276, DOI 10.1158/1535-7163.MCT-09-0235; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wong MH, 2014, CLIN CANCER RES, V20, P4047, DOI 10.1158/1078-0432.CCR-13-3377; Yaqoob U, 2012, CANCER RES, V72, P4047, DOI 10.1158/0008-5472.CAN-11-3907; Ye F, 2012, BLOOD, V119, P26, DOI 10.1182/blood-2011-04-292128; Zeng FW, 2014, ANTI-CANCER DRUG, V25, P663, DOI 10.1097/CAD.0000000000000091	40	33	34	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2543	2552		10.1038/onc.2016.407	http://dx.doi.org/10.1038/onc.2016.407			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27797376				2022-12-28	WOS:000400597300005
J	Sareddy, GR; Viswanadhapalli, S; Surapaneni, P; Suzuki, T; Brenner, A; Vadlamudi, RK				Sareddy, G. R.; Viswanadhapalli, S.; Surapaneni, P.; Suzuki, T.; Brenner, A.; Vadlamudi, R. K.			Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; HISTONE DEMETHYLASE; ER STRESS; GLIOBLASTOMA CELLS; LSD1; TARGET; MECHANISMS; GROWTH; HETEROGENEITY; CONTRIBUTES	Glioma stem cells (GSCs) have a central role in glioblastoma (GBM) development and chemo/radiation resistance, and their elimination is critical for the development of efficient therapeutic strategies. Recently, we showed that lysine demethylase KDM1A is overexpressed in GBM. In the present study, we determined whether KDM1A modulates GSCs stemness and differentiation and tested the utility of two novel KDM1A-specific inhibitors (NCL-1 and NCD-38) to promote differentiation and apoptosis of GSCs. The efficacy of KDM1A targeting drugs was tested on purified GSCs isolated from established and patient-derived GBMs using both in vitro assays and in vivo orthotopic preclinical models. Our results suggested that KDM1A is highly expressed in GSCs and knockdown of KDM1A using shRNA-reduced GSCs stemness and induced the differentiation. Pharmacological inhibition of KDM1A using NCL-1 and NCD-38 significantly reduced the cell viability, neurosphere formation and induced apoptosis of GSCs with little effect on differentiated cells. In preclinical studies using orthotopic models, NCL-1 and NCD-38 significantly reduced GSCs-driven tumor progression and improved mice survival. RNA-sequencing analysis showed that KDM1A inhibitors modulate several pathways related to stemness, differentiation and apoptosis. Mechanistic studies showed that KDM1A inhibitors induce activation of the unfolded protein response (UPR) pathway. These results strongly suggest that selective targeting of KDM1A using NCL-1 and NCD-38 is a promising therapeutic strategy for elimination of GSCs.	[Sareddy, G. R.; Viswanadhapalli, S.; Surapaneni, P.; Vadlamudi, R. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA; [Suzuki, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan; [Suzuki, T.] Japan Sci & Technol Agcy JST, CREST, Saitama, Japan; [Brenner, A.; Vadlamudi, R. K.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA; [Brenner, A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Hematol & Oncol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Kyoto Prefectural University of Medicine; Japan Science & Technology Agency (JST); Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sareddy, GR; Vadlamudi, RK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.	Sareddy@uthscsa.edu; Vadlamudi@uthscsa.edu		Viswanadhapalli, Suryavathi/0000-0002-7381-6962	AACR-AMGEN Inc. [14-40-11-SARE]; CPRIT training grant [RP140105]; NCI Grant [CA178499]; NATIONAL CANCER INSTITUTE [R01CA178499] Funding Source: NIH RePORTER	AACR-AMGEN Inc.; CPRIT training grant; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the 2014 AACR-AMGEN Inc. fellowship in clinical/translational cancer research (Grant Number: 14-40-11-SARE) and CPRIT training grant (RP140105) awarded to GRS and NCI Grant CA178499 (RKV and AB).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Bai Y, 2014, GLIA, V62, P1687, DOI 10.1002/glia.22708; Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Cho YM, 2009, EXP MOL MED, V41, P440, DOI 10.3858/emm.2009.41.6.049; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Crespo I, 2015, AM J PATHOL, V185, P1820, DOI 10.1016/j.ajpath.2015.02.023; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364; Diaz-Villanueva JF, 2015, INT J MOL SCI, V16, P17193, DOI 10.3390/ijms160817193; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ge WS, 2014, BIOMATERIALS, V35, P6015, DOI 10.1016/j.biomaterials.2014.04.055; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Khan IS, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14509; Kondo Y, 2014, CANCER SCI, V105, P363, DOI 10.1111/cas.12379; Kozono D, 2015, P NATL ACAD SCI USA, V112, pE4055, DOI 10.1073/pnas.1501967112; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Lee YS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/520578; Lei ZJ, 2015, ONCOGENE, V34, P3188, DOI 10.1038/onc.2015.129; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999; Ogasawara D, 2011, BIOORGAN MED CHEM, V19, P3702, DOI 10.1016/j.bmc.2010.12.024; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pajtler KW, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-19; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sareddy GR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24185; Sareddy GR, 2013, ONCOTARGET, V4, P18, DOI 10.18632/oncotarget.725; Sareddy GR, 2012, MOL CANCER THER, V11, P1174, DOI 10.1158/1535-7163.MCT-11-0960; Sato A, 2011, STEM CELLS, V29, P1942, DOI 10.1002/stem.753; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shao GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15344; Singh MM, 2011, NEURO-ONCOLOGY, V13, P894, DOI 10.1093/neuonc/nor049; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wang J, 2011, EURASIP J WIREL COMM, DOI 10.1155/2011/785437; Wang LW, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004021; Wang M., 2015, CAN J AGR ECON, V1, P1; Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016; Xie Q, 2015, ONCOTARGET, V6, P13241, DOI 10.18632/oncotarget.3676; Xu HM, 2014, J BIOL CHEM, V289, P26290, DOI 10.1074/jbc.M114.572560; Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zhang XC, 2007, INT J DEV NEUROSCI, V25, P455, DOI 10.1016/j.ijdevneu.2007.08.007; Zhao X, 2015, ANIM BIOL, V65, P1, DOI 10.1163/15707563-00002455; Zhao ZK, 2012, WORLD J GASTROENTERO, V18, P6651, DOI 10.3748/wjg.v18.i45.6651	74	51	51	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2423	2434		10.1038/onc.2016.395	http://dx.doi.org/10.1038/onc.2016.395			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27893719	Green Accepted			2022-12-28	WOS:000400268900008
J	Liao, YH; Chiang, KH; Shieh, JM; Huang, CR; Shen, CJ; Huang, WC; Chen, BK				Liao, Y-H; Chiang, K-H; Shieh, J-M; Huang, C-R; Shen, C-J; Huang, W-C; Chen, B-K			Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE 4; COLORECTAL-CANCER; FACTOR RECEPTOR; VASCULAR-PERMEABILITY; ACTIVATION; EXPRESSION; INVASION; ANGIOGENESIS; DEGRADATION; PROGRESSION	Epidermal growth factor (EGF) is important for cancer cell proliferation, angiogenesis and metastasis in many types of cancer. However, the mechanisms involved in EGF-induced head and neck squamous cell carcinoma (HNSCC) metastasis remain largely unknown. In this study, we reveal that angiopoietin-like 4 (ANGPTL4) plays an important role in the regulation of EGF-induced cancer metastasis. We showed that EGF-induced ANGPTL4 expression promoted anoikis resistance and cancer cell migration and invasion in HNSCC. In addition, depletion of ANGPTL4 inhibited EGF-induced cancer cell invasion. Autocrine production of EGF-induced ANGPTL4 regulated the expression of matrix metalloproteinases (MMPs). The induction of MMP-1 gene expression by ANGPTL4-activated integrin beta 1 signalling occurred through the AP-1 binding site in the MMP-1 gene promoter. Furthermore, down-regulation of MMP-1 impeded EGF- and recombinant ANGPTL4-enhanced HNSCC cell migration and invasion. Depletion of ANGPTL4 significantly blocked EGF-primed extravasation and metastatic seeding of tumour cells and MMP-1 expression in lungs. However, no effect of ANGPTL4 on tumour growth was observed. These results suggest that EGF-induced expression and autocrine production of ANGPTL4 enhances HNSCC metastasis via the up-regulation of MMP-1 expression. Inhibition of ANGPTL4 expression may be a potential strategy for the treatment of EGFR-mediated HNSCC metastasis.	[Liao, Y-H; Huang, C-R; Shen, C-J; Huang, W-C; Chen, B-K] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Chiang, K-H; Shieh, J-M] Chi Mei Med Ctr, Dept Chest Med, Tainan, Taiwan; [Huang, C-R] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Huang, W-C] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan; [Chen, B-K] Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan, Taiwan; [Chen, B-K] Taipei Med Univ, Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan	National Cheng Kung University; Chi Mei Hospital; Taipei Medical University; Academia Sinica - Taiwan; National Cheng Kung University; Taipei Medical University	Huang, WC; Chen, BK (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	wchuang1@gate.sinica.edu.tw; bkchen58@mail.ncku.edu.tw	Huang, Wan-Chen/N-2472-2019	Huang, Wan-Chen/0000-0002-7341-4373; Huang, Chi-Ruei/0000-0001-9646-8852; Chen, Ben-Kuen/0000-0002-4720-4364	Ministry of Science and Technology of Taiwan [NSC 102-2628-B-006- 011-MY3, MOST 105-2320-B-006-022-MY3]; National Cheng Kung University	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University	This work was supported by the Ministry of Science and Technology of Taiwan [Grant NSC 102-2628-B-006- 011-MY3; MOST 105-2320-B-006-022-MY3]; and National Cheng Kung University [the Headquarters of University Advancement]. We thank for the kind gift of MMP-1 gene promoter-PGL3 from Dr Ju-Ming Wang.	Akishima-Fukasawa Y, 2011, HISTOPATHOLOGY, V59, P470, DOI 10.1111/j.1365-2559.2011.03964.x; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796; Chang WC, 2015, ONCOTARGET, V6, P7741, DOI 10.18632/oncotarget.3482; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31; Kersten S, 2009, ARTERIOSCL THROM VAS, V29, P969, DOI 10.1161/ATVBAHA.108.182147; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Kuo TC, 2013, J CLIN INVEST, V123, P1082, DOI 10.1172/JCI64044; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Maekawa Yuichiro, 2011, Inflammation & Allergy Drug Targets, V10, P229; Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200; Masuelli L, 2012, J CELL PHYSIOL, V227, P3344, DOI 10.1002/jcp.24034; Mathieu M, 2014, J BIOL CHEM, V289, P8402, DOI 10.1074/jbc.M113.539825; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murata M, 2009, J ORTHOP RES, V27, P50, DOI 10.1002/jor.20703; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Sun Y, 2014, ONCOL LETT, V8, P211, DOI 10.3892/ol.2014.2071; Tanaka J, 2015, J ORAL PATHOL MED, V44, P126, DOI 10.1111/jop.12212; Terada LS, 2011, CANCER CELL, V19, P297, DOI 10.1016/j.ccr.2011.02.019; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Xiao YC, 2015, CANCER LETT, V361, P22, DOI 10.1016/j.canlet.2015.02.021; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175	41	40	41	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2228	2242		10.1038/onc.2016.371	http://dx.doi.org/10.1038/onc.2016.371			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27797381	Green Published, hybrid			2022-12-28	WOS:000399782700004
J	Smith, CIE				Smith, C. I. E.			From identification of the BTK kinase to effective management of leukemia	ONCOGENE			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS-TYROSINE-KINASE; X-LINKED AGAMMAGLOBULINEMIA; MANTLE-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; FACTOR-KAPPA-B; TEC-FAMILY; PH DOMAIN; IBRUTINIB RESISTANCE; INHIBITOR IBRUTINIB	BTK is a cytoplasmic protein-tyrosine kinase, whose corresponding gene was isolated in the early 1990s. BTK was initially identified by positional cloning of the gene causing X-linked agammaglobulinemia and independently in a search for new kinases. Given the phenotype of affected patients, namely lack of B-lymphocytes and plasma cells with the ensuing inability to mount humoral immune responses, BTK inhibitors were anticipated to have beneficial effects on antibody-mediated pathologies, such as autoimmunity. In contrast to, for example, the SRC-family of cytoplasmic kinases, there was no obvious way in which structural alterations would yield constitutively active forms of BTK, and such mutations were also not found in leukemias or lymphomas. In 2007, the first efficient inhibitor, ibrutinib, was reported and soon became approved both in the United States and in Europe for the treatment of three B-cell malignancies, mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Over the past few years, additional inhibitors have been developed, with acalabrutinib being more selective, and recently demonstrating fewer clinical adverse effects. The antitumor mechanism is also not related to mutations in BTK. Instead tumor residency in lymphoid organs is inhibited, making these drugs highly versatile. BTK is one of the only 10 human kinases that carry a cysteine in the adenosine triphosphate-binding cleft. As this allows for covalent, irreversible inhibitor binding, it provides these compounds with a highly advantageous character. This quality may be crucial and bodes well for the future of BTK-modifying medicines, which have been estimated to reach annual multi-billion dollar sales in the future.	[Smith, C. I. E.] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Clin Res Ctr, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital	Smith, CIE (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Clin Res Ctr, SE-14186 Huddinge, Sweden.	edvard.smith@ki.se		SMITH, C. I. Edvard/0000-0003-1907-3392	Swedish Cancer Society [CAN2013/389]; Swedish Medical Research Council [K2015-68X-11247-21-3]; Swedish County Council [ALF-project 2012006]	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish County Council	This work was supported by the Swedish Cancer Society (CAN2013/389), the Swedish Medical Research Council (K2015-68X-11247-21-3) and the Swedish County Council (ALF-project 2012006). I thank Anna Berglof, Qing Wang, Abdulrahman Hamasy and Rula Zain for their kind help and Anthony Wright, Birgitta Sander and Anders Osterborg for valuable comments on the manuscript.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Baba K, 1999, MOL CELL BIOL, V19, P4405; Baba Y, 2016, CURR TOP MICROBIOL, V393, P143, DOI 10.1007/82_2015_477; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Berglof A, 2015, SCAND J IMMUNOL, V82, P208, DOI 10.1111/sji.12333; Berglof A, 2013, EXPERT REV CLIN IMMU, V9, P1205, DOI 10.1586/1744666X.2013.850030; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brown JR, 2016, HAEMATOLOGICA, V101, P295, DOI 10.3324/haematol.2015.140806; BRUTON OC, 1952, PEDIATRICS, V9, P722; Burger JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11589; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chen SS, 2016, LEUKEMIA, V30, P833, DOI 10.1038/leu.2015.316; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; COHN E J, 1947, Praxis, V36, P280; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; COOPER MD, 1971, LANCET, V2, P791; Davids MS, 2012, OPEN J HEMATOL, V3, pi, DOI DOI 10.13055/OJHMT_3_S1_03; de Rooij MFM, 2015, BLOOD, V125, P2306, DOI 10.1182/blood-2014-12-619163; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Derudder E, 2016, P NATL ACAD SCI USA, V113, P5065, DOI 10.1073/pnas.1604529113; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Evans EK, 2013, J PHARMACOL EXP THER, V346, P219, DOI 10.1124/jpet.113.203489; Farooqui MZH, 2015, LANCET ONCOL, V16, P169, DOI 10.1016/S1470-2045(14)71182-9; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; GARDULF A, 1991, LANCET, V338, P162; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; GUIOLI S, 1989, HUM GENET, V84, P19, DOI 10.1007/BF00210664; Hamada N, 2005, FEBS LETT, V579, P4131, DOI 10.1016/j.febslet.2005.06.042; Hamada-Kawaguchi N, 2014, SCIENCE, V343, P294, DOI 10.1126/science.1244512; Hamasy A, 2017, LEUKEMIA, V31, P177, DOI 10.1038/leu.2016.153; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Jolles S, 2015, CLIN EXP IMMUNOL, V179, P146, DOI 10.1111/cei.12485; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; KWAN SP, 1990, GENOMICS, V6, P238, DOI 10.1016/0888-7543(90)90562-9; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; Maddocks K, 2015, BLOOD, V125, P242, DOI 10.1182/blood-2014-08-597914; Maddocks KJ, 2015, JAMA ONCOL, V1, P80, DOI 10.1001/jamaoncol.2014.218; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Martin P, 2016, BLOOD, V127, P1559, DOI 10.1182/blood-2015-10-673145; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Mohammad DK, 2013, MOL CELL BIOL, V33, P3214, DOI 10.1128/MCB.00247-13; Muller S, 1996, ONCOGENE, V13, P1955; NAOR D, 1969, AUST J EXP BIOL MED, V47, P759, DOI 10.1038/icb.1969.173; Nawaz HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035640; Noordzij JG, 2002, PEDIATR RES, V51, P159, DOI 10.1203/00006450-200202000-00007; O'Brien S, 2014, LANCET ONCOL, V15, P48, DOI 10.1016/S1470-2045(13)70513-8; Ortutay C, 2008, ADV GENET, V64, P51, DOI 10.1016/S0065-2660(08)00803-1; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANGER R, 1963, LANCET, V1, P859; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SMITH CIE, 1987, ANN CLIN RES, V19, P220; Smith CIE, 1997, ADV GENET, V35, P57, DOI 10.1016/S0065-2660(08)60448-4; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Smith CIE, 1996, IMMUNOL TODAY, V17, P495, DOI 10.1016/0167-5699(96)30063-7; Stiff A, 2016, CANCER RES, V76, P2125, DOI 10.1158/0008-5472.CAN-15-1490; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Tiselius A, 1937, BIOCHEM J, V31, P313, DOI 10.1042/bj0310313; Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Valiaho J, 2006, HUM MUTAT, V27, P1209, DOI 10.1002/humu.20410; Valiaho J, 2015, HUM MUTAT, V36, P638, DOI 10.1002/humu.22791; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Waldenstrom J, 1944, ACTA MED SCAND, V117, P216; Walter HS, 2016, BLOOD, V127, P411, DOI 10.1182/blood-2015-08-664086; Wang ML, 2016, LANCET ONCOL, V17, P48, DOI 10.1016/S1470-2045(15)00438-6; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Wilson WH, 2016, NEW ENGL J MED, V374, P386, DOI 10.1056/NEJMe1515235; Winkelstein JA, 2014, PRIMARY IMMUNODEFICIENCY DISORDERS: A HISTORIC AND SCIENTIFIC PERSPECTIVE, P128; Winqvist M, 2016, HAEMATOLOGICA, V101, P1573, DOI 10.3324/haematol.2016.144576; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Woyach JA, 2014, BLOOD, V123, P1207, DOI 10.1182/blood-2013-07-515361; Yang G, 2016, BLOOD, V127, P3237, DOI 10.1182/blood-2016-01-695098; Yigit B, 2016, ONCOTARGET, V7, P26346, DOI 10.18632/oncotarget.8378; Younes A, 2014, LANCET ONCOL, V15, P1019, DOI 10.1016/S1470-2045(14)70311-0; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Yu L, 2006, J BIOL CHEM, V281, P18201, DOI 10.1074/jbc.M603090200; ZECH L, 1983, INT J CANCER, V32, P431, DOI 10.1002/ijc.2910320406; ZECH L, 1984, NATURE, V308, P858, DOI 10.1038/308858a0; Zoncu R, 2009, CELL, V136, P1110, DOI 10.1016/j.cell.2009.01.032	99	38	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2045	2053		10.1038/onc.2016.343	http://dx.doi.org/10.1038/onc.2016.343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27669440	Green Published, hybrid			2022-12-28	WOS:000399782500001
J	Liu, CC; Cai, DL; Sun, F; Wu, ZH; Yue, B; Zhao, SL; Wu, XS; Zhang, M; Zhu, XW; Peng, ZH; Yan, DW				Liu, C-C; Cai, D-L; Sun, F.; Wu, Z-H; Yue, B.; Zhao, S-L; Wu, X-S; Zhang, M.; Zhu, X-W; Peng, Z-H; Yan, D-W			FERMT1 mediates epithelial-mesenchymal transition to promote colon cancer metastasis via modulation of beta-catenin transcriptional activity	ONCOGENE			English	Article							COLORECTAL-CANCER; KINDLIN-1; WNT; EXPRESSION; INHIBITION; CARCINOMA; ADHESION; COMPLEX; PROLIFERATION; KERATINOCYTES	We previously demonstrated that fermitin family member 1 (FERMT1) was significantly overexpressed in colon cancer (CC) and associated with poor metastasis-free survival. This study aimed to investigate the precise role of FERMT1 in CC metastasis and the mechanism by which FERMT1 is involved in the epithelial-mesenchymal transition (EMT). Correlations between FERMT1 and EMT markers (E-cadherin, Slug, N-cadherin and beta-catenin) were examined via immunohistochemistry in a cohort of CC tissues and adjacent normal colon mucosae. A series of in vitro and in vivo assays were performed to elucidate the function of FERMT1 in CC metastasis and underlying mechanisms. The upregulated expression of FERMT1 in CC tissues correlated positively with that of Slug, N-cadherin and beta-catenin, but correlated inversely with E-cadherin expression. Altered FERMT1 expression led to marked changes in the proliferation, migration, invasion and EMT markers of CC cells both in vitro and in vivo. Investigations of underlying mechanisms found that FERMT1 interacted directly with beta-catenin and activated the Wnt/beta-catenin signaling pathway by decreasing the phosphorylation level of beta-catenin, enhancing beta-catenin nuclear translocation and increasing the transcriptional activity of beta-catenin/TCF/LEF. Activation of the Wnt/beta-catenin pathway by CHIR99021 reversed the effect of FERMT1 knockdown, whereas inhibition of the Wnt/beta-catenin pathway by XAV939 impaired the effect of FERMT1 overexpression on EMT and cell motility. In conclusion, findings of this study suggest that FERMT1 activates the beta-catenin transcriptional activity to promote EMT in CC metastasis.	[Liu, C-C; Yue, B.; Zhao, S-L; Zhu, X-W; Peng, Z-H; Yan, D-W] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, 85 Wujin Rd, Shanghai 200080, Peoples R China; [Cai, D-L] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Drug Allocat Ctr, Sch Med, Shanghai, Peoples R China; [Sun, F.; Wu, X-S] Kunming Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 2, Kunming, Peoples R China; [Wu, Z-H] Qingdao Univ, Dept Hapatobiliary Surg, Affiliated Hosp, Qingdao, Peoples R China; [Zhang, M.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Pathol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Kunming Medical University; Qingdao University; Shanghai Jiao Tong University	Yan, DW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, 85 Wujin Rd, Shanghai 200080, Peoples R China.	yandw70@163.com			National Natural Science Foundation of China [81172328]; Medical Guidance Project of Shanghai Science and Technology Commission [114119a4600, 124119a1700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Guidance Project of Shanghai Science and Technology Commission	This work was supported by National Natural Science Foundation of China (no. 81172328) and Medical Guidance Project of Shanghai Science and Technology Commission (114119a4600) (124119a1700). We thank Jiachen Nan for her generous help.	Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Fagotto F, 2013, EMBO REP, V14, P422, DOI 10.1038/embor.2013.45; Fan JW, 2011, CLIN CANCER RES, V17, P2908, DOI 10.1158/1078-0432.CCR-10-2552; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Has C, 2008, BRIT J DERMATOL, V159, P1192, DOI 10.1111/j.1365-2133.2008.08760.x; Herz C, 2006, J BIOL CHEM, V281, P36082, DOI 10.1074/jbc.M606259200; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kern J S, 2007, J Pathol, V213, P462, DOI 10.1002/path.2253; Kiriyama K, 2013, ANTICANCER RES, V33, P167; Lai-Cheong JE, 2009, AM J PATHOL, V175, P1431, DOI 10.2353/ajpath.2009.081154; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Ma HX, 2015, TUMOR BIOL, V36, P4235, DOI 10.1007/s13277-015-3060-8; Mahawithitwong P, 2013, INT J ONCOL, V42, P1360, DOI 10.3892/ijo.2013.1838; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rognoni E, 2014, NAT MED, V20, P350, DOI 10.1038/nm.3490; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Sleeman JP, 2011, CELL, V145, DOI 10.1016/j.cell.2011.03.029; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Ussar S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000289; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Weng WH, 2015, INT J CANCER, V136, P493, DOI 10.1002/ijc.28722; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yan DW, 2010, BRIT J CANCER, V103, P961, DOI 10.1038/sj.bjc.6605870; Yu HY, 2014, CLIN CANCER RES, V20, P3434, DOI 10.1158/1078-0432.CCR-13-2952	43	70	71	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1779	1792		10.1038/onc.2016.339	http://dx.doi.org/10.1038/onc.2016.339			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27641329				2022-12-28	WOS:000398128900004
J	Daly, C; Castanaro, C; Zhang, W; Zhang, Q; Wei, Y; Ni, M; Young, TM; Zhang, L; Burova, E; Thurston, G				Daly, C.; Castanaro, C.; Zhang, W.; Zhang, Q.; Wei, Y.; Ni, M.; Young, T. M.; Zhang, L.; Burova, E.; Thurston, G.			FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling	ONCOGENE			English	Article							COMPARATIVE GENOMIC ANALYSIS; SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; GENE FUSIONS; LUNG-CANCER; CETUXIMAB; GROWTH; HEAD; ANTIBODY	The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment. However, as with other targeted therapies, intrinsic/acquired resistance mechanisms limit efficacy. In the FaDu HNSCC xenograft model, we show that combined blockade of EGFR and ERBB3 promotes rapid tumor regression, followed by the eventual outgrowth of resistant cells. RNA sequencing revealed that resistant cells express FGFR3-TACC3 fusion proteins, which were validated as drivers of the resistant phenotype by several approaches, including CRISPR-mediated inactivation of FGFR3-TACC3 fusion genes. Interestingly, analysis of signaling in resistant cell lines demonstrated that FGFR3-TACC3 fusion proteins promote resistance by preferentially substituting for EGFR/RAS/ERK signaling rather than ERBB3/PI3K/AKT signaling. Furthermore, although FGFR3-TACC3 fusion proteins promote resistance of additional EGFR-dependent HNSCC and lung cancer cell lines to EGFR blockade, they are unable to compensate for inhibition of PI3K signaling in PIK3CA-mutant HNSCC cell lines. Validation of FGFR3-TACC3 fusion proteins as endogenous drivers of resistance in our screen provides strong evidence that these fusions are capable of substituting for EGFR signaling. Thus, FGFR3-TACC3 fusion proteins may represent a novel mechanism of acquired resistance in EGFR-dependent cancers of multiple cell lineages.	[Daly, C.; Castanaro, C.; Zhang, W.; Zhang, Q.; Wei, Y.; Ni, M.; Young, T. M.; Zhang, L.; Burova, E.; Thurston, G.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA; [Zhang, Q.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA	Regeneron; Roche Holding; Genentech	Daly, C (corresponding author), Regeneron Pharmaceut Inc, Dept Oncol, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	christopher.daly@regeneron.com		Daly, Christopher/0000-0003-3800-8174; Thurston, Gavin/0000-0002-4105-5919	Regeneron Pharmaceuticals Inc.	Regeneron Pharmaceuticals Inc.(Regeneron)	We thank Elizabeth Pasnikowski, Chandrika Taduriyasas, Jennifer Espert and David D'Ambrosio for technical assistance and Neil Stahl and George Yancopoulos for helpful comments and suggestions. All research was fully supported by Regeneron Pharmaceuticals Inc.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Capelletti M, 2014, CLIN CANCER RES, V20, P6551, DOI 10.1158/1078-0432.CCR-14-1337; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; di Martino E, 2009, ONCOGENE, V28, P4306, DOI 10.1038/onc.2009.280; Di Stefano AL, 2015, CLIN CANCER RES, V21, P3307, DOI 10.1158/1078-0432.CCR-14-2199; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang S, 2013, CANCER RES, V73, P824, DOI 10.1158/0008-5472.CAN-12-1611; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Jiang N, 2014, MOL CANCER THER, V13, P1826, DOI 10.1158/1535-7163.MCT-13-1093; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Juanpere N, 2012, HUM PATHOL, V43, P1573, DOI 10.1016/j.humpath.2011.10.026; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Knowles MA, 2008, FUTURE ONCOL, V4, P71, DOI 10.2217/14796694.4.1.71; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LoRusso P, 2013, CLIN CANCER RES, V19, P3078, DOI 10.1158/1078-0432.CCR-12-3051; Marshall ME, 2011, CLIN CANCER RES, V17, P5016, DOI 10.1158/1078-0432.CCR-11-0050; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Nelson KN, 2016, MOL CANCER RES, V14, P458, DOI 10.1158/1541-7786.MCR-15-0497; Oliveras-Ferraros C, 2012, BRIT J CANCER, V106, P1406, DOI 10.1038/bjc.2012.103; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; [王如松 Wang Rusong], 2014, [生态学报, Acta Ecologica Sinica], V34, P1; Ware Kathryn E, 2010, PLoS One, V5, pe14117, DOI 10.1371/journal.pone.0014117; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Zhang L, 2014, MOL CANCER THER, V13, P1345, DOI 10.1158/1535-7163.MCT-13-1033	47	31	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					471	481		10.1038/onc.2016.216	http://dx.doi.org/10.1038/onc.2016.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345413	Green Published, hybrid			2022-12-28	WOS:000394166700004
J	De Martino, I; Visone, R; Fedele, M; Petrocca, F; Palmieri, D; Hoyos, JM; Forzati, F; Croce, CM; Fusco, A				De Martino, I.; Visone, R.; Fedele, M.; Petrocca, F.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Croce, C. M.; Fusco, A.			Regulation of microRNA expression by HMGA1 proteins (vol 28, pg 1432, 2009)	ONCOGENE			English	Correction															NCI NIH HHS [R35 CA197706] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA197706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		IDEMARTINO, 2009, ONCOGENE, V28, P1432, DOI DOI 10.1038/ONC.2008.495	1	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5817	5818		10.1038/onc.2016.136	http://dx.doi.org/10.1038/onc.2016.136			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27399337	Bronze			2022-12-28	WOS:000386998400012
J	Murray-Stewart, T; Sierra, JC; Piazuelo, MB; Mera, RM; Chaturvedi, R; Bravo, LE; Correa, P; Schneider, BG; Wilson, KT; Casero, RA				Murray-Stewart, T.; Sierra, J. C.; Piazuelo, M. B.; Mera, R. M.; Chaturvedi, R.; Bravo, L. E.; Correa, P.; Schneider, B. G.; Wilson, K. T.; Casero, R. A.			Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for Helicobacter pylori-induced gastric cancer	ONCOGENE			English	Article							ABERRANT DNA METHYLATION; HUMAN POLYAMINE OXIDASE; ULCERATIVE-COLITIS; EPITHELIAL-CELLS; INHIBITS PROLIFERATION; HYDROGEN-PEROXIDE; PROSTATE-CANCER; MICRORNA GENES; FIELD DEFECT; RISK	Chronic inflammation contributes to the development of various forms of cancer. The polyamine catabolic enzyme spermine oxidase (SMOX) is induced in chronic inflammatory conditions, including Helicobacter pylori-associated gastritis, where its production of hydrogen peroxide contributes to DNA damage and subsequent tumorigenesis. MicroRNA expression levels are also altered in inflammatory conditions; specifically, the tumor suppressor miR-124 becomes silenced by DNA methylation. We sought to determine if this repression of miR-124 is associated with elevated SMOX activity and concluded that miR-124 is indeed a negative regulator of SMOX. In gastric adenocarcinoma cells harboring highly methylated and silenced mir-124 gene loci, 5-azacytidine treatment allowed miR-124 re-expression and decreased SMOX expression. Overexpression of an exogenous miR-124-3p mimic repressed SMOX mRNA and protein expression as well as H2O2 production by >50% within 24 h. Reporter assays indicated that direct interaction of miR-124 with the 3 '-untranslated region of SMOX mRNA contributes to this negative regulation. Importantly, overexpression of miR-124 before infection with H. pylori prevented the induction of SMOX believed to contribute to inflammation-associated tumorigenesis. Compelling human in vivo data from H. pylori-positive gastritis tissues indicated that the mir-124 gene loci are more heavily methylated in a Colombian population characterized by elevated SMOX expression and a high risk for gastric cancer. Furthermore, the degree of mir-124 methylation significantly correlated with SMOX expression throughout the population. These results indicate a protective role for miR-124 through the inhibition of SMOX-mediated DNA damage in the etiology of H. pylori-associated gastric cancer.	[Murray-Stewart, T.; Casero, R. A.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Bldg,Room 551,1650 Orleans St, Baltimore, MD 21287 USA; [Sierra, J. C.; Piazuelo, M. B.; Mera, R. M.; Chaturvedi, R.; Correa, P.; Schneider, B. G.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN USA; [Chaturvedi, R.] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi, India; [Bravo, L. E.] Univ Valle, Sch Med, Dept Pathol, Cali, Colombia; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Johns Hopkins University; Johns Hopkins Medicine; Vanderbilt University; Jawaharlal Nehru University, New Delhi; Universidad del Valle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Casero, RA (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Bldg,Room 551,1650 Orleans St, Baltimore, MD 21287 USA.	rcasero@jhmi.edu	Stewart, Tracy Murray/B-6137-2017; Bravo, Luis Eduardo/G-9671-2013; Bravo, Luis Eduardo/AAB-7209-2019	Stewart, Tracy Murray/0000-0001-8679-6414; Bravo, Luis Eduardo/0000-0002-9708-0312; Casero, Robert/0000-0001-5653-3306; Wilson, Keith/0000-0003-4421-1830	National Institutes of Health [R01CA051085, R01CA098454, R01DK053620, R01CA190612, P01CA028842, P01CA116087, K01AT007324]; Samuel Waxman Cancer Research Foundation; Vanderbilt Digestive Disease Research Center [P30DK058404, UL1RR024975]; Office of Medical Research, Department of Veterans Affairs [1I01BX001453]; NATIONAL CANCER INSTITUTE [P01CA028842, P01CA116087, R01CA051085, R01CA190612, R01CA098454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; Vanderbilt Digestive Disease Research Center; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Alberto Delgado for his technical expertise and performance of SMOX immunohistochemistry studies. This study was supported by National Institutes of Health Grants R01CA051085 and R01CA098454 (to RAC), R01DK053620 and R01CA190612 (to KTW), P01CA028842 (to PC and KTW), P01CA116087 (to KTW), K01AT007324 (to RC), the Samuel Waxman Cancer Research Foundation (to RAC), the Vanderbilt Digestive Disease Research Center grant (P30DK058404), UL1RR024975 (Vanderbilt CTSA, Pilot Project to KTW) and Merit Review Grant 1I01BX001453 from the Office of Medical Research, Department of Veterans Affairs (to KTW).	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Asada K, 2015, GUT, V64, P388, DOI 10.1136/gutjnl-2014-307094; Babbar N, 2006, CANCER RES, V66, P11125, DOI 10.1158/0008-5472.CAN-06-3174; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camargo MC, 2004, HELICOBACTER, V9, P262, DOI 10.1111/j.1083-4389.2004.00221.x; Cervelli M, 2004, EUR J BIOCHEM, V271, P760, DOI 10.1111/j.1432-1033.2004.03979.x; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; Dalal RS, 2014, J LEUKOCYTE BIOL, V96, P213, DOI 10.1189/jlb.4BT0214-100R; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Ford Alexander C, 2014, BMJ, V348, pg3174, DOI 10.1136/bmj.g3174; Goodwin AC, 2008, PROSTATE, V68, P766, DOI 10.1002/pros.20735; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Goodwin CS, 1997, CLIN INFECT DIS, V25, P1017, DOI 10.1086/516077; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Hong SKS, 2010, INFLAMM BOWEL DIS, V16, P1557, DOI 10.1002/ibd.21224; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Malfertheiner P, 2005, AM J GASTROENTEROL, V100, P2100, DOI 10.1111/j.1572-0241.2005.41688.x; Murray-Stewart T, 2008, FEBS J, V275, P2795, DOI 10.1111/j.1742-4658.2008.06419.x; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4; Schneider BG, 2013, EPIGENETICS-US, V8, P1153, DOI 10.4161/epi.26072; Schneider BG, 2010, INT J CANCER, V127, P2588, DOI 10.1002/ijc.25274; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shimizu T, 2013, EUR UROL, V63, P1091, DOI 10.1016/j.eururo.2012.11.030; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Ueda Y, 2014, DIGEST DIS SCI, V59, P2444, DOI 10.1007/s10620-014-3193-4; Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011; Wang HY, 2015, ADV DRUG DELIVER REV, V81, P142, DOI 10.1016/j.addr.2014.10.031; Wang YL, 2001, CANCER RES, V61, P5370; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Xie LM, 2014, MOL CELL BIOCHEM, V392, P153, DOI 10.1007/s11010-014-2028-0; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511	50	39	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5480	5488		10.1038/onc.2016.91	http://dx.doi.org/10.1038/onc.2016.91			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041578	Green Accepted			2022-12-28	WOS:000386998200003
J	Graziano, S; Johnston, R; Deng, O; Zhang, J; Gonzalo, S				Graziano, S.; Johnston, R.; Deng, O.; Zhang, J.; Gonzalo, S.			Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence	ONCOGENE			English	Article							CATHEPSIN-L EXPRESSION; A-TYPE LAMINS; HOMOLOGOUS RECOMBINATION; BREAST-CANCER; DAMAGE RESPONSE; POLY(ADP-RIBOSE) POLYMERASE; GENOMIC INSTABILITY; CYSTEINE CATHEPSINS; CELLULAR SENESCENCE; CRITICAL MEDIATOR	Oncogenic Ras expression is associated with activation of the DNA damage response (DDR) pathway, as evidenced by elevated DNA damage, primarily DNA double-strand breaks (DSBs), and activation of DNA damage checkpoints, which in primary human cells leads to entry into senescence. DDR activation is viewed as a physiological barrier against uncontrolled proliferation in oncogenic Ras-expressing cells, and arises in response to genotoxic stress due to the production of reactive oxygen species that damage DNA and to hyper-replication stress. Although oncogene-induced senescence (OIS) is considered a tumor suppressor mechanism, the accumulation of DNA damage in senescent cells is thought to cause genomic instability, eventually allowing secondary hits in the genome that promote tumorigenesis. To date, the molecular mechanisms behind DNA repair defects during OIS remain poorly understood. Here, we show that oncogenic Ras expression in human primary cells results in the downregulation of BRCA1 and 53BP1, two key factors in DNA DSB repair by homologous recombination and non-homologous end joining, respectively. As a consequence, Ras-induced senescent cells are hindered in their ability to recruit BRCA1 and 53BP1 to DNA damage sites. Whereas BRCA1 is downregulated at transcripts levels, 53BP1 loss is caused by activation of cathepsin L-mediated degradation of 53BP1 protein. Moreover, we discovered a marked downregulation of vitamin D receptor (VDR) during OIS, and a role for the vitamin D/VDR axis regulating the levels of these DNA repair factors during OIS. This study reveals a new functional relationship between the oncogene Ras, the vitamin D/VDR axis and the expression of DNA repair factors, in the context of OIS. The observed deficiencies in DNA repair factors in senescent cells could contribute to the genomic instability that allows senescence bypass and tumorigenesis.	[Graziano, S.; Johnston, R.; Gonzalo, S.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1100S Grand Ave, St Louis, MO 63104 USA; [Deng, O.; Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA	Saint Louis University; Case Western Reserve University	Gonzalo, S (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1100S Grand Ave, St Louis, MO 63104 USA.	sgonzalo@slu.edu	Gonzalo, Susana/T-8275-2019	Graziano, Simona/0000-0003-2661-1240; Gonzalo, Susana/0000-0001-9631-1206; Johnston, Rachel/0000-0002-6738-813X; Deng, Ou/0000-0002-9933-1832	NATIONAL CANCER INSTITUTE [R01CA154625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094513] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA154625] Funding Source: Medline; NIGMS NIH HHS [R01 GM094513] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cao L, 2009, MOL CELL, V35, P534, DOI 10.1016/j.molcel.2009.06.037; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; Croke M, 2013, CELL CYCLE, V12, P3629, DOI 10.4161/cc.26582; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Deng CH, 2009, MOL ENDOCRINOL, V23, P226, DOI 10.1210/me.2008-0075; DENHARDT DT, 1987, ONCOGENE, V2, P55; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gonzalez-Suarez I, 2011, EMBO J, V30, P3383, DOI 10.1038/emboj.2011.225; Gonzalez-Suarez I, 2009, EMBO J, V28, P2414, DOI 10.1038/emboj.2009.196; Gonzalo S, 2014, J STEROID BIOCHEM, V144, P59, DOI 10.1016/j.jsbmb.2013.09.009; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Grotsky DA, 2013, J CELL BIOL, V200, P187, DOI 10.1083/jcb.201204053; Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Kass EM, 2010, CANCER CELL, V17, P423, DOI 10.1016/j.ccr.2010.04.021; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Klein HL, 2008, DNA REPAIR, V7, P686, DOI 10.1016/j.dnarep.2007.12.008; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lowndes NF, 2010, DNA REPAIR, V9, P1112, DOI 10.1016/j.dnarep.2010.07.012; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Narvaez CJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00213; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; Redwood AB, 2011, CELL CYCLE, V10, P3652, DOI 10.4161/cc.10.21.18201; Redwood AB, 2011, CELL CYCLE, V10, P2549, DOI 10.4161/cc.10.15.16531; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rozenchan PB, 2004, J STEROID BIOCHEM, V92, P89, DOI 10.1016/j.jsbmb.2004.05.007; Salomon DG, 2014, J NEURO-ONCOL, V118, P49, DOI 10.1007/s11060-014-1416-3; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Srinivasan M, 2011, J STEROID BIOCHEM, V123, P30, DOI 10.1016/j.jsbmb.2010.10.002; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Taber LM, 2009, J NUTR BIOCHEM, V20, P629, DOI 10.1016/j.jnutbio.2008.06.008; Tu ZG, 2013, CELL CYCLE, V12, P1653, DOI 10.4161/cc.24986; Tu ZG, 2011, DEV CELL, V21, P1077, DOI 10.1016/j.devcel.2011.10.010; Urbanelli L, 2010, MOL CELL BIOCHEM, V343, P49, DOI 10.1007/s11010-010-0497-3; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Yao S, 2013, J STEROID BIOCHEM, V136, P337, DOI 10.1016/j.jsbmb.2012.09.010; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhang JR, 2005, NAT STRUCT MOL BIOL, V12, P902, DOI 10.1038/nsmb991	61	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5362	5376		10.1038/onc.2016.77	http://dx.doi.org/10.1038/onc.2016.77			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041576	Green Accepted			2022-12-28	WOS:000386677800003
J	Obata, Y; Horikawa, K; Takahashi, T; Akieda, Y; Tsujimoto, M; Fletcher, JA; Esumi, H; Nishida, T; Abe, R				Obata, Y.; Horikawa, K.; Takahashi, T.; Akieda, Y.; Tsujimoto, M.; Fletcher, J. A.; Esumi, H.; Nishida, T.; Abe, R.			Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors	ONCOGENE			English	Article							C-KIT; ENDOPLASMIC-RETICULUM; INHIBITOR STI571; PI 3-KINASE; IMATINIB; MUTATIONS; ACTIVATION; MECHANISMS; RESISTANT; MEMBRANE	Gastrointestinal stromal tumors (GISTs) are caused by gain-of-function mutations in the Kit receptor tyrosine kinase. Most primary GIST patients respond to the Kit inhibitor imatinib, but this drug often becomes ineffective because of secondary mutations in the Kit kinase domain. The characteristic intracellular accumulation of imatinib-sensitive and - resistant Kit protein is well documented, but its relationship to oncogenic signaling remains unknown. Here, we show that in cancer tissue from primary GIST patients as well as in cell lines, mutant Kit accumulates on the Golgi apparatus, whereas normal Kit localizes to the plasma membrane (PM). In imatinib-resistant GIST with a secondary Kit mutation, Kit localizes predominantly on the Golgi apparatus. Both imatinib-sensitive and imatinib-resistant Kit (Kit(mut)) become fully auto-phosphorylated only on the Golgi and only if in a complex-glycosylated form. Kit(mut) accumulates on the Golgi during the early secretory pathway, but not after endocytosis. The aberrant kinase activity of Kit(mut) prevents its export from the Golgi to the PM. Furthermore, Kit(mut) on the Golgi signals and activates the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) pathway, signal transducer and activator of transcription 5 (STAT5), and the Mek-Erk pathway. Blocking the biosynthetic transport of Kit(mut) to the Golgi from the endoplasmic reticulum inhibits oncogenic signaling. PM localization of Kit(mut) is not required for its signaling. Activation of Src-family tyrosine kinases on the Golgi is essential for oncogenic Kit signaling. These results suggest that the Golgi apparatus serves as a platform for oncogenic Kit signaling. Our study demonstrates that Kit(mut)'s pathogenicity is related to its mislocalization, and may offer a new strategy for treating imatinib-resistant GISTs.	[Obata, Y.; Horikawa, K.; Akieda, Y.; Abe, R.] Tokyo Univ Sci, Res Inst Biomed Sci, Div Immunobiol, Yamazaki 2669, Noda, Chiba 2780022, Japan; [Takahashi, T.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka, Japan; [Tsujimoto, M.] Osaka Police Hosp, Dept Diagnost Pathol, Osaka, Osaka, Japan; [Fletcher, J. A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, J. A.] Harvard Med Sch, Boston, MA USA; [Esumi, H.] Tokyo Univ Sci, Res Inst Biomed Sci, Div Clin Res, Noda, Chiba, Japan; [Nishida, T.] Natl Canc Ctr, Chuo Ku, Tokyo, Japan	Tokyo University of Science; Osaka University; Osaka Police Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tokyo University of Science; National Cancer Center - Japan	Abe, R (corresponding author), Tokyo Univ Sci, Res Inst Biomed Sci, Div Immunobiol, Yamazaki 2669, Noda, Chiba 2780022, Japan.	rabe@rs.noda.tus.ac.jp		Akieda, Yuki/0000-0001-7899-3186	Japanese Ministry of Education, Culture, Sports, Science and Technology [16K18427, 16H05419, 15K06843]; Uehara Memorial Foundation; NOVARTIS FOUNDATION (Japan) for the Promotion of Science; Grants-in-Aid for Scientific Research [16K18427] Funding Source: KAKEN	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); NOVARTIS FOUNDATION (Japan) for the Promotion of Science(Novartis); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Eiji Miyoshi (Osaka University), Satoshi Owada (Tokai University), Dr Kazuo Kurokawa, and Dr Akihiko Nakano (RIKEN) for their helpful advice. We are grateful to Dr Rie Nakatsuka (Osaka University), Dr Shota Toyoshima, Dr Yasushi Hara, and Dr Isamu Shiina (Tokyo University of Science) for their helpful advice and sharing of materials throughout this study. This work was supported by a grant-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (16K18427 to YO, 16H05419 to TN, and 15K06843 to RA), a research grant from the Uehara Memorial Foundation (to YO and TN) and from the NOVARTIS FOUNDATION (Japan) for the Promotion of Science (to YO).	Agaimy A, 2013, INT J CLIN EXP PATHO, V6, P1839; Bahlawane C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0096-8; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Bosbach B, 2012, P NATL ACAD SCI USA, V109, pE2276, DOI 10.1073/pnas.1115240109; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Burger H, 2015, MOL PHARMACOL, V88, P477, DOI 10.1124/mol.114.097451; Chaix A, 2014, ONCOGENE, V33, P872, DOI 10.1038/onc.2013.12; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Debiec-Rychter M, 2006, EUR J CANCER, V42, P1093, DOI 10.1016/j.ejca.2006.01.030; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Edris B, 2013, P NATL ACAD SCI USA, V110, P3501, DOI 10.1073/pnas.1222893110; Emile JF, 2009, AM J SURG PATHOL, V33, P157, DOI 10.1097/PAS.0b013e3181883765; Fu D, 2014, NAT CHEM, V6, P615, DOI [10.1038/nchem.1961, 10.1038/NCHEM.1961]; Gibbs L, 2007, BBA-MOL CELL RES, V1773, P502, DOI 10.1016/j.bbamcr.2006.12.010; Gonzalez-Campora R, 2011, ANAL QUANT CYTOL, V33, P1; Gordon PM, 2010, J BIOL CHEM, V285, P14109, DOI 10.1074/jbc.M109.078592; Goss PE, 1995, CLIN CANCER RES, V1, P935; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Growney JD, 2005, BLOOD, V106, P721, DOI 10.1182/blood-2004-12-4617; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Jaramillo S, 2012, REV ESP ENFERM DIG, V104, P128, DOI 10.4321/s1130-01082012000300005; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kon S, 2013, J CLIN INVEST, V123, P1123, DOI 10.1172/JCI63711; Lasota J, 2008, HISTOPATHOLOGY, V53, P245, DOI 10.1111/j.1365-2559.2008.02977.x; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Ma PL, 2011, MOL CELL BIOL, V31, P4052, DOI 10.1128/MCB.05750-11; MAEDA H, 1992, DEVELOPMENT, V116, P369; Matsuda D, 2006, EXP CELL RES, V312, P1205, DOI 10.1016/j.yexcr.2006.02.003; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Nishida T, 2008, CANCER SCI, V99, P799, DOI 10.1111/j.1349-7006.2008.00727.x; Obata Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6715; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peterson MR, 2006, APPL IMMUNOHISTO M M, V14, P390, DOI 10.1097/01.pai.0000203038.33414.a3; Pulvirenti T, 2008, NAT CELL BIOL, V10, P912, DOI 10.1038/ncb1751; Ran LL, 2015, CANCER DISCOV, V5, P304, DOI 10.1158/2159-8290.CD-14-0985; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2006, LAB INVEST, V86, P981, DOI 10.1038/labinvest.3700466; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Schmidt-Arras D, 2014, J CELL SCI, V127, P341, DOI 10.1242/jcs.130294; SUCHY SF, 1995, HUM MOL GENET, V4, P2245, DOI 10.1093/hmg/4.12.2245; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Takahashi T, 2013, INT J CANCER, V133, P2737, DOI 10.1002/ijc.28282; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Vanderwinden JM, 2006, CELL SIGNAL, V18, P661, DOI 10.1016/j.cellsig.2005.06.008; von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025; Watanuki Z, 2014, BIOCHEM BIOPH RES CO, V455, P269, DOI 10.1016/j.bbrc.2014.11.003; Xiang ZF, 2007, MOL CELL BIOL, V27, P267, DOI 10.1128/MCB.01153-06; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	72	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3661	3672		10.1038/onc.2016.519	http://dx.doi.org/10.1038/onc.2016.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192400	Green Published, hybrid			2022-12-28	WOS:000404349700002
J	Vaquero, J; Ho-Bouldoires, THN; Claperon, A; Fouassier, L				Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Claperon, A.; Fouassier, L.			Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance	ONCOGENE			English	Review							BINDING PHOSPHOPROTEIN 50; ACTIN CYTOSKELETON REORGANIZATION; CXCR2 MACROMOLECULAR COMPLEX; CAMP-MEDIATED INHIBITION; BORDER NA+/H+ EXCHANGER; NUCLEAR NHERF1; CELL-PROLIFERATION; FACTOR-1 NHERF1; ASSOCIATING PROTEIN; KINASE ACTIVATION	The transmission of cellular information requires fine and subtle regulation of proteins that need to interact in a coordinated and specific way to form efficient signaling networks. The spatial and temporal coordination relies on scaffold proteins. Thanks to protein interaction domains such as PDZ domains, scaffold proteins organize multiprotein complexes enabling the proper transmission of cellular information through intracellular networks. NHERF1/EBP50 is a PDZ-scaffold protein that was initially identified as an organizer and regulator of transporters and channels at the apical side of epithelia through actin-binding ezrinmoesin-radixin proteins. Since, NHERF1/EBP50 has emerged as a major regulator of cancer signaling network by assembling cancerrelated proteins. The PDZ-scaffold EBP50 carries either anti-tumor or pro-tumor functions, two antinomic functions dictated by EBP50 expression or subcellular localization. The dual function of NHERF1/EBP50 encompasses the regulation of several major signaling pathways engaged in cancer, including the receptor tyrosine kinases PDGFR and EGFR, PI3K/PTEN/AKT and Wnt-beta-catenin pathways.	[Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Claperon, A.; Fouassier, L.] UPMC Univ Paris 06, Sorbonne Univ, CRSA, INSERM, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France; [Vaquero, J.; Nguyen Ho-Bouldoires, T. H.] Fdn ARC, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Fouassier, L (corresponding author), UPMC Univ Paris 06, Sorbonne Univ, CRSA, INSERM, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	laura.fouassier@inserm.fr	Vaquero, Javier/B-7147-2019; Fouassier, Laura/M-7556-2017	Vaquero, Javier/0000-0002-6020-6962; Fouassier, Laura/0000-0001-6377-5610	Ministere de l'Enseignement Superieur et de la Recherche; Fondation de France [2011-00025574, 2014 00047502]; Fondation ARC [DOC20130606463, PDF2014601431]; La Ligue National contre le Cancer [RS14/75-112]; GEFLUC; Spanish Association for the Study of the Liver (AEEH)	Ministere de l'Enseignement Superieur et de la Recherche; Fondation de France(Fondation de France); Fondation ARC; La Ligue National contre le Cancer; GEFLUC; Spanish Association for the Study of the Liver (AEEH)	THB was supported by the 'Ministere de l'Enseignement Superieur et de la Recherche', Fondation de France No. 2011-00025574 and Fondation ARC No. DOC20130606463. LF is supported by grants from Fondation de France (No. 2014 00047502), La Ligue National contre le Cancer (No. RS14/75-112) and GEFLUC. JV is recipient of two following postdoctoral fellowships from the Spanish Association for the Study of the Liver (AEEH) and the Fondation ARC No. PDF2014601431. The authors thank Yves Chretien for the graphic support.	Abeysundara N, 2014, DEV DYNAM, V243, P1554, DOI 10.1002/dvdy.24187; Accardi R, 2011, J VIROL, V85, P8208, DOI 10.1128/JVI.00114-11; Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Baeyens N, 2011, J CELL BIOCHEM, V112, P2574, DOI 10.1002/jcb.23183; Bartholow TL, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-12; Bellizzi A, 2015, INT J ONCOL, V46, P1214, DOI 10.3892/ijo.2014.2805; Bellizzi A, 2011, HISTOPATHOLOGY, V58, P1086, DOI 10.1111/j.1365-2559.2011.03844.x; Beltrami S, 2013, ANTICANCER RES, V33, P1; Boratko A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035595; Broere N, 2009, PFLUG ARCH EUR J PHY, V457, P1079, DOI 10.1007/s00424-008-0579-1; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Bryant DM, 2014, DEV CELL, V31, P171, DOI 10.1016/j.devcel.2014.08.027; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Cardone RA, 2012, MOL BIOL CELL, V23, P2028, DOI 10.1091/mbc.E11-11-0911; Chen JY, 2012, CELL DEATH DIFFER, V19, P1027, DOI 10.1038/cdd.2012.4; Cheng H, 2009, STRUCTURE, V17, P660, DOI 10.1016/j.str.2009.03.009; Cheng S, 2013, FEBS LETT, V587, P3289, DOI 10.1016/j.febslet.2013.08.026; Chiba H, 2006, J CELL BIOL, V175, P971, DOI 10.1083/jcb.200608012; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Claperon A, 2012, ONCOGENE, V31, P1376, DOI 10.1038/onc.2011.334; Cornez I, 2010, FEBS LETT, V584, P2681, DOI 10.1016/j.febslet.2010.04.056; Cortese MS, 2008, PROG BIOPHYS MOL BIO, V98, P85, DOI 10.1016/j.pbiomolbio.2008.05.007; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Du GF, 2016, ANTICANCER RES, V36, P1165; Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fang X-Y, 2015, J INVEST DERMATOL, V135, P1; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Fouassier L, 2005, EXP CELL RES, V306, P264, DOI 10.1016/j.yexcr.2005.02.011; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; Fouassier L, 2009, AM J PATHOL, V174, P869, DOI 10.2353/ajpath.2009.080079; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garbett D, 2010, J CELL BIOL, V191, P397, DOI 10.1083/jcb.201004115; Garcia GG, 2007, J IMMUNOL, V179, P6403, DOI 10.4049/jimmunol.179.10.6403; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Georgescu MM, 2016, NEOPLASIA, V18, P512, DOI 10.1016/j.neo.2016.07.003; Georgescu MM, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0197-z; Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004; Georgescu MM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1992; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Good MC, 2011, SCIENCE, V332, P680, DOI 10.1126/science.1198701; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hanono A, 2006, J CELL BIOL, V175, P803, DOI 10.1083/jcb.200604046; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Ho-Bouldoires THN, 2015, FREE RADICAL BIO MED, V89, P34, DOI 10.1016/j.freeradbiomed.2015.07.011; Hou YN, 2015, STEM CELL RES, V14, P133, DOI 10.1016/j.scr.2014.12.001; Hsu YH, 2010, AM J PATHOL, V176, P3050, DOI 10.2353/ajpath.2010.090539; Hughes SC, 2010, J CELL SCI, V123, P1099, DOI 10.1242/jcs.059469; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Ji MY, 2012, J MOL HISTOL, V43, P517, DOI 10.1007/s10735-012-9424-0; Jiang YY, 2014, BIOCHEM BIOPH RES CO, V446, P638, DOI 10.1016/j.bbrc.2014.03.028; Karn T, 2011, BREAST CANCER RES TR, V130, P409, DOI 10.1007/s10549-010-1333-x; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kishore R, 2005, J CLIN INVEST, V115, P1785, DOI 10.1172/JCI22849; Kislin KL, 2009, NEOPLASIA, V11, P377, DOI 10.1593/neo.81572; Kocher O, 1999, LAB INVEST, V79, P1161; Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Kremer KN, 2015, J BIOL CHEM, V290, P29478, DOI 10.1074/jbc.M115.668160; Langeberg LK, 2015, NAT REV MOL CELL BIO, V16, P232, DOI 10.1038/nrm3966; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee HH, 2015, AM J CANCER RES, V5, P2944; Leslie KL, 2013, J BIOL CHEM, V288, P36426, DOI 10.1074/jbc.M113.483339; Li HL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0162-x; Li JQ, 2007, J BIOL CHEM, V282, P27086, DOI 10.1074/jbc.M702019200; Lim H, 2016, ONCOTARGET, V7, P10283, DOI 10.18632/oncotarget.7184; Lin YY, 2012, J CLIN INVEST, V122, P1881, DOI 10.1172/JCI45661; Liu H, 2015, IEEE T IND INFORM, V11, P406, DOI 10.1109/TII.2015.2397878; Liu L, 2012, J BIOL CHEM, V287, P43312, DOI 10.1074/jbc.M112.422766; Kreimann EL, 2015, ONCOL LETT, V10, P3722, DOI 10.3892/ol.2015.3796; Lu G., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1016/J.M0L-MET.2013.07.005.(IN; Malfettone A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-106; Malfettone A, 2012, EXP MOL PATHOL, V92, P296, DOI 10.1016/j.yexmp.2012.03.004; Mangia A, 2015, CANCER BIOL THER, V16, P1140, DOI 10.1080/15384047.2015.1056414; Mangia A, 2015, MOL BIOTECHNOL, V57, P549, DOI 10.1007/s12033-015-9848-3; Mangia A, 2012, ONCOL REP, V28, P889, DOI 10.3892/or.2012.1895; Mangia A, 2009, HISTOPATHOLOGY, V55, P600, DOI 10.1111/j.1365-2559.2009.03424.x; Mangia A, 2011, HUM PATHOL, V42, P1589, DOI 10.1016/j.humpath.2011.01.010; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Meng R, 2016, ONCOTARGET; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Paradiso A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.439; Peng ZQ, 2016, INT J ONCOL, V49, P1737, DOI 10.3892/ijo.2016.3655; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Schirosi L, 2016, ONCOTARGET; Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-362; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; Sheng R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2221; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Smith PM, 2003, ENDOCRINE, V22, P119, DOI 10.1385/ENDO:22:2:119; Song GJ, 2015, J BIOL CHEM, V290, P2879, DOI 10.1074/jbc.M114.609768; Song GJ, 2012, J MOL CELL CARDIOL, V53, P809, DOI 10.1016/j.yjmcc.2012.08.022; Song GJ, 2012, ARTERIOSCL THROM VAS, V32, P33, DOI 10.1161/ATVBAHA.111.235200; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stalker TJ, 2009, J THROMB HAEMOST, V7, P1886, DOI 10.1111/j.1538-7836.2009.03606.x; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stokka AJ, 2010, BIOCHEM J, V425, P381, DOI 10.1042/BJ20091136; Sun CY, 2013, MOL CELLS, V36, P47, DOI 10.1007/s10059-013-0014-0; Sun LC, 2016, FASEB J, V30, P578, DOI 10.1096/fj.15-275586; Tabrizi AD, 2010, INT J GYNECOL PATHOL, V29, P99, DOI 10.1097/PGP.0b013e3181bbbcc1; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tan PC, 2006, STEM CELLS, V24, P1150, DOI 10.1634/stemcells.2005-0426; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vitureira N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012003; Voltz JW, 2007, J BIOL CHEM, V282, P33879, DOI 10.1074/jbc.M703481200; Vondriska TM, 2004, J MOL CELL CARDIOL, V37, P391, DOI 10.1016/j.yjmcc.2004.04.021; Wang B, 2008, MOL BIOL CELL, V19, P1637, DOI 10.1091/mbc.E07-11-1114; Wang L, 2014, EUR REV MED PHARMACO, V18, P3854; Wang S, 2013, TRANSL ONCOL, V6, P216, DOI 10.1593/tlo.13133; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Weinman EJ, 2010, J BIOL CHEM, V285, P25134, DOI 10.1074/jbc.M110.132423; Weinman EJ, 2010, J BIOL CHEM, V285, P13454, DOI 10.1074/jbc.M109.094359; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Wheeler DS, 2011, ONCOGENE, V30, P32, DOI 10.1038/onc.2010.389; Wu YN, 2012, J BIOL CHEM, V287, P5744, DOI 10.1074/jbc.M111.315762; Yang LY, 2011, ENDOCRINOLOGY, V152, P4537, DOI 10.1210/en.2011-1207; Yao WF, 2012, AMINO ACIDS, V43, P2027, DOI 10.1007/s00726-012-1277-z; Yin G, 2011, BRIT J DERMATOL, V164, P1043, DOI 10.1111/j.1365-2133.2010.10192.x; Yonglitthipagon P, 2012, HUM PATHOL, V43, P1719, DOI 10.1016/j.humpath.2011.11.021; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	151	53	57	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3067	3079		10.1038/onc.2016.462	http://dx.doi.org/10.1038/onc.2016.462			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068322				2022-12-28	WOS:000402617900001
J	Bogoevska, V; Wolters-Eisfeld, G; Hofmann, BT; El Gammal, AT; Mercanoglu, B; Gebauer, F; Vashist, YK; Bogoevski, D; Perez, D; Gagliani, N; Izbicki, JR; Bockhorn, M; Gungor, C				Bogoevska, V.; Wolters-Eisfeld, G.; Hofmann, B. T.; El Gammal, A. T.; Mercanoglu, B.; Gebauer, F.; Vashist, Y. K.; Bogoevski, D.; Perez, D.; Gagliani, N.; Izbicki, J. R.; Bockhorn, M.; Guengoer, C.			HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer	ONCOGENE			English	Article							ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; N-WASP; PROTEIN; GROWTH; TRANSCRIPTION; NETWORK; TARGETS	Colorectal cancer (CRC) is a complex disease with still unsatisfactory prognosis even in western societies, although substantial progress has been made in pre-screening programs, surgical techniques and targeted therapy options. Mediator of motility-1 (Memo-1) was previously recognized as an important effector of cell migration downstream of receptor tyrosine kinase signaling in breast cancer. This study identified Memo-1 as frequently overexpressed in CRC and established a close link between extracellular HER2 activation, AhR/ARNT transcriptional activity and Memo-1 expression. Dissection of the hMemo-1 gene promoter using reporter assays and chromatin IP techniques revealed recruitment of Aryl hydrocarbon receptor (AhR)/Aryl hydrocarbon receptor nuclear-translocator (ARNT) complex, which positively influenced Memo-1 expression in cancer cells. We found that Memo-1 depletion negatively influenced the cellular actin network and that its expression is required for HER2-mediated cell migration and invasion. Moreover, analyses of Memo-1 expression in primary CRC revealed correlation with clinical parameters that point to Memo-1 as a new prognostic factor of aggressive disease in CRC patients. Altogether, these observations demonstrate that Memo-1 is an important downstream regulator of HER2-driven CRC cell migration and invasion through connecting extracellular signals from membrane to the cytoskeletal actin network.	[Bogoevska, V.] Cardiologicum Hamburg Res & Study Ctr, Hamburg, Germany; [Bogoevska, V.; Wolters-Eisfeld, G.; Hofmann, B. T.; El Gammal, A. T.; Mercanoglu, B.; Gebauer, F.; Vashist, Y. K.; Bogoevski, D.; Perez, D.; Gagliani, N.; Izbicki, J. R.; Bockhorn, M.; Guengoer, C.] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany; [Vashist, Y. K.] Kantonsspital Aarau AG, Sect Visceral Surg, Dept Surg, Aarau, Switzerland; [Gagliani, N.] Univ Med Ctr, Dept Med, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Kantonsspital Aarau AG (KSA); University of Hamburg; University Medical Center Hamburg-Eppendorf	Gungor, C (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany.	c.guengoer@uke.de	Vashist, Yogesh/AFH-9205-2022; Vashist, Yogesh/AAF-3529-2022; Wolters-Eisfeld, Gerrit/H-8333-2019; Vashist, Yogesh/ABE-4001-2020	Wolters-Eisfeld, Gerrit/0000-0002-2984-6515; Perez, Daniel/0000-0002-3154-7311; Gagliani, Nicola/0000-0001-8514-1395	'Roggenbuck Foundation', Hamburg, Germany	'Roggenbuck Foundation', Hamburg, Germany	We thank A Heinecke, P Merkert and P Schroder for excellent technical assistance and Dr M Linnebacher for providing primary CRC cells. This work (CG) was partially funded by the 'Roggenbuck Foundation', Hamburg, Germany.	Applewhite DA, 2007, MOL BIOL CELL, V18, P2579, DOI 10.1091/mbc.e06-11-0990; Atlas E, 2003, MOL CANCER RES, V1, P165; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Carvajal-Gonzalez JM, 2009, MOL BIOL CELL, V20, P1715, DOI 10.1091/mbc.E08-05-0451; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gramatzki D, 2009, ONCOGENE, V28, P2593, DOI 10.1038/onc.2009.104; Gungor C, 2007, P NATL ACAD SCI USA, V104, P15000, DOI 10.1073/pnas.0703738104; Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839; Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang K, 2013, J BIOL CHEM, V288, P24590, DOI 10.1074/jbc.M113.467837; Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630; Kovacs EM, 2011, NAT CELL BIOL, V13, P934, DOI 10.1038/ncb2290; Lai DW, 2014, ONCOTARGET, V5, P7788, DOI 10.18632/oncotarget.2307; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; MacDonald G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004870; Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Momeny M, 2015, ONCOTARGET, V6, P3932, DOI 10.18632/oncotarget.2846; Oberlander M, 2013, LANGENBECK ARCH SURG, V398, P251, DOI 10.1007/s00423-012-1043-4; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Qiu C, 2008, J BIOL CHEM, V283, P2734, DOI 10.1074/jbc.M703523200; Rawnaq T, 2014, MOL CANCER RES, V12, P670, DOI 10.1158/1541-7786.MCR-13-0467; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Romiti A, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0496-z; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327; Stier S, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/271246; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Yang MH, 2011, LEUKEMIA LYMPHOMA, V52, P298, DOI 10.3109/10428194.2010.538776; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107; Zegers Mirjam M, 2014, Small GTPases, V5, pe28997, DOI 10.4161/sgtp.28997; Zhao S, 2013, CANCER LETT, V330, P41, DOI 10.1016/j.canlet.2012.11.021	39	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2394	2404		10.1038/onc.2016.390	http://dx.doi.org/10.1038/onc.2016.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27941874				2022-12-28	WOS:000400268900006
J	Blomme, A; Costanza, B; de Tullio, P; Thiry, M; Van Simaeys, G; Boutry, S; Doumont, G; Di Valentin, E; Hirano, T; Yokobori, T; Gofflot, S; Peulen, O; Bellahcene, A; Sherer, F; Le Goff, C; Cavalier, E; Mouithys-Mickalad, A; Jouret, F; Cusumano, PG; Lifrange, E; Muller, RN; Goldman, S; Delvenne, P; De Pauw, E; Nishiyama, M; Castronovo, V; Turtoi, A				Blomme, A.; Costanza, B.; de Tullio, P.; Thiry, M.; Van Simaeys, G.; Boutry, S.; Doumont, G.; Di Valentin, E.; Hirano, T.; Yokobori, T.; Gofflot, S.; Peulen, O.; Bellahcene, A.; Sherer, F.; Le Goff, C.; Cavalier, E.; Mouithys-Mickalad, A.; Jouret, F.; Cusumano, P. G.; Lifrange, E.; Muller, R. N.; Goldman, S.; Delvenne, P.; De Pauw, E.; Nishiyama, M.; Castronovo, V.; Turtoi, A.			Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer	ONCOGENE			English	Article							TRAFFICKING; ENDOCYTOSIS; ENDOSOME; PROTEINS; CAVEOLAE; REVEALS; BIOLOGY; GROWTH; CELLS	Myoferlin is a multiple C2-domain-containing protein that regulates membrane repair, tyrosine kinase receptor function and endocytosis in myoblasts and endothelial cells. Recently it has been reported as overexpressed in several cancers and shown to contribute to proliferation, migration and invasion of cancer cells. We have previously demonstrated that myoferlin regulates epidermal growth factor receptor activity in breast cancer. In the current study, we report a consistent overexpression of myoferlin in triple-negative breast cancer cells (TNBC) over cells originating from other breast cancer subtypes. Using a combination of proteomics, metabolomics and electron microscopy, we demonstrate that myoferlin depletion results in marked alteration of endosomal system and metabolism. Mechanistically, myoferlin depletion caused impaired vesicle traffic that led to a misbalance of saturated/unsaturated fatty acids. This provoked mitochondrial dysfunction in TNBC cells. As a consequence of the major metabolic stress, TNBC cells rapidly triggered AMP activated protein kinase-mediated metabolic reprogramming to glycolysis. This reduced their ability to balance between oxidative phosphorylation and glycolysis, rendering TNBC cells metabolically inflexible, and more sensitive to metabolic drug targeting in vitro. In line with this, our in vivo findings demonstrated a significantly reduced capacity of myoferlin-deficient TNBC cells to metastasise to lungs. The significance of this observation was further supported by clinical data, showing that TNBC patients whose tumors overexpress myoferlin have worst distant metastasis-free and overall survivals. This novel insight into myoferlin function establishes an important link between vesicle traffic, cancer metabolism and progression, offering new diagnostic and therapeutic concepts to develop treatments for TNBC patients.	[Blomme, A.; Costanza, B.; Peulen, O.; Bellahcene, A.; Castronovo, V.; Turtoi, A.] Univ Liege, Metastasis Res Lab, GIGA Canc, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium; [Costanza, B.; Yokobori, T.; Nishiyama, M.; Turtoi, A.] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [de Tullio, P.] Univ Liege, CIRM, Liege, Belgium; [Thiry, M.] Univ Liege, Lab Cell Biol, Fac Sci, Liege, Belgium; [Van Simaeys, G.; Boutry, S.; Doumont, G.; Sherer, F.; Muller, R. N.; Goldman, S.] Ctr Microscopy & Mol Imaging, Charleroi, Belgium; [Van Simaeys, G.; Goldman, S.] Univ Libre Bruxelles, Dept Nucl Med, Hop Erasme, Brussels, Belgium; [Boutry, S.; Muller, R. N.] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Di Valentin, E.] Univ Liege, GIGA Viral Vectors Platform, Liege, Belgium; [Hirano, T.] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Gofflot, S.] Univ Liege, BIOTHEQUE, Liege, Belgium; [Le Goff, C.; Cavalier, E.] Univ Liege, Univ Hosp, Dept Clin Chem, Liege, Belgium; [Mouithys-Mickalad, A.] Univ Liege, Ctr Oxygen Res & Dev, Liege, Belgium; [Jouret, F.] Univ Liege, GIGA Cardiovasc Sci, Liege, Belgium; [Cusumano, P. G.; Lifrange, E.] Univ Liege, Univ Hosp, Dept Senol, Liege, Belgium; [Delvenne, P.] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium; [De Pauw, E.; Turtoi, A.] Univ Liege, Mass Spectrometry Lab, Liege, Belgium	University of Liege; Gunma University; University of Liege; University of Liege; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons; University of Liege; Gunma University; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Turtoi, A (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium.	a.turtoi@ulg.ac.be	Cavalier, Etienne/E-8661-2011; Blomme, Arnaud/AAM-1440-2020; Peulen, Olivier/C-1250-2018; Blomme, Arnaud/AGO-7915-2022; Costanza, Brunella/AAB-6354-2022; De Tullio, Pascal/ABE-5585-2021; Turtoi, Andrei/ABD-1271-2021; Van Simaeys, Gaetan/AAR-8082-2020	Cavalier, Etienne/0000-0003-0947-2226; Peulen, Olivier/0000-0002-6933-0134; Blomme, Arnaud/0000-0003-4183-8726; Turtoi, Andrei/0000-0003-3813-6635; Van Simaeys, Gaetan/0000-0002-2678-542X; Costanza, Brunella/0000-0001-8279-805X; Di Valentin, Emmanuel/0000-0002-5287-7950; De Pauw, Edwin/0000-0003-3475-1315	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS); Fonds Erasme; Convention de Recherche Association Vincotte Nuclear-AVN; Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund; Wallonia (FEDER)	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds Erasme; Convention de Recherche Association Vincotte Nuclear-AVN; Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund(European Commission); Wallonia (FEDER)	We acknowledge the experimental support of Dr Chantal Humblet and Mrs Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese (GIGA-imaging platform, ULg), Mr Vincent Hennequiere and Mrs Naima Maloujahmoum (Metastasis Research Laboratory) for experimental support. We are also thankful to the institutional Biobank of the University Hospital Liege for providing patient material. Mr Mathieu Roch (CMMI) is thanked for his help in tumor volume measurements on MR images. We are grateful to Mrs Marie-Aline Laute and Mr Nicolas Passon, the Cyclotron team (Erasme Hospital, Brussels, Belgium) and Dr. Bolag Altan (Gunma University) for technical assistance. The results shown in this work are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was supported with grants from the University of Liege (Concerted Research Action Program (IDEA project)), National Fund for Scientific Research (FNRS), Fonds Erasme, Convention de Recherche Association Vincotte Nuclear-AVN and Gunma University (GIAR Research Program for Omics-Based Medical Science). Andrei Turtoi and Arnaud Blomme are post-doctoral research fellows (FNRS/Televie), Akeila Bellahcene and Pascal de Tullio are senior research associates (FNRS). The Center for Microscopy and Molecular Imaging (CMMI) as well as Gilles Doumont are supported by the European Regional Development Fund and Wallonia (FEDER). No funding bodies had any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Antonescu CN, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016964; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Chen JLY, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000293; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Griguer CE, 2005, J NEURO-ONCOL, V74, P123, DOI 10.1007/s11060-004-6404-6; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hullin-Matsuda F, 2014, SEMIN CELL DEV BIOL, V31, P48, DOI 10.1016/j.semcdb.2014.04.010; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kiss AL, 2012, ADV EXP MED BIOL, V729, P14, DOI 10.1007/978-1-4614-1222-9_2; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Leung C, 2013, AM J PATHOL, V182, P1900, DOI 10.1016/j.ajpath.2013.01.041; Li RG, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0037127, 10.1371/journal.pone.0029392, 10.1371/journal.pone.0051897]; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Matheus N, 2014, PHYTOCHEM ANALYSIS, V25, P342, DOI 10.1002/pca.2498; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Miccheli A, 2006, BIOCHIMIE, V88, P437, DOI 10.1016/j.biochi.2005.10.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Toole SA, 2013, J CLIN PATHOL, V66, P530, DOI 10.1136/jclinpath-2012-201361; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Penzo D, 2002, BBA-BIOENERGETICS, V1555, P160, DOI 10.1016/S0005-2728(02)00272-4; Pilch PF, 2011, TRENDS ENDOCRIN MET, V22, P318, DOI 10.1016/j.tem.2011.04.001; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029; Sachen KL, 2012, BLOOD, V120, P4182, DOI 10.1182/blood-2012-05-427534; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; Unger RH, 2010, BBA-MOL CELL BIOL L, V1801, P209, DOI 10.1016/j.bbalip.2009.10.006; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Volakis LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086110; Wang WS, 2013, J PROTEOMICS, V91, P453, DOI 10.1016/j.jprot.2013.06.032; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928	44	36	37	3	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2116	2130		10.1038/onc.2016.369	http://dx.doi.org/10.1038/onc.2016.369			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27775075				2022-12-28	WOS:000399782500008
J	Tominaga, K; Shimamura, T; Kimura, N; Murayama, T; Matsubara, D; Kanauchi, H; Niida, A; Shimizu, S; Nishioka, K; Tsuji, EI; Yano, M; Sugano, S; Shimono, Y; Ishii, H; Saya, H; Mori, M; Akashi, K; Tada, KI; Ogawa, T; Tojo, A; Miyano, S; Gotoh, N				Tominaga, K.; Shimamura, T.; Kimura, N.; Murayama, T.; Matsubara, D.; Kanauchi, H.; Niida, A.; Shimizu, S.; Nishioka, K.; Tsuji, E-I; Yano, M.; Sugano, S.; Shimono, Y.; Ishii, H.; Saya, H.; Mori, M.; Akashi, K.; Tada, K-I; Ogawa, T.; Tojo, A.; Miyano, S.; Gotoh, N.			Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells	ONCOGENE			English	Article							NF-KAPPA-B; SIGNALING PATHWAYS; HUMAN MAMMARY; ID PROTEINS; EXPRESSION; INSULIN; INFLAMMATION; POPULATIONS; METASTASIS; REGULATORS	The transcription factor nuclear factor-kappa B (NF-kappa B) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-kappa B activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1R(high) CSC-enriched population in a patient-derived xenograft model. Thus, NF-kappa B may trigger IGF2-ID1-IGF2-positive feedback circuits that allow cancer stem-like cells to appear. Then, they may become addicted to the circuits. As the circuits are the Achilles' heels of CSCs, it will be critical to break them for eradication of CSCs.	[Tominaga, K.; Kimura, N.; Murayama, T.; Tojo, A.; Gotoh, N.] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan; [Tominaga, K.] Japan Soc Promot Sci, Tokyo, Japan; [Shimamura, T.; Niida, A.; Miyano, S.] Univ Tokyo, Inst Med Sci, Lab DNA informat Anal, Minato Ku, Tokyo, Japan; [Murayama, T.; Gotoh, N.] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan; [Murayama, T.; Sugano, S.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Funct Genom,Minato Ku, Tokyo, Japan; [Matsubara, D.] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Minato Ku, Tokyo, Japan; [Kanauchi, H.] Showa Gen Hosp, Dept Breast & Endocrine Surg, Kodaira, Tokyo, Japan; [Shimizu, S.] Showa Gen Hosp, Dept Pathol Diag, Kodaira, Tokyo, Japan; [Nishioka, K.; Tsuji, E-I; Tada, K-I; Ogawa, T.] Univ Tokyo, Grad Sch Med, Dept Breast & Endocrine Surg, Bunkyo Ku, Tokyo, Japan; [Yano, M.] Minami Machida Hosp, Dept Surg, Machida, Tokyo, Japan; [Shimono, Y.] Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Kobe, Hyogo, Japan; [Ishii, H.] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan; [Saya, H.] Keio Univ, Grad Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo, Japan; [Mori, M.] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan; [Akashi, K.] Kyushu Univ, Grad Sch Med, Dept Med & Biosyst Sci, Fukuoka, Japan	University of Tokyo; Japan Society for the Promotion of Science; University of Tokyo; Kanazawa University; University of Tokyo; University of Tokyo; University of Tokyo; Kobe University; Osaka University; Keio University; Osaka University; Kyushu University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan.; Gotoh, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	ngotoh@ims.u-tokyo.ac.jp	Ishii, Hideshi/AAV-5317-2020; GOTOH, Noriko/D-8430-2015; Saya, Hideyuki/J-4325-2013	Shimono, Yohei/0000-0002-6256-4704; Shimamura, Teppei/0000-0003-2994-872X; Saya, Hideyuki/0000-0001-6610-1902; Gotoh, Noriko/0000-0003-3733-260X; Murayama, Takahiko/0000-0003-0764-8646; Miyano, Satoru/0000-0002-1753-6616; Tominaga, Kana/0000-0001-5136-5091	MEXT [22130009]; JSPS [15H04294]; Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control; JSPS; Grants-in-Aid for Scientific Research [15K14381] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Nakauchi, Y Ishii and A Fujita for their help with flow cytometry. We are grateful to A Umezawa for his kind gift of DHMEQ. We are grateful to S Akinaga and N Shiraishi in Kyowa Hakko Kirin Co. Ltd for their kind gift of KM1468. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT (22130009), a Grant-in-Aid for Scientific Research (B) from JSPS (15H04294) and a research grant from the Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control (to NG). This work was supported by Grant-in-Aid for JSPS Fellows (to KT).	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; AJCC, 2010, CANC STAGING MANUAL; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Badve S, 2012, LANCET ONCOL, V13, pE43, DOI 10.1016/S1470-2045(11)70191-7; Bair E, 2006, J AM STAT ASSOC, V101, P119, DOI 10.1198/016214505000000628; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gombos A, 2012, INVEST NEW DRUG, V30, P2433, DOI 10.1007/s10637-012-9811-0; Gotoh N, 2011, CANC STEM CELLS THEO, P261; Goya M, 2004, CANCER RES, V64, P6252, DOI 10.1158/0008-5472.CAN-04-0919; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hinohara K, 2010, CURR OPIN PHARMACOL, V10, P650, DOI 10.1016/j.coph.2010.08.003; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Lewitzky M, 2007, CURR OPIN BIOTECH, V18, P467, DOI 10.1016/j.copbio.2007.09.007; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Miyamoto S, 2005, CLIN CANCER RES, V11, P3494, DOI 10.1158/1078-0432.CCR-04-1701; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Murayama T, 2016, CANCER RES, V76, P974, DOI 10.1158/0008-5472.CAN-15-2135; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643; Perry SS, 2007, BLOOD, V110, P2351, DOI 10.1182/blood-2007-01-069914; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Sottoriva A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001132; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Wee ZN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9746; Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yi TF, 2014, P NATL ACAD SCI USA, V111, pE2182, DOI 10.1073/pnas.1404943111; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29	51	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1276	1286		10.1038/onc.2016.293	http://dx.doi.org/10.1038/onc.2016.293			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546618	Green Published, hybrid			2022-12-28	WOS:000395861300011
J	Witt, AE; Lee, CW; Lee, TI; Azzam, DJ; Wang, B; Caslini, C; Petrocca, F; Grosso, J; Jones, M; Cohick, EB; Gropper, AB; Wahlestedt, C; Richardson, AL; Shiekhattar, R; Young, RA; Ince, TA				Witt, A. E.; Lee, C-W; Lee, T. I.; Azzam, D. J.; Wang, B.; Caslini, C.; Petrocca, F.; Grosso, J.; Jones, M.; Cohick, E. B.; Gropper, A. B.; Wahlestedt, C.; Richardson, A. L.; Shiekhattar, R.; Young, R. A.; Ince, T. A.			Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; TUMOR-INITIATING CELLS; POOR-PROGNOSIS; EXPRESSION; DIFFERENTIATION; INHIBITOR; MIR-34A; BENZAMIDE; SIGNATURE; CARCINOMA	Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are resistant to conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest in CSCs, it has been difficult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present evidence that specific histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumour-cells (nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into CSC-specific therapies.	[Witt, A. E.; Wang, B.; Caslini, C.; Grosso, J.; Jones, M.; Ince, T. A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr,Dept Pathol, Braman Family Breast Canc Inst,Interdisciplinary, Miami, FL 33136 USA; [Lee, C-W; Cohick, E. B.; Richardson, A. L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Lee, T. I.; Cohick, E. B.; Gropper, A. B.; Young, R. A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Azzam, D. J.; Wahlestedt, C.] Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Dept Psychiat & Behav Sci, Miami, FL 33136 USA; [Petrocca, F.] Harvard Med Sch, Dept Pediat, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA; [Shiekhattar, R.] Univ Miami, Miller Sch Med, Dept Human Genet, Sylvester Comprehens Canc, Biomed Res Bldg, Miami, FL 33136 USA	University of Miami; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Miami; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Miami	Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst,Dept Pathol,TA I, Braman Family Breast Canc Inst,Sylvester Comprehe, Biomed Res Bldg BRB Room 907, Miami, FL 33136 USA.	TInce@med.miami.edu	Azzam, Diana/ABB-8342-2021; Caslini, Corrado/W-6123-2019; Young, Richard A/F-6495-2012	Azzam, Diana/0000-0002-2605-8855; Caslini, Corrado/0000-0001-8326-8368; Young, Richard A/0000-0001-8855-8647; Cohick, Evan/0000-0002-0824-9148; Ince, Tan/0000-0003-0315-6425	Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; Women's Cancer Association; DoD-CDMRP Ovarian Cancer Research Program Resource Development Grant [W81XWH-14-1-0160, OC130649]; National Cancer Institute, Roadmap Epigenomics project [R01-CA146445-01]; NATIONAL CANCER INSTITUTE [R01CA146445, K22CA184244, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM105754, R01GM078455] Funding Source: NIH RePORTER	Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; Women's Cancer Association; DoD-CDMRP Ovarian Cancer Research Program Resource Development Grant; National Cancer Institute, Roadmap Epigenomics project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded by grants from: (1) Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami (TAI); (2) Breast Cancer Research Foundation, New York, NY (TAI); (3) Women's Cancer Association (TAI); (4) DoD-CDMRP Ovarian Cancer Research Program (W81XWH-14-1-0160) Resource Development Grant OC130649 (TAI), and (5) National Cancer Institute, Roadmap Epigenomics project (R01-CA146445-01) to TAI, TIL and RAY. We thank Jayanta Debnath for his help with 3D morphogenesis assays, Dr Antonello Mai for providing MC1575, Chuck Harrell for help with mRNA expression array analysis, P.L. Guevara for help with FACs analysis, Noriyuki Kasahara and Sara Collins for transduction of OCI-P5x cell line with luciferase and F. Reinhardt for technical assistance.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558; Beckers T, 2007, INT J CANCER, V121, P1138, DOI 10.1002/ijc.22751; Belsky DW, 2013, JAMA PSYCHIAT, V70, P534, DOI 10.1001/jamapsychiatry.2013.736; Boissinot M, 2012, LEUKEMIA RES, V36, P1304, DOI 10.1016/j.leukres.2012.07.002; Carrasco E, 2014, EUR J CLIN INVEST, V44, P678, DOI 10.1111/eci.12276; Chikamatsu K, 2013, CANCER SCI, V104, P1468, DOI 10.1111/cas.12271; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Clocchiatti A, 2013, FASEB J, V27, P942, DOI 10.1096/fj.12-209346; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Debeb BG, 2012, STEM CELLS, V30, P2366, DOI 10.1002/stem.1219; Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694; Gao HF, 2013, J NEURO-ONCOL, V113, P221, DOI 10.1007/s11060-013-1119-1; Garcia-Manero G, 2008, BLOOD, V112, P981, DOI 10.1182/blood-2007-10-115873; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Higashijima J, 2011, ONCOL REP, V26, P343, DOI 10.3892/or.2011.1312; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419; Jiao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042564; Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r65; Kasler HG, 2011, J IMMUNOL, V186, P4782, DOI 10.4049/jimmunol.1001179; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151; Kok M, 2009, J PATHOL, V218, P316, DOI 10.1002/path.2544; Leth-Larsen R, 2012, MOL MED, V18, P1109, DOI 10.2119/molmed.2012.00091; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; McCool KW, 2007, J BIOL CHEM, V282, P6696, DOI 10.1074/jbc.M609519200; Merritt MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080314; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019; Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a; Munster PN, 2001, CANCER RES, V61, P8492; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rowehl RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099091; Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877; Sauder CAM, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-20; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674; Vincent A, 2012, BBA-REV CANCER, V1826, P83, DOI 10.1016/j.bbcan.2012.03.009; Wang Y, 2015, AM J TRANSL RES, V7, P111; Williams K, 2013, EXP BIOL MED, V238, P324, DOI 10.1177/1535370213480714; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495; Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Zhang L, 2010, J BIOL CHEM, V285, P38463, DOI 10.1074/jbc.M110.153999; Zhu CH, 2011, J MOL MED, V89, P279, DOI 10.1007/s00109-010-0701-7	59	97	102	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1707	1720		10.1038/onc.2016.337	http://dx.doi.org/10.1038/onc.2016.337			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27694895	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000397460600010
J	Hu, Y; Su, H; Liu, C; Wang, Z; Huang, L; Wang, Q; Liu, S; Chen, S; Zhou, J; Li, P; Chen, Z; Liu, H; Qing, G				Hu, Y.; Su, H.; Liu, C.; Wang, Z.; Huang, L.; Wang, Q.; Liu, S.; Chen, S.; Zhou, J.; Li, P.; Chen, Z.; Liu, H.; Qing, G.			DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-SECRETASE INHIBITORS; MULTIPLE-MYELOMA; BETA-TRCP; INCREASES CHEMOSENSITIVITY; GLUCOCORTICOID RESISTANCE; UBIQUITIN LIGASE; MTOR INHIBITOR; ACTIVATION; EXPRESSION	Aberrant activation of NOTCH1 signaling plays a vital role in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). Yet the molecular events downstream of NOTCH1 that drive T-cell leukemogenesis remain incompletely understood. Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies. Mechanistically, we demonstrated NOTCH1 directly bound to and activated the human DEPTOR promoter in T-ALL cells. DEPTOR depletion abolished cellular proliferation, attenuated glycolytic metabolism and enhanced cell death, while ectopically expressed DEPTOR significantly promoted cell growth and glycolysis. We further showed that DEPTOR depletion inhibited while its overexpression enhanced AKT activation in T-ALL cells. Importantly, AKT inhibition completely abrogated DEPTOR-mediated cell growth advantages. Moreover, DEPTOR depletion in a human T-ALL xenograft model significantly delayed T-ALL onset and caused a substantial decrease of AKT activation in leukemic blasts. We thus reveal a novel mechanism involved in NOTCH1-driven leukemogenesis, identifying the transcriptional control of DEPTOR and its regulation of AKT as additional key elements of the leukemogenic program activated by NOTCH1.	[Hu, Y.; Liu, C.; Wang, Z.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China; [Su, H.; Chen, Z.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China; [Huang, L.; Zhou, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China; [Wang, Q.; Chen, S.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis,Minist Hlth, Suzhou, Peoples R China; [Liu, S.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat Hematol, Wuhan, Peoples R China; [Li, P.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, South China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China; [Liu, H.; Qing, G.] Wuhan Univ, Inst Med Res, 185 Donghu Rd, Wuhan 430071, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Soochow University - China; Huazhong University of Science & Technology; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Wuhan University	Liu, H; Qing, G (corresponding author), Wuhan Univ, Inst Med Res, 185 Donghu Rd, Wuhan 430071, Peoples R China.	hudanliu@whu.edu.cn; qingguoliang@whu.edu.cn	Li, Peng/AER-7520-2022; Huang, Liang/I-3299-2019; Huang, Liang/L-6106-2013	Huang, Liang/0000-0002-8370-3232; Huang, Liang/0000-0002-8370-3232; Li, Peng/0000-0003-4530-2400	National Natural Science Foundation of China [81470332, 81272211, 81372205]; New Investigator Foundation, State Education Ministry of China [20120142120097]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Investigator Foundation, State Education Ministry of China	We thank Drs Warren Pear (University of Pennsylvania, Philadelphia, PA, US), Hongbing Shu and Zan Huang (Wuhan University, Wuhan, People's Republic of China), Yi Sun (Zhejiang University, Hangzhou, People's Republic of China) for sharing reagents. This work was supported by grants from the National Natural Science Foundation of China, 81470332 and 81272211 to HL, and 81372205 to GQ and New Investigator Foundation, State Education Ministry of China 20120142120097 to HL.	Bruneau S, 2013, BLOOD, V122, P1833, DOI 10.1182/blood-2013-03-488486; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hu YF, 2015, MOL CANCER THER, V14, P289, DOI 10.1158/1535-7163.MCT-14-0501; Khwaja SS, 2010, J CLIN INVEST, V120, P2537, DOI 10.1172/JCI41277; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Laplante M, 2012, CELL METAB, V16, P202, DOI 10.1016/j.cmet.2012.07.008; Liu HD, 2010, GENE DEV, V24, P2395, DOI 10.1101/gad.1975210; Lu B, 2015, CELL MOL LIFE SCI, V72, P821, DOI 10.1007/s00018-014-1704-2; Margolin AA, 2009, P NATL ACAD SCI USA, V106, P244, DOI 10.1073/pnas.0806445106; Medyouf H, 2011, J EXP MED, V208, P1809, DOI 10.1084/jem.20110121; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Meng ZX, 2013, NAT MED, V19, P640, DOI 10.1038/nm.3144; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Paganin M, 2011, BLOOD REV, V25, P83, DOI 10.1016/j.blre.2010.09.004; Palomero T, 2008, CLIN CANCER RES, V14, P5314, DOI 10.1158/1078-0432.CCR-07-4864; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Proud CG, 2009, J MOL CELL BIOL, V1, P61, DOI 10.1093/jmcb/mjp012; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109; Real PJ, 2009, NAT MED, V15, P50, DOI 10.1038/nm.1900; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Schnell SA, 2015, BLOOD, V125, P2806, DOI 10.1182/blood-2014-10-608448; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; van Stralen E, 2009, EXP HEMATOL, V37, P78, DOI 10.1016/j.exphem.2008.08.006; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang HF, 2011, P NATL ACAD SCI USA, V108, P14908, DOI 10.1073/pnas.1109023108; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xiao YR, 2015, HAEMATOLOGICA, V100, P585, DOI 10.3324/haematol.2014.118612; Ye W, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0156-y; Zhang HR, 2013, J INT MED RES, V41, P584, DOI 10.1177/0300060513480920; Zhang HR, 2013, INT J MOL MED, V31, P1127, DOI 10.3892/ijmm.2013.1299; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029	46	30	32	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1038	1047		10.1038/onc.2016.275	http://dx.doi.org/10.1038/onc.2016.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593934				2022-12-28	WOS:000395371500002
J	Hwang, MH; Cho, KH; Jeong, KJ; Park, YY; Kim, JM; Yu, SL; Park, CG; Mills, GB; Lee, HY				Hwang, M. H.; Cho, K. H.; Jeong, K. J.; Park, Y-Y; Kim, J. M.; Yu, S-L; Park, C. G.; Mills, G. B.; Lee, H. Y.			RCP induces Slug expression and cancer cell invasion by stabilizing beta 1 integrin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRIN BETA-1; HUMAN BREAST; OVARIAN; SNAIL; OVEREXPRESSION; METASTASIS; MIGRATION; ADHESION; LEADS	Rab coupling protein (RCP)-induced tumor cell migration has been implicated in tumor pathophysiology and patient outcomes. In the present study, we demonstrate that RCP stabilizes beta 1 integrin leading to increased beta 1 integrin levels and activation of a signaling cascade culminating in Slug induction, epithelial-to-mesenchymal transition and increased invasion. Ectopic expression of RCP induced Slug expression. Silencing beta 1 integrin efficiently inhibited RCP-induced Slug expression and subsequent cancer cell invasion. Conversely, ectopic expression of beta 1 integrin was sufficient to induce Slug expression. Pharmacological inhibition of integrin linked kinase ( ILK), EGFR and NF-kappa B, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly inhibited RCP-induced Slug expression and cancer cell invasion. Strikingly, ectopic expression of RCP was sufficient to enhance metastasis of ovarian cancer cells to the lung. Collectively, we demonstrate a mechanism by which RCP promotes cancer cell aggressiveness through sequential beta 1 integrin stabilization, activation of an ILK/EGFR/Ras/NF-kappa B signaling cascade and subsequent Slug expression.	[Hwang, M. H.; Cho, K. H.; Yu, S-L; Park, C. G.; Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, 821 Myunggok Med Bldg,158 Gwanjeodong Ro, Daejeon 35365, South Korea; [Hwang, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA; [Jeong, K. J.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Park, Y-Y] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci,Dept Convergence Med, Seoul, South Korea; [Kim, J. M.] Chungnam Natl Univ, Reg Canc Ctr, Canc Res Inst, Sch Med, Daejeon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Infect Signaling Network Res Ctr, Sch Med, Daejeon, South Korea	Konyang University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Ulsan; Asan Medical Center; Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Coll Med, Dept Pharmacol, 821 Myunggok Med Bldg,158 Gwanjeodong Ro, Daejeon 35365, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022	Mills, Gordon/0000-0002-0144-9614; KIM, JIN MAN/0000-0003-0905-9730	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2014R1A2A1A11051091]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This study was supported by a grant from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2014R1A2A1A11051091).	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Arboleda MJ, 2003, CANCER RES, V63, P196; Azimifar SB, 2012, J CELL SCI, V125, P435, DOI 10.1242/jcs.091652; Braune S, 2015, CLIN HEMORHEOL MICRO, V61, P225, DOI 10.3233/CH-151995; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Choi MJ, 2015, ONCOGENE, V34, P3402, DOI 10.1038/onc.2014.270; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; Ju LX, 2013, CANCER BIOMARK, V13, P329, DOI 10.3233/CBM-130362; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Krishnan M, 2013, MOL BIOL CELL, V24, P818, DOI 10.1091/mbc.E12-10-0745; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Lee M, 2010, INT J RADIAT ONCOL, V76, P1528, DOI 10.1016/j.ijrobp.2009.11.022; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Rhee CM, 2016, NEPHROL DIAL TRANSPL, V31, P992, DOI 10.1093/ndt/gfv341; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Toguri JT, 2015, CLIN HEMORHEOL MICRO, V61, P237, DOI 10.3233/CH-151996; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622	34	32	32	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1102	1111		10.1038/onc.2016.277	http://dx.doi.org/10.1038/onc.2016.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524413				2022-12-28	WOS:000395371500008
J	Kao, YC; Jheng, JR; Pan, HJ; Liao, WY; Lee, CH; Kuo, PL				Kao, Y-C; Jheng, J-R; Pan, H-J; Liao, W-Y; Lee, C-H; Kuo, P-L			Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling	ONCOGENE			English	Article							INTERSTITIAL FLUID PRESSURE; PROGNOSTIC-FACTORS; CERVIX CANCER; METASTASIS; TUMOR; MIGRATION; ACTIVATION; MELANOMA; INVASION; PATHWAYS	The mechanical characteristics presented in cancer microenvironment are known to have pivotal roles in cancer metastasis, which accounts for the leading cause of death from malignant tumors. However, while a uniformly distributed high interstitial fluid pressure (IFP) is a common feature in solid tumors, the effects of high IFP on the motility and invasiveness of cancer cells remain obscure. Using cell-culture devices that simulated increased IFP conditions by applying hydrostatic pressure (HP) ranging from 0 to 20 mm Hg to the cells, we found that the elevated HPs increased the migration speeds, invasiveness, cell volume, filopodial number and aquaporin-1 (AQP1), Snail and vinculin expression levels, as well as phosphorylation of caveolin-1 and extracellular signalregulated kinase1/2 (ERK1/2), in the lung cancer cells CL1-5 and A549. The increases of migration speed and cell volume correlated temporally with the increase of AQP1 expression. The elevated HP-induced migration acceleration was hindered by AQP1 knockdown using small interfering RNA (siRNA) transfection. Inhibition of ERK1/2 phosphorylation using the mitogen-activated protein kinase kinase inhibitor PD98059 abrogated the elevated HP-induced AQP1 upregulation and migration acceleration in the cancer cells. Caveolin-1 knockdown by siRNA transfection attenuated the HP-induced, ERK1/2-depedent AQP1 upregulation and migration acceleration. Further biochemical studies revealed that the caveolin-1 activation-driven ERK1/2 signaling is mediated by Akt1/2 phosphorylation. By contrast, the elevated HPs had negligible effects on the migration speed and volume of normal bronchial epithelial cells. These results disclose a novel mechanism relating high IFP to the invasiveness of cancer cells and highlight potential targets to impede cancer spreading.	[Kao, Y-C; Jheng, J-R; Kuo, P-L] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 10617, Taiwan; [Kao, Y-C; Pan, H-J; Lee, C-H] Acad Sinica, Res Ctr Appl Sci, 128,Sec 2,Acad Rd, Taipei 11529, Taiwan; [Liao, W-Y] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Liao, W-Y] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Lee, C-H] Natl Yang Ming Univ, Inst Biophoton, Taipei, Taiwan; [Lee, C-H] Natl Taiwan Univ, Dept Phys, Taipei, Taiwan; [Kuo, P-L] Natl Taiwan Univ, Dept Elect Engn, Taipei, Taiwan; [Kuo, P-L] Natl Taiwan Univ Hosp, Dept Rehabil, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Kuo, PL (corresponding author), Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 10617, Taiwan.; Lee, CH (corresponding author), Acad Sinica, Res Ctr Appl Sci, 128,Sec 2,Acad Rd, Taipei 11529, Taiwan.	clee@gate.sinica.edu.tw; poling@ntu.edu.tw	Lee, Chau-Hwang/B-2204-2008; Liao, Wei-Yu/HGE-3881-2022	Lee, Chau-Hwang/0000-0001-5013-7062; LIAO, WEI-YU/0000-0001-6383-3470	Taiwan Ministry of Science of Technology [MOST 102-2221-E-002-066, 103-2320-B-002-004-MY3, 103-2112-M-001-019-MY3]	Taiwan Ministry of Science of Technology	This work was supported by the grants from the Taiwan Ministry of Science of Technology (Grant Nos. MOST 102-2221-E-002-066, 103-2320-B-002-004-MY3 and 103-2112-M-001-019-MY3).	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Arciszewski MB, 2011, ANN ANAT, V193, P81, DOI 10.1016/j.aanat.2010.11.003; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; BOUCHER Y, 1990, CANCER RES, V50, P4478; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; CURTI BD, 1993, CANCER RES, V53, P2204; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Dubroca C, 2007, CARDIOVASC RES, V73, P190, DOI 10.1016/j.cardiores.2006.10.020; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Fyles A, 2006, RADIOTHER ONCOL, V80, P132, DOI 10.1016/j.radonc.2006.07.014; Gomes LR, 2015, ONCOGENE, V34, P5329, DOI 10.1038/onc.2014.461; Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hoque MO, 2006, AM J PATHOL, V168, P1345, DOI 10.2353/ajpath.2006.050596; Hu J, 2006, FASEB J, V20, P1892, DOI 10.1096/fj.06-5930fje; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Ji L, 2008, NAT CELL BIOL, V10, P1393, DOI 10.1038/ncb1797; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kelley LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013847; Kovbasnjuk O, 2005, P NATL ACAD SCI USA, V102, P19087, DOI 10.1073/pnas.0506474102; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Liao WY, 2015, J PATHOL, V235, P50, DOI 10.1002/path.4421; Liou YR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089767; Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212; Luo DX, 2010, BIOCHEM BIOPH RES CO, V391, P1693, DOI 10.1016/j.bbrc.2009.12.132; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Merikallio H, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-104; Milosevic M, 2001, CANCER RES, V61, P6400; Muriel O, 2011, J CELL SCI, V124, P2763, DOI 10.1242/jcs.080804; Nicchia GP, 2013, J MOL MED, V91, P613, DOI 10.1007/s00109-012-0977-x; Pan SH, 2011, J CLIN INVEST, V121, P3189, DOI 10.1172/JCI42975; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512; Radel C, 2005, AM J PHYSIOL-HEART C, V288, pH936, DOI 10.1152/ajpheart.00519.2004; Ribatti D, 2014, BBA-GEN SUBJECTS, V1840, P1550, DOI 10.1016/j.bbagen.2013.09.025; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rofstad EK, 2002, CANCER RES, V62, P661; Rubashkin MG, 2014, CANCER RES, V74, P4597, DOI 10.1158/0008-5472.CAN-13-3698; Rubin K, 2000, INT J CANCER, V86, P636, DOI 10.1002/(SICI)1097-0215(20000601)86:5<636::AID-IJC6>3.0.CO;2-R; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stroka KM, 2014, CELL, V157, P611, DOI 10.1016/j.cell.2014.02.052; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wang CC, 2011, LAB CHIP, V11, P695, DOI 10.1039/c0lc00155d; Wang CC, 2009, OPT LETT, V34, P3538, DOI 10.1364/OL.34.003538; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Zhang BF, 2007, CELL SIGNAL, V19, P1690, DOI 10.1016/j.cellsig.2007.03.005	52	21	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					863	874		10.1038/onc.2016.255	http://dx.doi.org/10.1038/onc.2016.255			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27499095				2022-12-28	WOS:000394168200013
J	Saini, U; Naidu, S; ElNaggar, AC; Bid, HK; Wallbillich, JJ; Bixel, K; Bolyard, C; Suarez, AA; Kaur, B; Kuppusamy, P; Hays, J; Goodfellow, PJ; Cohn, DE; Selvendiran, K				Saini, U.; Naidu, S.; ElNaggar, A. C.; Bid, H. K.; Wallbillich, J. J.; Bixel, K.; Bolyard, C.; Suarez, A. A.; Kaur, B.; Kuppusamy, P.; Hays, J.; Goodfellow, P. J.; Cohn, D. E.; Selvendiran, K.			Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target	ONCOGENE			English	Article							SIGNAL TRANSDUCER; CURCUMIN ANALOG; ANTITUMOR; CELLS; HO-3867; INHIBITOR; ACTIVATION; APOPTOSIS; MODEL; PHOSPHORYLATION	Although activation of the STAT3 pathway has been associated with tumor progression in a wide variety of cancer types (including ovarian cancer), the precise mechanism of invasion and metastasis due to STAT3 are not fully delineated in ovarian cancer. We found that pSTAT3 Tyr705 is constitutively activated in patient ascites and ascites-derived ovarian cancer cells (ADOCCs), and the range of STAT3 expression could be very high to low. In vivo transplantation of ADOCCs with high pSTAT3 expression into the ovarian bursa of mice resulted in a large primary tumor and widespread peritoneal metastases. In contrast, ADOCCs with low STAT3 expression or ADOCCs with STAT3 expression knockdown, led to reduced tumor growth and an absence of metastases in vivo. Cytokines derived from the ADOCC culture medium activate the interleukin (IL)-6/STAT pathway in the STAT3 knockout (KO) cells, compensating for the absence of inherent STAT3 in the cells. Treatment with HO-3867 (a novel STAT3 inhibitor at 100 p.p.m. in an orthotopic murine model) significantly suppressed ovarian tumor growth, angiogenesis and metastasis by targeting STAT3 and its downstream proteins. HO-3867 was found to have cytotoxic effects in ex vivo cultures of freshly collected human ovarian cancers, including those resistant to platinum-based chemotherapy. Our results show that STAT3 is necessary for ovarian tumor progression/metastasis and highlight the potential for targeting STAT3 by HO-3867 as a therapeutic strategy for ovarian cancer.	[Saini, U.; Naidu, S.; ElNaggar, A. C.; Bid, H. K.; Wallbillich, J. J.; Bixel, K.; Suarez, A. A.; Hays, J.; Goodfellow, P. J.; Cohn, D. E.; Selvendiran, K.] Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Div Gynecol Oncol, Columbus, OH 43210 USA; [Bolyard, C.; Kaur, B.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Kuppusamy, P.] Dartmouth Med Sch, Dept Radiol, Hanover, NH USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Dartmouth College	Cohn, DE; Selvendiran, K (corresponding author), Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Div Gynecol Oncol, Columbus, OH 43210 USA.	david.cohn@osumc.edu; selvendiran.karuppaiyah@osumc.edu	Hays, John/H-3968-2012; ElNaggar, Adam/V-6999-2019	ElNaggar, Adam/0000-0003-3409-583X; Cohn, David/0000-0002-3036-6172; Wallbillich, John/0000-0001-5913-8088	Ovarian Cancer Research Fund (OCRF); NCI [RO1-CA176078]; Drug Development Institute pilot grant; OSU CCC Internal grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD085817] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA163205, R01CA176078, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund (OCRF); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Drug Development Institute pilot grant; OSU CCC Internal grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr John Hays for his willingness to pre-review this manuscript and provide valuable comments and suggestions. We also thank Dr Vinay Puduvalli and his lab members (including Jihong Xu) for providing access to their vibrating microtome. We extend additional thanks to Dr Mitch Phelps and Dr Yonghua Ling of the Pharmacoanalytical Shared Resource (PhASR), for LC MS analysis of drug bioabsorption and metabolism. The authors are also thankful to the undergraduate students Ross Wanner, Riley Maria, Roman Zingarelli and Jack Fowler for the cell culture and basic assay help. This work was funded by Ovarian Cancer Research Fund (OCRF), NCI RO1-CA176078 grant and Drug Development Institute pilot grant (KS and DEC), and OSU CCC Internal grant to DEC.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Bill MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-165; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Cheng XL, 2010, BIOORGAN MED CHEM, V18, P4509, DOI 10.1016/j.bmc.2010.04.066; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Dayton A, 2010, CANCER BIOL THER, V10, P1027, DOI 10.4161/cbt.10.10.13250; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Goff BA, 2015, GYNECOL ONCOL, V136, P1, DOI 10.1016/j.ygyno.2014.12.008; Greten FR, 2010, NAT MED, V16, P1085, DOI 10.1038/nm1010-1085; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P2970, DOI 10.1002/cncr.25869; Huang F, 2008, ACTA BIOCH BIOPH SIN, V40, P519, DOI 10.1111/j.1745-7270.2008.00424.x; Kalai T, 2011, J MED CHEM, V54, P5414, DOI 10.1021/jm200353f; Kim D, 2014, CANCER RES, V74, P2144, DOI 10.1158/0008-5472.CAN-13-2187; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Matte I, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-288; McCann Georgia A, 2014, Oncoscience, V1, P216; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; Pirnia F, 2006, ANTICANCER RES, V26, P1765; Pradeep S, 2015, CANCER CELL, V28, P610, DOI 10.1016/j.ccell.2015.09.008; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Putoczki T, 2010, J LEUKOCYTE BIOL, V88, P1109, DOI 10.1189/jlb.0410226; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062; Selvendiran K, 2010, MOL CANCER RES, V8, P1188, DOI 10.1158/1541-7786.MCR-10-0201; Selvendiran K, 2010, MOL CANCER THER, V9, P1169, DOI 10.1158/1535-7163.MCT-09-1207; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Seo JM, 2012, J BIOL CHEM, V287, P13840, DOI 10.1074/jbc.M111.317131; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tierney BJ, 2014, GYNECOL ONCOL, V135, P133, DOI 10.1016/j.ygyno.2014.07.087; Tierney BJ, 2012, CANCER BIOL THER, V13, P766, DOI 10.4161/cbt.20559; Vaira V, 2010, P NATL ACAD SCI USA, V107, P8352, DOI 10.1073/pnas.0907676107; Venkatesh S, 2000, J PHARM SCI-US, V89, P145, DOI 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6; Wen W, 2014, MOL CANCER THER, V13, P3037, DOI 10.1158/1535-7163.MCT-14-0077; Yoo JY, 2014, CLIN CANCER RES, V20, P3787, DOI 10.1158/1078-0432.CCR-14-0553; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109	49	74	78	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					168	181		10.1038/onc.2016.197	http://dx.doi.org/10.1038/onc.2016.197			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27292260	Green Accepted			2022-12-28	WOS:000393938100003
J	Iltzsche, F; Simon, K; Stopp, S; Pattschull, G; Francke, S; Wolter, P; Hauser, S; Murphy, DJ; Garcia, P; Rosenwald, A; Gaubatz, S				Iltzsche, F.; Simon, K.; Stopp, S.; Pattschull, G.; Francke, S.; Wolter, P.; Hauser, S.; Murphy, D. J.; Garcia, P.; Rosenwald, A.; Gaubatz, S.			An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma	ONCOGENE			English	Article							B-MYB; IN-VIVO; K-RAS; CHROMOSOMAL INSTABILITY; EXPRESSION PROFILES; MOTOR PROTEINS; G(2)/M GENES; CANCER; COMPLEX; TRANSCRIPTION	The conserved Myb-MuvB (MMB) multiprotein complex has an important role in transcriptional activation of mitotic genes. MMB target genes are overexpressed in several different cancer types and their elevated expression is associated with an advanced tumor state and a poor prognosis. This suggests that MMB could contribute to tumorigenesis by mediating overexpression of mitotic genes. However, although MMB has been extensively characterized biochemically, the requirement for MMB in tumorigenesis in vivo has not been investigated. Here we demonstrate.that MMB is required for tumor formation in a mouse model of lung cancer driven by oncogenic K-RAS. We also identify a requirement for the mitotic kinesin KIF23, a key target gene of MMB, in tumorigenesis. RNA interference-mediated depletion of KIF23 inhibited lung tumor formation in vivo and induced apoptosis in lung cancer cell lines. Our results suggest that inhibition of KIF23 could be a strategy for treatment of lung cancer.	[Iltzsche, F.; Simon, K.; Stopp, S.; Pattschull, G.; Francke, S.; Wolter, P.; Hauser, S.; Gaubatz, S.] Univ Wurzburg, Theodor Boveri Inst, Dept Physiol Chem, Bioctr, Wurzburg, Germany; [Murphy, D. J.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Murphy, D. J.] CRUK Beatson Inst, Glasgow, Lanark, Scotland; [Garcia, P.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Rosenwald, A.; Gaubatz, S.] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Rosenwald, A.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany	University of Wurzburg; University of Glasgow; Beatson Institute; University of Birmingham; University of Wurzburg; University of Wurzburg	Gaubatz, S (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Hubland, D-97074 Wurzburg, Bavaria, Germany.	stefan.gaubatz@biozentrum.uni-wuerzburg.de	Garcia, Paloma/AFO-2595-2022; Murphy, Daniel/V-1079-2019	Murphy, Daniel/0000-0002-5538-5468; Gaubatz, Stefan/0000-0001-8751-4191; Garcia, Paloma/0000-0001-5582-8575	Deutsche Krebshilfe [110928]; Sander Stiftung [2015.038.1]; DFG [GA 575/5-2]	Deutsche Krebshilfe(Deutsche Krebshilfe); Sander Stiftung; DFG(German Research Foundation (DFG))	We thank Tyler Jacks, Anton Berns, Roger Watson, Geert Carmeliet, Thorsten Stiewe and Andras Nagy for reagents, and Sabine Roth and Susi Spahr for excellent technical help. We thank all members of the laboratory for their suggestions and critical reading of the manuscript. This work was supported by grants from the Deutsche Krebshilfe (110928), Sander Stiftung (2015.038.1) and DFG (GA 575/5-2) towards SG.	Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bowman BM, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005607; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Esterlechner J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062882; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063187; Garcia P, 2005, GENESIS, V43, P189, DOI 10.1002/gene.20170; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; Marino S, 2000, GENE DEV, V14, P994; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Takahashi S, 2012, J NEURO-ONCOL, V106, P519, DOI 10.1007/s11060-011-0706-2; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tavner F, 2007, ONCOGENE, V26, P2727, DOI 10.1038/sj.onc.1210087; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Valk K, 2010, ONCOLOGY-BASEL, V79, P283, DOI 10.1159/000322116; White EA, 2012, CYTOSKELETON, V69, P882, DOI 10.1002/cm.21065; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433	48	31	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					110	121		10.1038/onc.2016.181	http://dx.doi.org/10.1038/onc.2016.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212033	Green Published, Green Accepted			2022-12-28	WOS:000394069100010
J	Martinelli, GB; Olivari, D; Cecconi, ADR; Talamini, L; Ottoboni, L; Lecker, SH; Stretch, C; Baracos, VE; Bathe, OF; Resovi, A; Giavazzi, R; Cervo, L; Piccirillo, R				Martinelli, G. B.; Olivari, D.; Cecconi, A. D. Re; Talamini, L.; Ottoboni, L.; Lecker, S. H.; Stretch, C.; Baracos, V. E.; Bathe, O. F.; Resovi, A.; Giavazzi, R.; Cervo, L.; Piccirillo, R.			Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; SKELETAL-MUSCLE; CHEMOKINE RECEPTOR; PROGENITOR CELLS; WEIGHT-LOSS; CXCR4; INTERLEUKIN-6; DEGRADATION; REGENERATION; EXPRESSION	Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (alpha, beta, gamma) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1 alpha or SDF1 beta had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time-and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.	[Martinelli, G. B.; Olivari, D.; Cecconi, A. D. Re; Talamini, L.; Giavazzi, R.; Piccirillo, R.] IRCCS Mario Negri Inst Pharmacol Res, Dept Oncol, Via G La Masa 19, I-20156 Milan, Italy; [Ottoboni, L.] INSpe, San Raffaele Sci Inst, Milan, Italy; [Lecker, S. H.] Beth Israel Deaconess Med Ctr, Boston, MA USA; [Stretch, C.; Baracos, V. E.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada; [Bathe, O. F.] Univ Calgary, Dept Surg & Oncol, Calgary, AB, Canada; [Resovi, A.] IRCCS Mario Negri Inst Pharmacol Res, Tumor Angiogenesis Unit, Dept Oncol, Bergamo, Italy; [Cervo, L.] IRCCS Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Harvard University; Beth Israel Deaconess Medical Center; University of Alberta; University of Calgary; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Piccirillo, R (corresponding author), IRCCS Mario Negri Inst Pharmacol Res, Dept Oncol, Via G La Masa 19, I-20156 Milan, Italy.	rosanna.piccirillo@marionegri.it	RE CECCONI, ANDREA DAVID/AAG-4949-2021; Giavazzi, Raffaella/ABB-9768-2020; Cervo, Luigi/AAA-8081-2020; Resovi, Andrea/ABG-7483-2021; Piccirillo, Rosanna/K-6619-2016; Piccirillo, Rosanna/AAQ-3653-2020; Giavazzi, Raffaella/J-7424-2018; Olivari, Davide/AAC-4733-2022	RE CECCONI, ANDREA DAVID/0000-0003-1502-9108; Giavazzi, Raffaella/0000-0001-5249-8208; Cervo, Luigi/0000-0003-1314-1876; Resovi, Andrea/0000-0001-9560-0815; Piccirillo, Rosanna/0000-0002-1613-9352; Piccirillo, Rosanna/0000-0002-1613-9352; Olivari, Davide/0000-0003-0802-6603; Talamini, Laura/0000-0001-6010-2947; Stretch, Cynthia/0000-0002-5152-2728	Italian Association for Cancer Research [AIRC Start-UP 11423, AIRC-IG 14532, AIRC 12182]; Union under the Marie Curie International Reintegration Grant [PIRG08-GA-2010-277008]; Fondazione Veronesi; FISM [2012/B/10]; Fondazione Eugenio Morandi	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Union under the Marie Curie International Reintegration Grant; Fondazione Veronesi(Fondazione Umberto Veronesi); FISM(Fondazione Italiana Sclerosi Multipla (FISM)); Fondazione Eugenio Morandi	We are grateful to the Italian Association for Cancer Research (AIRC Start-UP 11423 to RP and AIRC-IG 14532 and AIRC 12182 to RG) and the Union under the Marie Curie International Reintegration Grant (PIRG08-GA-2010-277008 to RP). LO is the recipient of a training research fellowship from 'Fondazione Veronesi' and of a grant from FISM (2012/B/10). AR is the recipient of a fellowship from 'Fondazione Eugenio Morandi'. We thank JD Baggott for help with the editing.	Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829; Bedard N, 2015, FASEB J, V29, P3889, DOI 10.1096/fj.15-270579; Bennani-Baiti N, 2011, SUPPORT CARE CANCER, V19, P1451, DOI 10.1007/s00520-010-0972-0; Bobadilla M, 2014, STEM CELLS DEV, V23, P1417, DOI 10.1089/scd.2013.0491; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Chong SW, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-54; Debnath B, 2013, THERANOSTICS, V3, P47, DOI 10.7150/thno.5376; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; FEARON KCH, 1991, ANN SURG, V213, P26, DOI 10.1097/00000658-199101000-00005; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; He WA, 2013, J CLIN INVEST, V123, P4821, DOI 10.1172/JCI68523; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Janowski M, 2009, CELL ADHES MIGR, V3, P243, DOI 10.4161/cam.3.3.8260; Jatoi A, 2007, CANCER, V110, P1396, DOI 10.1002/cncr.22944; Kuroda K, 2007, UROLOGY, V69, P113, DOI 10.1016/j.urology.2006.09.039; Leal MA, 2014, DEV DYNAM, V243, P509, DOI 10.1002/dvdy.24092; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Melchonna R, 2010, MUSCLE NERVE, V41, P828, DOI 10.1002/mus.21611; Mines MA, 2009, J BIOL CHEM, V284, P5742, DOI 10.1074/jbc.M808507200; Minetti GC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002038; Navegantes LCC, 2002, CURR OPIN CLIN NUTR, V5, P281, DOI 10.1097/00075197-200205000-00007; Oka M, 1996, CANCER RES, V56, P2776; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; OVESEN L, 1993, J CLIN ONCOL, V11, P2043, DOI 10.1200/JCO.1993.11.10.2043; Perez AL, 2009, MUSCLE NERVE, V40, P562, DOI 10.1002/mus.21317; Piccirillo R, 2012, EMBO J, V31, P3334, DOI 10.1038/emboj.2012.178; Pillarisetti K, 2001, INFLAMMATION, V25, P293, DOI 10.1023/A:1012808525370; Porporato PE, 2013, J CLIN INVEST, V123, P611, DOI 10.1172/JCI39920; Pretto F, 2015, ONCOTARGET, V6, P3043, DOI 10.18632/oncotarget.2812; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scott HR, 1996, BRIT J CANCER, V73, P1560, DOI 10.1038/bjc.1996.294; Steen A, 2009, MINI-REV MED CHEM, V9, P1605, DOI 10.2174/138955709791012265; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Toledo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113931; Toschi A, 2011, MOL ENDOCRINOL, V25, P1661, DOI 10.1210/me.2011-1049; Wang H, 2010, CELL SIGNAL, V22, P1022, DOI 10.1016/j.cellsig.2010.02.005; White JP, 2014, P NATL ACAD SCI USA, V111, P15756, DOI 10.1073/pnas.1417898111; WHITE ME, 1988, J ANIM SCI, V66, P34, DOI 10.2527/jas1988.66134x; Wiedenmann Bertram, 2008, J Support Oncol, V6, P18; Wiegant J, 2002, CANCER GENET CYTOGEN, V139, P126, DOI 10.1016/S0165-4608(02)00623-4; Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001; Zhang LP, 2013, CELL METAB, V18, P368, DOI 10.1016/j.cmet.2013.07.012; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Zheng H, 2007, J CARDIOVASC PHARM, V50, P274, DOI 10.1097/FJC.0b013e318093ec8f	50	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6212	6222		10.1038/onc.2016.153	http://dx.doi.org/10.1038/onc.2016.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27212031				2022-12-28	WOS:000388857700006
J	Chen, CH; Chang, WH; Su, KY; Ku, WH; Chang, GC; Hong, QS; Hsiao, YJ; Chen, HC; Chen, HY; Wu, R; Yang, PC; Chen, JJW; Yu, SL				Chen, C-H; Chang, W-H; Su, K-Y; Ku, W-H; Chang, G-C; Hong, Q-S; Hsiao, Y-J; Chen, H-C; Chen, H-Y; Wu, R.; Yang, P-C; Chen, J. J. W.; Yu, S-L			HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms	ONCOGENE			English	Article							CELL LUNG-CANCER; FAMILY KINASES; G-PROTEINS; PHASE-II; C-SRC; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; TARGETING SRC; BETA-CATENIN; SH2 DOMAIN	HLJ1 (DNAJB4), a DNAJ/Hsp40 chaperone, has emerged as a novel prognostic marker in lung cancers; however, the molecular contribution and functionality in neoplastic diseases remain to be established. This study demonstrated that HLJ1 inhibits epithelial-mesenchymal transition in vitro and reduces lung cancer metastasis in vivo. Using shRNA silencing and ectopic expression of HLJ1, we found that HLJ1 not only suppresses catalytic activity of Src but also downregulates the formation of oncogenic complexes associated with the EGFR, FAK and STAT3 signaling pathways. A screen of specimens from HLJ1-knockout mice and lung cancer patients validated that HLJ1 expression is inversely correlated with Src activity. Mechanistically, HLJ1 protein directly bound to catalytic and protein-binding domains of Src through its amino acid Y172 and the P301/P304 motif. Following Src-induced HLJ1 phosphorylation at Y172, HLJ1-Src interaction was elevated, resulting in Src inhibition and malignancy suppression. Interestingly, both Src-binding regions also occurred in other DNAJB family members and contributed to anti-invasive activities of DNAJB proteins. We conclude that HLJ1 is an endogenous Src inhibitor that can suppress cancer metastasis through complex interacting mechanisms. This HLJ1-Src complex might provide a promising molecular model for developing new anticancer strategies.	[Chen, C-H; Wu, R.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; [Chen, C-H; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; [Chen, C-H] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA; [Chang, W-H; Yang, P-C] Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; [Su, K-Y; Hong, Q-S; Hsiao, Y-J; Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan; [Su, K-Y; Yu, S-L] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Ku, W-H] Taipei Inst Pathol, Taipei, Taiwan; [Chang, G-C] Taichung Vet Gen Hosp, Div Chest Med, Taichung, Taiwan; [Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Chen, H-Y] Acad Sinica, Inst Stat Sci, Taipei, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, J. J. W.] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan; [Chen, J. J. W.] Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Grad Inst Pathol, Taipei, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Ctr Optoclect Biomed, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taichung Veterans General Hospital; National Chung Hsing University; Academia Sinica - Taiwan; National Taiwan University; National Chung Hsing University; National Chung Hsing University; National Taiwan University; National Taiwan University; National Taiwan University	Yu, SL (corresponding author), Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan.; Chen, JJW (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.	jwchen@dragon.nchu.cdu.tw; slyu@ntu.edu.tw	Chen, Hsuan-Yu/AAE-8428-2019; SU, KANG-YI/GNM-5753-2022	SU, KANG-YI/0000-0002-6538-9526; YU, SUNG-LIANG/0000-0003-4535-9036; Hsiao, Yi-Jing/0000-0001-8780-8800; Chang, Wen-Hsin/0000-0002-8027-302X; Chen, Jeremy J.W./0000-0003-1049-3825	Ministry of Science and Technology, Taiwan, ROC [NSC 98-2314-B-005-001-MY3, NSC 102-2911-I-002-303, NSC 103-2911-I-002-303]; National Taiwan University [102R7557, 103R7557]; Tobacco-Related Disease Research Program (TRDRP) [23FT-0104]; Ministry of Education, Taiwan, ROC	Ministry of Science and Technology, Taiwan, ROC(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University); Tobacco-Related Disease Research Program (TRDRP)(University of California System); Ministry of Education, Taiwan, ROC(Ministry of Education, Taiwan)	We thank Dr Po-Chao Chan (Department of Life Science, National Chung Hsing University, Taichung, Taiwan) and Dr Samuel Chung (Department of Internal Medicine, University of California Davis, Davis, CA, USA) for useful discussion; Dr Yung-Hao Wong (Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan) for the advice regarding protein docking; Dr Yu-Ching Lin (UNIMED Healthcare Inc., Taiwan) and the Center for Innovative Therapeutics Discovery of National Taiwan University for technological support in ForteBio system; and the Integrated Core Facility for Functional Genomics of the National Core Facility Program for Biotechnology (NCFPB) for technological support. This work was supported by grants from the Ministry of Science and Technology, Taiwan, ROC (NSC 98-2314-B-005-001-MY3, NSC 102-2911-I-002-303 and NSC 103-2911-I-002-303) and National Taiwan University (102R7557 and 103R7557), as well as in part by the Tobacco-Related Disease Research Program (TRDRP; 23FT-0104 to C-H Chen) and by the Ministry of Education, Taiwan, ROC under the ATU plan.	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Brunner AM, 2013, J THORAC ONCOL, V8, P1434, DOI 10.1097/JTO.0b013e3182a47162; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang TP, 2010, CANCER RES, V70, P1656, DOI 10.1158/0008-5472.CAN-09-2453; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chen CH, 2010, EXP CELL RES, V316, P2910, DOI 10.1016/j.yexcr.2010.06.027; Chen JJW, 2001, CANCER RES, V61, P5223; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kraskouskaya D, 2013, CHEM SOC REV, V42, P3337, DOI 10.1039/c3cs35449k; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liu Y, 2014, INT J CLIN EXP PATHO, V7, P969; Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4; Mitra A, 2012, ONCOGENE, V31, P4472, DOI 10.1038/onc.2011.623; Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Rahmani Z, 2006, J CELL SCI, V119, P646, DOI 10.1242/jcs.02778; Rothschild SI, 2010, CLIN LUNG CANCER, V11, P238, DOI 10.3816/CLC.2010.n.030; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Sterrenberg JN, 2011, CANCER LETT, V312, P129, DOI 10.1016/j.canlet.2011.08.019; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	46	18	18	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5674	5685		10.1038/onc.2016.106	http://dx.doi.org/10.1038/onc.2016.106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065329				2022-12-28	WOS:000386998300010
J	Nguyen, PH; Giraud, J; Staedel, C; Chambonnier, L; Dubus, P; Chevret, E; Boeuf, H; Gauthereau, X; Rousseau, B; Fevre, M; Soubeyran, I; Belleannee, G; Evrard, S; Collet, D; Megraud, F; Varon, C				Nguyen, P. H.; Giraud, J.; Staedel, C.; Chambonnier, L.; Dubus, P.; Chevret, E.; Boeuf, H.; Gauthereau, X.; Rousseau, B.; Fevre, M.; Soubeyran, I.; Belleannee, G.; Evrard, S.; Collet, D.; Megraud, F.; Varon, C.			All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HELICOBACTER-PYLORI INFECTION; ALDEHYDE DEHYDROGENASES; CELLULAR-LEVELS; RECEPTOR-ALPHA; BREAST-CANCER; PATHWAY; EXPRESSION; IDENTIFICATION; CHEMOTHERAPY	Gastric carcinoma is the third leading cause of cancer-related death worldwide. This cancer, most of the time metastatic, is essentially treated by surgery associated with conventional chemotherapy, and has a poor prognosis. The existence of cancer stem cells (CSC) expressing CD44 and a high aldehyde dehydrogenase (ALDH) activity has recently been demonstrated in gastric carcinoma and has opened new perspectives to develop targeted therapy. In this study, we evaluated the effects of all-transretinoic acid (ATRA) on CSCs in human gastric carcinoma. ATRA effects were evaluated on the proliferation and tumorigenic properties of gastric carcinoma cells from patient-derived tumors and cell lines in conventional 2D cultures, in 3D culture systems (tumorsphere assay) and in mouse xenograft models. ATRA inhibited both tumorspheres initiation and growth in vitro, which was associated with a cell-cycle arrest through the upregulation of cyclin-dependent kinase (CDK) inhibitors and the downregulation of cell-cycle progression activators. More importantly, ATRA downregulated the expression of the CSC markers CD44 and ALDH as well as stemness genes such as Klf4 and Sox2 and induced differentiation of tumorspheres. Finally, 2 weeks of daily ATRA treatment were sufficient to inhibit gastric tumor progression in vivo, which was associated with a decrease in CD44, ALDH1, Ki67 and PCNA expression in the remaining tumor cells. Administration of ATRA appears to be a potent strategy to efficiently inhibit tumor growth and more importantly to target gastric CSCs in both intestinal and diffuse types of gastric carcinoma.	[Nguyen, P. H.; Giraud, J.; Chambonnier, L.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Nguyen, P. H.; Giraud, J.; Staedel, C.; Chambonnier, L.; Dubus, P.; Chevret, E.; Boeuf, H.; Gauthereau, X.; Rousseau, B.; Fevre, M.; Megraud, F.; Varon, C.] Univ Bordeaux, Bordeaux, France; [Staedel, C.] INSERM, ARNA Lab, U869, Bordeaux, France; [Dubus, P.; Chevret, E.] Univ Bordeaux, EA2406, Bordeaux, France; [Dubus, P.; Megraud, F.] Univ Hosp Ctr, Bordeaux, France; [Boeuf, H.; Gauthereau, X.] CIRID, UMR CNRS 5164, Bordeaux, France; [Rousseau, B.; Fevre, M.] Univ Bordeaux, Serv Commun Animaleries, Bordeaux, France; [Soubeyran, I.] Inst Bergonie, Dept Biopathol, Bordeaux, France; [Belleannee, G.] Haut Leveque Hosp, Dept Histopathol Tumors, Bordeaux, France; [Evrard, S.] Inst Bergonie, Dept Digest Oncol, Bordeaux, France; [Collet, D.] Haut Leveque Hosp, Dept Digest Surg, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; CHU Bordeaux; UNICANCER; Institut Bergonie; CHU Bordeaux	Varon, C (corresponding author), Univ Bordeaux, INSERM, U853, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	christine.varon@u-bordeaux.fr		Giraud, Julie/0000-0001-6173-4276; Dubus, Pierre/0000-0003-1803-4711; Varon, Christine/0000-0003-4026-2016; Megraud, Francis/0000-0002-2481-1612; Staedel, Cathy/0000-0003-0488-0239; EVRARD, Serge/0000-0003-1063-6822	French 'Institut National du Cancer' [2014-152]; French 'Association pour la Recherche contre le Cancer' [8412]; Institut National du Cancer [2014-152, 07/3D1616/IABC-23-12/NC-NG]; Conseil Regional d'Aquitaine [20071301017, 20081302203]; French National Society for Gastroenterology; SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [INCa-DGOS-INSERM 6046]	French 'Institut National du Cancer'; French 'Association pour la Recherche contre le Cancer'(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine); French National Society for Gastroenterology; SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie)	The post-doctoral fellowship of Julie Giraud was granted by the French 'Institut National du Cancer' (grant 2014-152). We thank Vincent Pitard and Santiago Gonzalez (Flow Cytometry and FACS Platform, University of Bordeaux), Lamia Azzi-Martin and Jacky Ferrer (EA2406, University of Bordeaux), Elodie Siffre and Armelle Menard (INSERM U853) for technical assistance and helpful advice. We thank the French 'Association pour la Recherche contre le Cancer' (grant number 8412), the 'Institut National du Cancer' (grant 07/3D1616/IABC-23-12/NC-NG and grant 2014-152), the 'Conseil Regional d'Aquitaine' (grant numbers 20071301017 and 20081302203) and the French National Society for Gastroenterology for financial support. This project is part of SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie; grant INCa-DGOS-INSERM 6046).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bessede E, 2015, ONCOGENE, V34, P2547, DOI 10.1038/onc.2014.187; Bessede E, 2014, ONCOGENE, V33, P4123, DOI 10.1038/onc.2013.380; Chao TY, 1997, BRIT J CANCER, V75, P1284, DOI 10.1038/bjc.1997.218; Chen WJ, 2013, HEPATO-GASTROENTEROL, V60, P949, DOI 10.5754/hge12881; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Connolly RM, 2013, CLIN CANCER RES, V19, P1651, DOI 10.1158/1078-0432.CCR-12-3175; Czyzewska J, 2009, FOLIA HISTOCHEM CYTO, V47, P289, DOI 10.2478/v10042-009-0042-y; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019569; Flejou Jean-Francois, 2011, Ann Pathol, V31, pS27, DOI 10.1016/j.annpat.2011.08.001; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; IARC, 1994, IARC MON EV CARC RIS, V61, P177; Isozaki H, 1996, J SURG ONCOL, V61, P106, DOI 10.1002/(SICI)1096-9098(199602)61:2<106::AID-JSO4>3.0.CO;2-G; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Liu S, 2001, WORLD J GASTROENTERO, V7, P662; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Megraud F, 2015, CLIN MICROBIOL INFEC, V21, P984, DOI 10.1016/j.cmi.2015.06.004; Nishikawa S, 2013, INT J ONCOL, V42, P1437, DOI 10.3892/ijo.2013.1837; Schenk T, 2014, BRIT J CANCER, V111, P2039, DOI 10.1038/bjc.2014.412; Shin CS, 2013, MOL PHARMACEUT, V10, P2167, DOI 10.1021/mp300595a; SHYU RY, 1995, EUR J CANCER, V31A, P237, DOI 10.1016/0959-8049(94)00481-J; Sladek NE, 2002, CANCER CHEMOTH PHARM, V49, P309, DOI 10.1007/s00280-001-0412-4; Sreerama L, 1997, CLIN CANCER RES, V3, P1901; Staedel C, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.18; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Zhang JP, 2007, J DIGEST DIS, V8, P29, DOI 10.1111/j.1443-9573.2007.00280.x	36	82	83	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5619	5628		10.1038/onc.2016.87	http://dx.doi.org/10.1038/onc.2016.87			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27157616				2022-12-28	WOS:000386998300005
J	Hermanns, C; Hampl, V; Holzer, K; Aigner, A; Penkava, J; Frank, N; Martin, DE; Maier, KC; Waldburger, N; Roessler, S; Goppelt-Struebe, M; Akrap, I; Thavamani, A; Singer, S; Nordheim, A; Gudermann, T; Muehlich, S				Hermanns, C.; Hampl, V.; Holzer, K.; Aigner, A.; Penkava, J.; Frank, N.; Martin, D. E.; Maier, K. C.; Waldburger, N.; Roessler, S.; Goppelt-Struebe, M.; Akrap, I.; Thavamani, A.; Singer, S.; Nordheim, A.; Gudermann, T.; Muehlich, S.			The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTIONAL RESPONSE; TUMOR-SUPPRESSOR; ACTIN DYNAMICS; FACTOR SRF; GROWTH; COACTIVATOR; LOCALIZATION; RESISTANCE; REGULATOR	Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are transcriptional coactivators of Serum Response Factor (SRF) with an essential role for hepatocellular carcinoma (HCC) growth and oncogene-induced senescence. In this report, we identified myoferlin as a novel MKL/SRF target gene by gene expression profiling and verification in vivo in HCC xenografts. Myoferlin was overexpressed in human and murine HCCs triggered by conditional expression of constitutively active SRF-VP16 protein in hepatocytes. Furthermore, myoferlin was required for HCC cell invasion, proliferation and anchorage-independent cell growth. We provide evidence that myoferlin is a crucial gene target of MKL1/2 mediating its effect on oncogene-induced senescence by modulating the activation state of the EGFR and downstream MAPK and p16-/Rb pathways. Depletion of myoferlin in tumour cells from SRF-VP16-derived murine HCCs induced a senescence phenotype. These findings identify MKL1/2 and myoferlin as novel therapeutic targets to treat human HCC by a senescence-inducing strategy.	[Hermanns, C.; Hampl, V.; Penkava, J.; Frank, N.; Gudermann, T.; Muehlich, S.] Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany; [Holzer, K.; Waldburger, N.; Roessler, S.; Singer, S.] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Aigner, A.] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Clin Pharmacol, Leipzig, Germany; [Martin, D. E.; Maier, K. C.] Ludwig Maximilians Univ Munchen, Dept Chem & Pharm, Gene Ctr, Munich, Germany; [Goppelt-Struebe, M.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Akrap, I.; Thavamani, A.; Nordheim, A.] Tuebingen Univ, Interfac Inst Cell Biol, Tubingen, Germany; [Nordheim, A.] German Canc Consortium DKTK, Heidelberg, Germany; [Nordheim, A.] DKFZ, Heidelberg, Germany	University of Munich; Ruprecht Karls University Heidelberg; Leipzig University; University of Munich; University of Erlangen Nuremberg; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Muehlich, S (corresponding author), Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany.	susanne.muehlich@lrz.uni-muenchen.de	Aigner, Achim/R-4429-2017; Thavamani, Abhishek/I-3207-2018; Roessler, Stephanie/J-8432-2019	Aigner, Achim/0000-0002-2778-6256; Thavamani, Abhishek/0000-0001-7187-9188; Roessler, Stephanie/0000-0002-5333-5942	NCT; Deutsche Forschungsgemeinschaft [MU 2737/2-2]; Deutsche Krebshilfe [109886]; DKTK (German Cancer Consortium); DFG [Si 1487/3-1]; HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship	NCT; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); DKTK (German Cancer Consortium); DFG(German Research Foundation (DFG)); HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship	We thank Elizabeth McNally and Alexis Demonbreun for the myoferlin promoter construct, and Veronika Geissler and Esther Herpel from the NCT tissue bank in Heidelberg for their support. Funded by grant MU 2737/2-2 of the Deutsche Forschungsgemeinschaft. Alfred Nordheim was supported by the Deutsche Krebshilfe (grant 109886) and DKTK (German Cancer Consortium). Stephan Singer was supported by DFG (grant Si 1487/3-1), and by an HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship.	Bae JS, 2014, INT J ONCOL, V44, P129, DOI 10.3892/ijo.2013.2154; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giehl K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121589; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hobel S, 2010, J GENE MED, V12, P287, DOI 10.1002/jgm.1431; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kircher P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad2959; Kwon CY, 2010, INT J ONCOL, V37, P837, DOI 10.3892/ijo_00000734; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Muehlich S, 2012, ONCOGENE, V31, P3913, DOI 10.1038/onc.2011.560; Muehlich S, 2007, AM J PHYSIOL-CELL PH, V292, pC1732, DOI 10.1152/ajpcell.00552.2006; Ohrnberger S, 2015, HEPATOLOGY, V61, P979, DOI 10.1002/hep.27539; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Park MY, 2007, INT J ONCOL, V31, P1309; Reschke M, 2010, HEPATOLOGY, V51, P1383, DOI 10.1002/hep.23428; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Winkler J, 2014, HEPATOLOGY, V60, P884, DOI 10.1002/hep.27207; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yuan BZ, 1998, CANCER RES, V58, P2196	34	24	24	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3464	3476		10.1038/onc.2016.496	http://dx.doi.org/10.1038/onc.2016.496			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114277				2022-12-28	WOS:000403340700010
J	Zhao, B; Hu, W; Kumar, S; Gonyo, P; Rana, U; Liu, Z; Wang, B; Duong, WQ; Yang, Z; Williams, CL; Miao, QR				Zhao, B.; Hu, W.; Kumar, S.; Gonyo, P.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Yang, Z.; Williams, C. L.; Miao, Q. R.			The Nogo-B receptor promotes Ras plasma membrane localization and activation	ONCOGENE			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHASE; MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-CANCER; H-RAS; K-RAS; MALIGNANT-TRANSFORMATION; DRUG-RESISTANCE; FAMILY PROTEINS; PDE-DELTA; IN-VITRO	The localization of prenylated Ras at the plasma membrane promotes activation of Ras by receptor tyrosine kinases and stimulates oncogenic signaling by mutant Ras. The Nogo-B receptor (NgBR) is a transmembrane receptor that contains a conserved hydrophobic pocket. Here, we demonstrate that the NgBR promotes the membrane accumulation of Ras by directly binding prenylated Ras at the plasma membrane. We show that NgBR knockdown diminishes the membrane localization of Ras in multiple cell types. NgBR overexpression in NIH-3T3 fibroblasts increases membrane-associated Ras, induces the transformed phenotype in vitro, and promotes the formation of fibrosarcoma in nude mice. NgBR knockdown in human breast cancer cells reduces Ras membrane localization, inhibits epidermal growth factor (EGF)-stimulated Ras signaling and diminishes tumorigenesis of xenografts in nude mice. Our data demonstrate that NgBR is a unique receptor that promotes accumulation of prenylated Ras at the plasma membrane and promotes EGF pathways.	[Zhao, B.; Hu, W.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Miao, Q. R.] Med Coll Wisconsin, Dept Surg, Childrens Res Inst, Div Pediat Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Zhao, B.; Hu, W.; Kumar, S.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Miao, Q. R.] Med Coll Wisconsin, Dept Pathol, Childrens Res Inst, Div Pediat Pathol, Milwaukee, WI 53226 USA; [Zhao, B.] Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci, Dalian, Liaoning, Peoples R China; [Gonyo, P.; Williams, C. L.; Miao, Q. R.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Wang, B.] China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China; [Yang, Z.] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI USA	Medical College of Wisconsin; Medical College of Wisconsin; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Medical College of Wisconsin; China-Japan Friendship Hospital; Wayne State University	Miao, QR (corresponding author), Med Coll Wisconsin, Dept Surg & Pathol, Childrens Res Inst, Div Pediat Surg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Miao, QR (corresponding author), Med Coll Wisconsin, Dept Surg & Pathol, Childrens Res Inst, Div Pediat Pathol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	qmiao@mcw.edu	Miao, Qing/K-3186-2019	Miao, Qing/0000-0002-3125-1238; Duong, William/0000-0002-2879-8590	Division of Pediatric Surgery, Medical College of Wisconsin (MCW); AHA [SDG 0730079N]; NIH [R01HL108938, R01 CA188871, R01HL128647]; American Cancer Society [86-004-26]; Kathy Duffey Fogarty Award for breast cancer research; Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant; AHA postdoctoral fellowship [13POST13940002, 11POST5690035]; China State Key Basic Research Program [2016YFA0501401]; Hundred Talents Program of CAS; Rock River Cancer Research Foundation; Division of Pediatric Pathology, Medical College of Wisconsin; Advancing a Healthier Wisconsin endowment; Wisconsin Breast Cancer Showhouse (WBCS); We Care Fund; NATIONAL CANCER INSTITUTE [R01CA188871] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108938, R01HL128647] Funding Source: NIH RePORTER	Division of Pediatric Surgery, Medical College of Wisconsin (MCW); AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Kathy Duffey Fogarty Award for breast cancer research; Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant; AHA postdoctoral fellowship(American Heart Association); China State Key Basic Research Program; Hundred Talents Program of CAS(Chinese Academy of Sciences); Rock River Cancer Research Foundation; Division of Pediatric Pathology, Medical College of Wisconsin; Advancing a Healthier Wisconsin endowment; Wisconsin Breast Cancer Showhouse (WBCS); We Care Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr John Hancock at University of Texas Health Science Center at Houston generously provided pEGFP-C1 vector. This work is supported in part by start-up funds from Division of Pediatric Surgery and Division of Pediatric Pathology, Medical College of Wisconsin (MCW) and Advancing a Healthier Wisconsin endowment to MCW, AHA SDG 0730079N, NIH R01HL108938, Wisconsin Breast Cancer Showhouse (WBCS), Institutional Research Grant # 86-004-26 from the American Cancer Society, We Care Fund, Kathy Duffey Fogarty Award for breast cancer research, State of Wisconsin Tax Check-off program for breast & prostate cancer research and Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant to QRM., AHA postdoctoral fellowship 13POST13940002 and 11POST5690035, China State Key Basic Research Program Grant 2016YFA0501401 and the support from the Hundred Talents Program of CAS to BZ. Additional support was provided by NIH R01 CA188871 (CLW), the Rock River Cancer Research Foundation (CLW), and the Nancy Laning Sobczak, PhD., Breast Cancer Research Award (CLW), NIH R01HL128647 (ZY).	Abramovitz A, 2012, BIOCHEMISTRY-US, V51, P715, DOI 10.1021/bi201211v; Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Belanis L, 2008, MOL BIOL CELL, V19, P1404, DOI 10.1091/mbc.E07-10-1053; Bernhard EJ, 1998, CANCER RES, V58, P1754; Brunsveld L, 2009, BBA-BIOMEMBRANES, V1788, P273, DOI 10.1016/j.bbamem.2008.08.006; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; Chen APC, 2005, BIOCHEM J, V386, P169, DOI 10.1042/BJ20040785; CLARK R, 1988, CANCER RES, V48, P4689; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; DATI C, 1991, INT J CANCER, V47, P833, DOI 10.1002/ijc.2910470607; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; Dong CY, 2016, ONCOTARGET, V7, P8850, DOI 10.18632/oncotarget.7091; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Harrison KD, 2011, EMBO J, V30, P2490, DOI 10.1038/emboj.2011.147; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Miao RQ, 2006, P NATL ACAD SCI USA, V103, P10997, DOI 10.1073/pnas.0602427103; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8; Omerovic J, 2009, FEBS J, V276, P1817, DOI 10.1111/j.1742-4658.2009.06928.x; Parish CA, 1997, BIOCHEMISTRY-US, V36, P2686, DOI 10.1021/bi961844r; Park EJ, 2016, EMBO REP, V17, P167, DOI 10.15252/embr.201540789; Park EJ, 2014, CELL METAB, V20, P448, DOI 10.1016/j.cmet.2014.06.016; Pechlivanis M, 2006, BBA-PROTEINS PROTEOM, V1764, P1914, DOI 10.1016/j.bbapap.2006.09.017; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Rana U, 2016, DEV BIOL, V410, P190, DOI 10.1016/j.ydbio.2015.12.023; REDMOND SMS, 1988, ONCOGENE, V2, P259; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rocks O, 2006, CURR OPIN CELL BIOL, V18, P351, DOI 10.1016/j.ceb.2006.06.007; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Rotblat B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011991; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schmick M, 2015, TRENDS CELL BIOL, V25, P190, DOI 10.1016/j.tcb.2015.02.004; Shalom-Feuerstein R, 2008, CANCER RES, V68, P6608, DOI 10.1158/0008-5472.CAN-08-1117; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978-1-61779-012-6_9; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078083; WATSON DMA, 1991, BREAST CANCER RES TR, V17, P161, DOI 10.1007/BF01806365; Weise K, 2013, FARADAY DISCUSS, V161, P549, DOI 10.1039/c2fd20100c; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhao B, BLOOD, V116, P5423; Zhao BF, 2015, J PROTEOMICS, V112, P38, DOI 10.1016/j.jprot.2014.08.007; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	71	21	22	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3406	3416		10.1038/onc.2016.484	http://dx.doi.org/10.1038/onc.2016.484			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28068323	Green Accepted			2022-12-28	WOS:000403340700005
J	Wang, SA; Wang, YC; Chuang, YP; Huang, YH; Su, WC; Chang, WC; Hung, JJ				Wang, S-A; Wang, Y-C; Chuang, Y-P; Huang, Y-H; Su, W-C; Chang, W-C; Hung, J-J			EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis	ONCOGENE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LUNG-CARCINOMA; CELL-CYCLE; CANCER; BAX; DISEASE; ASSOCIATION; APOPTOSIS; USP24; USP40	In this study, several cancer-related proteins (Bax, p300, E2F4 and securin) have been proven to be substrates of ubiquitin-specific peptidase 24 (USP24), and relevance has been shown between USP24 and its substrates in samples from clinical lung cancer patients. Silencing USP24 increases the cancer formation by inhibiting cellular apoptosis and increasing cellular proliferation. Epidermal growth factor ( EGF) treatment, and the Kras(G12D) and EGFR(L858R) mutations decrease USP24 protein stability via EGF- or CDK1-mediated phosphorylation at Ser1616, Ser2047 and Ser2604. Knockdown of USP24 decreases Bax and p300 levels, and reduces Ku70 acetylation, thereby preventing cancer cell apoptosis. In addition, knockdown of USP24 increases cell cycle progression by enhancing the G1-S transition and metaphase-anaphase transition. The molecular mechanism involves a decrease in the USP24 level, which reduces the expression of E2F4 and its partner TFDP1, and thus increases the G1/S transition. In conclusion, the USP24 level was decreased during the early stage of cancer and the mitotic stage of the cell cycle to regulate its substrates p300, Bax, E2F4 and securin, resulting in decreased cell apoptosis and increased cell cycle progression and, thus, cancer formation.	[Wang, S-A; Huang, Y-H; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Wang, S-A; Hung, J-J] Natl Cheng Kung Univ, Dept Biotechnol & Bioind Sci, Coll Biosci & Biotechnol, Tainan, Taiwan; [Wang, Y-C; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan, Taiwan; [Chuang, Y-P] Natl Cheng Kung Univ, Dept Pharmacol, Tainan, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med & Hosp, Tainan, Taiwan; [Chang, W-C] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Taipei Medical University; National Cheng Kung University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw		Wang, Shao-an/0000-0002-5473-4195; Wang, Yi-Chang/0000-0001-9346-5234; Su, Wu-Chou/0000-0003-2953-4105	Ministry of Science and Technology, Taiwan [104-2923-B-038-002-MY3, 103-2320-B-006-035-MY3, 103-2321-B-006-023]; Taiwan Protein Project [MOST105-0210-01-12-01]; National Cheng Kung University Hospital [DOH105-TD-PB-111-NSC101]; Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Protein Project; National Cheng Kung University Hospital; Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	We are grateful for the support from the Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We would also like to acknowledge the TCGA Research Network for providing mRNA sequencing data. This work was supported by the grants (104-2923-B-038-002-MY3, 103-2320-B-006-035-MY3 and 103-2321-B-006-023) obtained from the Ministry of Science and Technology, Taiwan. This work was also supported by the Taiwan Protein Project (MOST105-0210-01-12-01). This work was also supported by the grants DOH105-TD-PB-111-NSC101 obtained from National Cheng Kung University Hospital.	Amsel AD, 2008, P NATL ACAD SCI USA, V105, P5117, DOI 10.1073/pnas.0706700105; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blons H, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-25; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Heideker J, 2015, BIOCHEM J, V465, P1, DOI 10.1042/BJ20140496; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Li YH, 2006, HUM MUTAT, V27, P1017, DOI 10.1002/humu.20382; Liu CC, 2014, NUCLEIC ACIDS RES, V42, P9543, DOI 10.1093/nar/gku675; Lukas J, 2004, NATURE, V432, P564, DOI 10.1038/432564a; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; SUN JZ, 1995, CANCER RES, V55, P4243; Takahashi Y, 2000, GENE DEV, V14, P804; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang YC, 2016, ONCOGENE, V35, P3669, DOI 10.1038/onc.2015.432; Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu YR, 2010, CLIN CHIM ACTA, V411, P955, DOI 10.1016/j.cca.2010.03.013; Zhang YH, 1997, GENOMICS, V39, P95, DOI 10.1006/geno.1996.4473; Zhao B, 2012, EUR NEUROL, V68, P181, DOI 10.1159/000339641; Zhao GY, 2015, TUMOR BIOL, V36, P1721, DOI 10.1007/s13277-014-2773-4	26	13	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2930	2945		10.1038/onc.2016.445	http://dx.doi.org/10.1038/onc.2016.445			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991932	Green Published, hybrid			2022-12-28	WOS:000402000400002
J	Dawar, S; Lim, Y; Puccini, J; White, M; Thomas, P; Bouchier-Hayes, L; Green, DR; Dorstyn, L; Kumar, S				Dawar, S.; Lim, Y.; Puccini, J.; White, M.; Thomas, P.; Bouchier-Hayes, L.; Green, D. R.; Dorstyn, L.; Kumar, S.			Caspase-2-mediated cell death is required for deleting aneuploid cells	ONCOGENE			English	Article							POLO-LIKE KINASE; SPINDLE ASSEMBLY CHECKPOINT; STRESS-INDUCED APOPTOSIS; DNA-DAMAGE RESPONSE; MITOTIC CATASTROPHE; CHROMOSOMAL INSTABILITY; TUMOR SUPPRESSION; MECHANISM; CANCER; ACTIVATION	Caspase-2, one of the most evolutionarily conserved of the caspase family, has been implicated in maintenance of chromosomal stability and tumour suppression. Caspase-2 deficient (Casp2(-/-)) mice develop normally but show premature ageing-related traits and when challenged by certain stressors, succumb to enhanced tumour development and aneuploidy. To test how caspase-2 protects against chromosomal instability, we utilized an ex vivo system for aneuploidy where primary splenocytes from Casp2(-/-)mice were exposed to anti-mitotic drugs and followed up by live cell imaging. Our data show that caspase-2 is required for deleting mitotically aberrant cells. Acute silencing of caspase-2 in cultured human cells recapitulated these results. We further generated Casp2(C320S) mutant mice to demonstrate that caspase-2 catalytic activity is essential for its function in limiting aneuploidy. Our results provide direct evidence that the apoptotic activity of caspase-2 is necessary for deleting cells with mitotic aberrations to limit aneuploidy.	[Dawar, S.; Lim, Y.; Puccini, J.; Dorstyn, L.; Kumar, S.] Univ South Australia, Ctr Canc Biol, Frome Rd, Adelaide, SA 5001, Australia; [Puccini, J.] NYU, Dept Biochem & Mol Pharmacol, New York, NY USA; [Puccini, J.] NYU, Dept Med, 550 1St Ave, New York, NY 10016 USA; [White, M.; Thomas, P.] Univ Adelaide, Sch Biol Sci, SA Genome Editing Facil, Adelaide, SA, Australia; [White, M.; Thomas, P.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [Bouchier-Hayes, L.] Baylor Coll Med, Dept Pediat Hematol, Houston, TX 77030 USA; [Green, D. R.] St Jude Childrens Res Hosp, Immunol Dept, 332 N Lauderdale St, Memphis, TN 38105 USA	Centre for Cancer Biology; University of South Australia; New York University; New York University; University of Adelaide; Robinson Research Institute; University of Adelaide; Baylor College of Medicine; St Jude Children's Research Hospital	Kumar, S (corresponding author), Univ South Australia, Ctr Canc Biol, Frome Rd, Adelaide, SA 5001, Australia.	sharad.kumar@unisa.edu.au	Dorstyn, Loretta/F-3673-2013; Bouchier-Hayes, Lisa/T-9491-2019; Kumar, Sharad/AAX-7787-2020; Dawar, Swati/AAX-1062-2021; Green, Douglas R/N-8083-2018	Dorstyn, Loretta/0000-0001-9886-0989; Bouchier-Hayes, Lisa/0000-0003-3886-5977; Kumar, Sharad/0000-0001-7126-9814; Green, Douglas R/0000-0002-7332-1417; Lim, Yoon/0000-0003-1110-1969	National Health and Medical Research Council [1043057]; UniSA Presidential Award;  [1103006]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); UniSA Presidential Award; 	We thank staff at the SA Pathology animal resource facility for help in maintaining the mouse strains and members of our laboratory for discussions and useful comments. Funding for this work was provided by the National Health and Medical Research Council project grant (1043057) and a Senior Principal Research Fellowship (1103006) to Sharad Kumar. Loretta Dorstyn was a Cancer Council Research Fellow and Swati Dawar is supported by a UniSA Presidential Award.	Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Belkhiri A, 2012, CLIN CANCER RES, V18, P3889, DOI 10.1158/1078-0432.CCR-11-3182; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Choi M, 2015, CANCER LETT, V357, P591, DOI 10.1016/j.canlet.2014.12.023; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Decordier I, 2002, MUTAGENESIS, V17, P337, DOI 10.1093/mutage/17.4.337; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Dorstyn L, 2014, METHODS MOL BIOL, V1133, P71, DOI 10.1007/978-1-4939-0357-3_4; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li M, 2009, CELL CYCLE, V8, P3440, DOI 10.4161/cc.8.21.9688; Lu B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012963; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Palmisiano ND, 2015, AM J HEMATOL, V90, P1071, DOI 10.1002/ajh.24177; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Parsons MJ., 2015, COLD SPRING HARB PRO, V2015; Peterson SE, 2012, J NEUROSCI, V32, P16213, DOI 10.1523/JNEUROSCI.3706-12.2012; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shalini S, 2016, CELL DEATH DIFFER, V23, P1727, DOI 10.1038/cdd.2016.81; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Taghiyev Agshin F, 2011, Genes Cancer, V2, P745, DOI 10.1177/1947601911426007; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wasch R, 2010, RECENT RESULTS CANC, V184, P215, DOI 10.1007/978-3-642-01222-8_15; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030	54	42	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2704	2714		10.1038/onc.2016.423	http://dx.doi.org/10.1038/onc.2016.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991927	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000401120900008
J	Su, X; Napoli, M; Abbas, HA; Venkatanarayan, A; Bui, NHB; Coarfa, C; Gi, YJ; Kittrell, F; Gunaratne, PH; Medina, D; Rosen, JM; Behbod, F; Flores, ER				Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Coarfa, C.; Gi, Y. J.; Kittrell, F.; Gunaratne, P. H.; Medina, D.; Rosen, J. M.; Behbod, F.; Flores, E. R.			TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway	ONCOGENE			English	Article							STEM-CELL MARKERS; BREAST-CANCER; EPITHELIAL MIGRATION; GLAND DEVELOPMENT; SELF-RENEWAL; P63; EXPRESSION; MORPHOGENESIS; POLARITY; DELTA-NP63	Mechanisms regulating the transition of mammary epithelial cells (MECs) to mammary stem cells (MaSCs) and to tumor-initiating cells (TICs) have not been entirely elucidated. The p53 family member, p63, is critical for mammary gland development and contains transactivation domain isoforms, which have tumor-suppressive activities, and the Delta N isoforms, which act as oncogenes. In the clinic, p63 is often used as a diagnostic marker, and further analysis of the function of TAp63 in the mammary gland is critical for improved diagnosis and patient care. Loss of TAp63 in mice leads to the formation of aggressive metastatic mammary adenocarcinoma at 9-16 months of age. Here we show that TAp63 is crucial for the transition of mammary cancer cells to TICs. When TAp63 is lost, MECs express embryonic and MaSC signatures and activate the Hippo pathway. These data indicate a crucial role for TAp63 in mammary TICs and provide a mechanism for its role as a tumor-and metastasis-suppressor in breast cancer.	[Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Gi, Y. J.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Gi, Y. J.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Venkatanarayan, A.; Bui, N. H. B.; Kittrell, F.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Canc Biol & Evolut Program, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Coarfa, C.; Medina, D.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gunaratne, P. H.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Behbod, F.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; Baylor College of Medicine; University of Houston System; University of Houston; University of Kansas; University of Kansas Medical Center	Flores, ER (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	elsa.flores@moffitt.org		Napoli, Marco/0000-0001-7192-5252; Bui, Ngoc/0000-0001-5161-1133	National Cancer Institute (NCI) [R35CA197452, R01CA160394, R01CA134796]; Cancer Prevention & Research Institute of Texas (CPRIT) [RP120124, RP150094]; Hildegardo E and Olga M. Flores Foundation; NCI-Cancer Center Core Grant (University of Texas MD Anderson Cancer Center) [CA-16672]; Cancer Prevention and Research Institute of Texas [RP140106]; American Cancer Society grant [IRG-09-062-01];  [R01CA16303]; NATIONAL CANCER INSTITUTE [R35CA197452, P30CA016672, R01CA134796, R01CA160394] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention & Research Institute of Texas (CPRIT); Hildegardo E and Olga M. Flores Foundation; NCI-Cancer Center Core Grant (University of Texas MD Anderson Cancer Center); Cancer Prevention and Research Institute of Texas; American Cancer Society grant(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the work of Henry P Adams, Microscopy Core of the Genetics Department. We also thank Leif Ellisen for the kind gift of the TAp63 shRNA. This study was funded by R35CA197452, R01CA160394 and R01CA134796 from the National Cancer Institute (NCI) and RP120124 and RP150094 from the Cancer Prevention & Research Institute of Texas (CPRIT) and funding from the Hildegardo E and Olga M. Flores Foundation to ERF, NCI-Cancer Center Core Grant (CA-16672) (University of Texas MD Anderson Cancer Center) and R01CA16303 to JMR. ERF is an NCI Outstanding Investigator, a Moffitt Distinguished Scholar, a scholar of the Leukemia and Lymphoma Society, the Rita Allen Foundation and the V Foundation for Cancer Research. MN is a CPRIT-TRIUMPH Scholar and was supported by a Research Training Award from the Cancer Prevention and Research Institute of Texas (RP140106). HAA is an Odyssey Fellow at MD Anderson Cancer Center. FB was supported in part by an American Cancer Society grant (IRG-09-062-01), awarded to the University of Kansas Medical Center.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Amin N, 2012, FRONT BIOSCI-LANDMRK, V17, P784, DOI 10.2741/3957; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Biernaskie J, 2009, CELL STEM CELL, V5, P610, DOI 10.1016/j.stem.2009.10.019; Chakravarti D, 2014, P NATL ACAD SCI USA, V111, pE572, DOI 10.1073/pnas.1319743111; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kostera MI, 2004, J DERMATOL SCI, V34, P3, DOI 10.1016/j.jdermsci.2003.10.003; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0070-0; Li N, 2008, STEM CELLS, V26, P1253, DOI 10.1634/stemcells.2007-0691; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nguyen-Ngoc KV, 2015, METHODS MOL BIOL, V1189, P135, DOI 10.1007/978-1-4939-1164-6_10; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tsang JYS, 2012, BREAST CANCER RES TR, V136, P407, DOI 10.1007/s10549-012-2271-6; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Venkatanarayan A, 2015, NATURE, V517, P626, DOI 10.1038/nature13910; Yamben IF, 2013, DEV BIOL, V384, P41, DOI 10.1016/j.ydbio.2013.09.027; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yates LL, 2013, DEV BIOL, V373, P267, DOI 10.1016/j.ydbio.2012.11.012; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhao R, 2014, DEV CELL, V30, P151, DOI 10.1016/j.devcel.2014.06.004	51	23	24	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2377	2393		10.1038/onc.2016.388	http://dx.doi.org/10.1038/onc.2016.388			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27869165	Green Published, hybrid			2022-12-28	WOS:000400268900005
J	Mowers, EE; Sharifi, MN; Macleod, KF				Mowers, E. E.; Sharifi, M. N.; Macleod, K. F.			Autophagy in cancer metastasis	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE; HYPOXIA-INDUCED AUTOPHAGY; SUPPRESSOR GENE ARHI; BREAST-CANCER; EXTRACELLULAR-MATRIX; STEM-CELLS; OVARIAN-CANCER; TUMOR-CELLS; BONE-MARROW	Autophagy is a highly conserved self-degradative process that has a key role in cellular stress responses and survival. Recent work has begun to explore the function of autophagy in cancer metastasis, which is of particular interest given the dearth of effective therapeutic options for metastatic disease. Autophagy is induced upon progression of various human cancers to metastasis and together with data from genetically engineered mice and experimental metastasis models, a role for autophagy at nearly every phase of the metastatic cascade has been identified. Specifically, autophagy has been shown to be involved in modulating tumor cell motility and invasion, cancer stem cell viability and differentiation, resistance to anoikis, epithelial-to-mesenchymal transition, tumor cell dormancy and escape from immune surveillance, with emerging functions in establishing the pre-metastatic niche and other aspects of metastasis. In this review, we provide a general overview of how autophagy modulates cancer metastasis and discuss the significance of new findings for disease management.	[Mowers, E. E.; Sharifi, M. N.; Macleod, K. F.] Univ Chicago, Ben May Dept Canc Res, 929 East 57th St GCIS W338, Chicago, IL 60422 USA; [Mowers, E. E.] Univ Chicago, Interdisciplinary Scientist Training Program, Chicago, IL 60637 USA; [Sharifi, M. N.] Univ Chicago, Med Scientist Training Program, Chicago, IL USA; [Sharifi, M. N.; Macleod, K. F.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Macleod, KF (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 East 57th St GCIS W338, Chicago, IL 60422 USA.	kmacleod@uchicago.edu		Sharifi, Marina/0000-0003-0128-3033	NIH [RO1 CA 162405, T32 GM007281, T32 CA009594]; NATIONAL CANCER INSTITUTE [R01CA162405, T32CA009594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Grant support for this work includes NIH RO1 CA 162405 to KFM, T32 GM007281 supported EEM and T32 CA009594 supported MNS.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Belaid A, 2013, CANCER RES, V73, P4311, DOI 10.1158/0008-5472.CAN-12-4142; Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Capparelli C, 2012, CELL CYCLE, V11, P2285, DOI 10.4161/cc.20718; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen GC, 2008, AUTOPHAGY, V4, P37, DOI 10.4161/auto.5141; Chen N, 2013, AUTOPHAGY, V9, P1214, DOI 10.4161/auto.24870; Chen S, 2016, GENE DEV, V30, P856, DOI 10.1101/gad.276428.115; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Deretic V, 2012, TRENDS CELL BIOL, V22, P397, DOI 10.1016/j.tcb.2012.04.008; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Ewing J, 1928, NEOPLASTIC DIS TREAT; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frasa MAM, 2010, CURR BIOL, V20, P198, DOI 10.1016/j.cub.2009.12.053; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200; Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Han CR, 2011, TOHOKU J EXP MED, V223, P243, DOI 10.1620/tjem.223.243; Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Jiang S, 2013, J INNATE IMMUN, V5, P471, DOI 10.1159/000346707; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kadandale P, 2010, P NATL ACAD SCI USA, V107, P10502, DOI 10.1073/pnas.0914168107; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Karrison TG, 1999, JNCI-J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075; Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim SI, 2012, J BIOL CHEM, V287, P11677, DOI 10.1074/jbc.M111.308460; Kim YH, 2016, FEBS LETT, V590, P1365, DOI 10.1002/1873-3468.12172; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Ladoire S, 2016, AUTOPHAGY, V12, P864, DOI 10.1080/15548627.2016.1154244; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451; Lu Z, 2014, CELL DEATH DIFFER, V21, P1275, DOI 10.1038/cdd.2014.48; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017; Macintosh RL, 2012, CELL CYCLE, V11, P2022, DOI 10.4161/cc.20424; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; McGowan PM, 2009, FUTURE ONCOL, V5, P1083, DOI [10.2217/fon.09.73, 10.2217/FON.09.73]; Meade J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019684; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mleczak A, 2013, CELL SIGNAL, V25, P1, DOI 10.1016/j.cellsig.2012.09.010; Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakano A, 2010, NAT CELL BIOL, V12, P583, DOI 10.1038/ncb2060; Neill T, 2014, AM J PATHOL, V184, P2146, DOI 10.1016/j.ajpath.2014.05.010; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Oliver L, 2012, STEM CELLS DEV, V21, P2779, DOI 10.1089/scd.2012.0124; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398; Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375; Roh-Johnson M, 2014, ONCOGENE, V33, P4203, DOI 10.1038/onc.2013.377; Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93; Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Tra T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027485; Till A, 2015, AUTOPHAGY, V11, P1652, DOI 10.1080/15548627.2015.1059558; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vazquez P, 2012, AUTOPHAGY, V8, P187, DOI 10.4161/auto.8.2.18535; Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Witkiewicz AK, 2009, CANCER BIOL THER, V8, P1071, DOI 10.4161/cbt.8.11.8874; Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhao H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0475-1; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	178	289	301	3	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1619	1630		10.1038/onc.2016.333	http://dx.doi.org/10.1038/onc.2016.333			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27593926	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000397460600002
J	Staffas, A; Arabanian, LS; Wei, SY; Jansson, A; Stahlman, S; Johansson, P; Fogelstrand, L; Cammenga, J; Kuchenbauer, F; Palmqvist, L				Staffas, A.; Arabanian, L. S.; Wei, S. Y.; Jansson, A.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Cammenga, J.; Kuchenbauer, F.; Palmqvist, L.			Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; HEMATOPOIETIC STEM-CELL; BONE-MARROW-CELLS; HOXA9; GENE; EXPRESSION; MUTATION; RECEPTOR; LIGAND; AC220	HOXA9, MEIS1 and FLT3 are genes frequently upregulated in human acute myeloid leukemia. Hoxa9 and Meis1 also cooperate to induce aggressive AML with high Flt3 expression in mice, suggesting an important role for Flt3 in Hoxa9/Meis1-induced leukemogenesis. To define the role of Flt3 in AML with high Hoxa9/Meis1, we treated mice with Hoxa9/Meis1-induced AML with the Flt3 inhibitor AC220, used an Flt3-ligand (FL -/-) knockout model, and investigated whether overexpression of Flt3 could induce leukemia together with overexpression of Hoxa9. Flt3 inhibition by AC220 did not delay AML development in mice transplanted with bone marrow cells overexpressing Hoxa9 and Meis1. In addition, Hoxa9/Meis1 cells induced AML in FL -/- mice as rapid as in wild-type mice. However, FL -/- mice had reduced organ infiltration compared with wild-type mice, suggesting some Flt3 dependent effect on leukemic invasiveness. Interestingly, leukemic Hoxa9/Meis1 cells from sick mice expressed high levels of Flt3 regardless of presence of its ligand, showing that Flt3 is a passive marker on these cells. In line with this, combined engineered overexpression of Flt3 and Hoxa9 did not accelerate the progression to AML. We conclude that the Hoxa9- and Meis1-associated upregulation of Flt3 is not a requirement for leukemic progression induced by Hoxa9 and Meis1.	[Staffas, A.; Arabanian, L. S.; Wei, S. Y.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Palmqvist, L.] Univ Gothenburg, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden; [Staffas, A.; Jansson, A.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Palmqvist, L.] Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, S-41345 Gothenburg, Sweden; [Wei, S. Y.] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden; [Cammenga, J.] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Cammenga, J.] Linkoping Univ Hosp, Dept Hematol, Linkoping, Sweden; [Kuchenbauer, F.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany	University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Linkoping University; Linkoping University; Ulm University	Palmqvist, L (corresponding author), Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, S-41345 Gothenburg, Sweden.	lars.palmqvist@clinchem.gu.se		Kuchenbauer, Florian/0000-0002-9820-3409	Swedish Cancer Society [CAN2014/525]; Vastra Gotalandsregionen [ALFGBG-431881]; Deutsche Krebshilfe [109420]; European Hematology Association; Deutsche Forschungsgemeinschaft [SFB 1074]; Assar Gabrielsson's foundation	Swedish Cancer Society(Swedish Cancer Society); Vastra Gotalandsregionen; Deutsche Krebshilfe(Deutsche Krebshilfe); European Hematology Association; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Assar Gabrielsson's foundation	We wish to thank Carina Wasslavik, Christina Nilsson, and Susanne Li for valuable technical assistance. This work was supported by grants to LP from the Swedish Cancer Society (CAN2014/525) and the Vastra Gotalandsregionen (ALFGBG-431881). FK was supported by grants from Deutsche Krebshilfe grant 109420 ( Max-Eder program), fellowship 2010/04 by the European Hematology Association, and by the Deutsche Forschungsgemeinschaft (SFB 1074, project A5). SYW was supported by a grant from Assar Gabrielsson's foundation.	Argiropoulos B, 2008, EXP HEMATOL, V36, P845, DOI 10.1016/j.exphem.2008.02.011; Balgobind BV, 2011, LEUKEMIA, V25, P1239, DOI 10.1038/leu.2011.90; BRASEL K, 1995, LEUKEMIA, V9, P1212; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Kampa-Schittenhelm KM, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-19; Kikushige Y, 2008, J IMMUNOL, V180, P7358, DOI 10.4049/jimmunol.180.11.7358; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Konig H, 2015, EXPERT OPIN THER TAR, V19, P37, DOI 10.1517/14728222.2014.960843; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kuchenbauer F, 2005, HAEMATOLOGICA, V90, P1617; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Lisovsky M, 1996, LEUKEMIA, V10, P1012; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Morgado E, 2007, BLOOD, V109, P4020, DOI 10.1182/blood-2006-01-039586; Nakao M, 1996, LEUKEMIA, V10, P1911; Palmqvist L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000768; Palmqvist L, 2006, BLOOD, V108, P1030, DOI 10.1182/blood-2005-12-007005; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; SB H, 2013, DESIGNING CLIN RES E; Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Staffas A, 2011, BLOOD, V118, P5905, DOI 10.1182/blood-2011-05-353185; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Taylor SJ, 2012, BLOOD, V120, P4049, DOI 10.1182/blood-2012-06-436675; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034	33	10	10	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1516	1524		10.1038/onc.2016.318	http://dx.doi.org/10.1038/onc.2016.318			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617578				2022-12-28	WOS:000397458100006
J	Cidre-Aranaz, F; Grunewald, TGP; Surdez, D; Garcia-Garcia, L; Lazaro, JC; Kirchner, T; Gonzalez-Gonzalez, L; Sastre, A; Garcia-Miguel, P; Lopez-Perez, SE; Monzon, S; Delattre, O; Alonso, J				Cidre-Aranaz, F.; Gruenewald, T. G. P.; Surdez, D.; Garcia-Garcia, L.; Lazaro, J. Carlos; Kirchner, T.; Gonzalez-Gonzalez, L.; Sastre, A.; Garcia-Miguel, P.; Lopez-Perez, S. E.; Monzon, S.; Delattre, O.; Alonso, J.			EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLECULAR PATHOGENESIS; EWS/FLI1 ONCOPROTEIN; DOWN-REGULATION; TARGET GENES; EXPRESSION; MIGRATION; INVASION; RECEPTOR; FUSION	Ewing sarcoma is characterized by chromosomal translocations fusing the EWS gene with various members of the ETS family of transcription factors, most commonly FLI1. EWS-FLI1 is an aberrant transcription factor driving Ewing sarcoma tumorigenesis by either transcriptionally inducing or repressing specific target genes. Herein, we showed that Sprouty 1 (SPRY1), which is a physiological negative feedback inhibitor downstream of fibroblast growth factor (FGF) receptors (FGFRs) and other RAS-activating receptors, is an EWS-FLI1 repressed gene. EWS-FLI1 knockdown specifically increased the expression of SPRY1, while other Sprouty family members remained unaffected. Analysis of SPRY1 expression in a panel of Ewing sarcoma cells showed that SPRY1 was not expressed in Ewing sarcoma cell lines, suggesting that it could act as a tumor suppressor gene in these cells. In agreement, induction of SPRY1 in three different Ewing sarcoma cell lines functionally impaired proliferation, clonogenic growth and migration. In addition, SPRY1 expression inhibited extracellular signal-related kinase/mitogen-activated protein kinase (MAPK) signaling induced by serum and basic FGF (bFGF). Moreover, treatment of Ewing sarcoma cells with the potent FGFR inhibitor PD-173074 reduced bFGF-induced proliferation, colony formation and in vivo tumor growth in a dose-dependent manner, thus mimicking SPRY1 activity in Ewing sarcoma cells. Although the expression of SPRY1 was low when compared with other tumors, SPRY1 was variably expressed in primary Ewing sarcoma tumors and higher expression levels were significantly associated with improved outcome in a large patient cohort. Taken together, our data indicate that EWS-FLI1-mediated repression of SPRY1 leads to unrestrained bFGF-induced cell proliferation, suggesting that targeting the FGFR/MAPK pathway can constitute a promising therapeutic approach for this devastating disease.	[Cidre-Aranaz, F.; Garcia-Garcia, L.; Lazaro, J. Carlos; Gonzalez-Gonzalez, L.; Lopez-Perez, S. E.; Monzon, S.; Alonso, J.] Inst Salud Carlos III, Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Ctra Majadahonda Pozuelo Km 2, Majadahonda Madrid 28220, Spain; [Gruenewald, T. G. P.; Surdez, D.; Delattre, O.] Genet & Biol Canc Inst Curie Res Ctr, INSERM U830, Paris, France; [Gruenewald, T. G. P.] Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Munich, Germany; [Sastre, A.; Garcia-Miguel, P.] Hosp Infantil Univ La Paz, Unidad Hematooncol Pediat, Madrid, Spain; [Monzon, S.] Inst Salud Carlos III, CIBERER U758, Madrid, Spain	Instituto de Salud Carlos III; Instituto de Investigacion de Enfermedades Raras (IIER); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; University of Munich; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III	Alonso, J (corresponding author), Inst Salud Carlos III, Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Ctra Majadahonda Pozuelo Km 2, Majadahonda Madrid 28220, Spain.	fjalonso@isciii.es	Alonso, Javier/B-6012-2013; Surdez, Didier/ABG-4565-2020; Monzon, Sara/AAG-2909-2021; Grünewald, Thomas G. P./O-2317-2013	Alonso, Javier/0000-0002-6287-8391; Monzon, Sara/0000-0002-0740-6324; Grünewald, Thomas G. P./0000-0003-0920-7377; GARCIA, LAURA/0000-0002-8585-849X; Gonzalez-Gonzalez, Laura/0000-0003-0372-2650; Cidre Aranaz, Florencia/0000-0002-0246-7179; delattre, olivier/0000-0002-8730-2276	Asociacion Pablo Ugarte and Miguelanez SA; ASION-La Hucha de Tomas; Fundacion La Sonrisa de Alex; Instituto de Salud Carlos III [PI12/00816, RTICC RD12/0036/0027]; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung; Walter Schulz Foundation; German Cancer Aid [DKH-111886, DKH-70112257]; Ligue Nationale Contre Le Cancer (Equipe labellisee); European PROVABES grant; Reinhard Frank Foundation; Fritz Thyssen Foundation [FTH-40.15.0.030MN]; European ASSET grant; European EEC FP7 grant	Asociacion Pablo Ugarte and Miguelanez SA; ASION-La Hucha de Tomas; Fundacion La Sonrisa de Alex; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung; Walter Schulz Foundation; German Cancer Aid(Deutsche Krebshilfe); Ligue Nationale Contre Le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); European PROVABES grant; Reinhard Frank Foundation; Fritz Thyssen Foundation; European ASSET grant; European EEC FP7 grant	FC-A, LG-G, JCL, AS, PG-M, SEL-P, SM and JA are supported by Asociacion Pablo Ugarte and Miguelanez SA, ASION-La Hucha de Tomas, Fundacion La Sonrisa de Alex and Instituto de Salud Carlos III (PI12/00816 and Spanish Cancer Network RTICC RD12/0036/0027). TGPG is supported by a grant from 'Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed)', the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation, by LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative, the 'Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung', the Walter Schulz Foundation, the Fritz Thyssen Foundation (FTH-40.15.0.030MN) and by the German Cancer Aid (DKH-111886 and DKH-70112257). The 'Genetics and Biology of Cancers' team (TGPG, DS and OD) is supported by grants from the Ligue Nationale Contre Le Cancer (Equipe labellisee). This work was also supported by the European PROVABES, ASSET and EEC FP7 grants. We also thank the following associations for their invaluable support: the Societe Francaise des Cancers de l'Enfant, Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon, Enfants et Sante and les Amis de Claire. We thank Dr S Navarro (University of Valencia, Valencia, Spain) and Dr TJ Triche (Children's Hospital Los Angeles, Los Angeles, USA) for providing us with Ewing sarcoma cell lines A4573 and TTC-466, respectively.	Agelopoulos K, 2015, CLIN CANCER RES, V21, P4935, DOI 10.1158/1078-0432.CCR-14-2744; Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Chalkiadaki G, 2009, INT J BIOCHEM CELL B, V41, P1323, DOI 10.1016/j.biocel.2008.11.008; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Cidre-Aranaz F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00162; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190; Garcia-Aragoncillo E, 2008, ONCOGENE, V27, P6034, DOI 10.1038/onc.2008.203; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Grohar PJ, 2013, PHARMACOL THERAPEUT, V137, P216, DOI 10.1016/j.pharmthera.2012.10.004; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Grunewald TGP, 2015, NAT GENET, V47, P1073, DOI 10.1038/ng.3363; Grunewald TGP, 2012, MOL CANCER RES, V10, P52, DOI 10.1158/1541-7786.MCR-11-0524; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Kamura S, 2010, BRIT J CANCER, V103, P370, DOI 10.1038/sj.bjc.6605775; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 2003, ONCOGENE, V22, P3193, DOI 10.1038/sj.onc.1206391; Kovar H, 2014, EXPERT OPIN THER TAR, V18, P1315, DOI 10.1517/14728222.2014.947963; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Kwabi-Addo B, 2009, EPIGENETICS, V4, P54, DOI 10.4161/epi.4.1.7400; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Liu XZ, 2014, ADV MATER INTERFACES, V1, DOI 10.1002/admi.201300053; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Macia A, 2012, ONCOGENE, V31, P3961, DOI 10.1038/onc.2011.556; Mackintosh C, 2010, CANCER BIOL THER, V9, P655, DOI 10.4161/cbt.9.9.11511; Masoumi-Moghaddam S, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-61; Mekkawy AH, 2014, TUMOR BIOL, V35, P5037, DOI 10.1007/s13277-014-1665-y; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Minowada G, 1999, DEVELOPMENT, V126, P4465; Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Surdez D, 2012, CANCER RES, V72, P4494, DOI 10.1158/0008-5472.CAN-12-0371; Terada N, 2014, J CELL BIOCHEM, V115, P1505, DOI 10.1002/jcb.24805; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Wiles ET, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059369; Willier S, 2013, BIOL CELL, V105, P317, DOI 10.1111/boc.201300011; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yue PYK, 2010, J BIOMOL SCREEN, V15, P427, DOI 10.1177/1087057110361772; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710; Zhu LM, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00230	52	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					766	776		10.1038/onc.2016.244	http://dx.doi.org/10.1038/onc.2016.244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27375017	Green Accepted			2022-12-28	WOS:000394168200004
J	Hsu, TI; Lin, SC; Lu, PS; Chang, WC; Hung, CY; Yeh, YM; Su, WC; Liao, PC; Hung, JJ				Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, C-Y; Yeh, Y-M; Su, W-C; Liao, P-C; Hung, J-J			MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy (vol 34, pg 826, 2015)	ONCOGENE			English	Correction													Hsu, Tsung-I/AAK-9942-2020	Hsu, Tsung-I/0000-0002-7524-7740				Hsu TI, 2015, ONCOGENE, V34, P826, DOI 10.1038/onc.2014.22	1	4	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					875	876		10.1038/onc.2016.274	http://dx.doi.org/10.1038/onc.2016.274			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27477695	Bronze			2022-12-28	WOS:000394168200014
J	Garg, N; Bakhshinyan, D; Venugopal, C; Mahendram, S; Rosa, DA; Vijayakumar, T; Manoranjan, B; Hallett, R; McFarlane, N; Delaney, KH; Kwiecien, JM; Arpin, CC; Lai, PS; Gomez-Biagi, RF; Ali, AM; de Araujo, ED; Ajani, OA; Hassell, JA; Gunning, PT; Singh, SK				Garg, N.; Bakhshinyan, D.; Venugopal, C.; Mahendram, S.; Rosa, D. A.; Vijayakumar, T.; Manoranjan, B.; Hallett, R.; McFarlane, N.; Delaney, K. H.; Kwiecien, J. M.; Arpin, C. C.; Lai, P-S; Gomez-Biagi, R. F.; Ali, A. M.; de Araujo, E. D.; Ajani, O. A.; Hassell, J. A.; Gunning, P. T.; Singh, S. K.			CD133(+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence	ONCOGENE			English	Article							CANCER STEM-CELLS; SMALL-MOLECULE INHIBITOR; SUPPRESSES GROWTH; CYCLE ARREST; EXPRESSION; APOPTOSIS; PROLIFERATION; SUBGROUPS; PATHWAY; TARGET	Medulloblastoma (MB), the most common malignant paediatric brain tumor, is currently treated using a combination of surgery, craniospinal radiotherapy and chemotherapy. Owing to MB stem cells (MBSCs), a subset of MB patients remains untreatable despite standard therapy. CD133 is used to identify MBSCs although its functional role in tumorigenesis has yet to be determined. In this work, we showed enrichment of CD133 in Group 3 MB is associated with increased rate of metastasis and poor clinical outcome. The signal transducers and activators of transcription-3 (STAT3) pathway are selectively activated in CD133(+) MBSCs and promote tumorigenesis through regulation of c-MYC, a key genetic driver of Group 3 MB. We screened compound libraries for STAT3 inhibitors and treatment with the selected STAT3 inhibitors resulted in tumor size reduction in vivo. We propose that inhibition of STAT3 signaling in MBSCs may represent a potential therapeutic strategy to treat patients with recurrent MB.	[Garg, N.; Bakhshinyan, D.; Venugopal, C.; Mahendram, S.; Vijayakumar, T.; Manoranjan, B.; McFarlane, N.; Hassell, J. A.; Singh, S. K.] McMaster Stem Cell & Canc Res Inst, Hamilton, ON, Canada; [Garg, N.; Venugopal, C.; Mahendram, S.; Vijayakumar, T.; McFarlane, N.; Ajani, O. A.; Singh, S. K.] McMaster Univ, Dept Surg, Fac Hlth Sci, Hamilton, ON, Canada; [Bakhshinyan, D.; Vijayakumar, T.; Manoranjan, B.; Hassell, J. A.; Singh, S. K.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [Rosa, D. A.; Arpin, C. C.; Lai, P-S; Gomez-Biagi, R. F.; de Araujo, E. D.; Gunning, P. T.] Univ Toronto, Dept Chem, Mississauga, ON, Canada; [Manoranjan, B.; Singh, S. K.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada; [Hallett, R.; Hassell, J. A.] McMaster Univ, McMaster Ctr Funct Genom, Hamilton, ON, Canada; [Delaney, K. H.; Kwiecien, J. M.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Kwiecien, J. M.] Med Univ Lublin, Dept Neurosurg & Paediat Neurosurg, Lublin, Poland; [Ali, A. M.] Assiut Univ, Dept Med Chem, Fac Pharm, Assiut, Egypt; [Hassell, J. A.] McMaster Univ, Dept Pathol, Hamilton, ON, Canada; [Hassell, J. A.] McMaster Univ, Dept Mol Med, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Mississauga; McMaster University; McMaster University; McMaster University; Medical University of Lublin; Egyptian Knowledge Bank (EKB); Assiut University; McMaster University; McMaster University	Singh, SK (corresponding author), McMaster Univ, Stem Cell & Canc Res Inst, MDCL 5027,1280 Main St West, Hamilton, ON L8S 4K1, Canada.	ssingh@mcmaster.ca	Singh, Sheila K/W-2799-2018; Garg, Neha/AAG-5180-2020	Singh, Sheila K/0000-0003-1272-5300; Garg, Neha/0000-0003-2227-8292; Ali, Ahmed Magdy/0000-0001-7913-8544	Department of Surgery at McMaster University; Canada Research Chair award; Canadian Institutes of Health Research (CIHR) Operating Grant [RN193483-299211, MOP-142353]; Stem Cell Network Drug Discovery Grant; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute; Terry Fox Research Institute New Investigator Award; Alberta Innovates; Stem Cell Network; CIHR; ORF; CFI	Department of Surgery at McMaster University; Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Canadian Institutes of Health Research (CIHR) Operating Grant(Canadian Institutes of Health Research (CIHR)); Stem Cell Network Drug Discovery Grant; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Terry Fox Research Institute New Investigator Award; Alberta Innovates; Stem Cell Network; CIHR(Canadian Institutes of Health Research (CIHR)); ORF; CFI(Canada Foundation for Innovation)	Dr Sheila K Singh is supported by funds from the Department of Surgery at McMaster University, Canada Research Chair award, Canadian Institutes of Health Research (CIHR) Operating Grant #RN193483-299211, Stem Cell Network Drug Discovery Grant, Ontario Institute for Cancer Research Cancer Stem Cell Program, the Canadian Cancer Society Research Institute and Terry Fox Research Institute New Investigator Award. The Alberta Innovates, Stem Cell Network, CIHR, ORF and CFI fund Dr Patrick T. Gunning's research. Dr John A. Hassell is supported by the funds from CIHR Operating Grant # MOP-142353	Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Ashizawa T, 2013, INT J ONCOL, V43, P219, DOI 10.3892/ijo.2013.1916; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang CJ, 2012, CHILD NERV SYST, V28, P363, DOI 10.1007/s00381-011-1672-x; Chen FX, 2010, J MOL NEUROSCI, V40, P353, DOI 10.1007/s12031-009-9323-3; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Cox CV, 2009, BLOOD, V113, P3287, DOI 10.1182/blood-2008-04-154187; Ding BB, 2008, BLOOD, V111, P1515, DOI 10.1182/blood-2007-04-087734; Eiring AM, 2015, LEUKEMIA, V29, P586, DOI 10.1038/leu.2014.245; FRIEDMAN HS, 1992, CANCER RES, V52, P5373; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086; Gu CY, 2011, ONCOL LETT, V2, P357, DOI 10.3892/ol.2011.235; Haftchenary S, 2013, ACS MED CHEM LETT, V4, P1102, DOI 10.1021/ml4003138; Haftchenary S, 2011, ANTI-CANCER DRUG, V22, P115, DOI 10.1097/CAD.0b013e328341185b; Holtick U, 2005, LEUKEMIA, V19, P936, DOI 10.1038/sj.leu.2403750; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li GH, 2010, INT J ONCOL, V37, P103, DOI 10.3892/ijo_00000658; Lin L, 2011, BIOCHEM BIOPH RES CO, V416, P246, DOI 10.1016/j.bbrc.2011.10.112; Mabbott DJ, 2005, J CLIN ONCOL, V23, P2256, DOI 10.1200/JCO.2005.01.158; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Sai K, 2012, J NEURO-ONCOL, V107, P487, DOI 10.1007/s11060-011-0786-z; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Singh M, 2015, ONCOTARGET, V6, P27461, DOI 10.18632/oncotarget.4742; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Stechishin OD, 2013, NEURO-ONCOLOGY, V15, P198, DOI 10.1093/neuonc/nos302; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Venugopal C, 2015, CLIN CANCER RES, V21, P5324, DOI 10.1158/1078-0432.CCR-14-3147; Venugopal C, 2012, JOVE-J VIS EXP, DOI 10.3791/4111; Wang XiaoLi, 2012, Agricultural Biotechnology, V1, P1; Won C, 2015, HEPATOLOGY, V62, P1160, DOI 10.1002/hep.27968; Xiao H, 2015, J BIOL CHEM, V290, P3418, DOI 10.1074/jbc.M114.616748; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	55	38	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					606	617		10.1038/onc.2016.235	http://dx.doi.org/10.1038/onc.2016.235			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27775079	Green Published, hybrid			2022-12-28	WOS:000394167700003
J	Tournillon, AS; Lopez, I; Malbert-Colas, L; Findakly, S; Naski, N; Olivares-Illana, V; Karakostis, K; Vojtesek, B; Nylander, K; Fahraeus, R				Tournillon, A-S; Lopez, I.; Malbert-Colas, L.; Findakly, S.; Naski, N.; Olivares-Illana, V.; Karakostis, K.; Vojtesek, B.; Nylander, K.; Fahraeus, R.			p53 binds the mdmx mRNA and controls its translation	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DNA-DAMAGE; EMBRYONIC LETHALITY; FEEDBACK LOOP; ACTIVATION; PROTEIN; GENE; DOMAIN; AMPLIFICATION; RECOGNITION	MDMX and MDM2 are two nonredundant essential regulators of p53 tumor suppressor activity. MDM2 controls p53 expression levels, whereas MDMX is predominantly a negative regulator of p53 trans-activity. The feedback loops between MDM2 and p53 are well studied and involve both negative and positive regulation on transcriptional, translational and post-translational levels but little is known on the regulatory pathways between p53 and MDMX. Here we show that overexpression of p53 suppresses mdmx mRNA translation in vitro and in cell-based assays. The core domain of p53 binds the 5' untranslated region (UTR) of the mdmx mRNA in a zinc-dependent manner that together with a trans-suppression domain located in p53 N-terminus controls MDMX synthesis. This interaction can be visualized in the nuclear and cytoplasmic compartment. Fusion of the mdmx 5' UTR to the ovalbumin open reading frame leads to suppression of ovalbumin synthesis. Interestingly, the transcription inactive p53 mutant R273H has a different RNA-binding profile compared with the wild-type p53 and differentiates the synthesis of MDMX isoforms. This study describes p53 as a trans-suppressor of the mdmx mRNA and adds a further level to the intricate feedback system that exist between p53 and its key regulatory factors and emphasizes the important role of mRNA translation control in regulating protein expression in the p53 pathway.	[Tournillon, A-S; Lopez, I.; Malbert-Colas, L.; Findakly, S.; Naski, N.; Karakostis, K.; Fahraeus, R.] Univ Paris 07, Hop St Louis, Inst Natl Sante & Rech Med, Inst Genet Mol,Equipe Labellisee Ligue Canc,UMR11, 27 Rue Juliette Dodu, F-75010 Paris, France; [Olivares-Illana, V.] Univ Auonoma San Luis Potosi, Inst Fis, San Luis Potosi, Mexico; [Vojtesek, B.; Fahraeus, R.] Masaryk Mem Canc Inst, RECAMO, Brno, Czech Republic; [Nylander, K.; Fahraeus, R.] Umea Univ, Dept Med Biosci, Umea, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute; Umea University	Fahraeus, R (corresponding author), Univ Paris 07, Hop St Louis, Inst Natl Sante & Rech Med, Inst Genet Mol,Equipe Labellisee Ligue Canc,UMR11, 27 Rue Juliette Dodu, F-75010 Paris, France.	robin.fahraeus@inserm.fr	Karakostis, Konstantinos/AGJ-3251-2022; Karakostis, Konstantinos/ABC-9700-2020; Karakostis, Konstantinos/GNW-4090-2022; Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Karakostis, Konstantinos/0000-0003-1122-7860; Olivares-Illana, Vanesa/0000-0001-6949-5986; Lopez, Ignacio/0000-0001-9669-8906	la Ligue Contre le Cancer; PACRI; AXA Research Fund; Fondation pour la Recherche Medicale [FDT20150532276]; GACR [16-07321S]; MH CZ-DRO (MMCI) [00209805]; Inserm;  [MEYS-NPS I-L01413]	la Ligue Contre le Cancer(Ligue nationale contre le cancer); PACRI; AXA Research Fund(AXA Research Fund); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); GACR(Grant Agency of the Czech Republic); MH CZ-DRO (MMCI); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); 	This work was supported by la Ligue Contre le Cancer and Inserm. A-ST is supported by PACRI. IL is supported by AXA Research Fund and Fondation pour la Recherche Medicale (FDT20150532276). BV was supported by GACR 16-07321S and BV and RF were supported by MEYS-NPS I-L01413 and MH CZ-DRO (MMCI, 00209805). We thank the IUH platform for technical assistance.	Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hudson WH, 2014, NAT REV MOL CELL BIO, V15, P749, DOI 10.1038/nrm3884; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Lopez I, 2015, CELL CYCLE, V14, P3373, DOI 10.1080/15384101.2015.1090066; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Malbert-Colas L, 2014, MOL CELL, V54, P500, DOI 10.1016/j.molcel.2014.02.035; Mandke P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042034; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Mlynarczyk C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6067; Montes de Oca LR, 1995, NATURE, V378, P203; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naski N, 2009, CELL CYCLE, V8, P31, DOI 10.4161/cc.8.1.7326; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Riley KJL, 2007, RNA, V13, P1825, DOI 10.1261/rna.673407; Riley KJL, 2006, RNA, V12, P620, DOI 10.1261/rna.2286706; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Scrable H, 2005, INT J BIOCHEM CELL B, V37, P913, DOI 10.1016/j.biocel.2004.11.014; Suswam EA, 2005, NUCLEIC ACIDS RES, V33, P4507, DOI 10.1093/nar/gki763; Tournillon AS, 2015, CELL CYCLE, V14, P449, DOI 10.4161/15384101.2014.977081; Vise PD, 2005, NUCLEIC ACIDS RES, V33, P2061, DOI 10.1093/nar/gki336; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	37	17	17	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					723	730		10.1038/onc.2016.236	http://dx.doi.org/10.1038/onc.2016.236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375027				2022-12-28	WOS:000394167700013
J	Wang, Y; Justilien, V; Brennan, KI; Jamieson, L; Murray, NR; Fields, AP				Wang, Y.; Justilien, V.; Brennan, K. I.; Jamieson, L.; Murray, N. R.; Fields, A. P.			PKC iota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis	ONCOGENE			English	Article							PROTEIN-KINASE-C; POOR-PROGNOSIS; ONCOGENE; OVERREPRESENTATION; OVEREXPRESSION; PROLIFERATION; EXPRESSION; ANGIOMOTIN; PHENOTYPE; EFFECTOR	Atypical protein kinase C iota (PKC iota) is an oncogene in lung and ovarian cancer. The PKC iota gene PRKCI is targeted for frequent tumorspecific copy number gain (CNG) in both lung squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC). We recently demonstrated that in LSCC cells PRKCI CNG functions to drive transformed growth and tumorigenicity by activating PKC iota-dependent cell autonomous Hedgehog (Hh) signaling. Here, we assessed whether OSC cells harboring PRKCI CNG exhibit similar PKC iota-dependent Hh signaling. Surprisingly, we find that whereas PKC iota is required for the transformed growth of OSC cells harboring PRKCI CNG, these cells do not exhibit PKC iota-dependent Hh signaling or Hh-dependent proliferation. Rather, transformed growth of OSC cells is regulated by PKC iota-dependent nuclear localization of the oncogenic transcription factor, YAP1. Lentiviral shRNA-mediated knockdown (KD) of PKC iota leads to decreased nuclear YAP1 and increased YAP1 binding to angiomotin (AMOT), which sequesters YAP1 in the cytoplasm. Biochemical analysis reveals that PKC iota directly phosphorylates AMOT at a unique site, Thr750, whose phosphorylation inhibits YAP1 binding. Pharmacologic inhibition of PKC iota decreases YAP1 nuclear localization and blocks OSC tumor growth in vitro and in vivo. Immunohistochemical analysis reveals a strong positive correlation between tumor PKC iota expression and nuclear YAP1 in primary OSC tumor samples, indicating the clinical relevance of PKC iota-YAP1 signaling. Our results uncover a novel PKC iota-AMOT-YAP1 signaling axis that promotes OSC tumor growth, and provide a rationale for therapeutic targeting of this pathway for treatment of OSC.	[Wang, Y.; Justilien, V.; Brennan, K. I.; Jamieson, L.; Murray, N. R.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Murray, NR; Fields, AP (corresponding author), Mayo Clin Florida, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu			Mayo Clinic Specialized Program in Research Excellence (SPORE) grant from the National Institutes of Health [CA136393]; Ovarian Cancer Research Fund; National Cancer Institute [R21 CA204938-01, R01 CA081436-18]; George Haub Family Career Development Award; NATIONAL CANCER INSTITUTE [R01CA081436, P50CA136393, R21CA204938] Funding Source: NIH RePORTER	Mayo Clinic Specialized Program in Research Excellence (SPORE) grant from the National Institutes of Health; Ovarian Cancer Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); George Haub Family Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kim Kalli and the Mayo Clinic Ovarian SPORE Tissue shared resource for ovarian cancer tissue microarrays, The Mayo Clinic Cytogenetics Core for FISH analysis, Ms Brandy Edenfield for tissue processing and immunohistochemical staining, and Kayla Lewis, Capella Weems and Dr Christelle Colin Cassin for technical assistance. This research was supported by the Mayo Clinic Specialized Program in Research Excellence (SPORE) grant CA136393 from the National Institutes of Health (APF is a Project Leader on this grant), a post-doctoral fellowship award from the Ovarian Cancer Research Fund to YW, National Cancer Institute grants R21 CA204938-01 (to VJ) and R01 CA081436-18 (to APF), and the George Haub Family Career Development Award (to VJ). APF is the Monica Flynn Jacoby Professor of Cancer Research, an endowment fund that provides partial support for his research program.	Algeciras-Schimnich A, 2010, CLIN CHEM, V56, P391, DOI 10.1373/clinchem.2009.134015; Ali SA, 2016, CANCER CELL, V29, P367, DOI 10.1016/j.ccell.2016.02.012; Archibald A, 2015, MOL BIOL CELL, V26, P3578, DOI 10.1091/mbc.E15-05-0265; Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Butler AM, 2015, ONCOTARGET, V6, P15297, DOI 10.18632/oncotarget.3812; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Haverty PM, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-21; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Jatoi A, 2015, ONCOLOGY-BASEL, V88, P208, DOI 10.1159/000369257; Jeong GO, 2013, CELL PHYSIOL BIOCHEM, V32, P253, DOI 10.1159/000354434; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Korkmaz T, 2016, CRIT REV ONCOL HEMAT, V98, P180, DOI 10.1016/j.critrevonc.2015.10.006; Llado V, 2015, CELL REP, V10, P740, DOI 10.1016/j.celrep.2015.01.007; Martin LP, 2009, SEMIN ONCOL, V36, P112, DOI 10.1053/j.seminoncol.2008.12.003; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Parker PJ, 2014, BIOCHEM PHARMACOL, V88, P1, DOI 10.1016/j.bcp.2013.10.023; Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rho SB, 2009, BIOTECHNOL LETT, V31, P23, DOI 10.1007/s10529-008-9845-8; Shen HM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0117-2; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; Wang Y, 2013, MOL CANCER RES, V11, P1624, DOI 10.1158/1541-7786.MCR-13-0371-T; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	39	32	37	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					534	545		10.1038/onc.2016.224	http://dx.doi.org/10.1038/onc.2016.224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321186	Green Accepted			2022-12-28	WOS:000394166700010
J	Dong, H; Ma, L; Gan, J; Lin, W; Chen, C; Yao, Z; Du, L; Zheng, L; Ke, C; Huang, X; Song, H; Kumar, R; Yeung, SC; Zhang, H				Dong, H.; Ma, L.; Gan, J.; Lin, W.; Chen, C.; Yao, Z.; Du, L.; Zheng, L.; Ke, C.; Huang, X.; Song, H.; Kumar, R.; Yeung, S. C.; Zhang, H.			PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; MAMMARY TUMORIGENESIS; CANCER PATIENTS; RECEPTOR; ACTIVATION; EXPRESSION; TRANSFORMATION; THERAPY	The plasma membrane-associated tyrosine phosphatase PTPRO is frequently transcriptionally repressed in cancers and signifies poor prognosis of breast cancer patients. In this study, deletion of Ptpro in MMTV-Erbb2 transgenic mice dramatically shortened the mammary tumor latency and accelerated tumor growth due to loss of Ptpro within the breast cancer cells but not in surrounding tissue as confirmed by hetero-transplantation studies. Both in vitro and in vivo data demonstrated that the phosphatase activity was required for the inactivation of ERBB2 and its downstream signaling. PTPRO regulated the phosphorylation status of ERBB2 at Y1248. Co-immunoprecipitation and proximity ligation assay (Duolink) indicated that PTPRO directly physically interacted with ERBB2. Moreover, PTPRO phosphatase activity shortened the half-life of ERBB2 by increasing endocytotic degradation. PTPRO reexpression by demethylation treatment using 5-azacytidine reduced the proliferation and colony formation potential in ERBB2positive breast cancer cells. Taken together, PTPRO inhibited ERBB2-driven breast cancer through dephosphorylation leading to dual effects of ERBB2 signaling suppression and endosomal internalization of ERBB2, Therefore, reexpression of PTPRO may be a potential therapy for ERBB2-overexpressing breast cancer.	[Dong, H.; Gan, J.; Lin, W.; Chen, C.; Yao, Z.; Du, L.; Zheng, L.; Ke, C.; Yeung, S. C.; Zhang, H.] Shantou Univ, Canc Res Ctr, Coll Med, Xinling Rd 22, Shantou 515041, Peoples R China; [Ma, L.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA; [Huang, X.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Peoples R China; [Song, H.] Xi An Jiao Tong Univ, Dept Cell Biol, Suzhou Acad, Suzhou, Peoples R China; [Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Zhang, H.] Shantou Univ, Coll Med, Affiliated Canc Hosp, Dept Biotherapy, Shantou, Peoples R China	Shantou University; University of Texas System; UTMD Anderson Cancer Center; Nanjing University; Xi'an Jiaotong University; George Washington University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Shantou University	Zhang, H (corresponding author), Shantou Univ, Canc Res Ctr, Coll Med, Xinling Rd 22, Shantou 515041, Peoples R China.; Yeung, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; haozhang@stu.edu.cn	Yeung, Sai-Ching/AAI-6178-2021; Kumar, Rakesh/ABD-1065-2020; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Kumar, Rakesh/0000-0001-7664-0803; huang, xingxu/0000-0001-8934-1247; Du, Liang/0000-0002-1191-2465	National Natural Science Foundation of China NSFC [81071736, 30973508, 81572876, 31271495]; Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases	National Natural Science Foundation of China NSFC(National Natural Science Foundation of China (NSFC)); Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases	This work was supported in part by National Natural Science Foundation of China NSFC (81071736, 30973508 and 81572876 to HZ and 31271495 to HS), the funding for Collaborative and Creative Center, Molecular Diagnosis and Personalized Medicine, Shantou University, Guangdong Province, and the funding from the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases. We thank Dr Stanley Lin for the careful reading the manuscript.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Anthis NJ, 2009, J BIOL CHEM, V284, P36700, DOI 10.1074/jbc.M109.061275; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen B, 2005, J NEUROSCI, V25, P880, DOI 10.1523/JNEUROSCI.4365-04.2005; Cicenas J, 2006, EUR J CANCER, V42, P636, DOI 10.1016/j.ejca.2005.11.012; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gensler M, 2004, J BIOL CHEM, V279, P12110, DOI 10.1074/jbc.M309527200; Gradishar WJ, 2013, ANN ONCOL, V24, P2492, DOI 10.1093/annonc/mdt217; Hayashi N, 2011, ONCOLOGIST, V16, P956, DOI 10.1634/theoncologist.2010-0409; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Huang YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-245; Hudelist G, 2006, INT J CANCER, V118, P1126, DOI 10.1002/ijc.21492; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Meyer DS, 2014, ONCOGENE, V33, P398, DOI 10.1038/onc.2012.585; Miaczynska M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009035; Monast CS, 2012, BIOPHYS J, V102, P2012, DOI 10.1016/j.bpj.2012.03.037; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Schneeberger VE, 2015, ONCOTARGET, V6, P6191, DOI 10.18632/oncotarget.3356; Stepanek L, 2001, J CELL BIOL, V154, P867, DOI 10.1083/jcb.200105019; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Taniyama K, 2008, BREAST CANCER-TOKYO, V15, P231, DOI 10.1007/s12282-007-0026-8; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wang HM, 2014, CELL RES, V24, P1067, DOI 10.1038/cr.2014.99; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zhang H, 2004, CANCER RES, V64, P7169, DOI 10.1158/0008-5472.CAN-04-1176; Zhang H, 2006, GENE DEV, V20, P2943, DOI 10.1101/gad.1461706; Zhao S, 2015, ONCOGENE, V34, P3885, DOI 10.1038/onc.2014.326; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	53	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					410	422		10.1038/onc.2016.213	http://dx.doi.org/10.1038/onc.2016.213			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345410	Green Published, hybrid			2022-12-28	WOS:000394166000010
J	De Cian, MC; Pauper, E; Bandiera, R; Vidal, VPI; Sacco, S; Gregoire, EP; Chassot, AA; Panzolini, C; Wilhelm, D; Pailhoux, E; Youssef, SA; de Bruin, A; Teerds, K; Schedl, A; Gillot, I; Chaboissier, MC				De Cian, M-C; Pauper, E.; Bandiera, R.; Vidal, V. P. I.; Sacco, S.; Gregoire, E. P.; Chassot, A-A; Panzolini, C.; Wilhelm, D.; Pailhoux, E.; Youssef, S. A.; de Bruin, A.; Teerds, K.; Schedl, A.; Gillot, I.; Chaboissier, M-C			Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary	ONCOGENE			English	Article							BETA-CATENIN; FOLLICULAR DEVELOPMENT; SERTOLI-CELLS; DIFFERENTIATION; RSPO1; SPECIFICATION; DISRUPTION; EXPRESSION; CADHERINS; ATRESIA	R-spondin1 is a secreted regulator of WNT signaling, involved in both embryonic development and homeostasis of adult organs. It can have a dual role, acting either as a mitogen or as a tumor suppressor. During ovarian development, Rspo1 is a key factor required for sex determination and differentiation of the follicular cell progenitors, but is downregulated after birth. In human, increased RSPO1 expression is associated with ovarian carcinomas, but it is not clear whether it is a cause or a consequence of the tumorigenic process. To address the role of Rspo1 expression in adult ovaries, we generated an Rspol gain-of-function mouse model. Females were hypofertile and exhibited various ovarian defects, ranging from cysts to ovarian tumors. Detailed phenotypical characterization showed anomalies in the ovulation process. Although follicles responded to initial follicle-stimulating hormone stimulation and developed normally until the pre-ovulatory stage, they did not progress any further. Although non-ovulated oocytes degenerated, the surrounding follicular cells did not begin atresia. RSPO1-induced expression not only promotes canonical WNT signaling but also alters granulosa cell fate decisions by maintaining epithelial-like traits in these cells. This prevents follicle cells from undergoing apoptosis, leading to the accumulation of granulosa cell tumors that reactivates the epithelial program from their progenitors. Taken together, our data demonstrate that activation of RSPO1 is sufficient in promoting ovarian tumors and thus supports a direct involvement of this gene in the commencement of ovarian cancers.	[De Cian, M-C; Pauper, E.; Vidal, V. P. I.; Sacco, S.; Gregoire, E. P.; Chassot, A-A; Panzolini, C.; Schedl, A.; Gillot, I.; Chaboissier, M-C] Univ Nice Sophia Antipolis, iBV, CNRS, INSERM, Nice, France; [De Cian, M-C] Univ Corte, EA 7310, Corte, France; [Bandiera, R.] Univ Cambridge, Wellcome Trust Med Res Council Cambridge Stem Cel, Cambridge CB2 1TN, England; [Wilhelm, D.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia; [Pailhoux, E.] Univ Paris Saclay, INRA, UMR BDR, ENVA, Jouy En Josas, France; [Youssef, S. A.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dutch Mol Pathol Ctr, Dept Pathobiol, Utrecht, Netherlands; [de Bruin, A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands; [Teerds, K.] Wageningen Univ, Dept Human & Anim Physiol, Wageningen, Netherlands	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Cambridge; University of Melbourne; Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Utrecht University; University of Groningen; Wageningen University & Research	Gillot, I; Chaboissier, MC (corresponding author), Univ Nice Sophia Antipolis, iBV, UFR Sci, Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	gillot@unice.fr; marie-christine.chaboissier@unice.fr	CHABOISSIER, Marie-Christine/AAZ-5905-2021; Wilhelm, Dagmar/B-6915-2009; vidal, valerie/S-2597-2019; Schedl, Andreas/F-8823-2015; de Bruin, Alain/AAL-9195-2020; Chassot, Anne-Amandine/O-2102-2016; Vidal, Valerie/M-1477-2018; Teerds, Katja/H-7580-2019; CHABOISSIER, Marie-Christine/F-6166-2019; Grégoire, Elodie P./CAG-7541-2022; Schedl, Andreas/GOP-3427-2022	CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Wilhelm, Dagmar/0000-0002-7757-4075; Schedl, Andreas/0000-0001-9380-7396; Chassot, Anne-Amandine/0000-0003-1242-9456; Teerds, Katja/0000-0002-0930-1198; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Grégoire, Elodie P./0000-0001-7614-4754; 	Fondation ARC pour la Recherche sur le Cancer [PJA 20131200236]; Agence Nationale de la Recherche [ANR-09-GENM-009-03, ANR-11-LABX-0028-01]; INRA; Ligue Nationale contre le Cancer	Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); INRA; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	We thank Mireille Cutajar-Bossert for her work and management of funding and also Fariba Jianmotamedi, Aurelie Charlet and Beatrice Polo for their punctual help in this work. We are thankful to Walter Birchmeier (Berlin, Germany) for the Axin2<SUP>+/LacZ</SUP> mice and Ken Morohashi (Fukuoka, Japan) for the SF1 antibody. We thank Aitana Perea-Gomez for critical reading of the manuscript. This work was supported by grants from the Fondation ARC pour la Recherche sur le Cancer (PJA 20131200236) and Agence Nationale de la Recherche (ANR-09-GENM-009-03 and ANR-11-LABX-0028-01). EP was supported by a fellowship from INRA and Ligue Nationale contre le Cancer.	Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Auguste A, 2011, SEX DEV, V5, P304, DOI 10.1159/000334517; Bandiera R, 2013, DEV CELL, V27, P5, DOI 10.1016/j.devcel.2013.09.003; Bingham NC, 2006, GENESIS, V44, P419, DOI 10.1002/dvg.20231; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; Chassot AA, 2012, DEVELOPMENT, V139, P4461, DOI 10.1242/dev.078972; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Durlinger ALL, 2002, REPRODUCTION, V124, P601, DOI 10.1530/reprod/124.5.601; Fan HY, 2010, MOL ENDOCRINOL, V24, P1529, DOI 10.1210/me.2010-0141; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hatano O, 1996, GENES CELLS, V1, P663, DOI 10.1046/j.1365-2443.1996.00254.x; Hirshfield AN, 1997, ENVIRON MOL MUTAGEN, V29, P10; Huang CCJ, 2010, ENDOCRINOLOGY, V151, P1119, DOI 10.1210/en.2009-0814; Jamieson S, 2012, ENDOCR REV, V33, P109, DOI 10.1210/er.2011-0014; Karl J, 1998, DEV BIOL, V203, P323, DOI 10.1006/dbio.1998.9068; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim AC, 2008, DEVELOPMENT, V135, P2593, DOI 10.1242/dev.021493; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Liu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7934; Liu Z. H., 2015, HIGHWAY, V2015, P1, DOI DOI 10.1016/J.FUPR0C.2015.01.025; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lyashenko N, 2011, NAT CELL BIOL, V13, P753, DOI 10.1038/ncb2260; Maatouk DM, 2008, HUM MOL GENET, V17, P2949, DOI 10.1093/hmg/ddn193; Maatouk DM, 2013, DEV BIOL, V383, P295, DOI 10.1016/j.ydbio.2013.08.026; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Makrigiannakis A, 1999, AM J PATHOL, V154, P1391, DOI 10.1016/S0002-9440(10)65393-X; Mork L, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095208; Mullany LK, 2012, ENDOCRINOLOGY, V153, P1585, DOI 10.1210/en.2011-2121; Ng A, 2014, NAT CELL BIOL, V16, P745, DOI 10.1038/ncb3000; OSMAN P, 1985, J REPROD FERTIL, V73, P261, DOI 10.1530/jrf.0.0730261; Pan HJ, 2014, ENDOCRINOLOGY, V155, P3624, DOI 10.1210/en.2013-2183; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Rastetter RH, 2014, DEV BIOL, V394, P242, DOI 10.1016/j.ydbio.2014.08.013; Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049; Rowlands TM, 2000, REV REPROD, V5, P53; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sun XF, 2014, FASEB J, V28, P2380, DOI 10.1096/fj.13-248344; Svingen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052620; Tomaselli S, 2008, HUM MUTAT, V29, P220, DOI 10.1002/humu.20665; Tomaselli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016366; Tomizuka K, 2008, HUM MOL GENET, V17, P1278, DOI 10.1093/hmg/ddn036; Zheng WJ, 2014, HUM MOL GENET, V23, P920, DOI 10.1093/hmg/ddt486	48	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					208	218		10.1038/onc.2016.191	http://dx.doi.org/10.1038/onc.2016.191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270435	Green Published, hybrid			2022-12-28	WOS:000393938100006
J	Zhen, Y; Fang, W; Zhao, M; Luo, R; Liu, Y; Fu, Q; Chen, Y; Cheng, C; Zhang, Y; Liu, Z				Zhen, Y.; Fang, W.; Zhao, M.; Luo, R.; Liu, Y.; Fu, Q.; Chen, Y.; Cheng, C.; Zhang, Y.; Liu, Z.			miR-374a-CCND 1-pPI3KJAKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; LUNG-CANCER; CYCLE PROGRESSION; GENE-EXPRESSION; DOWN-REGULATION; OVARIAN-CANCER; C-MYC; PROLIFERATION; PROMOTES	miR-374a has been reported to function as an oncogene during tumor pathogenesis. In this study, miR-374a is observed to reduce nasopharyngeal carcinoma (NPC) cell proliferation, migration, invasion, metastasis and cisplatin (DDP) resistance in vitro and in vivo. Mechanistic analyses indicate that miR-374a directly targets CCND1 to inactivate pPI3K/pAKT/c-JUN forming a negative feedback loop, as well as suppressing downstream signals related to cell cycle progression and epithelial mesenchymal transition (EMT). Interestingly, we also observed that miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPl3K/pAICT/c-JUN signaling. In clinical specimens, miR-374a was positively and negatively correlated with expression of PDCD4 and CCND1, respectively. Our studies are the first to demonstrate that the miR-374a-CCND1-pPl3K/AKT-c-JUN feedback loop induced by PDCD4 supresses NPC cell growth, metastasis and chemotherapy resistance.	[Zhen, Y.; Fang, W.; Luo, R.] Southern Med Univ, TCM Integrated Hosp, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Zhen, Y.] Guangdong Med Univ, Affiliated Hosp, Inst Resp Dis, Zhanjiang, Peoples R China; [Zhen, Y.; Fang, W.; Zhao, M.; Liu, Y.; Fu, Q.; Chen, Y.; Cheng, C.; Liu, Z.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, Y.; Liu, Z.] Guangzhou Med Univ, Sch Basic Med, Dept Pathol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Guangdong Medical University; Southern Medical University - China; Guangzhou Medical University	Fang, W; Liu, Z (corresponding author), Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China.	fangweiyi1975@163.com; narcissus_jane@163.com			National Nature Science Fund of China [81372184, 81401906]; Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province [Yq2013136]; Guangdong Province Education Foundation [2014KTSCX107]; Yangcheng Scholar Research Projects from Universities of Guangzhou [12A011D]	National Nature Science Fund of China(National Natural Science Foundation of China (NSFC)); Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province; Guangdong Province Education Foundation; Yangcheng Scholar Research Projects from Universities of Guangzhou	This study was supported by National Nature Science Fund of China (No. 81372184 and No. 81401906) (http://www.nsfc.gov.cn), the Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province (No. Yq2013136), Guangdong Province Education Foundation (No. 2014KTSCX107), and Yangcheng Scholar Research Projects from Universities of Guangzhou (No. 12A011D). We are also grateful to Dr Douglas E Linn (Brigham & Women's Hospital, Boston, MA, USA) for critical reading of the manuscript.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Cai LM, 2015, ONCOGENE, V34, P2156, DOI 10.1038/onc.2014.341; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; JIANG W, 1993, ONCOGENE, V8, P3447; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lei K, 2008, ONCOGENE, V27, P4877, DOI 10.1038/onc.2008.132; Li JY, 2013, ASIAN PAC J CANCER P, V14, P1715, DOI 10.7314/APJCP.2013.14.3.1715; Liao HZ, 2015, ONCOTARGET, V6, P8914, DOI 10.18632/oncotarget.3563; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Miko E, 2009, EXP LUNG RES, V35, P646, DOI 10.3109/01902140902822312; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419; Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Vosa U, 2011, GENE CHROMOSOME CANC, V50, P812, DOI 10.1002/gcc.20902; Walsh AM, 2015, MOL CANCER RES, V13, P1227, DOI 10.1158/1541-7786.MCR-14-0183-T; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.186; Wu AB, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-38; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Yu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.153; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671; Zhao MY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11309; Zhen Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.376; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108; Zhou Y, 2015, ONCOTARGET, V6, P10350, DOI 10.18632/oncotarget.3585	37	79	85	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					275	285		10.1038/onc.2016.201	http://dx.doi.org/10.1038/onc.2016.201			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270423				2022-12-28	WOS:000393938100012
J	Skalka, N; Caspi, M; Lahav-Ariel, L; Loh, YP; Hirschberg, K; Rosin-Arbesfeld, R				Skalka, N.; Caspi, M.; Lahav-Ariel, L.; Loh, Y. P.; Hirschberg, K.; Rosin-Arbesfeld, R.			Carboxypeptidase E (CPE) inhibits the secretion and activity of Wnt3a	ONCOGENE			English	Article							CELL-PROLIFERATION; ENDOCRINE; AUTOPHAGY; SURVIVAL; STRESS	The Wnt pathway has essential roles in cell proliferation, cell fate determination and tumorigenesis by regulating the expression of a wide range of target genes. As a core signaling cascade, the canonical Wnt pathway is regulated at different levels by numerous proteins. We have previously shown that carboxypeptidase E (CPE) is a novel regulator of the canonical Wnt signaling pathway. Here, we show that CPE and the Wnt3a ligand are co-secreted from cells. We show that although the C'-terminal Lys residue of Wnt3a is critical for its activity and is important for the effect of CPE on the Wnt pathway, CPE does not execute its effect by removing this Wnt3a residue. Interestingly, CPE through its N'-terminal sequence, forms aggregates with Wnt3a and possible endoplasmic reticulum (ER) stress leading to its loss of function. Together, our current results provide a mechanistic insight into the way CPE regulates the canonical Wnt signaling pathway.	[Skalka, N.; Caspi, M.; Lahav-Ariel, L.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel; [Loh, Y. P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Neurobiol, Program Dev Neurosci, NIH, Bethesda, MD USA; [Hirschberg, K.] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.	arina@post.tau.ac.il			Rising Tide Foundation for Clinical Cancer Research; Gateway for Cancer Research Foundation; Israel Science Foundation [20120016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER	Rising Tide Foundation for Clinical Cancer Research; Gateway for Cancer Research Foundation; Israel Science Foundation(Israel Science Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by Rising Tide Foundation for Clinical Cancer Research, by the Gateway for Cancer Research Foundation and by the Israel Science Foundation (Grant no. 20120016).	Bar F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102347; Cawley NX, 2012, ENDOCR REV, V33, P216, DOI 10.1210/er.2011-1039; Chen YX, 2014, NEUROSCI BULL, V30, P282, DOI 10.1007/s12264-013-1408-x; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Du C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033830; FRICKER LD, 1983, J BIOL CHEM, V258, P950; He P, 2004, HUM PATHOL, V35, P1196, DOI 10.1016/j.humpath.2004.06.014; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Holzer T, 2012, FEBS LETT, V586, P1638, DOI 10.1016/j.febslet.2012.04.035; Kim HJ, 2014, MOL CELLS, V37, P685, DOI 10.14348/molcells.2014.0179; Kunz M, 2004, DEV BIOL, V273, P390, DOI 10.1016/j.ydbio.2004.06.015; Li XH, 2015, INFLAMM RES, V64, P1, DOI 10.1007/s00011-014-0772-y; Liang XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-412; Liu AA, 2014, TUMOR BIOL, V35, P12459, DOI 10.1007/s13277-014-2564-y; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Murthy SRK, 2013, ENDOCRINOLOGY, V154, P3284, DOI 10.1210/en.2013-1118; Murthy SRK, 2013, CANCER LETT, V341, P204, DOI 10.1016/j.canlet.2013.08.011; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Park JJ, 2008, MOL ENDOCRINOL, V22, P989, DOI 10.1210/me.2007-0473; Polakis P, 2000, GENE DEV, V14, P1837; Qian YM, 1999, J BIOL CHEM, V274, P11582, DOI 10.1074/jbc.274.17.11582; Qin XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112996; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rhinn M, 2005, DEVELOPMENT, V132, P1261, DOI 10.1242/dev.01685; Selvaraj P, 2015, MOL CELL NEUROSCI, V68, P222, DOI 10.1016/j.mcn.2015.08.005; Sharma K, 2016, BIOCHEM PHARMACOL, V103, P17, DOI 10.1016/j.bcp.2015.12.018; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Skalka N, 2013, ONCOGENE, V32, P2836, DOI 10.1038/onc.2012.308; Thouennon E, 2015, J NEUROCHEM, V134, P463, DOI 10.1111/jnc.13152; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Wallkamm V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109428; Wang L, 2009, J BONE MINER RES, V24, P265, DOI [10.1359/jbmr.081014, 10.1359/JBMR.081014]; Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864; Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218; Zhou K, 2013, TUMOR BIOL, V34, P3691, DOI 10.1007/s13277-013-0952-3	38	7	7	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6416	6428		10.1038/onc.2016.173	http://dx.doi.org/10.1038/onc.2016.173			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27375026	Bronze			2022-12-28	WOS:000390247600006
J	Li, Y; Bouchlaka, MN; Wolff, J; Grindle, KM; Lu, L; Qian, S; Zhong, X; Pflum, N; Jobin, P; Kahl, BS; Eickhoff, JC; Wuerzberger-Davis, SM; Miyamoto, S; Thomas, CJ; Yang, DT; Capitini, CM; Rui, L				Li, Y.; Bouchlaka, M. N.; Wolff, J.; Grindle, K. M.; Lu, L.; Qian, S.; Zhong, X.; Pflum, N.; Jobin, P.; Kahl, B. S.; Eickhoff, J. C.; Wuerzberger-Davis, S. M.; Miyamoto, S.; Thomas, C. J.; Yang, D. T.; Capitini, C. M.; Rui, L.			FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; FACTOR-KAPPA-B; BAFF-R; IBRUTINIB; RECEPTOR; SURVIVAL; THERAPY; INHIBITION; MUTATIONS	Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired resistance to ibrutinib have developed in a significant number of these patients. A combinatory strategy targeting multiple oncogenic pathways is critical to enhance the efficacy of ibrutinib. Here, we focus on the BCL2 anti-apoptotic pathway. In a tissue microarray of 62 MCL samples, BCL2 expression positively correlated with BTK expression. Increased levels of BCL2 were shown to be due to a defect in protein degradation because of no or little expression of the E3 ubiquitin ligase FBXO10, as well as transcriptional upregulation through BTK-mediated canonical nuclear factor-kappa B activation. RNA-seq analysis confirmed that a set of anti-apoptotic genes (for example, BCL2, BCL-XL and DAD1) was downregulated by BTK short hairpin RNA. The downregulated genes also included those that are critical for B-cell growth and proliferation, such as BCL6, MYC, PIK3CA and BAFF-R. Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in inhibiting growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo. These results suggest co-targeting of BTK and BCL2 as a new therapeutic strategy in MCL, especially for patients with primary resistance to ibrutinib.	[Li, Y.; Wolff, J.; Grindle, K. M.; Pflum, N.; Jobin, P.; Kahl, B. S.; Rui, L.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Li, Y.; Bouchlaka, M. N.; Grindle, K. M.; Kahl, B. S.; Wuerzberger-Davis, S. M.; Miyamoto, S.; Yang, D. T.; Capitini, C. M.; Rui, L.] Univ Wisconsin, Carbone Canc Ctr, Sch Med & Publ Hlth, Madison, WI USA; [Bouchlaka, M. N.; Capitini, C. M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Lu, L.; Qian, S.; Zhong, X.] Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI USA; [Lu, L.; Qian, S.; Zhong, X.] Univ Wisconsin, Genet Lab, Madison, WI USA; [Eickhoff, J. C.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA; [Wuerzberger-Davis, S. M.; Miyamoto, S.] Univ Wisconsin, Dept Oncol, Sch Med & Publ Hlth, Madison, WI USA; [Thomas, C. J.] NIH, Div Preclin Innovat, Chem Genom Ctr, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA; [Yang, D. T.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA; [Kahl, B. S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)	Yang, DT; Capitini, CM; Rui, L (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Div Hematol Oncol, Dept Med, 1111 Highland Ave, Madison, WI 53705 USA.	dtyang@wisc.edu; ccapitini@pediatrics.wisc.edu; lrui@medicine.wisc.edu	li, rui/GSD-4367-2022; rui, li/GYR-3791-2022; Capitini, Christian M/I-4288-2019	Capitini, Christian M/0000-0002-2276-6731; Thomas, Craig/0000-0001-9386-9001; Bouchlaka, Myriam/0000-0003-2865-0817	UW-Madison Start-up funds; KL2 Scholar Award [UL1TR0000427, KL2TR000428]; NIH [R01 CA187299]; MACC fund; National Institutes of Health/National Cancer Institute [K08 CA174750]; USDA National Institute of Food and Agriculture [Hatch 1002874]; UW Forward Lymphoma Fund; University of Wisconsin Carbone Cancer Center (UWCCC); NIH/NCI UW Comprehensive Cancer Center Support [P30 CA014520]; NATIONAL CANCER INSTITUTE [K08CA174750, R01CA187299, P30CA014520] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER	UW-Madison Start-up funds; KL2 Scholar Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MACC fund; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USDA National Institute of Food and Agriculture(United States Department of Agriculture (USDA)); UW Forward Lymphoma Fund; University of Wisconsin Carbone Cancer Center (UWCCC); NIH/NCI UW Comprehensive Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr Louis Staudt for providing the reagents, Dr Sameer Mathur for providing peripheral blood mononuclear cells, Dr Wei Huang for helping with analysis of immunohistochemical data, Drs Debra Bloom and Peiman Hematti for providing CD40, BAFF and BAFF receptor antibody, and Kirsti Walker for monitoring xenografted mice. This work was supported by the UW-Madison Start-up funds, KL2 Scholar Award (UL1TR0000427 and KL2TR000428), and NIH R01 CA187299 to LR, the MACC fund and the National Institutes of Health/National Cancer Institute (K08 CA174750) to CMC, the UW-Madison Start-up funds and USDA National Institute of Food and Agriculture (Hatch 1002874) to XZ, and the UW Forward Lymphoma Fund. We thank the University of Wisconsin Carbone Cancer Center (UWCCC) for the funds to complete this project. This work was also supported in part by NIH/NCI P30 CA014520- UW Comprehensive Cancer Center Support.	Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Briones J, 2002, EXP HEMATOL, V30, P135, DOI 10.1016/S0301-472X(01)00774-3; Chiorazzi M, 2013, P NATL ACAD SCI USA, V110, P3943, DOI 10.1073/pnas.1217271110; Chiorazzi N, 2005, ANN NY ACAD SCI, V1062, P1, DOI 10.1196/annals.1358.002; Chiron D, 2015, ONCOTARGET, V6, P8750, DOI 10.18632/oncotarget.3275; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; Cinar M, 2013, LEUKEMIA RES, V37, P1271, DOI 10.1016/j.leukres.2013.07.028; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Freedman AS, 2014, AM J HEMATOL, V89, P429, DOI 10.1002/ajh.23674; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Hadzidimitriou A, 2011, BLOOD, V118, P3088, DOI 10.1182/blood-2011-03-343434; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Hendriks RW, 2014, NAT REV CANCER, V14, P219, DOI 10.1038/nrc3702; Herman SEM, 2013, LEUKEMIA, V27, P2311, DOI 10.1038/leu.2013.131; Hiddemann W, 2014, LEUKEMIA, V28, P1388, DOI 10.1038/leu.2014.91; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Kenkre VP, 2012, CURR HEMATOL MALIG R, V7, P216, DOI 10.1007/s11899-012-0127-0; Knezevich S, 2005, LEUKEMIA, V19, P659, DOI 10.1038/sj.leu.2403661; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Ma J, 2014, BRIT J HAEMATOL, V166, P849, DOI 10.1111/bjh.12974; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; Novak AJ, 2004, BLOOD, V104, P2247, DOI 10.1182/blood-2004-02-0762; O'Brien S, 2014, LANCET ONCOL, V15, P48, DOI 10.1016/S1470-2045(13)70513-8; Oberley MJ, 2013, HISTOPATHOLOGY, V63, P499, DOI 10.1111/his.12207; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paterson JC, 2006, HAEMATOLOGICA, V91, P772; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rinaldi A, 2006, BRIT J HAEMATOL, V132, P303, DOI 10.1111/j.1365-2141.2005.05883.x; Schuetz JM, 2012, LEUKEMIA, V26, P1383, DOI 10.1038/leu.2011.378; Shinners NP, 2007, J IMMUNOL, V179, P3872, DOI 10.4049/jimmunol.179.6.3872; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Takahata H, 2010, J CLIN EXP HEMATOP, V50, P121, DOI 10.3960/jslrt.50.121; Tracey L, 2005, J PATHOL, V206, P123, DOI 10.1002/path.1768; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tucker CA, 2008, MOL CANCER THER, V7, P749, DOI 10.1158/1535-7163.MCT-07-0302; Wada K, 2009, HISTOPATHOLOGY, V54, P221, DOI 10.1111/j.1365-2559.2008.03203.x; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Zhang J, 2014, BLOOD, V123, P2988, DOI 10.1182/blood-2013-07-517177; Zhao XX, 2015, BRIT J HAEMATOL, V168, P765, DOI 10.1111/bjh.13149	55	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6223	6234		10.1038/onc.2016.155	http://dx.doi.org/10.1038/onc.2016.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157620	Green Accepted			2022-12-28	WOS:000388857700007
J	Gupta, A; Hossain, MM; Miller, N; Kerin, M; Callagy, G; Gupta, S				Gupta, A.; Hossain, M. M.; Miller, N.; Kerin, M.; Callagy, G.; Gupta, S.			NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2 alpha-ATF4 signalling in breast cancer	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; STEROID-RECEPTOR COACTIVATOR-3; ENDOPLASMIC-RETICULUM STRESS; CELL FATE DECISIONS; ER STRESS; TRANSLATIONAL REGULATION; MESSENGER-RNA; PERK; ACTIVATION; EXPRESSION	XBP1 is a multitasking transcription factor and a key component of the unfolded protein response (UPR). Despite the wealth of knowledge about the role of XBP1 in luminal/ER-positive breast cancer, not much is known about the effectors of XBP1 in this context. Here we show that NCOA3 is a transcriptional target of XBP1. We observed increased expression of NCOA3 during conditions of UPR and oestrogen (E2) stimulation. Further investigations revealed a role for the IRE1-XBP1 axis in the induction of NCOA3 during UPR and oestrogen signalling. We identify a novel role for NCOA3 in activation of PERK-ATF4 axis during UPR where knockdown of NCOA3 compromised the optimal activation of the PERK-ATF4 pathway. We found that NCOA3 is required for induction of XBP1 during E2 stimulation and uncover a positive feedback regulatory loop that maintains high levels of NCOA3 and XBP1 in breast cancer. Furthermore, upregulated NCOA3 was required for XBP1-mediated resistance to antihormonal agents. Increased expression of NCOA3 was associated with poor prognosis and higher levels of XBP1-S in breast cancer tissues. Our results uncover a novel steroid hormone-independent role for NCOA3 in UPR signalling. Further we identify a positive feedback regulatory loop consisting of XBP1 and NCOA3 that maintains high levels of NCOA3 and XBP1 expression in breast cancer tissues. Taken together our data identify XBP1-NCOA3 axis that regulates cell fate decisions in ER-positive breast cancer cells.	[Gupta, A.; Hossain, M. M.; Callagy, G.; Gupta, S.] Natl Univ Ireland, Lambe Inst Translat Res, Sch Med, Discipline Pathol, Galway, Ireland; [Miller, N.; Kerin, M.] Natl Univ Ireland, Inst Clin Sci, Sch Med, Discipline Surg, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Gupta, S (corresponding author), Natl Univ Ireland, Inst Clin Sci, Sch Med, Discipline Pathol, Galway H91 REW4, Ireland.	sanjeev.gupta@nuigalway.ie	Miller, Nicola/F-4009-2018; gupta, sanjeev/B-2824-2008; Gupta, Sanjeev/AAG-9749-2020	Miller, Nicola/0000-0002-5416-7047; gupta, sanjeev/0000-0002-4691-6853; Gupta, Sanjeev/0000-0002-4691-6853; Kerin, Michael/0000-0003-4164-5561; Gupta, Ananya/0000-0001-8920-0815; Hossain, Muhammad Mosaraf/0000-0002-1308-1116	Health Research Board [HRA_HSR/2010/24]; Breast Cancer campaign [2011PR26]; Breast Cancer Campaign [2011MayPR26] Funding Source: researchfish	Health Research Board; Breast Cancer campaign; Breast Cancer Campaign	This publication has emanated from research conducted with the financial support of Health Research Board (grant number HRA_HSR/2010/24) and Breast Cancer campaign (grant number 2011PR26).	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073870; Cawley K, 2011, METHOD ENZYMOL, V490, P31, DOI 10.1016/B978-0-12-385114-7.00002-7; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Clarke R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00140; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gupta AK, 2015, SCI REP-UK, V5, DOI 10.1038/srep12522; Gupta A, 2015, METHODS MOL BIOL, V1292, P19, DOI 10.1007/978-1-4939-2522-3_2; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; Gupta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008008; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hu R, 2015, MOL CELL BIOL, V35, P379, DOI 10.1128/MCB.00847-14; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Kakiuchi C, 2006, J NEUROCHEM, V97, P545, DOI 10.1111/j.1471-4159.2006.03772.x; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lydon JP, 2011, ENDOCRINOLOGY, V152, P19, DOI 10.1210/en.2010-1012; Mujcic H, 2013, CLIN CANCER RES, V19, P6126, DOI 10.1158/1078-0432.CCR-13-0526; Murphy LC, 2000, CANCER RES, V60, P6266; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Read D.E., 2012, ENDOPLASMIC RETICULU, P143, DOI [10.1007/978-94-007-4351-9_6, DOI 10.1007/978-94-007-4351-9_6]; Reineke EL, 2014, J BIOL CHEM, V289, P17721, DOI 10.1074/jbc.M113.539908; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Samali A, 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/830307, DOI 10.1155/2010/830307]; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang H, 2004, CANCER RES, V64, P7169, DOI 10.1158/0008-5472.CAN-04-1176; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	48	26	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5860	5871		10.1038/onc.2016.121	http://dx.doi.org/10.1038/onc.2016.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109102	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000387560800005
J	Yang, XZ; Li, XX; Zhang, YJ; Rodriguez-Rodriguez, L; Xiang, MQ; Wang, HY; Zheng, XFS				Yang, X-Z; Li, X-X; Zhang, Y-J; Rodriguez-Rodriguez, L.; Xiang, M-Q; Wang, H-Y; Zheng, X. F. S.			Rab1 in cell signaling, cancer and other diseases	ONCOGENE			English	Review							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM STRESS; ALPHA-SYNUCLEIN; MAMMALIAN TARGET; HEPATOCELLULAR CARCINOMAS; TRAPP COMPLEXES; SMALL GTPASES; EXPRESSION; MTORC1; LOCALIZATION	The endoplasmic reticulum (ER) and Golgi membrane system have major roles in cell signaling and regulation of the biosynthesis/transport of proteins and lipids in response to environmental cues such as amino acid and cholesterol levels. Rab1 is the founding member of the Rab small GTPase family, which is known to mediate dynamic membrane trafficking between ER and Golgi. Growing evidence indicate that Rab1 proteins have important functions beyond their classical vesicular transport functions, including nutrient sensing and signaling, cell migration and presentation of cell-surface receptors. Moreover, deregulation of RAB1 expression has been linked to a myriad of human diseases such as cancer, cardiomyopathy and Parkinson's disease. Further investigating these new physiological and pathological functions of Rab1 should provide new opportunities for better understanding of the disease processes and may lead to more effective therapeutic interventions.	[Yang, X-Z; Li, X-X; Wang, H-Y; Zheng, X. F. S.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, Y-J; Rodriguez-Rodriguez, L.; Wang, H-Y; Zheng, X. F. S.] Rutgers State Univ, Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Zhang, Y-J] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Oncol Dept, Shanghai, Peoples R China; [Rodriguez-Rodriguez, L.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [Xiang, M-Q] Rutgers State Univ, Ctr Adv Biotechnol & Med, New Brunswick, NJ USA; [Xiang, M-Q] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ USA; [Xiang, M-Q] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China; [Wang, H-Y; Zheng, X. F. S.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08903 USA	State Key Lab Oncology South China; Sun Yat Sen University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sun Yat Sen University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Zheng, XFS (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08903 USA.; Zheng, XFS (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA.	zhengst@cinj.rutgers.edu	Li, Xiao-xing/B-9114-2008	Li, Xiao-xing/0000-0001-8791-7505	NIH R01 grants [CA123391, CA166575, CA173519]; National Natural Science Foundation of China [81171891, 81270035, 81572440]; Recruitment Program of Global Experts; Lead Talent of Guangdong Province; Natural Science Foundation of Guangdong Province [2015A030306047]; Research Fund of State Key Laboratory of Oncology in South China; Shanghai Pujiang Program [15PJ1404900]; NATIONAL CANCER INSTITUTE [R01CA099004, R01CA166575, R01CA173519, R01CA123391] Funding Source: NIH RePORTER	NIH R01 grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Recruitment Program of Global Experts; Lead Talent of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Research Fund of State Key Laboratory of Oncology in South China; Shanghai Pujiang Program(Shanghai Pujiang Program); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Related work in authors' laboratories was supported by NIH R01 grants CA123391, CA166575 and CA173519, the National Natural Science Foundation of China, grant nos: 81171891, 81270035 and 81572440, the Recruitment Program of Global Experts, the Lead Talent of Guangdong Province, the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (no: 2015A030306047), the Research Fund of State Key Laboratory of Oncology in South China, and Shanghai Pujiang Program 15PJ1404900.	Abd Elmageed ZY, 2014, STEM CELLS, V32, P983, DOI 10.1002/stem.1619; Abraham RT, 2015, SCIENCE, V347, P128, DOI 10.1126/science.aaa4570; ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561; Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; Bao ZS, 2014, CNS NEUROSCI THER, V20, P112, DOI 10.1111/cns.12171; Barrowman J, 2010, NAT REV MOL CELL BIO, V11, P759, DOI 10.1038/nrm2999; Cervigne NK, 2014, HUM MOL GENET, V23, P2618, DOI 10.1093/hmg/ddt657; Charng WL, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001777; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Coune PG, 2011, J PARKINSON DIS, V1, P373, DOI 10.3233/JPD-2011-11058; Dehay B, 2015, LANCET NEUROL, V14, P855, DOI 10.1016/S1474-4422(15)00006-X; Demmel L, 2008, MOL BIOL CELL, V19, P1046, DOI 10.1091/mbc.E07-02-0134; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007; Filipeanu CM, 2008, METHOD ENZYMOL, V438, P217, DOI 10.1016/S0076-6879(07)38015-4; Frasa MAM, 2012, NAT REV MOL CELL BIO, V13, P67, DOI 10.1038/nrm3267; Han JB, 2015, NATURE, V524, P243, DOI 10.1038/nature14557; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang W, 2009, VISUAL NEUROSCI, V26, P443, DOI 10.1017/S0952523809990277; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Hwang YS, 2012, BIOL PHARM BULL, V35, P289, DOI 10.1248/bpb.35.289; Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kopan Raphael, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011213; Kumar A, 2004, MOL VIS, V10, P399; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Li H, 2006, NATURE, V442, P1058, DOI 10.1038/nature05020; Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483; Liu XY, 2007, MOL BIOL CELL, V18, P1073, DOI 10.1091/mbc.E06-05-0406; Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x; Meiling-Wesse K, 2005, J BIOL CHEM, V280, P33669, DOI 10.1074/jbc.M501701200; Muller MP, 2010, SCIENCE, V329, P946, DOI 10.1126/science.1192276; Mukherjee S, 2011, NATURE, V477, P103, DOI 10.1038/nature10335; Nalesnik MA, 2012, AM J PATHOL, V180, P1495, DOI 10.1016/j.ajpath.2011.12.021; Neunuebel MR, 2011, SCIENCE, V333, P453, DOI 10.1126/science.1207193; Nikoshkov A, 2015, INT J ONCOL, V46, P107, DOI 10.3892/ijo.2014.2724; Park JS, 2014, DNA CELL BIOL, V33, P155, DOI 10.1089/dna.2013.2213; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Puria R, 2008, P NATL ACAD SCI USA, V105, P7194, DOI 10.1073/pnas.0801087105; Roberg KJ, 1997, GENETICS, V147, P1569; Sanchez-Gurmaches J, 2014, CANCER CELL, V26, P601, DOI 10.1016/j.ccell.2014.10.011; SARASTE J, 1995, J CELL SCI, V108, P1541; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; Sciarretta S, 2014, CIRC RES, V114, P549, DOI 10.1161/CIRCRESAHA.114.302022; Sherwood RK, 2013, CELL HOST MICROBE, V14, P256, DOI 10.1016/j.chom.2013.08.010; Shimada K, 2005, BRIT J CANCER, V92, P1915, DOI 10.1038/sj.bjc.6602594; Stein MP, 2012, TRAFFIC, V13, P1565, DOI 10.1111/tra.12000; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Thomas JD, 2014, CANCER CELL, V26, P754, DOI 10.1016/j.ccell.2014.09.008; TOUCHOT N, 1989, FEBS LETT, V256, P79, DOI 10.1016/0014-5793(89)81722-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; Tsang CK, 2007, EMBO J, V26, P448, DOI 10.1038/sj.emboj.7601488; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; Wang CR, 2010, J BIOL CHEM, V285, P29398, DOI 10.1074/jbc.M110.141440; Wang J, 2015, J CELL BIOL, V210, P273, DOI 10.1083/jcb.201408075; Wang J, 2013, P NATL ACAD SCI USA, V110, P9800, DOI 10.1073/pnas.1302337110; Wei LX, 2015, J CARDIOVASC PHARM, V65, P357, DOI 10.1097/FJC.0000000000000203; Winslow AR, 2010, J CELL BIOL, V190, P1023, DOI 10.1083/jcb.201003122; Wu GY, 2008, METHOD ENZYMOL, V438, P227, DOI 10.1016/S0076-6879(07)38016-6; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Xu BH, 2015, ONCOTARGET, V6, P20813, DOI 10.18632/oncotarget.5175; Yang Y, 2015, ONCOTARGET, V6, P16227, DOI 10.18632/oncotarget.3970; Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167; Zhuang XL, 2010, ENDOCRINOLOGY, V151, P5114, DOI 10.1210/en.2010-0422	72	52	52	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5699	5704		10.1038/onc.2016.81	http://dx.doi.org/10.1038/onc.2016.81			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27041585	Green Accepted			2022-12-28	WOS:000386998400001
J	Xi, G; Hayes, E; Lewis, R; Ichi, S; Mania-Farnell, B; Shim, K; Takao, T; Allender, E; Mayanil, CS; Tomita, T				Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.			RETRACTION: CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-kappa B pathway in multidrug-resistant glioblastoma cells in vitro (Retraction of vol 35, pg 241, 2016)	ONCOGENE			English	Retraction																		Xi G, 2016, ONCOGENE, V35, P241, DOI 10.1038/onc.2015.78	1	9	12	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5576	5576		10.1038/onc.2016.64	http://dx.doi.org/10.1038/onc.2016.64			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27593924	Bronze			2022-12-28	WOS:000386998200011
J	Zhou, H; Liu, Y; Zhu, R; Ding, F; Wan, Y; Li, Y; Liu, Z				Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Wan, Y.; Li, Y.; Liu, Z.			FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation	ONCOGENE			English	Article							F-BOX PROTEIN; SCF UBIQUITIN LIGASE; P38-ALPHA MAP KINASE; INDUCED DNA-DAMAGE; TUMOR-SUPPRESSOR; CELL PROLIFERATION; DOWN-REGULATION; MUSCLE ATROPHY; GENE; IDENTIFICATION	Kruppel- like factor 4 (KLF4, GKLF) is a zinc-finger transcription factor involved in a large variety of cellular processes, including apoptosis, cell cycle progression, as well as stem cell renewal. KLF4 is critical for cell fate decision and has an ambivalent role in tumorigenesis. Emerging data keep reminding us that KLF4 dysregulation either facilitates or impedes tumor progression, making it important to clarify the regulating network of KLF4. Like most transcription factors, KLF4 has a rather short half-life within the cell and its turnover must be carefully orchestrated by ubiquitination and ubiquitin-proteasome system. To better understand the mechanism of KLF4 ubiquitination, we performed a genome-wide screen of E3 ligase small interfering RNA library based on western blot and identified SCF-FBXO32 to be a new E3 ligase, which is responsible for KLF4 ubiquitination and degradation. The F-box domain is critical for FBXO32-dependent KLF4 ubiquitination and degradation. Furthermore, we demonstrated that FBXO32 physically interacts with the N-terminus (1-60 aa) of KLF4 via its C-terminus (228-355 aa) and directly targets KLF4 for ubiquitination and degradation. We also found out that p38 mitogen-activated protein kinase pathway may be implicated in FBXO32-mediated ubiquitination of KLF4, as p38 kinase inhibitor coincidently abrogates endogenous KLF4 ubiquitination and degradation, as well as FBXO32-dependent exogenous KLF4 ubiquitination and degradation. Finally, FBXO32 inhibits colony formation in vitro and primary tumor initiation and growth in vivo through targeting KLF4 into degradation. Our findings thus further elucidate the tumor-suppressive function of FBXO32 in breast cancer. These results expand our understanding of the posttranslational modification of KLF4 and of its role in breast cancer development and provide a potential target for diagnosis and therapeutic treatment of breast cancer.	[Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Peking Union Med Coll, Collaborat Innovat Ctr Canc Med, Beijing 100021, Peoples R China; [Wan, Y.] Univ Pittsburgh, Dept Cell Biol, Sch Med, Pittsburgh, PA USA; [Wan, Y.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, Y; Liu, Z (corresponding author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Li, Y; Liu, Z (corresponding author), Peking Union Med Coll, Collaborat Innovat Ctr Canc Med, Beijing 100021, Peoples R China.	liyi@cicams.ac.cn; liuzh@cicams.ac.cn	Liu, Yongshuo/GRX-6416-2022; Liu, Yongshuo/AGZ-8274-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139	National Natural Science Foundation of China [81130043, 81420108025]; Ministry of Science and Technology [2016YFC1302100, 2013CB911004]; NATIONAL CANCER INSTITUTE [R01CA202963, R01CA154695] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded by National Natural Science Foundation of China (81130043 and 81420108025) and grants from the Ministry of Science and Technology (2016YFC1302100 and 2013CB911004).	Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen ZY, 2005, CANCER RES, V65, P10394, DOI 10.1158/0008-5472.CAN-05-2059; Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138; Derbre F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046668; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 2000, CANCER RES, V60, P6488; Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guo W, 2015, NEOPLASMA, V62, P646, DOI 10.4149/neo_2015_078; Hu D, 2012, J BIOL CHEM, V287, P13584, DOI 10.1074/jbc.M112.343566; Hu D, 2011, J BIOL CHEM, V286, P6890, DOI 10.1074/jbc.M110.179952; Hu WX, 2009, CLIN CANCER RES, V15, P5688, DOI 10.1158/1078-0432.CCR-09-0310; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Jogo M, 2009, FEBS LETT, V583, P2715, DOI 10.1016/j.febslet.2009.07.033; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Li Y, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002392; Luo AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096610; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Skaar JR, 2009, CELL, V137, DOI 10.1016/j.cell.2009.05.039; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tetreault MP, 2010, GASTROENTEROLOGY, V139, P171, DOI 10.1053/j.gastro.2010.03.048; Tian X, 2015, ONCOTARGET, V6, P22767, DOI 10.18632/oncotarget.4082; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou QB, 2009, CANCER RES, V69, P8284, DOI 10.1158/0008-5472.CAN-09-1345	50	41	43	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3312	3321		10.1038/onc.2016.479	http://dx.doi.org/10.1038/onc.2016.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068319	Green Accepted			2022-12-28	WOS:000402869800010
J	Tonelli, C; Morelli, MJ; Sabo, A; Verrecchia, A; Rotta, L; Capra, T; Bianchi, S; Campaner, S; Amati, B				Tonelli, C.; Morelli, M. J.; Sabo, A.; Verrecchia, A.; Rotta, L.; Capra, T.; Bianchi, S.; Campaner, S.; Amati, B.			Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; TUMOR SUPPRESSION; P53 RESTORATION; GENE; CHEMORESISTANCE; PATHWAY; BINDING; MECHANISMS; ALIGNMENT	The tumour suppressor p53 is a transcription factor that controls cellular stress responses. Here, we dissected the transcriptional programmes triggered upon restoration of p53 in Myc-driven lymphomas, based on the integrated analysis of p53 genomic occupancy and gene regulation. p53 binding sites were identified at promoters and enhancers, both characterized by the preexistence of active chromatin marks. Only a small fraction of these sites showed the 20 base-pair p53 consensus motif, suggesting that p53 recruitment to genomic DNA was primarily mediated through protein-protein interactions in a chromatin context. p53 also targeted distal sites devoid of activation marks, at which binding was prevalently driven by sequence recognition. In all instances, the relevant motif was the canonical unsplit consensus element, with no clear evidence for p53 recruitment by split motifs. At promoters, p53 binding to the consensus motif was associated with gene induction, but not repression, indicating that the latter was most likely indirect. Altogether, our data highlight key features of genome recognition by p53 and provide unprecedented insight into the pathways associated with p53 reactivation and tumour regression, paving the way for their therapeutic application.	[Tonelli, C.; Verrecchia, A.; Rotta, L.; Capra, T.; Amati, B.] European Inst Oncol IEO, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy; [Morelli, M. J.; Sabo, A.; Bianchi, S.; Campaner, S.; Amati, B.] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), European Inst Oncol IEO, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@ieo.it	Capra, Thelma/AAN-4064-2020; Verrecchia, Alessandro/AAQ-6454-2020; Morelli, Marco/AAN-1879-2020; Rotta, Luca/AAB-9751-2019; Sabò, Arianna/J-9531-2018; Amati, Bruno/AAM-3418-2020	Verrecchia, Alessandro/0000-0002-8596-6650; Morelli, Marco/0000-0003-1862-667X; Rotta, Luca/0000-0001-6915-1120; Sabò, Arianna/0000-0002-9542-0045; CAMPANER, Stefano/0000-0003-4547-6849; Amati, Bruno/0000-0002-2958-1799; Tonelli, Claudia/0000-0002-5626-3403	European Research Council (ERC); Italian Health Ministry; Italian Association for Cancer Research (AIRC); Fondazione Cariplo	European Research Council (ERC)(European Research Council (ERC)European Commission); Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo(Fondazione Cariplo)	This work was supported by grants from the European Research Council (ERC), the Italian Health Ministry, Fondazione Cariplo and the Italian Association for Cancer Research (AIRC) to Bruno Amati.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Chang GS, 2014, CELL REP, V8, P513, DOI 10.1016/j.celrep.2014.06.030; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Renault VM, 2011, ONCOGENE, V30, P3207, DOI 10.1038/onc.2011.35; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sabo PJ, 2006, NAT METHODS, V3, P511, DOI 10.1038/NMETH890; Sammons MA, 2015, GENOME RES, V25, P179, DOI 10.1101/gr.181883.114; Schlereth K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003726; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Smeenk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017574; Su D, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004885; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tonelli C, 2015, ONCOTARGET, V6, P24611, DOI 10.18632/oncotarget.5232; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	48	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2921	2929		10.1038/onc.2016.443	http://dx.doi.org/10.1038/onc.2016.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092679	Green Published, hybrid			2022-12-28	WOS:000402000400001
J	Dunnill, CJ; Ibraheem, K; Mohamed, A; Southgate, J; Georgopoulos, NT				Dunnill, C. J.; Ibraheem, K.; Mohamed, A.; Southgate, J.; Georgopoulos, N. T.			A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis	ONCOGENE			English	Article							HUMAN UROTHELIAL CELLS; IN-VITRO; C-JUN; ANTIOXIDANT PATHWAYS; EPITHELIAL-CELLS; CARCINOMA-CELLS; CD40 PATHWAY; CANCER-CELLS; JNK; ACTIVATION	CD40, a member of the tumour necrosis factor receptor (TNFR) superfamily, has the capacity to cause extensive apoptosis in carcinoma cells, while sparing normal epithelial cells. Yet, apoptosis is only achieved by membrane-presented CD40 ligand (mCD40L), as soluble receptor agonists are but weakly pro-apoptotic. Here, for the first time we have identified the precise signalling cascade underpinning mCD40L-mediated death as involving sequential TRAF3 stabilisation, ASK1 phosphorylation, MKK4 (but not MKK7) activation and JNK/AP-1 induction, leading to a Bak-and Bax-dependent mitochondrial apoptosis pathway. TRAF3 is central in the activation of the NADPH oxidase(Nox)-2 component p40phox and the elevation of reactive oxygen species (ROS) is essential in apoptosis. Strikingly, CD40 activation resulted in down-regulation of Thioredoxin (Trx)-1 to permit ASK1 activation and apoptosis. Although soluble receptor agonist alone could not induce death, combinatorial treatment incorporating soluble CD40 agonist and pharmacological inhibition of Trx-1 was functionally equivalent to the signal triggered by mCD40L. Finally, we demonstrate using normal, 'para-malignant' and tumour-derived cells that progression to malignant transformation is associated with increase in oxidative stress in epithelial cells, which coincides with increased susceptibility to CD40 killing, while in normal cells CD40 signalling is cytoprotective. Our studies have revealed the molecular nature of the tumour specificity of CD40 signalling and explained the differences in pro-apoptotic potential between soluble and membrane-bound CD40 agonists. Equally importantly, by exploiting a unique epithelial culture system that allowed us to monitor alterations in the redox-state of epithelial cells at different stages of malignant transformation, our study reveals how pro-apoptotic signals can elevate ROS past a previously hypothesised 'lethal pro-apoptotic threshold' to induce death; an observation that is both of fundamental importance and carries implications for cancer therapy.	[Dunnill, C. J.; Ibraheem, K.; Mohamed, A.; Georgopoulos, N. T.] Univ Huddersfield, Sch Appl Sci, Dept Biol Sci, Huddersfield HD1 3DH, W Yorkshire, England; [Southgate, J.] Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York, N Yorkshire, England	University of Huddersfield; University of York - UK	Georgopoulos, NT (corresponding author), Univ Huddersfield, Sch Appl Sci, Dept Biol Sci, Huddersfield HD1 3DH, W Yorkshire, England.	N.Georgopoulos@hud.ac.uk	Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X	York Against Cancer	York Against Cancer	The authors are grateful to all clinical colleagues for the supply of normal urothelial tissue, and would like to thank Prof Alan Melcher and Dr Liz Illett (Targeted & Biological Therapies Group, Leeds Institute of Cancer and Pathology, University of Leeds, UK) for the provision of the G28-5 antibody and fruitful discussions. JS holds a research chair supported by York Against Cancer.	Al-Tameemi W, 2014, TOXICOL IN VITRO, V28, P1366, DOI 10.1016/j.tiv.2014.07.011; Albarbar B, 2015, CYTOKINE GROWTH F R, V26, P659, DOI 10.1016/j.cytogfr.2015.05.001; Altenburg A, 1999, J IMMUNOL, V162, P4140; Baker AF, 2006, J LAB CLIN MED, V147, P83, DOI 10.1016/j.lab.2005.09.001; Baxendale AJ, 2005, ONCOGENE, V24, P7913, DOI 10.1038/sj.onc.1208929; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bhogal RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030867; Bishop GA, 2007, ADV EXP MED BIOL, V597, P131; Booth C, 1997, LAB INVEST, V76, P843; Bugajska U, 2002, J NATL CANCER I, V94, P1381; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Crallan RA, 2006, CARCINOGENESIS, V27, P374, DOI 10.1093/carcin/bgi266; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Duffy CL, 2003, VIROLOGY, V314, P196, DOI 10.1016/S0042-6822(03)00390-8; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Eliopoulos AG, 2004, CURR OPIN PHARMACOL, V4, P360, DOI 10.1016/j.coph.2004.02.008; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Elmetwali T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-52; Elmetwali T, 2010, J IMMUNOL, V184, P1111, DOI 10.4049/jimmunol.0900528; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Georgopoulos NT, 2007, INT J CANCER, V121, P1373, DOI 10.1002/ijc.22846; Georgopoulos NT, 2011, EUR UROL, V60, P141, DOI 10.1016/j.eururo.2011.02.022; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hill KS, 2008, J IMMUNOL, V181, P3108, DOI 10.4049/jimmunol.181.5.3108; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980; Jin HO, 2006, J CELL PHYSIOL, V206, P477, DOI 10.1002/jcp.20488; JOHNSON PWM, 1993, BLOOD, V82, P1848, DOI 10.1182/blood.V82.6.1848.bloodjournal8261848; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Nishiyama A, 1999, IMMUNOL LETT, V68, P155, DOI 10.1016/S0165-2478(99)00045-0; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Ramanathan RK, 2012, INVEST NEW DRUG, V30, P1591, DOI 10.1007/s10637-011-9739-9; Reznikoff CA, 1996, CANCER RES, V56, P2886; Saretzki G, 2009, EXP GERONTOL, V44, P485, DOI 10.1016/j.exger.2009.05.004; Schattner E, 1996, IMMUNOL RES, V15, P246, DOI 10.1007/BF02918252; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Shaw NJ, 2005, INT J CANCER, V116, P634, DOI 10.1002/ijc.21114; Simic T, 2009, NAT REV UROL, V6, P281, DOI 10.1038/nrurol.2009.49; Soga Mayumi, 2012, Int J Cell Biol, V2012, P439587, DOI 10.1155/2012/439587; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Southgate J, 2012, CULT EPITHEL CELLS, P381; Stewart R, 2007, J IMMUNOL, V179, P2705, DOI 10.4049/jimmunol.179.5.2705; T Georgopoulos N, 2006, CELL DEATH DIFFER, V13, P1789, DOI 10.1038/sj.cdd.4401859; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vardouli L, 2009, CANCER GENE THER, V16, P848, DOI 10.1038/cgt.2009.31; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang HCR, 2011, NAT REV UROL, V8, P608, DOI 10.1038/nrurol.2011.135; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Yodoi J, 2001, BIOFACTORS, V15, P107, DOI 10.1002/biof.5520150212; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	64	16	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2515	2528		10.1038/onc.2016.401	http://dx.doi.org/10.1038/onc.2016.401			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27869172	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000400597300003
J	Murga-Zamalloa, CA; Mendoza-Reinoso, V; Sahasrabuddhe, AA; Rolland, D; Hwang, SR; McDonnell, SRP; Sciallis, AP; Wilcox, RA; Bashur, V; Elenitoba-Johnson, K; Lim, MS				Murga-Zamalloa, C. A.; Mendoza-Reinoso, V.; Sahasrabuddhe, A. A.; Rolland, D.; Hwang, S. R.; McDonnell, S. R. P.; Sciallis, A. P.; Wilcox, R. A.; Bashur, V.; Elenitoba-Johnson, K.; Lim, M. S.			NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma	ONCOGENE			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN POLYMERIZATION; KINASE ALK; INVADOPODIUM FORMATION; IMMUNOLOGICAL SYNAPSE; TYROSINE KINASE; WIP; MACROPHAGES; PODOSOMES; DYNAMICS	Mechanisms by which NPM-ALK signaling regulates cell migration, invasion and contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely understood. In an attempt to identify novel actin signaling pathways regulated by NPM-ALK, a comprehensive phosphoproteome analysis of ALCL cell lines was performed in the presence or absence of NPM-ALK activity. Numerous phosphoproteins involved in actin dynamics including Wiskott-Aldrich syndrome protein (WASp) were regulated by NPM-ALK. Network analysis revealed that WASp is a central component of the NPM-ALK-dependent actin signaling pathway. Here we show that NPM-ALK phosphorylates WASp at its known activation site (Y290) as well as at a novel residue (Y102). Phosphorylation of WASp at Y102 negatively regulates its interaction with Wiskott-Aldrich interacting protein and decreases its protein stability. Phosphorylation of WASp at Y102 enhances anchorage-independent growth and tumor growth in an in vivo xenograft model and enhances invasive properties of ALCL. We show that knock-down of WASp or expression of Y102F mutant of WASp decreases colony formation and in vivo tumor growth. Our results show that WASp is a novel substrate of ALK and has a critical role in regulating invasiveness and oncogenesis of ALCL.	[Murga-Zamalloa, C. A.; Mendoza-Reinoso, V.; Sahasrabuddhe, A. A.; Rolland, D.; Hwang, S. R.; McDonnell, S. R. P.; Sciallis, A. P.; Bashur, V.; Elenitoba-Johnson, K.; Lim, M. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Rolland, D.; Elenitoba-Johnson, K.; Lim, M. S.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Wilcox, R. A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Pennsylvania; University of Michigan System; University of Michigan	Lim, MS (corresponding author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.	Megan.Lim@uphs.upenn.edu	Rolland, Delphine/ABG-2497-2021; Murga-Zamalloa, Carlos/AAX-9387-2021	Murga-Zamalloa, Carlos/0000-0002-2238-5066; Lim, Megan/0000-0002-0415-2867; Hwang, Steven/0000-0002-6536-1291; Mendoza-Reinoso, Veronica/0000-0003-1776-4229; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Rolland, Delphine/0000-0002-7801-6534	Department of Pathology, University of Michigan [R01 CA140806-01, R01 DE119249, R01 CA136905]; HONORS-ASH award	Department of Pathology, University of Michigan(University of Michigan System); HONORS-ASH award	This work was supported by the Department of Pathology, University of Michigan and R01 CA140806-01 (MSL), R01 DE119249, R01 CA136905 (KSJ-EJ) and HONORS-ASH award (CMZ).	Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Ambrogio C, 2008, CANCER RES, V68, P8899, DOI 10.1158/0008-5472.CAN-08-2568; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Badolato R, 1998, J IMMUNOL, V161, P1026; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blundell MP, 2009, P NATL ACAD SCI USA, V106, P15738, DOI 10.1073/pnas.0904346106; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Chou HC, 2006, CURR BIOL, V16, P2337, DOI 10.1016/j.cub.2006.10.037; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cory GOC, 1996, J IMMUNOL, V157, P3791; Cougoule C, 2012, EUR J CELL BIOL, V91, P938, DOI 10.1016/j.ejcb.2012.07.002; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; Dovas Athanassios, 2010, Commun Integr Biol, V3, P101; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jin P, 2011, DEV CELL, V20, P623, DOI 10.1016/j.devcel.2011.04.007; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Lagarrigue F, 2010, CANCER RES, V70, P6978, DOI 10.1158/0008-5472.CAN-10-0861; Lane J, 2014, CANCER GENOM PROTEOM, V11, P155; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Linder S, 2003, IMMUNOL CELL BIOL, V81, P130, DOI 10.1046/j.0818-9641.2002.01147.x; McDonnell SRP, 2012, ONCOGENE, V31, P3733, DOI 10.1038/onc.2011.542; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Oda A, 2001, BLOOD, V97, P2633, DOI 10.1182/blood.V97.9.2633; Ott GR, 2011, J MED CHEM, V54, P6328, DOI 10.1021/jm200758k; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Slupianek A, 2001, CANCER RES, V61, P2194; Stewart DM, 1999, J IMMUNOL, V162, P5019; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tripathy R, 2011, BIOORG MED CHEM LETT, V21, P7261, DOI 10.1016/j.bmcl.2011.10.055; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wolf K, 2003, BLOOD, V102, P3262, DOI 10.1182/blood-2002-12-3791; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	45	10	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2085	2094		10.1038/onc.2016.366	http://dx.doi.org/10.1038/onc.2016.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27694894				2022-12-28	WOS:000399782500005
J	Nickerson, ML; Das, S; Im, KM; Turan, S; Berndt, SI; Li, H; Lou, H; Brodie, SA; Billaud, JN; Zhang, T; Bouk, AJ; Butcher, D; Wang, Z; Sun, L; Misner, K; Tan, W; Esnakula, A; Esposito, D; Huang, WY; Hoover, RN; Tucker, MA; Keller, JR; Boland, J; Brown, K; Anderson, SK; Moore, LE; Isaacs, WB; Chanock, SJ; Yeager, M; Dean, M; Andresson, T				Nickerson, M. L.; Das, S.; Im, K. M.; Turan, S.; Berndt, S. I.; Li, H.; Lou, H.; Brodie, S. A.; Billaud, J. N.; Zhang, T.; Bouk, A. J.; Butcher, D.; Wang, Z.; Sun, L.; Misner, K.; Tan, W.; Esnakula, A.; Esposito, D.; Huang, W. Y.; Hoover, R. N.; Tucker, M. A.; Keller, J. R.; Boland, J.; Brown, K.; Anderson, S. K.; Moore, L. E.; Isaacs, W. B.; Chanock, S. J.; Yeager, M.; Dean, M.; Andresson, T.			TET2 binds the androgen receptor and loss is associated with prostate cancer	ONCOGENE			English	Article							GENE; MUTATIONS; LANDSCAPE; HYDROXYMETHYLATION; IDENTIFICATION; HOMEODOMAIN; PREDICTION; INSIGHT; GENOME	Genetic alterations associated with prostate cancer (PCa) may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease. Previously, we characterized somatic alterations in metastatic tumours in the methylcytosine dioxygenase ten-eleven translocation 2 (TET2), which is altered in 5-15% of myeloid, kidney, colon and PCas. Genome-wide association studies previously identified non-coding risk variants associated with PCa and melanoma. We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2. Oligonucleotides containing two risk variants are bound by the transcription factor octamer-binding protein 1 (Oct1/POU2F1) and TET2 and Oct1 expression are positively correlated in prostate tumours. TET2 is expressed in normal prostate tissue and reduced in a subset of tumours from the Cancer Genome Atlas (TCGA). Small interfering RNA-mediated TET2 knockdown (KD) increases LNCaP cell proliferation, migration and wound healing, verifying loss drives a cancer phenotype. Endogenous TET2 bound the androgen receptor (AR) and AR-coactivator proteins in LNCaP cell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression. Published data reveal TET2 binding sites and hydroxymethylcytosine proximal to KLK3. A gene co-expression network identified using TCGA prostate tumour RNA-sequencing identifies co-regulated cancer genes associated with 2-oxoglutarate (2-OG) and succinate metabolism, including TET2, lysine demethylase (KDM) KDM6A, BRCA1-associated BAP1, and citric acid cycle enzymes IDH1/2, SDHA/B, and FH. The co-expression signature is conserved across 31 TCGA cancers suggesting a putative role for TET2 as an energy sensor (of 2-OG) that modifies aspects of androgen-AR signalling. Decreased TET2 mRNA expression in TCGA PCa tumours is strongly associated with reduced patient survival, indicating reduced expression in tumours may be an informative biomarker of disease progression and perhaps metastatic disease.	[Nickerson, M. L.; Turan, S.; Li, H.; Lou, H.; Misner, K.; Tan, W.; Anderson, S. K.; Dean, M.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Das, S.; Andresson, T.] Leidos Biomed Res Inc, Prot Characterizat Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Im, K. M.] Data Sci Genom, Ellicott City, MD USA; [Berndt, S. I.; Brodie, S. A.; Bouk, A. J.; Wang, Z.; Huang, W. Y.; Hoover, R. N.; Tucker, M. A.; Boland, J.; Moore, L. E.; Chanock, S. J.; Yeager, M.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Li, H.; Lou, H.] Leidos Biomed Res Inc, Basic Res Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Brodie, S. A.; Boland, J.; Yeager, M.] Leidos Biomed Res Inc, Canc Genom Res, Frederick Natl Lab Canc Res, Frederick, MD USA; [Billaud, J. N.] Ingenu Syst Inc, Redwood City, CA USA; [Nickerson, M. L.; Zhang, T.; Brown, K.; Dean, M.] NCI, Lab Translat Genom, 8717 Grovemont Circle,Rm 225C, Bethesda, MD 20892 USA; [Butcher, D.] Leidos Biomed Res Inc, Pathol & Histotechnol Lab, Frederick Natl Lab Canc Res, Frederick, MD USA; [Sun, L.; Keller, J. R.] NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21701 USA; [Esnakula, A.] Howard Univ, Coll Med, Dept Pathol, Howard Univ Hosp, Washington, DC USA; [Esposito, D.] Leidos Biomed Res Inc, Prot Express Lab, Frederick Natl Lab Canc Res, Frederick, MD USA; [Isaacs, W. B.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Nickerson, ML (corresponding author), NCI, Lab Translat Genom, 8717 Grovemont Circle,Rm 225C, Bethesda, MD 20892 USA.	nickersonml@mail.nih.gov	Brodie, Seth/U-9035-2019; Dean, Michael C/G-8172-2012; Anderson, Stephen K/B-1727-2012; Dean, Michael/R-7501-2019; Keller, Jonathan R./O-6677-2018; Yeager, Meredith/AAA-5322-2020	Dean, Michael C/0000-0003-2234-0631; Anderson, Stephen K/0000-0002-7856-4266; Esposito, Dominic/0000-0002-9987-1687	Intramural Research Program of the National Institutes of Health; National Cancer Institute; Leidos Biomedical Research, Inc. [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC010001] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leidos Biomedical Research, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by the Intramural Research Program of the National Institutes of Health, the National Cancer Institute and by Leidos Biomedical Research, Inc., under contract # HHSN261200800001E.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Eeles RA, 2009, NAT GENET, V41, P1116, DOI 10.1038/ng.450; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fu LJ, 2014, J AM CHEM SOC, V136, P11582, DOI 10.1021/ja505305z; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Hu LL, 2015, NATURE, V527, P118, DOI 10.1038/nature15713; Hu LL, 2013, CELL, V155, P1545, DOI 10.1016/j.cell.2013.11.020; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Lilja H, 2008, NAT REV CANCER, V8, P268, DOI 10.1038/nrc2351; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Metzeler KH, 2011, J CLIN ONCOL, V29, P1373, DOI 10.1200/JCO.2010.32.7742; Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078-0432.CCR-14-0330; Nickerson ML, 2013, HUM MUTAT, V34, P1231, DOI 10.1002/humu.22346; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Passon DM, 2012, P NATL ACAD SCI USA, V109, P4846, DOI 10.1073/pnas.1120792109; Pena-Llopis S, 2013, CANCER RES, V73, P4173, DOI 10.1158/0008-5472.CAN-13-0360; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pomerantz MM, 2011, CANCER PREV RES, V4, P719, DOI 10.1158/1940-6207.CAPR-10-0292; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Scopim-Ribeiro R, 2015, EUR J HAEMATOL, V94, P413, DOI 10.1111/ejh.12445; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Serandour AA, 2012, NUCLEIC ACIDS RES, V40, P8255, DOI 10.1093/nar/gks595; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Setiawan VW, 2014, CARCINOGENESIS, V35, P2068, DOI 10.1093/carcin/bgu107; Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129; Song FJ, 2014, CARCINOGENESIS, V35, P2097, DOI 10.1093/carcin/bgu140; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takayama K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9219; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128	53	33	34	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2172	2183		10.1038/onc.2016.376	http://dx.doi.org/10.1038/onc.2016.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27819678	Green Accepted			2022-12-28	WOS:000399782500012
J	Xu, Z; Yang, F; Wei, D; Liu, B; Chen, C; Bao, Y; Wu, Z; Wu, D; Tan, H; Li, J; Wang, J; Liu, J; Sun, S; Qu, L; Wang, L				Xu, Z.; Yang, F.; Wei, D.; Liu, B.; Chen, C.; Bao, Y.; Wu, Z.; Wu, D.; Tan, H.; Li, J.; Wang, J.; Liu, J.; Sun, S.; Qu, L.; Wang, L.			Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; ANTITUMOR-ACTIVITY; CANCER; PROSTATE; INHIBITION; STAT3	Although the use of sorafenib appears to increase the survival rate of renal cell carcinoma (RCC) patients, there is also a proportion of patients who exhibit a poor primary response to sorafenib therapy. It is therefore critical to elucidate the mechanisms underlying sorafenib resistance and find representative biomarkers for sorafenib treatment in RCC patients. Herein, we identified a long non-coding RNA referred to as lncRNA-SRLR (sorafenib resistance-associated lncRNA in RCC) that is upregulated in intrinsically sorafenib-resistant RCCs. lncRNA-SRLR knockdown sensitized nonresponsive RCC cells to sorafenib treatment, whereas the overexpression of lncRNA-SRLR conferred sorafenib resistance to responsive RCC cells. Mechanistically, lncRNA-SRLR directly binds to NF-kappa B and promotes IL-6 transcription, leading to the activation of STAT3 and the development of sorafenib tolerance. A STAT3 inhibitor and IL-6-receptor antagonist both restored the response to sorafenib treatment. Moreover, a clinical investigation demonstrated that high levels of lncRNA-SRLR correlated with poor responses to sorafenib therapy in RCC patients. Collectively, lncRNA-SRLR may serve as not only a predictive biomarker for inherent sorafenib resistance but also as a therapeutic target to enhance responses to sorafenib in RCC patients.	[Xu, Z.; Liu, B.; Bao, Y.; Wu, Z.; Wu, D.; Tan, H.; Li, J.; Wang, J.; Liu, J.; Qu, L.; Wang, L.] Second Mil Med Univ, Changzheng Hosp, Dept Urol, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Yang, F.; Sun, S.] Second Mil Med Univ, Dept Med Genet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China; [Wei, D.] Shandong Univ, Shandong Prov Qianfoshan Hosp, Div Endocrinol, Dept Internal Med, Jinan, Peoples R China; [Chen, C.] Nanjing Univ, Jinling Hosp, Dept Med Oncol, Clin Sch Med, Nanjing, Jiangsu, Peoples R China; [Qu, L.] Nanjing Univ, Jinling Hosp, Dept Urol, Clin Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Naval Medical University; Naval Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Nanjing University; Nanjing University	Wang, L (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Urol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.; Sun, S (corresponding author), Second Mil Med Univ, Dept Med Genet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.; Qu, L (corresponding author), Nanjing Univ, Jinling Hosp, Dept Urol, Clin Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	shsun@vip.sina.com; septsoul@hotmail.com; wanglinhuicz@163.com	Yang, Fu/C-3786-2008; Yang, Fu/L-8441-2019	Yang, Fu/0000-0003-2459-3923; Qu, Le/0000-0001-9499-4277	National Natural Science Foundation of China [81272817, 81472691, 81572521]; Leading Talent Project of Shanghai [2013046]; Youth Talent Sailing Program of Shanghai Science and Technology Committee [16YF1403600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leading Talent Project of Shanghai; Youth Talent Sailing Program of Shanghai Science and Technology Committee	We thank Dr Feng Liu and Qifei Tao for editing this manuscript. This study was supported by grants from the National Natural Science Foundation of China (81272817, 81472691 and 81572521), the Leading Talent Project of Shanghai (2013046) and Youth Talent Sailing Program of Shanghai Science and Technology Committee (16YF1403600).	Abe H, 2013, INT J UROL, V20, P944, DOI 10.1111/iju.12187; Banfai B, 2012, GENOME RES, V22, P1646, DOI 10.1101/gr.134767.111; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Heng DY, 2012, ANN ONCOL, V23, P1549, DOI 10.1093/annonc/mdr533; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kharaziha P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.1; Kong J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-7; Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114586; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Ozturk G, 2012, EUR REV MED PHARMACO, V16, P2064; Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003; Patil S, 2012, J UROLOGY, V188, P2095, DOI 10.1016/j.juro.2012.08.026; Powles T, 2016, EUR UROL, V69, P4, DOI 10.1016/j.eururo.2015.10.017; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Sotillo E, 2011, NAT GENET, V43, P616, DOI 10.1038/ng.870; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Ye DW, 2014, ONCOTARGETS THER, V7, P925, DOI 10.2147/OTT.S41828; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	37	75	80	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1965	1977		10.1038/onc.2016.356	http://dx.doi.org/10.1038/onc.2016.356			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27841868				2022-12-28	WOS:000398898500007
J	Stojanovic, N; Hassan, Z; Wirth, M; Wenzel, P; Beyer, M; Schafer, C; Brand, P; Kroemer, A; Stauber, RH; Schmid, RM; Arlt, A; Sellmer, A; Mahboobi, S; Rad, R; Reichert, M; Saur, D; Kramer, OH; Schneider, G				Stojanovic, N.; Hassan, Z.; Wirth, M.; Wenzel, P.; Beyer, M.; Schaefer, C.; Brand, P.; Kroemer, A.; Stauber, R. H.; Schmid, R. M.; Arlt, A.; Sellmer, A.; Mahboobi, S.; Rad, R.; Reichert, M.; Saur, D.; Kraemer, O. H.; Schneider, G.			HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; MULTIPLE-MYELOMA; TRICHOSTATIN-A; BREAST-CANCER; MOUSE MODELS; CELL-LINES; STEM-CELLS; IN-VIVO	Mutation of p53 is a frequent genetic lesion in pancreatic cancer being an unmet clinical challenge. Mutants of p53 have lost the tumour-suppressive functions of wild type p53. In addition, p53 mutants exert tumour-promoting functions, qualifying them as important therapeutic targets. Here, we show that the class I histone deacetylases HDAC1 and HDAC2 contribute to maintain the expression of p53 mutants in human and genetically defined murine pancreatic cancer cells. Our data reveal that the inhibition of these HDACs with small molecule HDAC inhibitors (HDACi), as well as the specific genetic elimination of HDAC1 and HDAC2, reduce the expression of mutant p53 mRNA and protein levels. We further show that HDAC1, HDAC2 and MYC directly bind to the TP53 gene and that MYC recruitment drops upon HDAC inhibitor treatment. Therefore, our results illustrate a previously unrecognized class I HDAC-dependent control of the TP53 gene and provide evidence for a contribution of MYC. A combined approach targeting HDAC1/HDAC2 and MYC may present a novel and molecularly defined strategy to target mutant p53 in pancreatic cancer.	[Stojanovic, N.; Hassan, Z.; Wirth, M.; Wenzel, P.; Kroemer, A.; Schmid, R. M.; Rad, R.; Reichert, M.; Saur, D.; Schneider, G.] Tech Univ Munich, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Bavaria, Germany; [Beyer, M.; Kraemer, O. H.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Toxicol, Mainz, Germany; [Schaefer, C.; Brand, P.] Friedrich Schiller Univ Jena, CMB, Inst Biochem & Biophys, Jena, Germany; [Stauber, R. H.] Univ Med Ctr Mainz, Mol & Cellular Oncol ENT, Mainz, Germany; [Arlt, A.] Univ Hosp Schleswig Holstein, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1 1, Kiel, Germany; [Sellmer, A.; Mahboobi, S.] Univ Regensburg, Inst Pharm, Fac Chem & Pharm, Dept Pharmaceut Chem 1, Regensburg, Germany; [Rad, R.; Saur, D.] German Canc Res Ctr, Heidelberg, Germany; [Rad, R.; Saur, D.] German Canc Consortium DKTK, Heidelberg, Germany; [Reichert, M.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Johannes Gutenberg University of Mainz; Friedrich Schiller University of Jena; Johannes Gutenberg University of Mainz; University of Kiel; Schleswig Holstein University Hospital; University of Regensburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine	Kramer, OH; Schneider, G (corresponding author), Tech Univ Munich, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Bavaria, Germany.	okraemer@uni-mainz.de; guenter.schneider@tum.de	Reichert, Maximilian/GOH-1246-2022; Krämer, Oliver H/L-9266-2015; Saur, Dieter/O-8355-2015; Arlt, Alexander/G-7308-2019; Wirth, Matthias/AEG-6333-2022	Krämer, Oliver H/0000-0003-3973-045X; Saur, Dieter/0000-0001-5874-0210; Arlt, Alexander/0000-0002-6160-1059; Wirth, Matthias/0000-0002-8340-0872	Deutsche Krebshilfe [110908, 110909, 111273]; Wilhelm-Sander Stiftung [2016.004.1, 2010.078.1]; Else Kroner-Fresenius-Stiftung [2016_A43]; Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/2-1 t, SFB824/C9, KR 2291/4-1/MA, 2183/1-1, KR 2291/5-1]; DKTK Joint Funding	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm-Sander Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DKTK Joint Funding	We thank Dr E. Olson, Dr T. Jacks, Dr A. Lowy, Dr P. Soriano, and Dr D. Tuveson for providing mouse lines. We thank Dr A. Bradley for support and help during the transfer of mouse lines. This work was supported by: Deutsche Krebshilfe [110908 to G.S., 110909 to O.H.K., and 111273 to M.R.], Wilhelm-Sander Stiftung [2016.004.1 to S.M. and G.S., 2010.078.1 to O.H.K], Else Kroner-Fresenius-Stiftung (2016_A43 to M.W.), Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/2-1 to G.S.; SFB824/C9 to G.S. and D.S.; KR 2291/4-1/MA; 2183/1-1 to O.H.K. and S.M., and KR 2291/5-1 to O.H.K.], and DKTK Joint Funding [to R.R., D.S., and G.S.].	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Azmi AS, 2010, EUR J CANCER, V46, P1122, DOI 10.1016/j.ejca.2010.01.015; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Bradner JE, 2010, P NATL ACAD SCI USA, V107, P12617, DOI 10.1073/pnas.1006774107; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Chang DK, 2014, CURR OPIN GENET DEV, V24, P74, DOI 10.1016/j.gde.2013.12.001; Conradt L, 2013, INT J CANCER, V132, P2248, DOI 10.1002/ijc.27916; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Diersch S, 2016, ONCOGENE, V35, P3880, DOI 10.1038/onc.2015.437; Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002; Dovey OM, 2010, CELL CYCLE, V9, P2700, DOI 10.4161/cc.9.14.12626; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Fiorini C, 2015, BBA-MOL CELL RES, V1853, P89, DOI 10.1016/j.bbamcr.2014.10.003; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Geismann C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.417; Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Jamaladdin S, 2014, P NATL ACAD SCI USA, V111, P9840, DOI 10.1073/pnas.1321330111; Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Kubicek S, 2012, P NATL ACAD SCI USA, V109, P5364, DOI 10.1073/pnas.1201079109; Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558; Labisso WL, 2012, CELL CYCLE, V11, P1593, DOI 10.4161/cc.20008; Lauffer BEL, 2013, J BIOL CHEM, V288, P26926, DOI 10.1074/jbc.M113.490706; Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li YQ, 2008, CANCER RES, V68, P1723, DOI 10.1158/0008-5472.CAN-07-1963; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Mahboobi S., 2016, PCT Int. Appl., Patent No. [WO 2016020369 A1, 2016020369, WO2016020369A1]; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Matthews GM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.306; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Murakami J, 2005, CANCER CHEMOTH PHARM, V56, P22, DOI 10.1007/s00280-004-0976-x; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Ossewaarde JM, 1996, APPL ENVIRON MICROB, V62, P328, DOI 10.1128/AEM.62.2.328-331.1996; Ouaissi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108520; Pei YX, 2016, CANCER CELL, V29, P311, DOI 10.1016/j.ccell.2016.02.011; Peltonen K, 2005, PIGM CELL RES, V18, P196, DOI 10.1111/j.1600-0749.2005.00225.x; Peulen O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075102; Piacentini P, 2006, VIRCHOWS ARCH, V448, P797, DOI 10.1007/s00428-006-0173-x; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sachweh MCC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.61; Saldana-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683; Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Scholz C, 2015, NAT BIOTECHNOL, V33, P415, DOI 10.1038/nbt.3130; Schuler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80; Shortt J, 2014, CELL REP, V7, P1009, DOI 10.1016/j.celrep.2014.04.008; Sonnemann J, 2014, BRIT J CANCER, V110, P656, DOI 10.1038/bjc.2013.742; Sui X, 2009, ONCOGENE, V28, P709, DOI 10.1038/onc.2008.423; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wagner T, 2014, BBA-REV CANCER, V1846, P524, DOI 10.1016/j.bbcan.2014.07.010; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang ZT, 2016, CELL SIGNAL, V28, P506, DOI 10.1016/j.cellsig.2016.02.006; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Wirth M, 2016, TRENDS CANCER, V2, P1, DOI 10.1016/j.trecan.2015.12.002; Wirth M, 2016, MOL CANCER THER, V15, P1792, DOI 10.1158/1535-7163.MCT-16-0050; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Wirth M, 2011, PANCREAS, V40, P144, DOI 10.1097/MPA.0b013e3181f7e41c; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yu XD, 2002, J NATL CANCER I, V94, P504; Zappasodi R, 2014, INT J CANCER, V135, P2034, DOI 10.1002/ijc.28852; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	86	64	65	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1804	1815		10.1038/onc.2016.344	http://dx.doi.org/10.1038/onc.2016.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721407				2022-12-28	WOS:000398128900006
J	Wang, J; Zhang, B; Wu, H; Cai, J; Sui, X; Wang, Y; Li, H; Qiu, Y; Wang, T; Chen, Z; Zhu, Q; Xia, H; Song, W; Xiang, AP				Wang, J.; Zhang, B.; Wu, H.; Cai, J.; Sui, X.; Wang, Y.; Li, H.; Qiu, Y.; Wang, T.; Chen, Z.; Zhu, Q.; Xia, H.; Song, W.; Xiang, A. P.			CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells	ONCOGENE			English	Article							INITIATING CELLS; PHENOTYPIC CHARACTERIZATION; METASTATIC CAPACITY; POOR-PROGNOSIS; COLON; ALPHA; MOUSE; TARGET; TUMORS; OVEREXPRESSION	Colorectal cancer (CRC) is one of the top three most prevalent and deadly cancers. A cancer stem cell (CSC) sub-population that is characterized by the abilities of tumor initiation, self-renewal, metastasis and resistance to chemotherapy can suggest new therapeutic targets. However, no such sub-population has been conclusively identified for CRC, and we lack any marker to identify cells with all of the above characteristics. Here, we report that CD51(+) CRC cells displayed greater sphere-forming and tumorigenic capacities, increased migratory and invasive potentials, and enhanced chemoresistance compared with CD51(-) CRC cells. CD51 knockdown reduced the side population, sphere formation, cell motility and inhibited tumor incidence and metastasis in an in vivo tumor model. Furthermore, CD51 could bind transforming growth factor beta (TGF-beta) receptors, and that it upregulated TGF-beta/Smad signaling. These results indicate that CD51 is a novel functional marker for colorectal CSCs which may provide an therapeutic target for the efficient elimination of colorectal CSCs.	[Wang, J.; Zhang, B.; Wu, H.; Xia, H.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Hosp, Program Stem Cells & Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Wang, J.; Zhang, B.; Wu, H.; Cai, J.; Wang, Y.; Li, H.; Qiu, Y.; Wang, T.; Xiang, A. P.] Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, 74,Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Cai, J.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Guangdong, Peoples R China; [Sui, X.; Zhu, Q.] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China; [Chen, Z.; Song, W.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Pancreat Surg, Guangzhou, Guangdong, Peoples R China; [Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Xi'an Jiaotong University; Sun Yat Sen University; Sun Yat Sen University	Xiang, AP (corresponding author), Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, 74,Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.; Song, W (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	songwu@mail.sysu.edu.cn; xiangp@mail.sysu.edu.cn	Cai, Jianye/GOK-2676-2022	Wu, Hao-Xiang/0000-0001-6719-7133	National Basic Research Program of China [2012CBA01302]; National Natural Science Foundation of China [81425016, 81270646]; Natural Science Foundation of Guangdong Province [S2013030013305, S20120011190, 2015A030312013]; Key Scientific and Technological Projects of Guangdong Province [2014B020226002, 2015B020226004, 2014B020228003, 2015B020228001]; Key Scientific and Technological Program of Guangzhou City [201400000003-3, 201508020262, 201300000089]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Scientific and Technological Projects of Guangdong Province; Key Scientific and Technological Program of Guangzhou City; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	This work was supported by the National Basic Research Program of China (2012CBA01302); the National Natural Science Foundation of China (81425016, 81270646); the Natural Science Foundation of Guangdong Province (S2013030013305, S20120011190, 2015A030312013); the Key Scientific and Technological Projects of Guangdong Province (2014B020226002, 2015B020226004, 2014B020228003, 2015B020228001); Key Scientific and Technological Program of Guangzhou City (201400000003-3, 201508020262, 201300000089); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2013).	Abetov D, 2015, TUMOR BIOL, V36, P1339, DOI 10.1007/s13277-015-3198-4; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Colak S, 2014, CELL DEATH DIFFER, V21, P1170, DOI 10.1038/cdd.2014.37; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Emmink BL, 2011, GASTROENTEROLOGY, V141, P269, DOI 10.1053/j.gastro.2011.03.052; Fang DD, 2010, BRIT J CANCER, V102, P1265, DOI 10.1038/sj.bjc.6605610; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Gemei M, 2013, CANCER-AM CANCER SOC, V119, P729, DOI 10.1002/cncr.27794; Ha SY, 2014, J CLIN PATHOL, V67, P576, DOI 10.1136/jclinpath-2013-202163; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Henderson NC, 2013, NAT MED, V19, P1617, DOI 10.1038/nm.3282; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jiang MH, 2014, CELL RES, V24, P1466, DOI 10.1038/cr.2014.149; Ke Q, 2013, HUM MOL GENET, V22, P2221, DOI 10.1093/hmg/ddt074; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Levin TG, 2010, GASTROENTEROLOGY, V139, P2072, DOI 10.1053/j.gastro.2010.08.053; Li WQ, 2015, BIOMATERIALS, V39, P75, DOI 10.1016/j.biomaterials.2014.10.056; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu XJ, 2008, PERSPECT MED CHEM, V2, P57; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pan QZ, 2015, STEM CELLS, V33, P354, DOI 10.1002/stem.1850; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991; Thien A, 2015, DEV CELL, V32, P617, DOI 10.1016/j.devcel.2015.01.026; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; Todaro M, 2008, CELL CYCLE, V7, P309, DOI 10.4161/cc.7.3.5389; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267; Waisberg J, 2014, ANTICANCER RES, V34, P5599; Wang J, 2016, ONCOGENE, V35, P3139, DOI 10.1038/onc.2015.370; WERSTO RP, 1991, CANCER, V67, P106, DOI 10.1002/1097-0142(19910101)67:1<106::AID-CNCR2820670120>3.0.CO;2-I; Wilson BJ, 2011, CURR COLORECT CANC R, V7, P128, DOI 10.1007/s11888-011-0093-2; Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016; Xu S, 2015, ONCOGENE, V34, P1520, DOI 10.1038/onc.2014.95; Yan M, 2013, MOL CELL PROTEOMICS, V12, P3271, DOI 10.1074/mcp.M112.025460; Yang CP, 2015, ONCOTARGET, V6, P27714, DOI 10.18632/oncotarget.4663; Yang L, 2014, MODERN PATHOL, V27, P775, DOI 10.1038/modpathol.2013.189; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012	67	17	18	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1351	1363		10.1038/onc.2016.299	http://dx.doi.org/10.1038/onc.2016.299			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593923				2022-12-28	WOS:000395862500004
J	Talamillo, A; Grande, L; Ruiz-Ontanon, P; Velasquez, C; Mollinedo, P; Torices, S; Sanchez-Gomez, P; Aznar, A; Esparis-Ogando, A; Lopez-Lopez, C; Lafita, C; Berciano, MT; Montero, JA; Vazquez-Barquero, A; Segura, V; Villagra, NT; Pandiella, A; Lafarga, M; Leon, J; Martinez-Climent, JA; Sanz-Moreno, V; Fernandez-Luna, JL				Talamillo, A.; Grande, L.; Ruiz-Ontanon, P.; Velasquez, C.; Mollinedo, P.; Torices, S.; Sanchez-Gomez, P.; Aznar, A.; Esparis-Ogando, A.; Lopez-Lopez, C.; Lafita, C.; Berciano, M. T.; Montero, J. A.; Vazquez-Barquero, A.; Segura, V.; Villagra, N. T.; Pandiella, A.; Lafarga, M.; Leon, J.; Martinez-Climent, J. A.; Sanz-Moreno, V.; Fernandez-Luna, J. L.			ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; IN-VIVO; INTRACELLULAR DOMAIN; GENE-EXPRESSION; C-MYC; CANCER GENOMICS; GLIOMA; INVASION; GTPASES; ACTIVATION	Long-term survival remains low for most patients with glioblastoma (GBM), which reveals the need for markers of disease outcome and novel therapeutic targets. We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells. Differentiation of glioblastoma stem-like cells drives the nuclear translocation of an intracellular fragment of ODZ1 through proteolytic cleavage by signal peptide peptidase-like 2a. The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo. Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells. This activity is mediated by an ODZ1-triggered transcriptional pathway, through the E-box binding Myc protein, that promotes the expression and activation of Ras homolog family member A (RhoA) and subsequent activation of Rho-associated, coiled-coil containing protein kinase (ROCK). Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice. Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival. Our findings establish a novel marker of invading GBM cells and consequently a potential marker of disease progression and a therapeutic target in GBM.	[Talamillo, A.; Grande, L.; Ruiz-Ontanon, P.; Mollinedo, P.; Torices, S.; Fernandez-Luna, J. L.] Hosp Valdecilla IDIVAl, Coll Genetica, Santander, Spain; [Velasquez, C.; Vazquez-Barquero, A.] Hosp Valdecilla IDIVAl, Neurosurg Serv, Santander, Spain; [Sanchez-Gomez, P.] Inst Salud Carlos lll, Unit Neuro Oncol, Madrid, Spain; [Aznar, A.; Segura, V.; Martinez-Climent, J. A.] CIMA, Pamplona, Spain; [Esparis-Ogando, A.] Ctr Investigo Canc, Salamanca, Spain; [Lopez-Lopez, C.] Hosp Valdecilla IDIVAL, Service Oncol Media, Santander, Spain; [Lafita, C.; Leon, J.] IBBTEC, CSIC, Coll Cantabria, Santander, Spain; [Berciano, M. T.; Montero, J. A.; Lafarga, M.] Coll Canatbria, Dept Anatomia & Biol Celular, Santander, Spain; [Villagra, N. T.] IDIVAL, Hosp Valdesilla, Serv Anatomia, Santander, Spain; [Sanz-Moreno, V.] Kings Coll london, Sch Biomed & Hlth Serv, Randall Div Cell & Mol Biophys, London, England; [Fernandez-Luna, J. L.] Hosp Valdecilla IDIVAL, Coll Gentica, 39008 Santander, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); University of London; King's College London; Hospital Universitario Marques de Valdecilla (HUMV)	Fernandez-Luna, JL (corresponding author), Hosp Valdecilla IDIVAl, Coll Genetica, Santander, Spain.	fluna@humv.es	Leon, Javier/K-4615-2014; Sánchez-Gómez, Pilar/K-8256-2014; Martinez-Climent, Jose A/I-9199-2012; Lafarga, Miguel/K-3733-2014; Esparís-Ogando, Aucena/O-5326-2017; Talamillo, Ana/AAA-4633-2019; Pandiella, Atanasio/O-5180-2014; Velasquez, Carlos/N-6669-2016; Segura, Victor/E-4531-2010; Teran-Villagra, Nuria/P-3016-2016	Sánchez-Gómez, Pilar/0000-0002-0709-4973; Martinez-Climent, Jose A/0000-0002-7938-3950; Esparís-Ogando, Aucena/0000-0003-4550-4192; Talamillo, Ana/0000-0003-3089-7675; Pandiella, Atanasio/0000-0002-4704-8971; Leon, Javier/0000-0001-5803-0112; Berciano, Maria T./0000-0002-8225-6995; LOPEZ LOPEZ, CARLOS/0000-0002-8901-741X; Lafarga, Miguel/0000-0003-3402-1152; Velasquez, Carlos/0000-0002-4443-5888; Lafita Navarro, Maria del Carmen/0000-0002-7266-651X; Segura, Victor/0000-0002-7740-6290; Sanz-Moreno, Victoria/0000-0002-5096-9456; Teran-Villagra, Nuria/0000-0002-3746-455X	Instituto de Salud Carlos III (ISCIII) [PI13/01760, PI12/00775, SAF2014-53526R]; program Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD12/0036/0022, RD12/0036/0027, RD12/0036/0063, RD12/0036/0003, RD12-0036-0033]; Instituto de Investigacion Valdecilla (IDIVAL) grant [APG/03]; Cancer Research UK [C33043/A12065]; Royal Society [RG110591]; Cancer Research UK [12065] Funding Source: researchfish	Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); program Red Tematica de Investigacion Cooperativa en Cancer (RTICC); Instituto de Investigacion Valdecilla (IDIVAL) grant; Cancer Research UK(Cancer Research UK); Royal Society(Royal Society of London); Cancer Research UK(Cancer Research UK)	This work was supported by the Instituto de Salud Carlos III (ISCIII), grants PI13/01760 (JLF-L), PI12/00775 (PS-G) and SAF2014-53526R (JL), and program Red Tematica de Investigacion Cooperativa en Cancer (RTICC) grants RD12/0036/0022 (JLF-L), RD12/0036/0027 (PS-G), RD12/0036/0063 (JAM-C), RD12/0036/0003 (AP) and RD12-0036-0033 (JL), Instituto de Investigacion Valdecilla (IDIVAL) grant APG/03 to JLF-L, and Cancer Research UK C33043/A12065 and Royal Society RG110591 to VS-M. We thank R. Galli for kindly providing RG1 cell line. We also thank M.E. Fernandez-Valle for helping with magnetic resonance imaging experiments.	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bernard D, 2003, J CLIN INVEST, V112, P1724; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Danussi C, 2013, CANCER RES, V73, P5140, DOI 10.1158/0008-5472.CAN-13-1168-T; Deng L, 2010, CANCER BIOL THER, V9, P875, DOI 10.4161/cbt.9.11.11634; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Grande L, 2012, J BIOL CHEM, V287, P26495, DOI 10.1074/jbc.M112.376319; Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hirata E, 2012, J CELL SCI, V125, P858, DOI 10.1242/jcs.089995; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jin X, 2013, CANCER LETT, V328, P235, DOI 10.1016/j.canlet.2012.09.005; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kenzelmann D, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-30; Kirkin V, 2007, CELL DEATH DIFFER, V14, P1678, DOI 10.1038/sj.cdd.4402175; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lee KG, 2007, CELL CYCLE, V6, P1487; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Mazzoleni S, 2010, CANCER RES, V70, P7500, DOI 10.1158/0008-5472.CAN-10-2353; Mosca TJ, 2012, NATURE, V484, P237, DOI 10.1038/nature10923; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Nunes SM, 2005, EXP CELL RES, V305, P122, DOI 10.1016/j.yexcr.2004.12.020; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pozo N, 2013, J CLIN INVEST, V123, P2475, DOI 10.1172/JCI63623; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Ruiz-Ontanon P, 2013, STEM CELLS, V31, P1075, DOI 10.1002/stem.1349; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scholer J, 2015, J BIOL CHEM, V290, P8154, DOI 10.1074/jbc.M114.615922; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shervington A, 2006, MOL CELL BIOCHEM, V283, P1, DOI 10.1007/s11010-006-2495-z; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tucker RP, 2012, MOL BIOL EVOL, V29, P1019, DOI 10.1093/molbev/msr271; Wang H, 2014, ONCOGENE, V33, P1558, DOI 10.1038/onc.2013.97; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Wong SY, 2015, CANCER RES, V75, P1113, DOI 10.1158/0008-5472.CAN-13-3426; Yan B, 2006, NEUROSCI LETT, V407, P124, DOI 10.1016/j.neulet.2006.08.032; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ying Z, 2013, CANCER RES, V73, P990, DOI 10.1158/0008-5472.CAN-12-2895; Zhang M, 2006, EMBO J, V25, P5284, DOI 10.1038/sj.emboj.7601406; Zhang SY, 2009, MOL CANCER RES, V7, P570, DOI 10.1158/1541-7786.MCR-08-0248; Zhang W, 2014, MOL MED REP, V10, P113, DOI 10.3892/mmr.2014.2152; Zohrabian VM, 2009, ANTICANCER RES, V29, P119	53	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1733	1744		10.1038/onc.2016.341	http://dx.doi.org/10.1038/onc.2016.341			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27641332	Green Submitted, Green Accepted			2022-12-28	WOS:000397460600012
J	Xu, MM; Pu, Y; Weichselbaum, RR; Fu, YX				Xu, M. Michelle; Pu, Y.; Weichselbaum, R. R.; Fu, Y-X			Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy	ONCOGENE			English	Review							CYCLIC GMP-AMP; IMMUNOGENIC CELL-DEATH; CYTOSOLIC DNA SENSOR; I INTERFERON; CALRETICULIN EXPOSURE; IMMUNE-SYSTEM; TUMOR MICROENVIRONMENT; ANTI-CD20 ANTIBODY; METASTATIC CANCER; RADIATION	In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8(+) T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.	[Xu, M. Michelle; Weichselbaum, R. R.; Fu, Y-X] Univ Chicago, Dept Pathol & Radiat Oncol, Chicago, IL 60637 USA; [Xu, M. Michelle; Fu, Y-X] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA; [Pu, Y.; Fu, Y-X] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol & Immunol, Dallas, TX 75390 USA	University of Chicago; University of Chicago; University of Texas System; University of Texas Southwestern Medical Center Dallas	Weichselbaum, RR; Fu, YX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 6000 Harry Hines Blvd,ND6 200, Dallas, TX 75235 USA.	rrw@radonc.uchicago.edu; yang-xin.fu@utsouthwestern.edu			US National Institutes of Health [CA141975]; Ludwig Foundation; NATIONAL CANCER INSTITUTE [R01CA134563, R01CA141975] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was, in part, supported by US National Institutes of Health Grants CA141975 (to Y-XF), a grant from the Ludwig Foundation (to RRW) and a generous gift from The Foglia Foundation (to Y-XF and RRW).	Abes R, 2010, BLOOD, V116, P926, DOI 10.1182/blood-2009-10-248609; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Baselga J, 2001, ANN ONCOL, V12, P35, DOI 10.1023/A:1011163824080; Baselga J, 2001, EUR J CANCER, V37, pS16; Benavides LC, 2009, CLIN CANCER RES, V15, P2895, DOI 10.1158/1078-0432.CCR-08-1126; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Correale P, 2012, INT J CANCER, V130, P1577, DOI 10.1002/ijc.26181; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Deng L, 2015, CLIN CANC RES; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Dovedi SJ, 2013, BLOOD, V121, P251, DOI 10.1182/blood-2012-05-432393; Formenti SC, 2013, JNCI-J NATL CANCER I, V105, P256, DOI 10.1093/jnci/djs629; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998; Gameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719; Gandhi SJ, 2015, CANCER LETT, V368, P185, DOI 10.1016/j.canlet.2015.03.024; Ganss R, 2002, CANCER RES, V62, P1462; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gehrmann M, 2005, CELL DEATH DIFFER, V12, P38, DOI 10.1038/sj.cdd.4401510; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008; Hong WK, 2010, EMIL FREI III CANC M; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kurts C, 2010, NAT REV IMMUNOL, V10, P403, DOI 10.1038/nri2780; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Lim SH, 2011, BLOOD, V118, P2530, DOI 10.1182/blood-2011-01-330357; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Liu RR, 2012, CANCER IMMUNOL IMMUN, V61, P855, DOI 10.1007/s00262-011-1146-8; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Minard-Colin V, 2008, BLOOD, V112, P1205, DOI 10.1182/blood-2008-01-135160; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Salama JK, 2012, CANCER-AM CANCER SOC, V118, P2962, DOI 10.1002/cncr.26611; Schaue D, 2012, INT J RADIAT ONCOL, V83, P1306, DOI 10.1016/j.ijrobp.2011.09.049; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Stagg J, 2011, P NATL ACAD SCI USA, V108, P7142, DOI 10.1073/pnas.1016569108; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Suzuki Y, 2012, CANCER RES, V72, P3967, DOI 10.1158/0008-5472.CAN-12-0851; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Westover KD, 2015, LUNG CANCER, V89, P87, DOI 10.1016/j.lungcan.2015.04.009; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu CY, 2014, CLIN CANCER RES, V20, P644, DOI 10.1158/1078-0432.CCR-13-1334; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yang XM, 2013, MOL THER, V21, P91, DOI 10.1038/mt.2012.184; Zelenay S, 2013, TRENDS IMMUNOL, V34, P329, DOI 10.1016/j.it.2013.03.005; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	86	10	10	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					585	592		10.1038/onc.2016.231	http://dx.doi.org/10.1038/onc.2016.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27425593	Green Accepted			2022-12-28	WOS:000394167700001
J	Behnan, J; Stangeland, B; Hosainey, SAM; Joel, M; Olsen, TK; Micci, F; Glover, JC; Isakson, P; Brinchmann, JE				Behnan, J.; Stangeland, B.; Hosainey, S. A. M.; Joel, M.; Olsen, T. K.; Micci, F.; Glover, J. C.; Isakson, P.; Brinchmann, J. E.			Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; HUMAN GLIOBLASTOMA; HUMAN GLIOMAS; LINES; BONE; IDENTIFICATION; HETEROGENEITY; PROLIFERATION; ANGIOGENESIS; PROGRESSION	Glioblastoma Multiforme (GBM) is characterized by high cancer cell heterogeneity and the presence of a complex tumor microenvironment. Those factors are a key obstacle for the treatment of this tumor type. To model the disease in mice, the current strategy is to grow GBM cells in serum-free non-adherent condition, which maintains their tumor-initiating potential. However, the so-generated tumors are histologically different from the one of origin. In this work, we performed high-throughput marker expression analysis and investigated the tumorigenicity of GBM cells enriched under different culture conditions. We identified a marker panel that distinguished tumorigenic sphere cultures from non-tumorigenic serum cultures (high CD56, SOX2, SOX9, and low CD105, CD248, aSMA). Contrary to previous work, we found that 'mixed cell cultures' grown in serum conditions are tumorigenic and express cancer stem cell (CSC) markers. As well, 1% serum plus bFGF and TGF-alpha preserved the tumorigenicity of sphere cultures and induced epithelial-to-mesenchymal transition gene expression. Furthermore, we identified 12 genes that could replace the 840 genes of The Cancer Genome Atlas (TCGA) used for GBM-subtyping. Our data suggest that the tumorigenicity of GBM cultures depend on cell culture strategies that retain CSCs in culture rather than the presence of serum in the cell culture medium.	[Behnan, J.; Stangeland, B.; Glover, J. C.; Brinchmann, J. E.] Oslo Univ Hosp, Norwegian Ctr Stem Cell Res, Dept Immunol, 4950 Nydalen, N-0424 Oslo, Norway; [Behnan, J.; Stangeland, B.; Glover, J. C.; Brinchmann, J. E.] Univ Oslo, Fac Med, Inst Basic Med Sci, Dept Mol Med, Oslo, Norway; [Stangeland, B.] Oslo Univ Hosp, Inst Surg Res, Dept Neurosurg, Oslo, Norway; [Hosainey, S. A. M.] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; [Hosainey, S. A. M.] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Joel, M.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway; [Olsen, T. K.; Micci, F.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Genet & Informat, Sect Canc Cytogenet, Oslo, Norway; [Olsen, T. K.; Micci, F.] Univ Oslo, Ctr Canc Biomed, Oslo, Norway; [Isakson, P.] Sahlgrens Univ Hosp, Dept Clin Immunol & Transfus Med, Gothenburg, Sweden	University of Oslo; University of Oslo; Norwegian University of Science & Technology (NTNU); University of Oslo; University of Oslo; University of Oslo; University of Oslo; Sahlgrenska University Hospital	Behnan, J (corresponding author), Oslo Univ Hosp, Norwegian Ctr Stem Cell Res, Dept Immunol, 4950 Nydalen, N-0424 Oslo, Norway.	jinan.bahnan@rr-research.no	Stangeland, Biljana/W-4912-2019; Behnan, Jinan/C-9263-2009	Stangeland, Biljana/0000-0002-1723-9742; Behnan, Jinan/0000-0001-5780-0971	Neurosurgery Department and Institute for Surgical Research; Research Council of Norway; Helse Sor-Ost; Oslo University Hospital	Neurosurgery Department and Institute for Surgical Research; Research Council of Norway(Research Council of Norway); Helse Sor-Ost; Oslo University Hospital	We thank Neurosurgery Department and Institute for Surgical Research for provision of patients' samples and financial support. Grazyna Babinska, Hong Qu, Birthe Mikkelsen, Aphirak Juthajan and Petter Brandal for technical support; Yan Zhang for flow cytometry core facility. High-resolution histological images were acquired at the Norbrain Slide Scanning Facility at the Institute of Basic Medical Sciences, the University of Oslo, funded by the Research Council of Norway. We also thank Marianne Hanna for participating in the graphic drawing; Wayne Murrell for improving the language clarity; Jan Helge Solbakk and Peter Kierulf for guidance. This work was funded by Helse Sor-Ost and Oslo University Hospital. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database (accession number GSE74571).	[Anonymous], 2011, GUIDE CARE USE LAB A; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barrantes-Freer A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130519; Behnan J, 2014, STEM CELLS, V32, P1110, DOI 10.1002/stem.1614; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111; DeCarvalho AC, 2010, STEM CELLS, V28, P181, DOI 10.1002/stem.264; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hadjipanayis CG, 2009, J MOL MED, V87, P363, DOI 10.1007/s00109-009-0440-9; Hagerstrand D, 2011, NEURO-ONCOLOGY, V13, P1178, DOI 10.1093/neuonc/nor113; Herlofsen SR, 2011, TISSUE ENG PT A, V17, P1003, DOI [10.1089/ten.TEA.2010.0499, 10.1089/ten.tea.2010.0499]; Hong X, 2012, INT J ONCOL, V41, P1693, DOI 10.3892/ijo.2012.1592; Hossain A, 2015, STEM CELLS, V33, P2400, DOI 10.1002/stem.2053; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Murrell W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071334; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Soeda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep07979; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stoczynska-Fidelus E, 2014, TUMOR BIOL, V35, P11311, DOI 10.1007/s13277-014-2444-5; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang L, 2012, MED ONCOL, V29, P3484, DOI 10.1007/s12032-012-0267-z; Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042	39	38	38	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					570	584		10.1038/onc.2016.230	http://dx.doi.org/10.1038/onc.2016.230			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345406	Green Published, hybrid			2022-12-28	WOS:000394166700013
J	Liu, F; Yuan, JH; Huang, JF; Yang, F; Wang, TT; Ma, JZ; Zhang, L; Zhou, CC; Wang, F; Yu, J; Zhou, WP; Sun, SH				Liu, F.; Yuan, J-H; Huang, J-F; Yang, F.; Wang, T-T; Ma, J-Z; Zhang, L.; Zhou, C-C; Wang, F.; Yu, J.; Zhou, W-P; Sun, S-H			Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a	ONCOGENE			English	Article							INACTIVATION CENTER REGION; CHROMATIN-STRUCTURE; MIRNA PROMOTERS; LIVER-CANCER; SURVIVAL; DISEASE; EPIDEMIOLOGY; PROGRESSION; ACTIVATION; EXPRESSION	It has long been known that males are more susceptible than females to hepatocellular carcinoma (HCC), but the reason remains elusive. In this study, we investigated the expression and function of the long noncoding RNA FTX (lnc-FTX), an X-inactive-specific transcript (XIST) regulator transcribed from the X chromosome inactivation center, in both HCC and HCC gender disparity. lnc-FTX is expressed at higher levels in female livers than in male livers and is significantly downregulated in HCC tissues compared with normal liver tissues. Patients with higher lnc-FTX expression exhibited longer survival, suggesting that lnc-FTX is a useful prognostic factor for HCC patients. lnc-FTX inhibits HCC cell growth and metastasis both in vitro and in vivo. Mechanistically, lnc-FTX represses Wnt/beta-catenin signaling activity by competitively sponging miR-374a and inhibits HCC cell epithelial-mesenchymal transition and invasion. In addition, lnc-FTX binds to the DNA replication licensing factor MCM2, thereby impeding DNA replication and inhibiting proliferation in HCC cells. In conclusion, these findings suggest that lnc-FTX may act as a tumor suppressor in HCC through physically binding miR-374a and MCM2. It may also be one of the reasons for HCC gender disparity and may potentially contribute to HCC treatment.	[Liu, F.; Yuan, J-H; Huang, J-F; Yang, F.; Wang, T-T; Ma, J-Z; Zhang, L.; Zhou, C-C; Wang, F.; Sun, S-H] Second Mil Med Univ, Dept Med Genet, 800 Xiang Yin Rd, Shanghai 200433, Peoples R China; [Yu, J.; Zhou, W-P] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China	Naval Medical University; Naval Medical University	Sun, SH (corresponding author), Second Mil Med Univ, Dept Med Genet, 800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	shsun@vip.sina.com	Ma, Jinzhao/M-6520-2014; Yuan, Ji-hang/AAH-4918-2021; Yang, Fu/C-3786-2008; Yang, Fu/L-8441-2019; Zhou, Weiping/AGI-5344-2022	Ma, Jinzhao/0000-0002-9367-6602; Yang, Fu/0000-0003-2459-3923; , Jin-Feng/0000-0002-4757-3418	State Key Program of National Natural Science Foundation of China [81330037]; National Key Basic Research Program of China (973 Program) [2015CB554004]; National Natural Science Foundation of China [31201025, 81301831, 81301692, 81472691, 81402269]; National Natural Science Foundation of Shanghai [13ZR1448300]	State Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shanghai	We thank Dr Le Qu and Mr Zhi-peng Xu from Department of Urology, Shanghai Changzheng Hospital and Dr Sheng-Xian Yuan and Dr Qi-Fei Tao from the Third Department of Hepatic Surgery, Eastern Hepatobiliary Hospital for technical assistance. This work was supported by grants from the State Key Program of National Natural Science Foundation of China (grant nos 81330037), the National Key Basic Research Program of China (973 Program) (grant nos 2015CB554004), the National Natural Science Foundation of China (grant nos 31201025, 81301831, 81301692, 81472691 and 81402269, and the National Natural Science Foundation of Shanghai (13ZR1448300).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Buch SC, 2008, HEPATOL INT, V2, P95, DOI 10.1007/s12072-007-9041-2; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Chureau C, 2002, GENOME RES, V12, P894, DOI 10.1101/gr.152902; Chureau C, 2011, HUM MOL GENET, V20, P705, DOI 10.1093/hmg/ddq516; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dohmen K, 2003, J GASTROEN HEPATOL, V18, P267, DOI 10.1046/j.1440-1746.2003.02936.x; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351; Giaginis C, 2009, DIGEST DIS SCI, V54, P282, DOI 10.1007/s10620-008-0305-z; Hartwell HJ, 2014, P NATL ACAD SCI USA, V111, P11455, DOI 10.1073/pnas.1404267111; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ma Y, 2015, GUT; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Quaglia A, 2006, LIVER INT, V26, P424, DOI 10.1111/j.1478-3231.2006.01242.x; Reena RMZ, 2008, ANN DIAGN PATHOL, V12, P340, DOI 10.1016/j.anndiagpath.2008.04.001; Reiche K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106076; Remus D, 2009, CELL, V139, P719, DOI 10.1016/j.cell.2009.10.015; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Sun Meiqian, 2010, Front Biosci (Elite Ed), V2, P829; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Xu D, 2013, HEPATOLOGY, V58, P739, DOI 10.1002/hep.26361; Yang DY, 2014, CANCER-AM CANCER SOC, V120, P3707, DOI 10.1002/cncr.28912; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011; Zinchuk V, 2007, ACTA HISTOCHEM CYTOC, V40, P101, DOI 10.1267/ahc.07002	39	142	145	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5422	5434		10.1038/onc.2016.80	http://dx.doi.org/10.1038/onc.2016.80			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065331				2022-12-28	WOS:000386677800008
J	Worrillow, L; Baskaran, P; Care, MA; Varghese, A; Munir, T; Evans, PA; O'Connor, SJ; Rawstron, A; Hazelwood, L; Tooze, RM; Hillmen, P; Newton, DJ				Worrillow, L.; Baskaran, P.; Care, M. A.; Varghese, A.; Munir, T.; Evans, P. A.; O'Connor, S. J.; Rawstron, A.; Hazelwood, L.; Tooze, R. M.; Hillmen, P.; Newton, D. J.			An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases	ONCOGENE			English	Article							SUBCLONAL MUTATIONS; 17P DELETION; MUTANT P53; EVOLUTION; THERAPY; ALEMTUZUMAB; FLUDARABINE; RESISTANCE; SURVIVAL; IMPACT	Chronic lymphocytic leukaemia (CLL) is the most common clonal B-cell disorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains largely incurable. Current front-line regimes include agents such as fludarabine, which act primarily via the DNA damage response pathway. Key to this is the transcription factor p53. Mutations in the TP53 gene, altering p53 functionality, are associated with genetic instability, and are present in aggressive CLL. Furthermore, the emergence of clonal TP53 mutations in relapsed CLL, refractory to DNA-damaging therapy, suggests that accurate detection of sub-clonal TP53 mutations prior to and during treatment may be indicative of early relapse. In this study, we describe a novel deep sequencing workflow using multiple polymerases to generate sequencing libraries (MuPol-Seq), facilitating accurate detection of TP53 mutations at a frequency as low as 0.3%, in presentation CLL cases tested. As these mutations were mostly clustered within the regions of TP53 encoding DNA-binding domains, essential for DNA contact and structural architecture, they are likely to be of prognostic relevance in disease progression. The workflow described here has the potential to be implemented routinely to identify rare mutations across a range of diseases.	[Worrillow, L.; Care, M. A.; Tooze, R. M.; Hillmen, P.; Newton, D. J.] Univ Leeds, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England; [Baskaran, P.] Max Planck Inst Dev Biol, Dept Evolutionary Biol, Tubingen, Germany; [Varghese, A.; Munir, T.; Evans, P. A.; O'Connor, S. J.; Rawstron, A.] Leeds Teaching Hosp Natl Hlth Serv Trust, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England; [Hazelwood, L.] Univ Cambridge, Canc Res UK, Ling Ka Shing Ctr, Cambridge, England	University of Leeds; Max Planck Society; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Newton, DJ (corresponding author), Univ Leeds, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England.	D.J.Newton@leeds.ac.uk	Newton, Darren/CAA-0475-2022; Care, Matthew/P-2987-2019	Care, Matthew/0000-0001-6584-5889; Tooze, Reuben/0000-0003-2915-7119; Baskaran, Praveen/0000-0003-2275-3516	Kay Kendall Leukaemia Fund	Kay Kendall Leukaemia Fund	This project was funded by the Kay Kendall Leukaemia Fund (www.kklf.org.uk). We would also like to thank the staff in the Haematological Malignancy Diagnostic Services Unit at Leeds Teaching Hospital who provided information on diagnostic patient data and samples for the study, and the sequencing facility at the University of Leeds who provided a technical service running the Illumina next-generation sequencing systems.	Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Campbell PJ, 2008, P NATL ACAD SCI USA, V105, P13081, DOI 10.1073/pnas.0801523105; Delgado J, 2012, BRIT J HAEMATOL, V157, P67, DOI 10.1111/j.1365-2141.2011.09000.x; Dicker F, 2009, LEUKEMIA, V23, P117, DOI 10.1038/leu.2008.274; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Gonzalez D, 2011, J CLIN ONCOL, V29, P2223, DOI 10.1200/JCO.2010.32.0838; Gravanis I, 2010, ONCOLOGIST, V15, P1335, DOI 10.1634/theoncologist.2010-0255; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Huggett JF, 2015, CLIN CHEM, V61, P79, DOI 10.1373/clinchem.2014.221366; Huse SM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r143; Jethwa A, 2013, BRIT J HAEMATOL, V163, P496, DOI 10.1111/bjh.12539; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; Komarova NL, 2014, P NATL ACAD SCI USA, V111, P13906, DOI 10.1073/pnas.1409362111; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Malcikova J, 2015, LEUKEMIA, V29, P877, DOI 10.1038/leu.2014.297; Mclnerney P, 2014, MOL BIOL INT, V2014; Mohr J, 2011, BLOOD, V117, P1622, DOI 10.1182/blood-2010-08-300160; Nakamura S, 2011, EXP BIOL MED, V236, P968, DOI 10.1258/ebm.2011.010378; Ojha J, 2015, BLOOD, V125, P492, DOI 10.1182/blood-2014-06-580563; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rossi D, 2014, BLOOD, V123, P2139, DOI 10.1182/blood-2013-11-539726; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schuh A, 2012, BLOOD, V120, P4191, DOI 10.1182/blood-2012-05-433540; Stieglitz E, 2015, BLOOD, V125, P516, DOI 10.1182/blood-2014-09-601690; Stilgenbauer S, 2009, J CLIN ONCOL, V27, P3994, DOI 10.1200/JCO.2008.21.1128; Stocks MB, 2012, BIOINFORMATICS, V28, P2059, DOI 10.1093/bioinformatics/bts311; Tian K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072303; Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wang J, 2014, ELIFE, V3, DOI 10.7554/eLife.03496; Wawrzyniak E, 2014, EUR J HAEMATOL, V92, P91, DOI 10.1111/ejh.12215; Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	48	3	3	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5328	5336		10.1038/onc.2016.73	http://dx.doi.org/10.1038/onc.2016.73			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041575	Green Accepted			2022-12-28	WOS:000386053000011
J	Anadon, C; Guil, S; Simo-Riudalbas, L; Moutinho, C; Setien, F; Martinez-Cardus, A; Moran, S; Villanueva, A; Calaf, M; Vidal, A; Lazo, PA; Zondervan, I; Savola, S; Kohno, T; Yokota, J; de Pouplana, LR; Esteller, M				Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Villanueva, A.; Calaf, M.; Vidal, A.; Lazo, P. A.; Zondervan, I.; Savola, S.; Kohno, T.; Yokota, J.; Ribas de Pouplana, L.; Esteller, M.			Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis (vol 35, pg 4407, 2016)	ONCOGENE			English	Correction													Martinez, Anna/AAA-4939-2020; Esteller, Manel/L-5956-2014; Lazo, Pedro A./M-6435-2014; Moran, Sebastian/G-5293-2013	Esteller, Manel/0000-0003-4490-6093; Lazo, Pedro A./0000-0001-8997-3025; Moran, Sebastian/0000-0003-4192-8983; Martinez Cardus, Anna/0000-0002-3937-8794				Anadon C, 2016, ONCOGENE, V35, P4407, DOI 10.1038/onc.2015.469	1	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33								10.1038/onc.2016.27	http://dx.doi.org/10.1038/onc.2016.27			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	27345394	Green Published, hybrid			2022-12-28	WOS:000382152100015
J	Guo, A; Lu, P; Lee, J; Zhen, C; Chiosis, G; Wang, YL				Guo, A.; Lu, P.; Lee, J.; Zhen, C.; Chiosis, G.; Wang, Y. L.			HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; IBRUTINIB RESISTANCE; INHIBITOR IBRUTINIB; ANTITUMOR-ACTIVITY; LYMPHOMA; MECHANISMS; MUTATIONS; PROTEINS; TARGETS; BTK	Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanisms leading to BCR over-activity in CLL are not fully understood. In this study, we found that HSP90, a highly conserved molecular chaperone, is overexpressed in CLL compared with resting B cells. HSP90 overexpression is accompanied by the overexpression of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT. Chemical and immune-precipitation demonstrated that these BCR constituents are present in a multi-client chaperone complex with HSP90. Inhibition of HSP90 with PU-H71 destabilized the BCR kinases and caused apoptosis of CLL cells through the mitochondrial apoptotic pathway. Further, PU-H71 induced apoptosis in the presence of stromal co-culture or cytoprotective survival signals. Finally, genetic knockdown of HSP90 and its client AKT, but not BTK, reduced CLL viability. Overall, our study suggests that the chaperone function of HSP90 contributes to the over-activity of the BCR signaling in CLL and inhibition of HSP90 has the potential to achieve a multi-targeting effect. Thus, HSP90 inhibition may be explored to prevent or overcome drug resistance to single targeting agents.	[Guo, A.; Lu, P.; Lee, J.; Zhen, C.; Wang, Y. L.] Univ Chicago, Dept Pathol, Div Genom & Mol Pathol, Chicago, IL 60637 USA; [Chiosis, G.] Mem Sloan Kettering Canc Ctr, Program Chem Biol, 1275 York Ave, New York, NY 10021 USA; [Chiosis, G.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	University of Chicago; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Wang, YL (corresponding author), Univ Chicago, Dept Pathol, MC1089,N316,5841 South Maryland Ave, Chicago, IL 60637 USA.	ylwang@bsd.uchicago.edu	Wang, Y. Lynn/GRF-6667-2022	Wang, Y. Lynn/0000-0003-0773-1212; Lee, Justine C./0000-0002-8943-0837; Lee, Jimmy/0000-0002-5547-4858	NATIONAL CANCER INSTITUTE [P30CA008748, P50CA192937, R01CA172546, P01CA186866, R21CA158609] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000459] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH076499] Funding Source: NIH RePORTER; NCATS NIH HHS [TL1 TR000459] Funding Source: Medline; NCI NIH HHS [R21 CA158609, P50 CA192937, R01 CA172546, P01 CA186866, P30 CA008748] Funding Source: Medline; NCRR NIH HHS [UL1 RR024996] Funding Source: Medline; NIMH NIH HHS [R03 MH076499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Andersen OS, 2013, NAT CHEM BIOL, V9, P667, DOI 10.1038/nchembio.1368; Balakrishnan K, 2009, BLOOD, V113, P149, DOI 10.1182/blood-2008-02-138560; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Cheng SH, 2011, BLOOD, V118, P6342, DOI 10.1182/blood-2011-02-333773; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Duhren-von Minden M, 2012, NATURE, V489, P309, DOI 10.1038/nature11309; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gerecitano JF, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2537; Goldstein RL, 2015, J CLIN INVEST, V125, P4559, DOI 10.1172/JCI80714; Grzybowska-Izydorczyk O, 2010, EUR J CANCER, V46, P800, DOI 10.1016/j.ejca.2009.11.023; Guo AL, 2016, ONCOTARGET, V7, P4598, DOI 10.18632/oncotarget.6727; Haerzschel A, 2016, ANN HEMATOL, V95, P1979, DOI 10.1007/s00277-016-2788-6; Hayden RE, 2012, LEUKEMIA LYMPHOMA, V53, P537, DOI 10.3109/10428194.2011.610014; Hertlein E, 2010, BLOOD, V116, P45, DOI 10.1182/blood-2010-01-263756; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Liu TM, 2015, BLOOD, V126, P61, DOI 10.1182/blood-2015-02-626846; Lu P, 2009, LEUKEMIA, V23, P807, DOI 10.1038/leu.2008.304; Ma J, 2015, ONCOTARGET, V6, P43881, DOI 10.18632/oncotarget.6316; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Rai KR, 2016, AM J HEMATOL, V91, P330, DOI 10.1002/ajh.24282; Robertson LE, 1996, LEUKEMIA, V10, P456; Scaltriti M, 2012, CLIN CANCER RES, V18, P4508, DOI 10.1158/1078-0432.CCR-11-2138; Sharman J, 2015, BLOOD, V125, P2336, DOI 10.1182/blood-2014-08-595934; Shrestha L, 2016, CELL CHEM BIOL, V23, P158, DOI 10.1016/j.chembiol.2015.12.006; Song ZB, 2010, CLIN CANCER RES, V16, P587, DOI 10.1158/1078-0432.CCR-09-1519; Taldone T, 2014, TRENDS PHARMACOL SCI, V35, P48, DOI 10.1016/j.tips.2014.09.001; Trentin L, 2008, BLOOD, V112, P4665, DOI 10.1182/blood-2008-02-139139; Walsby E, 2012, ONCOTARGET, V3, P525; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Yang C, 2008, LEUKEMIA, V22, P1755, DOI 10.1038/leu.2008.163; Zong HL, 2015, CELL REP, V13, P2159, DOI 10.1016/j.celrep.2015.10.073	41	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3441	3449		10.1038/onc.2016.494	http://dx.doi.org/10.1038/onc.2016.494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114285	Green Accepted			2022-12-28	WOS:000403340700008
J	Delyon, J; Servy, A; Laugier, F; Andre, J; Ortonne, N; Battistella, M; Mourah, S; Bensussan, A; Lebbe, C; Dumaz, N				Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Ortonne, N.; Battistella, M.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.			PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma	ONCOGENE			English	Article							IMPROVED SURVIVAL; MEK INHIBITION; CANCER; PHOSPHODIESTERASE-4; GROWTH; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; PATHWAY; RISK	The cyclic AMP (cAMP) signaling pathway is critical in melanocyte biology for regulating differentiation. It is downregulated by phosphodiesterase (PDE) enzymes, which degrade cAMP itself. In melanoma evidence suggests that inhibition of the cAMP pathway by PDE type 4 (PDE4) favors tumor progression. For example, in melanomas harboring RAS mutations, the overexpression of PDE4 is crucial for MAPK pathway activation and proliferation induced by oncogenic RAS. Here we showed that PDE4D is overexpressed in BRAF-mutated melanoma cell lines, constitutively disrupting the cAMP pathway activation. PDE4D promoted melanoma invasion by interacting with focal adhesion kinase (FAK) through the scaffolding protein RACK1. Inhibition of PDE4 activity or inhibition of PDE4D interaction with FAK reduced invasion. PDE4D expression is increased in patients with advanced melanoma and PDE4D-FAK interaction is detectable in situ in metastatic melanoma. Our study establishes the role of PDE4D in BRAF-mutated melanoma as regulator of cell invasion, and suggests its potential as a target for preventing metastatic	[Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.] INSERM, Ctr Rech Peau, U976, F-75010 Paris, France; [Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.] Univ Paris Diderot, Sorbonne Paris Cite, UMR 976, F-75010 Paris, France; [Delyon, J.; Lebbe, C.] Hop St Louis, AP HP, Dept Dermatol, Paris, France; [Ortonne, N.] Hop Henri Mondor, AP HP, Dept Pathol, Creteil, France; [Ortonne, N.] Hop Henri Mondor, AP HP, INSERM, U955,Equipe 9, Creteil, France; [Ortonne, N.] Univ Paris Est Creteil Val de Marne, Fac Med, Creteil, France; [Battistella, M.] Hop St Louis, AP HP, Dept Pathol, Paris, France; [Battistella, M.] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, U1165, Paris, France; [Mourah, S.] Hop St Louis, AP HP, Lab Pharmacol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Dumaz, N (corresponding author), Hop St Louis, INSERM, Ctr Rech Peau, U976, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	nicolas.dumaz@inserm.fr	Dumaz, Nicolas/B-5907-2008; Bensussan, Armand/E-5434-2017; Battistella, Maxime/K-2949-2012; Delyon, Julie/O-5147-2019	Dumaz, Nicolas/0000-0003-3511-2160; Battistella, Maxime/0000-0002-7053-7431; Delyon, Julie/0000-0002-4557-3377; Bensussan, Armand/0000-0002-0409-2497; Ortonne, Nicolas/0000-0003-0111-7422	INSERM; fondation ARC pour la recherche sur le cancer (Poste Accueil); Ligue Contre le Cancer Comite de Paris; GEFLUC Paris-Ile-de-France; fondation ARC pour la recherche sur le cancer; Universite Paris Diderot	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); fondation ARC pour la recherche sur le cancer (Poste Accueil)(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer Comite de Paris(Ligue nationale contre le cancer); GEFLUC Paris-Ile-de-France; fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); Universite Paris Diderot	Julie Delyon was supported by INSERM and the fondation ARC pour la recherche sur le cancer (Poste Accueil). This research was supported by grants from the Ligue Contre le Cancer Comite de Paris, the GEFLUC Paris-Ile-de-France, the fondation ARC pour la recherche sur le cancer, INSERM and Universite Paris Diderot.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Khaled M, 2010, GENE DEV, V24, P2276, DOI 10.1101/gad.1937710; Krayem M, 2014, EUR J CANCER, V50, P1310, DOI 10.1016/j.ejca.2014.01.021; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Lin DC, 2013, P NATL ACAD SCI USA, V110, P6109, DOI 10.1073/pnas.1218206110; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003; Lyons J, 2013, P NATL ACAD SCI USA, V110, P13845, DOI 10.1073/pnas.1201917110; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Mayer JE, 2014, J AM ACAD DERMATOL, V71, DOI [10.1016/j.jaad.2014.05.045, 10.1016/j.jaad.2014.05.046]; Murata K, 2001, CLIN EXP METASTAS, V18, P599, DOI 10.1023/A:1011926116777; Narita M, 2007, ONCOL REP, V17, P1133; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Powers GL, 2015, MOL CANCER RES, V13, P149, DOI 10.1158/1541-7786.MCR-14-0110; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Rodriguez CI, 2014, ARCH BIOCHEM BIOPHYS, V563, P22, DOI 10.1016/j.abb.2014.07.003; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Takeuchi H, 2003, CANCER RES, V63, P441; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	38	18	19	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3252	3262		10.1038/onc.2016.469	http://dx.doi.org/10.1038/onc.2016.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092671				2022-12-28	WOS:000402869800005
J	Pomeroy, EJ; Lee, LA; Lee, RDW; Schirm, DK; Temiz, NA; Ma, J; Gruber, TA; Diaz-Flores, E; Moriarity, BS; Downing, JR; Shannon, KM; Largaespada, DA; Eckfeldt, CE				Pomeroy, E. J.; Lee, L. A.; Lee, R. D. W.; Schirm, D. K.; Temiz, N. A.; Ma, J.; Gruber, T. A.; Diaz-Flores, E.; Moriarity, B. S.; Downing, J. R.; Shannon, K. M.; Largaespada, D. A.; Eckfeldt, C. E.			Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia	ONCOGENE			English	Article							PANCREATIC-CANCER GROWTH; TYROSINE KINASE; MEK INHIBITION; TARGETING RAS; SELF-RENEWAL; RESISTANCE; MELANOMA; CELLS; KRAS; BRAF	Somatic mutations that lead to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cancer and frequently occur in acute myeloid leukemia (AML). An inducible NRAS(V12)-driven AML mouse model has established a critical role for continued NRAS(V12) expression in leukemia maintenance. In this model genetic suppression of NRAS(V12) expression results in rapid leukemia remission, but some mice undergo spontaneous relapse with NRAS(V12)-independent (NRI) AMLs providing an opportunity to identify mechanisms that bypass the requirement for Ras oncogene activity and drive leukemia relapse. We found that relapsed NRI AMLs are devoid of NRAS(V12) expression and signaling through the major oncogenic Ras effector pathways, phosphatidylinositol-3-kinase and mitogen-activated protein kinase, but express higher levels of an alternate Ras effector, Ralb, and exhibit NRI phosphorylation of the RALB effector TBK1, implicating RALB signaling in AML relapse. Functional studies confirmed that inhibiting CDK5-mediated RALB activation with a clinically relevant experimental drug, dinaciclib, led to potent RALB-dependent antileukemic effects in human AML cell lines, induced apoptosis in patient-derived AML samples in vitro and led to a 2-log reduction in the leukemic burden in patient-derived xenograft mice. Furthermore, dinaciclib potently suppressed the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development of relapsed AML in vivo. Our findings demonstrate that Ras oncogene-independent activation of RALB signaling is a therapeutically targetable mechanism of escape from NRAS oncogene addiction in AML.	[Pomeroy, E. J.; Lee, L. A.; Lee, R. D. W.; Schirm, D. K.; Eckfeldt, C. E.] Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Med, 420 Delaware St SE,MMC 480,PWB 14-242, Minneapolis, MN 55455 USA; [Temiz, N. A.; Moriarity, B. S.; Largaespada, D. A.; Eckfeldt, C. E.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Ma, J.; Gruber, T. A.; Downing, J. R.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gruber, T. A.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Diaz-Flores, E.; Shannon, K. M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Moriarity, B. S.; Largaespada, D. A.] Dept Pediat, Div Hematol & Oncol, Minneapolis, MN USA; [Largaespada, D. A.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities	Eckfeldt, CE (corresponding author), Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Med, 420 Delaware St SE,MMC 480,PWB 14-242, Minneapolis, MN 55455 USA.	eckf0002@umn.edu	Downing, James R./N-8102-2018; Gruber, Tanja/AAH-1248-2021	Eckfeldt, Craig/0000-0003-2834-0421; Pomeroy, Emily/0000-0001-7690-3570; Lee, Lindsey/0000-0002-7082-5484	University of Minnesota Masonic Cancer Center; National Cancer Institute [P30CA77598]; Minnesota Masonic Charities; Killebrew-Thompson Memorial Fund; University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation; University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research [LLS7019-04]; National Heart Lung and Blood Institute [T32HL007062]; NATIONAL CANCER INSTITUTE [P30CA077598, P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007062] Funding Source: NIH RePORTER	University of Minnesota Masonic Cancer Center; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Minnesota Masonic Charities; Killebrew-Thompson Memorial Fund; University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation; University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research(Leukemia and Lymphoma Society); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by funding from the University of Minnesota Masonic Cancer Center and Academic Health Center Flow Cytometry Resource, Research Animal Resources, Heme Malignancy Tissue Bank and Imaging Center that are supported by the National Cancer Institute (P30CA77598), Minnesota Masonic Charities and the Killebrew-Thompson Memorial Fund; the University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation and the University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research LLS7019-04 (DAL); National Heart Lung and Blood Institute T32HL007062 (CEE). DAL and KMS are American Cancer Society Research Professors.	Baker A, 2016, CANCER RES, V76, P1158, DOI 10.1158/0008-5472.CAN-15-1070; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Berns K, 2012, DRUG RESIST UPDATE, V15, P268, DOI 10.1016/j.drup.2012.10.002; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Collins CT, 2016, ONCOGENE, V35, P1090, DOI 10.1038/onc.2015.174; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckfeldt CE, 2016, RALB PROVIDES CRITIC; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Feldmann G, 2010, CANCER RES, V70, P4460, DOI 10.1158/0008-5472.CAN-09-1107; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gu TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019169; Huw LY, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.46; Iyengar S, 2013, BLOOD, V121, P2274, DOI 10.1182/blood-2012-10-460832; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim WI, 2009, BLOOD, V113, P1086, DOI 10.1182/blood-2008-01-132316; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Patel JP, 2012, HEMATOL-AM SOC HEMAT, P28, DOI 10.1182/asheducation-2012.1.28; Peschard P, 2012, CURR BIOL, V22, P2063, DOI 10.1016/j.cub.2012.09.013; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Ricciardi MR, 2005, LEUKEMIA, V19, P1543, DOI 10.1038/sj.leu.2403859; Rushworth SA, 2014, BLOOD, V123, P1229, DOI 10.1182/blood-2013-06-511154; Sachs Z, 2014, BLOOD, V124, P3274, DOI 10.1182/blood-2013-08-521708; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Van Meter MEM, 2007, BLOOD, V109, P3945, DOI 10.1182/blood-2006-09-047530; Vigil D, 2010, J BIOL CHEM, V285, P34729, DOI 10.1074/jbc.M110.116756; Yan C, 2014, NATURE, V515, P443, DOI 10.1038/nature13713; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	52	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3263	3273		10.1038/onc.2016.471	http://dx.doi.org/10.1038/onc.2016.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991934	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000402869800006
J	Hsieh, CH; Chou, YT; Kuo, MH; Tsai, HP; Chang, JL; Wu, CW				Hsieh, C-H; Chou, Y-T; Kuo, M-H; Tsai, H-P; Chang, J-L; Wu, C-W			A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NONSMALL CELL LUNG; OVARIAN-CANCER; HB-EGF; CLINICAL-SIGNIFICANCE; TRANSCRIPTION FACTOR; CITED FAMILY; EXPRESSION; MUTATIONS; LIGANDS	Aberrant epidermal growth factor (EGF) receptor (EGFR) signaling contributes to neoplastic initiation and progression in lung. Mutated EGFR has become as an important therapeutic target in lung cancer, whereas targeted treatment is not available for wildtype EGFR or its ligands. In this study, we found that heparin-binding (HB)-EGF, a member of the EGF family, was highly expressed in a subset of lung cancer, proliferation of which was dependent on HB-EGF signaling. Silencing of HB-EGF with RNA interference inhibited cell cycle progression in lung cancer cells. We observed that, upon HB-EGF induction, CITED4 was induced through a signal transducer and activator of transcription 3 (STAT3)-dependent pathway, regulating cell proliferation. CITED4 interacted with MYC and potentiated MYC-mediated transactivation of the CCND1 promoter, leading to cell cycle progression. Correlation analysis revealed that HB-EGF and CITED4 were significantly positively associated in primary lung tumors, and expression of HB-EGF predicted a poor survival outcome in patients. In vitro and in vivo experiments revealed that pharmacological inhibition of HB-EGF with CRM197 significantly attenuated tumor cell growth. Thus, CITED4 functions as a molecular switch in HB-EGF-induced growth control, and HB-EGF provides a novel therapeutic target for lung cancer intervention.	[Hsieh, C-H; Wu, C-W] Natl Yang Ming Univ, Inst Microbiol & Immunol, 155,Sect 2,Linong St, Taipei 112, Taiwan; [Chou, Y-T; Kuo, M-H; Wu, C-W] Natl Tsing Hua Univ, Inst Biotechnol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300, Taiwan; [Tsai, H-P] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Chang, J-L] Taoyuan Armed Forces Gen Hosp, Dept Pathol & Lab Med, Taoyuan, Taiwan; [Chang, J-L] Ming Chuan Univ, Dept Biomed Engn, Taoyuan, Taiwan	National Yang Ming Chiao Tung University; National Tsing Hua University; Kaohsiung Medical University; Ming Chuan University	Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, 155,Sect 2,Linong St, Taipei 112, Taiwan.; Chou, YT (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300, Taiwan.	ytchou@life.nthu.edu.tw; cwwu@ym.edu.tw		Chou, Yu-Ting/0000-0001-9274-8603	National Yang-Ming University; National Tsing Hua University; Institute of Biomedical Sciences, Academia Sinica; Ministry of Science and Technology, Executive Yuan, Taiwan, ROC [MOST104-2321-B-010-007, MOST103-2320-B-007-006-MY3]	National Yang-Ming University; National Tsing Hua University; Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan); Ministry of Science and Technology, Executive Yuan, Taiwan, ROC	This research was supported by National Yang-Ming University, National Tsing Hua University, the Institute of Biomedical Sciences, Academia Sinica and the Ministry of Science and Technology (MOST104-2321-B-010-007 and MOST103-2320-B-007-006-MY3), Executive Yuan, Taiwan, ROC.	Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036; Boyle S, 2007, DEV DYNAM, V236, P2321, DOI 10.1002/dvdy.21242; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chou YT, 2006, ONCOGENE, V25, P5547, DOI 10.1038/sj.onc.1209552; Chou YT, 2012, CELL DEATH DIFFER, V19, P2015, DOI 10.1038/cdd.2012.91; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Harada D, 2014, CANCERS, V6, P708, DOI 10.3390/cancers6020708; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kageyama T, 2007, J BIOCHEM, V142, P95, DOI 10.1093/jb/mvm116; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; Laurie SA, 2013, J CLIN ONCOL, V31, P1061, DOI 10.1200/JCO.2012.43.4522; Leslie CC, 1997, AM J RESP CELL MOL, V16, P379, DOI 10.1165/ajrcmb.16.4.9115748; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Naef M, 1996, INT J CANCER, V66, P315; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Qu X, 2007, EMBO J, V26, P4445, DOI 10.1038/sj.emboj.7601883; RUSCH V, 1993, CANCER RES, V53, P2379; Ryall KA, 2014, J MOL CELL CARDIOL, V72, P74, DOI 10.1016/j.yjmcc.2014.02.013; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Thogersen VB, 2001, CANCER RES, V61, P6227; Vinante F, 2013, TOXINS, V5, P1180, DOI 10.3390/toxins5061180; Volante M, 2007, CANCER, V110, P1321, DOI 10.1002/cncr.22903; Wang YL, 2009, J PHYSIOL-LONDON, V587, P1739, DOI 10.1113/jphysiol.2008.163899; Wei X, 2015, TRENDS CARDIOVAS MED, V25, P529, DOI 10.1016/j.tcm.2014.12.014; Weninger WJ, 2005, DEVELOPMENT, V132, P1337, DOI 10.1242/dev.01696; Wu WJ, 2007, MOL CANCER THER, V6, P2652, DOI 10.1158/1535-7163.MCT-06-0759; Yagi H, 2005, BRIT J CANCER, V92, P1737, DOI 10.1038/sj.bjc.6602536; Yahata T, 2002, GENOMICS, V80, P601, DOI 10.1006/geno.2002.7005	42	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2946	2956		10.1038/onc.2016.465	http://dx.doi.org/10.1038/onc.2016.465			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092674				2022-12-28	WOS:000402000400003
J	Yang, J; Lu, C; Wei, J; Guo, Y; Liu, W; Luo, L; Fisch, G; Li, X				Yang, J.; Lu, C.; Wei, J.; Guo, Y.; Liu, W.; Luo, L.; Fisch, G.; Li, X.			Inhibition of KPNA4 attenuates prostate cancer metastasis	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TNF-ALPHA; ANDROGEN RECEPTOR; BREAST-CANCER; IMPORTIN ALPHA-3; MACROPHAGES; EXPRESSION; CELLS; ACTIVATION	Prostate cancer (PCa) is a common cancer in men. Although current treatments effectively palliate symptoms and prolong life, the metastatic PCa remains incurable. It is important to find biomarkers and targets to improve metastatic PCa diagnosis and treatment. Here we report a novel correlation between karyopherin alpha 4 (KPNA4) and PCa pathological stages. KPNA4 mediates the cytoplasm-to- nucleus translocation of transcription factors, including nuclear factor kappa B, although its role in PCa was largely unknown. We find that knockdown of KPNA4 reduces cell migration in multiple PCa cell lines, suggesting a role of KPNA4 in PCa progression. Indeed, stable knockdown of KPNA4 significantly reduces PCa invasion and distant metastasis in mouse models. Functionally, KPNA4 alters tumor microenvironment in terms of macrophage polarization and osteoclastogenesis by modulating tumor necrosis factor (TNF)-alpha and -beta. Further, KPNA4 is proved as a direct target of miR-708, a tumor-suppressive microRNA. We disclose the role of miR-708-KPNA4-TNF axes in PCa metastasis and KPNA4's potential as a novel biomarker for PCa metastasis.	[Yang, J.; Lu, C.; Guo, Y.; Liu, W.; Luo, L.; Li, X.] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, Room 901D,345 East 24th St, New York, NY 10010 USA; [Wei, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Obstet & Gynaecol, Tongji Hosp, Wuhan, Peoples R China; [Fisch, G.] CUNY, Baruch Coll, Dept Stat & Comp Informat Syst, New York, NY 10021 USA; [Li, X.] NYU, Langone Med Ctr, Dept Urol, New York, NY USA	New York University; Huazhong University of Science & Technology; City University of New York (CUNY) System; Baruch College (CUNY); New York University; NYU Langone Medical Center	Li, X (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, Room 901D,345 East 24th St, New York, NY 10010 USA.	xl15@nyu.edu	Yang, Jian/E-1051-2015	Li, Xin/0000-0002-7414-5734	NIH [R01CA180277, R03CA172894]; NYU CTSA [1UL1TR001445, 1KL2TR001446, 1TL1TR001447]; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health; NATIONAL CANCER INSTITUTE [R01CA180277, R03CA172894] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001445] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU CTSA; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by NIH grants R01CA180277 and R03CA172894 to Xin Li, and in part by the NYU CTSA grant numbers 1UL1TR001445, 1KL2TR001446 and 1TL1TR001447 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health. We thank Dr Deepak Saxena (New York University, New York, NY, USA) for the proofreading.	Abravanel DL, 2015, J CLIN INVEST, V125, P2484, DOI 10.1172/JCI74883; Adams DL, 2014, P NATL ACAD SCI USA, V111, P3514, DOI 10.1073/pnas.1320198111; Agrawal T, 2012, J CLIN IMMUNOL, V32, P1093, DOI 10.1007/s10875-012-9696-x; Ahluwalia A, 2014, AM J PHYSIOL-GASTR L, V306, pG338, DOI 10.1152/ajpgi.00382.2013; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834; Chen PC, 2014, ONCOTARGET, V5, P1595, DOI 10.18632/oncotarget.1570; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Fang LY, 2013, CANCER RES, V73, P5633, DOI 10.1158/0008-5472.CAN-12-3228; Feng FY, 2016, P NATL ACAD SCI USA, V113, P473, DOI 10.1073/pnas.1522938113; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70; Gerondalds S, 2014, NAT IMMUNOL, V15, P15, DOI 10.1038/ni.2785; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hu X, 2014, J IMMUNOL, V192, P1320, DOI 10.4049/jimmunol.1203195; Ikenberg K, 2014, J PATHOL, V234, P239, DOI 10.1002/path.4390; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Jin R, 2015, ONCOGENE, V34, P3700, DOI 10.1038/onc.2014.302; Jin RJ, 2014, CANCER RES, V74, P2763, DOI 10.1158/0008-5472.CAN-13-2543; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Li X, 2009, CANCER RES, V69, P1685, DOI 10.1158/0008-5472.CAN-08-2164; Liang JQ, 2015, AM J CANCER RES, V5, P1124; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mak P, 2015, ONCOTARGET, V6, P40247, DOI 10.18632/oncotarget.5377; Mortezavi A, 2011, CLIN CANCER RES, V17, P1111, DOI 10.1158/1078-0432.CCR-10-0081; Nadiminty N, 2010, CANCER RES, V70, P3309, DOI 10.1158/0008-5472.CAN-09-3703; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rachidi Saleh M, 2013, PLoS One, V8, pe57911, DOI 10.1371/journal.pone.0057911; Ryu S, 2013, CANCER CELL, V23, P63, DOI 10.1016/j.ccr.2012.11.019; Sachan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068247; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Sakai M, 2010, ANTICANCER RES, V30, P851; Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004-1211; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathopoulos GT, 2007, CANCER RES, V67, P9825, DOI 10.1158/0008-5472.CAN-07-1064; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Wang HQ, 2015, CELL BIOSCI, V5, DOI 10.1186/2045-3701-5-4; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Xu AX, 2015, ONCOL LETT, V10, P1402, DOI 10.3892/ol.2015.3472; Yang J, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.18; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Zadran S, 2013, P NATL ACAD SCI USA, V110, P19160, DOI 10.1073/pnas.1316991110; Zhang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065896; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224	66	30	31	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2868	2878		10.1038/onc.2016.440	http://dx.doi.org/10.1038/onc.2016.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941876	Green Accepted			2022-12-28	WOS:000401697800009
J	Burgess, M; Mapp, S; Mazzieri, R; Cheung, C; Chambers, L; Mattarollo, SR; Mollee, P; Gill, D; Saunders, NA				Burgess, M.; Mapp, S.; Mazzieri, R.; Cheung, C.; Chambers, L.; Mattarollo, S. R.; Mollee, P.; Gill, D.; Saunders, N. A.			Increased Fc gamma RIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients	ONCOGENE			English	Article							NURSE-LIKE CELLS; IN-VITRO; MACROPHAGES; RITUXIMAB; EXPRESSION; IDELALISIB; IBRUTINIB; CANCER; CLL; STRATEGIES	Resistance to therapeutic antibodies in chronic lymphocytic leukaemia (CLL) is common. In this study, we show that therapeutic antibodies against CD62L (CD62L-Ab) or CD20 (obinutuzumab) were able to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADP) in primary cultures of CLL cells. CLL cells derived from patients with active disease requiring treatment displayed resistance to these antibodies, whereas patients with stable disease were sensitive. Using enrichment strategies and transcriptomic analyses, we show that antibody-dependent tumour cell killing was Fc gamma R-dependent and mediated by macrophages. Moreover, we show that resistance cannot be attributed to total numbers or established subtypes of monocytes/macrophages, or the efficiency with which they bind an immune complex. Rather, ADCC/ADP resistance was due to reduced signalling activity through the activating Fc gamma Rs resulting in the transfer of dominance to the inhibitory Fc gamma RIIb within macrophages. Most significantly, we show that resistance is an actionable event that could be reversed using inhibitors of Fc gamma RIIb signalling in primary cultures of CLL cells that were previously insensitive to obinutuzumab or CD62L-Ab.	[Burgess, M.; Mazzieri, R.; Mattarollo, S. R.; Gill, D.; Saunders, N. A.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia; [Burgess, M.; Mapp, S.; Cheung, C.; Chambers, L.; Mollee, P.; Gill, D.] Princess Alexandra Hosp, Dept Haematol, Canc Serv, Ipswich Rd, Woolloongabba, Qld 4102, Australia; [Mollee, P.] Univ Queensland, Sch Med, Translat Res Inst, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland	Gill, D (corresponding author), Princess Alexandra Hosp, Dept Haematol, Canc Serv, Ipswich Rd, Woolloongabba, Qld 4102, Australia.; Saunders, NA (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Ipswich Rd, Woolloongabba, Qld 4102, Australia.	Devinder.gill@health.qld.gov.au; nsaunders@uq.edu.au	saunders, nicholas/AAJ-6101-2020; Mollee, Peter/A-6677-2012; Mazzieri, Roberta/C-9773-2015	saunders, nicholas/0000-0002-2478-3420; Mollee, Peter/0000-0002-8537-1198; Mazzieri, Roberta/0000-0002-5172-0927	Australian NHMRC [APP1049182]; Cancer Council Queensland [APP1025479]; Senior Research Fellowship - Cancer Council Queensland	Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); Senior Research Fellowship - Cancer Council Queensland(Cancer Council Queensland)	We gratefully acknowledge the patients who donated samples for this study. We also gratefully acknowledge the constructive comments of Professor Maher Gandhi before submission. NS is supported by grants from the Australian NHMRC (#APP1049182) and the Cancer Council Queensland (#APP1025479). NS is supported by a Senior Research Fellowship awarded by the Cancer Council Queensland.	ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Awan FT, 2014, CLIN CANCER RES, V20, P5869, DOI 10.1158/1078-0432.CCR-14-1889; Bhattacharya N, 2011, BRIT J HAEMATOL, V154, P349, DOI 10.1111/j.1365-2141.2011.08747.x; Boissard F, 2015, LEUKEMIA LYMPHOMA, V56, P1570, DOI 10.3109/10428194.2014.991731; Bournazos S, 2009, CLIN EXP IMMUNOL, V157, P244, DOI 10.1111/j.1365-2249.2009.03980.x; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2014, LANCET ONCOL, V15, P1090, DOI 10.1016/S1470-2045(14)70335-3; Burger JA, 2014, NAT REV CLIN ONCOL, V11, P184, DOI 10.1038/nrclinonc.2014.42; Burgess M, 2016, GENOM DATA, V7, P4, DOI 10.1016/j.gdata.2015.11.010; Burgess M, 2013, CLIN CANCER RES, V19, P5675, DOI 10.1158/1078-0432.CCR-13-1037; Burgess M, 2012, LEUKEMIA LYMPHOMA, V53, P1988, DOI 10.3109/10428194.2012.672735; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Filip AA, 2013, BLOOD CELL MOL DIS, V50, P263, DOI 10.1016/j.bcmd.2012.12.003; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Giannoni P, 2014, HAEMATOLOGICA, V99, P1078, DOI 10.3324/haematol.2013.091405; Gu  B, 2001, LEUKEMIA LYMPHOMA, V42, P5, DOI 10.3109/10428190109097671; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2013, BLOOD, V122, P3723, DOI 10.1182/blood-2013-05-498287; Herter S, 2014, J IMMUNOL, V192, P2252, DOI 10.4049/jimmunol.1301249; Jaglowski SM, 2015, BLOOD, V126, P842, DOI 10.1182/blood-2014-12-617522; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Mellor JD, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-1; Morabito F, 2015, LEUKEMIA LYMPHOMA, V56, P3250, DOI 10.3109/10428194.2015.1061193; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Pallasch CP, 2014, CELL, V156, P590, DOI 10.1016/j.cell.2013.12.041; Patz M, 2011, BRIT J HAEMATOL, V152, P295, DOI 10.1111/j.1365-2141.2010.08428.x; Robak T, 2014, EXPERT REV HEMATOL, V7, P841, DOI 10.1586/17474086.2014.963048; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Tsukada N, 2002, BLOOD, V99, P1030, DOI 10.1182/blood.V99.3.1030; Ysebaert L, 2011, LEUKEMIA LYMPHOMA, V52, P1404, DOI 10.3109/10428194.2011.568078	32	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2366	2376		10.1038/onc.2016.387	http://dx.doi.org/10.1038/onc.2016.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27748757				2022-12-28	WOS:000400268900004
J	Zhong, T; Men, Y; Lu, L; Geng, T; Zhou, J; Mitsuhashi, A; Shozu, M; Maihle, NJ; Carmichael, GG; Taylor, HS; Huang, Y				Zhong, T.; Men, Y.; Lu, L.; Geng, T.; Zhou, J.; Mitsuhashi, A.; Shozu, M.; Maihle, N. J.; Carmichael, G. G.; Taylor, H. S.; Huang, Y.			Metformin alters DNA methylation genome-wide via the H19/SAHH axis	ONCOGENE			English	Article							LONG NONCODING RNA; GENE-EXPRESSION; PROSTATE-CANCER; CELLS; DRUG; CONTRIBUTES; METASTASIS; METABOLISM; MICRORNAS; PROMOTES	The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line drug for type 2 diabetes, remain elusive. Here we report that metformin induces genome-wide alterations in DNA methylation by modulating the activity of S-adenosylhomocysteine hydrolase (SAHH). Exposing cancer cells to metformin leads to hypermethylation of tumor-promoting pathway genes and concomitant inhibition of cell proliferation. Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. H19 knockdown activates SAHH, enabling DNA methyltransferase 3B to methylate a subset of genes. This metformin-induced H19 repression and alteration of gene methylation are recapitulated in endometrial cancer tissue samples obtained from patients treated with antidiabetic doses of metformin. Our findings unveil a novel mechanism of action for the drug metformin with implications for the molecular basis of epigenetic dysregulation in cancer. This novel mechanism of action also may be occurring in normal cells.	Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA; Gannan Med Univ, Affiliated Hosp 1, Dept Lab Med, Ganzhou, Jiangxi, Peoples R China; Sichuan Univ, West China Hosp Stomatol, Dept Head & Neck Surg, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; Yale Univ, Sch Med, Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, 310 Cedar St,LSOG 205C, New Haven, CT 06510 USA; Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol, Xian, Shaanxi, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China; Chiba Univ, Grad Sch Med, Dept Reprod Med, Chiba, Japan; Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; Univ Connecticut, Farmington, CT USA	Yale University; Gannan Medical University; Sichuan University; Yale University; Xi'an Jiaotong University; Zhejiang University; Chiba University; University System of Georgia; Augusta University; University of Connecticut		Yingqun.huang@yale.edu	Zhou, Jichun/Q-8646-2019; Zhong, Tianyu/HCG-8326-2022	Zhou, Jichun/0000-0002-0727-4034; Zhong, Tianyu/0000-0003-1934-0032	Bennack-Polan Foundation; NIGMS [R01 HD072418]; national Natural Science Foundation of China [81602471]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072418] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Bennack-Polan Foundation; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); national Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Alessandro Santin for the gift of ARK2 cells. This work was supported by grants from Bennack-Polan Foundation and Discover to Cure to YH, R01 HD072418 from the NIGMS to GGC and national Natural Science Foundation of China (No. 81602471) to JZ.	Albitar L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-166; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Gao Y, 2014, NUCLEIC ACIDS RES, V42, P13799, DOI 10.1093/nar/gku1160; Graham JR, 2010, MOL CELL BIOL, V30, P5295, DOI 10.1128/MCB.00303-10; Gravina GL, 2011, ENDOCRINOLOGY, V152, P4550, DOI 10.1210/en.2011-1056; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Jin BL, 2012, CELL REP, V2, P1411, DOI 10.1016/j.celrep.2012.10.017; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Matouk IJ, 2016, ONCOTARGET, V7, P3748, DOI 10.18632/oncotarget.6387; Merry CR, 2015, HUM MOL GENET, V24, P6240, DOI 10.1093/hmg/ddv343; Milinkovic V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082108; Mitsuhashi A, 2014, CANCER-AM CANCER SOC, V120, P2986, DOI 10.1002/cncr.28853; Oliveras-Ferraros C, 2011, CELL CYCLE, V10, P1144, DOI 10.4161/cc.10.7.15210; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Poulain M, 2014, MOL HUM REPROD, V20, P960, DOI 10.1093/molehr/gau058; Pryor R, 2015, BIOCHEM J, V471, P307, DOI 10.1042/BJ20150497; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008; Su B, 2015, HEPATOLOGY, V61, P585, DOI 10.1002/hep.27551; Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Xu WJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0425-6; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221	32	81	86	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2345	2354		10.1038/onc.2016.391	http://dx.doi.org/10.1038/onc.2016.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775072	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000400268900002
J	Yu, T; Yang, G; Hou, Y; Tang, X; Wu, C; Wu, XA; Guo, L; Zhu, Q; Luo, H; Du, YE; Wen, S; Xu, L; Yin, J; Tu, G; Liu, M				Yu, T.; Yang, G.; Hou, Y.; Tang, X.; Wu, C.; Wu, X-A; Guo, L.; Zhu, Q.; Luo, H.; Du, Y-E; Wen, S.; Xu, L.; Yin, J.; Tu, G.; Liu, M.			Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance	ONCOGENE			English	Article							BREAST-CANCER; ESTROGEN-RECEPTOR; NUCLEAR EXPORT; OVARIAN-CANCER; PROGNOSTIC VALUE; PLASMA-MEMBRANE; LUNG-CANCER; FDG UPTAKE; GPR30; MICROENVIRONMENT	Multiple drug resistance is a challenging issue in the clinic. There is growing evidence that the G-protein-coupled estrogen receptor (GPER) is a novel mediator in the development of multidrug resistance in both estrogen receptor (ER)-positive and -negative breast cancers, and that cancer-associated fibroblasts (CAFs) in the tumor microenvironment may be a new agent that promotes drug resistance in tumor cells. However, the role of cytoplasmic GPER of CAFs on tumor therapy remains unclear. Here we first show that the breast tumor cell-activated PI3K/AKT (phosphoinositide 3-kinase/AKT) signaling pathway induces the cytoplasmic GPER translocation of CAFs in a CRM1-dependent pattern, and leads to the activation of a novel estrogen/GPER/cAMP/PKA/CREB signaling axis that triggers the aerobic glycolysis switch in CAFs. The glycolytic CAFs feed the extra pyruvate and lactate to tumor cells for augmentation of mitochondrial activity, and this energy metabolically coupled in a 'host-parasite relationship' between catabolic CAFs and anabolic cancer cells confers the tumor cells with multiple drug resistance to several conventional clinical treatments including endocrine therapy (tamoxifen), Her-2-targeted therapy (herceptin) and chemotherapy (epirubicin). Moreover, the clinical data from F-18-fluorodeoxyglucose positron emission tomography/computed tomography further present a strong association between the GPER/cAMP/PKA/CREB pathway of stromal fibroblasts with tumor metabolic activity and clinical treatment, suggesting that targeting cytoplasmic GPER in CAFs may rescue the drug sensitivity in patients with breast cancer. Thus, our data define novel insights into the stromal GPER-mediated multiple drug resistance from the point of reprogramming of tumor energy metabolism and provide the rationale for CAFs as a promising target for clinical therapy.	[Yu, T.; Yang, G.; Wu, C.; Wu, X-A; Guo, L.; Zhu, Q.; Tu, G.] Chongqing Med Univ, Dept Endocrine & Breast Surg, Affiliated Hosp 1, 1 You Yi Rd, Chongqing 400016, Peoples R China; [Yu, T.; Hou, Y.; Tang, X.; Du, Y-E; Wen, S.; Xu, L.; Yin, J.; Liu, M.] Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, 1 You Yi Rd, Chongqing 400016, Peoples R China; [Yu, T.] Jiangxi Canc Hosp, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China; [Luo, H.] Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Tu, G (corresponding author), Chongqing Med Univ, Dept Endocrine & Breast Surg, Affiliated Hosp 1, 1 You Yi Rd, Chongqing 400016, Peoples R China.; Liu, M (corresponding author), Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, 1 You Yi Rd, Chongqing 400016, Peoples R China.	tugang68@126.com; mliu-hncq@hotmail.com			National Natural Science Foundation of China [NSFC 81372398, NSFC 81472676, NSFC 31171336]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (NSFC 81372398) (to GT) and by National Natural Science Foundation of China (NSFC 81472676, NSFC 31171336) (to ML).	Ahn S, 2012, TUMOR BIOL, V33, P1573, DOI 10.1007/s13277-012-0411-6; Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Bonuccelli G, 2010, CELL CYCLE, V9, P1960, DOI 10.4161/cc.9.10.11601; Cheng SB, 2011, STEROIDS, V76, P892, DOI 10.1016/j.steroids.2011.02.018; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590; De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458; de Kruijf EM, 2011, BREAST CANCER RES TR, V125, P687, DOI 10.1007/s10549-010-0855-6; DeFranco DB, 2001, CURR BIOL, V11, pR1036, DOI 10.1016/S0960-9822(01)00619-4; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Dennison JB, 2013, CLIN CANCER RES, V19, P3703, DOI 10.1158/1078-0432.CCR-13-0623; Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9; Farace P, 2009, EUR J NUCL MED MOL I, V36, P616, DOI 10.1007/s00259-008-1012-x; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2012, ENDOCRINOLOGY, V153, P2953, DOI 10.1210/en.2012-1061; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fujiwara S, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-35; Girgert R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-935; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Huang T, 2012, J NUCL MED, V53, P1262, DOI 10.2967/jnumed.111.098087; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; Ji JY, 2003, CIRC RES, V92, P279, DOI 10.1161/01.RES.0000057753.57106.0B; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kim MY, 2015, NUCLEIC ACIDS RES, V43, P1609, DOI 10.1093/nar/gkv026; Kitajima K, 2016, JPN J RADIOL, V34, P220, DOI 10.1007/s11604-015-0515-1; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lin BC, 2009, CANCER RES, V69, P5415, DOI 10.1158/0008-5472.CAN-08-1622; Liu Y, 2015, AM J TRANSL RES, V7, P967; Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125; Luo HJ, 2014, ENDOCR-RELAT CANCER, V21, P355, DOI 10.1530/ERC-13-0237; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3956, DOI 10.4161/cc.22136; Martinez-Outschoorn UE, 2012, CELL METAB, V15, P4, DOI 10.1016/j.cmet.2011.12.011; Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mo ZQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3581; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Pugachev A, 2005, INT J RADIAT ONCOL, V62, P545, DOI 10.1016/j.ijrobp.2005.02.009; Pupo M, 2013, MOL CELL ENDOCRINOL, V376, P23, DOI 10.1016/j.mce.2013.05.023; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Scaling AL, 2014, HORM CANCER-US, V5, P146, DOI 10.1007/s12672-014-0174-1; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Sotgia F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2892; Tang X, 2016, CELL DEATH DIFFER, V23, P132, DOI 10.1038/cdd.2015.78; Vivacqua A, 2015, ONCOTARGET, V6, P16573, DOI 10.18632/oncotarget.4117; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Yu TH, 2014, J STEROID BIOCHEM, V143, P392, DOI 10.1016/j.jsbmb.2014.05.003; Zhang GJ, 2015, J NUCL MED, V56, P607, DOI 10.2967/jnumed.114.148254; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zucchetti AE, 2014, HEPATOLOGY, V59, P1016, DOI 10.1002/hep.26752	59	78	83	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2131	2145		10.1038/onc.2016.370	http://dx.doi.org/10.1038/onc.2016.370			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721408				2022-12-28	WOS:000399782500009
J	Tong, J; Tan, S; Zou, F; Yu, J; Zhang, L				Tong, J.; Tan, S.; Zou, F.; Yu, J.; Zhang, L.			FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation	ONCOGENE			English	Article							UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; MULTIKINASE INHIBITOR; APOPTOTIC RESPONSE; DOWN-REGULATION; REGORAFENIB; SORAFENIB; SURVIVAL; PATHWAY; CELLS	Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of FBW7, an E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRCs, contribute to resistance to targeted therapies. CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitivity to these agents is not affected by oncogenic mutations in KRAS, BRAF, PIK3CA or p53. These cells are defective in apoptosis owing to blocked degradation of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro and in vivo drug-resistance phenotypes of FBW7-mutant cells. CRC cells selected for regorafenib resistance have progressive enrichment of pre-existing FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies, and Mcl-1 as an attractive therapeutic target.	[Tong, J.; Tan, S.; Zhang, L.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Tan, S.; Zou, F.] Sichuan Univ, Col Life Sci, Chengdu, Peoples R China; [Yu, J.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Sichuan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Dept Pharmacol & Chem Biol, UPCI Res Pavil,Room 2-42a,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Tong, Jingshan/0000-0003-1640-5769; Zou, Fangdong/0000-0002-2133-4320	U.S. National Institute of Health [CA106348, CA172136, CA203028, U01DK085570, AI068021]; American Cancer Society grant [RGS-10-124-01-CCE];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA106348, R01CA203028, P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society grant(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank our lab members for critical reading. This work is supported by U.S. National Institute of Health grants (CA106348, CA172136 and CA203028 to LZ; U01DK085570 and AI068021 to JY) and American Cancer Society grant (RGS-10-124-01-CCE to JY). This project used the UPCI shared facilities that were supported in part by award P30CA047904.	Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Chan SL, 2014, EXPERT OPIN DRUG MET, V10, P1607, DOI 10.1517/17425255.2014.970169; Chen DS, 2014, ONCOTARGET, V5, P8107, DOI 10.18632/oncotarget.2440; Chen DS, 2014, CLIN CANCER RES, V20, P3472, DOI 10.1158/1078-0432.CCR-13-2944; Choudhary GS, 2015, ONCOTARGET, V6, P16912, DOI 10.18632/oncotarget.4857; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; He L, 2013, CANCER DISCOV, V3, P324, DOI 10.1158/2159-8290.CD-12-0417; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Lerner M, 2011, CELL CYCLE, V10, P2172, DOI 10.4161/cc.10.13.16248; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mojsa B, 2014, CELLS-BASEL, V3, P418, DOI 10.3390/cells3020418; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Peng R, 2013, CELL DEATH DIFFER, V20, P744, DOI 10.1038/cdd.2013.4; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Schulein-Volk C, 2014, CELL REP, V9, P1099, DOI 10.1016/j.celrep.2014.09.057; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Varadarajan S, 2013, CELL DEATH DIFFER, V20, P1475, DOI 10.1038/cdd.2013.79; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	47	114	116	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					787	796		10.1038/onc.2016.247	http://dx.doi.org/10.1038/onc.2016.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399335	Green Accepted			2022-12-28	WOS:000394168200006
J	Zhou, Y; Frings, O; Branca, RM; Boekel, J; le Sage, C; Fredlund, E; Agami, R; Orre, LM				Zhou, Y.; Frings, O.; Branca, R. M.; Boekel, J.; le Sage, C.; Fredlund, E.; Agami, R.; Orre, L. M.			microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network	ONCOGENE			English	Article							ADVANCED BREAST-CANCER; EMBRYONIC STEM-CELLS; MASS-SPECTROMETRY; TUMOR INVASION; FEEDBACK LOOP; EXPRESSION; TARGETS; P53; PROLIFERATION; SENESCENCE	microRNA (miRNA) dysregulation is a common feature of cancer cells, but the complex roles of miRNAs in cancer are not fully elucidated. Here, we used functional genomics to identify oncogenic miRNAs in non-small cell lung cancer and evaluate their impact on response to epidermal growth factor (EGFR)-targeting therapy. Our data demonstrate that miRNAs with an AAGUGC motif in their seed sequence increase both cancer cell proliferation and sensitivity to EGFR inhibitors. Global transcriptomics, proteomics and target prediction resulted in the identification of several tumor suppressors involved in the G1/5 transition as AAGUGC-miRNA targets. The clinical implications of our findings were evaluated by analysis of AAGUGC-miRNA expression in multiple cancer types, supporting the link between this miRNA seed family, their tumor suppressor targets and cancer cell proliferation. In conclusion, we propose the AAGUGC seed motif as an oncomotif and that oncomotif-miRNAs promote cancer cell proliferation. These findings have potential therapeutic implications, especially in selecting patients for EGFR-targeting therapy.	[Zhou, Y.; Frings, O.; Branca, R. M.; Boekel, J.; Fredlund, E.; Orre, L. M.] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Box 1031, SE-17121 Stockholm, Sweden; [Boekel, J.] Bioinformat Infrastruct Life Sci, Stockholm, Sweden; [le Sage, C.; Agami, R.] Netherlands Canc Inst, Div Biol Stress Response, Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Orre, LM (corresponding author), Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Box 1031, SE-17121 Stockholm, Sweden.	lukas.orre@ki.se	agami, reuven/GOG-8289-2022	Zhou Tran, Yan/0000-0003-3500-8304; Branca, Rui/0000-0003-3890-6476; Agami, Reuven/0000-0002-2848-2473; Orre, Lukas/0000-0002-0384-1003	Swedish Cancer Society; Swedish Research Council; Stockholm's county council; AstraZeneca	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm's county council; AstraZeneca(AstraZeneca)	Funding for this study from the Swedish Cancer Society, Swedish Research Council and Stockholm's county council and AstraZeneca is gratefully acknowledged. We would like to acknowledge the Clinical Proteomics Mass Spectrometry, National Genomics Infrastructure (NGI), UPPMAX and BILS at Science for Life Laboratory for providing experimental and computational support.	Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Borgdorff V, 2010, ONCOGENE, V29, P2262, DOI 10.1038/onc.2009.497; Borgstrom E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019119; Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6277; Kleinman CL, 2014, NAT GENET, V46, P39, DOI 10.1038/ng.2849; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Li M, 2009, 2009 INTERNATIONAL FORUM ON COMPUTER SCIENCE-TECHNOLOGY AND APPLICATIONS, VOL 3, PROCEEDINGS, P41, DOI 10.1109/IFCSTA.2009.248; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lundin S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010029; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Palmer RD, 2010, CANCER RES, V70, P2911, DOI 10.1158/0008-5472.CAN-09-3301; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Rippe V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009485; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Seok H, 2016, MOL CELLS; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stelzer Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3724; Sturm M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-163; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Zhang Y, 2015, BRIT J CANCER, V112, P365, DOI 10.1038/bjc.2014.593	63	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					731	745		10.1038/onc.2016.242	http://dx.doi.org/10.1038/onc.2016.242			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27477696	Green Published, hybrid			2022-12-28	WOS:000394168200001
J	Sheng, YH; He, Y; Hasnain, SZ; Wang, R; Tong, H; Clarke, DT; Lourie, R; Oancea, I; Wong, KY; Lumley, JW; Florin, TH; Sutton, P; Hooper, JD; McMillan, NA; McGuckin, MA				Sheng, Y. H.; He, Y.; Hasnain, S. Z.; Wang, R.; Tong, H.; Clarke, D. T.; Lourie, R.; Oancea, I.; Wong, K. Y.; Lumley, J. W.; Florin, T. H.; Sutton, P.; Hooper, J. D.; McMillan, N. A.; McGuckin, M. A.			MUC13 protects colorectal cancer cells from death by activating the NF-kappa B pathway and is a potential therapeutic target	ONCOGENE			English	Article							SURFACE MUCIN; MUCOSAL BARRIER; EXPRESSION; ONCOPROTEIN; INFLAMMATION; RESISTANCE; OVEREXPRESSION; ADENOCARCINOMA; SIRNA	MUC13 is a transmembrane mucin glycoprotein that is over produced by many cancers, although its functions are not fully understood. Nuclear factor-kappa B (NF-kappa B) is a key transcription factor promoting cancer cell survival, but therapeutically targeting this pathway has proved difficult because NF-kappa B has pleiotropic functions. Here, we report that MUC13 prevents colorectal cancer cell death by promoting two distinct pathways of NF-kappa B activation, consequently upregulating BCL-XL. MUC13 promoted tumor necrosis factor (TNF)-induced NF-kappa B activation by interacting with TNFR1 and the E3 ligase, cIAP1, to increase ubiquitination of RIPK1. MUC13 also promoted genotoxin-induced NF-kappa B activation by increasing phosphorylation of ATM and SUMOylation of NF-kappa B essential modulator. Moreover, elevated expression of cytoplasmic MUC13 and NF-kappa B correlated with colorectal cancer progression and metastases. Our demonstration that MUC13 enhances NF-kappa B signaling in response to both TNF and DNA-damaging agents provides a new molecular target for specific inhibition of NFB activation. As proof of principle, silencing MUC13 sensitized colorectal cancer cells to killing by cytotoxic drugs and inflammatory signals and abolished chemotherapy-induced enrichment of CD133(+) CD44(+) cancer stem cells, slowed xenograft growth in mice, and synergized with 5-fluourouracil to induce tumor regression. Therefore, these data indicate that combining chemotherapy and MUC13 antagonism could improve the treatment of metastatic cancers.	[Sheng, Y. H.; Hasnain, S. Z.; Wang, R.; Tong, H.; Lourie, R.; Oancea, I.; Wong, K. Y.; McGuckin, M. A.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, 37 Kent St, Brisbane, Qld 4102, Australia; [He, Y.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Biol Grp, Brisbane, Qld, Australia; [Clarke, D. T.; McMillan, N. A.] Griffith Univ, Sch Med Sci, Mol Basis Dis Program, Gold Coast Campus, Southport, Qld, Australia; [Lourie, R.; Oancea, I.; Florin, T. H.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Bowel Dis Grp, Brisbane, Qld, Australia; [Lumley, J. W.] Wesley Hosp, Auchenflower, Australia; [Sutton, P.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Mucosal Immunol, Melbourne, Vic, Australia; [Sutton, P.] Univ Melbourne, Sch Vet & Agr Sci, Ctr Anim Biotechnol, Melbourne, Vic, Australia; [Sutton, P.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Mater Research; University of Queensland; Mater Research; University of Queensland; Griffith University; Mater Research; University of Queensland; Wesley Hospital; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne	McGuckin, MA (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, 37 Kent St, Brisbane, Qld 4102, Australia.	michael.mcguckin@mater.uq.edu.au	Hasnain, Sumaira Z/N-3412-2014; Wang, Ran/AAP-1920-2020; Oancea, Iulia/F-3202-2017; McGuckin, Michael/G-2310-2010; sheng, yong H/C-5052-2013; McMillan, Nigel/AAQ-5416-2021; Hooper, John/C-1481-2016	Hasnain, Sumaira Z/0000-0001-8577-8628; Wang, Ran/0000-0002-1741-6446; Oancea, Iulia/0000-0001-5978-5963; McGuckin, Michael/0000-0002-8375-2675; sheng, yong H/0000-0002-4623-9098; HE, Yaowu/0000-0002-7828-263X; Sutton, Philip/0000-0003-3129-1800; Hooper, John/0000-0003-1054-8486; McMillan, Nigel/0000-0002-9471-1406	Australian National Health and Medical Research Council (NHMRC) [1060698]; Mater Foundation; NHMRC Principal Research Fellowship; Australian Government	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Mater Foundation; NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR)	This work was supported by the Australian National Health and Medical Research Council (NHMRC) project grant 1060698 and by funding from the Mater Foundation. MAM is supported by an NHMRC Principal Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government. We acknowledge the technical assistance of the TRI core facilities for flow cytometry, microscopy and biological resources. We thank Michael R Tallack for help with Chip analysis and John Silke for providing feedback on our manuscript.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Deng M, 2013, ASIAN PAC J CANCER P, V14, P127, DOI 10.7314/APJCP.2013.14.1.127; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Gupta BK, 2014, J GASTROENTEROL, V49, P1378, DOI 10.1007/s00535-013-0885-z; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Iwai K, 2012, TRENDS CELL BIOL, V22, P355, DOI 10.1016/j.tcb.2012.04.001; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Nishii Y, 2015, INT J ONCOL, V46, P1781, DOI 10.3892/ijo.2015.2880; Sheng YH, 2013, MUCOSAL IMMUNOL, V6, P557, DOI 10.1038/mi.2012.98; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x; Silke J, 2014, IAPS NECROPTOTIC CEL, P57; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Wu SY, 2009, PHARM RES-DORDR, V26, P512, DOI 10.1007/s11095-008-9766-1	44	40	41	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					700	713		10.1038/onc.2016.241	http://dx.doi.org/10.1038/onc.2016.241			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27399336	Green Published, hybrid			2022-12-28	WOS:000394167700011
J	Sun, H; He, L; Wu, H; Pan, F; Wu, X; Zhao, J; Hu, Z; Sekhar, C; Li, H; Zheng, L; Chen, H; Shen, BH; Guo, Z				Sun, H.; He, L.; Wu, H.; Pan, F.; Wu, X.; Zhao, J.; Hu, Z.; Sekhar, C.; Li, H.; Zheng, L.; Chen, H.; Shen, B. H.; Guo, Z.			The FEN1 L209P mutation interferes with long-patch base excision repair and induces cellular transformation	ONCOGENE			English	Article							DNA-POLYMERASE-BETA; STRAND BREAK REPAIR; HUMAN FLAP ENDONUCLEASE-1; LUNG-CANCER; MUTANT MICE; SACCHAROMYCES-CEREVISIAE; REPLICATION STRESS; TUMOR PROGRESSION; ESCHERICHIA-COLI; MAMMALIAN-CELLS	Flap endonuclease-1 (FEN1) is a multifunctional, structure-specific nuclease that has a critical role in maintaining human genome stability. FEN1 mutations have been detected in human cancer specimens and have been suggested to cause genomic instability and cancer predisposition. However, the exact relationship between FEN1 deficiency and cancer susceptibility remains unclear. In the current work, we report a novel colorectal cancer-associated FEN1 mutation, L209P. This mutant protein lacks the FEN, exonuclease (EXO) and gap endonuclease (GEN) activities of FEN1 but retains DNA-binding affinity. The L209P FEN1 variant interferes with the function of the wild-type FEN1 enzyme in a dominant-negative manner and impairs long-patch base excision repair in vitro and in vivo. Expression of L209P FEN1 sensitizes cells to DNA damage, resulting in endogenous genomic instability and cellular transformation, as well as tumor growth in a mouse xenograft model. These data indicate that human cancer associated genetic alterations in the FEN1 gene can contribute substantially to cancer development.	[Sun, H.; He, L.; Wu, H.; Pan, F.; Zhao, J.; Hu, Z.; Sekhar, C.; Guo, Z.] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China; [Wu, X.] Southeast Univ, Affiliated Hosp 2, Hosp Nanjing 2, Nanjing, Jiangsu, Peoples R China; [Li, H.; Zheng, L.; Shen, B. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Li, H.; Zheng, L.; Shen, B. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Genet & Epigenet, Duarte, CA USA; [Chen, H.] Shanghai Jiao Tong Univ, RenJi Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200001, Peoples R China	Nanjing Normal University; Southeast University - China; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Shanghai Jiao Tong University	Guo, Z (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China.; Shen, BH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA.; Chen, H (corresponding author), Shanghai Jiao Tong Univ, RenJi Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200001, Peoples R China.	chenhaoyan@gmail.com; bshen@coh.org; guozgang@gmail.com		k, chandrasekhar/0000-0002-6900-9447; Shen, Binghui/0000-0002-4408-407X	Ministry of Science and Technology of China [2013CB911600]; National Natural Science Foundation of China [31271449]; Jiangsu Provincial Natural Science Foundation [BK20130044, BK20130061, BK2011783]; Research Fund for the Doctoral Program of Higher Education of China (RFDP) [20133207110005]; Program for New Century Excellent Talents in University of Ministry of Education of China [NCET-13-0868]; Priority Academic Program Development Award for Jiangsu Higher Education Institutions; NIH [RO1 CA085344]; NCI-designated cancer center [P30 CA033572]; NATIONAL CANCER INSTITUTE [R01CA085344, R01CA073764, P30CA033572] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Research Fund for the Doctoral Program of Higher Education of China (RFDP)(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET)); Priority Academic Program Development Award for Jiangsu Higher Education Institutions; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI-designated cancer center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work is supported by Ministry of Science and Technology of China (2013CB911600), National Natural Science Foundation of China (31271449), Jiangsu Provincial Natural Science Foundation (BK20130044, BK20130061, BK2011783), The Research Fund for the Doctoral Program of Higher Education of China (RFDP) (20133207110005), The Program for New Century Excellent Talents in University of Ministry of Education of China (NCET-13-0868) and the Priority Academic Program Development Award for Jiangsu Higher Education Institutions. The work was also partially supported by an NIH grant RO1 CA085344 to BHS and NCI-designated cancer center support grant P30 CA033572. We also thank Dr Nancy Linford for her professional editing of the manuscript.	Adams MM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-19; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bajpayee M, 2002, MUTAT RES-GEN TOX EN, V520, P83, DOI 10.1016/S1383-5718(02)00175-4; Balakrishnan L, 2013, ANNU REV BIOCHEM, V82, P119, DOI 10.1146/annurev-biochem-072511-122603; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Chang JS, 2009, CARCINOGENESIS, V30, P78, DOI 10.1093/carcin/bgn261; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chung L, 2015, ONCOGENE, V34, P902, DOI 10.1038/onc.2014.19; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Demple B, 2005, DNA REPAIR, V4, P1442, DOI 10.1016/j.dnarep.2005.09.004; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Du JA, 2010, ACTA BIOCH BIOPH SIN, V42, P839, DOI 10.1093/abbs/gmq095; El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Figueroa JD, 2007, HUM GENET, V121, P233, DOI 10.1007/s00439-006-0294-y; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gao J, 2015, APPL BIOCHEM BIOTECH, V176, P454, DOI 10.1007/s12010-015-1587-1; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gembka A, 2007, NUCLEIC ACIDS RES, V35, P2596, DOI 10.1093/nar/gkl1139; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Guo Z, 2012, COCHRANE DB SYST REV, V5, P1; Guo ZG, 2008, MOL CELL BIOL, V28, P4310, DOI 10.1128/MCB.00200-08; Guo ZG, 2008, J MOL BIOL, V377, P679, DOI 10.1016/j.jmb.2007.10.074; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P1, DOI 10.1016/S1383-5718(02)00109-2; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling CF, 2015, WORLD J MICROB BIOT, V31, P681, DOI 10.1007/s11274-015-1804-7; Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Noon AT, 2011, DNA REPAIR, V10, P1071, DOI 10.1016/j.dnarep.2011.07.012; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Pascucci B, 2005, NUCLEIC ACIDS RES, V33, P280, DOI 10.1093/nar/gki168; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Sato M, 2003, ONCOGENE, V22, P7243, DOI 10.1038/sj.onc.1206977; Sattler U, 2003, EMBO REP, V4, P363, DOI 10.1038/sj.embor.embor796; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Soza S, 2009, MOL CELL BIOL, V29, P2032, DOI 10.1128/MCB.01730-08; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Szczesny B, 2008, J BIOL CHEM, V283, P26349, DOI 10.1074/jbc.M803491200; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsutakawa SE, 2011, CELL, V145, P198, DOI 10.1016/j.cell.2011.03.004; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wu ZX, 2012, MUTAT RES-FUND MOL M, V731, P85, DOI 10.1016/j.mrfmmm.2011.11.009; Xu H, 2011, ONCOGENE, V30, P1072, DOI 10.1038/onc.2010.482; Yamada Y, 2005, ANN NY ACAD SCI, V1049, P9, DOI 10.1196/annals.1334.002; Yang M, 2009, HUM MUTAT, V30, P1320, DOI 10.1002/humu.21060; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang B, 2014, NAT GENET, V46, P533, DOI 10.1038/ng.2985; Zharkov DO, 2008, CELL MOL LIFE SCI, V65, P1544, DOI 10.1007/s00018-008-7543-2; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825; Zheng L, 2011, CELL RES, V21, P1052, DOI 10.1038/cr.2011.35; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884	83	24	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					194	207		10.1038/onc.2016.188	http://dx.doi.org/10.1038/onc.2016.188			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270424	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000393938100005
J	Rohrig, F; Vorlova, S; Hoffmann, H; Wartenberg, M; Escorcia, FE; Keller, S; Tenspoldel, M; Weigand, I; Gatzner, S; Manova, K; Penack, O; Scheinberg, DA; Rosenwald, A; Ergun, S; Granot, Z; Henke, E				Roehrig, F.; Vorlova, S.; Hoffmann, H.; Wartenberg, M.; Escorcia, F. E.; Keller, S.; Tenspoldel, M.; Weigand, I.; Gaetzner, S.; Manova, K.; Penack, O.; Scheinberg, D. A.; Rosenwald, A.; Erguen, S.; Granot, Z.; Henke, E.			VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors	ONCOGENE			English	Article							FACTOR RECEPTOR-2 BLOCKADE; LYSYL OXIDASE; GROWTH-FACTOR; ANTITUMOR-ACTIVITY; VASCULAR NORMALIZATION; BLOOD-VESSELS; IN-VIVO; BEVACIZUMAB; IMPROVES; BIODISTRIBUTION	The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a major obstacle to the treatment of cancer. Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause phenotypic alteration and maturation of the tumor's vasculature. However, whether this consistently improves delivery and subsequent response to therapy is still controversial. Clinical results indicate that not all patients benefit from antiangiogenic treatment, necessitating the development of criteria to predict the effect of these agents in individual tumors. We demonstrate that, in anti-VEGF-refractory murine tumors, vascular changes after VEGF ablation result in reduced delivery leading to therapeutic failure. In these tumors, the impaired response after anti-VEGF treatment is directly linked to strong deposition of fibrillar extracellular matrix (ECM) components and high expression of lysyl oxidases. The resulting condensed, highly crosslinked ECM impeded drug permeation, protecting tumor cells from exposure to small-molecule drugs. The reduced vascular density after anti-VEGF treatment further decreased delivery in these tumors, an effect not compensated by the improved vessel quality. Pharmacological inhibition of lysyl oxidases improved drug delivery in various tumor models and reversed the negative effect of VEGF ablation on drug delivery and therapeutic response in anti-VEGF-resistant tumors. In conclusion, the vascular changes after anti-VEGF therapy can have a context-dependent negative impact on overall therapeutic efficacy. A determining factor is the tumor ECM, which strongly influences the effect of anti-VEGF therapy. Our results reveal the prospect to revert a possible negative effect and to potentiate responsiveness to antiangiogenic therapy by concomitantly targeting ECM-modifying enzymes.	[Roehrig, F.; Hoffmann, H.; Keller, S.; Tenspoldel, M.; Weigand, I.; Erguen, S.; Henke, E.] Univ Wurzburg, Inst Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany; [Roehrig, F.; Vorlova, S.; Hoffmann, H.; Gaetzner, S.; Henke, E.] Univ Klinikum Wurzburg, Inst Expt Biomed, Wurzburg, Germany; [Roehrig, F.; Hoffmann, H.; Henke, E.] Univ Wurzburg, Grad Sch Life Sci, Wurzburg, Germany; [Wartenberg, M.; Rosenwald, A.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Wartenberg, M.; Rosenwald, A.] CCCMF, Wurzburg, Germany; [Escorcia, F. E.; Scheinberg, D. A.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA; [Manova, K.] Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, 1275 York Ave, New York, NY 10021 USA; [Penack, O.] Univ Klinikum Charite, Med Klin Schwerpunkt Hamatol Onkol & Tumorimmunol, Berlin, Germany; [Granot, Z.] Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, Jerusalem, Israel; [Granot, Z.] Hebrew Univ Jerusalem, Hadassah Med Sch, Jerusalem, Israel	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hebrew University of Jerusalem	Henke, E (corresponding author), Univ Wurzburg, Inst Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany.	erik.henke@uni-wuerzburg.de	Escorcia, Freddy E/GVS-4521-2022; Henke, Erik/AAG-7053-2020; Penack, Olaf/L-1068-2016	Henke, Erik/0000-0003-2380-2682; Wartenberg, Martin/0000-0002-5378-3825; Penack, Olaf/0000-0003-4876-802X; Rohrig, Florian/0000-0002-6879-7883; Escorcia, Freddy E/0000-0002-0727-3242	Deutsche Forschungsgemeinschaft (DFG) [HE3565/1-1, HE3565/2-1, HE3565/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Robert Benezra (Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center) for helpful discussion; Thomas Jarchau (Institute for clinical Biochemistry and Pathobiochemistry, Univeritatsklinikum Wurzburg) for a thorough correction of the manuscript; and Afshar Barlas, Mesruh Turkekul (Molecular Cytology Core facility, Memorial Sloan-Kettering Cancer Center) and Oliver Reinhardt (Biology Master Course, Universitat Wurzburg) for help with experiments. Funding was provided by the Deutsche Forschungsgemeinschaft (DFG Grant Nos. HE3565/1-1, HE3565/2-1 and HE3565/3-1 to EH).	Arjaans M, 2013, CANCER RES, V73, P3347, DOI 10.1158/0008-5472.CAN-12-3518; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Cesca M, 2009, NEOPLASIA, V11, P1155, DOI 10.1593/neo.09866; Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291; Constantinidou A, 2013, EXPERT REV ANTICANC, V13, P211, DOI [10.1586/ERA.12.161, 10.1586/era.12.161]; Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; DUNN JF, 1995, MAGN RESON MED, V34, P515, DOI 10.1002/mrm.1910340405; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Escorcia FE, 2010, CANCER RES, V70, P9277, DOI 10.1158/0008-5472.CAN-10-2029; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gangloff A, 2005, J NUCL MED, V46, P1866; Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556; Heskamp S, 2013, INT J CANCER, V133, P307, DOI 10.1002/ijc.28046; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kato Y, 2006, MAGN RESON MED, V55, P755, DOI 10.1002/mrm.20831; Kesner AL, 2007, J NUCL MED, V48, P2021, DOI 10.2967/jnumed.107.045716; Kim S, 2012, MOL VIS, V18, P265; Kratz F., 2011, DRUG DELIVERY ONCOLO, V1, pLIX; Krishnamachary B, 2003, CANCER RES, V63, P1138; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Lin KY, 2008, TRANSL ONCOL, V1, P84, DOI 10.1593/tlo.08118; Liu JQ, 2012, P NATL ACAD SCI USA, V109, P16618, DOI 10.1073/pnas.1117610109; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242; Memon AA, 2009, CANCER RES, V69, P873, DOI 10.1158/0008-5472.CAN-08-3118; Mendenhall WM, 2009, AM J CLIN ONCOL-CANC, V32, P436, DOI 10.1097/COC.0b013e318173a54f; Minko T, 2000, PHARMACEUT RES, V17, P505, DOI 10.1023/A:1007500412442; Phillips PG, 2011, ANTICANCER RES, V31, P411; Primeau AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274; Rodriguez HM, 2010, J BIOL CHEM, V285, P20964, DOI 10.1074/jbc.M109.094136; Sandhu JK, 2000, J NATL CANCER I, V92, P1429, DOI 10.1093/jnci/92.17.1429; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Staffhorst RWHM, 2008, ANTI-CANCER DRUG, V19, P721, DOI 10.1097/CAD.0b013e328304355f; Stylianopoulos T, 2013, P NATL ACAD SCI USA, V110, P18632, DOI 10.1073/pnas.1318415110; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Turley RS, 2012, CLIN CANCER RES, V18, P3328, DOI 10.1158/1078-0432.CCR-11-3000; Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023; Wilgus ML, 2011, CANCER-AM CANCER SOC, V117, P2186, DOI 10.1002/cncr.25768; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; WILMARTH KR, 1992, J TOXICOL ENV HEALTH, V37, P411, DOI 10.1080/15287399209531680; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xie J, 2012, INT ORTHOP, V36, P207, DOI 10.1007/s00264-011-1261-3	55	17	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					1	12		10.1038/onc.2016.182	http://dx.doi.org/10.1038/onc.2016.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270432	Green Published, hybrid			2022-12-28	WOS:000394069100001
J	Sharma, P; Kuehn, MR				Sharma, P.; Kuehn, M. R.			SENP1-modulated sumoylation regulates retinoblastoma protein (RB) and Lamin A/C interaction and stabilization	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; A-TYPE LAMINS; PROSTATE-CANCER; SUMO; MUTATIONS; SENP1; MECHANISMS; PATHWAY; GENE; PROLIFERATION	The retinoblastoma tumor suppressor protein (RB) plays a critical role in cell proliferation and differentiation and its inactivation is a frequent underlying factor in tumorigenesis. While the regulation of RB function by phosphorylation is well studied, proteasome-mediated RB protein degradation is emerging as an important regulatory mechanism. Although our understanding of RB turnover is currently limited, there is evidence that the nuclear lamina filament protein Lamin A/C protects RB from proteasomal degradation. Here we show that SUMO1 conjugation of RB and Lamin A/C is modulated by the SUMO protease SENP1 and that sumoylation of both proteins is required for their interaction. Importantly, this SUMO1-dependent complex protects both RB and Lamin A/C from proteasomal turnover.	[Sharma, P.; Kuehn, M. R.] NCI, NIH, Frederick, MD 21701 USA; [Sharma, P.] NHGRI, Undiagnosed Dis Program, UDP Translat Lab, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kuehn, MR (corresponding author), NCI, NIH, Frederick, MD 21701 USA.	mkuehn@mail.nih.gov	Sharma, Prashant/ABH-1968-2021		Intramural Research Program of the National Cancer Institute, National Institutes of Health	Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Stefano Campaner (IIT, Milan) for discussions, and Alessandra Mazzoni (AIRC, Milan), Shyam Sharan (NCI, Frederick), Sushil Rane (NIDDK, Bethesda) and Tom Misteli (NCI, Bethesda) for comments on the manuscript. This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.	AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Bawa-Khalfe T, 2010, J BIOL CHEM, V285, P25859, DOI 10.1074/jbc.M110.134874; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Burdelski C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1555-8; Butin-Israeli V, 2012, TRENDS GENET, V28, P464, DOI 10.1016/j.tig.2012.06.001; Cao HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/s10038-003-0025-3; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Dechat T, 2010, COLD SH Q B, V75, P533, DOI 10.1101/sqb.2010.75.018; Dechat T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000547; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Dittmer T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-222; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Evdokimov E, 2008, J CELL SCI, V121, P4106, DOI 10.1242/jcs.038570; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Huang W., 2012, EVID-BASED COMPL ALT, V2012, P1, DOI DOI 10.1155/2012/910520; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kennedy BK, 2014, ADV EXP MED BIOL, V773, P127, DOI 10.1007/978-1-4899-8032-8_6; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Li T, 2013, UROL ONCOL-SEMIN ORI, V31, P1539, DOI 10.1016/j.urolonc.2012.03.007; Ma CC, 2014, TUMOR BIOL, V35, P12729, DOI 10.1007/s13277-014-2598-1; Macdonald James I, 2012, Genes Cancer, V3, P619, DOI 10.1177/1947601912473305; Maraldi NM, 2011, J CELL BIOCHEM, V112, P979, DOI 10.1002/jcb.22992; Marji J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011132; Markiewicz E, 2002, MOL BIOL CELL, V13, P4401, DOI 10.1091/mbc.E02-07-0450; Mu JW, 2014, CHINESE MED J-PEKING, V127, P4060, DOI 10.3760/cma.j.issn.0366-6999.20141013; Muchir A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/hmg/9.9.1453; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Pekovic V, 2007, J CELL BIOL, V176, P163, DOI 10.1083/jcb.200606139; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Sharma P, 2013, CELL REP, V3, P1640, DOI 10.1016/j.celrep.2013.04.016; Sharma P, 2010, J CELL SCI, V123, P1227, DOI 10.1242/jcs.060160; Simon DN, 2013, MOL BIOL CELL, V24, P342, DOI 10.1091/mbc.E12-07-0527; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Wang C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/328707; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wang Q., 2013, POWERTECH POWERTECH, P1; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Xu Y, 2011, CANCER LETT, V309, P78, DOI 10.1016/j.canlet.2011.05.019; Xu Z, 2009, ANTIOXID REDOX SIGN, V11, P1453, DOI [10.1089/ars.2008.2182, 10.1089/ARS.2008.2182]; Yamaguchi T, 2005, MOL CELL BIOL, V25, P5171, DOI 10.1128/MCB.25.12.5171-5182.2005; Yan XM, 2016, BIOTECHNOL APPL BIOC, V63, P435, DOI 10.1002/bab.1375; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Zhang YQ, 2008, J CELL BIOL, V182, P35, DOI 10.1083/jcb.200712124	52	15	16	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6429	6438		10.1038/onc.2016.177	http://dx.doi.org/10.1038/onc.2016.177			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27270425				2022-12-28	WOS:000390247600007
J	Turpin, J; Ling, C; Crosby, EJ; Hartman, ZC; Simond, AM; Chodosh, LA; Rennhack, JP; Andrechek, ER; Ozcelik, J; Hallett, M; Mills, GB; Cardiff, RD; Gray, JW; Griffith, OL; Muller, WJ				Turpin, J.; Ling, C.; Crosby, E. J.; Hartman, Z. C.; Simond, A. M.; Chodosh, L. A.; Rennhack, J. P.; Andrechek, E. R.; Ozcelik, J.; Hallett, M.; Mills, G. B.; Cardiff, R. D.; Gray, J. W.; Griffith, O. L.; Muller, W. J.			The ErbB2 Delta Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSGENIC MICE; MAMMARY-TUMORS; ACTIVATING MUTATIONS; ELEVATED EXPRESSION; ENRICHMENT ANALYSIS; NEU PROTOONCOGENE; PROGRESSION; INDUCTION; HER2	Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20-30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2 Delta Ex16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2 Delta Ex16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2 Delta Ex16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2 Delta Ex16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2 Delta Ex16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2 Delta Ex16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.	[Turpin, J.; Ling, C.; Simond, A. M.; Ozcelik, J.; Hallett, M.; Muller, W. J.] Goodman Canc Ctr, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada; [Turpin, J.; Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Crosby, E. J.; Hartman, Z. C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Chodosh, L. A.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rennhack, J. P.; Andrechek, E. R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Mills, G. B.] MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Cardiff, R. D.] Univ Calif Davis, Dept Pathol, Ctr Comparat Med, Davis, CA 95616 USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Griffith, O. L.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO USA; [Muller, W. J.] McGill Univ, Dept Med, Montreal, PQ, Canada	McGill University; Duke University; University of Pennsylvania; Pennsylvania Medicine; Michigan State University; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis; Oregon Health & Science University; Washington University (WUSTL); McGill University	Muller, WJ (corresponding author), Goodman Canc Ctr, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca	Gray, Joe/AAX-9549-2020	Rennhack, Jonathan/0000-0001-6306-195X; Hallett, Michael/0000-0001-6738-6786; Andrechek, Eran/0000-0002-8680-3423	Terry Fox Foundation [020002]; Canadian Institutes of Health Research [MOP 93525, MOP 89751]; National Institutes of Health [PO1 (2PO1CA099031-06A1)]; CRC Chair in Molecular Oncology; Department of Defense Breast Cancer Predoctoral Traineeship [W81XWH 10-1-0114]; Susan G Komen Breast Cancer Foundation [CCR14299200]; NIH-NCI [T32-CA009111]; NIH [R01CA160514]; US-NCI [U01 CA141582]; NATIONAL CANCER INSTITUTE [P01CA099031, P30CA016672, T32CA009111, F99CA212221, R01CA160514, U01CA141582] Funding Source: NIH RePORTER	Terry Fox Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CRC Chair in Molecular Oncology; Department of Defense Breast Cancer Predoctoral Traineeship; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jonathan Rayment, Dr Dongmei Zuo, and Ms Virginie Sanguin-Gendreau for their important involvement in this project. This study was supported by grants awarded to WJM from the Terry Fox Foundation (#020002), the Canadian Institutes of Health Research (MOP 93525 and MOP 89751) and the National Institutes of Health PO1 (2PO1CA099031-06A1). WJM is supported by CRC Chair in Molecular Oncology. JT was supported by the Department of Defense Breast Cancer Predoctoral Traineeship award #W81XWH 10-1-0114. ZCH was supported by Susan G Komen Breast Cancer Foundation (CCR14299200) and NIH-NCI (T32-CA009111). ERA is supported by NIH grant R01CA160514. RDC is supported by a US-NCI grant U01 CA141582. MMTV/ErbB2 transgenic mice were a generous donation from Genentech.	Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Castagnoli L, 2014, CANCER RES, V74, P6248, DOI 10.1158/0008-5472.CAN-14-0983; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Chan R, 1999, ANN NY ACAD SCI, V889, P45, DOI 10.1111/j.1749-6632.1999.tb08722.x; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen YL, 2015, J CLIN INVEST, V125, P1147, DOI 10.1172/JCI74725; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Diessner J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.115; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Griffith M, 2010, NAT METHODS, V7, P843, DOI [10.1038/NMETH.1503, 10.1038/nmeth.1503]; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; McCormack VA, 2016, CANCER EPIDEMIOL, V40, P141, DOI 10.1016/j.canep.2015.11.015; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Perry MC, 2014, MOL CELL BIOL, V34, P4232, DOI 10.1128/MCB.00895-14; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309	46	41	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6053	6064		10.1038/onc.2016.129	http://dx.doi.org/10.1038/onc.2016.129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157621	Green Accepted, Green Submitted			2022-12-28	WOS:000388509800002
J	Pant, V; Xiong, S; Chau, G; Tsai, K; Shetty, G; Lozano, G				Pant, V.; Xiong, S.; Chau, G.; Tsai, K.; Shetty, G.; Lozano, G.			Distinct downstream targets manifest p53-dependent pathologies in mice	ONCOGENE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53 INHIBITION; MDM2; EXPRESSION; DIFFERENTIATION; INACTIVATION; ACTIVATION; MUTATIONS; STABILITY	Mdm2, the principal negative regulator of p53, is critical for survival, a fact clearly demonstrated by the p53-dependent death of germline or conditional mice following deletion of Mdm2. On the other hand, Mdm2 hypomorphic (Mdm2(Puro Delta 7-12)) or heterozygous (Mdm2(+/-)) mice that express either 30 or 50% of normal Mdm2 levels, respectively, are viable but present distinct phenotypes because of increased p53 activity. Mdm2 levels are also transcriptionally regulated by p53. We evaluated the significance of this reciprocal relationship in a new hypomorphic mouse model inheriting an aberrant Mdm2 allele with insertion of the neomycin cassette and deletion of 184-bp sequence in intron 3. These mice also carry mutations in the Mdm2 P2-promoter and thus express suboptimal levels of Mdm2 entirely encoded from the P1-promoter. Resulting mice exhibit abnormalities in skin pigmentation and reproductive tissue architecture, and are subfertile. Notably, all these phenotypes are rescued on a p53-null background. Furthermore, these phenotypes depend on distinct p53 downstream activities as genetic ablation of the pro-apoptotic gene Puma reverts the reproductive abnormalities but not skin hyperpigmentation, whereas deletion of cell cycle arrest gene p21 does not rescue either phenotype. Moreover, p53-mediated upregulation of Kitl influences skin pigmentation. Altogether, these data emphasize tissue-specific p53 activities that regulate cell fate.	[Pant, V.; Xiong, S.; Chau, G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Tsai, K.] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA; [Shetty, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org	Xiong, Shunbin/AAR-5823-2021	Chau, Gilda/0000-0002-7907-3290; Shetty, Gunapala/0000-0001-5786-0667; Pant, Vinod/0000-0002-3286-1804	NCI Cancer Center Support Grant [CA16672]; NIH grant [CA47296]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA047296] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Mdm2<SUP>PND/PND</SUP> mice were made by the GEM Facility at the MDACC funded by an NCI Cancer Center Support Grant (CA16672). The studies were supported by NIH grant CA47296 to GL.	ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, COLD SPRING HARB SYM, V59, P225, DOI 10.1101/SQB.1994.059.01.027; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Liu G, 2007, J PATHOL, V213, P360, DOI 10.1002/path.2238; LUNA RMD, 1995, NATURE, V378, P203; Marino S, 2000, GENE DEV, V14, P994; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; McGowan KA, 2011, BLOOD, V118, P3622, DOI 10.1182/blood-2010-11-318584; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Pant V, 2014, ONCOTARGET, V5, P1149, DOI 10.18632/oncotarget.1797; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Perry ME, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000968; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Shetty G, 2001, ENDOCRINOLOGY, V142, P2789, DOI 10.1210/en.142.7.2789; Steingrimsson E, 2006, DEV DYNAM, V235, P2401, DOI 10.1002/dvdy.20840; Sullivan JM, 2012, RADIAT RES, V177, P307, DOI 10.1667/RR2545.1; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Terzian T, 2011, J PATHOL, V224, P540, DOI 10.1002/path.2891; Vanover JC, 2009, PIGM CELL MELANOMA R, V22, P827, DOI 10.1111/j.1755-148X.2009.00617.x; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zeron-Medina J, 2013, CELL, V155, P410, DOI 10.1016/j.cell.2013.09.017; Zhang Y, 2014, J PATHOL, V233, P380, DOI 10.1002/path.4368	37	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5713	5721		10.1038/onc.2016.111	http://dx.doi.org/10.1038/onc.2016.111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065327	Green Accepted			2022-12-28	WOS:000386998400003
J	Hobbs, RP; Batazzi, AS; Han, MC; Coulombe, PA				Hobbs, R. P.; Batazzi, A. S.; Han, M. C.; Coulombe, P. A.			Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo	ONCOGENE			English	Article							ATYPICAL SQUAMOUS-CELLS; INTRAEPITHELIAL NEOPLASIA; UNDETERMINED SIGNIFICANCE; DIAGNOSTIC-VALUE; GENE-EXPRESSION; RESERVE CELLS; MARKER; CYTOKERATIN-17; CANCER; CARCINOMA	Despite preventive human papilloma virus (HPV) vaccination efforts, cervical cancer remains a leading cause of death in women worldwide. Development of therapeutic approaches for cervical cancer are hampered by a lack of mechanistic insight during tumorigenesis. The cytoskeletal protein Keratin 17 (KRT17;K17) is robustly expressed in a broad array of carcinomas, including in cervical tumors, where it has both diagnostic and prognostic value. In this study, we have established multiple functional roles for K17 in the promotion of cervical tumorigenesis in vivo using the established HPV16(tg) mouse model for cervical squamous cell carcinoma. In HPV16tg/+;Krt17(-/-)relative to HPV16(tg/+) reference female mice, onset of cervical lesions is delayed and closely paralleled by marked reductions in hyperplasia, dysplasia and vascularization. In addition, loss of Krt17 is associated with a cytokine polarization and recruitment of effector immune cells to lesion-prone cervical epithelia. Further, we observed marked enhancement of terminal differentiation in HPV16(tg/+); Krt17(-/-)cervical epithelium accompanied by a stimulation and expansion in the expression of p63, a known basal/reserve cell marker in this tissue. Altogether, the data suggest that the loss of Krt17 may foster an overall protective environment for lesion-prone cervical tissue. In addition to providing new insights into the immunomodulatory and cellular mechanisms of cervical tumorigenesis, these findings may help guide the development of future therapies including vaccines.	[Hobbs, R. P.; Batazzi, A. S.; Han, M. C.; Coulombe, P. A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 North Wolfe St, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canccr Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Coulombe, PA (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 North Wolfe St, Baltimore, MD 21205 USA.	coulombe@jhu.edu			NIH [CA160255, AR44232]; NIH training grant from the National Institutes of Health [CA009110]; NATIONAL CANCER INSTITUTE [R01CA160255, T32CA009110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044232] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH training grant from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank members of the Coulombe laboratory for support, Dr Michelle Kerns for critical reading of the manuscript and Drs Janice Evans, Hyo Lee and TC Wu for advice and assistance. These studies were supported by NIH research grants CA160255 and AR44232 (to PAC) and NIH training grant CA009110 (to RH) from the National Institutes of Health.	Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Chen Y, 2011, ONCOLOGY-BASEL, V80, P333, DOI 10.1159/000329098; Chung BM, 2015, J CELL BIOL, V208, P613, DOI 10.1083/jcb.201408026; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Cohen-Kerem R, 2004, ANN OTO RHINOL LARYN, V113, P821, DOI 10.1177/000348940411301008; DePianto D, 2010, NAT GENET, V42, P910, DOI 10.1038/ng.665; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Escobar-Hoyos LF, 2015, CANCER RES, V75, P3650, DOI 10.1158/0008-5472.CAN-15-0293; Escobar-Hoyos LF, 2014, MODERN PATHOL, V27, P621, DOI 10.1038/modpathol.2013.166; Feng DQ, 2009, ONCOL REP, V22, P1129, DOI 10.3892/or_00000545; Freeman AK, 2011, SEMIN CELL DEV BIOL, V22, P681, DOI 10.1016/j.semcdb.2011.08.009; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Hobbs RP, 2015, NAT GENET, V47, P933, DOI 10.1038/ng.3355; Hopman AHN, 2006, J PATHOL, V210, P412, DOI 10.1002/path.2070; Hopman AHN, 2004, J PATHOL, V202, P23, DOI 10.1002/path.1490; Ide M, 2012, ANN SURG ONCOL, V19, P3506, DOI 10.1245/s10434-012-2437-9; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Lee BN, 2004, CLIN DIAGN LAB IMMUN, V11, P239, DOI 10.1128/CDLI.11.2.239-244.2004; Martens J, 1999, CANCER CYTOPATHOL, V87, P87, DOI 10.1002/(SICI)1097-0142(19990425)87:2<87::AID-CNCR8>3.0.CO;2-L; Martens JE, 2004, ANTICANCER RES, V24, P771; Martens JE, 2009, INT J GYNECOL PATHOL, V28, P381, DOI 10.1097/PGP.0b013e31819932f8; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; Mighty KK, 2014, RECENT RESULTS CANC, V193, P135, DOI 10.1007/978-3-642-38965-8_8; MITCHELL MF, 1994, CANCER EPIDEM BIOMAR, V3, P619; Patterson AL, 2013, CELL CYCLE, V12, P2888, DOI 10.4161/cc.25917; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Rodriguez R, 2008, INT J GYNECOL PATHOL, V27, P108, DOI 10.1097/pgp.0b013e31804216b8; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SMEDTS F, 1992, AM J PATHOL, V140, P601; Sun B, 2015, INT J CLIN EXP PATHO, V8, P1783; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Toyoshima T, 2008, J CANCER RES CLIN, V134, P515, DOI 10.1007/s00432-007-0308-8; Van de Putte G, 2003, GYNECOL ONCOL, V89, P140, DOI 10.1016/S0090-8258(03)00010-6; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Wang YF, 2013, TUMOR BIOL, V34, P1685, DOI 10.1007/s13277-013-0703-5	41	37	37	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5653	5662		10.1038/onc.2016.102	http://dx.doi.org/10.1038/onc.2016.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065324	Green Accepted			2022-12-28	WOS:000386998300008
J	Luo, C; Shu, Y; Luo, J; Liu, D; Huang, DS; Han, Y; Chen, C; Li, YC; Zou, JM; Qin, J; Wang, Y; Li, D; Wang, SS; Zhang, GM; Chen, J; Feng, ZH				Luo, C.; Shu, Y.; Luo, J.; Liu, D.; Huang, D-S; Han, Y.; Chen, C.; Li, Y-C; Zou, J-M; Qin, J.; Wang, Y.; Li, D.; Wang, S-S; Zhang, G-M; Chen, J.; Feng, Z-H			Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TGF-BETA; CANCER-CELLS; INNATE INFLAMMATION; GENE-EXPRESSION; IN-VITRO; IL-1; RECEPTOR; ACTIVATION; INHIBITION	Multiple signaling pathways that promote tumor cell metastasis are differentially activated in low/non-metastatic and metastatic tumor cells, resulting in the differential expression of metastasis-related genes. The underlying mechanism may involve the alterations of the intrinsic negative regulation in tumor cells. Here we report that the differential expression of interleukin-37b (IL-37b) in tumor cells alters the intrinsic negative regulation of signaling pathways, resulting in the difference of metastatic capacity. IL-37b could bind Smad3 and suppress Smad pathway by interfering with the formation and nuclear translocation of Smad2/3/4 complex. In turn, Smad3 could function as a co-regulator, enabling IL-37b to suppress multiple non-Smad pathways. IL-37b-Smad3 translocated into nucleus to upregulate the expression of non-receptor protein tyrosine phosphatases (PTPNs), thus promoting dephosphorylation to suppress the activation of tyrosine phosphorylation-dependent signaling pathways such as ERK, p38 MAPK, JNK, PI3K, NF-kappa B, and STAT3 pathways. Intriguingly, 13 of 17 PTPNs, most of which are metastasis suppressors, were downregulated in metastatic tumor cells because of the low expression of IL-37b. The marked decrease of intracellular IL-37b attenuated the intrinsic negative regulation in tumor cells, resulting in the enhanced activation of multiple signaling pathways and the increased capacity of invasiveness and metastatic colonization. Consistently, low expression of IL-37b in tumors was significantly associated with poor prognosis of cancer patients. Taken together, these findings reveal that intracellular IL-37b is a critical factor in the negative regulation of multiple signaling pathways that modulate the expression of metastasis-related genes, and suggest that IL-37b expression in tumor cells can potentially be a histopathological prognostic parameter for cancer patients and a therapeutic target for preventing tumor metastasis.	[Luo, C.; Shu, Y.; Luo, J.; Li, Y-C; Zou, J-M; Qin, J.; Wang, Y.; Li, D.; Wang, S-S; Zhang, G-M; Chen, J.; Feng, Z-H] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China; [Liu, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Biol Res Ctr, Wuhan, Peoples R China; [Huang, D-S; Han, Y.] Zhejiang Prov Peoples Hosp, Clin Res Inst, Hangzhou, Zhejiang, Peoples R China; [Chen, C.] Wuhan Univ, Renmin Hosp, Res Inst Otolaryngol Head & Neck Surg, Wuhan 430060, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Zhejiang Provincial People's Hospital; Wuhan University	Chen, J (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China.	chenjuanlinda69@163.com; fengzhg_tj@163.com			National Natural Science Foundation of China [81472704, 30830095, 81272314]; National Development Program (973) For Key Basic Research of China [2009CB521806]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Development Program (973) For Key Basic Research of China(National Basic Research Program of China)	We thank Zhi-Hui Liang, Hui-Fen Zhu, Sheng-Hong Liu for technical assistance; Professor Guan-Xin Shen, Xiong-Wen Wu, Xin-Xing Wu, Zhan-Qiu Yang for their valuable comments and critical review of the manuscript. This work was supported by National Natural Science Foundation of China (no. 81472704 and 30830095 to Z-HF, and 81272314 to G-MZ), and National Development Program (973) For Key Basic Research of China (no. 2009CB521806 to Z-HF).	Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bettaieb A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-13; Boraschi D, 2011, EUR CYTOKINE NETW, V22, P127, DOI 10.1684/ecn.2011.0288; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Fekete T, 2012, INT J CANCER, V131, P95, DOI 10.1002/ijc.26364; Feng XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079857; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; Gao ZH, 2014, NATURE, V516, P349, DOI 10.1038/nature13921; Gong W, 2008, INT J CANCER, V123, P702, DOI 10.1002/ijc.23553; Ida M, 1996, BIOCHEM PHARMACOL, V51, P1061, DOI 10.1016/0006-2952(95)02438-7; Jiang YZ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0695-7; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kumar S, 2002, CYTOKINE, V18, P61, DOI 10.1006/cyto.2002.0873; Kuwada Y, 2003, INT J ONCOL, V22, P765; Lane AE, 2010, BIOCHEM J, V430, P161, DOI 10.1042/BJ20100082; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Li S, 2012, CANCER RES, V72, P865, DOI 10.1158/0008-5472.CAN-11-1357; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; Liao SJ, 2012, BREAST CANCER RES TR, V133, P853, DOI 10.1007/s10549-011-1844-0; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu DW, 2012, INT J MOL SCI, V13, P828, DOI 10.3390/ijms13010828; Ludyga N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-28; Marshall JC, 2009, MOL CELL BIOCHEM, V329, P115, DOI 10.1007/s11010-009-0116-3; Marshall JCA, 2012, JNCI-J NATL CANCER I, V104, P1306, DOI 10.1093/jnci/djs319; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; Ozaki I, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00078; Palmieri D, 2006, J BIOENERG BIOMEMBR, V38, P151, DOI 10.1007/s10863-006-9039-9; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Sastry SK, 2011, BIOCHEM PHARMACOL, V82, P435, DOI 10.1016/j.bcp.2011.06.016; Schneider MA, 2015, CLIN CANCER RES, V21, P3529, DOI 10.1158/1078-0432.CCR-14-2464; Sharma S, 2008, J IMMUNOL, V180, P5477, DOI 10.4049/jimmunol.180.8.5477; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Wang ZH, 2013, J IMMUNOL, V190, P2415, DOI 10.4049/jimmunol.1202535; Wu WS, 2008, CANCER METAST REV, V27, P303, DOI 10.1007/s10555-008-9112-4; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang P, 2013, J IMMUNOL, V190, P1685, DOI 10.4049/jimmunol.1202384; Zhou YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065906	54	23	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2889	2899		10.1038/onc.2016.444	http://dx.doi.org/10.1038/onc.2016.444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28092676				2022-12-28	WOS:000401697800011
J	McCurdy, SR; Pacal, M; Ahmad, M; Bremner, R				McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.			A CDK2 activity signature predicts outcome in CDK2-low cancers	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; TERMINAL DOMAIN CTD; CELL-CYCLE; TUMOR SUPPRESSION; TARGET GENES; IDENTIFICATION; PHOSPHORYLATION; CARCINOMA; MICE; RETINOBLASTOMA	The role of cyclin-dependent kinase 2 (CDK2) in cancer is controversial. A major hurdle is the availability of tools to easily assess its activity across many samples. Here, we introduce a transcriptional signature to specifically track CDK2 activity. It responds to genetic and chemical perturbations in the CDK-RB-E2F axis, correlates with mitotic rate in vitro and in vivo and reacts rapidly to changes in CDK2 activity during cell cycle progression. We find that CDK2 activity is specifically elevated in human testes, mirroring its critical function in mice, and report very distinct profiles across human cancers. Increased CDK2 activity decreases risk in colon cancer, but elevates poor outcome two-to fivefold in specific tumors, including low grade glioma, kidney, thyroid, adrenocortical and prostate cancer. These are typically 'CDK2-low' cancers, suggesting that above a certain threshold CDK2 promotes progression, but further increases do not influence outcome. Multivariate analysis revealed that the CDK2 signature is the most important predictive feature in these cancers versus dozens of other clinical parameters, such as tumor grade or mitotic index. Thus, transcriptome data provides a novel, straightforward method to monitor CDK2 activity, implicates key roles for the kinase in a subset of human tissues and tumors and enhances cancer risk prediction. The strategy used here for CDK2 could be applied to other kinases that influence transcription.	[McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.] Sinai Hlth Syst, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Room 840 600 Univ Ave, Toronto, ON M5G 1X5, Canada; [McCurdy, S. R.; Bremner, R.] Univ Toronto, Dept Lab Med & Pathobiol, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Bremner, R (corresponding author), Sinai Hlth Syst, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Room 840 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	bremner@lunenfeld.ca	Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212	Canadian Institutes for Health Research (CIHR); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; Peterborough KM Hunter Foundation; CIHR (Vanier Graduate Scholarship); CIHR Biological Therapeutics Program; Krembil Foundation	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; Peterborough KM Hunter Foundation; CIHR (Vanier Graduate Scholarship)(Canadian Institutes of Health Research (CIHR)); CIHR Biological Therapeutics Program(Canadian Institutes of Health Research (CIHR)); Krembil Foundation	We thank G Bader, F Roth and J Wrana for helpful comments. This project was funded by grants to RB from the Canadian Institutes for Health Research (CIHR), Foundation Fighting Blindness Canada, Krembil Foundation, Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Terry Fox Research Institute. SRM was supported by scholarships from Peterborough KM Hunter Foundation, CIHR (Vanier Graduate Scholarship) and the CIHR Biological Therapeutics Program.	Adler AS, 2012, CANCER RES, V72, P2129, DOI 10.1158/0008-5472.CAN-11-3886; Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Berkofsky-Fessler W, 2009, MOL CANCER THER, V8, P2517, DOI 10.1158/1535-7163.MCT-09-0083; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chi Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r149; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gillam MP, 2014, ONCOGENE, V124, P1056; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Hongo F, 2014, UROL ONCOL-SEMIN ORI, V32, P1240, DOI 10.1016/j.urolonc.2014.05.006; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishihara H, 2005, BBA-MOL BASIS DIS, V1741, P226, DOI 10.1016/j.bbadis.2005.06.001; Kim SJ, 2008, ANN ONCOL, V19, P68, DOI 10.1093/annonc/mdm358; Kim SJ, 2012, ANN ONCOL, V23, P891, DOI 10.1093/annonc/mdr340; Kronja I, 2011, PHILOS T R SOC B, V366, P3638, DOI 10.1098/rstb.2011.0084; Kubo H, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-755; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li JQ, 2001, HUM PATHOL, V32, P945, DOI 10.1053/hupa.2001.27116; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Macias E, 2007, CANCER RES, V67, P9713, DOI 10.1158/0008-5472.CAN-07-2119; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Ray D, 2011, NEOPLASIA, V13, P439, DOI 10.1593/neo.101704; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Stojadinovic A, 2003, MODERN PATHOL, V16, P742, DOI 10.1097/01.MP.0000081730.72305.81; Stojadinovic A, 2002, J CLIN ONCOL, V20, P941, DOI 10.1200/JCO.2002.20.4.941; Tsutsui T, 2011, GENES CELLS, V16, P1208, DOI 10.1111/j.1365-2443.2011.01565.x; Wang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034247; WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253; Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239	59	23	24	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2491	2502		10.1038/onc.2016.409	http://dx.doi.org/10.1038/onc.2016.409			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819669				2022-12-28	WOS:000400597300001
J	Martin, EE; Huang, W; Anwar, T; Arellano-Garcia, C; Burman, B; Guan, JL; Gonzalez, ME; Kleer, CG				Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Guan, J-L; Gonzalez, M. E.; Kleer, C. G.			MMTV-cre; Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; P63 EXPRESSION; MAMMARY-TUMORS; CANCER; WISP3; CELLS; INVASION; GENE; METASTASIS; INVOLUTION	Metaplastic breast carcinoma is an aggressive form of invasive breast cancer with histological evidence of epithelial to mesenchymal transition (EMT). However, the defining molecular events are unknown. Here we show that CCN6 (WISP3), a secreted matricellular protein of the CCN (CYR61/CTGF/NOV) family, is significantly downregulated in clinical samples of human spindle cell metaplastic breast carcinoma. We generated a mouse model of mammary epithelial-specific Ccn6 deletion by developing a floxed Ccn6 mouse which was bred with an MMTV-Cre mouse. Ccn6(fl/fl); MMTV-Cre mice displayed severe defects in ductal branching and abnormal age-related involution compared to littermate controls. Ccn6(fl/fl); MMTV-Cre mice developed invasive high grade mammary carcinomas with bona fide EMT, histologically similar to human metaplastic breast carcinomas. Global gene expression profiling of Ccn6(fl/fl) mammary carcinomas and comparison of orthologous genes with a human metaplastic carcinoma signature revealed a significant overlap of 87 genes (P = 5x10(-11)). Among the shared deregulated genes between mouse and human are important regulators of epithelial morphogenesis including Cdh1, Ck19, Cldn3 and 4, Ddr1, and Wnt10a. These results document a causal role for Ccn6 deletion in the pathogenesis of metaplastic carcinomas with histological and molecular similarities with human disease. We provide a platform to study new targets in the diagnosis and treatment of human metaplastic carcinomas, and a new disease relevant model in which to test new treatment strategies.	[Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Gonzalez, M. E.; Kleer, C. G.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Gonzalez, M. E.; Kleer, C. G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Anwar, T.] Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA; [Anwar, T.] Univ Michigan, Mol & Cellular Pathol Grad Program, Ann Arbor, MI 48109 USA; [Arellano-Garcia, C.] Univ Michigan, Postbaccalaureate Res Educ Program, Ann Arbor, MI 48109 USA; [Guan, J-L] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati	Kleer, CG (corresponding author), Univ Michigan, Dept Pathol, Comprehens Canc Ctr 4217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu		Arellano-Garcia, Caroline/0000-0002-4103-4042	National Institutes of Health (NIH) grant [R01CA125577, R01CA107469, F30CA196084, R25GM086262]; University of Michigan's Cancer Center [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [R01CA125577, K08CA090876, P30CA046592, F30CA196084, R01CA107469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM086262] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan's Cancer Center(University of Michigan System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health (NIH) grant R01CA125577 and R01CA107469 (C.G.K), F30CA196084 (T.A), R25GM086262 (PREP program, C.A-G), and the University of Michigan's Cancer Center Support grant 5 P30 CA46592. We thank Dr Stephen Weiss for the MMTV-Cre line A mice in FVB background, and members of the Kleer lab for critical review of the manuscript.	Anwar TE, 2013, HUM PATHOL, V44, P1457, DOI 10.1016/j.humpath.2013.01.005; Bae SY, 2011, BREAST CANCER RES TR, V126, P471, DOI 10.1007/s10549-011-1359-8; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Ferguson BW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036618; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hennessy BT, 2006, ANN ONCOL, V17, P605, DOI 10.1093/annonc/mdl006; Huang W, 2008, AM J PATHOL, V172, P893, DOI 10.2353/ajpath.2008.070899; Huang W, 2016, ONCOTARGET, V7, P25180, DOI 10.18632/oncotarget.7734; Huang W, 2010, CANCER RES, V70, P3340, DOI 10.1158/0008-5472.CAN-09-4225; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; JONES L P, 2011, J CANC SCI THER S, V2, P1, DOI [DOI 10.4172/1948-5956.S2-004, 10.4172/1948-5956]; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kleer CG, 2004, NEOPLASIA, V6, P179, DOI 10.1593/neo.03316; Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kutz WE, 2005, MOL CELL BIOL, V25, P414, DOI 10.1128/MCB.25.1.414-421.2005; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li Y, 2015, ONCOTARGET, V6, P32656, DOI 10.18632/oncotarget.5328; Lorenzatti G, 2011, J CELL SCI, V124, P1752, DOI 10.1242/jcs.084194; Luini A, 2007, BREAST CANCER RES TR, V101, P349, DOI 10.1007/s10549-006-9301-1; McAllister KA, 2002, CANCER RES, V62, P990; Milanese TR, 2006, J NATL CANCER I, V98, P1600, DOI 10.1093/jnci/djj439; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; OBERMAN HA, 1987, AM J SURG PATHOL, V11, P918, DOI 10.1097/00000478-198712000-00002; Pal A, 2012, NEOPLASIA, V14, P1067, DOI 10.1593/neo.121322; Pal A, 2012, CANCER RES, V72, P4818, DOI 10.1158/0008-5472.CAN-12-0154; Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Radisky DC, 2009, J MAMMARY GLAND BIOL, V14, P181, DOI 10.1007/s10911-009-9123-y; Rakha EA, 2015, BRIT J CANCER, V112, P283, DOI 10.1038/bjc.2014.592; Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341; Reis JS, 2003, APPL IMMUNOHISTO M M, V11, P1, DOI 10.1097/00022744-200303000-00001; Reis JS, 2003, HISTOPATHOLOGY, V42, P94, DOI 10.1046/j.1365-2559.2003.01513_2.x; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Rungta S, 2012, ARCH PATHOL LAB MED, V136, P896, DOI 10.5858/arpa.2012-0166-CR; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Toy KA, 2015, BREAST CANCER RES TR, V150, P9, DOI 10.1007/s10549-015-3285-7; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; Weigelt B, 2015, MODERN PATHOL, V28, P340, DOI 10.1038/modpathol.2014.142; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang YH, 2012, MODERN PATHOL, V25, P178, DOI 10.1038/modpathol.2011.167; Zhang YH, 2005, BREAST CANCER RES, V7, pR1080, DOI 10.1186/bcr1351; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	52	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2275	2285		10.1038/onc.2016.381	http://dx.doi.org/10.1038/onc.2016.381			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819674	Green Accepted			2022-12-28	WOS:000399782700008
J	Sochalska, M; Schuler, F; Weiss, JG; Prchal-Murphy, M; Sexl, V; Villunger, A				Sochalska, M.; Schuler, F.; Weiss, J. G.; Prchal-Murphy, M.; Sexl, V.; Villunger, A.			MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-X-L; LEUKOCYTE DEVELOPMENT; MYELOID-LEUKEMIA; IN-VIVO; FAMILY; A1/BFL-1; MICE; RESISTANCE; APOPTOSIS	Rearrangements of MYC or ABL proto-oncogenes lead to deregulated expression of key-regulators of cell cycle and cell survival, thereby constituting important drivers of blood cancer. Members of the BCL-2 family of apoptosis regulators contribute to oncogenic transformation downstream of these oncogenes, but the role of anti-apoptotic BCL2A1/A1 in transformation and drug resistance caused by deregulation of these oncogenes remains enigmatic. Here we analyzed the role of A1 in MYC as well as ABL kinase-driven blood cancer in mice, employing in vivo RNAi. We report that overexpression of either oncogene leads to a significant increase in A1 protein levels in otherwise A1-negative B cell progenitors, indicating a key role downstream of these oncogenes to secure survival during transformation. Knockdown of A1 by RNAi, however, did not impact on tumor latency in v-Abl-driven pre-B-ALL. In contrast, A1 knockdown in premalignant E mu-MYC mice caused a significant reduction of transgenic pre-B cells without impacting on tumor latency as the emerging lymphomas escaped silencing of A1 expression. These findings identify A1 as a MYC target that can be induced prematurely during B cell development to aid expansion of otherwise cell-death-prone MYC transgenic pre-B cells. Hence, A1 should be considered as a putative drug target in MYC-driven blood cancer.	[Sochalska, M.; Schuler, F.; Weiss, J. G.; Villunger, A.] Med Univ Innsbruck, Div Dev Immunol, Bioctr, Innrain 80, A-6020 Innsbruck, Austria; [Prchal-Murphy, M.; Sexl, V.] Univ Vet Med, Inst Pharmacol & Toxicol, Dept Biomed Sci, Vienna, Austria; [Villunger, A.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; University of Veterinary Medicine Vienna	Villunger, A (corresponding author), Med Univ Innsbruck, Div Dev Immunol, Bioctr, Innrain 80, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Sexl, Veronika/B-8657-2016	Sexl, Veronika/0000-0001-9363-0412; Sochalska, Maja/0000-0002-6665-3309	Austrian Science Fund (FWF) [I1298 (FOR-2036)]; MCBO Doctoral College 'Molecular Cell Biology and Oncology' [W1101]; 'Osterreichische Krebshilfe Tirol'; Doc-fellowship from the Austrian Academy of Science (OAW);  [SFB-F47]; Austrian Science Fund (FWF) [I 1298] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); MCBO Doctoral College 'Molecular Cell Biology and Oncology'; 'Osterreichische Krebshilfe Tirol'; Doc-fellowship from the Austrian Academy of Science (OAW); ; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are grateful to K Rossi, C Soratroi and I Gaggl for excellent technical assistance and animal care as well as to S Tuzlak for western analysis of Vav-BFL-1 mice and S Herzog for MYC expression constructs and discussion. We also thank J Borst (NKI) and M Herold (WEHI) for anti-BFL-1 antiserum and anti-A1 antibodies, respectively, and M Hartl for MYC inhibitors. This work was supported by grants from the Austrian Science Fund (FWF), grant I1298 (FOR-2036) and the MCBO Doctoral College 'Molecular Cell Biology and Oncology' (W1101) and the 'Osterreichische Krebshilfe Tirol' to AV and the SFB-F47 to VS. FS is supported by a Doc-fellowship from the Austrian Academy of Science (OAW).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Carter MJ, 2016, CELL DEATH DIFFER, V23, P303, DOI 10.1038/cdd.2015.97; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kelly PN, 2011, BLOOD, V118, P6380, DOI 10.1182/blood-2011-07-367672; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lang MJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.519; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057; Ogilvy S, 1999, BLOOD, V94, P1855; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ottina E, 2015, J IMMUNOL, V194, P1316, DOI 10.4049/jimmunol.1400637; Ottina E, 2012, BLOOD, V119, P6032, DOI 10.1182/blood-2011-12-399089; Ottina E, 2012, EXP CELL RES, V318, P1291, DOI 10.1016/j.yexcr.2012.01.021; Pegman PM, 2006, J VIROL, V80, P8133, DOI 10.1128/JVI.00278-06; Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988; Sochalska M, 2016, CELL DEATH DIFFER, V23, P628, DOI 10.1038/cdd.2015.130; Sochalska M, 2015, FEBS J, V282, P834, DOI 10.1111/febs.13188; Vier J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.23; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Warsch W, 2013, BLOOD, V122, P2167, DOI 10.1182/blood-2013-02-485573; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	33	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2066	2073		10.1038/onc.2016.362	http://dx.doi.org/10.1038/onc.2016.362			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27694901	Green Published, hybrid			2022-12-28	WOS:000399782500003
J	Tsai, CT; So, CWE				Tsai, C. T.; So, C. W. E.			Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; MLL-REARRANGED LEUKEMIA; MIXED-LINEAGE LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; HEMATOPOIETIC STEM-CELLS; MYELODYSPLASTIC SYNDROME; MLL-AF9-MEDIATED LEUKEMOGENESIS; H3K79 METHYLTRANSFERASE; MLL-AF9 LEUKEMIA; FUSION LEUKEMIA	While the current epigenetic drug development is still largely restricted to target DNA methylome, emerging evidence indicates that histone methylome is indeed another major epigenetic determinant for gene expression and frequently deregulated in acute myeloid leukaemia (AML). The recent advances in dissecting the molecular regulation and targeting histone methylome in AML together with the success in developing lead compounds specific to key histone methylation-modifying enzymes have revealed new opportunities for effective leukaemia treatment. In this article, we will review the emerging functions of histone methyltransferases and histone demethylases in AML, especially MLL-rearranged leukaemia. We will also examine recent preclinical and clinical studies that show significant promises of targeting these histone methylation-modifying enzymes for AML treatment.	[Tsai, C. T.; So, C. W. E.] Kings Coll London, Leukaemia & Stem Cell Biol Grp, Div Canc Studies, Dept Haematol Med,Rayne Inst, Denmark Hill Campus,123 Coldharbour Lane, London SE5 9NU, England	University of London; King's College London	So, CWE (corresponding author), Kings Coll London, Leukaemia & Stem Cell Biol Grp, Div Canc Studies, Dept Haematol Med,Rayne Inst, Denmark Hill Campus,123 Coldharbour Lane, London SE5 9NU, England.	eric.so@kcl.ac.uk	Tsai, Chiou-Tsun/AAO-6782-2021		Bloodwise; Cancer Research UK; Cancer Research UK [16753] Funding Source: researchfish; Medical Research Council [G0800892] Funding Source: researchfish; MRC [G0800892] Funding Source: UKRI	Bloodwise; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We wish to thank Drs Bernd Zeisig and Ngai Cheung in the lab for their useful inputs. This work is supported by Bloodwise and Cancer Research UK.	Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Chang MJ, 2010, CANCER RES, V70, P10234, DOI 10.1158/0008-5472.CAN-10-3294; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen M, 2015, GENE DEV, V29, P2123, DOI 10.1101/gad.267278.115; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Cheung N, 2016, CANCER CELL, V29, P32, DOI 10.1016/j.ccell.2015.12.007; Cheung N, 2011, FEBS LETT, V585, P2100, DOI 10.1016/j.febslet.2011.03.068; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Danis E, 2015, EXP HEMATOL, V43, P930, DOI 10.1016/j.exphem.2015.06.005; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deshpande AJ, 2013, BLOOD, V121, P2533, DOI 10.1182/blood-2012-11-465120; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Fung TK, 2013, ONCOTARGET, V4, P1128, DOI 10.18632/oncotarget.1244; Gahr M, 2013, EUR NEUROPSYCHOPHARM, V23, P1364, DOI 10.1016/j.euroneuro.2013.05.009; Garcia-Manero G, 2012, J CLIN ONCOL, V30, P2204, DOI 10.1200/JCO.2011.38.3265; Greenblatt SM, 2014, LEUKEMIA, V28, P1396, DOI 10.1038/leu.2014.94; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Hou HA, 2012, BLOOD, V119, P559, DOI 10.1182/blood-2011-07-369934; Huls G, 2015, BLOOD, V126, P283, DOI 10.1182/blood-2015-06-648071; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kronke J, 2013, BLOOD, V122, P100, DOI 10.1182/blood-2013-01-479188; Labbe RM, 2014, AM J TRANSL RES, V6, P1; Lau PNI, 2016, TRANSL EPIGENET SER, P63, DOI 10.1016/B978-0-12-799958-6.00004-4; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Mochizuki-Kashio M, 2015, BLOOD, V126, P1172, DOI 10.1182/blood-2015-03-634428; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Pratcorona M, 2012, HAEMATOL-HEMATOL J, V97, P388, DOI 10.3324/haematol.2011.051532; Puda A, 2012, AM J HEMATOL, V87, P245, DOI 10.1002/ajh.22257; Quintas-Cardama A, 2011, LEUKEMIA, V25, P226, DOI 10.1038/leu.2010.276; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Sahtoe DD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10292; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Sroczynska P, 2014, BLOOD, V123, P1870, DOI 10.1182/blood-2013-08-522094; Wong SHK, 2015, CANCER CELL, V28, P198, DOI 10.1016/j.ccell.2015.06.003; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Zeisig BB, 2016, CHROMOSOMAL TRANSLOC, P223; Zeisig BB, 2008, CANCER CELL, V14, P345, DOI 10.1016/j.ccr.2008.10.008; Zeisig Bernd B, 2012, Cancer Cell, V22, P698, DOI 10.1016/j.ccr.2012.10.017; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827; Zhu N, 2016, J CLIN INVEST, V126, P997, DOI 10.1172/JCI82978; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	74	30	32	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1753	1759		10.1038/onc.2016.315	http://dx.doi.org/10.1038/onc.2016.315			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27593928	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000398128900001
J	Stirzaker, C; Song, JZ; Ng, W; Du, Q; Armstrong, NJ; Locke, WJ; Statham, AL; French, H; Pidsley, R; Valdes-Mora, F; Zotenko, E; Clark, SJ				Stirzaker, C.; Song, J. Z.; Ng, W.; Du, Q.; Armstrong, N. J.; Locke, W. J.; Statham, A. L.; French, H.; Pidsley, R.; Valdes-Mora, F.; Zotenko, E.; Clark, S. J.			Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DOMAIN PROTEIN-2; X-CHROMOSOME; CHROMATIN; PROMOTER; HYPERMETHYLATION; REPRESSION; COMPLEX; ASSOCIATION; EXPRESSION	Cancer is characterised by DNA hypermethylation and gene silencing of CpG island-associated promoters, including tumoursuppressor genes. The methyl-CpG-binding domain (MBD) family of proteins bind to methylated DNA and can aid in the mediation of gene silencing through interaction with histone deacetylases and histone methyltransferases. However, the mechanisms responsible for eliciting CpG island hypermethylation in cancer, and the potential role that MBD proteins play in modulation of the methylome remain unclear. Our previous work demonstrated that MBD2 preferentially binds to the hypermethylated GSTP1 promoter CpG island in prostate cancer cells. Here, we use functional genetic approaches to investigate if MBD2 plays an active role in reshaping the DNA methylation landscape at this locus and genome-wide. First, we show that loss of MBD2 results in inhibition of both maintenance and spread of de novo methylation of a transfected construct containing the GSTP1 promoter CpG island in prostate cancer cells and Mbd2(-/-) mouse fibroblasts. De novo methylation was rescued by transient expression of Mbd2 in Mbd2(-/-) cells. Second, we show that MBD2 depletion triggers significant hypomethylation genome-wide in prostate cancer cells with concomitant loss of MBD2 binding at promoter and enhancer regulatory regions. Finally, CpG islands and shores that become hypomethylated after MBD2 depletion in LNCaP cancer cells show significant hypermethylation in clinical prostate cancer samples, highlighting a potential active role of MBD2 in promoting cancer-specific hypermethylation. Importantly, co-immunoprecipiation of MBD2 shows that MBD2 associates with DNA methyltransferase enzymes 1 and 3A. Together our results demonstrate that MBD2 has a critical role in `rewriting' the cancer methylome at specific regulatory regions.	[Stirzaker, C.; Song, J. Z.; Ng, W.; Du, Q.; Locke, W. J.; Statham, A. L.; French, H.; Pidsley, R.; Valdes-Mora, F.; Zotenko, E.; Clark, S. J.] Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, Sydney, NSW, Australia; [Stirzaker, C.; Clark, S. J.] Univ NSW, St Vincents Clin Sch, Sydney, NSW, Australia; [Armstrong, N. J.] Murdoch Univ, SEIT, Math & Stat, Murdoch, WA, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Murdoch University	Clark, SJ (corresponding author), Garvan Inst Med Res, Genom & Epigenet Div, 384 Victoria St, Sydney, NSW 2010, Australia.	s.clark@garvan.org.au	Mora, Fatima Valdes/AAB-9728-2021; Armstrong, Nicola J./AAF-3045-2021; Locke, Warwick/G-3152-2017; Clark, Susan J/B-2272-2008; French, Hugh/L-7817-2014	Mora, Fatima Valdes/0000-0001-7490-0114; Armstrong, Nicola J./0000-0002-4477-293X; Locke, Warwick/0000-0002-9281-0363; Clark, Susan J/0000-0001-5925-5030; Stirzaker, Clare/0000-0001-5601-3140; Pidsley, Ruth/0000-0002-1386-1374; Du, Qian/0000-0003-3393-681X; French, Hugh/0000-0001-7464-6929	National Health and Medical Research Council project grants [1029584, 1088144]; NHMRC Fellowship [1063559]	National Health and Medical Research Council project grants; NHMRC Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	We thank Brigid O'Gorman for preparation of figures and reviewing the manuscript. Mouse fibroblast Mbd2 - / - and wild-type cells were gratefully received as a gift from Adrian Bird. The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We thank the Ramaciotti Centre, University of New South Wales (Sydney, Australia) for conducting the Affymetrix array experiments and the Australian Genome Research Facility for the HM450K arrays. This work is supported by National Health and Medical Research Council project grants (1029584 and 1088144) and NHMRC Fellowship to SJC (1063559) The contents of the published material are solely the responsibility of the administering institution and individual authors and do not reflect the views of the NHMRC.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; Barr H, 2007, MOL CELL BIOL, V27, P3750, DOI 10.1128/MCB.02204-06; Baubec T, 2014, CURR OPIN GENET DEV, V25, P85, DOI 10.1016/j.gde.2013.11.015; Baubec T, 2013, CELL, V153, P480, DOI 10.1016/j.cell.2013.03.011; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Chatagnon A, 2011, EPIGENETICS-US, V6, P1295, DOI 10.4161/epi.6.11.17875; Chatagnon A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009665; Chatagnon A, 2009, CARCINOGENESIS, V30, P28, DOI 10.1093/carcin/bgn240; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Du Q, 2015, EPIGENOMICS-UK, V7, P1051, DOI 10.2217/epi.15.39; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Gunther K, 2013, NUCLEIC ACIDS RES, V41, P3010, DOI 10.1093/nar/gkt035; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lopez-Serra L, 2008, ONCOGENE, V27, P3556, DOI 10.1038/sj.onc.1211022; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Menafra R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099603; Mian OY, 2011, MOL CANCER RES, V9, P1152, DOI 10.1158/1541-7786.MCR-11-0252; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Stirzaker C, 2014, TRENDS GENET, V30, P75, DOI 10.1016/j.tig.2013.11.004; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang LQ, 2013, MOL CELL BIOL, V33, P4106, DOI 10.1128/MCB.00144-13; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	55	40	44	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1328	1338		10.1038/onc.2016.297	http://dx.doi.org/10.1038/onc.2016.297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593931				2022-12-28	WOS:000395862500002
J	Izrailit, J; Jaiswal, A; Zheng, W; Moran, MF; Reedijk, M				Izrailit, J.; Jaiswal, A.; Zheng, W.; Moran, M. F.; Reedijk, M.			Cellular stress induces TRB3/USP9x-dependent Notch activation in cancer	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; BREAST-CANCER; POOR-PROGNOSIS; BETA-CATENIN; MIND BOMB; ER STRESS; TRB3; PROTEIN; ENDOCYTOSIS; DEGRADATION	Expression of the Notch ligand JAG1 and Notch pathway activation promote poor prognosis, basal-like breast cancer. We have recently shown that the pseudokinase Tribbles homolog 3 (TRB3) regulates JAG1 expression in this malignancy. TRB3 is a stress and metabolic sensor, and here we show that nutrient deprivation or endoplasmic reticulum stress markedly upregulate TRB3, which serves as a scaffold for the deubiquitinase USP9x. USP9x in turn stimulates JAG1 activity through two mechanisms: (1) through TRB3 deubiquitination and stabilization, and (2) through deubiquitination and activation of Mind Bomb 1, an E3 ligase required for JAG1 ubiquitination-mediated endocytosis and Notch activation. These USP9x activities are confined to the signal-sending cell of a cell pair undergoing Notch signaling. We demonstrate that USP9x is required for TRB3 upregulation and Notch activation in response to cellular stress in basal-like breast cancer cells. These data suggest that TRB3 functions as a sensor of tumor microenvironmental stress and together with USP9x induces the cell survival and tumor-promoting activities of Notch. These findings identify a novel mechanism by which cancer cells survive in their hostile environment and provide potential therapeutic targets in breast cancer.	[Izrailit, J.; Jaiswal, A.; Zheng, W.; Reedijk, M.] Ontario Canc Inst, Campbell Family Inst Canc Res, Toronto, ON, Canada; [Izrailit, J.; Jaiswal, A.; Reedijk, M.] Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; [Moran, M. F.] Hosp Sick Children, Program Mol Struct & Funct, Toronto, ON, Canada; [Moran, M. F.] Univ Toronto, Dept Med Genet, Toronto, ON, Canada; [Reedijk, M.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 3-130, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Reedijk, M (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 3-130, Toronto, ON M5G 2M9, Canada.	michael.reedijk@uhn.ca	Moran, Michael/GYD-3631-2022		Canadian Breast Cancer Foundation; Ontario Ministry of Health and Long Term Care	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	This study was supported by funds to MR from the Canadian Breast Cancer Foundation. This research was funded in part by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC. We thank J Tong for technical support, and B Martin and P Taylor for bioinformatic support.	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Choe EA, 2007, J NEUROSCI, V27, P9503, DOI 10.1523/JNEUROSCI.1408-07.2007; Dobens LL, 2012, DEV DYNAM, V241, P1239, DOI 10.1002/dvdy.23822; Du KY, 2009, MOL ENDOCRINOL, V23, P475, DOI 10.1210/me.2008-0284; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Hansson EM, 2010, J CELL SCI, V123, P2931, DOI 10.1242/jcs.073239; Harris DR, 2012, CANCER BIOL THER, V13, P1319, DOI 10.4161/cbt.21792; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Irshad K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118201; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koritzinsky M, 2013, J CELL BIOL, V203, P615, DOI 10.1083/jcb.201307185; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Li D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00254; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Lohan F, 2013, BIOCHEM SOC T, V41, P1096, DOI 10.1042/BST20130105; Meloty-Kapella L, 2012, DEV CELL, V22, P1299, DOI 10.1016/j.devcel.2012.04.005; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Murray RZ, 2004, MOL BIOL CELL, V15, P1591, DOI 10.1091/mbc.E03-08-0630; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Nichols JT, 2007, J CELL BIOL, V176, P445, DOI 10.1083/jcb.200609014; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ord D, 2007, EXP CELL RES, V313, P3556, DOI 10.1016/j.yexcr.2007.07.017; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ohoka N, 2010, BIOCHEM BIOPH RES CO, V392, P289, DOI 10.1016/j.bbrc.2009.12.175; Ossipova O, 2009, DEV CELL, V17, P222, DOI 10.1016/j.devcel.2009.06.010; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; Pal A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0461-3; Parks AL, 2000, DEVELOPMENT, V127, P1373; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Tong JF, 2014, MOL CELL PROTEOMICS, V13, P1644, DOI 10.1074/mcp.M114.038596; Tseng LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093394; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Wang Y, 2015, J THORAC DIS, V7, P672, DOI 10.3978/j.issn.2072-1439.2015.04.28; Weinmaster G, 2011, DEV CELL, V21, P134, DOI 10.1016/j.devcel.2011.06.006; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Xie Y, 2013, J BIOL CHEM, V288, P2976, DOI 10.1074/jbc.M112.430066; Zhou M, 2015, BIOCHEM BIOPH RES CO, V459, P333, DOI 10.1016/j.bbrc.2015.02.115; Zhou Y, 2008, CELL SIGNAL, V20, P942, DOI 10.1016/j.cellsig.2008.01.010	50	36	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1048	1057		10.1038/onc.2016.276	http://dx.doi.org/10.1038/onc.2016.276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593927				2022-12-28	WOS:000395371500003
J	Ki, DH; He, S; Rodig, S; Look, AT				Ki, D. H.; He, S.; Rodig, S.; Look, A. T.			Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX10; NEUROFIBROMATOSIS TYPE-1; SUPPRESSOR GENE; ZEBRAFISH; SENSITIVITY; IMATINIB; CANCER; MUTATIONS; MUTANT; GLIOBLASTOMAS	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, frequently metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited genetic disease in humans. Although loss of the NF1 gene predisposes to MPNST induction, relatively long tumor latency in NF1 patients suggests that additional genetic or epigenetic abnormalities are needed for the development of these nerve sheath malignancies. To study the molecular pathways contributing to the formation of MPNSTs in NF1 patients, we used a zebrafish tumor model defined by nf1 loss in a p53-deficient background together with the overexpression of either wild-type or constitutively activated PDGFRA (platelet-derived growth factor receptor-a) under control of the sox10 neural crest-specific promoter. Here we demonstrate the accelerated onset and increased penetrance of MPNST formation in fish overexpressing both the wild-type and the mutant PDGFRA transgenes in cells of neural crest origin. Interestingly, overexpression of the wild-type PDGFRA was even more potent in promoting transformation than the mutant PDGFRA, which is important because similar to 78% of human MPNSTs have expression of wild-type PDGFRA, whereas only 5% harbor activating mutations of the gene encoding this receptor. Further analysis revealed the induction of cellular senescence in zebrafish embryos overexpressing mutant, but not wild-type, PDGFRA, suggesting a mechanism through which the oncogenic activity of the mutant receptor is tempered by the activation of premature cellular senescence in an NF1-deficient background. Taken together, our study suggests a model in which overexpression of wild-type PDGFRA associated with NF1 deficiency leads to aberrant activation of downstream RAS signaling and thus contributes importantly to MPNST development-a prediction supported by the ability of the kinase inhibitor sunitinib alone and in combination with the MEK inhibitor trametinib to retard MPNST progression in transgenic fish overexpressing the wild-type receptor.	[Ki, D. H.; He, S.; Look, A. T.] Childrens Hosp Boston, Harvard Med School, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA; [Rodig, S.] Brigham & Womens Hosp, Boston, MA USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Look, AT (corresponding author), Childrens Hosp Boston, Harvard Med School, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA.	Thomas_look@dfci.harvard.edu	Rodig, Scott/Y-3889-2019	Ki, Dong Hyuk/0000-0002-1571-7077	Department of Defense [W81XWH-12-1-0125]; Children's Tumor Foundation; NF1 Research Consortium Fund; Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program	Department of Defense(United States Department of Defense); Children's Tumor Foundation; NF1 Research Consortium Fund; Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program	This work was supported by the Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program, a grant from Department of Defense (W81XWH-12-1-0125), a Drug Discovery Initiative Award from the Children's Tumor Foundation and the NF1 Research Consortium Fund. We thank John Gilbert for editorial review and critical comments, and Dr Donna Neuberg for biostatistical advice regarding the sample size, statistical power and most appropriate statistical tests. We are grateful to Hillary Layden and Shawna Chamberlin for their expert assistance with zebrafish husbandry and to Dr Eric Holland for providing the wildtype and mutant PDGFRA cDNAs.	Alexander A, 1998, Front Biosci, V3, pd729; Aoki M, 2007, LAB INVEST, V87, P767, DOI 10.1038/labinvest.3700591; Baker SA, 2013, J PHYSIOL-LONDON, V591, P6193, DOI 10.1113/jphysiol.2013.264747; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clarke ID, 2003, ONCOGENE, V22, P722, DOI 10.1038/sj.onc.1206160; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Demoulin JB, 2012, AM J BLOOD RES, V2, P44; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dutton JR, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-105; Evans DGR, 2011, EUR J HUM GENET, V19, P1187, DOI 10.1038/ejhg.2011.113; Ferrari Andrea, 2007, Paediatr Drugs, V9, P239, DOI 10.2165/00148581-200709040-00005; Fortman BJ, 2001, RADIOGRAPHICS, V21, P601, DOI 10.1148/radiographics.21.3.g01ma05601; Holtkamp N, 2004, ACTA NEUROPATHOL, V107, P159, DOI 10.1007/s00401-003-0797-8; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Keng Vincent W., 2012, Sarcoma, V2012, P620834, DOI 10.1155/2012/620834; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kourea HP, 1998, CANCER, V82, P2191, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2191::AID-CNCR14>3.0.CO;2-P; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Lee JS, 2010, HUM MOL GENET, V19, P4643, DOI 10.1093/hmg/ddq395; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Macdonald R, 1999, METH MOL B, V127, P77, DOI 10.1385/1-59259-678-9:77; Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; Medves S, 2012, J CELL MOL MED, V16, P237, DOI 10.1111/j.1582-4934.2011.01415.x; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Ozawa T, 2010, GENE DEV, V24, P2205, DOI 10.1101/gad.1972310; Perrone F, 2009, NEURO-ONCOLOGY, V11, P725, DOI 10.1215/15228517-2009-003; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Rubin JB, 2005, NAT REV CANCER, V5, P557, DOI 10.1038/nrc1653; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Tao T, 2013, CELL RES, V23, P620, DOI 10.1038/cr.2013.16; Thway K, 2014, ANN DIAGN PATHOL, V18, P109, DOI 10.1016/j.anndiagpath.2013.10.007; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Velghe AI, 2014, ONCOGENE, V33, P2568, DOI 10.1038/onc.2013.218; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wong WW, 1998, INT J RADIAT ONCOL, V42, P351, DOI 10.1016/S0360-3016(98)00223-5; Zietsch J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011858	50	22	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1058	1068		10.1038/onc.2016.269	http://dx.doi.org/10.1038/onc.2016.269			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27477693	Green Published, hybrid			2022-12-28	WOS:000395371500004
J	Blanchart, A; Fernando, R; Haring, M; Assaife-Lopes, N; Romanov, RA; Andang, M; Harkany, T; Ernfors, P				Blanchart, A.; Fernando, R.; Haring, M.; Assaife-Lopes, N.; Romanov, R. A.; Andang, M.; Harkany, T.; Ernfors, P.			Endogenous GAB(AA) receptor activity suppresses glioma growth	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; STEM-CELL; TUMOR PROGRESSION; INITIATING CELLS; SELF-RENEWAL; BRAIN-TUMORS; FACTOR-B; PDGF-B; GLIOBLASTOMA; GABA	Although genome alterations driving glioma by fueling cell malignancy have largely been resolved, less is known of the impact of tumor environment on disease progression. Here, we demonstrate functional GABAA receptor-activated currents in human glioblastoma cells and show the existence of a continuous GABA signaling within the tumor cell mass that significantly affects tumor growth and survival expectancy in mouse models. Endogenous GABA released by tumor cells, attenuates proliferation of the glioma cells with enriched expression of stem/progenitor markers and with competence to seed growth of new tumors. Our results suggest that GABA levels rapidly increase in tumors impeding further growth. Thus, shunting chloride ions by a maintained local GABAA receptor activity within glioma cells has a significant impact on tumor development by attenuating proliferation, reducing tumor growth and prolonging survival, a mechanism that may have important impact on therapy resistance and recurrence following tumor resection.	[Blanchart, A.; Fernando, R.; Haring, M.; Assaife-Lopes, N.; Harkany, T.; Ernfors, P.] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Scheeles VA, S-17177 Stockholm, Sweden; [Romanov, R. A.; Harkany, T.] Med Univ Vienna, Ctr Brain Res, Dept Mol Neurosci, Vienna, Austria; [Andang, M.] Karolinska Inst, Dept Physiol & Pharmacol Biophys Stem Cell & Tiss, Stockholm, Sweden; [Fernando, R.] Hop St Eloi, Inst Neurosci Montpellier, INSERM U1051, BP 74103, Montpellier, France	Karolinska Institutet; Medical University of Vienna; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Scheeles VA, S-17177 Stockholm, Sweden.	patrik.ernfors@ki.se	Romanov, Roman/J-2349-2015; Andäng, Michael/GRE-9898-2022	Romanov, Roman/0000-0002-3937-518X; Harkany, Tibor/0000-0002-6637-5900; Andang, Michael/0000-0002-2886-7891	Wallenberg Foundation; Swedish Research Council for Medicine and Health; Swedish Cancer Society grant; SFO grant; Swedish Brain Foundation; Wallenberg Scholar and Soderberg Foundation; ERC advanced grant [232675]; European Commission FP7 (Marie Curie Actions) [GA-2012-600394]; NovoNordisk Foundation; European Commission FP7 PAINCAGE grant; Alzheimers Research UK [ART-EG2009A-1] Funding Source: researchfish; Novo Nordisk Fonden [NNF14OC0010695, NNF15OC0015964, NNF17OC0027294] Funding Source: researchfish	Wallenberg Foundation(European Commission); Swedish Research Council for Medicine and Health; Swedish Cancer Society grant; SFO grant; Swedish Brain Foundation; Wallenberg Scholar and Soderberg Foundation; ERC advanced grant(European Research Council (ERC)); European Commission FP7 (Marie Curie Actions); NovoNordisk Foundation(Novo Nordisk Foundation); European Commission FP7 PAINCAGE grant; Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Dr Lene Uhrbom for critically reading our manuscript and for kindly providing the Gtv-a/p19ARF WT and KO mice, Dr Jonas Frisen for kindly providing the Nestin: CrexRosa26LacZ and Helena Samuelsson for technical support, the CLICK Imaging Facility supported by the Wallenberg Foundation. This work was supported by the Swedish Research Council for Medicine and Health, the Swedish Cancer Society and SFO grants, the Swedish Brain Foundation, Wallenberg Scholar and Soderberg Foundation. ERC advanced grant (232675). RAR is an EMBO long-term research fellow (ALTF 596-2014) co-funded by the European Commission FP7 (Marie Curie Actions, EMBOCOFUND2012, GA-2012-600394), NovoNordisk Foundation, Swedish Brain Foundation and European Commission FP7 PAINCAGE grant to TH.	Andang M, 2008, NAT PROTOC, V3, P1013, DOI 10.1038/nprot.2008.65; Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barami K, 2009, J CLIN NEUROSCI, V16, P195, DOI 10.1016/j.jocn.2008.03.006; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bleau AM, 2009, CELL CYCLE, V8, P2936; Bolteus AJ, 2004, J NEUROSCI, V24, P7623, DOI 10.1523/JNEUROSCI.1999-04.2004; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carlen M, 2006, EXP CELL RES, V312, P2851, DOI 10.1016/j.yexcr.2006.05.012; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chandra D, 2010, NEUROPSYCHOPHARMACOL, V35, P999, DOI 10.1038/npp.2009.203; CURTIS DR, 1970, NATURE, V228, P676, DOI 10.1038/228676a0; D'Urso PI, 2012, INT J ONCOL, V41, P228, DOI 10.3892/ijo.2012.1420; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Fernando RN, 2011, P NATL ACAD SCI USA, V108, P5837, DOI 10.1073/pnas.1014993108; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jiang YW, 2011, NEOPLASIA, V13, P492, DOI 10.1593/neo.11314; KROGSGAARDLARSEN P, 1979, J NEUROCHEM, V32, P1717, DOI 10.1111/j.1471-4159.1979.tb02284.x; Labrakakis C, 1998, EUR J NEUROSCI, V10, P231, DOI 10.1046/j.1460-9568.1998.00036.x; Lee C, 2012, STEM CELLS, V30, P1064, DOI 10.1002/stem.1081; Li SC, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-41; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; Mares P, 2000, EPILEPSY RES, V42, P183, DOI 10.1016/S0920-1211(00)00179-0; Noble M, 2004, TRENDS NEUROSCI, V27, P148, DOI 10.1016/j.tins.2003.12.007; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Platel JC, 2008, J PHYSIOL-LONDON, V586, P3739, DOI 10.1113/jphysiol.2008.155325; Prestegarden L, 2010, CANCER RES, V70, P4274, DOI 10.1158/0008-5472.CAN-09-3904; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smits A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037041; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Synowitz M, 2001, EUR J NEUROSCI, V14, P1294, DOI 10.1046/j.0953-816x.2001.01764.x; Tchougounova E, 2007, ONCOGENE, V26, P6289, DOI 10.1038/sj.onc.1210455; Terrile M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-550; Ueno S, 1997, J NEUROSCI, V17, P625; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 1998, CANCER RES, V58, P5275; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang DD, 2003, J PHYSIOL-LONDON, V550, P785, DOI 10.1113/jphysiol.2003.042572; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Young SZ, 2009, PHYSIOLOGY, V24, P171, DOI 10.1152/physiol.00002.2009; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	55	37	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					777	786		10.1038/onc.2016.245	http://dx.doi.org/10.1038/onc.2016.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27375015				2022-12-28	WOS:000394168200005
J	Zhang, X; Zhang, L; Du, Y; Zheng, H; Zhang, P; Sun, Y; Wang, Y; Chen, J; Ding, P; Wang, N; Yang, C; Huang, T; Yao, X; Qiao, Q; Gu, H; Cai, G; Cai, S; Zhou, X; Hu, W				Zhang, X.; Zhang, L.; Du, Y.; Zheng, H.; Zhang, P.; Sun, Y.; Wang, Y.; Chen, J.; Ding, P.; Wang, N.; Yang, C.; Huang, T.; Yao, X.; Qiao, Q.; Gu, H.; Cai, G.; Cai, S.; Zhou, X.; Hu, W.			A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer	ONCOGENE			English	Article							FORKHEAD BOX M1; RHO-ASSOCIATED KINASE; COILED-COILS; TARGET; TUMORIGENESIS; TRANSCRIPTION; PROGRESSION; INHIBITION; EXPRESSION; INVASION	Epithelial-mesenchymal transition (EMT) is a critical event in metastasis of colorectal cancer (CRC). Rho/ROCKs signaling has a pivotal role in orchestrating actin cytoskeleton, leading to EMT and cancer invasion. However, the underlying mechanisms for ROCKs activation are not fully understood. Here, we identified FOXM1D, a novel isoform of Forkhead box M1 (FOXM1) that has a pivotal role in ROCKs activation by directly interacting with coiled-coil region of ROCK2. FOXM1D overexpression significantly polymerizes actin assembly and impairs E-cadherin expression, resulting in EMT and metastasis in xenograft mouse model and knockdown of FOXM1D has the opposite effect. Moreover, a high FOXM1D level correlates closely with clinical CRC metastasis. FOXM1D-induced ROCKs activation could be abrogated by the ROCKs inhibitors Y-27632 and fasudil. These observations indicate that the FOXM1D-ROCK2 interaction is crucial for Rho/ROCKs signaling and provide novel insight into actin cytoskeleton regulation and therapeutic potential for CRC metastasis.	[Zhang, X.; Zhang, L.; Du, Y.; Zhang, P.; Sun, Y.; Chen, J.; Ding, P.; Wang, N.; Qiao, Q.; Gu, H.; Hu, W.] Fudan Univ, Shanghai Canc Ctr, Collaborat Innovat Ctr Canc Med, Shanghai Med Coll, Shanghai, Peoples R China; [Zhang, X.; Zhang, L.; Du, Y.; Zhang, P.; Sun, Y.; Chen, J.; Ding, P.; Wang, N.; Qiao, Q.; Gu, H.; Hu, W.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Zheng, H.; Wang, Y.; Cai, G.; Cai, S.] Fudan Univ, Shanghai Med Coll, Dept Colorectal Surg, Shanghai, Peoples R China; [Yang, C.; Zhou, X.] Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China; [Huang, T.; Yao, X.] Shanghai Tenth Peoples Hosp, Dept Urol, Shanghai, Peoples R China; [Hu, W.] Fudan Univ, Shanghai Med Coll, Dept Immunol, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Naval Medical University; Fudan University	Hu, W (corresponding author), Fudan Univ, Shanghai Canc Ctr, Inst Canc, 270 Dongan Rd, Shanghai 200032, Peoples R China.	weiguohu@fudan.edu.cn	Zhang, Long/HCI-5197-2022; Hu, Weiguo/AAP-2239-2021	Hu, Weiguo/0000-0002-7397-6800; Chen, Jianfeng/0000-0002-4182-145X	Major State Basic Research Development Program of China [2013CB910802]; National Natural Science Foundation of China [81171910, 81372258]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	Major State Basic Research Development Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	This research was supported by the Major State Basic Research Development Program of China (2013CB910802), the National Natural Science Foundation of China (81171910, 81372258) and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning to WH. We thank Professor Thomas M Roberts (DFCI, Harvard Medical School) and Professor Hua Lu (Department of Biochemistry and Molecular Biology, Tulane University) for scientific suggestions and critical reading of this manuscript. We are also grateful to Dr Yuhu Xin for assistance with confocal microscopy; to Mrs Ping Zhang for assistance with flow cytometry; to Dr Yi Qin, who provided the pCMV-C-FLAG and pCMV-C-HA plasmids; to Professor Yanhui Xu, who kindly provided the modified pGEX-6P-1 plasmid; and to Professor Shenglin Huang, who provided the p-pLVX-IRES-Neo and pwpxl-eGFP-2A-CBGr99 lentiviral vectors; to Dr Fangning Wan for advices on statistics and revision of manuscript.	Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kim YH, 2014, J FOOD SAFETY, V34, P1, DOI 10.1111/jfs.12088; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liu J, 2008, EURASIP J ADV SIG PR, DOI 10.1155/2008/162587; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Liu PY, 2008, METHOD ENZYMOL, V439, P181, DOI 10.1016/S0076-6879(07)00414-4; Liu X, 2015, FUTURE ONCOL, V11, P2911, DOI 10.2217/fon.15.235; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Park H, 2011, J HIGH ENERGY PHYS, DOI [10.1007/JHEP10(2011)092, 10.1155/2011/485173]; Parry DAD, 2008, J STRUCT BIOL, V163, P258, DOI 10.1016/j.jsb.2008.01.016; Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Shi JW, 2013, CELL CYCLE, V12, P1119, DOI 10.4161/cc.24164; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sun LC, 2011, AM J PATHOL, V179, P380, DOI 10.1016/j.ajpath.2011.03.046; Teh MT, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00146; Tseng William, 2007, J Vis Exp, P484, DOI 10.3791/484; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang Y., 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang C, 2013, CANCER LETT, V340, P104, DOI 10.1016/j.canlet.2013.07.004; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016	42	31	35	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					807	819		10.1038/onc.2016.249	http://dx.doi.org/10.1038/onc.2016.249			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399334	Green Published, hybrid			2022-12-28	WOS:000394168200008
J	Kim, JE; Shin, JS; Moon, JH; Hong, SW; Jung, DJ; Kim, JH; Hwang, IY; Shin, YJ; Gong, EY; Lee, DH; Kim, SM; Lee, EY; Kim, YS; Kim, D; Hur, D; Kim, TW; Kim, KP; Jin, DH; Lee, WJ				Kim, J-E; Shin, J-S; Moon, J-H; Hong, S-W; Jung, D-J; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, Y. S.; Kim, D.; Hur, D.; Kim, T. W.; Kim, K-p; Jin, D-H; Lee, W-J			Foxp3 is a key downstream regulator of p53-mediated cellular senescence	ONCOGENE			English	Article							HUMAN-DIPLOID CELLS; DNA-DAMAGE; REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; ONCOGENIC RAS; MUTANT P53; LIFE-SPAN; CANCER; EXPRESSION	The downstream events and target genes of p53 in the process of senescence are not fully understood. Here, we report a novel function of the forkhead transcription factor Foxp3, which is a key player in mediating T-cell inhibitory functions, in p53-mediated cellular senescence. The overexpression of Foxp3 in mouse embryonic fibroblasts (MEFs) accelerates senescence, whereas Foxp3 knockdown leads to escape from p53-mediated senescence in p53-expressing MEFs. Consistent with these results, Foxp3 expression resulted in the induction of senescence in epithelial cancer cells, including MCF7 and HCT116 cells. Foxp3 overexpression also increased the intracellular levels of reactive oxygen species (ROS). The ROS inhibitor N-acetyl-L-cysteine rescued cells from Foxp3-expression-induced senescence. Furthermore, the elevated ROS levels that accompanied Foxp3 overexpression were paralleled by an increase in p21 expression. Knockdown of p21 in Foxp3-expressing MEFs abrogated the Foxp3-dependent increase in ROS levels, indicating that Foxp3 acts through the induction of p21 and the subsequent ROS elevation to trigger senescence. Collectively, these results suggest that Foxp3 is a downstream target of p53 that is sufficient to induce p21 expression, ROS production and p53-mediated senescence.	[Kim, J-E; Jung, D-J; Lee, W-J] Seoul Natl Univ, Coll Med, Dept Anat, Seoul, South Korea; [Kim, J-E; Jung, D-J; Lee, W-J] Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul, South Korea; [Shin, J-S; Moon, J-H; Hong, S-W; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, T. W.; Kim, K-p; Jin, D-H] Asan Inst Life Sci, Asan Med Ctr, Innovat Canc Res, Seoul, South Korea; [Shin, J-S; Moon, J-H; Hong, S-W; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, T. W.; Kim, K-p; Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea; [Kim, Y. S.; Kim, D.; Hur, D.] Inje Univ, Coll Med, Dept Anat, Busan, South Korea; [Kim, Y. S.; Kim, D.; Hur, D.] Inje Univ, Coll Med, Res Ctr Tumor Immunol, Busan, South Korea; [Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; Inje University; Inje University; University of Ulsan; Asan Medical Center	Kim, KP (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.; Jin, DH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.	kkp1122@amc.seoul.kr; inno183@amc.seoul.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2013R1A1A2013233]; National Research Foundation of Korea (NRF) grant - Korean government (MEST), Seoul, Republic of Korea [NRF-2013R1A2A2A01067394]; Korea Government (Ministry of Education, Science and Technology) [NRF-2010355-000062]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of KoreaNational Research Council for Economics, Humanities & Social Sciences, Republic of Korea); National Research Foundation of Korea (NRF) grant - Korean government (MEST), Seoul, Republic of Korea(National Research Foundation of KoreaMinistry of Education, Science & Technology (MEST), Republic of Korea); Korea Government (Ministry of Education, Science and Technology)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This study was supported by grants from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2013233), and the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2013R1A2A2A01067394), Seoul, Republic of Korea. The National Research Foundation of Korea Grant funded by the Korea Government (Ministry of Education, Science and Technology) (NRF-2010355-000062).	Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Grimmig T, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24521; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Inoue T, 2009, CANCER SCI, V100, P1275, DOI 10.1111/j.1349-7006.2009.01166.x; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kim HJ, 2009, CELLS TISSUES ORGANS, V190, P1, DOI 10.1159/000153041; Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1; Le Bras S, 2006, J CLIN INVEST, V116, P1473, DOI 10.1172/JCI28880; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Ma GF, 2014, BRIT J CANCER, V110, P1552, DOI 10.1038/bjc.2014.47; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x; Winerdal ME, 2011, BJU INT, V108, P1672, DOI 10.1111/j.1464-410X.2010.10020.x; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	36	16	16	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					219	230		10.1038/onc.2016.193	http://dx.doi.org/10.1038/onc.2016.193			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27238838				2022-12-28	WOS:000393938100007
J	Mondal, B; Patil, V; Shwetha, SD; Sravani, K; Hegde, AS; Arivazhagan, A; Santosh, V; Kanduri, M; Somasundaram, K				Mondal, B.; Patil, V.; Shwetha, S. D.; Sravani, K.; Hegde, A. S.; Arivazhagan, A.; Santosh, V.; Kanduri, M.; Somasundaram, K.			Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration	ONCOGENE			English	Article							TGF-BETA; DNA METHYLATION; BINDING-PROTEIN; GLIOBLASTOMA; TEMOZOLOMIDE; ACTIVATION; EXPRESSION; PROTEOGLYCANS; RADIOTHERAPY; SURVIVAL	An integrative functional genomics study of multiple forms of data are vital for discovering molecular drivers of cancer development and progression. Here, we present an integrated genomic strategy utilizing DNA methylation and transcriptome profile data to discover epigenetically regulated genes implicated in cancer development and invasive progression. More specifically, this analysis identified fibromodulin (FMOD) as a glioblastoma (GBM) upregulated gene because of the loss of promoter methylation. Secreted FMOD promotes glioma cell migration through its ability to induce filamentous actin stress fiber formation. Treatment with cytochalasin D, an actin polymerization inhibitor, significantly reduced the FMOD-induced glioma cell migration. Small interfering RNA and small molecule inhibitor-based studies identified that FMOD-induced glioma cell migration is dependent on integrin-FAK-Src-Rho-ROCK signaling pathway. FMOD lacking C-terminus LRR11 domain (Delta FMOD), which does not bind collagen type I, failed to induce integrin and promote glioma cell migration. Further, FMOD-induced integrin activation and migration was abrogated by a 9-mer wild-type peptide from the FMOD C-terminus. However, the same peptide with mutation in two residues essential for FMOD interaction with collagen type I failed to compete with FMOD, thus signifying the importance of collagen type IFMOD interaction in integrin activation. Chromatin immunoprecipitation-PCR experiments revealed that transforming growth factor beta-1 (TGF-beta 1) regulates FMOD expression through epigenetic remodeling of FMOD promoter that involved demethylation and gain of active histone marks with a simultaneous loss of DNMT3A and EZH2 occupancy, but enrichment of Sma- and Mad related protein-2 (SMAD2) and CBP. FMOD silencing inhibited the TGF-beta 1-mediated glioma cell migration significantly. In univariate and multivariate Cox regression analysis, both FMOD promoter methylation and transcript levels predicted prognosis in GBM. Thus, this study identified several epigenetically regulated alterations responsible for cancer development and progression. Specifically, we found that secreted FMOD as an important regulator of glioma cell migration downstream of TGF-beta 1 pathway and forms a potential basis for therapeutic intervention in GBM.	[Mondal, B.; Patil, V.; Somasundaram, K.] Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India; [Shwetha, S. D.; Sravani, K.; Santosh, V.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India; [Hegde, A. S.] Sri Satya Sai Inst Higher Med Sci, Dept Neurosurg, Bangalore, Karnataka, India; [Arivazhagan, A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India; [Kanduri, M.] Sahlgrens Univ Hosp, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden	Indian Institute of Science (IISC) - Bangalore; National Institute of Mental Health & Neurosciences - India; National Institute of Mental Health & Neurosciences - India; Sahlgrenska University Hospital	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	kanduri, meena/AAG-1813-2019; KANDURI, MEENA/AAI-6169-2021	KANDURI, MEENA/0000-0003-2781-4779; Mondal, Baisakhi/0000-0002-8171-4333	DBT, Government of India; IISc	DBT, Government of India(Department of Biotechnology (DBT) India); IISc	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas (TCGA) pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions, which constitute the TCGA research network, can be found at http://cancergenome.nih.gov/. The use of data sets from Institute NC and GSE22866 is acknowledged. IISc NGS facility is acknowledged for methylation and microarray experiments. KS thanks DBT, Government of India for financial support. KS is a JC Bose Fellow of the Department of Science and Technology. BM acknowledges IISc for the fellowship.	Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Beiko J, 2014, NEURO-ONCOLOGY, V16, P81, DOI 10.1093/neuonc/not159; Bevilacqua MA, 2005, J BIOL CHEM, V280, P31809, DOI 10.1074/jbc.M414677200; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Chopra S, 2015, EXP CELL RES, V334, P246, DOI 10.1016/j.yexcr.2015.03.001; Choudhury A, 2010, BRIT J HAEMATOL, V151, P327, DOI 10.1111/j.1365-2141.2010.08362.x; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Fernandez AF, 2012, TRENDS GENET, V28, P474, DOI 10.1016/j.tig.2012.05.006; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Ortuno MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612; Kalamajski S, 2007, J BIOL CHEM, V282, P26740, DOI 10.1074/jbc.M704026200; Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001; Lin LC, 2014, CLIN EXP METASTAS, V31, P881, DOI 10.1007/s10585-014-9677-y; Lu Y, 2011, ONCOL REP, V25, P1329, DOI 10.3892/or.2011.1195; Luo XR, 2008, J IMMUNOL, V180, P2757, DOI 10.4049/jimmunol.180.5.2757; Mayr C, 2005, BLOOD, V105, P1566, DOI 10.1182/blood-2004-04-1233; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oldberg A, 2007, P NATL ACAD SCI USA, V104, P13966, DOI 10.1073/pnas.0702014104; Pan XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060335; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Scherer HJ, 1940, J NEUROL PSYCHIATRY, V3, P147, DOI 10.1136/jnnp.3.2.147; Shukla S, 2014, CURR SCI INDIA, V107, P815; Shukla S, 2013, CANCER RES, V73, P6563, DOI 10.1158/0008-5472.CAN-13-0298; Srinivasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017438; Stricker J, 2010, J BIOMECH, V43, P9, DOI 10.1016/j.jbiomech.2009.09.003; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vega FM, 2007, CELL, V129, P1430, DOI 10.1016/j.cell.2007.06.021; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Zheng Z, 2011, J INVEST DERMATOL, V131, P769, DOI 10.1038/jid.2010.381	49	24	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					71	83		10.1038/onc.2016.176	http://dx.doi.org/10.1038/onc.2016.176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212030				2022-12-28	WOS:000394069100007
J	Obinata, D; Takayama, K; Fujiwara, K; Suzuki, T; Tsutsumi, S; Fukuda, N; Nagase, H; Fujimura, T; Urano, T; Homma, Y; Aburatani, H; Takahashi, S; Inoue, S				Obinata, D.; Takayama, K.; Fujiwara, K.; Suzuki, T.; Tsutsumi, S.; Fukuda, N.; Nagase, H.; Fujimura, T.; Urano, T.; Homma, Y.; Aburatani, H.; Takahashi, S.; Inoue, S.			Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth	ONCOGENE			English	Article							PYRROLE-IMIDAZOLE POLYAMIDE; ACYL-COA SYNTHETASE-5; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DNA; PROGRESSION; IDENTIFICATION; SUPPRESSION; RECOGNITION; NETWORK	Androgen receptor (AR) functions as a ligand-dependent transcription factor to regulate its downstream signaling for prostate cancer progression. AR complex formation by multiple transcription factors is important for enhancer activity and transcriptional regulation. However, the significance of such collaborative transcription factors has not been fully understood. In this study, we show that Oct1, an AR collaborative factor, coordinates genome-wide AR signaling for prostate cancer growth. Using global analysis by chromatin immunoprecipitation sequencing (ChIP-seq), we found that Oct1 is recruited to AR-binding enhancer/promoter regions and facilitates androgen signaling. Moreover, a major target of AR/Oct1 complex, acyl-CoA synthetase 3 (ACSL3), contributes to tumor growth in nude mice, and its high expression is associated with poor prognosis in prostate cancer patients. Next, we examined the therapeutic effects of pyrrole-imidazole polyamides that target the Oct1-binding sequence identified in the center of the ACSL3 AR-binding site. We observed that treatment with Oct1 polyamide severely blocked the Oct1 binding at the ACSL3 enhancer responsible for its transcriptional activity and ACSL3 induction. In addition, Oct1 polyamides suppressed castration-resistant tumor growth and specifically repressed global Oct1 chromatin association and androgen signaling in prostate cancer cells, with few nonspecific effects on basal promoter activity. Thus, targeting Oct1 binding could be a novel therapeutic strategy for AR-activated castration-resistant prostate cancer.	[Obinata, D.; Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Tokyo, Japan; [Obinata, D.; Takahashi, S.] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; [Takayama, K.; Inoue, S.] Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontr, Tokyo, Japan; [Fujiwara, K.] Nihon Univ, Sch Med, Dept Med, Div Gen Med, Tokyo, Japan; [Suzuki, T.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi, Japan; [Tsutsumi, S.; Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Tokyo, Japan; [Fukuda, N.] Nihon Univ, Sch Med, Dept Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan; [Nagase, H.] Chiba Canc Ctr, Res Inst, Lab Canc Genet, Chiba, Japan; [Fujimura, T.; Homma, Y.] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; [Inoue, S.] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan	University of Tokyo; Nihon University; University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Nihon University; Tohoku University; University of Tokyo; Nihon University; Chiba Cancer Center; University of Tokyo; Saitama Medical University	Inoue, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Bunkyo Ku, Tokyo 1138655, Japan.	sinoue@tmig.or.jp	Urano, Tomohiko/AFS-9574-2022; Takayama, Kenichi/AAK-9238-2020	Fukuda, Noboru/0000-0003-0098-054X; Nagase, Hiroki/0000-0002-3992-5399	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Society for the Promotion of Science (JSPS), Japan [15K15353, 15K15581, 25293214, 15K10610]; MHLW, Japan; Nihon University Medical Alumni Association; Japanese Urological Association; Advanced Research for Medical Products Mining Program, NIBIO, Japan; Takeda Science Foundation; Mochida Memorial Research Foundation, Japan; Grants-in-Aid for Scientific Research [25112001, 16K09796] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW, Japan; Nihon University Medical Alumni Association; Japanese Urological Association(Japanese Urological Association); Advanced Research for Medical Products Mining Program, NIBIO, Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Research Foundation, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank N Sasaki, T Oishi, S Takada, A Ito and E Sakamoto for technical assistance. This work was supported by grants of the Cell Innovation Program (SI) and P-Direct (SI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; by Grants-in-Aid for SI (no. 15K15353), KT (no. 15K15581), TU (no. 25293214) and ST (no. 15K10610) from the Japan Society for the Promotion of Science (JSPS), Japan; by Grants-in-Aid (SI) from the MHLW, Japan; by the 2010 Research Grant of the 60th Anniversary Memorial Fund (DO) from Nihon University Medical Alumni Association; by the Young Researcher Promotion Grant (DO) from The Japanese Urological Association; by the Advanced Research for Medical Products Mining Program (SI), NIBIO, Japan; by grants from Takeda Science Foundation (SI and KT), by a grant from Mochida Memorial Research Foundation (KT), Japan.	Attard G, 2008, BRIT J CANCER, V99, P314, DOI 10.1038/sj.bjc.6604472; Barfeld SJ, 2014, ENDOCR-RELAT CANCER, V21, pT57, DOI 10.1530/ERC-13-0515; Bu SY, 2009, J BIOL CHEM, V284, P30474, DOI 10.1074/jbc.M109.036665; Chang YS, 2011, J CELL BIOCHEM, V112, P881, DOI 10.1002/jcb.22996; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2; Dervan PB, 2001, BIOORGAN MED CHEM, V9, P2215, DOI 10.1016/S0968-0896(01)00262-0; Fujimoto Y, 2007, J LIPID RES, V48, P1280, DOI 10.1194/jlr.M700050-JLR200; Gassler N, 2005, J PATHOL, V207, P295, DOI 10.1002/path.1831; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Jariwala U, 2009, PROSTATE, V69, P392, DOI 10.1002/pros.20893; Jin Y, 2015, EMBO MOL MED, V7, P315, DOI 10.15252/emmm.201404181; Kim JY, 2014, MOL CELL, V54, P613, DOI 10.1016/j.molcel.2014.03.043; Maloberti PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015540; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda H, 2011, KIDNEY INT, V79, P46, DOI 10.1038/ki.2010.330; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Minekura H, 2001, GENE, V278, P185, DOI 10.1016/S0378-1119(01)00714-4; Monaco ME, 2010, TRANSL ONCOL, V3, P91, DOI 10.1593/tlo.09202; Murty MSRC, 2004, BIOL PHARM BULL, V27, P468, DOI 10.1248/bpb.27.468; Nagashima T, 2009, BIOL PHARM BULL, V32, P921, DOI 10.1248/bpb.32.921; Nickols NG, 2007, P NATL ACAD SCI USA, V104, P10418, DOI 10.1073/pnas.0704217104; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Raskatov JA, 2012, P NATL ACAD SCI USA, V109, P16041, DOI 10.1073/pnas.1214267109; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama K, 2015, ONCOTARGET, V6, P2263, DOI 10.18632/oncotarget.2949; Takayama K, 2014, MOL ENDOCRINOL, V28, P2012, DOI 10.1210/me.2014-1171; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tan PY, 2012, MOL CELL BIOL, V32, P399, DOI 10.1128/MCB.05958-11; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang XF, 2010, CANCER SCI, V101, P759, DOI 10.1111/j.1349-7006.2009.01435.x; Wu MH, 2011, INT J MOL MED, V27, P655, DOI 10.3892/ijmm.2011.624; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Yang F, 2013, P NATL ACAD SCI USA, V110, P1863, DOI 10.1073/pnas.1222035110; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158	47	29	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6350	6358		10.1038/onc.2016.171	http://dx.doi.org/10.1038/onc.2016.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270436				2022-12-28	WOS:000390247000008
J	Miller, A; McLeod, L; Alhayyani, S; Szczepny, A; Watkins, DN; Chen, W; Enriori, P; Ferlin, W; Ruwanpura, S; Jenkins, BJ				Miller, A.; McLeod, L.; Alhayyani, S.; Szczepny, A.; Watkins, D. N.; Chen, W.; Enriori, P.; Ferlin, W.; Ruwanpura, S.; Jenkins, B. J.			Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma	ONCOGENE			English	Article							WEIGHT-LOSS; RECEPTOR ANTIBODY; CANCER; INTERLEUKIN-6; PROGRESSION; SURVIVAL; STAT3	Lung cancer is the leading cause of cancer death worldwide, and is frequently associated with the devastating paraneoplastic syndrome of cachexia. The potent immunomodulatory cytokine interleukin (IL)-6 has been linked with the development of lung cancer as well as cachexia; however, the mechanisms by which IL-6 promotes muscle wasting in lung cancer cachexia are ill-defined. In this study, we report that the gp130(F/F) knock-in mouse model displaying hyperactivation of the latent transcription factor STAT3 via the common IL-6 cytokine family signalling receptor, gp130, develops cachexia during Kras-driven lung carcinogenesis. Specifically, exacerbated weight loss, early mortality and reduced muscle and adipose tissue mass were features of the gp130(F/F): Kras(G12D) model, but not parental Kras(G12D) mice in which STAT3 was not hyperactivated. Gene expression profiling of muscle tissue in cachectic gp130(F/F): Kras(G12D) mice revealed the upregulation of IL-6 and STAT3-target genes compared with Kras(G12D) muscle tissue. These cachectic features of gp130(F/F): Kras(G12D) mice were abrogated upon the genetic normalization of STAT3 activation or ablation of IL-6 in gp130(F/F): Kras(G12D): Stat3(-/+) or gp130(F/F): Kras(G12D): Il6(-/-)mice, respectively. Furthermore, protein levels of the soluble IL-6 receptor (sIL-6R), which is the central facilitator of IL-6 trans-signalling, were elevated in cachectic muscle from gp130(F/F): Kras(G12D) mice, and the specific blockade of IL-6 trans-signalling, but not classical signalling, with an anti-IL-6R antibody ameliorated cachexia-related characteristics in gp130(F/F): Kras(G12D) mice. Collectively, these preclinical findings identify transsignalling via STAT3 as the signalling modality by which IL-6 promotes muscle wasting in lung cancer cachexia, and therefore support the clinical evaluation of the IL-6 trans-signalling/STAT3 axis as a therapeutic target in advanced lung cancer patients presenting with cachexia.	[Miller, A.; McLeod, L.; Alhayyani, S.; Szczepny, A.; Watkins, D. N.; Ruwanpura, S.; Jenkins, B. J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Miller, A.] Monash Hlth, Monash Med Ctr, Gen & Resp Med, Clayton, Vic, Australia; [McLeod, L.; Alhayyani, S.; Szczepny, A.; Ruwanpura, S.; Jenkins, B. J.] Monash Univ, Dept Mol Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Alhayyani, S.] King Abdulaziz Univ, Dept Biol Sci, Rabigh Coll Sci & Art, Jeddah, Saudi Arabia; [Watkins, D. N.] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Chen, W.; Enriori, P.] Monash Univ, Dept Physiol, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Ferlin, W.] NovImmune SA, Geneva, Switzerland	Hudson Institute of Medical Research; Monash University; Monash University; King Abdulaziz University; Garvan Institute of Medical Research; Monash University; NovImmune SA	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	brendan.jenkins@hudson.org.au	Alhayyani/AAR-7025-2020; Miller, Alistair/AAE-8766-2022	Miller, Alistair/0000-0002-0439-9747; Ruwanpura, saleela/0000-0002-4074-2012; Jenkins, Brendan/0000-0002-7552-4656	National Health and Medical Research Council (NHMRC) of Australia; Lung Cancer Research Foundation; NHMRC; Victorian Government of Australia	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Lung Cancer Research Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government of Australia	This work was supported by grants awarded by the National Health and Medical Research Council (NHMRC) of Australia and the Lung Cancer Research Foundation, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. SMR is supported by a NHMRC Post-doctoral Training Fellowship. BJJ is supported by a NHMRC Senior Medical Research Fellowship.	Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436; Ando K, 2013, J CLIN ONCOL, V31, pE69, DOI 10.1200/JCO.2012.44.2020; Angevin E, 2014, CLIN CANCER RES, V20, P2192, DOI 10.1158/1078-0432.CCR-13-2200; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007; Bayliss TJ, 2011, EXPERT OPIN BIOL TH, V11, P1663, DOI 10.1517/14712598.2011.627850; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Bonetto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022538; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Del Ferraro C, 2012, J HOSP PALLIAT NURS, V14, P397, DOI 10.1097/NJH.0b013e31825f3470; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001; Gilabert M, 2014, J CELL PHYSIOL, V229, P1437, DOI 10.1002/jcp.24580; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Lacroix M, 2015, J BIOL CHEM, V290, P26943, DOI 10.1074/jbc.M115.682138; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Lissilaa R, 2010, J IMMUNOL, V185, P5512, DOI 10.4049/jimmunol.1002015; OHE Y, 1993, BRIT J CANCER, V67, P939, DOI 10.1038/bjc.1993.174; Puppa MJ, 2014, FASEB J, V28, P998, DOI 10.1096/fj.13-240580; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Ross PJ, 2004, BRIT J CANCER, V90, P1905, DOI 10.1038/sj.bjc.6601781; Ruwanpura SM, 2012, AM J PHYSIOL-LUNG C, V302, P1627, DOI 10.1152/ajplung.00285.2011; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Scott HR, 1996, BRIT J CANCER, V73, P1560, DOI 10.1038/bjc.1996.294; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Songur N, 2004, TUMORI J, V90, P196, DOI 10.1177/030089160409000207; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Tan BHL, 2011, J GENET, V90, P165, DOI 10.1007/s12041-011-0027-4; Tsujinaka T, 1996, J CLIN INVEST, V97, P244, DOI 10.1172/JCI118398; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; VANDENBREKEL AJS, 1995, J CLIN ONCOL, V13, P2600, DOI 10.1200/JCO.1995.13.10.2600; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	36	54	55	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3059	3066		10.1038/onc.2016.437	http://dx.doi.org/10.1038/onc.2016.437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27893707				2022-12-28	WOS:000402000400013
J	Wijetunga, NA; Pascual, M; Tozour, J; Delahaye, F; Alani, M; Adeyeye, M; Wolkoff, AW; Verma, A; Greally, JM				Wijetunga, N. A.; Pascual, M.; Tozour, J.; Delahaye, F.; Alani, M.; Adeyeye, M.; Wolkoff, A. W.; Verma, A.; Greally, J. M.			A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets	ONCOGENE			English	Article							HEPATITIS-C VIRUS; ENDOPLASMIC-RETICULUM STRESS; TUMOR-SUPPRESSOR GENES; SMALL MAF PROTEINS; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; HUMAN GENOME; MESENCHYMAL TRANSITION; ABERRANT METHYLATION; MOLECULAR SIGNATURE	The predisposition of patients with Hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) involves components of viral infection, inflammation and time. The development of multifocal, genetically distinct tumours is suggestive of a field defect affecting the entire liver. The molecular susceptibility mediating such a field defect is not understood. One potential mediator of long-term cellular reprogramming is heritable (epigenetic) regulation of transcription, exemplified by DNA methylation. We studied epigenetic and transcriptional changes in HCV-infected livers in comparison with control, uninfected livers and HCC, allowing us to identify pre-neoplastic epigenetic and transcriptional events. We find the HCV-infected liver to have a pattern of acquisition of DNA methylation targeted to candidate enhancers active in liver cells, enriched for the binding sites of the FOXA1, FOXA2 and HNF4A transcription factors. These enhancers can be subdivided into those proximal to genes implicated in liver cancer or to genes involved in stem cell development, the latter distinguished by increased CG dinucleotide density and polycomb-mediated repression, manifested by the additional acquisition of histone H3 lysine 27 trimethylation (H3K27me3). Transcriptional studies on our samples showed that the increased DNA methylation at enhancers was associated with decreased local gene expression, results validated in independent samples from The Cancer Genome Atlas. Pharmacological depletion of H3K27me3 using the EZH2 inhibitor GSK343 in HepG2 cells suppressed cell growth and also revealed that local acquired DNA methylation was not dependent upon the presence of polycomb-mediated repression. The results support a model of HCV infection influencing the binding of transcription factors to cognate sites in the genome, with consequent local acquisition of DNA methylation, and the added repressive influence of polycomb at a subset of CG-dense cis-regulatory sequences. These epigenetic events occur before neoplastic transformation, resulting in what may be a pharmacologically reversible epigenetic field defect in HCV-infected liver.	[Wijetunga, N. A.; Pascual, M.; Tozour, J.; Adeyeye, M.; Greally, J. M.] Dept Genet, Bronx, NY USA; [Wijetunga, N. A.; Pascual, M.; Tozour, J.; Adeyeye, M.; Greally, J. M.] Ctr Epigen, Bronx, NY USA; [Pascual, M.] IDISNA, Oncohematol Dept, CIMA, Pamplona, Spain; [Delahaye, F.] Dept Obstet Gynecol & Womens Hlth, Bronx, NY USA; [Alani, M.; Wolkoff, A. W.] Dept Med, Div Gastroenterol & Liver Dis, Bronx, NY USA; [Alani, M.; Wolkoff, A. W.] Marion Bessin Liver Res Ctr, Bronx, NY USA; [Verma, A.] Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Greally, JM (corresponding author), Albert Einstein Coll Med, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	john.greally@einstein.yu.edu	Pascual, Marién/F-6661-2013; Greally, John/AAF-9540-2019	Pascual, Marién/0000-0002-1678-1054; Greally, John/0000-0001-6069-7960; Delahaye, Fabien/0000-0002-9921-8653; Adeyeye, Mary/0000-0003-4900-2237	NIH [30 DK041296]; MSTP program at Albert Einstein College of Medicine [NIH T32 GM007288]; Sara Borrell fellowship [CD12/00540]; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK098408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSTP program at Albert Einstein College of Medicine; Sara Borrell fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the assistance in sample procurement from Ms. Estella Forbes, Dr Steven Libutti, Dr Jonathan Schwartz, Dr Milan Kinkhabwala, Dr Sarah Bellemare and Dr Harmit Kalia at the Montefiore-Einstein Center for Cancer Care. Support for work: Support for this work was in part from NIH P30 DK041296 (Marion Bessin Liver Research Center (JM Greally, AW Wolkoff), and the MSTP program at Albert Einstein College of Medicine (Einstein) (NA Wijetunga, J Tozour, NIH T32 GM007288). M Pascual is supported by a Sara Borrell fellowship CD12/00540. This manuscript was published in partial fulfillment of the requirements for a PhD in Biomedical Sciences at Einstein (NA Wijetunga).	ALAM T, 1992, J BIOL CHEM, V267, P5021; Alder O, 2014, CELL REP, V9, P261, DOI 10.1016/j.celrep.2014.08.046; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; Aran D, 2013, CELL, V154, P11, DOI 10.1016/j.cell.2013.06.018; Archer KJ, 2010, MOL GENET GENOMICS, V283, P341, DOI 10.1007/s00438-010-0522-y; Arensdorf AM, 2013, J CELL SCI, V126, P4026, DOI 10.1242/jcs.130757; Banerjee A, 2010, J VIROL, V84, P5936, DOI 10.1128/JVI.02344-09; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bochkis IM, 2008, NAT MED, V14, P828, DOI 10.1038/nm.1853; Bockmuhl Y, 2015, EPIGENETICS-US, V10, P247, DOI 10.1080/15592294.2015.1017199; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Colombo M, 2015, DIGEST LIVER DIS, V47, P727, DOI 10.1016/j.dld.2015.04.003; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Couvert P, 2008, WORLD J GASTROENTERO, V14, P5419, DOI 10.3748/wjg.14.5419; Dammacco F, 2000, SEMIN LIVER DIS, V20, P143, DOI 10.1055/s-2000-9613; DeLaForest A, 2011, DEVELOPMENT, V138, P4143, DOI 10.1242/dev.062547; Delahaye F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6187; Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eads CA, 2000, CANCER RES, V60, P5021; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feldmann A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003994; Feo F, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2014.12.08; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Heuck CJ, 2013, J IMMUNOL, V190, P2966, DOI 10.4049/jimmunol.1202493; Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026; Hogart A, 2012, GENOME RES, V22, P1407, DOI 10.1101/gr.132878.111; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hu CY, 2014, CLIN CANCER RES, V20, P4349, DOI 10.1158/1078-0432.CCR-14-0494; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jelic S, 2010, ANN ONCOL, V21, pv59, DOI 10.1093/annonc/mdq166; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241; Kim JW, 2004, HEPATOLOGY, V39, P518, DOI 10.1002/hep.20053; Koike K, 2014, RECENT RESULTS CANC, V193, P97, DOI 10.1007/978-3-642-38965-8_6; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Lu CY, 2009, GENE CHROMOSOME CANC, V48, P1057, DOI 10.1002/gcc.20708; Machida K, 2004, J VIROL, V78, P8835, DOI 10.1128/JVI.78.16.8835-8843.2004; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Machida K, 2010, J IMMUNOL, V185, P6985, DOI 10.4049/jimmunol.1000618; Meir O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009516; Minguez B, 2011, J HEPATOL, V55, P1325, DOI 10.1016/j.jhep.2011.02.034; Moriya K, 2001, CANCER RES, V61, P4365; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110; Ohguchi H, 2008, MOL CELL BIOL, V28, P3917, DOI 10.1128/MCB.02154-07; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Palomer X, 2013, INT J CARDIOL, V168, P3160, DOI 10.1016/j.ijcard.2013.07.150; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Ptashne M, 2013, FASEB J, V27, P1, DOI 10.1096/fj.13-0101ufm; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474; Rush Margaret, 2009, Epigenetics, V4, P404; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Schwartz Myron E, 2013, Recent Results Cancer Res, V190, P85, DOI 10.1007/978-3-642-16037-0_6; Shen J, 2013, EPIGENETICS-US, V8, P34, DOI 10.4161/epi.23062; Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569; Signolet J, 2015, FEBS J, V282, P1692, DOI 10.1111/febs.13132; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111; Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Suzuki M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-4-r36; Taberlay PC, 2014, GENOME RES, V24, P1421, DOI 10.1101/gr.163485.113; Tanigawa S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.448; Tao Y, 2011, P NATL ACAD SCI USA, V108, P12042, DOI 10.1073/pnas.1108715108; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Umer M, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-117; Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346; Villacorte M, 2013, ONCOGENE, V32, P3477, DOI 10.1038/onc.2012.376; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijetunga NA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6195; Won KJ, 2013, NUCLEIC ACIDS RES, V41, P4423, DOI 10.1093/nar/gkt143; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yagi K, 2012, AM J PATHOL, V180, P616, DOI 10.1016/j.ajpath.2011.10.010; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamazaki H, 2012, MOL CELL BIOL, V32, P808, DOI 10.1128/MCB.06543-11; Yang M, 2013, J CELL SCI, V126, P5692, DOI 10.1242/jcs.135053; Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900; Zhao Hongtao, 2013, Hepatobiliary Surg Nutr, V2, P78, DOI 10.3978/j.issn.2304-3881.2012.12.12; Zhao W, 2006, INT J ONCOL, V28, P1081; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433; Zimmerman TL, 2006, J BIOL CHEM, V281, P15434, DOI 10.1074/jbc.M508277200; Zogopoulos George, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P1434	128	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2030	2044		10.1038/onc.2016.340	http://dx.doi.org/10.1038/onc.2016.340			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27721404	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000398898500013
J	Chan, DW; Hui, WWY; Wang, JJ; Yung, MMH; Hui, LMN; Qin, Y; Liang, RR; Leung, THY; Xu, D; Chan, KKL; Yao, KM; Tsang, BK; Ngan, HYS				Chan, D. W.; Hui, W. W. Y.; Wang, J. J.; Yung, M. M. H.; Hui, L. M. N.; Qin, Y.; Liang, R. R.; Leung, T. H. Y.; Xu, D.; Chan, K. K. L.; Yao, K-M; Tsang, B. K.; Ngan, H. Y. S.			DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling	ONCOGENE			English	Article							FORKHEAD BOX M1; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; TGF-BETA; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; GENE-EXPRESSION; POOR-PROGNOSIS; INVASION; MIGRATION	Recent evidence from a comprehensive genome analysis and functional studies have revealed that FOXM1 is a crucial metastatic regulator that drives cancer progression. However, the regulatory mechanism by which FOXM1 exerts its metastatic functions in cancer cells remains obscure. Here, we report that DLX1 acts as a FOXM1 downstream target, exerting pro-metastatic function in ovarian cancers. Both FOXM1 isoforms (FOXM1B or FOXM1C) could transcriptionally upregulate DLX1 through two conserved binding sites, located at + 61 to + 69bp downstream (TFBS1) and -675 to -667bp upstream (TFBS2) of the DLX1 promoter, respectively. This regulation was further accentuated by the significant correlation between the nuclear expression of FOXM1 and DLX1 in high-grade serous ovarian cancers. Functionally, the ectopic expression of DLX1 promoted ovarian cancer cell growth, cell migration/ invasion and intraperitoneal dissemination of ovarian cancer in mice, whereas small interfering RNA-mediated DLX1 knockdown in FOXM1-overexpressing ovarian cancer cells abrogated these oncogenic capacities. In contrast, depletion of FOXM1 by shRNAi only partially attenuated tumor growth and exerted almost no effect on cell migration/invasion and the intraperitoneal dissemination of DLX1-overexpressing ovarian cancer cells. Furthermore, the mechanistic studies showed that DLX1 positively modulates transforming growth factor-beta (TGF-beta) signaling by upregulating PAI-1 and JUNB through direct interaction with SMAD4 in the nucleus upon TGF-beta 1 induction. Taken together, these data strongly suggest that DLX1 has a pivotal role in FOXM1 signaling to promote cancer aggressiveness through intensifying TGF-beta/SMAD4 signaling in high-grade serous ovarian cancer cells.	[Chan, D. W.; Hui, W. W. Y.; Yung, M. M. H.; Hui, L. M. N.; Liang, R. R.; Leung, T. H. Y.; Chan, K. K. L.; Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Wang, J. J.; Yao, K-M] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Wang, J. J.; Qin, Y.] Univ Hong Kong, Ctr Genom Sci, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Xu, D.] Shanghai Jiao Tong Univ, Dept Med Lab Sci, Sch Med, Shanghai, Peoples R China; [Xu, D.] Hudson Inst Med Res, Clayton, Vic, Australia; [Tsang, B. K.] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Tsang, B. K.] Univ Ottawa, Dept Obstet & Gynaecol, Interdisciplinary Sch Hlth Sci, Ottawa, ON, Canada; [Tsang, B. K.] Univ Ottawa, Dept Cellular & Mol Med, Interdisciplinary Sch Hlth Sci, Ottawa, ON, Canada; [Tsang, B. K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; Shanghai Jiao Tong University; Hudson Institute of Medical Research; Macau University of Science & Technology; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Chan, DW (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, L747 Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	dwchan@hku.hk	Chan, David/O-9896-2018; YUNG, Mingo Ming Ho/AHB-5775-2022; Leung, Rongrui/GQY-7360-2022; /C-4457-2009; Wang, Junwen/D-3700-2011	Chan, David/0000-0002-6951-3467; YUNG, Mingo Ming Ho/0000-0003-0903-1164; /0000-0002-5923-0869; Wang, Junwen/0000-0002-4432-4707; Ngan, Hextan Y S/0000-0003-3945-159X	Wong Check She Charitable Foundation; NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER	Wong Check She Charitable Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Shigeru Chiba (Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan) for providing pTracer-CMV-DLX1-Flag plasmid, Professor Makoto Mark Taketo (Graduate School of Medicine, Kyoto University, Sakyo, Kyoto, Japan) for providing Myc-tagged SMAD4 expressing plasmid, and Prof. George Tsao (Department of Anatomy, The University of Hong Kong) for providing HOSE 6-3, HOSE 17-1 and HOSE 11-12. This study was supported by Wong Check She Charitable Foundation.	Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cantile M, 2005, J CELL PHYSIOL, V205, P202, DOI 10.1002/jcp.20384; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chan DW, 2009, BRIT J CANCER, V101, P1433, DOI 10.1038/sj.bjc.6605316; Chan DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052578; Chan DW, 2011, J PATHOL, V225, P525, DOI 10.1002/path.2901; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Cobos I, 2005, NAT NEUROSCI, V8, P1059, DOI 10.1038/nn1499; Cobos I, 2007, NEURON, V54, P873, DOI 10.1016/j.neuron.2007.05.024; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eeckhoute J, 2009, J CELL SCI, V122, P4027, DOI 10.1242/jcs.054916; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Hara F, 2007, AM J PATHOL, V170, P1594, DOI 10.2353/ajpath.2007.061025; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lam AKY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00011; Lam AY, 2013, FRONT MOL CELL ONCOL, V3, P1; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Le TN, 2007, J BIOL CHEM, V282, P19071, DOI 10.1074/jbc.M607486200; Levy S, 2002, MAMM GENOME, V13, P510, DOI 10.1007/s00335-002-2175-6; Lezot F, 2008, J CELL PHYSIOL, V216, P688, DOI 10.1002/jcp.21448; Li JP, 2012, FEBS LETT, V586, P3761, DOI 10.1016/j.febslet.2012.09.016; Li MJ, 2010, BIOINFORMATICS, V26, P2897, DOI 10.1093/bioinformatics/btq540; Lin SW, 2007, EXP CELL RES, V313, P602, DOI 10.1016/j.yexcr.2006.11.003; Lin SW, 2001, CLIN EXP METASTAS, V18, P493; Lok GTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023790; Maira M, 2010, J NEURODEV DISORD, V2, P48, DOI [10.1007/s11689-009-9035-6, 10.1007/s11689-009-9040-9]; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Merlo GR, 2000, INT J DEV BIOL, V44, P619; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Myatt S.S., 2008, CANCER, V8, P242, DOI DOI 10.1038/NRC2223-C2; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; Potter GB, 2009, MOL CELL NEUROSCI, V40, P167, DOI 10.1016/j.mcn.2008.10.003; Qin J, 2011, NUCLEIC ACIDS RES, V39, pW430, DOI 10.1093/nar/gkr332; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Shiou SR, 2006, J BIOL CHEM, V281, P33971, DOI 10.1074/jbc.M607010200; Starkova J, UP REGULATION HOMEOD; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tan YF, 2010, CANCER RES, V70, P9197, DOI 10.1158/0008-5472.CAN-10-1568; Teng Y, 2014, CELL PHYSIOL BIOCHEM, V33, P717, DOI 10.1159/000358647; Trinh BQ, 2011, ONCOGENE, V30, P2718, DOI 10.1038/onc.2011.4; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wen N, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-134; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978-0-12-407173-5.00004-2; Xia JT, 2012, PANCREAS, V41, P629, DOI 10.1097/MPA.0b013e31823bcef2; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.333; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhang LM, 2012, INT J BIOL SCI, V8, P1178, DOI 10.7150/ijbs.4458; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968	65	33	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1404	1416		10.1038/onc.2016.307	http://dx.doi.org/10.1038/onc.2016.307			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593933	Green Published, hybrid			2022-12-28	WOS:000395862500009
J	Lu, W; Liu, S; Li, B; Xie, Y; Izban, MG; Ballard, BR; Sathyanarayana, SA; Adunyah, SE; Matusik, RJ; Chen, Z				Lu, W.; Liu, S.; Li, B.; Xie, Y.; Izban, M. G.; Ballard, B. R.; Sathyanarayana, S. A.; Adunyah, S. E.; Matusik, R. J.; Chen, Z.			SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; MEDIATED DEGRADATION; CELLULAR SENESCENCE; PROTEIN STABILITY; GENE-EXPRESSION; DOWN-REGULATION; LIGASE; POLYCOMB; COMPLEX; KINASE	EZH2 is crucial for the progression of prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) through upregulation and activation of progenitor genes, as well as androgen receptor (AR)-target genes. However, the mechanisms by which EZH2 is regulated in PCa and CRPC remain elusive. Here we report that EZH2 is post-transcriptionally regulated by SKP2 in vitro in cultured cells and in vivo in mouse models. We observed aberrant upregulation of Skp2, Ezh2 and histone H3 lysine 27 trimethylation (H3K27me3) in both Pten null mouse embryonic fibroblasts (MEFs) and Pten null mouse prostate tissues. Loss of Skp2 resulted in a striking decrease of Ezh2 levels in Pten/Trp53 double-null MEFs and in prostate tumors of Pten/Trp53 double-null mutant mice. SKP2 knockdown decreased EZH2 levels in human PCa cells through upregulation of TRAF6-mediated and lysine(K) 63-linked ubiquitination of EZH2 for degradation. Ectopic expression of TRAF6 promoted the K63-linked ubiquitination of EZH2 to decrease EZH2 and H3K27me3 levels in PCa cells. In contrast, TRAF6 knockdown resulted in a reduced EZH2 ubiquitination with an increase of EZH2 and H3K27me3 levels in PCa cells. Furthermore, the catalytically dead mutant TRAF6 C70A abolished the TRAF6-mediated polyubiquitination of recombinant human EZH2 in vitro. Most importantly, a concurrent elevation of Skp2 and Ezh2 was found in CRPC tumors of Pten/Trp53 mutant mice, and expression levels of SKP2 and EZH2 were positively correlated in human PCa specimens. Taken together, our findings revealed a novel mechanism on EZH2 ubiquitination and an important signaling network of SKP2-TRAF6-EZH2/H3K27me3, and targeting SKP2-EZH2 pathway may be a promising therapeutic strategy for CRPC treatment.	[Lu, W.; Liu, S.; Li, B.; Adunyah, S. E.; Chen, Z.] Meharry Med Coll, Dept Biochem & Canc Biol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA; [Xie, Y.] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, Astana, Kazakhstan; [Izban, M. G.; Ballard, B. R.] Meharry Med Coll, Dept Pathol Anat & Cell Biol, Nashville, TN 37208 USA; [Sathyanarayana, S. A.] Meharry Med Coll, Dept Surg, Nashville, TN 37208 USA; [Matusik, R. J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37212 USA	Meharry Medical College; Nazarbayev University; Meharry Medical College; Meharry Medical College; Vanderbilt University	Chen, Z (corresponding author), Meharry Med Coll, Dept Biochem & Canc Biol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	zchen@mmc.edu		Matusik, Robert/0000-0003-2057-9892	NIH [MD004038, DK055748, CA163069, MD007593, MD007586, DA036420, S10RR0254970, UL1TR000445-06]; National Institute on Minority Health and Health Disparities [U54MD007593, G12MD007586, R01MD004038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Dr Jae-Il Park for Flag-EZH2 plasmid, Dr Paul Bates and Dr Zhaocai (Joe) Zhou for Myc-TRAF6 and Myc-TRAF6-C70A plasmids, Dr Edward W. Harhaj for ubiquitin and ubiquitin mutant plasmids, and Dr Hui-Kuan Lin for GST, GST-TRAF6 and GST-TRAF6-C70A plasmids. HA-tagged EZH2 is a gift from Kristian Helin (Addgene plasmid # 24230).<SUP>54</SUP> This work was supported in part by NIH grants MD004038, DK055748, CA163069, MD007593 and UL1TR000445-06. Human tissue staining, microscopy experiments and data analysis were performed through the Human Tissue & Pathology Core and Morphology Core of Meharry Medical College, supported in part by NIH grants MD007593, MD007586, DA036420 and S10RR0254970.	Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Cocka LJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002931; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117; Ferreira JV, 2015, SCI REP-UK, V5, DOI 10.1038/srep10210; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Huang FT, 2013, P NATL ACAD SCI USA, V110, P15722, DOI 10.1073/pnas.1308014110; Jiao S, 2015, NAT IMMUNOL, V16, P246, DOI 10.1038/ni.3097; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Li B, 2014, PROSTATE, V74, P421, DOI 10.1002/pros.22763; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lin TY, 2012, ONCOGENE, V31, P3287, DOI 10.1038/onc.2011.491; Lu WF, 2015, ONCOTARGET, V6, P771, DOI 10.18632/oncotarget.2718; Lu WF, 2013, MOL ENDOCRINOL, V27, P635, DOI 10.1210/me.2012-1294; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shen Z, 2013, BBA-MOL CELL RES, V1833, P2190, DOI 10.1016/j.bbamcr.2013.05.014; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sugeno N, 2014, J BIOL CHEM, V289, P18137, DOI 10.1074/jbc.M113.529461; Valdes-Mora F, 2015, ONCOGENE, V34, P1609, DOI 10.1038/onc.2014.111; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang WL, 2010, ONCOGENE, V29, P4493, DOI 10.1038/onc.2010.190; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zhang L, 2013, J LIPID RES, V54, P1410, DOI 10.1194/jlr.M035774; Zoabi M, 2011, BIOCHEM BIOPH RES CO, V408, P393, DOI 10.1016/j.bbrc.2011.04.025	54	34	37	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1364	1373		10.1038/onc.2016.300	http://dx.doi.org/10.1038/onc.2016.300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27869166	Green Accepted			2022-12-28	WOS:000395862500005
J	Zhang, S; Zhou, B; Wang, L; Li, P; Bennett, B; Snyder, R; Garantziotis, S; Fargo, D; Cox, A; Chen, L; Hu, G				Zhang, S.; Zhou, B.; Wang, L.; Li, P.; Bennett, Bd; Snyder, R.; Garantziotis, S.; Fargo, Dc; Cox, Ad; Chen, L.; Hu, G.			INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; AMPLIFICATION; PLURIPOTENCY; REPLICATION; MECHANISMS; LANDSCAPE; BIOLOGY; ENZYME; GENES	Epigenetic regulators are attractive targets for the development of new cancer therapies. Among them, the ATP-dependent chromatin remodeling complexes control the chromatin architecture and have important roles in gene regulation. They are often found to be mutated and de-regulated in cancers, but how they influence the cancer gene expression program during cancer initiation and progression is not fully understood. Here we show that the INO80 chromatin remodeling complex is required for oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC). Ino80, the SWI/SNF ATPase in the complex, is highly expressed in NSCLC cells compared with normal lung epithelia cells. Further, its expression, as well as that of another subunit Ino80B, negatively correlates with disease prognosis in lung cancer patients. Functionally, INO80 silencing inhibits NSCLC cell proliferation and anchorage-independent growth in vitro and tumor formation in mouse xenografts. It occupies enhancer regions near lung cancer-associated genes, and its occupancy correlates with increased genome accessibility and enhanced expression of downstream genes. Together, our study defines a critical role of INO80 in promoting oncogenic transcription and NSCLC tumorigenesis, and reveals a potential treatment strategy for inhibiting the cancer transcription network by targeting the INO80 chromatin remodeling complex.	[Zhang, S.; Chen, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Pulm & Crit Care Med, Beijing 100853, Peoples R China; [Zhou, B.; Cox, Ad] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Zhou, B.; Wang, L.] Fuwai Hosp, Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [Zhou, B.; Wang, L.] Fuwai Hosp, Chinese Acad Med Sci, Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China; [Wang, L.; Li, P.; Hu, G.] Natl Inst Environm Hlth Sci, Epigenet & Stem Cell Biol Lab, 111 TW Alexander Dr,Bldg 101,Room A314, Res Triangle Pk, NC 27709 USA; [Bennett, Bd; Fargo, Dc] Natl Inst Environm Hlth Sci, Integrat Bioinformat, Res Triangle Pk, NC USA; [Snyder, R.; Garantziotis, S.] Natl Inst Environm Hlth Sci, Clin Res Branch, Res Triangle Pk, NC USA	Chinese People's Liberation Army General Hospital; University of North Carolina; University of North Carolina Chapel Hill; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Pulm & Crit Care Med, Beijing 100853, Peoples R China.; Hu, G (corresponding author), Natl Inst Environm Hlth Sci, Epigenet & Stem Cell Biol Lab, 111 TW Alexander Dr,Bldg 101,Room A314, Res Triangle Pk, NC 27709 USA.	CLA_301@163.com; hug4@niehs.nih.gov	Hu, Guang/E-7474-2016; Garantziotis, Stavros/A-6903-2009	Hu, Guang/0000-0003-0437-4723; Garantziotis, Stavros/0000-0003-4007-375X; Cox, Adrienne D./0000-0002-4901-2454; Chen, Liang-an/0000-0002-1829-3134	Intramural Research Program of the NIH; National Institute of Environmental Health Sciences [Z01ES102745]; National Institutes of Health Grants [CA042978, CA161494]; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIDES102465, ZIAES102605, ZIAES102745] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the NIEHS Animal, Epigenomics and Bioinformatics core facilities for assistance with various techniques and experiments. This study was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Z01ES102745 (to GH) and by National Institutes of Health Grants CA042978 and CA161494 (to ADC).	Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Baykara O, 2015, J CANCER, V6, P270, DOI 10.7150/jca.10638; Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Conaway RC, 2009, TRENDS BIOCHEM SCI, V34, P71, DOI 10.1016/j.tibs.2008.10.010; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hu GQ, 2011, GENOME RES, V21, P1650, DOI 10.1101/gr.121145.111; Jakopovic M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00261; Job B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015145; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kim J, 2011, GENOME MED, V3, DOI 10.1186/gm291; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Laurette P, 2015, ELIFE, V4, DOI 10.7554/eLife.06857; Linxweiler M, 2012, AM J PATHOL, V180, P473, DOI 10.1016/j.ajpath.2011.10.039; Liu SV, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00135; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Narlikar GJ, 2013, CELL, V154, P490, DOI 10.1016/j.cell.2013.07.011; Papamichos-Chronakis M, 2011, CELL, V144, P200, DOI 10.1016/j.cell.2010.12.021; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Viktorsson K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.28; Wang L, 2014, CELL STEM CELL, V14, P575, DOI 10.1016/j.stem.2014.02.013; Watanabe S, 2010, COLD SH Q B, V75, P35, DOI 10.1101/sqb.2010.75.063; Watanabe S, 2013, SCIENCE, V340, P195, DOI 10.1126/science.1229758; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009	35	22	22	5	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1430	1439		10.1038/onc.2016.311	http://dx.doi.org/10.1038/onc.2016.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641337	Green Accepted			2022-12-28	WOS:000395862500011
J	Tsuruyama, T; Hiratsuka, T; Yamada, N				Tsuruyama, T.; Hiratsuka, T.; Yamada, N.			Hotspots of MLV integration in the hematopoietic tumor genome	ONCOGENE			English	Review							MURINE LEUKEMIA-VIRUS; PRE-B LYMPHOMAS; GENE-THERAPY; INSERTIONAL MUTAGENESIS; RETROVIRAL INTEGRATION; SITE SELECTION; CELL EXPANSION; SL/KH STRAIN; N-MYC; C-MYC	Extensive research has been performed regarding the integration sites of murine leukemia retrovirus (MLV) for the identification of proto-oncogenes. To date, the overlap of mutations within specific oligonucleotides across different tumor genomes has been regarded as a rare event; however, a recent study of MLV integration into the oncogene Zfp521 suggested the existence of a hotspot oligonucleotide for MLV integration. In the current review, we discuss the hotspots of MLV integration into several genes: c-Myc, Stat5a and N-myc, as well as ZFP521, as examined in tumor genomes. From this, MLV integration convergence within specific oligonucleotides is not necessarily a rare event. This short review aims to promote re-consideration of MLV integration within the tumor genome, which involves both well-known and potentially newly identified and novel mechanisms and specifications.	[Tsuruyama, T.; Hiratsuka, T.] Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Kyoto 6068501, Japan; [Tsuruyama, T.; Yamada, N.] Kyoto Univ, Ctr Anat Pathol & Forens Med Res, Grad Sch Med, Kyoto, Japan	Kyoto University; Kyoto University	Tsuruyama, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Kyoto 6068501, Japan.	tsuruyam@kuhp.kyoto-u.ac.jp			 [2502]		This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas, MEXT, Japan (project title 'Synergy of Fluctuation and Structure' and number 2502). This funding agency had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript.	Abujiang P, 1996, LAB ANIM SCI, V46, P410; Aiyer S, 2014, NUCLEIC ACIDS RES, V42, P5917, DOI 10.1093/nar/gku175; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; Belkina AC, 2014, J LEUKOCYTE BIOL, V95, P451, DOI 10.1189/jlb.1112588; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Crowe BL, 2016, P NATL ACAD SCI USA, V113, P2086, DOI 10.1073/pnas.1516813113; Dave UP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000491; De Ravin SS, 2014, J VIROL, V88, P4504, DOI 10.1128/JVI.00011-14; De Rijck J, 2013, CELL REP, V5, P886, DOI 10.1016/j.celrep.2013.09.040; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Elis E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003103; Felice B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004571; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Gao FJ, 2015, CELL IMMUNOL, V294, P1, DOI 10.1016/j.cellimm.2015.01.010; Ginn SL, 2005, MED J AUSTRALIA, V182, P458, DOI 10.5694/j.1326-5377.2005.tb06785.x; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Gupta SS, 2013, J VIROL, V87, P12721, DOI 10.1128/JVI.01942-13; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HARANGHERA N, 1995, LEUKEMIA, V9, P1199; Hiai H, 1999, Prog Exp Tumor Res, V35, P64; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; Hiratsuka T, 2016, ONCOGENE, V35, P3227, DOI 10.1038/onc.2015.385; Hiratsuka T, 2008, LEUKEMIA RES, V32, P309, DOI 10.1016/j.leukres.2007.05.013; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Jin G, 2003, CANCER SCI, V94, P791, DOI 10.1111/j.1349-7006.2003.tb01520.x; Kaszynski RH, 2010, CANCER SCI, V101, P800, DOI 10.1111/j.1349-7006.2009.01437.x; Katane M, 2004, J GENE MED, V6, P260, DOI 10.1002/jgm.487; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; KURDIHAIDAR B, 1993, GENOMICS, V15, P305, DOI 10.1006/geno.1993.1061; Kvaratskhelia M, 2014, NUCLEIC ACIDS RES, V42, P10209, DOI 10.1093/nar/gku769; LaFave MC, 2014, NUCLEIC ACIDS RES, V42, P4257, DOI 10.1093/nar/gkt1399; LENZ J, 1982, J VIROL, V43, P943, DOI 10.1128/JVI.43.3.943-951.1982; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Lu LM, 1999, CANCER RES, V59, P2593; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mortuza GB, 2008, J MOL BIOL, V376, P1493, DOI 10.1016/j.jmb.2007.12.043; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nielsen AA, 2005, J VIROL, V79, P67, DOI 10.1128/JVI.79.1.67-78.2005; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Pike-Overzet K, 2007, MOL THER, V15, P1910, DOI 10.1038/sj.mt.6300297; RASSART E, 1986, J VIROL, V58, P96, DOI 10.1128/JVI.58.1.96-106.1986; Ruiz-Herguido C, 2012, J EXP MED, V209, P1457, DOI 10.1084/jem.20120225; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; Sharma A, 2013, P NATL ACAD SCI USA, V110, P12036, DOI 10.1073/pnas.1307157110; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; SHIMADA MO, 1993, LEUKEMIA RES, V17, P573, DOI 10.1016/0145-2126(93)90087-2; Sorensen AB, 1996, J VIROL, V70, P4063; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215; Swazo NK, 2006, J MED PHILOS, V31, P533, DOI 10.1080/03605310600912709; TAMURA T, 1989, J CANCER RES CLIN, V115, P235, DOI 10.1007/BF00391695; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Tsuruyama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031533; Tsuruyama T, 2011, AM J PATHOL, V178, P1374, DOI 10.1016/j.ajpath.2010.12.012; Tsuruyama T, 2010, J LEUKOCYTE BIOL, V88, P107, DOI 10.1189/jlb.1109748; Umehara T, 2010, J BIOL CHEM, V285, P7610, DOI 10.1074/jbc.M109.062422; VANBEVEREN C, 1980, P NATL ACAD SCI-BIOL, V77, P3307; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vollmuth F, 2009, J BIOL CHEM, V284, P36547, DOI 10.1074/jbc.M109.033712; Wang GP, 2007, GENOME RES, V17, P1186, DOI 10.1101/gr.6286907; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; YAMADA Y, 1994, CANCER RES, V54, P403; Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047	78	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1169	1175		10.1038/onc.2016.285	http://dx.doi.org/10.1038/onc.2016.285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27721401	hybrid, Green Published			2022-12-28	WOS:000395861300001
J	Wu, J; Liu, W; Williams, JP; Ratner, N				Wu, J.; Liu, W.; Williams, J. P.; Ratner, N.			EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCHWANN-CELLS; SHEATH TUMORS; TYPE-1 NF1; EGFR; INHIBITION; EXPRESSION; PHENOTYPE; PLEXIFORM; ORIGIN	Neurofibromatosis type 1 (NF1) is an inherited disease in which affected patients are predisposed to develop benign Schwann cell (SC) tumours called neurofibromas. In the mouse, loss of Nf1 in the SC lineage causes neurofibroma formation. The tyrosine kinase receptor EGFR is expressed in Schwann cell precursors (SCP), which have been implicated in plexiform neurofibroma initiation. To test if EGFR activity affects neurofibroma initiation, size, and/or number, we studied mice expressing human EGFR in SCs and SCP in the context of mice that form neurofibromas. Neurofibroma number increased in homozygous CNP-hEGFR mice versus heterozygous littermates, and neurofibroma number and size increased when CNP-hEGFR was crossed to Nf1(fl/fl); DhhCre mice. Conversely, diminished EGFR signalling in Nf1(fl/fl); DhhCre; Wa2/+ mice decreased neurofibroma number. In vivo transplantation verified the correlation between EGFR activity and neurofibroma formation. Mechanistically, expression of CNP-hEGFR increased SCP/neurofibroma-initiating cell self-renewal, a surrogate for tumour initiation, and activated P-Stat3. Further, Il-6 reinforced Jak2/ Stat3 activation in SCPs and SCs. These gain-and loss-of function assays show that levels of tyrosine kinase expression in SCPs modify neurofibroma initiation.	[Wu, J.; Liu, W.; Williams, J. P.; Ratner, N.] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst,Div Expt Hematol & Canc Bio, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Liu, W.] Shandong Univ, Dept Pediat Surg, Prov Hosp Affiliated, Jinan, Peoples R China; [Williams, J. P.] San Antonio Mil Med Ctr Neurol, JBSA, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati; Shandong University; San Antonio Military Medical Center	Ratner, N (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst,Div Expt Hematol & Canc Bio, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org	Williams, Jon/AAP-2761-2020	RATNER, NANCY/0000-0001-5030-9354	DAMD New Investigator Award [W81XWH-11-1-0259]; NIH [R01 NS28840]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840, R01NS086219] Funding Source: NIH RePORTER	DAMD New Investigator Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Luis F Parada (Memorial Sloan Kettering, NY) for Nf1<SUP>fl/fl</SUP> mice and Dr Anat O Stemmer-Rachamimov (Massachusetts General Hospital) for assistance with mouse pathology. We thank Dr Adam Lane (CCHMC) for consultation on statistical analysis. This work was supported by a DAMD New Investigator Award (W81XWH-11-1-0259) (Jianqiang Wu) and NIH R01 NS28840 (Nancy Ratner).	Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Chen SZ, 2003, NAT NEUROSCI, V6, P1186, DOI 10.1038/nn1139; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; EASTON DF, 1993, AM J HUM GENET, V53, P305; Gomez-Sanchez JA, 2009, J NEUROSCI, V29, P11304, DOI 10.1523/JNEUROSCI.1753-09.2009; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Kazmi SJ, 2013, AM J PATHOL, V182, P646, DOI 10.1016/j.ajpath.2012.11.017; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Leppig KA, 1997, AM J MED GENET, V73, P197, DOI 10.1002/(SICI)1096-8628(1997)73:2<197::AID-AJMG17>3.0.CO;2-P; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li H, 2016, ONCOGENE, V35, P1468, DOI 10.1038/onc.2015.207; Li HZ, 2002, CANCER RES, V62, P4507; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Mautner VF, 2010, J MED GENET, V47, P623, DOI 10.1136/jmg.2009.075937; Mayes DA, 2011, CANCER RES, V71, P4675, DOI 10.1158/0008-5472.CAN-10-4558; Ratner N, 2006, METHOD ENZYMOL, V407, P22, DOI 10.1016/S0076-6879(05)07003-5; Ribeiro S, 2013, CELL REP, V5, P126, DOI 10.1016/j.celrep.2013.08.033; Rieley MB, 2011, AM J MED GENET A, V155A, P478, DOI 10.1002/ajmg.a.33851; Rizvi TA, 2002, J NEUROSCI, V22, P9831; Ryan MA, 2010, NAT MED, V16, P1141, DOI 10.1038/nm.2217; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walrath JC, 2009, MAMM GENOME, V20, P214, DOI 10.1007/s00335-009-9179-4; Wang L, 2009, NEUROREPORT, V20, P663, DOI 10.1097/WNR.0b013e32832a09f8; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu JQ, 2006, AM J PATHOL, V168, P1686, DOI 10.2353/ajpath.2006.050859; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	44	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1669	1677		10.1038/onc.2016.386	http://dx.doi.org/10.1038/onc.2016.386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27748759	Green Accepted			2022-12-28	WOS:000397460600006
J	Battistelli, C; Cicchini, C; Santangelo, L; Tramontano, A; Grassi, L; Gonzalez, FJ; de Nonno, V; Grassi, G; Amicone, L; Tripodi, M				Battistelli, C.; Cicchini, C.; Santangelo, L.; Tramontano, A.; Grassi, L.; Gonzalez, F. J.; de Nonno, V.; Grassi, G.; Amicone, L.; Tripodi, M.			The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition	ONCOGENE			English	Article							LONG NONCODING RNA; NUCLEAR FACTOR 4-ALPHA; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTORS; COMPLEX 2; CHROMATIN MODIFICATION; CARCINOMA PROGRESSION; MOLECULAR-MECHANISMS; EMT/MET DYNAMICS; GENE-EXPRESSION	The transcription factor Snail is a master regulator of cellular identity and epithelial-to-mesenchymal transition (EMT) directly repressing a broad repertoire of epithelial genes. How chromatin modifiers instrumental to its activity are recruited to Snail-specific binding sites is unclear. Here we report that the long non-coding RNA (lncRNA) HOTAIR (for HOX Transcript Antisense Intergenic RNA) mediates a physical interaction between Snail and enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of the polycomb-repressive complex 2 and the main writer of chromatin-repressive marks. The Snail-repressive activity, here monitored on genes with a pivotal function in epithelial and hepatic morphogenesis, differentiation and cell-type identity, depends on the formation of a tripartite Snail/HOTAIR/EZH2 complex. These results demonstrate an lncRNA-mediated mechanism by which a transcriptional factor conveys a general chromatin modifier to specific genes, thereby allowing the execution of hepatocyte transdifferentiation; moreover, they highlight HOTAIR as a crucial player in the Snail-mediated EMT.	[Battistelli, C.; Cicchini, C.; Santangelo, L.; de Nonno, V.; Amicone, L.; Tripodi, M.] Sapienza Univ Rome, Ist Pasteur Italia Fdn Cenci Bolognetti, Dept Cellular Biotechnol & Haematol, Sez Genet Mol, Rome, Italy; [Tramontano, A.] Sapienza Univ Rome, Ist Pasteur Italia Fdn Cenci Bolognetti, Dept Phys, Rome, Italy; [Grassi, L.] Sapienza Univ Rome, Dept Phys, Rome, Italy; [Gonzalez, F. J.] NCI, Ctr Canc Res, Lab Metab, NIH, Bethesda, MD 20892 USA; [Grassi, G.; Tripodi, M.] IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Lazzaro Spallanzani	Cicchini, C; Tripodi, M (corresponding author), Sapienza Univ Rome, Fdn Cenci Bolognetti, Ist Pasteur Italia, Dipartimento Biotecnol Cellulari & Ematol,Sez Gen, Viale Regina Elena 324, I-00161 Rome, Italy.	cicchini@bce.uniroma1.it; tripodi@bce.uniroma1.it	Tripodi, Marco/F-1143-2011; Battistelli, Cecilia/AFD-8694-2022; Grassi, Luigi/E-5877-2011; Tripodi, Marco/ABO-1160-2022	Tripodi, Marco/0000-0001-6135-971X; Battistelli, Cecilia/0000-0002-5611-7377; Tripodi, Marco/0000-0001-6135-971X; Grassi, Luigi/0000-0002-6308-7540; Grassi, Germana/0000-0001-8168-8721	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 14114]; Ministero della Salute; Ministero Universita e Ricerca Scientifica [PRIN 20108XYHJS]; Epigenomics Flagship Project-EPIGEN; NATIONAL CANCER INSTITUTE [ZIABC005562] Funding Source: NIH RePORTER	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Ministero Universita e Ricerca Scientifica(Ministry of Education, Universities and Research (MIUR)); Epigenomics Flagship Project-EPIGEN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank I Bozzoni and SA Ciafre for suggestions and critical revision of the manuscript. This was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 14114; Ministero della Salute; Ministero Universita e Ricerca Scientifica PRIN 20108XYHJS; Epigenomics Flagship Project-EPIGEN.	Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Arnold P, 2013, GENOME RES, V23, P60, DOI 10.1101/gr.142661.112; Battistelli C, 2014, J CELL SCI, V127, P3757, DOI 10.1242/jcs.149427; Bolotin E, 2010, HEPATOLOGY, V51, P642, DOI 10.1002/hep.23357; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005; Cicchini C, 2006, J CELL PHYSIOL, V209, P230, DOI 10.1002/jcp.20730; Cicchini C, 2015, BBA-GENE REGUL MECH, V1849, P919, DOI 10.1016/j.bbagrm.2015.05.005; Cicchini C, 2015, LIVER INT, V35, P302, DOI 10.1111/liv.12577; Cifuentes-Rojas C, 2014, MOL CELL, V55, P171, DOI 10.1016/j.molcel.2014.05.009; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Courel M, 2008, DEV DYNAM, V237, P1232, DOI 10.1002/dvdy.21516; Dahm GM, 2012, JOVE-J VIS EXP, DOI 10.3791/3851; Davidovich C, 2013, NAT STRUCT MOL BIOL, V20, P1250, DOI 10.1038/nsmb.2679; Deb G, 2014, MOL CANCER RES, V12, P639, DOI 10.1158/1541-7786.MCR-13-0546; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Geng YJ, 2011, J INT MED RES, V39, P2119, DOI 10.1177/147323001103900608; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Huang RYJ, 2012, J CELL SCI, V125, P4417, DOI 10.1242/jcs.099697; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kaneko S, 2013, NAT STRUCT MOL BIOL, V20, P1258, DOI 10.1038/nsmb.2700; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kretz M, 2014, MOL CELL, V55, P157, DOI 10.1016/j.molcel.2014.07.002; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li LJ, 2013, CELL REP, V5, P3, DOI 10.1016/j.celrep.2013.09.003; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tien CL, 2015, DEVELOPMENT, V142, P722, DOI 10.1242/dev.111997; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wongtrakoongate P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005615; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017; Yu M, 2012, MOL CELL, V45, P330, DOI 10.1016/j.molcel.2011.11.032; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	57	113	117	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					942	955		10.1038/onc.2016.260	http://dx.doi.org/10.1038/onc.2016.260			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452518	Green Published, hybrid			2022-12-28	WOS:000394169100007
J	Su, Q; Zhang, B; Zhang, L; Dang, T; Rowley, D; Ittmann, M; Xin, L				Su, Q.; Zhang, B.; Zhang, L.; Dang, T.; Rowley, D.; Ittmann, M.; Xin, L.			Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; STEM-CELLS; E-CADHERIN; NOTCH; MECHANISM; TUMORIGENESIS; PROGRESSION; EXPRESSION; MICROENVIRONMENT	The role of Notch signaling in prostate cancer has not been defined definitively. Several large scale tissue microarray studies have revealed that the expression of some Notch signaling components including the Jagged1 ligand are upregulated in advanced human prostate cancer specimens. Jagged1 expressed by tumor cells may activate Notch signaling in both adjacent tumor cells and cells in tumor microenvironment. However, it remains undetermined whether increased Jagged1 expression reflects a cause for or a consequence of tumor progression in vivo. To address this question, we generated a novel R26-LSL-JAG1 mouse model that enables spatiotemporal Jagged1 expression. Prostate specific upregulation of Jagged1 neither interferes with prostate epithelial homeostasis nor significantly accelerates tumor initiation or progression in the prostate-specific Pten deletion mouse model for prostate cancer. However, Jagged1 upregulation results in increased inflammatory foci in tumors and incidence of intracystic adenocarcinoma. In addition, Jagged1 overexpression upregulates Tgf beta signaling in prostate stromal cells and promotes progression of a reactive stromal microenvironment in the Pten null prostate cancer model. Collectively, Jagged1 overexpression does not significantly accelerate prostate cancer initiation and progression in the context of loss-of-function of Pten, but alters tumor histopathology and microenvironment. Our study also highlights an understudied role of Notch signaling in regulating prostatic stromal homeostasis.	[Su, Q.; Zhang, B.; Zhang, L.; Dang, T.; Rowley, D.; Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Su, Q.] Baylor Coll Med, Grad Program Integrat Mol & Biomed Sci, Houston, TX 77030 USA; [Rowley, D.; Ittmann, M.; Xin, L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Ittmann, M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Ittmann, M.] Baylor Coll Med, Vet Affairs Med Ctr, Michael E DeBakey Dept, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Xin, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu			NIH [P30 AI036211, P30 CA125123, S10 RR024574, R01 CA190378, CA196570]; Mouse Embryonic Stem Cell Core at Baylor College of Medicine; NCI; NATIONAL CANCER INSTITUTE [P30CA125123, R21CA196570, R01CA190378] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mouse Embryonic Stem Cell Core at Baylor College of Medicine; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Spyros Artavanis-Tsakonas for providing the human Jagged1 cDNA, the technical support by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom. This work is supported by NIH R01 CA190378 (L.X.), CA196570 (L.X.), NIH P30 CA125123 (the Cancer Center Shared Resources Grant), the Mouse Embryonic Stem Cell Core at Baylor College of Medicine and NCI.	Alme AKB, 2016, UROL ONCOL-SEMIN ORI, V34, P171, DOI 10.1016/j.urolonc.2016.01.006; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Barron DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013751; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Dalrymple S, 2005, CANCER RES, V65, P9269, DOI 10.1158/0008-5472.CAN-04-3989; Danza G, 2013, INT J CANCER, V133, P2577, DOI 10.1002/ijc.28293; del Alamo D, 2011, CURR BIOL, V21, pR40, DOI 10.1016/j.cub.2010.10.034; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Gibb DR, 2011, J IMMUNOL, V186, P4244, DOI 10.4049/jimmunol.1003318; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Kwon OJ, 2016, J CLIN INVEST; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Njuguna J., 2013, NANOPROD REV J, V1, P1, DOI DOI 10.1074/JBC.M112.443580; Orr B, 2009, ENDOCRINOLOGY, V150, P463, DOI 10.1210/en.2008-0383; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pedrosa AR, 2015, ONCOTARGET, V6, P24404, DOI 10.18632/oncotarget.4380; Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Shou JY, 2001, CANCER RES, V61, P7291; Steg AD, 2011, CLIN CANCER RES, V17, P5674, DOI 10.1158/1078-0432.CCR-11-0432; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Terada N, 2014, J CELL BIOCHEM, V115, P1505, DOI 10.1002/jcb.24805; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vallejo DM, 2011, EMBO J, V30, P756, DOI 10.1038/emboj.2010.358; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Z., 2011, INFORM RES, V2011, P1, DOI DOI 10.1111/J.1365-313X.2011.04659.X; Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu XY, 2011, DEV BIOL, V356, P337, DOI 10.1016/j.ydbio.2011.05.659; Yong T, 2011, J CELL BIOCHEM, V112, P2340, DOI 10.1002/jcb.23157; Yu YC, 2014, ASIAN TEST SYMPOSIUM, P1, DOI 10.1109/ATS.2014.13	49	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					618	627		10.1038/onc.2016.232	http://dx.doi.org/10.1038/onc.2016.232			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345403	Green Accepted			2022-12-28	WOS:000394167700004
J	Gallastegui, E; Bicer, A; Orlando, S; Besson, A; Pujol, MJ; Bachs, O				Gallastegui, E.; Bicer, A.; Orlando, S.; Besson, A.; Pujol, M. J.; Bachs, O.			p27(Kip1) represses the Pitx2-mediated expression of p21(Cip1) and regulates DNA replication during cell cycle progression	ONCOGENE			English	Article							CDK INHIBITORS; PITX2; ACTIVATION; P21; DIFFERENTIATION; PROLIFERATION; REQUIREMENT; QUIESCENCE; RELEVANCE; MIGRATION	The tumor suppressor p21 regulates cell cycle progression and peaks at mid/late G1. However, the mechanisms regulating its expression during cell cycle are poorly understood. We found that embryonic fibroblasts from p27 null mice at early passages progress slowly through the cell cycle. These cells present an elevated basal expression of p21 suggesting that p27 participates to its repression. Mechanistically, we found that p27 represses the expression of Pitx2 (an activator of p21 expression) by associating with the ASE- regulatory region of this gene together with an E2F4 repressive complex. Furthermore, we found that Pitx2 binds to the p21 promoter and induces its transcription. Finally, silencing Pitx2 or p21 in proliferating cells accelerates DNA replication and cell cycle progression. Collectively, these results demonstrate an unprecedented connection between p27, Pitx2 and p21 relevant for the regulation of cell cycle progression and cancer and for understanding human pathologies associated with p27 germline mutations.	[Gallastegui, E.; Bicer, A.; Orlando, S.; Pujol, M. J.; Bachs, O.] Univ Barcelona, IDIBAPS, Dept Cell Biol Immunol & Neurosci, Barcelona, Spain; [Besson, A.] INSERM, UMR1037, Canc Res Ctr Toulouse, Toulouse, France; [Besson, A.] Univ Toulouse, Toulouse, France; [Besson, A.] CNRS ERL5294, Toulouse, France	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Bachs, O (corresponding author), Univ Barcelona, Biomed, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Besson, Arnaud/J-6254-2014; Bicer, Atilla/AAA-6738-2019; Orlando, Serena/AAA-7963-2019	Besson, Arnaud/0000-0002-9599-3943; Bicer, Atilla/0000-0003-4032-6534; Gallastegui Calvache, Edurne/0000-0003-0768-8648	Ministerio de Economia y Competitividad (MINECO) [SAF2012-38078]; Instituto de Salud Carlos III [RD12/0036/0054]; Fondation ARC pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; Institut National du Cancer	Ministerio de Economia y Competitividad (MINECO); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France)	We would like to thank to Dr Hiroshi Hamada, Dr Chrissa Kioussi, Dr Charles P Emerson and Dr Nobuko Hagiwara for the kind gift of Pitx2-ASE luciferase vector, the expression vector for Pitx2, the expression vector for Zic1 and the expression vector for Sox6, respectively. This work was supported by grants from the Ministerio de Economia y Competitividad (MINECO) SAF2012-38078 and from the Instituto de Salud Carlos III RD12/0036/0054. AB is supported by grants from the Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer and Institut National du Cancer. The data set has been deposited in ArrayExpress accession number E-MTAB-2790.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Cao HJ, 2010, DEV BIOL, V347, P289, DOI 10.1016/j.ydbio.2010.08.031; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; de la Grange P, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-180; Dickson DW, 2009, LANCET NEUROL, V8, P1150, DOI 10.1016/S1474-4422(09)70238-8; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fung FKC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037076; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gallastegui E, 2011, J VIROL, V85, P3187, DOI 10.1128/JVI.01920-10; Heldring N, 2012, CNS NEUROL DISORD-DR, V11, P884, DOI 10.2174/1871527311201070884; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Houtmeyers R, 2013, CELL MOL LIFE SCI, V70, P3791, DOI 10.1007/s00018-013-1285-5; Huang Y, 2010, CELL CYCLE, V9, P1333, DOI 10.4161/cc.9.7.11126; Jaime M, 2002, HEPATOLOGY, V35, P1063, DOI 10.1053/jhep.2002.32678; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Liu Y, 2013, MOL CELL BIOCHEM, V384, P221, DOI 10.1007/s11010-013-1801-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malumbres M, 2011, PHYSIOL REV, V91, P973, DOI 10.1152/physrev.00025.2010; Meeh PF, 2009, NEOPLASIA, V11, P1074, DOI 10.1593/neo.09808; Montavon T, 2014, SEMIN CELL DEV BIOL, V34, P76, DOI 10.1016/j.semcdb.2014.06.005; Moreno CS, 2005, CANCER RES, V65, P10214, DOI 10.1158/0008-5472.CAN-05-0884; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Orlando S, 2015, NUCLEIC ACIDS RES, V43, P6860, DOI 10.1093/nar/gkv593; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; SALA A, 1994, CANCER RES, V54, P1402; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004	37	5	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					350	361		10.1038/onc.2016.200	http://dx.doi.org/10.1038/onc.2016.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270438				2022-12-28	WOS:000394166000005
J	Hollstein, M; Alexandrov, LB; Wild, CP; Ardin, M; Zavadil, J				Hollstein, M.; Alexandrov, L. B.; Wild, C. P.; Ardin, M.; Zavadil, J.			Base changes in tumour DNA have the power to reveal the causes and evolution of cancer	ONCOGENE			English	Review							MUTATIONAL SIGNATURES; HEPATOCELLULAR-CARCINOMA; P53 MUTATIONS; LUNG-CANCER; SOMATIC MUTATIONS; ARISTOLOCHIC ACID; GENOMIC LANDSCAPE; CELL CARCINOMA; RISK-FACTORS; GENE	Next-generation sequencing (NGS) technology has demonstrated that the cancer genomes are peppered with mutations. Although most somatic tumour mutations are unlikely to have any role in the cancer process per se, the spectra of DNA sequence changes in tumour mutation catalogues have the potential to identify the mutagens, and to reveal the mutagenic processes responsible for human cancer. Very recently, a novel approach for data mining of the vast compilations of tumour NGS data succeeded in separating and precisely defining at least 30 distinct patterns of sequence change hidden in mutation databases. At least half of these mutational signatures can be readily assigned to known human carcinogenic exposures or endogenous mechanisms of mutagenesis. A quantum leap in our knowledge of mutagenesis in human cancers has resulted, stimulating a flurry of research activity. We trace here the major findings leading first to the hypothesis that carcinogenic insults leave characteristic imprints on the DNA sequence of tumours, and culminating in empirical evidence from NGS data that well-defined carcinogen mutational signatures are indeed present in tumour genomic DNA from a variety of cancer types. The notion that tumour DNAs can divulge environmental sources of mutation is now a well-accepted fact. This approach to cancer aetiology has also incriminated various endogenous, enzyme-driven processes that increase the somatic mutation load in sporadic cancers. The tasks now confronting the field of molecular epidemiology are to assign mutagenic processes to orphan and newly discovered tumour mutation patterns, and to determine whether avoidable cancer risk factors influence signatures produced by endogenous enzymatic mechanisms. Innovative research with experimental models and exploitation of the geographical heterogeneity in cancer incidence can address these challenges.	[Hollstein, M.; Ardin, M.; Zavadil, J.] World Hlth Org, Int Agcy Res Canc, Mol Mech & Biomarkers, 150 Cours Albert Thomas, F-69008 Lyon, France; [Hollstein, M.] Univ Leeds, Fac Med & Hlth, Leeds LS2 9JT, W Yorkshire, England; [Alexandrov, L. B.] Los Alamos Natl Lab, Theoret Biol & Biophys T 6, POB 1663, Los Alamos, NM 87545 USA; [Alexandrov, L. B.] Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM USA; [Wild, C. P.] World Hlth Org, Int Agcy Res Canc, Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); University of Leeds; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; World Health Organization; International Agency for Research on Cancer (IARC)	Hollstein, M; Zavadil, J (corresponding author), World Hlth Org, Int Agcy Res Canc, Mol Mech & Biomarkers, 150 Cours Albert Thomas, F-69008 Lyon, France.; Alexandrov, LB (corresponding author), Los Alamos Natl Lab, Theoret Biol & Biophys T 6, POB 1663, Los Alamos, NM 87545 USA.	M.Hollstein@leeds.ac.uk; lba@lanl.gov; zavadilj@iarc.fr	Alexandrov, Ludmil/AAS-1454-2021; Wild, Christopher/ABC-6260-2020; Zavadil, Jiri/ABG-1780-2020	Alexandrov, Ludmil/0000-0003-3596-4515; Wild, Christopher/0000-0003-0249-8669; Zavadil, Jiri/0000-0003-0640-5562	INCa-INSERM Plan Cancer grant; J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory	INCa-INSERM Plan Cancer grant; J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory	We acknowledge these funding sources: INCa-INSERM 2015 Plan Cancer grant to JZ; LBA is supported through the J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory.	Alexandrov LB, 2015, NAT GENET, V47, P1402, DOI 10.1038/ng.3441; Alexandrov LB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9683; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Brennan P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005522; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Castells X, 2015, CANCER EPIDEM BIOMAR, V24, P1873, DOI 10.1158/1055-9965.EPI-15-0553; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Fedeles BI, 2015, P NATL ACAD SCI USA, V112, pE4571, DOI 10.1073/pnas.1507709112; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fischer A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r39; Flibotte S, 2010, GENETICS, V185, P431, DOI 10.1534/genetics.110.116616; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gohler S, 2016, J CANCER RES CLIN, V142, P273, DOI 10.1007/s00432-015-2038-7; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; Grollman AP, 2013, ENVIRON MOL MUTAGEN, V54, P1, DOI 10.1002/em.21756; Gu XW, 2012, CURR OPIN HEMATOL, V19, P292, DOI 10.1097/MOH.0b013e328353da3a; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoang ML, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 2013, MUTAT RES-REV MUTAT, V753, P41, DOI 10.1016/j.mrrev.2013.02.003; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Jelakovic B, 2015, INT J CANCER, V136, P2967, DOI 10.1002/ijc.29338; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Krishnan VG, 2014, CANCER RES, V74, P6071, DOI 10.1158/0008-5472.CAN-13-3195; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Maslov AY, 2015, MUTAT RES-FUND MOL M, V776, P136, DOI 10.1016/j.mrfmmm.2015.03.014; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P5135, DOI 10.1073/pnas.72.12.5135; Meier B, 2014, GENOME RES, V24, P1624, DOI 10.1101/gr.175547.114; MILLER JH, 1982, CELL, V31, P5, DOI 10.1016/0092-8674(82)90398-1; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pettersen HS, 2015, DNA REPAIR, V25, P60, DOI 10.1016/j.dnarep.2014.11.006; Pfeifer GP, 2015, CURR OPIN ONCOL, V27, P71, DOI 10.1097/CCO.0000000000000152; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pickering CR, 2014, CLIN CANCER RES, V20, P3842, DOI 10.1158/1078-0432.CCR-14-0565; Poon SL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0161-3; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Rebhandl Stefan, 2015, Oncoscience, V2, P320; Roberts SA, 2014, BIOESSAYS, V36, P382, DOI 10.1002/bies.201300140; Ross-Innes CS, 2015, NAT GENET, V47, P1038, DOI 10.1038/ng.3357; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Segovia R, 2015, TRENDS GENET, V31, P465, DOI 10.1016/j.tig.2015.04.001; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shiraishi Y, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005657; Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202; Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004; Stewart B, 2014, WORLD CANC REPORT 20; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tam AS, 2016, G3-GENES GENOM GENET, V6, P133, DOI 10.1534/g3.115.021915; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Warren CJ, 2015, J VIROL, V89, P688, DOI 10.1128/JVI.02383-14; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; WOGAN GN, 1992, CANCER RES, V52, pS2114; Wu S, 2016, NATURE, V529, P43, DOI 10.1038/nature16166; Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017; Zhang YN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/190629; Zou SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6696; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	99	40	43	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					158	167		10.1038/onc.2016.192	http://dx.doi.org/10.1038/onc.2016.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270430	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000393938100002
J	Liceras-Boillos, P; Garcia-Navas, R; Ginel-Picardo, A; Anta, B; Perez-Andres, M; Lillo, C; Gomez, C; Jimeno, D; Fernandez-Medarde, A; Baltanas, FC; Santos, E				Liceras-Boillos, P.; Garcia-Navas, R.; Ginel-Picardo, A.; Anta, B.; Perez-Andres, M.; Lillo, C.; Gomez, C.; Jimeno, D.; Fernandez-Medarde, A.; Baltanas, F. C.; Santos, E.			Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MEDIATED ERK ACTIVATION; RAS ACTIVATION; SIGNALING PATHWAYS; MALIGNANT-TRANSFORMATION; SUPEROXIDE-PRODUCTION; IN-VITRO; K-RAS; CELLS; ASSAY	Using a 4-hydroxytamoxifen (4OHT)-inducible, conditional Sos1-null mutation, we analyzed wild-type (WT), single Sos1-KO, Sos2-KO and double Sos1/2 KO primary mouse embryonic fibroblasts (MEF) with an aim at evaluating the functional specificity or redundancy of the Sos1 and Sos2 alleles at the cellular level. The 4OHT-induced Sos1-KO and Sos1/2-DKO MEFs exhibited distinct flat morphology, enlarged cell perimeter and altered cytoskeletal organization that were not observed in the WT and Sos2-KO counterparts. The Sos1-KO and Sos1/2-DKO MEFs also displayed significant accumulation, in comparison with WT and Sos2-KO MEFs, of cytoplasmic vesicular bodies identified as autophagosomes containing degraded mitochondria by means of electron microscopy and specific markers. Cellular proliferation and migration were impaired in Sos1-KO and Sos1/2-DKO MEFs in comparison with WT and Sos2-KO MEFs, whereas cell adhesion was only impaired upon depletion of both Sos isoforms. RasGTP formation was practically absent in Sos1/2-DKO MEFs as compared with the other genotypes and extracellular signal-regulated kinase phosphorylation showed only significant reduction after combined Sos1/2 depletion. Consistent with a mitophagic phenotype, in vivo labeling with specific fluorophores uncovered increased levels of oxidative stress (elevated intracellular reactive oxygen species and mitochondrial superoxide and loss of mitochondrial membrane potential) in the Sos1-KO and the Sos1/2-DKO cells as compared with Sos2-KO and WT MEFs. Interestingly, treatment of the MEF cultures with antioxidants corrected the altered phenotypes of Sos1-KO and Sos1/2-DKO MEFs by restoring their altered perimeter size and proliferative rate to levels similar to those of WT and Sos2-KO MEFs. Our data uncover a direct mechanistic link between Sos1 and control of intracellular oxidative stress, and demonstrate functional prevalence of Sos1 over Sos2 with regards to cellular proliferation and viability.	[Liceras-Boillos, P.; Garcia-Navas, R.; Ginel-Picardo, A.; Anta, B.; Perez-Andres, M.; Gomez, C.; Jimeno, D.; Fernandez-Medarde, A.; Baltanas, F. C.; Santos, E.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Unamuno, Salamanca 37007, Spain; [Lillo, C.] Univ Salamanca, INCYL, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Baltanas, FC; Santos, E (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Unamuno, Salamanca 37007, Spain.	baltanas@usal.es; esantos@usal.es	Baltanas, Fernando C./D-4756-2018; Fernández-Medarde, Alberto/B-3839-2017; Lillo, Concepcion/A-6321-2009; Baltanas, Fernando C./AAU-7451-2021; Perez-Andres, Martin/B-3692-2019; Garcia Navas, Rosula/D-5135-2018; Jimeno, David/D-3096-2018	Baltanas, Fernando C./0000-0001-8110-0991; Fernández-Medarde, Alberto/0000-0002-1230-5501; Lillo, Concepcion/0000-0001-5814-9826; Baltanas, Fernando C./0000-0001-8110-0991; Perez-Andres, Martin/0000-0003-4599-0776; Garcia Navas, Rosula/0000-0002-8956-3904; Jimeno, David/0000-0001-7876-0083	ISCIII (MINECO) [FIS PI13/02846, RTICC RD12/0036/0001, RD12/0036/0048]; JCyL, Spain [SA181U13, BIO/SA03/14]; FEDER-JCyL; Fondo Social Europeo; AECC	ISCIII (MINECO); JCyL, Spain(Junta de Castilla y Leon); FEDER-JCyL; Fondo Social Europeo(European Social Fund (ESF)European Commission); AECC	This work was supported by grants FIS PI13/02846, RTICC RD12/0036/0001 and RD12/0036/0048 from ISCIII (MINECO) and grants SA181U13 and BIO/SA03/14 from JCyL, Spain. PL-B, RG-N and CG were supported by FEDER-JCyL, Fondo Social Europeo and AECC, respectively. Nuria Calzada is gratefully acknowledged for technical assistance.	Arai JA, 2009, NEUROSCI LETT, V455, P22, DOI 10.1016/j.neulet.2009.03.047; Azrak SS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-731; Baltanas FC, 2013, MOL CELL BIOL, V33, P4562, DOI 10.1128/MCB.01026-13; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Cardoso CMP, 2003, TOXICOL IN VITRO, V17, P663, DOI 10.1016/S0887-2333(03)00106-1; Castellano Esther, 2011, Genes Cancer, V2, P216, DOI 10.1177/1947601911408081; Castellano E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r123; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen PC, 2010, J CLIN INVEST, V120, P4353, DOI 10.1172/JCI43910; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI 10.1517/14728220802517901 ; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Groves JT, 2010, NAT STRUCT MOL BIOL, V17, P659, DOI 10.1038/nsmb.1844; Guittard G., 2015, EUR J IMMUNOL; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hennig A, 2015, BIOL CHEM, V396, P831, DOI 10.1515/hsz-2014-0257; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Huang AC, 2009, IN VIVO, V23, P613; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765; Kortum RL, 2012, MOL CELL BIOL, V32, P2748, DOI 10.1128/MCB.00317-12; Kortum RL, 2011, P NATL ACAD SCI USA, V108, P12407, DOI 10.1073/pnas.1104295108; Kumkhaek C, 2013, BLOOD, V121, P3216, DOI 10.1182/blood-2011-10-385252; Lee EJ, 2006, J DENT RES, V85, P1050, DOI 10.1177/154405910608501115; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang HL, 2010, FREE RADICAL BIO MED, V49, P1550, DOI 10.1016/j.freeradbiomed.2010.08.018; Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Marino G, 2011, MOL CELL, V42, P1, DOI 10.1016/j.molcel.2011.03.003; Martin-Encabo S, 2007, EXP CELL RES, V313, P3881, DOI 10.1016/j.yexcr.2007.07.036; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022-1759(97)00043-4; Neuzil J, 2012, CELL RES, V22, P285, DOI 10.1038/cr.2011.160; Nimnual Anjaruwee, 2002, Sci STKE, V2002, ppe36, DOI 10.1126/stke.2002.145.pe36; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Park D, 2000, BIOCHEMISTRY-US, V39, P12513, DOI 10.1021/bi000995y; Pierre S, 2011, BIOCHEM PHARMACOL, V81, P304, DOI 10.1016/j.bcp.2010.10.003; Poltorak M, 2014, EUR J IMMUNOL, V44, P1535, DOI 10.1002/eji.201344046; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Rojas Jose M, 2011, Genes Cancer, V2, P298, DOI 10.1177/1947601911408078; Roose JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Timofeeva OA, 2009, INT J ONCOL, V35, P751, DOI 10.3892/ijo_00000388; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Warnecke N, 2012, EMBO REP, V13, P386, DOI 10.1038/embor.2012.17; Yokosuka T, 2013, CANCER CHEMOTH PHARM, V72, P1335, DOI 10.1007/s00280-013-2303-x; Yoo SG, 2012, INT J DISTRIB SENS N, DOI 10.1155/2012/382810	65	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6389	6402		10.1038/onc.2016.169	http://dx.doi.org/10.1038/onc.2016.169			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27157612				2022-12-28	WOS:000390247600004
J	Meng, Y; Wang, L; Chen, D; Chang, Y; Zhang, M; Xu, JJ; Zhou, R; Zhang, QY				Meng, Y.; Wang, L.; Chen, D.; Chang, Y.; Zhang, M.; Xu, J-J; Zhou, R.; Zhang, Q-Y			LAPTM4B: an oncogene in various solid tumors and its functions	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC MARKER; GENE POLYMORPHISM; POOR-PROGNOSIS; CANCER SUSCEPTIBILITY; OVEREXPRESSION; CARCINOMA; AUTOPHAGY; METASTASIS; ANGIOGENESIS; ASSOCIATION	The oncogene Lysosome-associated protein transmembrane-4 beta (LAPTM4B) gene was identified, and the polymorphism region in the 5'-UTR of this gene was certified to be associated with tumor susceptibility. LAPTM4B-35 protein was found to be highly expressed in various solid tumors and could be a poor prognosis marker. The functions of LAPTM4B in solid tumors were also explored. It is suggested that LAPTM4B could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance.	[Meng, Y.; Wang, L.; Chen, D.; Chang, Y.; Zhang, M.; Xu, J-J; Zhang, Q-Y] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Clin Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China; [Zhou, R.] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing, Peoples R China	Peking University; Peking University	Zhang, QY (corresponding author), Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Clin Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.	zhqy_208@163.com		Meng, Zhang/0000-0003-1653-9230	National Natural Science Foundation of China [81572910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all subjects who participated in this study. This work was supported by the National Natural Science Foundation of China (No. 81572910).	Blom T, 2015, NAT CHEM BIOL, V11, P799, DOI [10.1038/NCHEMBIO.1889, 10.1038/nchembio.1889]; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cheng XJ, 2008, ANN ONCOL, V19, P527, DOI 10.1093/annonc/mdm469; Fan MR, 2012, CANCER EPIDEMIOL, V36, P364, DOI 10.1016/j.canep.2011.12.004; Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Kadara H, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju004; Kang Y, 2012, AM J SURG, V204, P677, DOI 10.1016/j.amjsurg.2012.02.003; Kasper G, 2005, CANCER LETT, V224, P93, DOI 10.1016/j.canlet.2004.10.004; Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362; Lee HM, 2010, BLOOD, V116, P720, DOI 10.1182/blood-2009-11-253872; Leone RD, 2013, TRENDS ENDOCRIN MET, V24, P209, DOI 10.1016/j.tem.2013.01.008; Li L, 2010, ONCOGENE, V29, P5785, DOI 10.1038/onc.2010.303; Li X, 2012, ORG MED CHEM LETT, V2, P2, DOI DOI 10.1371/J0URNAL.P0NE.0044916; Li Y, 2011, CANCER RES, V71, P7481, DOI 10.1158/0008-5472.CAN-11-0940; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Liu J.J., 2000, J BEIJING MED U, V32, P411; Liu LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118026; Liu XD, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/4/045203; Liu Xinrong, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P340; Liu Y, 2007, ANN ONCOL, V18, P311, DOI 10.1093/annonc/mdl394; Meng FL, 2010, INT J GYNECOL CANCER, V20, P745, DOI 10.1111/IGC.0b013e3181e02f90; Meng FL, 2016, TUMOR BIOL, V37, P4849, DOI 10.1007/s13277-015-4319-9; Meng FL, 2015, CELL PHYSIOL BIOCHEM, V37, P890, DOI 10.1159/000430216; Meng FL, 2013, BIOMARKERS, V18, P136, DOI 10.3109/1354750X.2012.752526; Meng FL, 2011, CANCER-AM CANCER SOC, V117, P2652, DOI 10.1002/cncr.25833; Meng FL, 2010, INT J GYNECOL PATHOL, V29, P587, DOI 10.1097/PGP.0b013e3181e0898e; Milkereit R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8250; Milkereit R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027478; Shaker O, 2015, J MED BIOCHEM, V34, P393, DOI 10.2478/jomb-2014-0067; Shao GZ, 2003, ONCOGENE, V22, P5060, DOI 10.1038/sj.onc.1206832; SUN L, 2007, ZHONG LIU FANG ZHI Y, V4, P245; Tan XJ, 2016, TRENDS CELL BIOL, V26, P352, DOI 10.1016/j.tcb.2015.12.006; Tan XJ, 2015, EMBO J, V34, P475, DOI 10.15252/embj.201489425; Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006; Tang H, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0974-8; Tang H, 2014, ONCOL REP, V31, P2454, DOI 10.3892/or.2014.3116; Wang B, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0470-6; Wang S, 2012, ANN ONCOL, V23, P1864, DOI 10.1093/annonc/mdr538; Xia LZ, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0941-7; Xiao M, 2013, J CANCER RES CLIN, V139, P661, DOI 10.1007/s00432-012-1368-y; Xu Y, 2012, JPN J CLIN ONCOL, V42, P413, DOI 10.1093/jjco/hys026; Xue Shi-Lin, 2007, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V23, P45; Yang H, 2012, MED ONCOL, V29, P2809, DOI 10.1007/s12032-012-0173-4; Yang H, 2010, CANCER LETT, V294, P236, DOI 10.1016/j.canlet.2010.02.006; Yang H, 2010, J SURG ONCOL, V101, P363, DOI 10.1002/jso.21489; Yang H, 2010, J CANCER RES CLIN, V136, P275, DOI 10.1007/s00432-009-0659-4; Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yin MZ, 2012, INT J GYNECOL CANCER, V22, P54, DOI 10.1097/IGC.0b013e318234f9ac; Yin MZ, 2011, INT J CANCER, V129, P629, DOI 10.1002/ijc.25689; Zhai GJ, 2012, MED ONCOL, V29, P2744, DOI 10.1007/s12032-011-0139-y; Zhang G, 2012, J INT MED RES, V40, P1275, DOI 10.1177/147323001204000406; Zhang H, LAPTM4B 35 PROTEIN P; Zhang HT, 2015, ONCOTARGET, V6, P6092, DOI 10.18632/oncotarget.3341; Zhang H, 2014, MATH PROBL ENG, V2014, DOI [10.1155/2014/183580, 10.1007/978-3-319-07200-5_1]; Zhang M, 2013, MERIT RES J PHARM PH, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0057520; Zhang M, 2014, TRANSL ONCOL, V7, P638, DOI 10.1016/j.tranon.2014.07.001; Zhou L, 2008, CANCER LETT, V264, P209, DOI 10.1016/j.canlet.2008.01.025; Zhou L, 2007, EUR J CANCER, V43, P809, DOI 10.1016/j.ejca.2006.10.025; Zhou L, 2011, SURGERY, V150, P25, DOI 10.1016/j.surg.2010.12.010; Zhou L, 2010, AM J SURG, V199, P515, DOI 10.1016/j.amjsurg.2009.03.031	62	42	47	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6359	6365		10.1038/onc.2016.189	http://dx.doi.org/10.1038/onc.2016.189			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27212036	Green Published, hybrid			2022-12-28	WOS:000390247600001
J	Rajabi, H; Tagde, A; Alam, M; Bouillez, A; Pitroda, S; Suzuki, Y; Kufe, D				Rajabi, H.; Tagde, A.; Alam, M.; Bouillez, A.; Pitroda, S.; Suzuki, Y.; Kufe, D.			DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ZINC-FINGER PROTEINS; BREAST-CANCER CELLS; TRANSCRIPTIONAL REGULATION; MAINTENANCE METHYLATION; LUNG-CANCER; DE-NOVO; EXPRESSION; GENE; 3B	Aberrant expression of the DNA methyltransferases (DNMTs) and disruption of DNA methylation patterns are associated with carcinogenesis and cancer cell survival. The oncogenic MUC1-C protein is aberrantly overexpressed in diverse carcinomas; however, there is no known link between MUC1-C and DNA methylation. Our results demonstrate that MUC1-C induces the expression of DNMT1 and DNMT3b, but not DNMT3a, in breast and other carcinoma cell types. We show that MUC1-C occupies the DNMT1 and DNMT3b promoters in complexes with NF-kappa B p65 and drives DNMT1 and DNMT3b transcription. In this way, MUC1-C controls global DNA methylation as determined by analysis of LINE-1 repeat elements. The results further demonstrate that targeting MUC1-C downregulates DNA methylation of the CDH1 tumor suppressor gene in association with induction of E-cadherin expression. These findings provide compelling evidence that MUC1-C is of functional importance to induction of DNMT1 and DNMT3b and, in turn, changes in DNA methylation patterns in cancer cells.	[Rajabi, H.; Tagde, A.; Alam, M.; Bouillez, A.; Suzuki, Y.; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Pitroda, S.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Suzuki, Y.] Osaka Police Hosp, Dept Surg Gastroenterol, Osaka, Osaka 5430035, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Osaka Police Hospital	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this paper was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480, and by the Lung Cancer Research Foundation.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Berger N, 2007, EXP HEMATOL, V35, P1495, DOI 10.1016/j.exphem.2007.07.006; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Gnemmi V, 2014, CANCER LETT, V346, P225, DOI 10.1016/j.canlet.2013.12.029; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Ko YG, 2005, J BIOL CHEM, V280, P9627, DOI 10.1074/jbc.M413822200; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Lin RK, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-46; Lisanti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079044; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Qu Y, 2010, AM J CLIN PATHOL, V134, P826, DOI 10.1309/AJCPHGQ69FXDFWII; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Ratnam S, 2002, DEV BIOL, V245, P304, DOI 10.1006/dbio.2002.0628; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rodic N, 2014, AM J PATHOL, V184, P1280, DOI 10.1016/j.ajpath.2014.01.007; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen N, 2014, ONCOTARGET, V5, P5494, DOI 10.18632/oncotarget.2131; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tubio JMC, 2014, SCIENCE, V345, P531, DOI 10.1126/science.1251343; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Yamada N, 2008, CANCER RES, V68, P2708, DOI 10.1158/0008-5472.CAN-07-6844; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; ZRIHANLICHT S, 1995, INT J CANCER, V62, P245, DOI 10.1002/ijc.2910620303	41	59	62	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6439	6445		10.1038/onc.2016.180	http://dx.doi.org/10.1038/onc.2016.180			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27212035	Green Accepted, Green Submitted			2022-12-28	WOS:000390247600008
J	Varga, MG; Shaffer, CL; Sierra, JC; Suarez, G; Piazuelo, MB; Whitaker, ME; Romero-Gallo, J; Krishna, US; Delgado, A; Gomez, MA; Good, JAD; Almqvist, F; Skaar, EP; Correa, P; Wilson, KT; Hadjifrangiskou, M; Peek, RM				Varga, M. G.; Shaffer, C. L.; Sierra, J. C.; Suarez, G.; Piazuelo, M. B.; Whitaker, M. E.; Romero-Gallo, J.; Krishna, U. S.; Delgado, A.; Gomez, M. A.; Good, J. A. D.; Almqvist, F.; Skaar, E. P.; Correa, P.; Wilson, K. T.; Hadjifrangiskou, M.; Peek, R. M.			Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system	ONCOGENE			English	Article							GASTRIC EPITHELIAL-CELLS; PATTERN-RECOGNITION RECEPTORS; IN-VITRO; BACTERIAL; INDUCTION; RISK; INFECTION; ISLAND; GENES; CONJUGATION	Helicobacter pylori (H. pylori) is the strongest identified risk factor for gastric cancer, the third most common cause of cancer-related death worldwide. An H. pylori constituent that augments cancer risk is the strain-specific cag pathogenicity island, which encodes a type IV secretion system (T4SS) that translocates a pro-inflammatory and oncogenic protein, CagA, into epithelial cells. However, the majority of persons colonized with CagA+ H. pylori strains do not develop cancer, suggesting that other microbial effectors also have a role in carcinogenesis. Toll-like receptor 9 (TLR9) is an endosome bound, innate immune receptor that detects and responds to hypo-methylated CpG DNA motifs that are most commonly found in microbial genomes. High-expression tlr9 polymorphisms have been linked to the development of premalignant lesions in the stomach. We now demonstrate that levels of H. pylorimediated TLR9 activation and expression are directly related to gastric cancer risk in human populations. Mechanistically, we show for the first time that the H. pylori cancer-associated cag T4SS is required for TLR9 activation and that H. pylori DNA is actively translocated by the cag T4SS to engage this host receptor. Activation of TLR9 occurs through a contact-dependent mechanism between pathogen and host, and involves transfer of microbial DNA that is both protected as well as exposed during transport. These results indicate that TLR9 activation via the cag island may modify the risk for malignancy within the context of H. pylori infection and provide an important framework for future studies investigating the microbial-epithelial interface in gastric carcinogenesis.	[Varga, M. G.; Wilson, K. T.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Shaffer, C. L.; Skaar, E. P.; Wilson, K. T.; Hadjifrangiskou, M.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Sierra, J. C.; Suarez, G.; Piazuelo, M. B.; Whitaker, M. E.; Romero-Gallo, J.; Krishna, U. S.; Delgado, A.; Correa, P.; Wilson, K. T.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; [Gomez, M. A.] Univ Nacl Colombia, Dept Internal Med, Gastroenterol Unit, Sch Med, Bogota, Colombia; [Good, J. A. D.; Almqvist, F.] Umea Univ, Dept Chem, Umea, Sweden; [Good, J. A. D.; Almqvist, F.] Umea Univ, Umea Ctr Microbial Res, Umea, Sweden; [Skaar, E. P.; Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Universidad Nacional de Colombia; Umea University; Umea University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, 2215 Garland Ave 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu	Varga, Matthew Gordon/I-5056-2019; Shaffer, Carrie/X-6106-2019	Varga, Matthew Gordon/0000-0002-2075-3224; Wilson, Keith/0000-0003-4421-1830; Gomez, Martin/0000-0002-2377-6544; Shaffer, Carrie L./0000-0002-7457-7422; Good, James/0000-0003-2377-030X; Almqvist, Fredrik/0000-0002-0504-4446	NIH [R01-DK58587, R01-CA77955, P01-CA116087, P30-DK058404]; Vanderbilt CTSA grant from NCATS/NIH (VICTR award) [UL1 TR000445, VR7227]; Department of Veterans Affairs Merit Review grant [I01BX001453];  [APS 1-04-520-9211];  [R01-DK053620];  [R01-CA190612];  [P01-CA028842]; NATIONAL CANCER INSTITUTE [P01CA116087, R01CA077955, P01CA028842, R01CA190612] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK053620, T35DK007383, R01DK058587] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt CTSA grant from NCATS/NIH (VICTR award); Department of Veterans Affairs Merit Review grant(US Department of Veterans Affairs); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge the following core laboratories and personnel at Vanderbilt University for their contributions to these studies: Tissue Acquisition and Pathology Core; Division of Animal Care; Cell Imaging Shared Resource Core (CISR) and the Digestive Disease Research Center. This work was supported by NIH R01-DK58587, R01-CA77955, P01-CA116087 and P30-DK058404 (RMP); Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH (VICTR award VR7227), APS 1-04-520-9211 and institutional funds (MH); R01-DK053620, R01-CA190612, and a Department of Veterans Affairs Merit Review grant I01BX001453 (KTW); and P01-CA028842 (KTW and PC).	Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alvarez-Arellano L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101342; Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Barrozo RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003189; Barton GM, 2008, J CLIN INVEST, V118, P413, DOI 10.1172/JCI34431; Basso D, 2008, GASTROENTEROLOGY, V135, P91, DOI 10.1053/j.gastro.2008.03.041; Bates S, 1998, J BACTERIOL, V180, P6538, DOI 10.1128/JB.180.24.6538-6543.1998; BLASER MJ, 1995, CANCER RES, V55, P2111; Bravo LE, 2002, AM J GASTROENTEROL, V97, P2839, DOI 10.1111/j.1572-0241.2002.07031.x; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Castano-Rodriguez N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00336; Castano-Rodriguez N, 2014, HUM IMMUNOL, V75, P808, DOI 10.1016/j.humimm.2014.06.001; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chang YJ, 2005, J IMMUNOL, V175, P8242, DOI 10.4049/jimmunol.175.12.8242; Chang YJ, 2004, MOL PHARMACOL, V66, P1465, DOI 10.1124/mol.104.005199; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; CHILTON MD, 1977, CELL, V11, P263, DOI 10.1016/0092-8674(77)90043-5; Christie PJ, 2014, BBA-MOL CELL RES, V1843, P1578, DOI 10.1016/j.bbamcr.2013.12.019; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CRABTREE JE, 1993, GUT, V34, P1339, DOI 10.1136/gut.34.10.1339; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; CUELLO C, 1976, JNCI-J NATL CANCER I, V57, P1015, DOI 10.1093/jnci/57.5.1015; Ernst PB, 2006, GASTROENTEROLOGY, V130, P188, DOI 10.1053/j.gastro.2005.06.032; Fernandez-Gonzalez E, 2014, J GASTROENTEROL, V49, P594, DOI 10.1007/s00535-014-0938-y; Fernandez-Gonzalez E, 2011, J BACTERIOL, V193, P6257, DOI 10.1128/JB.05905-11; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Fischer W, 2010, NUCLEIC ACIDS RES, V38, P6089, DOI 10.1093/nar/gkq378; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Hamilton HL, 2005, MOL MICROBIOL, V55, P1704, DOI 10.1111/j.1365-2958.2005.04521.x; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ilvesaro JM, 2008, MOL CANCER RES, V6, P1534, DOI 10.1158/1541-7786.MCR-07-2005; Johnson EM, 2014, INFECT IMMUN, V82, P3457, DOI 10.1128/IAI.01640-14; Kauppila JH, 2013, APMIS, V121, P511, DOI 10.1111/apm.12016; Kersulyte D, 2003, J BACTERIOL, V185, P3764, DOI 10.1128/JB.185.13.3764-3772.2003; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Linz B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5165; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Otani K, 2012, BIOCHEM BIOPH RES CO, V426, P342, DOI 10.1016/j.bbrc.2012.08.080; Pachathundikandi SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/192420; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Rad R, 2009, GASTROENTEROLOGY, V136, P2247, DOI 10.1053/j.gastro.2009.02.066; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schroder G, 2011, P NATL ACAD SCI USA, V108, P14643, DOI 10.1073/pnas.1019074108; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Shaffer CL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002237; Sierra JC, 2013, AM J PHYSIOL-GASTR L, V305, pG196, DOI 10.1152/ajpgi.00495.2012; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Torres J, 2005, CANCER EPIDEM BIOMAR, V14, P1874, DOI 10.1158/1055-9965.EPI-05-0113; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang TR, 2014, INT J CLIN EXP PATHO, V7, P6950; Waters VL, 2001, NAT GENET, V29, P375, DOI 10.1038/ng779	62	65	67	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6262	6269		10.1038/onc.2016.158	http://dx.doi.org/10.1038/onc.2016.158			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157617	Green Accepted			2022-12-28	WOS:000388857700010
J	Hasanov, E; Chen, G; Chowdhury, P; Weldon, J; Ding, Z; Jonasch, E; Sen, S; Walker, CL; Dere, R				Hasanov, E.; Chen, G.; Chowdhury, P.; Weldon, J.; Ding, Z.; Jonasch, E.; Sen, S.; Walker, C. L.; Dere, R.			Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL	ONCOGENE			English	Article							VON-HIPPEL-LINDAU; TUMOR-SUPPRESSOR PROTEIN; RENAL-CELL CARCINOMA; RNA-POLYMERASE-II; SKELETAL-MUSCLE PROGENITORS; AURORA-A KINASE; PROLINE HYDROXYLATION; PROLYL HYDROXYLATION; CANCER GENOMICS; PRIMARY CILIUM	The hypoxia-regulated tumor-suppressor von Hippel-Lindau (VHL) is an E3 ligase that recognizes its substrates as part of an oxygen-dependent prolyl hydroxylase (PHD) reaction, with hypoxia-inducible factor a (HIF alpha) being its most notable substrate. Here we report that VHL has an equally important function distinct from its hypoxia-regulated activity. We find that Aurora kinase A (AURKA) is a novel, hypoxia-independent target for VHL ubiquitination. In contrast to its hypoxia-regulated activity, VHL mono-, rather than poly-ubiquitinates AURKA, in a PHD-independent reaction targeting AURKA for degradation in quiescent cells, where degradation of AURKA is required to maintain the primary cilium. Tumor-associated variants of VHL differentiate between these two functions, as a pathogenic VHL mutant that retains intrinsic ability to ubiquitinate HIFa is unable to ubiquitinate AURKA. Together, these data identify VHL as an E3 ligase with important cellular functions under both normoxic and hypoxic conditions.	[Hasanov, E.; Chen, G.; Chowdhury, P.; Weldon, J.; Walker, C. L.; Dere, R.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX USA; [Hasanov, E.] Hacettepe Univ, Dept Basic Oncol, Canc Inst, Ankara, Turkey; [Chowdhury, P.; Walker, C. L.; Dere, R.] Baylor Coll Med, Ctr Precis Environm Hlth, One Baylor Plaza,BCM130, Houston, TX 77030 USA; [Ding, Z.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Jonasch, E.] UT MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA; [Sen, S.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Hacettepe University; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Dere, R (corresponding author), Baylor Coll Med, Ctr Precis Environm Hlth, One Baylor Plaza,BCM130, Houston, TX 77030 USA.	ruhee.dere@bcm.edu	Hasanov, Elshad/AAO-8340-2021	Hasanov, Elshad/0000-0002-7195-0842	Robert A Welch Endowed Chair in Chemistry [BE-0023]; NATIONAL CANCER INSTITUTE [R01CA143811] Funding Source: NIH RePORTER	Robert A Welch Endowed Chair in Chemistry; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors would like to thank T Berry and S Bai for technical assistance. This work was supported by a Robert A Welch Endowed Chair in Chemistry (BE-0023) to CLW.	Anderson K, 2011, J BIOL CHEM, V286, P42027, DOI 10.1074/jbc.M111.303222; Basten Sander G, 2013, Cilia, V2, P6, DOI 10.1186/2046-2530-2-6; Basten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046-2530-2-2; Boutet SC, 2007, CELL, V130, P349, DOI 10.1016/j.cell.2007.05.044; Boutet SC, 2010, MOL CELL, V40, P749, DOI 10.1016/j.molcel.2010.09.029; Carvallo L, 2010, J BIOL CHEM, V285, P29546, DOI 10.1074/jbc.M110.155812; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Coon TA, 2012, CELL CYCLE, V11, P721, DOI 10.4161/cc.11.4.19171; Dere R, 2015, J AM SOC NEPHROL, V26, P553, DOI 10.1681/ASN.2013090984; Ding ZY, 2014, CANCER RES, V74, P3127, DOI 10.1158/0008-5472.CAN-13-3213; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferchichi I, 2012, DIS MARKERS, V33, P333, DOI [10.1155/2012/804708, 10.3233/DMA-2012-00942]; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hamano K, 2002, J UROLOGY, V167, P713, DOI 10.1016/S0022-5347(01)69132-8; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Izawa Ichiro, 2015, Cilia, V4, P12, DOI 10.1186/s13630-015-0021-1; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kasap E, 2016, TUMOR BIOL, V37, P3071, DOI 10.1007/s13277-015-4131-6; Kuehn EW, 2007, CANCER RES, V67, P4537, DOI 10.1158/0008-5472.CAN-07-0391; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lai YL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016975; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lolkema MP, 2008, EUR J HUM GENET, V16, P73, DOI 10.1038/sj.ejhg.5201930; Lolkema MP, 2007, FEBS LETT, V581, P4571, DOI 10.1016/j.febslet.2007.08.050; Martin B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067071; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Perera AD, 2000, CLIN CANCER RES, V6, P1518; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Randall JM, 2014, CANCER METAST REV, V33, P1109, DOI 10.1007/s10555-014-9533-1; Romain CV, 2014, ANTICANCER RES, V34, P2269; Sadowski M, 2012, IUBMB LIFE, V64, P136, DOI 10.1002/iub.589; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Seeger-Nukpezah Tamina, 2013, Drug Discov Today Dis Mech, V10, pe135; Shabek N, 2012, MOL CELL, V48, P87, DOI 10.1016/j.molcel.2012.07.011; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Xie L, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000444; Xue J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035848; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936	53	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3450	3463		10.1038/onc.2016.495	http://dx.doi.org/10.1038/onc.2016.495			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114281	hybrid, Green Published			2022-12-28	WOS:000403340700009
J	Yang, N; Wang, C; Wang, Z; Zona, S; Lin, SX; Wang, X; Yan, M; Zheng, FM; Li, SS; Xu, B; Bella, L; Yong, JS; Lam, EWF; Liu, Q				Yang, N.; Wang, C.; Wang, Z.; Zona, S.; Lin, S-X; Wang, X.; Yan, M.; Zheng, F-M; Li, S-S; Xu, B.; Bella, L.; Yong, J-S; Lam, E. W-F; Liu, Q.			FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; SELECTIVE AURORA; EXPRESSION; INHIBITOR; FOXO3A; CARCINOMA; PROTEINS; MLN8237	Substantial evidence suggests that breast cancer initiation, recurrence and drug resistance is supported by breast cancer stem cells (BCSCs). Recently, we reported a novel role of Aurora kinase A (AURKA) in BCSCs, as a transactivating co-factor in the induction of the c-Myc oncoprotein. However, the mode of action and transcriptional network of nuclear AURKA in BCSCs remain unknown. Here, we report that nuclear AURKA can be recruited by Forkhead box subclass M1 (FOXM1) as a co-factor to transactivate FOXM1 target genes in a kinase-independent manner. In addition, we show that AURKA and FOXM1 participate in a tightly coupled positive feedback loop to enhance BCSC phenotype. Indeed, kinase-dead AURKA can effectively transactivate the FOXM1 promoter through a Forkhead response element, whereas FOXM1 can activate AURKA expression at the transcriptional level in a similar manner. Consistently, breast cancer patient samples portrayed a strong and significant correlation between the expression levels of FOXM1 and AURKA. Moreover, both FOXM1 and AURKA were essential for maintaining the BCSC population. Finally, we demonstrated that the AURKA inhibitor AKI603 and FOXM1 inhibitor thiostrepton acted synergistically to inhibit cytoplasmic AURKA activity and disrupt the nuclear AURKA/FOXM1-positive feedback loop, respectively, resulting in a more effective inhibition of the tumorigenicity and self-renewal ability of BCSCs. Collectively, our study uncovers a previously unknown tightly coupled positive feedback signalling loop between AURKA and FOXM1, crucial for BCSC self-renewal. Remarkably, our data reveal a novel potential therapeutic strategy for targeting both the cytoplasmic and nuclear AURKA function to effectively eliminate BCSCs, so as to overcome both breast cancer and drug resistance.	[Yang, N.; Wang, C.; Wang, Z.; Lin, S-X; Wang, X.; Yan, M.; Li, S-S; Liu, Q.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, N.; Wang, C.; Wang, Z.; Lin, S-X; Wang, X.; Yan, M.; Li, S-S; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Yang, N.; Xu, B.] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Lab Med, Guangzhou, Guangdong, Peoples R China; [Zona, S.; Bella, L.; Yong, J-S; Lam, E. W-F] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England; [Zheng, F-M] Sun Yat Sen Univ, Eastern Hosp, Affiliated Hosp 1, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Guangzhou Medical University; Imperial College London; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, 651 Dongfeng Rd East, Guangzhou, Guangdong, Peoples R China.; Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.; Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China.	eric.lam@imperial.ac.uk; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	National Basic Research Program of China (973 Program) [2012CB967000]; National Natural Science Foundation of China [81630005, 81130040, 81573025, 81301734, 81602434]; Program for Innovative Research Team in University [IRT13049]; Liaoning [NSF2014029102]; Natural Science Foundation of Guangdong [2016A030311038]; Cancer Now [2012MayPR070, 2012NovPhD016]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Imperial College London; MRC [MR/N012097/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team in University; Liaoning; Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Cancer Now; CRUK(Cancer Research UK); Breast Cancer Now; Imperial College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Quentin Liu's lab members for their critical commends and technical support. This work is supported by the National Basic Research Program of China (973 Program; no. 2012CB967000 to Q Liu), National Natural Science Foundation of China (no. 81630005, 81130040 and 81573025 to Q Liu; no. 81301734 to Z Wang; no. 81602434 to N Yang), Program for Innovative Research Team in University (IRT13049 to Q Liu), Liaoning (NSF2014029102 to Q Liu) and Natural Science Foundation of Guangdong (2016A030311038 to Q.L.). Eric W-F Lam's work is supported by Cancer Now (2012MayPR070 and 2012NovPhD016) and CRUK (A12011) and Breast. Stefania Zona and Laura Bella are supported by Breast Cancer Now (2012MayPR070 and 2012NovPhD016, respectively). Jay-Sze Yong is supported by an Imperial College London studentship.	Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; Burum-Auensen E, 2007, J HISTOCHEM CYTOCHEM, V55, P477, DOI 10.1369/jhc.6A7077.2007; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cervantes A, 2012, CLIN CANCER RES, V18, P4764, DOI 10.1158/1078-0432.CCR-12-0571; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Cheng C, 2012, MOL PHARMACEUT, V9, P1971, DOI 10.1021/mp2006714; Cheung CH, 2014, EXPERT OPIN THER PAT, V24, P1021; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Consolaro F, 2015, INT J ONCOL, V47, P1230, DOI 10.3892/ijo.2015.3139; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Friedberg JW, 2014, J CLIN ONCOL, V32, P44, DOI 10.1200/JCO.2012.46.8793; Gomes AR, 2013, CHIN J CANCER, V32, P365, DOI 10.5732/cjc.012.10277; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hay AE, 2015, LEUKEMIA LYMPHOMA, V2015, P1; Hobbelen PHF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099366, 10.1371/journal.pone.0087348, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0091910, 10.1371/journal.pone.0093049, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0087588, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0095536]; Huang XF, 2008, BLOOD, V111, P2854, DOI 10.1182/blood-2007-07-099325; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kristeleit R, 2009, J CLIN ONCOL, P27; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Mosse YP, 2012, CLIN CANCER RES, V18, P6058, DOI 10.1158/1078-0432.CCR-11-3251; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Piazzolla D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5226; Qu Hongzhu, 2013, Genomics Proteomics Bioinformatics, V11, P135, DOI 10.1016/j.gpb.2013.05.001; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tamotsu K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1329-3; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tanaka T, 1999, CANCER RES, V59, P2041; Velasco-Velazquez MA, 2012, INT J BIOCHEM CELL B, V44, P573, DOI 10.1016/j.biocel.2011.12.020; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	48	59	59	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3428	3440		10.1038/onc.2016.490	http://dx.doi.org/10.1038/onc.2016.490			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114286	Green Published, hybrid			2022-12-28	WOS:000403340700007
J	Endo, H; Okami, J; Okuyama, H; Nishizawa, Y; Imamura, F; Inoue, M				Endo, H.; Okami, J.; Okuyama, H.; Nishizawa, Y.; Imamura, F.; Inoue, M.			The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE; GEFITINIB RESISTANCE; ACQUIRED-RESISTANCE; PROTEIN-SYNTHESIS; RECEPTOR; PATHWAY; QUIESCENCE; PROMOTES; SURVIVAL; MUTANT	The biologic activity of individual cancer cells is highly heterogeneous. Hypoxia, one of the prominent features of a tumor microenvironment, is thought to be causal in generating this cellular heterogeneity. In this study, we revealed that primary lung cancer cells harboring activating epidermal growth factor receptor (EGFR) mutations generally entered a dormant state when hypoxic. We found that heterodimer formation of the ERBB family receptor tyrosine kinases (RTKs), and their subsequent downstream signaling, was diminished under hypoxic conditions, although phosphorylation of the EGFR was retained. Dormant lung cancer cells were found to be resistant to EGFR tyrosine kinase inhibitor (TKI) treatment. In terms of mechanism, we found that a negative regulator of ERBB signaling, MIG6/ERRFI1/RALT/Gene33, was induced by hypoxia both in vitro and in vivo. MIG6 expression prevented heterodimer formation of ERBB family RTKs, and suppressed their downstream signaling. Knockdown of MIG6 enhanced tumor cell growth under hypoxic conditions, and promoted the phosphorylation of ERK and AKT via increased EGFR-HER3 binding. Critically, sensitivity to an EGFR-TKI, as well as to irradiation under hypoxic conditions, was increased in MIG6 knockdown cells. The expression of MIG6 was partly correlated with a pS6 negative zone in patient tumors. Analyses of tumor sections from 68 patients with activating EGFR mutations showed that patients with high MIG6 expression showed significantly shorter survival after EGFR-TKI treatment than other groups. Collectively, our data suggest that dormant cancer cells with a high MIG6 expression level might be one of the causes of EGFR-TKI resistance in EGFR mutant lung cancer cells.	[Endo, H.; Okuyama, H.; Inoue, M.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan; [Okami, J.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka, Japan; [Nishizawa, Y.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka, Japan; [Imamura, F.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Osaka, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases	Inoue, M (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.	inoue-ma2@mc.pref.osaka.jp	Okami, Jiro/AAE-3837-2021		JSPS [26111005]; KAKENHI [25461937]; Grants-in-Aid for Scientific Research [26111005] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr T Tabuchi and Dr K Fukui for statistical counseling, N Kanto and T Yasuda for technical assistance, and M Izutsu for secretarial assistance. This work was supported by JSPS Grant-in-Aid for Scientific Research on Innovative Areas (26111005) (to MI) and KAKENHI (25461937) (to HE).	Abravanel DL, 2015, J CLIN INVEST, V125, P2484, DOI 10.1172/JCI74883; Aguirre-Ghiso JA, 2004, CANCER RES, V64, P7336, DOI 10.1158/0008-5472.CAN-04-0113; Ameri K, 2015, CELL REP; Amin R, 2016, MOL ONCOL, V10, P575, DOI 10.1016/j.molonc.2015.11.009; Anastasi S, 2016, SEMIN CELL DEV BIOL, V50, P115, DOI 10.1016/j.semcdb.2015.10.001; Bui AT, 2015, CELL CYCLE, V14, P1218, DOI 10.1080/15384101.2015.1014145; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Chang XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068966; Crea F, 2015, TRENDS MOL MED, V21, P206, DOI 10.1016/j.molmed.2015.02.005; Endo H, 2007, CANCER RES, V67, P8095, DOI 10.1158/0008-5472.CAN-06-3389; Endo H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098858; Endo H, 2013, J THORAC ONCOL, V8, P131, DOI 10.1097/JTO.0b013e3182779ccf; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1786; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Lafont JE, 2008, J BIOL CHEM, V283, P4778, DOI 10.1074/jbc.M707729200; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Minakata K, 2012, CANCER SCI, V103, P1946, DOI 10.1111/j.1349-7006.2012.02408.x; Nakajima A, 2015, INT J CANCER, V136, P2949, DOI 10.1002/ijc.29349; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peart T, 2015, ONCOTARGET, V6, P22424, DOI 10.18632/oncotarget.4211; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sato Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24823; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Swinson DEB, 2003, J CLIN ONCOL, V21, P473, DOI 10.1200/JCO.2003.11.132; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tiram G, 2016, ACS NANO, V10, P2028, DOI 10.1021/acsnano.5b06189; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; Wang N, 2015, FASEB J, V29, P3141, DOI 10.1096/fj.14-266379; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Xu DZ, 2006, MOL CELL BIOL, V26, P5043, DOI 10.1128/MCB.02387-05; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Young RM, 2008, J BIOL CHEM, V283, P16309, DOI 10.1074/jbc.M710079200; Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790	53	22	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2824	2834		10.1038/onc.2016.431	http://dx.doi.org/10.1038/onc.2016.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893711				2022-12-28	WOS:000401697800005
J	Bucay, N; Sekhon, K; Yang, T; Majid, S; Shahryari, V; Hsieh, C; Mitsui, Y; Deng, G; Tabatabai, ZL; Yamamura, S; Calin, GA; Dahiya, R; Tanaka, Y; Saini, S				Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Calin, G. A.; Dahiya, R.; Tanaka, Y.; Saini, S.			MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; STEM-CELLS; INTEGRATIVE ANALYSIS; DOWN-REGULATION; CYCLE ARREST; GLIOMA-CELLS; EXPRESSION; CARCINOMA; DELETIONS; PROGRESSION	A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383- is frequently downregulated in prostate cancer, has a critical role in determining tumor- initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor- initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor- initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.	[Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Dahiya, R.; Tanaka, Y.; Saini, S.] Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA; [Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Dahiya, R.; Tanaka, Y.; Saini, S.] Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Noncoding RNA Ctr, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Texas System; UTMD Anderson Cancer Center	Saini, S (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.; Saini, S (corresponding author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA.; Saini, S (corresponding author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA.	Sharanjot.Saini@ucsf.edu	Calin, George/E-9390-2011	Calin, George/0000-0001-6704-5615; Calin, George/0000-0002-7427-0578	National Cancer Institute at the National Institutes of Health [RO1CA177984, RO1CA138642]; VA program project on PCa [BX001604]; NATIONAL CANCER INSTITUTE [R01CA182905, R01CA138642, R01CA177984] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002690, IP1BX001604] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); VA program project on PCa; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Roger Erickson for his support and assistance with preparation of the manuscript. We acknowledge UCSF CTSI (Dr Iryna V. Lobach) for help with statistical analysis. This work was supported by the National Cancer Institute at the National Institutes of Health (Grant Number RO1CA177984, RO1CA138642), VA program project on PCa (BX001604).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; BOVA GS, 1993, CANCER RES, V53, P3869; Brooks DD, 2010, J NATL MED ASSOC, V102, P423, DOI 10.1016/S0027-9684(15)30578-2; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; El Gammal AT, 2010, CLIN CANCER RES, V16, P56, DOI 10.1158/1078-0432.CCR-09-1423; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Han SL, 2015, CANCER LETT, V366, P61, DOI 10.1016/j.canlet.2015.06.004; He ZW, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0557-0; Hsieh IS, 2013, CARCINOGENESIS, V34, P530, DOI 10.1093/carcin/bgs371; Huang HL, 2014, CELL SIGNAL, V26, P903, DOI 10.1016/j.cellsig.2014.01.016; KAGAN J, 1995, ONCOGENE, V11, P2121; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Li HW, 2011, J SURG ONCOL, V103, P558, DOI 10.1002/jso.21806; Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70; Liao XH, 2015, CELL SIGNAL, V27, P2285, DOI 10.1016/j.cellsig.2015.08.005; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu W, 2006, GENE CHROMOSOME CANC, V45, P509, DOI 10.1002/gcc.20314; MACOSKA JA, 1995, CANCER RES, V55, P5390; Matsuyama H, 2003, AKTUEL UROL, V34, P247; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Matsuyama H, 2007, CANCER GENET CYTOGEN, V174, P24, DOI 10.1016/j.cancergencyto.2006.11.008; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Piovani G, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-25; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Saini S, 2016, CELL ONCOL, V39, P97, DOI 10.1007/s13402-016-0268-6; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wicha MS, 2011, NAT MED, V17, P162, DOI 10.1038/nm0211-162; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; Xu DW, 2015, TUMOR BIOL, V36, P7743, DOI 10.1007/s13277-015-3378-2; Xu Z, 2014, BIOCHEM BIOPH RES CO, V453, P833, DOI 10.1016/j.bbrc.2014.10.047; Yang K, 2010, AM J TRANSL RES, V2, P88; Yang K, 2009, INT J CLIN EXP PATHO, V2, P361; Yin MM, 2014, J BIOL CHEM, V289, P18239, DOI 10.1074/jbc.M113.546044; Zhao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110472	52	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2667	2679		10.1038/onc.2016.419	http://dx.doi.org/10.1038/onc.2016.419			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893706	Green Accepted, Green Submitted			2022-12-28	WOS:000401120900005
J	Schrock, MS; Batar, B; Lee, J; Druck, T; Ferguson, B; Cho, JH; Akakpo, K; Hagrass, H; Heerema, NA; Xia, F; Parvin, JD; Aldaz, CM; Huebner, K				Schrock, M. S.; Batar, B.; Lee, J.; Druck, T.; Ferguson, B.; Cho, J. H.; Akakpo, K.; Hagrass, H.; Heerema, N. A.; Xia, F.; Parvin, J. D.; Aldaz, C. M.; Huebner, K.			Wwox-Brca1 interaction: role in DNA repair pathway choice	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HOMOLOGOUS RECOMBINATION; WWOX; BRCA1; ASSOCIATION; INHIBITION; DAMAGE; ATM	In this study, loss of expression of the fragile site-encoded Wwox protein was found to contribute to radiation and cisplatin resistance of cells, responses that could be associated with cancer recurrence and poor outcome. WWOX gene deletions occur in a variety of human cancer types, and reduced Wwox protein expression can be detected early during cancer development. We found that Wwox loss is followed by mild chromosome instability in genomes of mouse embryo fibroblast cells from Wwox-knockout mice. Human and mouse cells deficient for Wwox also exhibit significantly enhanced survival of ionizing radiation and bleomycin treatment, agents that induce double-strand breaks (DSBs). Cancer cells that survive radiation recur more rapidly in a xenograft model of irradiated breast cancer cells; Wwox-deficient cells exhibited significantly shorter tumor latencies vs Wwox-expressing cells. This Wwox effect has important consequences in human disease: in a cohort of cancer patients treated with radiation, Wwox deficiency significantly correlated with shorter overall survival times. In examining mechanisms underlying Wwox-dependent survival differences, we found that Wwox-deficient cells exhibit enhanced homology directed repair (HDR) and decreased nonhomologous end-joining (NHEJ) repair, suggesting that Wwox contributes to DNA DSB repair pathway choice. Upon silencing of Rad51, a protein critical for HDR, Wwox-deficient cells were resensitized to radiation. We also demonstrated interaction of Wwox with Brca1, a driver of HDR, and show via immunofluorescent detection of repair proteins at ionizing radiation-induced DNA damage foci that Wwox expression suppresses DSB repair at the end-resection step of HDR. We propose a genome caretaker function for WWOX, in which Brca1-Wwox interaction supports NHEJ as the dominant DSB repair pathway in Wwox-sufficient cells. Taken together, the experimental results suggest that reduced Wwox expression, a common occurrence in cancers, dysregulates DSB repair, enhancing efficiency of likely mutagenic repair, and enabling radiation and cisplatin treatment resistance.	[Schrock, M. S.; Batar, B.; Druck, T.; Akakpo, K.; Hagrass, H.; Huebner, K.] Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Schrock, M. S.; Batar, B.; Druck, T.; Cho, J. H.; Akakpo, K.; Hagrass, H.; Heerema, N. A.; Xia, F.; Parvin, J. D.; Huebner, K.] Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Lee, J.; Ferguson, B.; Aldaz, C. M.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Sci Pk,1808 Pk Rd 1C, Smithville, TX 78957 USA; [Cho, J. H.; Xia, F.] Ohio State Univ, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA; [Heerema, N. A.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Parvin, J. D.] Ohio State Univ, Wexner Med Ctr, Dept Biomed Informat, Div Computat Biol & Bioinformat, Columbus, OH 43210 USA; [Hagrass, H.] Zagazig Univ, Zagazig, Egypt; [Xia, F.] Univ Arkansas Med Sci, Dept Radiat Oncol, Little Rock, AR 72205 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Egyptian Knowledge Bank (EKB); Zagazig University; University of Arkansas System; University of Arkansas Medical Sciences	Aldaz, CM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Sci Pk,1808 Pk Rd 1C, Smithville, TX 78957 USA.; Huebner, K (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Ctr Comprehens Canc, Biomed Res Tower,Room 916,460 W 12th Ave, Columbus, OH 43210 USA.	maaldaz@mdanderson.org; kay.huebner@osumc.edu	Aldaz, C. Marcelo/E-7868-2011; Parvin, Jeffrey D/C-8955-2009; Batar, Bahadir/F-4724-2018	Aldaz, C. Marcelo/0000-0002-2453-2939; Akakpo, Kenneth/0000-0003-4720-7626	Pelotonia [9T32OD010429, CA154200, R01CA120516]; NIH/NCI [R01 CA102444, CA198228]; Scientific and Technological Research Council of Turkey (TUBITAK); Egyptian Cultural and Educational Bureau; breast cancer support foundations; Stefanie Spielman Fund of the OSUCCC; Anne M Wolfe Foundation; NATIONAL CANCER INSTITUTE [R01CA102444, P30CA016672, U01CA154200, R01CA120516, P30CA016058, R21CA198228] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD010429] Funding Source: NIH RePORTER	Pelotonia; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Egyptian Cultural and Educational Bureau(Egyptian Cultural & Educational Bureau); breast cancer support foundations; Stefanie Spielman Fund of the OSUCCC; Anne M Wolfe Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by Pelotonia Graduate and Post-Doctoral Fellowships (to MS, BB), 9T32OD010429 (to MS), CA154200 (to KH), R01CA120516 (to KH), NIH/NCI R01 CA102444 (to CMA), CA198228 (to JP), a fellowship from the Scientific and Technological Research Council of Turkey (TUBITAK to BB) and a graduate research scholarship from the Egyptian Cultural and Educational Bureau (to HH). We thank the OSU CMIF shared Facility for confocal microscopy and the Genome Quebec company for assistance with CNA experiments. We also thank Matthew Guggenbiller (OSUMC) for help with the analysis of the brain cancer cohort and Megan Lowery and Richard D Wood (The University of Texas MD Anderson Cancer Center, Smithville, TX, USA) for providing the data in Figure 1d and Jenna Karras and T Banerjee for helpful discussions. We are especially appreciative of the additional funding by the breast cancer support foundations, the Stefanie Spielman Fund of the OSUCCC and the Anne M Wolfe Foundation (Anne's Army).	Abdeen SK, 2011, ONCOGENE, V30, P3900, DOI 10.1038/onc.2011.115; Abu-Odeh M, 2014, P NATL ACAD SCI USA, V111, pE4716, DOI 10.1073/pnas.1409252111; Aldaz CM, 2014, BBA-REV CANCER, V1846, P188, DOI 10.1016/j.bbcan.2014.06.001; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilan RI, 2009, ENDOCRINOLOGY, V150, P1530, DOI 10.1210/en.2008-1087; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Bednarek AK, 2000, CANCER RES, V60, P2140; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Choo A, 2015, GENE CHROMOSOME CANC, V54, P745, DOI 10.1002/gcc.22286; Christou Charita M, 2013, Biology (Basel), V2, P40, DOI 10.3390/biology2010040; Ferguson BW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-593; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hartmann C, 1999, INT J ONCOL, V15, P975; Hu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084638; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039588; Lim YC, 2014, MOL ONCOL, V8, P1603, DOI 10.1016/j.molonc.2014.06.012; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Ludes-Meyers JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007775; Miuma S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080730; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Salah Z, 2010, FUTURE ONCOL, V6, P249, DOI [10.2217/fon.09.152, 10.2217/FON.09.152]; Saldivar JC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003077; Sankaran S, 2006, CANCER RES, V66, P4100, DOI 10.1158/0008-5472.CAN-05-4430; Scarpace L, 2015, CANC IMAG ARCH; Schrock MS, 2015, EXP BIOL MED, V240, P296, DOI 10.1177/1535370214561590; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Veronese A, 2011, P NATL ACAD SCI USA, V108, P4840, DOI 10.1073/pnas.1101734108; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zimmerman M, 2014, TRENDS CELL BIOL, V24, P108, DOI 10.1016/j.tcb.2013.09.003	41	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2215	2227		10.1038/onc.2016.389	http://dx.doi.org/10.1038/onc.2016.389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27869163	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000399782700003
J	Capdevila, J; Casanovas, O; Salazar, R; Castellano, D; Segura, A; Fuster, P; Aller, J; Garcia-Carbonero, R; Jimenez-Fonseca, P; Grande, E; Castano, JP				Capdevila, J.; Casanovas, O.; Salazar, R.; Castellano, D.; Segura, A.; Fuster, P.; Aller, J.; Garcia-Carbonero, R.; Jimenez-Fonseca, P.; Grande, E.; Castano, J. P.			Translational research in neuroendocrine tumors: pitfalls and opportunities	ONCOGENE			English	Review							MULTIPLE ENDOCRINE NEOPLASIA; PHASE-II; MULTISTAGE TUMORIGENESIS; DEPOT OCTREOTIDE; GROWTH-FACTOR; MTOR PATHWAY; MOUSE MODEL; CARCINOID-SYNDROME; TARGETED THERAPY; POOR-PROGNOSIS	Interest in research on neuroendocrine tumors (NETs) has grown in the past 10 years, coinciding with improvements in our understanding of the molecular pathogenesis of NETs. In addition, NETs have become one of the most exciting settings for drug development. Two targeted agents for the management of advanced pancreatic NETs have been approved, but the development of targeted agents for NETs is limited by problems with both patient selection and demonstration of activity. In this review, we analyze these limitations and discuss ways to increase the predictive value of preclinical models for target discovery and drug development. The role of translational research and 'omics' methodologies is emphasized, with the final aim of developing personalized medicine. Because NETs usually grow slowly and metastatic tumors are found at easily accessible locations, and owing to improvements in techniques for liquid biopsies, NETs provide a unique opportunity to obtain tumor samples at all stages of the evolution of the disease and to adapt treatment to changes in tumor biology. Combining clinical and translational research is essential to achieve progress in the NET field. Slow growth and genetic stability limit and challenge both the availability and further development of preclinical models of NETs, one of the most crucial unmet research needs in the field. Finally, we suggest some useful approaches for improving clinical drug development for NETs: moving from classical RECIST-based response end points to survival parameters; searching for different criteria to define response rates (for example, antiangiogenic effects and metabolic responses); implementing randomized phase II studies to avoid single-arm phase II studies that produce limited data on drug efficacy; and using predictive biomarkers for patient selection.	[Capdevila, J.] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, VHIO, Med Oncol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Casanovas, O.] Inst Catalan Oncol IDIBELL, ProCURE Res Program, Barcelona, Spain; [Salazar, R.] Univ Barcelona, Catalan Inst Oncol IDIBELL, Oncol Dept, Barcelona, Spain; [Castellano, D.] Hosp Univ 12 Octubre, Oncol Dept, Madrid, Spain; [Segura, A.] Hosp Univ & Politecn La Fe, Oncol Dept, Valencia, Spain; [Fuster, P.] Hosp Univ Son Espases, Oncol Dept, Palma De Mallorca, Spain; [Aller, J.] Puerta de Hierro Univ Hosp, Dept Endocrinol, Madrid, Spain; [Garcia-Carbonero, R.] Hosp Univ Doce Octubre Ctr, Spanish Minist Sci & Innovat, Med Oncol Dept, RTICC,Inst Salud Carlos 3, Madrid, Spain; [Jimenez-Fonseca, P.] Cent Asturias Univ Hosp, Dept Med Oncol, Oviedo, Spain; [Grande, E.] Hosp Univ Ramon y Cajal, Oncol Dept, Madrid, Spain; [Castano, J. P.] Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain; [Castano, J. P.] Reina Sofia Univ Hosp, Cordoba, Spain; [Castano, J. P.] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Cordoba, Spain; [Castano, J. P.] CIBER Fisiopatol Obesidad & Nutr, Cordoba, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Hospital Universitario 12 de Octubre; Hospital Universitari i Politecnic La Fe; Hospital Universitari Son Espases; Hospital Puerta de Hierro-Majadahonda; Hospital Universitario Ramon y Cajal; Hospital Universitario Reina Sofia - Cordoba; Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Capdevila, J (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp, VHIO, Med Oncol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	jacapdevila@vhebron.net	Miquel, Josep Maria/AAG-3508-2019; Jimenez-Fonseca, Paula/AAA-1272-2020; Castaño, Justo P/A-7124-2010; Casanovas, Oriol/L-5210-2014	Castaño, Justo P/0000-0002-3145-7287; Casanovas, Oriol/0000-0002-4298-3995; Salazar, Ramon/0000-0001-9419-6232; Aller, Javier/0000-0001-6334-9072; Garcia-Carbonero, Rocio/0000-0002-3342-397X	Novartis	Novartis(Novartis)	The authors are grateful to Novartis for the unrestricted grant that made this paper possible and to Javier Mas for editorial support. International networks focused in neuroendocrine tumor management are redesigning the strategies in translational research to optimize preclinical and patient-derived tumor models to better predict efficacy in clinical setting.	Alkatout I, 2015, MODERN PATHOL, V28, P69, DOI 10.1038/modpathol.2014.82; Asa SL, 2011, MODERN PATHOL, V24, pS66, DOI 10.1038/modpathol.2010.127; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Capdevila J, 2011, CANCER DISCOV, V1, P213, DOI 10.1158/2159-8290.CD-11-0151; Capurso G, 2012, J MOL ENDOCRINOL, V49, pR37, DOI 10.1530/JME-12-0069; Castano JP, 2014, CANCER METAST REV, V33, P353, DOI 10.1007/s10555-013-9465-1; Castellano D, 2013, EUR J CANCER, V49, P3780, DOI 10.1016/j.ejca.2013.06.042; Chan J, 2014, CURR TREAT OPTION ON, V15, P365, DOI 10.1007/s11864-014-0294-4; Chan JA, 2012, J CLIN ONCOL, V30, P2963, DOI 10.1200/JCO.2011.40.3147; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CORBETT TH, 1984, CANCER RES, V44, P717; Couderc C, 2015, MOL CELL ENDOCRINOL, V399, P154, DOI 10.1016/j.mce.2014.09.006; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; De Dosso S, 2013, CANCER METAST REV, V32, P465, DOI 10.1007/s10555-013-9421-0; de Wilde RF, 2012, NAT REV GASTRO HEPAT, V9, P199, DOI 10.1038/nrgastro.2012.9; DEVITA VT, 1973, NEW ENGL J MED, V288, P998, DOI 10.1056/NEJM197305102881905; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Duran I, 2006, BRIT J CANCER, V95, P1148, DOI 10.1038/sj.bjc.6603419; Duran-Prado M, 2012, ONCOGENE, V31, P2049, DOI 10.1038/onc.2011.389; Elsasser SJ, 2011, SCIENCE, V331, P1145, DOI 10.1126/science.1203280; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Grande E, 2015, ANN ONCOL, V26, P1987, DOI 10.1093/annonc/mdv252; Grande E, 2013, ASCO M, V31, P4140; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; House MG, 2003, ANN SURG, V238, P423, DOI 10.1097/01.sla.0000086659.49569.9e; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Karpathakis A, 2013, ENDOCR-RELAT CANCER, V20, pR65, DOI 10.1530/ERC-12-0338; Kidd M, 2015, ENDOCR-RELAT CANCER, V22, P561, DOI 10.1530/ERC-15-0092; Kidd M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-595; Kolby L, 2005, BRIT J CANCER, V93, P1144, DOI 10.1038/sj.bjc.6602845; Kolby L, 2001, AM J PATHOL, V158, P745, DOI 10.1016/S0002-9440(10)64017-5; Kulke MH, 2015, NEUROENDOCRINOLOGY, V102, P131; Kulke MH, 2008, J CLIN ONCOL, V26, P3403, DOI 10.1200/JCO.2007.15.9020; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; Kulke MH, 2015, ASCO M, V33, P4005, DOI DOI 10.1200/JC0.2015.33.15_; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Meeker A, 2014, MOL CELL ENDOCRINOL, V386, P101, DOI 10.1016/j.mce.2013.07.015; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Meric-Bernstam F, 2012, CLIN CANCER RES, V18, P1777, DOI 10.1158/1078-0432.CCR-11-2123; Missiaglia E, 2010, J CLIN ONCOL, V28, P245, DOI 10.1200/JCO.2008.21.5988; Modlin IM, 2003, CANCER-AM CANCER SOC, V97, P934, DOI 10.1002/cncr.11105; Modlin IM, 2006, J CLIN ENDOCR METAB, V91, P2340, DOI 10.1210/jc.2006-0110; Musunuru S, 2005, J SURG RES, V126, P102, DOI 10.1016/j.jss.2005.01.003; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; NILSSON O, 1992, YALE J BIOL MED, V65, P741; Oberg K, 2012, ANN ONCOL, V23, P124, DOI 10.1093/annonc/mds295; Oberg K, 2013, CLIN CANCER RES, V19, P2842, DOI 10.1158/1078-0432.CCR-12-3458; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; PARANGI S, 1995, CANCER RES, V55, P6071; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; Pavel ME, 2012, J CLIN ONCOL, V30; Pavel ME, 2011, LANCET, V378, P2005, DOI 10.1016/S0140-6736(11)61742-X; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Phan AT, 2015, LANCET ONCOL, V16, P695, DOI 10.1016/S1470-2045(15)70136-1; Qian ZR, 2013, J CLIN ONCOL, V31, P3418, DOI 10.1200/JCO.2012.46.6946; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reidy-Lagunes DL, 2012, CANCER-AM CANCER SOC, V118, P4795, DOI 10.1002/cncr.27459; Sampedro-Nunez M, 2016, ONCOTARGET, V7, P6593, DOI 10.18632/oncotarget.6565; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Strosberg JR, 2011, CANCER-AM CANCER SOC, V117, P268, DOI 10.1002/cncr.25425; Yao JC, 2014, ANN ONCOL, V25; Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2008, J CLIN ONCOL, V26, P1316, DOI 10.1200/JCO.2007.13.6374; Yao JC, 2016, LANCET, V387, P968, DOI 10.1016/S0140-6736(15)00817-X; Yao JC, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4004; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yao JC, 2010, J CLIN ONCOL, V28, P69, DOI 10.1200/JCO.2009.24.2669; Zikusoka MN, 2005, CANCER-AM CANCER SOC, V104, P2292, DOI 10.1002/cncr.21451; Zurita AJ, 2015, BRIT J CANCER, V112, P1199, DOI 10.1038/bjc.2015.73	82	27	27	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1899	1907		10.1038/onc.2016.316	http://dx.doi.org/10.1038/onc.2016.316			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27641330				2022-12-28	WOS:000398898500001
J	Richards, KE; Zeleniak, AE; Fishel, ML; Wu, J; Littlepage, LE; Hill, R				Richards, K. E.; Zeleniak, A. E.; Fishel, M. L.; Wu, J.; Littlepage, L. E.; Hill, R.			Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; ANTITUMOR-ACTIVITY; KAPPA-B; GEMCITABINE; RESISTANCE; CHEMOTHERAPY; METASTASIS; MICROENVIRONMENT; INHIBITION; TARGET	Cancer-associated fibroblasts (CAFs) comprise the majority of the tumor bulk of pancreatic ductal adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus predominantly on targeting the proliferation of rapidly growing cancer epithelial cells. We know that this is largely ineffective with resistance arising in most tumors following exposure to chemotherapy. Despite the long-standing recognition of the prominence of CAFs in PDAC, the effect of chemotherapy on CAFs and how they may contribute to drug resistance in neighboring cancer cells is not well characterized. Here, we show that CAFs exposed to chemotherapy have an active role in regulating the survival and proliferation of cancer cells. We found that CAFs are intrinsically resistant to gemcitabine, the chemotherapeutic standard of care for PDAC. Further, CAFs exposed to gemcitabine significantly increase the release of extracellular vesicles called exosomes. These exosomes increased chemoresistance-inducing factor, Snail, in recipient epithelial cells and promote proliferation and drug resistance. Finally, treatment of gemcitabine-exposed CAFs with an inhibitor of exosome release, GW4869, significantly reduces survival in co-cultured epithelial cells, signifying an important role of CAF exosomes in chemotherapeutic drug resistance. Collectively, these findings show the potential for exosome inhibitors as treatment options alongside chemotherapy for overcoming PDAC chemoresistance.	[Richards, K. E.; Zeleniak, A. E.; Hill, R.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; [Richards, K. E.; Zeleniak, A. E.; Wu, J.; Littlepage, L. E.; Hill, R.] Univ Notre Dame, Harper Canc Res Inst, Dept Biol Sci, South Bend, IN USA; [Zeleniak, A. E.; Littlepage, L. E.; Hill, R.] Univ Notre Dame, Integrated Biomed Sci Program, South Bend, IN USA; [Fishel, M. L.] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Fishel, M. L.] Indiana Univ, Dept Pharmacol, Indianapolis, IN 46204 USA; [Fishel, M. L.; Littlepage, L. E.; Hill, R.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA; [Fishel, M. L.] Indiana Univ, Dept Toxicol, Indianapolis, IN 46204 USA; [Wu, J.; Littlepage, L. E.] Univ Notre Dame, Dept Chem, Notre Dame, IN 46556 USA; [Wu, J.; Littlepage, L. E.] Univ Notre Dame, Dept Biochem, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Notre Dame; University of Notre Dame	Hill, R (corresponding author), Harper Canc Res Inst, Dept Biol Sci, A126 Harper Hall,1234 North Notre Dame Ave, South Bend, IN 46617 USA.	rhill3@nd.edu	Hill, Reginald/D-2270-2016; Fishel, Melissa L./AAH-6608-2020	Fishel, Melissa L./0000-0002-9436-6382; Zeleniak, Ann/0000-0002-7974-9617	Indiana CTSI; Harper Cancer Research Institute of Notre Dame; Walther Cancer Foundation; Joseph D Boyle Memorial Fund; National Institutes of Health, NCI [CA167291]; Biomedical Research Grant; Jeff Gordon Children's Foundation; NATIONAL CANCER INSTITUTE [R01CA167291] Funding Source: NIH RePORTER	Indiana CTSI; Harper Cancer Research Institute of Notre Dame; Walther Cancer Foundation; Joseph D Boyle Memorial Fund; National Institutes of Health, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Biomedical Research Grant; Jeff Gordon Children's Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Robert Stahelin of the Indiana University School of Medicine for generously allowing us to use his particle analyzer and ultracentrifuge, Dr Niranjan Awasthi of the Indiana University School of Medicine-South Bend for helpful discussions and Dr Steven Ruggiero of the University of Notre Dame for allowing us to perform light transmission spectroscopy in his lab. This research was funded by the Indiana CTSI and Harper Cancer Research Institute of Notre Dame.; Financial Information: R Hill was awarded financial support from the Walther Cancer Foundation and the Joseph D Boyle Memorial Fund. Work by ML Fishel was supported by grants from the National Institutes of Health, NCI CA167291, with additional support from the Biomedical Research Grant and in part by Jeff Gordon Children's Foundation.	Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arora S, 2013, J BIOL CHEM, V288, P21197, DOI 10.1074/jbc.M113.484576; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330; Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158/0008-5472.CAN-08-4235; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Cheng L, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23743; Chernyshev VS, 2015, ANAL BIOANAL CHEM, V407, P3285, DOI 10.1007/s00216-015-8535-3; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Essandoh K, 2015, BBA-MOL BASIS DIS, V1852, P2362, DOI 10.1016/j.bbadis.2015.08.010; Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Kadera BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071978; Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Lee TH, 2014, BIOCHEM BIOPH RES CO, V451, P295, DOI 10.1016/j.bbrc.2014.07.109; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Mirjam C Boelens, CELL, V159, P499; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Quint K, 2012, INT J ONCOL, V41, P2093, DOI 10.3892/ijo.2012.1648; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ray Katrina, 2015, Nat Rev Gastroenterol Hepatol, V12, P371, DOI 10.1038/nrgastro.2015.93; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Sun N, 2015, ANAL BIOCHEM, V484, P58, DOI 10.1016/j.ab.2015.05.004; Svensson KJ, 2013, J BIOL CHEM, V288, P17713, DOI 10.1074/jbc.M112.445403; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	40	417	445	14	268	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1770	1778		10.1038/onc.2016.353	http://dx.doi.org/10.1038/onc.2016.353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27669441	Green Accepted, Green Submitted			2022-12-28	WOS:000398128900003
J	Uo, T; Dvinge, H; Sprenger, CC; Bradley, RK; Nelson, PS; Plymate, SR				Uo, T.; Dvinge, H.; Sprenger, C. C.; Bradley, R. K.; Nelson, P. S.; Plymate, S. R.			Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain	ONCOGENE			English	Article							HEAT-SHOCK PROTEIN; PROSTATE-CANCER; GLUCOCORTICOID-RECEPTOR; NUCLEAR-LOCALIZATION; INCREASED SURVIVAL; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; ACTIVATION; EXPRESSION	The presence of intact ligand-binding domain (LBD) ensures the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces structural reorganization of LBD resulting in release of AR from HSP90, suppression of nuclear export which otherwise dominates over import and nuclear translocation of AR as a transcription factor. Thus, loss or defects of the LBD abolish constraint from un-liganded LBD as exemplified by constitutively active AR variants (AR-Vs), which are associated with emerging resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC). Recent analysis of the AR splicing landscapes revealed mCRPC harboring multiple AR-Vs with diverse patterns of inclusion/exclusion of exons (exons 4-8) corresponding to LBD to produce namely exon-skipping variants. In silico construction for these AR-Vs revealed four novel AR-Vs having unique features: Exclusion of specified exons introduces a frameshift in variants v5es, v6es and v7es. ARv56es maintains the reading frame resulting in the inclusion of the C-terminal half of the LBD. We systematically characterized these AR-Vs regarding their subcellular localization, affinity for HSP90 and transactivation capability. Notably, ARv5es was free from HSP90, exclusively nuclear, and constitutively active similarly as previously reported for v567es. In contrast, v6es and v7es were similar in that they are cytoplasmic, transcriptionally inactive and bind HSP90, ARv56es was present in both nucleus and cytoplasm, does not bind HSP90 and is transcriptionally inactive. Converting these transcriptionally inactive AR-Vs into active forms, we identified the two separate elements that allosterically suppress otherwise constitutively active AR-Vs; one in exon 5 for v6es and v7es and the other in exon 8 for v56es. Our findings identify a novel constitutively active AR-V, ARv5es and establish a method to predict potential activities of AR-Vs carrying impaired LBD.	[Uo, T.; Dvinge, H.; Plymate, S. R.] Univ Washington, Dept Med, Harborview Res & Training Bldg,Box 359625,325 9th, Seattle, WA 98195 USA; [Dvinge, H.; Bradley, R. K.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Computat Biol Program, 1124 Columbia St, Seattle, WA 98104 USA; [Dvinge, H.; Bradley, R. K.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Human Biol Div, 1124 Columbia St, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Plymate, SR (corresponding author), Univ Washington, Dept Med, Harborview Res & Training Bldg,Box 359625,325 9th, Seattle, WA 98195 USA.	splymate@u.washington.edu		Bradley, Robert/0000-0002-8046-1063; Dvinge, Heidi/0000-0003-1741-0738	Department of Defense [W81XWH-12-PCRP-TIA]; Veterans Affairs Research Program; National Cancer of Institute [P01CA163227, P50 CA 097186]; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA163227] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD020069] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003324] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Veterans Affairs Research Program; National Cancer of Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Defense (W81XWH-12-PCRP-TIA), Veterans Affairs Research Program (to SRP) and National Cancer of Institute (P01CA163227, P50 CA 097186) (to SRP and PSN).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Centenera MM, 2008, MOL ENDOCRINOL, V22, P2373, DOI 10.1210/me.2008-0017; Ceraline J, 2004, INT J CANCER, V108, P152, DOI 10.1002/ijc.11404; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Darshan MS, 2011, CANCER RES, V71, P6019, DOI 10.1158/0008-5472.CAN-11-1417; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Gillis JL, 2013, ONCOTARGET, V4, P691, DOI 10.18632/oncotarget.975; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Helsen C, 2012, MOL CELL BIOL, V32, P3033, DOI 10.1128/MCB.00151-12; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MARIVOET S, 1992, MOL CELL ENDOCRINOL, V88, P165, DOI 10.1016/0303-7207(92)90021-W; Mostaghel EA, 2014, CLIN CANCER RES, V20, P791, DOI 10.1158/1078-0432.CCR-12-3601; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sprenger CCT, 2014, HORM CANCER-US, V5, P207, DOI 10.1007/s12672-014-0177-y; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Storer CL, 2011, TRENDS ENDOCRIN MET, V22, P481, DOI 10.1016/j.tem.2011.08.001; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; TAKAHASHI H, 1995, CANCER RES, V55, P1621; Tan MHE, 2015, ACTA PHARMACOL SIN, V36, P3, DOI 10.1038/aps.2014.18; Thadani-Mulero M, 2014, CANCER RES, V74, P2270, DOI 10.1158/0008-5472.CAN-13-2876; van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026; Wang D, 2015, MOL ENDOCRINOL, V29, P1731, DOI 10.1210/me.2015-1112; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; WEN W, 1994, J BIOL CHEM, V269, P32214; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yang X, 2011, J BIOL CHEM, V286, P36152, DOI 10.1074/jbc.M111.265124; Zhang GY, 2015, ONCOTARGET, V6, P23358, DOI 10.18632/oncotarget.4396; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	58	5	5	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1440	1450		10.1038/onc.2016.313	http://dx.doi.org/10.1038/onc.2016.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27694897	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000395862500012
J	Chang, SS; Yamaguchi, H; Xia, W; Lim, SO; Khotskaya, Y; Wu, Y; Chang, WC; Liu, Q; Hung, MC				Chang, S-S; Yamaguchi, H.; Xia, W.; Lim, S-O; Khotskaya, Y.; Wu, Y.; Chang, W-C; Liu, Q.; Hung, M-C			Aurora A kinase activates YAP signaling in triple-negative breast cancer	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; HIPPO PATHWAY; CELL-MIGRATION; PROTEIN; PHOSPHORYLATION; KIBRA; COMPLEX; CHEMORESISTANCE; REGULATOR; TAZ	The Yes-associated protein (YAP) is an effector that transduces the output of the Hippo pathway to transcriptional modulation. Considering the role of YAP in cancers, this protein has emerged as a key node in malignancy development. In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-mediated transcriptional machinery. Specifically, YAP associates with Aurora A predominantly in the nucleus. Activation of Aurora A can impinge on YAP activity through direct phosphorylation. Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-negative breast cancer (TNBC). We herein provide evidence to establish the functional relevance of this newly discovered regulatory axis in TNBC.	[Chang, S-S; Yamaguchi, H.; Xia, W.; Lim, S-O; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Chang, S-S; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA; [Khotskaya, Y.] Univ Texas Houston, MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Nahyan Inst Personalized, Houston, TX USA; [Wu, Y.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA; [Chang, W-C; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Liu, Q.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Liu, Q.] Dalian Med Univ, First Affiliated Hosp, Collaborat Innovat Ctr Onco, Inst Canc Stem Cell, Dalian, Peoples R China; [Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Lim, Seung-Oe/D-3703-2011	Hung, Mien-Chie/0000-0003-4317-4740; 	National Institutes of Health [CA109311, CA099031]; Cancer Center Support [CA016672]; National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE) [MOST 105-2911-I-002-302]; Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW105-TDU-B-212-134003]; Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support; National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); International Research-intensive Centers of Excellence in Taiwan (I-RiCE); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence; Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded in part by the following: National Institutes of Health grants (CA109311, CA099031 and Cancer Center Support Grant CA016672); National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund (to M-CH); Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003); Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund. We also thank Tamara K Locke of the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for her editorial assistance.	Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953; Chen J, 2012, CURR BIOL, V22, P1582, DOI 10.1016/j.cub.2012.06.074; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Kim M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6370; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Poon CLC, 2012, CURR BIOL, V22, P1587, DOI 10.1016/j.cub.2012.06.075; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Song SM, 2015, CLIN CANCER RES, V21, P2580, DOI 10.1158/1078-0432.CCR-14-2191; Sun SG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9402; Sun Y, 2015, AM J TRANSL RES, V7, P319; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Wang G, 2004, J VIROL, V78, P7097, DOI 10.1128/JVI.78.13.7097-7111.2004; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xiao L, 2011, J BIOL CHEM, V286, P36304, DOI 10.1074/jbc.M111.246850; Yabuta N, 2011, CELL CYCLE, V10, P2724, DOI 10.4161/cc.10.16.16873; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang J, 2013, INT J CANCER, V133, P2706, DOI 10.1002/ijc.28277; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zhang K, 2014, ONCOTARGET, V5, P12916, DOI 10.18632/oncotarget.2682; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao YL, 2014, CANCER RES, V74, P4493, DOI 10.1158/0008-5472.CAN-13-2712; Zorba A, 2014, ELIFE, V3, DOI 10.7554/eLife.02667	57	33	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1265	1275		10.1038/onc.2016.292	http://dx.doi.org/10.1038/onc.2016.292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27593935				2022-12-28	WOS:000395861300010
J	Vinyoles, M; Del Valle-Perez, B; Curto, J; Padilla, M; Villarroel, A; Yang, J; de Herreros, AG; Dunach, M				Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Yang, J.; de Herreros, A. G.; Dunach, M.			Activation of CK1 epsilon by PP2A/PR61 epsilon is required for the initiation of Wnt signaling	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; CASEIN KINASE 1; BETA-CATENIN; LRP6 PHOSPHORYLATION; REGULATORY SUBUNIT; TRANSCRIPTIONAL ACTIVITY; COMPLEX; P120-CATENIN; BINDING; DOMAIN	Canonical Wnt signaling induces the stabilization of beta-catenin, its translocation to the nucleus and the activation of target promoters. This pathway is initiated by the binding of Wnt ligands to the Frizzled receptor, the association of the LRP5/6 coreceptor and the formation of a complex comprising Dvl-2, Axin and protein kinases CK1 alpha, epsilon, gamma and GSK3. Among these, activation of CK1 epsilon, constitutively bound to LRP5/6 through p120-catenin, is required for the association of the rest of the components. We describe here that CK1 epsilon is activated by the PP2A/PR61 epsilon phosphatase. Binding of Wnt ligands promotes the interaction of LRP5/6-associated CK1 epsilon with Frizzled-bound PR61 epsilon regulatory subunit, facilitating the access of PP2A catalytic subunit to CK1 epsilon and its activation, what enables the recruitment of Dvl-2 to the receptor complex and the initiation of the Wnt pathway. Our results uncover the mechanism of activation of the canonical Wnt pathway by its ligands.	[Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Dunach, M.] Univ Autonoma Barcelona, Fac Med, CEB, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain; [Vinyoles, M.; de Herreros, A. G.] Inst Hosp Mar Invest Med IMIM, Programa Recerca Canc, Barcelona, Spain; [Yang, J.] Univ Illinois, Coll Vet Med, Dept Comparat Biosci, Urbana, IL USA; [de Herreros, A. G.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); University of Illinois System; University of Illinois Urbana-Champaign; Pompeu Fabra University	Dunach, M (corresponding author), Univ Autonoma Barcelona, Fac Med, CEB, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain.; de Herreros, AG (corresponding author), IMIM, Parc Recerca Biomed Barcelona,C Doctor Aiguader, E-08003 Barcelona, Spain.	agarcia@imim.es; mireia.dunach@uab.es	Dunach, Mireia/E-3604-2015; Vinyoles, Meritxell/AAA-5302-2019	Dunach, Mireia/0000-0001-9844-5603; 	Ministerio de Economia y Competitividad [BFU2012-31554, BFU2015-65153-R, SAF2013-48849-C2-R1]; Fundacio La Marato de TV3 [120130]; ICREA Academia from Generalitat de Catalunya [2014SGR-32]; ISCIII/FEDER [RD12/0036/005]; FPI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111816, R35GM131810] Funding Source: NIH RePORTER	Ministerio de Economia y Competitividad(Spanish Government); Fundacio La Marato de TV3; ICREA Academia from Generalitat de Catalunya(ICREA); ISCIII/FEDER(Spanish Government); FPI(Spanish Government); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Gonzalez-Sancho, C Niehrs, A Bigas and A Kikuchi for providing reagents and N Ontiveros for excellent technical assistance. This work was funded by grants from the Ministerio de Economia y Competitividad (BFU2012-31554 and BFU2015-65153-R, both MINECO/FEDER, to MD and SAF2013-48849-C2-R1 to AGH) and Fundacio La Marato de TV3 (120130) to MD and AGH. Support from ICREA Academia, 2014SGR-32 from Generalitat de Catalunya and ISCIII/FEDER (RD12/0036/005) is also appreciated. MV was a recipient of a predoctoral fellowship from FPI.	Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Casagolda D, 2010, J CELL SCI, V123, P2621, DOI 10.1242/jcs.067512; Castano J, 2007, MOL CELL BIOL, V27, P1745, DOI 10.1128/MCB.01974-06; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cruciat CM, 2014, CURR OPIN CELL BIOL, V31, P46, DOI 10.1016/j.ceb.2014.08.003; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Cselenyi CS, 2008, P NATL ACAD SCI USA, V105, P8032, DOI 10.1073/pnas.0803025105; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; del Valle-Perez B, 2011, MOL CELL BIOL, V31, P2877, DOI 10.1128/MCB.01466-10; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Hay E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349-08; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Jin Z, 2009, J BIOL CHEM, V284, P7190, DOI 10.1074/jbc.M807907200; Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748-1716.2011.02294.x; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liang J, 2011, MOL CELL BIOL, V31, P2577, DOI 10.1128/MCB.05103-11; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880; Mi KH, 2006, J BIOL CHEM, V281, P4787, DOI 10.1074/jbc.M508657200; Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018-010-0329-3; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tanneberger K, 2011, EMBO J, V30, P1433, DOI 10.1038/emboj.2011.28; Tauriello DVF, 2012, P NATL ACAD SCI USA, V109, pE812, DOI 10.1073/pnas.1114802109; Valls G, 2012, J CELL SCI, V125, P5288, DOI 10.1242/jcs.101030; Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yang J, 2003, DEVELOPMENT, V130, P5569, DOI 10.1242/dev.00762; Yu J, 2014, BIOSCIENCE REP, V34; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	45	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					429	438		10.1038/onc.2016.209	http://dx.doi.org/10.1038/onc.2016.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321178	Green Accepted			2022-12-28	WOS:000394166000012
J	D'Brot, A; Kurtz, P; Regan, E; Jakubowski, B; Abrams, JM				D'Brot, A.; Kurtz, P.; Regan, E.; Jakubowski, B.; Abrams, J. M.			A platform for interrogating cancer-associated p53 alleles (vol 36, pg 286, 2017)	ONCOGENE			English	Correction																		D'Brot A, 2017, ONCOGENE, V36, P286, DOI 10.1038/onc.2016.48	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					292	292		10.1038/onc.2016.190	http://dx.doi.org/10.1038/onc.2016.190			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27991923	Bronze			2022-12-28	WOS:000393938100014
J	Liu, Z; Lam, N; Wang, E; Virden, RA; Pawel, B; Attiyeh, EF; Maris, JM; Thiele, CJ				Liu, Z.; Lam, N.; Wang, E.; Virden, R. A.; Pawel, B.; Attiyeh, E. F.; Maris, J. M.; Thiele, C. J.			Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNALS; TRANSCRIPTION FACTOR; P53 TETRAMERIZATION; GENE-EXPRESSION; CRM1 INHIBITOR; DNA-DAMAGE; IN-VIVO; PROTEIN; LOCALIZATION; PHOSPHORYLATION	As a transcription factor, localization to the nucleus and the recruitment of cofactors to regulate gene transcription is essential. Nuclear localization and nucleosome remodeling and histone deacetylase (NuRD) complex binding are required for the zinc-finger transcription factor CASZ1 to function as a neuroblastoma (NB) tumor suppressor. However, the critical amino acids (AAs) that are required for CASZ1 interaction with NuRD complex and the regulation of CASZ1 subcellular localization have not been characterized. Through alanine scanning, immunofluorescence cell staining and co-immunoprecipitation, we define a critical region at the CASZ1 N terminus (AAs 23-40) that mediates the CASZ1b nuclear localization and NuRD interaction. Furthermore, we identified a nuclear export signal (NES) at the N terminus (AAs 176-192) that contributes to CASZ1 nuclear-cytoplasmic shuttling in a chromosomal maintenance 1 -dependent manner. An analysis of CASZ1 protein expression in a primary NB tissue microarray shows that high nuclear CASZ1 staining is detected in tumor samples from NB patients with good prognosis. In contrast, cytoplasmic-restricted CASZ1 staining or low nuclear CASZ1 staining is found in tumor samples from patients with poor prognosis. These findings provide insight into mechanisms by which CASZ1 regulates transcription, and suggests that regulation of CASZ1 subcellular localization may impact its function in normal development and pathologic conditions such as NB tumorigenesis.	[Liu, Z.; Lam, N.; Wang, E.; Virden, R. A.; Thiele, C. J.] NCI, Pediat Oncol Branch, 9000 Rockville Pike,Bldg 10,Room 1W-3940,MSC 1105, Bethesda, MD 20892 USA; [Pawel, B.; Attiyeh, E. F.; Maris, J. M.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thiele, CJ (corresponding author), NCI, Pediat Oncol Branch, 9000 Rockville Pike,Bldg 10,Room 1W-3940,MSC 1105, Bethesda, MD 20892 USA.	thielec@mail.nih.gov			Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010788] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gregory Wray from the Institute for Genome Sciences and Policy, Duke University for generously providing the tyrosine hydroxylase promoter-pGL4.1-luc (TH-Luc) construct; Nisha Pawer and Neeraj Prasad of the POB, NCI for making the CASZ1b and mutant-EGFP constructs. We appreciate the insightful discussions with Drs Dinah Singer and David Levens of the CCR, NCI on this study. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute and Center for Cancer Research.	Bottardi S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004827; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Charpentier MS, 2013, DEV CELL, V25, P132, DOI 10.1016/j.devcel.2013.03.003; Chayka O, 2009, JNCI-J NATL CANCER I, V101, P663, DOI 10.1093/jnci/djp063; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; CUI X, 1992, DEVELOPMENT, V116, P943; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Foo RSY, 2007, P NATL ACAD SCI USA, V104, P20826, DOI 10.1073/pnas.0710017104; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gerecitano J, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0067-3; Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230; Hoff AM, 2015, ONCOTARGET, V6, P36587, DOI 10.18632/oncotarget.5500; Ishizawa J, 2015, PHARMACOL THERAPEUT, V153, P25, DOI 10.1016/j.pharmthera.2015.06.001; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Jordan VK, 2015, APPL CLIN GENET, V8, P189, DOI 10.2147/TACG.S65698; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kulisz A, 2008, MOL CELL BIOL, V28, P1553, DOI 10.1128/MCB.00935-07; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu Z, 2011, CELL DEATH DIFFER, V18, P1174, DOI 10.1038/cdd.2010.187; Liu ZT, 2011, EURASIP J ADV SIG PR, DOI 10.1155/2011/490289; Liu ZZ, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00001; Liu ZH, 2006, BIOCHEM BIOPH RES CO, V344, P834, DOI 10.1016/j.bbrc.2006.03.207; Liu ZH, 2014, J BIOL CHEM, V289, P29801, DOI 10.1074/jbc.M114.570416; Malki S, 2010, INT J BIOCHEM CELL B, V42, P411, DOI 10.1016/j.biocel.2009.09.020; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mattar P, 2015, NEURON, V85, P497, DOI 10.1016/j.neuron.2014.12.052; MELLERICK DM, 1992, NEURON, V9, P789, DOI 10.1016/0896-6273(92)90234-5; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Nguyen Kevin T, 2012, Int J Biochem Mol Biol, V3, P137; Nie LH, 2007, J BIOL CHEM, V282, P14616, DOI 10.1074/jbc.M610515200; Prieto G, 2014, BIOINFORMATICS, V30, P1220, DOI 10.1093/bioinformatics/btu016; Ranganathan P, 2012, BLOOD, V120, P1765, DOI 10.1182/blood-2012-04-423160; Rehberg S, 2002, MOL CELL BIOL, V22, P5826, DOI 10.1128/MCB.22.16.5826-5834.2002; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sakakibara K, 2011, BLOOD, V118, P3922, DOI 10.1182/blood-2011-01-333138; Schmitz M, 2012, INT J CANCER, V131, pE593, DOI 10.1002/ijc.27433; Schulte JH, 2009, INT J CANCER, V124, P2488, DOI 10.1002/ijc.24204; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeuchi F, 2010, CIRCULATION, V121, P2302, DOI 10.1161/CIRCULATIONAHA.109.904664; Vacalla CMH, 2002, MECH DEVELOP, V118, P265, DOI 10.1016/S0925-4773(02)00282-4; Virden RA, 2012, MOL CELL BIOL, V32, P1518, DOI 10.1128/MCB.06039-11; Wang C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001564; Warner LR, 2009, BRAIN RES, V1288, P1, DOI 10.1016/j.brainres.2009.06.086; Winter C, 2008, PEDIATR BLOOD CANCER, V51, P10, DOI 10.1002/pbc.21475; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	52	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					97	109		10.1038/onc.2016.179	http://dx.doi.org/10.1038/onc.2016.179			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270431	Green Accepted			2022-12-28	WOS:000394069100009
J	Yang, Y; Huycke, MM; Herman, TS; Wang, X				Yang, Y.; Huycke, M. M.; Herman, T. S.; Wang, X.			Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer	ONCOGENE			English	Article							FAECALIS-INFECTED MACROPHAGES; TRANSCRIPTION FACTOR; C-JUN; OXIDATIVE STRESS; CELL-LINES; GENETIC-POLYMORPHISM; SIGNALING PATHWAY; EPITHELIAL-CELLS; RESPONSE ELEMENT; HUMAN TISSUES	Glutathione S-transferase alpha 4 (GSTA4) is a phase II detoxifying enzyme that metabolizes electrophiles and carcinogens including 4-hydroxy-2-nonenal (4-HNE), an endogenous carcinogen that contributes to colorectal carcinogenesis. In this study, we investigated GSTA4 expression and regulation in murine primary colonic epithelial cells, microbiome-driven murine colitis and human carcinomas. Exposure of YAMC cells to 4-HNE induced Gsta4 expression. Using an inflammation-associated model of colorectal cancer (CRC), Gsta4 expression increased in vivo in colon macrophages and serum after 2 weeks of colonization of IL-10 deficient (Il10(-/-)) mice with Enterococcus faecalis. Increased expression was noted after 9 months of colonization in colon macrophages and epithelia in areas of inflammation. In human colon biopsies, immunohistochemistry showed no GSTA4 expression in normal epithelial cells, whereas GSTA4 was strongly expressed in the neoplastic epithelia of invasive carcinomas. For tubular adenomas, increased expression was primarily noted in stromal macrophages. Increased GSTA4 was confirmed in established human CRC cell lines and associated with 4-HNE-protein adducts in human colon adenomas and CRC. Next, we showed that 4-HNE induced activation of c-Jun and Nrf2, two components of the oncogenic transcription factor AP-1. AP-1 inhibitors and gene-specific small interfering RNAs partially suppressed GSTA4 expression. Co-immunoprecipitation confirmed interactions between c-Jun and Nrf2 supporting a role for AP-1 in regulating 4-HNE-induced GSTA4 expression. These findings demonstrate GSTA4 activation during 4-HNE-induced neoplastic transformation in colorectal carcinogenesis. GSTA4 is a potential surrogate biomarker for CRC screening and should provide novel approaches for chemoprevention.	[Yang, Y.; Herman, T. S.; Wang, X.] Univ Oklahoma, Hlth Sci Ctr, Dept Radiat Oncol, Oklahoma City, OK USA; [Yang, Y.; Huycke, M. M.; Wang, X.] Oklahoma City VA Hlth Care Syst, Muchmore Labs Infect Dis Res, Oklahoma City, OK USA; [Huycke, M. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Wang, X (corresponding author), Univ Oklahoma, Dept Radiat Oncol, Hlth Sci Ctr, VA Med Ctr, 921 NE 13th St,Room 3R-109, Oklahoma City, OK 73104 USA.	xingmin-wang@ouhsc.edu	Huycke, Mark M./AAG-9384-2020; Wang, Xingmin/GOV-6306-2022	Huycke, Mark/0000-0002-6110-5629	Oklahoma Center for the Advancement of Science and Technology [HR10-032]; Francis Duffy Endowment	Oklahoma Center for the Advancement of Science and Technology; Francis Duffy Endowment	We thank Jim Henthorn in the Flow Cytometry and Imaging Laboratory, the Histology and Immunohistochemistry Core in the Peggy and Charles Stephenson Cancer Center (NIH GM103639) at the University of Oklahoma Health Sciences Center for technical assistance. Supported in part by Oklahoma Center for the Advancement of Science and Technology grant HR10-032 (XW) and Francis Duffy Endowment.	Abel EL, 2010, JNCI-J NATL CANCER I, V102, P1663, DOI 10.1093/jnci/djq392; Apidianakis Y, 2012, FASEB J, V26, P730, DOI 10.1096/fj.11-192484; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Bakuradze T, 2010, MOL NUTR FOOD RES, V54, P1734, DOI 10.1002/mnfr.201000147; Barrera G, 2004, FREE RADICAL BIO MED, V37, P597, DOI 10.1016/j.freeradbiomed.2004.05.023; Chaudhary P, 2013, J BIOL CHEM, V288, P20532, DOI 10.1074/jbc.M113.467662; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Coles BF, 2005, METHOD ENZYMOL, V401, P9, DOI 10.1016/S0076-6879(05)01002-5; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Desmots F, 2005, FEBS LETT, V579, P5691, DOI 10.1016/j.febslet.2005.08.088; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211; Diribarne G, 2009, RNA BIOL, V6, P122, DOI 10.4161/rna.6.2.8115; Edalat M, 2004, HISTOCHEM CELL BIOL, V122, P151, DOI 10.1007/s00418-004-0688-7; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Feng ZH, 2004, P NATL ACAD SCI USA, V101, P8598, DOI 10.1073/pnas.0402794101; Fontana MF, 2015, J IMMUNOL, V194, P177, DOI 10.4049/jimmunol.1401595; Giera S, 2010, TOXICOL SCI, V115, P22, DOI 10.1093/toxsci/kfq033; Hasselblatt P, 2008, ONCOGENE, V27, P6102, DOI 10.1038/onc.2008.211; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Johns LE, 2000, MUTAGENESIS, V15, P399, DOI 10.1093/mutage/15.5.399; Kalinina EV, 2012, B EXP BIOL MED+, V154, P64, DOI 10.1007/s10517-012-1876-4; Kumagai T, 2004, J BIOL CHEM, V279, P48389, DOI 10.1074/jbc.M409935200; Levy S, 2009, FREE RADICAL BIO MED, V47, P1172, DOI 10.1016/j.freeradbiomed.2009.07.036; Matsumura T, 2013, FASEB J, V27, P3198, DOI 10.1096/fj.12-222745; Miller DP, 2003, EPIDEMIOLOGY, V14, P545, DOI 10.1097/01.ede.0000073120.46981.24; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Miyanishi K, 2001, GASTROENTEROLOGY, V121, P865, DOI 10.1053/gast.2001.27982; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Nobuoka A, 2004, GASTROENTEROLOGY, V127, P428, DOI 10.1053/j.gastro.2004.05.021; Nomani H, 2005, CLIN BIOCHEM, V38, P621, DOI 10.1016/j.clinbiochem.2005.04.004; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Ritchie KJ, 2009, P NATL ACAD SCI USA, V106, P20859, DOI 10.1073/pnas.0911351106; Sawers L, 2014, BRIT J CANCER, V111, P1150, DOI 10.1038/bjc.2014.386; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Searchfield L, 2011, HISTOPATHOLOGY, V58, P180, DOI 10.1111/j.1365-2559.2010.03733.x; Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Shimizu T, 2010, CANCER SCI, V101, P1093, DOI 10.1111/j.1349-7006.2010.01508.x; Shireman LM, 2010, ARCH BIOCHEM BIOPHYS, V504, P182, DOI 10.1016/j.abb.2010.09.005; Sirota R, 2015, REDOX BIOL, V4, P48, DOI 10.1016/j.redox.2014.11.012; Sweeney C, 2002, TOXICOLOGY, V181, P83, DOI 10.1016/S0300-483X(02)00259-7; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Wang XM, 2015, GUT, V64, P459, DOI 10.1136/gutjnl-2014-307213; Wang XM, 2013, CANCER PREV RES, V6, P206, DOI 10.1158/1940-6207.CAPR-12-0350; Wang XM, 2012, GASTROENTEROLOGY, V142, P543, DOI 10.1053/j.gastro.2011.11.020; Wang XM, 2008, CANCER RES, V68, P9909, DOI 10.1158/0008-5472.CAN-08-1551; West JD, 2005, CHEM RES TOXICOL, V18, P1642, DOI 10.1021/tx050211n; Yang YH, 2013, TRANSL ONCOL, V6, P596, DOI 10.1593/tlo.13412; Zarrouki B, 2007, FEBS LETT, V581, P2394, DOI 10.1016/j.febslet.2007.04.048; ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821	55	15	15	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5795	5806		10.1038/onc.2016.113	http://dx.doi.org/10.1038/onc.2016.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065323	Green Accepted			2022-12-28	WOS:000386998400010
J	Powley, IR; Hughes, MA; Cain, K; MacFarlane, M				Powley, I. R.; Hughes, M. A.; Cain, K.; MacFarlane, M.			Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex	ONCOGENE			English	Article							SIGNALING COMPLEX; CELL-DEATH; APOPTOSIS; MUTATIONS; RECONSTITUTION; ACTIVATION; MECHANISM; SURVIVAL; REVEALS; KINASES	Caspase-8 is a key initiator of apoptotic cell death where it functions as the apical protease in death receptor-mediated apoptosis triggered via the death-inducing signalling complex (DISC). However, the observation that caspase-8 is upregulated in many common tumour types led to the discovery of alternative non-apoptotic, pro-survival functions, many of which are contingent on phosphorylation of a tyrosine residue (Y380) found in the linker region between the two catalytic domains of the enzyme. Furthermore, Src-mediated Y380 phosphorylation leads to increased resistance to CD95-induced apoptosis; however, the mechanism underlying this impaired response to extrinsic apoptotic stimuli has not been identified. Consequently, we have employed a number of model systems to further dissect this protective mechanism. First, using an in vitro DISC model together with recombinant procaspase-8 variants, we show that Y380 phosphorylation inhibits procaspase-8 activation at the CD95 DISC, thereby preventing downstream activation of the caspase cascade. Second, we validated this finding in a cellular context using transfected neuroblastoma cell lines deficient in caspase-8. Reconstitution of these lines with phosphomimetic-caspase-8 results in increased resistance to CD95-mediated apoptosis and enhanced cell migration. When the in vitro DISC is assembled in the presence of cell lysate, caspase-8 Y380 phosphorylation attenuates DISC activity by inhibiting procaspase-8 autoproteolytic activity but not recruitment or homodimerization of caspase-8 within the complex. Once incorporated into the DISC, phosphorylated caspase-8 is unable to be released from the complex; this inhibits further cycling and release of active catalytic subunits into the cytoplasm, thus resulting in increased apoptotic resistance. Taken together, our novel findings expand our understanding of the key mechanisms underlying the anti-apoptotic functions of caspase-8 which may act as a critical block to existing antitumour therapies. Importantly, reversal or inhibition of caspase-8 phosphorylation may prove a valuable avenue to explore for sensitization of resistant tumours to extrinsic apoptotic stimuli.	[Powley, I. R.; Hughes, M. A.; Cain, K.; MacFarlane, M.] MRC, Toxicol Unit, Hodgkin Budding,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England	University of Leicester	MacFarlane, M (corresponding author), MRC, Toxicol Unit, Hodgkin Budding,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk			UK Medical Research Council (MRC); Medical Research Council [MC_U132685863] Funding Source: researchfish; MRC [MC_U132685863] Funding Source: UKRI	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We would like to thank Dr T Chernova for her valuable advice regarding qRT-PCR design and analysis. This work was supported by the UK Medical Research Council (MRC).	Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Ando M, 2013, CANCER SCI, V104, P1002, DOI 10.1111/cas.12191; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dickens LS, 2012, EXP CELL RES, V318, P1269, DOI 10.1016/j.yexcr.2012.04.005; Frisch SM, 2008, CANCER RES, V68, P4491, DOI 10.1158/0008-5472.CAN-08-0952; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hughes MA, 2015, COLD SPRING HARB PRO, V12; Hughes MA, 2013, METHODS, V61, P98, DOI 10.1016/j.ymeth.2013.02.006; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; Jia SH, 2008, J BIOL CHEM, V283, P5402, DOI 10.1074/jbc.M706462200; Keller N, 2010, CELL DEATH DIFFER, V17, P710, DOI 10.1038/cdd.2009.155; Keller N, 2009, STRUCTURE, V17, P438, DOI 10.1016/j.str.2008.12.019; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Langlais C, 2015, COLD SPRING HARB PRO, V12; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Mandal R, 2014, MOL ONCOL, V8, P232, DOI 10.1016/j.molonc.2013.11.003; Matthess Y, 2014, MOL ONCOL, V8, P596, DOI 10.1016/j.molonc.2013.12.013; Oberst A, 2010, J BIOL CHEM, V285, P16632, DOI 10.1074/jbc.M109.095083; Parrish A.B., 2013, COLD SPRING HARB PER, V5, P5, DOI DOI 10.1101/CSHPERSPECT.A008672; Salvesen GS, 2014, SEMIN IMMUNOL, V26, P246, DOI 10.1016/j.smim.2014.03.005; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Senft J, 2007, CANCER RES, V67, P11505, DOI 10.1158/0008-5472.CAN-07-5755; Soung YH, 2005, CANCER RES, V65, P815; Torres VA, 2008, J BIOL CHEM, V283, P36280, DOI 10.1074/jbc.M805878200; Xu J, 2013, J BIOL CHEM, V288, P33263, DOI 10.1074/jbc.M113.508093; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zonta F, 2014, BLOOD, V123, P875, DOI 10.1182/blood-2013-02-485540	30	23	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5629	5640		10.1038/onc.2016.99	http://dx.doi.org/10.1038/onc.2016.99			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27109099	Green Published, hybrid			2022-12-28	WOS:000386998300006
J	Wu, J; Lu, M; Li, Y; Shang, YK; Wang, SJ; Meng, Y; Wang, Z; Li, ZS; Chen, H; Chen, ZN; Bian, H				Wu, J.; Lu, M.; Li, Y.; Shang, Y-K; Wang, S-J; Meng, Y.; Wang, Z.; Li, Z-S; Chen, H.; Chen, Z-N; Bian, H.			Regulation of a TGF-beta 1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; TUMOR-INITIATING CELLS; CANCER STEM-CELLS; CELLULAR PLASTICITY; CLONAL EVOLUTION; EMT/MET DYNAMICS; PROMOTES; DEDIFFERENTIATION; METASTASIS	Cellular plasticity has an important role in the progression of hepatocellular carcinoma (HCC). In this study, the involvement of a TGF-beta 1-CD147 self-sustaining network in the regulation of the dedifferentiation progress was fully explored in HCC cell lines, hepatocyte-specific basigin/CD147-knockout mice and human HCC tissues. We demonstrated that TGF-beta 1 stimulation upregulated CD147 expression and mediated the dedifferentiation of HCC cells, whereas all-trans-retinoic acid induced the downregulation of CD147 and promoted differentiation in HCC cells. Overexpression of CD147 induced the dedifferentiation and enhanced the malignancy of HCC cells, and increased the transcriptional expression of TGF-beta 1 by activating beta-catenin. CD147-induced matrix metalloproteinase (MMP) production activated pro-TGF-beta 1. The activated TGF-beta 1 signaling subsequently repressed the HNF4a expression via Smad-Snail1 signaling and enhanced the dedifferentiation progress. Hepatocyte-specific basigin/CD147-knockout mice decreased the susceptibility to N-nitrosodiethylamine-induced tumorigenesis by suppressing TGF-beta 1-CD147 signaling and inhibiting dedifferentiation in hepatocytes during tumor progression. CD147 was positively correlated with TGF-beta 1 and negatively correlated with HNF4a in human HCC tissues. Positive CD147 staining and lower HNF4a levels in tumor tissues were significantly associated with poor survival of patients with HCC. The overexpression of HNF4a and Smad7 and the deletion of CD147 by lentiviral vectors jointly reprogrammed the expression profile of hepatocyte markers and attenuated malignant properties including proliferation, cell survival and tumor growth of HCC cells. Our results highlight the important role of the TGF-beta 1-CD147 self-sustaining network in driving HCC development by regulating differentiation plasticity, which provides a strong basis for further investigations of the differentiation therapy of HCC targeting TGF-beta 1 and CD147.	[Wu, J.; Lu, M.; Shang, Y-K; Wang, S-J; Meng, Y.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Cell Engn Res Ctr, State Key Lab Canc Biol, Dept Cell Biol, 169,Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Li, Y.] PLA 323 Hosp, Dept Oncol, Xian, Peoples R China; [Wang, Z.; Li, Z-S] Fourth Mil Med Univ, Dept Pathol, Xian, Peoples R China; [Chen, H.] Peking Univ, Canc Hosp, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Peking University	Chen, ZN; Bian, H (corresponding author), Fourth Mil Med Univ, Cell Engn Res Ctr, State Key Lab Canc Biol, Dept Cell Biol, 169,Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	znchen@fmmu.edu.cn; hjbian@fmmu.edu.cn		Chen, Zhi-Nan/0000-0001-5512-4623	National Natural Science Foundation of China [31401222, 31571434, 31401190, 81172144]; National Science and Technology Major Project [2012ZX10002-015, 2012AA020806, 2015CB553701]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project	We thank professor Mien-Chie Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) for providing pEGFP-Snail1, and we thank professor Ye-Guang Chen (School of Life Science, Tsinghua University) for providing pcDNA-Flag-Smad7. This work was supported by grants from the National Natural Science Foundation of China (No. 31401222, 31571434, 31401190 and 81172144) and the National Science and Technology Major Project (No. 2012ZX10002-015, 2012AA020806 and 2015CB553701).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ber S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030759; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cicchini C, 2015, BBA-GENE REGUL MECH, V1849, P919, DOI 10.1016/j.bbagrm.2015.05.005; Cicchini C, 2015, LIVER INT, V35, P302, DOI 10.1111/liv.12577; Cozzolino AM, 2013, J HEPATOL, V58, P65, DOI 10.1016/j.jhep.2012.08.023; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Erez N, 2013, NATURE, V500, P37, DOI 10.1038/nature12459; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Giannelli G, 2014, CANCER RES, V74, P1890, DOI 10.1158/0008-5472.CAN-14-0243; Giannelli G, 2011, BBA-REV CANCER, V1815, P214, DOI 10.1016/j.bbcan.2010.11.004; Godoy P, 2009, HEPATOLOGY, V49, P2031, DOI 10.1002/hep.22880; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grusch M, 2010, CURR CANCER DRUG TAR, V10, P849, DOI 10.2174/156800910793357943; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Janiszewska M, 2015, CELL STEM CELL, V16, P11, DOI 10.1016/j.stem.2014.12.011; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khayati F, 2015, ONCOTARGET, V6, P9766, DOI 10.18632/oncotarget.2870; Kim SC, 2014, HEPATOLOGY, V59, P1750, DOI 10.1002/hep.26699; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Liu Y, 2015, ONCOGENE, V34, P5524, DOI 10.1038/onc.2015.7; Lu M, 2015, J MOL HISTOL, V46, P79, DOI 10.1007/s10735-014-9602-3; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Meyer C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.204; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Pisco AO, 2015, BRIT J CANCER, V112, P1725, DOI 10.1038/bjc.2015.146; Salomao M, 2012, DIAGN HISTOPATHOL, V18, P37; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Sun BC, 2008, CELL CYCLE, V7, P934, DOI 10.4161/cc.7.7.5622; Suzuki T, 2002, J GASTROEN HEPATOL, V17, P994, DOI 10.1046/j.1440-1746.2002.02774.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang J, 2012, CELL DEATH DIFFER, V19, P1779, DOI 10.1038/cdd.2012.60; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Ulianich L, 2008, J CELL SCI, V121, P477, DOI 10.1242/jcs.017202; Varga J, 2014, FEBS LETT, V588, P2422, DOI 10.1016/j.febslet.2014.06.019; Walesky C, 2013, HEPATOLOGY, V57, P2480, DOI 10.1002/hep.26251; Wei Q, 2016, ONCOGENE, V35, P2655, DOI 10.1038/onc.2015.328; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Yao H, 2014, INT J BIOL SCI, V10, P43, DOI 10.7150/ijbs.6818; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin C, 2008, HEPATOLOGY, V48, P1528, DOI 10.1002/hep.22510; Zeng X, 2011, HEPATOLOGY, V54, P2036, DOI 10.1002/hep.24647; Zhang HX, 2013, STEM CELLS, V31, P433, DOI 10.1002/stem.1298; Zhang Y, 2013, J HEPATOL, V59, P1255, DOI 10.1016/j.jhep.2013.07.009; Zhao P, 2011, HEPATOLOGY, V54, P2012, DOI 10.1002/hep.24592; Zhu D, 2015, NAT MED, V21, P572, DOI 10.1038/nm.3867; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	56	26	26	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5468	5479		10.1038/onc.2016.89	http://dx.doi.org/10.1038/onc.2016.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041581				2022-12-28	WOS:000386998200002
J	Bhattacharya, S; Chalk, AM; Ng, AJM; Martin, TJ; Zannettino, AC; Purton, LE; Lu, J; Baker, EK; Walkley, CR				Bhattacharya, S.; Chalk, A. M.; Ng, A. J. M.; Martin, T. J.; Zannettino, A. C.; Purton, L. E.; Lu, J.; Baker, E. K.; Walkley, C. R.			Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death	ONCOGENE			English	Article							TARGETING ROCK1; POOR-PROGNOSIS; MOUSE MODEL; KINASE; MICRORNA-148A; PROGRESSION; RIP1; GENE; HYPERMETHYLATION; IDENTIFICATION	Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at similar to 70% for patients with localized disease. Those with disseminated disease have an similar to 20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.	[Bhattacharya, S.; Chalk, A. M.; Ng, A. J. M.; Martin, T. J.; Purton, L. E.; Baker, E. K.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic, Australia; [Zannettino, A. C.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia; [Zannettino, A. C.] Univ Adelaide, Fac Hlth Sci, Sch Med, Myeloma Res Lab, Adelaide, SA, Australia; [Purton, L. E.; Walkley, C. R.] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia; [Lu, J.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Fitzroy, Vic, Australia; [Baker, E. K.; Walkley, C. R.] Yale Univ, Dept Genet, New Haven, CT USA; [Baker, E. K.; Walkley, C. R.] Yale Univ, Yale Stem Cell Ctr, New Haven, CT USA	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI); St. Vincent's Institute of Medical Research; Yale University; Yale University	Walkley, CR (corresponding author), St Vincents Inst, 9 Princes St, Fitzroy, Vic 3065, Australia.	cwalkley@svi.edu.au	Chalk, Alistair/O-3522-2019; Ng, Alvin/AAQ-5759-2020; Walkley, Carl/AAO-6021-2020; Purton, Louise/AAI-8956-2021	Chalk, Alistair/0000-0002-9630-6236; Walkley, Carl/0000-0002-4784-9031; Purton, Louise/0000-0001-6593-3168; Zannettino, Andrew/0000-0002-6646-6167	National Health and Medical Research Council (NHMRC), Australia; Cancer Council of Victoria; Cure Cancer Australia Foundation; 5point foundation; Zig Inge Foundation; NHMRC Career Development Award; NHMRC Dora Lush postgraduate scholarship; Victorian State Government OIS Program; Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation	National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cure Cancer Australia Foundation; 5point foundation; Zig Inge Foundation; NHMRC Career Development Award(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Dora Lush postgraduate scholarship(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government OIS Program; Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation	We thank A Pfeiffer (University of Bonn) for providing the miR-155-5p sponge, control sponge and miR-155-5p overexpression vector. We thank A Gupte for technical assistance; C Hawkins for discussion and comments; the BioResource Facility (St Vincent's Hospital) for housing and care of experimental animals, and M Thomson (SVI Flow Cytometry Facility) for help with FACS analysis. This work was supported by grants from the National Health and Medical Research Council (NHMRC), Australia (CW and TJM), Cancer Council of Victoria (CW and EB); Cure Cancer Australia Foundation (EB); 5point foundation (EB); Zig Inge Foundation (CW); NHMRC Career Development Award (CW); NHMRC Dora Lush postgraduate scholarship (SB); in part by the Victorian State Government OIS Program (to St. Vincent's Institute); CW was the Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation.	Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756-3282(02)00858-X; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Dohi O, 2013, INT J ONCOL, V42, P411, DOI 10.3892/ijo.2012.1724; Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866; Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406; Kim S, 2010, CANCER SCI, V101, P2425, DOI 10.1111/j.1349-7006.2010.01697.x; Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010-013-1682-y; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012; Lv HC, 2014, EXP THER MED, V8, P1575, DOI 10.3892/etm.2014.1942; Ma WL, 2014, TUMOR BIOL, V35, P12467, DOI 10.1007/s13277-014-2565-x; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Sarver AL, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun JX, 2014, ONCOTARGETS THER, V7, P853, DOI 10.2147/OTT.S60888; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010-013-1786-4; Wu XY, 2013, INT J MED SCI, V10, P676, DOI 10.7150/ijms.5528; Yang J, 2013, MOL CELL BIOCHEM, V381, P9, DOI 10.1007/s11010-013-1677-8; Yen CC, 2009, INT J ONCOL, V35, P775, DOI 10.3892/ijo_00000390; Yuan J, 2009, CANCER INVEST, V27, P435, DOI 10.1080/07357900802491477; Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127386; Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zhu A, 2012, MED ONCOL, V29, P2701, DOI 10.1007/s12032-011-0134-3	57	48	50	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5282	5294		10.1038/onc.2016.68	http://dx.doi.org/10.1038/onc.2016.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041566				2022-12-28	WOS:000386053000007
J	Mao, X; Gauche, C; Coughtrie, MWH; Bui, C; Gulberti, S; Merhi-Soussi, F; Ramalanjaona, N; Bertin-Jung, I; Diot, A; Dumas, D; Caires, ND; Thompson, AM; Bourdon, JC; Ouzzine, M; Fournel-Gigleux, S				Mao, X.; Gauche, C.; Coughtrie, M. W. H.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Diot, A.; Dumas, D.; Caires, N. De Freitas; Thompson, A. M.; Bourdon, J-C; Ouzzine, M.; Fournel-Gigleux, S.			The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; EXPRESSION; RECEPTOR; CELLS; PROTEOGLYCANS; METHYLATION; MAMMARY; HYPERMETHYLATION; BIOSYNTHESIS; SPECIFICITY	Heparan sulfate (HS) proteoglycan chains are key components of the breast tumor microenvironment that critically influence the behavior of cancer cells. It is established that abnormal synthesis and processing of HS play a prominent role in tumorigenesis, albeit mechanisms remain mostly obscure. HS function is mainly controlled by sulfotransferases, and here we report a novel cellular and pathophysiological significance for the 3-O-sulfotransferase 3-OST3A (HS3ST3A), catalyzing the final maturation step of HS, in breast cancer. We show that 3-OST3A is epigenetically repressed in all breast cancer cell lines of a panel representative of distinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloan-kettering breast cancer (SKBR3) cells. Epigenetic mechanisms involved both DNA methylation and histone modifications, producing different repressive chromatin environments depending on the cell molecular signature. Gain and loss of function experiments by cDNA and siRNA transfection revealed profound effects of 3-OST3A expression on cell behavior including apoptosis, proliferation, response to trastuzumab in vitro and tumor growth in xenografted mice. 3-OST3A exerted dual activities acting as tumor-suppressor in lumA-michigan cancer foundation (MCF)-7 and triple negative-MD Anderson (MDA) metastatic breast (MB)-231 cells, or as an oncogenic factor in HER2+-SKBR3 cells. Mechanistically, fluorescence-resonance energy transfer-fluorescence-lifetime imaging microscopy experiments indicated that the effects of 3-OST3A in MCF-7 cells were mediated by altered interactions between HS and fibroblast growth factor-7 (FGF-7). Further, this interplay between HS and FGF-7 modulated downstream ERK, AKT and p38 cascades, suggesting that altering 3-O-sulfation affects FGFR2IIIb-mediated signaling. Corroborating our cellular data, a clinical study conducted in a cohort of breast cancer patients uncovered that, in HER2+ patients, high level expression of 3-OST3A in tumors was associated with reduced relapse-free survival. Our findings define 3-OST3A as a novel regulator of breast cancer pathogenicity, displaying tumor-suppressive or oncogenic activities in a cell-and tumor-dependent context, and demonstrate the clinical value of the HS-O-sulfotransferase 3-OST3A as a prognostic marker in HER2+ patients.	[Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine IMoPA, CNRS, UMR 7365, MolCelTEG Team, Vandoeuvre Les Nancy, France; [Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine, Fac Med, Glycofluo Platform, Biopole, Campus Biol Sante, Vandoeuvre Les Nancy, France; [Mao, X.] Luxembourg Inst Hlth, Lab Expt Canc Res, Luxembourg, Luxembourg; [Coughtrie, M. W. H.; Diot, A.; Bourdon, J-C] Univ Dundee, Med Res Inst, Div Canc Res, Dundee, Scotland; [Coughtrie, M. W. H.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Dumas, D.] PTIBC IBISA Nancy, Cellular & Tissular Core Imaging Facil, Vandoeuvre Les Nancy, France; [Caires, N. De Freitas] INSERM, U1019E11, Lille, France; [Thompson, A. M.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; Universite de Lorraine; Luxembourg Institute of Health; University of Dundee; University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; UTMD Anderson Cancer Center	Fournel-Gigleux, S (corresponding author), Univ Lorraine, Univ Lorraine IMoPA, MolCelTEG Team, UMR 7365,CNRS,Biopole,Fac Med, Campus Biol Sante,CS 50184, F-54505 Vandoeuvre Les Nancy, Lorraine, France.	sylvie.fournel-gigleux@univ-lorraine.fr	Ouzzine, Mohamed/G-4368-2013; Coughtrie, Michael/C-3855-2009; JC, Bourdon/A-4439-2008	Coughtrie, Michael/0000-0003-1989-1416; JC, Bourdon/0000-0003-4623-9386; GULBERTI, Sandrine/0000-0002-9378-4697; OUZZINE, Mohamed/0000-0003-0058-4950	Agence Nationale de la Recherche (ANR-GAG Network) [ANR-08-PCVI-0023]; Royal Society; Region Lorraine; Lorraine University; International Associated Laboratory (SFGEN); Cancer Research UK (CRUK); NHS Tayside through the Chief Scientist Office; Agence Nationale de la Recherche (ANR Meca-GT) [ANR-13-BSV8-0011-01]; NHS Tayside through Health Sciences Scotland; Breast Cancer Campaign; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Agence Nationale de la Recherche (ANR-GAG Network)(French National Research Agency (ANR)); Royal Society(Royal Society of London); Region Lorraine(Region Grand-Est); Lorraine University; International Associated Laboratory (SFGEN); Cancer Research UK (CRUK)(Cancer Research UK); NHS Tayside through the Chief Scientist Office; Agence Nationale de la Recherche (ANR Meca-GT)(French National Research Agency (ANR)); NHS Tayside through Health Sciences Scotland; Breast Cancer Campaign; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Philippe Lassalle (INSERM U1019E11, Campus Institut Pasteur de Lille, Lille, France) is gratefully acknowledged for support with the xenograft experiments and for helpful discussion. Matthieu Chabel and Anne Robert are acknowledged for excellent technical assistance and Xiaomeng Pang is acknowledged for performing methylation analysis. This work was supported by Agence Nationale de la Recherche (ANR-GAG Network ANR-08-PCVI-0023 and ANR Meca-GT ANR-13-BSV8-0011-01), a Royal Society International Joint grant (to MWHC and SF-G), grants from Region Lorraine and Lorraine University to SF-G and to NR, and was carried out under auspices of the International Associated Laboratory (SFGEN) funded between CNRS-UL (SF-G) and University of Dundee (J-CB and MWHC). Tayside Tissue Bank is supported by Breast Cancer Campaign, Cancer Research UK (CRUK) and by NHS Tayside through the Chief Scientist Office and Health Sciences Scotland (formerly the Scottish Academic Health Science Collaboration, AHSC).	Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Breton C, 2012, CURR OPIN STRUC BIOL, V22, P540, DOI 10.1016/j.sbi.2012.06.007; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Bui C, 2010, FASEB J, V24, P436, DOI 10.1096/fj.09-136291; Cha JY, 2008, MOL CANCER RES, V6, P435, DOI 10.1158/1541-7786.MCR-07-0187; Cha JYY, 2009, J BIOL CHEM, V284, P6227, DOI 10.1074/jbc.M803998200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Hwang JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079634; Jacquemier J, 1998, J PATHOL, V186, P269, DOI 10.1002/(SICI)1096-9896(1998110)186:3<269::AID-PATH187>3.0.CO;2-G; Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lofgren L, 2007, ANTICANCER RES, V27, P3045; Luo YD, 2006, J BIOL CHEM, V281, P21052, DOI 10.1074/jbc.M601559200; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; Mehta M, 2010, ANTICANCER RES, V30, P4883; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Nieto L, 2013, CHEMBIOCHEM, V14, P1732, DOI 10.1002/cbic.201300313; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Purdie CA, 2010, HISTOPATHOLOGY, V56, P702, DOI 10.1111/j.1365-2559.2010.03533.x; Raman Karthik, 2010, Curr Chem Biol, V4, P20; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679; Song K, 2011, CANCER BIOL THER, V12, P388, DOI 10.4161/cbt.12.5.15957; Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300; Thacker BE, 2014, MATRIX BIOL, V35, P60, DOI 10.1016/j.matbio.2013.12.001; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Xu RY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.398826; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zang XP, 2004, CLIN EXP METASTAS, V21, P437, DOI 10.1007/s10585-004-2051-8	48	20	20	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5043	5055		10.1038/onc.2016.44	http://dx.doi.org/10.1038/onc.2016.44			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041583	Green Submitted			2022-12-28	WOS:000383965300008
J	De Donatis, GM; Le Pape, E; Pierron, A; Cheli, Y; Hofman, V; Hofman, P; Allegra, M; Zahaf, K; Bahadoran, P; Rocchi, S; Bertolotto, C; Ballotti, R; Passeron, T				De Donatis, G. M.; Le Pape, E.; Pierron, A.; Cheli, Y.; Hofman, V.; Hofman, P.; Allegra, M.; Zahaf, K.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.; Passeron, T.			NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2 (vol 35, pg 2735, 2016)	ONCOGENE			English	Correction													Bertolotto, Corine/AAF-6634-2021; Cheli, Yann/O-5783-2016; Rocchi, Stephane/O-4152-2016; Hofman, Paul/P-7654-2018	Bertolotto, Corine/0000-0001-6971-7753; Cheli, Yann/0000-0001-9839-4332; Rocchi, Stephane/0000-0002-0943-1304; Hofman, Paul/0000-0003-0431-9353; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908; Passeron, Thierry/0000-0002-0797-6570				De Donatis GM, 2016, ONCOGENE, V35, P2735, DOI 10.1038/onc.2015.331	1	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2813	2813		10.1038/onc.2015.468	http://dx.doi.org/10.1038/onc.2015.468			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	27225420	Bronze			2022-12-28	WOS:000377472700014
J	Wong, CC; Qian, Y; Yu, J				Wong, C. C.; Qian, Y.; Yu, J.			Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches	ONCOGENE			English	Review							NICOTINAMIDE N-METHYLTRANSFERASE; HEXOSAMINE BIOSYNTHETIC-PATHWAY; ATP-CITRATE LYASE; HISTONE DEACETYLASE SIRT6; SQUAMOUS-CELL CARCINOMA; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; O-GLCNAC; ISOCITRATE DEHYDROGENASE; SUCCINATE-DEHYDROGENASE	Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA and histone modification enzymes at the metabolite level. Conversely, epigenetic mechanisms regulate the expression of metabolic genes, thereby altering the metabolome. Epigenetic-metabolomic interplay has a critical role in tumourigenesis by coordinately sustaining cell proliferation, metastasis and pluripotency. Understanding the link between epigenetics and metabolism could unravel novel molecular targets, whose intervention may lead to improvements in cancer treatment. In this review, we summarized the recent discoveries linking epigenetics and metabolism and their underlying roles in tumorigenesis; and highlighted the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these abnormalities in cancer.	[Wong, C. C.; Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China; [Qian, Y.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China; [Qian, Y.] Zhejiang Univ, Inst Gastroenterol, Hangzhou, Zhejiang, Peoples R China	Chinese University of Hong Kong; Zhejiang University; Zhejiang University	Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, Shenzhen Res Inst,Prince Wales Hosp, Rm 707A,7-F,Li Ka Shing Med Sci Bldg, Hong Kong, Hong Kong, Peoples R China.; Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst,Princ, Rm 707A,7-F,Li Ka Shing Med Sci Bldg, Hong Kong, Hong Kong, Peoples R China.	chichun.wong@cuhk.edu.hk; junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-GRF from Hong Kong [14114615, 766613]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China [81502064]	RGC-GRF from Hong Kong; Shenzhen Municipal Science and Technology RD fund; Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by research funds from RGC-GRF (14114615 and 766613) from Hong Kong; Shenzhen Municipal Science and Technology R&D fund (JCYJ20130401151108652) and Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China (81502064).	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Alcarraz-Vizan G, 2010, METABOLOMICS, V6, P229, DOI 10.1007/s11306-009-0192-0; Alvarez-Nunez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17; Amoedo ND, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022264; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Brown JM, 1998, CANCER RES, V58, P1408; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Castoldi M, 2011, J CLIN INVEST, V121, P1386, DOI 10.1172/JCI44883; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; CHEN W, 1992, BIOCHIMIE, V74, P867, DOI 10.1016/0300-9084(92)90070-U; Chen YH, 2013, DIABETES, V62, P2278, DOI 10.2337/db12-0963; Choi GCG, 2014, MOL CANCER RES, V12, P228, DOI 10.1158/1541-7786.MCR-13-0195; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497; Chu BF, 2013, CANCER CHEMOTH PHARM, V71, P115, DOI 10.1007/s00280-012-1986-8; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Cluntun AA, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0135-3; Cunningham JM, 1998, CANCER RES, V58, P3455; Dai DW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-478; Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Daud AI, 2009, CLIN CANCER RES, V15, P2479, DOI 10.1158/1078-0432.CCR-08-1931; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Davis MI, 2014, J BIOL CHEM, V289, P13717, DOI 10.1074/jbc.M113.511030; Dehennaut V, 2007, J BIOL CHEM, V282, P12527, DOI 10.1074/jbc.M700444200; Deng GJ, 2015, J BIOL CHEM, V290, P762, DOI 10.1074/jbc.M114.608497; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; DiNardo C, 2015, HAEMATOLOGICA, V100, P216; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Edmunds LR, 2014, J BIOL CHEM, V289, P25382, DOI 10.1074/jbc.M114.580662; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Ellwood-Yen K, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3116; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feldman JL, 2013, J BIOL CHEM, V288, P31350, DOI 10.1074/jbc.C113.511261; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fong JJ, 2012, J BIOL CHEM, V287, P12195, DOI 10.1074/jbc.M111.315804; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656; Gambichler T, 2013, MELANOMA RES, V23, P218, DOI 10.1097/CMR.0b013e32835f9bd4; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gregersen LH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-232; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Gupta V, 2014, CURR PHARM DESIGN, V20, P1706, DOI 10.2174/13816128113199990536; Haase C, 2007, J NUCL MED, V48, P2063, DOI 10.2967/jnumed.107.043620; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hattori M, 2015, EXP DERMATOL, V24, P841, DOI 10.1111/exd.12767; Hatzimichael E, 2010, EUR J HAEMATOL, V84, P47, DOI 10.1111/j.1600-0609.2009.01344.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensen EF, 2011, FAM CANCER, V10, P355, DOI 10.1007/s10689-010-9402-1; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Ito R, 2014, GENES CELLS, V19, P52, DOI 10.1111/gtc.12107; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001; Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Kantorovich V, 2010, BEST PRACT RES CL EN, V24, P415, DOI 10.1016/j.beem.2010.04.001; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kernytsky A, 2015, BLOOD, V125, P296, DOI 10.1182/blood-2013-10-533604; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Kim Hyo-Joon, 2015, J Cancer Prev, V20, P78, DOI 10.15430/JCP.2015.20.1.78; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li H, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-110; Li L., 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813; Li XL, 2011, INT J BIOL SCI, V7, P575, DOI 10.7150/ijbs.7.575; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Lin SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21184; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lopez-Serra P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4608; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040; Martinez-Chantar ML, 2008, HEPATOLOGY, V47, P1191, DOI 10.1002/hep.22159; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Momparler RL, 2015, EXPERT OPIN INV DRUG, V24, P1031, DOI 10.1517/13543784.2015.1051220; Momparler RL, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-19; Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001; Morani F, 2014, J MOL ENDOCRINOL, V53, P247, DOI 10.1530/JME-14-0118; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Mudd SH, 2001, J INHERIT METAB DIS, V24, P448, DOI 10.1023/A:1010577512912; Munoz-Pinedo C, 2013, CANCER RES, V73, P4185, DOI 10.1158/0008-5472.CAN-13-0512; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Myers SA, 2011, P NATL ACAD SCI USA, V108, P9490, DOI 10.1073/pnas.1019289108; Nakagawa M, 2007, ONCOL REP, V18, P769; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Olivier-Van Stichelen S, 2014, FASEB J, V28, P3325, DOI 10.1096/fj.13-243535; Olivier-Van Stichelen Stephanie, 2012, Am J Physiol Endocrinol Metab, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Onodera Y, 2014, J CLIN INVEST, V124, P367, DOI 10.1172/JCI63146; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002; Peschiaroli A, 2013, ONCOGENE, V32, P797, DOI 10.1038/onc.2012.100; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Place TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014617; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094; Ranuncolo SM, 2012, J BIOL CHEM, V287, P23549, DOI 10.1074/jbc.M111.330910; Rathore MG, 2012, INT J BIOCHEM CELL B, V44, P1448, DOI 10.1016/j.biocel.2012.05.011; Rawluszko AA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-526; Ricketts CJ, 2012, J UROLOGY, V188, P2063, DOI 10.1016/j.juro.2012.08.030; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Rodrigues MF, 2015, J CELL BIOCHEM, V116, P797, DOI 10.1002/jcb.25036; Rodriguez-Paredes M, 2011, CANCER DISCOV, V1, P557, DOI 10.1158/2159-8290.CD-11-0271; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Rzem R, 2004, P NATL ACAD SCI USA, V101, P16849, DOI 10.1073/pnas.0404840101; Sakabe K, 2010, J BIOL CHEM, V285, P34460, DOI 10.1074/jbc.M110.158170; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schmitt AM, 2009, ENDOCR-RELAT CANCER, V16, P1219, DOI 10.1677/ERC-08-0297; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Shih AH, 2014, BLOOD, V124, P237; Shim EH, 2014, CANCER DISCOV, V4, P1290, DOI 10.1158/2159-8290.CD-13-0696; Shin JY, 2013, CELL REP, V5, P654, DOI 10.1016/j.celrep.2013.10.007; Simpson NE, 2012, EPIGENETICS-US, V7, P1413, DOI 10.4161/epi.22713; Simpson NE, 2012, BREAST CANCER RES TR, V133, P959, DOI 10.1007/s10549-011-1871-x; Skowronski K, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12400; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang SW, 2011, CARCINOGENESIS, V32, P138, DOI 10.1093/carcin/bgq225; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Thomas MG, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.200; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Venneti S, 2013, J NEUROPATH EXP NEUR, V72, P298, DOI 10.1097/NEN.0b013e3182898113; Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wardell SE, 2009, MOL ENDOCRINOL, V23, P388, DOI 10.1210/me.2008-0179; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Witta SE, 2012, J CLIN ONCOL, V30, P2248, DOI 10.1200/JCO.2011.38.9411; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227; Wu Y, 2008, ONCOGENE, V27, P6679, DOI 10.1038/onc.2008.264; Xiao CY, 2010, J BIOL CHEM, V285, P36776, DOI 10.1074/jbc.M110.168039; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yamasaki T, 2013, CANCER SCI, V104, P1411, DOI 10.1111/cas.12240; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yen K, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.240.240; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoshino H, 2013, CANCER SCI, V104, P1567, DOI 10.1111/cas.12280; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zhang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089202; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879; Zhao SG, 2013, CANCER LETT, V333, P253, DOI 10.1016/j.canlet.2013.01.039; Zheng BS, 2013, ACS MED CHEM LETT, V4, P542, DOI 10.1021/ml400036z; Zhong L, 2010, TRANSCR-AUSTIN, V1, P17, DOI 10.4161/trns.1.1.12143; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhou FX, 2016, J STEROID BIOCHEM, V159, P19, DOI 10.1016/j.jsbmb.2016.02.015	225	159	162	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3359	3374		10.1038/onc.2016.485	http://dx.doi.org/10.1038/onc.2016.485			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092669	Green Published, hybrid			2022-12-28	WOS:000403340700001
J	Zhang, D; Jin, N; Sun, W; Li, X; Liu, B; Xie, Z; Qu, J; Xu, J; Yang, X; Su, Y; Tang, S; Han, H; Chen, D; Ding, J; Tan, M; Huang, M; Geng, M				Zhang, D.; Jin, N.; Sun, W.; Li, X.; Liu, B.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Han, H.; Chen, D.; Ding, J.; Tan, M.; Huang, M.; Geng, M.			Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity	ONCOGENE			English	Article							PYRUVATE-KINASE M2; GENE-TRANSCRIPTION; CREATINE-KINASE; ACTIN ACTA2; GLYCOLYSIS; TARGET; IDENTIFICATION; PHOSPHATASE; ISOENZYMES; APOPTOSIS	Phosphoglycerate mutase 1 (PGAM1) is a glycolytic enzyme that coordinates glycolysis and biosynthesis to promote cancer growth via its metabolic activity. Here, we report the discovery of a non-metabolic function of PGAM1 in promoting cancer metastasis. A proteomic study identified a-smooth muscle actin (ACTA2) as a PGAM1-associated protein. PGAM1 modulated actin filaments assembly, cell motility and cancer cell migration via directly interacting with ACTA2, which was independent of its metabolic activity. The enzymatically inactive H186R mutant retained its association with ACTA2, whereas 201-210 amino acids deleted PGAM1 mutant lost the interaction with ACTA2 regardless of intact metabolic activity. Importantly, PGAM1 knockdown decreased metastatic potential of breast cancer cells in vivo and PGAM1 and ACTA2 were jointly associated with the prognosis of breast cancer patients. Together, this study provided the first evidence revealing a non-metabolic function of PGAM1 in promoting cell migration, and gained new insights into the role of PGAM1 in cancer progression.	[Zhang, D.; Jin, N.; Sun, W.; Li, X.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Ding, J.; Huang, M.; Geng, M.] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Room 2431,555 Zuchongzhi Rd,Room 1320, Shanghai 201203, Peoples R China; [Liu, B.; Tan, M.] Chinese Acad Sci, Shanghai Inst Mat Med, Chem Prote Ctr, State Key Lab Drug Res, Shanghai, Peoples R China; [Han, H.; Chen, D.] Chinese Acad Sci, Shanghai Inst Mat Med, Lab Pharmaceut Anal, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Huang, M; Geng, M (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Room 2431,555 Zuchongzhi Rd,Room 1320, Shanghai 201203, Peoples R China.	mhuang@simm.ac.cn; mygeng@simm.ac.cn	Tan, Minjia/C-4491-2014; huang, min/AAC-6965-2022	Tan, Minjia/0000-0002-6784-9653; 	China International Science and Technology Cooperation Program [2015DFM30040]; National Science and Technology Major Project [2015ZX09101009]; National Natural Science Foundation of China [81573464, 81321092]; NSFC-Shandong Joint Fund for Marine Science Research Centers [U1406402]	China International Science and Technology Cooperation Program; National Science and Technology Major Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NSFC-Shandong Joint Fund for Marine Science Research Centers	This work was supported by the China International Science and Technology Cooperation Program (No. 2015DFM30040 to MH), the National Science and Technology Major Project (No. 2015ZX09101009 to MH), grants from the National Natural Science Foundation of China (No. 81573464 to MH, No. 81321092 to JD) and NSFC-Shandong Joint Fund for Marine Science Research Centers (No. U1406402 to JD)	Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Croise Pauline, 2014, Small GTPases, V5, pe29469, DOI 10.4161/sgtp.29469; Durany N, 1997, BRIT J CANCER, V76, P1139, DOI 10.1038/bjc.1997.525; Durany N, 2000, BRIT J CANCER, V82, P20; Engel M, 2004, J BIOL CHEM, V279, P35803, DOI 10.1074/jbc.M402768200; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fothergill-Gilmore L. A., 1989, ADV ENZYMOLOGY RELAT, V62, P227; Fritz G, 2006, CURR CANCER DRUG TAR, V6, P1, DOI 10.2174/156800906775471752; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Guo DC, 2007, NAT GENET, V39, P1488, DOI 10.1038/ng.2007.6; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lee HW, 2013, CLIN CANCER RES, V19, P5879, DOI 10.1158/1078-0432.CCR-13-1181; Lee HW, 2012, INT J ONCOL, V41, P2013, DOI 10.3892/ijo.2012.1663; Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Morisaki H, 2009, HUM MUTAT, V30, P1406, DOI 10.1002/humu.21081; Narayanan NK, 2004, CANCER DETECT PREV, V28, P443, DOI 10.1016/j.cdp.2004.08.009; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Ren FL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-81; Rockey DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077166; Thomasson MS, 2013, ANAL BIOCHEM, V443, P156, DOI 10.1016/j.ab.2013.09.008; Turhani D, 2006, ELECTROPHORESIS, V27, P1417, DOI 10.1002/elps.200500510; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yeh CS, 2008, ONCOL REP, V19, P81	38	54	57	3	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2900	2909		10.1038/onc.2016.446	http://dx.doi.org/10.1038/onc.2016.446			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991922				2022-12-28	WOS:000401697800012
J	Fan, H; Cui, Z; Zhang, H; Mani, SK; Diab, A; Lefrancois, L; Fares, N; Merle, P; Andrisani, O				Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Lefrancois, L.; Fares, N.; Merle, P.; Andrisani, O.			DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection	ONCOGENE			English	Article							RNA-POLYMERASE-II; STEM-CELL PLURIPOTENCY; PROTEIN 4; METHYLATION; TRANSCRIPTION; EXPRESSION; PROMOTER; COMPLEX; ESBAF	Sal-like protein 4 (SALL4), an embryonic stem cell transcriptional regulator, is re-expressed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection. Herein, we investigated the mechanism of SALL4 re-expression in HBV-related HCCs. We performed bisulfite sequencing PCR of genomic DNA isolated from HBV-related HCCs and HBV replicating cells, and examined DNA methylation of a CpG island located downstream from SALL4 transcriptional start site (TSS). HBV-related HCCs expressing increased SALL4 exhibited demethylation of specific CpG sites downstream of SALL4 TSS. Similarly, SALL4 re-expression and demethylation of these CpGs was observed in HBV replicating cells. SALL4 is also re-expressed in poor prognosis HCCs of other etiologies. Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethylation of these CpG sites. To understand how CpG demethylation downstream of SALL4 TSS regulates SALL4 transcription, we quantified by chromatin immunoprecipitation (ChIP) assays RNA polymerase II occupancy of SALL4 gene, as a function of HBV replication. In absence of HBV replication, RNA polymerase II associated with SALL4 exon1. By contrast, in HBV replicating cells RNA polymerase II occupancy of all SALL4 exons increased, suggesting CpG demethylation downstream from SALL4 TSS influences SALL4 transcriptional elongation. Intriguingly, demethylated CpGs downstream from SALL4 TSS are within binding sites of octamer-binding transcription factor 4 (OCT4) and signal transducer and activator of transcription3 (STAT3). ChIP assays confirmed occupancy of these sites by OCT4 and STAT3 in HBV replicating cells, and sequential ChIP assays demonstrated co-occupancy with chromatin remodeling BRG1/Brahma-associated factors. BRG1 knockdown reduced SALL4 expression, whereas BRG1 overexpression increased SALL4 transcription in HBV replicating cells. We conclude demethylation of CpGs located within OCT4 and STAT3 cis-acting elements, downstream of SALL4 TSS, enables OCT4 and STAT3 binding, recruitment of BRG1, and enhanced RNA polymerase II elongation and SALL4 transcription.	[Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Andrisani, O.] Dept Basic Med Sci, W Lafayette, IN USA; [Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Andrisani, O.] Purdue Univ, Purdue Ctr Canc Res, 205 Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA; [Lefrancois, L.; Fares, N.; Merle, P.] INSERM, UMR 1052, Ctr Rech Cancerol Lyon, Lyon, France	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Andrisani, O (corresponding author), Purdue Univ, Dept Basic Med Sci, 205 Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu	Diab, Ahmed/X-5165-2018; Kailasam Mani, Saravana Kumar/I-8731-2019	Diab, Ahmed/0000-0001-6626-7013; Kailasam Mani, Saravana Kumar/0000-0002-0407-2314; Andrisani, Ourania/0000-0002-6230-0303; Fares, Nadim/0000-0002-8954-3938	NIH [DK044533, P30CA023168]; French grants PAIR-CHC from Institute National du Cancer (INCa) [2009-143]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); French grants PAIR-CHC from Institute National du Cancer (INCa); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK044533 to OA, and French grants PAIR-CHC 2009 (contract #2009-143, project ENELIVI) from Institute National du Cancer (INCa) to PM. Shared Resources (flow cytometry and DNA sequencing) are supported by NIH grant P30CA023168 to Purdue Center for Cancer Research.	Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bard JD, 2009, FASEB J, V23, P1405, DOI 10.1096/fj.08-117721; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Buganim Y, 2014, CELL STEM CELL, V15, P295, DOI 10.1016/j.stem.2014.07.003; Choi JK, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r89; Fan H, 2016, ONCOGENE, V35, P715, DOI 10.1038/onc.2015.122; Gong FD, 2015, GENE DEV, V29, P197, DOI 10.1101/gad.252189.114; He J, 2013, INT J BIOCHEM CELL B, V45, P1962, DOI 10.1016/j.biocel.2013.06.008; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ho L, 2011, NAT CELL BIOL, V13, P903, DOI 10.1038/ncb2285; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jung YK, 2016, ANN SURG TREAT RES, V91, P23, DOI 10.4174/astr.2016.91.1.23; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liao HF, 2014, DEVELOPMENT, V141, P2402, DOI 10.1242/dev.105130; Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483; Mani SKK, 2016, J HEPATOL, V65, P888, DOI 10.1016/j.jhep.2016.05.022; Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272; Marquardt JU, 2013, NEW ENGL J MED, V368, P2316, DOI 10.1056/NEJMe1303026; Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024; Nishino K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013017; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Oikawa T, 2009, GASTROENTEROLOGY, V136, P1000, DOI 10.1053/j.gastro.2008.11.018; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Park H, 2015, J PATHOL TRANSL MED, V49, P373, DOI 10.4132/jptm.2015.07.09; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Selth LA, 2009, COLD SPRING HARBOR P, V2009; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Veloso A, 2014, GENOME RES, V24, P896, DOI 10.1101/gr.171405.113; Yang JC, 2012, J BIOL CHEM, V287, P1996, DOI 10.1074/jbc.M111.308734; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yin F, 2016, WORLD J GASTROENTERO, V22, P2837, DOI 10.3748/wjg.v22.i9.2837; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; Zeng SS, 2014, J HEPATOL, V60, P127, DOI 10.1016/j.jhep.2013.08.024; Zhang H, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/175940; Zhang H, 2016, HEPATOLOGY, V64, P1033, DOI 10.1002/hep.28698; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	41	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2435	2445		10.1038/onc.2016.399	http://dx.doi.org/10.1038/onc.2016.399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27797380	Green Accepted			2022-12-28	WOS:000400268900009
J	Matsumura, K; Kawasaki, Y; Miyamoto, M; Kamoshida, Y; Nakamura, J; Negishi, L; Suda, S; Akiyama, T				Matsumura, K.; Kawasaki, Y.; Miyamoto, M.; Kamoshida, Y.; Nakamura, J.; Negishi, L.; Suda, S.; Akiyama, T.			f0 The novel G-quadruplex-containing long non-coding RNA GSEC antagonizes DHX36 and modulates colon cancer cell migration	ONCOGENE			English	Article							HUMAN COLORECTAL-CANCER; TETRAMOLECULAR QUADRUPLEX; RESOLVING ACTIVITY; PROSTATE-CANCER; MAJOR SOURCE; PROMOTES; EXPRESSION; METASTASIS; GROWTH; GENE	Long non-coding RNAs (lncRNAs) are frequently dysregulated in a variety of human cancers. However, their biological roles in these cancers remain incompletely understood. In this study, we analyze the gene expression profiles of colon cancer tissues and identify a previously unannotated lncRNA, FLJ39051, that we term GSEC (G-quadruplex-forming sequence containing lncRNA), as a lncRNA that is upregulated in colorectal cancer. We further demonstrate that knockdown of GSEC results in the reduction of colon cancer cell motility. We also show that GSEC binds to the DEAH box polypeptide 36 (DHX36) RNA helicase via its G-quadruplex-forming sequence and inhibits DHX36 G-quadruplex unwinding activity. Moreover, knockdown of DHX36 restores the reduced migratory activity of colon cancer cells caused by GSEC knockdown. These results suggest that GSEC plays an important role in colon cancer cell migration by inhibiting the function of DHX36 via its G-quadruplex structure.	[Matsumura, K.; Kawasaki, Y.; Miyamoto, M.; Kamoshida, Y.; Nakamura, J.; Negishi, L.; Suda, S.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp			Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct); Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science [13J08104]	Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network) and Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan and Japan Society for the Promotion of Science Grant-in-Aid for JSPS Fellows (Grant Number 13J08104).	Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Bicker S, 2013, GENE DEV, V27, P991, DOI 10.1101/gad.211243.112; Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032; Booy EP, 2012, NUCLEIC ACIDS RES, V40, P4110, DOI 10.1093/nar/gkr1306; Booy EP, 2014, NUCLEIC ACIDS RES, V42, P3346, DOI 10.1093/nar/gkt1340; Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Creacy SD, 2008, J BIOL CHEM, V283, P34626, DOI 10.1074/jbc.M806277200; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Huang WW, 2012, NUCLEIC ACIDS RES, V40, P1033, DOI 10.1093/nar/gkr849; Jayaraj GG, 2012, RNA BIOL, V9, P81, DOI 10.4161/rna.9.1.18047; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kim HN, 2011, J BONE MINER RES, V26, P2161, DOI 10.1002/jbmr.426; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lam MTY, 2014, TRENDS BIOCHEM SCI, V39, P170, DOI 10.1016/j.tibs.2014.02.007; Lin NW, 2014, MOL CELL, V53, P1005, DOI 10.1016/j.molcel.2014.01.021; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Millevoi S, 2012, WIRES RNA, V3, P495, DOI 10.1002/wrna.1113; O'Leary VB, 2015, CELL REP, V11, P474, DOI 10.1016/j.celrep.2015.03.043; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vaughn JP, 2005, J BIOL CHEM, V280, P38117, DOI 10.1074/jbc.C500348200; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013; Yanagida S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01305; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	44	63	66	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1191	1199		10.1038/onc.2016.282	http://dx.doi.org/10.1038/onc.2016.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27797375				2022-12-28	WOS:000395861300003
J	Pan, Y; Wang, S; Su, B; Zhou, F; Zhang, R; Xu, T; Zhang, R; Leventaki, V; Drakos, E; Liu, W; Claret, FX				Pan, Y.; Wang, S.; Su, B.; Zhou, F.; Zhang, R.; Xu, T.; Zhang, R.; Leventaki, V.; Drakos, E.; Liu, W.; Claret, F. X.			Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression	ONCOGENE			English	Article							DOMAIN-BINDING PROTEIN-1; NASOPHARYNGEAL CARCINOMA; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; MOLECULAR TARGETS; DNA-DAMAGE; GROWTH; P27(KIP1); APOPTOSIS; RADIOTHERAPY	Our previous studies demonstrated that Jab1/Csn5 overexpression is correlated with low survival rates in cancer patients, including nasopharyngeal carcinoma (NPC), breast cancer and hepatocellular carcinoma, and contributes to NPC's resistance to radiotherapy and cisplatin by regulating DNA damage and repair pathways. However, the molecular mechanism by which Jab1/Csn5 expression is upregulated in NPCs has yet to be determined. In the present study, we identified the upstream regulator of Jab1/Csn5 expression and demonstrated its role in intrinsic resistance of NPC cells to treatment with cisplatin. Signal transducer and activator of transcription-3 (Stat3) expression correlates with and contributes to Jab1/Csn5 transcription. Consistently, silencing of Stat3 in tumors reduced Jab1/Csn5 expression, thereby sensitizing NPC cells to cisplatin-induced apoptosis both in vitro and in vivo. Mechanistically, Stat3 transcriptionally regulated Jab1/Csn5. Furthermore, high mRNA expression levels of Stat3 or Jab1 in colon cancer, breast cancer and glioblastoma are associated with significantly shorter survival times from the R2 online database. These findings identify a novel Stat3-Jab1/Csn5 signaling axis in cancer pathogenesis with therapeutic and prognostic relevance.	[Pan, Y.] Jiangnan Univ, Affiliated Hosp, Sch Med, Dept Pathol, Wuxi, Peoples R China; [Pan, Y.; Wang, S.; Su, B.; Zhang, R.; Xu, T.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St Unit 950, Houston, TX 77030 USA; [Wang, S.] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Zhou, F.] Wuhan Univ, Zhongnan Hosp, Dept Hematol, Wuhan, Peoples R China; [Zhang, R.] Sun Yat Sen Univ, Ctr Canc, Dept Endoscopy, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Leventaki, V.; Drakos, E.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Liu, W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Claret, F. X.] Univ Texas Houston, Grad Sch Biomed Sci, Experimental Therapeut Acad Program & Canc Biol P, Houston, TX USA; [Leventaki, V.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Drakos, E.] Univ Crete, Sch Med, Dept Pathol, Iraklion, Greece	Jiangnan University; University of Texas System; UTMD Anderson Cancer Center; Guangzhou University of Chinese Medicine; Wuhan University; State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; St Jude Children's Research Hospital; University of Crete	Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St Unit 950, Houston, TX 77030 USA.	fxclaret@mdanderson.org	Claret, Francois X/R-2104-2016; Wang, Sumei/V-2800-2019; Leventaki, Vasiliki/N-8175-2018	Claret, Francois X/0000-0003-4629-6495; Wang, Sumei/0000-0002-2011-4019; Zhou, Fuling/0000-0003-0982-0382; Pan, Yunbao/0000-0002-6311-2945	National Natural Science Foundation of China [81372816]; Fundamental Research Funds for the Central Universities [JUSRP115A31]; NIH [R01CA90853, P30CA016672]; University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kwok-Wai Lo, The Chinese University of Hong Kong for providing EBV-positive NPC cell line C666.1. We thank Markeda Wade in the Department of Scientific Publications at MD Anderson Cancer Center for editing the manuscript. This study was supported by in part by grants from the National Natural Science Foundation of China (81372816), Fundamental Research Funds for the Central Universities (JUSRP115A31), NIH grant R01CA90853, University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center and by the NIH award P30CA016672.	Adachi M, 2012, ORAL ONCOL, V48, P1220, DOI 10.1016/j.oraloncology.2012.06.006; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng SH, 2000, INT J RADIAT ONCOL, V48, P1323, DOI 10.1016/S0360-3016(00)00779-3; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Fletcher S, 2009, BIOCHEM CELL BIOL, V87, P825, DOI [10.1139/O09-044, 10.1139/o09-044]; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; Liu YP, 2008, INT J MOL MED, V21, P153; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ong YK, 2003, EUR J CANCER, V39, P1535, DOI 10.1016/S0959-8049(03)00310-1; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Pan YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054565; Pan YB, 2012, CANCER LETT, V326, P155, DOI 10.1016/j.canlet.2012.07.033; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Sui L, 2001, CLIN CANCER RES, V7, P4130; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weerasinghe P, 2007, INT J ONCOL, V31, P129; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	43	41	41	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1069	1079		10.1038/onc.2016.271	http://dx.doi.org/10.1038/onc.2016.271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524414	Green Accepted			2022-12-28	WOS:000395371500005
J	Ferrer, CM; Lu, TY; Bacigalupa, ZA; Katsetos, CD; Sinclair, DA; Reginato, MJ				Ferrer, C. M.; Lu, T. Y.; Bacigalupa, Z. A.; Katsetos, C. D.; Sinclair, D. A.; Reginato, M. J.			O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway	ONCOGENE			English	Article							BETA-N-ACETYLGLUCOSAMINE; PROTEIN-KINASE AMPK; GLCNAC TRANSFERASE; TRANSCRIPTION FACTOR; CYTOSOLIC PROTEINS; CROSS-TALK; METABOLISM; TUMORIGENESIS; SIRTUINS; CELLS	Tumors utilize aerobic glycolysis to support growth and invasion. However, the molecular mechanisms that link metabolism with invasion are not well understood. The nutrient sensor O-linked-beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) modifies intracellular proteins with N-acetylglucosamine. Cancers display elevated O-GlcNAcylation and suppression of O-GlcNAcylation inhibits cancer invasion and metastasis. Here, we show that the regulation of cancer invasion by OGT is dependent on the NAD+-dependent deacetylase SIRT1. Reducing O-GlcNAcylation elevates SIRT1 levels and activity in an AMPK (AMP-activated protein kinase a)-dependent manner. Reduced O-GlcNAcylation in cancer cells leads to SIRT1-mediated proteasomal degradation of oncogenic transcription factor FOXM1 in an MEK/ERK-dependent manner. SIRT1 is critical for OGT-mediated regulation of FOXM1 ubiquitination and reducing SIRT1 activity reverses OGT-mediated regulation of FOXM1. Moreover, we show that SIRT1 levels are required for OGT-mediated regulation of invasion and metastasis in breast cancer cells. Thus, O-GlcNAcylation is a central component linking metabolism to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.	[Katsetos, C. D.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Katsetos, C. D.] Drexel Univ, Coll Med, St Christophers Hosp Children, Dept Pediat, Philadelphia, PA 19104 USA; [Sinclair, D. A.] Harvard Med Sch, Dept Genet, Paul F Glenn Labs Biol Mech Aging, Boston, MA USA	Drexel University; Drexel University; Harvard University; Harvard Medical School	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245N 15th St,NCB Room 11117, Philadelphia, PA 19102 USA.	Mauricio.Reginato@drexelmed.edu		Sinclair, David/0000-0002-9936-436X	NCI [CA183574, CA155413]; NIH/NIA [AG028730]; NATIONAL CANCER INSTITUTE [R01CA155413, F31CA183574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028730, R37AG028730] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Valerie Sodi for critical reading of this manuscript. This work is supported by NCI grants CA183574 (to CMF), CA155413 (to MJR) and NIH/NIA grant AG028730 (to DAS).	Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588; Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101; Bullen JW, 2014, J BIOL CHEM, V289, P10592, DOI 10.1074/jbc.M113.523068; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chang HC, 2014, TRENDS ENDOCRIN MET, V25, P138, DOI 10.1016/j.tem.2013.12.001; Choi JE, 2014, CURR OPIN GENET DEV, V26, P24, DOI 10.1016/j.gde.2014.05.005; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Ferrer CM, 2014, METHODS MOL BIOL, V1176, P73, DOI 10.1007/978-1-4939-0992-6_7; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Fulop N, 2008, BIOGERONTOLOGY, V9, P139, DOI 10.1007/s10522-007-9123-5; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Gu YC, 2010, CANCER RES, V70, P6344, DOI 10.1158/0008-5472.CAN-09-1887; Guarente L, 2011, COLD SH Q B, V76, P81, DOI 10.1101/sqb.2011.76.010629; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lau AW, 2014, AM J CANCER RES, V4, P245; Lewis BA, 2014, J BIOL CHEM, V289, P34440, DOI 10.1074/jbc.R114.595439; Lok GTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023790; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Lynch TP, 2011, CELL CYCLE, V10, P1712, DOI 10.4161/cc.10.11.15561; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Roth M, 2014, ONCOGENE, V33, P1609, DOI 10.1038/onc.2013.120; Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Yang YR, 2015, ONCOTARGET, V6, P12529, DOI 10.18632/oncotarget.3725; Yang YR, 2012, AGING CELL, V11, P439, DOI 10.1111/j.1474-9726.2012.00801.x; Yeung F, 2015, ONCOGENE, V34, P798, DOI 10.1038/onc.2014.39; Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1	52	61	63	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					559	569		10.1038/onc.2016.228	http://dx.doi.org/10.1038/onc.2016.228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345396	Green Accepted, Green Submitted			2022-12-28	WOS:000394166700012
J	Jeong, M; Lee, EW; Seong, D; Seo, J; Kim, JH; Grootjans, S; Kim, SY; Vandenabeele, P; Song, J				Jeong, M.; Lee, E-W; Seong, D.; Seo, J.; Kim, J-H; Grootjans, S.; Kim, S-Y; Vandenabeele, P.; Song, J.			USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability	ONCOGENE			English	Article							FLICE-INHIBITORY PROTEIN; TUMOR-NECROSIS-FACTOR; CELL LUNG-CANCER; SIGNALING COMPLEX; C-FLIP; CASPASE-8 ACTIVATION; CFLIP ISOFORMS; TRAIL; DEGRADATION; PATHWAY	FLICE-like inhibitory protein (FLIP) is a critical regulator of death receptor-mediated apoptosis. Here, we found ubiquitin-specific peptidase 8 (USP8) to be a novel deubiquitylase of the long isoform of FLIP (FLIPL). USP8 directly deubiquitylates and stabilizes FLIPL, but not the short isoform. USP8 depletion induces FLIPL destabilization, promoting anti-Fas-, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- and tumor necrosis factor alpha-induced extrinsic apoptosis by facilitating death-inducing signaling complex or TNFR1 complex II formation, which results in the activation of caspase-8 and caspase-3. USP8 mRNA levels are elevated in melanoma and cervical cancers, and the protein levels of USP8 and FLIPL are positively correlated in these cancer cell lines. Xenograft analyses using ME-180 cervical cancer cells showed that USP8 depletion attenuated tumor growth upon TRAIL injection. Taken together, our data indicate that USP8 functions as a novel deubiquitylase of FLIPL and inhibits extrinsic apoptosis by stabilizing FLIPL.	[Jeong, M.; Lee, E-W; Seong, D.; Seo, J.; Kim, J-H; Song, J.] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Yonsei Ro 50, Seoul 120749, South Korea; [Grootjans, S.; Vandenabeele, P.] VIB, Inflammat Res Ctr, Zwijnaarde Ghent, Belgium; [Grootjans, S.; Vandenabeele, P.] Univ Ghent, Dept Biomed Mol Biol, Zwijnaarde Ghent, Belgium; [Kim, S-Y] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, Goyang, South Korea	Yonsei University; Flanders Institute for Biotechnology (VIB); Ghent University; National Cancer Center - Korea (NCC)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Yonsei Ro 50, Seoul 120749, South Korea.	jso678@yonsei.ac.kr	Lee, Eun-Woo/AAP-9603-2020; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; Grootjans, Sasker/N-3262-2013	Vandenabeele, Peter/0000-0002-6669-8822; Grootjans, Sasker/0000-0002-8385-2545; Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1A3A2066581]; Ministry of Education [2012R1A6A3A04040105]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Ministry of Education	This work was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A3A2066581) (to J Song) and by the Ministry of Education (2012R1A6A3A04040105) (to E-WL).	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Byun S, 2013, CLIN CANCER RES, V19, P3894, DOI 10.1158/1078-0432.CCR-12-3696; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chanvorachote P, 2005, J BIOL CHEM, V280, P42044, DOI 10.1074/jbc.M510080200; den Hollander MW, 2013, CANCER LETT, V332, P194, DOI 10.1016/j.canlet.2012.04.007; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dillon CP, 2012, CELL REPORTS, V1, P401, DOI 10.1016/j.celrep.2012.03.010; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; French LE, 2003, CELL DEATH DIFFER, V10, P117, DOI 10.1038/sj.cdd.4401185; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guedat P, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S14; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hughes MA, 2016, MOL CELL, V61, P834, DOI 10.1016/j.molcel.2016.02.023; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kaunisto A, 2009, CELL DEATH DIFFER, V16, P1215, DOI 10.1038/cdd.2009.35; Kavuri SM, 2011, J BIOL CHEM, V286, P16631, DOI 10.1074/jbc.M110.148585; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lee EW, 2015, CELL DEATH DIFFER, V22, P1463, DOI 10.1038/cdd.2014.234; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; Maksimovic-Ivanic D, 2012, IMMUNOL RES, V52, P157, DOI 10.1007/s12026-012-8284-8; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Panner A, 2010, CANCER RES, V70, P5046, DOI 10.1158/0008-5472.CAN-09-3979; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Pop C, 2011, BIOCHEM J, V433, P447, DOI 10.1042/BJ20101738; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Shirley S, 2013, CANCER LETT, V332, P141, DOI 10.1016/j.canlet.2010.10.009; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007; Symons A, 2006, TRENDS IMMUNOL, V27, P40, DOI 10.1016/j.it.2005.11.007; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vandenabeele P, 2012, CELL DEATH DIFFER, V19, P1093, DOI 10.1038/cdd.2012.65; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Weinlich R, 2011, TRENDS CELL BIOL, V21, P630, DOI 10.1016/j.tcb.2011.09.002; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yerbes R, 2012, CELL DEATH DIFFER, V19, P1908, DOI 10.1038/cdd.2012.78; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299	64	36	36	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					458	470		10.1038/onc.2016.215	http://dx.doi.org/10.1038/onc.2016.215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321185				2022-12-28	WOS:000394166700003
J	Yu, PF; Huang, Y; Han, YY; Lin, LY; Sun, WH; Rabson, AB; Wang, Y; Shi, YF				Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Rabson, A. B.; Wang, Y.; Shi, Y. F.			TNF alpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils	ONCOGENE			English	Article							TUMOR-ASSOCIATED NEUTROPHILS; STEM-CELLS; BONE-MARROW; MIGRATION; MOBILIZATION; IMMUNOSUPPRESSION; INTERLEUKIN-6; CHEMOKINES; CONTRIBUTE; HALLMARKS	Mesenchymal stromal cells (MSCs) tend to infiltrate into tumors and form a major component of the tumor microenvironment. Our previous work demonstrated that tumor necrosis factor a (TNF alpha)-activated MSCs significantly promoted tumor growth. However, the role of TNF alpha-treated MSCs in tumor metastasis remains elusive. Employing a lung metastasis model of murine breast cancer, we found that TNF alpha-activated MSCs strikingly enhanced tumor metastasis compared with normal MSCs. We analyzed the chemokine profiles and found that the expression of CCL5, CCR2 and CXCR2 ligands were enhanced in TNF alpha-activated MSCs. Using genetic or pharmacological strategies to inhibit CCL5 or CCR2, we demonstrated that CCL5 and CCR2 ligands were indispensable in supporting TNF alpha-activated MSCs to promote tumor metastasis. Analysis of immune cells revealed that CXCR2 ligands (CXCL1, CXCL 2 and CXCL5) expressed by TNF alpha-activated MSCs efficiently recruited CXCR2(+) neutrophils into tumor. These neutrophils were responsible for the pro-metastatic effect of MSCs since inhibition of this chemotaxis abolished increased neutrophil recruitment and tumor metastasis. The interaction between neutrophils and tumor cells resulted in markedly elevated metastasis-related genes by tumor cells, including CXCR4, CXCR7, MMP12, MMP13, IL-6 and TGF beta. Importantly, in IL8(high) human breast cancer samples, we also observed similar alterations of gene expression. Collectively, our findings demonstrate that TNF alpha-activated MSCs promote tumor metastasis via CXCR2(+) neutrophil recruitment.	[Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Wang, Y.; Shi, Y. F.] Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Stem Cell Biol,Inst Hlth Sci,Sch Med, Shanghai, Peoples R China; [Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Shanghai, Peoples R China; [Rabson, A. B.; Shi, Y. F.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Wang, Y; Shi, YF (corresponding author), Shanghai Jiao Tong Univ, Univ Chinese Acad Sci, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	HUANG, YIN/AAH-6871-2020; Shi, Yufang/AAE-4431-2020; Yu, Pengfei/AHC-3497-2022	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; Yu, Pengfei/0000-0002-3894-5697; Sun, Weihong/0000-0002-6292-903X; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Sciences [XDA 01040100]; Ministry of Science and Technology of China [2015CB964400]; Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone [ZJ2014-ZD-002]; Programs of National Natural Science of China [81330046, 81273316, 81571612, 81530043]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Rising-Star Program [14QA1404200]; Youth Innovation Promotion Association, Chinese Academy of Sciences	Scientific Innovation Project of the Chinese Academy of Sciences; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Rising-Star Program; Youth Innovation Promotion Association, Chinese Academy of Sciences	This study was supported by grants from the Scientific Innovation Project of the Chinese Academy of Sciences (XDA 01040100), the Ministry of Science and Technology of China (2015CB964400), Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone (ZJ2014-ZD-002), the Programs of National Natural Science of China (81330046, 81273316, 81571612, 81530043), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Rising-Star Program (14QA1404200) and Youth Innovation Promotion Association, Chinese Academy of Sciences.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Ardi VC, 2007, P NATL ACAD SCI USA, V104, P20262, DOI 10.1073/pnas.0706438104; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; De Luca A, 2012, J CELL BIOCHEM, V113, P3363, DOI 10.1002/jcb.24212; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; El-Haibi CP, 2010, J MAMMARY GLAND BIOL, V15, P399, DOI 10.1007/s10911-010-9196-7; Fridlender ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031524; Fridlender ZG, 2012, CARCINOGENESIS, V33, P949, DOI 10.1093/carcin/bgs123; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Gijsbers K, 2005, EXP CELL RES, V303, P331, DOI 10.1016/j.yexcr.2004.09.027; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; Halpern JL, 2011, CANCER LETT, V308, P91, DOI 10.1016/j.canlet.2011.04.018; Han X, 2014, CELL DEATH DIFFER, V21, P1758, DOI 10.1038/cdd.2014.85; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Hu PP, 2015, TUMOR BIOL, V36, P7789, DOI 10.1007/s13277-015-3484-1; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Jochems C, 2011, EXP BIOL MED, V236, P567, DOI 10.1258/ebm.2011.011007; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Lourenco S, 2015, J IMMUNOL, V194, P3463, DOI 10.4049/jimmunol.1402097; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416; Rattigan Y, 2010, EXP CELL RES, V316, P3417, DOI 10.1016/j.yexcr.2010.07.002; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Xu GW, 2007, BIOCHEM BIOPH RES CO, V361, P745, DOI 10.1016/j.bbrc.2007.07.052; Yan B, 2013, J IMMUNOL, V190, P5882, DOI 10.4049/jimmunol.1201881; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang LL, 2008, EURASIP J WIREL COMM, DOI 10.1155/2008/541410; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397	52	127	129	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					482	490		10.1038/onc.2016.217	http://dx.doi.org/10.1038/onc.2016.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375023	Green Published, hybrid			2022-12-28	WOS:000394166700005
J	Lu, J; Song, G; Tang, Q; Yin, J; Zou, C; Zhao, Z; Xie, X; Xu, H; Huang, G; Wang, J; Lee, DF; Khokha, R; Yang, H; Shen, J				Lu, J.; Song, G.; Tang, Q.; Yin, J.; Zou, C.; Zhao, Z.; Xie, X.; Xu, H.; Huang, G.; Wang, J.; Lee, D-F; Khokha, R.; Yang, H.; Shen, J.			MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1	ONCOGENE			English	Article							SELF-RENEWAL; ALDEHYDE DEHYDROGENASE; CANCER; NOTCH; DIFFERENTIATION; MICRORNA-26A; TUMORIGENESIS; PATHWAY; PROLIFERATION; REGENERATION	MicroRNAs (miRNAs) are important epigenetic regulators of gene expression. Although several miRNAs have been implicated in osteosarcoma, their role in regulation of osteosarcoma cancer stem cells (CSCs) remains unknown. Here we demonstrated that miR-26a is downregulated in osteosarcoma CSCs when derived by either sarcosphere generation, chemodrug or aldehyde dehydrogenase (ALDH) activity selection. Lentiviral overexpression of miR-26a in ZOS and 143B osteosarcoma cells decreases the expression of stem cell markers and suppresses sarcosphere formation, as well as ALDH activity. Moreover, miR-26a overexpression inhibits the tumor cell growth both in vitro and in vivo. We further demonstrate that miR-26a directly target Jagged1, one of the Notch ligand, and that its tumor suppressive effects are mediated through inhibition of Jaggedl/Notch signaling. Importantly, reduced miR-26a expression, as determined by in situ hybridization in patient tumors (n=92), is associated with lung metastasis and poor overall survival of osteosarcoma patients. Together, these data suggest the essential role of miR-26a/Jaggedl/Notch pathway in regulating the stem cell-like traits of osteosarcoma cells and provide a potential target for osteosarcoma therapy.	[Lu, J.; Song, G.; Tang, Q.; Yin, J.; Zou, C.; Zhao, Z.; Xie, X.; Xu, H.; Huang, G.; Wang, J.; Shen, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China; [Lee, D-F] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Khokha, R.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; University of Texas System; University of Texas Health Science Center Houston; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Sun Yat Sen University	Shen, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.; Yang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	yanghl@mail.sysu.edu.cn; shenjingnan@126.com		Khokha, Rama/0000-0002-6028-1524	National Natural Science Foundation of China [81272939, 81472506]; Natural Science Foundation of Guangdong Province [S2013020012460]; National Institutes of Health (NIH) Pathway to Independence Award [R00 CA181496]; CPRIT Award [RR160019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Institutes of Health (NIH) Pathway to Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT Award	This research was supported by National Natural Science Foundation of China (81272939 and 81472506 to JS) and Natural Science Foundation of Guangdong Province (S2013020012460 to JS). D-FL is the Cancer Prevention Research Institute of Texas (CPRIT) scholar in Cancer Research and supported by National Institutes of Health (NIH) Pathway to Independence Award R00 CA181496 and CPRIT Award RR160019. We thank Jingling Zhao (Sun Yat-Sen University) for expert technical assistance and Meghan Lambie (University of Toronto) for language editing.	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Dey BK, 2012, GENE DEV, V26, P2180, DOI 10.1101/gad.198085.112; Di Fiore R, 2014, INT J ONCOL, V45, P2013, DOI 10.3892/ijo.2014.2618; Donnem T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-6; Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fu XH, 2013, P NATL ACAD SCI USA, V110, P17892, DOI 10.1073/pnas.1317397110; Fujiwara T, 2014, STEM CELLS, V32, P959, DOI 10.1002/stem.1618; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c; Hopkins TG, 2016, NUCLEIC ACIDS RES, V44, P1227, DOI 10.1093/nar/gkv1515; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052; Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234; Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Mu XD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00143; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Salvatori B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.151; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-78; Siegel HJ, 2008, EXPERT REV ANTICANC, V8, P1257, DOI 10.1586/14737140.8.8.1257; Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060; Tang QL, 2012, JNCI-J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210; Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Wang X., 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072015; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang AD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/187509; Zou CY, 2008, ACTA PHARMACOL SIN, V29, P325, DOI 10.1111/j.1745-7254.2008.00756.x	44	70	75	4	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					231	241		10.1038/onc.2016.194	http://dx.doi.org/10.1038/onc.2016.194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270422				2022-12-28	WOS:000393938100008
J	Selth, LA; Das, R; Townley, SL; Coutinho, I; Hanson, AR; Centenera, MM; Stylianou, N; Sweeney, K; Soekmadji, C; Jovanovic, L; Nelson, CC; Zoubeidi, A; Butler, LM; Goodall, GJ; HoIlier, BG; Gregory, PA; Tilley, WD				Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Stylianou, N.; Sweeney, K.; Soekmadji, C.; Jovanovic, L.; Nelson, C. C.; Zoubeidi, A.; Butler, L. M.; Goodall, G. J.; HoIlier, B. G.; Gregory, P. A.; Tilley, W. D.			A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer	ONCOGENE			English	Article							MICRORNA EXPRESSION PROFILES; CIRCULATING TUMOR-CELLS; MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; METASTATIC COLONIZATION; MIR-200 FAMILY; BREAST-CANCER; MESSENGER-RNA; PROGRESSION; REPRESSION	MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti -invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.	[Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Tilley, W. D.] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Level 4,Hanson Inst Bldg,DX 650 801, Adelaide, SA 5005, Australia; [Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Butler, L. M.; Tilley, W. D.] Univ Adelaide, Freemasons Fdn, Ctr Mens Hlth, Discipline Med, Adelaide, SA, Australia; [Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Butler, L. M.; Goodall, G. J.; Gregory, P. A.; Tilley, W. D.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Centenera, M. M.; Butler, L. M.] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia; [Stylianou, N.; Sweeney, K.; Soekmadji, C.; Jovanovic, L.; Nelson, C. C.; HoIlier, B. G.] Queensland Univ Technol, Princess Alexandra Hosp, Translat Res Inst,Inst Hlth & Biomed Innovat, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld, Australia; [Zoubeidi, A.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Goodall, G. J.; Gregory, P. A.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ South Australia, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Hanson Institute; University of Adelaide; University of Adelaide; University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI); Queensland University of Technology (QUT); University of British Columbia; Centre for Cancer Biology; SA Pathology; University of South Australia; University of Adelaide	Selth, LA (corresponding author), Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Level 4,Hanson Inst Bldg,DX 650 801, Adelaide, SA 5005, Australia.	luke.selth@adelaide.edu.au	Stylianou, Nataly/GOP-1782-2022; Gregory, Philip/F-4089-2013; Selth, Luke/AAH-4823-2021; Butler, Lisa/AAP-9088-2020; Butler, Lisa M/C-9843-2010; Soekmadji, Carolina/M-2757-2016	Gregory, Philip/0000-0002-0999-0632; Selth, Luke/0000-0002-4686-1418; Butler, Lisa/0000-0003-2698-3220; Soekmadji, Carolina/0000-0002-6920-6627; coutinho, isabel/0000-0003-3389-033X; centenera, margaret/0000-0002-2206-0632; Stylianou, Nataly/0000-0002-8006-5730; Goodall, Gregory/0000-0003-1294-0692; Tilley, Wayne/0000-0003-1893-2626	Young Investigator Awards from the Prostate Cancer Foundation [14]; Prostate Cancer Foundation of Australia (PCFA)/Movember [YI 0810, YI 0412]; PCFA/Movember/Cancer Australia [1012337, 1043482]; National Health and Medical Research Council [1083961]; Cancer Council of South Australia; Queensland government Smart Futures Fund Fellowship; Movember Foundation; Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	Young Investigator Awards from the Prostate Cancer Foundation; Prostate Cancer Foundation of Australia (PCFA)/Movember; PCFA/Movember/Cancer Australia; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia(Cancer Council South Australia); Queensland government Smart Futures Fund Fellowship; Movember Foundation; Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards; National Breast Cancer Foundation	The YAP1 3'-UTR plasmids were a kind gift from Prof Takashi Takahashi, Nagoya University. The results published here are in part based on the data generated by The Cancer Genome Atlas, established by the National Cancer Institute and the National Human Genome Research Institute, and we are grateful to the specimen donors and relevant research groups associated with this project. We also acknowledge the ENCODE Consortium and the Myers laboratory at the HudsonAlpha Institute for Biotechnology for generating the ZEB1 ChIP-seq data set used in this study. This work was supported by: Young Investigator Awards from the Prostate Cancer Foundation (the Foundation 14 award; LAS) and the Prostate Cancer Foundation of Australia (PCFA)/Movember (YI 0810; LAS, YI 0412; MMC) and grants from PCFA/Movember/Cancer Australia (Grant IDs 1012337 and 1043482; WDT, LAS and LMB) and the National Health and Medical Research Council (Grant ID 1083961). PAG is supported by a Beat Cancer Project fellowship from the Cancer Council of South Australia. BGH is supported by a Queensland government Smart Futures Fund Fellowship. The research programs of LAS, MMC, LMB, CCN, BGH and WDT are supported by the Movember Foundation and the Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Banyard J, 2013, SCI REP-UK, V3, DOI 10.1038/srep03151; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Christensen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096767; Chu ML, 2014, ONCOL REP, V31, P34, DOI 10.3892/or.2013.2810; Costa-Pinheiro P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0076-2; Das R, 2014, TRENDS MOL MED, V20, P643, DOI 10.1016/j.molmed.2014.09.004; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Souza Rocha Simonini P, 2010, CANCER RES, V70, P9175, DOI DOI 10.1158/0008-5472.CAN-10-1318; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gasch C, 2015, SCI REP-UK, V5, DOI 10.1038/srep15980; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Kohn KW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035716; Kolesnikoff N, 2014, J BIOL CHEM, V289, P11194, DOI 10.1074/jbc.M113.529172; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Lokman NA, 2012, INT J MOL SCI, V13, P9959, DOI 10.3390/ijms13089959; Madhavan D, 2012, CLIN CANCER RES, V18, P5972, DOI 10.1158/1078-0432.CCR-12-1407; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marrocco DL, 2007, MOL CANCER THER, V6, P51, DOI 10.1158/1535-7163.MCT-06-0144; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Moore NL, 2012, ENDOCR-RELAT CANCER, V19, P599, DOI 10.1530/ERC-12-0065; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Schaefer A, 2010, NAT REV UROL, V7, P286, DOI 10.1038/nrurol.2010.45; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Selth LA, 2013, BRIT J CANCER, V109, P641, DOI 10.1038/bjc.2013.369; Selth LA, 2012, ENDOCR-RELAT CANCER, V19, pR99, DOI 10.1530/ERC-12-0010; Selth LA, 2012, INT J CANCER, V131, P652, DOI 10.1002/ijc.26405; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Sokilde R, 2011, MOL CANCER THER, V10, P375, DOI 10.1158/1535-7163.MCT-10-0605; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wach S, 2012, INT J CANCER, V130, P611, DOI 10.1002/ijc.26064; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Wu JN, 2014, CANCER-AM CANCER SOC, V120, P818, DOI 10.1002/cncr.28485; Yu XZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030605; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6	55	81	84	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					24	34		10.1038/onc.2016.185	http://dx.doi.org/10.1038/onc.2016.185			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270433	Green Accepted			2022-12-28	WOS:000394069100003
J	Sanduja, S; Feng, Y; Mathis, RA; Sokol, ES; Reinhardt, F; Halaban, R; Gupta, PB				Sanduja, S.; Feng, Y.; Mathis, R. A.; Sokol, E. S.; Reinhardt, F.; Halaban, R.; Gupta, P. B.			AMPK promotes tolerance to Ras pathway inhibition by activating autophagy	ONCOGENE			English	Article							INITIATING KINASE ULK1; TUMOR-SUPPRESSOR LKB1; ADVANCED MELANOMA; BRAF; RESISTANCE; PROLIFERATION; BRAF(V600E); VEMURAFENIB; METABOLISM; SURVIVAL	Targeted inhibitors of oncogenic Ras (rat sarcoma viral oncogene)-Raf signaling have shown great promise in the clinic, but resistance remains a major challenge: 30% of tumors with pathway mutations do not respond to targeted inhibitors, and of the 70% that do respond, all eventually develop resistance. Before cancer cells acquire resistance, they respond to initial drug treatment either by undergoing apoptosis ('addiction') or by surviving treatment albeit with reduced growth ('tolerance'). As these drug-tolerant cells serve as a reservoir from which resistant cells eventually emerge, inhibiting the pathways that confer tolerance could potentially delay or even prevent recurrence. Here, we show that melanomas and other cancers acquire tolerance to Ras-Raf pathway inhibitors by activating autophagy, which is mediated by the cellular energy sensor AMP-activated protein kinase (AMPK). Blocking this AMPK-mediated autophagy sensitizes drug-tolerant melanomas to Ras-Raf pathway inhibitors. Conversely, activating AMPK signaling and autophagy enables melanomas that would otherwise be addicted to the Ras-Raf pathway to instead tolerate pathway inhibition. These findings identify a key mechanism of tolerance to Ras-Raf pathway inhibitors and suggest that blocking either AMPK or autophagy in combination with these targeted inhibitors could increase tumor regression and decrease the likelihood of eventual recurrence.	[Sanduja, S.; Feng, Y.; Mathis, R. A.; Sokol, E. S.; Reinhardt, F.; Gupta, P. B.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Mathis, R. A.; Sokol, E. S.; Gupta, P. B.] MIT, Dept Biol, Cambridge, MA USA; [Halaban, R.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Gupta, P. B.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Gupta, P. B.] Harvard Stem Cell Inst, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Yale University; Massachusetts Institute of Technology (MIT); Harvard University	Gupta, PB (corresponding author), Whitehead Inst Biomed Res, Biol, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	pgupta@wi.mit.edu			Ellison Foundation; Melanoma Research Alliance [311800]; Yale SPORE in Skin Cancer - National Cancer Institute [1 P50 CA121974]; NSFGRFP [1122374]; NATIONAL CANCER INSTITUTE [P50CA121973, P50CA121974] Funding Source: NIH RePORTER	Ellison Foundation(Lawrence Ellison Foundation); Melanoma Research Alliance; Yale SPORE in Skin Cancer - National Cancer Institute; NSFGRFP(National Science Foundation (NSF)NSF - Office of the Director (OD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tyler Jacks for providing us with mouse KRAS<SUP>mut</SUP>/p53<SUP>-/-</SUP> NSCLC line, the Whitehead flow cytometry facility, and Nicki Watson and Wendy Salmon at the Whitehead Keck Imaging Facility for microscopy services. We thank Dr David Pincus and Dr Luke Whitesell for critical reading of the manuscript. This research was supported by grants from the Ellison Foundation (PBG) and Melanoma Research Alliance (#311800; PBG), a Yale SPORE in Skin Cancer funded by the National Cancer Institute (#1 P50 CA121974; RH), and funds from the NSFGRFP (#1122374; ESS).	Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Flaherty KT, 2010, ANN INTERN MED, V153, P587, DOI 10.7326/0003-4819-153-9-201011020-00008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gamrekelashvili J, 2007, J IMMUNOL, V178, P1573, DOI 10.4049/jimmunol.178.3.1573; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909; Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petti C, 2012, MELANOMA RES, V22, P341, DOI 10.1097/CMR.0b013e3283544929; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2010, CURR OPIN INVEST DR, V11, P699; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	44	34	34	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5295	5303		10.1038/onc.2016.70	http://dx.doi.org/10.1038/onc.2016.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041569	Green Submitted, Green Accepted			2022-12-28	WOS:000386053000008
J	Xiong, H; Ni, Z; He, J; Jiang, S; Li, X; He, J; Gong, W; Zheng, L; Chen, S; Li, B; Zhang, N; Lyu, X; Huang, G; Chen, B; Zhang, Y; He, F				Xiong, H.; Ni, Z.; He, J.; Jiang, S.; Li, X.; He, J.; Gong, W.; Zheng, L.; Chen, S.; Li, B.; Zhang, N.; Lyu, X.; Huang, G.; Chen, B.; Zhang, Y.; He, F.			LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells	ONCOGENE			English	Article							LONG NONCODING RNA; DOWN-REGULATION; USP22; CANCER; ACTIVATION; CHEMORESISTANCE; PROLIFERATION; CONTRIBUTES; MAINTENANCE; SUPPRESSES	Considerable evidences have shown that autophagy has an important role in tumor chemoresistance. However, it is still unknown whether the lncRNA HULC (highly upregulated in liver cancer) is involved in autophagy and chemoresistance of hepatocellular carcinoma (HCC). In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy. Silencing of HULC sensitized HCC cells to the three antitumor reagents via inhibiting protective autophagy. Ectopic expression of HULC elicited the autophagy of HCC cells through stabilizing silent information regulator 1 (Sirt1) protein. The investigation for the corresponding mechanism by which HULC stabilized Sirt1 revealed that HULC upregulated ubiquitin-specific peptidase 22 (USP22), leading to the decrease of ubiquitin-mediated degradation of Sirt1 protein by removing the conjugated polyubiquitin chains from Sirt1. Moreover, we found that miR-6825-5p, miR-6845-5p and miR-6886-3p could decrease the level of USP22 protein by binding to the 3'-untranlated region of USP22 mRNA. All the three microRNAs (miRNAs) were downregulated by HULC, which resulted in the elevation of USP22. In addition, we showed that the level of HULC was positively correlated with that of Sirt1 protein in human HCC tissues. Collectively, our data reveals that the pathway 'HULC/USP22/Sirt1/protective autophagy' attenuates the sensitivity of HCC cells to chemotherapeutic agents, suggesting that this pathway may be a novel target for developing sensitizing strategy to HCC chemotherapy.	[Xiong, H.; Ni, Z.; Jiang, S.; Li, X.; He, J.; Gong, W.; Chen, S.; Li, B.; Zhang, N.; Lyu, X.; Huang, G.; Zhang, Y.; He, F.] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China; [He, J.] Third Mil Med Univ, Coll Prevent Med, Battal Students 17, Chongqing, Peoples R China; [Zheng, L.] Third Mil Med Univ, Xinqiao Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Chen, B.] Third Mil Med Univ, Lab Anim Ctr, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Chen, B; Zhang, Y; He, F (corresponding author), Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	chenbb81@126.com; tmmubiozy@163.com; hefengtian06@aliyun.com	He, Feng/HHS-6457-2022; HUANG, GANG/AAO-5503-2020	He, Feng/0000-0002-1996-0744; zhenhong, ni/0000-0002-7464-4074	National Natural Science Foundation of China [81672377, 31470066, 81472291, 81272690]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81672377, 31470066, 81472291 and 81272690).	Armour SM, 2013, MOL CELL BIOL, V33, P1487, DOI 10.1128/MCB.00971-12; Bae HJ, 2014, ONCOGENE, V33, P2557, DOI 10.1038/onc.2013.216; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Guo XL, 2014, CANCER LETT, V346, P278, DOI 10.1016/j.canlet.2014.01.011; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; He JB, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/605946; Helwak A, 2013, CELL, V153, P654, DOI 10.1016/j.cell.2013.03.043; Hu C, 2014, ONCOGENE, V33, P2888, DOI 10.1038/onc.2013.250; Hu C, 2015, GUT, V66, P31, DOI [10.1136/gutjn1-2015-309322, DOI 10.1136/GUTJN1-2015-309322]; Khorshid M, 2013, NAT METHODS, V10, P253, DOI [10.1038/NMETH.2341, 10.1038/nmeth.2341]; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Li L, 2014, CELL STEM CELL, V15, P431, DOI 10.1016/j.stem.2014.08.001; Li Q, 2015, AUTOPHAGY, V11, P1293, DOI 10.1080/15548627.2015.1058474; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Lu ZP, 2016, ONCOTARGET, V7, P241, DOI 10.18632/oncotarget.6280; Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405; Peng LR, 2015, J BIOL CHEM, V290, P8904, DOI 10.1074/jbc.M114.612796; Qiu GL, 2015, FEBS LETT, V589, P2034, DOI 10.1016/j.febslet.2015.05.042; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Shteingauz A, 2015, CANCER RES, V75, P3946, DOI 10.1158/0008-5472.CAN-15-0037; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Song YM, 2015, AUTOPHAGY, V11, P46, DOI 10.4161/15548627.2014.984271; Tang B, 2015, ONCOTARGET, V6, P12654, DOI 10.18632/oncotarget.3705; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhou P, 2014, CELL SIGNAL, V26, P1347, DOI 10.1016/j.cellsig.2014.02.020	40	260	282	7	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3528	3540		10.1038/onc.2016.521	http://dx.doi.org/10.1038/onc.2016.521			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166203				2022-12-28	WOS:000403878600003
J	Volpin, F; Casaos, J; Sesen, J; Mangraviti, A; Choi, J; Gorelick, N; Frikeche, J; Lott, T; Felder, R; Scotland, SJ; Eisinger-Mathason, TSK; Brem, H; Tyler, B; Skuli, N				Volpin, F.; Casaos, J.; Sesen, J.; Mangraviti, A.; Choi, J.; Gorelick, N.; Frikeche, J.; Lott, T.; Felder, R.; Scotland, S. J.; Eisinger-Mathason, T. S. K.; Brem, H.; Tyler, B.; Skuli, N.			Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic	ONCOGENE			English	Article							INITIATION-FACTOR 4E; ACUTE MYELOID-LEUKEMIA; ADJUVANT TEMOZOLOMIDE; STEM-CELLS; INHIBITION; EIF4E; TRANSLATION; TARGET; TUMORS; RADIOTHERAPY	The median survival for glioblastoma patients is similar to 15 months despite aggressive surgery and radio-chemotherapy approaches. Thus, developing new therapeutics is necessary to improve the treatment of these invasive brain tumors, which are known to show high levels of the eukaryotic initiation factor, eIF4E, a potent oncogene. Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C treatment. Here, we report the effect of ribavirin on proliferation, cell cycle, cell death and migration of several human and murine glioma cell lines, as well as human glioblastoma stem-like cells, in vitro. In addition, we tested ribavirin efficacy in vivo, alone and in combination with temozolomide and radiation. Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. We also demonstrate that ribavirin treatment in combination with temozolomide or irradiation increases cell death in glioma cells. Finally and most importantly, ribavirin treatment in vivo significantly enhances chemoradiotherapy efficacy and improves survival of rats and mice orthotopically implanted with gliosarcoma tumors or glioma stem-like cells, respectively. On the basis of these results, we propose that ribavirin represents a new therapeutic option for glioblastoma patients as an enhancer of the cytotoxic effects of temozolomide and radiotherapy.	[Volpin, F.; Casaos, J.; Sesen, J.; Mangraviti, A.; Choi, J.; Gorelick, N.; Frikeche, J.; Lott, T.; Felder, R.; Scotland, S. J.; Brem, H.; Tyler, B.; Skuli, N.] Johns Hopkins Univ, Dept Neurosurg, Hunterian Neurosurg Res Lab, Johns Hopkins Sch Med, Baltimore, MD USA; [Sesen, J.; Skuli, N.] CRCT, INSERM U1037, Toulouse, France; [Eisinger-Mathason, T. S. K.] Univ Penn, Dept Pathol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Pennsylvania; Pennsylvania Medicine	Skuli, N (corresponding author), Johns Hopkins Univ, Dept Neurosurg, Hunterian Brain Tumor Lab, 1550 Orleans St,Koch Canc Res Bldg, Baltimore, MD 21231 USA.	nicolas.skuli@inserm.fr		Skuli, Sarah/0000-0001-7711-0732; FRIKECHE, Jihane/0000-0003-1291-6908; Gorelick, Noah/0000-0003-1313-1061; Mangraviti, Antonella/0000-0003-2843-0718	INSERM [U1037SPDOTSKULI]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank the Hunterian Neurosurgical Research Laboratory, Dr Thomas Simon for helpful comments, and Mr and Mrs Peter Jennison and Mr and Mrs Josh Fidler for their kind and generous support. This work was supported by INSERM (Grant number: U1037SPDOTSKULI).	Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Assouline S, 2015, HAEMATOLOGICA, V100, pE7, DOI 10.3324/haematol.2014.111245; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169; Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506; Chen DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087281; Colombo G, 2011, ANTIVIR RES, V92, P408, DOI 10.1016/j.antiviral.2011.09.012; Dadgostari S, 2004, DRUG CHEM TOXICOL, V27, P191, DOI 10.1081/DCT-200031953; De La Cruz-Hernandez E, 2015, ONCOL REP, V33, P2384, DOI 10.3892/or.2015.3816; Dubois L, 2009, INT J RADIAT ONCOL, V73, P1219, DOI 10.1016/j.ijrobp.2008.12.003; EGGLESTON M, 1987, INFECT CONT HOSP EP, V8, P215, DOI 10.1017/S0195941700065978; Fan TY, 2014, INT J CLIN EXP PATHO, V7, P6662; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gallia GL, 2009, MOL CANCER THER, V8, P386, DOI 10.1158/1535-7163.MCT-08-0680; Ge YQ, 2010, BIOCHEM BIOPH RES CO, V397, P711, DOI 10.1016/j.bbrc.2010.06.015; Grzmil M, 2014, J CLIN INVEST, V124, P742, DOI 10.1172/JCI70198; Gu X, 2005, APPL IMMUNOHISTO M M, V13, P178, DOI 10.1097/01.pai.0000135615.07325.a2; Harvie P, 1996, J ACQ IMMUN DEF SYND, V12, P451, DOI 10.1097/00042560-199608150-00003; Hayman TJ, 2012, CANCER RES, V72, P2362, DOI 10.1158/0008-5472.CAN-12-0329; Hsieh AC, 2010, CLIN CANCER RES, V16, P4914, DOI 10.1158/1078-0432.CCR-10-0433; Jeulin H, 2009, ANTIVIR RES, V81, P261, DOI 10.1016/j.antiviral.2008.12.006; Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Kokeny S, 2009, ANTICANCER RES, V29, P1971; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Loustaud-Ratti V, 2016, WORLD J HEPATOL, V8, P123, DOI 10.4254/wjh.v8.i2.123; Mangraviti A, 2016, BIOMATERIALS, V100, P53, DOI 10.1016/j.biomaterials.2016.05.025; McGirt MJ, 2009, J NEUROSURG, V110, P583, DOI 10.3171/2008.5.17557; Mijatovic S, 2005, CELL MOL LIFE SCI, V62, P589, DOI 10.1007/s00018-005-4425-8; Myung JK, 2014, INT J CLIN EXP PATHO, V7, P1977; Narayana K, 2002, MUTAT RES-GEN TOX EN, V521, P179, DOI 10.1016/S1383-5718(02)00239-5; Ogino A, 2014, ONCOL LETT, V8, P2469, DOI 10.3892/ol.2014.2569; Olah E, 2006, ADV ENZYME REGUL, V46, P176, DOI 10.1016/j.advenzreg.2006.01.002; Paeshuyse J, 2011, CURR OPIN VIROL, V1, P590, DOI 10.1016/j.coviro.2011.10.030; Papanagnou P, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9020024; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Pettersson F, 2014, EXPERT OPIN THER TAR, V18, P1035, DOI 10.1517/14728222.2014.937426; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Richard SM, 2015, J CANCER RES THER, V11, P336, DOI 10.4103/0973-1482.157317; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russmann S, 2006, CURR MED CHEM, V13, P3351, DOI 10.2174/092986706778773059; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; SCHEIDEL LM, 1987, VIROLOGY, V158, P1, DOI 10.1016/0042-6822(87)90230-3; Scotland S, 2013, LEUKEMIA, V27, P2129, DOI 10.1038/leu.2013.107; Sesen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123721; Sesen J, 2014, INT J MOL SCI, V15, P2172, DOI 10.3390/ijms15022172; Shi FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136746; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sunayama J, 2010, STEM CELLS, V28, P1930, DOI 10.1002/stem.521; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tamburini J, 2009, CELL CYCLE, V8, P3893, DOI 10.4161/cc.8.23.10091; Vallee S, 2000, EUR J PHARMACOL, V404, P49, DOI 10.1016/S0014-2999(00)00596-3; Vignon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068425; Wicks RT, 2015, NEURO-ONCOLOGY, V17, P70, DOI 10.1093/neuonc/nou143; Zambon AC, 2010, CYTOM PART A, V77A, P564, DOI 10.1002/cyto.a.20890; Zekri ARN, 2014, J ADV RES, V5, P27, DOI 10.1016/j.jare.2012.11.002; Zhang W, 2014, GENET MOL BIOL, V37, P716, DOI 10.1590/S1415-47572014000500015; Zopf S, 2016, WORLD J HEPATOL, V8, P139, DOI 10.4254/wjh.v8.i3.139	63	33	33	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3037	3047		10.1038/onc.2016.457	http://dx.doi.org/10.1038/onc.2016.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941882				2022-12-28	WOS:000402000400011
J	Zhu, W; Gliddon, BL; Jarman, KE; Moretti, PAB; Tin, T; Parise, LV; Woodcock, JM; Powell, JA; Ruszkiewicz, A; Pitman, MR; Pitson, SM				Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Parise, L. V.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.			CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1	ONCOGENE			English	Article							BREAST-CANCER; CYTOPLASMIC DOMAIN; BINDING PROTEIN; PHOSPHORYLATION; CELLS; IDENTIFICATION; TRANSLOCATION; ACTIVATION; PATHWAYS; SURVIVAL	CIB1 (calcium and integrin binding protein 1) is a small intracellular protein with numerous interacting partners, and hence has been implicated in various cellular functions. Recent studies have revealed emerging roles of CIB1 in regulating cancer cell survival and angiogenesis, although the mechanisms involved have remained largely undefined. In investigating the oncogenic function of CIB1, we initially found that CIB1 is widely up-regulated across a diverse range of cancers, with this upregulation frequently correlating with oncogenic mutations of KRas. Consistent with this, we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca2+-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. Thus, we examined the role this may play in oncogenesis. Consistent with these findings, we demonstrated here that over-expression of CIB1 by itself is sufficient to drive localisation of SK1 to the plasma membrane and enhance the membrane-associated enzymatic activity of SK1, as well as its oncogenic signalling. We subsequently demonstrated that elevated levels of CIB1 resulted in full neoplastic transformation, in a manner dependent on SK1. In agreement with our previous findings that SK1 is a downstream mediator of oncogenic signalling by Ras, we found that targeting CIB1 also inhibited neoplastic growth of cells induced by oncogenic Ras, suggesting an important pro-tumorigenic role for CIB1. Thus, we have demonstrated for the first time a role for CIB1 in neoplastic transformation, and revealed a novel mechanism facilitating oncogenic signalling by Ras and SK1.	[Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.] Univ South Australia, Ctr Canc Biol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia; [Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.] SA Pathol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia; [Zhu, W.; Jarman, K. E.; Pitson, S. M.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Parise, L. V.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; [Powell, J. A.; Pitson, S. M.] Univ Adelaide, Sch Med, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; University of South Australia; SA Pathology; University of Adelaide; University of North Carolina; University of North Carolina Chapel Hill; University of Adelaide	Pitson, SM (corresponding author), Univ South Australia, Ctr Canc Biol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia.; Pitson, SM (corresponding author), SA Pathol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@unisa.edu.au	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Powell, jason/0000-0001-8493-9178; Gliddon, Briony/0000-0003-3928-7478; Moretti, Paul/0000-0002-3523-1496; Pitman, Melissa/0000-0002-9587-3837; Woodcock, Joanna/0000-0001-5127-9687; Zhu, Layla/0000-0002-6413-699X	Fay Fuller Foundation [1004695]; National Health and Medical Research Council of Australia [508098, 1042589]; University of Adelaide Graduate Research and Research Training Scheme Scholarships, an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Foundation Early Career Fellowship; Imperial Cancer Research Fund, London; Institute for Molecular Bioscience, Brisbane; Osaka University;  [NIH 1R01HL092544]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092544] Funding Source: NIH RePORTER	Fay Fuller Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Adelaide Graduate Research and Research Training Scheme Scholarships, an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Foundation Early Career Fellowship; Imperial Cancer Research Fund, London; Institute for Molecular Bioscience, Brisbane; Osaka University; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Fay Fuller Foundation, Project Grant (1004695) and Senior Research Fellowships (508098 and 1042589) from the National Health and Medical Research Council of Australia (to SMP), NIH 1R01HL092544 (to LVP), University of Adelaide Graduate Research and Research Training Scheme Scholarships (to WZ), an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship (to KEJ) and a RAH Research Foundation Early Career Fellowship (to MRP). We thank J Downward (Imperial Cancer Research Fund, London) and R Parton (Institute for Molecular Bioscience, Brisbane) for providing the H- and KRas plasmids, respectively, and M Okabe (Osaka University) for providing the pCX-EGFP plasmid. Some of the data shown are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adams DR, 2016, TRENDS BIOCHEM SCI, V41, P395, DOI 10.1016/j.tibs.2016.02.007; Al-Jehani RM, 1998, J NATL CANCER I, V90, P540, DOI 10.1093/jnci/90.7.540; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Armacki M, 2014, ONCOGENE, V33, P1167, DOI 10.1038/onc.2013.43; Black JL, 2015, BREAST CANCER RES TR, V152, P337, DOI 10.1007/s10549-015-3458-4; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; French KJ, 2003, CANCER RES, V63, P5962; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gault CR, 2012, J BIOL CHEM, V287, P31794, DOI 10.1074/jbc.M112.385765; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Heffernan-Stroud LA, 2013, ADV CANCER RES, V117, P201, DOI 10.1016/B978-0-12-394274-6.00007-8; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Leisner TM, 2013, ONCOGENE, V32, P4017, DOI 10.1038/onc.2012.408; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagayoshi Y, 2014, ANN SURG ONCOL, V21, P459, DOI 10.1245/s10434-014-3574-0; Naik MU, 2009, J THROMB HAEMOST, V7, P1906, DOI 10.1111/j.1538-7836.2009.03581.x; Naik MU, 2011, J CELL BIOCHEM, V112, P3289, DOI 10.1002/jcb.23255; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Pitman MR, 2015, ONCOTARGET, V6, P7065, DOI 10.18632/oncotarget.3178; Pitman Melissa R, 2012, Methods Mol Biol, V874, P21, DOI 10.1007/978-1-61779-800-9_2; Pitman MR, 2011, INT J BIOCHEM CELL B, V43, P342, DOI 10.1016/j.biocel.2010.11.001; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Plowman SJ, 2008, MOL CELL BIOL, V28, P4377, DOI 10.1128/MCB.00050-08; Powell JA, 2009, BLOOD, V114, P4859, DOI 10.1182/blood-2009-02-204818; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Tong JR, 2011, J BIOSCIENCES, V36, P659, DOI 10.1007/s12038-011-9101-6; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamniuk AP, 2006, CALCIUM BINDING PROT, V1, P150; Yoon KW, 2009, P NATL ACAD SCI USA, V106, P17389, DOI 10.1073/pnas.0812259106; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17	48	23	23	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2619	2627		10.1038/onc.2016.428	http://dx.doi.org/10.1038/onc.2016.428			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941888	Green Accepted, Green Submitted			2022-12-28	WOS:000400597300012
J	Qi, DL; Cobrinik, D				Qi, D-L; Cobrinik, D.			MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation	ONCOGENE			English	Article							TUMOR SUPPRESSION; GENE-EXPRESSION; P53 ACTIVATION; CANCER-THERAPY; DNA-DAMAGE; RB; P14(ARF); NEUROBLASTOMA; PATHWAYS; MICE	Retinoblastomas can arise from cone photoreceptor precursors in response to the loss of pRB function. Cone precursor-specific circuitry cooperates with pRB loss to initiate this process and subsequently contributes to the malignancy. Intrinsic high-level MDM2 expression is a key component of the cone precursor circuitry and is thought to inactivate p53-mediated tumor surveillance, which could otherwise be induced in response to pRB loss. However, the MDM2-related MDM4 has also been proposed to abrogate p53-mediated tumor surveillance in the absence of detectable MDM2 in retinoblastoma cells, bringing into question the importance of high-level MDM2 versus MDM4 expression. Here we report that high-level MDM2 but not MDM4 has a consistent critical role in retinoblastoma cell proliferation in vitro, as well as in orthotopic xenografts. Reduction of either MDM2 or MDM4 weakly induced p53, yet reduction of MDM2 but not MDM4 severely impaired proliferation and survival through a p53-independent mechanism. Specifically, MDM2 upregulated the mRNA expression and translation of another component of the cone circuitry, MYCN, in retinoblastoma cells. Moreover, MYCN was essential to retinoblastoma cell growth and tumor formation, and ectopic MYCN partially reversed the effects of MDM2 depletion, indicating that MYCN is an important MDM2 target. These findings indicate that high-level MDM2 expression is needed in order to perform a critical p53-independent function and may obviate the need for genomic alterations to the p53 pathway during retinoblastoma tumorigenesis.	[Qi, D-L; Cobrinik, D.] Childrens Hosp Los Angeles, Dept Surg, Div Ophthalmol, Vis Ctr, Los Angeles, CA 90027 USA; [Qi, D-L; Cobrinik, D.] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Cobrinik, D (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,MS 163, Los Angeles, CA 90027 USA.	dcobrinik@chla.usc.edu			NIH [1R01CA137124, P30CA014089]; Saban Research Institute Research Career Development Fellowship; Research to Prevent Blindness (New York, New York); Larry & Celia Moh Foundation; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA137124] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Saban Research Institute Research Career Development Fellowship; Research to Prevent Blindness (New York, New York)(Research to Prevent Blindness (RPB)); Larry & Celia Moh Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	D-L Qi and D Cobrinik designed the study. D-L Qi conducted all the experiments. D-L Qi and D Cobrinik wrote the manuscript. We thank Xiaoliang Leon Xu for early passage retinoblastoma cell preparations, Narine Harutyunyan and Jennifer Aparicio for CHLAVC-RB43, Pat Reynolds and A Linn Murphree for CHLA-RB215 cells, and the Saban Research Institute Research Imaging Core for assistance. This study was supported by NIH grants 1R01CA137124 and P30CA014089, by a Saban Research Institute Research Career Development Fellowship to D-L Qi, by Research to Prevent Blindness (New York, New York), by the Larry & Celia Moh Foundation and by the charitable support of the Nautica Malibu Triathlon event produced by MESP, Inc.	Ajioka I, 2007, CELL, V131, P378, DOI 10.1016/j.cell.2007.09.036; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brennan RC, 2011, CANCER RES, V71, P4205, DOI 10.1158/0008-5472.CAN-11-0058; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cobrinik D, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-72; Cobrinik D, 2015, EBIOMEDICINE, V2, P623, DOI 10.1016/j.ebiom.2015.07.023; Cobrinik D, 2013, GENE CHROMOSOME CANC, V52, P1150, DOI 10.1002/gcc.22110; Dieterich DC, 2006, P NATL ACAD SCI USA, V103, P9482, DOI 10.1073/pnas.0601637103; DIMARAS H, 2015, NAT REV DIS PRIMERS, V1, P1, DOI DOI 10.1038/NRDP.2015.21.ACCESSED; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Evans L, 2015, CANCER LETT, V363, P37, DOI 10.1016/j.canlet.2015.03.044; Gratias S, 2005, INT J CANCER, V116, P555, DOI 10.1002/ijc.21051; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Guo Y, 2008, BIOCHEM BIOPH RES CO, V375, P1, DOI 10.1016/j.bbrc.2008.07.055; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Kooi IE, 2015, EBIOMEDICINE, V2, P660, DOI 10.1016/j.ebiom.2015.06.022; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee TC, 2006, INVEST OPHTH VIS SCI, V47, P5590, DOI 10.1167/iovs.06-0063; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; McEvoy J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042739; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Miles WO, 2014, EMBO J, V33, P2201, DOI 10.15252/embj.201488057; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Theriault BL, 2014, CLIN EXP OPHTHALMOL, V42, P33, DOI 10.1111/ceo.12132; To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Xu XLL, 2014, NATURE, V514, P385, DOI 10.1038/nature13813; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051	53	30	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1760	1769		10.1038/onc.2016.350	http://dx.doi.org/10.1038/onc.2016.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27748758	Green Accepted			2022-12-28	WOS:000398128900002
J	Apicella, M; Migliore, C; Capeloa, T; Menegon, S; Cargnelutti, M; Degiuli, M; Sapino, A; Sottile, A; Sarotto, I; Casorzo, L; Cassoni, P; De Simone, M; Comoglio, PM; Marsoni, S; Corso, S; Giordano, S				Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Degiuli, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; Cassoni, P.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.			Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; GENE AMPLIFICATION; LUNG-CANCER; ACTIVATION; MUTATIONS; ADENOCARCINOMA; SENSITIVITY; INHIBITORS; GEFITINIB; GROWTH	Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level ( 26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.	[Apicella, M.; Migliore, C.; Corso, S.; Giordano, S.] Univ Torino, Dept Oncol, Candiolo, Italy; [Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy; [Capeloa, T.] Univ Torino, Dept Clin & Biol Sci, Orbassano, Italy; [Degiuli, M.] Osped Molinette, Dept Surg, Turin, Italy; [Sapino, A.; Cassoni, P.] Univ Torino, Dept Med Sci, Turin, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Corso, S; Giordano, S (corresponding author), Univ Torino, IRCCS, FPO, Candiolo Canc Inst,Dept Oncol, Str Prov 142, I-10060 Turin, Italy.	simona.corso@unito.it; silvia.giordano@unito.it	Sapino, Anna/AGY-9901-2022; Giordano, Silvia/J-9858-2018; Sapino, Anna/J-4113-2018; Casorzo, Laura/AAB-7684-2020; Cassoni, Paola/I-8544-2018; sarotto, ivana/AAB-7797-2020	Sapino, Anna/0000-0003-3542-9571; Giordano, Silvia/0000-0003-1854-1086; Sapino, Anna/0000-0003-3542-9571; Casorzo, Laura/0000-0002-2509-7369; CORSO, Simona/0000-0002-5069-1503; Menegon, Silvia/0000-0002-5078-2464; Migliore, Cristina/0000-0003-3722-2814; Marsoni, Silvia/0000-0002-5361-7122; sottile, antonino/0000-0003-4252-3240; Comoglio, Paolo/0000-0002-7056-5328	Italian Association for Cancer Research (AIRC) [15464]; Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	We thank all our colleagues for helpful scientific discussion; Drs Martinoglio, Porporato and Buscarino for technical support with RT-PCR and sequencing; Dr Perra for tumor microdissection; Dr Giove for support with immunohistochemistry; animal facility employees; Dr Natale for critical manuscript reading. SG and SC are EuroPDX Consortium members. This work was funded by the Italian Association for Cancer Research (AIRC); IG grant 15464 to SG and Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2013.	Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2102er11; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Crew KD, 2004, SEMIN ONCOL, V31, P450, DOI 10.1053/j.seminoncol.2004.04.021; Cunningham D, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.16; Doi T., 2015, J CLIN ONCOL S3, V33; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Puri Neelu, 2008, J Carcinog, V7, P9; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Shah AM, 2015, J CLIN ONCOL, V33; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166	33	22	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1200	1210		10.1038/onc.2016.283	http://dx.doi.org/10.1038/onc.2016.283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524418				2022-12-28	WOS:000395861300004
J	Matsuura, K; Huang, NJ; Cocce, K; Zhang, L; Kornbluth, S				Matsuura, K.; Huang, N-J; Cocce, K.; Zhang, L.; Kornbluth, S.			Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; E3 LIGASE; SUBSTRATE RECOGNITION; KINASE DYRK2; BAX; EDD; DEGRADATION; APOPTOSIS; RECEPTOR; TRIM39	Evasion of apoptosis allows many cancers to resist chemotherapy. Apoptosis is mediated by the serial activation of caspase family proteins. These proteases are often activated upon the release of cytochrome c from the mitochondria, which is promoted by the proapoptotic Bcl-2 family protein, Bax. This function of Bax is enhanced by the MOAP-1 (modulator of apoptosis protein 1) protein in response to DNA damage. Previously, we reported that MOAP-1 is targeted for ubiquitylation and degradation by the APC/CCdh1 ubiquitin ligase. In this study, we identify the HECT (homologous to the E6-AP carboxyl terminus) family E3 ubiquitin ligase, UBR5, as a novel ubiquitin ligase for MOAP-1. We demonstrate that UBR5 interacts physically with MOAP-1, ubiquitylates MOAP-1 in vitro and inhibits MOAP-1 stability in cultured cells. In addition, we show that Dyrk2 kinase, a reported UBR5 interactor, cooperates with UBR5 in mediating MOAP-1 ubiquitylation. Importantly, we found that cisplatin-resistant ovarian cancer cell lines exhibit lower levels of MOAP-1 accumulation than their sensitive counterparts upon cisplatin treatment, consistent with the previously reported role of MOAP-1 in modulating cisplatin-induced apoptosis. Accordingly, UBR5 knockdown increased MOAP-1 expression, enhanced Bax activation and sensitized otherwise resistant cells to cisplatin-induced apoptosis. Furthermore, UBR5 expression was higher in ovarian cancers from cisplatin-resistant patients than from cisplatin-responsive patients. These results show that UBR5 downregulates proapoptotic MOAP-1 and suggest that UBR5 can confer cisplatin resistance in ovarian cancer. Thus UBR5 may be an attractive therapeutic target for ovarian cancer treatment.	[Matsuura, K.; Huang, N-J; Cocce, K.; Zhang, L.; Kornbluth, S.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 220 Allen Bldg,Box 90005, Durham, NC 27710 USA; [Huang, N-J] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Duke University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Huang, NJ; Zhang, L; Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 220 Allen Bldg,Box 90005, Durham, NC 27710 USA.	njhuang@wi.mit.edu; liguo.zhang@duke.edu; sally.kornbluth@duke.edu		Matsuura, Kenkyo/0000-0003-4612-6031	NIH [CA102707]; NRSA [5F30CA183395-03]; NATIONAL CANCER INSTITUTE [F30CA183395, R01CA102707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080333, T32GM007171] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ethan Whitaker, Regina Whitaker and Susan Murphy (Duke University) for ovarian cancer cell lines, human ovarian cancer patient samples and technical help with staining and imaging; Meredith Turner and Will Thompson (Proteomics and Metabolomics Core Facility at Duke University) for mass spectrometric analysis; Subbareddy Maddika (The Centre for DNA Fingerprinting and Diagnostics) for UBR5, VprBP, DDB1 and Dyrk2 constructs. We also thank Denise Ribar for excellent technical assistance. We also appreciate the members of the Kornbluth laboratory for valuable discussion. This work was supported by NIH CA102707 to SK and NRSA 5F30CA183395-03 to KC.	Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Barnett JC, 2010, GYNECOL ONCOL, V116, P556, DOI 10.1016/j.ygyno.2009.11.020; Bradley A, 2014, CARCINOGENESIS, V35, P1100, DOI 10.1093/carcin/bgt489; Choo Yeun Su, 2009, J Vis Exp, DOI 10.3791/1293; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Cojocaru M, 2011, J BIOL CHEM, V286, P5012, DOI 10.1074/jbc.M110.176628; Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006; Fu NY, 2007, P NATL ACAD SCI USA, V104, P10051, DOI 10.1073/pnas.0700007104; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Huang NJ, 2012, J CELL BIOL, V197, P361, DOI [10.1083/jcb.201111141, 10.1083/jcb.201108062]; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jung HY, 2013, J BIOL CHEM, V288, P7252, DOI 10.1074/jbc.M112.416792; Law J, 2015, J BIOL CHEM, V290, P24100, DOI 10.1074/jbc.M115.648345; Law Jennifer, 2012, Mol Biol Int, V2012, P536802, DOI 10.1155/2012/536802; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Lee SS, 2009, EXP CELL RES, V315, P1313, DOI 10.1016/j.yexcr.2008.11.021; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ling SY, 2011, J BIOL CHEM, V286, P14972, DOI 10.1074/jbc.M110.182527; Maddika S, 2009, NAT CELL BIOL, V11, P409, DOI 10.1038/ncb1848; Meissner B, 2013, BLOOD, V121, P3161, DOI 10.1182/blood-2013-01-478834; Munoz MA, 2007, CELL CYCLE, V6, P3070, DOI 10.4161/cc.6.24.5021; Nakagawa T, 2013, BMC MOL BIOL, V14, DOI 10.1186/1471-2199-14-22; O'Brien PM, 2008, BRIT J CANCER, V98, P1085, DOI 10.1038/sj.bjc.6604281; Ong SS, 2014, BIOCHEM J, V459, P193, DOI 10.1042/BJ20130558; Rutz S, 2015, NATURE, V518, P417, DOI 10.1038/nature13979; Sriram SM, 2011, NAT REV MOL CELL BIO, V12, P735, DOI 10.1038/nrm3217; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Zhang LG, 2012, P NATL ACAD SCI USA, V109, P20931, DOI 10.1073/pnas.1212047110	35	42	44	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1698	1706		10.1038/onc.2016.336	http://dx.doi.org/10.1038/onc.2016.336			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27721409	Green Published, hybrid			2022-12-28	WOS:000397460600009
J	Marom, A; Barak, AF; Kramer, MP; Lewinsky, H; Binsky-Ehrenreich, I; Cohen, S; Tsitsou-Kampeli, A; Kalchenko, V; Kuznetsov, Y; Mirkin, V; Dezorella, N; Shapiro, M; Schwartzberg, PL; Cohen, Y; Shvidel, L; Haran, M; Becker-Herman, S; Herishanu, Y; Shachar, I				Marom, A.; Barak, A. F.; Kramer, M. P.; Lewinsky, H.; Binsky-Ehrenreich, I.; Cohen, S.; Tsitsou-Kampeli, A.; Kalchenko, V.; Kuznetsov, Y.; Mirkin, V.; Dezorella, N.; Shapiro, M.; Schwartzberg, P. L.; Cohen, Y.; Shvidel, L.; Haran, M.; Becker-Herman, S.; Herishanu, Y.; Shachar, I.			CD84 mediates CLL-microenvironment interactions	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELLS; BONE-MARROW; CD74-DEPENDENT MANNER; EXPRESSION; APOPTOSIS; SURVIVAL; CHEMOKINES; MIGRATION; RECEPTOR	Chronic lymphocytic leukemia (CLL) is a malignant disease of small mature lymphocytes. Signals from the CLL microenvironment promote progression of the disease and induce drug resistance. This phenomenon is largely dependent on direct contact between the malignant B cells and stromal cells. CD84 belongs to the signaling lymphocyte activation molecule family of immunoreceptors, which self-associates, forming an orthogonal homophilic dimer. We therefore hypothesized that CD84 may bridge between CLL cells and their microenvironment, promoting cell survival. Our in vitro results show that CD84 expressed on CLL cells interact with CD84 expressed on cells in their microenvironment, inducing cell survival in both sides. Blocking CD84 in vitro and in vivo disrupt the interaction of CLL cells with their microenvironment, resulting in induced cell death. Thus, our findings suggest novel therapeutic strategies based on the blockade of this CD84- dependent survival pathway.	[Marom, A.; Barak, A. F.; Kramer, M. P.; Lewinsky, H.; Binsky-Ehrenreich, I.; Cohen, S.; Tsitsou-Kampeli, A.; Becker-Herman, S.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, 234 Herzel St, IL-76100 Rehovot, Israel; [Kalchenko, V.; Kuznetsov, Y.] Weizmann Inst Sci, Dept Vet Resources, Rehovot, Israel; [Mirkin, V.; Shvidel, L.; Haran, M.] Kaplan Med Ctr, Hematol Inst, Rehovot, Israel; [Dezorella, N.; Shapiro, M.; Herishanu, Y.] Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel; [Schwartzberg, P. L.] NHGRI, NIH, Bethesda, MA USA; [Cohen, Y.] Laniado Med Ctr, Sanz Med Ctr, Dept Hematol, Netanya, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, 234 Herzel St, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il	Kramer, Matthias/L-1782-2016; Kalchenko, Vyacheslav/F-2924-2012; Kramer, Matthias P/A-6224-2009	Kramer, Matthias/0000-0002-0289-5261; Dezorella, Nili/0000-0003-4376-3131; Kalchenko, Vyacheslav/0000-0002-3166-7049	Israel Science Foundation; Israel Cancer association; Israel Cancer Research Fund (ICRF); DKFZ-MOST cooperation in cancer research; Quinquin foundation; Rubenstein charitable foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000123] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Israel Cancer association; Israel Cancer Research Fund (ICRF); DKFZ-MOST cooperation in cancer research; Quinquin foundation; Rubenstein charitable foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank members of the Shachar laboratory for fruitful discussion and support. IS is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair. This research was supported by the Israel Science Foundation, Israel Cancer association, Israel Cancer Research Fund (ICRF), DKFZ-MOST cooperation in cancer research, Quinquin foundation and Rubenstein charitable foundation.	Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Binder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015992; BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Binsky I, 2010, J IMMUNOL, V184, P4761, DOI 10.4049/jimmunol.0904149; Binsky-Ehrenreich I, 2014, ONCOGENE, V33, P1006, DOI 10.1038/onc.2013.31; Bojarska-Junak A, 2008, LEUKEMIA RES, V32, P225, DOI 10.1016/j.leukres.2007.06.007; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2007, LEUKEMIA RES, V31, P887, DOI 10.1016/j.leukres.2006.12.004; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Burger JA, 2009, BLOOD, V113, P3050, DOI 10.1182/blood-2008-07-170415; Calpe S, 2008, ADV IMMUNOL, V97, P177, DOI 10.1016/S0065-2776(08)00004-7; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Cohen Y, 2014, ACTA HAEMATOL-BASEL, V132, P129, DOI 10.1159/000357101; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Gordin M, 2010, J IMMUNOL, V185, P2020, DOI 10.4049/jimmunol.0902566; Guan E, 2002, J BIOL CHEM, V277, P32348, DOI 10.1074/jbc.M203077200; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2015, AM J HEMATOL, V90, P446, DOI 10.1002/ajh.23979; Haran M, 2004, LEUKEMIA, V18, P1948, DOI 10.1038/sj.leu.2403512; Hofbauer JP, 2011, LEUKEMIA, V25, P1452, DOI 10.1038/leu.2011.111; Kalchenko V, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2364903; Kay NE, 2007, LEUKEMIA RES, V31, P899, DOI 10.1016/j.leukres.2006.11.024; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI200523409; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Nicholas NS, 2016, BBA-MOL CELL RES, V1863, P471, DOI 10.1016/j.bbamcr.2015.11.003; Plander M, 2011, ANN HEMATOL, V90, P1381, DOI 10.1007/s00277-011-1218-z; Ramsay AD, 2013, BRIT J HAEMATOL, V162, P15, DOI 10.1111/bjh.12344; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Reittie JE, 1996, LEUKEMIA LYMPHOMA, V22, P83, DOI 10.3109/10428199609051732; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Sivina M, 2011, BLOOD, V117, P1662, DOI 10.1182/blood-2010-09-307249; ten Hacken E, 2014, PHARMACOL THERAPEUT, V144, P338, DOI 10.1016/j.pharmthera.2014.07.003; Witowski J, 2001, AM J PATHOL, V158, P1441, DOI 10.1016/S0002-9440(10)64095-3; Witowski J, 2006, PERITON DIALYSIS INT, V26, P292; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Zucchetto A, 2009, CANCER RES, V69, P4001, DOI 10.1158/0008-5472.CAN-08-4173	41	14	14	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					628	638		10.1038/onc.2016.238	http://dx.doi.org/10.1038/onc.2016.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27452524				2022-12-28	WOS:000394167700005
J	Agaesse, G; Barbollat-Boutrand, L; Sulpice, E; Bhajun, R; El Kharbili, M; Berthier-Vergnes, O; Degoul, F; de la Fouchardiere, A; Berger, E; Voeltzel, T; Lamartine, J; Gidrol, X; Masse, I				Agaesse, G.; Barbollat-Boutrand, L.; Sulpice, E.; Bhajun, R.; El Kharbili, M.; Berthier-Vergnes, O.; Degoul, F.; de la Fouchardiere, A.; Berger, E.; Voeltzel, T.; Lamartine, J.; Gidrol, X.; Masse, I.			A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion	ONCOGENE			English	Article							MEDIATOR COMPLEX; CELL-PROLIFERATION; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; TETRASPANIN CO-029; OVARIAN-CANCER; GROWTH; MED19; METASTASIS; EXPRESSION	Melanoma is the deadliest form of skin cancer owing to its proclivity to metastasise, and recently developed therapies have not yielded the expected results, because almost all patients relapse. Therefore, understanding the molecular mechanisms that underlie early invasion by melanoma cells is crucial to improving patient survival. We have previously shown that, whereas the Tetraspanin 8 protein (Tspan8) is undetectable in normal skin and benign lesions, its expression arises with the progression of melanoma and is sufficient to increase cell invasiveness. Therefore, to identify Tspan8 transcriptional regulators that could explain the onset of Tspan8 expression, thereby conferring an invasive phenotype, we performed an innovative RNA interference-based screen, which, for the first time, identified several Tspan8 repressors and activators, such as GSK3 beta, PTEN, IQGAP1, TPT1 and LCMR1. LCMR1 is a recently identified protein that is overexpressed in numerous carcinomas; its expression and role, however, had not previously been studied in melanoma. The present study identified Tspan8 as the first LCMR1 target that could explain its function in carcinogenesis. LCMR1 modulation was sufficient to positively regulate endogenous Tspan8 expression, with concomitant in vitro phenotypic changes such as loss of melanoma cell-matrix adherence and increase in invasion, and Tspan8 expression promoted tumourigenicity in vivo. Moreover, LCMR1 and Tspan8 overexpression were shown to correlate in melanoma lesions, and both proteins could be downregulated in vitro by vemurafenib. In conclusion, this study highlights the importance of Tspan8 and its regulators in the control of early melanoma invasion and suggests that they may be promising new therapeutic targets downstream of the RAF-MEK-ERK signalling pathway.	[Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] Univ Lyon, Lyon, France; [Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] Univ Lyon 1, Lyon, France; [Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] CNRS, Ctr Genet & Physiol Mol & Cellulaires, UMR5534, Villeurbanne, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] Univ Grenoble Alpes, Grenoble, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] CEA, BIG BGE, Biom, Grenoble, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] INSERM, BGE, Grenoble, France; [Degoul, F.] Univ Auvergne, Clermont Univ, Imagerie Mol & Therapie Vectorisee, Clermont Ferrand, France; INSERM, U 990, Clermont Ferrand, France; [de la Fouchardiere, A.] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Berger, E.] Univ Lyon, INRA 1397, INSA, Lab CarMeN,INSERM 1060, Lyon, France; [Voeltzel, T.] Univ Lyon 1, Inserm U1052, CNRS UMR5286, Ctr Rech Cancerol Lyon, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Masse, I (corresponding author), Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaires, CNRS, UMR5534, Batiment Mendel 2eme Etage,16 Rue Dubois, F-69622 Villeurbanne, France.	ingrid.masse@univ-lyon1.fr	de la Fouchardiere, Arnaud/I-2807-2019; DEGOUL, Francoise/L-4856-2015; DEGOUL, Francoise/Q-4745-2019	de la Fouchardiere, Arnaud/0000-0003-2251-8241; DEGOUL, Francoise/0000-0002-0206-3350; DEGOUL, Francoise/0000-0002-0206-3350; Lamartine, Jerome/0000-0003-2322-1618; MASSE, Ingrid/0000-0003-3193-970X; Voeltzel, Thibault/0000-0001-7099-8716; Gidrol, Xavier/0000-0002-4233-3749; Sulpice, Eric/0000-0001-7695-0561	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association 'Vaincre le Melanome'; Roche Company	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association 'Vaincre le Melanome'; Roche Company	We thank Elise Malandain for technical assistance and Cyril Py for immunohistochemical processing, Stephanie Combe and Patricia Obeid for RNAi screening, Alain Geloen for adhesion assays, and Tiffany Witkowski and Janine Papon for experiments on mice. This work was supported by a grant from the French Society for Dermatological Research (SRD) and a grant from La Ligue Contre le Cancer (Comite Ardeche) and a grant from the association 'Vaincre le Melanome'. We acknowledge the Roche Company for financial support for manuscript writing and publication.	Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; Berthier-Vergnes O, 2011, BRIT J CANCER, V104, P155, DOI 10.1038/sj.bjc.6605994; BERTHIERVERGNES O, 1993, LANCET, V341, P1292, DOI 10.1016/0140-6736(93)91205-Z; Byers Hugh Randolph, 1992, Journal of Dermatology (Tokyo), V19, P847; Chen LA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-18; Cochran AJ, 1999, HUM PATHOL, V30, P556, DOI 10.1016/S0046-8177(99)90201-0; Colombino M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.136; Conde-Perez A, 2012, FUTURE ONCOL, V8, P1109, DOI [10.2217/fon.12.106, 10.2217/FON.12.106]; Cui XG, 2011, BMB REP, V44, P547, DOI 10.5483/BMBRep.2011.44.8.547; Ding XF, 2012, GENE, V504, P262, DOI 10.1016/j.gene.2012.04.033; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Gesierich S, 2006, CANCER RES, V66, P7083, DOI 10.1158/0008-5472.CAN-06-0391; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Ishimura N, 2003, CANCER LETT, V199, P169, DOI 10.1016/S0304-3835(03)00384-7; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Ji-Fu E, 2012, MOL BIOL REP, V39, P3675, DOI 10.1007/s11033-011-1142-2; John JK, 2012, J INVEST DERMATOL, V132, P2818, DOI 10.1038/jid.2012.237; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kubic JD, 2012, MOL CANCER RES, V10, P1065, DOI 10.1158/1541-7786.MCR-11-0387; Le Naour F, 2006, MOL CELL PROTEOMICS, V5, P845, DOI 10.1074/mcp.M500330-MCP200; LeNaour F, 1996, ONCOGENE, V13, P481; Li LH, 2011, CANCER CHEMOTH PHARM, V68, P207, DOI 10.1007/s00280-010-1468-9; Li XH, 2011, CANCER BIOTHER RADIO, V26, P495, DOI 10.1089/cbr.2010.0863; Liu YT, 2012, MOL MED REP, V6, P1050, DOI 10.3892/mmr.2012.1065; Lu Z., 2015, MATH PROBLEM ENG, V2015, P1, DOI DOI 10.3389/FPSYG.2015; Mekky RY, 2015, J INFECTION, V70, P78, DOI 10.1016/j.jinf.2014.08.013; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Plaschka C, 2015, NATURE, V518, P376, DOI 10.1038/nature14229; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Spagnolo F, 2014, ONCOTARGET, V5, P10206, DOI 10.18632/oncotarget.2602; Sun M, 2011, MOL CELL BIOCHEM, V355, P27, DOI 10.1007/s11010-011-0835-0; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wang TJ, 2011, ONCOL RES, V19, P193, DOI 10.3727/096504011X12970940207760; Wei LS, 2015, INT J CLIN EXP MED, V8, P8599; Wen H, 2013, ANN DIAGN PATHOL, V17, P259, DOI 10.1016/j.anndiagpath.2012.11.004; Xu YQ, 2012, PROG NEUROBIOL, V97, P1, DOI 10.1016/j.pneurobio.2012.02.002; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Yu WX, 2014, EUR J CANCER, V50, P1125, DOI 10.1016/j.ejca.2014.01.030; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhang H, 2012, UROL ONCOL-SEMIN ORI, V30, P920, DOI 10.1016/j.urolonc.2010.10.003; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zhu LJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-116; Zou SW, 2011, ACTA PHARMACOL SIN, V32, P354, DOI 10.1038/aps.2010.223	55	13	13	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					446	457		10.1038/onc.2016.219	http://dx.doi.org/10.1038/onc.2016.219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375018				2022-12-28	WOS:000394166700002
J	Xu, LZ; Li, SS; Zhou, W; Kang, ZJ; Zhang, QX; Kamran, M; Xu, J; Liang, DP; Wang, CL; Hou, ZJ; Wan, XB; Wang, HJ; Lam, EWF; Zhao, ZW; Liu, Q				Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Zhang, Q-X; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Wan, X-B; Wang, H-J; Lam, E. W-F; Zhao, Z-W; Liu, Q.			p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; C-MYC; PROSPECTIVE IDENTIFICATION; INITIATING CELLS; BINDING PROTEIN; AURORA KINASE; P62; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION	Aberrant p62 overexpression has been implicated in breast cancer development. Here, we found that p62 expression was elevated in breast cancer stem cells (BCSCs), including CD44(+)CD24(-) fractions, mammospheres, ALDH1(+) populations and side population cells. Indeed, short-hairpin RNA (shRNA)-mediated knockdown of p62 impaired breast cancer cells from self-renewing under anchorageindependent conditions, whereas ectopic overexpression of p62 enhanced the self-renewal ability of breast cancer cells in vitro. Genetic depletion of p62 robustly inhibited tumor-initiating frequencies, as well as growth rates of BCSC-derived tumor xenografts in immunodeficient mice. Consistently, immunohistochemical analysis of clinical breast tumor tissues showed that high p62 expression levels were linked to poorer clinical outcome. Further gene expression profiling analysis revealed that p62 was positively correlated with MYC expression level, which mediated the function of p62 in promoting breast cancer stem-like properties. MYC mRNA level was reduced upon p62 deletion by siRNA and increased with p62 overexpression in breast cancer cells, suggesting that p62 positively regulated MYC mRNA. Interestingly, p62 did not transactivate MYC promoter. Instead, p62 delayed the degradation of MYC mRNA by repressing the expression of let-7a and let-7b, thus promoting MYC mRNA stabilization at the post-transcriptional level. Consistently, let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization. Together, these findings unveiled a previously unappreciated role of p62 in the regulation of BCSCs, assigning p62 as a promising therapeutic target for breast cancer treatments.	[Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Affiliated Hosp 2, 9 Western Sect,Lvshun South St, Dalian 116044, Liaoning, Peoples R China; [Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Liu, Q.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, Q-X] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wan, X-B] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Wang, H-J] Dalian Med Univ, Affiliated Hosp 1, Dept Breast Surg, Dalian, Peoples R China; [Lam, E. W-F] Imperial Coll London, Dept Surg & Canc, London, England; [Zhao, Z-W] Dalian Med Univ, Affiliated Hosp 2, Dept Breast Surg, 467 Zhongshan Rd, Dalian 116000, Liaoning, Peoples R China	Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Guangdong Pharmaceutical University; Sun Yat Sen University; Dalian Medical University; Imperial College London; Dalian Medical University	Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Affiliated Hosp 2, 9 Western Sect,Lvshun South St, Dalian 116044, Liaoning, Peoples R China.; Zhao, ZW (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dept Breast Surg, 467 Zhongshan Rd, Dalian 116000, Liaoning, Peoples R China.	dlzhaozw@163.com; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; KAMRAN, MUHAMMAD/0000-0002-5157-5459	National Basic Research Program of China (973 Program) [2012CB967000]; National Natural Science Foundation of China [81573025, 81201686, 81402445]; National Natural Science Foundation of Liaoning [NSF2014029102]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; MRC [MR/N012097/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Liaoning; CRUK(Cancer Research UK); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Quentin Liu's laboratory members for their critical commends and technical support. We also thank them for their critical reading of the manuscript. This work is supported by the National Basic Research Program of China (973 Program; No. 2012CB967000 to QL), National Natural Science Foundation of China (No. 81573025 to QL), the Liaoning (NSF2014029102 to QL), National Natural Science Foundation of China (No. 81201686 to JX), National Natural Science Foundation of China (No. 81402445 to C- LW). EW-FL's work is supported by CRUK (A12011) and Breast Cancer Now (2012MayPR070; 2012NovPhD016). See Supplementary Materials and Methods.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Filipova A, 2014, TUMORI J, V100, P363, DOI 10.1700/1636.17886; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gaffan J, 2006, J CLIN ONCOL, V24, P1932, DOI 10.1200/JCO.2005.02.6617; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lin Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-59; Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YC, 2012, BIOCHEM BIOPH RES CO, V417, P371, DOI 10.1016/j.bbrc.2011.11.119; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nigam A, 2013, INDIAN J SURG, V75, P170, DOI 10.1007/s12262-012-0616-3; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schmidt EV, 2009, CELL CYCLE, V8, P1344, DOI 10.4161/cc.8.9.8215; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wong TS, 2011, J CANCER RES CLIN, V137, P415, DOI 10.1007/s00432-010-0898-4; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Xu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056919; Xu LZ, 2014, ONCOTARGET, V5, P7498, DOI 10.18632/oncotarget.2241; Yang XJ, 2015, ONCOL REP, V33, P1723, DOI 10.3892/or.2015.3757; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029	62	52	53	2	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					304	317		10.1038/onc.2016.202	http://dx.doi.org/10.1038/onc.2016.202			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345399	Green Published, hybrid			2022-12-28	WOS:000394166000002
J	Zhao, H; Lu, Z; Bauzon, F; Fu, H; Cui, J; Locker, J; Zhu, L				Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Locker, J.; Zhu, L.			p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer	ONCOGENE			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; CONDITIONAL MOUSE MODEL; CDK INHIBITOR; CELLULAR SENESCENCE; ORGANOID CULTURES; P27 DEGRADATION; P27(KIP1); LIGASE; TUMORIGENESIS; SCFSKP2	SCFSkp2/Cks1 ubiquitinates Thr187-phosphorylated p27 for degradation. Overexpression of Skp2 coupled with underexpression of p27 are frequent characteristics of cancer cells. When the role of SCFSkp2/Cksl - mediated p27 ubiquitination in cancer was specifically tested by p27 Thr187-to-Ala knockin (p27T187A KI), it was found dispensable for Kras(G12D)-induced lung tumorigenesis but essential for Rbl-deficient pituitary tumorigenesis. Here we identify pRb and p53 doubly deficient (DKO) prostate tumorigenesis as a context in which p27 ubiquitination by SCFSkp2/Cks1 is required for p27 downregulation. p27 protein accumulated in prostate when p27T187A KI mice underwent DKO prostate tumorigenesis. p27T187A KI or Skp2 knockdown (KD) induced similar degrees of p27 protein accumulation in DKO prostate cells, and Skp2 KD did not further increase p27 protein in DKO prostate cells that contained p27T187A KI (AADKO prostate cells). p27T187A KI activated an E2F1-p73-apoptosis axis in DKO prostate tumorigenesis, slowed disease progression and significantly extended survival. Querying co-occurrence relationships among RB1, TP53, PTEN, NKX3-1 and MYC in TCGA of prostate cancer identified co-inactivation of RB1 and TP53 as the only statistically significant co-occurrences in metastatic castration-resistant prostate cancer (mCRPC). Together, our study identifies Skp2/Cks1 pocket inhibitors as potential therapeutics for mCRPC. Procedures for establishing mCRPC organoid cultures from contemporary patients were recently established. An Skp2/Cks1 pocket inhibitor preferentially collapsed DKO prostate tumor organoids over AADKO organoids, which spontaneously disintegrated over time when DKO prostate tumor organoids grew larger, setting the stage to translate mouse model findings to precision medicine in the clinic on the organoid platform.	[Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10467 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Dept Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10467 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA; [Locker, J.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA USA; [Lu, Z.] Fuzhou Univ, Coll Biol Sci & Engn, Fuzhou 350108, Fujian, Peoples R China; [Fu, H.] Shenyang Med Coll, Dept Biochem, Shenyang 110034, Liaoning, Peoples R China	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fuzhou University; Shenyang Medical College	Zhu, L (corresponding author), Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.; Zhu, L (corresponding author), Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.	liang.zhu@einstein.yu.edu		Lu, Zhonglei/0000-0002-8915-4828	NIH [RO1CA127901, RO1CA131421]; Albert Einstein Comprehensive Cancer Research Center [5P30CA13330]; Liver Research Center [5P30DK061153]; DOD PCRP Postdoctoral Fellowship [PC121837]; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA127901, R01CA201458, R01CA131421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061153, P30DK041296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Albert Einstein Comprehensive Cancer Research Center; Liver Research Center; DOD PCRP Postdoctoral Fellowship; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants RO1CA127901and RO1CA131421 (LZ), Albert Einstein Comprehensive Cancer Research Center (5P30CA13330) and Liver Research Center (5P30DK061153) provided core facility support. HZ was a recipient of DOD PCRP Postdoctoral Fellowship (PC121837), and LZ was a Irma T Hirschl Career Scientist Award recipient. We thank Dr James Roberts for providing the p27T187A KI mice.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Cao XX, 2011, J BIOL CHEM, V286, P33447, DOI 10.1074/jbc.M111.225565; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Chua CW, 2014, NAT CELL BIOL, V16, P951, DOI 10.1038/ncb3047; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gillet JP, 2013, JNCI-J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Hattori T, 2007, CANCER RES, V67, P10789, DOI 10.1158/0008-5472.CAN-07-2033; Havens CG, 2009, MOL CELL, V35, P93, DOI 10.1016/j.molcel.2009.05.012; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Miranda-Carboni GA, 2008, GENE DEV, V22, P3121, DOI 10.1101/gad.1692808; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morris MJ, 2007, J UROLOGY, V178, P2378, DOI 10.1016/j.juro.2007.08.015; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sato T, 2015, CELL, V161, DOI 10.1016/j.cell.2015.06.028; Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Starostina NG, 2010, DEV CELL, V19, P753, DOI 10.1016/j.devcel.2010.10.013; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Sun DQ, 2006, BIOTECHNIQUES, V41, P59, DOI 10.2144/000112203; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yung Y, 2007, J CELL BIOL, V178, P741, DOI 10.1083/jcb.200703034; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zhao HL, 2015, J BIOL CHEM, V290, P5797, DOI 10.1074/jbc.M114.625350; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	58	12	12	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					60	70		10.1038/onc.2016.175	http://dx.doi.org/10.1038/onc.2016.175			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27181203	Green Accepted			2022-12-28	WOS:000394069100006
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2 (vol 27, pg 6571, 2008)	ONCOGENE			English	Correction													Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6446	6446		10.1038/onc.2016.210	http://dx.doi.org/10.1038/onc.2016.210			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27375019	Bronze			2022-12-28	WOS:000390247600009
J	Hein, AL; Post, CM; Sheinin, YM; Lakshmanan, I; Natarajan, A; Enke, CA; Batra, SK; Ouellette, MM; Yan, Y				Hein, A. L.; Post, C. M.; Sheinin, Y. M.; Lakshmanan, I.; Natarajan, A.; Enke, C. A.; Batra, S. K.; Ouellette, M. M.; Yan, Y.			RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment	ONCOGENE			English	Article							NF-KAPPA-B; POTENTIAL THERAPEUTIC TARGET; SIGNALING PATHWAYS; GAMMA-IRRADIATION; DNA-REPAIR; TRASTUZUMAB RESISTANCE; IONIZING-RADIATION; COLORECTAL-CANCER; ERK ACTIVATION; CYCLE ARREST	Radiation therapy is a staple approach for cancer treatment, whereas radioresistance of cancer cells remains a substantial clinical problem. In response to ionizing radiation (IR) induced DNA damage, cancer cells can sustain/activate pro-survival signaling pathways, leading to apoptotic resistance and induction of cell cycle checkpoint/DNA repair. Previous studies show that Rac1 GTPase is overexpressed/hyperactivated in breast cancer cells and is associated with poor prognosis. Studies from our laboratory reveal that Rac1 activity is necessary for G2/M checkpoint activation and cell survival in response to IR exposure of breast and pancreatic cancer cells. In this study, we investigated the effect of Rac1 on the survival of breast cancer cells treated with hyperfractionated radiation (HFR), which is used clinically for cancer treatment. Results in this report indicate that Rac1 protein expression is increased in the breast cancer cells that survived HFR compared with parental cells. Furthermore, this increase of Rac1 is associated with enhanced activities of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and nuclear factor-.B (NF-.B) signaling pathways and increased levels of anti-apoptotic protein Bcl-xL and Mcl-1, which are downstream targets of ERK1/2 and NF-.B signaling pathways. Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate that Rac1 inhibition decreases the phosphorylation of ERK1/2 and inhibitory kappa Ba (I kappa Ba), as well as the levels of Bcl-xL and Mcl-1 protein in the HFR-selected breast cancer cells. Moreover, inhibition of Rac1 using either small molecule inhibitor or dominant-negative N17Rac1 abrogates clonogenic survival of HFR-selected breast cancer cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apoptosis induction. Collectively, results in this report suggest that Rac1 signaling is essential for the survival of breast cancer cells subjected to HFR and implicate Rac1 in radioresistance of breast cancer cells. These studies also provide the basis to explore Rac1 as a therapeutic target for radioresistant breast cancer cells.	[Hein, A. L.; Post, C. M.; Enke, C. A.; Yan, Y.] Univ Nebraska Med Ctr, Dept Radiat Oncol, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA; [Sheinin, Y. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Lakshmanan, I.; Batra, S. K.; Yan, Y.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Natarajan, A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Ouellette, M. M.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Yan, Y (corresponding author), Univ Nebraska Med Ctr, Dept Radiat Oncol, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	yyan@unmc.edu		Natarajan, Amarnath/0000-0001-5067-0203; Hein, Ashley/0000-0002-3309-2218; Post, Carl/0000-0003-1018-693X; lakshmanan, Imayavaramban/0000-0003-1733-2223	Pilot Project [5P30GM106397, P50CA127297]; NATIONAL CANCER INSTITUTE [P50CA127297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106397] Funding Source: NIH RePORTER	Pilot Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vimla Band for 76N cells and Dr Toren Finkel for Ad.N17Rac1 and Ad. dl312 adenoviral vectors. This work was supported, in parts, by Pilot Project Funding from 5P30GM106397 to YY and AN, and P50CA127297 to SKB, MMO and YY.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Arnold Christoph R, 2014, Oncoscience, V1, P513; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1; Cai ZL, 2011, INT J RADIAT BIOL, V87, P1135, DOI 10.3109/09553002.2011.622033; Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515; Chen BPC, 2012, CANCER LETT, V327, P103, DOI 10.1016/j.canlet.2011.12.004; Cuadrado A, 2014, J BIOL CHEM, V289, P15244, DOI 10.1074/jbc.M113.540633; DeSantis C, 2014, CANC TREATMENT SURVI, P3; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Espinha G, 2015, MOL CELL BIOCHEM, V404, P281, DOI 10.1007/s11010-015-2388-0; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Jiang DH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092398; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kunz M, 2014, EUR J CELL BIOL, V93, P1, DOI 10.1016/j.ejcb.2013.12.002; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leve F, 2012, J CELL BIOCHEM, V113, P2549, DOI 10.1002/jcb.24153; Magne N, 2006, CANCER LETT, V231, P158, DOI 10.1016/j.canlet.2005.01.022; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Opferman JT, 2016, FEBS J, V283, P2661, DOI 10.1111/febs.13472; Pessetto ZY, 2012, BREAST CANCER RES TR, V134, P511, DOI 10.1007/s10549-012-2079-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sahlberg SH, 2014, TUMOR BIOL, V35, P3525, DOI 10.1007/s13277-013-1465-9; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shiao YH, 2000, CANCER EPIDEM BIOMAR, V9, P631; Shimura T, 2011, INT J RADIAT ONCOL, V80, P540, DOI 10.1016/j.ijrobp.2010.12.065; Skvortsov S, 2014, BRIT J CANCER, V110, P2677, DOI 10.1038/bjc.2014.221; Skvortsova I, 2015, SEMIN CANCER BIOL, V35, P39, DOI 10.1016/j.semcancer.2015.09.009; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sooman L, 2013, CANCER CHEMOTH PHARM, V72, P329, DOI 10.1007/s00280-013-2197-7; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Toulany M, 2012, MOL CANCER RES, V10, P945, DOI 10.1158/1541-7786.MCR-11-0592; Valerie K, 2007, MOL CANCER THER, V6, P789, DOI 10.1158/1535-7163.MCT-06-0596; Wang W, 2015, CURR MED CHEM, V22, P264; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Wetterskog D, 2014, ONCOGENE, V33, P966, DOI 10.1038/onc.2013.41; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 2014, ONCOTARGET, V5, P10251, DOI 10.18632/oncotarget.2500; Yan Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3164; Zhao XS, 2010, P NATL ACAD SCI USA, V107, P14146, DOI 10.1073/pnas.1009030107; Zhao Y, 2011, CANCER LETT, V313, P54, DOI 10.1016/j.canlet.2011.08.023	62	48	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6319	6329		10.1038/onc.2016.163	http://dx.doi.org/10.1038/onc.2016.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181206	Green Accepted			2022-12-28	WOS:000390247000005
J	Leslie, PL; Zhang, Y				Leslie, P. L.; Zhang, Y.			MDM2 oligomers: antagonizers of the guardian of the genome	ONCOGENE			English	Review							UBIQUITIN LIGASE ACTIVITY; AUTOREGULATORY FEEDBACK LOOP; HUMAN TUMOR-CELLS; ACTIVITY IN-VIVO; DNA-DAMAGE; RING DOMAIN; P53 ACTIVITY; E3 LIGASE; ACIDIC DOMAIN; PROMOTES UBIQUITINATION	Over two decades of MDM2 research has resulted in the accumulation of a wealth of knowledge of many aspects of MDM2 regulation and function, particularly with respect to its most prominent target, p53. For example, recent knock-in mouse studies have shown that MDM2 heterooligomer formation with its homolog, MDMX, is necessary and sufficient in utero to suppress p53 but is dispensable during adulthood. However, despite crucial advances such as these, several aspects regarding basic in vivo functions of MDM2 remain unknown. In one such example, although abundant evidence suggests that MDM2 forms homooligomers and heterooligomers with MDMX, the function and regulation of these homo-and heterooligomers in vivo remain incompletely understood. In this review, we discuss the current state of our knowledge of MDM2 oligomerization as well as current efforts to target the MDM2 oligomer as a broad therapeutic option for cancer treatment.	[Leslie, P. L.; Zhang, Y.] Univ North Carolina Chapel Hill, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27599 USA; [Leslie, P. L.; Zhang, Y.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA; [Leslie, P. L.] Univ North Carolina Chapel Hill, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC USA; [Zhang, Y.] Xuzhou Med Coll, Lab Biol Canc Therapy, Xuzhou, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xuzhou Medical University	Zhang, Y (corresponding author), Univ North Carolina Chapel Hill, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27599 USA.; Zhang, Y (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA.	ypzhang@med.unc.edu			National Institutes of Health [CA127770, CA167637]; University of North Carolina Genetics and Molecular Biology Training Grant [5T32 GM007092]; NSFC; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; NATIONAL CANCER INSTITUTE [R01CA167637, R01CA100302, R01CA155235, R01CA127770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of North Carolina Genetics and Molecular Biology Training Grant; NSFC(National Natural Science Foundation of China (NSFC)); Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA127770 and CA167637 (to YZ). This work was also supported by a fellowship from the University of North Carolina Genetics and Molecular Biology Training Grant 5T32 GM007092 (to PL), and grants from the NSFC and Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy (to YZ).	Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Aziz MH, 2011, ONCOGENE, V30, P4678, DOI 10.1038/onc.2011.185; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bista M, 2013, P NATL ACAD SCI USA, V110, P17814, DOI 10.1073/pnas.1317398110; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Burgess A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00007; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112; Chen LH, 2015, P NATL ACAD SCI USA, V112, P4624, DOI 10.1073/pnas.1420833112; Cheng Q, 2014, MOL CELL BIOL, V34, P2800, DOI 10.1128/MCB.00246-14; Cheng Q, 2011, MOL CELL BIOL, V31, P4951, DOI 10.1128/MCB.05553-11; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dang JJ, 2002, CANCER RES, V62, P1222; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dolezelova P, 2012, CELL CYCLE, V11, P953, DOI 10.4161/cc.11.5.19445; Egorova O, 2014, BIOCHEM BIOPH RES CO, V447, P696, DOI 10.1016/j.bbrc.2014.04.065; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Graves B, 2012, P NATL ACAD SCI USA, V109, P11788, DOI 10.1073/pnas.1203789109; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herman AG, 2011, CANCER DISCOV, V1, P312, DOI 10.1158/2159-8290.CD-11-0104; Hjerrild M, 2001, BIOCHEM J, V355, P347, DOI 10.1042/0264-6021:3550347; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Iyappan S, 2010, J BIOL CHEM, V285, P33065, DOI 10.1074/jbc.M110.115113; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Khoo KH, 2014, NAT REV DRUG DISCOV, V13, DOI 10.1038/nrd4288; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lamberti A, 2015, ELECTROPHORESIS, V36, P552, DOI 10.1002/elps.201400424; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4814; Lehmann S, 2012, J CLIN ONCOL, V30, P3633, DOI 10.1200/JCO.2011.40.7783; LENG P, 1995, ONCOGENE, V10, P1275; Leslie PL, 2015, J BIOL CHEM, V290, P12941, DOI 10.1074/jbc.M115.644435; Li BZ, 2010, CELL CYCLE, V9, P1411, DOI 10.4161/cc.9.7.11255; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Li X, 2012, ONCOGENE, V31, P3721, DOI 10.1038/onc.2011.534; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Moll UM, 2003, MOL CANCER RES, V1, P1001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 2011, GENE, V486, P23, DOI 10.1016/j.gene.2011.06.030; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Noguchi T, 2013, BIOORG MED CHEM LETT, V23, P3802, DOI 10.1016/j.bmcl.2013.04.094; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pellegrino M, 2015, CANCER RES, V75, P4560, DOI 10.1158/0008-5472.CAN-15-0439; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Riedinger C, 2009, FUTURE MED CHEM, V1, P1075, DOI 10.4155/FMC.09.75; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; SCHMID P, 1991, DEVELOPMENT, V113, P857; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Stad R, 2000, J BIOL CHEM, V275, P28039; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tollini LA, 2014, CANCER CELL, V26, P235, DOI 10.1016/j.ccr.2014.06.006; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wade M, 2012, ONCOGENE, V31, P4789, DOI 10.1038/onc.2011.625; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xiong XF, 2014, ELIFE, V3, DOI 10.7554/eLife.02236; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [张燕 Zhang Yan], 2003, [水土保持通报, Bulletin of Soil and Water Conservation], V23, P23; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang ZM, 2014, ACS MED CHEM LETT, V5, P124, DOI 10.1021/ml400359z; Zheng JG, 2015, GENE DEV, V29, P1524, DOI 10.1101/gad.261792.115; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	131	10	10	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6157	6165		10.1038/onc.2016.88	http://dx.doi.org/10.1038/onc.2016.88			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27041565	Green Submitted, Green Accepted			2022-12-28	WOS:000388857700001
J	Paul, PJ; Raghu, D; Chan, AL; Gulati, T; Lambeth, L; Takano, E; Herold, MJ; Hagekyriakou, J; Vessella, RL; Fedele, C; Shackleton, M; Williams, ED; Fox, S; Williams, S; Haupt, S; Gamell, C; Haupt, Y				Paul, P. J.; Raghu, D.; Chan, A-L; Gulati, T.; Lambeth, L.; Takano, E.; Herold, M. J.; Hagekyriakou, J.; Vessella, R. L.; Fedele, C.; Shackleton, M.; Williams, E. D.; Fox, S.; Williams, S.; Haupt, S.; Gamell, C.; Haupt, Y.			Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP	ONCOGENE			English	Article							PROTEASOME INHIBITOR BORTEZOMIB; PML-INDUCED SENESCENCE; DRIVEN; CELLS; FIBROBLASTS; PROGRESSION; MOUSE; DEATH	Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP-PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.	[Paul, P. J.; Raghu, D.; Gulati, T.; Haupt, Y.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Paul, P. J.; Raghu, D.; Chan, A-L; Gulati, T.; Lambeth, L.; Haupt, S.; Gamell, C.; Haupt, Y.] Peter MacCallum Canc Ctr, Tumor Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia; [Takano, E.; Fedele, C.; Shackleton, M.; Fox, S.] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia; [Herold, M. J.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc, Parkville, Vic, Australia; [Herold, M. J.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Hagekyriakou, J.] Peter MacCallum Canc Ctr, Dept Phys Sci, Melbourne, Vic, Australia; [Vessella, R. L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Fedele, C.; Shackleton, M.] Peter MacCallum Canc Ctr, Canc Dev & Treatment Lab, Melbourne, Vic, Australia; [Fedele, C.; Shackleton, M.; Williams, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Div Radiat Oncol & Canc Imaging, Melbourne, Vic, Australia; [Williams, E. D.] Queensland Univ Technol, Australian Prostate Canc Res Ctr, Brisbane, Qld, Australia; [Haupt, Y.] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Paul, P. J.] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Tumor Pathol Dept, Gliwice Branch, Gliwice, Poland; [Chan, A-L] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia; [Lambeth, L.] Murdoch Childrens Res Inst, Parkville, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Walter & Eliza Hall Institute; University of Melbourne; Peter Maccallum Cancer Center; University of Washington; University of Washington Seattle; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Queensland University of Technology (QUT); Monash University; University of Melbourne; Maria Sklodowska-Curie National Research Institute of Oncology; Australian Regenerative Medicine Institute; Monash University; Murdoch Children's Research Institute	Gamell, C (corresponding author), Peter MacCallum Canc Ctr, Tumor Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	Cristina.Gamell@petermac.org	Williams, Elizabeth D/B-1538-2008; Herold, Marco J/C-8039-2013; Fox, Stephen/G-9719-2016	Williams, Elizabeth D/0000-0002-3364-6655; Herold, Marco J/0000-0001-7539-7581; Paul, Piotr Jan/0000-0002-2319-224X; Fox, Stephen/0000-0002-7648-8896; Raghu, Dinesh/0000-0002-8960-6222; Gulati, Twishi/0000-0003-3841-8392; Chan, Ai-Leen/0000-0003-3553-7249; Gamell, Cristina/0000-0003-0720-2652; Haupt, Ygal/0000-0001-5925-0096	NHMRC [1049179, 1063389, 9628426, 1049720]; PCF creativity grant; CCV grant [1085154]; VCA Richard Pratt Fellowship in Prostate Cancer Research; PCFA grant [NDDA-1811]; Pfizer Australia; Veski foundings; Foundation of the Peter MacCallum Cancer Centre	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); PCF creativity grant; CCV grant(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VCA Richard Pratt Fellowship in Prostate Cancer Research; PCFA grant; Pfizer Australia(PfizerPfizer Australia); Veski foundings; Foundation of the Peter MacCallum Cancer Centre	This work was supported by NHMRC project grants (1049179 and 1063389) and NHMRC Fellowship to YH (9628426), NHMRC project grant to MJH (1049720), PCF creativity grant to SW and YH, CCV grant (1085154), VCA Richard Pratt Fellowship in Prostate Cancer Research to CG, the PCFA grant (NDDA-1811) to EW, Pfizer Australia, NHMRC and Veski foundings to MS, and a prostate initiative grant from the Foundation of the Peter MacCallum Cancer Centre. PrEC line was a generous gift from Dr Patrick Humbert and Helen Pearson at Peter MacCallum Cancer Centre.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; Birch SE, 2014, ANN ONCOL, V25, P2392, DOI 10.1093/annonc/mdu454; Chen RH, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-81; Christian PA, 2009, CANCER BIOL THER, V8, P73, DOI 10.4161/cbt.8.1.7132; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044; Dreicer R, 2007, CLIN CANCER RES, V13, P1208, DOI 10.1158/1078-0432.CCR-06-2046; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gamell C, 2014, FEBS LETT, V588, P2653, DOI 10.1016/j.febslet.2014.02.007; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hurwitz Arthur A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2005s45; Ivanschitz L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00171; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kraft AS, 2011, CANCER BIOL THER, V12, P119, DOI 10.4161/cbt.12.2.15723; Levav-Cohen Y, 2012, ONCOGENE, V31, P2199, DOI 10.1038/onc.2011.402; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Oh W, 2009, J CELL SCI, V122, P2613, DOI 10.1242/jcs.048066; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Papandreou CN, 2004, CANCER RES, V64, P5036, DOI 10.1158/0008-5472.CAN-03-2707; Pernicova Z, 2011, NEOPLASIA, V13, P526, DOI 10.1593/neo.11182; Price Nancy, 2004, Clin Prostate Cancer, V3, P141; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Srinivasan S, 2011, BBA-GENE REGUL MECH, V1809, P119, DOI 10.1016/j.bbagrm.2010.08.011; Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wolyniec K, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00124; Wolyniec K, 2012, CELL CYCLE, V11, P3705, DOI 10.4161/cc.22043; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Yamagishi Y, 2011, CHEM BIOL, V18, P1562, DOI 10.1016/j.chembiol.2011.09.013	38	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6235	6245		10.1038/onc.2016.159	http://dx.doi.org/10.1038/onc.2016.159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27641331				2022-12-28	WOS:000388857700008
J	Chien, CW; Hou, PC; Wu, HC; Chang, YL; Lin, SC; Lin, SC; Lin, BW; Lee, JC; Chang, YJ; Sun, HS; Tsai, SJ				Chien, C-W; Hou, P-C; Wu, H-C; Chang, Y-L; Lin, S-C; Lin, S-C; Lin, B-W; Lee, J-C; Chang, Y-J; Sun, H. S.; Tsai, S-J			Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; ARREST-SPECIFIC GENE-6; MONOCLONAL-ANTIBODY; BREAST-CANCER; COLORECTAL-CANCER; STEM-CELLS; AXL; SURVIVAL; GROWTH; OVEREXPRESSION	Colon cancer is the third leading cause of death from cancer worldwide with less than 10% survival rate at the late stage. Although mutations of certain genes have been implicated in familial colon cancer development, the etiology of the majority of colon cancer remains unknown. Herein, we identified TYRO3 as a potential oncogene. Immunohistochemical staining results demonstrated that levels of TYRO3 were markedly elevated in polyps and colon cancer cells and were negatively correlated with prognosis. Overexpression of TYRO3 enhanced cell motility, invasion, anchorage-independent growth and metastatic ability, while knockdown of TYRO3 impaired all these processes. Results from meta-analysis showed that TYRO3 was associated with epithelial-mesenchymal transition (EMT) signatures. Gain-of-function and loss-of-function experiments demonstrated that expression of SNAI1, the master regulator of EMT, was regulated by TYRO3 and played a major role in mediating TYRO3-induced EMT processes. The murine model also demonstrated that Tyro3 and Snai1 were upregulated in the early stage of colon cancer development. To provide a proof-of-concept that TYRO3 is a druggable target in colon cancer therapy, we raised anti-TYRO3 human antibodies and showed that treatment with the human antibody abolished TYRO3-induced EMT process. More importantly, administration of this anti-TYRO3 antibody increased drug sensitivity in primary cultured colon cancer cells and xenografted mouse tumors. These findings demonstrate that TYRO3 is a novel oncogene and a druggable target in colon cancer.	[Chien, C-W; Hou, P-C; Sun, H. S.; Tsai, S-J] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Wu, H-C; Chang, Y-L] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan; [Lin, S-C; Tsai, S-J] Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 701, Taiwan; [Lin, S-C; Lin, B-W; Lee, J-C] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan, Taiwan; [Chang, Y-J] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Sun, H. S.] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, 1 Univ Rd, Tainan 701, Taiwan	National Cheng Kung University; Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University	Tsai, SJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 701, Taiwan.; Sun, HS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Mol Med, 1 Univ Rd, Tainan 701, Taiwan.	hssun@mail.ncku.edu.tw; seantsai@mail.ncku.edu.tw	Wu, Han-Chung/B-1209-2011; Tsai, Shaw-Jenq/AAG-6569-2019	Wu, Han-Chung/0000-0002-5185-1169; TSAI, SHAW-JENQ/0000-0002-3569-5813; Hou, Pei-Chi/0000-0002-3709-5934; Sun, Sunny/0000-0002-3661-4448	National Science Council of Taiwan [NSC 101-2321-B-006-020, NSC 102-2321-B-006-011]; Top University Grant of National Cheng Kung University [D103-35A17]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Top University Grant of National Cheng Kung University	We thank Miss Yi-Hsuan Yeh and Miss Yi-Chen Tang for technical assistance with IHC and animal study. This work was supported by grants from National Science Council of Taiwan (NSC 101-2321-B-006-020 and NSC 102-2321-B-006-011) and by Top University Grant of National Cheng Kung University (grant # D103-35A17).	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; CARON PC, 1994, CANCER, V73, P1049, DOI 10.1002/1097-0142(19940201)73:3+<1049::AID-CNCR2820731344>3.0.CO;2-1; Chan HH, 2007, NUCL ACIDS RES; Chien CW, 2008, CLIN CANCER RES, V14, P8043, DOI 10.1158/1078-0432.CCR-08-1651; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Duijkers FAM, 2013, GENE, V521, P62, DOI 10.1016/j.gene.2013.03.029; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gerloff J, 2012, AM J PATHOL, V180, P2134, DOI 10.1016/j.ajpath.2012.01.036; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Golan T, 2013, CANCER-AM CANCER SOC, V119, P3084, DOI 10.1002/cncr.28143; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Lu RM, 2011, BIOMATERIALS, V32, P3265, DOI 10.1016/j.biomaterials.2010.12.061; Neubauer A, 1997, LEUKEMIA LYMPHOMA, V25, P91, DOI 10.3109/10428199709042499; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Sun WS, 2003, MOL HUM REPROD, V9, P701, DOI 10.1093/molehr/gag082; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Taylor ICA, 1995, ONCOGENE, V11, P2619; Zhu ST, 2009, P NATL ACAD SCI USA, V106, P17025, DOI 10.1073/pnas.0909292106	32	46	46	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5872	5881		10.1038/onc.2016.120	http://dx.doi.org/10.1038/onc.2016.120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27132510				2022-12-28	WOS:000387560800006
J	Englund, E; Bartoschek, M; Reitsma, B; Jacobsson, L; Escudero-Esparza, A; Orimo, A; Leandersson, K; Hagerling, C; Aspberg, A; Storm, P; Okroj, M; Mulder, H; Jirstrom, K; Pretras, K; Blom, AM				Englund, E.; Bartoschek, M.; Reitsma, B.; Jacobsson, L.; Escudero-Esparza, A.; Orimo, A.; Leandersson, K.; Hagerling, C.; Aspberg, A.; Storm, P.; Okroj, M.; Mulder, H.; Jirstrom, K.; Pretras, K.; Blom, A. M.			Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; EXPRESSION; COMPLEMENT; COMP; ACTIVATION; DOMAIN; BETA; ER	Cartilage oligomeric matrix protein (COMP) is a soluble pentameric protein expressed in cartilage and involved in collagen organization. Tissue microarrays derived from two cohorts of patients with breast cancer (n= 122 and n = 498) were immunostained, revealing varying expression of COMP, both in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Breast cancer cells, MDA-MB-231, stably expressing COMP were injected into the mammary fat pad of SCID (CB-17/Icr-Prkdc(scid)/Rj) mice. Tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control, mock-transfected, tumors. In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of matrix metalloprotease-9. Furthermore, microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. This observation was confirmed in vitro as COMP-expressing cells showed better survival as well as a higher rate of protein synthesis when treated with brefeldin A, compared with control cells. Further, COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect. Thus, in vitro measurement of cell respiration indicated decreased mitochondrial metabolism. In conclusion, COMP is a novel biomarker in breast cancer, which contributes to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.	[Englund, E.; Reitsma, B.; Escudero-Esparza, A.; Okroj, M.; Blom, A. M.] Lund Univ, Dept Translat Med, Div Med Prot Chem, Malmo, Sweden; [Bartoschek, M.; Pretras, K.] Lund Univ, Dept Lab Med, Div Translat Canc Res, Lund, Sweden; [Jacobsson, L.; Mulder, H.] Lund Univ, Unit Mol Metab, Dept Clin Sci Malmo, Lund, Sweden; [Orimo, A.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo, Japan; [Leandersson, K.; Hagerling, C.] Lund Univ, Ctr Mol Pathol, Dept Lab Med, Malmo, Sweden; [Aspberg, A.] Lund Univ, Dept Clin Sci Lund, Div Rheumatol & Mol Skeletal Biol, Lund, Sweden; [Storm, P.] Lund Univ, Dept Clin Sci Malmo, Div Diabet & Endocrinol, Malmo, Sweden; [Okroj, M.] Med Univ Gdansk, UG MUG, Intercollegiate Fac Biotechnol, Dept Med Biotechnol, Gdansk, Poland; [Jirstrom, K.] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden	Lund University; Lund University; Lund University; Juntendo University; Lund University; Lund University; Lund University; Fahrenheit Universities; Medical University Gdansk; Lund University	Blom, AM (corresponding author), Lund Univ, Skane Univ Hosp, Wallenberg Lab, Div Med Prot Chem,Dept Translat Med, Inga Maria Nilssons St 53, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734; Pietras, Kristian/0000-0001-6738-4705; Storm, Petter/0000-0002-7655-3731; Mulder, Hindrik/0000-0002-6593-8417; Aspberg, Anders/0000-0002-6588-6944; Orimo, Akira/0000-0001-5330-7282	Cancerfonden; Swedish Research Council [K2012-66X-14928-09-5]; Swedish Government Funds for Clinical research; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; King Gustav V's 80th anniversary; Knut and Alice Wallenberg; Inga-Britt and Arne Lundberg; Royal Physiographic Society; Skane University Hospital; National Science Centre, Poland [2014/14/E/NZ6/00182]; Grants-in-Aid for Scientific Research [15K14385] Funding Source: KAKEN	Cancerfonden(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Government Funds for Clinical research; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; King Gustav V's 80th anniversary; Knut and Alice Wallenberg(Knut & Alice Wallenberg Foundation); Inga-Britt and Arne Lundberg; Royal Physiographic Society; Skane University Hospital; National Science Centre, Poland(National Science Centre, Poland); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Cancerfonden, the Swedish Research Council (K2012-66X-14928-09-5), the Swedish Government Funds for Clinical research (ALF) and the Foundations of Osterlund, Crafoord, Greta and Johan Kock, King Gustav V's 80th anniversary, Knut and Alice Wallenberg and Inga-Britt and Arne Lundberg, Royal Physiographic Society, as well as a grant from the Skane University Hospital. MO was supported by National Science Centre, Poland (2014/14/E/NZ6/00182).	Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Agarwal P, 2013, MATRIX BIOL, V32, P325, DOI 10.1016/j.matbio.2013.02.010; Anderson BO, 2008, CANCER-AM CANCER SOC, V113, P2221, DOI 10.1002/cncr.23844; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Borgquist S, 2008, J CLIN PATHOL, V61, P197, DOI 10.1136/jcp.2006.040378; Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146; Briggs MD, 2014, EUR J HUM GENET, V22, P1278, DOI 10.1038/ejhg.2014.30; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Englund E, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1734-7; Escudero-Esparza A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-43; Farina G, 2006, MATRIX BIOL, V25, P213, DOI 10.1016/j.matbio.2006.01.007; Furge K, 2012, PGSEA PARAMETRIC GEN; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Happonen KE, 2010, ARTHRITIS RHEUM-US, V62, P3574, DOI 10.1002/art.27720; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Hesselstrand R, 2008, ANN RHEUM DIS, V67, P1242, DOI 10.1136/ard.2007.082099; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kung LHW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117016; Lynch JM, 2012, CELL, V149, P1257, DOI 10.1016/j.cell.2012.03.050; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Otteby KE, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4410; Ryden L, 2005, J CLIN ONCOL, V23, P4695, DOI 10.1200/JCO.2005.08.126; Sodersten F, 2006, CONNECT TISSUE RES, V47, P85, DOI 10.1080/03008200600584124; Svensson KJ, 2011, INT J ONCOL, V39, P1421, DOI 10.3892/ijo.2011.1164; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	31	49	50	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5585	5596		10.1038/onc.2016.98	http://dx.doi.org/10.1038/onc.2016.98			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065333				2022-12-28	WOS:000386998300002
J	Na, TY; Ka, NL; Rhee, H; Kyeong, D; Kim, MH; Seong, JK; Park, YN; Lee, MO				Na, T-Y; Ka, N-L; Rhee, H.; Kyeong, D.; Kim, M-H; Seong, J. K.; Park, Y. N.; Lee, M-O			Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; DAMAGE RESPONSE; EXCISION-REPAIR; LIVER-CANCER; CHROMATIN; CELLS; TRANSCRIPTION; ACCUMULATION; INVOLVEMENT; INVASION	Hepatitis B virus X protein (HBx) contributes to the development of hepatocellular carcinoma (HCC), probably by regulating activities of many host or viral proteins through protein-protein interactions. In this study, we identified poly(ADP-ribose) polymerase (PARP1), a crucial factor in DNA repair, as an HBx-interacting protein using a proteomics approach. Coimmunoprecipitation and proximity ligation assays confirmed the binding and colocalization of HBx and PARP1 in the nucleus. The carboxyl-terminus of HBx protein bound to the catalytic domain of PARP1, and this binding reduced the enzymatic activity of PARP1 in both in vitro and in vivo assays. HBx interrupted the binding of PARP1 to Sirt6, which catalyzes the mono-ADP-ribosylation required for DNA repair. Consistently, overexpression of HBx inhibited the clearance of gamma H2AX DNA repair foci generated under oxidative stress in Chang liver cells. Recruitment of the DNA repair complex to the site-specific double-strand breaks was inhibited in the presence of HBx, when measured by laser microirradiation assay and damage-specific chromatin immunoprecipitation assays. Consequently, HBx increased signs of DNA damage such as accumulation of 8-hydroxy-2'-deoxyguanosine and comet formation, which were reversed by overexpression of PARP1 and/or Sirt6. Finally, the interaction between PARP1 and Sirt6 was markedly lower in the livers of HBx-transgenic mice and specimens obtained from HCC patients to compare with the corresponding control. Our data suggest that the physical interaction of HBx and PARP1 accelerates DNA damage by inhibiting recruitment of the DNA repair complex to the damaged DNA sites, which may lead to the onset of hepatocarcinogenesis.	[Na, T-Y; Ka, N-L; Kim, M-H; Lee, M-O] Seoul Natl Univ, Coll Pharm, San 56-1 Sillim Dong, Seoul 151742, South Korea; [Na, T-Y; Ka, N-L; Kim, M-H; Lee, M-O] Seoul Natl Univ, Bio MAX Inst, Seoul, South Korea; [Rhee, H.; Park, Y. N.] Yonsei Univ, Coll Med, Integrated Genom Res Ctr Metab Regulat, Dept Pathol, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Coll Vet Med, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Seoul Natl Univ, Program Canc Biol, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Korea Mouse Phenotyping Ctr, Seoul, South Korea; [Park, Y. N.] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Sillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Rhee, Hyungjin/T-7619-2019	Seong, Je Kyung/0000-0003-1177-6958; Rhee, Hyungjin/0000-0001-7759-4458; Park, Young Nyun/0000-0003-0357-7967; Kyung, Dongsoo/0000-0003-2910-0120	National R&D Program for Cancer Control, Ministry of Health Welfare, Korea [1220110]; Bio & Medical Technology Development Program [2012M3A9B6055338];  [NRF-2014R1A2A1A10052265]	National R&D Program for Cancer Control, Ministry of Health Welfare, Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Bio & Medical Technology Development Program; 	This work was supported by grants from NRF-2014R1A2A1A10052265, the National R&D Program for Cancer Control, Ministry of Health & Welfare, Korea (1220110) and the Bio & Medical Technology Development Program (2012M3A9B6055338).	Abd Elmageed ZY, 2012, CELL SIGNAL, V24, P1, DOI 10.1016/j.cellsig.2011.07.019; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bolukbas C, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-95; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Dandri M, 2002, HEPATOLOGY, V35, P217, DOI 10.1053/jhep.2002.30203; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Deng BA, 2015, GENE, V571, P292, DOI 10.1016/j.gene.2015.06.083; Di Giammartino DC, 2013, MOL CELL, V49, P7, DOI 10.1016/j.molcel.2012.11.005; Fujita N, 2008, J VIRAL HEPATITIS, V15, P498, DOI 10.1111/j.1365-2893.2008.00972.x; Gehrke R, 2004, DIGESTION, V70, P117, DOI 10.1159/000080930; Higgs MR, 2014, J GEN VIROL, V95, P991, DOI 10.1099/vir.0.059485-0; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Iizuka N, 2006, J CANCER RES CLIN, V132, P473, DOI 10.1007/s00432-006-0094-8; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kew MC, 2011, J GASTROEN HEPATOL, V26, P144, DOI 10.1111/j.1440-1746.2010.06546.x; Ko HL, 2011, HEPATOLOGY, V54, P1190, DOI 10.1002/hep.24502; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lee NS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10463; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Liu HO, 2012, CANCER SCI, V103, P2072, DOI 10.1111/cas.12017; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marquardt JU, 2013, HEPATOLOGY, V58, P1054, DOI 10.1002/hep.26413; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Min S, 2014, CELL CYCLE, V13, P666, DOI 10.4161/cc.27548; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Nomura F, 2000, J GASTROEN HEPATOL, V15, P529, DOI 10.1046/j.1440-1746.2000.02193.x; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Piskunova Tatiana S, 2008, Curr Gerontol Geriatr Res, P754190, DOI 10.1155/2008/754190; Qadri I, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-48; Sala A, 2008, PLOS BIOL, V6, P2329, DOI 10.1371/journal.pbio.0060252; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Shimizu S, 2004, ONCOL REP, V12, P821; SHIMODA R, 1994, CANCER RES, V54, P3171; Sousa FG, 2012, CARCINOGENESIS, V33, P1433, DOI 10.1093/carcin/bgs132; Srisuttee R, 2012, ONCOL REP, V28, P276, DOI 10.3892/or.2012.1798; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; van de Klundert MAA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048940; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Xu C, 2014, CANCER LETT, V345, P216, DOI 10.1016/j.canlet.2013.08.035; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879	52	31	32	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5435	5445		10.1038/onc.2016.82	http://dx.doi.org/10.1038/onc.2016.82			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041572				2022-12-28	WOS:000386677800009
J	Black, SA; Nelson, AC; Gurule, NJ; Futscher, BW; Lyons, TR				Black, S. A.; Nelson, A. C.; Gurule, N. J.; Futscher, B. W.; Lyons, T. R.			Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression	ONCOGENE			English	Article							CARCINOMA IN-SITU; MAMMARY-TUMOR; CANCER; EXPRESSION; MODEL; ARCHITECTURE; METASTASIS; SIGNATURE; RESPONSES; GUIDANCE	Understanding what drives breast tumor progression is of utmost importance for blocking tumor metastasis; we have identified that semaphorin 7a is a potent driver of ductal carcinoma in situ (DCIS) progression. Semaphorin 7a is a glycophosphatidylinositol membrane-anchored protein that promotes attachment and spreading in multiple cell types. Here, we show that increased expression of SEMA7A occurs in a large percentage of breast cancers and is associated with decreased overall and distant metastasis-free survival. In both in vitro and in vivo models, short hairpin-mediated silencing of SEMA7A reveals roles for semaphorin 7a in the promotion of DCIS growth, motility and invasion as well as lymphangiogenesis in the tumor microenvironment. Our studies also uncover a relationship between COX-2 and semaphorin 7a expression and suggest that semaphorin 7a promotes tumor cell invasion on collagen and lymphangiogenesis via activation of beta(1)-integrin receptor. Our results suggest that semaphorin 7a may be novel target for blocking breast tumor progression.	[Black, S. A.; Gurule, N. J.; Lyons, T. R.] Univ Colorado Anschutz Med Campus, Sch Med, Dept Med, Div Med Oncol, Aurora, CO USA; [Nelson, A. C.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Gurule, N. J.; Lyons, T. R.] Univ Colorado Anschutz Med Campus, Univ Colorado Canc Biol Grad Program, Aurora, CO USA; [Futscher, B. W.] Univ Arizona, Univ Arizona Canc Ctr, Tucson, AZ USA; [Futscher, B. W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; [Lyons, T. R.] Univ Colorado Anschutz Med Campus, Univ Colorado Canc Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Arizona; University of Arizona; University of Colorado System; University of Colorado Anschutz Medical Campus	Lyons, TR (corresponding author), Univ Colorado Anschutz Med Campus, Div Med Oncol, MS8117,L18-8103,12801 East 17th Ave, Aurora, CO 80045 USA.	Traci.Lyons@ucdenver.edu			Cancer League of Colorado CCTSI Mentored Career Development Award [1KL2TR001080-01]; CCTSI CO PILOT NIH/NCI [M-13-161, 1R21CA185226-01]; University of Colorado Cancer Center Summer Fellowship; Cancer League of Colorado;  [U01CA153086]; NATIONAL CANCER INSTITUTE [R21CA185226] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001080] Funding Source: NIH RePORTER	Cancer League of Colorado CCTSI Mentored Career Development Award; CCTSI CO PILOT NIH/NCI; University of Colorado Cancer Center Summer Fellowship; Cancer League of Colorado; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We gratefully acknowledge K Polyak and A Marusyk (Harvard Medical School) for providing MCF10DCIS parental cells and shCOX-2 derivatives; AC Tan, K Hunter (NCI), J Richer, T Rogers and M Gordon for advice on dataset analysis; L Crump, A Elder, M Kobritz, J Pruitt, A Pham, S Tarullo and V Wessells for technical support; V Borges and P Schedin for critical review of the manuscript and crucial advice. This work was supported by Cancer League of Colorado, 1KL2TR001080-01 CCTSI Mentored Career Development Award, CCTSI CO PILOT M-13-161 and 1R21CA185226-01 NIH/NCI to TL. University of Colorado Cancer Center Summer Fellowship and Cancer League of Colorado to SB and U01CA153086 to BF.	Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Allegra M, 2012, MOL BIOL CELL, V23, P3873, DOI 10.1091/mbc.E12-04-0276; ASLAKSON CJ, 1991, INT J CANCER, V47, P466, DOI 10.1002/ijc.2910470327; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Czopik AK, 2006, IMMUNITY, V24, P591, DOI 10.1016/j.immuni.2006.03.013; Delorme G, 2005, BIOL CELL, V97, P589; Esserman L, 2015, JAMA ONCOL, V1, P881, DOI 10.1001/jamaoncol.2015.2607; Formolo CA, 2011, J PROTEOME RES, V10, P3149, DOI 10.1021/pr200210w; Garcia-Areas R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00017; Gelfand MV, 2009, TRENDS CELL BIOL, V19, P99, DOI 10.1016/j.tcb.2009.01.001; Ghanem RC, 2011, CURR EYE RES, V36, P989, DOI 10.3109/02713683.2011.593730; Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Koh JM, 2006, J HUM GENET, V51, P112, DOI 10.1007/s10038-005-0331-z; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; Maurin JC, 2005, MATRIX BIOL, V24, P232, DOI 10.1016/j.matbio.2005.03.005; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Moserle L, 2012, EMBO MOL MED, V4, P168, DOI 10.1002/emmm.201200206; Narod SA, 2015, JAMA ONCOL, V1, P888, DOI 10.1001/jamaoncol.2015.2510; Pasterkamp RJ, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-98; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Scott GA, 2008, J INVEST DERMATOL, V128, P151, DOI 10.1038/sj.jid.5700974; Stefanou D, 2004, HISTOL HISTOPATHOL, V19, P465, DOI 10.14670/HH-19.465; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764	35	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5170	5178		10.1038/onc.2016.49	http://dx.doi.org/10.1038/onc.2016.49			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27065336	Green Accepted			2022-12-28	WOS:000384433000008
J	Ko, C; Kim, YG; Le, TP; Choi, KW				Ko, C.; Kim, Y-G; Le, T. P.; Choi, K-W			Twinstar/cofilin is required for regulation of epithelial integrity and tissue growth in Drosophila	ONCOGENE			English	Article							ACTIN-CAPPING-PROTEIN; HIPPO PATHWAY; CELL POLARITY; F-ACTIN; SIGNALING PATHWAYS; COFILIN; APOPTOSIS; SLINGSHOT; MIGRATION; PROLIFERATION	Regulation of actin assembly and depolymerization is important for the organization of epithelia. Recent studies have shown that the actin-capping proteins are required to prevent cell extrusion and inappropriate activation of Yorkie (Yki) activity in Drosophila, implicating the importance of actin regulation for epithelial integrity and Yki-dependent tissue growth. However, the role of Twinstar (Tsr), the Drosophila homolog for cofilin/actin depolymerization factor (ADF), in epithelial integrity and Hippo signaling is unknown. Here we demonstrate that reduction of Tsr by RNA interference (RNAi) or mutant clones in wing imaginal disc induces not only F-actin accumulation but also ectopic expression of Wingless (Wg) and Yki target gene expanded (ex). Knockdown of Yki in Tsr-depleted cells reduced the level of ectopic Wg expression. Reduced Tsr also led to downregulation of cell junction proteins and extrusion of affected cells from the basal part of the epithelium. Rho GTPase 1 was upregulated in Tsr-depleted tissue, supporting the Tsr function in the inhibition of cell extrusion from the epithelium. Tsr is also required for blocking cell death and c-Jun N-terminal kinase (JNK) signaling. Ectopic JNK activation induced caspase activation but did not cause cell extrusion. Further, the invasiveness of Tsr-depleted cells was not suppressed by inhibition of cell death or JNK signaling. In contrast, Yki upregulation was significantly suppressed by cell death inhibition. Taken together, our data suggest that Tsr is required for cell survival and tissue growth by regulating JNK and Yki signaling while maintaining the epithelial integrity by controlling cell junctions. This study provides an insight into potential roles of ADF/cofilin in invasive cell migration and tumor suppression in higher animals.	[Ko, C.; Kim, Y-G; Le, T. P.; Choi, K-W] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	National Research Foundation of Korea - Korean, Ministry of Education, Science and Technology [NRF-2011-0028326, 2014K1A1A2042982]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084947] Funding Source: NIH RePORTER	National Research Foundation of Korea - Korean, Ministry of Education, Science and Technology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Drs David Helfman and Kyung-Ok Cho for critical comments on the manuscript. We thank Drs Florence Janody, Jongkyeong Chung and Kenneth Irvine for providing flies and antibodies mentioned in the text. We acknowledge the Bloomington Drosophila Stock Center, DGGC, the NIG-Fly Stock Center and the Developmental Studies Hybridoma Bank for fly stocks and antibodies. We thank the TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947) for providing transgenic RNAi fly stocks. This research was supported by a National Research Laboratory Grant (NRF-2011-0028326) and a Global Research Laboratory Grant (2014K1A1A2042982) through the National Research Foundation of Korea, funded by the Korean, Ministry of Education, Science and Technology.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Blair A, 2006, DEVELOPMENT, V133, P1789, DOI 10.1242/dev.02320; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Chen J, 2001, NAT CELL BIOL, V3, P204, DOI 10.1038/35055120; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Janody F, 2006, DEVELOPMENT, V133, P3349, DOI 10.1242/dev.02511; Jezowska B, 2011, DEV BIOL, V360, P143, DOI 10.1016/j.ydbio.2011.09.016; Lee YJ, 2005, CELL BIOL INT, V29, P877, DOI 10.1016/j.cellbi.2005.07.005; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lin CM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-46; Liu XF, 2000, DEV BIOL, V228, P287, DOI 10.1006/dbio.2000.9939; Maloney MT, 2007, MOL NEUROBIOL, V35, P21, DOI 10.1007/BF02700622; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Nakajima Y, 2013, NATURE, V500, P359, DOI 10.1038/nature12335; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; Ng JL, 2004, NEURON, V44, P779, DOI 10.1016/j.neuron.2004.11.014; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Pham H, 2008, DEV BIOL, V318, P82, DOI 10.1016/j.ydbio.2008.03.006; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Rogers EM, 2005, MECH DEVELOP, V122, P1194, DOI 10.1016/j.mod.2005.07.002; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Schlote, 1984, DROS INFORM SERV, V60, P210; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Sun GP, 2011, DEV BIOL, V350, P139, DOI 10.1016/j.ydbio.2010.11.036; Tahtamouni LH, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-45; Tsai CH, 2009, CELL CYCLE, V8, P2365, DOI 10.4161/cc.8.15.9072; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; XU T, 1993, DEVELOPMENT, V117, P1223	40	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5144	5154		10.1038/onc.2016.46	http://dx.doi.org/10.1038/onc.2016.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27041568				2022-12-28	WOS:000384433000006
J	Masilamani, AP; Ferrarese, R; Kling, E; Thudi, NK; Kim, H; Scholtens, DM; Dai, F; Hadler, M; Unterkircher, T; Platania, L; Weyerbrock, A; Prinz, M; Gillespie, GY; Harsh, GR IV; Bredel, M; Carro, MS				Masilamani, A. P.; Ferrarese, R.; Kling, E.; Thudi, N. K.; Kim, H.; Scholtens, D. M.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Prinz, M.; Gillespie, G. Y.; Harsh, G. R., IV; Bredel, M.; Carro, M. S.			KLF6 depletion promotes NF-kappa B signaling in glioblastoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; KRUPPEL-LIKE FACTOR-6; ZINC-FINGER PROTEIN; EXPRESSION; MUTATIONS; CELL; ACTIVATION; TRANSCRIPTION; APOPTOSIS; TARGETS	Dysregulation of the NF-kappa B transcription factor occurs in many cancer types. Kruppel-like family of transcription factors (KLFs) regulate the expression of genes involved in cell proliferation, differentiation and survival. Here, we report a new mechanism of NF kappa B activation in glioblastoma through depletion of the KLF6 tumor suppressor. We show that KLF6 transactivates multiple genes negatively controlling the NF-kappa B pathway and consequently reduces NF-kappa B nuclear localization and downregulates NF-kappa B targets. Reconstitution of KLF6 attenuates their malignant phenotype and induces neural-like differentiation and senescence, consistent with NF-kappa B pathway inhibition. KLF6 is heterozygously deleted in 74.5% of the analyzed glioblastomas and predicts unfavorable patient prognosis suggesting that haploinsufficiency is a clinically relevant means of evading KLF6-dependent regulation of NF-kappa B. Together, our study identifies a new mechanism by which KLF6 regulates NF-kappa B signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss.	[Masilamani, A. P.; Ferrarese, R.; Kling, E.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Carro, M. S.] Univ Freiburg, Med Ctr, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany; [Masilamani, A. P.; Ferrarese, R.; Kling, E.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Carro, M. S.] Univ Freiburg, Fac Med, Freiburg, Germany; [Thudi, N. K.; Bredel, M.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Radiat Oncol, 1700 6th Ave South Birmingham, Birmingham, AL 35233 USA; [Kim, H.] Jackson Lab Genom Med, Farmington, CT USA; [Scholtens, D. M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Prinz, M.] Univ Freiburg, Inst Neuropathol, Freiburg, Germany; [Prinz, M.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany; [Gillespie, G. Y.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Neurosurg, Birmingham, AL USA; [Harsh, G. R., IV] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	University of Freiburg; University of Freiburg; University of Alabama System; University of Alabama Birmingham; Jackson Laboratory; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Freiburg; University of Freiburg; University of Alabama System; University of Alabama Birmingham; Stanford University	Carro, MS (corresponding author), Univ Freiburg, Med Ctr, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany.; Bredel, M (corresponding author), Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Radiat Oncol, 1700 6th Ave South Birmingham, Birmingham, AL 35233 USA.	mbredel@uab.edu; maria.carro@uniklinik-freiburg.de	Stella, Maria Stella/GVS-1585-2022; Ferrarese, Roberto/GSJ-3449-2022	Ferrarese, Roberto/0000-0003-0625-3319; Carro, Maria Stella/0000-0002-8570-7691; Masilamani, Anie Priscilla/0000-0003-2503-1244; Gillespie, George/0000-0001-6436-9542; Weyerbrock, Astrid/0000-0001-9060-4462	National Cancer Institute [P20 CA151129-01A1/UAB]; German Cancer Aid Grant Award, State of Alabama Investment Pool for Action (IMPACT) funds [107714]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); German Cancer Aid Grant Award, State of Alabama Investment Pool for Action (IMPACT) funds	This study was supported by National Cancer Institute grant P20 CA151129-01A1/UAB Specialized Program of Research Excellence (SPORE) in Brain Cancer (M Bredel), German Cancer Aid Grant Award (107714, M Bredel), State of Alabama Investment Pool for Action (IMPACT) funds (M Bredel). We thank Jugen Beck (University of Freiburg) for helping in preparing reagents, Maria Oberle (University of Freiburg) for help with mice brain histology, Dr Veerle Baekelandt (University of Leuven) for providing the PCHMWS- eGFP- IRES lentiviral vector, Dr Thomas Brabletz (University of Erlangen) for providing NF-<INF>k</INF>B luciferase vectors and Darren O hAilin (University of Freiburg) and Susanne Nozell (UAB) for editing the manuscript.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Angileri FF, 2008, CANCER-AM CANCER SOC, V112, P2258, DOI 10.1002/cncr.23407; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Camacho-Vanegas O, 2007, INT J CANCER, V121, P1390, DOI 10.1002/ijc.22809; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Date D, 2014, J BIOL CHEM, V289, P10318, DOI 10.1074/jbc.M113.526749; Difeo A, 2008, CANCER RES, V68, P965, DOI 10.1158/0008-5472.CAN-07-2604; Difeo A, 2009, CANCER RES, V69, P4733, DOI 10.1158/0008-5472.CAN-08-4282; Difeo A, 2009, DRUG RESIST UPDATE, V12, P1, DOI 10.1016/j.drup.2008.11.001; Dionyssiou MG, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044-5040-3-7; Eckhardt I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.457; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Ferrarese R, 2014, J CLIN INVEST, V124, P2861, DOI 10.1172/JCI68836; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Goldmann T, 2015, EMBO J, V34, P1612, DOI 10.15252/embj.201490791; Gurevich I, 2012, BBA-GENE REGUL MECH, V1819, P1, DOI 10.1016/j.bbagrm.2011.09.006; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hoeferlin L Alexis, 2011, Genes Cancer, V2, P889, DOI 10.1177/1947601911432495; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Jennewein C, 2012, ONCOGENE, V31, P1468, DOI 10.1038/onc.2011.333; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keung EZ, 2015, J CLIN INVEST, V125, P2965, DOI 10.1172/JCI77976; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koivisto PA, 2004, INT J CANCER, V111, P642, DOI 10.1002/ijc.20301; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lai TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073153; Lee DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057489; Lee YD, 2014, BMB REP, V47, P262, DOI 10.5483/BMBRep.2014.47.5.172; Masica DL, 2011, CANCER RES, V71, P4550, DOI 10.1158/0008-5472.CAN-11-0180; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Montanini L, 2004, INT J CANCER, V111, P640, DOI 10.1002/ijc.20303; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Narla G, 2008, J CLIN INVEST, V118, P2711, DOI 10.1172/JCI34780; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Osborne J, 2005, INT J CANCER, V116, P646, DOI 10.1002/ijc.21036; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rodriguez E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012639; Sadelain Michel, 2011, Nat Rev Cancer, V12, P51, DOI 10.1038/nrc3179; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Takemura M, 2002, J NEUROSCI, V22, P6972; Tracey L, 2005, J PATHOL, V206, P123, DOI 10.1002/path.1768; Tsunoda Keishi, 2005, Brain Tumor Pathol, V22, P79, DOI 10.1007/s10014-005-0186-1; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Watanabe A, 2006, J NEURO-ONCOL, V77, P25, DOI 10.1007/s11060-005-9010-3; Westhoff MA, 2013, MOL CANCER RES, V11, P1611, DOI 10.1158/1541-7786.MCR-13-0435-T; Yao YL, 2015, CNS NEUROSCI THER, V21, P40, DOI 10.1111/cns.12321; Zhang Y, 2014, J BIOL CHEM, V289, P12876, DOI 10.1074/jbc.M113.535831	61	24	24	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3562	3575		10.1038/onc.2016.507	http://dx.doi.org/10.1038/onc.2016.507			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166199	Green Published, hybrid			2022-12-28	WOS:000403878600006
J	Meng, Z; Ma, X; Du, J; Wang, X; He, M; Gu, Y; Zhang, J; Han, W; Fang, Z; Gan, X; Van Ness, C; Fu, X; Schones, DE; Xu, R; Huang, W				Meng, Z.; Ma, X.; Du, J.; Wang, X.; He, M.; Gu, Y.; Zhang, J.; Han, W.; Fang, Z.; Gan, X.; Van Ness, C.; Fu, X.; Schones, D. E.; Xu, R.; Huang, W.			CAMK2 gamma antagonizes mTORC1 activation during hepatocarcinogenesis	ONCOGENE			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE-II; NF-KAPPA-B; FARNESOID-X RECEPTOR; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; PEPTIDE ARRAYS; CHEMICAL HEPATOCARCINOGENESIS; SIGNAL INTEGRATION; CRITICAL REGULATOR	Hepatocellular carcinoma (HCC) is one of the most deadly cancers that still lacks effective treatments. Dysregulation of kinase signaling has frequently been reported to contribute to HCC. In this study, we used bioinformatic approaches to identify kinases that regulate gene expression changes in human HCCs and two murine HCC models. We identified a role for calcium/calmodulin-dependent protein kinases II gamma isoform (CAMK2 gamma) in hepatocarcinogenesis. CAMK2 gamma(-/-) mice displayed severely enhanced chemical-induced hepatocarcinogenesis compared with wild-type controls. Mechanistically, CAMK2 gamma deletion potentiates hepatic activation of mechanistic target of rapamycin complex 1 (mTORC1), which results in hyperproliferation of hepatocytes. Inhibition of mTORC1 by rapamycin effectively attenuates the compensatory proliferation of hepatocytes in CAMK2 gamma(-/-) livers. We further demonstrated that CAMK2 gamma suppressed growth factor-or insulin-induced mTORC1 activation by inhibiting IRS1/AKT signaling. Taken together, our results reveal a novel mechanism by which CAMK2 gamma antagonizes mTORC1 activation during hepatocarcinogenesis.	[Meng, Z.; Ma, X.; Du, J.; Wang, X.; Gu, Y.; Zhang, J.; Gan, X.; Van Ness, C.; Fu, X.; Schones, D. E.; Xu, R.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Complicat & Metab, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Ma, X.; Du, J.; Schones, D. E.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA; [He, M.] Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China; [Gu, Y.; Xu, R.] Zhejiang Univ, China Natl Minist Educ, Key Lab Canc Prevent & Intervent, Dept Hematol, Hangzhou, Zhejiang, Peoples R China; [Zhang, J.; Xu, R.] Zhejiang Univ, Canc Inst, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China; [Han, W.; Fang, Z.] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China; [Fu, X.] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Fu, X.] Sichuan Univ, Canc Ctr, Collaborat Innovat Ctr Biotherapy, West China Hosp,West China Med Sch, Chengdu, Sichuan, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Guangxi Medical University; Zhejiang University; Zhejiang University; Zhejiang University; Sichuan University; Sichuan University	Xu, R; Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Complicat & Metab, 1500 E Duarte Rd, Duarte, CA 91010 USA.	zrxyk10@zju.edu.cn; whuang@coh.org	Ma, Xiaoxiao/AFB-9086-2022	Ma, Xiaoxiao/0000-0001-8661-5660; Fang, Zhipeng/0000-0001-5720-1709; Fu, Xianghui/0000-0001-9808-3892	NCI [1R01-CA139158]; National Natural Science Foundation of China [81270601, 81328016]; NATIONAL CANCER INSTITUTE [R01CA139158, P30CA033572] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Johannes Backs for providing the Camk2 gamma KO mice. We also thank Dr Richard Ermel and the Animal Resource center for the technique support in animal experiments. Similarly, we thank Dr Yun Yen and Yafan Wang and the Translational Research Core for providing reagents. This work is supported in part by NCI 1R01-CA139158 and the National Natural Science Foundation of China (81270601 and 81328016).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Arsenault R, 2011, PROTEOMICS, V11, P4595, DOI 10.1002/pmic.201100296; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Azeloglu EU, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004621; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chen EY, 2012, BIOINFORMATICS, V28, P105, DOI 10.1093/bioinformatics/btr625; Chen WM, 2013, BIOINFORMATICS, V29, P2435, DOI 10.1093/bioinformatics/btt387; Cretich M, 2006, BIOMOL ENG, V23, P77, DOI 10.1016/j.bioeng.2006.02.001; De Minicis S, 2007, GASTROENTEROLOGY, V132, P1937, DOI 10.1053/j.gastro.2007.02.033; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Ella E, 2014, ONCOTARGET, V5, P10318, DOI 10.18632/oncotarget.2515; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Feng GS, 2012, CANCER CELL, V21, P150, DOI 10.1016/j.ccr.2012.01.001; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Goldman A, 2014, MOL CELL, V55, P422, DOI 10.1016/j.molcel.2014.05.012; Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hell JW, 2014, NEURON, V81, P249, DOI 10.1016/j.neuron.2013.12.024; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Huang WD, 2005, MOL ENDOCRINOL, V19, P1646, DOI 10.1210/me.2004-0520; Illario M, 2009, CELL SIGNAL, V21, P786, DOI 10.1016/j.cellsig.2009.01.022; Ishiguro K, 2006, MOL CELL BIOL, V26, P5497, DOI 10.1128/MCB.02469-05; Kenerson HL, 2013, GASTROENTEROLOGY, V144, P1055, DOI 10.1053/j.gastro.2013.01.053; Kim I, 2007, CARCINOGENESIS, V28, P940, DOI 10.1093/carcin/bgl249; Kim MS, 2016, PROTEOMICS, V16, P700, DOI 10.1002/pmic.201500355; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lachmann A, 2009, BIOINFORMATICS, V25, P684, DOI 10.1093/bioinformatics/btp026; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Liu NA, 2012, MOL ENDOCRINOL, V26, P775, DOI 10.1210/me.2011-1383; Liu Y, 2014, COMPUT STRUCT BIOTEC, V10, P90, DOI 10.1016/j.csbj.2014.07.003; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314; Meng ZP, 2012, J HEPATOL, V57, P1004, DOI 10.1016/j.jhep.2012.06.016; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Ozcan L, 2013, CELL METAB, V18, P803, DOI 10.1016/j.cmet.2013.10.011; Ozcan L, 2012, CELL METAB, V15, P739, DOI 10.1016/j.cmet.2012.03.002; Papa S, 2008, J CLIN INVEST, V118, P1911, DOI 10.1172/JCI33913; Patsenker E, 2011, J HEPATOL, V55, P388, DOI 10.1016/j.jhep.2010.10.044; Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Rabinowitz KM, 2013, GASTROENTEROLOGY, V144, P601, DOI 10.1053/j.gastro.2012.12.001; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7; Rexer BN, 2011, ONCOGENE, V30, P4163, DOI 10.1038/onc.2011.130; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Satow R, 2010, CLIN CANCER RES, V16, P2518, DOI 10.1158/1078-0432.CCR-09-2214; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222; Swaminathan PD, 2011, J CLIN INVEST, V121, P3277, DOI 10.1172/JCI57833; Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196; Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857; Vasudevan HN, 2014, DEV CELL, V31, P332, DOI 10.1016/j.devcel.2014.10.005; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhang ZJ, 2012, J CLIN ENDOCR METAB, V97, P2347, DOI 10.1210/jc.2012-1267; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	77	12	12	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2446	2456		10.1038/onc.2016.400	http://dx.doi.org/10.1038/onc.2016.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819676	Green Accepted			2022-12-28	WOS:000400268900010
J	Hiken, JF; McDonald, JI; Decker, KF; Sanchez, C; Hoog, J; VanderKraats, ND; Jung, KL; Akinhanmi, M; Rois, LE; Ellis, MJ; Edwards, JR				Hiken, J. F.; McDonald, J. I.; Decker, K. F.; Sanchez, C.; Hoog, J.; VanderKraats, N. D.; Jung, K. L.; Akinhanmi, M.; Rois, L. E.; Ellis, M. J.; Edwards, J. R.			Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITION; HUMAN ESTROGEN-RECEPTOR; DNA METHYLATION; GENE-EXPRESSION; PROTEIN-KINASE; SYNERGISTIC ACTIVATION; AROMATASE INHIBITORS; CELLS; ALPHA; PHOSPHORYLATION	Approximately 75% of breast cancers express estrogen receptor a (ER alpha) and depend on estrogen signals for continued growth. Aromatase inhibitors (AIs) prevent estrogen production and inhibit ER signaling, resulting in decreased cancer recurrence and mortality. Advanced tumors treated with AIs almost always develop resistance to these drugs via the upregulation of alternative growth signals. The mechanisms that drive this resistance-especially epigenetic events that alter gene expression-are, however, not well understood. Genome-wide DNA methylation and expression analysis of cell line models of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated after demethylation in resistant cells. Knockdown and inhibitor studies demonstrate that PTGER4 is essential for estrogen-independent growth. Our exploratory analysis of downstream signaling indicates that PTGER4 likely promotes AI resistance via ligand-independent activation of the ER alpha-cofactor CARM1. We believe that we have discovered a novel epigenetic mechanism for altering cell signaling and acquiring endocrine therapy resistance. Our findings indicate that PTGER4 is a potential drug target in AI-resistant cancers. In addition, the epigenetic component of PTGER4 regulation suggests that further study of PTGER4 may yield valuable insights into how DNA methylation-targeted diagnoses and treatments can improve AI-resistant breast cancer treatment.	[Hiken, J. F.; McDonald, J. I.; Decker, K. F.; VanderKraats, N. D.; Jung, K. L.; Akinhanmi, M.; Rois, L. E.; Edwards, J. R.] Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA; [Sanchez, C.] Pontificia Univ Catolica Chile, Haematol Oncol, Dept Canc Programme, Sch Med, Santiago, Chile; [Hoog, J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Ellis, M. J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	Washington University (WUSTL); Pontificia Universidad Catolica de Chile; Washington University (WUSTL); Baylor College of Medicine	Edwards, JR (corresponding author), Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA.	jedwards@dom.wustl.edu		Jung, Kyle/0000-0002-6694-4333	NIH [R00 CA127360, R21 LM011199, 2T32GM007067-37, P30 CA91842, UL1 TR000448]; Department of Defense [W81XWH-11-1-0401]; Siteman Cancer Center Breast Cancer Program career development award; NATIONAL CANCER INSTITUTE [R00CA127360, P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108811] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R21LM011199] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Siteman Cancer Center Breast Cancer Program career development award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank C de Guzman-Strong and S Matkovich for their comments on the manuscript. This work was supported by grants NIH R00 CA127360, NIH R21 LM011199, NIH 2T32GM007067-37, Department of Defense W81XWH-11-1-0401 and a Siteman Cancer Center Breast Cancer Program career development award to JRE. We also thank the Genome Technology Access Center at the Washington University School of Medicine for help with genomic analysis (partially supported by NIH P30 CA91842 and NIH UL1 TR000448).	Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109; Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; FERGUSON AT, 1995, CANCER RES, V55, P2279; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737; Kim JH, 2012, MOL CELLS, V33, P127, DOI 10.1007/s10059-012-2182-8; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Ma XR, 2006, CANCER RES, V66, P2923, DOI 10.1158/0008-5472.CAN-05-4348; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Olson JA, 2009, J AM COLL SURGEONS, V208, P906, DOI 10.1016/j.jamcollsurg.2009.01.035; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458; Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833; Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474; VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195; Zhang QX, 1997, CANCER RES, V57, P1244; Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5; Zilli M, 2009, BBA-REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003	55	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2319	2327		10.1038/onc.2016.397	http://dx.doi.org/10.1038/onc.2016.397			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27869171	Green Accepted, Green Submitted			2022-12-28	WOS:000399782700012
J	Huang, PH; Lu, PJ; Ding, LY; Chu, PC; Hsu, WY; Chen, CS; Tsao, CC; Chen, BH; Lee, CT; Shan, YS; Chen, CS				Huang, P-H; Lu, P-J; Ding, L-Y; Chu, P-C; Hsu, W-Y; Chen, C-S; Tsao, C-C; Chen, B-H; Lee, C-T; Shan, Y-S; Chen, C-S			TGF beta promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE ACTIVITY; GROWTH-FACTOR-BETA; TUMOR-MICROENVIRONMENT; PROTOONCOGENE PRODUCT; PROSTATE-CANCER; LUNG-CANCER; EXPRESSION; METHYLATION; PROTEIN; ADENOCARCINOMA	The highly homeostasis-resistant nature of cancer cells leads to their escape from treatment and to liver metastasis, which in turn makes pancreatic ductal adenocarcinoma (PDAC) difficult to treat, especially the squamous/epithelial-to-mesenchymal transition (EMT)-like subtype. As the molecular mechanisms underlying tumour heterogeneity remain elusive, we investigated whether epigenetic regulation might explain inter-individual differences in the progression of specific subtypes. DNA methylation profiling performed on cancer tissues prior to chemo/radiotherapy identified one hypermethylated CpG site (CpG6882469) in the VAV1 gene body that was correlated with demethylation of two promoter CpGs (CpG6772370/CpG6772811) in both PDAC and peripheral blood. Transforming growth factor beta treatment induced gene-body hypermethylation, dissociation of DNMT1 from the promoter, and VAV1 expression via SMAD4 and mutant Kras(G12D). Pharmacological inhibition of TGF beta-VAV1 signalling decreased the squamous/EMT-like cancer cells, promoted nuclear VAV1 localization, and enhanced the efficacy of gemcitabine in prolonging the survival of (KPC)-C-fl/fl mice. Together, the three VAV1 CpGs serve as biomarkers for prognosis and early detection, and the TGF beta-VAV1 axis represents a therapeutic target.	[Huang, P-H; Ding, L-Y; Hsu, W-Y; Chen, C-S; Chen, B-H] Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med, Tainan, Taiwan; [Huang, P-H; Lu, P-J; Ding, L-Y; Chu, P-C; Chen, C-S; Shan, Y-S; Chen, C-S] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Lu, P-J; Tsao, C-C; Shan, Y-S] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 1 Univ Rd, Tainan 701, Taiwan; [Chu, P-C; Chen, C-S] Acad Sinica, Inst Biol Chem, 128,Acad Rd Sect 2, Taipei 115, Taiwan; [Lee, C-T] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan, Taiwan; [Shan, Y-S] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan; [Chen, C-S] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500 W 12Th Ave, Columbus, OH 43210 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; University System of Ohio; Ohio State University	Shan, YS (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.; Chen, CS (corresponding author), Acad Sinica, Inst Biol Chem, 128,Acad Rd Sect 2, Taipei 115, Taiwan.	ysshan@mail.ncku.edu.tw; chencs@gate.sinica.edu.tw			Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University; Ministry of Science and Technology, Taiwan [MOST102-2320-B-006-050, MOST104-2320-B-006-028-]; Ministry of Health and Welfare, Taiwan [MOHW104-TDU-B-211-124-003]; Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan [MOST 105-2321-B-001-064]	Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Health and Welfare, Taiwan; Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan	The authors acknowledge the assistance of Yi-Chen Chen, Pei-Rong Gu, and Hui-Ling Tung, as well as assistance from the following core facilities: the Clinical Medicine Research Center of National Cheng Kung University Hospital, the Animal Center of National Cheng Kung University, and the National Center for Genome Medicine (technical/bioinformatics). The authors would like to thank Drs Yi-Chuang Liao and Po-Min Chiang for pathological consultations and Dr Cindy Lee for manuscript editing. This work is supported by the Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University to PJL and CSC; and grants MOST102-2320-B-006-050 and MOST104-2320-B-006-028- from the Ministry of Science and Technology, Taiwan, to PHH; MOHW104-TDU-B-211-124-003 from the Ministry of Health and Welfare, Taiwan, to YSS; and MOST 105-2321-B-001-064 from the Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan, to CSC.	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Bai LY, 2013, BIOCHEM PHARMACOL, V86, P1430, DOI 10.1016/j.bcp.2013.09.002; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bertagnolo V, 2005, EXP CELL RES, V306, P56, DOI 10.1016/j.yexcr.2004.12.001; Brugnoli F, 2010, EXP CELL RES, V316, P38, DOI 10.1016/j.yexcr.2009.09.004; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dong ZJ, 2012, IMMUNITY, V36, P974, DOI 10.1016/j.immuni.2012.03.023; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Gaspar NJ, 2007, MOL PHARMACOL, V72, P152, DOI 10.1124/mol.106.029025; Gore AJ, 2014, J CLIN INVEST, V124, P338, DOI 10.1172/JCI71526; Grassilli S, 2014, ONCOTARGET, V5, P4320, DOI 10.18632/oncotarget.2011; Grimmer MR, 2014, EPIGENOMICS-UK, V6, P493, DOI [10.2217/EPI.14.30, 10.2217/epi.14.30]; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hou YC, 2014, CANCER-AM CANCER SOC, V120, P2766, DOI 10.1002/cncr.28774; Houlard M, 2005, ONCOGENE, V24, P28, DOI 10.1038/sj.onc.1208043; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Huang PH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003816; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Katzav S, 2015, ONCOTARGET, V6, P28731, DOI 10.18632/oncotarget.5086; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Ksionda O, 2012, J CELL SCI, V125, P5302, DOI 10.1242/jcs.105148; Li RM, 2009, CANCER BIOL THER, V8, P1402, DOI 10.4161/cbt.8.14.8882; Lindsey JC, 2015, ONCOGENE, V34, P4746, DOI 10.1038/onc.2014.405; Garcia JL, 2012, J NEURO-ONCOL, V110, P69, DOI 10.1007/s11060-012-0936-y; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Miletic AV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006599; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nolz JC, 2005, TRENDS CELL BIOL, V15, P514, DOI 10.1016/j.tcb.2005.08.003; Ostapoff KT, 2014, CANCER RES, V74, P4996, DOI 10.1158/0008-5472.CAN-13-1807; Qi Y, 2015, AM J CANCER RES, V5, P2491; Razanadrakoto L, 2015, ONCOTARGET, V6, P2524, DOI 10.18632/oncotarget.2629; Razidlo GL, 2015, CANCER RES, V75, P2907, DOI 10.1158/0008-5472.CAN-14-3103; Razidlo GL, 2013, DEV CELL, V24, P573, DOI 10.1016/j.devcel.2013.02.010; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Saveliev A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000420; Sebban S, 2014, ONCOTARGET, V5, P9214, DOI 10.18632/oncotarget.2400; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vidakovic AT, 2015, CELL REP, V13, P2480, DOI 10.1016/j.celrep.2015.11.040; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028	51	20	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2202	2214		10.1038/onc.2016.378	http://dx.doi.org/10.1038/onc.2016.378			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27893715				2022-12-28	WOS:000399782700002
J	Sizemore, GM; Balakrishnan, S; Hammer, AM; Thies, KA; Trimboli, AJ; Wallace, JA; Sizemore, ST; Kladney, RD; Woelke, SA; Yu, L; Fernandez, SA; Chakravarti, A; Leone, G; Ostrowski, MC				Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Yu, L.; Fernandez, S. A.; Chakravarti, A.; Leone, G.; Ostrowski, M. C.			Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; BREAST-CANCER; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; GENE-EXPRESSION; TRANSGENIC MICE; THY NEIGHBOR; SELF-RENEWAL; NICHE; TUMORIGENESIS	Fibroblasts within the mammary tumor microenvironment are active participants in carcinogenesis mediating both tumor initiation and progression. Our group has previously demonstrated that genetic loss of phosphatase and tensin homolog (PTEN) in mammary fibroblasts induces an oncogenic secretome that remodels the extracellular milieu accelerating ErbB2-driven mammary tumor progression. While these prior studies highlighted a tumor suppressive role for stromal PTEN, how the adjacent normal epithelium transforms in response to PTEN loss was not previously addressed. To identify these early events, we have evaluated both phenotypic and genetic changes within the pre-neoplastic mammary epithelium of mice with and without stromal PTEN expression. We report that fibroblast-specific PTEN deletion greatly restricts mammary ductal elongation and induces aberrant alveolar side-branching. These mice concomitantly exhibit an expansion of the mammary epithelial stem cell (MaSC) enriched basal/myoepithelial population and an increase in in vitro stem cell activity. Further analysis revealed that NOTCH signaling, specifically through NOTCH3, is diminished in these cells. Mechanistically, JAGGED-1, a transmembrane ligand for the NOTCH receptor, is downregulated in the PTEN-null fibroblasts leading to a loss in the paracrine activation of NOTCH signaling from the surrounding stroma. Reintroduction of JAGGED-1 expression within the PTEN-null fibroblasts was sufficient to abrogate the observed increase in colony forming activity implying a direct role for stromal JAGGED-1 in regulation of MaSC properties. Importantly, breast cancer patients whose tumors express both low stromal JAG1 and low stromal PTEN exhibit a shorter time to recurrence than those whose tumors express low levels of either alone suggesting similar stromal signaling in advanced disease. Combined, these results unveil a novel stromal PTEN-to-JAGGED-1 axis in maintaining the MaSC niche, and subsequently inhibiting breast cancer initiation and disease progression.	[Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Kladney, R. D.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Sizemore, S. T.; Chakravarti, A.] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA; [Yu, L.; Fernandez, S. A.] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Sizemore, GM; Ostrowski, MC (corresponding author), Ohio State Univ, Dept Canc Biol & Genet, Comprehens Canc, 570A Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	gina.sizemore@osumc.edu; michael.ostrowski@osumc.edu	Sizemore, Gina/ABI-7542-2020; yu, lianbo/B-3472-2010; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NIH [PO1CA097189]; Department of Defense [W81XWH-14-1-0040]; Pelotonia Fellowship Program; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Pelotonia Fellowship Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jason Bice and Daphne Bryant (Solid Tumor Biology Program-Histology Core), Bryan McElwain and Katrina Miller (OSUCCC-Analytic Cytometry) and Sarah Warner (OSUCCC-Genomics) for technical support. This study was supported by the NIH (PO1CA097189, MCO and GL), the Department of Defense (W81XWH-14-1-0040, GMS) and the Pelotonia Fellowship Program (SB and GMS).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Boquest AC, 2005, MOL BIOL CELL, V16, P1131, DOI 10.1091/mbc.E04-10-0949; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Ghiabi P, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0386-3; Ghiabi P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112424; Ha HY, 2001, CANCER RES, V61, P984; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kessenbrock K, 2015, MATRIX BIOL, V44-46, P184, DOI 10.1016/j.matbio.2015.01.022; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Liu JC, 2012, P NATL ACAD SCI USA, V109, P5832, DOI 10.1073/pnas.1201105109; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Parsonage G, 2005, TRENDS IMMUNOL, V26, P150, DOI 10.1016/j.it.2004.11.014; Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244; Qiu M, 2013, CANCER LETT, V328, P261, DOI 10.1016/j.canlet.2012.09.023; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Robinson GW, 2008, CELL STEM CELL, V3, P359, DOI 10.1016/j.stem.2008.09.014; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Xing F, 2013, EMBO MOL MED, V5, P384, DOI 10.1002/emmm.201201623; Xu KL, 2012, CANCER CELL, V21, P626, DOI 10.1016/j.ccr.2012.03.041; Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299	58	20	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2297	2308		10.1038/onc.2016.383	http://dx.doi.org/10.1038/onc.2016.383			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27797378	Green Accepted			2022-12-28	WOS:000399782700010
J	Yang, C; Li, Z; Bhatt, T; Dickler, M; Giri, D; Scaltriti, M; Baselga, J; Rosen, N; Chandarlapaty, S				Yang, C.; Li, Z.; Bhatt, T.; Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.			Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence	ONCOGENE			English	Article							KINASE 4/6 INHIBITOR; ESTROGEN-RECEPTOR; CELL-CYCLE; ENDOCRINE THERAPY; PD 0332991; OVEREXPRESSION; D1; DIFFERENTIATION; TRANSCRIPTION; PALBOCICLIB	Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas. ATP-competitive inhibitors against this complex have been recently advanced in the clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). However, resistance to these compounds has begun to emerge often months to years after their initiation. We investigated potential mechanisms of resistance using cell line models that are highly sensitive to this class of drugs. After prolonged exposure to the selective and potent CDK4/6 inhibitor LY2835219, clones emerged and several were found to harbor amplification of the CDK6 kinase. Amplification of CDK6 resulted in a marked increase in CDK6 expression and reduced response of the CDK4/6 target, phospho-Rb (pRb), to CDK4/6 inhibitors. Knockdown of CDK6 restored drug sensitivity, while enforced overexpression of CDK6 was sufficient to mediate drug resistance. Not only did CDK6 overexpression mediate resistance to CDK4/6 inhibitors but it also led to reduced expression of the ER and progesterone receptor (PR), and diminished responsiveness to ER antagonism. The reduced ER/PR expression after CDK4/6 inhibitor resistance was additionally observed in tumor biopsy specimens from patients treated with these drugs. Alternative mechanisms of resistance to CDK4/6 inhibitors such as loss of pRb and cyclin E1 overexpression also exhibited decreased hormone responsiveness, suggesting that the clinical paradigm of sequential endocrine-based therapy may be ineffective in some settings of acquired CDK4/6 resistance.	[Yang, C.; Li, Z.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China; [Yang, C.; Li, Z.; Bhatt, T.; Baselga, J.; Chandarlapaty, S.] MSKCC, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA; [Dickler, M.; Baselga, J.; Chandarlapaty, S.] MSKCC, Dept Med, Breast Med Serv, New York, NY 10065 USA; [Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.] Weill Cornell Med Coll, New York, NY USA; [Giri, D.; Scaltriti, M.] MSKCC, Dept Pathol, New York, NY 10065 USA; [Rosen, N.] MSKCC, Mol Pharmacol Program, New York, NY 10065 USA	Xi'an Jiaotong University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chandarlapaty, S (corresponding author), MSKCC, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA.	chandars@mskcc.org	Yang, Chengcheng/AAU-1342-2021; Rosen, Neal/ABF-2677-2020		Shen Family Foundation; Susan G Komen; Breast Cancer Research Foundation; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA094060] Funding Source: NIH RePORTER	Shen Family Foundation; Susan G Komen(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NCI Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was generously supported by funds from the Shen Family Foundation, Susan G Komen and the Breast Cancer Research Foundation. The Marie-Jose and Henry R Kravis Center for Molecular Oncology as well as NCI Cancer Center Support Grant (CCSG, P30 CA08748) additionally supported this work. We thank Weiyi Toy for her critical feedback.	Alves CL, 2016, CLIN CANC RES; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; CC O'Sullivan, 2015, INT J CANC CLIN RES, V2, pii; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, CELL CYCLE, V11, P2756, DOI 10.4161/cc.21195; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Infante JR, 2014, ASCO ANN M P; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; KARNIK PS, 1994, CANCER RES, V54, P349; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Navarro F, 2009, BLOOD, V114, P2181, DOI 10.1182/blood-2009-02-205062; Patnaik A, 2014, ASCO ANN M P; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tigan AS, 2016, ONCOGENE, V35, P3083, DOI 10.1038/onc.2015.407; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Umemura S, 2009, BRIT J CANCER, V100, P764, DOI 10.1038/sj.bjc.6604900; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	38	187	193	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2255	2264		10.1038/onc.2016.379	http://dx.doi.org/10.1038/onc.2016.379			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748766	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000399782700006
J	Peng, DH; Ungewiss, C; Tong, P; Byers, LA; Wang, J; Canales, JR; Villalobos, PA; Uraoka, N; Mino, B; Behrens, C; Wistuba, II; Han, RI; Wanna, CA; Fahrenholtz, M; Grande-Allen, KJ; Creighton, CJ; Gibbons, DL				Peng, D. H.; Ungewiss, C.; Tong, P.; Byers, L. A.; Wang, J.; Canales, J. R.; Villalobos, P. A.; Uraoka, N.; Mino, B.; Behrens, C.; Wistuba, I. I.; Han, R. I.; Wanna, C. A.; Fahrenholtz, M.; Grande-Allen, K. J.; Creighton, C. J.; Gibbons, D. L.			ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LYSYL OXIDASE; THERAPEUTIC TARGET; MIR-200 FAMILY; SECRETED LOXL2; EXPRESSION; EMT; ADENOCARCINOMA; ENZYME; CELLS	Lung cancer is the leading cause of cancer-related deaths, primarily due to distant metastatic disease. Metastatic lung cancer cells can undergo an epithelial-to-mesenchymal transition (EMT) regulated by various transcription factors, including a double-negative feedback loop between the microRNA-200 (miR-200) family and ZEB1, but the precise mechanisms by which ZEB1-dependent EMT promotes malignancy remain largely undefined. Although the cell-intrinsic effects of EMT are important for tumor progression, the reciprocal dynamic crosstalk between mesenchymal cancer cells and the extracellular matrix (ECM) is equally critical in regulating invasion and metastasis. Investigating the collaborative effect of EMT and ECM in the metastatic process reveals increased collagen deposition in metastatic tumor tissues as a direct consequence of amplified collagen gene expression in ZEB1-activated mesenchymal lung cancer cells. In addition, collagen fibers in metastatic lung tumors exhibit greater linearity and organization as a result of collagen crosslinking by the lysyl oxidase (LOX) family of enzymes. Expression of the LOX and LOXL2 isoforms is directly regulated by miR-200 and ZEB1, respectively, and their upregulation in metastatic tumors and mesenchymal cell lines is coordinated to that of collagen. Functionally, LOXL2, as opposed to LOX, is the principal isoform that crosslinks and stabilizes insoluble collagen deposition in tumor tissues. In turn, focal adhesion formation and FAK/SRC signaling is activated in mesenchymal tumor cells by crosslinked collagen in the ECM. Our study is the first to validate direct regulation of LOX and LOXL2 by the miR-200/ZEB1 axis, defines a novel mechanism driving tumor metastasis, delineates collagen as a prognostic marker, and identifies LOXL2 as a potential therapeutic target against tumor progression.	[Peng, D. H.; Ungewiss, C.; Byers, L. A.; Behrens, C.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA; [Peng, D. H.; Ungewiss, C.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Tong, P.; Wang, J.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Canales, J. R.; Villalobos, P. A.; Uraoka, N.; Mino, B.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Han, R. I.; Wanna, C. A.; Fahrenholtz, M.; Grande-Allen, K. J.] Rice Univ, Dept Bioengn, Houston, TX USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Rice University; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.	dlgibbon@mdanderson.org	Villalobos, Pamela/AAM-2677-2021	Fahrenholtz, Monica/0000-0003-4112-8230; Han, Richard I/0000-0002-8332-622X; Peng, David/0000-0003-0511-1888	NCI [K08 CA151661, RP120713 C2 and NCI grant CA125123]; MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer [RP120713 P2]; CPRIT [RP120713 P2, RP120713 C2]; CPRIT Graduate Scholar Training Grant [RP140106]; Lung SPORE [P50 CA070907]; Cancer Center Support Grant [CCSG CA016672]; Mary K Chapman Foundation; Jeane F Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE [K08CA151651, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CPRIT; CPRIT Graduate Scholar Training Grant; Lung SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Mary K Chapman Foundation; Jeane F Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr G Goodall (University of Adelaide, Australia) for the kind gift of the pTRIPz-miR-200 expression constructs. We thank Dr M Dickinson (Baylor College of Medicine, Houston, TX, USA) for providing access to the multiphoton microscope for SHG analysis. We would like to thank members of the Gibbons lab for their assistance and critical reading of the manuscript. This work was supported by NCI K08 CA151661 (DLG), an MD Anderson Cancer Center Physician Scientist Award (DLG), Rexanna's Foundation for Fighting Lung Cancer (DLG) and CPRIT grant RP120713 P2 (DLG and JG-A). DP was supported by a CPRIT Graduate Scholar Training Grant (RP140106). JW and PT are supported by Lung SPORE (P50 CA070907), Cancer Center Support Grant (CCSG CA016672) and Mary K Chapman Foundation. CJC was supported by CPRIT grant RP120713 C2 and NCI grant CA125123. LAB and DLG are R Lee Clark Fellows of the University of Texas MD Anderson Cancer Center, supported by the Jeane F Shelby Scholarship Fund.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Alderton GK, 2013, NAT REV CANCER, V13, P3, DOI 10.1038/nrc3428; Baker AM, 2011, JNCI-J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569; Barker HE, 2013, MOL CANCER RES, V11, P1425, DOI 10.1158/1541-7786.MCR-13-0033-T; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Canesin G, 2015, ONCOGENE, V34, P951, DOI 10.1038/onc.2014.23; CHAUDHURI BB, 1993, PATTERN RECOGN LETT, V14, P147, DOI 10.1016/0167-8655(93)90088-U; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Gill BJ, 2012, CANCER RES, V72, P6013, DOI 10.1158/0008-5472.CAN-12-0895; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hollosi P, 2009, INT J CANCER, V125, P318, DOI 10.1002/ijc.24308; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Leight JL, 2012, MOL BIOL CELL, V23, P781, DOI 10.1091/mbc.E11-06-0537; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lucero HA, 2006, CELL MOL LIFE SCI, V63, P2304, DOI 10.1007/s00018-006-6149-9; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peng L, 2009, CARCINOGENESIS, V30, P1660, DOI 10.1093/carcin/bgp178; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Rossi MA, 1998, CIRCULATION, V97, P934, DOI 10.1161/01.CIR.97.9.934; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Shintani Y, 2008, AM J RESP CELL MOL, V38, P95, DOI 10.1165/rcmb.2007-0071OC; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Ungewiss C, 2016, SCI REP-UK, V6, DOI 10.1038/srep18652; Vadasz Z, 2005, J HEPATOL, V43, P499, DOI 10.1016/j.jhep.2005.02.052; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xiao Dakai, 2010, J Thorac Dis, V2, P154, DOI 10.3978/j.issn.2072-1439.2010.02.03.7; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YA, 2014, J CLIN INVEST, V124, P2696, DOI 10.1172/JCI72171; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Zhan P, 2012, MED ONCOL, V29, P648, DOI 10.1007/s12032-011-9959-z	58	115	119	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1925	1938		10.1038/onc.2016.358	http://dx.doi.org/10.1038/onc.2016.358			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694892	Green Accepted			2022-12-28	WOS:000398898500004
J	Bernardini, JP; Lazarou, M; Dewson, G				Bernardini, J. P.; Lazarou, M.; Dewson, G.			Parkin and mitophagy in cancer	ONCOGENE			English	Review							RECESSIVE JUVENILE PARKINSONISM; MITOCHONDRIAL COMPLEX-I; TUMOR-SUPPRESSOR GENE; EARLY-ONSET PARKINSONISM; HUMAN-MELANOMA CELLS; BCL-X-L; BREAST-CANCER; OXIDATIVE STRESS; OVARIAN-CANCER; PINK1-DEPENDENT PHOSPHORYLATION	Mitophagy, the selective engulfment and clearance of mitochondria, is essential for the homeostasis of a healthy network of functioning mitochondria and prevents excessive production of cytotoxic reactive oxygen species from damaged mitochondria. The mitochondrially targeted PTEN-induced kinase-1 ( PINK1) and the E3 ubiquitin ligase Parkin are well-established synergistic mediators of the mitophagy of dysfunctional mitochondria. This pathway relies on the ubiquitination of a number of mitochondrial outer membrane substrates and subsequent docking of autophagy receptor proteins to selectively clear mitochondria. There are also alternate Parkin-independent mitophagy pathways mediated by BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 and Nip-3 like protein X as well as other effectors. There is increasing evidence that ablation of mitophagy accelerates a number of pathologies. Familial Parkinsonism is associated with loss-of-function mutations in PINK1 and Parkin. A growing number of studies have observed a correlation between impaired Parkin activity and enhanced cancer development, leading to the emerging concept that Parkin activity, or mitophagy in general, is a tumour suppression mechanism. This review examines the molecular mechanisms of mitophagy and highlights the potential links between Parkin and the hallmarks of cancer that may influence tumour development and progression.	[Bernardini, J. P.; Dewson, G.] Walter & Eliza Hall Inst Med Res, Cell Signaling & Cell Death Div, Melbourne, Vic, Australia; [Bernardini, J. P.; Dewson, G.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Lazarou, M.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic, Australia	University of Melbourne; Monash University	Dewson, G (corresponding author), Walter & Eliza Hall Inst Med Res, Cell Signalling & Cell Death Div, 1G Royal Parade, Melbourne, Vic 3052, Australia.	dewson@wehi.edu.au	Datta, Sayantan/D-1369-2010; dewson, grant/C-7646-2013; 高, 雨莉/HGU-8187-2022	dewson, grant/0000-0003-4251-8898; Lazarou, Michael/0000-0003-2150-5545; Bernardini, Jonathan/0000-0002-5767-7624	Australian Research Council Future Fellowship [FT100100791]; Victorian State Government; Australian Government NHMRC IRIISS	Australian Research Council Future Fellowship(Australian Research Council); Victorian State Government; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia)	The authors acknowledge Paul Ekert and Jamie Fletcher for advice and discussions in the preparation of the manuscript. GD is supported by an Australian Research Council Future Fellowship (#FT100100791). Supported through operational infrastructure grants through the Victorian State Government Operational Infrastructure Support and the Australian Government NHMRC IRIISS.	Alvero AB, 2011, MOL CANCER THER, V10, P1385, DOI 10.1158/1535-7163.MCT-11-0023; Balliet RM, 2011, CELL CYCLE, V10, P4065, DOI 10.4161/cc.10.23.18254; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bento CF, 2015, DNA CELL BIOL, V34, P228, DOI 10.1089/dna.2014.2745; Bingol B, 2014, NATURE, V510, P370, DOI 10.1038/nature13418; Birsa N, 2014, J BIOL CHEM, V289, P14569, DOI 10.1074/jbc.M114.563031; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carroll RG, 2014, CELL REP, V9, P1538, DOI 10.1016/j.celrep.2014.10.046; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Charan RA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.278; Chen D, 2010, J BIOL CHEM, V285, P38214, DOI 10.1074/jbc.M110.101469; Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034; Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031; Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908; Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; CLEETER MWJ, 1992, J NEUROCHEM, V58, P786, DOI 10.1111/j.1471-4159.1992.tb09789.x; Cornelissen T, 2014, HUM MOL GENET, V23, P5227, DOI 10.1093/hmg/ddu244; Courjal F, 1996, INT J CANCER, V69, P247; Cunningham CN, 2015, NAT CELL BIOL, V17, P160, DOI 10.1038/ncb3097; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Dasgupta S, 2012, J CELL PHYSIOL, V227, P2451, DOI 10.1002/jcp.22980; Deas E, 2011, HUM MOL GENET, V20, P867, DOI 10.1093/hmg/ddq526; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115; Durcan TM, 2014, EMBO J, V33, P2473, DOI 10.15252/embj.201489729; Foroud T, 2003, NEUROLOGY, V60, P796, DOI 10.1212/01.WNL.0000049470.00180.07; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Fu M, 2013, MOL BIOL CELL, V24, P1153, DOI 10.1091/mbc.E12-08-0607; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; GILLETT C, 1994, CANCER RES, V54, P1812; Gong GH, 2015, SCIENCE, V350, DOI 10.1126/science.aad2459; Gong YX, 2014, NAT GENET, V46, P588, DOI 10.1038/ng.2981; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Hatano Y, 2004, NEUROLOGY, V63, P1482, DOI 10.1212/01.WNL.0000142258.29304.FE; Hatano Y, 2004, ANN NEUROL, V56, P424, DOI 10.1002/ana.20251; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2006, ARCH NEUROL-CHICAGO, V63, P833, DOI 10.1001/archneur.63.6.833; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Heo JM, 2015, MOL CELL, V60, P7, DOI 10.1016/j.molcel.2015.08.016; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001; Hristova VA, 2009, J BIOL CHEM, V284, P14978, DOI 10.1074/jbc.M808700200; Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340; Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Inzelberg R, 2007, NEUROLOGY, V69, P1542, DOI 10.1212/01.wnl.0000277638.63767.b8; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Jin SM, 2013, AUTOPHAGY, V9, P1750, DOI 10.4161/auto.26122; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Johnson BN, 2012, P NATL ACAD SCI USA, V109, P6283, DOI 10.1073/pnas.1113248109; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; Kandala PK, 2012, ONCOTARGET, V3, P435; Kane LA, 2014, J CELL BIOL, V205, P143, DOI 10.1083/jcb.201402104; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Kay DM, 2010, NEUROLOGY, V75, P1189, DOI 10.1212/WNL.0b013e3181f4d832; Kazlauskaite A, 2015, EMBO REP, V16, P939, DOI 10.15252/embr.201540352; Kazlauskaite A, 2014, BIOCHEM J, V460, P127, DOI 10.1042/BJ20140334; Kim KY, 2011, J CLIN INVEST, V121, P3701, DOI 10.1172/JCI44736; Kim SY, 2012, CLIN GENET, V82, P77, DOI 10.1111/j.1399-0004.2011.01693.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kondapalli C, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120080; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392; Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; Landes T, 2010, EMBO REP, V11, P459, DOI 10.1038/embor.2010.50; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893; Lazarou M, 2015, IMMUNOL CELL BIOL, V93, P3, DOI 10.1038/icb.2014.75; Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014; Lee KS, 2013, GENE DEV, V27, P2642, DOI 10.1101/gad.225169.113; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; Liang JR, 2015, EMBO REP, V16, P618, DOI 10.15252/embr.201439820; Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200; Lu W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147792; Lu W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5930; Lucking CB, 1998, LANCET, V352, P1355, DOI 10.1016/S0140-6736(05)60746-5; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Maes H, 2014, MITOCHONDRION, V19, P58, DOI 10.1016/j.mito.2014.07.003; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P4152, DOI 10.4161/cc.22226; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Meissner C, 2011, J NEUROCHEM, V117, P856, DOI 10.1111/j.1471-4159.2011.07253.x; MOLLER H, 1995, BRIT MED J, V310, P1500, DOI 10.1136/bmj.310.6993.1500; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Morris LGT, 2010, ONCOGENE, V29, P3453, DOI 10.1038/onc.2010.127; Mulholland PJ, 2006, CELL CYCLE, V5, P783, DOI 10.4161/cc.5.7.2631; Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Okatsu K, 2013, J BIOL CHEM, V288, P36372, DOI 10.1074/jbc.M113.509653; Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x; Olsen JH, 2005, BRIT J CANCER, V92, P201, DOI 10.1038/sj.bjc.6602279; Ordureau A, 2015, P NATL ACAD SCI USA, V112, P6637, DOI 10.1073/pnas.1506593112; Ordureau A, 2014, MOL CELL, V56, P360, DOI 10.1016/j.molcel.2014.09.007; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Otera H, 2011, J BIOCHEM, V149, P241, DOI 10.1093/jb/mvr002; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez FA, 2005, P NATL ACAD SCI USA, V102, P2174, DOI 10.1073/pnas.0409598102; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Pickrell AM, 2015, NEURON, V87, P371, DOI 10.1016/j.neuron.2015.06.034; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Plun-Favreau H, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001257; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Quinsay MN, 2010, J MOL CELL CARDIOL, V48, P1146, DOI 10.1016/j.yjmcc.2009.12.004; Radogna F, 2016, ONCOGENE, V35, P3839, DOI 10.1038/onc.2015.455; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Richter B, 2016, P NATL ACAD SCI USA, V113, P4039, DOI 10.1073/pnas.1523926113; Riley BE, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2982; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Saito S, 1996, CANCER RES, V56, P5586; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043; Scarffe LA, 2014, TRENDS NEUROSCI, V37, P315, DOI 10.1016/j.tins.2014.03.004; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; SERSHEN H, 1985, EUR J PHARMACOL, V113, P135, DOI 10.1016/0014-2999(85)90355-3; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Tait SWG, 2013, CELL REP, V5, P878, DOI 10.1016/j.celrep.2013.10.034; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Trempe JF, 2013, SCIENCE, V340, P1451, DOI 10.1126/science.1237908; Trempe JF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00038; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Viotti J, 2014, ONCOGENE, V33, P1764, DOI 10.1038/onc.2013.124; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; WAGNER GC, 1985, NEUROPHARMACOLOGY, V24, P1261, DOI 10.1016/0028-3908(85)90164-9; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang HX, 2011, J BIOL CHEM, V286, P11649, DOI 10.1074/jbc.M110.144238; Wang M, 2001, J NEUROCHEM, V77, P1561, DOI 10.1046/j.1471-4159.2001.00372.x; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; West AB, 2004, J BIOL CHEM, V279, P28896, DOI 10.1074/jbc.M400126200; Whitworth AJ, 2008, DIS MODEL MECH, V1, P168, DOI 10.1242/dmm.000109; Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111; Wu H, 2014, AUTOPHAGY, V10, P1712, DOI 10.4161/auto.29568; Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501; Xia M, 2014, ONCOTARGET, V5, P3907, DOI 10.18632/oncotarget.2028; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Xu L, 2014, J MOL MED, V92, P31, DOI 10.1007/s00109-013-1107-0; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yamano K, 2013, AUTOPHAGY, V9, P1758, DOI 10.4161/auto.24633; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Yun JN, 2014, ELIFE, V3, DOI 10.7554/eLife.01958; Zanchetta LM, 2011, INT J RADIAT BIOL, V87, P506, DOI 10.3109/09553002.2011.556175; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang CG, 2014, CURR BIOL, V24, P1854, DOI 10.1016/j.cub.2014.07.014; Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345; Ziviani E, 2010, P NATL ACAD SCI USA, V107, P5018, DOI 10.1073/pnas.0913485107	205	141	152	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1315	1327		10.1038/onc.2016.302	http://dx.doi.org/10.1038/onc.2016.302			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593930				2022-12-28	WOS:000395862500001
J	Seviour, EG; Sehgal, V; Mishra, D; Rupaimoole, R; Rodriguez-Aguayo, C; Lopez-Berestein, G; Lee, JS; Sood, AK; Kim, MP; Mills, GB; Ram, PT				Seviour, E. G.; Sehgal, V.; Mishra, D.; Rupaimoole, R.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Lee, J-S; Sood, A. K.; Kim, M. P.; Mills, G. B.; Ram, P. T.			Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p	ONCOGENE			English	Article							LUNG-CANCER; DNA METHYLATION; K-RAS; EXPRESSION; PATHWAYS; YAP	KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3' UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3' UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.	[Seviour, E. G.; Sehgal, V.; Lee, J-S; Mills, G. B.; Ram, P. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Mishra, D.; Kim, M. P.] Methodist Hosp, Res Inst, 6535 Fannin, Houston, TX 77030 USA; [Rupaimoole, R.; Sood, A. K.] UTMDACC, Dept Gynecol Oncol, Houston, TX USA; [Rodriguez-Aguayo, C.; Lopez-Berestein, G.] UTMDACC, Dept Expt Therapeut, Houston, TX USA; [Lopez-Berestein, G.; Lee, J-S; Sood, A. K.; Ram, P. T.] UTMDACC, Ctr RNA Interference & Noncoding RNA, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ram, PT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pram@mdanderson.org	Sood, Anoop Kumar/A-7344-2013	Sood, Anoop Kumar/0000-0001-5702-4108; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Mishra, Dhruva/0000-0001-8651-005X; Ram, Prahlad/0000-0003-4739-3166; Mills, Gordon/0000-0002-0144-9614	NIH/NCI ICBP [U54-CA112970]; CCBTP training grant from the CPRIT; NIH [UH2 TR000943]; RGK Foundation; CPRIT [RP110595]; NATIONAL CANCER INSTITUTE [U54CA112970, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER	NIH/NCI ICBP; CCBTP training grant from the CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	All the data reported in the paper are presented. The microarray data are available from GEO under the accession number GSE73194. The work presented here was funded by NIH/NCI ICBP grant U54-CA112970 (Project 2 PI-JWG, Project 4 Co-PI's PTR and GBM), VS was funded by the CCBTP training grant from the CPRIT, and grants from the NIH (UH2 TR000943), the RGK Foundation, and CPRIT RP110595 (AKS).	Agarwal A, 2008, LEUKEMIA, V22, P2269, DOI 10.1038/leu.2008.124; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BOS JL, 1989, CANCER RES, V49, P4682; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; Grana TM, 2002, CANCER RES, V62, P4142; Grechukhina O, 2012, EMBO MOL MED, V4, P206, DOI 10.1002/emmm.201100200; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Iliopoulos D, 2011, CANCER RES, V71, P5144, DOI 10.1158/0008-5472.CAN-11-0425; Jancik S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/150960; Jiao LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032068; Kalinichenko VV, 2015, EXPERT OPIN THER TAR, V19, P865, DOI 10.1517/14728222.2015.1042366; Katzel JA, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Komurov K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-282; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Lv L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.367; Mishra DK, 2015, ANN THORAC SURG, V99, P1149, DOI 10.1016/j.athoracsur.2014.08.085; Mishra DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045308; Mishra DK, 2012, ANN THORAC SURG, V93, P1075, DOI 10.1016/j.athoracsur.2012.01.011; Moss TJ, 2015, NPJ SYST BIOL APPL, V1, DOI 10.1038/npjsba.2015.1; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Rosell R, 1995, SEMIN ONCOL, V22, P12; Seviour EG, 2016, ONCOGENE, V35, P801, DOI 10.1038/onc.2015.177; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Uberall I, 2008, EXP MOL PATHOL, V84, P79, DOI 10.1016/j.yexmp.2007.12.002; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	36	34	34	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1339	1350		10.1038/onc.2016.308	http://dx.doi.org/10.1038/onc.2016.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27669434	Green Accepted			2022-12-28	WOS:000395862500003
J	Zeng, Q; Chen, J; Li, Y; Werle, KD; Zhao, RX; Quan, CS; Wang, YS; Zhai, YX; Wang, JW; Youssef, M; Cui, R; Liang, J; Genovese, N; Chow, LT; Li, YL; Xu, ZX				Zeng, Q.; Chen, J.; Li, Y.; Werle, K. D.; Zhao, R-X; Quan, C-S; Wang, Y-S; Zhai, Y-X; Wang, J-W; Youssef, M.; Cui, R.; Liang, J.; Genovese, N.; Chow, L. T.; Li, Y-L; Xu, Z-X			LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; HEXOKINASE II; TUMOR INITIATION; LUNG-CANCER; ONCOPROTEIN; PATHWAYS; GROWTH; ROS; IDENTIFICATION	Liver kinase B1 (LKB1) is mutationally inactivated in Peutz-Jeghers syndrome and in a variety of cancers including human papillomavirus (HPV)-caused cervical cancer. However, the significance of LKB1 mutations in cervical cancer initiation and progress has not been examined. Herein, we demonstrated that, in mouse embryonic fibroblasts, loss of LKB1 and transduction of HPV16 E6/E7 had an additive effect on constraining cell senescence while promoting cell proliferation and increasing glucose consumption, lactate production and ATP generation. Knockdown of LKB1 increased and ectopic expression of LKB1 decreased glycolysis, anchorage-independent cell growth, and cell migration and invasion in HPV-transformed cells. In the tumorigenesis and lung metastasis model in syngeneic mice, depletion of LKB1 markedly increased tumor metastatic colonies in lungs without affecting subcutaneous tumor growth. We showed that HPV16 E6/E7 enhanced the expression of hexokinase-II (HK-II) in the glycolytic pathway through elevated c-MYC. Ectopic LKB1 reduced HK-II along with glycolysis. The inverse relationship between HK-II and LKB1 was also observed in normal and HPV-associated cervical lesions. We propose that LKB1 acts as a safeguard against HPV-stimulated aerobic glycolysis and tumor progression. These findings may eventually aid in the development of therapeutic strategy for HPV-associated malignancies by targeting cell metabolism.	[Zeng, Q.; Quan, C-S; Wang, Y-S; Zhai, Y-X; Wang, J-W; Li, Y-L; Xu, Z-X] Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, 126 Xin Min Ave, Changchun, Peoples R China; [Zeng, Q.; Chen, J.; Li, Y.; Werle, K. D.; Zhao, R-X; Youssef, M.; Xu, Z-X] Univ Alabama Birmingham, Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL USA; [Cui, R.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA USA; [Liang, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Genovese, N.; Chow, L. T.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA	Jilin University; University of Alabama System; University of Alabama Birmingham; Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham	Li, YL; Xu, ZX (corresponding author), Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, 126 Xin Min Ave, Changchun, Peoples R China.; Chow, LT (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA.	ltchow@uab.edu; ylli@jlu.edu.cn; zhixiangxu08@gmail.com			National Cancer Institute [R01CA133053, R01CA83679]; UAB Comprehensive Cancer Center Pilot Program Project [IRG-60-001-50]; National Natural Science Foundation of China [81271853, 81272243, 81573087]; National 863 Program of China [2004AA205020]; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA083679, R01CA133053] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UAB Comprehensive Cancer Center Pilot Program Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 863 Program of China(National High Technology Research and Development Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute R01CA133053, R01CA83679, and the UAB Comprehensive Cancer Center Pilot Program Project IRG-60-001-50. The work was also supported by the National Natural Science Foundation of China Nos 81271853, 81272243 and 81573087, and the National 863 Program of China No. 2004AA205020.	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Anflous-Pharayra K, 2007, BBA-BIOENERGETICS, V1767, P136, DOI 10.1016/j.bbabio.2006.11.013; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; AYRE HA, 1966, BRIT J CANCER, V20, P743, DOI 10.1038/bjc.1966.85; Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109; Dendele B, 2012, TOXICOL IN VITRO, V26, P94, DOI 10.1016/j.tiv.2011.11.001; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Dupuy F, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-18; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Galloway DA, 2015, CURR OPIN VIROL, V14, P87, DOI 10.1016/j.coviro.2015.09.001; Hardie DG, 2014, J INTERN MED, V276, P543, DOI 10.1111/joim.12268; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji HX, 1998, INT J CANCER, V78, P41, DOI 10.1002/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.0.CO;2-X; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Mack HID, 2013, VIROLOGY, V446, P9, DOI 10.1016/j.virol.2013.07.009; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; McCabe MT, 2010, CANCER GENET CYTOGEN, V197, P130, DOI 10.1016/j.cancergencyto.2009.11.017; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Psyrri A, 2008, NAT CLIN PRACT ONCOL, V5, P24, DOI 10.1038/ncponc0984; Roberts DJ, 2015, CELL DEATH DIFFER, V22, P248, DOI 10.1038/cdd.2014.173; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10; Walenta S, 2000, CANCER RES, V60, P916; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu RX, 2012, EMBO MOL MED, V4, P633, DOI 10.1002/emmm.201200240; Xiao XX, 2012, GYNECOL ONCOL, V127, P249, DOI 10.1016/j.ygyno.2012.06.032; Xu HG, 2015, ONCOGENE, V34, P3848, DOI 10.1038/onc.2014.315; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110; Zeng QH, 2016, P NATL ACAD SCI USA, V113, P9333, DOI 10.1073/pnas.1606801113; Zheng L, 2008, GENES CELLS, V13, P285, DOI 10.1111/j.1365-2443.2008.01162.x; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	55	42	45	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1245	1255		10.1038/onc.2016.290	http://dx.doi.org/10.1038/onc.2016.290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546620	Green Accepted			2022-12-28	WOS:000395861300008
J	Hou, J; Deng, Q; Zhou, J; Zou, J; Zhang, Y; Tan, P; Zhang, W; Cui, H				Hou, J.; Deng, Q.; Zhou, J.; Zou, J.; Zhang, Y.; Tan, P.; Zhang, W.; Cui, H.			CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR	ONCOGENE			English	Article							PHASE-II TRIAL; COP9 SIGNALOSOME; MALIGNANT GLIOMAS; BREAST-CANCER; GROWTH; PHOSPHORYLATION; CLASSIFICATION; SUBUNIT-6; ERLOTINIB; CHAPERONE	CSN6, a critical subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), has received attention as a regulator of the degradation of cancer-related proteins such as p53, c-myc and c-Jun, through the ubiquitin-proteasome system, suggesting its importance in cancerogenesis. However, the biological functions and molecular mechanisms of CSN6 in glioblastoma (GBM) remain poorly understood. Here, we report that GBM tumors overexpressed CSN6 compared with normal brain tissues and that CSN6 promoted GBM cell proliferation, migration, invasion and tumorigenesis. Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was used to reveal that the proliferative and metastatic effects of CSN6 on GBM cells were EGFR dependent. We also found that CSN6 positively regulated EGFR stability via reduced levels of EGFR ubiquitination, thereby elevating steady expression of EGFR. In addition, this study is the first description of a novel role for the CSN6-interacting E3 ligase, CHIP (carboxyl terminus of heat-shock protein 70-interacting protein), regulating EGFR ubiquitination in cancer cells. We showed that CSN6 associated with CHIP and led to CHIP destabilization by increasing CHIP self-ubiquitination. Moreover, CSN6 decreased CHIP expression and increased EGFR expression in the tumor samples. Deregulation of this axis promoted GBM cell's proliferation and metastasis. Thus, our study provides insights into the applicability of using the CSN6-CHIP-EGFR axis as a potential therapeutic target in cancer.	[Hou, J.; Deng, Q.; Zou, J.; Zhang, Y.; Tan, P.; Zhang, W.; Cui, H.] Southwest Univ, Cell Biol Lab, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Zhou, J.] Chinese Peoples Liberat Army, Rocket Force Gen Hosp, Dept Neurosurg, Beijing, Peoples R China	Southwest University - China	Cui, H (corresponding author), Southwest Univ, Cell Biol Lab, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.	hongjuan.cui@gmail.com			Research Fund for the Doctoral Program of Higher Education of China [20130182110003]; National Basic Research Program of China [2012cb114603]; National Natural Science Foundation of China [81502574, 31501100]	Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Research Fund for the Doctoral Program of Higher Education of China (20130182110003), the National Basic Research Program of China (No. 2012cb114603) and the National Natural Science Foundation of China (81502574 and 31501100).	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Cao Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116934; Chen J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6384; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fang LK, 2015, CANCER CELL, V28, P183, DOI 10.1016/j.ccell.2015.07.004; Forozan F, 2000, CANCER RES, V60, P4519; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gao SJ, 2015, ONCOTARGET, V6, P28026, DOI 10.18632/oncotarget.4731; Gusmaroli G, 2007, PLANT CELL, V19, P564, DOI 10.1105/tpc.106.047571; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lee M. H., 2011, CELL CYCLE, V10, P3057, DOI [DOI 10.4161/CC.10.18, 10.4161/cc.10.18.17320, DOI 10.4161/CC.10.18.17320]; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282; Peng ZH, 2001, PLANT CELL, V13, P2393, DOI 10.1105/tpc.13.11.2393; Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015; Riddick G, 2011, NAT REV NEUROL, V7, P439, DOI 10.1038/nrneurol.2011.100; Ronnebaum SM, 2013, MOL CELL BIOL, V33, P4461, DOI 10.1128/MCB.00480-13; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; Wang TX, 2014, ONCOTARGET, V5, P1969, DOI 10.18632/oncotarget.1890; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	53	54	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1134	1144		10.1038/onc.2016.280	http://dx.doi.org/10.1038/onc.2016.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27546621				2022-12-28	WOS:000395371500011
J	Huang, MY; Xuan, F; Liu, W; Cui, HJ				Huang, M-Y; Xuan, F.; Liu, W.; Cui, H-J			MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation	ONCOGENE			English	Article							MYC TARGET GENE; CHROMATIN MODIFICATIONS; COLON-CANCER; LUNG-CANCER; EXPRESSION; GROWTH; MDIG; NEUROBLASTOMA; CELLS	It is generally known that histone demethylases regulate gene transcription by altering the methylate status on histones, but their roles in cancers and the underlying molecular mechanisms still remain unclear. MYC-induced nuclear antigen (MINA) is reported to be a histone demethylase and highly expressed in many cancers. Here, for the first time, we show that MINA is involved in glioblastoma carcinogenesis and reveal the probable mechanisms of it in cell-cycle control. Kaplan-Meier analysis of progressionfree survival showed that high MINA expression was strongly correlated with poor outcome and advancing tumor stage. MINA knockdown significantly repressed the cell proliferation and tumorigenesis abilities of glioblastoma cells in vitro and in vivo that were rescued by overexpressing the full-length MINA afterwards. Microarray analysis after knockdown of MINA revealed that MINA probably regulated glioblastoma carcinogenesis through the predominant cell-cycle pathways. Further investigation showed that MINA deficiency led to a cell-cycle arrest in G1 and G2 phases. And among the downstream genes, we found that cyclins and cyclin-dependent kinases were directly activated by MINA via the demethylation of H3K9me3.	[Huang, M-Y; Xuan, F.; Liu, W.; Cui, H-J] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China	Southwest University - China	Cui, HJ (corresponding author), Southwest Univ, Dept Cell Biol, State Key Lab Silkworm Genome Biol, 2 Tianshenglu, Chongqing 400716, Peoples R China.	hongjuan.cui@gmail.com	Xuan, Fan/G-6580-2016	Xuan, Fan/0000-0002-8070-3309	National Basic Research Program of China [2012CB114603]; National Natural Science Foundation of China [31501100, 81502574]; Research Fund for the Doctoral Program of Higher Education of China [20130182110003]; Basal Research Fund of Central Higher Education Institutions [XDJK2016D003]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Basal Research Fund of Central Higher Education Institutions	This work was supported by the National Basic Research Program of China (No. 2012CB114603), the National Natural Science Foundation of China (No. 31501100, 81502574), the Research Fund for the Doctoral Program of Higher Education of China (20130182110003) and the Basal Research Fund of Central Higher Education Institutions (XDJK2016D003).	Benjamin R, 2003, CANCER J, V9, P82, DOI 10.1097/00130404-200303000-00003; Chen BL, 2013, ONCOTARGET, V4, P1427, DOI 10.18632/oncotarget.1155; Chowdhury R, 2014, NATURE, V510, P422, DOI 10.1038/nature13263; Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176; Eilbracht J, 2005, EUR J CELL BIOL, V84, P279, DOI 10.1016/j.ejcb.2004.12.022; Fukahori S, 2007, J PEDIATR SURG, V42, P1831, DOI 10.1016/j.jpedsurg.2007.07.008; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009; Komiya K, 2010, LUNG CANCER, V69, P232, DOI 10.1016/j.lungcan.2009.10.010; Komiya K, 2010, J CANCER RES CLIN, V136, P465, DOI 10.1007/s00432-009-0679-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lin HQ, 2010, CELL RES, V20, P899, DOI 10.1038/cr.2010.84; Lu YJ, 2009, CELL CYCLE, V8, P2101, DOI 10.4161/cc.8.13.8927; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tan XP, 2014, CELL BIOCHEM BIOPHYS, V69, P619, DOI 10.1007/s12013-014-9841-7; Tan XP, 2012, ONCOL LETT, V3, P1037, DOI 10.3892/ol.2012.620; Teye K, 2004, AM J PATHOL, V164, P205, DOI 10.1016/S0002-9440(10)63111-2; Teye K, 2007, ONCOL REP, V18, P841; Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290; Tsuneoka M, 2004, CLIN CANCER RES, V10, P7347, DOI 10.1158/1078-0432.CCR-03-0543; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; Wang M, 2015, ONCOTARGET, V6, P9517, DOI 10.18632/oncotarget.3367; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Xing J, 2014, ONCOL REP, V31, P634, DOI 10.3892/or.2013.2918; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yang R, 2015, ONCOTARGET, V6, P7644, DOI 10.18632/oncotarget.3223; Yu M, 2014, PLOS ONE, V9; Zhang YD, 2005, ONCOGENE, V24, P4873, DOI 10.1038/sj.onc.1208668; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	33	33	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					387	396		10.1038/onc.2016.208	http://dx.doi.org/10.1038/onc.2016.208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27292258				2022-12-28	WOS:000394166000008
J	Banasavadi-Siddegowda, YK; Russell, L; Frair, E; Karkhanis, VA; Relation, T; Yoo, JY; Zhang, J; Sif, S; Imitola, J; Baiocchi, R; Kaur, B				Banasavadi-Siddegowda, Y. K.; Russell, L.; Frair, E.; Karkhanis, V. A.; Relation, T.; Yoo, J. Y.; Zhang, J.; Sif, S.; Imitola, J.; Baiocchi, R.; Kaur, B.			PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; CELLULAR SENESCENCE; HUMAN BRAIN; STEM-CELL; SURVIVAL; GENE; PHOSPHATASE; EXPRESSION; INHIBITORS	Glioblastoma (GBM) represents the most common and aggressive histologic subtype among malignant astrocytoma and is associated with poor outcomes because of heterogeneous tumour cell population including mature non-stem-like cell and immature stem-like cells within the tumour. Thus, it is critical to find new target-specific therapeutic modalities. Protein arginine methyltransferase enzyme 5 (PRMT5) regulates many cellular processes through its methylation activity and its overexpression in GBM is associated with more aggressive disease. Previously, we have shown that silencing of PRMT5 expression in differentiated GBM cell lines results in apoptosis and reduced tumour growth in mice. Here, we report the critical role of PRMT5 in GBM differentiated cells (GBMDC) grown in serum and GBM neurospheres (GBMNS) grown as neurospheres in vitro. Our results uncover a very significant role for PRMT5 in GBMNS self-renewal capacity and proliferation. PRMT5 knockdown in GBMDC led to apoptosis, knockdown in GBMNS led to G1 cell cycle arrest through upregulation of p27 and hypophoshorylation of retinoblastoma protein, leading to senescence. Comparison of impact of PRMT5 on cellular signalling by the Human Phospho-Kinase Array and chromatin immunoprecipitation-PCR revealed that unlike GBMDC, PRMT5 regulates PTEN expression and controls Akt and ERk activity in GBMNS. In vivo transient depletion of PRMT5 decreased intracranial tumour size and growth rate in mice implanted with both primary tumour-derived GBMNS and GBMDC. This is the first study to identify PTEN as a potential downstream target of PRMT5 and PRMT5 is vital to support both mature and immature GBM tumour cell populations.	[Banasavadi-Siddegowda, Y. K.; Russell, L.; Frair, E.; Relation, T.; Yoo, J. Y.; Kaur, B.] Ohio State Univ, Coll Med, Dept Neurol Surg, 410W 12th Ave,CCC Room 385D, Columbus, OH 43210 USA; [Karkhanis, V. A.; Baiocchi, R.] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, 400W 12th Ave,CCC 453, Columbus, OH 43210 USA; [Zhang, J.] Ctr Biostat, Dept Biomed Informat, Columbus, OH USA; [Sif, S.] Qatar Univ, Coll Arts & Sci, Dept Biol & Environm Sci, Doha, Qatar; [Imitola, J.] Ohio State Univ, Coll Med, Dept Neurol, Lab Neural Stem Cells & Funct Neurogenet,Div Neur, Columbus, OH 43210 USA; [Imitola, J.] Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Qatar University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kaur, B (corresponding author), Ohio State Univ, Coll Med, Dept Neurol Surg, 410W 12th Ave,CCC Room 385D, Columbus, OH 43210 USA.; Baiocchi, R (corresponding author), Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, 400W 12th Ave,CCC 453, Columbus, OH 43210 USA.	robert.baiocchi@osumc.edu; kaur.11@osu.edu	Sif, Said/AAE-5554-2019	/0000-0002-4730-6918; Sif, Said/0000-0001-6268-1145; Yoo, Ji Young/0000-0002-6767-1111	NIH RO1 [CA150153, NS064607]; NIH P01 [CA163205]; NIH P30 [NS045758]; NIH [R21 NS071346];  [IRG-67-003-50]; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA163205, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS071346, P30NS045758, R01NS064607] Funding Source: NIH RePORTER	NIH RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH P01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH P30; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was financially supported by: Kaur: NIH RO1 (CA150153), NIH P01 (CA163205), NIH P30 (NS045758), NIH RO1 (NS064607); Baiocchi: NIH R21 NS071346 and Yoo: IRG-67-003-50.	ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Han XS, 2014, J NEURO-ONCOL, V118, P61, DOI 10.1007/s11060-014-1419-0; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907; Karberg S, 2009, CELL, V139, P1029, DOI 10.1016/j.cell.2009.11.038; KATO J, 1993, GENE DEV, V7, P331; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Masui K, 2012, NEUROPATH APPL NEURO, V38, P271, DOI 10.1111/j.1365-2990.2011.01238.x; McDowell KA, 2011, CURR PHARM DESIGN, V17, P2411; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tan W, 2015, J CELL BIOCHEM, V116, P1583, DOI 10.1002/jcb.25112; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Yen F, 2014, CANCER RES, V74, P1752; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	46	71	73	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					263	274		10.1038/onc.2016.199	http://dx.doi.org/10.1038/onc.2016.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27292259	Green Accepted			2022-12-28	WOS:000393938100011
J	Chiu, LY; Hsin, IL; Yang, TY; Sung, WW; Chi, JY; Chang, JT; Ko, JL; Sheu, GT				Chiu, L-Y; Hsin, I-L; Yang, T-Y; Sung, W-W; Chi, J-Y; Chang, J. T.; Ko, J-L; Sheu, G-T			The ERK-ZEB1 pathway mediates epithelial mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SNAIL; TGF-BETA; E-CADHERIN; THYMIDYLATE SYNTHASE; SIGNALING PATHWAYS; MULTITARGETED ANTIFOLATE; MULTIDRUG-RESISTANCE; CARCINOMA-CELLS; SMAD PROTEINS; TUMOR-CELLS	High thymidylate synthase (TS) level in cancer tissue is considered to result in resistance to pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To further investigate the mechanism of pemetrexed resistance and potential prognostic outcomes in lung cancer, we established pemetrexed-resistant lung adenocarcinoma cell sublines from CL1 harboring a mutated TP53 gene (R248W) and A549 harboring wild-type TP53. We found the TS expression is upregulated in both pemetrexed-resistant sublines and the reduced TS level achieved through shRNA inhibition resulted in higher pemetrexed sensitivity. We also demonstrated that the acquisitions of pemetrexed resistance enhances epithelial mesenchymal transition (EMT) in vivo with a mice animal model and in vitro with CL1 and A549 sublines, which was associated with upregulation of ZEB1 which, in turn, downregulates E-cadherin and upregulates fibronectin. When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities. Therefore, the ERK-mediated pathways induce apoptosis with pemetrexed treatment, and may in turn mediate EMT when cancer cells are resistant to pemetrexed. We further demonstrated that the growth of pemetrexed-resistant tumors could be inhibited by vinblastine in vivo and vincristine in vitro. Our data indicate that pemetrexed resistance could be relieved by non-cross-resistant chemotherapeutic drugs such as vinca alkaloids and might be independent to TP53 status. Furthermore, the phosphorylation of ERK was reduced by vincristine. This finding provides a new insight for overcoming pemetrexed resistance and metastasis by application of vinca alkaloids.	[Chiu, L-Y; Chi, J-Y; Chang, J. T.; Ko, J-L; Sheu, G-T] Chung Shan Med Univ, Inst Med, Res Bldg Room 702,110 Sec 1,Jianguo N Rd, Taichung 402, Taiwan; [Hsin, I-L] Changhua Christian Hosp, Inflammat Res & Drug Dev Ctr, Changhua, Taiwan; [Yang, T-Y] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan; [Sung, W-W] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Sung, W-W] Chung Shan Med Univ Hosp, Dept Med Educ, Taichung, Taiwan; [Sung, W-W] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli, Taiwan; [Ko, J-L; Sheu, G-T] Chung Shan Med Univ Hosp, Dept Med Oncol & Chest Med, Taichung, Taiwan	Chung Shan Medical University; Changhua Christian Hospital; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Sheu, GT (corresponding author), Chung Shan Med Univ, Inst Med, Res Bldg Room 702,110 Sec 1,Jianguo N Rd, Taichung 402, Taiwan.	gtsheu@csmu.edu.tw	Chang, Jinghua/AAV-5620-2021; Sheu, Gwo-Tarng/H-8855-2019; Sung, Wen-Wei/P-5053-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375; Sung, Wen-Wei/0000-0002-2375-0029; Ko, Jiunn-Liang/0000-0001-6855-9239	Ministry of Science and Technology, Taiwan [MOST-103-2320-6-040-015, MOST-104-2320-B-040-003]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-103-2320-6-040-015, MOST-104-2320-B-040-003).	Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bakin AV, 2002, J CELL SCI, V115, P3193; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Buque A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063338; Calvert H, 2002, SEMIN ONCOL, V29, P54, DOI 10.1053/sonc.2002.30761; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen CY, 2011, LUNG CANCER, V74, P132, DOI 10.1016/j.lungcan.2011.01.024; Chiu LY, 2010, TOXICOL LETT, V192, P408, DOI 10.1016/j.toxlet.2009.11.018; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Kajiyama H, 2007, INT J ONCOL, V31, P277; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Liu Y, 2013, CANCER CHEMOTH PHARM, V72, P1125, DOI 10.1007/s00280-013-2299-2; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Massague J, 2000, GENE DEV, V14, P627; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Moudi M, 2013, INT J PREVENTIVE MED, V4, P1231; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Ozasa H, 2010, CANCER SCI, V101, P161, DOI 10.1111/j.1349-7006.2009.01358.x; Piek E, 1999, J CELL SCI, V112, P4557; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Rollins KD, 2005, CLIN THER, V27, P1343, DOI 10.1016/j.clinthera.2005.09.010; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Schultz RM, 1999, ANTICANCER RES, V19, P437; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Shih C, 1997, CANCER RES, V57, P1116; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Takkunen M, 2006, J HISTOCHEM CYTOCHEM, V54, P1263, DOI 10.1369/jhc.6A6958.2006; Tavares ALP, 2006, DEV DYNAM, V235, P1589, DOI 10.1002/dvdy.20771; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang T, 2011, TRANSPORT DYNAMICS, P663; Yang TY, 2013, MOL CARCINOGEN, V52, P183, DOI 10.1002/mc.21842; Yee DS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-162; Zhang D, 2011, CANCER LETT, V309, P228, DOI 10.1016/j.canlet.2011.06.006; Zucali PA, 2014, LUNG CANCER, V84, P265, DOI 10.1016/j.lungcan.2013.11.011	47	74	76	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					242	253		10.1038/onc.2016.195	http://dx.doi.org/10.1038/onc.2016.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270426	Green Published, hybrid			2022-12-28	WOS:000393938100009
J	Elf, S; Lin, R; Xia, S; Pan, Y; Shan, C; Wu, S; Lonial, S; Gaddh, M; Arellano, ML; Khoury, HJ; Khuri, FR; Lee, BH; Boggon, TJ; Fan, J; Chen, J				Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Wu, S.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Lee, B. H.; Boggon, T. J.; Fan, J.; Chen, J.			Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin	ONCOGENE			English	Article							PROTEIN-KINASE; CANCER CELLS; DEFICIENCY; AMPK; ATTACHMENT; FAMILY	The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP enzyme, 6-phosphogluconate dehydrogenase (6PGD), using our novel small-molecule 6PGD inhibitors Physcion and its derivative 53, shows anticancer effects. Notably, humans with genetic deficiency of either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs. Inspired by these clinical observations, we examined the anticancer potential of combined treatment with 6PGD inhibitors and antimalarial drugs. We found that stable knockdown of 6PGD sensitizes leukemia cells to antimalarial agent dihydroartemisinin (DHA). Combined treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inhibition of human leukemia cell viability. Moreover, our combined therapy synergistically attenuates tumor growth in xenograft nude mice injected with human K562 leukemia cells and cell viability of primary leukemia cells from human patients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells and mononucleocytes from healthy human donors. Our findings reveal the potential for combined therapy using optimized doses of Physcion and DHA as a novel antileukemia treatment without inducing hemolysis.	[Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Fan, J.; Chen, J.] Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA; [Wu, S.] Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA; [Lee, B. H.] Novartis Inst BioMed Res, Cambridge, MA USA; [Boggon, T. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Emory University; Emory University; Novartis; Yale University	Chen, J (corresponding author), Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA.	jchen@emory.edu	Xia, Siyuan/AAM-9606-2020; Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Xia, Siyuan/0000-0001-6756-3519	NIH [CA140515, CA183594, CA174786]; Pharmacological Sciences Training Grant [T32 GM008602]; DoD [W81XWH-12-1-0217]; NATIONAL CANCER INSTITUTE [R01CA174786, R01CA140515, R01CA183594, R01CA120272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmacological Sciences Training Grant; DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Hematology Division Tissue Bank, Winship Cancer Institute of Emory for providing primary tissue samples from leukemia patients. This work was supported in part by NIH grants CA140515, CA183594, CA174786 (to JC), the Pharmacological Sciences Training Grant T32 GM008602 (to SE), DoD grant W81XWH-12-1-0217 (to JC). SE is an NIH pre-doctoral fellow and an ARCS Foundation Scholar. JC is WCI 5K Scholar, Georgia Cancer Coalition Distinguished Scholar, American Cancer Society Basic Research Scholar and Scholar of the Leukemia and Lymphoma Society.	BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Caprari P, 2001, ANN HEMATOL, V80, P41, DOI 10.1007/s002770000233; Chakrabarti KR, 2015, ONCOTARGET, V6, P36292, DOI 10.18632/oncotarget.5345; Choudhury Yashmin, 2014, Oncoscience, V1, P446; Corrons JLV, 1996, AM J HEMATOL, V53, P221; Di JM, 2010, MOL BIOL REP, V37, P1849, DOI 10.1007/s11033-009-9620-5; Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; HA J, 1994, J BIOL CHEM, V269, P22162; Hadad S, 2008, 2008 ASCO BREAST CAN; Hadad SM, 2014, CLIN TRANSL ONCOL, V16, P746, DOI 10.1007/s12094-013-1144-8; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Spears LD, 2010, FASEB J S, V24, pIb674; Wang SJ, 2011, CANCER CHEMOTH PHARM, V68, P1421, DOI 10.1007/s00280-011-1643-7	15	42	43	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					254	262		10.1038/onc.2016.196	http://dx.doi.org/10.1038/onc.2016.196			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270429	Green Accepted			2022-12-28	WOS:000393938100010
J	Ramadoss, S; Guo, G; Wang, CY				Ramadoss, S.; Guo, G.; Wang, C-Y			Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53	ONCOGENE			English	Article							STEM-CELLS; MESENCHYMAL TRANSITION; TUMOR; METHYLATION; ACETYLATION; TRANSCRIPTION; METASTASIS; ACTIVATION; MECHANISMS; BIOLOGY	Invasive growth and apoptosis resistance of breast cancer cells are associated with metastasis and disease relapse. Here we identified that the lysine-specific demethylase KDM3A played a dual role in breast cancer cell invasion and apoptosis by demethylating histone and the non-histone protein p53, respectively. While inducing pro-invasive genes by erasing repressive histone H3 lysine 9 methylation, KDM3A promotes chemoresistance by demethylating p53. KDM3A suppressed pro-apoptotic functions of p53 by erasing p53-K372me1, as this methylation is crucial for the stability of chromatin-bound p53. Unexpectedly, depletion of KDM3A was capable of reactivating mutated p53 to induce the expression of pro-apoptotic genes in breast cancer with mutant p53. Moreover, KDM3A knockdown also potently inhibited tumorigenic potentials of breast cancer stem-like cells and rendered them sensitive to apoptosis induced by chemotherapeutic drugs. Taken together, our results suggest that KDM3A might be a potential therapeutic target for human breast cancer treatment and prevention.	[Ramadoss, S.; Guo, G.; Wang, C-Y] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, 10833 Le Conte Ave, Los Angeles, CA 90095 USA; [Ramadoss, S.; Guo, G.; Wang, C-Y] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA; [Wang, C-Y] Univ Calif Los Angeles, Dept Bioengn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Wang, CY (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.; Wang, CY (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	cunywang@ucla.edu			NIH [R3713848, DE15964]; Shapiro Family Charitable Foundation; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023874, R37DE013848, R01DE015964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shapiro Family Charitable Foundation; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the NIH grants R3713848 and DE15964 and the Shapiro Family Charitable Foundation. We thank Dr Yi Zhang for the generous gift of KDM3A plasmid.	Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Cheng L, 2010, TOXICOL PATHOL, V38, P62, DOI 10.1177/0192623309354109; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Ginestier C, 2012, CELL CYCLE, V11, P2583, DOI 10.4161/cc.21092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Joerger AC, 2007, ADV CANCER RES, V97, P1, DOI 10.1016/S0065-230X(06)97001-8; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Kwon M, 2014, CANCER GENE THER, V21, P179, DOI 10.1038/cgt.2014.17; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Perez RE, 2010, J CELL PHYSIOL, V225, P394, DOI 10.1002/jcp.22285; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10; Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	46	63	69	0	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					47	59		10.1038/onc.2016.174	http://dx.doi.org/10.1038/onc.2016.174			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270439	Green Accepted			2022-12-28	WOS:000394069100005
J	Cheng, Y; Ren, X; Yuan, Y; Shan, Y; Li, L; Chen, X; Zhang, L; Takahashi, Y; Yang, JW; Han, B; Liao, J; Li, Y; Harvey, H; Ryazanov, A; Robertson, GP; Wan, G; Liu, D; Chen, AF; Tao, Y; Yang, JM				Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J-M			eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis	ONCOGENE			English	Article							ELONGATION FACTOR-2 KINASE; CANCER-ASSOCIATED FIBROBLASTS; HISTONE DEACETYLASE SIRT6; PYRUVATE-KINASE; TUMOR-GROWTH; FACTOR-II; C-MYC; DEPENDENT PHOSPHORYLATION; CONFERS RESISTANCE; AEROBIC GLYCOLYSIS	Cancer cells predominantly metabolize glucose by glycolysis to produce energy in order to meet their metabolic requirement, a phenomenon known as Warburg effect. Although Warburg effect is considered a peculiarity critical for survival and proliferation of cancer cells, the regulatory mechanisms behind this phenomenon remain incompletely understood. We report here that eukaryotic elongation factor-2 kinase (eEF-2K), a negative regulator of protein synthesis, has a critical role in promoting glycolysis in cancer cells. We showed that deficiency in eEF-2K significantly reduced the uptake of glucose and decreased the productions of lactate and adenosine triphosphate in tumor cells and in the Ras-transformed mouse embryonic fibroblasts. We further demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A), a key factor that facilitates the ubiquitin-proteasomal degradation of c-Myc protein, as knockdown of eEF-2K expression led to a significant increase in PP2A-A protein synthesis and remarkable downregulation of c-Myc and pyruvate kinase M2 isoform, the key glycolytic enzyme transcriptionally activated by c-Myc. In addition, depletion of eEF-2K reduced the ability of the transformed cells to proliferate and enhanced the sensitivity of tumor cells to chemotherapy both in vitro and in vivo. These results, which uncover a role of the eEF-2K-mediated control of PP2A-A in tumor cell glycolysis, provide new insights into the regulation of the Warburg effect.	[Cheng, Y.; Li, L.] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, 110 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Li, Y.; Robertson, G. P.; Wan, G.; Yang, J-M] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol, Hershey, PA USA; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Robertson, G. P.; Wan, G.; Yang, J-M] Milton S Hershey Med Ctr, Hershey, PA USA; [Yuan, Y.; Liu, D.] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Spokane, WA USA; [Han, B.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pathol, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Div Biostat & Bioinformat, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Med, Hershey, PA USA; [Harvey, H.] Rutgers State Univ, Robert Wood Jonson Med Sch, Dept Pharmacol, Piscataway, NJ USA; [Ryazanov, A.] Cent S Univ, Coll Pharm, Ctr Vasc & Translat Med, Changsha, Hunan, Peoples R China; [Ryazanov, A.] Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Chen, A. F.] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Hunan, Peoples R China; [Chen, A. F.] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Changsha, Hunan, Peoples R China	Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Central South University; Central South University; Central South University; Central South University	Cheng, Y (corresponding author), Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, 110 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Yang, JM (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.; Yang, JM (corresponding author), Penn State Coll Med, Penn State Hershey Canc Inst, 500 Univ Dr, Hershey, PA 17033 USA.	chengyan0677@163.com; juy16@psu.edu	ryazanov, alexey/J-8081-2017; Wan, Guohui/G-3904-2011	Wan, Guohui/0000-0001-5170-7282; Takahashi, Yoshinori/0000-0002-8004-4817	National Basic Research Program of China (973 Program) [2015CB910700, 2014CB542400]; National Natural Science Foundation of China [81422051, 81472593, 31401208, 81372427]; National Basic Research Program of China [2015CB553903]; US Department of Defense [BC103654]; US Public Health Service [NIH/NCI R01CA135038]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); US Department of Defense(United States Department of Defense); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	We sincerely thank Dr Zhimin Lu (MD Anderson Cancer Center, USA) and Drs Jing Chen and Taro Hitosugi (Emory University School of Medicine) for PKM2 plasmids, Dr Christopher Proud (University of Southampton, UK) for eEF-2K plasmid and Dr Jayanta Debnath (University of California San Francisco, USA) for H-Ras<SUP>V12</SUP> retroviral plasmid. This work was supported by grants from the National Basic Research Program of China (973 Program) 2015CB910700 (to YC), 2014CB542400 (to AFC); the National Natural Science Foundation of China 81422051, 81472593 and 31401208 (to YC); the National Basic Research Program of China 2015CB553903 (to YT) and the National Natural Science Foundation of China 81372427 (to YT); the US Department of Defense BC103654 (to YC); and the US Public Health Service NIH/NCI R01CA135038 (to J-MY).	Arguelles S, 2014, FREE RADICAL BIO MED, V67, P131, DOI 10.1016/j.freeradbiomed.2013.10.015; BAGAGLIO DM, 1994, CELL GROWTH DIFFER, V5, P1403; BAGAGLIO DM, 1993, CANCER RES, V53, P2260; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Capparelli C, 2012, CELL CYCLE, V11, P2272, DOI 10.4161/cc.20717; Capparelli C, 2012, CELL CYCLE, V11, P2285, DOI 10.4161/cc.20718; Cheng Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.254; Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801; Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889; Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715; Chu HP, 2014, DEV CELL, V28, P561, DOI 10.1016/j.devcel.2014.01.027; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fu X, 2015, J BIOL CHEM, V290, P26445, DOI 10.1074/jbc.M115.665232; Gonzalez-Teran B, 2013, J CLIN INVEST, V123, P164, DOI 10.1172/JCI65124; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gupta S, 2005, CANCER BIOL THER, V4, P87; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; Kenney JW, 2016, J NEUROCHEM, V136, P276, DOI 10.1111/jnc.13407; Kenney Justin W., 2014, Advances in Biological Regulation, V55, P15, DOI 10.1016/j.jbior.2014.04.003; Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maher JC, 2007, MOL CANCER THER, V6, P732, DOI 10.1158/1535-7163.MCT-06-0407; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Moore CEJ, 2015, MOL CELL BIOL, V35, P1788, DOI 10.1128/MCB.01457-14; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Proud CG, 2015, BIOCHEM SOC T, V43, P328, DOI 10.1042/BST20140323; Ran C, 2013, CANCER RES, V73, P1831, DOI 10.1158/0008-5472.CAN-12-2460; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Tekedereli I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041171; Wang XM, 2015, BIOCHEM J, V467, P321, DOI 10.1042/BJ20150089; Wang XM, 2014, MOL CELL BIOL, V34, P4088, DOI 10.1128/MCB.01035-14; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872; Xie JL, 2015, MOL CELL BIOL, V35, P1805, DOI 10.1128/MCB.00012-15; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	55	31	32	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6293	6308		10.1038/onc.2016.166	http://dx.doi.org/10.1038/onc.2016.166			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181208				2022-12-28	WOS:000390247000003
J	Farmaki, E; Chatzistamou, I; Kaza, V; Kiaris, H				Farmaki, E.; Chatzistamou, I.; Kaza, V.; Kiaris, H.			A CCL8 gradient drives breast cancer cell dissemination	ONCOGENE			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-2; TUMOR-ASSOCIATED MACROPHAGES; HUMAN MONOCLONAL-ANTIBODY; CHEMOKINE LIGAND 2; CARLUMAB CNTO 888; METASTASIS; PROGRESSION; MICROENVIRONMENT; FIBROBLASTS; RECEPTORS	The migration of cancer cells towards gradients of chemoattractive factors represents a potential, yet elusive, mechanism that may contribute to cancer cell dissemination. Here we provide evidence for the maintenance of a gradient of increasing CCL8 concentration between the epithelium, the stroma and the periphery that is instrumental for breast cancer cells' dissemination. In response to signals elicited by the neoplastic epithelium, CCL8 production is enhanced in stromal fibroblasts at the tumor margins and in tissues at which breast cancer cells tend to metastasize such as the lungs and the brain. Manipulation of CCL8 activity influences the histology of the tumors and promotes major steps of the metastatic process such as invasion to adjacent stroma, intravasation and ultimately extravasation and seeding. These findings exemplify how gradients of chemoattractive factors such as CCL8, drive metastasis and suggest that interference with their operation may provide means for breast cancer management.	[Farmaki, E.; Kaza, V.; Kiaris, H.] Univ South Carolina, Dept Drug Discovery & Biomed Sci, CLS 713,715 Sumter St, Columbia, SC 29208 USA; [Chatzistamou, I.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Chatzistamou, I.] Univ Athens, Sch Dent, Dept Basic Sci, Athens, Greece; [Kiaris, H.] Univ Athens, Sch Med, Dept Biochem, Athens, Greece	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens	Kiaris, H (corresponding author), Univ South Carolina, Dept Drug Discovery & Biomed Sci, CLS 713,715 Sumter St, Columbia, SC 29208 USA.	kiarish@sccp.sc.edu		Kiaris, Hippokratis/0000-0002-8999-8289	NIH [5P30GM103336-02]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103336] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Professors I Roninson, E Broude and JE Schwarzbauer for useful comments and suggestions, and F Marini for sharing the EO771 cells. This study was supported by a pilot grant 5P30GM103336-02 from NIH.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003; Barbai T, 2015, ONCOTARGET, V6, P29111, DOI 10.18632/oncotarget.5059; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; Bouquet F, 2011, CLIN CANCER RES, V17, P6754, DOI 10.1158/1078-0432.CCR-11-0544; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CASEY AE, 1951, P SOC EXP BIOL MED, V77, P358; Chatzistamou I, 2011, CELL ONCOL, V34, P483, DOI 10.1007/s13402-011-0044-6; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140; Das S, 2013, J EXP MED, V210, P1509, DOI 10.1084/jem.20111627; Fanti P, 2003, ENDOCRINE, V22, P161, DOI 10.1385/ENDO:22:2:161; Fenner J, 2014, SCI REP-UK, V4, DOI 10.1038/srep05512; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hollmen M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09188; Hu B, 2012, CELL, V149, P1207, DOI 10.1016/j.cell.2012.03.048; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Pitteri SJ, 2011, CANCER RES, V71, P5090, DOI 10.1158/0008-5472.CAN-11-0568; Rafii S, 2003, CANCER CELL, V4, P331, DOI 10.1016/S1535-6108(03)00278-2; Rajaram M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003789; Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Sandhu SK, 2013, CANCER CHEMOTH PHARM, V71, P1041, DOI 10.1007/s00280-013-2099-8; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Torres S, 2013, CLIN CANCER RES, V19, P6006, DOI 10.1158/1078-0432.CCR-13-1130; Trimis G, 2008, HUM MOL GENET, V17, P3596, DOI 10.1093/hmg/ddn252; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007	39	51	53	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6309	6318		10.1038/onc.2016.161	http://dx.doi.org/10.1038/onc.2016.161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181207	Green Accepted			2022-12-28	WOS:000390247000004
J	Sankar, S; Bell, R; Stephens, B; Zhuo, R; Sharma, S; Bearss, DJ; Lessnick, SL				Sankar, S.; Bell, R.; Stephens, B.; Zhuo, R.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.			Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma (vol 32, pg 5089, 2012)	ONCOGENE			English	Correction														Bearss, David/0000-0002-4458-826X				Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525	1	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6155	6156		10.1038/onc.2016.142	http://dx.doi.org/10.1038/onc.2016.142			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27345405	Bronze			2022-12-28	WOS:000388509800012
J	Wang, S; Pan, Y; Zhang, R; Xu, T; Wu, W; Zhang, R; Wang, C; Huang, H; Calin, CA; Yang, H; Claret, FX				Wang, S.; Pan, Y.; Zhang, R.; Xu, T.; Wu, W.; Zhang, R.; Wang, C.; Huang, H.; Calin, C. A.; Yang, H.; Claret, F. X.			Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELL-GROWTH; DNA-DAMAGE; MICRORNAS; BINDING; REPAIR; TUMORIGENESIS; INVOLVEMENT; PROGRESSION; INHIBITION	Radiotherapy is the standard therapy for nasopharyngeal carcinoma (NPC); however, radioresistance can hinder successful treatment. Here we report that microRNA (miR)-24 acts as a tumor suppressor and radiosensitizer in NPC cells and xenografts by targeting Jab1/CSN5. Although accumulating evidence has shown that Jab1/CSN5 functions as an oncoprotein in human cancers, its regulation through miRs has not been described. In this study, we found that Jab1/CSN5 functioned in a manner opposite to that of miR-24 in NPC tumorigenesis and radioresistance. We demonstrated that miR-24 inhibits Jab1/CSN5 translation via direct binding to its 3'untranslated region (3'UTR) and 5'UTR, leading to tumor growth inhibition, and sensitizes NPC tumors to radiation in vivo. Furthermore, silencing Jab1/CSN5 phenocopied the function of miR-24 in NPC cells after ionizing radiation treatment, resulting in increased apoptosis. Finally, we analyzed 50 paired samples of primary and matched recurrent NPC tissues from 25 NPC patients and subjected them to high-throughput genomic quantitative nuclease protection assay for quantifying simultaneously miR and mRNA levels. Our results showed that miR-24 levels were significantly decreased in recurrent NPC and that levels of Jab1/CSN5, as its target, were higher than those in primary NPC. Together, our findings indicate that miR-24 inhibits NPC tumor growth and increases NPC radiosensitivity by directly regulating Jab1/CSN5 and that both miR-24 and Jab1/CSN5 can serve as prognostic markers for NPC recurrence; this, in turn, may provide a promising therapeutic strategy for reversing NPC radioresistance.	[Wang, S.; Wu, W.] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou 510370, Guangdong, Peoples R China; [Wang, S.; Xu, T.; Wang, C.; Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China; [Wang, S.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 6767 Bertner Ave, Houston, TX 77030 USA; [Pan, Y.] Jiangnan Univ, Wuxi Med Sch, Affiliated Hosp, Dept Pathol, Wuxi, Peoples R China; [Zhang, R.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Endoscopy, Guangzhou, Guangdong, Peoples R China; [Xu, T.] Sun Yat Sen Univ, Peoples Hosp Foshan 1, Dept Radiat Oncol, Foshan, Peoples R China; [Huang, H.] Shantou Cent Hosp, Ctr Canc, Dept Radiat, Oncol, Shantou, Peoples R China; [Calin, C. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, C. A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Claret, F. X.] Univ Texas Grad Sch Biomed Sci Houston, Expt Therapeut Acad Program & Canc Biol Program, Houston, TX USA	Guangzhou University of Chinese Medicine; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Jiangnan University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, S (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou 510370, Guangdong, Peoples R China.; Yang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China.; Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 6767 Bertner Ave, Houston, TX 77030 USA.	wangsumei198708@163.com; yanghl@mail.sysu.edu.cn; fxclaret@mdanderson.org	Claret, Francois X/R-2104-2016; Wang, Sumei/V-2800-2019	Claret, Francois X/0000-0003-4629-6495; Wang, Sumei/0000-0002-2011-4019; Pan, Yunbao/0000-0002-6311-2945	China Scholarship Council [201206380043]; National Natural Science Foundation of China [81071837, 81372410, 30670627]; Scientific and Technological Project of Guangdong, China [2008A030201009, 2010B050700016]; National Cancer Institute [R01-CA90853]; Sister Institution Network Fund (FXC); University of Texas MD Anderson Functional Proteomics Core Facility (NCI) [CA16672]; NATIONAL CANCER INSTITUTE [R01CA090853, R01CA182905, P30CA016672] Funding Source: NIH RePORTER	China Scholarship Council(China Scholarship Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific and Technological Project of Guangdong, China; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sister Institution Network Fund (FXC); University of Texas MD Anderson Functional Proteomics Core Facility (NCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michael Worley and the Department of Scientific Publications at MD Anderson Cancer Center for editing the manuscript. This study was supported by a fellowship from the China Scholarship Council (201206380043 to SW), the National Natural Science Foundation of China (81071837, 81372410 and 30670627 to HY) and the Scientific and Technological Project of Guangdong, China (2008A030201009 and 2010B050700016 to HY) and by grants from the National Cancer Institute (R01-CA90853 to FXC), the Sister Institution Network Fund (FXC) and The University of Texas MD Anderson Functional Proteomics Core Facility (NCI Cancer Center Support Grant CA16672).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Chan ATC, 2010, ANN ONCOL, V21, pv187, DOI 10.1093/annonc/mdq186; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Chhabra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-232; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Hsu MC, 2008, CLIN CANCER RES, V14, P4045, DOI 10.1158/1078-0432.CCR-07-5040; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126; Lim WT, 2011, CLIN CANCER RES, V17, P5481, DOI 10.1158/1078-0432.CCR-10-3409; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; MCCARTY KS, 1986, CANCER RES, V46, P4244; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Pan YB, 2012, CANCER LETT, V326, P155, DOI 10.1016/j.canlet.2012.07.033; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Pechhold S, 2009, NAT BIOTECHNOL, V27, P1038, DOI 10.1038/nbt.1579; Qu CJ, 2012, CELL CYCLE, V11, P785, DOI 10.4161/cc.11.4.19228; Qu YM, 2010, J CANCER RES CLIN, V136, P953, DOI 10.1007/s00432-009-0739-5; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; SHAM JST, 1990, LANCET, V335, P371, DOI 10.1016/0140-6736(90)90206-K; Sorrells S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002922; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709; Wang SM, 2014, MOL CANCER THER, V13, P3163, DOI 10.1158/1535-7163.MCT-14-0317; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Xie Y, 2013, ONCOGENE, V32, P2442, DOI 10.1038/onc.2012.258; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008	51	60	64	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6096	6108		10.1038/onc.2016.147	http://dx.doi.org/10.1038/onc.2016.147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157611	Green Accepted			2022-12-28	WOS:000388509800006
J	Jiang, CC; Croft, A; Tseng, HY; Guo, ST; Jin, L; Hersey, P; Zhang, XD				Jiang, C. C.; Croft, A.; Tseng, H-Y; Guo, S. T.; Jin, L.; Hersey, P.; Zhang, X. D.			Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma (vol 33, pg 2577, 2013)	ONCOGENE			English	Correction													Tseng, Cindy Hsin-Yi/AAB-8958-2022	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515				Jiang CC, 2014, ONCOGENE, V33, P2577, DOI 10.1038/onc.2013.237	1	0	0	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6044	6044		10.1038/onc.2016.144	http://dx.doi.org/10.1038/onc.2016.144			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27345411	Bronze			2022-12-28	WOS:000388509400012
J	Agarwal, E; Robb, CM; Smith, LM; Brattain, MG; Wang, J; Black, JD; Chowdhury, S				Agarwal, E.; Robb, C. M.; Smith, L. M.; Brattain, M. G.; Wang, J.; Black, J. D.; Chowdhury, S.			Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis	ONCOGENE			English	Article							HUMAN COLON-CARCINOMA; GROWTH-FACTOR-BETA; BREAST-CANCER; TUMOR-SUPPRESSOR; CELL-MIGRATION; UP-REGULATION; KINASE-B; ACTIN POLYMERIZATION; BLADDER-CANCER; MIM	Survival signaling is critical for the metastatic program of cancer cells. The current study investigated the role of Akt survival proteins in colorectal cancer (CRC) metastasis and explored potential mechanisms of Akt-mediated metastasis regulation. Using an orthotopic implantation model in mice, which uniquely recapitulates the entire multistep process of CRC metastasis, combined with an inducible system of short hairpin RNA-mediated Akt isoform knockdown in human CRC cells, our studies confirm a role of Akt2 in CRC cell dissemination to distant organs in vivo. Akt2 deficiency profoundly inhibited the development of liver lesions in mice, whereas Akt1 had no effect under the experimental conditions used in the study. Array analysis of human metastatic genes identified the scaffolding protein metastasis suppressor 1 (MTSS1) as a novel Akt2-regulated gene. Inducible loss of Akt2 in CRC cells robustly upregulated MTSS1 at the messenger RNA and protein level, and the accumulated protein was functionally active as shown by its ability to engage an MTSS1-Src-cortactin inhibitory axis. MTSS1 expression led to a marked reduction in levels of functional cortacin (pcortactin Y421), an actin nucleation-promoting factor that has a crucial role in cancer cell invasion and metastasis. MTSS1 was also shown to mediate suppressive effects of Akt2 deficiency on CRC cell viability, survival, migration and actin polymerization in vitro. The relevance of these findings to human CRC is supported by analysis of The Cancer Genome Atlas (TCGA) and NCBI GEO data sets, which demonstrated inverse changes in expression of Akt2 and MTSS1 during CRC progression. Taken together, the data identify MTSS1 as a new Akt2-regulated gene, and point to suppression of MTSS1 as a key step in the metastasis-promoting effects of Akt2 in CRC cells.	[Agarwal, E.; Robb, C. M.; Brattain, M. G.; Wang, J.; Black, J. D.] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; [Agarwal, E.; Brattain, M. G.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Smith, L. M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA; [Chowdhury, S.] Boston Univ, Med Ctr, Dept Med, Sect Gastroenterol, EBRC Room 525,650 Albany St, Boston, MA 02118 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Boston University	Black, JD (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA.; Chowdhury, S (corresponding author), Boston Univ, Med Ctr, Dept Med, Sect Gastroenterol, EBRC Room 525,650 Albany St, Boston, MA 02118 USA.	jennifer.black@unmc.edu; sanjib@bu.edu		Agarwal, Ekta/0000-0002-5992-3358	NIH R01 [CA038173, CA054807, DK60632]; UNMC Cancer Center [CA036727]; NATIONAL CANCER INSTITUTE [R01CA054807, R21CA191894, R37CA038173, R01CA038173, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060632, R56DK060632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106397] Funding Source: NIH RePORTER	NIH R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNMC Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH R01 grants CA038173 and CA054807 to MGB, by DK60632 to JDB and by UNMC Cancer Center Support Grant CA036727. We thank Katie Bailey for assistance with animal surgeries; Dr Adrian Black for critical reading of the manuscript and many helpful discussions, as well as analysis of Oncomine data; Drs Babu Guda and Xiao Peng (Bioinformatics and Systems Biology Core, UNMC) for help with The Cancer Genome Atlas database, and the Confocal Imaging and Histology Cores at UNMC for assistance with tissue processing and microscopy.	Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145; Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025; Arboleda MJ, 2003, CANCER RES, V63, P196; Bershteyn M, 2010, DEV CELL, V19, P270, DOI 10.1016/j.devcel.2010.07.009; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chau NM, 2004, BREAST CANCER RES, V6, P55, DOI 10.1186/bcr739; Chaudhary F, 2014, BIOCHEM J, V465, P89; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chowdhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019335; Chowdhury SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068818; Du P, 2013, J EXP THER ONCOL, V10, P91; Du P, 2011, ANTICANCER RES, V31, P3205; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Furbert-Harris PM, 2003, CELL MOL BIOL, V49, P1009; Geng L, 2014, ONCOGENE, V33, P5332, DOI 10.1038/onc.2013.478; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Guo XN, 2007, CANCER RES, V67, P5851, DOI 10.1158/0008-5472.CAN-07-0049; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jahid S, 2012, CANCER DISCOV, V2, P540, DOI 10.1158/2159-8290.CD-11-0267; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin KT, 2012, ONCOL LETT, V3, P11, DOI 10.3892/ol.2011.432; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kruchten AE, 2008, AM J PHYSIOL-CELL PH, V295, pC1113, DOI 10.1152/ajpcell.00238.2008; La Rocca G, 2009, J CELL PHYSIOL, V220, P485, DOI 10.1002/jcp.21796; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Leiphrakpam PD, 2014, CELL SIGNAL, V26, P868, DOI 10.1016/j.cellsig.2014.01.014; Li J, 2016, TUMOR BIOL, V37, P8765, DOI 10.1007/s13277-015-4396-9; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Loberg RD, 2005, INT J ONCOL, V26, P1699; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049067; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; National Cancer Institute, 2010, SEER STAT FACT SHEET; Navenot JM, 2009, MOL PHARMACOL, V75, P1074, DOI 10.1124/mol.108.054270; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schemionek M, 2016, LEUKEMIA, V30, P823, DOI 10.1038/leu.2015.329; Schemionek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125783; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Wang DZ, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/471020; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang J, 2009, J BIOL CHEM, V284, P10912, DOI 10.1074/jbc.M809551200; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams B, 2014, MELANOMA RES, V24, P404, DOI 10.1097/CMR.0000000000000077; WOLMARK N, 1983, CANCER, V51, P1315, DOI 10.1002/1097-0142(19830401)51:7<1315::AID-CNCR2820510723>3.0.CO;2-0; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Wu WY, 2014, MOL CELL BIOCHEM, V388, P249, DOI 10.1007/s11010-013-1916-z; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xu M, 2012, CELL MOL LIFE SCI, V69, P3601, DOI 10.1007/s00018-012-1129-8; Ye SC, 1999, CANCER RES, V59, P4725; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhou L, 2016, PATHOL ONCOL RES, V22, P7, DOI 10.1007/s12253-015-9963-2; Zhou WW, 2012, ACTA BIOCH BIOPH SIN, V44, P838, DOI 10.1093/abbs/gms071	73	30	31	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3104	3118		10.1038/onc.2016.460	http://dx.doi.org/10.1038/onc.2016.460			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068324	Green Accepted			2022-12-28	WOS:000402617900004
J	Main, HG; Xie, J; Muralidhar, GG; Elfituri, O; Xu, H; Kajdacsy-Balla, AA; Barbolina, MV				Main, H. Gurler; Xie, J.; Muralidhar, G. G.; Elfituri, O.; Xu, H.; Kajdacsy-Balla, A. A.; Barbolina, M. V.			Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CX3CR1; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; CANCER; CX(3)CR1; CELLS; EXPRESSION; MIGRATION; ORIGIN; IDENTIFICATION	Epithelial ovarian carcinoma is the most common cause of death from gynecologic cancers largely due to advanced, relapsed and chemotherapy-resistant peritoneal metastasis, which is refractory to the currently used treatment approaches. Mechanisms supporting advanced and relapsed peritoneal metastasis are largely unknown, precluding development of more effective targeted therapies. In this study, we investigated the function of a potentially targetable fractalkine axis in the formation and the development of advanced and relapsed peritoneal metastasis and its impact on patients' outcomes. Our mouse model studies support a role for the fractalkine receptor (CX(3)CR1) in the initiation of peritoneal adhesion important for recolonization of relapsed peritoneal metastasis. We show that downregulation of CX(3)CR1 results in reduction of metastatic burden at several peritoneal sites commonly colonized by advanced and relapsed metastatic ovarian carcinoma. We show that the chemokine fractalkine (CX(3)CL1), an activating ligand of CX(3)CR1, regulates organ-specific peritoneal colonization. High expression of CX(3)CR1 correlates with significantly shorter survival, specifically in post-menopausal patients with advanced and terminal stages of the disease. Taken together, our studies support a key regulatory role for the fractalkine axis in advanced and relapsed peritoneal metastasis in epithelial ovarian carcinoma.	[Main, H. Gurler; Xie, J.; Muralidhar, G. G.; Barbolina, M. V.] Univ Illinois, Dept Biopharmaceut Sci, 833 South Wood St, Chicago, IL 60612 USA; [Elfituri, O.; Xu, H.; Kajdacsy-Balla, A. A.] Univ Illinois, Dept Pathol, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Barbolina, MV (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, 833 South Wood St, Chicago, IL 60612 USA.	mvb@uic.edu	Xie, Jia/L-5939-2019		National Cancer Institute [CA160917]; Ovarian Cancer Research Foundation Liz Tilberis Scholar Award; NATIONAL CANCER INSTITUTE [R21CA160917] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Foundation Liz Tilberis Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs William Beck, Joanna Burdette, Jonna Frasor and Peter Penzes for their helpful suggestions on various methods and data analysis as well as critical reading of the manuscript. This study was supported by the National Cancer Institute (grant # CA160917 to MVB) and Ovarian Cancer Research Foundation Liz Tilberis Scholar Award (to MVB).	Auersperg N, 2011, INT J GYNECOL PATHOL, V30, P12, DOI 10.1097/PGP.0b013e3181f45f3e; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bookman MA, 2012, CLIN OBSTET GYNECOL, V55, P96, DOI 10.1097/GRF.0b013e31824b45da; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Chang SJ, 2015, J GYNECOL ONCOL, V26, P336, DOI 10.3802/jgo.2015.26.4.336; Chi DS, 2012, GYNECOL ONCOL, V124, P10, DOI 10.1016/j.ygyno.2011.08.014; Colombo PE, 2014, CRIT REV ONCOL HEMAT, V89, P207, DOI 10.1016/j.critrevonc.2013.08.017; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Crum CP, 2013, J PATHOL, V231, P402, DOI 10.1002/path.4263; Davis A, 2014, GYNECOL ONCOL, V133, P624, DOI 10.1016/j.ygyno.2014.02.038; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Dorgham K, 2009, J LEUKOCYTE BIOL, V86, P903, DOI 10.1189/jlb.0308158; Dubeau L, 2013, ANN ONCOL, V24, P28, DOI 10.1093/annonc/mdt308; Dubeau L, 2008, LANCET ONCOL, V9, P1191, DOI 10.1016/S1470-2045(08)70308-5; Erreni M, 2016, J IMMUNOL, V196, P902, DOI 10.4049/jimmunol.1501335; Gaudin F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021546; Gurler H, 2015, BIOMOLECULES, V5, P3438, DOI 10.3390/biom5043438; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hundhausen Christian, 2003, Blood, V102, P1186; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Karlstrom S, 2013, J MED CHEM, V56, P3177, DOI 10.1021/jm3012273; Kim M, 2012, MOL CANCER RES, V10, P1419, DOI 10.1158/1541-7786.MCR-12-0361; Kim M, 2012, MOL CANCER RES, V10, P11, DOI 10.1158/1541-7786.MCR-11-0256; Kurman RJ, 2013, ANN ONCOL, V24, P16, DOI 10.1093/annonc/mdt463; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Medina-Contreras O, 2011, J CLIN INVEST, V121, P4787, DOI 10.1172/JCI59150; Pomel Christophe, 2007, Cancer Imaging, V7, P210, DOI 10.1102/1470-7330.2007.0030; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rooper L, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-57; Seward SM, 2015, CANCER METAST REV, V34, P5, DOI 10.1007/s10555-014-9536-y; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tautermann CS, 2014, BIOORG MED CHEM LETT, V24, P4073, DOI 10.1016/j.bmcl.2014.07.009; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Tsubota K, 2009, INVEST OPHTH VIS SCI, V50, P4753, DOI 10.1167/iovs.08-2596; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Walton J, 2016, CANCER RES, V76, P6118, DOI 10.1158/0008-5472.CAN-16-1272; Wiedemeyer WR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00034; Wollberg AR, 2014, P NATL ACAD SCI USA, V111, P5409, DOI 10.1073/pnas.1316510111; Zhang Q, 2004, HUM REPROD, V19, P409, DOI 10.1093/humrep/deh085	52	18	18	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3025	3036		10.1038/onc.2016.456	http://dx.doi.org/10.1038/onc.2016.456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941884	Green Accepted			2022-12-28	WOS:000402000400010
J	Wang, X; Lang, M; Zhao, T; Feng, X; Zheng, C; Huang, C; Hao, J; Dong, J; Luo, L; Li, X; Lan, C; Yu, W; Yu, M; Yang, S; Ren, H				Wang, X.; Lang, M.; Zhao, T.; Feng, X.; Zheng, C.; Huang, C.; Hao, J.; Dong, J.; Luo, L.; Li, X.; Lan, C.; Yu, W.; Yu, M.; Yang, S.; Ren, H.			Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+) Treg cells in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							REGULATORY T-CELLS; TUMOR-CELLS; CARCINOMA CELLS; IMMUNE ESCAPE; MURINE MODEL; EXPRESSION; ANTIBODY; INFILTRATION; INHIBITION; INFECTION	Forkheadbox protein 3 (FOXP3), initially identified as a key transcription factor for regulatory T cells (Treg cells), was also expressed in many tumors including pancreatic ductal adenocarcinoma (PDAC). However, its role in PDAC progression remains elusive. In this study, we utilized 120 PDAC tissues after radical resection to detect cancer-FOXP3 and Treg cells by immunohistochemistry and evaluated clinical and pathological features of these patients. Cancer-FOXP3 was positively correlated with Treg cells accumulation in tumor tissues derived from PDAC patients. In addition, high cancer-FOXP3 expression was associated with increased tumor volumes and poor prognosis in PDAC especially combined with high levels of Treg cells. Overexpression of cancer-FOXP3 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell-depleted mice. Furthermore, CCL5 was directly trans-activated by cancer-FOXP3 and promoted the recruitment of Treg cells from peripheral blood to the tumor site in vitro and in vivo. This finding has been further reinforced by the evidence that Treg cells recruitment by cancer-FOXP3 was impaired by neutralization of CCL5, thereby inhibiting the growth of PDAC. In conclusion, cancer-FOXP3 serves as a prognostic biomarker and a crucial determinant of immunosuppressive microenvironment via recruiting Treg cells by directly trans-activating CCL5. Therefore, cancer-FOXP3 could be used to select patients with better response to CCL5/CCR5 blockade immunotherapy.	[Wang, X.; Lang, M.; Zhao, T.; Zheng, C.; Huang, C.; Hao, J.; Li, X.; Lan, C.; Yu, W.; Ren, H.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Dept Pancreat Canc, Tianjin, Peoples R China; [Feng, X.] Chinese Acad Med Sci, Inst Hematol & Hosp Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China; [Feng, X.] Peking Union Med Coll, Tianjin, Peoples R China; [Dong, J.; Yu, W.] Tianjin Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Tianjin, Peoples R China; [Luo, L.] Hepingqu Gynaecol & Obster Hosp, Dept Gynaecol, Tianjin, Peoples R China; [Yang, S.] Penn State Coll Med, Hershey, PA USA	Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tianjin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ren, H (corresponding author), Tianjin Med Univ, Dept Pancreat Canc, Canc Inst & Hosp, Tianjin 300060, Peoples R China.	renhe@tjmuch.com		WANG, XIUCHAO/0000-0002-3205-8544	National Natural Science Foundation of China [81272685, 81525021, 81672431, 81672435, 81502067, 81302082, 31471340, 31470957, 81401957, 81472264]; National Key Clinical Specialist Construction Programs of China [2013-544]; Key Program of Public Health Bureau Foundation of Tianjin [15KG 144]; NATIONAL CANCER INSTITUTE [R01CA175741] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Clinical Specialist Construction Programs of China; Key Program of Public Health Bureau Foundation of Tianjin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Natural Science Foundation of China (grants 81272685, 81525021, 81672431, 81672435, 81502067, 81302082, 31471340, 31470957, 81401957 and 81472264), the National Key Clinical Specialist Construction Programs of China (no. 2013-544) and Key Program of Public Health Bureau Foundation of Tianjin (15KG 144).	Bayry J, 2008, P NATL ACAD SCI USA, V105, P10221, DOI 10.1073/pnas.0803453105; Borczuk AC, 2008, ONCOGENE, V27, P557, DOI 10.1038/sj.onc.1210662; Cavassani KA, 2006, J IMMUNOL, V177, P5811, DOI 10.4049/jimmunol.177.9.5811; deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216; Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Foley K, 2016, CANCER LETT, V381, P244, DOI 10.1016/j.canlet.2015.12.020; Generali D, 2009, CLIN CANCER RES, V15, P1046, DOI 10.1158/1078-0432.CCR-08-1507; Heinze E, 2009, INT J ONCOL, V35, P167, DOI 10.3892/ijo_00000325; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Jacobs JFM, 2010, CLIN CANCER RES, V16, P5067, DOI 10.1158/1078-0432.CCR-10-1757; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; Kryczek I, 2009, CANCER RES, V69, P3995, DOI 10.1158/0008-5472.CAN-08-3804; Kurose K, 2015, CLIN CANCER RES, V21, P4327, DOI 10.1158/1078-0432.CCR-15-0357; Li X, 2007, CANCER LETT, V253, P144, DOI 10.1016/j.canlet.2007.01.024; Lin YC, 2009, J IMMUNOL, V182, P6095, DOI 10.4049/jimmunol.0803829; Lutz ER, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.962401; Ma C, 2015, BIOCHEM BIOPH RES CO, V458, P234, DOI 10.1016/j.bbrc.2015.01.067; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Menetrier-Caux C, 2012, ONCOIMMUNOLOGY, V1, P759, DOI 10.4161/onci.19680; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Pastille E, 2014, CANCER RES, V74, P4258, DOI 10.1158/0008-5472.CAN-13-3065; Pillarisetty VG, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.950171; Qin XJ, 2009, CLIN CANCER RES, V15, P2231, DOI 10.1158/1078-0432.CCR-08-2641; Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Strauss L, 2009, J IMMUNOL, V182, P1469, DOI 10.4049/jimmunol.182.3.1469; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tang YK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088267; Triulzi T, 2013, J CELL PHYSIOL, V228, P30, DOI 10.1002/jcp.24125; Trujillo G, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-18; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Wang YP, 2014, CANCER RES, V74, P2217, DOI 10.1158/0008-5472.CAN-13-2928; Ward ST, 2015, BRIT J CANCER, V112, P319, DOI 10.1038/bjc.2014.572; Yamamoto T, 2012, PANCREAS, V41, P409, DOI 10.1097/MPA.0b013e3182373a66; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yoshii M, 2012, BRIT J CANCER, V106, P1668, DOI 10.1038/bjc.2012.141; Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956; Zhao TS, 2015, ONCOTARGET, V6, P2250, DOI 10.18632/oncotarget.2948; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	48	120	126	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3048	3058		10.1038/onc.2016.458	http://dx.doi.org/10.1038/onc.2016.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991933	Green Published, hybrid			2022-12-28	WOS:000402000400012
J	Dermit, M; Casado, P; Rajeeve, V; Wilkes, EH; Foxler, DE; Campbell, H; Critchlow, S; Sharp, TV; Gribben, JG; Unwin, R; Cutillas, PR				Dermit, M.; Casado, P.; Rajeeve, V.; Wilkes, E. H.; Foxler, D. E.; Campbell, H.; Critchlow, S.; Sharp, T. V.; Gribben, J. G.; Unwin, R.; Cutillas, P. R.			Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition	ONCOGENE			English	Article							IN-VITRO; MYC; EXPRESSION; THERAPY; REVEALS; PATHWAY; APOPTOSIS; HYPOXIA; SGK1	Compounds targeting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling are being investigated in multiple clinical settings, but drug resistance may reduce their benefit. Compound rechallenge after drug holidays can overcome such resistance, yet little is known about the impact of drug holidays on cell biochemistry. We found that PI3K inhibitor (PI3Ki)-resistant cells cultured in the absence of PI3Ki developed a proliferative defect, increased oxygen consumption and accumulated reactive oxygen species (ROS), leading to lactate production through hypoxia-inducible factor-1 alpha. This metabolic imbalance was reversed by mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Interestingly, neither AKT nor c-MYC was involved in mediating the metabolic phenotype, despite the latter contributing to resistant cells' proliferation. These data suggest that an AKT-independent PI3K/mTORC1 axis operates in these cells. The excessive ROS hampered cell division, and the metabolic phenotype made resistant cells more sensitive to hydrogen peroxide and nutrient starvation. Thus, the proliferative defect of PI3Ki-resistant cells during drug holidays is caused by defective metabolic adaptation to chronic PI3K/ mTOR pathway inhibition. This metabolic imbalance may open the therapeutic window for challenge with metabolic drugs during drug holidays.	[Dermit, M.; Casado, P.; Rajeeve, V.; Wilkes, E. H.; Cutillas, P. R.] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, Cell Signalling Prote, London, England; [Foxler, D. E.; Sharp, T. V.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Campbell, H.; Critchlow, S.] AstraZeneca, Oncol iMED, Macclesfield, Cheshire, England; [Gribben, J. G.] Queen Mary Univ London, Barts Canc Inst, Canc Immunol Grp, Ctr Haematooncol, London, England; [Unwin, R.] UCL, UCL Ctr Nephrol, Royal Free Campus & Hosp, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London; AstraZeneca; University of London; Queen Mary University London; University of London; University College London	Cutillas, PR (corresponding author), Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	p.cutillas@qmul.ac.uk	Izquierdo, Pedro Casado/AAD-9960-2021; Dermit, Maria/AAH-9618-2019; Sharp, Tyson/AAD-6190-2020	Izquierdo, Pedro Casado/0000-0002-4207-9349; Sharp, Tyson/0000-0003-1861-7984; Foxler, Daniel/0000-0003-3753-0278; Dermit, Maria/0000-0002-6287-8367	St Peters Trust; Barts and The London Charity [BLT 297/2249]; BBSRC [BB/M006174/1]; BBSRC [BB/G015023/1, BB/L027755/1] Funding Source: UKRI; MRC [MR/N009185/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/L027755/1, BB/M006174/1, BB/G015023/1] Funding Source: researchfish; Cancer Research UK [12733] Funding Source: researchfish; Medical Research Council [MR/N009185/1] Funding Source: researchfish	St Peters Trust; Barts and The London Charity; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Gemma Bridge for advice with Seahorse experiments and Dr Soong and Dr Baselga for kindly providing LB771-HNC, CAL33, KYSE70 and KYSE180 parental/resistant pairs of cells. This work was supported by St Peters Trust and Barts and The London Charity (BLT 297/2249). PRC was supported by BBSRC Grant BB/M006174/1	Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; Bey EA, 2007, P NATL ACAD SCI USA, V104, P11832, DOI 10.1073/pnas.0702176104; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Carracedo A, 2008, CELL CYCLE, V7, P3805, DOI 10.4161/cc.7.24.7244; Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454; Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanfstein B, 2011, HAEMATOL-HEMATOL J, V96, P360, DOI 10.3324/haematol.2010.030999; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kessler J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-605; Kim SY, 2006, EXP MOL MED, V38, P535, DOI 10.1038/emm.2006.63; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Mahalingaiah PKS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087371; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Miskimins WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085576; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Park JH, 2013, BIOCHEM BIOPH RES CO, V433, P420, DOI 10.1016/j.bbrc.2013.02.108; Piguet AC, 2014, CLIN SCI, V126, P775, DOI 10.1042/CS20130081; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Rehan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109705; Sceneay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066388; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Tagami M, 1998, LAB INVEST, V78, P1415; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Widlansky ME, 2011, ANTIOXID REDOX SIGN, V15, P1517, DOI 10.1089/ars.2010.3642; Wilkes EH, 2015, P NATL ACAD SCI USA, V112, P7719, DOI 10.1073/pnas.1423344112; Zhu CP, 2014, SCI REP-UK, V4, DOI 10.1038/srep05029	50	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2762	2774		10.1038/onc.2016.435	http://dx.doi.org/10.1038/onc.2016.435			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991931	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000401120900013
J	Yu, X; Li, S				Yu, X.; Li, S.			Non- metabolic functions of glycolytic enzymes in tumorigenesis	ONCOGENE			English	Review							PYRUVATE-KINASE M2; AUTOCRINE MOTILITY FACTOR; LACTATE-DEHYDROGENASE; PROTEIN-KINASE; ACETYL-COA; HISTONE MODIFICATION; GENE-TRANSCRIPTION; HEXOKINASE-II; CELL-GROWTH; CANCER	Cancer cells reprogram their metabolism to meet the requirement for survival and rapid growth. One hallmark of cancer metabolism is elevated aerobic glycolysis and reduced oxidative phosphorylation. Emerging evidence showed that most glycolytic enzymes are deregulated in cancer cells and play important roles in tumorigenesis. Recent studies revealed that all essential glycolytic enzymes can be translocated into nucleus where they participate in tumor progression independent of their canonical metabolic roles. These noncanonical functions include anti-apoptosis, regulation of epigenetic modifications, modulation of transcription factors and co-factors, extracellular cytokine, protein kinase activity and mTORC1 signaling pathway, suggesting that these multifaceted glycolytic enzymes not only function in canonical metabolism but also directly link metabolism to epigenetic and transcription programs implicated in tumorigenesis. These findings underscore our understanding about how tumor cells adapt to nutrient and fuel availability in the environment and most importantly, provide insights into development of cancer therapy.	[Yu, X.; Li, S.] Hubei Univ, Coll Life Sci, Hubei Collaborat Innovat Ctr Green Transformat Bi, Wuhan, Hubei, Peoples R China	Hubei University	Li, S (corresponding author), Hubei Univ, Coll Life Sci, 368 Youyi Rd, Wuhan 430062, Hubei, Peoples R China.	shanshanyxl@hotmail.com	Li, Shanshan/AAF-4758-2020	Li, Shanshan/0000-0002-0359-2369; Li, Shanshan/0000-0002-6424-2792	National Nature Science Foundation of China [31671335, 31600046]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We apologize to colleagues whose work cannot be cited here because of space limitation. We thank members of Li laboratory for critical reading of this manuscript. This work was funded by grants from National Nature Science Foundation of China (No. 31671335 to S Li; No. 31600046 to X Yu).	ADAMS V, 1991, BIOCHEM BIOPH RES CO, V177, P1101, DOI 10.1016/0006-291X(91)90652-N; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Araki K, 2009, J BIOL CHEM, V284, P32305, DOI 10.1074/jbc.M109.008250; Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200; Boukouris AE, 2016, TRENDS BIOCHEM SCI, V41, P712, DOI 10.1016/j.tibs.2016.05.013; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Castonguay Z, 2014, BIOCHEM BIOPH RES CO, V454, P172, DOI 10.1016/j.bbrc.2014.10.071; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Fairbank M, 2009, MOL BIOSYST, V5, P793, DOI 10.1039/b820820b; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Fan J, 2015, ACS CHEM BIOL, V10, P95, DOI 10.1021/cb500846u; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Friis RMN, 2009, NUCLEIC ACIDS RES, V37, P3969, DOI 10.1093/nar/gkp270; Fu M, 2011, CELL DEATH DIFFER, V18, P1057, DOI 10.1038/cdd.2010.181; Galdieri L, 2016, MOL CELL BIOL, V36, P1064, DOI 10.1128/MCB.00770-15; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Gong L, 2014, ANTI-CANCER AGENT ME, V14, P771, DOI 10.2174/1871520614666140416105309; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; Gruning NM, 2011, CELL METAB, V14, P415, DOI 10.1016/j.cmet.2011.06.017; Haga A, 2003, INT J CANCER, V107, P707, DOI 10.1002/ijc.11449; He CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21524; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043; Katoh Y, 2011, MOL CELL, V41, P554, DOI 10.1016/j.molcel.2011.02.018; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kennedy KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075154; Kera Y, 2013, J BIOL CHEM, V288, P13592, DOI 10.1074/jbc.M112.429738; Khalid MH, 1999, J NEUROSURG, V90, P918, DOI 10.3171/jns.1999.90.5.0918; Kho DH, 2014, CANCER RES, V74, P2229, DOI 10.1158/0008-5472.CAN-13-2937; Kho DH, 2013, CANCER RES, V73, P1411, DOI 10.1158/0008-5472.CAN-12-2149; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; Kong LB, 2016, ARCH VIROL, V161, P2149, DOI 10.1007/s00705-016-2892-x; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Lee MN, 2009, MOL CELL BIOL, V29, P3991, DOI 10.1128/MCB.00165-09; Li SS, 2015, MOL CELL, V60, P408, DOI 10.1016/j.molcel.2015.09.024; Li SS, 2014, REV MED VIROL, V24, P223, DOI 10.1002/rmv.1783; Li SS, 2009, J BIOL CHEM, V284, P9411, DOI 10.1074/jbc.M809617200; Li S, 2008, P NATL ACAD SCI USA, V105, P18243, DOI 10.1073/pnas.0804530105; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Lucarelli G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002117; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Matsuda S, 2016, NUCLEIC ACIDS RES, V44, P636, DOI 10.1093/nar/gkv967; McBrian MA, 2013, MOL CELL, V49, P310, DOI 10.1016/j.molcel.2012.10.025; Mehrotra S, 2014, BBA-GENE REGUL MECH, V1839, P751, DOI 10.1016/j.bbagrm.2014.05.029; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; Olson KA, 2016, TRENDS BIOCHEM SCI, V41, P219, DOI 10.1016/j.tibs.2016.01.002; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ringel AE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003871; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ryall JG, 2015, CELL STEM CELL, V17, P651, DOI 10.1016/j.stem.2015.11.012; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140; Su XY, 2016, CURR OPIN CHEM BIOL, V30, P52, DOI 10.1016/j.cbpa.2015.10.030; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Sun S, 2015, BRIT J CANCER, V112, P1332, DOI 10.1038/bjc.2015.114; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Tanaka Y, 2015, MOL CELL BIOL, V35, P4170, DOI 10.1128/MCB.00579-15; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Ventura M, 2010, INT J BIOCHEM CELL B, V42, P1672, DOI 10.1016/j.biocel.2010.06.014; WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987; Xu YF, 2012, MOL CELL, V48, P52, DOI 10.1016/j.molcel.2012.07.013; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhang JY, 2015, CANCER BIOL MED, V12, P10, DOI 10.7497/j.issn.2095-3941.2014.0019; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	85	69	70	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2629	2636		10.1038/onc.2016.410	http://dx.doi.org/10.1038/onc.2016.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27797379				2022-12-28	WOS:000401120900001
J	Liu, H; Qiu, H; Song, Y; Liu, Y; Wang, H; Lu, M; Deng, M; Gu, Y; Yin, J; Luo, K; Zhang, Z; Jia, X; Zheng, G; He, Z				Liu, H.; Qiu, H.; Song, Y.; Liu, Y.; Wang, H.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.			Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; EPITHELIAL-MESENCHYMAL TRANSITION; KINASE INHIBITOR P27; C-MYC; CLINICAL-IMPLICATIONS; PHOSPHORYLATES P27; CYTOPLASMIC P27; PARP INHIBITION; POOR-PROGNOSIS; LUNG-CANCER	Triple-negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets; as a consequence, TNBC exhibits poor clinical outcome. In this study, we showed that cancerous inhibitor of protein phosphatase 2A (Cip2a) represents a promising target in TNBC because Cip2a was highly expressed in TNBC cells and tumor tissues, and its expression showed an inverse correlation with overall survival in patients with TNBC. We found that inhibition of Cip2a in TNBC cells induced cell cycle arrest at the G2/M phase, inhibited cell proliferation and delayed tumor growth in the xenograft model. Moreover, Cip2a markedly decreased the expression and nuclear localization of p27Kip1 and this is critical for the ability of Cip2a to promote TNBC progression. Mechanistically, our studies showed that Cip2a promoted p27Kip1 phosphoration at Ser10 via inhibiting Akt-associated PP2A activity, which seems to relocalize p27Kip1 to the cytoplasm in TNBC cells. On the other hand, Cip2a also recruited c-myc to mediate the transcriptional inhibition of p27Kip1. Notably, we observed negative correlation between Cip2a and p27Kip1 expression in TNBC specimens. In addition, our data showed that Cip2a depletion could sensitize TNBC to PARP inhibition. Collectively, these data suggested that Cip2a effectively promotes TNBC cell cycle progression and tumor growth via regulation of PP2A/c-myc/p27Kip1 signaling, which could serve as a potential therapeutic target for TNBC patients.	[Liu, H.; Qiu, H.; Song, Y.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.] Guangzhou Med Univ, Canc Hosp, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [Liu, H.; Qiu, H.; Song, Y.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.] Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [Liu, Y.] Guangdong Inst Microbiol, Guangdong Prov Key Lab Microbial Culture Collect, Guangzhou, Guangdong, Peoples R China; [Wang, H.] Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial & Biochem Pharm, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; Sun Yat Sen University	He, Z (corresponding author), Guangzhou Med Univ, Canc Hosp, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.; He, Z (corresponding author), Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.	hezhimin2005@yahoo.com		Liu, Hao/0000-0001-6338-4003	National Natural Science Foundation of China [81472184, 81402497]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81472184, No. 81402497).	Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldacchino S, 2014, EPMA J, V5, DOI 10.1186/1878-5085-5-3; Bockelman C, 2012, CANCER BIOL THER, V13, P289, DOI [10.4161/cbt.18922, 10.4161/cbt.13.5.18922]; Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Choi YA, 2011, FEBS LETT, V585, P755, DOI 10.1016/j.febslet.2011.01.018; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; De P, 2015, AM J CANCER RES, V5, P2872; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hnit SST, 2015, INT J BIOCHEM CELL B, V68, P9, DOI 10.1016/j.biocel.2015.08.005; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Iwase H, 2010, BREAST CANCER-TOKYO, V17, P118, DOI 10.1007/s12282-009-0113-0; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2015, ONCOTARGET, V6, P19661, DOI 10.18632/oncotarget.3875; Khanna A, 2013, CANCER RES, V73, P6548, DOI 10.1158/0008-5472.CAN-13-1994; Kim JS, 2013, CANCER RES, V73, P6667, DOI 10.1158/0008-5472.CAN-13-0888; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292; Lee TY, 2010, J BIOL CHEM, V285, P21567, DOI 10.1074/jbc.M109.094953; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2015, ONCOTARGET, V6, P14913, DOI 10.18632/oncotarget.3818; Lucas CM, 2011, BLOOD, V117, P6660, DOI 10.1182/blood-2010-08-304477; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Nacusi LP, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-11; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Niemela M, 2012, ONCOGENE, V31, P4266, DOI 10.1038/onc.2011.599; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Puustinen P, 2014, J CELL BIOL, V204, P713, DOI 10.1083/jcb.201304012; Qu W, 2012, MED ONCOL, V29, P113, DOI 10.1007/s12032-010-9768-9; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; See WL, 2010, ONCOGENE, V29, P1720, DOI 10.1038/onc.2009.465; Serres MP, 2011, ONCOGENE, V30, P2846, DOI 10.1038/onc.2011.9; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tseng LM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3175; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wu Y, 2015, CANCER LETT, V356, P646, DOI 10.1016/j.canlet.2014.10.013; Yanagi T, 2014, CANCER RES, V74, P5795, DOI 10.1158/0008-5472.CAN-14-0872; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yu GZ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0524-9; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473	58	14	15	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1952	1964		10.1038/onc.2016.355	http://dx.doi.org/10.1038/onc.2016.355			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694903				2022-12-28	WOS:000398898500006
J	McNair, C; Urbanucci, A; Comstock, CES; Augello, MA; Goodwin, JF; Launchbury, R; Zhao, SG; Schiewer, MJ; Ertel, A; Karnes, J; Davicioni, E; Wang, L; Wang, Q; Mills, IG; Feng, FY; Li, W; Carroll, JS; Knudsen, KE				McNair, C.; Urbanucci, A.; Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; Launchbury, R.; Zhao, S. G.; Schiewer, M. J.; Ertel, A.; Karnes, J.; Davicioni, E.; Wang, L.; Wang, Q.; Mills, I. G.; Feng, F. Y.; Li, W.; Carroll, J. S.; Knudsen, K. E.			Cell cycle-coupled expansion of AR activity promotes cancer progression	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; RESISTANT PROSTATE-CANCER; ANDROGEN RECEPTOR; TRANSCRIPTIONAL REGULATION; CERAMIDE 1-PHOSPHATE; SIGNALING PATHWAYS; DNA-REPAIR; IN-VITRO; C-JUN; GROWTH	The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While initially effective, recurrent tumors ultimately arise for which there is no durable cure. Despite the dependence of PCa on AR activity throughout the course of disease, delineation of the AR-dependent transcriptional network that governs disease progression remains elusive, and the function of AR in mitotically active cells is not well understood. Analyzing AR activity as a function of cell cycle revealed an unexpected and highly expanded repertoire of AR-regulated gene networks in actively cycling cells. New AR functions segregated into two major clusters: those that are specific to cycling cells and retained throughout the mitotic cell cycle ('Cell Cycle Common'), versus those that were specifically enriched in a subset of cell cycle phases ('Phase Restricted'). Further analyses identified previously unrecognized AR functions in major pathways associated with clinical PCa progression. Illustrating the impact of these unmasked AR-driven pathways, dihydroceramide desaturase 1 was identified as an AR-regulated gene in mitotically active cells that promoted pro-metastatic phenotypes, and in advanced PCa proved to be highly associated with development of metastases, recurrence after therapeutic intervention and reduced overall survival. Taken together, these findings delineate AR function in mitotically active tumor cells, thus providing critical insight into the molecular basis by which AR promotes development of lethal PCa and nominate new avenues for therapeutic intervention.	[McNair, C.; Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; Schiewer, M. J.; Ertel, A.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA; [Urbanucci, A.; Mills, I. G.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway NCMM, Prostate Canc Res Grp, Oslo, Norway; [Urbanucci, A.; Mills, I. G.] Oslo Univ Hosp, Oslo, Norway; [Urbanucci, A.; Mills, I. G.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway; [Launchbury, R.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge Res Inst, Cambridge, England; [Zhao, S. G.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Karnes, J.; Wang, L.] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Rochester, MN USA; [Davicioni, E.] GenomeDx Biosci, San Diego, CA USA; [Wang, Q.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Mills, I. G.] Queens Univ, Ctr Canc Res & Cell Biol, Prostate Canc UK Movember Ctr Excellence Prostat, Belfast, Antrim, North Ireland; [Feng, F. Y.] Univ Calif San Francisco, Dept Radiat Oncol Urol & Med, San Francisco, CA 94143 USA; [Feng, F. Y.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Li, W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Li, W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Jefferson University; University of Oslo; University of Oslo; University of Oslo; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Michigan System; University of Michigan; Mayo Clinic; GenomeDx Biosciences; University System of Ohio; Ohio State University; Queens University Belfast; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.; Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Urol, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.; Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu	Mills, Ian/AAK-9292-2020; zhao, shuangling/HCI-6255-2022; Urbanucci, Alfonso/S-4450-2019	Mills, Ian/0000-0001-5347-5083; Urbanucci, Alfonso/0000-0003-2931-3652; Wang, Liguo/0000-0003-2072-4826; Knudsen, Karen/0000-0002-1301-890X; Schiewer, Matthew/0000-0002-2325-4228; McNair, Christopher/0000-0003-3204-8482; Carroll, Jason/0000-0003-3643-0080	PCF; NCI [CA159945, CA176401]; Pennsylvania Department of Health;  [R01HG007538];  [R01CA193466];  [P30-CA056036]; Cancer Research UK [20411] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA159945, R01CA176401, P30CA056036, R01CA193466] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG007538] Funding Source: NIH RePORTER	PCF; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pennsylvania Department of Health; ; ; ; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We gratefully thank Mandeep Takhar for her assistance in providing microarray data analysis, K Knudsen lab members for their input, Bin Fang for assistance in creation of motif diagrams and E Schade for graphical support and expertise. This work was supported by grants to WL (R01HG007538 and R01CA193466), SGZ by the PCF, and to KEK by grants from the NCI (CA159945, CA176401), P30-CA056036, and in part by a grant to KEK with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions.	Augello MA, 2015, EMBO MOL MED, V7, P628, DOI 10.15252/emmm.201404242; Augello MA, 2014, CANCER METAST REV, V33, P399, DOI 10.1007/s10555-013-9471-3; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Barfeld SJ, 2014, ENDOCR-RELAT CANCER, V21, pT57, DOI 10.1530/ERC-13-0515; Beekman KW, 2008, UROL ONCOL-SEMIN ORI, V26, P415, DOI 10.1016/j.urolonc.2007.11.003; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Chen SY, 2006, ONCOGENE, V25, P7212, DOI 10.1038/sj.onc.1209705; Chua SS, 2004, VITAM HORM, V68, P231; Comstock CES, 2013, ONCOGENE, V32, P5481, DOI 10.1038/onc.2013.83; Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138; Gangoiti P, 2008, CELL SIGNAL, V20, P726, DOI 10.1016/j.cellsig.2007.12.008; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Grabowska MM, 2014, MOL ENDOCRINOL, V28, P949, DOI 10.1210/me.2013-1213; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Jian H, 2015, CELL SIGNAL, V27, P1208, DOI 10.1016/j.cellsig.2015.02.027; Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Knudsen KE, 1999, CANCER RES, V59, P2297; Koryakina Y, 2015, ENDOCR-RELAT CANCER, V22, P249, DOI 10.1530/ERC-14-0549; Lazarini M, 2013, BBA-MOL BASIS DIS, V1832, P365, DOI 10.1016/j.bbadis.2012.11.010; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Liu WS, 2015, ONCOTARGET, V6, P8851, DOI 10.18632/oncotarget.3316; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Mallik I, 2008, BBA-MOL CELL RES, V1783, P1737, DOI 10.1016/j.bbamcr.2008.05.006; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Venant H, 2015, MOL CANCER THER, V14, P2744, DOI 10.1158/1535-7163.MCT-15-0279; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Williams K, 2012, CANCER RES, V72, P5407, DOI 10.1158/0008-5472.CAN-12-1158; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Yun EJ, 2015, ONCOGENE, V34, P2741, DOI 10.1038/onc.2014.215; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhou W, 2009, MOL CARCINOGEN, V48, P886, DOI 10.1002/mc.20533	65	24	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1655	1668		10.1038/onc.2016.334	http://dx.doi.org/10.1038/onc.2016.334			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27669432	Green Accepted, Green Submitted			2022-12-28	WOS:000397460600005
J	Deng, Y; Cheng, J; Fu, B; Liu, W; Chen, G; Zhang, Q; Yang, Y				Deng, Y.; Cheng, J.; Fu, B.; Liu, W.; Chen, G.; Zhang, Q.; Yang, Y.			Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; TUMOR MICROENVIRONMENT; PERIPHERAL-BLOOD; T-CELLS; INFLAMMATION; MECHANISM; PROMOTE; MODULATION; EXPANSION; MELANOMA	A major barrier to effective cancer immunotherapy is immune suppression in favor of tumor progression. Additionally, the accumulation of myeloid-derived suppressor cells (MDSCs) has recently been recognized as a major mechanism of the promotion of immune suppression. However, how MDSCs are induced and the cells from which they arise remains unknown. Although studies have demonstrated that tumor-derived cytokines promote MDSC accumulation and activation, little is known regarding the role of the tumor stroma in MDSC accumulation and activation. In this study, we identified a novel mechanism of MDSC differentiation. Tumor-associated fibroblasts (TAFs) attracted monocytes by the stromal cell-derived factor (SDF)-1a/CXCR4 pathway and induced their differentiation into MDSCs through interleukin (IL)-6-mediated STAT3 activation. TAF-treated monocytes (T-MDSCs) then impaired T-cell proliferation and altered the phenotype and/or function of T-cells in an STAT3-dependent manner. CD11b(+) myeloid cells, which resembled T-MDSCs both phenotypically and functionally, were primarily in the peritumoral stroma and a positive association with TAFs in vivo. Additionally, a negative association between CD11b(+) myeloid cell densities and overall survival was observed. An increased number of stromal CD11b(+) myeloid cells was correlated with Hepatocellular Carcinoma (HCC) progression. Together, our results are the first to show that TAF-derived cytokines, such as IL-6 and SDF-1a, can induce MDSC generation and activation and then impair human anti-tumor immune responses, which create favorable conditions for HCC progression. These data also suggest an important role for STAT3 activation in TAF-mediated MDSC generation and MDSC-mediated immune suppression. Consequently, methods in which immunotherapy is combined with IL-6, SDF-1a or STAT3 inhibition may offer an improved option to eliminate suppressive CD11b(+) myeloid cells in HCC patients.	[Deng, Y.; Cheng, J.; Fu, B.; Chen, G.; Yang, Y.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Deng, Y.; Cheng, J.; Liu, W.; Chen, G.; Zhang, Q.; Yang, Y.] Guangdong Prov Key Lab Liver Dis Res, Guangzhou, Guangdong, Peoples R China; [Zhang, Q.] Sun Yat Sen Univ, Affiliated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou 510630, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Yang, Y (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.; Zhang, Q (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou 510630, Guangdong, Peoples R China.	kee_kee@126.com; yysysu@163.com	yang, yang/HGT-7999-2022; Lang, Ming/HIK-0758-2022; yang, yang/GVT-5210-2022	Zhang, Qi/0000-0001-9916-8919	National Natural Science Foundation of China [81372243, 81172036, 81170451, 81370575, 81370555]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by: National Natural Science Foundation of China (81372243, 81172036, 81170451, 81370575, 81370555).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Balsamo M, 2009, P NATL ACAD SCI USA, V106, P20847, DOI 10.1073/pnas.0906481106; Barclay WW, 2008, STEM CELLS, V26, P600, DOI 10.1634/stemcells.2007-0309; Barnas JL, 2010, J IMMUNOL, V185, P2681, DOI 10.4049/jimmunol.1000896; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Berking C, 2001, CANCER RES, V61, P8306; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Fortin CF, 2007, BIOGERONTOLOGY, V8, P173, DOI 10.1007/s10522-006-9067-1; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jia CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063243; Kuang DM, 2008, J IMMUNOL, V181, P3089, DOI 10.4049/jimmunol.181.5.3089; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kusmartsev S, 2008, CLIN CANCER RES, V14, P8270, DOI 10.1158/1078-0432.CCR-08-0165; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Li TJ, 2012, CANCER LETT, V318, P154, DOI 10.1016/j.canlet.2011.12.020; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Mandruzzato S, 2009, J IMMUNOL, V182, P6562, DOI 10.4049/jimmunol.0803831; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Ohishi W, 2014, INT J CANCER, V134, P154, DOI 10.1002/ijc.28337; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Su XM, 2010, J IMMUNOL, V184, P1630, DOI 10.4049/jimmunol.0902813; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yan DH, 2013, EUR J IMMUNOL, V43, P2943, DOI 10.1002/eji.201343472; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505	48	86	98	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1090	1101		10.1038/onc.2016.273	http://dx.doi.org/10.1038/onc.2016.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593937				2022-12-28	WOS:000395371500007
J	Wang, F; Gao, C; Lu, J; Tatetsu, H; Williams, DA; Muller, LU; Cui, W; Chai, L				Wang, F.; Gao, C.; Lu, J.; Tatetsu, H.; Williams, D. A.; Mueller, L. U.; Cui, W.; Chai, L.			Leukemic survival factor SALL4 contributes to defective DNA damage repair	ONCOGENE			English	Article							EARLY EMBRYONIC-DEVELOPMENT; FANCONI-ANEMIA PATHWAY; STEM-CELL FACTOR; HEMATOPOIETIC STEM; OKIHIRO-SYNDROME; HOMOLOGOUS RECOMBINATION; MUTATIONS; GENE; FANCD2; MONOUBIQUITINATION	SALL4 is aberrantly expressed in human myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We have generated a SALL4 transgenic (SALL4B Tg) mouse model with pre-leukemic MDS-like symptoms that transform to AML over time. This makes our mouse model applicable for studying human MDS/AML diseases. Characterization of the leukemic initiation population in this model leads to the discovery that Fancl (Fanconi anemia, complementation group L) is downregulated in SALL4B Tg leukemic and pre-leukemic cells. Similar to the reported Fanconi anemia (FA) mouse model, chromosomal instability with radial changes can be detected in pre-leukemic SALL4B Tg bone marrow (BM) cells after DNA damage challenge. Results from additional studies using DNA damage repair reporter assays support a role of SALL4 in inhibiting the homologous recombination pathway. Intriguingly, unlike the FA mouse model, after DNA damage challenge, SALL4B Tg BM cells can survive and generate hematopoietic colonies. We further elucidated that the mechanism by which SALL4 promotes cell survival is through Bcl2 activation. Overall, our studies demonstrate for the first time that SALL4 has a negative impact in DNA damage repair, and support the model of dual functional properties of SALL4 in leukemogenesis through inhibiting DNA damage repair and promoting cell survival.	[Wang, F.; Gao, C.; Lu, J.; Tatetsu, H.; Chai, L.] Harvard Med Sch, Brigham & Womens Hosp, Joint Program Transfus Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Wang, F.; Cui, W.] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China; [Wang, F.; Cui, W.] Chinese Acad Med Sci, Beijing, Peoples R China; [Williams, D. A.; Mueller, L. U.] Harvard Med Sch, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA; [Mueller, L. U.] Genentech Inc, San Francisco, CA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Harvard University; Boston Children's Hospital; Harvard Medical School; Roche Holding; Genentech	Chai, L (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Joint Program Transfus Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Cui, W (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing 100730, Peoples R China.	cuiw@pumch.cn; lchai@partners.org		Chai, Li/0000-0003-1937-4750	NIH [R03CA184531, PO1HL095489]; Lymphoma and Leukemia Society [SLP-8004-14, TRP-6482-16]; V cancer research Foundation; National Natural Science Foundation of China (NSFC) [81071418, 81472029]; China Scholarship Council [201206210154]; NATIONAL CANCER INSTITUTE [R03CA184531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL095489] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lymphoma and Leukemia Society(Leukemia and Lymphoma Society); V cancer research Foundation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	L Chai and W Cui designed the research, analyzed data and wrote the paper. F Wang and C Gao performed the research experiments, analyzed data and wrote the paper. J Lu and H Tatetsu performed the research experiments and analyzed the data. D Williams provided Fanca - / - mice and edited the paper. L Muller performed Fanca - / - mice related experiments. We also want to thank Dr S Xiao for providing DNA repair reporter plasmids, X Yao, and D Neuberg for statistic analysis, X Tian in assisting animal work, and N Kong in editing of the manuscript. This work was supported in part through NIH R03CA184531 and PO1HL095489, funding from Lymphoma and Leukemia Society (No. SLP-8004-14 and TRP-6482-16) and V cancer research Foundation (to L Chai), by the National Natural Science Foundation of China (NSFC) - 81071418 and 81472029 (to W Cui), and China Scholarship Council (No. 201206210154) (to F Wang).	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Alpi AF, 2008, MOL CELL, V32, P767, DOI 10.1016/j.molcel.2008.12.003; Alsner J, 2008, ACTA ONCOL, V47, P600, DOI 10.1080/02841860802047411; Bejar R, 2014, J CLIN ONCOL, V32, P2691, DOI 10.1200/JCO.2013.52.3381; Borozdin W, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019505; Cui W, 2006, MODERN PATHOL, V19, P1585, DOI 10.1038/modpathol.3800694; D'Andrea AD, 2010, NEW ENGL J MED, V362, P1909, DOI 10.1056/NEJMra0809889; Gao C, 1999, INT J MOL MED, V4, P291; Gao C, 2013, TRANSFUSION, V53, P1037, DOI 10.1111/j.1537-2995.2012.03888.x; Gurtan AM, 2006, J BIOL CHEM, V281, P10896, DOI 10.1074/jbc.M511411200; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hess CJ, 2008, CELL ONCOL, V30, P299, DOI 10.3233/CLO-2008-0426; Huard CC, 2014, P NATL ACAD SCI USA, V111, P2152, DOI 10.1073/pnas.1314226111; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Li AL, 2013, J CLIN INVEST, V123, P4195, DOI 10.1172/JCI62891; Lu J, 2011, LEUKEMIA, V25, P1211, DOI 10.1038/leu.2011.65; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Mao ZY, 2007, P NATL ACAD SCI USA, V104, P13068, DOI 10.1073/pnas.0702410104; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Milsom MD, 2009, BLOOD, V113, P5111, DOI 10.1182/blood-2008-09-180224; Muller LUW, 2008, MOL THER, V16, P1154, DOI 10.1038/mt.2008.67; Oostra AB, 2012, ANEMIA, V2012, DOI 10.1155/2012/238731; Paradisi I, 2007, AM J MED GENET A, V143A, P326, DOI 10.1002/ajmg.a.31603; Rego MA, 2012, BLOOD, V120, P2109, DOI 10.1182/blood-2012-02-410472; Rio P, 2002, BLOOD, V100, P2032; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Seluanov A., 2010, J VIS EXP; Singh TR, 2009, BLOOD, V114, P174, DOI 10.1182/blood-2009-02-207811; Wang F, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-73; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Warren M, 2007, GENESIS, V45, P51, DOI 10.1002/dvg.20264; Will B, 2010, BLOOD, V115, P2901, DOI 10.1182/blood-2009-03-209544; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	42	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6087	6095		10.1038/onc.2016.146	http://dx.doi.org/10.1038/onc.2016.146			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132514	Green Accepted, Green Submitted			2022-12-28	WOS:000388509800005
J	Zhao, C; Chen, X; Zang, D; Lan, X; Liao, S; Yang, C; Zhang, P; Wu, J; Li, X; Liu, N; Liao, Y; Huang, H; Shi, X; Jiang, L; Liu, X; He, Z; Dou, QP; Wang, X; Liu, J				Zhao, C.; Chen, X.; Zang, D.; Lan, X.; Liao, S.; Yang, C.; Zhang, P.; Wu, J.; Li, X.; Liu, N.; Liao, Y.; Huang, H.; Shi, X.; Jiang, L.; Liu, X.; He, Z.; Dou, Q. P.; Wang, X.; Liu, J.			A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy	ONCOGENE			English	Article							ANTIRHEUMATIC AGENT AURANOFIN; ACID INDUCES APOPTOSIS; MYELOID-LEUKEMIA CELLS; GAMBOGIC ACID; 26S PROTEASOME; IN-VITRO; DEGRADATION; RECRUITMENT; IMPAIRMENT; ACTIVATION	Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.	[Zhao, C.; Chen, X.; Zang, D.; Lan, X.; Liao, S.; Yang, C.; Zhang, P.; Wu, J.; Li, X.; Liu, N.; Liao, Y.; Huang, H.; Shi, X.; Jiang, L.; Wang, X.; Liu, J.] Guangzhou Med Univ, Dept Pathophysiol, Prot Modificat & Degradat Lab, State Key Lab Resp Dis, Dongfeng Xi Rd 195, Guangzhou 510182, Guangdong, Peoples R China; [Liu, N.] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Res Inst Cardiovasc Dis, Guangzhou, Guangdong, Peoples R China; [Liu, X.] Henan Univ, Coll Chem & Chem Engn, Inst Environm & Analyt Sci, Kaifeng, Peoples R China; [Liu, X.] Key Lab Nat Drug & Immune Engn Henan Prov, Kaifeng, Peoples R China; [He, Z.] Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China; [He, Z.] Guangzhou Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Dou, Q. P.] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI USA; [Wang, X.] Univ South Dakota, Sanford Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou Medical University; Henan University; Guangzhou Medical University; Guangzhou Medical University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University; Wayne State University; University of South Dakota	Liu, J (corresponding author), Guangzhou Med Univ, Dept Pathophysiol, Prot Modificat & Degradat Lab, State Key Lab Resp Dis, Dongfeng Xi Rd 195, Guangzhou 510182, Guangdong, Peoples R China.	jliu@gzhmu.edu.cn	Wang, Xuejun/K-8874-2013; Chen, Xin/ABJ-3846-2022; Wang, Xuejun/AAT-9490-2021	Wang, Xuejun/0000-0001-9267-1343; Chen, Xin/0000-0003-3668-4830; Wang, Xuejun/0000-0001-9267-1343; Dou, Qingping/0000-0002-6465-1473	National High Technology Research and Development Program of China [2006AA02Z4B5]; NSFC [81272451/H1609, 81472762/H1609]; MOE [20134423110002]; Guangdong Key Laboratory of Urology [2010A060801016]; US NIH [HL072166, HL085629]; NATIONAL CANCER INSTITUTE [R21CA184788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166, R01HL085629] Funding Source: NIH RePORTER	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); NSFC(National Natural Science Foundation of China (NSFC)); MOE(Ministry of Higher Education & Scientific Research (MHESR)); Guangdong Key Laboratory of Urology; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital and Sun Yat-Sen University for flow cytometry detection. This work was supported by the National High Technology Research and Development Program of China (2006AA02Z4B5), NSFC (81272451/H1609, 81472762/H1609), MOE (20134423110002) and Guangdong Key Laboratory of Urology (2010A060801016) (to JL) and in part by US NIH grants HL072166 and HL085629 (to XW).	Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Atasever B, 2010, INVEST NEW DRUG, V28, P421, DOI 10.1007/s10637-009-9272-2; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Chen D, 2007, CANCER RES, V67, P9258, DOI 10.1158/0008-5472.CAN-07-1813; Chen JN, 2004, TOXICOL APPL PHARM, V197, P40, DOI 10.1016/j.taap.2004.02.004; Chen X, 2014, ONCOTARGET, V5, P9118, DOI 10.18632/oncotarget.2361; Cvek B, 2008, J MED CHEM, V51, P6256, DOI 10.1021/jm8007807; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Denkhaus E, 2002, CRIT REV ONCOL HEMAT, V42, P35, DOI 10.1016/S1040-8428(01)00214-1; Dinning AJ, 1998, J APPL MICROBIOL, V85, P132; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351; Fraile JM, 2012, ONCOGENE, V31, P2373, DOI 10.1038/onc.2011.443; Frezza M, 2009, INORG CHEM, V48, P5928, DOI 10.1021/ic900276g; Huang HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049062; Huang HB, 2010, CELL RES, V20, P1372, DOI 10.1038/cr.2010.123; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Li XF, 2013, CELL REP, V3, P211, DOI 10.1016/j.celrep.2012.11.023; Liu JB, 2006, FASEB J, V20, P362, DOI 10.1096/fj.05-4869fje; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; Liu NN, 2014, SCI REP-UK, V4, DOI 10.1038/srep05240; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Milacic V, 2008, TOXICOL APPL PHARM, V231, P24, DOI 10.1016/j.taap.2008.03.009; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Shi XP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09694; Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063; Singhal S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S3; Tailler M, 2012, ONCOGENE, V31, P3536, DOI 10.1038/onc.2011.521; Tan J, 2010, BIOMETALS, V23, P1075, DOI 10.1007/s10534-010-9353-x; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Todi SV, 2011, TRENDS NEUROSCI, V34, P370, DOI 10.1016/j.tins.2011.05.004; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Verani CN, 2012, J INORG BIOCHEM, V106, P59, DOI 10.1016/j.jinorgbio.2011.09.003; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Yang HJ, 2009, INT J CANCER, V124, P2450, DOI 10.1002/ijc.24195; Yao TT, 2006, NAT CELL BIOL, V8, P994, DOI 10.1038/ncb1460	45	48	49	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5916	5927		10.1038/onc.2016.114	http://dx.doi.org/10.1038/onc.2016.114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27086925	Green Accepted			2022-12-28	WOS:000387560800010
J	Liu-Chittenden, Y; Jain, M; Gaskins, K; Wang, S; Merino, MJ; Kotian, S; Gara, SK; Davis, S; Zhang, L; Kebebew, E				Liu-Chittenden, Y.; Jain, M.; Gaskins, K.; Wang, S.; Merino, M. J.; Kotian, S.; Gara, S. Kumar; Davis, S.; Zhang, L.; Kebebew, E.			RARRES2 functions as a tumor suppressor by promoting beta-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma	ONCOGENE			English	Article							DENDRITIC CELLS; CANCER-THERAPY; HUMAN BLOOD; CHEMERIN; EXPRESSION; ACTIVATION; PATHWAY; CLASSIFICATION; INFLAMMATION; METABOLISM	Tumor suppressor genes and the immune system are critical players in inhibiting cancer initiation and/or progression. However, little is known about whether a tumor suppressor gene can function through both immune-dependent and - independent mechanisms. Retinoic acid receptor responder 2 (RARRES2) is transcriptionally downregulated in multiple cancer types. Previous studies suggested that it can serve as an immune-dependent tumor suppressor by acting as a chemoattractant to recruit anticancer immune cells expressing its receptor, the chemerin chemokine receptor 1 (CMKLR1), to sites of tumor. In this study, we investigated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy in which aberrant Wnt/beta-catenin signaling is frequently detected. We show that RARRES2 expression is downregulated in ACC as compared with normal and benign adrenocortical tissues, which is a result of CpG hypermethylation. Despite minimal CMKLR1 expression and lack of phenotypic tumor-suppressive effect with exogenous RARRES2 treatment, RARRES2 overexpression in ACC cell lines not only reduced cell proliferation, cell invasion and tumorigenicity in vitro, but also inhibited tumor growth in vivo in two immunodeficient mouse xenograft models. Mechanistically, RARRES2 overexpression in ACC cells inhibited Wnt/beta-catenin pathway activity by promoting beta-catenin phosphorylation and degradation, it also inhibited the phosphorylation of p38 mitogen-activated protein kinase. Thus our study identifies RARRES2 as a novel tumor suppressor for ACC, which can function through an immune-independent mechanism.	[Liu-Chittenden, Y.; Jain, M.; Gaskins, K.; Wang, S.; Kotian, S.; Gara, S. Kumar; Zhang, L.; Kebebew, E.] NCI, NIH, Endocrine Oncol Branch, 10 Ctr Dr,Room 4-5952, Bethesda, MD 20892 USA; [Merino, M. J.] NCI, NIH, Pathol Lab, Bethesda, MD 20892 USA; [Davis, S.] NIH, Ctr Canc Res, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kebebew, E (corresponding author), NCI, NIH, Endocrine Oncol Branch, 10 Ctr Dr,Room 4-5952, Bethesda, MD 20892 USA.	kebebewe@mail.nih.gov	Gara, Sudheer Kumar/E-8084-2016; Davis, Sean/AAD-1801-2021; Kotian, Shweta/GMX-3418-2022	Davis, Sean/0000-0002-8991-6458; Liu, Yi/0000-0001-6357-5360	intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health [1ZIABC01127506]; NATIONAL CANCER INSTITUTE [ZIABC011275] Funding Source: NIH RePORTER	intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (1ZIABC01127506). Supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (1ZIABC01127506).	Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bilimoria KY, 2008, CANCER, V113, P3130, DOI 10.1002/cncr.23886; Bondue B, 2011, CYTOKINE GROWTH F R, V22, P331, DOI 10.1016/j.cytogfr.2011.11.004; Bozaoglu K, 2007, ENDOCRINOLOGY, V148, P4687, DOI 10.1210/en.2007-0175; Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Ernst MC, 2010, TRENDS ENDOCRIN MET, V21, P660, DOI 10.1016/j.tem.2010.08.001; Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020; Fassnacht M, 2009, BEST PRACT RES CL EN, V23, P273, DOI 10.1016/j.beem.2008.10.008; Fernandez-Ranvier GG, 2008, ARCH SURG-CHICAGO, V143, P841, DOI 10.1001/archsurg.143.9.841; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744; Igea A, 2015, CANCER RES, V75, P3997, DOI 10.1158/0008-5472.CAN-15-0173; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Kerkhofs TMA, 2013, EUR J CANCER, V49, P2579, DOI 10.1016/j.ejca.2013.02.034; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Lin W, 2011, CLIN LAB, V57, P879; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rechache NS, 2012, J CLIN ENDOCR METAB, V97, pE1004, DOI 10.1210/jc.2011-3298; Salomon A, 2015, ONCOTARGET, V6, P11421, DOI 10.18632/oncotarget.3222; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Velazquez-Fernandez D, 2005, SURGERY, V138, P1087, DOI 10.1016/j.surg.2005.09.031; Vermi W, 2005, J EXP MED, V201, P509, DOI 10.1084/jem.20041310; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wittamer V, 2005, J IMMUNOL, V175, P487, DOI 10.4049/jimmunol.175.1.487; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Zabel BA, 2005, J IMMUNOL, V174, P244, DOI 10.4049/jimmunol.174.1.244; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zheng Y, 2008, EUR J DERMATOL, V18, P638, DOI 10.1684/ejd.2008.0511	38	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3541	3552		10.1038/onc.2016.497	http://dx.doi.org/10.1038/onc.2016.497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28114280	Green Accepted			2022-12-28	WOS:000403878600004
J	Erpenbeck, L; Schon, MP				Erpenbeck, L.; Schoen, M. P.			Neutrophil extracellular traps: protagonists of cancer progression?	ONCOGENE			English	Review							VON-WILLEBRAND-FACTOR; DEEP-VEIN THROMBOSIS; ELASTASE-MEDIATED DEGRADATION; TUMOR-CELLS; ANGIOGENIC SWITCH; VENOUS THROMBOSIS; LYMPHOCYTE RATIO; LIVER METASTASIS; NADPH OXIDASE; NET FORMATION	Neutrophil extracellular traps (NETs) are a defense mechanism first described to trap and kill bacteria and other pathogens. Increasingly, however, their involvement in the pathogenesis of inflammatory and malignant diseases is being recognized. Several recent studies have suggested important roles of NETs in tumor progression, metastasis and tumor-associated thrombosis. Although systematic studies to address the role of NETs in tumor development are still scarce, we will explore the emerging evidence for NETs as potential protagonists in malignant disease and highlight the mechanisms through which these effects may be exerted. Future questions arising from our current knowledge of direct and indirect interactions between NETs and cancer cells will be outlined and we will explore NETs as candidate pharmaceutical targets in cancer patients.	[Erpenbeck, L.; Schoen, M. P.] Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Robert Koch Str 40, D-37075 Gottingen, Germany	University of Gottingen	Erpenbeck, L (corresponding author), Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Robert Koch Str 40, D-37075 Gottingen, Germany.	luise.erpenbeck@med.uni-goettingen.de		Erpenbeck, Luise/0000-0002-6561-472X				Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Alfaro C, 2016, CLIN CANCER RES, V22, P3924, DOI 10.1158/1078-0432.CCR-15-2463; Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x; Amschler K, 2014, ACS NANO, V8, P9113, DOI 10.1021/nn502690b; An H, 2015, TUMOR BIOL, V37, P4523; Baj-Krzyworzeka M, 2010, ANTICANCER RES, V30, P3515; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bauer AT, 2015, BLOOD, V125, P3153, DOI 10.1182/blood-2014-08-595686; Ben-Smith A, 2001, BLOOD, V98, P1448, DOI 10.1182/blood.V98.5.1448; Berger-Achituv S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00048; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bodey B, 1996, ANTICANCER RES, V16, P3439; Brill A, 2012, J THROMB HAEMOST, V10, P136, DOI 10.1111/j.1538-7836.2011.04544.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Cedervall J, 2015, CANCER RES, V75, P2653, DOI 10.1158/0008-5472.CAN-14-3299; Chowdhury CS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4579; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Cools-Lartigue J., 2013, J CLIN INVEST, V67484; Cools-Lartigue J, 2014, CELL MOL LIFE SCI, V71, P4179, DOI 10.1007/s00018-014-1683-3; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Demers M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134073; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; Erpenbeck L, 2010, BLOOD, V115, P3427, DOI 10.1182/blood-2009-10-247296; Erpenbeck L, 2010, J INVEST DERMATOL, V130, P576, DOI 10.1038/jid.2009.278; Etulain J, 2015, BLOOD, V126, P242, DOI 10.1182/blood-2015-01-624023; Franchini M, 2013, THROMB RES, V131, P290, DOI 10.1016/j.thromres.2013.01.015; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gaida MM, 2012, EUR J IMMUNOL, V42, P3369, DOI 10.1002/eji.201242628; Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201; Geddings JE, 2013, BLOOD, V122, P1873, DOI 10.1182/blood-2013-04-460139; Grassle S, 2014, ARTERIOSCL THROM VAS, V34, P1382, DOI 10.1161/ATVBAHA.113.303016; Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037; Gupta AK, 2005, HUM IMMUNOL, V66, P1146, DOI 10.1016/j.humimm.2005.11.003; Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006; Heissig B, 2010, HISTOL HISTOPATHOL, V25, P765, DOI 10.14670/HH-25.765; Ho-Tin-Noe B, 2009, AM J PATHOL, V175, P1699, DOI 10.2353/ajpath.2009.090460; Houghton AM, 2010, CELL CYCLE, V9, P1732, DOI 10.4161/cc.9.9.11297; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Keshari RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048111; Knight JS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00380; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Kruss S, 2013, ACS NANO, V7, P9984, DOI 10.1021/nn403923h; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lewis HD, 2015, NAT CHEM BIOL, V11, P189, DOI 10.1038/nchembio.1735; Liang S, 2008, CELL MOL BIOENG, V1, P189, DOI 10.1007/s12195-008-0016-8; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; Martinod K, 2016, J THROMB HAEMOST, V14, P551, DOI 10.1111/jth.13239; Martinod K, 2015, BLOOD, V125, P1948, DOI 10.1182/blood-2014-07-587709; Martinod K, 2013, P NATL ACAD SCI USA, V110, P8674, DOI 10.1073/pnas.1301059110; Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184; McDonald B, 2009, INT J CANCER, V125, P1298, DOI 10.1002/ijc.24409; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Parker H, 2012, J LEUKOCYTE BIOL, V92, P841, DOI 10.1189/jlb.1211601; Perisanidis C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0334-5; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Quan JM, 2001, J PEDIATR-US, V139, P813, DOI 10.1067/mpd.2001.118570; Raftery MJ, 2014, J EXP MED, V211, P1484, DOI 10.1084/jem.20131092; Sangaletti S, 2014, CANCER DISCOV, V4, P110, DOI 10.1158/2159-8290.CD-13-0276; Sangaletti S, 2012, BLOOD, V120, P3007, DOI 10.1182/blood-2012-03-416156; Savchenko AS, 2014, BLOOD, V123, P141, DOI 10.1182/blood-2013-07-514992; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Spicer JD, 2012, CANCER RES, V72, P3919, DOI 10.1158/0008-5472.CAN-11-2393; Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507; SUGIHARA S, 1993, BRIT J CANCER, V67, P66, DOI 10.1038/bjc.1993.10; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Terraube V, 2007, THROMB RES, V120, pS64, DOI 10.1016/S0049-3848(07)70132-9; Thomas GM, 2015, J THROMB HAEMOST, V13, P1310, DOI 10.1111/jth.13002; Thomas MP, 2014, J IMMUNOL, V192, P5390, DOI 10.4049/jimmunol.1303296; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Wada Y, 2007, ONCOL REP, V17, P161; Wang JC, 2015, ONCOTARGET, V6, P42825, DOI 10.18632/oncotarget.5739; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; Wong SL, 2015, NAT MED, V21, P815, DOI 10.1038/nm.3887; Xiao WK, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-117; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Zhao JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033655	91	115	123	6	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2483	2490		10.1038/onc.2016.406	http://dx.doi.org/10.1038/onc.2016.406			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941879				2022-12-28	WOS:000400597300014
J	Masre, SF; Rath, N; Olson, MF; Greenhalgh, DA				Masre, S. F.; Rath, N.; Olson, M. F.; Greenhalgh, D. A.			ROCK2/ras(Ha) co-operation induces malignant conversion via p53 loss, elevated NF-kappa B and tenascin C-associated rigidity, but p21 inhibits ROCK2/NF-kappa B-mediated progression	ONCOGENE			English	Article							CYCLIC TENSILE STRAIN; TUMOR-CELL INVASION; CANCER-CELLS; EPIDERMAL HYPERPLASIA; SIGNALING PATHWAYS; TISSUE STIFFNESS; BREAST-CANCER; AKT ACTIVITY; RHO-GTPASES; DNA-DAMAGE	To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14. ROCKer) were crossed with mice expressing epidermal-activated ras(Ha) (HK1.ras(1205)). At 8 weeks, 4HT-treated K14. ROCKer/HK1.ras(1205) cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14. ROCKer/HK1.ras(1205) histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-kB expression. By 12 weeks, K14. ROCKer/HK1. ras(1205) wdSCCs exhibited increased NF-kB and novel tenascin C, indicative of elevated rigidity; yet despite continued ROCK2 activities/p-Mypt1 inactivation, progression to SCC required loss of compensatory p21 expression. K14. ROCKer/ HK1. ras1205 papillomatogenesis also required a wound promotion stimulus, confirmed by breeding K14. ROCKer into promotioninsensitive HK1. ras(1276) mice, suggesting a permissive K14. ROCKer/ HK1. ras1205 papilloma context (wound-promoted/NF-.B+/p53 -/ p21(+)) preceded K14. ROCKer-mediated (p-Mypt1/ tenascinC/rigidity) malignant conversion. Malignancy depended on ROCKer/ pMypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. Novel papilloma outgrowths appeared expressing intense, basal layer p21 that confined endogenous ROCK2/p-Mypt1/NF-k\B to supra-basal layers, and was paralleled by restored basal layer p53. In later SCCs, 4HT cessation became irrelevant as endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-kB expression and tenascin C-associated rigidity, with p-Mypt1 inactivation/actinomyosin-mediated contractility to facilitate invasion. However, p21-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 and rasHa/ROCK2/NF-kB signalling in skin carcinogenesis. Collectively, these data show that ROCK2 activation induces malignancy in rasHa-initiated/promoted papillomas in the context of p53 loss and novel NF-kB expression, whereas increased tissue rigidity and cell motility/contractility help mediate tumour progression.	[Masre, S. F.; Greenhalgh, D. A.] Glasgow Univ, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Sect Dermatol & Mol Carcinogenesis, Glasgow, Lanark, Scotland; [Masre, S. F.] Natl Univ Malaysia, Univ Kebangsaan, Fac Allied Hlth Sci, Biomed Sci Programme,Sch Diagnost & Appl Hlth Sci, Kuala Lumpur, Malaysia; [Rath, N.; Olson, M. F.] Canc Res UK, Beatson Inst Canc Res, Mol Cell Biol Lab, Glasgow, Lanark, Scotland; [Rath, N.; Olson, M. F.] Univ Glasgow, Inst Canc Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; Universiti Kebangsaan Malaysia; Beatson Institute; Cancer Research UK; University of Glasgow	Greenhalgh, DA (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Sect Dermatol & Mol Carcinogenesis, Level 2,New Lister Bldg,10 Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.	david.greenhalgh@glasgow.ac.uk	Masre, Siti Fathiah/M-3576-2017; Olson, Michael/ABA-4240-2021	Masre, Siti Fathiah/0000-0002-4202-2289; Olson, Michael/0000-0003-3428-3507	Government of Malaysia; Scott Endowment Fund, Dermatology, Glasgow University; Cancer Research UK; Cancer Research UK [18276] Funding Source: researchfish	Government of Malaysia; Scott Endowment Fund, Dermatology, Glasgow University; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Dr Jean Quinn for help and advice; Stuart Lannigan and Denis Duggan for assistance with animal husbandry. This work was supported by: The Government of Malaysia; the Scott Endowment Fund, Dermatology, Glasgow University; and Cancer Research UK.	Balmain A, 2014, J INVEST DERMATOL, V134, P2; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chiquet M, 2004, BBA-MOL CELL RES, V1693, P193, DOI 10.1016/j.bbamcr.2004.08.001; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ibbetson SJ, 2013, AM J PATHOL, V183, P930, DOI 10.1016/j.ajpath.2013.05.014; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Kumper S, 2011, CANCER CELL, V19, P695, DOI 10.1016/j.ccr.2011.05.021; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Lock FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008190; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Macdonald FH, 2014, ONCOGENE, V33, P4132, DOI 10.1038/onc.2013.372; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Sadok A, 2015, CANCER RES, V75, P2272, DOI 10.1158/0008-5472.CAN-14-2156; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Samuel MS, 2009, GENESIS, V47, P440, DOI 10.1002/dvg.20519; Sarasa-Renedo A, 2006, EXP CELL RES, V312, P1361, DOI 10.1016/j.yexcr.2005.12.025; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Shah KN, 2015, MOL CANCER THER, V14, P2411, DOI 10.1158/1535-7163.MCT-14-0689; Shi MY, 2015, APOPTOSIS, V20, P843, DOI 10.1007/s10495-015-1106-4; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Valastyan S, 2011, J CELL SCI, V124, P999, DOI 10.1242/jcs.081513; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; Yao DG, 2006, CANCER RES, V66, P1302, DOI 10.1158/0008-5472.CAN-05-2341; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	50	10	10	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2529	2542		10.1038/onc.2016.402	http://dx.doi.org/10.1038/onc.2016.402			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27991921	Green Accepted			2022-12-28	WOS:000400597300004
J	Chroma, K; Mistrik, M; Moudry, P; Gursky, J; Liptay, M; Strauss, R; Skrott, Z; Vrtel, R; Bartkova, J; Kramara, J; Bartek, J				Chroma, K.; Mistrik, M.; Moudry, P.; Gursky, J.; Liptay, M.; Strauss, R.; Skrott, Z.; Vrtel, R.; Bartkova, J.; Kramara, J.; Bartek, J.			Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; DAMAGE-RESPONSE; HOMOLOGOUS RECOMBINATION; 53BP1 RECRUITMENT; CHROMATIN RESPONSE; PARP INHIBITORS; PROTEIN; BRCA1; CELLS; ACCUMULATION	Chromatin DNA damage response (DDR) is orchestrated by the E3 ubiquitin ligase ring finger protein 168 (RNF168), resulting in ubiquitin-dependent recruitment of DDR factors and tumor suppressors breast cancer 1 (BRCA1) and p53 binding protein 1 (53BP1). This ubiquitin signaling regulates pathway choice for repair of DNA double-strand breaks (DSB), toxic lesions whose frequency increases during tumorigenesis. Recruitment of 53BP1 curbs DNA end resection, thereby limiting homologous recombination (HR) and directing DSB repair toward error-prone non-homologous end joining (NHEJ). Under cancer-associated ubiquitin starvation conditions reflecting endogenous or treatment-evoked proteotoxic stress, the ubiquitin-dependent accrual of 53BP1 and BRCA1 at the DNA damage sites is attenuated or lost. Challenging this current paradigm, here we identified diverse human cancer cell lines that display 53BP1 recruitment to DSB sites even under proteasome inhibitor-induced proteotoxic stress, that is, under substantial depletion of free ubiquitin. We show that central to this unexpected phenotype is overabundance of RNF168 that enables more efficient exploitation of the residual-free ubiquitin. Cells with elevated RNF168 are more resistant to combined treatment by ionizing radiation and proteasome inhibition, suggesting that such aberrant RNF168-mediated signaling might reflect adaptation to chronic proteotoxic and genotoxic stresses experienced by tumor cells. Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor. Overall, our data suggest that the deregulated RNF168/53BP1 pathway could promote tumorigenesis by selecting for a more robust, better stress-adapted cancer cell phenotype, through altered DNA repair, fueling genomic instability and tumor heterogeneity. Apart from providing insights into cancer (patho) biology, the elevated RNF168, documented here also by immunohistochemistry on human clinical tumor specimens, may impact responses to standard-of-care and some emerging targeted cancer therapies.	[Chroma, K.; Mistrik, M.; Moudry, P.; Gursky, J.; Liptay, M.; Skrott, Z.; Kramara, J.; Bartek, J.] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Hnevotinska 5, Olomouc 77515, Czech Republic; [Moudry, P.; Strauss, R.; Bartkova, J.; Bartek, J.] Danish Canc Soc Res Ctr, Genome Integr Unit, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; [Vrtel, R.] Univ Hosp Olomouc, Dept Clin Genet, Olomouc, Czech Republic; [Bartkova, J.; Bartek, J.] Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Sci Life Lab, Solna, Sweden	Palacky University Olomouc; Danish Cancer Society; University Hospital Olomouc; Karolinska Institutet	Kramara, J (corresponding author), Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Hnevotinska 5, Olomouc 77515, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Genome Integr Unit, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	juraj.kramara@upol.cz; jb@cancer.dk		Mistrik, Martin/0000-0002-2321-0348; Chroma, Katarina/0000-0003-0141-0469; Skrott, Zdenek/0000-0001-6004-3609	Grant Agency of the Czech Republic [13-17555S]; Czech National Program of Sustainability [LO1304]; Kellner Family Foundation; Norwegian Financial Mechanism CZ09 [PHOSCAN 7F14061]; MEYS CR [LM2015062]; EU operation program [CZ.1.07/2.3.00/30.0004]; Danish National Research Foundation [DNRF125]; Danish Cancer Society; Swedish Research Council; Lundbeck Foundation; Cancer Fonden; Danish Council for Independent Research;  [IGA-LF-2016-030]; Novo Nordisk Fonden [NNF15OC0016584, NNF12OC0002290] Funding Source: researchfish; The Danish Cancer Society [R124-A7785] Funding Source: researchfish	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Czech National Program of Sustainability; Kellner Family Foundation; Norwegian Financial Mechanism CZ09; MEYS CR; EU operation program; Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Society(Danish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Lundbeck Foundation(Lundbeckfonden); Cancer Fonden(Swedish Cancer Society); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); ; Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	We thank Jan Bouchal, Katerina Bouchalova and our colleagues from the Laboratory of Genome Integrity for technical assistance, suggestions and comments on the manuscript. This work was supported by grants from the following foundations: Grant Agency of the Czech Republic 13-17555S, Czech National Program of Sustainability LO1304, the Kellner Family Foundation, the Norwegian Financial Mechanism CZ09 (Project PHOSCAN 7F14061), MEYS CR (LM2015062 Czech-BioImaging), the internal grant IGA-LF-2016-030, the EU operation program CZ.1.07/2.3.00/30.0004, the Danish National Research Foundation (DNRF125, project CARD), Danish Cancer Society, the Swedish Research Council, the Lundbeck Foundation, Cancer Fonden, and the Danish Council for Independent Research.	Acs K, 2011, NAT STRUCT MOL BIOL, V18, P1345, DOI 10.1038/nsmb.2188; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bekker-Jensen S, 2010, NAT CELL BIOL, V12, P80, DOI 10.1038/ncb2008; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Callen E, 2013, CELL, V153, P1266, DOI 10.1016/j.cell.2013.05.023; Certo MT, 2011, NAT METHODS, V8, P671, DOI [10.1038/nmeth.1648, 10.1038/NMETH.1648]; Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Daley JM, 2014, MOL CELL BIOL, V34, P1380, DOI 10.1128/MCB.01639-13; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Densham RM, 2016, NAT STRUCT MOL BIOL, V23, P647, DOI 10.1038/nsmb.3236; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Devgan SS, 2011, CELL DEATH DIFFER, V18, P1500, DOI 10.1038/cdd.2011.18; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hjerpe R, 2012, BIOCHEM J, V441, P927, DOI 10.1042/BJ20111671; Inbar-Rozensal D, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2445; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; Kocylowski MK, 2015, CELL CYCLE, V14, P1748, DOI 10.1080/15384101.2015.1010918; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma T, 2013, MOL CELL, V49, P897, DOI 10.1016/j.molcel.2013.01.006; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Mistrik M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19567; Munoz MC, 2014, NUCLEIC ACIDS RES, V42, P7720, DOI 10.1093/nar/gku421; Munoz MC, 2012, J BIOL CHEM, V287, P40618, DOI 10.1074/jbc.M112.410951; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Ricks TK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00222; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499; Thorslund T, 2015, NATURE, V527, P389, DOI 10.1038/nature15401; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Watanabe S, 2013, NAT STRUCT MOL BIOL, V20, P1425, DOI 10.1038/nsmb.2702; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Zhao Y, 2014, TRENDS CELL BIOL, V24, P426, DOI 10.1016/j.tcb.2014.01.005; Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573; Zong DL, 2015, NUCLEIC ACIDS RES, V43, P4950, DOI 10.1093/nar/gkv336	59	25	25	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2405	2422		10.1038/onc.2016.392	http://dx.doi.org/10.1038/onc.2016.392			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27841863				2022-12-28	WOS:000400268900007
J	Hazawa, M; Lin, DC; Handral, H; Xu, L; Chen, Y; Jiang, YY; Mayakonda, A; Ding, LW; Meng, X; Sharma, A; Samuel, S; Movahednia, MM; Wong, RW; Yang, H; Tong, C; Koeffler, HP				Hazawa, M.; Lin, D-C; Handral, H.; Xu, L.; Chen, Y.; Jiang, Y-Y; Mayakonda, A.; Ding, L-W; Meng, X.; Sharma, A.; Samuel, S.; Movahednia, M. M.; Wong, R. W.; Yang, H.; Tong, C.; Koeffler, H. P.			ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma	ONCOGENE			English	Article								ZNF750 controls epithelial homeostasis by regulating epidermal-differentiation genes, a role underscored by its pathogenic mutations in esophageal squamous cell cancers (SCCs). However, the precise role of ZNF750 in SCC cell biology remains unclear. In this study, we report that ZNF750 is exclusively deleted, mutated and underexpressed in human SCCs, and low ZNF750 expression is associated with poor survival. Restoration of wildtype, but not mutant ZNF750 protein uniquely inhibited the malignant phenotypes of SCC cells both in vitro and in vivo. Notably, ZNF750 promoted the expression of a long non-coding RNA (TINCR), which mediated both cancer-inhibition and differentiation-induction effects of ZNF750. In addition, ZNF750 potently suppressed cell migration by directly inhibiting the transactivation of LAMC2. Together, our findings characterize ZNF750 as a crucial SCC-specific suppressor and uncover its novel anticancer-associated functions.	[Hazawa, M.; Lin, D-C; Xu, L.; Chen, Y.; Jiang, Y-Y; Mayakonda, A.; Ding, L-W; Meng, X.; Sharma, A.; Samuel, S.; Yang, H.; Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Hazawa, M.; Wong, R. W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bion Res Unit, Innovat Integrated Biores Core, Kanazawa, Ishikawa, Japan; [Lin, D-C; Koeffler, H. P.] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA; [Handral, H.; Movahednia, M. M.; Tong, C.] Natl Univ Singapore, Dept Oral & Maxillofacial Surg, Fac Dent, Singapore, Singapore; [Koeffler, H. P.] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore; [Koeffler, H. P.] Natl Univ Singapore, Singapore, Singapore	National University of Singapore; Kanazawa University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore; National University of Singapore; National University of Singapore	Hazawa, M (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa 9201192, Japan.; Lin, DC (corresponding author), Los Angeles Sch Med, Los Angeles, CA 90048 USA.	masaharu.akj@gmail.com; dchlin11@gmail.com	HAZAWA, Masaharu/A-6520-2016; Ding, Ling-Wen/H-6916-2019; Wong, Richard W./E-9155-2011; SHARMA, ARJUN/U-5920-2019; Hazawa, M/AAA-2712-2021; Tong CAO, iHuman/B-1008-2008; HANDRAL, HARISH/AAM-6564-2020; Xu, Liang/I-9877-2014	Ding, Ling-Wen/0000-0003-0022-1551; Tong CAO, iHuman/0000-0002-7994-9627; HANDRAL, HARISH/0000-0002-3892-3316; Xu, Liang/0000-0002-2700-4840; Sharma, ARJUN/0000-0002-5705-5470; Wong, Richard/0000-0002-2131-6595	Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award; NMRC Individual Research Grant [NMRC/1311/2011]; NMRC Centre Grant; American Society of Hematology Fellow Scholar Award; Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant [UL1TR000124]; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, under the Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); NMRC Individual Research Grant; NMRC Centre Grant(National Medical Research Council, Singapore); American Society of Hematology Fellow Scholar Award; Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, under the Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by the Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to HPK, NMRC Individual Research Grant (NMRC/1311/2011) and the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives. D-C.L was supported by American Society of Hematology Fellow Scholar Award, Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR000124. This study was partially supported by a generous donation from the Melamed family. This research was also supported by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006.	American Cancer Society, 2011, CANC FACTS FIG 2011; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Brooks YS, 2014, J CLIN INVEST, V124, P2260, DOI 10.1172/JCI72718; Degen M, 2012, AM J PATHOL, V180, P2462, DOI 10.1016/j.ajpath.2012.02.028; Garg M, 2014, EXPERT OPIN THER TAR, V18, P979, DOI 10.1517/14728222.2014.934814; Garg M, 2014, J CLIN ENDOCR METAB, V99, pE62, DOI 10.1210/jc.2013-2994; Hamasaki H, 2011, BRIT J CANCER, V6, P824; Hlubek F, 2001, CANCER RES, V61, P8089; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Khammanivong A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069395; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kypriotou M, 2012, EXP DERMATOL, V21, P643, DOI 10.1111/j.1600-0625.2012.01472.x; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lopez-Pajares V, 2015, DEV CELL, V32, P693, DOI 10.1016/j.devcel.2015.01.028; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Ono Y, 1999, CANCER, V85, P2315, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2315::AID-CNCR3>3.0.CO;2-Y; Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005; Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18; Yamamoto H, 2001, CLIN CANCER RES, V7, P896; Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005	24	70	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2243	2254		10.1038/onc.2016.377	http://dx.doi.org/10.1038/onc.2016.377			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819679	Green Published, hybrid			2022-12-28	WOS:000399782700005
J	Ihara, T; Hosokawa, Y; Kumazawa, K; Ishikawa, K; Fujimoto, J; Yamamoto, M; Muramkami, T; Goshima, N; Ito, E; Watanabe, S; Semba, K				Ihara, T.; Hosokawa, Y.; Kumazawa, K.; Ishikawa, K.; Fujimoto, J.; Yamamoto, M.; Muramkami, T.; Goshima, N.; Ito, E.; Watanabe, S.; Semba, K.			An in vivo screening system to identify tumorigenic genes	ONCOGENE			English	Article							PROTEIN-KINASE-A; CARNEY COMPLEX; LYSOPHOSPHATIDIC ACID; COUPLED RECEPTORS; TUMOR-GROWTH; CANCER; EXPRESSION; ADENOSINE; CELL	Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to similar to 70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34-43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.	[Ihara, T.; Hosokawa, Y.; Kumazawa, K.; Yamamoto, M.; Semba, K.] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo, Japan; [Ishikawa, K.; Fujimoto, J.] Japan Biol Informat Consortium, Tokyo, Japan; [Muramkami, T.] Takasaki Univ Hlth & Welf, Lab Tumor Biol, Fac Pharm, Takasaki, Gunma, Japan; [Goshima, N.] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery Molprof, Quantitat Prote Team, Tokyo, Japan; [Goshima, N.] Div Transcriptome Anal, Fukushima, Japan; [Ito, E.; Watanabe, S.] Div Gene Express Anal, Fukushima, Japan; [Semba, K.] Fukushima Med Univ, Div Gene Funct Anal, Translat Res Ctr, Fukushima, Japan	Waseda University; National Institute of Advanced Industrial Science & Technology (AIST); Fukushima Medical University	Semba, K (corresponding author), Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Shinjuku Ku, 2-2 Wakamatsu Cho, Tokyo 1628480, Japan.	ksemba@waseda.jp	直樹, 五島/M-8363-2018; Yamamoto, Mizuki/AAW-1688-2020	Yamamoto, Mizuki/0000-0003-3731-1702	JSPS KAKENHI Grant [23241064]	JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank our laboratory members, especially Kumiko Semba for secretarial assistance and Sakura Azuma-Tamamura for technical assistance. This work was conducted as part of the Fukushima Translational Research Project and supported, in part, by JSPS KAKENHI Grant Number 23241064, and a Grant-in-Aid for Scientific Research (A).	Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Beristain AG, 2015, ONCOGENE, V34, P1160, DOI 10.1038/onc.2014.41; Correa R, 2015, EUR J ENDOCRINOL, V173, pM85, DOI 10.1530/EJE-15-0209; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Doi A, 2015, MOL ONCOL, V9, P355, DOI 10.1016/j.molonc.2014.09.005; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Feigin ME, 2013, FEBS J, V280, P4729, DOI 10.1111/febs.12473; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Griffin KJ, 2004, J MED GENET, V41, P923, DOI 10.1136/jmg.2004.028043; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; Ito E, 2007, FEBS LETT, V581, P3909, DOI 10.1016/j.febslet.2007.07.016; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Matsui Atsuka, 2013, Biomol Concepts, V4, P567, DOI 10.1515/bmc-2013-0026; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476-5381.2011.01622.x; Naviglio S, 2009, EXPERT OPIN THER TAR, V13, P83, DOI [10.1517/14728220802602349, 10.1517/14728220802602349 ]; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Padmanabhan A, 2013, J BIOL CHEM, V288, P14158, DOI 10.1074/jbc.M112.432377; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Polanska UM, 2013, J CELL PHYSIOL, V228, P1651, DOI 10.1002/jcp.24347; Saito M, 2012, FEBS LETT, V586, P1708, DOI 10.1016/j.febslet.2012.05.003; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	30	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2023	2029		10.1038/onc.2016.351	http://dx.doi.org/10.1038/onc.2016.351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694896				2022-12-28	WOS:000398898500012
J	Chen, F; Zhang, Y; Parra, E; Rodriguez, J; Behrens, C; Akbani, R; Lu, Y; Kurie, JM; Gibbons, DL; Mills, GB; Wistuba, II; Creighton, CJ				Chen, F.; Zhang, Y.; Parra, E.; Rodriguez, J.; Behrens, C.; Akbani, R.; Lu, Y.; Kurie, J. M.; Gibbons, D. L.; Mills, G. B.; Wistuba, I. I.; Creighton, C. J.			Multiplatform-based molecular subtypes of non-small-cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; CARCINOMA	Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers -including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.	[Chen, F.; Zhang, Y.; Creighton, C. J.] Baylor Coll Med, Div Biostat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Parra, E.; Rodriguez, J.; Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc, Dept Translat Mol Pathol, Houston, TX USA; [Akbani, R.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Kurie, J. M.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, One Baylor Plaza MS305, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Creighton, CJ (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza MS305, Houston, TX 77030 USA.	creighto@bcm.edu		Mills, Gordon/0000-0002-0144-9614	National Institutes of Health (NIH) [2R01CA125123-09]; MD Anderson's Institutional Tissue Bank Award [2P30CA016672]; University of Texas Lung Specialized Programs of Research Excellence grant [P50CA70907]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP120713, RP150405]; Department of Defense PROSPECT grant [W81XWH-07-1-0306]; NATIONAL CANCER INSTITUTE [U24CA199461, U24CA210949, P50CA070907, U24CA210950, P30CA125123, U24CA143883, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's Institutional Tissue Bank Award; University of Texas Lung Specialized Programs of Research Excellence grant; Cancer Prevention and Research Institute of Texas (CPRIT); Department of Defense PROSPECT grant(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the following grants from the National Institutes of Health (NIH) grant 2R01CA125123-09 (C. Creighton), MD Anderson's Institutional Tissue Bank Award (2P30CA016672, I. Wistuba), and The University of Texas Lung Specialized Programs of Research Excellence grant (P50CA70907, I. Wistuba), Cancer Prevention and Research Institute of Texas (CPRIT) grant RP120713 C2 (C. Creighton) and P2 (D. Gibbons), and RP150405 (D. Gibbons) and Department of Defense PROSPECT grant (W81XWH-07-1-0306, I. Wistuba).	Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Chae YK, 2016, CLIN LUNG CANCER, V17, P350, DOI 10.1016/j.cllc.2016.03.011; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Chiriva-Internati M, 2012, INT REV IMMUNOL, V31, P321, DOI 10.3109/08830185.2012.723512; Ciuffreda L, 2014, CURR PHARM DESIGN, V20, P3944, DOI 10.2174/13816128113196660763; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Creighton Chad J, 2013, Cancer Manag Res, V5, P187, DOI 10.2147/CMAR.S35171; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Iyoda A, 2014, GEN THORAC CARDIOVAS, V62, P351, DOI 10.1007/s11748-014-0379-9; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; Mo QX, 2013, P NATL ACAD SCI USA, V110, P4245, DOI 10.1073/pnas.1208949110; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096	25	76	78	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1384	1393		10.1038/onc.2016.303	http://dx.doi.org/10.1038/onc.2016.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27775076	Green Accepted			2022-12-28	WOS:000395862500007
J	Zelenko, Z; Gallagher, EJ; Tobin-Hess, A; Belardi, V; Rostoker, R; Blank, J; Dina, Y; LeRoith, D				Zelenko, Z.; Gallagher, E. J.; Tobin-Hess, A.; Belardi, V.; Rostoker, R.; Blank, J.; Dina, Y.; LeRoith, D.			Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TYPE-2 DIABETES-MELLITUS; MICE LACKING VIMENTIN; BREAST-CANCER; IGF-I; INSULIN-RESISTANCE; CELL MIGRATION; INCREASED RISK; HYPERINSULINEMIA; INVASION	Increased breast cancer risk and mortality has been associated with obesity and type 2 diabetes (T2D). Hyperinsulinemia, a key factor in obesity, pre-diabetes and T2D, has been associated with decreased breast cancer survival. In this study, a mouse model of pre-diabetes (MKR mouse) was used to investigate the mechanisms through which endogenous hyperinsulinemia promotes mammary tumor metastases. The MKR mice developed larger primary tumors and greater number of pulmonary metastases compared with wild-type (WT) mice after injection with c-Myc/Vegf overexpressing MVT-1 cells. Analysis of the primary tumors showed significant increase in vimentin protein expression in the MKR mice compared with WT. We hypothesized that vimentin was an important mediator in the effect of hyperinsulinemia on breast cancer metastasis. Lentiviral short hairpin RNA knockdown of vimentin led to a significant decrease in invasion of the MVT-1 cells and abrogated the increase in cell invasion in response to insulin. In the pre-diabetic MKR mouse, vimentin knockdown led to a decrease in pulmonary metastases. In vitro, we found that insulin increased pAKT, prevented caspase 3 activation, and increased vimentin. Inhibiting the phosphatidylinositol 3 kinase/AKT pathway, using NVP-BKM120, increased active caspase 3 and decreased vimentin levels. This study is the first to show that vimentin has an important role in tumor metastasis in vivo in the setting of pre-diabetes and endogenous hyperinsulinemia. Vimentin targeting may be an important therapeutic strategy to reduce metastases in patients with obesity, pre-diabetes or T2D.	[Zelenko, Z.; Gallagher, E. J.; Tobin-Hess, A.; Belardi, V.; Blank, J.; Dina, Y.; LeRoith, D.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, One Gustave L Levy Pl,Box 1055, New York, NY 10029 USA; [Rostoker, R.; LeRoith, D.] CRIR, Haifa, Israel; [Rostoker, R.; LeRoith, D.] Technion, Fac Med, Diabet & Metab Clin Res Ctr Excellence, Haifa, Israel	Icahn School of Medicine at Mount Sinai; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	LeRoith, D (corresponding author), Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, One Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.	Derek.LeRoith@mssm.edu			NCI grant [2R01CA128799-06A1]; American Diabetes grant [1-13-BS-108]; NIH/NCI [1K08CA190770]; NCI Supplement [R01CA171558-02S1]; NATIONAL CANCER INSTITUTE [K08CA190770, R01CA128799, R01CA171558] Funding Source: NIH RePORTER	NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Diabetes grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Supplement; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NCI grant (grant 2R01CA128799-06A1) to DLR. American Diabetes grant 1-13-BS-108 to DLR. NIH/NCI 1K08CA190770 to EJG. NCI Supplement R01CA171558-02S1 to YD. Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo, University of Pisa to VB.	ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670; Beronja S, 2010, NAT MED, V16, P821, DOI 10.1038/nm.2167; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Chari ST, 2005, GASTROENTEROLOGY, V129, P504, DOI 10.1053/j.gastro.2005.05.007; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Ferguson RD, 2013, ENDOCR-RELAT CANCER, V20, P391, DOI 10.1530/ERC-12-0333; Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fierz Y, 2010, DIABETES, V59, P686, DOI 10.2337/db09-1291; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Gilles C, 1999, J CELL SCI, V112, P4615; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hines IN, 2011, AM J PATHOL, V179, P2855, DOI 10.1016/j.ajpath.2011.08.014; Lawlor DA, 2004, CANCER CAUSE CONTROL, V15, P267, DOI 10.1023/B:CACO.0000024225.14618.a8; LeRoith D, 2006, INT J BIOCHEM CELL B, V38, P904, DOI 10.1016/j.biocel.2005.01.019; Lipscombe LL, 2008, BREAST CANCER RES TR, V109, P389, DOI 10.1007/s10549-007-9654-0; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Onitilo AA, 2012, CANCER CAUSE CONTROL, V23, P967, DOI 10.1007/s10552-012-9972-3; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Redaniel MTM, 2012, CANCER CAUSE CONTROL, V23, P1785, DOI 10.1007/s10552-012-0057-0; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Shen XC, 2015, J BIOL CHEM, V290, P11578, DOI 10.1074/jbc.M114.620237; Svegliati-Baroni G, 2011, GUT, V60, P108, DOI 10.1136/gut.2010.219741; Tezcan O, 2014, BIOMED PHARMACOTHER, V68, P357, DOI 10.1016/j.biopha.2014.01.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wei JC, 2008, ANTICANCER RES, V28, P327; Yang Y, 2012, CANCER, V119, P1512; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zanders MMJ, 2013, MATURITAS, V74, P37, DOI 10.1016/j.maturitas.2012.10.007; Zhang PH, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-567; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	45	26	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1394	1403		10.1038/onc.2016.305	http://dx.doi.org/10.1038/onc.2016.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27568979	Green Accepted			2022-12-28	WOS:000395862500008
J	Shi, L; Wang, Y; Lu, Z; Zhang, H; Zhuang, N; Wang, B; Song, Z; Chen, G; Huang, C; Xu, D; Zhang, Y; Zhang, W; Gao, Y				Shi, L.; Wang, Y.; Lu, Z.; Zhang, H.; Zhuang, N.; Wang, B.; Song, Z.; Chen, G.; Huang, C.; Xu, D.; Zhang, Y.; Zhang, W.; Gao, Y.			miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; MOUSE MODEL; ACTIVATION; EXPRESSION; A20; RESISTANCE; GENE; HETEROGENEITY; MICRORNA-127	The coordination between cellular differentiation and the mesenchymal/stem transition is essential for both embryo development and neoplasia, suggesting a mechanistic link between these two major processes. In this work we show that miR-127, an embryoexpressing lung miRNA, was prominently induced in lung adenocarcinoma and correlated with poor prognosis. Elevated miR-127 level drove a pronounced shift from the epithelial to the mesenchymal phenotype in cancer cells, and this shift was associated with their acquisition of stem-like traits, increased resistance to the epidermal growth factor receptor inhibitor and tumor-propagating potential. In contrast, antagonizing miR-127 markedly reversed this malignant transition, compromised the stem-like properties and the in vivo tumorigenic capability of cancer cells. Importantly, a regulatory loop involving the inflammatory signals NF-.B, miR-127 and tumor necrosis factor alpha-induced protein 3 was uncovered as a self-reinforcing circuitry that ensured an aggressive transition in lung cancer. Thus, this work identifies a novel molecular mechanism linking stemness, malignancy and inflammation, opening a new avenue for cancer treatment.	[Shi, L.; Zhang, W.; Gao, Y.] Nanjing Univ Chinese Med, Sch Basic Med Sci, Dept Immunol, Nanjing, Jiangsu, Peoples R China; [Shi, L.; Wang, Y.; Lu, Z.; Zhang, H.; Zhuang, N.; Wang, B.; Xu, D.] Hangzhou Normal Univ, Sch Med, Dept Basic Med Sci, Hangzhou, Zhejiang, Peoples R China; [Song, Z.; Zhang, Y.] Zhejiang Canc Hosp, Key Lab Diag & Treatment Technol Thorac Oncol, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Chen, G.; Huang, C.] Hangzhou Normal Univ, Affiliated Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China; [Xu, D.] Monash Univ, Dept Mol & Translat Sci, Melbourne, Vic, Australia	Nanjing University of Chinese Medicine; Hangzhou Normal University; Zhejiang Cancer Hospital; Hangzhou Normal University; Monash University	Shi, L (corresponding author), Nanjing Univ Chinese Med, Sch Basic Med Sci, 138 Xianlin Rd, Nanjing 210046, Jiangsu, Peoples R China.	shi_liyun@msn.com		Shi, Liyun/0000-0003-3538-1571; Shi, Liyun/0000-0003-1767-0126	National Key Scientific Research Project [2012CB911200]; National Natural Scientific Funds of Science [81270066, 31200581, 81470210]	National Key Scientific Research Project; National Natural Scientific Funds of Science	We are grateful to Dr Weifeng Ni (the Animal Facility, Hangzhou Normal University) for his assistance in tumor xenograft experiments. This work was supported by the National Key Scientific Research Project (2012CB911200) and the National Natural Scientific Funds of Science (81270066, 31200581 and 81470210).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhaskaran M, 2009, PHYSIOL GENOMICS, V37, P268, DOI 10.1152/physiolgenomics.90268.2008; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; De S, 2014, P NATL ACAD SCI USA, V111, P11721, DOI 10.1073/pnas.1412390111; Edwards CA, 2008, PLOS BIOL, V6, P1292, DOI 10.1371/journal.pbio.0060135; Espin-Palazon R, 2014, CELL, V159, P1070, DOI 10.1016/j.cell.2014.10.031; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gazdar AF, 2009, NEW ENGL J MED, V361, P1018, DOI 10.1056/NEJMe0905763; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Goswami RS, 2013, J CLIN ONCOL, V31, P2903, DOI 10.1200/JCO.2012.45.3050; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hymowitz SG, 2010, NAT REV CANCER, V10, P332, DOI 10.1038/nrc2775; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ito M, 2015, DEVELOPMENT, V142, P2425, DOI 10.1242/dev.121996; Jeon YJ, 2015, P NATL ACAD SCI USA, V112, pE3355, DOI 10.1073/pnas.1504630112; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Li L, 2014, CLIN CANCER RES, V20, P2714, DOI 10.1158/1078-0432.CCR-13-2613; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Nakagawa MM, 2015, J EXP MED, V212, P203, DOI 10.1084/jem.20132544; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Potu H, 2010, CANCER RES, V70, P655, DOI 10.1158/0008-5472.CAN-09-1942; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Vande Walle L, 2014, NATURE, V512, P69, DOI 10.1038/nature13322; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang ZH, 2013, J BIOL CHEM, V288, P28893, DOI 10.1074/jbc.M113.502682; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yin C, 2013, HEPATOLOGY, V58, P1964, DOI 10.1002/hep.26573; Ying HJ, 2015, J IMMUNOL, V194, P1239, DOI 10.4049/jimmunol.1402088; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	50	54	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1631	1643		10.1038/onc.2016.332	http://dx.doi.org/10.1038/onc.2016.332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27869168				2022-12-28	WOS:000397460600003
J	Thompson, JM; Nguyen, QH; Singh, M; Pavesic, MW; Nesterenko, I; Nelson, LJ; Liao, AC; Razorenova, OV				Thompson, J. M.; Nguyen, Q. H.; Singh, M.; Pavesic, M. W.; Nesterenko, I.; Nelson, L. J.; Liao, A. C.; Razorenova, O. V.			Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR; UP-REGULATION; INTERFERON-ALPHA; ROCK-II; HYPOXIA; GENE; EXPRESSION; Y-27632; PROGRESSION	Clear cell renal cell carcinoma (CC-RCC) is the most lethal of all genitourinary cancers. The functional loss of the von Hippel-Lindau (VHL) gene occurs in 90% of CC-RCC, driving cancer progression. The objective of this study was to identify chemical compounds that are synthetically lethal with VHL deficiency in CC-RCC. An annotated chemical library, the library of pharmacologically active compounds (LOPAC), was screened in parallel on VHL-deficient RCC4 cells and RCC4VHL cells with re-introduced VHL. The ROCK inhibitor, Y-27632, was identified and validated for selective targeting of VHL-deficient CC-RCC in multiple genetic backgrounds by clonogenic assays. Downregulation of ROCK1 by small interfering RNA (siRNA) selectively reduced the colony-forming ability of VHL-deficient CC-RCC, thus mimicking the effect of Y-27632 treatment, whereas downregulation of ROCK2 had no effect. In addition, two other ROCK inhibitors, RKI 1447 and GSK 429286, selectively targeted VHL-deficient CC-RCC. CC-RCC treatment with ROCK inhibitors is cytotoxic and cytostatic based on bromodeoxyuridine (BrdU) assay, propidium iodide (PI) staining and growth curves, and blocks cell migration based on transwell assay. On the one hand, knockdown of hypoxia-inducible factor (HIF) beta in the VHL-deficient CC-RCC had a protective effect against Y-27632 treatment, mimicking VHL reintroduction. On the other hand, CC-RCCVHL cells were sensitized to Y-27632 treatment in hypoxia (2% O-2). These results suggest that synthetic lethality between ROCK inhibition and VHL deficiency is dependent on HIF activation. Moreover, HIF1 alpha or HIF2 alpha overexpression in CC-RCCVHL cells is sufficient to sensitize them to ROCK inhibition. Finally, Y-27632 treatment inhibited growth of subcutaneous 786-OT1 CC-RCC tumors in mice. Thus, ROCK inhibitors represent potential therapeutics for VHL-deficient CC-RCC.	[Thompson, J. M.; Nguyen, Q. H.; Singh, M.; Pavesic, M. W.; Nesterenko, I.; Nelson, L. J.; Liao, A. C.; Razorenova, O. V.] Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall Room 3010, Irvine, CA 92717 USA	University of California System; University of California Irvine	Razorenova, OV (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall Room 3010, Irvine, CA 92717 USA.	olgar@uci.edu			NCI [R03 CA202563-01]; NIH T32 [2T32CA009054-36A1]; NIH [T32 NS82174-3]; NIH ICTS [UL1 TR001414];  [ACS-IRG-98-279-10]; NATIONAL CANCER INSTITUTE [T32CA009054, R03CA202563] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001415, UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS082174] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH T32(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH ICTS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by ACS-IRG-98-279-10 and NCI R03 CA202563-01 to OVR, NIH T32 (2T32CA009054-36A1) to JMT, NIH T32 NS82174-3 to IN and NIH ICTS (UL1 TR001414) to LJN. We thank Dr David Fruman and Dr Hung Fan for critical reading of the manuscript and anonymous reviewers for constructive critique.	Abe H, 2008, BIOMED RES-TOKYO, V29, P155, DOI 10.2220/biomedres.29.155; Amin E, 2013, BIOL CHEM, V394, P1399, DOI 10.1515/hsz-2013-0181; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Buczek M, 2014, BBA-REV CANCER, V1845, P31, DOI 10.1016/j.bbcan.2013.10.001; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Escudier B, 2011, DRUGS R&D, V11, P113, DOI 10.2165/11591240-000000000-00000; Gilkes DM, 2014, P NATL ACAD SCI USA, V111, pE384, DOI 10.1073/pnas.1321510111; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Inan SY, 2008, BRIT J PHARMACOL, V155, P44, DOI 10.1038/bjp.2008.225; Isler D, 2014, PHARMACOL REP, V66, P114, DOI 10.1016/j.pharep.2013.06.006; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Liao DK, 2007, J CARDIOVASC PHARM, V50, P17, DOI 10.1097/FJC.0b013e318070d1bd; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Liu XZ, 2011, J ORTHOP RES, V29, P1259, DOI 10.1002/jor.21403; Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; Mleczak A, 2013, CELL SIGNAL, V25, P1, DOI 10.1016/j.cellsig.2012.09.010; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nagatoya K, 2002, KIDNEY INT, V61, P1684, DOI 10.1046/j.1523-1755.2002.00328.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Pinto A, 2014, CLIN GENITOURIN CANC, V12, P408, DOI 10.1016/j.clgc.2014.06.012; Razorenova OV, 2014, MOL CELL BIOL, V34, P739, DOI 10.1128/MCB.00644-12; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Razorenova OV, 2005, GENE, V350, P89, DOI 10.1016/j.gene.2005.02.006; Rikitake Y, 2005, STROKE, V36, P2251, DOI 10.1161/01.STR.0000181077.84981.11; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi JJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.10; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Sutphin PD, 2007, CANCER RES, V67, P5896, DOI 10.1158/0008-5472.CAN-07-0604; Takata K, 2008, MOL CANCER THER, V7, P1551, DOI 10.1158/1535-7163.MCT-07-0428; Thompson Jordan M., 2015, Yale Journal of Biology and Medicine, V88, P145; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Woldemichael GM, 2012, NEOPLASIA, V14, P771, DOI 10.1593/neo.12852; Wolff NC, 2015, ONCOTARGET, V6, P16951, DOI 10.18632/oncotarget.4773; Zhang C, 2014, ONCOGENE, V33, P5582, DOI 10.1038/onc.2013.505; Zhang QH, 2012, ADV DIFFER EQU-NY, DOI 10.1186/1687-1847-2012-136	54	22	22	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1080	1089		10.1038/onc.2016.272	http://dx.doi.org/10.1038/onc.2016.272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27841867	Green Accepted, Green Submitted			2022-12-28	WOS:000395371500006
J	Thapa, N; Tan, X; Choi, S; Wise, T; Anderson, RA				Thapa, N.; Tan, X.; Choi, S.; Wise, T.; Anderson, R. A.			PIPKI gamma and talin couple phosphoinositide and adhesion signaling to control the epithelial to mesenchymal transition	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL-PHOSPHATE KINASE; DIRECTIONALLY MIGRATING CELLS; I-GAMMA; E-CADHERIN; TUMOR-METASTASIS; TRAFFICKING; GROWTH; 5-KINASE; BINDING; CANCER	Epithelial cells acquire migratory/invasive and stemness traits upon conversion to the mesenchymal phenotype. The expression of E-cadherin is a key to this transition; yet precise understanding of the pathways involved in integrating E-cadherin loss to the gain of mesenchymal traits remains poorly understood. Here, we show that phosphoinositide-generating enzyme, PIPKI gamma, expression is upregulated upon epithelial-mesenchymal transition (EMT) and together with the cytoskeletal protein talin assemble into a signaling complex upon E-cadherin loss. PIPKI gamma and talin together control the adhesion and phosphoinositide signaling that regulates conversion to the mesenchymal phenotypes. PIPKI gamma and talin regulate the stability of E-cadherin transcriptional repressors, snail and slug, induced by transforming growth factor-beta 1 or extracellular matrix protein. Loss of PIPKI gamma or talin or their interaction impaired EMT and the acquisition of cell motility and stemness. This demonstrates a mechanism where a phosphoinositide-generating enzyme PIPKI gamma couples with a cytoskeletal protein talin to control the acquisition of mesenchymal phenotypes.	[Thapa, N.; Tan, X.; Choi, S.; Wise, T.; Anderson, R. A.] Univ Wisconsin, Sch Med & Publ Hlth, Mol & Cellular Pharmacol Program, 3750 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Mol & Cellular Pharmacol Program, 3750 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	raanders@wisc.edu	Tan, Xiaojun/N-2142-2017	Tan, Xiaojun/0000-0003-3300-2240; Wise, Thomas/0000-0001-7007-6279; Anderson, Richard/0000-0001-6265-8359	National Institute of Health (NIH) [CA104708, GM057549]; American Heart Association (AHA) [10POST4290052, 13PRE14690057]; Howard Hughes Medical Institute (HHMI) International Student Research Fellowship; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057549] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association (AHA)(American Heart Association); Howard Hughes Medical Institute (HHMI) International Student Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institute of Health (NIH) grants (CA104708 and GM057549) to RAA; American Heart Association (AHA) grants to NT (10POST4290052) and SC (13PRE14690057); and Howard Hughes Medical Institute (HHMI) International Student Research Fellowship to XT.	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Ben-Aissa K, 2012, J BIOL CHEM, V287, P16311, DOI 10.1074/jbc.M111.304881; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Chen YM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-5; Choi SY, 2015, BBA-MOL CELL BIOL L, V1851, P711, DOI 10.1016/j.bbalip.2015.01.009; Choi S, 2013, EMBO J, V32, P2617, DOI 10.1038/emboj.2013.191; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Granato DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098208; Heck JN, 2007, CRIT REV BIOCHEM MOL, V42, P15, DOI 10.1080/10409230601162752; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nieves B, 2010, J CELL SCI, V123, P1216, DOI 10.1242/jcs.056549; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park J, 2014, ONCOGENE, V33, P1649, DOI 10.1038/onc.2013.118; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Saltel F, 2009, J CELL BIOL, V187, P715, DOI 10.1083/jcb.200908134; Schill NJ, 2014, J CELL SCI, V127, P2189, DOI 10.1242/jcs.132423; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shintani Y, 2008, J CELL BIOL, V180, P1277, DOI 10.1083/jcb.200708137; Sun Y, 2007, J CELL BIOL, V178, P297, DOI 10.1083/jcb.200701078; Sun Y, 2013, BIOESSAYS, V35, P513, DOI 10.1002/bies.201200171; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Thapa N, 2015, J BIOL CHEM, V290, P18843, DOI 10.1074/jbc.M114.596742; Thapa N, 2013, J BIOL CHEM, V288, P34707, DOI 10.1074/jbc.M113.512848; Thapa N, 2012, CELL ADHES MIGR, V6, P409, DOI 10.4161/cam.21192; Thapa N, 2012, DEV CELL, V22, P116, DOI 10.1016/j.devcel.2011.10.030; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vitorino P, 2015, NATURE, V519, P425, DOI 10.1038/nature14323; Xiong XH, 2012, MOL BIOL CELL, V23, P87, DOI 10.1091/mbc.E11-05-0449; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	40	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					899	911		10.1038/onc.2016.267	http://dx.doi.org/10.1038/onc.2016.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452517	Green Accepted			2022-12-28	WOS:000394169100003
J	Nickerson, ML; Witte, N; Im, KM; Turan, S; Owens, C; Misner, K; Tsang, SX; Cai, Z; Wu, S; Dean, M; Costello, JC; Theodorescu, D				Nickerson, M. L.; Witte, N.; Im, K. M.; Turan, S.; Owens, C.; Misner, K.; Tsang, S. X.; Cai, Z.; Wu, S.; Dean, M.; Costello, J. C.; Theodorescu, D.			Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response	ONCOGENE			English	Article							INVASIVE BLADDER-CANCER; WHOLE-GENOME; IMPACT ANALYSIS; IDENTIFICATION; VISUALIZATION; ANNOTATION; RESOURCE; CHEMOSENSITIVITY; REGULARIZATION; COMBINATION	The utility of tumor-derived cell lines is dependent on their ability to recapitulate underlying genomic aberrations and primary tumor biology. Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA). We observed a mutation pattern associated with altered CpGs and APOBEC-family cytosine deaminases similar to mutation signatures derived from somatic alterations in muscle-invasive (Ml) primary tumors, highlighting a major mechanism(s) contributing to cancer associated alterations in the BCa cell line exomes. Non-silent sequence alterations were confirmed in 76 cancer-associated genes, including mutations that likely activate oncogenes TERT and PIK3CA, and alter chromatin-associated proteins (MLL3, ARID1A, CHD6 and KDM6A) and established BCa genes (TP53, RB1, CDKN2A and TSC1). We identified alterations in signaling pathways and proteins with related functions, including the PI3K/mTOR pathway, altered in 60% of lines; BRCA DNA repair, 44%; and SYNE1-SYNE2, 60%. Homozygous deletions of chromosome 9p21 are known to target the cell cycle regulators CDKN2A and CDKN2B. This loci was commonly lost in BCa cell lines and we show the deletions extended to the polyamine enzyme methylthioadenosine (MTA) phosphorylase (MTAP) in 36% of lines, transcription factor DMRTA1 (27%) and antiviral interferon epsilon (IFNE, 19%). Overall, the BCa cell line genomic aberrations were concordant with those found in BCa patient tumors. We used gene expression and copy number data to infer pathway activities for cell lines, then used the inferred pathway activities to build a predictive model of cisplatin response. When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response. Together, these data and analysis represent a valuable community resource to model basic tumor biology and to study the pharmacogenomics of BCa.	[Nickerson, M. L.; Turan, S.; Misner, K.; Dean, M.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Witte, N.; Costello, J. C.] Univ Colorado, Computat Biosci Program, Aurora, CO USA; [Im, K. M.] Data Sci Genom LLC, Ellicott City, MD USA; [Owens, C.; Theodorescu, D.] Univ Colorado, Dept Surg Urol, Aurora, CO USA; [Tsang, S. X.] BGI Shenzhen, Shenzhen, Peoples R China; [Cai, Z.; Wu, S.] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China; [Costello, J. C.; Theodorescu, D.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA; [Costello, J. C.; Theodorescu, D.] Univ Colorado, Ctr Comprehens Canc, Anschutz Med Campus,13001 E 17th Pl,F-434, Aurora, CO 80045 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Beijing Genomics Institute (BGI); Second People's Hospital of Shenzhen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Costello, JC (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA.; Theodorescu, D (corresponding author), Univ Colorado, Ctr Comprehens Canc, Anschutz Med Campus,13001 E 17th Pl,F-434, Aurora, CO 80045 USA.	james.costello@ucdenver.edu; dan.theodorescu@ucdenver.edu	Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631; Costello, James/0000-0003-3158-9682	NIH [CA143971, CA075115]; Intramural Research Program of the NIH; National Cancer Institute, Center for Cancer Research; National Library of Medicine T15 training grant [LM009451]; Shenzhen municipal science and technology project [CXZZ20140826163906370]; NATIONAL CANCER INSTITUTE [R01CA143971, R01CA075115, R29CA075115, P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM009451] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Library of Medicine T15 training grant; Shenzhen municipal science and technology project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We would like to thank Dr Neeraj Agarwal for providing the TERT experimental data. This work was in part supported by NIH grants CA143971 and CA075115 for DT; Intramural Research Program of the NIH, the National Cancer Institute, Center for Cancer Research for MLN and MD; National Library of Medicine T15 training grant LM009451 for NW; Shenzhen municipal science and technology project CXZZ20140826163906370 for SW.	1000 Genomes Project Consortium, 2012, Nature, V491, P56, DOI 10.1038/nature11632; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bertino JR, 2011, CANCER BIOL THER, V11, P627, DOI 10.4161/cbt.11.7.14948; Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200; Cao W, 2005, BIOCHEM BIOPH RES CO, V330, P1034, DOI 10.1016/j.bbrc.2005.02.188; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Earl J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1450-3; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fung KY, 2013, SCIENCE, V339, P1088, DOI 10.1126/science.1233321; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Goodspeed A, 2016, MOL CANCER RES, V14, P3, DOI 10.1158/1541-7786.MCR-15-0189; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497; Heidenblad M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-3; Hermant P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071320; Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim J, 2015, CLIN CANCER RES, V21, P4514, DOI 10.1158/1078-0432.CCR-14-1215; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li H, 2014, MOL CANCER RES, V12, P571, DOI 10.1158/1541-7786.MCR-13-0396; Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; Messing E, 2006, J UROLOGY, V176, P500, DOI 10.1016/j.juro.2006.03.061; Morrison CD, 2014, P NATL ACAD SCI USA, V111, pE672, DOI 10.1073/pnas.1313580111; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078-0432.CCR-14-0330; Plagnol V, 2012, BIOINFORMATICS, V28, P2747, DOI 10.1093/bioinformatics/bts526; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Seshan W, DNACOPY DNA COPY NUM; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith SC, 2011, LANCET ONCOL, V12, P137, DOI 10.1016/S1470-2045(10)70296-5; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; STADLER WM, 1994, CANCER RES, V54, P2060; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vuong H, 2015, BIOINFORMATICS, V31, P2748, DOI 10.1093/bioinformatics/btv200; Vuong H, 2014, BIOINFORMATICS, V30, P1013, DOI 10.1093/bioinformatics/btt655; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wijesundara DK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00412; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yap KL, 2014, CLIN CANCER RES, V20, P6605, DOI 10.1158/1078-0432.CCR-14-0257; Yu M, 2015, NATURE, V520, P307, DOI 10.1038/nature14397; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	56	59	60	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					35	46		10.1038/onc.2016.172	http://dx.doi.org/10.1038/onc.2016.172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270441	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000394069100004
J	Ghoochani, A; Schwarz, MA; Yakubov, E; Engelhorn, T; Doerfler, A; Buchfelder, M; Bucala, R; Savaskan, NE; Eyupoglu, IY				Ghoochani, A.; Schwarz, M. A.; Yakubov, E.; Engelhorn, T.; Doerfler, A.; Buchfelder, M.; Bucala, R.; Savaskan, N. E.; Eyupoglu, I. Y.			MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis	ONCOGENE			English	Article							MIGRATION-INHIBITORY FACTOR; MACROPHAGE; CELL; EXPRESSION; CD74; MIF; GLIOMAS; PROGRESSION; ACTIVATION; REGULATOR	Microglial cells in the brain tumor microenvironment are associated with enhanced glioma malignancy. They persist in an immunosuppressive M2 state at the peritumoral site and promote the growth of gliomas. Here, we investigated the underlying factors contributing to the abolished immune surveillance. We show that brain tumors escape pro-inflammatory M1 conversion of microglia via CD74 activation through the secretion of the cytokine macrophage migration inhibitory factor (MIF), which results in a M2 shift of microglial cells. Interruption of this glioma-microglial interaction through an antibody-neutralizing approach or small interfering RNA (siRNA)-mediated inhibition prolongs survival time in glioma-implanted mice by reinstating the microglial proinflammatory M1 function. We show that MIF-CD74 signaling inhibits interferon (IFN)-gamma secretion in microglia through phosphorylation of microglial ERK1/2 (extracellular signal-regulated protein kinases 1 and 2). The inhibition of MIF signaling or its receptor CD74 promotes IFN-gamma release and amplifies tumor death either through pharmacological inhibition or through siRNAmediated knockdown. The reinstated IFN-gamma secretion leads both to direct inhibition of glioma growth as well as inducing a M2 to M1 shift in glioma-associated microglia. Our data reveal that interference with the MIF signaling pathway represents a viable therapeutic option for the restoration of IFN-gamma-driven immune surveillance.	[Ghoochani, A.; Schwarz, M. A.; Yakubov, E.; Buchfelder, M.; Savaskan, N. E.; Eyupoglu, I. Y.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neurosurg, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany; [Engelhorn, T.; Doerfler, A.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neuroradiol, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany; [Bucala, R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Savaskan, N. E.] BiMECON Ent, Kurfurstenstr 21, Berlin, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Yale University	Eyupoglu, IY (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neurosurg, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany.	ilker.eyupoglu@uk-erlangen.de	Yakubov, Eduard/ABH-6173-2020; Savaskan, Nicolai/D-2923-2018	Yakubov, Eduard/0000-0002-5828-6609; Savaskan, Nicolai/0000-0003-1348-094X	German Research Foundation [DFG Ey 94/2-1]	German Research Foundation(German Research Foundation (DFG))	Our work is supported by the German Research Foundation (DFG Ey 94/2-1).	Baron N, 2011, J NEUROSCI RES, V89, P711, DOI 10.1002/jnr.22595; Becker-Herman S, 2005, MOL BIOL CELL, V16, P5061, DOI 10.1091/mbc.E05-04-0327; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Bryan KJ, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-13; Butrym A, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0560-5; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Engelhorn T, 2009, CANCER SCI, V100, P1856, DOI 10.1111/j.1349-7006.2009.01259.x; Eyupoglu IY, 2013, NAT REV NEUROL, V9, P141, DOI 10.1038/nrneurol.2012.279; Eyupoglu IY, 2005, J NEUROSURG, V102, P738, DOI 10.3171/jns.2005.102.4.0738; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Fingerle-Rowson G, 2009, MOL CELL BIOL, V29, P1922, DOI 10.1128/MCB.01907-08; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Gupta P, 2012, BLOOD, V119, P3767, DOI 10.1182/blood-2011-09-381988; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heneka M, 2014, J EXP MED, V211, P1500, DOI 10.1084/jem.2118insight1; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaufman JL, 2013, BRIT J HAEMATOL, V163, P478, DOI 10.1111/bjh.12565; Kitange GJ, 2010, J NEURO-ONCOL, V100, P177, DOI 10.1007/s11060-010-0186-9; Komohara Y, 2012, CANCER SCI, V103, P2165, DOI 10.1111/cas.12015; Komohara Y, 2009, CANCER SCI, V100, P2160, DOI 10.1111/j.1349-7006.2009.01296.x; Ku MC, 2013, ACTA NEUROPATHOL, V125, P609, DOI 10.1007/s00401-013-1079-8; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401-011-0858-3; Muller A, 2015, INT J CANCER, V137, P278, DOI 10.1002/ijc.29379; Nagata S, 2009, ANN SURG ONCOL, V16, P2531, DOI 10.1245/s10434-009-0532-3; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Savaskan NE, 2011, ONCOGENE, V30, P43, DOI 10.1038/onc.2010.391; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Schwartz V, 2009, FEBS LETT, V583, P2749, DOI 10.1016/j.febslet.2009.07.058; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Smith Amy M, 2013, Methods Mol Biol, V1041, P41, DOI 10.1007/978-1-62703-520-0_6; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Yaddanapudi K, 2016, CANCER IMMUNOL RES, V4, P101, DOI 10.1158/2326-6066.CIR-15-0070-T; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117	51	55	55	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6246	6261		10.1038/onc.2016.160	http://dx.doi.org/10.1038/onc.2016.160			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157615				2022-12-28	WOS:000388857700009
J	Campos, B; Olsen, LR; Urup, T; Poulsen, HS				Campos, B.; Olsen, L. R.; Urup, T.; Poulsen, H. S.			A comprehensive profile of recurrent glioblastoma	ONCOGENE			English	Review							CELL MARKER CD133; CANCER STEM-CELLS; ADJUVANT TEMOZOLOMIDE; PROMOTER METHYLATION; TUMOR; EXPRESSION; SURVIVAL; RADIOTHERAPY; HETEROGENEITY; CONCOMITANT	In spite of relentless efforts to devise new treatment strategies, primary glioblastomas invariably recur as aggressive, therapy-resistant relapses and patients rapidly succumb to these tumors. Many therapeutic agents are first tested in clinical trials involving recurrent glioblastomas. Remarkably, however, fundamental knowledge on the biology of recurrent glioblastoma is just slowly emerging. Here, we review current knowledge on recurrent glioblastoma and ask whether and how therapies change intra-tumor heterogeneity, molecular traits and growth pattern of glioblastoma, and to which extent this information can be exploited for therapeutic decision-making. We conclude that the ability to characterize and predict therapy-induced changes in recurrent glioblastoma will determine, whether, one day, glioblastoma can be contained in a state of chronic disease.	[Campos, B.] Heidelberg Univ, Dept Neurosurg, Div Expt Neurosurg, INF 400, D-69120 Heidelberg, Germany; [Olsen, L. R.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, Lyngby, Denmark; [Urup, T.; Poulsen, H. S.] Copenhagen Univ Hosp, Finsen Ctr, Dept Radiat Biol, Copenhagen, Denmark	Ruprecht Karls University Heidelberg; Technical University of Denmark; University of Copenhagen	Campos, B (corresponding author), Heidelberg Univ, Dept Neurosurg, Div Expt Neurosurg, INF 400, D-69120 Heidelberg, Germany.	benito.campos@med.uni-heidelberg.de	Urup, Thomas/AAC-9953-2020	Olsen, Lars Ronn/0000-0002-6725-7850				Andor N, 2014, BIOINFORMATICS, V30, P50, DOI 10.1093/bioinformatics/btt622; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BILZER T, 1991, ANTICANCER RES, V11, P547; Brandes AA, 2009, J CLIN ONCOL, V27, P1275, DOI 10.1200/JCO.2008.19.4969; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; Campos B, 2014, J PATHOL, V234, P23, DOI 10.1002/path.4366; Campos B, 2011, INT J CANCER, V128, P501, DOI 10.1002/ijc.25687; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christmann M, 2010, INT J CANCER, V127, P2106, DOI 10.1002/ijc.25229; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P37, DOI 10.1016/j.clineuro.2012.04.005; Deleyrolle LP, 2011, BRAIN, V134, P1331, DOI 10.1093/brain/awr081; Furuta T, 2014, BRAIN TUMOR PATHOL, V31, P32, DOI 10.1007/s10014-013-0142-4; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Ilhan-Mutlu A, 2013, J NEURO-ONCOL, V112, P347, DOI 10.1007/s11060-013-1078-6; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Iwamoto FM, 2009, NEUROLOGY, V73, P1200, DOI 10.1212/WNL.0b013e3181bc0184; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kim H, 2015, GENOME RES, V25, P316, DOI 10.1101/gr.180612.114; Kim J, 2015, CANCER CELL, V28, P318, DOI 10.1016/j.ccell.2015.07.013; Lathia JD, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.80; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Martinez R, 2003, BRAIN PATHOL, V13, P598; Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014; Martinez R, 2010, J NEURO-ONCOL, V96, P321, DOI 10.1007/s11060-009-9967-4; Marucci G, 2015, PATHOLOGICA, V107, P1; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pallini R, 2011, CANCER-AM CANCER SOC, V117, P162, DOI 10.1002/cncr.25581; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Poulsen HS, 2014, CANCER MANAG RES, V6, P373, DOI 10.2147/CMAR.S39306; Qazi MA, 2016, J NEURO-ONCOL, V126, P57, DOI 10.1007/s11060-015-1951-6; Reis RM, 2001, J NEUROPATH EXP NEUR, V60, P208, DOI 10.1093/jnen/60.2.208; Richichi C, 2013, NEOPLASIA, V15, P840, DOI 10.1593/neo.13662; Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963; Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652; Shinsato Y, 2013, ONCOTARGET, V4, P2261, DOI 10.18632/oncotarget.1302; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smets T, 2013, EUR RADIOL, V23, P1467, DOI 10.1007/s00330-012-2762-1; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stark AM, 2003, J NEUROL NEUROSUR PS, V74, P779, DOI 10.1136/jnnp.74.6.779; Stark AM, 2010, NEUROL RES, V32, P816, DOI 10.1179/016164110X12645013515052; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tamura K, 2013, J NEUROSURG, V119, P1145, DOI 10.3171/2013.7.JNS122417; Van Nifterik KA, 2006, J NEUROSURG, V105, P739, DOI 10.3171/jns.2006.105.5.739; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Yao XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057188; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932	56	99	104	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5819	5825		10.1038/onc.2016.85	http://dx.doi.org/10.1038/onc.2016.85			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27041580				2022-12-28	WOS:000387560800001
J	Yu-Rice, Y; Jin, Y; Han, B; Qu, Y; Johnson, J; Watanabe, T; Cheng, L; Deng, N; Tanaka, H; Gao, B; Liu, Z; Sun, Z; Bose, S; Giuliano, A; Cui, X				Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Cheng, L.; Deng, N.; Tanaka, H.; Gao, B.; Liu, Z.; Sun, Z.; Bose, S.; Giuliano, A. E.; Cui, X.			FOXC1 is involved in ERa silencing by counteracting GATA3 binding and is implicated in endocrine resistance	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION PATTERNS; BREAST-CANCER CELLS; TRANSCRIPTIONAL REGULATION; FORKHEAD DOMAIN; POOR-PROGNOSIS; TAMOXIFEN; PROTEIN; FOXA1; OVEREXPRESSION	Estrogen receptor-alpha (ER alpha) mediates the essential biological function of estrogen in breast development and tumorigenesis. Multiple mechanisms, including pioneer factors, coregulators and epigenetic modifications have been identified as regulators of ER alpha signaling in breast cancer. However, previous studies of ER alpha regulation have focused on luminal and HER2-positive subtypes rather than basal-like breast cancer (BLBC), in which ER alpha is underexpressed. In addition, mechanisms that account for the decrease or loss of ER expression in recurrent tumors after endocrine therapy remain elusive. Here, we demonstrate a novel FOXC1-driven mechanism that suppresses ERa expression in breast cancer. We find that FOXC1 competes with GATA-binding protein 3 (GATA3) for the same binding regions in the cis-regulatory elements upstream of the ER alpha gene and thereby downregulates ER alpha expression and consequently its transcriptional activity. The forkhead domain of FOXC1 is essential for the competition with GATA3 for DNA binding. Counteracting the action of GATA3 at the ER alpha promoter region, overexpression of FOXC1 hinders recruitment of RNA polymerase II and increases histone H3K9 trimethylation at ER alpha promoters. Importantly, ectopic FOXC1 expression in luminal breast cancer cells reduces sensitivity to estrogen and tamoxifen. Furthermore, in breast cancer patients with ER-positive primary tumors who received adjuvant tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors. Our findings highlight a clinically relevant mechanism that contributes to the low or absent ER alpha expression in BLBC. This study suggests a new paradigm to study ER alpha regulation during breast cancer progression and indicates a role of FOXC1 in the modulation of cellular response to endocrine treatment.	[Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Tanaka, H.; Gao, B.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Cheng, L.; Sun, Z.] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China; [Deng, N.; Liu, Z.] Cedars Sinai Med Ctr, Dept Surg, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA; [Bose, S.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Chongqing Medical University; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.	Xiaojiang.Cui@cshs.org		Johnson, Jeffrey/0000-0003-2912-443X; Tanaka, Hisashi/0000-0001-9223-4186	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Julia Gee for discussion about antiestrogen experiments. This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063) and David Salomon Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy to Xiaojiang Cui, the Fashion Footwear Charitable Foundation of New York, Inc., associates for Breast and Prostate Cancer Studies, the Margie and Robert E. Petersen Foundation, and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Bartkuhn M, 2008, BBA-MOL CELL RES, V1783, P2161, DOI 10.1016/j.bbamcr.2008.07.011; Becker M, 2005, MOL CANCER THER, V4, P151; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326; Bulger M, 2010, DEV BIOL, V339, P250, DOI 10.1016/j.ydbio.2009.11.035; Caizzi L, 2014, P NATL ACAD SCI USA, V111, P4892, DOI 10.1073/pnas.1315445111; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Gaughan L, 2013, NUCLEIC ACIDS RES, V41, P6892, DOI 10.1093/nar/gkt469; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368; Manavathi B, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00034; Marconett CN, 2010, MOL BIOL CELL, V21, P1166, DOI 10.1091/mbc.E09-08-0689; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Oyama M, 2011, J BIOL CHEM, V286, P818, DOI 10.1074/jbc.M110.156877; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Saleem RA, 2004, NUCLEIC ACIDS RES, V32, P4182, DOI 10.1093/nar/gkh742; Saleem RA, 2003, HUM MOL GENET, V12, P2993, DOI 10.1093/hmg/ddg324; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shenker NS, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1335-5; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sparano JA, 2010, SURG ONCOL CLIN N AM, V19, P581, DOI 10.1016/j.soc.2010.03.008; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277-012-0629-3; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347; Ye Q, 2015, AM J CANCER RES, V5, P1519; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193	49	21	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5400	5411		10.1038/onc.2016.78	http://dx.doi.org/10.1038/onc.2016.78			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041579	Green Accepted			2022-12-28	WOS:000386677800006
J	de Jeude, JFV; Meijer, BJ; Wielenga, MCB; Spaan, CN; Baan, B; Rosekrans, SL; Meisner, S; Shen, YH; Lee, AS; Paton, JC; Paton, AW; Muncan, V; van den Brink, GR; Heijmans, J				de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Lee, A. S.; Paton, J. C.; Paton, A. W.; Muncan, V.; van den Brink, G. R.; Heijmans, J.			Induction of endoplasmic reticulum stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells	ONCOGENE			English	Article							RAPID LOSS; IN-VIVO; EXPRESSION; DIFFERENTIATION; TUMORIGENESIS; CANCER; COLON; GENE; APOPTOSIS; ADENOMA	Intestinal epithelial stem cells are highly sensitive to differentiation induced by endoplasmic reticulum (ER) stress. Colorectal cancer develops from mutated intestinal epithelial stem cells. The most frequent initiating mutation occurs in Apc, which results in hyperactivated Wnt signalling. This causes hyperproliferation and reduced sensitivity to chemotherapy, but whether these mutated stem cells are sensitive to ER stress induced differentiation remains unknown. Here we examined this by generating mice in which both Apc and ER stress repressor chaperone Grp78 can be conditionally deleted from the intestinal epithelium. For molecular studies, we used intestinal organoids derived from these mice. Homozygous loss of Apc alone resulted in crypt elongation, activation of the Wnt signature and accumulation of intestinal epithelial stem cells, as expected. This phenotype was however completely rescued on activation of ER stress by additional deletion of Grp78. In these Apc-Grp78 double mutant animals, stem cells were rapidly lost and repopulation occurred by non-mutant cells that had escaped recombination, suggesting that Apc-Grp78 double mutant stem cells had lost self-renewal capacity. Although in Apc-Grp78 double mutant mice the Wnt signature was lost, these intestines exhibited ubiquitous epithelial presence of nuclear beta-catenin. This suggests that ER stress interferes with Wnt signalling downstream of nuclear beta-catenin. In conclusion, our findings indicate that ER stress signalling results in loss of Apc mutated intestinal epithelial stem cells by interference with the Wnt signature. In contrast to many known inhibitors of Wnt signalling, ER stress acts downstream of beta-catenin. Therefore, ER stress poses a promising target in colorectal cancers, which develop as a result of Wnt activating mutations.	[de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Muncan, V.; van den Brink, G. R.; Heijmans, J.] Acad Med Ctr, Tygat Inst Liver & Intestinal Res, Amsterdam, Netherlands; [de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Lee, A. S.; Muncan, V.; van den Brink, G. R.; Heijmans, J.] Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands; [Lee, A. S.] Univ Southern Calif, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA USA; [Paton, J. C.; Paton, A. W.] Univ Adelaide, Res Ctr Infect Dis, Dept Mol & Cellular Biol, Sch Biol Sci, Adelaide, SA, Australia; [Heijmans, J.] Acad Med Ctr, Dept Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Southern California; University of Adelaide	Heijmans, J (corresponding author), Acad Med Ctr, Dept Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.heijmans@amc.nl	Meijer, Bartolomeus/AAU-5300-2021	Heijmans, Jarom/0000-0001-9615-7851; Lee, Amy/0000-0002-0378-5443	VENI grant from the Dutch Organisation for Scientific Research (NWO); Dutch Cancer Foundation (KWF)	VENI grant from the Dutch Organisation for Scientific Research (NWO); Dutch Cancer Foundation (KWF)(KWF Kankerbestrijding)	This work was supported by a VENI grant from the Dutch Organisation for Scientific Research (NWO) and by a research stipendium from the Dutch Cancer Foundation (KWF).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Heijmans J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022620; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Holik AZ, 2013, STEM CELLS, V31, P2457, DOI 10.1002/stem.1498; Huels DJ, 2015, BRIT J CANCER, V113, P1, DOI 10.1038/bjc.2015.214; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341; Paton AW, 2006, NATURE, V443, P548, DOI 10.1038/nature05124; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Rosekrans SL, 2015, GUT, V64, P195, DOI 10.1136/gutjnl-2013-306347; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Dop WA, 2010, GASTROENTEROLOGY, V139, P1665, DOI 10.1053/j.gastro.2010.07.045; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; Verras M, 2008, MOL CELL BIOL, V28, P7212, DOI 10.1128/MCB.00947-08; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016; Wolfson JJ, 2008, CELL MICROBIOL, V10, P1775, DOI 10.1111/j.1462-5822.2008.01164.x; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5	44	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3397	3405		10.1038/onc.2016.326	http://dx.doi.org/10.1038/onc.2016.326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	27819675	Green Accepted, hybrid			2022-12-28	WOS:000403340700004
J	Zandvakili, I; Lin, Y; Morris, JC; Zheng, Y				Zandvakili, I.; Lin, Y.; Morris, J. C.; Zheng, Y.			Rho GTPases: Anti- or pro-neoplastic targets?	ONCOGENE			English	Review							CANCER-CELL MOTILITY; DRIVER MUTATIONS; RATIONAL DESIGN; TUMOR-FORMATION; PROTEIN-KINASE; BREAST-CANCER; LUNG-CANCER; PERINEURAL INVASION; PROTEOMIC ANALYSIS; SIGNALING AXIS	Rho GTPases are critical signal transducers of multiple pathways. They have been proposed to be useful anti-neoplastic targets for over two decades, especially in Ras-driven cancers. Until recently, however, few in vivo studies had been carried out to test this premise. Several recent mouse model studies have verified that Rac1, RhoA, and some of their effector proteins such as PAK and ROCK, are likely anti-cancer targets for treating K-Ras-driven tumours. Other seemingly contradictory studies have suggested that at least in certain instances inhibition of individual Rho GTPases may paradoxically result in pro-neoplastic effects. Significantly, both RhoA GTPase gain-and loss-of-function mutations have been discovered in primary leukemia/lymphoma and gastric cancer by human cancer genome sequencing efforts, suggesting both pro-and anti-neoplastic roles. In this review we summarize and integrate these unexpected findings and discuss the mechanistic implications in the design and application of Rho GTPase targeting strategies in future cancer therapies.	[Zandvakili, I.; Lin, Y.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Mol & Dev Biol Grad Program, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Univ Cincinnati, Coll Med, Med Scientist Training Program, Cincinnati, OH USA; [Morris, J. C.] Univ Cincinnati, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@cchmc.org	Zandvakili, Inuk/P-7241-2019	Zandvakili, Inuk/0000-0003-3409-0019	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH [R01 CA193350, R01 DK104814, R01 HL134617]; NATIONAL CANCER INSTITUTE [R01CA193350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, R01DK104814] Funding Source: NIH RePORTER	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge support from the University of Cincinnati Medical Scientist Training Program and the Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center. The work in the Yi Zheng lab is partly supported by NIH grants R01 CA193350, R01 DK104814 and R01 HL134617.	Abiatari I, 2009, MOL CANCER THER, V8, P1494, DOI 10.1158/1535-7163.MCT-08-0755; Alan Jamie K, 2013, Small GTPases, V4, P159, DOI 10.4161/sgtp.26530; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker MS, 2016, ONCOTARGET, V7, P51908, DOI 10.18632/oncotarget.10188; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Biro M, 2014, BRIT J PHARMACOL, V171, P5491, DOI 10.1111/bph.12658; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Bosco EE, 2012, CHEM BIOL, V19, P228, DOI 10.1016/j.chembiol.2011.12.017; Boulter Etienne, 2010, Small GTPases, V1, P65; Bousquet E, 2009, CANCER RES, V69, P6092, DOI 10.1158/0008-5472.CAN-08-4147; Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Chew TW, 2014, ONCOGENE, V33, P2717, DOI 10.1038/onc.2013.240; Chiba Shigeru, 2015, Small GTPases, V6, P100, DOI 10.4161/21541248.2014.988088; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; Croise P, 2016, ENDOCR-RELAT CANCER, V23, P281, DOI 10.1530/ERC-15-0502; Cullis J, 2014, CANCER CELL, V25, P181, DOI 10.1016/j.ccr.2014.01.025; Deribe YL, 2016, P NATL ACAD SCI USA, V113, pE1296, DOI 10.1073/pnas.1513801113; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evelyn CR, 2009, J BIOMOL SCREEN, V14, P161, DOI 10.1177/1087057108328761; Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Forti FL, 2007, ENDOCR-RELAT CANCER, V14, P1117, DOI 10.1677/ERC-07-0154; Frances D, 2015, ONCOGENE, V34, P5505, DOI 10.1038/onc.2014.471; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fukumoto Y, 2007, J CARDIOVASC PHARM, V49, P117, DOI 10.1097/FJC.0b013e31802ef532; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gilbert-Ross M, 2015, GENES DIS, V2, P2, DOI 10.1016/j.gendis.2014.10.001; Grogg MW, 2010, RHO GTPASES IN CANCER, P93, DOI 10.1007/978-1-4419-1111-7_6; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heckman-Stoddard BM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2352; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holderfield M, 2014, BRIT J CANCER, V111, P640, DOI 10.1038/bjc.2014.139; Hu LD, 2007, ONCOL REP, V17, P1383; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ishikawa S, 2016, BLOOD, V127, P524, DOI 10.1182/blood-2015-12-683458; Jiang WG, 2003, CLIN CANCER RES, V9, P6432; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Koide N, 2006, CLIN CANCER RES, V12, P2419, DOI 10.1158/1078-0432.CCR-05-1852; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kumper S, 2016, ELIFE, V5, DOI 10.7554/eLife.12203; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kumar RD, 2016, NAT GENET, V48, P1288, DOI 10.1038/ng.3658; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2016, CANCER RES, V76, P3826, DOI 10.1158/0008-5472.CAN-15-2923; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin M, 2004, BREAST CANCER RES TR, V84, P49, DOI 10.1023/B:BREA.0000018424.43445.f3; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu N, 2007, J MOL MED-JMM, V85, P1149, DOI 10.1007/s00109-007-0217-y; Maeda M, 2016, GASTRIC CANCER, V19, P326, DOI 10.1007/s10120-015-0525-9; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Manso R, 2014, BLOOD, V123, P2893, DOI 10.1182/blood-2014-02-555946; Rojas AM, 2012, J CELL BIOL, V196, P189, DOI 10.1083/jcb.201103008; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; McHenry PR, 2010, CURR DRUG TARGETS, V11, P1043, DOI 10.2174/138945010792006852; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; Meyer N, 2014, J INVEST DERMATOL, V134, P203, DOI 10.1038/jid.2013.278; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Mizukawa B, 2011, BLOOD, V118, P5235, DOI 10.1182/blood-2011-04-351817; Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Huynh N, 2015, RES REP BIOCHEM, V5, P119, DOI 10.2147/RRBC.S57278; Nohata N, 2016, DEV BIOL, V411, P183, DOI 10.1016/j.ydbio.2016.02.005; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Orgaz Jose L, 2014, Small GTPases, V5, pe29019, DOI 10.4161/sgtp.29019; Pajic Marina, 2015, Small GTPases, V6, P123, DOI 10.4161/21541248.2014.973749; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Pranatharthi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5785786; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riou P, 2010, BIOESSAYS, V32, P986, DOI 10.1002/bies.201000060; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Rocken C, 2016, J CLIN PATHOL, V69, P70, DOI 10.1136/jclinpath-2015-202980; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sakamori R, 2014, CANCER RES, V74, P5480, DOI 10.1158/0008-5472.CAN-14-0267; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Samuel MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017143; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shang X, 2013, P NATL ACAD SCI USA, V110, P3155, DOI 10.1073/pnas.1212324110; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shimokawa H, 2002, J CARDIOVASC PHARM, V40, P749; Silva AL, 2013, EUR J ENDOCRINOL, V168, P795, DOI 10.1530/EJE-12-0960; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Skalnikova H, 2011, J PROTEOME RES, V10, P404, DOI 10.1021/pr100468w; Smithers CC, 2016, CELLS, P5; Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Hengel J, 2008, GASTROENTEROLOGY, V134, P781, DOI 10.1053/j.gastro.2008.01.002; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicari RM, 2005, J AM COLL CARDIOL, V46, P1803, DOI 10.1016/j.jacc.2005.07.047; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Vogel CJ, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12364; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Wang DS, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017453; Wang J., 2016, SHOCK VIB, V2016, P1, DOI DOI 10.1155/2016/9371563; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008-5472.CAN-14-1232-T; Wei L, 2016, ARCH IMMUNOL THER EX, V64, P259, DOI 10.1007/s00005-015-0382-6; Welch Heidi C E, 2015, Small GTPases, V6, P49, DOI 10.4161/21541248.2014.973770; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu CYC, 2014, GASTROENTEROLOGY, V147, P1405, DOI 10.1053/j.gastro.2014.08.032; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yang L, 2007, BLOOD, V110, P3853, DOI 10.1182/blood-2007-03-079582; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916; Zandvakili I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127923; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhang SY, 2009, MOL CANCER RES, V7, P570, DOI 10.1158/1541-7786.MCR-08-0248; Zhao L, 2008, J PROTEOME RES, V7, P3994, DOI 10.1021/pr800271b; Zhao LA, 2010, FEBS J, V277, P4195, DOI 10.1111/j.1742-4658.2010.07808.x; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99; Zhou J, 2014, CANCER CELL, V26, P9, DOI 10.1016/j.ccr.2014.06.022; Zhou W, 2014, J PATHOL, V234, P502, DOI 10.1002/path.4412; Zhou X, 2013, J BIOL CHEM, V288, P36179, DOI 10.1074/jbc.R113.515486	161	60	63	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3213	3222		10.1038/onc.2016.473	http://dx.doi.org/10.1038/onc.2016.473			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991930	Green Accepted			2022-12-28	WOS:000402869800001
J	Kerr, C; Szmacinski, H; Fisher, ML; Nance, B; Lakowicz, JR; Akbar, A; Keillor, JW; Wong, TL; Godoy-Ruiz, R; Toth, EA; Weber, DJ; Eckert, RL				Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Akbar, A.; Keillor, J. W.; Wong, T. Lok; Godoy-Ruiz, R.; Toth, E. A.; Weber, D. J.; Eckert, R. L.			Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; MESENCHYMAL TRANSITION; INHIBITORS; LOCALIZATION; POTENT; FRET; DIFFERENTIATION; EXPRESSION; MECHANISM; DOMAIN	Type 2 transglutaminase (TG2) is an important cancer stem cell survival protein that exists in open and closed conformations. The major intracellular form is the closed conformation that functions as a GTP-binding GTPase and is required for cancer stem cell survival. However, at a finite rate, TG2 transitions to an open conformation that exposes the transamidase catalytic site involved in protein-protein crosslinking. The activities are mutually exclusive, as the closed conformation has GTP binding/GTPase activity, and the open conformation transamidase activity. We recently showed that GTP binding, but not transamidase activity, is required for TG2-dependent cancer stem cell invasion, migration and tumour formation. However, we were surprised that transamidase sites-specific inhibitors reduce cancer stem cell survival. We now show that compounds NC9, VA4 and VA5, which react exclusively at the TG2 transamidase site, inhibit both transamidase and GTP-binding activities. Transamidase activity is inhibited by direct inhibitor binding at the transamidase site, and GTP binding is blocked because inhibitor interaction at the transamidase site locks the protein in the extended/open conformation to disorganize/inactivate the GTP binding/GTPase site. These findings suggest that transamidase site-specific inhibitors can inhibit GTP binding/signalling by driving a conformation change that disorganizes the TG2 GTP binding to reduce TG2-dependent signalling, and that drugs designed to target this site may be potent anti-cancer agents.	[Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Toth, E. A.; Weber, D. J.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108N Greene St, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Toth, E. A.; Weber, D. J.; Eckert, R. L.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Wong, T. Lok; Toth, E. A.; Weber, D. J.] Inst Biosci & Biotechnol Res, Rockville, MD USA; [Wong, T. Lok; Toth, E. A.; Weber, D. J.] Ctr Biomol Therapeut, Rockville, MD USA; [Akbar, A.; Keillor, J. W.] Univ Ottawa, Dept Chem & Biomol Sci, Ottawa, ON, Canada	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Ottawa	Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108N Greene St, Baltimore, MD 21201 USA.	reckert@umaryland.edu	Godoy Ruiz, Raquel/GOH-1617-2022	GODOY-RUIZ, RAQUEL/0000-0003-4569-0781; Nance, Bailey/0000-0002-2617-651X	National Institutes of Health [R01-CA184027, R01-CA131074]; NATIONAL CANCER INSTITUTE [R01CA184027, R01CA131074] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grants R01-CA184027 and R01-CA131074 to Richard Eckert.	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Agnihotri N, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3371; Badarau E, 2013, AMINO ACIDS, V44, P119, DOI 10.1007/s00726-011-1188-4; Begg GE, 2006, J BIOL CHEM, V281, P12603, DOI 10.1074/jbc.M600146200; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Cariati M, 2008, HISTOPATHOLOGY, V52, P99, DOI 10.1111/j.1365-2559.2007.02895.x; Caron NS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044159; Chen Y, 2003, DIFFERENTIATION, V71, P528, DOI 10.1111/j.1432-0436.2003.07109007.x; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Clouthier CM, 2012, ANGEW CHEM INT EDIT, V51, P12464, DOI 10.1002/anie.201205575; Eckert RL, 2015, MOL CARCINOGEN, V54, P947, DOI 10.1002/mc.22375; Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013; Eckert RL, 2009, AMINO ACIDS, V36, P739, DOI 10.1007/s00726-008-0123-9; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Fu J, 2013, NEURO-ONCOLOGY, V15, P1353, DOI 10.1093/neuonc/not079; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Griffin M, 2008, BIOORG MED CHEM LETT, V18, P5559, DOI 10.1016/j.bmcl.2008.09.006; Gundemir S, 2012, BBA-MOL CELL RES, V1823, P406, DOI 10.1016/j.bbamcr.2011.09.012; Gundemir S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006123; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Jang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107005; Jans R, 2008, J INVEST DERMATOL, V128, P517, DOI 10.1038/sj.jid.5701035; Keillor JW, 2008, CAN J CHEM, V86, P271, DOI 10.1139/V08-024; Keillor JW, 2015, TRENDS PHARMACOL SCI, V36, P32, DOI 10.1016/j.tips.2014.10.014; Keillor JW, 2014, BIOORG CHEM, V57, P186, DOI 10.1016/j.bioorg.2014.06.003; Keillor Jeffrey W, 2011, Adv Enzymol Relat Areas Mol Biol, V78, P415; Kiraly R, 2009, FEBS J, V276, P7083, DOI 10.1111/j.1742-4658.2009.07420.x; Kumar A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3085; Kumar A, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020701, 10.1371/journal.pone.0018759, 10.1371/journal.pone.0026520]; Kumar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013390; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; LAKOWICZ JR, 1992, P NATL ACAD SCI USA, V89, P1271, DOI 10.1073/pnas.89.4.1271; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Mehta K, 2009, AMINO ACIDS, V36, P709, DOI 10.1007/s00726-008-0128-4; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Pardin C, 2008, CHEM BIOL DRUG DES, V72, P189, DOI 10.1111/j.1747-0285.2008.00696.x; Pardin C, 2009, BIOCHEMISTRY-US, V48, P3346, DOI 10.1021/bi802021c; Pavlyukov MS, 2012, BIOCHEM BIOPH RES CO, V421, P773, DOI 10.1016/j.bbrc.2012.04.082; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Prime ME, 2012, J MED CHEM, V55, P1021, DOI 10.1021/jm201310y; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rizzo MA, 2006, MICROSC MICROANAL, V12, P238, DOI 10.1017/S1431927606060235; Siegel M, 2007, PHARMACOL THERAPEUT, V115, P232, DOI 10.1016/j.pharmthera.2007.05.003; Stamnaes J, 2010, J BIOL CHEM, V285, P25402, DOI 10.1074/jbc.M109.097162; Sturniolo MT, 2005, ONCOGENE, V24, P2963, DOI 10.1038/sj.onc.1208392; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048	55	30	30	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2981	2990		10.1038/onc.2016.452	http://dx.doi.org/10.1038/onc.2016.452			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941875	Green Accepted			2022-12-28	WOS:000402000400006
J	Choi, YM; Kim, KB; Lee, JH; Chun, YK; An, IS; An, S; Bae, S				Choi, Y. M.; Kim, K. B.; Lee, J. H.; Chun, Y. K.; An, I. S.; An, S.; Bae, S.			DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer	ONCOGENE			English	Article							RNA-BINDING PROTEIN; PROMOTER METHYLATION; MYELOID-LEUKEMIA; RHOBTB2 DBC2; HEPATOCELLULAR-CARCINOMA; LIGASE COMPLEXES; DNA METHYLATION; BLADDER-CANCER; BTB PROTEINS; E3 LIGASE	The gene encoding 'deleted in breast cancer 2' (DBC2), also referred to as RHOBTB2 (Rho-related BTB domain-containing protein 2), is classified as a tumor suppressor gene. DBC2 is a substrate-specific adaptor protein for a novel class of Cullin-3 (CUL3)-based E3 ubiquitin ligases; however, it is unclear if the substrate adaptor function of DBC2 is required for its tumor suppressor activity. Furthermore, the key substrates of DBC2-mediated ubiquitination have yet to be identified. In the present study, we established a genome-wide human cDNA library-based in vitro ubiquitination target screening assay and identified Musashi-2 (MSI2) as a novel ubiquitination target protein of DBC2. MSI2 directly interacted with DBC2, and this interaction promoted MSI2 polyubiquitination and proteasomal degradation in breast cancer cells. Overexpression and knockdown experiments demonstrated that DBC2 suppressed MSI2-associated oncogenic functions and induced apoptosis. Immunohistochemistry analysis of a breast cancer tissue microarray revealed that DBC2 and MSI2 protein levels are inversely correlated in both normal breast tissues and breast cancer tissues. Taken together, these findings provide evidence that DBC2 suppresses tumorigenesis in breast cancer by ubiquitinating MSI2.	[Choi, Y. M.; An, S.; Bae, S.] Konkuk Univ, KU Ctr Integrated Sci & Technol, 120 Neungdong Ro, Seoul 05029, South Korea; [Choi, Y. M.; Kim, K. B.; An, I. S.] Korea Inst Dermatol Sci, 2nd Enterprise Res Bldg, Seoul, Chungcheongbuk, South Korea; [Lee, J. H.] Dankook Univ, Lab Mol Oncol, Coll Med, Cheil Gen Hosp, Seoul, South Korea; [Lee, J. H.; Chun, Y. K.] Dankook Univ, Womens Healthcare Ctr, Coll Med, Seoul, South Korea; [Chun, Y. K.] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Pathol, Seoul, South Korea	Konkuk University; Dankook University; Dankook University; Dankook University	Bae, S (corresponding author), Konkuk Univ, KU Ctr Integrated Sci & Technol, 120 Neungdong Ro, Seoul 05029, South Korea.	sbae@konkuk.ac.kr			KU Research Professor Program of Konkuk University; National Research Foundation of Korea (NRF) from the Ministry of Science, ICT and Future Planning [20110028646, 2013R1A1A1012205]	KU Research Professor Program of Konkuk University; National Research Foundation of Korea (NRF) from the Ministry of Science, ICT and Future Planning	We thank all the members of our research group for their support and advice during this study. This work was supported by the KU Research Professor Program of Konkuk University (to SB) and National Research Foundation of Korea (NRF) grants from the Ministry of Science, ICT and Future Planning (Grant 20110028646 to SA and Grant 2013R1A1A1012205 to SB).	Bae S, 2008, INT J MOL MED, V21, P381; Bae SH, 2012, CELL RES, V22, P873, DOI 10.1038/cr.2012.38; Barbouti A, 2003, CANCER RES, V63, P1202; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Berthold J, 2008, EXP CELL RES, V314, P3453, DOI 10.1016/j.yexcr.2008.09.005; Byers RJ, 2011, BLOOD, V118, P2857, DOI 10.1182/blood-2011-04-346767; Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004; Cho YG, 2008, ACTA ONCOL, V47, P366, DOI 10.1080/02841860701644094; Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857; Dong W, 2012, ASIAN PAC J CANCER P, V13, P2021, DOI 10.7314/APJCP.2012.13.5.2021; Figueroa P, 2005, PLANT CELL, V17, P1180, DOI 10.1105/tpc.105.031989; Freeman SN, 2010, CANCER BIOL THER, V10, P1123, DOI 10.4161/cbt.10.11.13786; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Fushman D, 2010, J MOL BIOL, V395, P803, DOI 10.1016/j.jmb.2009.10.039; Gao C, 2015, INT J ONCOL, V46, P732, DOI 10.3892/ijo.2014.2749; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Han LL, 2013, BIOTECHNOL LETT, V35, P1175, DOI 10.1007/s10529-013-1190-x; Han YX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136484; He L, 2014, J CELL MOL MED, V18, P49, DOI 10.1111/jcmm.12158; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Jin Z, 2013, CANCER BIOTHER RADIO, V28, P709, DOI 10.1089/cbr.2012.1386; Jung JH, 2011, CELL DEATH DIFFER, V18, P1865, DOI 10.1038/cdd.2011.57; Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Kharas MG, 2010, NAT MED, V16, P903, DOI 10.1038/nm.2187; Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022; Maerki S, 2009, J CELL BIOL, V187, P791, DOI 10.1083/jcb.200906117; Manjarrez JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090054; Mao HT, 2011, GENE, V486, P74, DOI 10.1016/j.gene.2011.07.018; Mao HT, 2010, MOL CARCINOGEN, V49, P283, DOI 10.1002/mc.20598; Nikpour P, 2011, J CELL MOL MED, V15, P1210, DOI 10.1111/j.1582-4934.2010.01090.x; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Sakakibara S, 2001, J NEUROSCI, V21, P8091, DOI 10.1523/JNEUROSCI.21-20-08091.2001; Shi Y, 2008, UROL ONCOL-SEMIN ORI, V26, P465, DOI 10.1016/j.urolonc.2007.08.009; Shilpa V, 2014, INDIAN J MED RES, V140, P616; Taggart J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10739; Tang WW, 2014, INT J MOL MED, V33, P722, DOI 10.3892/ijmm.2013.1593; Thol F, 2013, ANN HEMATOL, V92, P315, DOI 10.1007/s00277-012-1637-5; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Wang MH, 2015, AM J CANCER RES, V5, P1089; Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zhang HJ, 2014, EXP CELL RES, V320, P119, DOI 10.1016/j.yexcr.2013.09.009; Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004; Zmetakova I, 2013, NEOPLASMA, V60, P635, DOI 10.4149/neo_2013_082; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	17	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2802	2812		10.1038/onc.2016.441	http://dx.doi.org/10.1038/onc.2016.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941885	hybrid, Green Published			2022-12-28	WOS:000401697800003
J	Ma, SQ; Cao, BR; Zhang, H; Luo, LP; Ren, Y; Hu, T; Chen, CM				Ma, S. Q.; Cao, B. R.; Zhang, H.; Luo, L. P.; Ren, Y.; Hu, T.; Chen, C. M.			The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; INDEPENDENT MECHANISM; PROSTATE-CANCER; C-RAF-1 GENE; APOPTOSIS; EXPRESSION; MEK; ACTIVATION; PHOSPHORYLATION; OVEREXPRESSION	Raf-1 has an important role in cellular antiapoptosis. So far, there is no solid evidence that shows that Raf-1 mutation is associated with cancer development. In the course of further study of Raf-1 signaling, we have reported that Raf-1 hyperphosphorylation inhibits its kinase activity toward its downstream mitogen-activated protein kinase kinase 1/2 (MEK1/2) and proposed a model for negative feedback regulation of Raf-1. Here, we show that there is no hyperphosphorylation in some cancer cells, which results in increased kinase activity and enhances the antiapoptotic ability. Inhibition of either Raf-1 or ALG-2 (apoptosis-linked gene 2) expression results in apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase (ASK1/JNK) signaling activation, and cell sensitivity to chemotherapeutic reagents, indicating that inhibition of ASK1/JNK apoptotic signaling by Raf-1 is mediated by ALG-2. A previous report indicated that extracellular signal-regulated kinase 1/2 (ERK1/2) were responsible for Raf-1 hyperphosphorylation. However, our evidence shows that when ERK1/2 are activated and the Raf-1 gene is not mutated, Raf-1 is not hyperphosphorylated in these cells, indicating that ERK1/2 are not responsible for the Raf-1 hyperphosphorylation in these cancer cell lines. Surprisingly, we also found that Raf-1 is not a necessary kinase for MEK1/2 activation under normal tissue culture conditions, but is required for MEK1/2 activation under apoptosis-inducing conditions. Our research demonstrates that although Raf-1 gene is not mutated, an abnormality of Raf-1 kinase feedback regulation enhances its antiapoptotic function, and Raf-1 can still be a pharmaceutical target to increase chemotherapy or radiotherapy sensitivity in these cancer cells.	[Ma, S. Q.; Cao, B. R.; Zhang, H.; Luo, L. P.; Ren, Y.; Chen, C. M.] Sichuan Canc Hosp Inst, Dept Basic Res, 55 Renmin Ave Fourth Sect, Chengdu 610041, Sichuan, Peoples R China; [Hu, T.] Sichuan Canc Hosp Inst, Dept Gynecol Oncol, Chengdu, Peoples R China		Chen, CM (corresponding author), Sichuan Canc Hosp Inst, Dept Basic Res, 55 Renmin Ave Fourth Sect, Chengdu 610041, Sichuan, Peoples R China.	changmin_chen@sichuancancer.org	, 曹邦荣/AAN-3604-2020	Cao, Bangrong/0000-0002-3865-3563	Sichuan Scientific and Technology Department Basic Research Fund [2015JY0011]; Sichuan Cancer Hospital Research Fund	Sichuan Scientific and Technology Department Basic Research Fund; Sichuan Cancer Hospital Research Fund	This work was financially supported by Sichuan Scientific and Technology Department Basic Research Fund (2015JY0011) (to CC) and Sichuan Cancer Hospital Research Fund (to CC).	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Appert-Collin A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00283; Bieker R, 2003, CANCER RES, V63, P7241; Brady G, 2007, INT J ONCOL, V31, P875; Chen CM, 2005, BIOCHEM BIOPH RES CO, V333, P51, DOI 10.1016/j.bbrc.2005.05.074; Chen CM, 2004, BLOOD, V104, P73, DOI 10.1182/blood-2003-04-1340; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; CULIG Z, 1994, CANCER RES, V54, P5474; Cussenot O, 1997, ANN ENDOCRINOL-PARIS, V58, P370; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Hwang IS, 2002, FEBS LETT, V529, P183, DOI 10.1016/S0014-5793(02)03329-X; Kaplan PJ, 1996, CARCINOGENESIS, V17, P2571, DOI 10.1093/carcin/17.12.2571; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li R, 2004, PROSTATE, V58, P193, DOI 10.1002/pros.10321; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Murakami MS, 2001, SCI STKE, V2001, pE30; Osborne JK, 2012, CELL RES, V22, P14, DOI 10.1038/cr.2011.193; Park SJ, 2015, INT J CLIN EXP PATHO, V8, P8298; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001948; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; Segaliny AI, 2015, J BONE ONCOL, V4, P1, DOI 10.1016/j.jbo.2015.01.001; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Trojan L, 2004, UROL RES, V32, P97, DOI 10.1007/s00240-003-0383-5; Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317; Yu PC, 2014, MICROVASC RES, V96, P10, DOI 10.1016/j.mvr.2014.07.016; Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528	39	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2014	2022		10.1038/onc.2016.384	http://dx.doi.org/10.1038/onc.2016.384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27841865				2022-12-28	WOS:000398898500011
J	Faiao-Flores, F; Alves-Fernandes, DK; Pennacchi, PC; Sandri, S; Vicente, ALSA; Scapulatempo-Neto, C; Vazquez, VL; Reis, RM; Chauhan, J; Goding, CR; Smalley, KS; Maria-Engler, SS				Faiao-Flores, F.; Alves-Fernandes, D. K.; Pennacchi, P. C.; Sandri, S.; Vicente, A. L. S. A.; Scapulatempo-Neto, C.; Vazquez, V. L.; Reis, R. M.; Chauhan, J.; Goding, C. R.; Smalley, K. S.; Maria-Engler, S. S.			Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; BRAF INHIBITOR RESISTANCE; TGF-BETA; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; MEK INHIBITION; IN-VITRO; PATHWAY; EXPRESSION	BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important issue. Here we identified a previously unsuspected mechanism of BRAFi resistance driven by elevated Hedgehog (Hh) pathway activation that is observed in a cohort of melanoma patients after vemurafenib treatment. Specifically, we demonstrate that melanoma cell lines, with acquired in vitro-induced vemurafenib resistance, show increased levels of glioma-associated oncogene homolog 1 and 2 (GLI1/GLI2) compared with naive cells. We also observed these findings in clinical melanoma specimens. Moreover, the increased expression of the transcription factors GLI1/GLI2 was independent of canonical Hh signaling and was instead correlated with the noncanonical Hh pathway, involving TGF beta/SMAD (transforming growth factor-beta/Sma- and Mad-related family) signaling. Knockdown of GLI1 and GLI2 restored sensitivity to vemurafenib-resistant cells, an effect associated with both growth arrest and senescence. Treatment of vemurafenib-resistant cells with the GLI1/GLI2 inhibitor Gant61 led to decreased invasion of the melanoma cells in a three-dimensional skin reconstruct model and was associated with a decrease in metalloproteinase (MMP2/MMP9) expression and microphthalmia transcription factor upregulation. Gant61 monotherapy did not alter the drug sensitivity of naive cells, but could reverse the resistance of melanoma cells chronically treated with vemurafenib. We further noted that alternating dosing schedules of Gant61 and vemurafenib prevented the onset of BRAFi resistance, suggesting that this could be a potential therapeutic strategy for the prevention of therapeutic escape. Our results suggest that targeting the Hh pathway in BRAFi-resistant melanoma may represent a viable therapeutic strategy to restore vemurafenib sensitivity, reducing or even inhibiting the acquired chemoresistance in melanoma patients.	[Faiao-Flores, F.; Alves-Fernandes, D. K.; Pennacchi, P. C.; Sandri, S.; Maria-Engler, S. S.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol Anal, 580 Prof Lineu Prestes Ave,Bldg 17,Room 114, BR-05508000 Sao Paulo, Brazil; [Vicente, A. L. S. A.; Scapulatempo-Neto, C.; Vazquez, V. L.; Reis, R. M.] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil; [Scapulatempo-Neto, C.] Barretos Canc Hosp, Dept Pathol, Barretos, Brazil; [Vazquez, V. L.] Barretos Canc Hosp, Dept Surg Melanoma Sarcoma, Barretos, Brazil; [Reis, R. M.] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga, Portugal; [Reis, R. M.] 3Bs PT Govt Associate Lab, Braga, Guimaraes, Portugal; [Chauhan, J.; Goding, C. R.] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford, England; [Smalley, K. S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL USA	Universidade de Sao Paulo; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Universidade do Minho; Ludwig Institute for Cancer Research; University of Oxford; H Lee Moffitt Cancer Center & Research Institute	Maria-Engler, SS (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol Anal, 580 Prof Lineu Prestes Ave,Bldg 17,Room 114, BR-05508000 Sao Paulo, Brazil.	silvya@usp.br	Faião-Flores, Fernanda/F-7111-2012; Vazquez, Vinicius L/F-3574-2012; Pennacchi, Paula/L-2220-2015; Engler, Silvya Stuchi Maria/K-5936-2016; Vicente, Anna Luiza SA/E-3660-2017; Maria-Engler, Silvya/ABC-2016-2020; Reis, Rui Manuel/AAD-6470-2020; Alves-Fernandes, Debora Kristina/AAC-5983-2019; Reis, Rui Manuel/B-1744-2018; de lima vazquez, Vinicius/O-7780-2019; Sandri, Silvana/A-1650-2015; Alves-Fernandes, Débora Kristina/AAQ-3385-2020	Faião-Flores, Fernanda/0000-0003-3449-9930; Vazquez, Vinicius L/0000-0002-0325-5514; Pennacchi, Paula/0000-0003-0875-0263; Engler, Silvya Stuchi Maria/0000-0003-4771-6041; Vicente, Anna Luiza SA/0000-0003-3902-7772; Maria-Engler, Silvya/0000-0003-4771-6041; Reis, Rui Manuel/0000-0002-9639-7940; Reis, Rui Manuel/0000-0002-9639-7940; de lima vazquez, Vinicius/0000-0002-0325-5514; Alves-Fernandes, Débora Kristina/0000-0002-0917-9292; Scapulatempo-Neto, Cristovam/0000-0002-8920-6579; Smalley, Keiran/0000-0003-1089-9307; Goding, Colin/0000-0002-1614-3909	Fapesp [2012/04194-1, 2013/05172-4, 2014/24400-0, 2015/10821-7]; CNPq [150447/2013-2, 471512/2013-3]; PRODOC [3193-32/2010]; National Institutes of Health [R01 CA161107, R21 CA198550]; Skin SPORE [P50 CA168536]; NATIONAL CANCER INSTITUTE [P50CA168536, R21CA198550, R01CA161107] Funding Source: NIH RePORTER	Fapesp(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PRODOC; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Skin SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Walter Turato for help with technical advice and support in colony formation studies and Renata Albuquerque for the FACS analyses. This work was supported by Fapesp-grant number 2012/04194-1, 2013/05172-4, 2014/24400-0 and 2015/10821-7, CNPq-grant number 150447/2013-2 and 471512/2013-3 and PRODOC-grant no 3193-32/2010. Work in the lab of KS Smalley was supported by the National Institutes of Health grants R01 CA161107, R21 CA198550, and Skin SPORE grant P50 CA168536.	Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Brohem CA, 2012, PIGM CELL MELANOMA R, V25, P354, DOI 10.1111/j.1755-148X.2012.00992.x; Brohem CA, 2011, PIGM CELL MELANOMA R, V24, P35, DOI 10.1111/j.1755-148X.2010.00786.x; Carlino MS, 2014, MOL ONCOL, V8, P544, DOI 10.1016/j.molonc.2014.01.003; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chioni AM, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-8; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dennler S, 2009, J BIOL CHEM, V284, P31523, DOI 10.1074/jbc.M109.059964; Dugo M, 2015, ONCOTARGET, V6, P5118, DOI 10.18632/oncotarget.3007; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Faiao-Flores F, 2013, TUMOR BIOL, V34, P1235, DOI 10.1007/s13277-013-0666-6; Fan HX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0041-5; Fan YH, 2016, ONCOGENE, V35, P116, DOI 10.1038/onc.2015.67; Fedorenko IV, 2015, J INVEST DERMATOL, V135, P3115, DOI 10.1038/jid.2015.329; Fernandez Y, 2006, J BIOL CHEM, V281, P1107, DOI 10.1074/jbc.M511607200; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gonnissen A, 2015, ONCOTARGET, V6, P13899, DOI 10.18632/oncotarget.4224; Green DR, 2013, NAT MED, V19, P131, DOI 10.1038/nm.3076; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Huang LL, 2014, CLIN CANCER RES, V20, P1566, DOI 10.1158/1078-0432.CCR-13-2195; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Javelaud D, 2008, PIGM CELL MELANOMA R, V21, P123, DOI 10.1111/j.1755-148X.2008.00450.x; Javelaud D, 2012, FEBS LETT, V586, P2016, DOI 10.1016/j.febslet.2012.05.011; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lasfar A, 2010, CARCINOGENESIS, V31, P1710, DOI 10.1093/carcin/bgq155; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Long B, 2016, CELL PHYSIOL BIOCHEM, V38, P1288, DOI 10.1159/000443075; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Meani RE, 2014, AUSTRALAS J DERMATOL, V55, P218, DOI 10.1111/ajd.12196; Menon Dinoop R, 2013, Pigment Cell Melanoma Res, V26, P912, DOI 10.1111/pcmr.12139; Menzies AM, 2015, CANCER-AM CANCER SOC, V121, P3826, DOI 10.1002/cncr.29586; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Narita S, 2008, CLIN CANCER RES, V14, P5769, DOI 10.1158/1078-0432.CCR-07-4282; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Palle K, 2015, CANCERS, V7, P2330, DOI 10.3390/cancers7040894; Pan D, 2012, LEUKEMIA RES, V36, P742, DOI 10.1016/j.leukres.2012.02.012; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Pennacchi PC, 2015, TISSUE ENG PT A, V21, P2417, DOI [10.1089/ten.tea.2015.0009, 10.1089/ten.TEA.2015.0009]; Pierrat MJ, 2012, J BIOL CHEM, V287, P17996, DOI 10.1074/jbc.M112.358341; Queiroz KCS, 2010, ONCOGENE, V29, P6314, DOI 10.1038/onc.2010.375; Ruiz I, 2002, NAT REV CANCER, V2, P361, DOI DOI 10.1038/NRC796; Sabbatino F, 2014, ONCOTARGET, V5, P1926, DOI 10.18632/oncotarget.1878; Sandri S, 2016, PHARMACOL RES, V111, P523, DOI 10.1016/j.phrs.2016.07.017; Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356; Smalley KM, 2007, BRIT J CANCER, V96, P445, DOI 10.1038/sj.bjc.6603596; Smalley KSM, 2006, IN VITRO CELL DEV-AN, V42, P242; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Steg AD, 2012, MOL CANCER THER, V11, P1587, DOI 10.1158/1535-7163.MCT-11-1058; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tauro M, 2013, BIOORGAN MED CHEM, V21, P6456, DOI 10.1016/j.bmc.2013.08.054; Tirino V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.144; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wickstrom M, 2013, INT J CANCER, V132, P1516, DOI 10.1002/ijc.27820; Xu M, 2015, CANCER LETT, V369, P124, DOI 10.1016/j.canlet.2015.08.005; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou HM, 2012, IUBMB LIFE, V64, P889, DOI 10.1002/iub.1080; Zhou JC, 2016, CANCER LETT, V370, P313, DOI 10.1016/j.canlet.2015.11.006	84	52	53	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1849	1861		10.1038/onc.2016.348	http://dx.doi.org/10.1038/onc.2016.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27748762	Green Published, hybrid			2022-12-28	WOS:000398128900010
J	Frank, SR; Kollmann, CP; de Jeude, JFV; Thiagarajah, JR; Engelholm, LH; Frodin, M; Hansen, SH				Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Engelholm, L. H.; Frodin, M.; Hansen, S. H.			The focal adhesion-associated proteins DOCK5 and GIT2 comprise a rheostat in control of epithelial invasion	ONCOGENE			English	Article							PAXILLIN-KINASE-LINKER; TYROSINE PHOSPHORYLATION; CELL; SRC; ACTIVATION; FAMILY; FAK; COMPLEX; LOCALIZATION; RECRUITMENT	DOCK proteins are guanine nucleotide exchange factors for Rac and Cdc42 GTPases. DOCK1 is the founding member of the family and acts downstream of integrins via the canonical Crk-p130Cas complex to activate Rac GTPases in numerous contexts. In contrast, DOCK5, which possesses the greatest similarity to DOCK1, remains sparingly studied. Here we establish that DOCK5 has a non-redundant role in regulating motile and invasive capacities of epithelial cells. DOCK1 is constitutively associated with sites of integrin attachment termed focal adhesions (FAs). In contrast, we demonstrate that DOCK5 recruitment to FAs in Hela cells is restricted by GIT2, an established regulator of FA signaling. We determine that GIT2 is targeted to FAs in response to Rho-ROCK signaling and actomyosin contractility. Accordingly, inhibition of ROCK activity or MLC function promotes enrichment of DOCK5 in membrane protrusions and nascent cell-substratum adhesions. We further demonstrate that GIT2 inhibits the interaction of DOCK5 with Crk. Moreover, we show that depletion of GIT2 promotes DOCK5-dependent activation of the Crk-p130Cas signaling cascade to promote Rac1-mediated lamellipodial protrusion and FA turnover. The antagonism between GIT2 and DOCK5 extends to non-transformed MCF10A mammary epithelial cells, with DOCK5 'dialing-up' and GIT2 'dialing-down' invasiveness. Finally, we determine that DOCK5 inhibition attenuates invasion and metastasis of MDA-MB-231 cells and prolongs life span of mice injected with these cells. Collectively, our work identifies DOCK5 as a key regulator of epithelial invasion and metastasis, and demonstrates that suppression of DOCK5 by GIT2 represents a previously unappreciated mechanism for coordination of Rho and Rac GTPases.	[Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Hansen, S. H.] Childrens Hosp Boston, GI Cell Biol Res Lab, Boston, MA USA; [Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Hansen, S. H.] Harvard Med Sch, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA; [Engelholm, L. H.] Rigshosp, Finsen Lab, Copenhagen Bioctr, Copenhagen, Denmark; [Frodin, M.] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Rigshospitalet; University of Copenhagen; University of Copenhagen	Hansen, SH (corresponding author), Harvard Med Sch, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA.; Hansen, SH (corresponding author), Childrens Hosp Boston, GI Cell Biol, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA.	steen.hansen@childrens.harvard.edu		Hansen, Steen/0000-0002-9408-4676; Engelholm, Lars/0000-0002-6616-1232; Frodin, Morten/0000-0003-3691-9820	NIH [R01 CA142647]; Danish Cancer Society [R40-A1936-11-S2, R2-A132-02-S2]; Roy and Lynne Frank Foundation; NATIONAL CANCER INSTITUTE [R01CA142647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, T32DK007477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Danish Cancer Society(Danish Cancer Society); Roy and Lynne Frank Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by NIH R01 CA142647 to SHH, as well as grants from the Danish Cancer Society R40-A1936-11-S2 to SHH and R2-A132-02-S2 to MF. SHH is a recipient of an Endowed Investigatorship from the Roy and Lynne Frank Foundation.	Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cote JF, 2006, METHOD ENZYMOL, V406, P41, DOI 10.1016/S0076-6879(06)06004-6; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Frank SR, 2008, SEMIN CELL DEV BIOL, V19, P234, DOI 10.1016/j.semcdb.2008.01.002; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Frank SR, 2012, CURR BIOL, V22, P1747, DOI 10.1016/j.cub.2012.07.011; Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441; Guilluy C, 2011, TRENDS CELL BIOL, V21, P718, DOI 10.1016/j.tcb.2011.08.002; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kuo JC, 2011, NAT CELL BIOL, V13, P383, DOI 10.1038/ncb2216; Laurin M, 2008, P NATL ACAD SCI USA, V105, P15446, DOI 10.1073/pnas.0805546105; Laurin M, 2014, GENE DEV, V28, P533, DOI 10.1101/gad.236349.113; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Nielsen BS, 2001, AM J PATHOL, V158, P1997, DOI 10.1016/S0002-9440(10)64671-8; Nishikimi A, 2013, EXP CELL RES, V319, P2343, DOI 10.1016/j.yexcr.2013.07.024; Nishikimi A, 2012, CHEM BIOL, V19, P488, DOI 10.1016/j.chembiol.2012.03.008; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Ogawa K, 2014, J EXP MED, V211, P1401, DOI 10.1084/jem.20131926; Pasapera AM, 2010, J CELL BIOL, V188, P877, DOI 10.1083/jcb.200906012; Patel Manishha, 2011, Small GTPases, V2, P268; Phee H, 2010, NAT IMMUNOL, V11, P503, DOI 10.1038/ni.1868; Premkumar L, 2010, J BIOL CHEM, V285, P13211, DOI 10.1074/jbc.M110.102517; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Sanders MA, 2009, J BIOL CHEM, V284, P27, DOI 10.1074/jbc.M808010200; Sanematsu F, 2013, J BIOL CHEM, V288, P8092, DOI 10.1074/jbc.M112.410423; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Terasawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046277; Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282; Watanabe M, 2014, J IMMUNOL, V193, P5660, DOI 10.4049/jimmunol.1400885; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Yu JXA, 2009, MOL BIOL CELL, V20, P4706, DOI 10.1091/mbc.E09-07-0548	38	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1816	1828		10.1038/onc.2016.345	http://dx.doi.org/10.1038/onc.2016.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27669437	Green Submitted, Green Published, hybrid, Green Accepted			2022-12-28	WOS:000398128900007
J	Lone, MUD; Baghel, KS; Kanchan, RK; Shrivastava, R; Malik, SA; Tewari, BN; Tripathi, C; Negi, MPS; Garg, VK; Sharma, M; Bhatt, MLB; Bhadauria, S				Lone, M-U-D; Baghel, K. S.; Kanchan, R. K.; Shrivastava, R.; Malik, S. A.; Tewari, B. N.; Tripathi, C.; Negi, M. P. S.; Garg, V. K.; Sharma, M.; Bhatt, M. L. B.; Bhadauria, S.			Physical interaction of estrogen receptor with MnSOD: implication in mitochondrial O-2(center dot-) upregulation and mTORC2 potentiation in estrogen-responsive breast cancer cells	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; LYSINE ACETYLATION; GENE-EXPRESSION; DNA-DAMAGE; ALPHA; SIRT3; BETA; OVEREXPRESSION; CARCINOGENESIS	Augmented reactive oxygen species levels consequential to functional alteration of key mitochondrial attributes contribute to carcinogenesis, either directly via oxidative DNA damage infliction or indirectly via activation of oncogenic signaling cascades. We previously reported activation of a key oncogenic signaling cascade via mammalian target of rapamycin (mTOR) signaling complex-2 (mTORC2) owing to estrogen receptor (ER-alpha)-dependent augmentation of O-2(-) within the mitochondria of 17-beta-estradiol (E2)-stimulated breast cancer cells. Manganese superoxide dismutase (MnSOD) is the principal mitochondrial attribute governing mitochondrial O-2(-) homeostasis, raising the possibility that its functional alteration could be instrumental in augmenting mitochondrial O-2(-) levels in breast cancer cells. Here we show ER-dependent transient inhibition of MnSOD catalytic function in breast cancer cells. Catalytic function of MnSOD is tightly regulated at the post-translational level. Post-translational modifications such as phosphorylation, nitration and acetylation represent key regulatory means governing the catalytic function of MnSOD. Acetylation at lysine-68 (K68) inhibits MnSOD catalytic activity and thus represents an important post-translational regulatory mechanism in human cells. Using reciprocal immunoprecipitation and proximity ligation assay, we demonstrate the occurrence of direct physical interaction between ER-alpha and MnSOD in human breast cancer cells, which in turn was associated with potentiated acetylation of MnSOD at K68. In addition, we also observed diminished interaction of MnSOD with sirtuin-3, the key mitochondrial deacetylase that deacetylates MnSOD at critical K68 and thereby activates it for scavenging O-2(-). Consequently, compromised deacetylation of MnSOD at K68 leading to its inhibition and a resultant buildup of O-2(-) within the mitochondria culminated in the activation of mTORC2. In agreement with this, human breast cancer tissue specimen exhibited a positive correlation between acetyl-MnSODK68 levels and phospho-Ser(2481) mTOR levels. In addition to exposing the crosstalk of ER-alpha with MnSOD posttranslational regulatory mechanisms, these data also unravel a regulatory role of ER/MnSOD interaction as an important control switch for redox regulation of ER-alpha-responsive oncogenic signaling cascades. Furthermore, our study provides a mechanistic link for ER-alpha-dependent O-2(-) potentiation and resultant mTORC2 activation in breast cancer cells.	[Lone, M-U-D; Baghel, K. S.; Kanchan, R. K.; Shrivastava, R.; Malik, S. A.; Tripathi, C.; Bhadauria, S.] CSIR, Div Toxicol, Cent Drug Res Inst, Jankipuram Ext Sect 10, Lucknow 226031, Uttar Pradesh, India; [Tewari, B. N.] KGMU, Dept Surg Oncol, Lucknow, Uttar Pradesh, India; [Negi, M. P. S.] CSIR, CDRI, Dept Clin & Expt Med, Lucknow, Uttar Pradesh, India; [Garg, V. K.] Lucknow Canc Inst, Dept Oncosurg, Lucknow, Uttar Pradesh, India; [Sharma, M.] Lucknow Canc Inst, Dept Pathol, Lucknow, Uttar Pradesh, India; [Bhatt, M. L. B.] KGMU, Dept Radiotherapy, Lucknow, Uttar Pradesh, India; [Bhadauria, S.] Acad Sci & Innovat Res AcSIR, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); King George's Medical University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); King George's Medical University; Academy of Scientific & Innovative Research (AcSIR)	Bhadauria, S (corresponding author), CSIR, Div Toxicol, Cent Drug Res Inst, Jankipuram Ext Sect 10, Lucknow 226031, Uttar Pradesh, India.	smraticdri@gmail.com	tripathi, chakrapani/K-5220-2019; Kanchan, Ranjana Kumari/AAD-6218-2022; Lone, Mehraju Din/GQA-5070-2022	tripathi, chakrapani/0000-0002-0370-5829; Kanchan, Ranjana Kumari/0000-0002-9649-9488; Lone, Mehraju Din/0000-0001-8511-4207; Tewari, Brij Nath/0000-0002-1025-7411	DST [SR/FT/LS-169/2012]; CSIR India [BSC0103]; Indian Council of Medical Research, New Delhi [3/1/3/JRF-2011/HRD-69(12035)]	DST(Department of Science & Technology (India)); CSIR India(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research, New Delhi(Indian Council of Medical Research (ICMR))	We thank the Director of CDRI for providing the facility and infrastructure. We also thank Dr Kalyan Mitra and Dr Kavita Singh (SAIF) for providing microscopy facilities and Dr AL Vishwakarma (SAIF) for providing flow cytometry facilities. The financial grants received for this study were SR/FT/LS-169/2012 from DST and No. BSC0103 from CSIR India. Mehraj u din alone received fellowship from the Indian Council of Medical Research, New Delhi under ICMR-JRF scheme vide award letter no. 3/1/3/JRF-2011/HRD-69(12035). The institutional manuscript no. for this article is 9324.	Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BORRELLO S, 1993, MOL ASPECTS MED, V14, P253, DOI 10.1016/0098-2997(93)90012-3; Buetler TM, 2004, NEWS PHYSIOL SCI, V19, P120, DOI 10.1152/nips.01514.2003; Butterfield DA, 2013, ANTIOXID REDOX SIGN, V19, P823, DOI 10.1089/ars.2012.5027; Chen BH, 2009, INVEST OPHTH VIS SCI, V50, P5587, DOI 10.1167/iovs.09-3633; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009; Domej W, 2014, INT J CHRONIC OBSTR, V9, P1207, DOI 10.2147/COPD.S51226; Dwivedi SKD, 2011, MOL ENDOCRINOL, V25, P922, DOI 10.1210/me.2010-0512; Felty Q, 2005, BIOCHEMISTRY-US, V44, P6900, DOI 10.1021/bi047629p; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Hayashi SI, 2003, ENDOCR-RELAT CANCER, V10, P193, DOI 10.1677/erc.0.0100193; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kanchan RK, 2012, FREE RADICAL BIO MED, V53, P1929, DOI 10.1016/j.freeradbiomed.2012.08.595; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; MISRA HP, 1972, J BIOL CHEM, V247, P6960; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Quintela-Fandino M, 2010, CLIN TRANSL ONCOL, V12, P662, DOI 10.1007/s12094-010-0575-8; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Yan MH, 2013, FREE RADICAL BIO MED, V62, P90, DOI 10.1016/j.freeradbiomed.2012.11.014; Yan T, 1996, CANCER RES, V56, P2864	35	14	14	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1829	1839		10.1038/onc.2016.346	http://dx.doi.org/10.1038/onc.2016.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721400				2022-12-28	WOS:000398128900008
J	Hulsurkar, M; Li, Z; Zhang, Y; Li, X; Zheng, D; Li, W				Hulsurkar, M.; Li, Z.; Zhang, Y.; Li, X.; Zheng, D.; Li, W.			Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1	ONCOGENE			English	Article							CORONARY-HEART-DISEASE; PROTEIN-KINASE-A; HISTONE DEACETYLASE; CARDIAC-HYPERTROPHY; HDAC INHIBITORS; VALPROIC ACID; IN-VITRO; CELLS; RECEPTOR; GENOMICS	Chronic behavioral stress and beta-adrenergic signaling have been shown to promote cancer progression, whose underlying mechanisms are largely unclear, especially the involvement of epigenetic regulation. Histone deacetylase-2 (HDAC2), an epigenetic regulator, is critical for stress-induced cardiac hypertrophy. It is unknown whether it is necessary for beta-adrenergic signaling promoted cancer progression. Using xenograft models, we showed that chronic behavioral stress and beta-adrenergic signaling promote angiogenesis and prostate cancer progression. HDAC2 was induced by beta-adrenergic signaling in vitro and in mouse xenografts. We next uncovered that HDAC2 is a direct target of cAMP response element-binding protein (CREB) that is activated by beta-adrenergic signaling. Notably, HDAC2 is necessary for beta-adrenergic signaling to induce angiogenesis. We further demonstrated that, upon CREB activation, HDAC2 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor, through epigenetic regulation. Together, these data establish a novel pathway that HDAC2 and TSP1 act downstream of CREB activation in beta-adrenergic signaling to promote cancer progression.	[Hulsurkar, M.; Li, Z.; Zhang, Y.; Li, X.; Zheng, D.; Li, W.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, SRB 537C,1825 Pressler St, Houston, TX 77030 USA; [Hulsurkar, M.; Li, W.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Li, Z.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Breast & Thyroid Surg Ctr, Wuhan 430074, Peoples R China; [Zhang, Y.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China; [Li, X.] Taishan Med Univ, Liaocheng Clin Sch, Liaocheng Peoples Hosp, Liaocheng, Peoples R China; [Zheng, D.] Southern Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	University of Texas System; University of Texas Health Science Center Houston; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Shandong First Medical University & Shandong Academy of Medical Sciences; Southern Medical University - China	Li, W (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, SRB 537C,1825 Pressler St, Houston, TX 77030 USA.	wenliang.li@uth.tmc.edu	Hulsurkar, Mohit/L-9946-2019	Hulsurkar, Mohit/0000-0003-0595-6661	University of Texas System	University of Texas System	We are grateful to Dr Rebecca Berdeaux for providing us the CREB cDNA constructs. We are thankful to Drs Isaiah Fidler and Vihang Narkar for providing us PC3 and SVEC4-10 cells, respectively. We also would like to thank Dr Kendra Carmon for critical reading of this paper. This work was supported by a Rising STARS Award from University of Texas System (W Li).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Armaiz-Pena GN, 2013, BRAIN BEHAV IMMUN, V30, pS19, DOI 10.1016/j.bbi.2012.06.005; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Braadland PR, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00375; Byler TK, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-21; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; de Graaf C, 2008, J MED CHEM, V51, P4978, DOI 10.1021/jm800710x; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Govindan MV, 2010, J BIOL CHEM, V285, P4489, DOI 10.1074/jbc.M109.072728; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grytli HH, 2013, PROSTATE, V73, P250, DOI 10.1002/pros.22564; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Holmes S, 2013, CANCER EPIDEMIOL, V37, P881, DOI 10.1016/j.canep.2013.09.001; Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724; Kong YL, 2006, CIRCULATION, V113, P2579, DOI 10.1161/CIRCULATIONAHA.106.625467; Krantz DS, 2002, ANNU REV PSYCHOL, V53, P341, DOI 10.1146/annurev.psych.53.100901.135208; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Li LN, 2014, ONCOTARGET, V5, P10840, DOI 10.18632/oncotarget.2535; Lia WL, 2014, P NATL ACAD SCI USA, V111, P1521, DOI 10.1073/pnas.1320638111; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Manna PP, 2004, CANCER RES, V64, P1026, DOI 10.1158/0008-5472.CAN-03-1708; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Roberts W, 2010, BLOOD, V116, P4297, DOI 10.1182/blood-2010-01-265561; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sang M, 2016, ONCOTARGET, DOI 10.18632/oncotarget.9359.; Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wojtukiewicz MZ, 2001, NEOPLASIA, V3, P371, DOI 10.1038/sj.neo.7900184; Yang QW, 2007, CANCER RES, V67, P1716, DOI 10.1158/0008-5472.CAN-06-2595; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043	50	49	54	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1525	1536		10.1038/onc.2016.319	http://dx.doi.org/10.1038/onc.2016.319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27641328				2022-12-28	WOS:000397458100007
J	Lefort, S; Thuleau, A; Kieffer, Y; Sirven, P; Bieche, I; Marangoni, E; Vincent-Salomon, A; Mechta-Grigoriou, F				Lefort, S.; Thuleau, A.; Kieffer, Y.; Sirven, P.; Bieche, I.; Marangoni, E.; Vincent-Salomon, A.; Mechta-Grigoriou, F.			CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; GROWTH-STIMULATING FACTOR; WEAK PARTIAL AGONISTS; TUMOR-GROWTH; FUNCTIONAL EXPRESSION; DUCTAL CARCINOMA; PROGENITOR CELLS; METASTASIS; STEM; MICROENVIRONMENT	The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient-derived xenografts (PDX), which faithfully reproduce human tumor properties. We observed that two CXCR4 inhibitors, AMD3100 and TN14003, efficiently impair tumor growth and metastasis dissemination in both Herceptin-sensitive and Herceptin-resistant HER2 BC. Conversely, blocking CXCR4/CXCL12 pathway in triple-negative (TN) BC does not reduce tumor growth, and can even increase metastatic spread. Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.	[Lefort, S.; Kieffer, Y.; Sirven, P.; Mechta-Grigoriou, F.] Inst Curie Res Dept, Stress & Canc Lab, LNCC Labelized Team, 26 Rue Ulm, F-75248 Paris 05, France; [Lefort, S.; Kieffer, Y.; Sirven, P.; Mechta-Grigoriou, F.] INSERM, U830, Genet & Biol Canc, F-75248 Paris, France; [Thuleau, A.; Marangoni, E.] Inst Curie Res Dept, Translat Res Dept, Lab Pre Clin Invest, Paris, France; [Bieche, I.] Inst Curie Hosp Grp, Serv Genet, Unite Pharmacognet, Paris, France; [Vincent-Salomon, A.] Hosp Grp Paris, Inst Curie, Dept Pathol, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mechta-Grigoriou, F (corresponding author), PSL Res Univ, Inst Curie Res Dept, Stress & Canc Lab, LNCC Labelized Team, 26 Rue Ulm, Paris, France.	fatima.mechta-grigoriou@curie.fr	Marangoni, Elisabetta/GSO-3945-2022; MECHTA-GRIGORIOU, Fatima/C-5253-2017; Bièche, Ivan/O-7399-2017	Marangoni, Elisabetta/0000-0002-3337-6448; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; Bièche, Ivan/0000-0002-2430-5429; KIEFFER, Yann/0000-0003-2722-3071; Lefort, Sylvain/0000-0001-7320-4256	Fondation ARC; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Curie	Fondation ARC; Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Curie	We are grateful to M Cardon from the 'Stress and Cancer' lab, at the Institut Curie, as well as R Leclere, E Martel, M Richardson and A Nicolas from the experimental pathology platform for help and advice. We acknowledge O Mariani from CRB Institut Curie for her help in preparing RNA samples from patient tumors. We are grateful to all members of the animal facilities of Institute Curie for their helpful expertize. SL was supported by funding from the Fondation ARC. The experimental work was also supported by grants from the Institut National de la Sante et de la Recherche Medicale (Inserm) and the Institut Curie. FMG's laboratory is labelized by the Ligue Nationale Contre le Cancer (LNCC). We are very grateful to the LNCC, Institut Curie and Inserm for providing their support these last years. We also thank the Institut National du Cancer (INCa), the FRM and the Fondation ARC (Association pour la Recherche contre le Cancer).	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ara T, 2003, J IMMUNOL, V170, P4649, DOI 10.4049/jimmunol.170.9.4649; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Carion A, 2003, BRIT J HAEMATOL, V122, P918, DOI 10.1046/j.1365-2141.2003.04545.x; Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; De Falco V, 2007, CANCER RES, V67, P11821, DOI 10.1158/0008-5472.CAN-07-0899; Dommange F, 2006, FASEB J, V20, P1913, DOI 10.1096/fj.05-5667fje; Gruosso T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9583; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Hori T, 1998, J IMMUNOL, V160, P180; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liang SX, 2015, ONCOTARGET, V6, P1020, DOI 10.18632/oncotarget.2741; Liang ZX, 2007, BIOCHEM BIOPH RES CO, V363, P542, DOI 10.1016/j.bbrc.2007.09.007; Liang ZX, 2005, CANCER RES, V65, P967; Liekens S, 2010, CURR PHARM DESIGN, V16, P3903, DOI 10.2174/138161210794455003; Ling XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058426; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murdoch C, 1999, IMMUNOLOGY, V98, P36; Nafi SNM, 2014, ONCOTARGET, V5, P5934; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reyal F, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3095; Rhodes LV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-295; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Schmid BC, 2004, BREAST CANCER RES TR, V84, P247, DOI 10.1023/B:BREA.0000019962.18922.87; Sharma M, 2014, CELL ADHES MIGR, V8, P384, DOI 10.4161/cam.29285; Singh B, 2010, CLIN EXP METASTAS, V27, P233, DOI 10.1007/s10585-010-9321-4; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200; Xu TP, 2013, CANCER EPIDEMIOL, V37, P725, DOI 10.1016/j.canep.2013.04.017; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200; Zhang ZG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-49; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	49	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1211	1222		10.1038/onc.2016.284	http://dx.doi.org/10.1038/onc.2016.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27669438	Green Published, hybrid			2022-12-28	WOS:000395861300005
J	Murakami, S; Shahbazian, D; Surana, R; Zhang, W; Chen, H; Graham, GT; White, SM; Weiner, LM; Yi, C				Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G. T.; White, S. M.; Weiner, L. M.; Yi, C.			Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; SUPPRESSOR-CELLS; GM-CSF; BONE-MARROW; PROMOTES RESISTANCE; LUNG-CANCER; MUTANT KRAS; PROGRESSION; INFILTRATION; MACROPHAGES	Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high degree of inflammation and profound immune suppression. Here we identify Yes-associated protein (Yap) as a critical regulator of the immunosuppressive microenvironment in both mouse and human PDAC. Within Kras: p53 mutant pancreatic ductal cells, Yap drives the expression and secretion of multiple cytokines/chemokines, which in turn promote the differentiation and accumulation of myeloid-derived suppressor cells (MDSCs) both in vitro and in vivo. Pancreas-specific knockout of Yap or antibody-mediated depletion of MDSCs promoted macrophage reprogramming, reactivation of T cells, apoptosis of Kras mutant neoplastic ductal cells and pancreatic regeneration after acute pancreatitis. In primary human PDAC, YAP expression levels strongly correlate with an MDSC gene signature, and high expression of YAP or MDSC-related genes predicts decreased survival in PDAC patients. These results reveal multifaceted roles of YAP in PDAC pathogenesis and underscore its promise as a therapeutic target for this deadly disease.	[Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G. T.; White, S. M.; Weiner, L. M.; Yi, C.] Georgetown Univ Med Ctr, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20057 USA; [Zhang, W.] Nankai Univ, Coll Life Sci, Dept Canc Res, Tianjin, Peoples R China	Georgetown University; Nankai University	Yi, C (corresponding author), Georgetown Univ Med Ctr, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	cy232@georgetown.edu		Graham, Garrett/0000-0002-1097-0962	NIH [R01CA187090, R01CA50633]; V Foundation and the Advocure foundation; Cancer Center [CA051008]; Lombardi Cancer Center Shared Resources; NATIONAL CANCER INSTITUTE [T32CA009686, P30CA051008, R01CA187090, R01CA050633] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation and the Advocure foundation; Cancer Center; Lombardi Cancer Center Shared Resources; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs T Jacks (MIT), DJ Pan ( Johns Hopkins) and CV Wright (Vanderbilt) for producing and sharing the original mouse strains used in this study. We are grateful for the helpful suggestions and critical comments of our manuscript from Dr S Ostrand-Rosenberg (UMBC). We would also like to thank Dr Karen Creswell from the Flow Cytometry and Cell Sorting Shared Resource (FCSR) for her technical guidance. We appreciate the technical assistance from FCSR, Microscopy & Imaging Shared Resource (MISR), Histopathology & Tissue Shared Resource (HTSR) and Genomics & Epigenomics Shared Resource (GESR) at Lombardi Cancer Center Shared Resources. We thank the husbandry staff and technicians of the Division of Comparative Medicine (DCM) at Georgetown University for support in our animal studies. CY is supported by NIH (R01CA187090), the V Foundation and the Advocure foundation. LMW is the PI of NIH (R01CA50633), and Cancer Center Support Grant (CA051008) that also supports the Lombardi Cancer Center Shared Resources.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALDERSON MR, 1991, J EXP MED, V173, P923, DOI 10.1084/jem.173.4.923; Bardeesy N, 2001, SEMIN CANCER BIOL, V11, P201, DOI 10.1006/scbi.2000.0371; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bhatia M, 2004, AM J PHYSIOL-GASTR L, V286, pG189, DOI 10.1152/ajpgi.00304.2003; Brembeck FH, 2003, CANCER RES, V63, P2005; Calabro L, 2013, LANCET ONCOL, V14, P1104, DOI 10.1016/S1470-2045(13)70381-4; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; FAHEY TJ, 1992, J IMMUNOL, V148, P2764; FALK LA, 1988, J LEUKOCYTE BIOL, V43, P148, DOI 10.1002/jlb.43.2.148; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Grippo PJ, 2003, CANCER RES, V63, P2016; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Katoh H, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/159269; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Khaled YS, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/879897; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kurahara H, 2013, PANCREAS, V42, P155, DOI 10.1097/MPA.0b013e318254f2d1; Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426; Le DT, 2013, J IMMUNOTHER, V36, P382, DOI 10.1097/CJI.0b013e31829fb7a2; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lindell DM, 2001, INFECT IMMUN, V69, P6364, DOI 10.1128/IAI.69.10.6364-6369.2001; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Markowitz J, 2015, CANCER IMMUNOL IMMUN, V64, P149, DOI 10.1007/s00262-014-1618-8; Mok S, 2014, CANCER RES, V74, P153, DOI 10.1158/0008-5472.CAN-13-1816; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Munigala S, 2014, CLIN GASTROENTEROL H, V12, P1143, DOI 10.1016/j.cgh.2013.12.033; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parker KH, 2015, ADV CANCER RES, V128, P95, DOI 10.1016/bs.acr.2015.04.002; Phan VT, 2013, P NATL ACAD SCI USA, V110, P6079, DOI 10.1073/pnas.1303302110; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schutte M, 1997, CANCER RES, V57, P3126; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Strauss L, 2015, CANCER CELL, V28, P253, DOI 10.1016/j.ccell.2015.07.006; Stromnes IM, 2014, GUT, V63, P1769, DOI 10.1136/gutjnl-2013-306271; Surana R, 2014, CANCER IMMUNOL RES, V2, P1103, DOI 10.1158/2326-6066.CIR-14-0103; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Zeng LJ, 2014, J CANCER, V5, P754, DOI 10.7150/jca.10238; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang YL, 2009, J IMMUNOL, V182, P3801, DOI 10.4049/jimmunol.0801548; Zhao F, 2009, IMMUNOLOGY, V128, P141, DOI 10.1111/j.1365-2567.2009.03105.x; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	76	127	129	1	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1232	1244		10.1038/onc.2016.288	http://dx.doi.org/10.1038/onc.2016.288			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546622	Green Accepted			2022-12-28	WOS:000395861300007
J	Ramadoss, S; Sen, S; Ramachandran, I; Roy, S; Chaudhuri, G; Farias-Eisner, R				Ramadoss, S.; Sen, S.; Ramachandran, I.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.			Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance	ONCOGENE			English	Article							GENE-EXPRESSION; HISTONE; P53; CELLS; INHIBITION; RESISTANCE; CHROMATIN; MARKERS; JHDM2A	Ovarian cancer is the leading cause of death among all gynecological malignancies due to the development of acquired chemoresistance and disease relapse. Although the role of cancer stem cells (CSCs), a subset of tumor cells with the self-renewal and differentiation capabilities, in therapeutic resistance is beginning to be better understood, the significance of epigenetic regulatory mechanisms responsible for integrating the stemness with drug resistance remain poorly understood. Here we identified that lysine demethylase KDM3A as a critical regulator of ovarian cancer stemness and cisplatin resistance by inducing the expressions of pluripotent molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2 (Bcl-2), respectively. In addition, KDM3A induces ovarian cancer growth while antagonizing cellular senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1). The underlying mechanism of the noted biological processes include KDM3A-mediatedstimulation of Sox2 expression, and demethylating p53 protein and consequently, modulating its target genes such as Bcl-2 and p(21Waf1/Cip1) expression. Consistently, KDM3A depletion inhibited the growth of subcutaneously implanted cisplatin-resistant human ovarian cancer cells in athymic nude mice. Moreover, KDM3A is abundantly expressed and positively correlated with Sox2 expression in human ovarian cancer tissues. In brief, our findings reveal a novel mechanism by which KDM3A promotes ovarian CSCs, proliferation and chemoresistance and thus, highlights the significance of KDM3A as a novel therapeutic target for resistant ovarian cancer.	[Ramadoss, S.; Sen, S.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; [Ramachandran, I.] Univ Madras, Dr ALM PG Inst Basic Med Sci, Dept Endocrinol, Taramani Campus, Madras 600113, Tamil Nadu, India; [Chaudhuri, G.] Univ Calif Los Angeles, David Geffen Sch Med, Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Madras; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ramadoss, S; Farias-Eisner, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.	ramasiva@ucla.edu; rfeisner@mednet.ucla.edu			The Roberta Deutsch Foundation	The Roberta Deutsch Foundation	We acknowledge The Roberta Deutsch Foundation and Kelly Day for their financial support. We thank Professor Oliver Dorigo, Stanford University Medical Center, for the generous gift of cisplatin-resistant ovarian cancer cell lines. We thank Dr Xiangming Ding, UCLA Clinical Microarray Core for the statistical assistance.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Cioffi M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10357; Cohen Joshua G, 2014, World J Biol Chem, V5, P286, DOI 10.4331/wjbc.v5.i3.286; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Huang L, 2010, J CANCER RES CLIN, V136, P447, DOI 10.1007/s00432-009-0675-4; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Kong Yahui, 2011, J Aging Res, V2011, P963172, DOI 10.4061/2011/963172; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Liang DM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-201; Liu T, 2015, TUMOR BIOL, V36, P1881, DOI 10.1007/s13277-014-2790-3; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; McEvoy LM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1539-8; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Nair SS, 2012, MOL ONCOL, V6, P611, DOI 10.1016/j.molonc.2012.09.005; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10; Rasheed ZA, 2011, STEM CELLS, V29, P883, DOI 10.1002/stem.648; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tapia N, 2010, J EXP MED, V207, P2045, DOI 10.1084/jem.20101866; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018	36	30	32	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1537	1545		10.1038/onc.2016.320	http://dx.doi.org/10.1038/onc.2016.320			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27694900	Green Published, hybrid			2022-12-28	WOS:000397458100008
J	Suh, Y; Yoon, CH; Kim, RK; Lim, EJ; Oh, YS; Hwang, SG; An, S; Yoon, G; Gye, MC; Yi, JM; Kim, MJ; Lee, SJ				Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Oh, Y. S.; Hwang, S-G; An, S.; Yoon, G.; Gye, M. C.; Yi, J-M; Kim, M-J; Lee, S-J			Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells (vol 32, pg 4873, 2013)	ONCOGENE			English	Correction																		Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505	1	9	10	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1167	1168		10.1038/onc.2016.294	http://dx.doi.org/10.1038/onc.2016.294			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27841864	Bronze			2022-12-28	WOS:000395371500014
J	Wang, Y; Hong, X; Wang, J; Yin, Y; Zhang, Y; Zhou, Y; Piao, HI; Liang, Z; Zhang, L; Li, G; Xu, G; Kwiatkowski, DJ; Liu, Y				Wang, Y.; Hong, X.; Wang, J.; Yin, Y.; Zhang, Y.; Zhou, Y.; Piao, H-I; Liang, Z.; Zhang, L.; Li, G.; Xu, G.; Kwiatkowski, D. J.; Liu, Y.			Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth	ONCOGENE			English	Article							TSC2 GAP ACTIVITY; RHEB GTPASE; CELL-PROLIFERATION; MAMMALIAN TARGET; MTOR; ACTIVATION; KINASE; MUTATIONS; AMPK; IDENTIFICATION	Rheb is a Ras family GTPase, which binds to and activates mammalian target of rapamycin complex 1 (mTORC1) when GTP loaded. Recently, cancer genome sequencing efforts have identified recurrent Rheb Tyr35Asn mutations in kidney and endometrial carcinoma. Here we show that Rheb-Y35N causes not only constitutive mTORC1 activation, but sustained activation of the MEK-ERK pathway in a TSC1/TSC2/TBC1D7 protein complex and mTORC1-independent manner, contributing to intrinsic resistance to rapamycin. Rheb-Y35N transforms NIH3T3 cells, resulting in aggressive tumor formation in xenograft nude mice, which could be suppressed by combined treatment with rapamycin and an extracellular signal-regulated kinase (ERK) inhibitor. Furthermore, Rheb-Y35N inhibits AMPKa activation in response to nutrient depletion or 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), leading to attenuated phosphorylation of BRAF-S729 and retained mitogen-activated protein kinase (MAPK) activation. Finally, we demonstrate that Rheb-WT can bind AMPK to facilitate AMPK activation, whereas Rheb-Y35N competitively binds AMPK, impairing AMPK phosphorylation. In summary, our findings indicate that Rheb-Y35N is a dominantly active tumor driver that activates both mTORC1 and MAPK to promote tumor growth, suggesting a combination of mTORC1 and MAPK inhibitors may be of therapeutic value in patients whose cancers sustain this mutation.	[Wang, Y.; Yin, Y.; Piao, H-I; Liu, Y.] Chinese Acad Sci, Sci Res Ctr Translat Med, Dalian Inst Chem Phys, Dept Biotechnol, 457 Zhongshan Rd,Rm 114, Dalian 116023, Liaoning, Peoples R China; [Wang, Y.; Wang, J.] Dalian Univ, Sch Life Sci, Dalian, Peoples R China; [Hong, X.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; [Hong, X.] Peking Union Med Coll, Beijing, Peoples R China; [Zhang, Y.; Li, G.] Chinese Acad Sci, Dalian Inst Chem Phys, Dept Biotechnol, State Key Lab Mol React Dynam,Lab Mol Modelling &, Dalian, Peoples R China; [Zhou, Y.; Piao, H-I; Liang, Z.; Zhang, L.; Xu, G.; Liu, Y.] Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China; [Kwiatkowski, D. J.; Liu, Y.] Harvard Med Sch, Brigham & Women Hosp, Div Pulm & Crit Care Med, Boston, MA USA	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Dalian University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Liu, Y (corresponding author), Chinese Acad Sci, Sci Res Ctr Translat Med, Dalian Inst Chem Phys, Dept Biotechnol, 457 Zhongshan Rd,Rm 114, Dalian 116023, Liaoning, Peoples R China.; Kwiatkowski, DJ (corresponding author), Harvard Med Sch Thorn Bldg, Brigham & Womens Hosp, Div Pulm & Crit Care, RM 826c,20 Shattuck St, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu; yliuqq@dicp.ac.cn	Xu, Guowang/L-6910-2014	Xu, Guowang/0000-0003-4298-3554	NIH [NCI 1P01CA120964]; NATIONAL CANCER INSTITUTE [P01CA120964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH NCI 1P01CA120964. We thank Nathanael Gray, Heidi Greulich and John Blenis for the gift of reagents.	Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Choudhary S, 2007, MOL CANCER THER, V6, P1099, DOI 10.1158/1535-7163.MCT-06-0586; Eom M, 2008, PATHOL INT, V58, P226, DOI 10.1111/j.1440-1827.2008.02215.x; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Ghosh AP, 2015, ONCOTARGET, V6, P17895, DOI 10.18632/oncotarget.4963; Goorden SMI, 2011, MOL CELL BIOL, V31, P1672, DOI 10.1128/MCB.00985-10; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jeon MT, 2015, BIOMED REP, V3, P137, DOI 10.3892/br.2014.397; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Kim SY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.95; Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393; Lafourcade CA, 2013, J NEUROSCI, V33, P2419, DOI 10.1523/JNEUROSCI.1840-12.2013; Langendorf CG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10912; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467; Martin TD, 2014, MOL CELL, V53, P209, DOI 10.1016/j.molcel.2013.12.004; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Mazhab-Jafari MT, 2012, STRUCTURE, V20, P1528, DOI 10.1016/j.str.2012.06.013; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Wang YN, 2008, J MOL CELL CARDIOL, V45, P812, DOI 10.1016/j.yjmcc.2008.07.016; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	37	11	12	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					756	765		10.1038/onc.2016.246	http://dx.doi.org/10.1038/onc.2016.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399332				2022-12-28	WOS:000394168200003
J	Yu, PF; Huang, Y; Xu, CL; Lin, LY; Han, YY; Sun, WH; Hu, GH; Rabson, AB; Wang, Y; Shi, YF				Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Rabson, A. B.; Wang, Y.; Shi, Y. F.			Downregulation of CXCL12 in mesenchymal stromal cells by TGF beta promotes breast cancer metastasis	ONCOGENE			English	Article							STEM-CELLS; CHEMOKINE RECEPTOR; TUMOR-DEVELOPMENT; IN-VIVO; MIGRATION; GROWTH; RECRUITMENT; INTERLEUKIN-6; PROGRESSION; SECRETION	Mesenchymal stromal cells (MSCs) are one of major components of the tumour microenvironment. Recent studies have shown that MSC tumour residence and their close interactions with inflammatory factors are important factors that affect tumour progression. Among tumour-associated inflammatory factors, transforming growth factor beta (TGF beta) is regarded as a key determinant of malignancy. By employing a lung metastasis model of a murine breast cancer, we show here that the prometastatic effect of MSCs was dependent on their response to TGF beta. Interestingly, we found that MSC-produced CXCL12, an important chemokine in tumour metastasis, was markedly inhibited by TGF beta. Furthermore, silencing of CXCL12 in TGF beta-unresponsive MSCs restored their ability to promote tumour metastasis. We found that 4T1 breast cancer cells expressed high levels of CXCR7, but not of CXCR4, both of which are CXCL12 receptors. In presence of CXCL12, CXCR7 expression on tumour cells was decreased. Indeed, when CXCR7 was silenced in breast cancer cells, their metastatic ability was inhibited. Therefore, our data demonstrated that sustained expression of CXCL12 by MSCs in the primary tumour site inhibits metastasis through reduction of CXCR7, while, in the presence of TGF beta, this CXCL12 effect of MSCs on tumour cells is relieved. Importantly, elevated CXCR7 and depressed CXCL12 expression levels were prominent features of clinical breast cancer lesions and were related significantly with poor survival. Our findings reveal a novel mechanism of MSC effects on malignant cells through which crosstalk between MSCs and TGF beta regulates tumour metastasis.	[Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Wang, Y.; Shi, Y. F.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Shanghai, Peoples R China; [Rabson, A. B.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	HUANG, YIN/AAH-6871-2020; Shi, Yufang/AAE-4431-2020; Xu, Chunliang/R-7065-2018; Yu, Pengfei/AHC-3497-2022	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; Yu, Pengfei/0000-0002-3894-5697; Sun, Weihong/0000-0002-6292-903X; wang, ying/0000-0002-2571-9367; Hu, Guohong/0000-0002-2980-5166	Programs of National Natural Science of China [81330046, 81273316, 81571612, 81530043]; Scientific Innovation Project of the Chinese Academy of Science [XDA 01040100]; Ministry of Science and Technology of China [2015CB964400]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Rising-Star Program [14QA1404200]; Youth Innovation Promotion Association, Chinese Academy of Sciences	Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Rising-Star Program; Youth Innovation Promotion Association, Chinese Academy of Sciences	This study was supported by grants from the Programs of National Natural Science of China (81330046, 81273316, 81571612, 81530043), the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040100), the Ministry of Science and Technology of China (2015CB964400), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Rising-Star Program (14QA1404200) and the Youth Innovation Promotion Association, Chinese Academy of Sciences.	Arabanian LS, 2014, HAEMATOLOGICA, V99, P997, DOI 10.3324/haematol.2013.097675; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; De Luca A, 2012, J CELL BIOCHEM, V113, P3363, DOI 10.1002/jcb.24212; Duvall-Noelle N, 2016, ONCOGENE, V35, P1122, DOI 10.1038/onc.2015.166; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev-immunol-032712-095919; Ganju RK, 2012, SIGNALING PATHWAYS M, P221; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Meijer J, 2008, BRIT J CANCER, V99, P1493, DOI 10.1038/sj.bjc.6604727; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rattigan Y, 2010, EXP CELL RES, V316, P3417, DOI 10.1016/j.yexcr.2010.07.002; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Stacer AC, 2016, ONCOGENE, V35, P1716, DOI 10.1038/onc.2015.236; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Wright N, 2003, BLOOD, V102, P1978, DOI 10.1182/blood-2002-10-3190; Xu CL, 2014, J IMMUNOL, V192, P103, DOI 10.4049/jimmunol.1302164; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049	37	60	61	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					840	849		10.1038/onc.2016.252	http://dx.doi.org/10.1038/onc.2016.252			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27669436	Green Published, hybrid			2022-12-28	WOS:000394168200011
J	Werden, SJ; Sphyris, N; Sarkar, TR; Paranjape, AN; LaBaff, AM; Taube, JH; Hollier, BG; Ramirez-Pena, EQ; Soundararajan, R; den Hollander, P; Powell, E; Echeverria, GV; Miura, N; Chang, JT; Piwnica-Worms, H; Rosen, JM; Mani, SA				Werden, S. J.; Sphyris, N.; Sarkar, T. R.; Paranjape, A. N.; LaBaff, A. M.; Taube, J. H.; Hollier, B. G.; Ramirez-Pena, E. Q.; Soundararajan, R.; den Hollander, P.; Powell, E.; Echeverria, G. V.; Miura, N.; Chang, J. T.; Piwnica-Worms, H.; Rosen, J. M.; Mani, S. A.			Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ACTIVATED PROTEIN-KINASE; STEM-CELLS; SIGNALING PATHWAYS; MIR-200 FAMILY; INVASION; EMT; EXPRESSION; PLASTICITY; INSIGHTS	Metastatic competence is contingent upon the aberrant activation of a latent embryonic program, known as the epithelial-mesenchymal transition (EMT), which bestows stem cell properties as well as migratory and invasive capabilities upon differentiated tumor cells. We recently identified the transcription factor FOXC2 as a downstream effector of multiple EMT programs, independent of the EMT-inducing stimulus, and as a key player linking EMT, stem cell traits and metastatic competence in breast cancer. As such, FOXC2 could serve as a potential therapeutic target to attenuate metastasis. However, as FOXC2 is a transcription factor, it is difficult to target by conventional means such as small-molecule inhibitors. Herein, we identify the serine/threonine-specific kinase p38 as a druggable upstream regulator of FOXC2 stability and function that elicits phosphorylation of FOXC2 at serine 367 (S367). Using an orthotopic syngeneic mouse tumor model, we make the striking observation that inhibition of p38-FOXC2 signaling selectively attenuates metastasis without impacting primary tumor growth. In this model, circulating tumor cell numbers are significantly reduced in mice treated with the p38 inhibitor SB203580, relative to vehicle-treated counterparts. Accordingly, genetic or pharmacological inhibition of p38 decreases FOXC2 protein levels, reverts the EMT phenotype and compromises stem cell attributes in vitro. We also identify the EMT-regulator ZEB1-known to directly repress E-cadherin/CDH1-as a downstream target of FOXC2, critically dependent on its activation by p38. Consistent with the notion that activation of the p38-FOXC2 signaling axis represents a critical juncture in the acquisition of metastatic competence, the phosphomimetic FOXC2(S367E) mutant is refractory to p38 inhibition both in vitro and in vivo, whereas the non-phosphorylatable FOXC2(S367A) mutant fails to elicit EMT and upregulate ZEB1. Collectively, our data demonstrate that FOXC2 regulates EMT, stem cell traits, ZEB1 expression and metastasis in a p38-dependent manner, and attest to the potential utility of p38 inhibitors as antimetastatic agents.	[Werden, S. J.; Sphyris, N.; Sarkar, T. R.; Paranjape, A. N.; Taube, J. H.; Hollier, B. G.; Ramirez-Pena, E. Q.; Soundararajan, R.; den Hollander, P.; Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 W Holcombe Blvd, Houston, TX 77030 USA; [LaBaff, A. M.] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol, Houston, TX 77030 USA; [Powell, E.; Echeverria, G. V.; Piwnica-Worms, H.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka, Japan; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Rosen, J. M.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA; [Taube, J. H.] Baylor Univ, Waco, TX 76798 USA; [Hollier, B. G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4102, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Hamamatsu University School of Medicine; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor University; Queensland University of Technology (QUT)	Mani, SA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 W Holcombe Blvd, Houston, TX 77030 USA.	smani@mdanderson.org	Paranjape, Anurag N./P-1255-2018; Mani, Sendurai A./A-7244-2009; SPHYRIS, NATHALIE/GQY-6349-2022	Paranjape, Anurag N./0000-0001-6119-0766; Mani, Sendurai A./0000-0002-5918-4276; Taube, Joseph/0000-0002-3636-5189; Ramirez-Pena, Esmeralda/0000-0002-5200-7488; Echeverria, Gloria/0000-0002-3772-9298; Sphyris, Nathalie/0000-0003-1860-1958	National Institute of Health [5RO1CA155243]; Cancer Prevention and Research Institute of Texas [RP-130485]; Cancer Center Support Grant from the National Cancer Institute [5P30CA016672]; NATIONAL CANCER INSTITUTE [R01CA155243, P30CA016672] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Cancer Center Support Grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Mike Lewis, Dr Patricia Thompson and Dr Jody Vykoukal for helpful discussions. We particularly thank Dr Jonathan Kurie, Dr Robert Weinberg and Dr Mien-Chie Hung for critically reading the manuscript. This research was supported by grants from the National Institute of Health (5RO1CA155243) and the Cancer Prevention and Research Institute of Texas (RP-130485). SAM is an American Cancer Society M Patricia Alexander Research Scholar (121958-RSG-12-102-01-DDC). SJW received a Susan G Komen Breast Cancer Foundation Postdoctoral Fellowship. Flow cytometry, animal imaging and histopathology were in part funded by the Cancer Center Support Grant from the National Cancer Institute (5P30CA016672).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Aomatsu K, 2012, INVEST OPHTH VIS SCI, V53, P751, DOI 10.1167/iovs.11-8222; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; Blanco MA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2831; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Donnelly SM, 2014, CURR MED CHEM, V21, P501; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1869; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Kawano H, 2003, J AM SOC NEPHROL, V14, P584, DOI 10.1097/01.ASN.0000050415.97942.2F; Kopper F, 2014, CELL CYCLE, V13, P884, DOI 10.4161/cc.28292; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kume T, 2012, J ONCOL, V2012, DOI 10.1155/2012/204593; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Malinowsky K, 2012, TRANSL ONCOL, V5, P98, DOI 10.1593/tlo.11268; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Taube JH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02687; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048; Yoshizuka N, 2012, MOL CELL BIOL, V32, P606, DOI 10.1128/MCB.06301-11	45	37	42	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5977	5988		10.1038/onc.2016.203	http://dx.doi.org/10.1038/onc.2016.203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27292262	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000388509400005
J	Zhang, Z; Liu, X; Feng, B; Liu, N; Wu, Q; Han, Y; Nie, Y; Wu, K; Shi, Y; Fan, D				Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.			STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer (vol 34, pg 4808, 2014)	ONCOGENE			English	Correction																		Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404	1	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6043	6043		10.1038/onc.2016.140	http://dx.doi.org/10.1038/onc.2016.140			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27375024	Green Published, hybrid			2022-12-28	WOS:000388509400011
J	Xu, K; Wang, L; Feng, W; Feng, Y; Shu, HKG				Xu, K.; Wang, L.; Feng, W.; Feng, Y.; Shu, H-K G.			Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase	ONCOGENE			English	Article							LOOP-HELIX PROTEINS; HIGH-GRADE GLIOMA; DNA-DAMAGE; GENOMIC ANALYSIS; ID-1 PROTEIN; CELL-GROWTH; CANCER; GLIOBLASTOMA; EXPRESSION; DEPHOSPHORYLATION	Id1 is a helix-loop-helix transcriptional modulator that increases the aggressiveness of malignant glial neoplasms. Since most glioblastomas (GBMs) show increased phosphatidylinositol-3 kinase (PI-3K) signaling, we sought to determine whether this pathway regulates Id1 expression. Higher basal Id1 expression correlates with dysregulated PI-3K signaling in multiple established GBM cell lines. Further characterization of PI-3K-dependent Id1 regulation reveals that chemical or genetic inhibition of PI-3K signaling reduces Id1 protein but not mRNA expression. Overall, PI-3K signaling appears to enhance Id1 translation with no significant effect on its stability. PI-3K signaling is known to regulate protein translation through mTORC1-dependent phosphorylation of 4E-BP1, which reduces its association with and inhibition of the translation initiation factor eIF4E. Interestingly, while inhibition of PI-3K and AKT lowers 4E-BP1 phosphorylation and expression of Id1 in all cases, inhibition of TORC1 with rapamycin does not consistently have a similar effect, suggesting an alternative mechanism for PI-3K-dependent regulation of Id1 translation. We now identify a potential role for the serine-threonine phosphatase PPM1G in translational regulation of Id1 protein expression. PPM1G knockdown by siRNA increase both 4E-BP1 phosphorylation and Id1 expression and PPM1G and 4E-BP1 co-associates in GBM cells. Furthermore, PPM1G is a phosphoprotein and this phosphorylation appears to be regulated by PI-3K activity. Finally, PI-3K inhibition increases PPM1G activity when assessed by an in vitro phosphatase assay. Our findings provide the first evidence that the PI-3K/AKT signaling pathway modulates PPM1G activity resulting in a shift in the balance between hyperand hypo-phosphorylated 4E-BP1 and translational regulation of Id1 expression.	[Xu, K.; Wang, L.; Shu, H-K G.] Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA; [Xu, K.; Wang, L.; Shu, H-K G.] Emory Univ, Winship Canc Inst, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA; [Feng, W.; Feng, Y.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Shu, HKG (corresponding author), Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA.; Shu, HKG (corresponding author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA.	hgshu@emory.edu	FENG, WEI/B-8713-2018	FENG, WEI/0000-0002-9106-4258	Southeast Brain Tumor Foundation; Cancer Center grant from the National Cancer Institute [P30-CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER	Southeast Brain Tumor Foundation; Cancer Center grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Walter Curran for providing departmental funding support and Dr Chi-Ming Chang for helpful discussion in regard to this project. This work was supported in part by a grant (to H-KGS) from the Southeast Brain Tumor Foundation and a Cancer Center grant from the National Cancer Institute (P30-CA138292).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Allemand E, 2007, NAT STRUCT MOL BIOL, V14, P630, DOI 10.1038/nsmb1257; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beli P, 2012, MOL CELL, V46, P212, DOI 10.1016/j.molcel.2012.01.026; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Foster WH, 2013, DEV DYNAM, V242, P1101, DOI 10.1002/dvdy.23990; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Helmy K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046965; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Kimura H, 2006, J CELL BIOL, V175, P389, DOI 10.1083/jcb.200608001; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Liu JY, 2013, J BIOL CHEM, V288, P23225, DOI 10.1074/jbc.M113.492371; Lu R, 2004, P NATL ACAD SCI USA, V101, P15201, DOI 10.1073/pnas.0404995101; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Perry DM, 2012, J LIPID RES, V53, P1513, DOI 10.1194/jlr.M025395; Petri S, 2007, J CELL BIOL, V179, P451, DOI 10.1083/jcb.200704163; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Roux PP, 2012, COLD SPRING HARB PER, V4; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schindl M, 2001, CANCER RES, V61, P5703; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Xu KM, 2007, CANCER RES, V67, P6121, DOI 10.1158/0008-5472.CAN-07-0141; Xu KM, 2014, ONCOTARGET, V5, P1241, DOI 10.18632/oncotarget.1370	50	12	13	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5807	5816		10.1038/onc.2016.115	http://dx.doi.org/10.1038/onc.2016.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065332	Green Accepted			2022-12-28	WOS:000386998400011
J	Zhang, L; Zhang, W; Li, Y; Alvarez, A; Li, Z; Wang, Y; Song, L; Lv, D; Nakano, I; Hu, B; Cheng, SY; Feng, H				Zhang, L.; Zhang, W.; Li, Y.; Alvarez, A.; Li, Z.; Wang, Y.; Song, L.; Lv, D.; Nakano, I.; Hu, B.; Cheng, S-Y; Feng, H.			SHP-2-upregulated ZEB1 is important for PDGFR alpha-driven glioma epithelial-mesenchymal transition and invasion in mice and humans	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; E-CADHERIN; MIR-200 FAMILY; BETA-CATENIN; DEPENDENT MECHANISM; REPRESSORS ZEB1; LUNG-CANCER; STEM-CELLS; GLIOBLASTOMA; GROWTH	Gliomas are highly malignant brain tumors that are highly invasive and resistant to conventional therapy. Receptor tyrosine kinases (RTKs) such as PDGFR alpha (platelet-derived growth factor receptor-alpha), which show frequent aberrant activation in gliomas, are associated with a process of epithelial-mesenchymal transition (EMT), a cellular alteration that confers a more invasive and drug-resistant phenotype. Although this phenomenon is well documented in human cancers, the processes by which RTKs including PDGFR alpha mediate EMT are largely unknown. Here, we report that SHP-2 (encoded by PTPN11) upregulates an EMT inducer, ZEB1, to mediate PDGFR alpha-driven glioma EMT, invasion and growth in glioma cell lines and patient-derived glioma stem cells (GSCs) using cell culture and orthotopic xenograft models. ZEB1 and activated PDGFR alpha were coexpressed in invasive regions of mouse glioma xenografts and clinical glioma specimens. Glioma patients with high levels of both phospho-PDGFR alpha (p-PDGFR alpha) and ZEB1 had significantly shorter overall survival compared with those with low expression of p-PDGFR alpha and ZEB1. Knockdown of ZEB1 inhibited PDGFA/PDGFR alpha-stimulated glioma EMT, tumor growth and invasion in glioma cell lines and patient-derived GSCs. PDGFR alpha mutant deficient of SHP2 binding (PDGFR alpha-F720) or phosphoinositide 3-kinase (PI3K) binding (PDGFR alpha-F731/42), knockdown of SHP2 or treatments of pharmacological inhibitor for PDGFR alpha-signaling effectors attenuated PDGFA/PDGFR alpha-stimulated ZEB1 expression, cell migration and GSC proliferation. Importantly, SHP-2 acts together with PI3K/AKT to regulate a ZEB1-miR-200 feedback loop in PDGFR alpha-driven gliomas. Taken together, our findings uncover a new pathway in which ZEB1 functions as a key regulator for PDGFR alpha-driven glioma EMT, invasiveness and growth, suggesting that ZEB1 is a promising therapeutic target for treating gliomas with high PDGFR alpha activation.	[Zhang, L.; Zhang, W.; Li, Z.; Wang, Y.; Song, L.; Lv, D.; Cheng, S-Y; Feng, H.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Renji Med, Pu Jian Rd 160, Shanghai 200127, Peoples R China; [Li, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth,Pediat, Shanghai, Peoples R China; [Alvarez, A.; Hu, B.; Cheng, S-Y] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Neurol,Northwestern Brain Tumor Inst,Ctr Gen, Chicago, IL 60611 USA; [Nakano, I.] Univ Alabama Birmingham, Dept Neurosurg Cell Dev & Integrat Biol Biochem &, Birmingham, AL USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Alabama System; University of Alabama Birmingham	Feng, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Renji Med, Pu Jian Rd 160, Shanghai 200127, Peoples R China.	Fenghaizhong@sjtu.edu.cn	Nakano, Ichiro/AAR-9562-2020; Feng, Haizhong/E-5795-2017	Nakano, Ichiro/0000-0002-0916-3207; Feng, Haizhong/0000-0003-3552-6865	National Natural Science Foundation of China [81372704, 81572467, 81470315]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission [14ZZ111]; State Key Laboratory of Oncogenes and Related Genes in China [90-14-04]; Pujiang Talent Plan of Shanghai City, China [14PJ1406500]; Natural Science Foundation of Tianjin City, China [13JCYBJC39400]; Shanghai Jiao Tong University School of Medicine Hospital Fund [14XJ10069]; Science and Technology Commission of Shanghai Municipality, China [15ZR1425700]; US NIH [CA158911, NS093843, NS95634]; Zell Scholar Award from the Zell Family Foundation; Northwestern Brain Tumor Institute at Northwestern University; Brain Cancer Research Award from the James S McDonnell Foundation; NIH/NCI training grant [T32 CA070085]; NATIONAL CANCER INSTITUTE [R01CA159811, T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS093843, R01NS083767, R01NS095634] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission; State Key Laboratory of Oncogenes and Related Genes in China; Pujiang Talent Plan of Shanghai City, China; Natural Science Foundation of Tianjin City, China(Natural Science Foundation of Tianjin); Shanghai Jiao Tong University School of Medicine Hospital Fund; Science and Technology Commission of Shanghai Municipality, China(Science & Technology Commission of Shanghai Municipality (STCSM)); US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Zell Scholar Award from the Zell Family Foundation; Northwestern Brain Tumor Institute at Northwestern University; Brain Cancer Research Award from the James S McDonnell Foundation; NIH/NCI training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank E Van Meir for providing glioma cell lines, R Pangeni and N Sastry for editing the manuscript. This work was supported, in part, by National Natural Science Foundation of China (Nos. 81372704 and 81572467) to H Feng and (No. 81470315) (to YL); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission (No. 14ZZ111), the State Key Laboratory of Oncogenes and Related Genes in China (No. 90-14-04) (to HF); the Pujiang Talent Plan of Shanghai City, China (No. 14PJ1406500), Natural Science Foundation of Tianjin City, China (No. 13JCYBJC39400), Shanghai Jiao Tong University School of Medicine Hospital Fund (No. 14XJ10069) (to YL); Science and Technology Commission of Shanghai Municipality, China (15ZR1425700) (to ZL); US NIH Grants (CA158911, NS093843 and NS95634), a Zell Scholar Award from the Zell Family Foundation and funds from Northwestern Brain Tumor Institute at Northwestern University (to S-YC); a Brain Cancer Research Award from the James S McDonnell Foundation (to BH) and a NIH/NCI training grant T32 CA070085 (to AA).	Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chen WG, 2013, ONCOL LETT, V6, P1234, DOI 10.3892/ol.2013.1552; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dong PX, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0231-0; Du R, 2014, MOL BIOL CELL, V25, P2650, DOI 10.1091/mbc.E14-01-0044; Feng H, 2012, ONCOGENE, V31, P2691, DOI 10.1038/onc.2011.436; Feng HZ, 2014, J CLIN INVEST, V124, P3741, DOI 10.1172/JCI73093; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grille SJ, 2003, CANCER RES, V63, P2172; Imanishi Y, 2011, J BIOL CHEM, V286, P29249, DOI 10.1074/jbc.M111.235689; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Kong DJ, 2008, STEM CELLS, V26, P1425, DOI 10.1634/stemcells.2007-1076; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Meng FY, 2015, CANCER RES, V75, P584, DOI 10.1158/0008-5472.CAN-13-3029; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Van Stry M, 2005, P NATL ACAD SCI USA, V102, P8233, DOI 10.1073/pnas.0502885102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu KJ, 2012, CELL SIGNAL, V24, P2273, DOI 10.1016/j.cellsig.2012.08.004; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yoshida S, 1997, J CANCER RES CLIN, V123, P301, DOI 10.1007/s004320050062; Zang MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112908; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	48	66	71	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5641	5652		10.1038/onc.2016.100	http://dx.doi.org/10.1038/onc.2016.100			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27041571	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000386998300007
J	Stalin, J; Nollet, M; Garigue, P; Fernandez, S; Vivancos, L; Essaadi, A; Muller, A; Bachelier, R; Foucault-Bertaud, A; Fugazza, L; Leroyer, AS; Bardin, N; Guillet, B; Dignat-George, F; Blot-Chabaud, M				Stalin, J.; Nollet, M.; Garigue, P.; Fernandez, S.; Vivancos, L.; Essaadi, A.; Muller, A.; Bachelier, R.; Foucault-Bertaud, A.; Fugazza, L.; Leroyer, A. S.; Bardin, N.; Guillet, B.; Dignat-George, F.; Blot-Chabaud, M.			Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors	ONCOGENE			English	Article							ENDOTHELIAL PROGENITOR CELLS; HUMAN BREAST-CANCER; HUMAN-MELANOMA; ADHESION MOLECULE; PROSTATE-CANCER; C-MYC; EXPRESSION; THERAPY; ANGIOGENESIS; ANGIOMOTIN	CD146 (MUC-18, MCAM) expression on cancer cells correlates with cancer progression and a bad prognosis in several tumors, including melanoma and pancreatic tumors. Deciphering the mechanism mediating the CD146 role in cancer is essential for generating new therapeutic strategies. We found that CD146 expression in cancer cells is associated with a secretion of soluble CD146 (sCD146) that constitutes an active player in tumor development. Indeed, sCD146 induces the overexpression of its binding protein, angiomotin, on both endothelial and cancer cells and promotes both paracrine effects on angiogenesis and autocrine effects on cancer cells proliferation and survival. These last effects are mediated in part through the induction and phosphorylation of c-myc in cancer cells. In mice models xenografted with human CD146-positive melanoma or pancreatic cancer cells, administration of a novel monoclonal antibody specifically targeting sCD146, but not its membrane form, successfully suppresses tumor vascularization and growth. Our findings demonstrate that sCD146 secreted by CD146-positive tumors mediates important pro-angiogenic and pro-tumoral effects. Targeting sCD146 with a novel neutralizing antibody could thus constitute an innovative therapeutic strategy for the treatment of CD146-positive tumors.	[Stalin, J.; Nollet, M.; Garigue, P.; Vivancos, L.; Essaadi, A.; Muller, A.; Bachelier, R.; Foucault-Bertaud, A.; Leroyer, A. S.; Bardin, N.; Guillet, B.; Dignat-George, F.; Blot-Chabaud, M.] Aix Marseille Univ, UFR Pharm, INSERM, UMR S 1076, 27 Bd J Moulin, F-13005 Marseille, France; [Garigue, P.; Fernandez, S.; Guillet, B.] Aix Marseille Univ, CERIMED European Ctr Res Med Imaging, Marseille, France; [Fugazza, L.] Adv Accelerator Applicat SRL, Colleretto Giacosa, TO, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Blot-Chabaud, M (corresponding author), Aix Marseille Univ, UFR Pharm, INSERM, UMR S 1076, 27 Bd J Moulin, F-13005 Marseille, France.	marcel.blot-chabaud@laposte.net	Blot-Chabaud, Marcel/D-4064-2017; Bardin, Nathalie/AAL-3663-2020; DIGNAT-GEORGE, Françoise/R-1129-2016; NOLLET, MARIE/M-2752-2017; Leroyer, Aurelie S./M-4400-2016	Bardin, Nathalie/0000-0003-3680-082X; DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; NOLLET, MARIE/0000-0002-9667-8216; Leroyer, Aurelie S./0000-0002-8079-7122; Stalin, Jimmy/0000-0001-8092-7057	Inserm, Aix-Marseille University; Region Provence-Alpes-Cote d'Azur; Martine Midy Fundation; FRM; ANR	Inserm, Aix-Marseille University; Region Provence-Alpes-Cote d'Azur(Region Provence-Alpes-Cote d'Azur); Martine Midy Fundation; FRM(Fondation pour la Recherche Medicale); ANR(French National Research Agency (ANR))	We thank Biocytex company (Marseille, France) for rsCD146, CD146 Elisa and S-Endo-1 antibody. We thank E Mas, G Pommier, N Alfaidy and D Lombardo for providing us with several cell lines. This study was financed by grants from Inserm, Aix-Marseille University and ANR. Jimmy Stalin was financed by grants from Region Provence-Alpes-Cote d'Azur, FRM and Martine Midy Fundation.	Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Anfosso F, 2001, J BIOL CHEM, V276, P1564, DOI 10.1074/jbc.M007065200; Aulakh GK, 2014, CELL TISSUE RES, V355, P375, DOI 10.1007/s00441-013-1753-0; Bardin N, 2003, THROMB HAEMOSTASIS, V90, P915, DOI 10.1160/TH02-11-0285; Bardin N, 1998, FEBS LETT, V421, P12, DOI 10.1016/S0014-5793(97)01455-5; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Bardin N, 2009, ARTERIOSCL THROM VAS, V29, P746, DOI 10.1161/ATVBAHA.108.183251; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94; Dagur PK, 2014, CLIN IMMUNOL, V152, P36, DOI 10.1016/j.clim.2014.01.009; Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Feng G, 2012, INT UROL NEPHROL, V44, P1663, DOI 10.1007/s11255-012-0255-4; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gerber HP, 2005, CANCER RES, V65, P671; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Harhouri K, 2010, BLOOD, V115, P3843, DOI 10.1182/blood-2009-06-229591; Ilie M, 2014, BRIT J CANCER, V110, P1236, DOI 10.1038/bjc.2014.11; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jiang WG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-16; Kebir A, 2010, CIRC RES, V107, P66, DOI 10.1161/CIRCRESAHA.109.213827; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Liu JW, 2008, PROSTATE, V68, P418, DOI 10.1002/pros.20709; Liu WF, 2012, INT J MOL SCI, V13, P6399, DOI 10.3390/ijms13056399; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Mills L, 2002, CANCER RES, V62, P5106; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; Oka S, 2012, ANTICANCER RES, V32, P861; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Roudier E, 2009, J PHYSIOL-LONDON, V587, P4105, DOI 10.1113/jphysiol.2009.175554; Salgaller ML, 2003, CURR OPIN MOL THER, V5, P657; Satchi-Fainaro R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044395; SENGER DR, 1986, CANCER RES, V46, P5629; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shojaei F, 2007, CANCER J, V13, P345, DOI 10.1097/PPO.0b013e31815a7b69; Shojaei F, 2007, LAB INVEST, V87, P227, DOI 10.1038/labinvest.3700526; Stalin J, 2013, J BIOL CHEM, V288, P8991, DOI 10.1074/jbc.M112.446518; Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445; Wu GJ, 2005, J UROLOGY, V173, P1778, DOI 10.1097/01.ju.0000154643.30048.2c; Wu GJ, 2001, PROSTATE, V48, P305, DOI 10.1002/pros.1111; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Zabouo G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2215; Zeng GF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-113; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	50	30	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5489	5500		10.1038/onc.2016.83	http://dx.doi.org/10.1038/onc.2016.83			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27065325				2022-12-28	WOS:000386998200004
J	Yan, H; Tang, G; Wang, H; Hao, L; He, T; Sun, X; Ting, AH; Deng, A; Sun, S				Yan, H.; Tang, G.; Wang, H.; Hao, L.; He, T.; Sun, X.; Ting, A. H.; Deng, A.; Sun, S.			DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment (vol 35, pg 3995, 2016)	ONCOGENE			English	Correction																		Yan H, 2016, ONCOGENE, V35, P3995, DOI 10.1038/onc.2015.423	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4020	4020		10.1038/onc.2016.28	http://dx.doi.org/10.1038/onc.2016.28			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	27345404	Bronze			2022-12-28	WOS:000381013100014
J	Lau, TS; Chan, LKY; Wong, ECH; Hui, CWC; Sneddon, K; Cheung, H; Yim, SF; Lee, JHS; Yeung, CSY; Chung, TKH; Kwong, J				Lau, T-S; Chan, L. K-Y; Wong, E. C-H; Hui, C. W-C; Sneddon, K.; Cheung, T-H; Yim, S-F; Lee, J. H-S; Yeung, C. S-Y; Chung, T. K-H; Kwong, J.			A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNF alpha-TGF alpha-EGFR	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; THERAPEUTIC TARGET; MESOTHELIAL CELLS; DNA METHYLATION; EXPRESSION; MODEL; FIBROBLASTS; CARBOPLATIN; CARCINOMA	Peritoneum is the most common site for ovarian cancer metastasis. Here we investigate how cancer epigenetics regulates reciprocal tumor-stromal interactions in peritoneal metastasis of ovarian cancer. Firstly, we find that omental stromal fibroblasts enhance colony formation of metastatic ovarian cancer cells, and de novo expression of transforming growth factor-alpha (TGF-alpha) is induced in stromal fibroblasts co-cultured with ovarian cancer cells. We also observed an over-expression of tumor necrosis factoralpha (TNF-alpha) in ovarian cancer cells, which is regulated by promoter DNA hypomethylation as well as chromatin remodeling. Interestingly, this ovarian cancer-derived TNF-alpha induces TGF-alpha transcription in stromal fibroblasts through nuclear factor-kappa B (NF-kappa B). We further show that TGF-alpha secreted by stromal fibroblasts in turn promotes peritoneal metastasis of ovarian cancer through epidermal growth factor receptor (EGFR) signaling. Finally, we identify a TNF alpha-TGF alpha-EGFR interacting loop between tumor and stromal compartments of human omental metastases. Our results therefore demonstrate cancer epigenetics induces a loop of cancer-stroma-cancer interaction in omental microenvironment that promotes peritoneal metastasis of ovarian cancer cells via TNF alpha-TGF alpha-EGFR.	[Lau, T-S; Chan, L. K-Y; Sneddon, K.; Cheung, T-H; Yim, S-F; Lee, J. H-S; Yeung, C. S-Y; Chung, T. K-H; Kwong, J.] Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Wong, E. C-H; Hui, C. W-C] Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Kwong, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Block E,1-F, Shatin, Hong Kong, Peoples R China.	josephkwong@cuhk.edu.hk	Kwong, Joseph/H-2368-2013; Wong, Chi Hang/C-6909-2015; Wong, Chi Hang/ABE-8673-2021; Lau, Tat San/R-6722-2019	Kwong, Joseph/0000-0002-3380-6882; Wong, Chi Hang/0000-0003-4157-6287; Wong, Chi Hang/0000-0003-4157-6287; Lee, Ho Sze Jacqueline/0000-0002-3175-1144; CHUNG, Tony/0000-0002-6362-8546; Lau, Tat San/0000-0003-2315-9690	CUHK Research Committee Funding; Hong Kong Obstetrical and Gynaceological Trust Fund; Charlie Lee Charitable Foundation	CUHK Research Committee Funding; Hong Kong Obstetrical and Gynaceological Trust Fund; Charlie Lee Charitable Foundation	This research was supported by CUHK Research Committee Funding (Direct Grants for Research), Hong Kong Obstetrical and Gynaceological Trust Fund, and The Charlie Lee Charitable Foundation. The authors give special thanks to Alex Shu-Wing NG (Brigham and Women's Hospital, Harvard Medical School) and Ronny Drapkin (The Penn Ovarian Cancer Center, University of Pennsylvanian) for the FTSEC190 and FTSEC194 cell lines. The authors give thanks to Dr Gene Chi-Wai MAN, Mr Jianzhang WANG, Mr Long CUI, and Mr John Chun-Kit LI for technical supports; to Ms. Flora Pui-Ling TAM for processing clinical samples; and to Dr Amy Kit-Ying CHUNG for revising the manuscript.	Alt E, 2011, BIOL CELL, V103, P197, DOI 10.1042/BC20100117; Andersen P, 2008, INT J CANCER, V122, P342, DOI 10.1002/ijc.23109; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BAUKNECHT T, 1991, ANTICANCER RES, V11, P1523; Blank SV, 2010, GYNECOL ONCOL, V119, P451, DOI 10.1016/j.ygyno.2010.08.008; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; BUY JN, 1988, RADIOLOGY, V169, P691, DOI 10.1148/radiology.169.3.3186993; Cai J, 2012, CARCINOGENESIS, V33, P20, DOI 10.1093/carcin/bgr230; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; D'Antonio A, 2002, INT J ONCOL, V21, P941; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Glaysher S, 2013, BRIT J CANCER, V109, P1786, DOI 10.1038/bjc.2013.529; Gui T, 2012, CANCER EPIDEMIOL, V36, P490, DOI 10.1016/j.canep.2012.06.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karki P, 2017, MOL NEUROBIOL, V54, P964, DOI 10.1007/s12035-016-9705-9; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; KOHLER M, 1992, EUR J CANCER, V28A, P1432, DOI 10.1016/0959-8049(92)90538-D; Kwong J, 2009, NEOPLASIA, V11, P529, DOI 10.1593/neo.09112; LANGDON SP, 1988, CANCER RES, V48, P6166; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lassus H, 2006, J MOL MED-JMM, V84, P671, DOI 10.1007/s00109-006-0054-4; Lau TS, 2014, J PATHOL, V232, P43, DOI 10.1002/path.4258; Li HX, 2014, ARCH GYNECOL OBSTET, V290, P1067, DOI 10.1007/s00404-014-3377-3; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Milagrel CS, 2015, CANCER RES, V75, P1255, DOI 10.1158/0008-5472.CAN-14-1801; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ohta T, 2012, CANCER BIOL THER, V13, P408, DOI 10.4161/cbt.19292; Psyrri A, 2005, CLIN CANCER RES, V11, P8637, DOI 10.1158/1078-0432.CCR-05-1436; Qiu X, 2015, BIOCHEM BIOPH RES CO, V461, P128, DOI 10.1016/j.bbrc.2015.03.180; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Rizvi I, 2010, CANCER RES, V70, P9319, DOI 10.1158/0008-5472.CAN-10-1783; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Stadlmann S, 2006, MODERN PATHOL, V19, P607, DOI 10.1038/modpathol.3800575; Steffensen KD, 2008, CLIN CANCER RES, V14, P3278, DOI 10.1158/1078-0432.CCR-07-4171; Szlosarek PW, 2006, MOL CANCER THER, V5, P382, DOI 10.1158/1535-7163.MCT-05-0303; Teplinsky E, 2015, TRANSL CANCER RES, V4, P107, DOI 10.3978/j.issn.2218-676X.2015.01.01; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Vergote IB, 2014, J CLIN ONCOL, V32, P320, DOI 10.1200/JCO.2013.50.5669; Wang C, 2014, CANCER RES, V74, P3084, DOI 10.1158/0008-5472.CAN-13-3198; Wen W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0366-5; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	54	56	59	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3576	3587		10.1038/onc.2016.509	http://dx.doi.org/10.1038/onc.2016.509			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166193	Green Published, hybrid			2022-12-28	WOS:000403878600007
J	Yang, Q; Li, X; Chen, H; Cao, Y; Xiao, Q; He, Y; Wei, J; Zhou, J				Yang, Q.; Li, X.; Chen, H.; Cao, Y.; Xiao, Q.; He, Y.; Wei, J.; Zhou, J.			IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer	ONCOGENE			English	Article							TUMOR-METASTASIS; ACCUMULATION; ACTIVATION; DIFFERENTIATION; EXPANSION; CORRELATE	Accumulation of myeloid-derived suppressor cells (MDSCs) is one of the major obstacles against achieving appropriate anti-tumor immune responses and successful tumor immunotherapy. Granulocytic MDSCs (G-MDSCs) are common in tumor-bearing hosts. However, the mechanisms regulating the development of MDSCs, especially G-MDSCs, remain poorly understood. In this report, we showed that interferon regulatory factor 7 (IRF7) plays an important role in the development of G-MDSCs, but not monocytic MDSCs. IRF7 deficiency caused significant elevation of G-MDSCs, and therefore enhanced tumor growth and metastasis in mice. IRF7 deletion did not affect the suppressive activity of G-MDSCs. Mechanistic studies showed that S100A9, a negative regulator of myeloid cell differentiation, was transrepressed by the IRF7 protein. S100A9 knockdown almost completely abrogated the effects of IRF7 deletion on G-MDSC development and tumor metastasis. Importantly, IRF7 expression levels negatively correlated with the G-MDSC frequency and tumor metastasis, as well as S100A9 expression, in cancer patients. In summary, our study demonstrated that IRF7 represents a novel regulator of G-MDSC development in cancer, which may have predictive value for tumor progression.	[Yang, Q.; Zhou, J.] Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Med Ctr, Program Immunol, Guangzhou, Guangdong, Peoples R China; [Yang, Q.; Li, X.; Chen, H.; Cao, Y.; Xiao, Q.; He, Y.; Wei, J.; Zhou, J.] Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, 74 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Yang, Q.; Zhou, J.] Guangzhou Med Univ, Sch Basic Sci, Guangzhou, Guangdong, Peoples R China; [Li, X.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Zhou, J.] Sun Yat Sen Univ, Chinese Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University	Zhou, J (corresponding author), Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, 74 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	zhouj72@mail.sysu.edu.cn			National Natural Science Foundation of China [81571520, 91542112, 31270921]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); National Key Basic Research Program of China [2012CB524900]; Guangdong Innovative Research Team Program [2009010058]; Fundamental Research Funds for the Central Universities; Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project [B12003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); National Key Basic Research Program of China(National Basic Research Program of China); Guangdong Innovative Research Team Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project	This work was supported by the following grants to JZ: National Natural Science Foundation of China (No. 81571520; 91542112; and 31270921), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2014), National Key Basic Research Program of China (No. 2012CB524900), Guangdong Innovative Research Team Program (No. 2009010058), The Fundamental Research Funds for the Central Universities, the Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project (No. B12003).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Capietto AH, 2013, J EXP MED, V210, P2257, DOI 10.1084/jem.20130281; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Chernov AV, 2015, J BIOL CHEM, V290, P11771, DOI 10.1074/jbc.M114.622316; Clark HL, 2016, J IMMUNOL, V196, P336, DOI 10.4049/jimmunol.1502037; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056; Damuzzo V, 2015, CYTOM PART B-CLIN CY, V88, P77, DOI [10.1002/cyto.b.21206, 10.1002/cytob.21206]; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Hibino T, 2013, CANCER RES, V73, P172, DOI 10.1158/0008-5472.CAN-11-3843; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Kalathil S, 2013, CANCER RES, V73, P2435, DOI 10.1158/0008-5472.CAN-12-3381; Kim JK, 2015, TUMOR BIOL, V36, P5561, DOI 10.1007/s13277-015-3226-4; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; McNeill E, 2014, INT J CANCER, V135, P798, DOI 10.1002/ijc.28725; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Qin AP, 2013, J VIROL, V87, P1477, DOI 10.1128/JVI.01759-12; Romieu-Mourez R, 2006, CANCER RES, V66, P10576, DOI 10.1158/0008-5472.CAN-06-1279; Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Solito S, 2014, ANN NY ACAD SCI, V1319, P47, DOI 10.1111/nyas.12469; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Thevenot PT, 2014, IMMUNITY, V41, P389, DOI 10.1016/j.immuni.2014.08.015; Vasquez-Dunddel D, 2013, J CLIN INVEST, V123, P1580, DOI 10.1172/JCI60083; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang Q, 2014, BLOOD, V124, P1610, DOI 10.1182/blood-2014-03-559658; Yang Q, 2015, MOL CELL BIOL, V35, P63, DOI 10.1128/MCB.00805-14; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu LX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6256; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004	44	33	35	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2969	2980		10.1038/onc.2016.448	http://dx.doi.org/10.1038/onc.2016.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092673				2022-12-28	WOS:000402000400005
J	Feng, J; Li, L; Zhang, N; Liu, J; Zhang, L; Gao, H; Wang, G; Li, Y; Zhang, Y; Li, X; Liu, D; Lu, J; Huang, B				Feng, J.; Li, L.; Zhang, N.; Liu, J.; Zhang, L.; Gao, H.; Wang, G.; Li, Y.; Zhang, Y.; Li, X.; Liu, D.; Lu, J.; Huang, B.			Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms	ONCOGENE			English	Article							TANDEM MASS-SPECTROMETRY; SEX STEROID-HORMONES; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; RECEPTOR EXPRESSION; CHROMATIN IMMUNOPRECIPITATION; TESTOSTERONE LEVELS; SERUM TESTOSTERONE; DEMETHYLASE LSD1; DUCTAL CARCINOMA	The role of androgen and androgen receptor (AR) in breast carcinogenesis has long been a disputed issue. This report provides a mechanistic insight into how androgen and AR contributes to invasion and metastasis of breast cancer. We find that dihydrotestosterone (DHT) is able to induce the epithelial-to-mesenchymal transition in breast cancer cells in an AR-dependent/ estrogen receptor-independent manner. This process is dependent on the demethylation activity of lysine-specific demethylase 1A (LSD1) by epigenetically regulating the target genes E-cadherin and vimentin. In vivo, DHT promotes metastasis in a nude mouse model, and AR and LSD1 are indispensable in this process. We establish that higher expression of nucleus AR to cytoplasm AR associated with worse prognostic outcomes in breast cancer patient samples. This study maps an 'androgen-AR/LSD1-target genes' pathway in breast carcinogenesis, implicating the importance of hormonal balance in women, and the potential clinical significance of serum androgen and AR in prediction of breast cancer and selection of breast cancer therapy.	[Feng, J.; Li, L.; Liu, J.; Zhang, Y.; Huang, B.] Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China; [Li, L.] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Bone & Soft Tissue Tumors, Tianjin, Peoples R China; [Zhang, N.; Li, X.; Lu, J.] Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China; [Zhang, L.; Gao, H.] Jilin Univ, Dept Pathol, Hosp 2, Changchun, Peoples R China; [Wang, G.; Li, Y.] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China; [Liu, D.] Auckland Univ Technol, Sch Sci, Auckland, New Zealand	Northeast Normal University - China; Tianjin Medical University; Northeast Normal University - China; Jilin University; Northeast Normal University - China; Auckland University of Technology	Huang, B (corresponding author), Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China.; Lu, J (corresponding author), Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.	luj809@nenu.edu.cn; huangbq705@nenu.edu.cn		Feng, Jing-Xin/0000-0003-0677-2792	National Natural Science Foundation of China [31570718, 31571478, 31571317, 31371294]; University S & T Innovation Platform of Jilin Province for Economic Fungi [2014B-1]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University S & T Innovation Platform of Jilin Province for Economic Fungi	We thank Dr Wei Huang from School of Mathematics and Statistics of Northeast Normal University for kindly providing statistical analysis guidance. This work was supported by the grants from the National Natural Science Foundation of China (Grant numbers 31570718, 31571478, 31571317 and 31371294), and a grant from The University S & T Innovation Platform of Jilin Province for Economic Fungi (#2014B-1).	Abdulla A, 2014, J BIOL CHEM, V289, P29937, DOI 10.1074/jbc.M114.573659; Agrawal AK, 2008, FOLIA HISTOCHEM CYTO, V46, P269, DOI 10.2478/v10042-008-0039-y; Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Amente S, 2010, CELL CYCLE, V9, P3002, DOI 10.4161/cc.9.15.12499; Berrino F, 2005, INT J CANCER, V113, P499, DOI 10.1002/ijc.20582; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bui HN, 2013, STEROIDS, V78, P96, DOI 10.1016/j.steroids.2012.10.010; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Castellano I, 2010, BREAST CANCER RES TR, V124, P607, DOI 10.1007/s10549-010-0761-y; Chen J, 2013, J STEROID BIOCHEM, V137, P316, DOI 10.1016/j.jsbmb.2013.01.012; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dorgan JF, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2779; Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Fourkala EO, 2012, ENDOCR-RELAT CANCER, V19, P137, DOI 10.1530/ERC-11-0310; Garay JP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3112; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-149; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanley K, 2008, HUM PATHOL, V39, P386, DOI 10.1016/j.humpath.2007.07.007; Harmeyer KM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1347; Harwood DT, 2009, CLIN CHIM ACTA, V409, P78, DOI 10.1016/j.cca.2009.09.003; He JH, 2012, MED ONCOL, V29, P406, DOI 10.1007/s12032-011-9832-0; Hickey TE, 2015, ONCOTARGET, V6, P44728, DOI 10.18632/oncotarget.6296; Honma N, 2013, BREAST CANCER-TOKYO, V20, P323, DOI 10.1007/s12282-012-0337-2; Hu DG, 2014, HORM CANCER-US, V5, P61, DOI 10.1007/s12672-014-0171-4; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Kaaks R, 2005, JNCI-J NATL CANCER I, V97, P755, DOI 10.1093/jnci/dji132; Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038; Kocaturk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li YX, 2016, ONCOL REP, V35, P3586, DOI 10.3892/or.2016.4729; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Loibl S, 2011, BREAST CANCER RES TR, V130, P477, DOI 10.1007/s10549-011-1715-8; Luo HC, 2016, CELL REP, V15, P2665, DOI 10.1016/j.celrep.2016.05.050; Luo Xiang, 2010, Chin J Cancer, V29, P585; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; McNamara KM, 2010, J STEROID BIOCHEM, V121, P611, DOI 10.1016/j.jsbmb.2010.02.001; McNamara Keely M, 2013, Front Endocrinol (Lausanne), V4, P116, DOI 10.3389/fendo.2013.00116; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Micello D, 2010, VIRCHOWS ARCH, V457, P467, DOI 10.1007/s00428-010-0964-y; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nam HJ, 2014, MOL CELL, V53, P791, DOI 10.1016/j.molcel.2014.01.028; Narayanan R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103202; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ni L, 2013, MOL CELL BIOL, V33, P4766, DOI 10.1128/MCB.00647-13; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Park S, 2011, ANN ONCOL, V22, P1755, DOI 10.1093/annonc/mdq678; Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Peters KM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-132; Qu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082650; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Rothman MS, 2011, STEROIDS, V76, P177, DOI 10.1016/j.steroids.2010.10.010; Schippinger W, 2006, VIRCHOWS ARCH, V449, P24, DOI 10.1007/s00428-006-0213-6; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shufelt Chrisandra L, 2008, Menopause Int, V14, P117, DOI 10.1258/mi.2008.008015; Sieri S, 2009, CANCER EPIDEM BIOMAR, V18, P169, DOI 10.1158/1055-9965.EPI-08-0808; Spurdle AB, 1999, JNCI-J NATL CANCER I, V91, P961, DOI 10.1093/jnci/91.11.961; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DB, 2012, MED ONCOL, V29, P526, DOI 10.1007/s12032-011-9948-2; Tsutsumi Y, 2012, JPN J CLIN ONCOL, V42, P375, DOI 10.1093/jjco/hys034; Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Wang B, 2009, INT J CANCER, V124, P1892, DOI 10.1002/ijc.24132; Wang Y, 2011, ONCOGENE, V30, P4327, DOI 10.1038/onc.2011.144; Wang Y, 2013, HUM MOL GENET, V22, P2263, DOI 10.1093/hmg/ddt077; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Witzel I, 2013, J CANCER RES CLIN, V139, P809, DOI 10.1007/s00432-013-1382-8; Yu H, 2003, INT J CANCER, V105, P92, DOI 10.1002/ijc.11034; Yu Q, 2011, ANN ONCOL, V22, P1288, DOI 10.1093/annonc/mdq586; Zeleniuch-Jacquotte A, 2004, BRIT J CANCER, V90, P153, DOI 10.1038/sj.bjc.6601517	86	56	58	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2775	2790		10.1038/onc.2016.432	http://dx.doi.org/10.1038/onc.2016.432			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893717				2022-12-28	WOS:000401697800001
J	Hiraki, M; Maeda, T; Bouillez, A; Alam, M; Tagde, A; Hinohara, K; Suzuki, Y; Markert, T; Miyo, M; Komura, K; Ahmad, R; Rajabi, H; Kufe, D				Hiraki, M.; Maeda, T.; Bouillez, A.; Alam, M.; Tagde, A.; Hinohara, K.; Suzuki, Y.; Markert, T.; Miyo, M.; Komura, K.; Ahmad, R.; Rajabi, H.; Kufe, D.			MUC1-C activates BMI1 in human cancer cells	ONCOGENE			English	Article							POLYCOMB GROUP PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; DNA-DAMAGE RESPONSE; STEM-CELLS; SELF-RENEWAL; TRANSCRIPTION FACTOR; H2A UBIQUITYLATION; SENESCENT CELLS; BETA-CATENIN; HISTONE H2A	B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overexpressed in human carcinoma cells and has been linked to their self-renewal. There is no known relationship between MUC1-C and BMI1 in cancer. The present studies demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism in breast and other cancer cells. In addition, we show that MUC1-C blocks miR-200c-mediated downregulation of BMI1 expression. The functional significance of this MUC1-C -> BMI1 pathway is supported by the demonstration that targeting MUC1-C suppresses BMI1-induced ubiquitylation of H2A and thereby derepresses homeobox HOXC5 and HOXC13 gene expression. Notably, our results further show that MUC1-C binds directly to BMI1 and promotes occupancy of BMI1 on the CDKN2A promoter. In concert with BMI1-induced repression of the p16(INK4a) tumor suppressor, we found that targeting MUC1-C is associated with induction of p16(INK4a) expression. In support of these results, analysis of three gene expresssion data sets demonstrated highly significant correlations between MUC1-C and BMI1 in breast cancers. These findings uncover a previously unrecognized role for MUC1-C in driving BMI1 expression and in directly interacting with this stem cell factor, linking MUC1-C with function of the PRC1 in epigenetic gene silencing.	[Hiraki, M.; Maeda, T.; Bouillez, A.; Alam, M.; Tagde, A.; Hinohara, K.; Suzuki, Y.; Markert, T.; Miyo, M.; Komura, K.; Ahmad, R.; Rajabi, H.; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA; [Suzuki, Y.] Osaka Police Hosp, Dept Gastroenterol Surg, Kitayama Cho 10-31 Tennoji, Osaka, Osaka 5430035, Japan; [Ahmad, R.] King Saud Univ, Coll Med, Riyadh, Saudi Arabia	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Osaka Police Hospital; King Saud University	Kufe, D (corresponding author), Dana Farber Canc Inst, Med Oncol, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu		Ahmad, Rehan/0000-0003-2612-2818	National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA166480] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480 and by the Lung Cancer Research Foundation. The authors thank Dr Goberdhan P Dimri, Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC for kindly providing the pGL-BMI1PrWT and pGL-BMI1PrMut reporter vectors.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, MOL CANC RES; Alam M, 2015, MOL CANCER RES, V13, P449, DOI 10.1158/1541-7786.MCR-14-0363; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dimri M, 2016, ONCOTARGET, V7, P36220, DOI 10.18632/oncotarget.8811; Endoh M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002774; Fleming A, 2004, CELL, V119, P449, DOI 10.1016/j.cell.2004.11.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643; Hiraki M, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.5; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin XZ, 2015, BIOMOLECULES, V5, P3396, DOI 10.3390/biom5043396; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346; Meng S, 2010, J BIOL CHEM, V285, P33219, DOI 10.1074/jbc.M110.133686; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Rizo A, 2009, BLOOD, V114, P1498, DOI 10.1182/blood-2009-03-209734; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang YY, 2012, WORLD J SURG, V36, P1189, DOI 10.1007/s00268-012-1514-3; Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	63	36	36	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2791	2801		10.1038/onc.2016.439	http://dx.doi.org/10.1038/onc.2016.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893710	Green Accepted, Green Submitted			2022-12-28	WOS:000401697800002
J	Keysselt, K; Kreutzmann, T; Rother, K; Kerner, C; Krohn, K; Przybilla, J; Buske, P; Loffler-Wirth, H; Loeffler, M; Galle, J; Aust, G				Keysselt, K.; Kreutzmann, T.; Rother, K.; Kerner, C.; Krohn, K.; Przybilla, J.; Buske, P.; Loeffler-Wirth, H.; Loeffler, M.; Galle, J.; Aust, G.			Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency	ONCOGENE			English	Article							COLORECTAL-CANCER; LYNCH SYNDROME; TUMOR-DEVELOPMENT; TUMORIGENESIS; PROLIFERATION; MOUSE; NICHE; MODEL; NOTCH; HOMEOSTASIS	Mutations in mismatch repair (MMR) genes result in microsatellite instability (MSI) and early onset of colorectal cancer. To get mechanistic insights into the time scale, sequence and frequency of intestinal stem cell (ISC) transformation, we quantified MSI and growth characteristics of organoids of Msh2-deficient and control mice from birth until tumor formation and related them to tissue gene expression. Although in Msh2-deficient organoids MSI continuously increased from birth, growth characteristics remained stable at first. Months before tumor onset, normal Msh2-deficient tissue contained tumor precursor cells forming organoids with higher MSI, cystic growth and growth rates resembling temporarily those of tumor organoids. Consistently, Msh2-deficient tissue exhibited a tumor-like gene signature. Normal Msh2-deficient organoids showed increased inheritable transient cyst-like growth, which became independent of R-spondin. ISC transformation proceeded faster in vitro than in vivo independent of the underlying genotype but more under MMR deficiency. Transient cyst-like growth but not MSI was suppressed by aspirin. In summary, as highlighted by organoids, molecular alterations continuously proceeded long before tumor onset in MMR-deficient intestine, thus increasing its susceptibility for ISC transformation.	[Keysselt, K.; Kreutzmann, T.; Rother, K.; Kerner, C.; Aust, G.] Univ Leipzig, Dept Surg, Res Labs, Leipzig, Germany; [Rother, K.; Przybilla, J.; Buske, P.; Loeffler-Wirth, H.; Galle, J.] Univ Leipzig, Interdisciplinary Ctr Bioinformat IZBI, Leipzig, Germany; [Krohn, K.] Univ Leipzig, Core Unit DNA Technol, Interdisciplinary Ctr Clin Res Leipzig IZKF, Leipzig, Germany; [Loeffler, M.] Univ Leipzig, Inst Med Stat Informat & Epidemiol, Leipzig, Germany	Leipzig University; Leipzig University; Leipzig University; Leipzig University	Aust, G (corresponding author), Univ Leipzig, Fac Med, Res Labs, Dept Surg, Liebigstr 19, D-04103 Leipzig, Germany.	gabriela.aust@medizin.uni-leipzig.de	Rother, Karen/GQI-3824-2022; Rother, Karen/GQI-3786-2022	Kreutzmann, Tobias/0000-0002-6070-243X; Loeffler-Wirth, Henry/0000-0001-8239-440X	BMBF grant HNPCC-Sys [031 6065A]; BMBF grant INDRA [031A312]	BMBF grant HNPCC-Sys; BMBF grant INDRA	The study was supported by the BMBF grants HNPCC-Sys (grant number: 031 6065A) and INDRA (grant number: 031A312).	Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bhalla A, 2013, CLIN LAB MED, V33, P835, DOI 10.1016/j.cll.2013.10.001; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Finkbeiner SR, 2015, STEM CELL REP, V4, P1140, DOI 10.1016/j.stemcr.2015.04.010; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048; Germann M, 2014, STEM CELL RES, V13, P355, DOI 10.1016/j.scr.2014.08.002; Ghaleb AM, 2011, DEV BIOL, V349, P310, DOI 10.1016/j.ydbio.2010.11.001; Giardiello FM, 2014, GASTROENTEROLOGY, V147, P502, DOI 10.1053/j.gastro.2014.04.001; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Harris AR, 2014, J CELL SCI, V127, P2507, DOI 10.1242/jcs.142349; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Kortum B, 2015, GUT, V64, P1905, DOI 10.1136/gutjnl-2014-307663; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Lu YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063056; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Martinez P, 2009, AGING CELL, V8, P2, DOI 10.1111/j.1474-9726.2008.00441.x; Mcilhatton MA, 2011, CANCER PREV RES, V4, P684, DOI 10.1158/1940-6207.CAPR-10-0319; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Przybilla J, 2014, AGING CELL, V13, P320, DOI 10.1111/acel.12177; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Schwank G, 2013, CELL STEM CELL, V13, P653, DOI 10.1016/j.stem.2013.11.002; Staffa L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121980; Tao S, 2015, EMBO J, V34, P624, DOI 10.15252/embj.201490700; Tian H, 2015, CELL REP, V11, P33, DOI 10.1016/j.celrep.2015.03.007; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Woerner SM, 2015, MOL CARCINOGEN, V54, P1376, DOI 10.1002/mc.22213	40	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2750	2761		10.1038/onc.2016.429	http://dx.doi.org/10.1038/onc.2016.429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27941880	Green Published			2022-12-28	WOS:000401120900012
J	Kumazoe, M; Takai, M; Bae, J; Hiroi, S; Huang, Y; Takamatsu, K; Won, Y; Yamashita, M; Hidaka, S; Yamashita, S; Yamada, S; Murata, M; Tsukamoto, S; Tachibana, H				Kumazoe, M.; Takai, M.; Bae, J.; Hiroi, S.; Huang, Y.; Takamatsu, K.; Won, Y.; Yamashita, M.; Hidaka, S.; Yamashita, S.; Yamada, S.; Murata, M.; Tsukamoto, S.; Tachibana, H.			FOXO3 is essential for CD44 expression in pancreatic cancer cells	ONCOGENE			English	Article							STEM-CELLS; GEMCITABINE; IDENTIFICATION; BAY-41-2272; METASTASIS; RESISTANCE; APOPTOSIS; BREAST; CGMP	Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer and the 5-year survival rate is only 5%. Several studies have suggested that cancer stem cells (CSCs) are thought to be involved in recurrence and metastasis and so it is essential to establish an approach targeting CSCs. Here we have demonstrated that cyclic guanosine monophosphate (cGMP) suppressed CD44 expression and the properties of CSCs in PDAC. Microarray analysis suggested that cGMP inhibited Forkhead box O3 (FOXO3), which is known as a tumor suppressor. Surprisingly, our data demonstrated that FOXO3 is essential for CD44 expression and the properties of CSCs. Our data also indicated that patients with high FOXO3 activation signatures had poor prognoses. This evidence suggested that cGMP induction and FOXO3 inhibition could be ideal candidates for pancreatic CSC.	[Kumazoe, M.; Takai, M.; Bae, J.; Hiroi, S.; Huang, Y.; Takamatsu, K.; Won, Y.; Yamashita, M.; Hidaka, S.; Yamashita, S.; Yamada, S.; Murata, M.; Tsukamoto, S.; Tachibana, H.] Kyushu Univ, Div Appl Biol Chem, Dept Biosci & Biotechnol, Fac Agr, Fukuoka, Japan	Kyushu University	Kumazoe, M (corresponding author), Kyushu Univ, Div Appl Biol Chem, Dept Biosci & Biotechnol, Fac Agr,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	tatibana@agr.kyushu-u.ac.jp		Kumazoe, Motofumi/0000-0002-3002-2994	JSPS KAKENHI [22228002, 15H02448, 15K18821]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by JSPS KAKENHI grant 22228002 and 15H02448 to H Tachibana. This work was also supported in part by a Grant-in-Aid for JSPS Fellows to MK (PD) and JSPS KAKENHI grant 15K18821. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We appreciate the technical support from the Research Support Center, Graduate School of Medical Sciences, Kyushu University, and the Center for Accelerator and Beam Applied Science, Kyushu University. We thank Takeshi Iwasaki (Kyushu University, Faculty of Medicine) for helpful advice on bioinformatics analysis. The authors would like to thank Enago (www.enago.jp) for the English language review.	Adikrisna R, 2012, GASTROENTEROLOGY, V143, P234, DOI 10.1053/j.gastro.2012.03.054; Bera A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106343; Bischoff E, 2004, CIRCULATION, V110, pE320, DOI 10.1161/01.CIR.0000142209.28862.12; Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078-0432.CCR-10-1891; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Burnett Arthur L, 2006, J Clin Hypertens (Greenwich), V8, P53; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Eyster CA, 2011, MOL BIOL CELL, V22, P3218, DOI 10.1091/mbc.E10-11-0874; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ilmer Matthias, 2015, Genes Cancer, V6, P365; Klotz LO, 2015, REDOX BIOL, V6, P51, DOI 10.1016/j.redox.2015.06.019; Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Molejon MI, 2015, ONCOTARGET, V6, P7408, DOI 10.18632/oncotarget.3510; Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003; Ohara Y, 2013, CANCER SCI, V104, P1127, DOI 10.1111/cas.12198; Penchev VR, 2012, CLIN CANCER RES, V18, P4277, DOI 10.1158/1078-0432.CCR-11-3112; Quint K, 2012, INT J ONCOL, V41, P2093, DOI 10.3892/ijo.2012.1648; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Sergeant G, 2009, NAT REV CLIN ONCOL, V6, P580, DOI 10.1038/nrclinonc.2009.127; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050867; Stratford JK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000307; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Teixeira CE, 2006, HYPERTENSION, V47, P596, DOI 10.1161/01.HYP.0000199914.36936.1b; Vaz AP, 2014, J CANC STEM CELL RES, V2, P1, DOI [10.14343/jcscr.2014.2e1004, DOI 10.14343/JCSCR.2014.2E1004]; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188; Zhang G, 2013, CLIN CANCER RES, V19, P4983, DOI 10.1158/1078-0432.CCR-13-0209	40	34	37	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2643	2654		10.1038/onc.2016.426	http://dx.doi.org/10.1038/onc.2016.426			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893718				2022-12-28	WOS:000401120900003
J	Shi, ZM; Wang, L; Shen, H; Jiang, CF; Ge, X; Li, DM; Wen, YY; Sun, HR; Pan, MH; Li, W; Shu, YQ; Liu, LZ; Peiper, SC; He, J; Jiang, BH				Shi, Z-M; Wang, L.; Shen, H.; Jiang, C-F; Ge, X.; Li, D-M; Wen, Y-Y; Sun, H-R; Pan, M-H; Li, W.; Shu, Y-Q; Liu, L-Z; Peiper, S. C.; He, J.; Jiang, B-H			Downregulation of miR-218 contributes to epithelialmesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; CARCINOMA METASTASIS; PANCREATIC-CANCER; DRUG-RESISTANCE; OVARIAN-CANCER; COLON-CANCER; NUDE-MICE; TGF-BETA; CELLS	Epithelial-mesenchymal transition (EMT) has been recognized as a key element of cell migration and invasion in lung cancer; however, the underlying mechanisms are not fully elucidated. Recently, emerging evidence suggest that miRNAs have crucial roles in control of EMT and EMT-associated traits such as migration, invasion and chemoresistance. Here, we found that miR-218 expression levels were significantly downregulated in lung cancer tissues compared with adjacent non-cancerous tissues, and the levels of miR-218 were significantly associated with histological grades and lymph node metastasis. Overexpression of miR-218 inhibited cell migration and invasion as well as the EMT process. Of particular importance, miR-218 was involved in the metastatic process of lung cancer cells in vivo by suppressing local invasion and distant colonization. We identified Slug and ZEB2 as direct functional targets of miR-218. Inverse correlations were observed between miR-218 levels and Slug/ZEB2 levels in cancer tissue samples. In addition, overexpression of miR-218 in H1299 increased chemosensitivity of cells to cisplatin treatment through suppression of Slug and ZEB2. These findings highlight an important role of miR-218 in the regulation of EMT-related traits and metastasis of lung cancer in part by modulation of Slug/ZEB2 signaling, and provide a potential therapeutic strategy by targeting miR-218 in NSCLC.	[Shi, Z-M] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Shi, Z-M; Wang, L.; Jiang, C-F; Ge, X.; Li, D-M; Wen, Y-Y; Sun, H-R; Jiang, B-H] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Key Lab Human Funct Genom Jiangsu Prov, State Key Lab Reprod Med,Canc Ctr,Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Shen, H.; Shu, Y-Q] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Pan, M-H] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Li, W.] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Liu, L-Z; Peiper, S. C.; He, J.; Jiang, B-H] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Suite 334,Jefferson Alumni Hall, Philadelphia, PA 19107 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University; Jefferson University	He, J; Jiang, BH (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Suite 334,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.; Jiang, BH (corresponding author), Nanjing Med Univ, Dept Pathol, Nanjing 211166, Jiangsu, Peoples R China.	Jun.he@jefferson.edu; binghjiang@yahoo.com	sun, hao/GRS-7732-2022; Shu, Yongqian/ABD-5698-2021; Jiang, Chengfei/AFW-5879-2022	He, Jun/0000-0002-5162-6041; Jiang, Bing-Hua/0000-0003-4526-2031; Liu, Ling-Zhi/0000-0001-9234-457X; Hartl, Carla/0000-0001-9769-7462	National Natural Science Foundation of China [81472944, 81320108019, 81302182, 81270736, 81502170]; Research Special Fund for Public Welfare Industry of Health [201402008]; National Institutes of Health grants [R01ES020868, R01CA193511]; American Cancer Society [RSG NEC -129306]; NATIONAL CANCER INSTITUTE [R01CA193511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020868] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Special Fund for Public Welfare Industry of Health; National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by National Natural Science Foundation of China (81472944, 81320108019, 81302182, 81270736 and 81502170); The Research Special Fund for Public Welfare Industry of Health (201402008); by National Institutes of Health grants (R01ES020868 and R01CA193511); and by American Cancer Society (RSG NEC -129306).	An ZL, 1996, ANTICANCER RES, V16, P2545; [Anonymous], 2014, IEEE IJCNN; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Castoldi M, 2006, RNA, V12, P913, DOI 10.1261/rna.2332406; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fang S, 2014, EXP MOL PATHOL, V96, P438, DOI 10.1016/j.yexmp.2014.04.008; FENG B, 2015, CLIN SCI, V129, P673; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; FU XY, 1991, P NATL ACAD SCI USA, V88, P9345, DOI 10.1073/pnas.88.20.9345; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guan HY, 2013, J CLIN ENDOCR METAB, V98, pE1334, DOI 10.1210/jc.2013-1053; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Heist RS, 2012, CANCER CELL, V21; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katz MH, 2004, CLIN EXP METASTAS, V21, P7, DOI 10.1023/B:CLIN.0000017160.93812.3b; Ko H, 2013, CANCER LETT, V335, P205, DOI 10.1016/j.canlet.2013.02.018; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Li CH, 2013, GASTROENTEROLOGY, V144, P1086, DOI 10.1053/j.gastro.2013.01.058; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu LZ, 2008, CANCER RES, V68, P8183, DOI 10.1158/0008-5472.CAN-08-0819; Mallini P, 2014, CANCER TREAT REV, V40, P341, DOI 10.1016/j.ctrv.2013.09.008; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Nagaraju GP, 2015, MOL CARCINOGEN, V54, P1147, DOI 10.1002/mc.22185; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Oktyabri D, 2014, BIOCHEM BIOPH RES CO, V453, P124, DOI 10.1016/j.bbrc.2014.09.082; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pavelic SK, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-22; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qu JJ, 2015, INT J ONCOL, V47, P2141, DOI 10.3892/ijo.2015.3187; Sachdeva M, 2014, J CLIN INVEST, V124, P4305, DOI 10.1172/JCI77116; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang BR, 2016, ARCH TOXICOL, V90, P449, DOI 10.1007/s00204-014-1435-z; Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; Xie J, 2016, TUMOR BIOL, V37, P1197, DOI 10.1007/s13277-015-3831-2; Yang LH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13677; Yang M, 1999, CANCER RES, V59, P781; Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou XX, 2016, J AM SOC NEPHROL, V27, P2092, DOI 10.1681/ASN.2015040457; Zhu KG, 2016, ONCOTARGET, V7, P28075, DOI 10.18632/oncotarget.8576; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	63	100	104	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2577	2588		10.1038/onc.2016.414	http://dx.doi.org/10.1038/onc.2016.414			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	28192397	Green Published, hybrid			2022-12-28	WOS:000400597300008
J	Dokala, A; Thakur, SS				Dokala, A.; Thakur, S. S.			Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; LUNG-CANCER; GEFITINIB RESISTANCE; KINASE INHIBITORS; CRYSTAL-STRUCTURE; T790M MUTATION; FC-RECEPTORS; TUMOR-GROWTH; EXON 20; ACTIVATION	The epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity involved in regulation of cellular multiplication, survival, differentiation and metastasis. Our knowledge about function and complex management of these receptors has driving the development of specific and targeted treatment modalities for human cancers in the last 20 years. EGFR is the first receptor target against which monoclonal antibodies (mAb) have been evolved for cancer treatment. Here we review the biology of ErbB receptors, including their architecture, signaling, regulation and therapeutic strategies and the mechanisms of resistances offered by the receptors against small-molecule tyrosine kinases and resistance overcome implications of mAbs. The efficacy of EGFR-specific mAb in cancer depends on site specific extracellular region of EGFR, which has crucial role in process of dimerization and activation. This review highlights evolution of various resistance mechanisms due to consequences of current small-molecule anti-EGFR therapies.	[Dokala, A.; Thakur, S. S.] CSIR Ctr Cellular & Mol Biol CSIR CCMB, Prote & Cell Signaling, Hyderabad, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Thakur, SS (corresponding author), Ctr Cellular & Mol Biol, Prote & Cell Signaling, Lab E409, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	sst@ccmb.res.in		Thakur, Suman/0000-0001-5928-8836	Department of Biotechnology [GAP0405]; Council of Scientific and Industrial Research [BSC0208]; AB SCIEX, India	Department of Biotechnology; Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); AB SCIEX, India	We are thankful to the Department of Biotechnology (Grant Number GAP0405) and Council of Scientific and Industrial Research (Grant Number BSC0208) and AB SCIEX, India for funding and help. We are grateful to all the lab members for fruitful discussion.	AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alexander S, 2010, CURR PROTOC CELL BIO, V67, P1236; Altomare DA, 2012, CURR MED CHEM, V19, P3748; Arena S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5640; Arteaga CL, 2003, CLIN CANCER RES, V9, P1579; Athale CA, 2006, J THEOR BIOL, V238, P771, DOI 10.1016/j.jtbi.2005.06.029; Bidkhori G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048004; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; COSTA S, 1988, LANCET, V2, P1258; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Daoud MA, 2016, CANCER BIOL MED, V13, P136, DOI 10.28092/j.issn.2095-3941.2015.0009; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; DELARCO JE, 1980, J BIOL CHEM, V255, P3685; Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004; Deng QF, 2016, ONCOL LETT, V11, P535, DOI 10.3892/ol.2015.3945; DERYNCK R, 1987, CANCER RES, V47, P707; Dey N, 2015, AM J TRANSL RES, V7, P733; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; El-Obeid A, 2002, BIOCHEM BIOPH RES CO, V290, P349, DOI 10.1006/bbrc.2001.6210; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Emrah E, 2013, SCI SIGNAL, V11, P791; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Forde PM, 2015, CLIN ADV HEMATOL ONC, V13, P528; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Grunwald Viktor, 2002, Current Problems in Cancer, V26, P109; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hong YS, 2014, ONCOL REP, V31, P2619, DOI 10.3892/or.2014.3161; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Ju L, 2013, CANCER CELL INT, V13, P1523; Khan NA, 2014, CASE REP ONCOL, V7, P491, DOI 10.1159/000365325; Khelwatty SA, 2015, BRIT J CANCER, V113, P1010, DOI 10.1038/bjc.2015.319; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kim S, 2012, IEEE INT SYMP INTELL, P1, DOI 10.1109/ISIC.2012.6398245; Klapper LN, 2000, ADV CANCER RES, V77, P25; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li X, 2014, EXPERT OPIN THER TAR, V18, P1, DOI 10.1517/14728222.2014.859248; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Marschall ALJ, 2011, MABS-AUSTIN, V3, P3, DOI 10.4161/mabs.3.1.14110; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Martinelli E, 2007, CORE EVID, V2, P81; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793; Peled N, 2013, CELL ONCOL, V36, P277, DOI 10.1007/s13402-013-0133-9; Qin BL, 2006, CANCER CHEMOTH PHARM, V58, P577, DOI 10.1007/s00280-006-0219-4; Reguart Noemi, 2010, Cancer Manag Res, V2, P143; Rubin MS, 2000, P AN M AM SOC CLIN, V19, P474; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; Sanchez-Martin FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; SCHMITT DA, 1990, J INVEST DERMATOL, V94, pS15, DOI 10.1111/1523-1747.ep12874984; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Shi J, 2015, ONCOL REP, V33, P2703, DOI 10.3892/or.2015.3916; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suda K, 2014, LUNG CANCER, V85, P147, DOI 10.1016/j.lungcan.2014.05.018; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; TUIJNMAN WB, 1993, APMIS, V101, P319, DOI 10.1111/j.1699-0463.1993.tb00117.x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Ultan MD, 2010, CANCER RES, V15, P1625; Valley CC, 2015, MOL BIOL CELL, V26, P4087, DOI 10.1091/mbc.E15-05-0269; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Woo HS, 2014, INVEST NEW DRUG, V32, P1311, DOI 10.1007/s10637-014-0146-x; Wu K, 2013, ONCOTARGET, V4, P2430, DOI 10.18632/oncotarget.1431; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yokoyama H, 2006, BRIT J CANCER, V95, P1504, DOI 10.1038/sj.bjc.6603459; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yuriko I, 2013, FRONT CELL NEUROSCI, V7, P414; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	93	32	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2337	2344		10.1038/onc.2016.393	http://dx.doi.org/10.1038/onc.2016.393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775071				2022-12-28	WOS:000400268900001
J	Bruinsma, W; Aprelia, M; Garcia-Santisteban, I; Kool, J; Xu, YJ; Medema, RH				Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Kool, J.; Xu, Y. J.; Medema, R. H.			Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; CDK1 PHOSPHORYLATES SPAT-1/BORA; TRCP-DEPENDENT DEGRADATION; MITOTIC ENTRY; PLK1 PHOSPHORYLATION; CHECKPOINT RECOVERY; CELL-CYCLE; ACTIVATION; MITOSIS; PROGRESSION	When cells in G2 phase are challenged with DNA damage, several key mitotic regulators such as Cdk1/Cyclin B, Aurora A and Plk1 are inhibited to prevent entry into mitosis. Here we have studied how inhibition of Plk1 is established after DNA damage. Using a Forster resonance energy transfer (FRET)-based biosensor for Plk1 activity, we show that inhibition of Plk1 after DNA damage occurs with relatively slow kinetics and is entirely dependent on loss of Plk1-T210 phosphorylation. As T210 is phosphorylated by the kinase Aurora A in conjunction with its co-factor Bora, we investigated how they are affected by DNA damage. Interestingly, we find that the interaction between Bora and Plk1 remains intact during the early phases of the DNA damage response (DDR), whereas Plk1 activity is already inhibited at this stage. Expression of an Aurora A mutant that is refractory to inhibition by the DDR failed to prevent inhibition of Plk1 and loss of T210 phosphorylation, suggesting that inhibition of Plk1 may be established by perturbing recruitment of Aurora A by Bora. Indeed, expression of a fusion in which Aurora A was directly coupled to Bora prevented DNA damage-induced inhibition of Plk1 activity, as well as inhibition of T210 phosphorylation. Taken together, these data demonstrate that DNA damage affects the function of Aurora A at multiple levels: both by direct inhibition of Aurora A activity, as well as by perturbing the interaction with its co-activator Bora. We propose that the DDR targets recruitment of Aurora A to the Plk1/Bora complex to prevent activation of Plk1 during DNA damage in G2.	[Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Medema, R. H.] Netherlands Canc Inst, Dept Cell Biol, Amsterdam, Netherlands; [Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Medema, R. H.] Netherlands Canc Inst, Canc Genom Ctr CGC Nl, Amsterdam, Netherlands; [Bruinsma, W.; Aprelia, M.; Kool, J.; Xu, Y. J.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Bruinsma, W.; Aprelia, M.; Kool, J.; Xu, Y. J.; Medema, R. H.] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands; [Garcia-Santisteban, I.] Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, UPV EHU, Leioa, Spain; [Bruinsma, W.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10065 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Basque Country; Memorial Sloan Kettering Cancer Center	Medema, RH (corresponding author), Netherlands Canc Inst, Dept Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam Holland, Netherlands.	r.medema@nki.nl	Garcia-Santisteban, Iraia/AAS-1463-2020	Medema, Rene/0000-0002-6754-0381	Netherlands Genomics Initiative of NWO; NWO Gravitation; Basque Country Government (Spain)	Netherlands Genomics Initiative of NWO; NWO Gravitation; Basque Country Government (Spain)(Basque Government)	We thank L. Macurek (IMG, Prague) for the mCherry-Bora construct and members of the Medema laboratory for discussions. RM is supported by the Netherlands Genomics Initiative of NWO and by the NWO Gravitation program CancerGenomics.nl. WB, MA, JK and YJX are supported by the Netherlands Genomics Initiative of NWO. IGS was supported with a postdoctoral fellowship from the Basque Country Government (Spain).	Apweiler R, 2014, NUCLEIC ACIDS RES, V42, pD191, DOI 10.1093/nar/gkt1140; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Bruinsma W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00132; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Chan EHY, 2008, CHROMOSOMA, V117, P457, DOI 10.1007/s00412-008-0165-5; Chiyoda T, 2012, J CELL BIOL, V197, P625, DOI 10.1083/jcb.201110110; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Feine O, 2014, CELL CYCLE, V13, DOI 10.4161/cc.28630; Fuller BG, 2008, NATURE, V453, P1132, DOI 10.1038/nature06923; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Ikeda M, 2012, J BIOL CHEM, V287, P27670, DOI 10.1074/jbc.M112.378968; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lee YC, 2013, CELL CYCLE, V12, P953, DOI 10.4161/cc.23945; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Qin B, 2013, J BIOL CHEM, V288, P16139, DOI 10.1074/jbc.M113.456780; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tavernier N, 2015, J CELL BIOL, V208, P661, DOI 10.1083/jcb.201408064; Thomas Y, 2016, CELL REP, V15, P510, DOI 10.1016/j.celrep.2016.03.049; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vidanes GM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000286; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Yamashiro S, 2008, DEV CELL, V14, P787, DOI 10.1016/j.devcel.2008.02.013; Yang XM, 2009, J BIOL CHEM, V284, P18588, DOI 10.1074/jbc.C109.001560; Yata K, 2012, MOL CELL, V45, P371, DOI 10.1016/j.molcel.2011.12.028	41	24	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1840	1848		10.1038/onc.2016.347	http://dx.doi.org/10.1038/onc.2016.347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721411	Green Published, hybrid			2022-12-28	WOS:000398128900009
J	Kwak, T; Drews-Elger, K; Ergonul, A; Miller, PC; Braley, A; Hwang, GH; Zhao, D; Besser, A; Yamamoto, Y; Yamamoto, H; El-Ashry, D; Slingerland, JM; Lippman, ME; Hudson, BI				Kwak, T.; Drews-Elger, K.; Ergonul, A.; Miller, P. C.; Braley, A.; Hwang, G. H.; Zhao, D.; Besser, A.; Yamamoto, Y.; Yamamoto, H.; El-Ashry, D.; Slingerland, J. M.; Lippman, M. E.; Hudson, B. I.			Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis	ONCOGENE			English	Article							GLYCATION END-PRODUCTS; TUMOR MICROENVIRONMENT; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; DIABETES-MELLITUS; MOUSE MODEL; RECEPTOR; EXPRESSION; ACTIVATION; PROMOTES	The receptor for advanced glycation end products (RAGE) is highly expressed in various cancers and is correlated with poorer outcome in breast and other cancers. Here we tested the role of targeting RAGE by multiple approaches in the tumor and tumor microenvironment, to inhibit the metastatic process. We first tested how RAGE impacts tumor cell-intrinsic mechanisms using either RAGE overexpression or knockdown with short hairpin RNAs (shRNAs). RAGE ectopic overexpression in breast cancer cells increased MEK-EMT (MEK-epithelial-to-mesenchymal transition) signaling, transwell invasion and soft agar colony formation, and in vivo promoted lung metastasis independent of tumor growth. RAGE knockdown with multiple independent shRNAs in breast cancer cells led to decreased transwell invasion and soft agar colony formation, without affecting proliferation. In vivo, targeting RAGE shRNA knockdown in human and mouse breast cancer cells, decreased orthotopic tumor growth, reduced tumor angiogenesis and recruitment of inflammatory cells, and markedly decreased metastasis to the lung and liver in multiple xenograft and syngeneic mouse models. To test the non-tumor cell microenvironment role of RAGE, we performed syngeneic studies with orthotopically injected breast cancer cells in wild-type and RAGE-knockout C57BL6 mice. RAGE-knockout mice displayed striking impairment of tumor cell growth compared with wild-type mice, along with decreased mitogen-activated protein kinase signaling, tumor angiogenesis and inflammatory cell recruitment. To test the combined inhibition of RAGE in both tumor cell-intrinsic and nontumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week). Compared with vehicle, FPS-ZM1 inhibited primary tumor growth, inhibited tumor angiogenesis and inflammatory cell recruitment and, most importantly, prevented metastasis to the lung and liver. These data demonstrate that RAGE drives tumor progression and metastasis through distinct tumor cell-intrinsic and -extrinsic mechanisms, and may represent a novel and therapeutically viable approach for treating metastatic cancers.	[Kwak, T.; Hudson, B. I.] Univ Miami, Leonard M Miller Sch Med, Dept Cell Biol, 1550 NW 10th Ave,PAP Bldg,Room 528, Miami, FL 33136 USA; [Drews-Elger, K.; Ergonul, A.; Miller, P. C.; El-Ashry, D.; Lippman, M. E.; Hudson, B. I.] Univ Miami, Leonard M Miller Sch Med, Dept Med, Miami, FL USA; [Braley, A.; Slingerland, J. M.] Univ Miami, Leonard M Miller Sch Med, Dept Biochem, Miami, FL USA; [Hwang, G. H.; Zhao, D.; Besser, A.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Yamamoto, Y.; Yamamoto, H.] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa, Japan; [El-Ashry, D.; Slingerland, J. M.; Lippman, M. E.; Hudson, B. I.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; Kanazawa University; University of Miami	Hudson, BI (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Cell Biol, 1550 NW 10th Ave,PAP Bldg,Room 528, Miami, FL 33136 USA.	bhudson@med.miami.edu	Ergonul, Ayse Burcu/AFJ-8120-2022; Hudson, Barry/B-3122-2009; Ergonul, Ayse Burcu/AAF-4987-2022	Hudson, Barry/0000-0001-7647-8121; Drews-Elger, Katherine/0000-0001-9540-0610; Braley, Alexander/0000-0002-1443-1472	Susan G Komen for the Cure [CCR15331076]; American Cancer Society Institutional Research [98-277-10]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); American Cancer Society Institutional Research(American Cancer Society)	This research was supported by a Career Catalyst Research from Susan G Komen for the Cure Grant No. CCR15331076 and by the American Cancer Society Institutional Research Grant No. 98-277-10.	Abe R, 2008, CURR PHARM DESIGN, V14, P940, DOI 10.2174/138161208784139765; Allmen EU, 2008, PROSTATE, V68, P748, DOI 10.1002/pros.20736; Arumugam T, 2012, CLIN CANCER RES, V18, P4356, DOI 10.1158/1078-0432.CCR-12-0221; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bjork P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063012; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Drews-Elger K, 2014, BREAST CANCER RES TR, V148, P41, DOI 10.1007/s10549-014-3122-4; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hsieh HL, 2003, BIOCHEM BIOPH RES CO, V307, P375, DOI 10.1016/S0006-291X(03)01190-2; Huang JS, 2001, J CELL BIOCHEM, V81, P102, DOI 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y; Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jackel A, 1999, HAUTARZT, V50, P250, DOI 10.1007/s001050050897; Jules J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078267; Kalea AZ, 2010, CANCER RES, V70, P5628, DOI 10.1158/0008-5472.CAN-10-0595; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koch M, 2010, STRUCTURE, V18, P1342, DOI 10.1016/j.str.2010.05.017; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717; Leclerc E, 2007, J BIOL CHEM, V282, P31317, DOI 10.1074/jbc.M703951200; Liao SC, 2011, ASIAN PAC J CANCER P, V12, P1061; Logsdon CD, 2007, CURR MOL MED, V7, P777, DOI 10.2174/156652407783220697; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Myint KM, 2006, DIABETES, V55, P2510, DOI 10.2337/db06-0221; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Pietzsch J, 2009, AMINO ACIDS, V36, P381, DOI 10.1007/s00726-008-0097-7; Radia AM, 2013, INT J MOL SCI, V14, P7959, DOI 10.3390/ijms14047959; Sharaf H, 2015, BBA-MOL BASIS DIS, V1852, P429, DOI 10.1016/j.bbadis.2014.12.009; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; SIROTNAK FM, 1984, CANCER CHEMOTH PHARM, V12, P26; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Vernon PJ, 2013, J IMMUNOL, V190, P1372, DOI 10.4049/jimmunol.1201151; Xiong F, 2011, J BIOL CHEM, V286, P35061, DOI 10.1074/jbc.M111.261073; Yamagishi S, 2006, METABOLISM, V55, P1227, DOI 10.1016/j.metabol.2006.05.007; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yin CG, 2013, BREAST CANCER RES TR, V142, P297, DOI 10.1007/s10549-013-2737-1; Zen K, 2007, J IMMUNOL, V178, P2483, DOI 10.4049/jimmunol.178.4.2483; Zhou Z, 2006, J EXP MED, V203, P1067, DOI 10.1084/jem.20051947	56	76	82	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1559	1572		10.1038/onc.2016.324	http://dx.doi.org/10.1038/onc.2016.324			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27669433				2022-12-28	WOS:000397458100010
J	Safferthal, C; Rohde, K; Fulda, S				Safferthal, C.; Rohde, K.; Fulda, S.			Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells	ONCOGENE			English	Article							ALPHA-DEPENDENT APOPTOSIS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TNF-ALPHA; PHASE-I; DEATH; CANCER; ACTIVATION; EXPRESSION; PATHWAYS	Resistance to apoptosis, for example due to overexpression of Inhibitor of Apoptosis (IAP) proteins, is associated with poor prognosis in acute myeloid leukemia (AML). Here, we identify that Smac mimetics such as BV6, which antagonizes IAP proteins, elicit necroptosis in AML cells, in which apoptosis is inhibited pharmacologically by caspase inhibitors or genetically by caspase-8 knockdown. Importantly, BV6 triggers necroptosis also in apoptosis-resistant patient-derived AML blasts, underlining the clinical relevance of our findings. Mechanistically, we show that BV6-induced cell death depends on key components of necroptosis signaling such as RIP1, RIP3 and MLKL, since pharmacological or genetic inhibition of these proteins significantly protects AML cells from BV6-mediated cell death, whereas PGAM5 is dispensable. Interestingly, we identify constitutive tumor necrosis factor-alpha (TNF alpha) secretion and an autocrine/paracrine TNF alpha loop as critical mediators of BV6-induced necroptosis in AML cell lines and patient-derived blasts, as the TNF alpha-blocking antibody Enbrel or tumor necrosis factor-alpha receptor 1 (TNFR1) knockdown significantly rescue cell death. Notably, AML cells exhibit high basal levels of TNF alpha compared to non-malignant CD34+ cells, which is further increased by BV6. In conclusion, this is the first report showing that Smac mimetics circumvent apoptosis resistance in AML cells by inducing necroptosis in a TNF alpha- dependent manner, which has important implications for the development of new strategies to overcome treatment resistance in AML.	[Safferthal, C.; Rohde, K.; Fulda, S.] Goethe Univ, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)) [CI3 131A029B]; IUAP VII	BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)); IUAP VII	We thank X Wang (Beijing, China) for kindly providing PGAM5 antibody and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) and CI3 131A029B), IUAP VII (to SF).	Belz K, 2014, BLOOD, V124, P240, DOI 10.1182/blood-2013-05-500918; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bullinger L, 2007, BLOOD, V110, P1291, DOI 10.1182/blood-2006-10-049783; Carter BZ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt440; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Chromik J, 2014, CANCER LETT, V344, P101, DOI 10.1016/j.canlet.2013.10.018; Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014; DiPersio JF, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.7029; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2012, LEUKEMIA, V26, P1155, DOI 10.1038/leu.2012.4; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2015, CLIN CANCER RES, V21, P5030, DOI 10.1158/1078-0432.CCR-15-0365; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hess CJ, 2007, J CLIN ONCOL, V25, P1209, DOI 10.1200/JCO.2006.08.4061; Infante JR, 2014, J CLIN ONCOL, V32, P3103, DOI 10.1200/JCO.2013.52.3993; Lalaoui N, 2016, CANCER CELL, V29, P145, DOI 10.1016/j.ccell.2016.01.006; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Moriwaki K, 2016, J IMMUNOL, V196, P407, DOI 10.4049/jimmunol.1501662; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Schenk B, 2015, ONCOGENE, V34, P5796, DOI 10.1038/onc.2015.35; Servida F, 2011, INVEST NEW DRUG, V29, P1264, DOI 10.1007/s10637-010-9475-6; Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320; Steinwascher S, 2015, CANCER LETT, V366, P32, DOI 10.1016/j.canlet.2015.05.020; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Volk A, 2014, J EXP MED, V211, P1093, DOI 10.1084/jem.20130990; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Weisberg E, 2010, LEUKEMIA, V24, P2100, DOI 10.1038/leu.2010.212; Weisberg E, 2007, MOL CANCER THER, V6, P1951, DOI 10.1158/1535-7163.MCT-06-0810; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308	39	41	43	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1487	1502		10.1038/onc.2016.310	http://dx.doi.org/10.1038/onc.2016.310			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27869161				2022-12-28	WOS:000397458100004
J	Harjes, U; Bridges, E; Gharpure, KM; Roxanis, I; Sheldon, H; Miranda, F; Mangala, LS; Pradeep, S; Lopez-Berestein, G; Ahmed, A; Fielding, B; Sood, AK; Harris, AL				Harjes, U.; Bridges, E.; Gharpure, K. M.; Roxanis, I.; Sheldon, H.; Miranda, F.; Mangala, L. S.; Pradeep, S.; Lopez-Berestein, G.; Ahmed, A.; Fielding, B.; Sood, A. K.; Harris, A. L.			Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4	ONCOGENE			English	Article							ACID-BINDING PROTEIN; OXYGEN SPECIES PRODUCTION; OVARIAN-CANCER; FATTY-ACIDS; CELLS; GROWTH; PHOSPHORYLATION; ANGIOGENESIS; METABOLISM; ACTIVATION	Fatty acid binding protein 4 (FABP4) is a fatty acid chaperone, which is induced during adipocyte differentiation. Previously we have shown that FABP4 in endothelial cells is induced by the NOTCH1 signalling pathway, the latter of which is involved in mechanisms of resistance to antiangiogenic tumour therapy. Here, we investigated the role of FABP4 in endothelial fatty acid metabolism and tumour angiogenesis. We analysed the effect of transient FABP4 knockdown in human umbilical vein endothelial cells on fatty acid metabolism, viability and angiogenesis. Through therapeutic delivery of siRNA targeting mouse FABP4, we investigated the effect of endothelial FABP4 knockdown on tumour growth and blood vessel formation. In vitro, siRNA-mediated FABP4 knockdown in endothelial cells led to a marked increase of endothelial fatty acid oxidation, an increase of reactive oxygen species and decreased angiogenesis. In vivo, we found that increased NOTCH1 signalling in tumour xenografts led to increased expression of endothelial FABP4 that decreased when NOTCH1 and VEGFA inhibitors were used in combination. Angiogenesis, growth and metastasis in ovarian tumour xenografts were markedly inhibited by therapeutic siRNA delivery targeting mouse endothelial FABP4. Therapeutic targeting of endothelial FABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be investigated further.	[Harjes, U.; Bridges, E.; Sheldon, H.; Harris, A. L.] Univ Oxford, Dept Oncol, WIMM, Hypoxia & Growth Factor Grp, Oxford OX1 2JD, England; [Gharpure, K. M.; Mangala, L. S.; Pradeep, S.; Sood, A. K.] Univ Texas Austin, Dept Gynecol Oncol, Austin, TX 78712 USA; [Roxanis, I.] Oxford Univ Hosp, Dept Cellular Pathol, Oxford, England; [Roxanis, I.] John Radcliffe Hosp, NIHR Biomed Res Ctr Oxford, Oxford, England; [Miranda, F.; Ahmed, A.] Univ Oxford, Nuffield Dept Obstet & Gynaecol, WIMM, Ovarian Canc Cell Lab, Oxford OX1 2JD, England; [Mangala, L. S.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas Austin, MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Austin, TX 78712 USA; [Lopez-Berestein, G.; Sood, A. K.] Univ Texas Austin, Dept Canc Biol, Austin, TX 78712 USA; [Fielding, B.] Univ Surrey, Dept Nutr Sci, Guildford GU2 5XH, Surrey, England; [Harjes, U.] Univ Leuven, Dept Oncol, Lab Angiogenesis & Vasc Metab, B-3000 Leuven, Belgium; [Harjes, U.] VIB, Vesalius Res Ctr, Lab Angiogenesis & Vasc Metab, B-3000 Leuven, Belgium	University of Oxford; University of Texas System; University of Texas Austin; University of Oxford; University of Oxford; University of Texas System; University of Texas Austin; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; University of Surrey; KU Leuven; Flanders Institute for Biotechnology (VIB)	Harris, AL (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Osler Rd Headington, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Sood, Anoop Kumar/A-7344-2013	Harris, Adrian L/0000-0003-1376-8409; Sood, Anoop Kumar/0000-0001-5702-4108; Sheldon, Helen/0000-0002-0945-5496; Harjes, Ulrike/0000-0003-0376-1262; Gharpure, Kshipra/0000-0003-4954-5696	Cancer Research UK; Breast Cancer Research Foundation; NIH [CA109298, P50 CA083639, P50 CA098258, UH2 TR000943]; RGK Foundation; Glider Foundation; Betty Anne Asche Murray Distinguished Professorship; Altman Goldstein Discovery Fellowship; Medical research Council; Ovarian Cancer Action; Oxford Biomedical Research Centre, the National Institute of Health Research; National Health Service Biomedical Research Centre; NATIONAL CANCER INSTITUTE [R01CA109298, P50CA083639, P50CA098258, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER; Cancer Research UK [11359, 16466, 18974] Funding Source: researchfish; Medical Research Council [G0902418, G0300648] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; MRC [G0902418] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; Glider Foundation; Betty Anne Asche Murray Distinguished Professorship; Altman Goldstein Discovery Fellowship; Medical research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ovarian Cancer Action(Ovarian Cancer Action); Oxford Biomedical Research Centre, the National Institute of Health Research; National Health Service Biomedical Research Centre; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Portions of this work were supported by Cancer Research UK, Breast Cancer Research Foundation and National Health Service Biomedical Research Centre, the NIH (CA109298, P50 CA083639, P50 CA098258, UH2 TR000943), the RGK Foundation, the Glider Foundation and the Betty Anne Asche Murray Distinguished Professorship. KMG is supported by Altman Goldstein Discovery Fellowship. AA and FM are funded by the Medical research Council, Ovarian Cancer Action and the Oxford Biomedical Research Centre, the National Institute of Health Research.	Bao Zhengzheng, 2013, Genes Cancer, V4, P297, DOI 10.1177/1947601913499155; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046; Cataltepe O, 2012, NEUROPATH APPL NEURO, V38, P400, DOI 10.1111/j.1365-2990.2011.01237.x; Coe NR, 1999, J LIPID RES, V40, P967; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Elmasri H, 2009, FASEB J, V23, P3865, DOI 10.1096/fj.09-134882; Garin-Shkolnik T, 2014, DIABETES, V63, P900, DOI 10.2337/db13-0436; Harjes U, 2016, CRIT REV ONCOL HEMAT, V97, P15, DOI 10.1016/j.critrevonc.2015.10.011; Harjes U, 2014, J BIOL CHEM, V289, P23168, DOI 10.1074/jbc.M114.576512; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Hu W, 2011, CANCER RES, V71, P6030, DOI 10.1158/0008-5472.CAN-10-2719; Huang J, 2016, MOL CANCER THER, V15, P1344, DOI 10.1158/1535-7163.MCT-15-0144; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Mashek DG, 2006, CURR OPIN LIPIDOL, V17, P274, DOI 10.1097/01.mol.0000226119.20307.2b; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Olsauskas-Kuprys R, 2013, ONCOTARGETS THER, V6, P943, DOI 10.2147/OTT.S33766; Oza AM, 2015, LANCET ONCOL, V16, P928, DOI 10.1016/S1470-2045(15)00086-8; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Rosca MG, 2012, DIABETES, V61, P2074, DOI 10.2337/db11-1437; Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362; Schultheis B, 2014, J CLIN ONCOL, V32, P4141, DOI 10.1200/JCO.2013.55.0376; Smith AJ, 2007, J BIOL CHEM, V282, P32424, DOI 10.1074/jbc.M703730200; Smith NR, 2013, CLIN CANCER RES, V19, P6943, DOI 10.1158/1078-0432.CCR-13-1637; Wang HC, 2014, CLIN CHIM ACTA, V436, P243, DOI 10.1016/j.cca.2014.06.005; Wu JR, 2010, J BIOPHARM STAT, V20, P954, DOI 10.1080/10543401003618983	32	44	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					912	921		10.1038/onc.2016.256	http://dx.doi.org/10.1038/onc.2016.256			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27568980	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000394169100004
J	Cai, H; Liu, XB; Zheng, J; Xue, YX; Ma, J; Li, Z; Xi, Z; Li, ZQ; Bao, M; Liu, YH				Cai, Heng; Liu, Xiaobai; Zheng, Jian; Xue, Yixue; Ma, Jun; Li, Zhen; Xi, Zhuo; Li, Zhiqing; Bao, Min; Liu, Yunhui			Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; GLIOMA-CELLS; EXPRESSION; CANCER; TUG1; GROWTH; PROLIFERATION; APOPTOSIS; DIFFERENTIATION; PROMOTE	Angiogenesis is one of the critical biological elements affecting the development and progression of cancer. Long non-coding RNAs (lncRNAs) are important regulators and aberrantly expressed in various types of human cancer. Our previous studies indicated that lncRNA taurine upregulated 1 (TUG1) implicated in the regulation of blood-tumor barrier permeability; however, its role in glioblastoma angiogenesis still unclear. Here we demonstrated that TUG1 was up-expressed in human glioblastoma tissues and glioblastoma cell lines. Knockdown of TUG1 remarkably suppressed tumor-induced endothelial cell proliferation, migration and tube formation as well as reducing spheroid-based angiogenesis ability in vitro, which are the critical steps for tumor angiogenesis. Besides, knockdown of TUG1 significantly increased the expression of mircroRNA-299 (miR-299), which was down-expressed in glioblastoma tissues and glioblastoma cell lines. Bioinformatics analysis and luciferase reporter assay revealed that TUG1 influenced tumor angiogenesis via directly binding to the miR-299 and there was a reciprocal repression between TUG1 and miR-299 in the same RNA-induced silencing complex. Moreover, knockdown of TUG1 reduced the expression of vascular endothelial growth factor A (VEGFA), which was defined as a functional downstream target of miR-299. In addition, knockdown of TUG1, shown in the in vivo studies, has effects on suppressing tumor growth, reducing tumor microvessel density and decreasing the VEGFA expression by upregulating miR-299 in xenograft glioblastoma model. Overall, the results demonstrated that TUG1 enhances tumor-induced angiogenesis and VEGF expression through inhibiting miR-299. Also, the inhibition of TUG1 could provide a novel therapeutic target for glioblastoma treatment.	[Cai, Heng; Liu, Xiaobai; Zheng, Jian; Xi, Zhuo; Li, Zhiqing; Bao, Min; Liu, Yunhui] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China; [Xue, Yixue; Ma, Jun; Li, Zhen] China Med Univ, Dept Neurobiol, Coll Basic Med, Shenyang, Peoples R China	China Medical University; China Medical University	Liu, YH (corresponding author), China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China.	sj_neurosurgery@126.com			Natural Science Foundation of China [81172197, 81272564, 81272795, 81372484, 81573010]; Shenyang Science and Technology Plan Projects [F15-199-1-30, F15-199-1-57]; outstanding scientific fund of Shengjing hospital [201304]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenyang Science and Technology Plan Projects; outstanding scientific fund of Shengjing hospital	This work is supported by grants from the Natural Science Foundation of China (81172197, 81272564, 81272795, 81372484 and 81573010) and Shenyang Science and Technology Plan Projects (nos F15-199-1-30 and F15-199-1-57), and outstanding scientific fund of Shengjing hospital (no. 201304).	Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bai RY, 2011, TRENDS MOL MED, V17, P301, DOI 10.1016/j.molmed.2011.01.011; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Cai H, 2015, ONCOTARGET, V6, P19759, DOI 10.18632/oncotarget.4331; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chi AS, 2009, ONCOLOGIST, V14, P621, DOI 10.1634/theoncologist.2008-0272; Dunn IF, 2000, J NEURO-ONCOL, V50, P121, DOI 10.1023/A:1006436624862; Ezhilarasan R, 2007, INT J ONCOL, V30, P701; Folkerth RD, 2000, J NEURO-ONCOL, V50, P165, DOI 10.1023/A:1006499824379; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Gaiser T, 2009, NEUROCHEM INT, V54, P458, DOI 10.1016/j.neuint.2009.01.016; Han XR, 2015, FASEB J, V29, P3054, DOI 10.1096/fj.14-259952; Han YH, 2013, J SURG ONCOL, V107, P555, DOI 10.1002/jso.23264; Isin M, 2014, CLIN CHIM ACTA, V431, P255, DOI 10.1016/j.cca.2014.02.010; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jiang XC, 2016, J NEUROSURG, V124, P129, DOI [10.3171/2014.12.JNS1426, 10.3171/2014.12.JNS1426.test]; Jiao F, 2015, INT J MOL SCI, V16, P6677, DOI 10.3390/ijms16046677; Jouanneau E, 2008, NEUROSURGERY, V62, P31, DOI 10.1227/01.NEU.0000311060.65002.4E; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Ke J, 2015, ONCOTARGET, V6, P21934, DOI 10.18632/oncotarget.4290; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kobayashi H, 2016, BBA-GENE REGUL MECH, V1859, P71, DOI 10.1016/j.bbagrm.2015.08.007; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; Liu Q, 2015, J NEURO-ONCOL, V122, P283, DOI 10.1007/s11060-015-1718-0; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rapicavoli NA, 2009, DEV DYNAM, V238, P2103, DOI 10.1002/dvdy.21844; Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shevde LA, 2010, J CELL MOL MED, V14, P1693, DOI 10.1111/j.1582-4934.2009.00821.x; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Tate MC, 2009, NEUROTHERAPEUTICS, V6, P447, DOI 10.1016/j.nurt.2009.04.001; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang L, 2014, ONCOTARGET, V5, P5416, DOI 10.18632/oncotarget.2116; Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xu YT, 2015, TUMOR BIOL, V36, P1643, DOI 10.1007/s13277-014-2763-6; Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015; Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201; Zhang Q, 2013, ASIAN PAC J CANCER P, V14, P2311, DOI 10.7314/APJCP.2013.14.4.2311; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110; Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008	54	137	143	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					318	331		10.1038/onc.2016.212	http://dx.doi.org/10.1038/onc.2016.212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345398				2022-12-28	WOS:000394166000003
J	da Motta, LL; Ledaki, I; Purshouse, K; Haider, S; De Bastiani, MA; Baban, D; Morotti, M; Steers, G; Wigfield, S; Bridges, E; Li, JL; Knapp, S; Ebner, D; Klamt, F; Harris, AL; McIntyre, A				da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; De Bastiani, M. A.; Baban, D.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J-L; Knapp, S.; Ebner, D.; Klamt, F.; Harris, A. L.; McIntyre, A.			The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer	ONCOGENE			English	Article							BROMODOMAIN INHIBITION; EPIGENETIC READERS; ENERGY-METABOLISM; CELL METABOLISM; GENE-EXPRESSION; LYSYL OXIDASE; STEM-CELLS; CHIP-SEQ; IN-VIVO; C-MYC	The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.	[da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J-L; Harris, A. L.; McIntyre, A.] Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Labs, Oxford OX1 2JD, England; [da Motta, L. L.; De Bastiani, M. A.; Klamt, F.] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil; [da Motta, L. L.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil; [Baban, D.] Univ Oxford, Wellcome Trust Ctr Human Genet, High Throughput Genom, Oxford OX1 2JD, England; [Li, J-L] Univ Plymouth, Peninsula Schools Med & Dent, Inst Translat & Stratified Med, Plymouth PL4 8AA, Devon, England; [Knapp, S.] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford, England; [Knapp, S.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Campus Riedberg, Frankfurt, Germany; [Knapp, S.] Buchmann Inst Life Sci, Campus Riedberg, Frankfurt, Germany; [Ebner, D.] Univ Oxford, TDI, Nuffield Dept Med, Oxford, England; [McIntyre, A.] Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England	University of Oxford; Universidade Federal do Rio Grande do Sul; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); University of Oxford; Wellcome Centre for Human Genetics; University of Plymouth; University of Oxford; Goethe University Frankfurt; University of Oxford; University of Nottingham	McIntyre, A (corresponding author), Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England.; Harris, AL (corresponding author), Univ Oxford, Weatherall Inst Mol Med, Dept Oncol, Mol Oncol Labs, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk; alan.mcintyre@nottingham.ac.uk	Harris, Adrian L/ABA-3343-2020; Morotti, Matteo/AAE-8922-2020; De Bastiani, Marco Antônio/AAD-8366-2019; De Bastiani, Marco Antônio/AAO-3798-2020; Motta, Leonardo L/C-1551-2015; Knapp, Stefan/AAG-2347-2019	Harris, Adrian L/0000-0003-1376-8409; Morotti, Matteo/0000-0002-1790-1185; De Bastiani, Marco Antônio/0000-0003-3924-5278; Motta, Leonardo L/0000-0001-6364-5007; Knapp, Stefan/0000-0001-5995-6494; Ebner, Daniel/0000-0002-6495-7026; McIntyre, Alan/0000-0002-4791-7292; Purshouse, Karin/0000-0003-0942-6342	Cancer Research UK; Breast Cance Research Foundation; Breast Cancer Now; Oxford NIHR Biomedical Research Centre; CRUK Oxford Centre; CAPES Foundation/Brazil; Cancer Research UK [18974, 16466, 11359] Funding Source: researchfish; Medical Research Council [G0300648] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163, ACF-2015-13-008] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cance Research Foundation; Breast Cancer Now; Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); CRUK Oxford Centre; CAPES Foundation/Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by grants from Cancer Research UK (ALH), Breast Cance Research Foundation (ALH), Breast Cancer Now (AM), Oxford NIHR Biomedical Research Centre, and the CRUK Oxford Centre (ALH). Leonardo Lisboa da Motta has been awarded a scholarship from the CAPES Foundation/Brazil to conduct this study.	Alghamdi S, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0278-3; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernardi R, 2014, CELL RES, V24, P904, DOI 10.1038/cr.2014.61; Bid HK, MOL CANC THER; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Castro MAA, 2009, BIOINFORMATICS, V25, P1468, DOI 10.1093/bioinformatics/btp246; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dubois L, 2011, RADIOTHER ONCOL, V99, P424, DOI 10.1016/j.radonc.2011.05.045; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gieling RG, 2013, J ENZYM INHIB MED CH, V28, P360, DOI 10.3109/14756366.2012.736979; Gonzales-Cope M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2414-y; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Halliday GM, 2009, INT J BIOCHEM CELL B, V41, P725, DOI 10.1016/j.biocel.2008.04.026; Horne GA, 2015, STEM CELLS DEV, V24, P879, DOI 10.1089/scd.2014.0302; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kumler I, 2014, CANCER TREAT REV, V40, P960, DOI 10.1016/j.ctrv.2014.05.006; Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126; Rajagopalan V, 2014, CELL MOL NEUROBIOL, V34, P1059, DOI 10.1007/s10571-014-0083-4; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; SEMENZA GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI DOI 10.1016/J.BBAMCR.2015.05.036; Sena JA, 2013, MOL CELL BIOL, V33, P3849, DOI 10.1128/MCB.00731-13; Sengupta S, 2015, BREAST CANCER RES TR, V150, P265, DOI 10.1007/s10549-015-3319-1; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200; Wani NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3665; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; Waschow M., 2012, NAT METHODS, V9; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991; Wu T, 2015, STEM CELL REP, V4, P390, DOI 10.1016/j.stemcr.2015.01.012; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	59	93	93	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					122	132		10.1038/onc.2016.184	http://dx.doi.org/10.1038/onc.2016.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27292261	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000394069100011
J	Prazeres, H; Torres, J; Rodrigues, F; Pinto, M; Pastoriza, MC; Gomes, D; Cameselle-Teijeiro, J; Vidal, A; Martins, TC; Sobrinho-Simoes, M; Soares, P				Prazeres, H.; Torres, J.; Rodrigues, F.; Pinto, M.; Pastoriza, M. C.; Gomes, D.; Cameselle-Teijeiro, J.; Vidal, A.; Martins, T. C.; Sobrinho-Simoes, M.; Soares, P.			Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells (vol 30, pg 1302, 2010)	ONCOGENE			English	Correction													Pinto, Marta T/J-2519-2013; Soares, Paula/B-6054-2008; Vidal, Anxo/B-5010-2015	Pinto, Marta T/0000-0002-8521-2904; Soares, Paula/0000-0001-9607-6998; Vidal, Anxo/0000-0002-0866-4202; Sobrinho-Simoes, Manuel/0000-0003-1613-1235	FEDER funds through Programa Operacional Factores de Competitividade-COMPETE [FCOMP-01-0124-FEDER 011267]	FEDER funds through Programa Operacional Factores de Competitividade-COMPETE	This work was also supported by FEDER funds through Programa Operacional Factores de Competitividade-COMPETE (FCOMP-010124-FEDER 011267).	Prazeres H, 2011, ONCOGENE, V30, P1302, DOI 10.1038/onc.2010.512	1	7	7	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					146	146		10.1038/onc.2016.143	http://dx.doi.org/10.1038/onc.2016.143			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27499094	Bronze			2022-12-28	WOS:000394069100013
J	Fessler, E; Jansen, M; Melo, FDSE; Zhao, L; Prasetyanti, PR; Rodermond, H; Kandimalla, R; Linnekamp, JF; Franitza, M; van Hooff, SR; de Jong, JH; Oppeneer, SC; van Noesel, CJM; Dekker, E; Stassi, G; Wang, X; Medema, JP; Vermeulen, L				Fessler, E.; Jansen, M.; Melo, F. De Sousa E.; Zhao, L.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; Franitza, M.; van Hooff, S. R.; de Jong, J. H.; Oppeneer, S. C.; van Noesel, C. J. M.; Dekker, E.; Stassi, G.; Wang, X.; Medema, J. P.; Vermeulen, L.			A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype	ONCOGENE			English	Article							MIR-200 FAMILY; ANALYSES IDENTIFY; POOR SURVIVAL; EXPRESSION; TRANSITION; METASTASIS; ZEB1; EMT; HETEROGENEITY; PHENOTYPE	Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classification and treatment of this malignancy. There is no common genetic molecular feature that would allow for the identification of patients at risk for developing recurrences and thus selecting patients who would benefit from more stringent therapies still poses a major clinical challenge. Recently, an international multicenter consortium (CRC Subtyping Consortium) was established aiming at the classification of CRC patients in biologically homogeneous CRC subtypes. Four consensus molecular subtypes (CMSs) were identified, of which the mesenchymal CMS4 presented with worse prognosis signifying the importance of identifying these patients. Despite the large number of samples analyzed and their clear association with unifying biological programs and clinical features, single-driver mutations could not be identified and patients are heterogeneous with regard to currently used clinical markers. We therefore set out to define the regulatory mechanisms underlying the distinct gene expression profiles using a network-based approach involving multiple molecular modalities such as gene expression, methylation levels and microRNA (miR) expression. The miR-200 family presented as the most powerful determinant of CMS4-specific gene expression, tuning the majority of genes differentially expressed in the poor prognosis subtype, including genes associated with the epithelial-mesenchymal transition program. Furthermore, our data show that two epigenetic marks, namely the methylation of the two miR-200 promoter regions, can identify tumors belonging to the mesenchymal subtype and is predictive of disease-free survival in CRC patients. Importantly, epigenetic silencing of the miR-200 family is also detected in epithelial CRC cell lines that belong to the mesenchymal CMS. We thus show that determining regulatory networks is a powerful strategy to define drivers of distinct cancer subtypes, which possess the ability to identify subtype affiliation and to shed light on biological behavior.	[Fessler, E.; Melo, F. De Sousa E.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; van Hooff, S. R.; de Jong, J. H.; Medema, J. P.; Vermeulen, L.] Univ Amsterdam, Lab Expt Oncol & Radiobiol LEXOR, Ctr Expt Mol Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Fessler, E.; Melo, F. De Sousa E.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; van Hooff, S. R.; de Jong, J. H.; Medema, J. P.] Canc Genom Ctr, Utrecht, Netherlands; [Jansen, M.; van Noesel, C. J. M.] Univ Amsterdam, AMC, Dept Pathol, Amsterdam, Netherlands; [Zhao, L.; Wang, X.] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China; [Franitza, M.] Univ Cologne, CCG, Cologne, Germany; [Franitza, M.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Oppeneer, S. C.; Dekker, E.] Univ Amsterdam, AMC, Dept Gastroenterol, Amsterdam, Netherlands; [Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Cellular & Mol Pathophysiol Lab, Palermo, Italy; [Jansen, M.] Univ London, Barts Canc Inst, Ctr Tumour Biol, London, England; [Melo, F. De Sousa E.] Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; City University of Hong Kong; University of Cologne; University of Cologne; University of Amsterdam; Academic Medical Center Amsterdam; University of Palermo; University of London; Queen Mary University London; Roche Holding; Genentech	Medema, JP; Vermeulen, L (corresponding author), Univ Amsterdam, Lab Expt Oncol & Radiobiol LEXOR, Ctr Expt Mol Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Wang, X (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.	xin.wang@cityu.edu.hk; j.p.medema@amc.nl; l.vermeulen@amc.nl	Vermeulen, Louis/B-7488-2008; Stassi, Giorgio/AAC-1175-2022; Wang, Xin/A-1130-2012; Kandimalla, Raju/C-1400-2016	Vermeulen, Louis/0000-0002-6066-789X; Wang, Xin/0000-0002-5122-2418; Dekker, Evelien/0000-0002-4363-0745; Jansen, Marnix/0000-0003-0645-564X; Kandimalla, Raju/0000-0002-0342-5229; Medema, Jan Paul/0000-0003-3045-2924; Zhao, Lan/0000-0003-2681-7695	AMC Graduate School PhD Scholarship; KWF [UvA2009-4416, UvA2012-5735, UVA2011-4969, UVA2014-7245]; MLDS focus project [FP13-07]; NWO gravitation; Worldwide Cancer Research [14-1164]; Maag Lever Darm Stichting [MLDS-CDG 14-03]; European Research Council [ERG-StG 638193]; CityU Start-up Grant for New Faculty [7200455]; Research Grants Council of Hong Kong SAR [9048033]	AMC Graduate School PhD Scholarship; KWF; MLDS focus project; NWO gravitation; Worldwide Cancer Research; Maag Lever Darm Stichting; European Research Council(European Research Council (ERC)European Commission); CityU Start-up Grant for New Faculty; Research Grants Council of Hong Kong SAR(Hong Kong Research Grants Council)	This work was supported by an AMC Graduate School PhD Scholarship (EF), KWF grants (UvA2009-4416 and UvA2012-5735) KWF/Alpe d'Huzes program CONNECTION, MLDS focus project FP13-07 and NWO gravitation (JPM), KWF grants (UVA2011-4969 and UVA2014-7245), Worldwide Cancer Research (14-1164), the Maag Lever Darm Stichting (MLDS-CDG 14-03) and the European Research Council (ERG-StG 638193) (LV), CityU Start-up Grant for New Faculty (7200455) and an early career scheme grant from the Research Grants Council of Hong Kong SAR (9048033) (XW).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neves R., 2010, BMC RES NOTES, V3, P3, DOI DOI 10.1186/1756-0500-3-219; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828; Prasetyanti PR, 2013, METHODS MOL BIOL, V1035, P247, DOI 10.1007/978-1-62703-508-8_21; Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Song FJ, 2014, CLIN CANCER RES, V20, P878, DOI 10.1158/1078-0432.CCR-13-1844; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugai T, 2006, J MOL DIAGN, V8, P193, DOI 10.2353/jmoldx.2006.050052; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tian Y, 2014, J BIOL CHEM, V289, P36101, DOI 10.1074/jbc.M114.598383; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wang X, 2013, INT J BIOCHEM CELL B, V45, P2574, DOI 10.1016/j.biocel.2013.08.014; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang HM, 2012, NUCLEIC ACIDS RES, V40, pD144, DOI 10.1093/nar/gkr965; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	49	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6026	6037		10.1038/onc.2016.134	http://dx.doi.org/10.1038/onc.2016.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27157610	Green Published, hybrid			2022-12-28	WOS:000388509400009
J	Sewastianik, T; Szydlowski, M; Jablonska, E; Bialopiotrowicz, E; Kiliszek, P; Gorniak, P; Polak, A; Prochorec-Sobieszek, M; Szumera-Cieckiewicz, A; Kaminski, TS; Markowicz, S; Nowak, E; Grygorowicz, MA; Warzocha, K; Juszczynski, P				Sewastianik, T.; Szydlowski, M.; Jablonska, E.; Bialopiotrowicz, E.; Kiliszek, P.; Gorniak, P.; Polak, A.; Prochorec-Sobieszek, M.; Szumera-Cieckiewicz, A.; Kaminski, T. S.; Markowicz, S.; Nowak, E.; Grygorowicz, M. A.; Warzocha, K.; Juszczynski, P.			FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; THIOREDOXIN; EXPRESSION; APOPTOSIS; SURVIVAL; INHIBITOR; PATHWAYS; CANCER; GENE	Molecular profiling has led to identification of subtypes of diffuse large B-cell lymphomas (DLBCLs) differing in terms of oncogenic signaling and metabolic programs. The OxPhos-DLBCL subtype is characterized by enhanced mitochondrial oxidative phosphorylation. As increased oxidative metabolism leads to overproduction of potentially toxic reactive oxygen species (ROS), we sought to identify mechanisms responsible for adaptation of OxPhos cells to these conditions. Herein, we describe a mechanism involving the FOXO1-TXN-p300 redox-dependent circuit protecting OxPhos-DLBCL cells from ROS toxicity. We identify a BCL6-dependent transcriptional mechanism leading to relative TXN overexpression in OxPhos cells. We found that OxPhos cells lacking TXN were uniformly more sensitive to ROS and doxorubicin than control cells. Consistent with this, the overall survival of patients with high TXN mRNA expression, treated with doxorubicin-containing regimens, is significantly shorter than of those with low TXN mRNA expression. TXN overexpression curtails p300-mediated FOXO1 acetylation and its nuclear translocation in response to oxidative stress, thus attenuating FOXO1 transcriptional activity toward genes involved in apoptosis and cell cycle inhibition. We also demonstrate that FOXO1 knockdown in cells with silenced TXN expression markedly reduces ROS-induced apoptosis, indicating that FOXO1 is the major sensor and effector of oxidative stress in OxPhos-DLBCLs. These data highlight dynamic, context-dependent modulation of FOXO1 tumor-suppressor functions via acetylation and reveal potentially targetable vulnerabilities in these DLBCLs.	[Sewastianik, T.; Szydlowski, M.; Jablonska, E.; Bialopiotrowicz, E.; Kiliszek, P.; Gorniak, P.; Polak, A.; Prochorec-Sobieszek, M.; Szumera-Cieckiewicz, A.; Juszczynski, P.] Inst Hematol & Transfus Med, Dept Diagnost Hematol, Indiry Gandhi 14, PL-02776 Warsaw, Poland; [Kaminski, T. S.] Polish Acad Sci, Inst Phys Chem, Dept Soft Condensed Matter, Warsaw, Poland; [Markowicz, S.; Nowak, E.; Grygorowicz, M. A.] Maria Sklodowska Curie Mem Canc Center, Inst Oncol, Dept Immunol, Warsaw, Poland; [Warzocha, K.] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland	Polish Academy of Sciences; Institute of Physical Chemistry of the Polish Academy of Sciences; Maria Sklodowska-Curie National Research Institute of Oncology	Juszczynski, P (corresponding author), Inst Hematol & Transfus Med, Dept Diagnost Hematol, Indiry Gandhi 14, PL-02776 Warsaw, Poland.	pjuszczynski@ihit.waw.pl	Szumera-Ciećkiewicz, Anna/D-8391-2019; Bialopiotrowicz, Emilia/W-2322-2018; Szumera-Ciećkiewicz, Anna/AAR-8502-2021; Szydlowski, Maciej/P-4329-2019; Jablonska, Ewa/W-2303-2018; Prochorec-Sobieszek, Monika/AAD-5065-2020; Szydlowski, Maciej/W-5014-2018; Polak, Anna/AAA-7190-2020; Polak, Anna/W-2432-2018; Gorniak, Patryk/W-6301-2018; Kaminski, Tomasz/AAD-6449-2020; Juszczynski, Przemyslaw/W-9709-2018; Sewastianik, Tomasz/AAC-6293-2020	Szumera-Ciećkiewicz, Anna/0000-0001-5028-3422; Bialopiotrowicz, Emilia/0000-0002-9263-0928; Szumera-Ciećkiewicz, Anna/0000-0001-5028-3422; Szydlowski, Maciej/0000-0002-9419-121X; Jablonska, Ewa/0000-0002-5445-4249; Prochorec-Sobieszek, Monika/0000-0002-8109-9553; Szydlowski, Maciej/0000-0002-9419-121X; Polak, Anna/0000-0001-8686-3429; Polak, Anna/0000-0001-8686-3429; Gorniak, Patryk/0000-0002-2920-2672; Kaminski, Tomasz/0000-0001-5124-4548; Juszczynski, Przemyslaw/0000-0001-7215-0444; Sewastianik, Tomasz/0000-0003-4603-8517; Warzocha, Krzysztof/0000-0002-2396-3905; Markowicz, Sergiusz/0000-0003-1280-6514	Foundation for Polish Science [TEAM/2011-7/4]; European Regional Development Fund and Operational Program Innovative Economy; NanoFun [POIG.02.02.00-00-025/09]	Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); European Regional Development Fund and Operational Program Innovative Economy; NanoFun	This work and T.S. PhD scholarship are supported by a Foundation for Polish Science grant TEAM/2011-7/4, co-financed by the European Regional Development Fund and Operational Program Innovative Economy 2007-2013. This work was partly performed in the laboratories founded by NanoFun POIG.02.02.00-00-025/09.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; An NF, 2014, ADV CANCER RES, V122, P245, DOI 10.1016/B978-0-12-420117-0.00007-4; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Chen LF, 2013, CANCER CELL, V23, P826, DOI 10.1016/j.ccr.2013.05.002; Ci WM, 2009, BLOOD, V113, P5536, DOI 10.1182/blood-2008-12-193037; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dansen TB, 2009, NAT CHEM BIOL, V5, P664, DOI 10.1038/nchembio.194; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Juszczynski P, 2006, MOL CELL BIOL, V26, P5348, DOI 10.1128/MCB.02351-05; Juszczynski P, 2009, BLOOD, V114, P5315, DOI 10.1182/blood-2009-02-204362; Kiebala M, 2015, EXP HEMATOL, V43, P89, DOI 10.1016/j.exphem.2014.10.004; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li CP, 2012, ONCOTARGET, V3, P314, DOI 10.18632/oncotarget.463; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Mandal PK, 2010, CANCER RES, V70, P9505, DOI 10.1158/0008-5472.CAN-10-1509; Marinho HS, 2014, REDOX BIOL, V2, P535, DOI 10.1016/j.redox.2014.02.006; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; Szydlowski M, 2016, BLOOD, V127, P739, DOI 10.1182/blood-2015-06-654111; Szydlowski M, 2014, INT REV IMMUNOL, V33, P146, DOI 10.3109/08830185.2014.885022; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; Xie LK, 2012, BLOOD, V119, P3503, DOI 10.1182/blood-2011-09-381905; Yang Y, 2009, NEOPLASIA, V11, P313, DOI 10.1593/neo.81358; Yuan ZQ, 2009, J BIOL CHEM, V284, P11285, DOI 10.1074/jbc.M900461200	52	29	29	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5989	6000		10.1038/onc.2016.126	http://dx.doi.org/10.1038/onc.2016.126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27132507				2022-12-28	WOS:000388509400006
J	Jhan, JR; Andrechek, ER				Jhan, J-R; Andrechek, E. R.			Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis	ONCOGENE			English	Article							TRASTUZUMAB RESISTANCE; TRANSCRIPTION FACTORS; ADJUVANT BEVACIZUMAB; MOLECULAR PORTRAITS; TARGETED THERAPIES; LUNG-CANCER; IN-VITRO; INHIBITION; MODELS; CONTRIBUTES	Current therapeutic outcomes for breast cancer underscore the complexity of treating a heterogeneous disease. Indeed, studies have shown that differences in gene expression among patients with the same subtype of breast cancer are correlated with the response to treatment. This strongly suggests that there is an urgent need to treat breast cancer with a personalized approach. Here we employed cell signaling pathway signatures to predict pathway activity in subtypes of MMTV-Myc mammary tumors. We then split tumors into subsets and developed individualized combinatorial treatments for two subtypes with distinct pathway activation patterns. Elevation of the EGFR, RAS and TGF beta pathways was observed in one subtype whereas these pathways were not predicted to be active in the other subtype that had high predicted activity of the Myc, Stat3 and Akt pathways. In a proof-of-principle experiment, treatment of these two subtypes with targeted therapies inhibited tumor growth only in the subtype of tumor where the therapy was designed to be active. We then analyzed gene expression profiles of human breast cancer patients and patientderived xenograft (PDX) samples to predict pathway activity, and validated our approach of developing individualized treatments in mice with PDX tumors. Importantly, our combinatorial therapy resulted in tumor regression, including regression in PDX samples from triple-negative breast cancer. Together our data is a proof-of-principle experiment that demonstrates that cell signaling pathway signature-guided treatment for breast cancer is viable.	[Jhan, J-R; Andrechek, E. R.] Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.	andrech1@msu.edu			Susan Komen Career Catalyst [KG110510]; NIH [R011CA160514]	Susan Komen Career Catalyst; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the members of the Andrechek laboratory for helpful discussions. Funding for this project was provided by grants from Susan Komen Career Catalyst (KG110510) and NIH R011CA160514 to ERA.	Alok J., 2004, BIOINFORMATICS, V20, P3246; Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470-2045(15)00041-8; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; DaCosta BS, 2004, MOL PHARM, V65, P744, DOI DOI 10.1124/M0L.65.3.744; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Eo HS, 2012, MOL CELLS, V34, P393, DOI 10.1007/s10059-012-0177-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560; Hoefflin R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11845; Hollern DP, 2013, ONCOGENE, V32, P1296, DOI 10.1038/onc.2012.142; Hollern DP, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3672; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; 2007, CLIN CANCER RES, V13, P4429, DOI DOI 10.1158/1078-0432.CCR-06-3045	56	10	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3553	3561		10.1038/onc.2016.503	http://dx.doi.org/10.1038/onc.2016.503			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28135251				2022-12-28	WOS:000403878600005
J	Strickaert, A; Saiselet, M; Dom, G; De Deken, X; Dumont, JE; Feron, O; Sonveaux, P; Maenhaut, C				Strickaert, A.; Saiselet, M.; Dom, G.; De Deken, X.; Dumont, J. E.; Feron, O.; Sonveaux, P.; Maenhaut, C.			Cancer heterogeneity is not compatible with one unique cancer cell metabolic map	ONCOGENE			English	Review							CYCLIC HYPOXIA; TUMOR HYPOXIA; LACTATE; GLUTAMINE; GLUCOSE; GROWTH; ANGIOGENESIS; OXYGENATION; COMPARTMENTS; METASTASIS	The Warburg effect and its accompanying metabolic features (anaplerosis, cataplerosis) are presented in textbooks and reviews as a hallmark (general characteristic): the metabolic map of cancer. On the other hand, research articles on specific tumors since a few years emphasize various biological features of different cancers, different cells in a cancer and the dynamic heterogeneity of these cells. We have analysed the research literature of the subject and show the generality of a dynamic, evolving biological and metabolic, spatial and temporal heterogeneity of individual cancers. We conclude that there is no one metabolic map of cancer but several and describe the two extremes of a panel from the hypoxic to the normoxic state. The implications for the significance of general 'omic' studies, and on therapeutic conclusions drawn from them and for the diagnostic use of fractional biopsies is discussed.	[Strickaert, A.; Saiselet, M.; Dom, G.; De Deken, X.; Dumont, J. E.; Maenhaut, C.] ULB, IRIBHM, Campus Erasme,808 Route Lenn, B-1070 Brussels, Belgium; [Feron, O.; Sonveaux, P.] UCL, IREC, Pole Pharmacol & Therapeut, Brussels, Belgium	Universite Libre de Bruxelles; Universite Catholique Louvain	Dumont, JE (corresponding author), ULB, IRIBHM, Campus Erasme,808 Route Lenn, B-1070 Brussels, Belgium.	jedumont@ulb.ac.be	FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	EU Horizon Marie Sklodowska-Curie Innovative Training Networks (ITN) [642623 RADIATE]; Interuniversity Attraction Pole (IAP) grant from the Belgian Science Policy Office (Belspo) [UP7-03]; Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS); Televie; Belgian Fondation contre le Cancer [2012-186]; Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29); Welbio; Action de Recherche Concertee from the Communaute Francaise de Belgique [ARC 14/19-058]	EU Horizon Marie Sklodowska-Curie Innovative Training Networks (ITN); Interuniversity Attraction Pole (IAP) grant from the Belgian Science Policy Office (Belspo); Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS)(Fonds de la Recherche Scientifique - FNRS); Televie; Belgian Fondation contre le Cancer; Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29); Welbio(WELBIO); Action de Recherche Concertee from the Communaute Francaise de Belgique	The work of PS and OF is supported by EU Horizon2020 Marie Sklodowska-Curie Innovative Training Networks (ITN No. 642623 RADIATE), Interuniversity Attraction Pole (IAP) grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058), the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS), the Televie, and the Belgian Fondation contre le Cancer (2012-186). Pierre Sonveaux is a Research Associate of the F.R.S.-FNRS. Other authors of the University of Brussels are supported by the Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29) and Welbio.	Afonso J, 2016, CELL CYCLE, V15, P368, DOI 10.1080/15384101.2015.1121329; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Avery SV, 2006, NAT REV MICROBIOL, V4, P577, DOI 10.1038/nrmicro1460; Bhatia S, 2012, NAT BIOTECHNOL, V30, P604, DOI 10.1038/nbt.2294; Boidot R, 2014, ONCOTARGET, V5, P6947, DOI 10.18632/oncotarget.2285; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Cleary AS, 2015, SCIENCE, V350, P1174, DOI 10.1126/science.aad7103; Corbet C, 2015, CURR OPIN CLIN NUTR, V18, P346, DOI 10.1097/MCO.0000000000000178; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Daneau G, 2010, CLIN CANCER RES, V16, P410, DOI 10.1158/1078-0432.CCR-09-0583; Daye D, 2012, SEMIN CELL DEV BIOL, V23, P362, DOI 10.1016/j.semcdb.2012.02.002; Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724; Fernandez LC, 2016, NAT REV CANCER, V16, P43, DOI 10.1038/nrc.2015.1; Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Fiaschi T, 2013, CELL CYCLE, V12, P1791, DOI 10.4161/cc.24902; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Friedl P, 2004, CURR OPIN IMMUNOL, V16, P389, DOI 10.1016/j.coi.2004.05.022; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Galie M, 2007, NEOPLASIA, V9, P900, DOI 10.1593/neo.07541; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Hyodo F, 2012, INT J ONCOL, V41, P2103, DOI 10.3892/ijo.2012.1638; Jolly LA, 2016, CANCER RES, V76, P1804, DOI 10.1158/0008-5472.CAN-15-2351; Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11; Krall AS, 2015, NAT CELL BIOL, V17, P1515, DOI 10.1038/ncb3278; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; Ling SP, 2016, P NATL ACAD SCI USA, V113, pE663, DOI 10.1073/pnas.1600151113; Macaulay IC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004126; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x; Martinez-outschoorn UE, 2012, NIH PUBLIC ACCESS, V43, P1045; Martinive P, 2009, FEBS J, V276, P509, DOI 10.1111/j.1742-4658.2008.06798.x; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nakajima EC, 2013, MOL CARCINOGEN, V52, P329, DOI 10.1002/mc.21863; Natrajan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001961; Neveu MA, 2015, RADIOTHER ONCOL, V116, P400, DOI 10.1016/j.radonc.2015.04.023; Ostergaard L, 2013, CANCER RES, V73, P5618, DOI 10.1158/0008-5472.CAN-13-0964; Payen VL, 2015, CANCER J, V21, P75, DOI 10.1097/PPO.0000000000000098; Perez-Escuredo J, 2016, BBA-MOL CELL RES, V1863, P2481, DOI 10.1016/j.bbamcr.2016.03.013; Perez-Escuredo J, 2016, CELL CYCLE, V15, P72, DOI 10.1080/15384101.2015.1120930; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P172, DOI 10.4161/cc.23058; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Snijder B, 2011, NAT REV MOL CELL BIO, V12, P119, DOI 10.1038/nrm3044; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Tarabichi M, 2013, CANCER METAST REV, V32, P403, DOI 10.1007/s10555-013-9431-y; Tarabichi M, 2016, J PATHOL UNPUB; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Turtoi A, 2014, HEPATOLOGY, V59, P924, DOI 10.1002/hep.26608; van Staveren WCG, 2009, BBA-REV CANCER, V1795, P92, DOI 10.1016/j.bbcan.2008.12.004; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2000, CANCER RES, V60, P916; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang XY, 2016, CANCER RES, V76, P1305, DOI 10.1158/0008-5472.CAN-15-1907	78	62	63	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2637	2642		10.1038/onc.2016.411	http://dx.doi.org/10.1038/onc.2016.411			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27797377	Green Published, hybrid			2022-12-28	WOS:000401120900002
J	Liao, PH; Hsu, HH; Chen, TS; Chen, MC; Day, CH; Tu, CC; Lin, YM; Tsai, FJ; Kuo, WW; Huang, CY				Liao, P-H; Hsu, H-H; Chen, T-S; Chen, M-C; Day, C-H; Tu, C-C; Lin, Y-M; Tsai, F-J; Kuo, W-W; Huang, C-Y			Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; SIGNALING PATHWAY; PROSTATE-CANCER; MAMMARY-TUMORS; OVARIAN-CANCER; IN-VITRO; APICIDIN; TRANSLOCATION; ACTIVATION; EXPRESSION	Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Despite the availability of several treatment strategies, resistance to chemotherapeutic agents, which limits the effectiveness of anticancer drugs, is a major problem in cancer therapy. In this study, we used a histone deacetylases inhibitor (HDACi) to establish drug-resistant HCC cells and further analyzed the molecular mechanisms underlying the development of resistance in HCC cells. Compared with the parental cells, HDACi-resistant cells showed high metastatic and pro-survival abilities. Two-dimensional electrophoresis data showed that the cofilin-1 (CFL-1) protein was altered in HDACi-resistant cells and was highly expressed in resistant cells compared with parental cells. The molecular function of CFL-1 is actin depolymerization, and it is involved in tumor metastasis. In this study, we showed that CFL-1 inhibition decreased cell migration and increased cell apoptosis in HDACi-resistant cells. We observed that HDACi induced ROS accumulation in cells and apoptosis via promotion of the CFL-1 interaction with Bax and CFL-1 translocation to the mitochondria, resulting in cytochrome C release. Importantly, phosphorylation of CFL-1 by activated extracellular signal-regulated kinases 1 and 2 (ERK1/2) confers strong protection against HDAC inhibitor-induced cell injury. p-CFL-1 shows a loss of affinity with Bax and will not translocate to mitochondria, stably remaining in the cytoplasm. These results indicate that phosphorylation to inactivate CFL-1 decreased the chemosensitivity to HDAC inhibitors and resulting in drug resistance of HCC cells.	[Liao, P-H; Huang, C-Y] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Hsu, H-H] Mackay Mem Hosp, Div Colorectal Surg, Taipei, Taiwan; [Hsu, H-H] Nursing & Management Coll, Dept Mackay Med, Taipei, Taiwan; [Chen, T-S] China Med Univ Hosp, Biomat Translat Res Ctr, Taichung, Taiwan; [Chen, M-C] Taichung Vet Gen Hosp, Div Colorectal Surg, Taichung, Taiwan; [Day, C-H] Mei Ho Univ, Dept Nursing, Pingtung, Taiwan; [Tu, C-C] Armed Force Taichung Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan; [Lin, Y-M] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan; [Tsai, F-J; Huang, C-Y] China Med Univ, Grad Inst Chinese Med Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan; [Kuo, W-W] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Huang, C-Y] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan	China Medical University Taiwan; Mackay Memorial Hospital; Mackay Junior College of Medicine, Nursing & Management; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taichung Veterans General Hospital; Changhua Christian Hospital; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Huang, CY (corresponding author), China Med Univ, Grad Inst Chinese Med Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan.	cyhuang@mail.cmu.edu.tw	Chen, Tung-Sheng/U-4788-2019; Chen, Tung-Sheng/GPK-0411-2022	Chen, Tung-Sheng/0000-0002-4400-3428	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW105-TDU-B-212-133019]	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019).	Baylin SB, 2011, NAT MED, V17, P288, DOI 10.1038/nm0311-288; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Hsieh CH, 2013, BIOSCI BIOTECH BIOCH, V77, P2397, DOI 10.1271/bbb.130503; Hsieh YC, 2010, CHEM RES TOXICOL, V23, P1256, DOI 10.1021/tx100116a; Hsu HH, 2014, TUMOR BIOL, V35, P303, DOI 10.1007/s13277-013-1041-3; Huang X, 2013, J BIOL CHEM, V288, P36418, DOI 10.1074/jbc.M113.495713; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Klamt F, 2009, NAT CELL BIOL, V11, P1241, DOI 10.1038/ncb1968; Kotiadis VN, 2012, J CELL SCI, V125, P2288, DOI 10.1242/jcs.099390; Lai JP, 2009, J HEPATOL, V50, P1112, DOI 10.1016/j.jhep.2008.12.031; Li GB, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-50; Li M, 2013, ONCOL REP, V29, P58, DOI 10.3892/or.2012.2078; Lu L, 2015, ONCOL LETT, V9, P2757, DOI 10.3892/ol.2015.3133; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Posadas I, 2012, J NEUROCHEM, V120, P515, DOI 10.1111/j.1471-4159.2011.07599.x; Serezani CH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002448; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659; Stresing V, 2013, ONCOGENE, V32, P724, DOI 10.1038/onc.2012.93; Tahtamouni LH, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-45; Tang WW, 2011, DEV CELL, V21, P1038, DOI 10.1016/j.devcel.2011.10.023; Tu CC, 2013, CHINESE J PHYSIOL, V56, P326, DOI 10.4077/CJP.2013.BAB158; Wabnitz GH, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.36; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Wang ZQ, 2010, J CELL PHYSIOL, V224, P559, DOI 10.1002/jcp.22160; Weiller M, 2011, EXP TOXICOL PATHOL, V63, P511, DOI 10.1016/j.etp.2010.04.001; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zhang HH, 2015, MOL ENDOCRINOL, V29, P434, DOI 10.1210/me.2014-1297; Zhou JW, 2012, ONCOL LETT, V4, P1187, DOI 10.3892/ol.2012.897; Zhou Y, 2013, ONCOL REP, V29, P394, DOI 10.3892/or.2012.2115	34	30	31	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1978	1990		10.1038/onc.2016.357	http://dx.doi.org/10.1038/onc.2016.357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27748761				2022-12-28	WOS:000398898500008
J	Castagnoli, L; Ghedini, GC; Koschorke, A; Triulzi, T; Dugo, M; Gasparini, P; Casalini, P; Palladini, A; Iezzi, M; Lamolinara, A; Lollini, P; Nanni, P; Chiodoni, C; Tagliabue, E; Pupa, SM				Castagnoli, L.; Ghedini, G. C.; Koschorke, A.; Triulzi, T.; Dugo, M.; Gasparini, P.; Casalini, P.; Palladini, A.; Iezzi, M.; Lamolinara, A.; Lollini, Pl; Nanni, P.; Chiodoni, C.; Tagliabue, E.; Pupa, S. M.			Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-TUMORS; HER2; CELLS; NOTCH; CARCINOMA; MECHANISMS; PATHWAYS; GROWTH; MICE	We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2_1 and WTHER2_2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29(High)/CD24(+)/SCA1(Low) cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2_1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2-vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7_d16 and T47D_d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.	[Castagnoli, L.; Ghedini, G. C.; Koschorke, A.; Triulzi, T.; Tagliabue, E.; Pupa, S. M.] Fondazione IRCCS Inst Naz Tumori, Mol Targeting Unit, Dept Expt Oncol & Mol Med, Milan, Italy; [Dugo, M.] Fondazione IRCCS Inst Naz Tumori, Funct Genom & Bioinformat Core Facility, Dep Expt Oncol & Mol Med, Milan, Italy; [Gasparini, P.] Fondazione IRCCS Inst Naz Tumori, Tumor Genom, Dep Expt Oncol & Mol Med, Milan, Italy; [Palladini, A.; Lollini, Pl; Nanni, P.] Univ Bologna, Diagnostic & Specialty Med, Dept Expt, Lab Immunol & Biol Metastases, Bologna, Italy; [Iezzi, M.; Lamolinara, A.] Univ G dAnnunzio, Dept Med & Aging Sci, CESI Aging Res Ctr, Chieti, Italy; [Chiodoni, C.] Fondazione IRCSS Inst Natl, Dept Expt Oncol & mol med, Mol Immunol, Milan, Italy	University of Bologna; G d'Annunzio University of Chieti-Pescara	Pupa, SM (corresponding author), Fondazione IRCCS Inst Naz Tumori, Mol Targeting Unit, Dept Expt Oncol & Mol Med, Milan, Italy.	serenella.pupa@istitutotumori.mi.it	Iezzi, Manuela/AAB-7939-2019; Gasparini, Patrizia/Q-7626-2016; Tagliabue, Elda/B-9377-2017; Triulzi, Tiziana/C-1070-2017; Pupa, Serenella/K-6388-2016; Castagnoli, Lorenzo/J-1893-2014; lamolinara, alessia/AAB-8833-2019; Lollini, Pier Luigi/A-7644-2008; Chiodoni, Claudia/C-2172-2017; Koschorke, Ada/C-5576-2017; Dugo, Matteo/H-6860-2014	Iezzi, Manuela/0000-0002-6296-6498; Gasparini, Patrizia/0000-0002-9548-3724; Tagliabue, Elda/0000-0001-9877-2903; Triulzi, Tiziana/0000-0003-3050-8676; Pupa, Serenella/0000-0002-4592-6830; Castagnoli, Lorenzo/0000-0002-0220-6497; lamolinara, alessia/0000-0002-7421-4509; Lollini, Pier Luigi/0000-0003-1702-4108; Chiodoni, Claudia/0000-0002-7644-9969; Koschorke, Ada/0000-0002-4828-7405; Dugo, Matteo/0000-0001-9786-2763	Associazione Italiana Ricerca Cancro (AIRC) [10352, 16918, AIRC 15324]; Ministero Italiano della Salute [RF-2009-1532281];  [15002]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero Italiano della Salute(Ministry of Health, Italy); 	We thank Mrs Ghirelli and Mrs Ratti for technical assistance, the Functional Genomics Core Facility and the Flow Cytometry and Cell Sorting Facility of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan for their support in gene expression profile analyses and in the multiparametric cytofluorimetric analyses, and Mrs Mameli for secretarial assistance. This work was funded by grants from the Associazione Italiana Ricerca Cancro (AIRC) 10352 and 16918 to SM Pupa and AIRC 15324 to PL Lollini; Fellowship 15002 to L Castagnoli; and Ministero Italiano della Salute RF-2009-1532281 to SM Pupa.	Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Baker AT, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00360; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Campiglio M, 2013, BREAST CANCER RES TR, V141, P101, DOI 10.1007/s10549-013-2658-z; Castagnoli L, 2014, CANCER RES, V74, P6248, DOI 10.1158/0008-5472.CAN-14-0983; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; De Giovanni C, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3602; Farahani E, 2014, CARCINOGENESIS, V35, P747, DOI 10.1093/carcin/bgu045; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Farnie G, 2014, CELL CYCLE, V13, P418, DOI 10.4161/cc.27201; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Jackson Claire, 2013, Int J Cell Biol, V2013, P973584, DOI 10.1155/2013/973584; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Latorre IJ, 2000, MADAME CURIE BIOSCIE; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Marchini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018727; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Monteiro J, 2014, CARCINOGENESIS, V35, P2, DOI 10.1093/carcin/bgt279; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Prat A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju152; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Triulzi T, 2015, ONCOTARGET, V6, P28173, DOI 10.18632/oncotarget.4405; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Weigelt B, 2013, CANCER DISCOV, V3, P145, DOI 10.1158/2159-8290.CD-12-0585; Zagozdzon R, 2011, DRUG DISCOV TODAY, V16, P810, DOI 10.1016/j.drudis.2011.06.003; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809	45	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1721	1732		10.1038/onc.2016.338	http://dx.doi.org/10.1038/onc.2016.338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27641338	Green Published, hybrid			2022-12-28	WOS:000397460600011
J	Haase, G; Gavert, N; Brabletz, T; Ben-Ze'ev, A				Haase, G.; Gavert, N.; Brabletz, T.; Ben-Ze'ev, A.			A point mutation in the extracellular domain of L1 blocks its capacity to confer metastasis in colon cancer cells via CD10	ONCOGENE			English	Article							ADHESION MOLECULE L1; NEUTRAL ENDOPEPTIDASE; LIVER METASTASIS; EXPRESSION; BINDING; GENE; OUTGROWTH; TARGET; CAM; ENKEPHALINASE	The neural L1 transmembrane cell adhesion receptor of the immunoglobulin-like family is a target gene of Wnt-beta-catenin signaling in human colorectal cancer (CRC) cells and is expressed at the invasive edge of the tumor tissue. L1 overexpression in cultured CRC cells confers enhanced proliferation, motility and liver metastasis. We have analyzed the mechanisms of L1-mediated signaling in CRC cells by using various point mutations in the L1 ectodomain that are known to cause severe genetically inherited mental retardation disorders in patients. We found that all such L1 ectodomain mutations abolish the ability of L1 to confer metastatic properties in CRC cells. Using gene array analysis, we identified L1-mutation-specific gene expression signatures for the L1/H210Q and L1/D598N mutations. We identified CD10, a metalloprotease (neprilysin, neutral endopeptidase) and a gene that is specifically induced in CRC cells by L1 in an L1/H210Q mutation-specific manner. CD10 expression was required for the L1-mediated induction of cell proliferation, motility and metastasis, as suppression of CD10 levels in L1-expressing CRC cells abolished the L1 effects on CRC progression. The signaling from L1 to CD10 was mediated through the L1-ezrin-NF-.B pathway. In human CRC tissue L1 and CD10 were localized in partially overlapping regions in the more invasive areas of the tumor tissue. The results suggest that CD10 is a necessary component conferring the L1 effects in CRC cells. The identification of gene expression patterns of L1-domain-specific point mutations may provide novel markers and targets for interfering with L1-mediated CRC progression.	[Haase, G.; Brabletz, T.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Erlangen Nuernberg, Dept Expt Med, Erlangen, Germany	Weizmann Institute of Science; University of Erlangen Nuremberg	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		Gavert, Nancy/0000-0003-1639-4684; ben-ze'ev, avri/0000-0001-6113-3921	Israel Science Foundation (ISF); Israel Cancer Research Fund (ICRF)	Israel Science Foundation (ISF)(Israel Science Foundation); Israel Cancer Research Fund (ICRF)	We thank Drs N Iwata, M Shtutman, F Rathjen and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from the Israel Cancer Research Fund (ICRF). A B-Z is the incumbent of the Lunenfeld-Kunin professorial chair in genetics and cell biology.	Beer S, 1999, J CELL SCI, V112, P2667; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; De Angelis E, 2002, HUM MOL GENET, V11, P1, DOI 10.1093/hmg/11.1.1; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2013, CANCER RES, V73, P5754, DOI 10.1158/0008-5472.CAN-13-0576; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Koga Y, 2008, HISTOPATHOLOGY, V52, P569, DOI 10.1111/j.1365-2559.2008.02996.x; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; Ogawa H, 2002, HUM PATHOL, V33, P806, DOI 10.1053/hupa.2002.125773; Ohji Y, 2007, ONCOL REP, V17, P525; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; Schmid RS, 2008, CURR OPIN NEUROBIOL, V18, P245, DOI 10.1016/j.conb.2008.07.015; Shapiro B, 2015, ONCOTARGET, V6, P34389, DOI 10.18632/oncotarget.5360; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; Yao T, 2002, PATHOLOGY, V34, P556, DOI 10.1080/0031302021000035965-4	33	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1597	1606		10.1038/onc.2016.329	http://dx.doi.org/10.1038/onc.2016.329			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27641335				2022-12-28	WOS:000397458100013
J	Kondo, S; Wakae, K; Wakisaka, N; Nakanishi, Y; Ishikawa, K; Komori, T; Moriyama-Kita, M; Endo, K; Murono, S; Wang, Z; Kitamura, K; Nishiyama, T; Yamaguchi, K; Shigenobu, S; Muramatsu, M; Yoshizaki, T				Kondo, S.; Wakae, K.; Wakisaka, N.; Nakanishi, Y.; Ishikawa, K.; Komori, T.; Moriyama-Kita, M.; Endo, K.; Murono, S.; Wang, Z.; Kitamura, K.; Nishiyama, T.; Yamaguchi, K.; Shigenobu, S.; Muramatsu, M.; Yoshizaki, T.			APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers	ONCOGENE			English	Article							SIMPLEX-VIRUS 1; MUTATIONAL PROCESSES; CYTIDINE DEAMINASES; DNA; HYPERMUTATION; EXPRESSION; PATTERNS; TYPE-16; HEAD; RESTRICTION	The prevalence of human papillomavirus (HPV)-related oropharyngeal cancers has been increasing in developed countries. We recently demonstrated that members of the apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3, A3) family, which are antiviral factors, can induce hypermutation of HPV DNA in vitro. In the present study, we found numerous C-to-T and G-to-A hypermutations in the HPV16 genome in oropharyngeal cancer (OPC) biopsy samples using differential DNA denaturation PCR and next-generation sequencing. A3s were more abundantly expressed in HPV16-positive OPCs than in HPV-negative, as assessed using immunohistochemistry and reverse transcription quantitative PCR. In addition, interferons upregulated A3s in an HPV16-positive OPC cell line. Furthermore, quantitative PCR analysis of HPV DNA suggests that APOBEC3A (A3A) expression is strongly correlated with the integration of HPV DNA. These results suggest that HPV16 infection may upregulate A3A expression, thereby increasing the chance of viral DNA integration. The role of A3A in HPV-induced carcinogenesis is discussed.	[Kondo, S.; Wakisaka, N.; Nakanishi, Y.; Ishikawa, K.; Komori, T.; Moriyama-Kita, M.; Endo, K.; Murono, S.; Yoshizaki, T.] Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan; [Wakae, K.; Wang, Z.; Kitamura, K.; Muramatsu, M.] Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa, Japan; [Wang, Z.] Dalian Univ, Affiliated Zhongshan Hosp, Div Med Oncol, Dalian, Peoples R China; [Nishiyama, T.] Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa, Japan; [Yamaguchi, K.; Shigenobu, S.] Natl Inst Basic Biol, Funct Genom Facil, Okazaki, Aichi, Japan	Kanazawa University; Kanazawa University; Dalian University; Kanazawa University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kondo, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	tomoy@med.kanazawa-u.ac.jp	Kitamura, Kouichi/L-3654-2015; Shigenobu, Shuji/B-6239-2011	Kitamura, Kouichi/0000-0001-9692-8724; Shigenobu, Shuji/0000-0003-4640-2323; Yamaguchi, Katsushi/0000-0001-6871-7882	Ministry of Education, Science, Sports, Culture and Technology of Japan [A24689064, B23390396]; Grants-in-Aid for Scientific Research [26460993] Funding Source: KAKEN	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr H Joenje for providing the VU147T cell line. We thank Dr P Howley for providing p1203 PML2d HPV16 and p1321-HPV16 E6/E7. The authors would like to thank Ms A Akita and Ms M Koura for technical assistance. This study was supported by research grants from the Ministry of Education, Science, Sports, Culture and Technology of Japan (A24689064 for SK and B23390396 for TY).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2007, HUMAN PAPILLOMAVIRUS; Argyris EG, 2007, VIROLOGY, V367, P440, DOI 10.1016/j.virol.2007.06.010; Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Bulliard Y, 2011, J VIROL, V85, P1765, DOI 10.1128/JVI.01651-10; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Edge SB, 2009, CANC STAGING MANUAL; Gee P, 2011, J VIROL, V85, P9726, DOI 10.1128/JVI.05288-11; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Kim SH, 2007, INT J CANCER, V120, P1418, DOI 10.1002/ijc.22464; Kitamura K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003361; Kondo S, 2011, J VIROL, V85, P11255, DOI 10.1128/JVI.00188-11; Koning FA, 2009, J VIROL, V83, P9474, DOI 10.1128/JVI.01089-09; Krokan HE, 2014, DNA REPAIR, V19, P38, DOI 10.1016/j.dnarep.2014.03.028; Landry S, 2011, EMBO REP, V12, P444, DOI 10.1038/embor.2011.46; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Liang GX, 2013, P NATL ACAD SCI USA, V110, P2246, DOI 10.1073/pnas.1221921110; Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Mussil B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073641; Nagao S, 2002, J CLIN MICROBIOL, V40, P863, DOI 10.1128/JCM.40.3.863-867.2002; Nakanishi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062066; Nguyen DH, 2008, J VIROL, V82, P6852, DOI 10.1128/JVI.00465-08; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Noguchi C, 2007, J GEN VIROL, V88, P432, DOI 10.1099/vir.0.82319-0; Ohba K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097787; Okeoma CM, 2007, NATURE, V445, P927, DOI 10.1038/nature05540; Park IS, 2011, CANCER PREV RES, V4, P207, DOI 10.1158/1940-6207.CAPR-10-0147; Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192; Roberts I, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-57; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0; Suspene R, 2011, J VIROL, V85, P7594, DOI 10.1128/JVI.00290-11; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201; Wang Z, 2014, J VIROL, V88, P1308, DOI 10.1128/JVI.03091-13; Warren CJ, 2015, J VIROL, V89, P688, DOI 10.1128/JVI.02383-14; Wilczynski SP, 1998, AM J PATHOL, V152, P145; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	53	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1687	1697		10.1038/onc.2016.335	http://dx.doi.org/10.1038/onc.2016.335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27694899				2022-12-28	WOS:000397460600008
J	Tabaries, S; Siegel, PM				Tabaries, S.; Siegel, P. M.			The role of claudins in cancer metastasis	ONCOGENE			English	Review							CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; BLOOD-BRAIN-BARRIER; JUNCTION PROTEINS CLAUDIN-3; TIGHT-JUNCTION; BREAST-CANCER; COLORECTAL-CANCER; OVARIAN-CANCER; GENE-EXPRESSION; DECREASED EXPRESSION; REDUCED EXPRESSION	TJs are large intercellular adhesion complexes that maintain cell polarity in normal epithelia and endothelia. During the metastatic process, TJs must be 'loosened' or dismantled in cancer cells to enable migration and dissemination. Diminished TJ integrity must also occur within endothelial cells to allow intravasation and extravasation of cancer cells across endothelial barriers. Claudins are critical components of TJs, forming homo-and heteromeric interactions between the adjacent cells, which have been implicated as key modulators of carcinogenesis and metastasis. Numerous epithelial- derived cancers display altered claudin expression patterns and certain claudins can now be used as biomarkers to predict patient prognosis. Moreover, claudins have been functionally implicated in numerous steps of the metastatic cascade. The distinct roles played by claudins during the cancer progression to metastatic disease are just starting to be elucidated. A more complete understanding of the mechanisms through which claudins augment cancer metastasis is required to develop new therapeutic agents against this family of proteins. In this review, we will summarize the relationship between the claudin expression and clinical outcomes in diverse cancers, discuss tumor intrinisic roles through which claudins regulate metastasis and explore claudin-mediated functions within stromal cells that influence the metastatic process. Finally, we will consider possible strategies for targeting claudins that have the potential to improve the management of metastatic cancer.	[Tabaries, S.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada; [Tabaries, S.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca			CIHR [MOP-136907]	CIHR(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for their thoughtful comments on the manuscript. Research conducted in the author's laboratory was supported by grants from the CIHR (MOP-136907 to PMS). PMS is a William Dawson Scholar of McGill University.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Angelow S, 2008, AM J PHYSIOL-RENAL, V295, pF867, DOI 10.1152/ajprenal.90264.2008; AUGERON C, 1984, CANCER RES, V44, P3961; Avraham HK, 2014, J PATHOL, V232, P369, DOI 10.1002/path.4304; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385; Bhat AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037174; Black JD, 2015, TOXINS, V7, P1116, DOI 10.3390/toxins7041116; Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6; Bornholdt J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-65; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Casagrande F, 2011, CANCER-AM CANCER SOC, V117, P5519, DOI 10.1002/cncr.26215; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Che JJ, 2015, TUMOR BIOL, V36, P6559, DOI 10.1007/s13277-015-3350-1; Choi YL, 2007, HISTOL HISTOPATHOL, V22, P1185, DOI 10.14670/HH-22.1185; Cocco E, 2015, INT J CANCER, V137, P2618, DOI 10.1002/ijc.29632; Cocco E, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-349; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Dahiya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022119; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gao ZJ, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/981626; Gao ZJ, 2011, CLIN CANCER RES, V17, P1065, DOI 10.1158/1078-0432.CCR-10-1644; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gril B, 2010, EUR J CANCER, V46, P1204, DOI 10.1016/j.ejca.2010.02.033; Gunzel D, 2009, J CELL SCI, V122, P1507, DOI 10.1242/jcs.040113; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Hough CD, 2000, CANCER RES, V60, P6281; Huang J, 2015, ONCOTARGET, V6, P1652, DOI 10.18632/oncotarget.2936; Huang J, 2014, INT J ONCOL, V44, P1293, DOI 10.3892/ijo.2014.2298; Huang YH, 2009, P NATL ACAD SCI USA, V106, P3426, DOI 10.1073/pnas.0813348106; Huo Q, 2009, ANTICANCER RES, V29, P851; Hwang TL, 2014, ONCOL LETT, V8, P1367, DOI 10.3892/ol.2014.2295; Hwang TL, 2010, EXP THER MED, V1, P789, DOI 10.3892/etm.2010.116; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Jia W, 2014, MOL MED REP, V9, P779, DOI 10.3892/mmr.2013.1875; Jia W, 2013, ANTICANCER RES, V33, P2353; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Kim CJ, 2011, EUR J CANCER, V47, P918, DOI 10.1016/j.ejca.2010.11.007; Kim TH, 2008, HISTOPATHOLOGY, V53, P48, DOI 10.1111/j.1365-2559.2008.03052.x; Kimbung S, 2014, MOL ONCOL, V8, P119, DOI 10.1016/j.molonc.2013.10.002; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kleinberg L, 2008, HUM PATHOL, V39, P747, DOI 10.1016/j.humpath.2007.10.002; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Kominsky SL, 2007, CANCER RES, V67, P7977, DOI 10.1158/0008-5472.CAN-07-1314; Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Krizbai IA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123845; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Kulka J, 2009, PATHOL ONCOL RES, V15, P59, DOI 10.1007/s12253-008-9089-x; Kuwada M, 2015, CANCER LETT, V369, P212, DOI 10.1016/j.canlet.2015.08.019; Ladwein M, 2005, EXP CELL RES, V309, P345, DOI 10.1016/j.yexcr.2005.06.013; Lal-Nag M, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.32; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Landers KA, 2008, BRIT J CANCER, V99, P491, DOI 10.1038/sj.bjc.6604486; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lazo PA, 2007, CANCER SCI, V98, P1666, DOI 10.1111/j.1349-7006.2007.00584.x; Liu JX, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0626-2; Ma F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112765; Martin TA, 2008, J CELL BIOCHEM, V105, P41, DOI 10.1002/jcb.21797; Martin TA, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.26518; MCCLANE BA, 1988, J BIOL CHEM, V263, P2423; Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124; Micke P, 2014, INT J CANCER, V135, P2206, DOI 10.1002/ijc.28857; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; Mina LA, 2011, NAT REV CLIN ONCOL, V8, P325, DOI 10.1038/nrclinonc.2011.59; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154; Morohashi S, 2007, INT J MOL MED, V20, P139; Nakagawa S, 2011, INT J ONCOL, V39, P791, DOI 10.3892/ijo.2011.1102; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Neesse A, 2012, ARCH BIOCHEM BIOPHYS, V524, P64, DOI 10.1016/j.abb.2012.01.009; Neesse A, 2013, GUT, V62, P1034, DOI 10.1136/gutjnl-2012-302577; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Ohtani S, 2009, GASTRIC CANCER, V12, P43, DOI 10.1007/s10120-008-0497-0; Oshima T, 2008, ONCOL REP, V19, P953; Philip R, 2015, ONCOTARGET, V6, P2046, DOI 10.18632/oncotarget.2858; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; Pitule P, 2013, ANTICANCER RES, V33, P4855; Pope JL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-167; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Protze J, 2015, CELL MOL LIFE SCI, V72, P1417, DOI 10.1007/s00018-014-1761-6; Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Ren Y, 2013, MOL MED REP, V8, P1505, DOI 10.3892/mmr.2013.1675; Rodriguez PL, 2014, INT J CANCER, V134, P1034, DOI 10.1002/ijc.28433; Ruffer C, 2004, EUR J CELL BIOL, V83, P135, DOI 10.1078/0171-9335-00366; Saeki R, 2010, J PHARMACOL EXP THER, V334, P576, DOI 10.1124/jpet.110.168070; Santin AD, 2005, CANCER RES, V65, P4334, DOI 10.1158/0008-5472.CAN-04-3472; Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x; Sharma RK, 2016, CLIN EXP METASTAS, V33, P263, DOI 10.1007/s10585-015-9776-4; Sheehan GM, 2007, HUM PATHOL, V38, P564, DOI 10.1016/j.humpath.2006.11.007; Shibutani M, 2013, ANTICANCER RES, V33, P3301; Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001; Singh AB, 2012, CARCINOGENESIS, V33, P2538, DOI 10.1093/carcin/bgs275; Soini Y, 2004, HUM PATHOL, V35, P1531, DOI 10.1016/j.humpath.2004.09.015; Suzuki H, 2012, ANN NY ACAD SCI, V1258, P65, DOI 10.1111/j.1749-6632.2012.06503.x; Szasz AM, 2011, CLIN EXP METASTAS, V28, P55, DOI 10.1007/s10585-010-9357-5; Szasz AM, 2013, INT UROL NEPHROL, V45, P727, DOI 10.1007/s11255-013-0406-2; Szasz AM, 2010, BJU INT, V105, P716, DOI 10.1111/j.1464-410X.2009.08808.x; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Tabaries S, 2012, MOL CELL BIOL, V32, P2979, DOI 10.1128/MCB.00299-12; Takahashi A, 2011, CURR MED CHEM, V18, P1861, DOI 10.2174/092986711795496809; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; Tamura A, 2011, GASTROENTEROLOGY, V140, P913, DOI 10.1053/j.gastro.2010.08.006; Tanaka H, 2015, GUT, V64, P1529, DOI 10.1136/gutjnl-2014-308419; Tatum R, 2010, AM J PHYSIOL-RENAL, V298, pF24, DOI 10.1152/ajprenal.00450.2009; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Van Itallie CM, 2012, J CELL SCI, V125, P4902, DOI 10.1242/jcs.111237; Van Itallie CM, 2012, ANN NY ACAD SCI, V1258, P60, DOI 10.1111/j.1749-6632.2012.06541.x; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; Wada M, 2013, GASTROENTEROLOGY, V144, P369, DOI 10.1053/j.gastro.2012.10.035; Wang HM, 2015, INT J CLIN EXP PATHO, V8, P881; Wang Q, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S85478; Wilhelm I, 2013, INT J MOL SCI, V14, P1383, DOI 10.3390/ijms14011383; Yamamoto T, 2010, ONCOL LETT, V1, P501, DOI 10.3892/ol_00000088; Yao Q, 2010, BIOCHEM BIOPH RES CO, V398, P413, DOI 10.1016/j.bbrc.2010.06.089; Yoda S, 2014, LUNG CANCER, V85, P366, DOI 10.1016/j.lungcan.2014.06.009; Yoshida T, 2011, ANTICANCER RES, V31, P2517; Yu ASL, 2015, J AM SOC NEPHROL, V26, P11, DOI 10.1681/ASN.2014030284; Yu ASL, 2009, J GEN PHYSIOL, V133, P111, DOI 10.1085/jgp.200810154; Yuan XQ, 2009, MOL CANCER THER, V8, P1906, DOI 10.1158/1535-7163.MCT-09-0106; Zhang GJ, 2013, INT J MOL MED, V31, P1375, DOI 10.3892/ijmm.2013.1348; Zhu JL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-150	146	88	94	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1176	1190		10.1038/onc.2016.289	http://dx.doi.org/10.1038/onc.2016.289			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524421				2022-12-28	WOS:000395861300002
J	Zhan, T; Rindtorff, N; Boutros, M				Zhan, T.; Rindtorff, N.; Boutros, M.			Wnt signaling in cancer	ONCOGENE			English	Review							WNT/BETA-CATENIN PATHWAY; EPITHELIAL-MESENCHYMAL TRANSITION; PLANAR CELL POLARITY; LEUKEMIA STEM-CELLS; BETA-CATENIN; COLORECTAL-CANCER; BREAST-CANCER; CHROMOSOMAL INSTABILITY; PROTEIN STABILIZATION; BINDING PROTEIN	Wnt signaling is one of the key cascades regulating development and stemness, and has also been tightly associated with cancer. The role of Wnt signaling in carcinogenesis has most prominently been described for colorectal cancer, but aberrant Wnt signaling is observed in many more cancer entities. Here, we review current insights into novel components of Wnt pathways and describe their impact on cancer development. Furthermore, we highlight expanding functions of Wnt signaling for both solid and liquid tumors. We also describe current findings how Wnt signaling affects maintenance of cancer stem cells, metastasis and immune control. Finally, we provide an overview of current strategies to antagonize Wnt signaling in cancer and challenges that are associated with such approaches.	[Zhan, T.; Rindtorff, N.; Boutros, M.] Heidelberg Univ, Fac Med Mannheim, Div Signaling & Funct Genom, Dept Cell & Mol Biol,German Canc Res Ctr DKFZ, Heidelberg, Germany; [Zhan, T.] Heidelberg Univ, Med Fac Mannheim, Dept Internal Med 2, Mannheim, Germany; [Boutros, M.] German Canc Consortium DKTK, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Boutros, M (corresponding author), German Canc Res Ctr, Div Signaling & Funct Genom, Neuenheimer Feld 580, Heidelberg, Germany.	m.boutros@dkfz.de	Boutros, Michael/C-3566-2008	Boutros, Michael/0000-0002-9458-817X; Rindtorff, Niklas/0000-0003-3602-4170; Zhan, Tianzuo/0000-0002-9346-3180	DKFZ Postdoctoral Fellowship	DKFZ Postdoctoral Fellowship	We thank Iris Augustin, Fillip Port, Katharina Kober and Lucie Wolf for carefully reading the manuscript and contributing valuable ideas. T.Z. was supported by a DKFZ Postdoctoral Fellowship. We apologize to all colleagues whose work was not cited due to space constrains.	Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014; Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Andersson T., 2015, MOL CANCER THER, V14, pA116, DOI DOI 10.1158/1535-7163.TARG-15-A116; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452; Boutros M, 2016, DEV CELL, V36, P485, DOI 10.1016/j.devcel.2016.02.018; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Buechling T, 2011, EMBO REP, V12, P1265, DOI 10.1038/embor.2011.212; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Chan-on W, 2013, NAT GENET, V45, P1474, DOI 10.1038/ng.2806; Cheng CK, 2008, BLOOD, V112, P3391, DOI 10.1182/blood-2008-02-137083; Chevallier C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114717; Chien AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094748; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Coudreuse DYM, 2006, SCIENCE, V312, P921, DOI 10.1126/science.1124856; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Dahmen RP, 2001, CANCER RES, V61, P7039; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Davidson G, 2009, DEV CELL, V17, P788, DOI 10.1016/j.devcel.2009.11.006; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dodge ME, 2012, J BIOL CHEM, V287, P23246, DOI 10.1074/jbc.M112.372029; Dougherty DM, 2014, ONCOGENE, V96, P111; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Endo M, 2015, INT REV CEL MOL BIO, V314, P117, DOI 10.1016/bs.ircmb.2014.10.003; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640; Farin HF, 2016, NATURE, V530, P340, DOI 10.1038/nature16937; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gasnereau I, 2011, J BIOL CHEM, V286, P43324, DOI 10.1074/jbc.M111.307231; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Giambra V, 2015, BLOOD, V125, P3917, DOI 10.1182/blood-2014-10-609370; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Giraudet AL, 2014, J NUCL MED, V55; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Goeppert B, 2014, HEPATOLOGY, V59, P544, DOI 10.1002/hep.26721; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Heallen T, 2012, SCIENCE, V332, P458; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Huang YL, 2015, P NATL ACAD SCI USA, V112, P5732, DOI 10.1073/pnas.1423533112; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Isobe T, 2014, ELIFE, V3, DOI 10.7554/eLife.01977; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Katoh M, 2005, ONCOL REP, V14, P1583; Kaveri D, 2013, BLOOD, V122, P694, DOI 10.1182/blood-2012-12-471904; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kessenbrock K, 2013, CELL STEM CELL, V13, P300, DOI 10.1016/j.stem.2013.06.005; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Kim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019310; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899; Klauzinska M, 2012, J CELL PHYSIOL, V227, P1960, DOI 10.1002/jcp.22924; Koch S, 2015, CELL, V163, P1225, DOI 10.1016/j.cell.2015.10.029; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lane SW, 2011, BLOOD, V118, P2849, DOI 10.1182/blood-2011-03-345165; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lento W, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008011; Li J, 2013, CELL REP, V5, P1650, DOI 10.1016/j.celrep.2013.11.037; Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Lim XH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008029; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Linnskog R, 2014, MOL ONCOL, V8, P1365, DOI 10.1016/j.molonc.2014.05.008; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; Loilome W, 2014, TUMOR BIOL, V35, P5357, DOI 10.1007/s13277-014-1698-2; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Maheswaran S, 2010, CURR OPIN GENET DEV, V20, P96, DOI 10.1016/j.gde.2009.12.002; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Metcalfe C, 2010, J CELL SCI, V123, P1588, DOI 10.1242/jcs.067546; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Moskalev EA, 2012, BMC CANCER, V12, P1; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Mulligan KA, 2012, P NATL ACAD SCI USA, V109, P370, DOI 10.1073/pnas.1119197109; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Nagayama S, 2009, CANCER SCI, V100, P405, DOI 10.1111/j.1349-7006.2008.01052.x; Neumann S, 2009, TRAFFIC, V10, P334, DOI 10.1111/j.1600-0854.2008.00872.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nomachi A, 2008, J BIOL CHEM, V283, P27973, DOI 10.1074/jbc.M802325200; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Pawlikowski JS, 2013, P NATL ACAD SCI USA, V110, P16009, DOI 10.1073/pnas.1303491110; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Port F, 2011, EMBO REP, V12, P1144, DOI 10.1038/embor.2011.165; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Robert R, 2015, J CLIN ONCOL, V33; Rosenbluh J, 2013, CELL, V151, P1457; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sharma R., 1973, DROS INF SERVICE, V50, P134; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Smith DC, 2013, J CLIN ONCOL, V31; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Stolz A, 2015, EMBO REP, V16, P490, DOI 10.15252/embr.201439410; STOLZ W, 1989, CANCER-AM CANCER SOC, V63, P550, DOI 10.1002/1097-0142(19890201)63:3<550::AID-CNCR2820630325>3.0.CO;2-A; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Wang LL, 2014, BLOOD, V124, P1089, DOI 10.1182/blood-2014-01-552067; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YH, 2014, NAT CELL BIOL, V16, P1092, DOI 10.1038/ncb3050; Wang YQ, 2009, MOL CANCER THER, V8, P2103, DOI 10.1158/1535-7163.MCT-09-0282; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330; Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111; Yaguchi T, 2012, J IMMUNOL, V189, P2110, DOI 10.4049/jimmunol.1102282; Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145; Yang YZ, 2015, ANNU REV CELL DEV BI, V31, P623, DOI 10.1146/annurev-cellbio-100814-125315; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Yeung P, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1907; Yu J, 2014, DEV CELL, V29, P277, DOI 10.1016/j.devcel.2014.03.016; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607; Zhang C., 2015, MOL CANCER THER, V14, pA30; Zhang YQ, 2013, CANCER RES, V73, P4909, DOI 10.1158/0008-5472.CAN-12-4384	204	1334	1400	15	265	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1461	1473		10.1038/onc.2016.304	http://dx.doi.org/10.1038/onc.2016.304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617575	Green Published, hybrid			2022-12-28	WOS:000397458100001
J	Yang, G; Gong, Y; Wang, Q; Wang, L; Zhang, X				Yang, G.; Gong, Y.; Wang, Q.; Wang, L.; Zhang, X.			miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation	ONCOGENE			English	Article							MICRORNA EXPRESSION; TUMOR SUPPRESSION; PROTEIN LIGASE; PROTEASOME; BREAST; SIGNATURE; FAMILY; GENES; MDM2	During tumourigenesis, p53 functions as 'the guardian of the genome' because p53-dependent apoptosis strongly regulates the fate of cancer cells. Therefore, p53 regulation must be sensitive and accurate. p53 activity is regulated through its ubiquitination and deubiquitination. However, the role of microRNA in ubiquitin-mediated p53 degradation has not been previously studied. Our previous studies indicated that miR-100 is required for apoptosis. In the current study, the mechanism of p53 protein ubiquitination mediated by miR-100 was characterized. An analysis of primary tumour samples from gastric cancer patients showed a significant correlation between miR-100 upregulation and primary human gastric tumourigenesis and progression. The in vivo and in vitro data indicated that miR-100 antagonism specifically induced the apoptosis of poorly differentiated gastric cancer cells but not non-cancerous gastric cells, indicating that miR-100 has a crucial role in regulating the progression of gastric tumours. In the regulation of p53-dependent apoptosis, miR-100 antagonism inhibited ubiquitin-mediated p53 protein degradation by activating RNF144B, an E3 ubiquitination ligase. Consequently, the miR-100-RNF144B-pirh2-p53-dependent pathway was initiated. Our findings highlight a novel mechanism of ubiquitin-mediated p53 protein degradation in apoptosis.	[Yang, G.; Gong, Y.; Zhang, X.] Zhejiang Univ, Collaborat Innovat Ctr Deep Sea Biol, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China; [Yang, G.; Gong, Y.; Zhang, X.] Zhejiang Univ, Coll Life Sci, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China; [Wang, Q.; Wang, L.] Bengbu Med Coll, Affiliated Hosp 1, Dept Gastroenterol, Bengbu, Peoples R China	Zhejiang University; Zhejiang University; Bengbu Medical College	Zhang, X (corresponding author), Zhejiang Univ, Collaborat Innovat Ctr Deep Sea Biol, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China.; Zhang, X (corresponding author), Zhejiang Univ, Coll Life Sci, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China.	zxb0812@zju.edu.cn		Zhang, Xiaobo/0000-0003-4606-212X	National Natural Science Foundation of China [41276152, 31430089]; National Program on the Key Basic Research Project [2015CB755903]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Program on the Key Basic Research Project	This work was supported by the National Natural Science Foundation of China (41276152, 31430089) and the National Program on the Key Basic Research Project (2015CB755903).	Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Allende-Vega N, 2010, SEMIN CANCER BIOL, V20, P29, DOI 10.1016/j.semcancer.2009.10.004; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Conforti F, 2013, ONCOGENE, V32, P4758, DOI 10.1038/onc.2012.497; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Gong Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11650; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu W, 2009, CHINESE MED J-PEKING, V122, P2405, DOI 10.3760/cma.j.issn.0366-6999.2009.20.002; Liu ZQ, 2007, DEV DYNAM, V236, P2889, DOI 10.1002/dvdy.21302; Medina-Ramirez CM, 2011, CANCER RES, V71, P7705, DOI 10.1158/0008-5472.CAN-11-2192; Mercer J, 2007, MUTAT RES-FUND MOL M, V621, P75, DOI 10.1016/j.mrfmmm.2007.02.011; Motegi A, 2009, CANCER LETT, V283, P1, DOI 10.1016/j.canlet.2008.12.030; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tsvetkov P, 2011, J BIOL CHEM, V286, P8839, DOI 10.1074/jbc.M110.193276; Wang XJ, 2011, CELL CYCLE, V10, P4225, DOI 10.4161/cc.10.24.18662; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Yang G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039015; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	44	26	27	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1023	1037		10.1038/onc.2016.270	http://dx.doi.org/10.1038/onc.2016.270			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524417				2022-12-28	WOS:000395371500001
J	Cabrera, E; Hernandez-Perez, S; Koundrioukoff, S; Debatisse, M; Kim, D; Smolka, MB; Freire, R; Gillespie, DA				Cabrera, E.; Hernandez-Perez, S.; Koundrioukoff, S.; Debatisse, M.; Kim, D.; Smolka, M. B.; Freire, R.; Gillespie, D. A.			PERK inhibits DNA replication during the Unfolded Protein Response via Claspin and Chk1	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; TRANSLATION; ACTIVATION; DYNAMICS; IMPACT; LUMEN; CELLS; RATES	Stresses such as hypoxia, nutrient deprivation and acidification disturb protein folding in the endoplasmic reticulum (ER) and activate the Unfolded Protein Response (UPR) to trigger adaptive responses through the effectors, PERK, IRE1 and ATF6. Most of these responses relate to ER homoeostasis; however, here we show that the PERK branch of the UPR also controls DNA replication. Treatment of cells with the non-genotoxic UPR agonist thapsigargin led to a rapid inhibition of DNA synthesis that was attributable to a combination of DNA replication fork slowing and reduced replication origin firing. DNA synthesis inhibition was dependent on the UPR effector PERK and was associated with phosphorylation of the checkpoint adaptor protein Claspin and activation of the Chk1 effector kinase, both of which occurred in the absence of detectable DNA damage. Remarkably, thapsigargin did not inhibit bulk DNA synthesis or activate Chk1 in cells depleted of Claspin, or when Chk1 was depleted or subject to chemical inhibition. In each case thapsigargin-resistant DNA synthesis was due to an increase in replication origin firing that compensated for reduced fork progression. Taken together, our results unveil a new aspect of PERK function and previously unknown roles for Claspin and Chk1 as negative regulators of DNA replication in the absence of genotoxic stress. Because tumour cells proliferate in suboptimal environments, and frequently show evidence of UPR activation, this pathway could modulate the response to DNA replication-targeted chemotherapies.	[Cabrera, E.; Hernandez-Perez, S.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna, Tenerife, Spain; [Koundrioukoff, S.; Debatisse, M.] Inst Curie, Ctr Rech, CNRS, UMR 3244, Paris 05, France; [Koundrioukoff, S.; Debatisse, M.] UPMC Univ Paris 06, Sorbonne Univ, Paris, France; [Koundrioukoff, S.; Debatisse, M.] CNRS, UMR 3244, Paris, France; [Kim, D.; Smolka, M. B.] Cornell Univ, Dept Mol Biol & Genet, Weill Inst Cell & Mol Biol, Ithaca, NY USA; [Gillespie, D. A.] Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, San Cristobal la Laguna, Tenerife, Spain	Universidad de la Laguna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Cornell University; Universidad de la Laguna	Freire, R (corresponding author), Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna, Tenerife, Spain.; Gillespie, DA (corresponding author), Univ La Laguna, Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, San Cristobal la Laguna 38320, Tenerife, Spain.	rfreire@ull.es; dgillesp@ull.es	Gillespie, David/R-4771-2019; Freire, Raimundo/Q-7660-2019; Cabrera, Elisa/GPX-3455-2022	Gillespie, David/0000-0002-6338-0544; Freire, Raimundo/0000-0003-4473-8894; 	Spanish Ministry of Economy and Competitiveness [SAF2013-49149-R, BFU2014-51672-REDC]; Fundacion CajaCanarias [AP2015/008]; IMBRAIN Project - EU FP7 [FP7-REGPOT-2012-CT2012-31637-IMBRAIN]; Gobierno de Canarias; World Wide Cancer Research (WWCR) [12-0149]	Spanish Ministry of Economy and Competitiveness(Spanish Government); Fundacion CajaCanarias; IMBRAIN Project - EU FP7; Gobierno de Canarias; World Wide Cancer Research (WWCR)	This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2013-49149-R, BFU2014-51672-REDC to RF) and Fundacion CajaCanarias (AP2015/008 to RF), the IMBRAIN Project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN to DAG) funded by EU FP7 and Gobierno de Canarias, and World Wide Cancer Research (WWCR; Project grant no. 12-0149 to DAG).	Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Bianco JN, 2012, METHODS, V57, P149, DOI 10.1016/j.ymeth.2012.04.007; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Garrett MD, 2011, TRENDS PHARMACOL SCI, V32, P308, DOI 10.1016/j.tips.2011.02.014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Labit H, 2008, BIOTECHNIQUES, V45, P649, DOI 10.2144/000113002; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Maly DJ, 2014, NAT CHEM BIOL, V10, P892, DOI 10.1038/nchembio.1664; Malzer E, 2010, J CELL SCI, V123, P2892, DOI 10.1242/jcs.070078; Mann MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047931; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; Maya-Mendoza A, 2007, EMBO J, V26, P2719, DOI 10.1038/sj.emboj.7601714; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Palam LR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.264; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Pytel D, 2016, ONCOGENE, V35, P1207, DOI 10.1038/onc.2015.178; Scorah J, 2009, CELL CYCLE, V8, P1036, DOI 10.4161/cc.8.7.8040; Semple JI, 2007, CELL DEATH DIFFER, V14, P1433, DOI 10.1038/sj.cdd.4402134; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Smits VAJ, 2015, FEBS J, V282, P3681, DOI 10.1111/febs.13387; Techer H, 2013, J MOL BIOL, V425, P4845, DOI 10.1016/j.jmb.2013.03.040; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200	31	45	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					678	686		10.1038/onc.2016.239	http://dx.doi.org/10.1038/onc.2016.239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375025				2022-12-28	WOS:000394167700009
J	Cao, C; Vasilatos, SN; Bhargava, R; Fine, JL; Oesterreich, S; Davidson, NE; Huang, Y				Cao, C.; Vasilatos, S. N.; Bhargava, R.; Fine, J. L.; Oesterreich, S.; Davidson, N. E.; Huang, Y.			Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; PHASE-II TRIAL; COLORECTAL-CANCER; STABILIZES LSD1; SILENCED GENES; CELLS; VORINOSTAT; INHIBITORS; USP28; DIFFERENTIATION	We have previously demonstrated that crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs) facilitates breast cancer proliferation. However, the underlying mechanisms are largely unknown. Here, we report that expression of HDAC5 and LSD1 proteins were positively correlated in human breast cancer cell lines and tissue specimens of primary breast tumors. Protein expression of HDAC5 and LSD1 was significantly increased in primary breast cancer specimens in comparison with matched-normal adjacent tissues. Using HDAC5 deletion mutants and co-immunoprecipitation studies, we showed that HDAC5 physically interacted with the LSD1 complex through its domain containing nuclear localization sequence and phosphorylation sites. Although the in vitro acetylation assays revealed that HDAC5 decreased LSD1 protein acetylation, small interfering RNA (siRNA)-mediated HDAC5 knockdown did not alter the acetylation level of LSD1 in MDA-MB-231 cells. Overexpression of HDAC5 stabilized LSD1 protein and decreased the nuclear level of H3K4me1/me2 in MDA-MB-231 cells, whereas loss of HDAC5 by siRNA diminished LSD1 protein stability and demethylation activity. We further demonstrated that HDAC5 promoted the protein stability of USP28, a bona fide deubiquitinase of LSD1. Overexpression of USP28 largely reversed HDAC5-KD-induced LSD1 protein degradation, suggesting a role of HDAC5 as a positive regulator of LSD1 through upregulation of USP28 protein. Depletion of HDAC5 by shRNA hindered cellular proliferation, induced G1 cell cycle arrest, and attenuated migration and colony formation of breast cancer cells. A rescue study showed that increased growth of MDA-MB-231 cells by HDAC5 overexpression was reversed by concurrent LSD1 depletion, indicating that tumor-promoting activity of HDAC5 is an LSD1 dependent function. Moreover, overexpression of HDAC5 accelerated cellular proliferation and promoted acridine mutagen ICR191-induced transformation of MCF10A cells. Taken together, these results suggest that HDAC5 is critical in regulating LSD1 protein stability through post-translational modification, and the HDAC5-LSD1 axis has an important role in promoting breast cancer development and progression.	[Cao, C.; Vasilatos, S. N.; Bhargava, R.; Fine, J. L.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Cao, C.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Cao, C.; Vasilatos, S. N.; Bhargava, R.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Womens Canc Res Ctr, Pittsburgh, PA USA; [Bhargava, R.; Fine, J. L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huang, Y (corresponding author), Magee Womens Res Inst, Room 406,204 Craft Ave, Pittsburgh, PA 15213 USA.	yih26@pitt.edu	Huang, Yi/AAW-7892-2021; Cao, Chunyu/J-8622-2018; Fine, Jeffrey/H-6175-2013	Huang, Yi/0000-0002-9982-117X; Cao, Chunyu/0000-0003-3043-5673; Fine, Jeffrey/0000-0002-2678-8014	US Army Breast Cancer Research Program [W81XWH-14-1-0237, W81XWH-14-1-0238]; Breast Cancer Research Foundation; UPCI Genomics Core Facility - NCI [P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER	US Army Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; UPCI Genomics Core Facility - NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by US Army Breast Cancer Research Program (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED), Breast Cancer Research Foundation (to NED and SO) and UPCI Genomics Core Facility supported by NCI P30CA047904.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2; Chen WD, 2000, J NATL CANCER I, V92, P480, DOI 10.1093/jnci/92.6.480; Diefenbacher ME, 2014, J CLIN INVEST, V124, P3407, DOI 10.1172/JCI73733; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Greco TM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004317; Han X, 2014, MOL CELL, V55, P482, DOI 10.1016/j.molcel.2014.06.006; He P, 2015, INT J CLIN EXP MED, V8, P6510; Huang Y, 2003, CLIN CANCER RES, V9, P2769; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Katz TA, 2014, BREAST CANCER RES TR, V146, P99, DOI 10.1007/s10549-014-3012-9; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; Martin M, 2009, INT J DEV BIOL, V53, P291, DOI 10.1387/ijdb.082698mm; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nagasawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118002; Nowotarski SL, 2015, BIOORGAN MED CHEM, V23, P1601, DOI 10.1016/j.bmc.2015.01.049; Piao L, 2015, ONCOTARGET, V6, P16939, DOI 10.18632/oncotarget.4760; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sen N, 2013, MOL CELL, V52, P406, DOI 10.1016/j.molcel.2013.09.003; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shaw PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076220; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1; Zientek-Targosz H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-51	47	57	67	4	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					133	145		10.1038/onc.2016.186	http://dx.doi.org/10.1038/onc.2016.186			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212032	Green Accepted			2022-12-28	WOS:000394069100012
